The O +
dogma O +
of O +
exclusive O +
T O +
cell O +
recognition O +
of O +
peptide O -
- O -
major B-Gene +
histocompatibility I-Gene +
complex I-Gene +
( O -
pMHC O -
) O +
antigens O +
has O +
recently O +
been O +
challenged O +
( O -
Kaufmann O +
1996 O -
; O +
Melian O +
et O +
al. O +
1996 O -
; O +
Porcelli O +
et O +
al. O +
1996 O -
; O +
Carbone O +
and O +
Gleeson O +
1997 O -
; O +
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O -
. O +

Cells O +
presenting O +
nonpeptidic O +
or O +
modified O +
peptide O +
antigens O +
( O -
e.g. O -
, O +
glycopeptides O +
and O +
glycolipids O +
bound O +
to O +
class B-Gene +
I B-Gene +
and O +
II B-Gene +
MHC I-Gene -
, O +
and O +
MHC B-Gene +
class I-Gene +
I I-Gene -
– O -
like O +
CD1 B-Gene +
molecules I-Gene -
, O +
respectively O -
) O +
can O +
also O +
be O +
recognized O +
by O +
cytotoxic O +
T O +
cells O +
( O -
CTL O -
) O +
bearing O +
α B-Gene -
/ I-Gene -
β I-Gene +
or O +
γ B-Gene -
/ I-Gene -
δ I-Gene +
T I-Gene +
cell I-Gene +
receptors I-Gene +
( O -
TCR B-Gene -
) O +
( O -
Beckman O +
et O +
al. O +
1994 O -
; O +
Davis O +
and O +
Chien O +
1995 O -
; O +
Sieling O +
et O +
al. O +
1995 O -
; O +
Chien O +
et O +
al. O +
1996 O -
; O +
Kaufmann O +
1996 O +
; O +
reviewed O +
by O +
Porcelli O +
et O +
al. O +
1998 O +
) O -
. O +

However O -
, O +
the O +
structural O +
properties O +
of O +
these O +
unconventional O +
TCR B-Gene +
ligands O +
are O +
currently O +
undetermined O +
except O +
for O +
the O +
crystal O +
structure O +
of O +
mouse O +
CD1 B-Gene +
( O -
Zeng O +
et O +
al. O +
1997 O +
) O -
. O +

Conventional O +
T O +
cell O +
recognition O +
of O +
pMHC O +
has O +
been O +
widely O +
studied O +
( O -
Eisen O +
et O +
al. O +
1996 O -
; O +
Davis O +
et O +
al. O +
1998 O +
) O +
and O +
now O +
includes O +
the O +
recent O +
high O -
- O -
resolution O +
crystal O +
structures O +
of O +
intact O +
α B-Gene -
/ I-Gene -
β I-Gene +
TCR I-Gene -
- O -
pMHC B-Gene +
complexes O +
( O -
Garboczi O +
et O +
al. O +
1996 O -
; O +
Garcia O +
et O +
al. O +
1996 O -
, O +
Garcia O +
et O +
al. O +
1998 O -
; O +
Ding O +
et O +
al. O +
1998 O +
) O -
. O +

The O +
TCR B-Gene +
binds O +
the O +
pMHC B-Gene +
surface O +
in O +
a O +
diagonal O +
orientation O +
in O +
which O +
a O +
majority O +
of O +
the O +
intermolecular O +
interactions O +
are O +
derived O +
from O +
contact O +
of O +
CDRs B-Gene +
1 B-Gene +
and O +
2 B-Gene +
of O +
both O +
TCR B-Gene +
polypeptide O +
chains O +
with O +
highly O +
conserved O +
MHC B-Gene +
α1 O +
and O +
α2 O +
helical O +
residues O -
. O +

The O +
TCR B-Gene +
α O +
and O +
β O +
chain O +
hypervariable O +
CDR3 B-Gene +
loops O +
are O +
ideally O +
positioned O +
within O +
the O +
MHC B-Gene +
helices O +
to O +
examine O +
the O +
contents O +
of O +
the O +
peptide O +
binding O +
groove O +
and O +
hence O +
are O +
well O +
suited O +
for O +
their O +
role O +
in O +
peptide O -
- O -
antigen O +
recognition O -
. O +

The O +
consistent O +
diagonal O +
orientation O +
of O +
the O +
TCRs B-Gene +
over O +
the O +
pMHC B-Gene +
so O +
far O +
observed O +
allows O +
more O +
accurate O +
prediction O +
of O +
the O +
structural O +
determinants O +
of O +
MHC B-Gene -
- O -
bound O +
ligands O +
that O +
are O +
likely O +
to O +
be O +
responsible O +
for O +
T O +
cell O +
recognition O +
( O -
reviewed O +
by O +
Wilson O +
and O +
Garcia O +
1997 O +
) O -
. O +

The O +
biological O +
role O +
of O +
antigen O +
ligation O +
by O +
γ B-Gene -
/ I-Gene -
δ I-Gene +
TCR I-Gene +
in O +
T O +
cell O -
– O -
mediated O +
immunity O +
is O +
far O +
less O +
understood O -
. O +

Indeed O -
, O +
MHC B-Gene -
- O -
independent O +
recognition O +
of O +
ligands O +
by O +
γ O -
/ O -
δ O +
TCRs B-Gene +
was O +
anticipated O +
after O +
analysis O +
of O +
their O +
primary O +
structures O -
. O +

Similar O +
to O +
the O +
comparison O +
between O +
immunoglobin B-Gene +
( O -
Ig B-Gene -
) O +
VH B-Gene +
and O +
VL B-Gene +
CDR3 B-Gene +
loops O -
, O +
the O +
TCR B-Gene +
δ O +
chain O +
CDR3s B-Gene +
are O +
significantly O +
longer O +
and O +
more O +
heterogenous O +
in O +
length O +
than O +
those O +
of O +
the O +
γ O +
chain O +
( O -
Rock O +
et O +
al. O +
1994 O +
) O -
. O +

The O +
TCR B-Gene +
α O +
and O +
β O +
chain O +
CDR3s B-Gene +
are O +
both O +
long O +
and O +
homogeneous O +
in O +
length O -
. O +

Therefore O -
, O +
the O +
γ O +
and O +
δ O +
chain O +
pairings O +
suggest O +
γ O -
/ O -
δ O +
TCR B-Gene +
antigen O +
binding O +
is O +
more O +
closely O +
related O +
to O +
that O +
of O +
Ig B-Gene +
molecules O +
than O +
to O +
α O -
/ O -
β O +
TCR B-Gene +
( O -
Rock O +
et O +
al. O +
1994 O -
; O +
Davis O +
and O +
Chien O +
1995 O +
) O -
. O +

Many O +
γ O -
/ O -
δ O +
T O +
cell O +
effector O +
functions O +
overlap O +
with O +
those O +
of O +
α O -
/ O -
β O +
T O +
cells O -
; O +
however O -
, O +
γ O -
/ O -
δ O +
T O +
cells O +
differ O +
in O +
their O +
antigens O +
and O +
mode O +
of O +
ligand O +
recognition O +
that O +
may O +
be O +
reflected O +
in O +
their O +
localization O -
, O +
relative O +
population O -
, O +
and O +
activation O +
kinetics O +
( O -
Kaufmann O +
1996 O -
; O +
Boismenu O +
and O +
Havran O +
1997 O +
) O -
. O +

Glycosylation O +
is O +
a O +
common O +
posttranslational O +
modification O +
of O +
proteins B-Gene +
to O +
be O +
secreted O +
or O +
transported O +
to O +
the O +
cell O +
surface O +
( O -
Varki O +
1993 O +
) O -
. O +

Nevertheless O -
, O +
evidence O +
for O +
the O +
processing O +
of O +
glycoproteins B-Gene +
to O +
glycopeptides O +
and O +
subsequent O +
glycopeptide O +
presentation O +
by O +
MHC B-Gene +
class I-Gene +
I B-Gene +
( O -
MHC B-Gene +
I I-Gene -
) O +
or O +
II B-Gene +
( O -
MHC B-Gene +
II I-Gene -
) O +
receptors B-Gene +
during O +
normal O +
immune O +
responses O +
is O +
scarce O +
( O -
Carbone O +
and O +
Gleeson O +
1997 O -
; O +
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O -
. O +

Glycosylated O +
fragments O +
of O +
collagen B-Gene +
type I-Gene +
II I-Gene +
presented O +
by O +
MHC B-Gene +
II I-Gene +
I I-Gene -
- I-Gene -
Aq I-Gene +
( O -
Broddefalk O +
et O +
al. O +
1998 O +
) O +
and O +
the O +
O O -
- O -
linked O +
glycosylation O +
of O +
cytosolic O +
and O +
nuclear O +
proteins B-Gene +
with O +
a O +
single O +
N O -
- O -
acetylglucosamine O +
( O -
GlcNAc O -
) O +
( O -
Hart O +
et O +
al. O +
1989 O -
; O +
Haurum O +
et O +
al. O +
1994 O +
) O +
represent O +
two O +
possible O +
sources O +
of O +
natural O +
glycopeptides O +
for O +
T O +
cell O +
recognition O -
. O +

Studies O +
using O +
synthetic O +
glycopeptides O +
have O +
enhanced O +
our O +
understanding O +
of O +
oligosaccharide O +
recognition O +
by O +
T O +
cells O +
( O -
Carbone O +
and O +
Gleeson O +
1997 O -
; O +
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O -
. O +

The O +
ability O +
of O +
T O +
cells O +
to O +
recognize O +
carbohydrates O +
has O +
important O +
implications O -
, O +
as O +
some O +
glycoprotein B-Gene +
and O +
glycolipid O -
- O -
associated O +
oligosaccharides O +
have O +
been O +
identified O +
as O +
tumor O -
- O -
associated O +
antigens O +
( O -
TAA O -
; O +
Hakomori O +
1989 O +
) O -
. O +

In O +
the O +
first O +
demonstration O +
of O +
a O +
T O +
cell O +
response O +
to O +
a O +
naturally O +
occuring O +
glycan O -
, O +
immunization O +
with O +
synthetic O +
MHC B-Gene +
I I-Gene +
restricted O +
peptides O +
conjugated O +
with O +
GlcNAc O +
generated O +
glycopeptide O -
- O -
specific O +
CTL O +
( O -
Haurum O +
et O +
al. O +
1994 O +
) O -
. O +

Although O +
many O +
studies O +
have O +
demonstrated O +
the O +
fine O +
specificity O +
of O +
helper O +
T O +
cells O +
and O +
CTL O +
for O +
glycopeptide O +
versus O +
carrier O +
peptide O -
, O +
they O +
have O +
not O +
convincingly O +
demonstrated O +
TCR B-Gene +
recognition O +
of O +
the O +
carbohydrate O +
hapten O +
moiety O +
independent O +
of O +
the O +
restricting O +
MHC B-Gene +
background O +
or O +
carrier O +
peptide O -
. O +

We O +
have O +
found O +
that O +
immunization O +
with O +
MHC B-Gene +
I I-Gene +
H-2Kb I-Gene +
restricted O +
glycopeptide O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
( O -
Figure O +
1 O +
) O +
can O +
generate O +
polyclonal O +
CTL O +
that O +
specifically O +
kill O +
cells O +
presenting O +
the O +
glycopeptide O -
- O -
MHC B-Gene +
complex O +
( O -
gpMHC O -
) O +
as O +
well O +
as O +
a O +
glycolipid O +
with O +
the O +
galabiose O +
oligosaccharide O +
as O +
the O +
hydrophilic O +
head O +
group O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

Fractionation O +
of O +
the O +
CTL O +
population O +
by O +
TCR B-Gene +
expression O +
has O +
shown O +
glycopeptide O -
- O -
specific O +
killing O +
is O +
mediated O +
by O +
α O -
/ O -
β O +
T O +
cells O +
( O -
60 O -
% O +
of O +
the O +
CTL O -
) O -
, O +
and O +
glycolipid O -
- O -
specific O +
killing O +
by O +
γ O -
/ O -
δ O +
T O +
cells O +
( O -
10%–15 O -
% O +
of O +
the O +
CTL O -
) O -
. O +

The O +
MHC B-Gene -
- O -
restricted O +
α O -
/ O -
β O +
T O +
cell O +
response O +
to O +
the O +
glycopeptide O -
, O +
and O +
gpMHC O -
- O -
unrestricted O -
, O +
hapten O -
- O -
specific O +
response O +
of O +
γ O -
/ O -
δ O +
T O +
cells O +
correlate O +
well O +
with O +
the O +
antigen O +
recognition O +
abilities O +
of O +
each O +
T O +
cell O +
subset O -
. O +

Although O +
their O +
biological O +
properties O +
have O +
been O +
elucidated O -
, O +
the O +
structures O +
of O +
MHC B-Gene -
- O -
presented O +
glycopeptides O +
have O +
not O -
. O +

Structural O +
analysis O +
is O +
essential O +
since O +
a O +
majority O +
of O +
the O +
synthetic O +
glycopeptides O +
that O +
have O +
been O +
tested O +
have O +
failed O +
to O +
generate O +
carbohydrate O -
- O -
specific O +
T O +
cell O +
responses O +
( O -
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O -
. O +

Glycopeptides O +
with O +
centrally O +
located O +
oligosaccharides O -
, O +
such O +
as O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
, O +
have O +
clearly O +
been O +
the O +
most O +
immunogenic O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

Therefore O -
, O +
we O +
determined O +
the O +
crystal O +
structure O +
of O +
the O +
H-2Kb O +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
complex O +
at O +
2.2 O +
Å O +
resolution O +
to O +
identify O +
the O +
structural O +
determinants O +
critical O +
for O +
T O +
cell O +
activation O -
. O +

The O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
glycopeptide O +
structure O +
shows O +
that O +
glycan O +
position O -
, O +
linker O +
length O -
, O +
and O +
carbohydrate O +
size O +
are O +
important O +
for O +
recognition O +
and O +
discrimination O +
by O +
the O +
different O +
T O +
cells O +
and O +
can O +
be O +
rationalized O +
with O +
the O +
recently O +
determined O +
footprint O +
of O +
the O +
α B-Gene -
/ I-Gene -
β I-Gene +
T I-Gene +
cell I-Gene +
receptor I-Gene +
over O +
the O +
pMHC O +
( O -
Garboczi O +
et O +
al. O +
1996 O -
; O +
Garcia O +
et O +
al. O +
1996 O -
, O +
Garcia O +
et O +
al. O +
1998 O -
; O +
Ding O +
et O +
al. O +
1998 O +
) O -
. O +

Results O +
Chemical O +
Characteristics O +
of O +
the O +
Glycopeptides O +
and O +
Glycolipids O +
The O +
known O +
MHC B-Gene +
allele O -
- O -
specific O +
motifs O +
( O -
Rammensee O +
et O +
al. O +
1995 O +
) O +
and O +
available O +
crystal O +
structures O +
of O +
Kb O +
( O -
Fremont O +
et O +
al. O +
1992 O +
) O +
and O +
Db O +
( O -
Young O +
et O +
al. O +
1994 O +
) O +
were O +
utilized O +
in O +
glycopeptide O +
synthesis O +
and O +
design O +
( O -
Figure O +
1 O +
) O -
. O +

The O +
Db O +
-binding O +
peptides O +
were O +
ASNENMETM O +
from O +
PR8 B-Gene +
influenza I-Gene +
virus I-Gene +
nucleoprotein I-Gene +
( O -
NP O -
) O +
( O -
van O +
Bleek O +
and O +
Nathenson O +
1990 O +
) O +
and O +
SGPSNTPPEI O +
from O +
adenovirus B-Gene +
Ad5EI I-Gene +
protein I-Gene +
( O -
Rammensee O +
et O +
al. O +
1993 O +
) O -
. O +

The O +
Kb O +
-binding O +
peptides O +
were O +
FAPGNYPAL O +
from O +
Sendai B-Gene +
virus I-Gene +
NP I-Gene +
( O -
Schumacher O +
et O +
al. O +
1991 O +
) O +
and O +
RGYVYQGL O +
from O +
vesicular B-Gene +
stomatitis I-Gene +
virus I-Gene +
( I-Gene -
VSV I-Gene -
) I-Gene +
NP I-Gene +
( O -
van O +
Bleek O +
and O +
Nathenson O +
1990 O +
) O -
. O +

The O +
allele O -
- O -
specific O +
anchor O +
residues O +
for O +
Kb B-Gene +
and O +
Db B-Gene +
are O +
centrally O +
located O +
at O +
P5 O +
for O +
Db B-Gene +
and O +
P5 O +
( O -
8-mer O -
) O +
or O +
P6 O +
( O -
9-mer O -
) O +
for O +
Kb B-Gene +
( O -
Figure O +
1 O +
) O -
. O +

Five O +
carbohydrates O +
differing O +
in O +
size O +
and O +
chemical O +
structure O +
were O +
coupled O +
either O +
to O +
serine O -
, O +
cysteine O -
, O +
or O +
homocysteine O +
( O -
Figure O +
1 O +
) O -
. O +

Oligosaccharide O +
CD77 O +
is O +
the O +
Burkitt O +
lymphoma O +
TAA O +
( O -
Nudelman O +
et O +
al. O +
1983 O +
) O -
. O +

Lactose O +
and O +
GM3-lactam O +
are O +
also O +
tumor O -
- O -
associated O +
saccharides O +
( O -
Holmes O +
et O +
al. O +
1987 O -
; O +
Nores O +
et O +
al. O +
1987 O +
) O -
. O +

Galabiose O +
( O -
Gal O -
- O -
α O -
( O -
1,4 O -
) O -
-Galβ O +
or O +
Gal2 O +
) O +
is O +
an O +
integral O +
part O +
of O +
several O +
natural O +
glycolipid O +
head O +
groups O +
and O +
is O +
the O +
terminal O +
disaccharide O +
of O +
CD77 O +
( O -
Figure O +
1 O +
) O -
. O +

The O +
amino O +
acid O +
glycans O +
replaced O +
upward O -
- O -
pointed O +
residues O +
flanking O +
the O +
central O +
anchor O +
in O +
the O +
Kb B-Gene +
or O +
Db B-Gene +
peptides O +
or O +
were O +
added O +
to O +
their O +
termini O +
( O -
Figure O +
1 O +
; O +
Abdel O -
- O -
Motal O +
et O +
al. O +
1995 O -
, O +
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

Peptide O +
binding O +
to O +
MHC B-Gene +
I I-Gene +
was O +
unaffected O +
by O +
the O +
glycan O +
modifications O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
, O +
and O +
the O +
stability O +
of O +
the O +
glycopeptides O +
in O +
vivo O +
has O +
been O +
previously O +
demonstrated O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1993 O +
) O -
. O +

Monoclonal B-Gene +
antibody I-Gene +
( O -
MAb B-Gene -
) O +
detection O +
of O +
the O +
peptide O -
- O -
linked O +
carbohydrates O +
on O +
the O +
cell O +
surface O +
differed O +
depending O +
on O +
the O +
position O +
of O +
the O +
glycan O +
substitution O +
on O +
the O +
peptide O +
and O +
linker O +
length O -
. O +

Thus O -
, O +
antibody B-Gene +
binding O +
to O +
the O +
peptide O +
glycans O +
provided O +
a O +
measure O +
of O +
the O +
carbohydrate O +
exposure O +
in O +
the O +
various O +
pMHC O +
complexes O -
. O +

Carbohydrates O +
attached O +
at O +
internal O +
positions O +
in O +
the O +
peptide O +
by O +
the O +
serine O +
linker O +
were O +
poorly O +
detected O +
by O +
anti O -
- O -
carbohydrate O +
MAb B-Gene -
. O +

In O +
contrast O -
, O +
high O +
carbohydrate O +
exposure O +
was O +
detected O +
for O +
all O +
of O +
the O +
glycopeptides O +
that O +
had O +
N O -
- O -
terminal O +
cysteine O -
- O -
ethylene O +
extensions O +
or O +
with O +
the O +
homocysteine O +
linker O +
at O +
internal O +
positions O +
with O +
one O +
exception O +
( O -
ASN9 O -
- O -
6H O -
- O -
CD77Table O +
1 O +
) O -
. O +

The O +
anti O -
- O -
CD77 O +
MAb B-Gene +
is O +
of O +
the O +
IgM B-Gene +
type O +
and O +
may O +
not O +
be O +
optimal O +
for O +
binding O +
to O +
CD77 O +
in O +
the O +
context O +
of O +
the O +
pMHC O -
. O +

Carbohydrate O +
headgroups O +
in O +
all O +
of O +
the O +
glycolipids O -
, O +
after O +
liposomal O +
transfer O +
to O +
EL-4 O +
target O +
cells O -
, O +
were O +
highly O +
exposed O +
at O +
the O +
cell O +
surface O +
and O +
stable O +
for O +
at O +
least O +
24 O +
hr O +
under O +
tissue O +
culture O +
conditions O -
, O +
as O +
detected O +
with O +
the O +
corresponding O +
anti O -
- O -
carbohydrate O +
MAb B-Gene +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

Specificity O +
of O +
α O -
/ O -
β O +
and O +
γ O -
/ O -
δ O +
CTL O +
toward O +
Glycopeptides O +
and O +
Glycolipids O +
Immunizations O +
with O +
the O +
glycopeptide O +
panel O +
produced O +
a O +
wide O +
range O +
of O +
T O +
cell O +
responses O +
( O -
Table O +
1 O +
; O +
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

Glycosylation O +
of O +
the O +
peptide O +
termini O -
, O +
glycopeptides O +
with O +
internal O +
serine O -
- O -
coupled O +
oligosaccharides O -
, O +
and O +
Db B-Gene +
-binding O +
glycopeptides O +
produced O +
low O +
CTL O +
responses O +
in O +
general O +
with O +
no O +
evidence O +
for O +
any O +
carbohydrate O +
specificity O -
. O +

In O +
contrast O -
, O +
Kb B-Gene +
-binding O +
glycopeptides O -
, O +
RGY8 O -
- O -
4H O -
- O -
Gal2 O +
and O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
, O +
with O +
central O +
homocysteine O -
- O -
coupled O +
galabiose O +
generated O +
strong O +
bulk O +
CTL O +
responses O +
that O +
specifically O +
killed O +
glycopeptide O -
- O -
coated O +
target O +
cells O +
( O -
Table O +
1 O +
; O +
Figure O +
1 O +
) O -
. O +

Fractionation O +
of O +
the O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
generated O +
T O +
cell O +
population O +
based O +
on O +
α O -
/ O -
β O +
or O +
γ O -
/ O -
δ O +
TCR B-Gene +
expression O +
determined O +
glycopeptide O -
- O -
specific O +
killing O +
was O +
primarily O +
by O +
the O +
α O -
/ O -
β O +
T O +
cells O +
( O -
Table O +
1 O +
) O -
. O +

Interestingly O -
, O +
the O +
bulk O +
CTL O +
generated O +
with O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
also O +
killed O +
target O +
cells O +
coated O +
with O +
Db B-Gene +
-binding O +
glycopeptides O +
containing O +
homocysteine O -
- O -
coupled O +
galabiose O +
( O -
e.g. O -
, O +
ASN9 O -
- O -
6H O -
- O -
Gal2 O +
) O -
, O +
and O +
suggested O +
a O +
strict O +
carbohydrate O +
specificity O +
independent O +
of O +
the O +
pMHC O +
background O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

MHC B-Gene -
- O -
unrestricted O +
carbohydrate O +
specificity O +
was O +
unambiguously O +
determined O +
by O +
fusing O +
liposomes O +
composed O +
of O +
galabiose O +
containing O +
glycolipid O +
( O -
Figure O +
1C O +
) O +
with O +
EL-4 O -
, O +
YAC O -
- O -
I O -
, O +
and O +
P815 O +
cells O -
. O +

These O +
glycolipid O -
- O -
coated O +
target O +
cells O +
were O +
specifically O +
killed O +
by O +
a O +
small O +
γ O -
/ O -
δ O +
T O +
cell O +
subpopulation O +
present O +
in O +
the O +
bulk O +
CTL O +
generated O +
against O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
( O -
Table O +
1 O +
) O -
. O +

These O +
data O +
suggest O +
that O +
the O +
α O -
/ O -
β O +
and O +
γ O -
/ O -
δ O +
T O +
cells O +
recognized O +
different O +
portions O +
of O +
the O +
same O +
gpMHC O +
antigen O +
that O +
correlates O +
with O +
their O +
specific O +
killing O +
of O +
glycopeptide O -
- O -
coated O +
or O +
glycolipid O -
- O -
coated O +
target O +
cells O -
, O +
respectively O -
. O +

Thus O -
, O +
we O +
determined O +
the O +
H-2Kb B-Gene +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
crystal O +
structure O +
to O +
improve O +
our O +
understanding O +
of O +
carbohydrate O +
recognition O +
by O +
T O +
cells O -
. O +

RGY8 O -
- O -
6H O -
- O -
Gal2 O +
Glycopeptide O +
Structure O +
The O +
crystal O +
structure O +
of O +
Kb B-Gene +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
was O +
determined O +
using O +
well O -
- O -
developed O +
procedures O +
for O +
Kb B-Gene +
pMHC O +
complexes O +
( O -
see O +
Experimental O +
Procedures O -
) O -
. O +

The O +
final O +
model O +
included O +
the O +
H-2Kb B-Gene +
/glycopeptide O +
complex O -
, O +
four O +
well O -
- O -
ordered O +
N O -
- O -
linked O +
carbohydrates O +
to O +
the O +
MHC B-Gene -
, O +
and O +
108 O +
waters O +
( O -
Rcryst O +
22.4 O -
% O -
, O +
Rfree O +
27.9 O -
% O -
) O -
. O +

Electron O +
density O +
for O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
was O +
continuous O +
and O +
well O +
resolved O -
, O +
allowing O +
unambiguous O +
modeling O +
of O +
the O +
glycosylated O +
peptide O +
( O -
Figure O +
2 O +
) O -
. O +

The O +
glycopeptide O +
structure O +
is O +
nearly O +
identical O +
to O +
that O +
of O +
Kb B-Gene +
-bound O +
VSV-8 O +
for O +
the O +
common O +
residues O +
( O -
P1-P5 O -
, O +
P7-P8 O -
) O +
( O -
Fremont O +
et O +
al. O +
1992 O +
) O -
. O +

The O +
root O -
- O -
mean O -
- O -
square O +
deviation O +
( O -
r.m.s.d O -
) O +
is O +
only O +
0.19 O +
Å O +
for O +
the O +
equivalent O +
polyalanine O +
atoms O +
between O +
VSV-8 O +
and O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
after O +
the O +
Cα O +
atoms O +
of O +
the O +
Kb B-Gene +
α1 O +
α2 O +
superdomains O +
are O +
aligned O -
. O +

Many O +
interactions O +
between O +
the O +
glycopeptide O +
and O +
MHC B-Gene +
heavy O +
chain O -
, O +
including O +
water O -
- O -
mediated O +
hydrogen O +
bonds O -
, O +
are O +
also O +
shared O +
with O +
the O +
Kb B-Gene +
/VSV-8 O +
complex O +
( O -
Table O +
2 O +
) O -
; O +
however O -
, O +
the O +
glycosidic O +
modification O +
makes O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
the O +
largest O +
MHC B-Gene +
I I-Gene +
bound O +
antigen O +
to O +
have O +
its O +
structure O +
determined O +
to O +
date O -
. O +

The O +
homocysteine O +
galabiose O +
glycan O +
at O +
position O +
6 O +
of O +
the O +
peptide O +
( O -
HggP6 O -
) O +
extends O +
12 O +
Å O +
above O +
the O +
peptide O +
backbone O +
( O -
Figure O +
3A O +
and O +
Figure O +
3B O +
) O -
. O +

Arginine O -
, O +
the O +
longest O +
unmodified O +
amino O +
acid O -
, O +
can O +
only O +
extend O +
approximately O +
7 O +
Å O +
out O +
from O +
the O +
peptide O +
backbone O +
( O -
e.g. O -
, O +
see O +
ArgP1 O +
in O +
Figure O +
2 O +
and O +
Figure O +
3 O +
) O -
. O +

Interestingly O -
, O +
there O +
are O +
no O +
significant O +
alterations O +
of O +
the O +
Kb B-Gene +
structure O +
as O +
a O +
result O +
of O +
glycopeptide O +
binding O -
. O +

The O +
conformation O +
of O +
the O +
galabiose O +
thioether O +
linker O +
loosely O +
matches O +
that O +
of O +
VSV-8 O +
GlnP6 O +
for O +
the O +
first O +
few O +
equivalent O +
atom O +
positions O +
and O +
orients O +
HggP6 O +
toward O +
the O +
α2 O +
helix O +
( O -
Figure O +
3B O +
) O -
. O +

HggP6 O +
" O -
leans O -
" O +
on O +
the O +
α2 O +
helix O -
, O +
creating O +
several O +
contacts O +
unique O +
to O +
the O +
glycopeptide O +
( O -
Table O +
2 O +
) O -
, O +
but O +
does O +
not O +
make O +
any O +
hydrogen O +
bonds O -
. O +

In O +
the O +
absence O +
of O +
T B-Gene +
cell I-Gene +
receptor I-Gene +
ligation O +
or O +
any O +
direct O +
hydrogen O +
bonds O +
to O +
the O +
linker O +
or O +
sugars O +
from O +
the O +
Kb B-Gene +
α1 O +
α2 O +
domains O -
, O +
the O +
polar O +
and O +
hydrophobic O +
contacts O +
are O +
the O +
only O +
interactions O +
stabilizing O +
the O +
placement O +
of O +
the O +
glycosidic O +
modification O +
adjacent O +
to O +
the O +
α2 O +
helix O -
. O +

The O +
contacts O +
between O +
the O +
disaccharide O +
and O +
Kb B-Gene +
are O +
mainly O +
with O +
the O +
internal O +
galactose O +
residue O -
. O +

Only O +
a O +
single O +
contact O +
exists O +
between O +
the O +
Kb O +
α2 O +
domain O +
and O +
the O +
terminal O +
galactose O +
( O -
Table O +
2 O +
) O -
; O +
in O +
fact O -
, O +
both O +
sugars O +
of O +
the O +
galabiose O +
are O +
clasped O +
between O +
the O +
MHC B-Gene +
α2 O +
helix O +
and O +
the O +
β2 O +
m O +
subunit O +
of O +
a O +
neighboring O +
Kb B-Gene +
molecule O +
in O +
the O +
crystal O +
lattice O -
. O +

The O +
neighboring O +
β2 O +
m O +
is O +
on O +
the O +
opposite O +
side O +
of O +
galabiose O +
from O +
the O +
α2 O +
helix O -
. O +

Two O +
hydrogen O +
bonds O +
and O +
several O +
polar O +
interactions O +
between O +
HggP6 O +
and O +
neighboring O +
β2 O +
m O +
residues O +
Leuβ40 O -
, O +
Glyβ43 O -
, O +
Argβ81 O -
, O +
and O +
Lysβ83 O +
are O +
a O +
result O +
of O +
the O +
galabiose O +
entrapment O +
( O -
Table O +
2 O +
) O -
. O +

These O +
interactions O +
may O +
be O +
preventing O +
the O +
formation O +
of O +
other O +
hydrogen O +
bonds O +
between O +
galabiose O +
and O +
Kb B-Gene +
. O +

The O +
peptide O -
- O -
conjugated O +
galabiose O +
retains O +
a O +
structure O +
very O +
similar O +
to O +
that O +
of O +
the O +
free O +
disaccharide O +
( O -
Svensson O +
et O +
al. O +
1986 O +
) O -
. O +

Superposition O +
of O +
the O +
small O +
molecule O +
galabiose O +
crystal O +
structure O +
with O +
the O +
HggP6-linked O +
disaccharide O +
structure O +
gives O +
an O +
r.m.s.d O +
of O +
only O +
0.78 O +
Å. O +
The O +
two O +
galabiose O +
structures O +
differ O +
mainly O +
due O +
to O +
a O +
46 O -
° O +
difference O +
between O +
their O +
internal O +
glycosidic O +
dihedral O +
angles O -
, O +
presumably O +
due O +
to O +
contact O +
of O +
the O +
HggP6 O +
galabiose O +
with O +
the O +
neighboring O +
β2 O +
m O +
molecule O -
; O +
the O +
terminal O +
galactose O +
in O +
HggP6 O +
must O +
rotate O +
away O +
from O +
the O +
neighboring O +
β2 O +
m O +
molecule O +
to O +
avoid O +
forming O +
energetically O +
unfavorable O +
close O +
contacts O -
. O +

Disaccharide O +
Exposure O +
and O +
Mobility O +
The O +
galabiose O +
disaccharide O +
is O +
71 O -
% O +
exposed O +
to O +
solvent O +
in O +
the O +
crystal O +
structure O -
. O +

The O +
orientation O +
adopted O +
by O +
HggP6 O +
places O +
most O +
of O +
its O +
mass O +
into O +
the O +
open O +
space O +
between O +
the O +
α1 O +
α2 O +
helices O -
. O +

Thus O -
, O +
the O +
overall O +
exposed O +
surface O +
area O +
of O +
the O +
glycopeptide O +
is O +
substantially O +
greater O +
than O +
that O +
of O +
normal O +
peptides O +
bound O +
by O +
Kb B-Gene +
and O +
other O +
MHC B-Gene +
I I-Gene +
antigens O +
( O -
see O +
Figure O +
3D O +
and O +
Figure O +
3E O +
) O -
. O +

Contact O +
between O +
glycopeptide O +
residue O +
HggP6 O +
and O +
the O +
α2 O +
helix O +
also O +
contributes O +
to O +
significantly O +
more O +
Kb B-Gene +
-buried O +
surface O +
in O +
the O +
glycopeptide O +
complex O +
( O -
952 O +
Å2 O +
) O +
than O +
in O +
Kb B-Gene +
/VSV-8 O +
( O -
843 O +
Å2 O +
) O -
. O +

Modeling O +
studies O +
of O +
this O +
complex O +
show O +
that O +
the O +
galabiose O +
exposure O +
could O +
be O +
even O +
greater O -
. O +

Torsion O +
angles O +
for O +
the O +
relatively O +
long O +
thioether O -
- O -
hydrocarbon O +
linker O +
are O +
largely O +
unrestricted O -
. O +

Small O +
rotations O +
( O -
< O -
20 O -
° O -
) O +
of O +
just O +
two O +
of O +
the O +
linker O +
torsion O +
angles O +
can O +
free O +
the O +
galabiose O +
from O +
any O +
contact O +
with O +
the O +
Kb B-Gene +
α2 O +
helix O +
( O -
Figure O +
3C O +
) O -
. O +

The O +
repositioned O +
galabiose O +
would O +
be O +
100 O -
% O +
solvent O +
accessible O +
giving O +
the O +
glycopeptide O +
nearly O +
double O +
the O +
exposed O +
peptide O +
surface O +
area O +
of O +
other O +
MHC B-Gene -
- O -
bound O +
peptides O +
( O -
383 O +
Å2 O +
versus O +
150–220 O +
Å2 O +
) O -
. O +

Galabiose O -
- O -
specific O +
monoclonal B-Gene +
antibodies I-Gene +
strongly O +
recognize O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
treated O +
RMA O -
- O -
S O +
cells O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
, O +
providing O +
further O +
evidence O +
for O +
the O +
high O +
exposure O +
of O +
the O +
glycopeptide O -
- O -
attached O +
galabiose O -
. O +

The O +
MAb B-Gene +
could O +
possibly O +
recognize O +
the O +
galabiose O +
in O +
close O +
proximity O +
to O +
the O +
MHC B-Gene +
helices O -
, O +
but O +
small O +
haptens O +
are O +
more O +
commonly O +
buried O +
deep O +
within O +
the O +
immunoglobin B-Gene +
combining O +
site O +
( O -
reviewed O +
by O +
Wilson O +
and O +
Stanfield O +
1994 O +
) O -
. O +

The O +
unrestricted O +
access O +
to O +
the O +
galabiose O +
is O +
compatible O +
with O +
antibody B-Gene +
binding O +
of O +
small O +
haptens O +
and O +
therefore O +
supports O +
the O +
likelihood O +
of O +
HggP6 O +
conformations O +
that O +
fully O +
expose O +
the O +
carbohydrates O +
( O -
e.g. O +

Figure O +
3C O +
) O -
. O +

Carbohydrate O +
Dominance O +
of O +
the O +
TCR B-Gene +
Footprint O +
An O +
extended O +
glycan O +
linker O -
, O +
such O +
as O +
that O +
observed O +
in O +
the O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
crystal O +
structure O -
, O +
will O +
place O +
the O +
galabiose O +
well O +
above O +
the O +
peptide O +
backbone O +
in O +
the O +
pMHC O +
region O +
normally O +
covered O +
by O +
the O +
α O -
/ O -
β O +
TCR B-Gene +
CDR3 O +
loops O +
( O -
Garboczi O +
et O +
al. O +
1996 O -
; O +
Garcia O +
et O +
al. O +
1996 O -
, O +
Garcia O +
et O +
al. O +
1998 O -
; O +
Ding O +
et O +
al. O +
1998 O +
) O -
. O +

Torsion O +
angle O +
rotations O +
of O +
the O +
linker O +
can O +
result O +
in O +
large O +
lateral O +
movements O +
of O +
the O +
galabiose O -
; O +
however O -
, O +
the O +
central O +
peptide O +
attachment O +
site O -
, O +
combined O +
with O +
the O +
diagonal O +
orientation O +
of O +
the O +
TCR O +
over O +
the O +
MHC O +
binding O +
groove O -
, O +
still O +
keeps O +
the O +
galabiose O +
within O +
the O +
CDR3 O +
region O +
of O +
the O +
TCR B-Gene +
footprint O -
. O +

Therefore O -
, O +
direct O +
interactions O +
between O +
the O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
carbohydrates O +
and O +
the O +
TCR B-Gene +
CDR3 O +
loops O +
are O +
relatively O +
convincing O -
. O +

The O +
current O +
position O +
of O +
the O +
disaccharide O +
in O +
the O +
Kb B-Gene +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
crystal O +
structure O +
would O +
place O +
it O +
under O +
the O +
CDR3β O +
loop O +
and O +
next O +
to O +
a O +
key O +
β O +
chain O +
contact O +
patch O +
on O +
the O +
MHC B-Gene +
α2 O +
helix O +
( O -
residues O +
149–158 O -
) O -
. O +

TCR B-Gene +
recognition O +
of O +
the O +
galabiose O -
, O +
therefore O -
, O +
would O +
predominantly O +
involve O +
the O +
β O +
subunit O -
. O +

The O +
area O +
between O +
the O +
glycopeptide O +
and O +
the O +
α1 O +
helix O +
is O +
more O +
accessible O +
and O +
could O +
allow O +
TCR B-Gene +
α O +
and O +
β O +
subunit O +
contacts O +
directly O +
to O +
the O +
peptide O +
backbone O +
as O +
well O +
as O +
to O +
the O +
side O +
chains O -
. O +

TCR B-Gene +
corecognition O +
of O +
glycopeptide O +
and O +
MHC B-Gene +
residues O +
in O +
this O +
manner O +
favors O +
an O +
MHC B-Gene -
- O -
restricted O -
, O +
glycopeptide O -
- O -
specific O +
α O -
/ O -
β O +
T O +
cell O +
response O -
, O +
and O +
may O +
explain O +
the O +
low O -
- O -
level O +
bulk O +
CTL O +
cross O -
- O -
reactivity O +
to O +
the O +
carrier O +
peptide O +
stripped O +
of O +
carbohydrate O -
. O +

The O +
highly O +
exposed O +
galabiose O +
also O +
closely O +
matches O +
the O +
attributes O +
of O +
preferred O +
γ O -
/ O -
δ O +
T O +
cell O +
antigens O +
that O +
supports O +
the O +
dichotomy O +
of O +
the O +
anti O -
- O -
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
T O +
cell O +
response O -
. O +

Direct O -
, O +
immunoglobin O -
- O -
like O +
recognition O +
of O +
the O +
galabiose O -
, O +
either O +
as O +
a O +
highly O +
exposed O +
glycopeptide O +
hapten O +
or O +
glycolipid O +
headgroup O -
, O +
is O +
easily O +
conceivable O -
. O +

Complete O +
carbohydrate O +
exposure O +
can O +
be O +
achieved O +
by O +
varying O +
the O +
HggP6 O +
conformation O +
( O -
e.g. O +

Figure O +
3C O +
) O +
or O +
may O +
be O +
induced O +
through O +
TCR B-Gene +
binding O -
. O +

A O +
great O +
variety O +
of O +
TCR B-Gene +
docking O +
scenarios O +
and O +
HggP6 O +
conformations O +
appear O +
feasible O -
, O +
and O +
could O +
potentially O +
coexist O +
in O +
vivo O -
, O +
which O +
would O +
explain O +
the O +
simultaneous O +
generation O +
of O +
carbohydrate O -
- O -
specific O +
γ O -
/ O -
δ O +
CTL O +
and O +
glycopeptide O -
- O -
specific O +
α O -
/ O -
β O +
CTL O +
by O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
. O +

Discussion O +
Important O +
Structural O +
Features O +
of O +
the O +
Kb B-Gene +
/Glycopeptide O +
Complex O +

The O +
crystal O +
structure O +
of O +
H-2Kb B-Gene +
-bound O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
reveals O +
the O +
VSV-8 O +
carrier O +
peptide O +
and O +
Kb B-Gene +
structures O +
are O +
unaffected O +
by O +
the O +
peptide O +
glycosylation O -
; O +
thus O -
, O +
the O +
novel O +
features O +
of O +
the O +
glycopeptide O +
presentation O +
are O +
specifically O +
localized O +
to O +
the O +
carbohydrate O +
portion O +
of O +
the O +
ligand O -
. O +

Indeed O -
, O +
the O +
glycan O +
modification O +
places O +
the O +
galabiose O +
disaccharide O +
at O +
the O +
outer O +
limits O +
of O +
the O +
MHC B-Gene +
peptide O +
binding O +
groove O +
where O +
it O +
abuts O +
the O +
apex O +
of O +
the O +
α2 O +
helix O -
, O +
well O +
beyond O +
the O +
reach O +
of O +
normal O +
peptide O +
side O +
chains O -
. O +

The O +
galabiose O +
is O +
secured O +
at O +
this O +
position O +
more O +
by O +
intermolecular O +
crystal O +
contacts O +
to O +
a O +
neighboring O +
β2 O +
m O +
molecule O +
than O +
by O +
intramolecular O +
contacts O +
to O +
the O +
MHC B-Gene +
receptor B-Gene -
, O +
suggesting O +
that O +
HggP6 O +
may O +
have O +
significantly O +
more O +
conformational O +
freedom O +
in O +
solution O -
. O +

The O +
chemical O +
structure O -
, O +
P6 O +
substitution O +
site O -
, O +
and O +
size O +
of O +
the O +
Hgg O +
linker O +
favor O +
a O +
highly O +
exposed O +
hapten O +
moiety O +
in O +
virtually O +
any O +
linker O +
conformation O -
. O +

This O +
unusual O +
access O +
to O +
an O +
MHC B-Gene +
I I-Gene +
bound O +
ligand O +
allows O +
for O +
direct O +
TCR B-Gene +
interactions O +
with O +
the O +
galabiose O -
, O +
which O +
is O +
considerably O +
larger O +
than O +
an O +
amino O +
acid O +
side O +
chain O -
. O +

Alterations O +
in O +
the O +
shape O +
of O +
the O +
TCR B-Gene +
combining O +
site O -
, O +
such O +
as O +
large O +
conformational O +
adjustments O +
of O +
the O +
CDR3 O +
loops O -
, O +
may O +
be O +
required O +
for O +
a O +
TCR B-Gene +
to O +
bind O +
the O +
Kb B-Gene +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
disaccharide O +
compared O +
to O +
a O +
pMHC O -
. O +

Movements O +
of O +
up O +
to O +
several O +
angstroms O +
by O +
CDRs O +
1α O -
, O +
3α O -
, O +
and O +
3β O +
were O +
observed O +
in O +
comparisons O +
between O +
the O +
free O +
and O +
bound O +
structures O +
of O +
the O +
murine O +
2C O +
TCR B-Gene +
( O -
Garcia O +
et O +
al. O +
1998 O +
) O -
. O +

It O +
is O +
likely O +
that O +
CDR B-Gene +
flexibility O +
is O +
also O +
involved O -
, O +
although O +
to O +
a O +
lesser O +
extent O -
, O +
in O +
the O +
high O -
- O -
affinity O +
allorecognition O +
of O +
the O +
H-2Ld O +
/QL9 O +
peptide O +
complex O +
by O +
the O +
2C O +
TCR B-Gene -
. O +

A O +
model O +
of O +
the O +
2C O -
/ O -
Ld O +
interaction O +
( O -
Speir O +
et O +
al. O +
1998 O +
) O +
reveals O +
that O +
a O +
bulge O +
near O +
the O +
QL9 O +
C O +
terminus O -
, O +
as O +
a O +
result O +
of O +
a O +
ridge O +
in O +
the O +
Ld O +
binding O +
groove O +
floor O -
, O +
is O +
likely O +
to O +
greatly O +
increase O +
the O +
TCR B-Gene +
contact O +
with O +
the O +
QL9 O +
peptide O +
and O +
require O +
different O +
conformations O +
of O +
the O +
2C O +
CDRs B-Gene +
for O +
optimal O +
binding O +
compared O +
to O +
the O +
syngeneic O +
2C B-Gene -
/ I-Gene -
dEV8 I-Gene -
/ I-Gene -
Kb I-Gene +
complex O -
. O +

Alternatively O -
, O +
HggP6 O +
may O +
adopt O +
a O +
conformation O +
that O +
places O +
the O +
carbohydrate O +
into O +
a O +
cavity O +
between O +
the O +
TCR B-Gene +
α O +
and O +
β O +
chains O +
( O -
Garcia O +
et O +
al. O +
1996 O +
) O +
or O +
generally O +
between O +
the O +
TCR B-Gene +
and O +
pMHC O -
, O +
requiring O +
little O +
to O +
no O +
structural O +
adjustments O +
of O +
either O +
receptor O -
. O +

Indeed O -
, O +
the O +
TCR B-Gene -
- O -
pMHC O +
interfaces O +
are O +
extensive O +
but O +
exhibit O +
poor O +
shape O +
complementarity O -
, O +
leaving O +
large O +
cavities O +
between O +
the O +
contacting O +
surfaces O +
( O -
Garboczi O +
et O +
al. O +
1996 O -
; O +
Ding O +
et O +
al. O +
1998 O -
; O +
Garcia O +
et O +
al. O +
1998 O +
) O -
. O +

Regardless O +
of O +
the O +
poorly O +
formed O +
TCR B-Gene -
- O -
pMHC O +
interface O -
, O +
central O +
modifications O +
of O +
the O +
peptide O +
antigen O +
that O +
extend O +
outward O +
from O +
the O +
MHC B-Gene +
binding O +
groove O +
will O +
create O +
new O +
and O +
more O +
numerous O +
contacts O +
with O +
the O +
TCR B-Gene -
. O +

Glycopeptide O +
Structure O -
- O -
Function O +
Relationships O -
: O +

A O +
Beginning O +
MHC B-Gene +
I B-Gene +
and O +
II B-Gene +
bound O +
peptide O +
immunogens O +
with O +
glycosylation O +
sites O +
outside O +
of O +
the O +
central O +
peptide O +
residues O +
normally O +
fail O +
to O +
generate O +
glycopeptide O -
- O -
specific O +
CTL O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O -
; O +
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O -
. O +

It O +
is O +
now O +
apparent O +
that O +
glycans O +
at O +
these O +
positions O +
would O +
not O +
promote O +
contact O +
between O +
carbohydate O +
haptens O +
and O +
the O +
hypervariable O +
CDR3 O +
loops O +
of O +
an O +
α O -
/ O -
β O +
TCR B-Gene -
, O +
leading O +
to O +
the O +
killing O +
of O +
both O +
carrier O +
peptide O +
and O +
glycopeptide O +
coated O +
target O +
cells O +
by O +
the O +
CTL O +
generated O +
against O +
glycopeptides O +
with O +
noncentral O +
glycan O +
modifications O +
( O -
Ishioka O +
et O +
al. O +
1992 O -
; O +
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O -
; O +
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O -
. O +

Glycosylation O +
of O +
the O +
central O +
peptide O +
residues O +
places O +
the O +
carbohydrates O +
within O +
the O +
expected O +
TCR B-Gene +
CDR3α O +
and O +
3β O +
footprint O +
and O +
yields O +
glycopeptides O +
whose O +
immunogenicity O +
is O +
dependent O +
upon O +
the O +
linker O +
length O +
and O +
carbohydrate O +
size O -
. O +

Glycopeptides O +
incorporating O +
disaccharides O +
or O +
larger O +
carbohydrates O +
linked O +
to O +
serine O +
showed O +
weak O +
CTL O +
immunogenicity O -
, O +
as O +
well O +
as O +
poor O +
detection O +
by O +
carbohydrate O -
- O -
specific O +
MAb B-Gene +
on O +
the O +
cell O +
surface O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

In O +
contrast O -
, O +
GlcNAc O +
monosaccharides O +
coupled O +
to O +
peptides O +
with O +
serine O +
linkers O +
generate O +
CTL O +
that O +
are O +
able O +
to O +
discriminate O +
between O +
the O +
glycosylated O +
and O +
native O +
peptides O -
, O +
as O +
well O +
as O +
between O +
chemically O +
similar O +
glycopeptides O +
( O -
Haurum O +
et O +
al. O +
1994 O +
) O -
. O +

The O +
fine O +
specificity O +
demonstrated O +
in O +
T O +
cell O +
recognition O +
of O +
the O +
GlcNAc O -
- O -
based O +
glycopeptides O +
suggests O +
monosaccharides O +
attached O +
to O +
short O +
linkers O +
near O +
the O +
peptide O +
center O +
are O +
better O +
suited O +
for O +
glycopeptide O -
- O -
specific O +
α O -
/ O -
β O +
TCR B-Gene +
recognition O -
. O +

From O +
the O +
Kb B-Gene +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
structure O -
, O +
it O +
appears O +
the O +
greater O +
mass O +
of O +
the O +
serine O -
- O -
linked O +
disaccharides O +
and O +
larger O +
carbohydrates O +
will O +
be O +
confined O +
to O +
the O +
limited O +
space O +
between O +
the O +
MHC B-Gene +
helices O +
and O +
thus O +
may O +
interfere O +
with O +
TCR B-Gene -
- O -
MHC B-Gene +
interactions O +
and/or O +
hinder O +
specific O -
- O -
recognition O +
of O +
the O +
carbohydrates O +
by O +
the O +
TCR B-Gene -
. O +

The O +
smaller O +
size O +
of O +
monosaccharides O +
is O +
less O +
likely O +
to O +
disrupt O +
α O -
/ O -
β O +
TCR B-Gene +
interactions O +
within O +
the O +
MHC B-Gene +
binding O +
site O -
, O +
but O +
their O +
relatively O +
low O +
exposure O +
disfavors O +
a O +
carbohydrate O -
- O -
specific O +
γ O -
/ O -
δ O +
T O +
cell O +
response O +
( O -
Figure O +
4 O +
) O -
. O +

Longer O +
oligosaccharide O +
tethers O -
, O +
such O +
as O +
homocysteine O -
, O +
can O +
fully O +
expose O +
bound O +
carbohydrates O +
( O -
Figure O +
3 O +
and O +
Figure O +
4 O +
) O -
. O +

The O +
greater O +
exposure O +
results O +
in O +
facilitated O +
MAb B-Gene +
detection O +
of O +
the O +
sugars O +
and O +
strong O +
generation O +
of O +
carbohydrate O -
- O -
specific O +
CTL O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
, O +
presumably O +
through O +
direct O +
interaction O +
between O +
TCRs B-Gene +
and O +
the O +
carbohydrates O -
. O +

Furthermore O -
, O +
the O +
unobstructed O +
access O +
to O +
the O +
glycan O +
is O +
probably O +
a O +
key O +
factor O +
in O +
generating O +
an O +
MHC B-Gene -
- O -
unrestricted O +
γ O -
/ O -
δ O +
T O +
cell O +
response O -
. O +

Several O +
cross O -
- O -
reactive O +
T O +
cell O +
clones O +
to O +
MHC B-Gene +
bound O +
peptides O +
with O +
chemically O +
TNP O -
- O -
modified O +
lysine O +
residues O +
have O +
been O +
described O +
( O -
Martin O +
et O +
al. O +
1992 O +
) O -
. O +

TNP O +
exposure O -
, O +
when O +
attached O +
to O +
lysine O -
, O +
would O +
be O +
equivalent O +
to O +
that O +
of O +
homocysteine O -
- O -
linked O +
galabiose O -
, O +
and O +
could O +
be O +
responsible O +
for O +
the O +
immunodominance O +
of O +
the O +
TNP O +
epitopes O +
and O +
restriction O +
of O +
the O +
responding O +
T O +
cell O +
repertoire O +
( O -
Hochgeschwender O +
et O +
al. O +
1987 O +
) O -
. O +

Furthermore O -
, O +
the O +
specificity O +
of O +
the O +
cross O -
- O -
reactive O +
T O +
cells O +
only O +
for O +
TNP O -
- O -
lysine O +
located O +
near O +
the O +
center O +
of O +
the O +
peptide O -
, O +
and O +
the O +
freedom O +
of O +
one O +
TNP O -
- O -
specific O +
T O +
cell O +
hybridoma O +
from O +
class O +
II O +
polymophism O -
, O +
mirrors O +
the O +
behavior O +
of O +
carbohydrate O -
- O -
specific O +
CTL O +
( O -
Martin O +
et O +
al. O +
1992 O -
; O +
Kohler O +
et O +
al. O +
1997 O +
) O -
. O +

Thus O -
, O +
central O +
placement O +
and O +
extensive O +
exposure O +
are O +
common O +
factors O +
in O +
MHC O +
antigens O +
that O +
produce O +
enhanced O +
cross O -
- O -
reactivity O -
, O +
reduced O +
MHC O +
restriction O -
, O +
and O +
hapten O -
- O -
specfic O +
recognition O +
by O +
the O +
responding O +
T O +
cell O +
population O -
. O +

Poor O +
or O +
Diminished O +
CTL O +
Reactivity O +
to O +
Large O +
Oligosaccharides O +
and O +
Db B-Gene +
-Bound O +
Galabiose O +
Db B-Gene +
-bound O +
glycopeptides O +
with O +
homocysteine O +
linked O +
galabiose O +
( O -
e.g. O +

Figure O +
3F O +
) O +
are O +
poorly O +
immunogenic O -
, O +
and O +
Kb B-Gene +
-bound O +
glycopeptides O +
presenting O +
homocysteine O -
- O -
linked O +
CD77 O +
or O +
GM3-lactam O +
are O +
less O +
immunogenic O +
than O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
( O -
Table O +
1 O +
; O +
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

Interestingly O -
, O +
these O +
glycopeptide O +
designs O +
could O +
place O +
carbohydrate O +
structures O +
further O +
above O +
the O +
MHC B-Gene +
α1 O +
α2 O +
helices O +
than O +
observed O +
in O +
Kb B-Gene +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
( O -
Figure O +
4 O +
) O -
, O +
as O +
CD77 O +
and O +
GM3-lactam O +
are O +
larger O +
than O +
galabiose O +
by O +
one O +
sugar O +
unit O +
or O +
more O -
. O +

In O +
addition O -
, O +
the O +
Db B-Gene +
-binding O +
glycopeptides O +
have O +
a O +
large O +
arch O +
in O +
the O +
peptide O +
backbone O +
near O +
the O +
C O +
terminus O +
that O +
would O +
futher O +
elevate O +
glycans O +
attached O +
to O +
the O +
bulged O +
residues O +
( O -
Figure O +
3F O +
and O +
Figure O +
4 O +
; O +
Young O +
et O +
al. O +
1994 O +
) O -
. O +

Peptide O +
antigen O +
recognition O +
by O +
α O -
/ O -
β O +
TCR B-Gene +
normally O +
occurs O +
within O +
the O +
α1 O +
α2 O +
helices O +
and O +
may O -
, O +
therefore O -
, O +
fail O +
to O +
entirely O +
encompass O +
these O +
large O +
glycans O -
. O +

Furthermore O -
, O +
carbohydrates O +
outside O +
or O +
atop O +
the O +
α1 O +
α2 O +
helices O +
are O +
likely O +
to O +
disrupt O +
conserved O +
TCR B-Gene -
- O -
MHC B-Gene +
interactions O +
that O +
are O +
important O +
to O +
the O +
docking O -
, O +
orientation O -
, O +
and O +
proper O +
register O +
of O +
the O +
TCR B-Gene +
on O +
the O +
pMHC O +
molecule O +
and O +
hence O +
can O +
explain O +
the O +
reduced O -
, O +
poor O -
, O +
or O +
lack O +
of O +
CTL O +
reactivity O +
to O +
these O +
glycopeptides O +
( O -
Table O +
1 O +
) O -
. O +

γ O -
/ O -
δ O +
T O +
Cell O +
Response O +
to O +
Glycolipid O +
The O +
Kb B-Gene +
/RGY8 O -
- O -
6H O -
- O -
Gal2 O +
crystal O +
structure O +
supports O +
the O +
possibility O +
of O +
distinct O +
γ O -
/ O -
δ O +
CTL O +
stimulation O +
through O +
MHC B-Gene -
- O -
unrestricted O +
γ O -
/ O -
δ O +
TCR B-Gene +
recognition O +
of O +
the O +
exposed O +
carbohydrate O +
haptens O -
. O +

Indeed O -
, O +
the O +
γ O -
/ O -
δ O +
T O +
cells O +
may O +
be O +
directly O +
triggered O +
by O +
corresponding O +
galabiose O -
- O -
presenting O +
glycolipids O +
fused O +
with O +
target O +
cells O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

However O -
, O +
it O +
is O +
unknown O +
whether O +
MHC B-Gene -
- O -
unrestricted O +
antigen O +
binding O +
by O +
γ O -
/ O -
δ O +
TCR B-Gene +
allows O +
triggering O +
and O +
clonal O +
expansion O +
of O +
γ O -
/ O -
δ O +
CTL O +
in O +
the O +
present O +
system O -
. O +

Less O +
exposed O +
oligosaccharides O +
may O +
also O +
be O +
capable O +
of O +
generating O +
γ O -
/ O -
δ O +
CTL O -
, O +
but O +
peptide O +
and O +
MHC B-Gene +
residues O +
are O +
more O +
likely O +
to O +
be O +
in O +
close O +
proximity O +
to O +
these O +
carbohydrates O +
and O +
may O +
inhibit O +
γ O -
/ O -
δ O +
TCR B-Gene +
binding O -
. O +

Interestingly O -
, O +
the O +
inherent O +
linker O +
flexibility O +
of O +
HggP6 O +
in O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
may O +
provide O +
the O +
glycan O +
with O +
the O +
ability O +
to O +
switch O +
between O +
the O +
positions O +
and/or O +
structures O +
best O +
recognized O +
by O +
the O +
two O +
types O +
of O +
TCR B-Gene -
, O +
providing O +
a O +
rationale O +
for O +
the O +
concurrent O +
generation O +
of O +
glycopeptide O -
- O -
specific O +
α O -
/ O -
β O +
CTL O +
and O +
carbohydrate O -
- O -
specific O +
γ O -
/ O -
δ O +
CTL O -
. O +

Implications O +
for O +
T O +
Cell O +
Recognition O +
of O +
Natural O +
Glycopeptides O +
Glycosylation O +
of O +
secreted B-Gene -
, O +
cell B-Gene +
surface I-Gene -
, O +
nuclear B-Gene -
, O +
and O +
cytoplasmic B-Gene +
proteins I-Gene +
( O -
Hart O +
et O +
al. O +
1989 O +
) O +
is O +
a O +
common O +
posttranslational O +
modification O +
that O +
plays O +
a O +
crucial O +
role O +
in O +
molecular O +
structure O +
and O +
stability O -
, O +
masking O +
of O +
microorganism O +
target O +
epitopes O -
, O +
and O +
modulation O +
of O +
specific O +
protein B-Gene +
functions O +
( O -
Varki O +
1993 O +
) O -
. O +

The O +
small O +
number O +
of O +
natural O +
MHC B-Gene +
I O +
bound O +
glycopeptides O +
that O +
have O +
been O +
identified O +
may O +
reflect O +
their O +
limited O +
numbers O +
at O +
the O +
cell O +
surface O +
or O +
the O +
technical O +
difficulties O +
in O +
their O +
detection O +
( O -
Haurum O +
et O +
al. O +
1994 O +
) O -
, O +
but O +
not O +
necessarily O +
their O +
importance O +
in O +
the O +
cellular O +
immune O +
response O +
since O +
T O +
cell O +
avidity O +
for O +
pMHC O +
antigens O +
widely O +
varies O -
. O +

Our O +
results O -
, O +
together O +
with O +
those O +
from O +
other O +
studies O +
of O +
glycopeptide O +
immunogenicity O -
, O +
suggest O +
small O +
carbohydrates O +
( O -
mono O +
or O +
disaccharides O -
) O +
attached O +
to O +
short O -
, O +
centrally O +
placed O +
linkers O +
satisfy O +
α O -
/ O -
β O +
TCR B-Gene +
antigen O +
binding O +
preferences O -
, O +
and O +
that O +
carbohydrates O +
of O +
the O +
same O +
size O +
attached O +
to O +
slightly O +
longer O +
linkers O +
may O +
also O +
satisfy O +
the O +
requirements O +
for O +
γ O -
/ O -
δ O +
TCR B-Gene +
antigen O +
binding O +
( O -
Figure O +
4 O +
) O -
, O +
leading O +
to O +
glycopeptide O +
and O +
carbohydrate O -
- O -
specific O +
T O +
cell O +
responses O -
. O +

Asparagine O -
- O -
linked O +
glycans O +
have O +
a O +
pentasaccharide O +
core O +
decorated O +
by O +
further O +
carbohydrate O +
additions O +
( O -
Kornfeld O +
and O +
Kornfeld O +
1985 O +
) O -
; O +
therefore O -
, O +
the O +
corresponding O +
glycopeptides O +
would O +
not O +
be O +
well O +
suited O +
for O +
carbohydrate O -
- O -
specific O +
CTL O -
. O +

In O +
contrast O -
, O +
many O +
mucins B-Gene +
and O +
other O +
O O -
- O -
linked O +
glycoconjugates O +
found O +
in O +
the O +
cytoplasm O +
and O +
nucleus O +
are O +
composed O +
of O +
mono- O +
or O +
disaccharides O +
attached O +
to O +
serine O -
, O +
threonine O -
, O +
hydroxylysine O +
or O +
tyrosine O +
( O -
Hart O +
et O +
al. O +
1989 O -
; O +
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O +
and O -
, O +
therefore O -
, O +
are O +
more O +
promising O +
natural O +
glycan O +
antigens O +
for O +
T O +
cells O -
. O +

The O +
mucins B-Gene -
, O +
that O +
include O +
the O +
Tn O +
and O +
sialyl O +
Tn O +
epitopes O +
that O +
are O +
present O +
on O +
cancer O +
cells O +
and O +
HIV B-Gene +
envelope I-Gene +
glycoprotein I-Gene +
gp120 I-Gene +
( O -
Hansen O +
et O +
al. O +
1990 O +
) O -
, O +
can O +
be O +
recognized O +
by O +
T O +
cells O +
( O -
Galli O -
- O -
Stampino O +
et O +
al. O +
1997 O +
) O -
. O +

Carbohydrate O +
structures O +
that O +
are O +
not O +
well O +
represented O +
or O +
are O +
poorly O +
immunogenic O +
in O +
normal O +
antigen O +
presentation O +
could O +
also O +
be O +
used O +
in O +
synthetic O +
peptide O +
immunogens O +
to O +
activate O +
defined O -
, O +
carbohydrate O -
- O -
specific O +
T O +
cell O +
populations O -
. O +

The O +
ability O +
to O +
generate O +
or O +
enhance O +
the O +
Ig B-Gene -
- O -
like O -
, O +
MHC B-Gene -
- O -
unrestricted O +
γ O -
/ O -
δ O +
T O +
cell O +
responses O +
to O +
the O +
glycopeptide O +
could O +
further O +
augment O +
T O +
cell O +
surveillance O +
and O +
CTL O +
effector O +
functions O +
against O +
cells O +
presenting O +
the O +
corresponding O +
carbohydrate O +
hapten O -
. O +

Indeed O -
, O +
peptide O -
- O -
based O +
vaccines O +
able O +
to O +
generate O +
carbohydrate O -
- O -
specific O +
CTL O +
have O +
potential O +
clinical O +
applications O +
for O +
treatment O +
of O +
various O +
types O +
of O +
cancer O +
and O +
parasitic O +
infections O +
( O -
Lanzavecchia O +
1993 O -
; O +
Chesnut O +
et O +
al. O +
1995 O +
) O +
by O +
targeting O +
abnormal O +
glycosylation O +
produced O +
by O +
malignant O +
cells O +
or O +
oligosaccharide O +
structures O +
unique O +
to O +
microorganisms O +
( O -
Kaufmann O +
1996 O +
) O -
. O +

Experimental O +
Procedures O +
Carbohydrates O -
, O +
Glycopeptides O -
, O +
and O +
Glycolipids O +
Galabiose O +
( O -
Gal O -
- O -
α O -
( O -
1,4 O -
) O -
Gal O -
- O -
β O +
or O +
Gal2 O +
) O -
, O +
CD77 O +
( O -
Gal O -
- O -
α O -
( O -
1,4 O -
) O -
Gal O -
- O -
β O -
( O -
1,4 O -
) O -
Glc O -
- O -
β O -
) O -
, O +
lactose O +
( O -
Gal O -
- O -
β O -
( O -
1,4 O -
) O -
-Glc O -
- O -
β O -
) O -
, O +
GM3 O +
( O -
NeuAc O -
- O -
α O -
( O -
3 O -
) O -
-GalN O -
- O -
β O -
( O -
1,4 O -
) O -
Glc O -
- O -
β O -
) O -
, O +
and O +
GM3-lactam O +
were O +
synthesized O +
as O +
described O +
( O -
Figure O +
1 O +
; O +
Abdel O -
- O -
Motal O +
et O +
al. O +
1995 O -
; O +
Kihlberg O +
and O +
Elofsson O +
1997 O +
) O -
. O +

Monoclonal B-Gene +
antibodies I-Gene +
specific O +
for O +
the O +
carbohydrates O +
were O +
used O +
to O +
test O +
the O +
expression O +
of O +
carbohydrates O +
on O +
the O +
surface O +
of O +
glycopeptide O -
- O -
treated O +
RMA O -
- O -
S O +
cells O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

Glycopeptides O +
and O +
glycolipids O +
were O +
synthesized O +
and O +
tested O +
for O +
Kb B-Gene +
and O +
Db B-Gene +
-binding O +
capacity O -
, O +
carbohydrate O +
presentation O -
, O +
and O +
stability O +
in O +
vivo O +
as O +
described O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1995 O -
, O +
Abdel O -
- O -
Motal O +
et O +
al. O +
1996 O +
) O -
. O +

CTL O +
Generation O -
, O +
Assay O -
, O +
and O +
Fractionation O +
CTL O +
were O +
generated O +
by O +
immunization O +
of O +
C57BL O -
/ O -
6 O +
mice O +
with O +
100 O +
μg O +
glycopeptide O +
in O +
Freund O -
's O +
incomplete O +
adjuvant O +
at O +
the O +
base O +
of O +
the O +
tail O +
followed O +
by O +
in O +
vitro O +
restimulation O +
of O +
harvested O +
spleen O +
cells O -
, O +
as O +
described O +
( O -
Zhou O +
et O +
al. O +
1992 O +
) O -
. O +

CTL O +
were O +
tested O +
in O +
a O +
short O -
- O -
term O +
4 O +
hr O +
51 O +
Cr O -
- O -
release O +
assay O +
against O +
peptide- O -
, O +
glycopeptide- O +
or O +
glycolipid O -
- O -
treated O +
target O +
cells O -
. O +

Glycolipid O -
- O -
expressing O +
target O +
cells O +
were O +
produced O +
by O +
treatment O +
of O +
target O +
cells O +
with O +
liposomes O +
containing O +
the O +
different O +
glycolipids O +
as O +
described O +
( O -
Abdel O -
- O -
Motal O +
et O +
al. O +
1995 O +
) O -
. O +

CTL O +
populations O +
were O +
fractionated O +
using O +
either O +
anti O -
- O -
α O -
/ O -
β O +
or O +
γ O -
/ O -
δ O +
framework O +
MAb B-Gene +
on O +
magnetic O +
Dynabeads O +
( O -
Dynal O +
A. O +
S. O -
, O +
Norway O -
) O -
. O +

Preparation O +
and O +
Crystallization O +
of O +
the O +
Kb B-Gene +
-Glycopeptide O +
Complex O +
Purified O +
H-2Kb B-Gene +
was O +
incubated O +
with O +
a O +
5-fold O +
molar O +
excess O +
of O +
RGY8 O -
- O -
6H O -
- O -
Gal2 O +
for O +
5 O +
hr O +
at O +
room O +
temperature O +
( O -
see O +
Stura O +
et O +
al. O +
1992 O +
) O -
. O +

Centricon O +
10 O +
ultrafiltration O +
was O +
used O +
to O +
concentrate O +
the O +
MHC B-Gene +
complex O +
and O +
clear O +
any O +
free O +
peptide O +
simultaneously O -
. O +

An O +
exchange O +
of O +
bound O +
peptides O +
was O +
apparent O +
from O +
notable O +
band O +
shifts O +
between O +
treated O +
and O +
untreated O +
samples O +
subjected O +
to O +
IEF O +
electrophoresis O +
( O -
data O +
not O +
shown O -
; O +
see O +
also O +
Stura O +
et O +
al. O +
1992 O +
) O -
. O +

Large O +
single O +
crystals O +
were O +
grown O +
from O +
18 O +
mg O -
/ O -
ml O +
H-2Kb B-Gene +
in O +
2.3 O +
M O +
Na O -
/ O -
K O +
PO4 O +
, O +
2 O -
% O +
2-methyl-2,4-pentanediol O +
( O -
pH O +
6.4 O -
) O -
, O +
with O +
diffraction O +
to O +
approximately O +
2.0 O +
Å O +
resolution O -
. O +

Data O +
Collection O +
and O +
Processing O +
Diffraction O +
data O +
were O +
collected O +
in O +
house O +
from O +
a O +
flash O -
- O -
cooled O +
( O -
130 O +
K O -
, O +
25 O -
% O +
glycerol O -
) O +
single O +
crystal O +
( O -
0.5 O +
× O +
0.5 O +
× O +
0.3 O +
mm O -
) O +
with O +
a O +
30 O +
cm O +
MAR O +
image O +
plate O +
mounted O +
on O +
a O +
Siemens O +
M18X O +
CuKα O +
x O -
- O -
ray O +
generator O +
( O -
300 O +
μm O +
focal O +
cup O -
, O +
50 O +
kV O -
, O +
80 O +
mA O -
) O +
fitted O +
with O +
Supper O +
long O +
double O -
- O -
mirror O +
focusing O +
optics O -
. O +

The O +
data O +
were O +
indexed O +
and O +
integrated O +
with O +
the O +
program O +
DENZO O +
( O -
Otwinowski O +
and O +
Minor O +
1997 O +
) O -
. O +

The O +
crystals O +
are O +
orthorhombic O -
, O +
P21 O +
21 O +
2 O -
, O +
with O +
unit O +
cell O +
dimensions O +
a O +
= O +
135.9 O +
Å O -
, O +
b O +
= O +
86.8 O +
Å O -
, O +
and O +
c O +
= O +
45.0 O +
Å. O +
The O +
Vm O +
( O -
Matthews O +
1968 O +
) O +
of O +
2.86 O +
Å3 O +
Da−1 O +
indicated O +
one O +
molecule O +
per O +
asymmetric O +
unit O +
with O +
a O +
solvent O +
content O +
of O +
57 O -
% O -
. O +

The O +
data O +
were O +
merged O -
, O +
scaled O -
, O +
and O +
reduced O +
to O +
a O +
unique O +
reflection O +
set O +
using O +
the O +
program O +
SCALEPACK O +
( O -
Table O +
3 O +
; O +
Otwinowski O +
and O +
Minor O +
1997 O +
) O -
. O +

Model O +
Refinement O +
A O +
random O +
set O +
of O +
10 O -
% O +
of O +
the O +
reflections O +
between O +
18–2.1 O +
Å O +
were O +
excluded O +
from O +
refinement O +
to O +
monitor O +
Rfree O +
( O -
Brünger O +
1997 O +
) O -
. O +

Only O +
procedures O +
that O +
minimized O +
both O +
Rcryst O +
and O +
Rfree O +
were O +
utilized O -
. O +

Kb O +
/VSV-8 O +
coordinates O +
( O -
Fremont O +
et O +
al. O +
1992 O +
) O +
stripped O +
of O +
peptide O +
were O +
directly O +
refined O +
against O +
the O +
glycopeptide O +
data O +
using O +
X O -
- O -
PLOR O +
v3.851 O +
( O -
Brünger O +
et O +
al. O +
1987 O +
) O -
. O +

Rigid O +
body O +
refinement O +
from O +
8–2.1 O +
Å O +
resolution O +
( O -
F O -
/ O -
σF O +
> O +
2 O -
) O +
gave O +
an O +
Rcryst O +
of O +
36.6 O -
% O +
and O +
an O +
Rfree O +
of O +
35.7 O -
% O -
. O +

One O +
round O +
of O +
refinement O -
, O +
bulk O -
- O -
solvent O +
correction O -
, O +
and O +
model O +
rebuilding O +
was O +
performed O +
using O +
positional O +
minimization O +
and O +
iterative O +
slow O -
- O -
cooled O +
molecular O +
dynamics O +
as O +
implemented O +
in O +
X O -
- O -
PLOR O +
( O -
serial O +
slow O +
coolKleywegt O +
and O +
Jones O +
1997 O +
) O +
before O +
the O +
peptide O +
was O +
traced O +
( O -
Rcryst O +
27.5 O -
% O -
, O +
Rfree O +
32.5 O -
% O -
) O -
. O +

3Fo O +
-2Fc O +
, O +
2Fo O +
-Fc O +
shake O +
omit O +
( O -
McRee O +
1993 O +
) O -
, O +
and O +
shaken O -
, O +
σA O +
-weighted O +
( O -
Read O +
1986 O +
) O +
2Fo O +
-Fc O +
and O +
Fo O +
-Fc O +
electron O +
density O +
maps O +
were O +
computed O +
to O +
reduce O +
phase O +
bias O +
for O +
model O +
rebuilding O -
. O +

Strong O +
density O +
in O +
shaken O -
, O +
σA O +
-weighted O +
Fo O +
-Fc O +
maps O +
was O +
located O +
within O +
the O +
peptide O +
binding O +
groove O +
and O +
included O +
the O +
entire O +
glycosylated O +
homocysteine O +
at O +
position O +
six O +
( O -
HggP6 O -
; O +
Figure O +
2 O +
) O -
. O +

HggP6 O +
was O +
constructed O +
with O +
the O +
help O +
of O +
the O +
hetero O -
- O -
compound O +
libraries O +
( O -
e.g. O -
, O +
homocysteine O +
and O +
galactose O -
) O +
provided O +
by O +
G. O +
Kleywegt O -
's O +
web O +
site O +
( O -
http://alpha2.bmc.uu.se/hicup O +
; O +
Kleywegt O +
1995 O +
) O -
. O +

The O +
Rfree O +
for O +
the O +
outer O +
reflection O +
bin O +
failed O +
to O +
decline O -
, O +
probably O +
due O +
to O +
limited O +
data O +
completeness O -
; O +
therefore O -
, O +
the O +
high O +
resolution O +
limit O +
was O +
reduced O +
to O +
2.2 O +
Å O +
( O -
Table O +
3 O +
) O -
. O +

The O +
coordinates O +
and O +
reflection O +
data O +
( O -
keeping O +
the O +
same O +
Rfree O +
data O +
partition O -
) O +
were O +
converted O +
for O +
use O +
in O +
the O +
SHELXL O +
automated O +
water O +
divining O +
routine O +
( O -
Sheldrick O +
and O +
Schneider O +
1997 O +
) O +
and O +
108 O +
waters O +
were O +
retained O +
after O +
manual O +
inspection O -
. O +

The O +
final O +
rounds O +
of O +
positional O +
and O +
B O -
- O -
value O +
refinement O +
in O +
X O -
- O -
PLOR O +
gave O +
an O +
Rcryst O +
of O +
22.4 O -
% O +
and O +
an O +
Rfree O +
of O +
27.9 O -
% O +
( O -
Table O +
3 O +
) O -
. O +

Structural O +
Analysis O +
and O +
Illustrations O +
The O +
H-2Kb B-Gene +
glycopeptide O +
structure O +
was O +
compared O +
with O +
other O +
Kb B-Gene +
/peptide O +
complexes O +
( O -
PDB O +
accession O +
codes O +
2VAA O -
, O +
2VAB O -
; O +
Fremont O +
et O +
al. O +
1992 O +
) O -
, O +
the O +
H-2Db B-Gene +
/peptide O +
complex O +
( O -
1HOCYoung O +
et O +
al. O +
1994 O +
) O -
, O +
the O +
H-2Ld B-Gene +
/peptide O +
complex O +
( O -
1LDPSpeir O +
et O +
al. O +
1998 O +
) O -
, O +
the O +
HLA B-Gene -
- I-Gene -
A2 I-Gene -
/ O -
Influenza O +
M1 O +
peptide O +
complex O +
( O -
1HHIMadden O +
et O +
al. O +
1993 O +
) O -
, O +
and O +
various O +
complexes O +
of O +
HIV O -
- O -
derived O +
peptides O +
bound O +
to O +
HLA B-Gene +
molecules O +
B35 O -
, O +
B53 O -
, O +
and O +
B8 O +
( O -
1AGEReid O +
et O +
al. O +
1996 O +
; O +
1A1MSmith O +
et O +
al. O +
1996a O +
; O +
1A1NSmith O +
et O +
al. O +
1996b O +
) O -
. O +

PROCHECK O +
( O -
Laskowski O +
et O +
al. O +
1993 O +
) O +
was O +
used O +
to O +
examine O +
polypeptide O +
geometry O -
, O +
PROMOTIF O +
to O +
identify O +
secondary O +
structure O +
elements O +
( O -
Hutchinson O +
and O +
Thornton O +
1996 O +
) O -
, O +
CONTACSYM O +
( O -
Sheriff O +
et O +
al. O +
1987 O +
) O +
to O +
identify O +
van O +
der O +
Waals O +
contacts O +
up O +
to O +
4 O +
Å O +
apart O -
, O +
and O +
HBPLUS O +
( O -
McDonald O +
and O +
Thornton O +
1994 O +
) O +
to O +
locate O +
hydrogen O +
bond O +
pairs O +
using O +
both O +
distance O +
and O +
geometry O +
criteria O -
. O +

Buried O +
surface O +
areas O +
were O +
computed O +
with O +
MS O +
( O -
Connolly O +
1983 O +
) O +
using O +
a O +
1.4 O +
Å O +
radius O +
probe O -
. O +

Figure O +
2 O +
was O +
created O +
using O +
programs O +
O O +
( O -
Jones O +
et O +
al. O +
1991 O +
) O +
and O +
MolView O +
( O -
Smith O +
1995 O +
) O -
. O +

Figure O +
3 O +
was O +
created O +
using O +
MIDAS O +
( O -
Ferrin O +
et O +
al. O +
1988 O +
) O -
.§ O +

To O +
whom O +
correspondence O +
should O +
be O +
addressed O +
( O -
email O -
: O +
mikael.jondal@mtc.ki.se O +
[ O -
M. O +
J. O -
] O -
, O +
wilson@scripps.edu O +
[ O -
I. O +
A. O +
W. O -
] O -
) O -
. O +

Acknowledgements O +

We O +
thank O +
Wendy O +
Havran O +
for O +
critically O +
reading O +
the O +
manuscript O +
and O +
helpful O +
discussions O -
, O +
Andreas O +
Heine O +
for O +
assistance O +
with O +
program O +
SHELXL O -
, O +
and O +
David O +
Jewell O +
for O +
technical O +
assistance O -
. O +

This O +
study O +
was O +
supported O +
by O +
National O +
Institutes O +
of O +
Health O +
grants O +
CA58896 O +
( O -
I. O +
A. O +
W. O -
) O -
, O +
AI42266 O +
( O -
I. O +
A. O +
W. O -
) O -
, O +
and O +
a O +
postdoctoral O +
fellowship O +
from O +
National O +
Institutes O +
of O +
Health O +
training O +
grant O +
MH19185 O +
( O -
J. O +
A. O +
S. O -
) O -
. O +

This O +
is O +
manuscript O +
# O -
11737-MB O +
from O +
The O +
Scripps O +
Research O +
Institute O -
. O +

3,4-Dihydroxyphenylalanine B-Gene +
( I-Gene -
Dopa I-Gene -
) I-Gene +
decarboxylase I-Gene +
is O +
a O +
stereospecific O +
pyridoxal B-Gene +
5'-phosphate I-Gene +
( I-Gene -
PLP I-Gene -
) I-Gene -
-dependent I-Gene +
alpha I-Gene -
- I-Gene -
decarboxylase I-Gene +
that O +
converts O +
L O -
- O -
aromatic O +
amino O +
acids O +
into O +
their O +
corresponding O +
amines O -
. O +

We O +
now O +
report O +
that O +
reaction O +
of O +
the O +
enzyme B-Gene +
with O +
D-5-hydroxytryptophan O +
or O +
D O -
- O -
Dopa O +
results O +
in O +
a O +
time O -
- O -
dependent O +
inactivation O +
and O +
conversion O +
of O +
the O +
PLP O +
coenzyme O +
to O +
pyridoxamine O +
5'-phosphate O +
and O +
PLP O -
- O -
D O -
- O -
amino O +
acid O +
Pictet O -
- O -
Spengler O +
adducts O -
, O +
which O +
have O +
been O +
identified O +
by O +
high O +
performance O +
liquid O +
chromatography O -
. O +

We O +
also O +
show O +
that O +
the O +
reaction O +
specificity O +
of O +
Dopa B-Gene +
decarboxylase I-Gene +
toward O +
aromatic O +
amines O +
depends O +
on O +
the O +
experimental O +
conditions O -
. O +

Whereas O +
oxidative O +
deamination O +
occurs O +
under O +
aerobic O +
conditions O +
( O -
Bertoldi O -
, O +
M. O -
, O +
Moore O -
, O +
P. O +
S. O -
, O +
Maras O -
, O +
B. O -
, O +
Dominici O -
, O +
P. O -
, O +
and O +
Borri O +
Voltattorni O -
, O +
C. O +
( O -
1996 O -
) O +
J. O +
Biol O -
. O +

Chem O -
. O +
271 O -
, O +
23954 O -
- O -
23959 O -
; O +
Bertoldi O -
, O +
M. O -
, O +
Dominici O -
, O +
P. O -
, O +
Moore O -
, O +
P. O +
S. O -
, O +
Maras O -
, O +
B. O -
, O +
and O +
Borri O +
Voltattorni O -
, O +
C. O +
( O -
1998 O -
) O +
Biochemistry O +
37 O -
, O +
6552 O -
- O -
6561 O -
) O -
, O +
half O -
- O -
transamination O +
and O +
Pictet O -
- O -
Spengler O +
reactions O +
take O +
place O +
under O +
anaerobic O +
conditions O -
. O +

Moreover O -
, O +
we O +
examined O +
the O +
reaction O +
specificity O +
of O +
nicked O +
Dopa B-Gene +
decarboxylase I-Gene -
, O +
obtained O +
by O +
selective O +
tryptic O +
cleavage O +
of O +
the O +
native O +
enzyme B-Gene +
between O +
Lys334 O +
and O +
His335 O -
. O +

Although O +
this O +
enzymatic O +
species O +
does O +
not O +
exhibit O +
either O +
decarboxylase O +
or O +
oxidative O +
deamination O +
activities O -
, O +
it O +
retains O +
a O +
large O +
percentage O +
of O +
the O +
native O +
transaminase O +
activity O +
toward O +
D O -
- O -
aromatic O +
amino O +
acids O +
and O +
displays O +
a O +
slow O +
transaminase O +
activity O +
toward O +
aromatic O +
amines O -
. O +

These O +
transamination O +
reactions O +
occur O +
concomitantly O +
with O +
the O +
formation O +
of O +
cyclic O +
coenzyme O -
- O -
substrate O +
adducts O -
. O +

Together O +
with O +
additional O +
data O -
, O +
we O +
thus O +
suggest O +
that O +
native O +
Dopa B-Gene +
decarboxylase I-Gene +
can O +
exist O +
as O +
an O +
equilibrium O +
among O +
" O -
open O -
, O -
" O +
" O -
half O -
- O -
open O -
, O -
" O +
and O +
" O -
closed O -
" O +
forms O -
. O +

Diazaborine O +
and O +
isoniazid O +
are O -
, O +
at O +
first O +
sight O -
, O +
unrelated O +
anti O -
- O -
bacterial O +
agents O +
that O +
inhibit O +
the O +
enoyl B-Gene -
- I-Gene -
ACP I-Gene +
reductase I-Gene +
( O -
ENR B-Gene -
) O +
of O +
Escherichia O +
coli O +
and O +
Mycobacterium O +
tuberculosis O +
respectively O -
. O +

The O +
crystal O +
structures O +
of O +
these O +
enzymes B-Gene +
including O +
that O +
of O +
the O +
diazaborine O -
- O -
inhibited O +
E. O +
coli O +
ENR B-Gene +
have O +
been O +
obtained O +
at O +
high O +
resolution O -
. O +

Site O -
- O -
directed O +
mutagenesis O +
was O +
used O +
to O +
study O +
the O +
importance O +
of O +
amino O +
acid O +
residues O +
in O +
diazaborine O +
susceptibility O +
and O +
enzyme B-Gene +
function O -
. O +

The O +
results O +
show O +
that O +
drug O +
binding O +
and O +
inhibition O +
require O +
the O +
presence O +
of O +
a O +
glycine O +
residue O +
at O +
position O +
93 O +
of O +
E. O +
coli O +
ENR B-Gene +
or O +
at O +
the O +
structurally O +
equivalent O +
position O +
in O +
the O +
plant O +
homologue O -
, O +
which O +
is O +
naturally O +
resistant O +
to O +
the O +
drug O -
. O +

The O +
data O +
confirm O +
the O +
hypothesis O +
that O +
any O +
amino O +
acid O +
side O -
- O -
chain O +
other O +
than O +
hydrogen O +
at O +
this O +
position O +
within O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
these O +
enzymes B-Gene +
will O +
affect O +
diazaborine O +
resistance O +
by O +
encroaching O +
into O +
the O +
drug O +
binding O +
site O -
. O +

Substitutions O +
of O +
Gly-93 O +
by O +
amino O +
acids O +
with O +
small O +
side O -
- O -
chains O -
, O +
such O +
as O +
serine O -
, O +
alanine O -
, O +
cysteine O +
and O +
valine O -
, O +
hardly O +
affected O +
the O +
catalytic O +
parameters O +
and O +
rendered O +
the O +
bacterial O +
host O +
resistant O +
to O +
the O +
drug O -
. O +

Larger O +
amino O +
acid O +
side O -
- O -
chains O -
, O +
such O +
as O +
that O +
of O +
arginine O -
, O +
histidine O -
, O +
lysine O +
and O +
glutamine O -
, O +
completely O +
inactivated O +
the O +
activity O +
of O +
the O +
enzyme B-Gene -
. O +

OBJECTIVE O -
: O +
To O +
examine O +
exposure O -
- O -
response O +
relationships O +
in O +
the O +
occurrence O +
of O +
symptoms O +
of O +
the O +
eyes O +
and O +
airways O +
in O +
workers O +
exposed O +
to O +
methyltetrahydrophthalic O +
anhydride O +
( O -
MTHPA O -
) O -
. O +

METHODS O -
: O +
A O +
population O +
of O +
111 O +
workers O +
from O +
2 O +
condenser O +
plants O +
( O -
A O +
and O +
B O -
) O +
using O +
epoxy O +
resin O +
with O +
MTHPA O +
underwent O +
a O +
questionnaire O +
survey O +
and O +
serology O +
investigations O -
, O +
and O +
data O +
obtained O +
on O +
95 O +
subjects O +
in O +
assembly O +
and O +
inspection O +
lines O +
were O +
analyzed O +
for O +
this O +
study O -
. O +

RESULTS O -
: O +
In O +
all O -
, O +
24 O +
( O -
65 O -
% O -
) O +
of O +
37 O +
workers O +
in O +
plant O +
A O +
and O +
38 O +
( O -
66 O -
% O -
) O +
of O +
58 O +
workers O +
in O +
plant O +
B O +
had O +
positive O +
MTHPA O -
- O -
specific O +
IgE. O +
The O +
air O +
levels O +
of O +
MTHPA O +
detected O +
in O +
assembly O +
and O +
inspection O +
lines O +
were O +
higher O +
in O +
plant O +
A O +
than O +
in O +
plant O +
B O +
( O -
geometric O +
mean O +
25.5 O -
- O -
63.9 O +
and O +
4.93 O -
- O -
5.49 O +
microg O -
/ O -
m3 O -
, O +
respectively O -
) O -
. O +

IgE O -
- O -
sensitized O +
workers O +
in O +
each O +
plant O +
had O +
significantly O +
( O -
P O +
< O +
0.05 O -
) O +
more O +
complaints O +
regarding O +
the O +
eyes O +
and O +
nose O +
than O +
did O +
unsensitized O +
workers O -
, O +
suggesting O +
that O +
there O +
is O +
an O +
IgE O -
- O -
mediated O +
mechanism O +
in O +
most O +
of O +
these O +
symptoms O -
. O +

The O +
sensitized O +
workers O +
in O +
plant O +
A O +
had O +
higher O +
frequencies O +
for O +
symptoms O +
of O +
the O +
eyes O -
, O +
nose O -
, O +
and O +
pharynx O +
than O +
did O +
those O +
in O +
plant O +
B O +
( O -
P O +
< O +
0.02 O -
) O -
. O +

Furthermore O -
, O +
only O +
15 O -
% O +
of O +
persons O +
often O +
displayed O +
work O -
- O -
related O +
symptoms O +
among O +
the O +
20 O +
symptomatic O +
workers O +
in O +
plant O +
B O +
as O +
compared O +
with O +
73 O -
% O +
of O +
the O +
26 O +
symptomatic O +
workers O +
in O +
plant O +
A O +
( O -
P O +
< O +
0.0001 O -
) O -
. O +

These O +
results O +
can O +
be O +
explained O +
by O +
the O +
difference O +
in O +
the O +
MTHPA O +
levels O +
measured O +
in O +
the O +
lines O +
between O +
the O +
two O +
plants O -
. O +

In O +
plant O +
B O +
the O +
minimal O +
level O +
of O +
MTHPA O +
that O +
was O +
associated O +
with O +
work O -
- O -
related O +
symptoms O +
was O +
15 O -
- O -
22 O +
microg O -
/ O -
m3 O -
, O +
which O +
was O +
lower O +
than O +
the O +
geometric O +
mean O +
levels O +
detected O +
in O +
assembly O +
and O +
inspection O +
lines O +
in O +
plant O +
A. O +
CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O +
MTHPA O +
exposure O +
at O +
levels O +
above O +
15 O +
microg O -
/ O -
m3 O +
should O +
be O +
avoided O +
to O +
prevent O +
the O +
development O +
of O +
occupational O +
allergic O +
diseases O +
in O +
most O +
workers O -
. O +

We O +
investigated O +
the O +
protective O +
effect O +
of O +
fluvastatin O +
sodium O +
on O +
the O +
oxidation O +
of O +
low B-Gene -
- I-Gene -
density I-Gene +
lipoprotein I-Gene +
( O -
LDL B-Gene -
) O +
induced O +
in O +
vitro O +
by O +
copper O +
ions O -
. O +

The O +
extent O +
of O +
lipid O +
peroxidation O +
was O +
assessed O +
by O +
monitoring O +
the O +
increase O +
of O +
UV O +
absorbance O +
at O +
234 O +
nm O -
, O +
which O +
is O +
the O +
peak O +
absorbance O +
of O +
a O +
conjugated O +
diene O -
. O +

Fluvastatin O +
sodium O +
( O -
1 O -
- O -
30 O +
microM O -
) O +
not O +
only O +
prolonged O +
the O +
lag O +
time O +
of O +
oxidation O +
in O +
the O +
initiation O +
step O -
, O +
but O +
also O +
decreased O +
the O +
rate O +
of O +
oxidation O +
in O +
the O +
propagation O +
step O -
, O +
both O +
concentration O +
dependently O -
. O +

Fluvastatin O +
sodium O +
and O +
alpha O -
- O -
tocopherol O +
showed O +
an O +
additive O +
effect O +
when O +
both O +
compounds O +
were O +
added O +
before O +
oxidation O -
. O +

However O -
, O +
when O +
the O +
lag O +
time O +
was O +
prolonged O +
initially O +
by O +
alpha O -
- O -
tocopherol O -
, O +
and O +
fluvastatin O +
sodium O +
and O +
alpha O -
- O -
tocopherol O -
, O +
were O +
further O +
added O +
into O +
the O +
reaction O +
mixture O +
at O +
the O +
end O +
point O +
of O +
the O +
lag O +
phase O -
, O +
fluvastatin O +
sodium O +
still O +
showed O +
an O +
antioxidative O +
effect O -
, O +
whereas O +
alpha O -
- O -
tocopherol O +
showed O +
a O +
pro O -
- O -
oxidative O +
effect O -
. O +

Therefore O -
, O +
the O +
antioxidative O +
property O +
of O +
fluvastatin O +
sodium O +
differs O +
from O +
that O +
of O +
alpha O -
- O -
tocopherol O -
. O +

In O +
this O +
experiment O -
, O +
as O +
neither O +
the O +
double O +
bond O -
- O -
reduced O +
derivative O +
of O +
fluvastatin O +
sodium O +
nor O +
pravastatin O +
sodium O +
showed O +
any O +
protective O +
effect O -
, O +
we O +
concluded O +
that O +
the O +
antioxidative O +
effect O +
of O +
fluvastatin O +
sodium O +
is O +
not O +
a O +
common O +
property O +
of O +
3-hydroxy-3-methylglutaryl B-Gene +
coenzyme I-Gene +
A I-Gene +
( I-Gene -
HMG I-Gene -
- I-Gene -
CoA I-Gene -
) I-Gene +
reductase I-Gene +
inhibitors O -
, O +
but O +
may O +
be O +
derived O +
from O +
its O +
unique O +
chemical O +
structure O -
. O +

Since O +
the O +
oxidative O +
modification O +
of O +
LDL B-Gene +
plays O +
an O +
important O +
role O +
in O +
the O +
genesis O +
of O +
atherosclerosis O -
, O +
fluvastatin O +
sodium O +
may O +
help O +
reduce O +
the O +
risk O +
of O +
atherosclerosis O -
, O +
not O +
only O +
by O +
reducing O +
plasma O +
LDL B-Gene +
levels O +
but O +
also O +
by O +
protecting O +
LDL B-Gene +
from O +
oxidative O +
modification O -
. O +

Oxaliplatin O +
( O -
4 O +
mg O -
/ O -
kg O -
) O -
, O +
cisplatin O +
( O -
2 O +
mg O -
/ O -
kg O +
with O +
20 O +
mg O -
/ O -
kg O +
mannitol O -
) O +
and O +
ormaplatin O +
( O -
2 O +
mg O -
/ O -
kg O -
) O +
were O +
administered O +
i.p O -
. O +

twice O +
weekly O +
for O +
4.5 O +
weeks O -
. O +

Lactose O +
injections O +
( O -
0.9 O -
% O -
) O +
were O +
used O +
as O +
a O +
control O +
for O +
oxaliplatin O +
and O +
0.9 O -
% O +
saline O +
injections O +
were O +
used O +
as O +
a O +
control O +
for O +
cisplatin O +
and O +
ormaplatin O -
. O +

Morphometric O +
changes O +
to O +
dorsal O +
root O +
ganglia O +
L4-L6 O +
were O +
quantitated O +
as O +
a O +
measure O +
of O +
neurotoxicity O -
. O +

Drug O +
treatment O +
resulted O +
in O +
a O +
decrease O +
in O +
cell O +
and O +
nuclear O +
area O +
and O +
an O +
increase O +
in O +
the O +
percentage O +
of O +
cells O +
with O +
eccentric O +
nucleoli O +
for O +
neuronal O +
cell O +
bodies O +
in O +
the O +
DRG O -
. O +

Immediately O +
following O +
treatment O +
the O +
order O +
of O +
morphometric O +
changes O +
was O +
ormaplatin O +
> O +
cisplatin O +
> O +
or O +
= O +
oxaliplatin O -
. O +

The O +
accumulation O +
of O +
platinum O +
in O +
the O +
DRG O +
was O +
measured O +
by O +
inductively O +
coupled O +
plasma O +
mass O +
spectrometry O -
. O +

The O +
order O +
of O +
accumulation O +
was O +
cisplatin O +
> O +
oxaliplatin O +
> O +
ormaplatin O -
. O +

Following O +
an O +
8-week O +
recovery O +
period O +
the O +
order O +
of O +
morphometric O +
changes O +
to O +
the O +
DRG O +
was O +
ormaplatin O +
approximately O +
equal O +
to O +
oxaliplatin O +
> O +
cisplatin O -
. O +

This O +
correlated O +
with O +
a O +
greater O +
retention O +
of O +
platinum O +
by O +
the O +
DRG O +
for O +
ormaplatin O +
and O +
oxaliplatin O +
than O +
for O +
cisplatin O -
. O +

The O +
results O +
suggest O +
that O +
ormaplatin O +
is O +
uniquely O +
neurotoxic O +
immediately O +
following O +
treatment O +
in O +
the O +
Wistar O +
rat O +
model O -
. O +

However O -
, O +
following O +
an O +
8-week O +
recovery O +
period O +
both O +
ormaplatin O +
and O +
oxaliplatin O +
are O +
more O +
neurotoxic O +
than O +
cisplatin O +
and O +
this O +
neurotoxicity O +
correlates O +
with O +
a O +
greater O +
retention O +
of O +
platinum O +
by O +
the O +
DRG O -
. O +

1,2-Dichlorobenzene O +
( O -
1,2-DCB O -
) O +
is O +
a O +
potent O +
hepatotoxicant O +
in O +
male O +
Fischer O +
344 O +
( O -
F344 O -
) O +
rats O +
and O +
previous O +
studies O +
have O +
suggested O +
that O +
reactive O +
oxygen O +
species O +
may O +
play O +
a O +
role O +
in O +
the O +
development O +
of O +
hepatotoxicity O -
. O +

Since O +
reactive O +
oxygen O +
species O +
can O +
damage O +
lipid O +
membranes O -
, O +
this O +
study O +
was O +
conducted O +
to O +
determine O +
the O +
extent O +
of O +
lipid O +
peroxidation O +
after O +
administration O +
of O +
1,2-DCB O +
by O +
immuno O -
- O -
histochemical O +
analysis O +
of O +
4-hydroxynonenal B-Gene +
( I-Gene -
4-HNE I-Gene -
) I-Gene +
protein I-Gene +
adduct I-Gene +
formation O +
in O +
liver O +
and O +
conjugated O +
diene O +
formation O +
in O +
liver O +
and O +
serum O -
. O +

The O +
contribution O +
of O +
Kupffer O +
cells O +
to O +
the O +
lipid O +
peroxidation O +
was O +
also O +
investigated O -
. O +

Male O +
F344 O +
rats O +
were O +
administered O +
1,2-DCB O +
( O -
3.6 O +
mmol O -
/ O -
kg O +
i.p O -
. O +

in O +
corn O +
oil O -
) O +
and O +
killed O +
at O +
selected O +
times O +
between O +
3 O +
and O +
48 O +
h. O +
Time O +
course O +
studies O +
revealed O +
the O +
greatest O +
abundance O +
of O +
4-HNE B-Gene +
protein I-Gene +
adducts I-Gene +
in O +
the O +
centrilobular O +
regions O +
of O +
the O +
liver O +
24 O +
h O +
after O +
1,2-DCB O +
administration O -
, O +
with O +
much O +
lower O +
levels O +
at O +
16 O +
h. O +
Adducts O +
were O +
present O +
in O +
necrotic O +
and O +
vacuolized O +
centrilobular O +
hepatocytes O +
of O +
1,2-DCB O +
treated O +
rats O +
but O +
not O +
in O +
livers O +
of O +
controls O -
. O +

Further O -
, O +
conjugated O +
dienes O +
were O +
significantly O +
increased O +
in O +
liver O +
and O +
serum O +
16 O +
and O +
24 O +
h O +
after O +
1,2-DCB O +
administration O -
, O +
peaking O +
at O +
24 O +
h. O +
These O +
data O +
correlated O +
with O +
hepatocellular O +
injury O -
, O +
determined O +
by O +
serum O +
alanine B-Gene +
aminotransferase I-Gene +
activity O +
and O +
histopathological O +
evaluation O -
, O +
which O +
was O +
markedly O +
elevated O +
within O +
16 O +
h O +
and O +
peaked O +
at O +
24 O +
h. O +
When O +
rats O +
were O +
pretreated O +
with O +
gadolinium O +
chloride O +
( O -
GdCl3 O -
; O +
10 O +
mg O -
/ O -
kg O +
i.v O -
. O +

24 O +
h O +
prior O +
to O +
1,2-DCB O -
) O -
, O +
an O +
inhibitor O +
of O +
Kupffer O +
cells O -
, O +
hepatotoxicity O +
was O +
decreased O +
by O +
89 O +
and O +
86 O -
% O -
, O +
at O +
16 O +
and O +
24 O +
h O -
, O +
respectively O -
. O +

Conjugated O +
diene O +
concentrations O +
were O +
decreased O +
to O +
control O +
values O +
at O +
these O +
times O +
after O +
1,2-DCB O +
administration O -
. O +

Moreover O -
, O +
no O +
4-HNE B-Gene +
protein I-Gene +
adducts I-Gene +
were O +
detected O +
in O +
livers O +
of O +
1,2-DCB O -
- O -
treated O +
rats O +
pretreated O +
with O +
GdCl3 O -
. O +

Finally O -
, O +
Kupffer O +
cells O +
isolated O +
from O +
1,2-DCB O -
- O -
treated O +
rats O +
produced O +
significantly O +
more O +
superoxide O +
anion O +
than O +
Kupffer O +
cells O +
isolated O +
from O +
vehicle O +
controls O -
. O +

These O +
data O -
, O +
along O +
with O +
previous O +
findings O -
, O +
suggest O +
that O +
lipid O +
peroxidation O +
associated O +
with O +
1,2-DCB O +
is O +
mediated O +
in O +
part O +
by O +
Kupffer O +
cell O -
- O -
derived O +
reactive O +
oxygen O +
species O -
. O +

The O +
crystal O +
structure O +
of O +
gliclazide O -
, O +
N- O -
[ O -
( O -
perhydrocyclopenta O +
[ O -
c O -
] O -
pyrrol-2-yl O -
) O -
aminocarbonyl O -
] O -
-p O -
- O -
toluenesulfonamide O -
, O +
C15H21B3O3S O -
, O +
a O +
second O -
- O -
generation O +
oral O +
hypoglycemic O +
agent O -
, O +
contains O +
discrete O +
molecules O +
with O +
normal O +
molecular O +
dimensions O -
. O +

Both O +
of O +
the O +
five O -
- O -
membered O +
fused O +
rings O +
adopt O +
envelope O +
conformations O -
. O +

The O +
molecules O +
are O +
linked O +
into O +
chains O +
by O +
intermolecular O +
hydrogen O +
bonds O +
involving O +
amino O -
- O -
H O +
atoms O -
, O +
with O +
N O -
... O -
O O +
separations O +
of O +
2.967 O +
( O -
3 O -
) O +
and O +
2.949 O +
( O -
3 O -
) O +
A. O +

By O +
assaying O +
lactate B-Gene +
dehydrogenase I-Gene +
and O +
malondialdehyde O +
leakage O +
from O +
LLC O -
- O -
PK1 O +
cells O +
in O +
culture O -
, O +
a O +
study O +
was O +
conducted O +
to O +
clarify O +
whether O +
flavonoid O +
compounds O +
ameliorate O +
renal O +
cellular O +
injury O -
. O +

The O +
cells O +
were O +
cultured O +
with O +
various O +
concentrations O +
of O +
samples O +
under O +
routine O +
conditions O -
. O +

The O +
results O +
demonstrated O +
that O +
baicalin O -
, O +
cirsimaritin O -
, O +
6-hydroxyluteolin O -
, O +
luteolin O -
, O +
plantaginin O -
, O +
rhoifolin O -
, O +
sorbarin O -
, O +
afzelin O -
, O +
hyperin O -
, O +
isoquercitrin O -
, O +
isorhamnetin O -
, O +
kaempferitrin O -
, O +
kaempferol-7-glucoside O -
, O +
oxyayanin O +
A O -
, O +
quercetin O -
, O +
quercitrin O -
, O +
rhamnetin O +
and O +
rutin O +
exerted O +
marked O +
protective O +
effects O +
on O +
the O +
cells O -
, O +
whereas O +
acacetin O -
, O +
apigenin O -
, O +
apiin O -
, O +
cirsilineol O -
, O +
genkwanin O -
, O +
pectolinarin O +
and O +
tetramethylquercitin O +
had O +
virtually O +
no O +
effect O -
. O +

In O +
the O +
light O +
of O +
these O +
findings O -
, O +
we O +
propose O +
that O +
the O +
general O +
capability O +
of O +
these O +
compounds O +
is O +
largely O +
decided O +
by O +
the O +
number O +
and O +
position O +
of O +
phenolic O +
hydroxyl O +
groups O +
linked O +
to O +
the O +
structural O +
backbone O -
. O +

Dopamine B-Gene +
D4-like I-Gene +
binding I-Gene +
sites I-Gene +
are O +
abundant O +
in O +
human O +
cerebral O +
cortex O +
as O +
detected O +
by O +
[ O -
3H O -
] O -
nemonapride O -
. O +

The O +
extremely O +
low O +
density O +
of O +
D4 B-Gene +
mRNA O +
in O +
human O +
cerebral O +
cortex O +
is O +
inconsistent O +
with O +
the O +
high O +
amount O +
of O +
D4-like B-Gene +
binding I-Gene +
sites I-Gene -
. O +

To O +
investigate O +
the O +
nature O +
of O +
the O +
D4-like B-Gene +
receptors I-Gene -
, O +
[ B-Gene -
3H I-Gene -
] I-Gene -
nemonapride I-Gene +
binding I-Gene +
sites I-Gene +
in O +
the O +
nonhuman O +
primate O +
cerebral O +
cortex O +
were O +
characterized O -
. O +

Although O +
[ B-Gene -
3H I-Gene -
] I-Gene -
nemonapride I-Gene +
binding I-Gene +
sites I-Gene +
were O +
D4-like O -
, O +
displaceable O +
by O +
clozapine O +
but O +
not O +
raclopride O -
, O +
[ O -
3H O -
] O -
nemonapride O +
binding O +
was O +
not O +
displaced O +
by O +
selective O +
D4 O +
antagonists O +
but O +
was O +
displaced O +
by O +
the O +
selective O +
5-HT2A B-Gene +
antagonist O +
MDL100907 O -
. O +

Using O +
[ O -
3H O -
] O -
ketanserin O +
as O +
a O +
5-HT2A B-Gene +
ligand O -
, O +
nemonapride O +
showed O +
high O +
affinity O +
for O +
monkey O +
( O -
Ki O +
= O +
10.4 O +
nM O -
) O +
and O +
cloned O +
human O +
( O -
Ki O +
= O +
9.4 O +
nM O -
) O +
5-HT2A B-Gene +
receptors I-Gene -
, O +
while O +
its O +
affinity O +
for O +
rat O +
receptors B-Gene +
was O +
lower O +
( O -
Ki O +
= O +
140 O +
nM O -
) O -
. O +

The O +
present O +
study O +
demonstrates O +
that O +
cerebral O +
cortical O +
D4-like B-Gene +
binding I-Gene +
sites I-Gene +
labeled O +
by O +
[ O -
3H O -
] O -
nemonapride O +
in O +
nonhuman O +
primates O +
consist O +
of O +
a O +
very O +
small O +
portion O +
of O +
D4 B-Gene -
, O +
but O +
a O +
substantial O +
portion O +
of O +
5-HT2A B-Gene +
receptors I-Gene -
. O +

The O +
unexpectedly O +
high O +
affinity O +
of O +
nemonapride O +
for O +
primate O +
5-HT2A B-Gene +
receptor I-Gene +
suggests O +
reconsidering O +
previous O +
data O +
from O +
other O +
studies O +
using O +
[ O -
3H O -
] O -
nemonapride O -
, O +
particularly O +
those O +
on O +
D4-like B-Gene +
receptors I-Gene -
. I-Gene +

The O +
concentrations O +
of O +
adrenaline O -
, O +
noradrenaline O -
, O +
dopamine O -
, O +
aldosterone O -
, O +
the O +
atrial O +
natriuretic O +
hormone O -
, O +
and O +
plasma O +
renin O +
activity O +
were O +
investigated O +
in O +
50 O +
patients O +
with O +
mild O +
chronic O +
heart O +
failure O -
. O +

The O +
patients O +
received O +
oral O +
digoxin O +
chronically O +
in O +
a O +
daily O +
dose O +
of O +
0.125 O +
mg O -
. O +

On O +
the O +
basis O +
of O +
the O +
estimate O +
of O +
the O +
dosing O +
of O +
digoxin O +
these O +
patients O +
were O +
divided O +
into O +
two O +
groups O -
: O +
the O +
first O +
with O +
therapeutic O +
and O +
the O +
second O +
with O +
subtherapeutic O +
concentrations O +
of O +
digoxin O +
in O +
serum O -
. O +

The O +
therapeutic O +
concentration O +
of O +
digoxin O +
in O +
serum O +
was O +
found O +
in O +
23 O +
patients O +
( O -
46 O -
% O -
) O -
, O +
while O +
subtherapeutic O +
levels O +
were O +
found O +
in O +
27 O +
patients O +
( O -
54 O -
% O -
) O -
. O +

The O +
concentrations O +
of O +
noradrenaline O -
, O +
dopamine O -
, O +
the O +
renin B-Gene +
activity O +
of O +
plasma O -
, O +
aldosterone O +
and O +
the O +
atrial B-Gene +
natriuretic I-Gene +
hormone I-Gene +
in O +
the O +
blood O +
serum O +
in O +
the O +
group O +
of O +
patients O +
in O +
whom O +
the O +
presence O +
of O +
subtherapeutic O +
concentrations O +
of O +
digoxin O +
was O +
found O -
, O +
did O +
not O +
differ O +
essentially O +
from O +
the O +
concentration O +
that O +
was O +
observed O +
in O +
the O +
group O +
with O +
therapeutic O +
concentrations O -
. O +

Only O +
the O +
concentration O +
of O +
adrenaline O +
was O +
higher O +
( O -
p O +
< O +
0.05 O -
) O +
in O +
the O +
group O +
of O +
patients O +
with O +
therapeutic O +
concentrations O +
of O +
digoxin O -
. O +

The O +
above O +
results O +
reveal O +
that O +
the O +
neuroendocrine O +
activity O +
of O +
plasma O +
( O -
except O +
for O +
the O +
concentration O +
of O +
adrenaline O -
) O +
is O +
alike O +
in O +
both O +
ranges O +
of O +
digoxin O +
concentrations O +
in O +
serum O -
. O +

Three O +
series O +
of O +
cycloalkanecarboxylic O +
esters O +
derived O +
from O +
the O +
naturally O +
occurring O +
clavine O +
alkaloids O +
lysergol O -
, O +
dihydrolysergol O -
- O -
I O -
, O +
and O +
elymoclavine O +
were O +
synthesized O +
to O +
study O +
their O +
interaction O +
with O +
5-HT2A B-Gene +
receptors I-Gene +
and O +
alpha1-adrenoceptors B-Gene +
in O +
rat O +
tail O +
artery O +
and O +
aorta O -
, O +
respectively O -
. O +

Especially O +
cycloalkanecarboxylic O +
esters O +
derived O +
from O +
lysergol O +
showed O +
complex O +
behavior O +
as O +
partial O +
agonists O +
and O +
antagonists O +
of O +
the O +
contractile O +
effect O +
of O +
5-HT O -
. O +

Within O +
this O +
group O -
, O +
partial O +
5-HT2A B-Gene +
receptor I-Gene +
agonist O +
activity O +
was O +
most O +
potent O +
for O +
cyclopropanecarboxylic O +
ester O +
6a O +
( O -
pKP O +
= O +
7.67 O -
, O +
alpha O +
= O +
0.21 O -
) O +
and O +
decreased O +
as O +
the O +
volume O +
requirement O +
of O +
the O +
alicyclic O +
ring O +
increased O -
. O +

This O +
tendency O +
was O +
echoed O +
in O +
experiments O +
where O +
the O +
compounds O +
were O +
used O +
as O +
antagonists O +
of O +
the O +
contractile O +
effect O +
of O +
5-HT O -
. O +

From O +
the O +
structure O -
- O -
activity O +
study O -
, O +
the O +
N-1-isopropyl O +
homologue O +
of O +
6a O -
, O +
compound O +
6b O -
, O +
emerged O +
as O +
the O +
ligand O +
with O +
the O +
highest O +
affinity O +
for O +
rat O +
5-HT2A B-Gene +
receptors I-Gene +
( O -
pA2 O +
= O +
8.74 O -
) O -
. O +

For O +
cycloalkanecarboxylic O +
esters O +
derived O +
from O +
dihydrolysergol O -
- O -
I O +
and O +
elymoclavine O -
, O +
no O +
clear O +
structure O -
- O -
affinity O +
relationship O +
could O +
be O +
deduced O -
, O +
although O +
those O +
compounds O +
that O +
had O +
smaller O +
cycloalkyl O +
rings O +
in O +
the O +
acyl O +
portion O +
and O +
an O +
isopropyl O +
substituent O +
at O +
N-1 O +
showed O +
the O +
highest O +
5-HT2A B-Gene +
receptor I-Gene +
affinity O -
. O +

On O +
the O +
other O +
hand O -
, O +
cycloalkanecarboxylic O +
esters O +
derived O +
from O +
lysergol O -
, O +
dihydrolysergol O -
- O -
I O -
, O +
and O +
elymoclavine O +
displayed O +
low O +
or O +
marginal O +
affinity O +
at O +
alpha1-adrenoceptors B-Gene -
. I-Gene +

A O +
further O +
aim O +
of O +
the O +
study O +
was O +
to O +
examine O +
to O +
what O +
extent O +
the O +
complete O +
removal O +
of O +
the O +
acyl O +
portion O +
of O +
the O +
esters O +
would O +
affect O +
5-HT2A B-Gene +
receptor I-Gene +
affinity O -
. O +

The O +
parent O +
alcohols O +
of O +
the O +
three O +
series O +
of O +
N-1-isopropyl O +
homologues O -
, O +
1-isopropyllysergol O +
( O -
1b O -
) O -
, O +
1-isopropyldihydrolysergol O -
- O -
I O +
( O -
2b O -
) O -
, O +
and O +
1-isopropylelymoclavine O +
( O -
3b O -
) O -
, O +
displayed O +
higher O +
affinity O +
for O +
5-HT2A B-Gene +
receptors I-Gene +
( O -
pA2 O +
= O +
9.15 O -
, O +
8.50 O -
, O +
9.14 O -
) O +
than O +
the O +
corresponding O +
esters O -
. O +

Compounds O +
1b-3b O +
had O +
no O +
contractile O +
effects O +
by O +
themselves O +
and O +
displayed O +
low O +
affinity O +
at O +
guinea O -
- O -
pig O +
5-HT1B B-Gene +
receptors I-Gene +
and O +
rat O +
alpha1-adrenoceptors B-Gene -
. O +

The O +
high O +
affinity O +
for O +
rat O +
5-HT2A B-Gene +
receptors I-Gene +
was O +
retained O +
when O +
clavines O +
even O +
more O +
simple O +
in O +
structure O +
than O +
1b-3b O -
, O +
compounds O +
4b O +
and O +
5b O -
, O +
were O +
examined O +
as O +
5-HT2A B-Gene +
receptor I-Gene +
antagonists O -
. O +

The O +
nanomolar O +
antagonist O +
activity O +
of O +
simple O +
clavines O +
( O -
1b-5b O -
) O +
in O +
the O +
rat O +
suggests O +
that O +
the O +
indolo O -
[ O -
4,3-fg O -
] O -
quinoline O +
system O +
of O +
the O +
ergolines O +
is O +
the O +
molecular O +
fragment O +
that O +
is O +
responsible O +
for O +
5-HT2A B-Gene +
receptor I-Gene +
affinity O -
, O +
and O +
not O +
the O +
substituent O +
at O +
position O +
C-8 O -
. O +

Exposure O +
of O +
Clone O +
9 O +
cells O -
, O +
a O +
nontransformed O +
rat O +
liver O +
cell O +
line O +
expressing O +
only O +
the O +
Glutl O +
glucose B-Gene +
transporter I-Gene +
isoform O -
, O +
to O +
the O +
guanylyl B-Gene +
cyclase I-Gene +
inhibitor O +
LY-83583 O +
was O +
found O +
to O +
stimulate O +
the O +
rate O +
of O +
glucose O +
transport O +
( O -
approximately O +
7- O +
to O +
8-fold O +
in O +
1 O +
h O -
) O -
. O +

A O +
similar O +
response O +
to O +
LY-83583 O +
was O +
found O +
in O +
NIH O +
3T3 O +
fibroblasts O -
, O +
3T3-L1 O +
pre O -
- O -
adipocytes O -
, O +
and O +
C2C12 O +
myoblasts O -
. O +

Neither O +
the O +
rate O +
of O +
glucose O +
transport O +
in O +
cells O +
under O +
control O +
conditions O +
nor O +
the O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
was O +
altered O +
by O +
10 O -
, O +
50 O -
, O +
or O +
100 O +
microM O +
8-bromo O -
- O -
cGMP O +
or O +
by O +
addition O +
of O +
cGMP B-Gene +
phosphodiesterase I-Gene +
inhibitors O -
, O +
zaprinast O -
, O +
or O +
dipyridamole O +
suggesting O +
that O +
glucose O +
transport O +
and O +
the O +
response O +
to O +
LY-83583 O +
is O +
independent O +
of O +
cGMP O +
levels O -
. O +

In O +
addition O -
, O +
the O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
was O +
not O +
mediated O +
by O +
inhibition O +
of O +
oxidative O +
phosphorylation O -
, O +
since O +
exposure O +
to O +
the O +
agent O +
resulted O +
in O +
no O +
increase O +
in O +
lactate O +
production O -
. O +

Incubation O +
of O +
Clone O +
9 O +
cells O +
in O +
the O +
presence O +
of O +
the O +
phospholipase B-Gene +
C I-Gene +
inhibitor O +
U73122 O -
, O +
however O -
, O +
attenuated O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
. O +

Moreover O -
, O +
exposure O +
to O +
LY-83583 O +
resulted O +
in O +
a O +
rise O +
in O +
cell O +
diacylglycerol O +
content O -
, O +
and O +
preincubation O +
with O +
U73122 O +
significantly O +
diminished O +
this O +
rise O +
as O +
well O +
as O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
. O +

The O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
was O +
significantly O +
blocked O +
by O +
thapsigargin O -
. O +

Down O -
- O -
regulation O +
of O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
activity O -
, O +
resulting O +
from O +
24 O +
h O +
pre O -
- O -
incubation O +
in O +
the O +
presence O +
of O +
160 O +
nM O +
phorbol-12-myristate O +
13-acetate O -
, O +
did O +
not O +
attenuate O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
. O +

It O +
is O +
concluded O +
that O +
the O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
LY-83583 O +
is O +
independent O +
of O +
changes O +
in O +
cGMP O +
levels O -
, O +
is O +
not O +
mediated O +
by O +
inhibition O +
of O +
oxidative O +
phosphorylation O -
, O +
and O +
is O +
mediated O -
, O +
at O +
least O +
in O +
part O -
, O +
through O +
stimulation O +
of O +
the O +
phospholipase B-Gene +
C I-Gene +
pathway O -
. O +

Facilitative O +
transport O +
of O +
glucose O +
across O +
plasma O +
membranes O +
is O +
mediated O +
by O +
members O +
of O +
the O +
Na+ O +
-independent O +
family O +
of O +
glucose B-Gene +
transporter I-Gene +
molecules O +
( O -
Glut B-Gene -
) O +
which O +
are O +
expressed O +
in O +
a O +
tissue O -
- O -
specific O +
manner O +
( O -
Muekler O -
, O +
1990 O +
; O +
Pessin O +
and O +
Bell O -
, O +
1992 O +
; O +
Ismail O -
- O -
Beigi O -
, O +
1993 O +
) O -
. O +

Among O +
the O +
glucose B-Gene +
transporters I-Gene -
, O +
glucose B-Gene +
transporter-1 I-Gene +
is O +
present O +
in O +
varying O +
amounts O +
in O +
most O +
tissues O +
and O +
is O +
expressed O +
at O +
high O +
levels O +
in O +
the O +
brain O -
, O +
retina O -
, O +
placenta O -
, O +
human O +
erythrocytes O -
, O +
and O +
a O +
variety O +
of O +
cells O +
in O +
culture O +
( O -
Muekler O +
et O +
al. O -
, O +
1985 O +
; O +
Birnbaum O +
et O +
al. O -
, O +
1986 O +
; O +
Pessin O +
and O +
Bell O -
, O +
1992 O +
) O -
. O +

In O +
previous O +
studies O -
, O +
we O +
have O +
reported O +
that O +
the O +
rate O +
of O +
glucose O +
transport O +
in O +
Clone O +
9 O +
cells O -
, O +
a O +
nontransformed O +
rat O +
liver O +
cell O +
line O +
expressing O +
only O +
the O +
glucose B-Gene +
transporter-1 I-Gene +
isoform O -
, O +
is O +
markedly O +
augmented O +
in O +
response O +
to O +
inhibition O +
of O +
oxidative O +
phosphorylation O +
by O +
sodium O +
azide O +
or O +
cyanide O +
( O -
Mercado O +
et O +
al. O -
, O +
1989 O +
; O +
Shetty O +
et O +
al. O -
, O +
1992 O +
; O +
Becker O +
et O +
al. O -
, O +
1996 O +
; O +
Behrooz O +
and O +
Ismail O -
- O -
Beigi O -
, O +
1997 O +
) O -
. O +

It O +
has O +
also O +
been O +
shown O +
that O +
azide O +
and O +
other O +
inhibitors O +
of O +
oxidative O +
phosphorylation O +
increase O +
nitric O +
oxide O +
( O -
NO O -
) O +
levels O +
( O -
Schulz O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Since O +
NO O +
donors O -
, O +
such O +
as O +
sodium O +
nitroprusside O -
, O +
have O +
been O +
reported O +
to O +
stimulate O +
the O +
rate O +
of O +
glucose O +
transport O +
( O -
Balon O +
and O +
Nadler O -
, O +
1997 O +
; O +
Young O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
we O +
tested O +
the O +
possibility O +
that O +
the O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
inhibition O +
of O +
oxidative O +
phosphorylation O +
is O +
mediated O +
through O +
NO O +
signalling O +
mechanisms O -
. O +

Results O +
of O +
initial O +
studies O +
on O +
Clone O +
9 O +
cells O +
indicated O +
that O +
glucose O +
transport O +
was O +
enhanced O +
2- O +
to O +
3-fold O +
by O +
sodium O +
nitroprusside O +
( O -
Prasad O +
and O +
Ismail O -
- O -
Beigi O -
, O +
unpublished O +
observations O -
) O -
, O +
presumably O +
through O +
generation O +
of O +
NO O -
. O +

Since O +
it O +
is O +
well O -
- O -
known O +
that O +
many O +
actions O +
of O +
NO O +
are O +
mediated O +
by O +
stimulation O +
of O +
guanylyl B-Gene +
cyclase I-Gene +
activity O +
resulting O +
in O +
increased O +
cGMP O +
levels O -
, O +
we O +
tested O +
the O +
effect O +
of O +
LY-83583—a O +
well O +
documented O +
and O +
specific O +
inhibitor O +
of O +
guanylyl B-Gene +
cyclase I-Gene +
activity O +
( O -
Mulsch O +
et O +
al. O -
, O +
1988 O +
; O +
Stuart O -
- O -
Smith O +
et O +
al. O -
, O +
1998 O +
) O -
—on O +
the O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
sodium O +
nitroprusside O -
. O +

The O +
experimental O +
results O +
yielded O +
an O +
unexpected O +
finding O -
, O +
namely O +
that O +
exposure O +
to O +
LY-83583 O +
alone O +
resulted O +
in O +
a O +
marked O +
( O -
∼7 O +
fold O -
) O +
stimulation O +
of O +
glucose O +
transport O -
. O +

Studies O +
were O +
hence O +
performed O +
to O +
further O +
characterize O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
. O +

A O +
preliminary O +
report O +
of O +
some O +
of O +
the O +
findings O +
has O +
been O +
presented O +
( O -
Prasad O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Clone O +
9 O -
, O +
C2 O +
C12 O +
, O +
NIH O +
3T3 O -
, O +
and O +
3T3-L1 O +
cells O +
were O +
obtained O +
from O +
the O +
American O +
Type O +
Culture O +
Collection O +
( O -
Rockville O -
, O +
MD O -
) O -
. O +

Dulbecco O -
's O +
modified O +
Eagle O -
's O +
medium O +
( O -
DMEM O -
) O -
, O +
Hank O -
's O +
balanced O +
salt O +
solution O +
( O -
HBSS O -
) O -
, O +
calf O +
serum O -
, O +
and O +
fetal O +
bovine O +
serum O +
were O +
purchased O +
from O +
Gibco O +
BRL O +
( O -
Grand O +
Island O -
, O +
NY O -
) O -
. O +

Plastic O +
culture O +
dishes O +
were O +
obtained O +
from O +
Corning O +
Glass O +
Works O +
( O -
Medfield O -
, O +
MA O -
) O -
. O +

3-O O +
-Methyl O -
- O -
d O +
- O -
[ O -
3 O +
H O +
] O +
glucose O +
( O -
[ O -
3 O +
H O +
] O -
3-O O +
-methyl O +
glucose O -
) O +
( O -
3.4 O +
mCi O +
mmol−1 O +
) O -
, O +
and O +
sn O +
-1,2-diacylglycerol O +
assay O +
kit O +
were O +
purchased O +
from O +
Amersham O +
( O -
Arlington O +
Heights O -
, O +
IL O -
) O -
. O +

[ O -
32 O +
P O +
] O -
γ O -
- O -
ATP O +
( O -
4500 O +
Ci O +
mmol−1 O +
) O +
was O +
purchased O +
from O +
ICN O +
Biochemicals O +
( O -
Irvine O -
, O +
CA O -
) O -
. O +

LY-83583 O +
and O +
U73122 O +
( O -
Fig. O +
1 O +
) O -
, O +
dipyridamole O -
, O +
zaprinast O -
, O +
8-bromo O -
- O -
cGMP O -
, O +
and O +
phorbol-12-myristate O +
13-acetate O +
( O -
PMA O -
) O +
were O +
purchased O +
from O +
CalBiochem O +
( O -
La O +
Jolla O -
, O +
CA O -
) O -
. O +

Lactate O +
assay O +
kit O -
, O +
sodium O +
azide O -
, O +
cytochalasin O -
- O -
B O -
, O +
sodium O +
nitroprusside O -
, O +
trichloroacetic O +
acid O -
, O +
gamma B-Gene +
globulin I-Gene -
, O +
thapsigargin O -
, O +
phloretin O -
, O +
thin O -
- O -
layer O +
chromatography O +
plates O +
( O -
silica O +
gel O -
) O -
, O +
and O +
standard O +
chemical O +
compounds O +
were O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
) O -
. O +

Horse O +
anti B-Gene -
- I-Gene -
cGMP I-Gene +
antibody I-Gene +
and O +
[ O -
125 O +
I O +
] O -
cGMP O +
were O +
obtained O +
as O +
a O +
gift O +
from O +
Dr. O +
Chung O -
- O -
Ho O +
Chang O +
( O -
Chang O +
and O +
Song O -
, O +
1993 O +
) O -
. O +

Dimethyl O +
sulfoxide O +
( O -
DMSO O -
) O -
, O +
and O +
hydrochloric O +
acid O +
were O +
purchased O +
from O +
Fisher O +
Scientific O +
( O -
Fairlawn O -
, O +
NJ O -
) O -
. O +

2.2 O +
Cell O +
culture O +
Clone O +
9 O +
cells O +
were O +
maintained O +
in O +
Dulbecco O -
's O +
modified O +
eagle O +
medium O +
( O -
DMEM O -
; O +
5.6 O +
mM O +
glucose O -
) O +
containing O +
10 O -
% O +
calf O +
serum O +
at O +
37 O -
° O -
C O +
with O +
8 O -
% O +
CO2 O +
and O +
reached O +
confluence O +
after O +
∼4 O +
days O -
. O +

Cells O +
were O +
used O +
between O +
passages O +
27 O +
and O +
53 O -
. O +

NIH-3T3 O +
cells O -
, O +
3T3-L1 O +
cells O -
, O +
and O +
C2 O +
C12 O +
cells O +
were O +
grown O +
in O +
DMEM O +
containing O +
10 O -
% O +
fetal O +
bovine O +
serum O -
. O +

After O +
confluence O -
, O +
the O +
medium O +
was O +
replaced O +
with O +
serum O -
- O -
free O +
DMEM O +
24 O +
h O +
prior O +
to O +
initiation O +
of O +
all O +
experiments O -
. O +

Sodium O +
azide O +
and O +
8-bromo O -
- O -
cGMP O +
dissolved O +
in O +
40 O +
μl O +
of O +
DMEM O -
, O +
and O +
LY-83583 O -
, O +
thapsigargin O -
, O +
and O +
U73122 O +
dissolved O +
in O +
10 O +
μl O +
DMSO O +
were O +
added O +
directly O +
to O +
culture O +
dishes O +
at O +
appropriate O +
times O -
. O +

2.3 O +
Measurement O +
of O +
[ O -
3 O +
H O +
] O -
3-O O -
- O -
methyl O +
glucose O +
uptake O +
Cells O +
were O +
grown O +
on O +
60-mm O +
culture O +
dishes O -
. O +

Uptake O +
assay O +
was O +
performed O +
in O +
replicate O +
dishes O +
for O +
a O +
1.0 O +
to O +
1.5 O +
min O +
interval O -
, O +
as O +
described O +
previously O -
, O +
in O +
the O +
absence O +
and O +
presence O +
of O +
50 O +
μM O +
cytochalasin O +
B O +
( O -
Mercado O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

Cytochalasin O +
B O -
- O -
inhibitable O +
[ O -
3 O +
H O +
] O -
3-O O +
-methyl O -
- O -
d O +
-glucose O +
( O -
[ O -
3 O +
H O +
] O -
3-OMG O -
) O +
uptake O +
was O +
calculated O +
as O +
the O +
difference O +
in O +
uptake O +
in O +
the O +
absence O +
and O +
presence O +
of O +
cytochalasin O +
B O +
assayed O +
in O +
parallel O -
. O +

2.4 O +
Measurement O +
of O +
cGMP O +
Cells O +
grown O +
on O +
100-mm O +
culture O +
dishes O +
were O +
exposed O +
to O +
various O +
reagents O +
for O +
indicated O +
times O +
in O +
the O +
presence O +
of O +
10 O +
μM O +
dipyridamole O -
, O +
a O +
cGMP B-Gene +
phosphodiesterase I-Gene +
inhibitor O +
( O -
Beavo O +
and O +
Reifsnyder O -
, O +
1990 O +
) O -
. O +

Immediately O +
following O +
exposure O +
to O +
the O +
indicated O +
stimuli O -
, O +
cells O +
in O +
each O +
dish O +
were O +
washed O +
four O +
times O +
with O +
10 O +
ml O +
of O +
ice O -
- O -
cold O +
phosphate O -
- O -
buffered O +
saline O -
. O +

Following O +
complete O +
drainage O -
, O +
250 O +
μl O +
of O +
ice O -
- O -
cold O +
10 O -
% O +
trichloroacetic O +
acid O +
was O +
added O +
to O +
each O +
dish O +
and O +
dishes O +
were O +
immediately O +
placed O +
in O +
−80 O -
° O -
C O +
for O +
1 O +
h. O +
After O +
thawing O -
, O +
cells O +
were O +
scraped O +
and O +
centrifuged O +
at O +
14,000 O -
× O -
g O +
for O +
10 O +
min O +
at O +
4 O -
° O -
C O +
and O +
the O +
resulting O +
supernatants O +
were O +
placed O +
in O +
glass O +
tubes O -
. O +

50 O +
μl O +
of O +
1 O +
M O +
HCl O +
was O +
added O +
to O +
each O +
tube O -
, O +
and O +
the O +
aqueous O +
phase O +
was O +
extracted O +
3 O +
times O +
with O +
2 O +
ml O +
of O +
ethyl O +
ether O -
. O +

The O +
aqueous O +
phase O +
was O +
placed O +
in O +
uncapped O +
tubes O +
for O +
16 O +
h O +
at O +
room O +
temperature O +
to O +
allow O +
the O +
remaining O +
ether O +
to O +
evaporate O -
. O +

Next O -
, O +
50 O +
μl O +
of O +
1 O +
M O +
sodium O +
acetate O -
, O +
40 O +
μl O +
of O +
1 O +
M O +
NaOH O -
, O +
and O +
10 O +
μl O +
of O +
triethanolamine O -
: O -
acetic O +
anhydride O +
( O -
2:1 O -
, O +
v O -
/ O -
v O -
) O +
were O +
sequentially O +
added O +
to O +
each O +
tube O +
with O +
brief O +
mixing O +
after O +
each O +
addition O -
. O +

100 O +
μl O +
of O +
antibody B-Gene +
against O +
cGMP O +
and O +
100 O +
μl O +
of O +
[ O -
125 O +

I O +
] O +
cGMP O +
was O +
added O -
, O +
and O +
the O +
tubes O +
were O +
gently O +
shaken O +
for O +
4 O +
h O +
at O +
4 O -
° O -
C O -
. O +

Next O -
, O +
50 O +
μl O +
of O +
rabbit O +
gamma O +
globulin B-Gene +
was O +
added O +
to O +
each O +
sample O -
. O +

Following O +
the O +
addition O +
of O +
2 O +
ml O +
isopropanol O +
to O +
each O +
sample O -
, O +
tubes O +
were O +
centrifuged O +
at O +
2700 O -
× O -
g O +
for O +
30 O +
min O +
at O +
4 O -
° O -
C O -
. O +

Supernatants O +
were O +
decanted O +
and O +
pellets O +
were O +
dried O +
for O +
1 O +
h O +
at O +
room O +
temperature O -
. O +

Finally O -
, O +
samples O +
were O +
counted O +
in O +
a O +
gamma O +
counter O -
. O +

cGMP O +
content O +
in O +
samples O +
was O +
determined O +
using O +
cGMP O +
standards O +
assayed O +
in O +
parallel O +
( O -
Chang O +
and O +
Song O -
, O +
1993 O +
) O -
. O +

2.5 O +
Measurement O +
of O +
lactate O +
Lactate O +
concentration O +
in O +
the O +
medium O +
was O +
measured O +
in O +
cells O +
grown O +
in O +
60-mm O +
dishes O +
that O +
had O +
been O +
washed O +
once O +
with O +
4 O +
ml O +
of O +
Hank O -
's O +
balanced O +
salt O +
solution O +
and O +
incubated O +
in O +
the O +
presence O +
of O +
1 O +
ml O +
of O +
DMEM O +
for O +
1 O +
h O +
in O +
the O +
presence O +
or O +
absence O +
of O +
sodium O +
azide O +
or O +
LY-83583 O -
. O +

Samples O +
of O +
the O +
medium O +
were O +
analyzed O +
for O +
lactate O +
as O +
described O +
previously O +
and O +
in O +
the O +
kit O -
's O +
instruction O +
guide O +
( O -
Becker O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

2.6 O +
Assay O +
of O +
sn-1,2-diacylglycerol O +
After O +
addition O +
of O +
the O +
indicated O +
reagents O +
to O +
cells O -
, O +
plates O +
were O +
washed O +
twice O +
with O +
ice O -
- O -
cold O +
phosphate O -
- O -
buffered O +
saline O +
( O -
PBS O -
) O -
, O +
harvested O +
in O +
5 O +
ml O +
of O +
ice O -
- O -
cold O +
PBS O -
, O +
placed O +
in O +
15 O +
ml O +
Falcon O +
Blue O +
Max O +
Jr. O +
tubes O -
, O +
and O +
centrifuged O +
for O +
5 O +
min O +
at O +
720 O -
× O -
g O +
. O +

Pellets O +
were O +
resuspended O +
in O +
0.8 O +
ml O +
of O +
1 O +
M O +
NaCl O +
and O +
3 O +
ml O +
of O +
a O +
chloroform O -
: O -
methanol O +
( O -
1:2 O -
, O +
v O -
/ O -
v O -
) O +
was O +
added O -
, O +
and O +
the O +
tubes O +
were O +
shaken O +
vigorously O -
. O +

Then O -
, O +
1 O +
ml O +
of O +
1 O +
M O +
NaCl O +
and O +
1 O +
ml O +
of O +
chloroform O +
were O +
then O +
added O -
, O +
tubes O +
were O +
capped O -
, O +
vortexed O -
, O +
and O +
centrifuged O +
for O +
2 O +
min O +
at O +
2350 O -
× O -
g O +
. O +

Next O -
, O +
200 O +
μl O +
of O +
the O +
chloroform O +
phase O +
was O +
transferred O +
to O +
2 O +
ml O +
microfuge O +
tubes O -
, O +
and O +
samples O +
were O +
evaporated O +
to O +
dryness O +
in O +
a O +
speed O -
- O -
vac O +
for O +
1 O +
h. O +
Subsequent O +
steps O -
, O +
including O +
measurement O +
of O +
diacylglycerol O +
by O +
its O +
quantitative O +
conversion O +
to O +
[ O -
32 O +
P O +
] O -
phosphatidic O +
acid O +
in O +
the O +
presence O +
of O +
[ O -
32 O +
P O +
] O -
-γ O -
- O -
ATP O -
, O +
were O +
according O +
to O +
the O +
kit O -
's O +
instructions O -
. O +

Following O +
the O +
reaction O +
and O +
extraction O +
procedures O -
, O +
radioactivity O +
in O +
phosphatidic O +
acid O +
was O +
determined O +
by O +
thin O +
layer O +
chromatography O +
using O +
the O +
manufacturer O -
's O +
protocol O -
. O +

Bands O +
corresponding O +
to O +
[ O -
32 O +
P O +
] O -
phosphatidic O +
acid O +
( O -
detected O +
by O +
autoradiography O -
) O +
were O +
cut O -
- O -
out O +
and O +
counted O -
. O +

Diacylglycerol O +
content O +
in O +
samples O +
were O +
determined O +
using O +
diacylglycerol O +
standards O +
assayed O +
in O +
parallel O -
. O +

2.7 O +
Statistical O +
methods O +
All O +
values O +
are O +
expressed O +
as O +
means±S.E. O +
Student O -
's O +
unpaired O +
two O -
- O -
tailed O +
t O +
-test O +
was O +
used O -
, O +
and O +
a O +
P O +
value O +
of O +
< O -
0.05 O +
was O +
taken O +
to O +
be O +
significant O +
( O -
Snedecor O +
and O +
Cochran O -
, O +
1976 O +
) O -
. O +

3 O +
Results O +
3.1 O +
Enhancement O +
of O +
glucose O +
transport O +
in O +
Clone O +
9 O +
and O +
other O +
cells O +
in O +
response O +
to O +
LY-83583 O +
Exposure O +
of O +
Clone O +
9 O +
cells O +
to O +
10 O +
μM O +
LY-83583 O +
for O +
1 O +
h O +
stimulated O +
the O +
rate O +
of O +
cytochalasin O +
B O -
- O -
inhibitable O +
3-O O +
-methyl O +
glucose O +
transport O +
7.4±0.3 O +
fold O +
( O -
Fig. O +
2 O +
) O -
. O +

As O +
a O +
comparison O -
, O +
treatment O +
of O +
cells O +
with O +
10 O +
mM O +
sodium O +
azide O +
for O +
1 O +
h O -
, O +
an O +
inhibitor O +
of O +
oxidative O +
phosphorylation O +
known O +
to O +
stimulate O +
glucose O +
transport O +
in O +
the O +
cells O +
( O -
Shetty O +
et O +
al. O -
, O +
1992 O +
) O -
, O +
resulted O +
in O +
a O +
4.1±0.3-fold O +
increase O +
in O +
the O +
rate O +
of O +
glucose O +
uptake O -
. O +

To O +
determine O +
the O +
concentration O -
– O -
response O +
relationship O +
to O +
LY-83583 O -
, O +
Clone O +
9 O +
cells O +
were O +
exposed O +
to O +
0 O -
, O +
1 O -
, O +
3 O -
, O +
10 O -
, O +
and O +
33 O +
μM O +
LY-83583 O +
for O +
1 O +
h O +
prior O +
to O +
measurement O +
of O +
cytochalasin O +
B O -
- O -
inhibitable O +
[ O -
3 O +
H O +
] O -
3-O O +
-methyl O -
- O -
d O +
-glucose O +
( O -
[ O -
3 O +
H O +
] O -
3-OMG O -
) O +
uptake O -
; O +
rates O +
of O +
uptake O +
were O +
half O -
- O -
maximally O +
and O +
maximally O +
stimulated O +
at O +
∼0.8 O +
and O +
∼10 O +
μM O +
LY-83583 O -
, O +
respectively O +
( O -
Fig. O +
3 O +
A O -
) O -
. O +

The O +
time O -
- O -
course O +
of O +
the O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
was O +
also O +
determined O +
( O -
Fig. O +
3 O +
B O -
) O -
. O +

Rate O +
of O +
[ O -
3 O +
H O +
] O -
3-OMG O +
uptake O +
was O +
significantly O +
stimulated O +
after O +
10 O +
min O +
exposure O +
to O +
10 O +
μM O +
LY-83583 O -
, O +
and O +
reached O +
near O -
- O -
maximal O +
levels O +
at O +
90 O +
min O -
. O +

To O +
determine O +
whether O +
the O +
observed O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
LY-83583 O +
is O +
specific O +
to O +
Clone O +
9 O +
cells O -
, O +
we O +
measured O +
the O +
effect O +
of O +
LY-83583 O +
on O +
the O +
rate O +
of O +
[ O -
3 O +
H O +
] O -
3-OMG O +
uptake O +
in O +
three O +
additional O +
cell O +
types O -
, O +
all O +
of O +
which O +
express O +
only O +
the O +
glucose B-Gene +
transporter-1 I-Gene +
isoform O +
( O -
Harrison O +
et O +
al. O -
, O +
1991 O +
; O +
Kotliar O +
and O +
Pilch O -
, O +
1992 O +
; O +
Ismail O -
- O -
Beigi O -
, O +
unpublished O +
observations O -
) O -
; O +
the O +
results O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

In O +
response O +
to O +
exposure O +
to O +
10 O +
μM O +
LY-83583 O -
, O +
cytochalasin O +
B O -
- O -
inhibitable O +
[ O -
3 O +
H O +
] O -
3-OMG O +
uptake O +
was O +
stimulated O +
4.3- O -
, O +
5.0- O -
, O +
and O +
3.7-fold O +
in O +
NIH O +
3T3 O +
fibroblasts O -
, O +
3T3-L1 O +
preadipocytes O -
, O +
and O +
C2 O +
C12 O +
myoblasts O -
, O +
respectively O -
. O +

Taken O +
together O -
, O +
these O +
data O +
suggest O +
that O +
LY-83583 O +
evokes O +
a O +
marked O +
and O +
rapid O +
stimulation O +
of O +
glucose O +
transport O +
that O +
is O +
manifest O +
in O +
the O +
variety O +
of O +
cell O +
types O +
examined O -
. O +

3.2 O +
Effect O +
of O +
LY-83583 O +
on O +
intracellular O +
cGMP O +
levels O +
and O +
glucose O +
transport O +
The O +
observed O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
the O +
rate O +
of O +
glucose O +
transport O +
in O +
conjunction O +
with O +
its O +
known O +
inhibitory O +
action O +
on O +
guanylyl B-Gene +
cyclase I-Gene +
activity O +
leading O +
to O +
a O +
reduction O +
of O +
cellular O +
cGMP O +
levels O +
( O -
Diamond O +
and O +
Chu O -
, O +
1985 O +
; O +
Schmidt O +
et O +
al. O -
, O +
1985 O +
) O -
, O +
raised O +
the O +
possibility O +
that O +
a O +
decrease O +
in O +
cell O +
cGMP O +
levels O +
mediates O +
the O +
enhancement O +
of O +
glucose O +
transport O -
. O +

If O +
this O +
were O +
the O +
case O -
, O +
then O +
an O +
increase O +
in O +
cellular O +
cGMP O +
levels O +
should O +
abrogate O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
. O +

To O +
test O +
this O +
possibility O -
, O +
Clone O +
9 O +
cells O +
were O +
exposed O +
to O +
the O +
membrane O -
- O -
permeant O +
cGMP O +
analog O -
, O +
8-bromo O -
- O -
cGMP O -
, O +
in O +
the O +
presence O +
and O +
absence O +
of O +
LY-83583 O +
( O -
Fig. O +
4 O +
) O -
. O +

In O +
comparison O +
with O +
control O +
cells O -
, O +
and O +
as O +
already O +
noted O -
, O +
exposure O +
to O +
10 O +
μM O +
LY-83583 O +
alone O +
for O +
1 O +
h O +
resulted O +
in O +
7.1±0.3-fold O +
increase O +
in O +
the O +
rate O +
of O +
[ O -
3 O +
H O +
] O -
3-OMG O +
uptake O -
. O +

10 O +
μM O +
LY-83583 O +
in O +
the O +
presence O +
of O +
10 O +
μM O +
8-bromo O -
- O -
cGMP O +
also O +
resulted O +
in O +
a O +
7.0±0.2-fold O +
increase O +
in O +
the O +
rate O +
of O +
uptake O -
, O +
while O +
exposure O +
to O +
10 O +
μM O +
8-bromo O -
- O -
cGMP O +
alone O +
had O +
no O +
effect O +
on O +
the O +
rate O +
of O +
glucose O +
transport O -
. O +

In O +
additional O +
experiments O -
, O +
exposure O +
to O +
50 O +
or O +
100 O +
μM O +
8-bromo O -
- O -
cGMP O +
had O +
no O +
effect O +
on O +
either O +
the O +
basal O +
or O +
LY-83583-stimulated O +
rate O +
of O +
glucose O +
transport O +
( O -
data O +
not O +
shown O -
) O -
. O +

As O +
an O +
alternative O +
method O +
of O +
increasing O +
cellular O +
cGMP O +
levels O -
, O +
zaprinast O +
or O +
dipyridamole O -
, O +
cGMP B-Gene +
phosphodiesterase I-Gene +
inhibitors O -
, O +
were O +
employed O +
( O -
Beavo O +
and O +
Reifsnyder O -
, O +
1990 O +
) O -
. O +

The O +
stimulatory O +
effect O +
of O +
10 O +
μM O +
LY-83583 O +
was O +
largely O +
unaffected O +
by O +
the O +
presence O +
of O +
zaprinast O +
or O +
dipyridamole O -
, O +
and O +
zaprinast O +
and O +
dipyridamole O +
alone O +
had O +
no O +
significant O +
effect O +
of O +
the O +
basal O +
rate O +
of O +
glucose O +
uptake O +
( O -
Fig. O +
4 O +
) O -
. O +

To O +
verify O +
that O +
addition O +
of O +
8-bromo O -
- O -
cGMP O +
to O +
the O +
culture O +
dishes O +
resulted O +
in O +
elevated O +
intracellular O +
cGMP O +
levels O -
, O +
cell O +
cGMP O +
content O +
was O +
measured O +
by O +
radioimmunoassay O +
( O -
Fig. O +
5 O +
) O -
. O +

To O +
obtain O +
measurable O +
levels O +
of O +
cGMP O -
, O +
all O +
cells O +
were O +
exposed O +
to O +
10 O +
μM O +
dipyridamole O +
in O +
addition O +
to O +
the O +
test O +
agents O -
. O +

Addition O +
of O +
1 O +
μM O +
or O +
10 O +
μM O +
8-bromo O -
- O -
cGMP O +
resulted O +
in O +
significant O +
increases O +
in O +
cGMP O +
content O +
of O +
Clone O +
9 O +
cells O -
. O +

( O -
It O +
should O +
be O +
noted O +
that O +
cells O +
were O +
washed O +
four O +
times O +
to O +
remove O +
all O +
traces O +
of O +
external O +
8-bromo O -
- O -
cGMP O +
prior O +
to O +
lysis O +
of O +
the O +
cells O -
, O +
and O +
in O +
preliminary O +
experiments O -
, O +
cellular O +
cGMP O +
levels O +
were O +
the O +
same O +
after O +
two O +
versus O +
four O +
washes O +
prior O +
to O +
harvest O -
. O -
) O +

cGMP O +
levels O +
remained O +
unchanged O +
in O +
the O +
presence O +
of O +
10 O +
μM O +
LY-83583 O +
in O +
conjunction O +
with O +
dipyridamole O -
. O +

As O +
a O +
positive O +
control O -
, O +
exposure O +
of O +
cells O +
to O +
5 O +
mM O +
sodium O +
nitroprusside O +
resulted O +
in O +
a O +
significant O +
increase O +
in O +
cGMP O +
levels O -
, O +
and O +
this O +
effect O +
was O +
partially O +
blocked O +
by O +
LY-83583 O -
. O +

Taken O +
together O -
, O +
the O +
above O +
results O +
suggested O +
that O +
the O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
LY-83583 O +
is O +
independent O +
of O +
changes O +
in O +
intracellular O +
cGMP O +
levels O -
. O +

3.3 O +
Effect O +
of O +
LY-83583 O +
on O +
lactate O +
production O +
in O +
Clone O +
9 O +
cells O +
Other O +
potential O +
pathways O +
that O +
could O +
mediate O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O +
were O +
examined O -
. O +

We O +
have O +
previously O +
shown O +
that O +
inhibition O +
of O +
oxidative O +
phosphorylation O +
by O +
cyanide O +
or O +
azide O +
results O +
in O +
a O +
rapid O +
stimulation O +
of O +
glucose O +
transport O +
in O +
these O +
cells O +
( O -
Mercado O +
et O +
al. O -
, O +
1989 O +
; O +
Shetty O +
et O +
al. O -
, O +
1992 O +
; O +
Becker O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

In O +
addition O -
, O +
inhibition O +
of O +
oxidative O +
phosphorylation O +
leads O +
to O +
an O +
increase O +
in O +
cytosolic O +
NADH O -
/ O -
NAD+ O +
and O +
lactate O -
/ O -
pyruvate O +
ratios O +
and O +
results O +
in O +
a O +
marked O +
increase O +
in O +
the O +
rate O +
of O +
lactate O +
production O +
( O -
LaNoue O +
and O +
Schoolwerth O -
, O +
1979 O +
; O +
Becker O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

To O +
discern O +
whether O +
LY-83583 O -
's O +
stimulatory O +
effect O +
on O +
glucose O +
transport O +
is O +
in O +
response O +
to O +
a O +
potential O +
inhibition O +
of O +
oxidative O +
phosphorylation O +
by O +
the O +
agent O -
, O +
we O +
measured O +
the O +
rate O +
of O +
lactate O +
production O +
in O +
Clone O +
9 O +
cells O +
exposed O +
to O +
LY-83583 O +
( O -
Table O +
2 O +
) O -
; O +
lactate O +
produced O +
by O +
cells O +
treated O +
with O +
azide O +
served O +
as O +
a O +
positive O +
control O -
. O +

In O +
cells O +
treated O +
with O +
10 O +
μM O +
LY-83583 O +
for O +
1 O +
h O -
, O +
the O +
rate O +
of O +
lactate O +
production O +
averaged O +
2.1±0.15 O +
nmol O +
( O -
mg O +
protein O -
) O -
−1 O +
h−1 O +
which O +
was O +
not O +
different O +
than O +
the O +
rate O +
in O +
control O +
cells O -
. O +

3.4 O +
Role O +
of O +
activation O +
of O +
phospholipase B-Gene +
C I-Gene +
in O +
the O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
LY-83583 O +
The O +
possibility O +
that O +
activation O +
of O +
phospholipase B-Gene +
C I-Gene -
, O +
a O +
well O +
characterized O +
upstream O +
mediator O +
of O +
many O +
signalling O +
pathways O -
, O +
is O +
involved O +
in O +
LY-83583 O -
's O +
stimulation O +
of O +
glucose O +
transport O +
was O +
explored O -
. O +

We O +
first O +
investigated O +
the O +
effect O +
of O +
U73122 O +
on O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
; O +
U73122 O +
is O +
a O +
potent O +
inhibitor O +
of O +
phospholipase B-Gene +
C I-Gene +
with O +
an O +
IC50 O +
of O +
∼10 O +
μM O +
for O +
phospholipase B-Gene +
C I-Gene +
in O +
many O +
cell O +
types O +
( O -
De O +
Moel O +
et O +
al. O -
, O +
1995 O +
; O +
Wang O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
although O +
lower O +
IC50 O +
values O +
have O +
also O +
been O +
reported O +
( O -
Zheng O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

In O +
the O +
presence O +
of O +
10 O +
μM O +
U73122 O -
, O +
the O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
in O +
Clone O +
9 O +
cells O +
was O +
reduced O +
by O +
45 O -
% O +
( O -
Fig. O +
6 O +
) O -
; O +
cells O +
treated O +
with O +
10 O +
μM O +
U73122 O +
alone O +
exhibited O +
a O +
slight O +
( O -
1.3±0.1 O +
fold O -
) O +
increase O +
in O +
transport O -
, O +
which O +
was O +
not O +
significant O -
. O +

A O +
presumed O +
stimulation O +
of O +
phospholipase B-Gene +
C I-Gene +
activity O +
by O +
LY-83583 O +
would O +
be O +
predicted O +
to O +
increase O +
cellular O +
levels O +
of O +
sn O +
-1,2-diacylglycerol O -
, O +
a O +
product O +
of O +
the O +
reaction O +
catalyzed O +
by O +
phospholipase B-Gene +
C. I-Gene +
The O +
effect O +
of O +
LY-83583 O +
on O +
cellular O +
diacylglycerol O +
content O +
was O +
hence O +
assayed O +
by O +
measuring O +
the O +
production O +
of O +
[ O -
32 O +
P O +
] O +
phosphatidic O +
acid O +
in O +
the O +
presence O +
of O +
exogenously O +
added O +
32 O +
P O +
-labeled O +
ATP O +
and O +
diacylglycerol B-Gene +
kinase I-Gene +
( O -
see O +
Methods O +
) O -
. O +

Clone O +
9 O +
cells O +
exposed O +
to O +
10 O +
μM O +
LY-83583 O +
for O +
30 O +
min O +
exhibited O +
3.0±0.1-fold O +
increase O +
in O +
diacylglycerol O +
content O +
compared O +
to O +
untreated O +
control O +
cells O +
( O -
473±37 O +
to O +
1438±13 O +
pmol O +
( O -
mg O +
protein O -
) O -
−1 O +
) O +
( O -
Table O +
3 O +
) O -
. O +

In O +
contrast O -
, O +
cells O +
preincubated O +
with O +
10 O +
μM O +
U73122 O +
for O +
10 O +
min O +
prior O +
to O +
the O +
30 O +
min O +
exposure O +
to O +
LY-83583 O +
manifest O +
only O +
a O +
1.4±0.2-fold O +
increase O +
in O +
diacylglycerol O +
content O -
. O +

Exposure O +
to O +
10 O +
μM O +
U73122 O +
alone O +
also O +
increased O +
cell O +
diacylglycerol O +
content O -
; O +
the O +
reasons O +
for O +
this O +
unexpected O +
finding O +
is O +
not O +
known O -
. O +

Activation O +
of O +
phospholipase O +
C O +
by O +
LY-83583 O +
would O +
be O +
expected O +
to O +
results O +
in O +
an O +
inositol O +
1,4,5-trisphosphate O -
- O -
induced O +
release O +
of O +
Ca2 O -
+ O +
from O +
microsomal O +
stores O -
. O +

Moreover O -
, O +
the O +
presumed O +
release O +
of O +
Ca2 O -
+ O +
induced O +
by O +
LY-83583 O +
could O +
be O +
linked O +
to O +
the O +
LY-83583-induced O +
stimulation O +
of O +
glucose O +
transport O -
. O +

To O +
examine O +
this O +
possibility O -
, O +
we O +
employed O +
thapsigargin O -
, O +
a O +
potent O +
inhibitor O +
of O +
microsomal O +
Ca2 B-Gene -
+ I-Gene +
-ATPase I-Gene +
which O +
results O +
in O +
a O +
rapid O +
and O +
near O -
- O -
complete O +
depletion O +
of O +
microsomal O +
Ca2 O -
+ O +
stores O +
in O +
a O +
variety O +
of O +
cells O +
( O -
Moore O +
et O +
al. O -
, O +
1991 O +
; O +
Tsukamoto O +
and O +
Kaneko O -
, O +
1993 O +
) O -
. O +

The O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
was O +
significantly O +
reduced O +
in O +
cells O +
preincubated O +
for O +
10 O +
min O +
with O +
thapsigargin O +
( O -
Fig. O +
7 O +
) O -
; O +
10 O +
μM O +
thapsigargin O +
alone O +
caused O +
a O +
slight O +
increase O +
in O +
the O +
rate O +
of O +
transport O -
. O +

We O +
also O +
explored O +
the O +
possibility O +
that O +
stimulation O +
of O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
activity O +
( O -
perhaps O +
secondary O +
to O +
phospholipase B-Gene +
C I-Gene +
activation O -
) O +
mediates O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
. O +

Accordingly O -
, O +
cells O +
were O +
preincubated O +
for O +
24 O +
h O +
in O +
the O +
presence O +
of O +
diluent O +
( O -
DMSO O -
) O +
or O +
160 O +
nM O +
phorbol-12-myristate O +
13-acetate O +
( O -
PMA O -
) O +
to O +
` O -
down O -
- O -
regulate O -
' O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
activity O -
. O +

Following O +
this O +
treatment O -
, O +
cells O +
were O +
exposed O +
to O +
diluent O -
, O +
fresh O +
PMA O -
, O +
or O +
LY-83583 O +
( O -
Fig. O +
8 O +
) O -
. O +

The O +
results O +
showed O +
that O +
exposure O +
to O +
LY-83583 O +
was O +
associated O +
with O +
a O +
large O +
stimulation O +
of O +
glucose O +
transport O +
in O +
both O +
control O +
cells O +
and O +
in O +
cells O +
pre O -
- O -
exposed O +
to O +
PMA O -
. O +

4 O +
Discussion O +
The O +
experimental O +
results O +
obtained O +
in O +
this O +
study O +
present O +
several O +
novel O +
findings O -
. O +

First O +
, O +
LY-83583 O +
was O +
found O +
to O +
dramatically O +
enhance O +
the O +
rate O +
of O +
glucose O +
transport O -
, O +
and O +
the O +
response O +
was O +
observed O +
in O +
several O +
cell O +
systems O +
examined O -
; O +
Second O +
, O +
LY-83583 O -
's O +
effect O +
on O +
glucose O +
transport O +
appeared O +
to O +
be O +
independent O +
of O +
its O +
inhibitory O +
actions O +
on O +
guanylyl B-Gene +
cyclase I-Gene +
or O +
a O +
reduction O +
in O +
cellular O +
cGMP O +
levels O -
. O +

This O +
important O +
inference O +
is O +
based O +
on O +
the O +
finding O +
that O +
the O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
was O +
not O +
blocked O +
by O +
10 O +
to O +
100 O +
μM O +
8-bromo O -
- O -
cGMP O -
. O +

Moreover O -
, O +
addition O +
of O +
8-bromo O -
- O -
cGMP O +
( O -
up O +
to O +
100 O +
μM O -
) O +
did O +
not O +
alter O +
the O +
basal O +
rate O +
of O +
transport O -
; O +
Third O +
, O +
LY-83583 O -
's O +
effect O +
on O +
glucose O +
transport O +
was O +
shown O +
not O +
to O +
be O +
secondary O +
to O +
inhibition O +
of O +
oxidative O +
phosphorylation O -
; O +
and O +
Fourth O +
, O +
the O +
results O +
suggest O +
that O +
the O +
stimulation O +
of O +
transport O +
in O +
response O +
to O +
LY-83583 O +
is O +
mediated O -
, O +
at O +
least O +
in O +
part O -
, O +
by O +
activation O +
of O +
phospholipase B-Gene +
C. I-Gene +
The O +
present O +
studies O +
were O +
initiated O +
to O +
better O +
define O +
the O +
mechanisms O +
underlying O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
inhibition O +
of O +
oxidative O +
phosphorylation O +
by O +
azide O +
( O -
Shetty O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

Potential O +
signalling O +
pathways O +
considered O +
were O +
those O +
linked O +
to O +
nitric O +
oxide O +
generation O -
, O +
because O +
exposure O +
of O +
cells O +
to O +
azide O +
has O +
been O +
shown O +
to O +
stimulate O +
NO O +
production O +
( O -
Schulz O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
and O +
NO O +
has O +
been O +
proposed O +
to O +
stimulate O +
the O +
rate O +
of O +
glucose O +
transport O +
( O -
Balon O +
and O +
Nadler O -
, O +
1997 O +
; O +
Young O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

To O +
test O +
the O +
possibility O +
that O +
stimulation O +
of O +
guanylyl B-Gene +
cyclase I-Gene +
activity O +
mediates O +
the O +
stimulation O +
of O +
glucose O +
transport O +
in O +
response O +
to O +
LY-83583 O -
, O +
we O +
measured O +
the O +
effect O +
of O +
a O +
known O +
inhibitor O +
of O +
guanylyl B-Gene +
cyclase I-Gene +
activity O +
( O -
LY-83583 O -
) O +
on O +
sodium O +
nitroprusside O -
- O -
induced O +
enhancement O +
of O +
glucose O +
transport O -
. O +

The O +
experimental O +
results O +
identified O +
an O +
unexpected O +
and O +
novel O +
finding O -
, O +
namely O +
that O +
exposure O +
to O +
LY-83583 O +
alone O +
resulted O +
in O +
a O +
dramatic O +
stimulation O +
of O +
glucose O +
transport O -
. O +

It O +
is O +
well O -
- O -
documented O +
that O +
LY-83583 O +
is O +
a O +
potent O +
and O +
specific O +
inhibitor O +
of O +
guanylyl B-Gene +
cyclase I-Gene +
( O -
Diamond O +
and O +
Chu O -
, O +
1985 O +
; O +
Schmidt O +
et O +
al. O -
, O +
1985 O +
; O +
Mulsch O +
et O +
al. O -
, O +
1988 O +
; O +
Stuart O -
- O -
Smith O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

If O +
a O +
reduction O +
in O +
cell O +
cGMP O +
level O +
mediates O +
the O +
transport O +
response O +
to O +
LY-83583 O -
, O +
then O +
elevation O +
of O +
cGMP O +
levels O +
by O +
addition O +
of O +
8-bromo O -
- O -
cGMP O +
to O +
the O +
external O +
medium O -
, O +
or O +
prevention O +
of O +
endogenous O +
cGMP O +
hydrolysis O +
by O +
cGMP O -
- O -
specific O +
phosphodiesterase B-Gene +
inhibitors O +
( O -
such O +
as O +
zaprinast O +
or O +
dipyridamole O -
) O -
, O +
would O +
be O +
expected O +
to O +
significantly O +
attenuate O +
the O +
response O -
. O +

It O +
was O +
found O -
, O +
however O -
, O +
that O +
addition O +
of O +
exogenous O +
8-bromo O -
- O -
cGMP O +
( O -
up O +
to O +
100 O +
μM O -
) O +
or O +
zaprinast O +
or O +
dipyridamole O +
did O +
not O +
inhibit O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
. O +

To O +
verify O +
that O +
the O +
addition O +
of O +
8-bromo O -
- O -
cGMP O +
resulted O +
in O +
increased O +
intracellular O +
cGMP O +
levels O -
, O +
assays O +
were O +
performed O +
to O +
measure O +
cGMP O +
levels O +
directly O -
. O +

The O +
results O +
indicated O +
that O +
exposure O +
to O +
10 O +
μM O +
8-bromo O -
- O -
cGMP O +
resulted O +
in O +
elevated O +
cell O +
8-bromo O -
- O -
cGMP O +
levels O -
, O +
as O +
compared O +
to O +
control O +
cells O -
. O +

In O +
this O +
series O +
of O +
experiments O -
, O +
we O +
could O +
not O +
demonstrate O +
a O +
reduction O +
of O +
cGMP O +
levels O +
in O +
the O +
presence O +
of O +
LY-83583 O +
alone O -
. O +

While O +
this O +
latter O +
finding O +
remains O +
unexplained O -
, O +
it O +
is O +
possible O +
that O +
the O +
addition O +
of O +
dipyridamole O +
( O -
a O +
cGMP B-Gene +
phosphodiesterase I-Gene +
inhibitor O -
) O +
prior O +
to O +
exposure O +
to O +
LY-83583 O +
may O +
have O +
obscured O +
the O +
expected O +
decrease O +
in O +
intracellular O +
cGMP O +
concentration O -
. O +

( O -
The O +
very O +
low O +
levels O +
of O +
cGMP O +
in O +
cells O +
under O +
basal O +
conditions O +
in O +
the O +
absence O +
of O +
dipyridamole O +
were O +
unreliable O +
by O +
the O +
assay O +
employed O -
. O -
) O +

Taken O +
together O -
, O +
the O +
above O +
results O +
suggest O +
that O +
the O +
stimulation O +
of O +
glucose O +
transport O +
by O +
LY-83583 O +
is O +
independent O +
of O +
changes O +
in O +
intracellular O +
cGMP O +
concentration O -
. O +

It O +
has O +
been O +
reported O +
that O +
in O +
addition O +
to O +
LY-83583 O -
's O +
well O -
- O -
known O +
inhibitory O +
actions O +
on O +
guanylyl B-Gene +
cyclase I-Gene +
activity O -
, O +
LY-83583 O +
also O +
stimulates O +
intracellular O +
superoxide O +
formation O +
( O -
Baas O +
and O +
Berk O -
, O +
1995 O +
) O -
. O +

Reactive O +
oxygen O +
species O +
such O +
as O +
superoxide O +
and O +
hydrogen O +
peroxide O +
have O +
been O +
shown O +
not O +
only O +
to O +
stimulate O +
glucose O +
transport O +
( O -
Fischer O +
et O +
al. O -
, O +
1993 O +
; O +
Kozlovsky O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
but O +
also O +
to O +
enhance O +
phospholipase B-Gene +
C I-Gene +
activity O +
( O -
Kontos O +
and O +
Hess O -
, O +
1983 O +
) O -
. O +

We O +
hence O +
explored O +
the O +
possibility O +
that O +
the O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
is O +
mediated O +
through O +
activation O +
of O +
phospholipase B-Gene +
C. I-Gene +
The O +
following O +
experimental O +
results O +
are O +
consistent O +
with O +
the O +
above O +
possibility O -
, O +
namely O -
: O +
( O -
i O -
) O +
exposure O +
to O +
LY-83583 O +
resulted O +
in O +
a O +
significant O +
rise O +
in O +
cell O +
diacylglycerol O +
content O -
, O +
and O +
the O +
increase O +
in O +
diacylglycerol O +
was O +
diminished O +
by O +
U73122 O -
, O +
an O +
inhibitor O +
of O +
phospholipase B-Gene +
C I-Gene +
activity O -
; O +
( O -
ii O -
) O +
U73122 O +
attenuated O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
; O +
and O +
( O -
iii O -
) O +
the O +
stimulatory O +
effect O +
of O +
LY-83583 O +
on O +
glucose O +
transport O +
was O +
significantly O +
blocked O +
by O +
thapsigargin O -
, O +
a O +
specific O +
inhibitor O +
of O +
microsomal O +
Ca2 B-Gene -
+ I-Gene +
-ATPase I-Gene -
, O +
which O +
leads O +
to O +
a O +
depletion O +
of O +
Ca2 O -
+ O +
stores O +
from O +
the O +
microsomal O +
compartment O -
. O +

This O +
latter O +
result O +
is O +
consistent O +
with O +
other O +
reports O +
suggesting O +
that O +
the O +
downstream O +
effects O +
of O +
phospholipase B-Gene +
C I-Gene +
activation O +
and O +
the O +
attendant O +
increase O +
in O +
cell O +
inositol-1,4,5-triphosphate O +
levels O +
require O +
the O +
presence O +
of O +
normal O +
microsomal O +
calcium O +
stores O +
( O -
Daniell O +
and O +
Harris O -
, O +
1988 O +
) O -
. O +

The O +
observation O +
that O +
thapsigargin O +
only O +
partially O +
attenuated O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O +
suggests O +
that O +
other O +
sources O +
of O +
calcium O +
( O -
perhaps O +
from O +
the O +
extracellular O +
compartment O -
) O +
are O +
also O +
involved O +
in O +
the O +
response O -
. O +

Further O +
studies O +
are O +
required O +
to O +
delineate O +
the O +
relative O +
importance O +
of O +
various O +
calcium O +
sources O +
in O +
the O +
stimulation O +
of O +
glucose O +
transport O +
by O +
LY-83583 O -
. O +

Stimulation O +
of O +
phospholipase O +
C O +
activity O +
and O +
the O +
resultant O +
increase O +
in O +
diacylglycerol O +
and O +
intracellular O +
Ca2 O -
+ O +
would O +
be O +
expected O +
to O +
lead O +
to O +
stimulation O +
of O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
activity O -
. O +

It O +
is O +
also O +
well O +
established O +
that O +
prolonged O +
exposure O +
of O +
cells O +
to O +
phorbol O +
esters O +
( O -
such O +
as O +
PMA O -
) O +
results O +
in O +
` O -
down O -
- O -
regulation O -
' O +
of O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
activity O +
( O -
Bandyopadhyay O +
et O +
al. O -
, O +
1997 O +
; O +
Formisano O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Results O +
of O +
experiments O +
reported O +
herein O +
indicate O +
that O +
LY-83583 O -
's O +
effect O +
to O +
stimulate O +
glucose O +
transport O +
is O +
unaffected O +
in O +
cells O +
pre O -
- O -
exposed O +
to O +
PMA O -
. O +

However O -
, O +
since O +
not O +
all O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
isoforms O +
are O +
` O -
down O -
- O -
regulated O -
' O +
by O +
this O +
treatment O +
( O -
Bandyopadhyay O +
et O +
al. O -
, O +
1997 O +
; O +
Formisano O +
et O +
al. O -
, O +
1998 O +
) O +
it O +
is O +
possible O +
that O +
the O +
effect O +
of O +
phospholipase B-Gene +
C I-Gene +
is O +
mediated O +
by O +
these O +
diacylglycerol O -
- O -
insensitive O +
protein B-Gene +
kinase I-Gene +
C I-Gene +
isoforms O -
. O +

Further O +
studies O +
are O +
required O +
to O +
verify O +
the O +
mediating O +
role O +
of O +
the O +
phospholipase B-Gene +
C I-Gene +
pathway O +
in O +
the O +
glucose O +
transport O +
response O +
to O +
LY-83583 O -
, O +
and O +
to O +
determine O +
the O +
intermediate O +
steps O +
linking O +
phospholipase B-Gene +
C I-Gene +
activation O +
to O +
the O +
observed O +
stimulation O +
of O +
glucose O +
transport O -
. O +

Acknowledgements O +
The O +
authors O +
would O +
like O +
to O +
thank O +
Dr. O +
Amir O +
Hamrahian O +
for O +
his O +
help O +
in O +
performance O +
of O +
some O +
of O +
the O +
assays O -
. O +

This O +
study O +
was O +
supported O +
in O +
part O +
by O +
a O +
grant O +
from O +
the O +
National O +
Institutes O +
of O +
Health O +
( O -
# O -
DK45945 O -
) O -
. O +

Retinaldehyde O +
( O -
RAL O -
) O -
, O +
a O +
key O +
intermediate O +
in O +
retinoid O +
metabolism O -
, O +
acts O +
as O +
a O +
retinoic O +
acid O +
( O -
RA O -
) O +
precursor O -
, O +
but O +
is O +
also O +
reduced O +
to O +
retinol O +
( O -
ROH O -
) O -
, O +
which O +
can O +
subsequently O +
be O +
esterified O +
to O +
retinyl O +
esters O -
, O +
the O +
storage O +
form O +
of O +
vitamin O +
A. O +
Limited O +
information O +
is O +
available O +
on O +
the O +
metabolism O +
of O +
geometric O +
isomers O +
of O +
RAL O +
as O +
well O +
as O +
on O +
the O +
transplacental O +
distribution O +
of O +
their O +
metabolites O -
, O +
including O +
RA O +
isomers O -
. O +

Such O +
information O +
would O +
be O +
very O +
helpful O +
for O +
the O +
assessment O +
of O +
the O +
teratogenic O +
potency O +
of O +
RAL O +
isomers O -
, O +
as O +
teratogenesis O +
represents O +
a O +
major O +
side O +
effect O +
of O +
retinoid O +
use O +
in O +
pharmacotherapy O -
. O +

In O +
the O +
present O +
study O +
we O +
examined O +
concentrations O +
of O +
retinoids O +
in O +
plasma O -
, O +
maternal O +
tissues O -
, O +
and O +
embryos O +
of O +
pregnant O +
rats O +
2 O +
h O +
after O +
a O +
single O +
oral O +
dose O +
( O -
100 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O +
of O +
all O -
- O -
trans- O -
, O +
13-cis- O -
, O +
or O +
9-cis O -
- O -
RAL O +
on O +
gestational O +
day O +
13 O -
. O +

The O +
main O +
findings O +
of O +
this O +
study O +
were O +
the O +
very O +
similar O +
patterns O +
of O +
retinoid O +
metabolites O +
( O -
consisting O +
of O +
retinoids O +
with O +
mainly O +
the O +
all O -
- O -
trans O -
- O -
configuration O -
) O +
after O +
administration O +
of O +
all O -
- O -
trans- O +
and O +
13-cis O -
- O -
RAL O -
, O +
and O +
the O +
high O +
concentrations O +
of O +
9-cis O -
- O -
RA O -
, O +
9,13-dicis O -
- O -
RA O -
, O +
and O +
9-cis O -
- O -
retinoyl O -
- O -
beta O -
- O -
D O -
- O -
glucuronide O +
after O +
dosing O +
with O +
9-cis O -
- O -
RAL O -
. O +

In O +
addition O -
, O +
all O -
- O -
trans O -
- O -
RA O +
as O +
a O +
RAL O +
metabolite O +
reached O +
the O +
embryos O +
to O +
a O +
much O +
greater O +
extent O +
than O +
any O +
of O +
its O +
cis O -
- O -
isomers O -
. O +

The O +
results O +
are O +
discussed O +
in O +
view O +
of O +
in O +
vitro O +
data O +
on O +
enzymes B-Gene +
involved O +
in O +
the O +
biotransformation O +
of O +
RAL O +
isomers O -
. O +

UDP B-Gene -
- I-Gene -
glucose I-Gene -
: I-Gene +
anthocyanin I-Gene +
5-O I-Gene -
- I-Gene -
glucosyltransferase I-Gene +
( O -
5-GT B-Gene -
) O +
is O +
responsible O +
for O +
the O +
modification O +
of O +
anthocyanins O +
to O +
more O +
stable O +
molecules O +
in O +
complexes O +
for O +
co O -
- O -
pigmentation O -
, O +
supposedly O +
resulting O +
in O +
a O +
purple O +
hue O -
. O +

The O +
cDNA O +
encoding O +
5-GT B-Gene +
was O +
isolated O +
by O +
a O +
differential O +
display O +
applied O +
to O +
two O +
different O +
forms O +
of O +
anthocyanin O +
production O +
in O +
Perilla O +
frutescens O +
var O -
. O +

crispa O -
. O +

Differential O +
display O +
was O +
carried O +
out O +
for O +
mRNA O +
from O +
the O +
leaves O +
of O +
reddish O -
- O -
purple O +
and O +
green O +
forms O +
of O +
P. O +
frutescens O -
, O +
resulting O +
in O +
the O +
isolation O +
of O +
five O +
cDNA O +
clones O +
predominantly O +
expressed O +
in O +
the O +
red O +
form O -
. O +

The O +
cDNA O +
encoded O +
a O +
polypeptide B-Gene +
of O +
460 O +
amino O +
acids O -
, O +
exhibiting O +
a O +
low O +
homology O +
with O +
the O +
sequences O +
of O +
several O +
glucosyltransferases B-Gene +
including O +
UDP B-Gene -
- I-Gene -
glucose I-Gene -
: I-Gene +
anthocyanidin I-Gene +
3-O I-Gene -
- I-Gene -
glucosyltransferase I-Gene -
. O +

By O +
using O +
this O +
cDNA O +
as O +
the O +
probe O -
, O +
we O +
also O +
isolated O +
a O +
homologous O +
cDNA O +
clone O +
from O +
a O +
petal O +
cDNA O +
library O +
of O +
Verbena O +
hybrida O -
. O +

To O +
identify O +
the O +
biochemical O +
function O +
of O +
the O +
encoded O +
proteins B-Gene -
, O +
these O +
cDNAs O +
were O +
expressed O +
in O +
Saccharomyces O +
cerevisiae O +
cells O -
. O +

The O +
recombinant O +
proteins B-Gene +
in O +
the O +
yeast O +
extracts O +
catalyzed O +
the O +
conversion O +
of O +
anthocyanidin O +
3-O O -
- O -
glucosides O +
into O +
the O +
corresponding O +
anthocyanidin O +
3,5-di O -
- O -
O O -
- O -
glucosides O +
using O +
UDP O -
- O -
glucose O +
as O +
a O +
cofactor O -
, O +
indicating O +
the O +
identity O +
of O +
the O +
cDNAs O +
encoding O +
5-GT B-Gene -
. O +

Several O +
biochemical O +
properties O +
( O -
optimum O +
pH O -
, O +
Km O +
values O -
, O +
and O +
sensitivity O +
to O +
inhibitors O -
) O +
were O +
similar O +
to O +
those O +
reported O +
previously O +
for O +
5-GTs B-Gene -
. O +

Southern O +
blot O +
analysis O +
indicated O +
the O +
presence O +
of O +
two O +
copies O +
of O +
5-GT B-Gene +
genes O +
in O +
the O +
genome O +
of O +
both O +
red O +
and O +
green O +
forms O +
of O +
P. O +
frutescens O -
. O +

The O +
mRNA O +
accumulation O +
of O +
the O +
5-GT B-Gene +
gene O +
was O +
detected O +
in O +
the O +
leaves O +
of O +
the O +
red O +
form O +
but O +
not O +
in O +
those O +
of O +
the O +
green O +
form O +
and O +
was O +
induced O +
by O +
illumination O +
of O +
light O -
, O +
as O +
observed O +
for O +
other O +
structural O +
genes O +
for O +
anthocyanin O +
biosynthesis O +
in O +
P. O +
frutescens O -
. O +

The O +
cephalosporins O +
are O +
a O +
large O +
group O +
of O +
related O +
beta O -
- O -
lactam O +
antimicrobial O +
agents O -
. O +

Favorable O +
attributes O +
of O +
the O +
cephalosporins O +
include O +
low O +
rates O +
of O +
toxicity O -
, O +
relatively O +
broad O +
spectrum O +
of O +
activity O -
, O +
and O +
ease O +
of O +
administration O -
. O +

Various O +
cephalosporins O +
are O +
effective O +
for O +
treatment O +
of O +
many O +
conditions O -
, O +
including O +
pneumonia O -
, O +
skin O +
and O +
soft O +
tissue O +
infections O -
, O +
bacteremia O -
, O +
and O +
meningitis O -
. O +

Differences O +
among O +
the O +
numerous O +
cephalosporin O +
antimicrobial O +
agents O +
are O +
sometimes O +
subtle O -
; O +
however O -
, O +
an O +
understanding O +
of O +
these O +
differences O +
is O +
essential O +
for O +
optimal O +
use O +
of O +
these O +
agents O -
. O +

As O +
a O +
result O +
of O +
widespread O +
use O +
of O +
cephalosporins O -
, O +
bacterial O +
resistance O +
to O +
these O +
drugs O +
is O +
increasingly O +
common O -
. O +

New O -
, O +
fourth O -
- O -
generation O +
agents O +
( O -
such O +
as O +
cefepime O -
) O +
offer O +
an O +
alternative O +
for O +
the O +
treatment O +
of O +
infections O +
caused O +
by O +
some O +
drug O -
- O -
resistant O +
microorganisms O -
. O +

A O +
comparative O +
study O +
of O +
various O +
procedures O +
for O +
tryptophanyl O +
peptide O +
bond O +
cleavage O +
by O +
BNPS O -
- O -
skatole O +
[ O -
2- O -
( O -
2-nitrophenyl O -
) O -
-3-methyl-3-bromoindolenine O -
] O +
was O +
carried O +
out O +
on O +
native O +
and O +
on O +
reduced O +
and O +
alkylated O +
bovine O +
beta B-Gene -
- I-Gene -
lactoglobulin I-Gene +
( O -
BLG B-Gene -
) O -
. O +

The O +
reaction O +
yield O +
and O +
the O +
composition O +
of O +
the O +
derived O +
products O +
were O +
studied O +
in O +
acetic O +
acid O -
, O +
trifluoroacetic O +
acid O +
( O -
TFA O -
) O -
, O +
and O +
ethanol O -
/ O -
TFA O -
. O +

For O +
BNPS O -
- O -
skatole O +
removal O -
, O +
extraction O +
by O +
water O +
or O +
ethyl O +
ether O +
was O +
compared O +
with O +
dialysis O +
and O +
gel O +
filtration O -
. O +

The O +
three O +
expected O +
peptides O +
( O -
1 O -
- O -
19 O -
, O +
20 O -
- O -
61 O -
, O +
62 O -
- O -
162 O -
) O +
and O +
incomplete O +
cleaved O +
fragments O +
( O -
1 O -
- O -
61 O -
, O +
20 O -
- O -
162 O -
) O +
were O +
separated O +
and O +
characterized O +
by O +
electrophoresis O -
, O +
reverse O -
- O -
phase O +
high O -
- O -
performance O +
liquid O +
chromatography O -
, O +
and O +
mass O +
spectrometry O -
. O +

The O +
highest O +
hydrolysis O +
yield O +
( O -
67.4 O -
% O -
) O +
occurred O +
with O +
native O +
BLG B-Gene +
cleaved O +
in O +
88 O -
% O +
acetic O +
acid O +
at O +
47 O +
degrees O +
C O +
for O +
60 O +
min O -
. O +

Subsequent O +
water O +
extraction O +
and O +
gel O +
filtration O +
led O +
to O +
total O +
recovery O +
of O +
the O +
material O -
, O +
but O +
reagent O +
elimination O +
was O +
only O +
quantitative O +
after O +
gel O +
filtration O -
. O +

Cleavage O +
specificity O +
was O +
ensured O +
by O +
mass O +
spectrometry O +
and O +
the O +
amino O +
acid O +
composition O +
of O +
peptides O +
1 O -
- O -
19 O +
and O +
62 O -
- O -
162 O -
. O +

The O +
chemical O +
side O +
reactions O +
identified O +
are O +
discussed O -
. O +

We O +
conducted O +
a O +
study O +
of O +
the O +
patterns O +
and O +
dynamics O +
of O +
oxidized O +
fatty O +
acid O +
derivatives O +
( O -
oxylipins O -
) O +
in O +
potato O +
leaves O +
infected O +
with O +
the O +
late O -
- O -
blight O +
pathogen O +
Phytophthora O +
infestans O -
. O +

Two O +
18-carbon O +
divinyl O +
ether O +
fatty O +
acids O -
, O +
colneleic O +
acid O +
and O +
colnelenic O +
acid O -
, O +
accumulated O +
during O +
disease O +
development O -
. O +

To O +
date O -
, O +
there O +
are O +
no O +
reports O +
that O +
such O +
compounds O +
have O +
been O +
detected O +
in O +
higher O +
plants O -
. O +

The O +
divinyl O +
ether O +
fatty O +
acids O +
accumulate O +
more O +
rapidly O +
in O +
potato O +
cultivar O +
Matilda O +
( O -
a O +
cultivar O +
with O +
increased O +
resistance O +
to O +
late O +
blight O -
) O +
than O +
in O +
cultivar O +
Bintje O -
, O +
a O +
susceptible O +
cultivar O -
. O +

Colnelenic O +
acid O +
reached O +
levels O +
of O +
up O +
to O +
approximately O +
24 O +
nmol O +
( O -
7 O +
microgram O -
) O +
per O +
g O +
fresh O +
weight O +
of O +
tissue O +
in O +
infected O +
leaves O -
. O +

By O +
contrast O -
, O +
levels O +
of O +
members O +
of O +
the O +
jasmonic O +
acid O +
family O +
did O +
not O +
change O +
significantly O +
during O +
pathogenesis O -
. O +

The O +
divinyl O +
ethers O +
also O +
accumulated O +
during O +
the O +
incompatible O +
interaction O +
of O +
tobacco O +
with O +
tobacco O +
mosaic O +
virus O -
. O +

Colneleic O +
and O +
colnelenic O +
acids O +
were O +
found O +
to O +
be O +
inhibitory O +
to O +
P. O +
infestans O -
, O +
suggesting O +
a O +
function O +
in O +
plant O +
defense O +
for O +
divinyl O +
ethers O -
, O +
which O +
are O +
unstable O +
compounds O +
rarely O +
encountered O +
in O +
biological O +
systems O -
. O +

Tyrosinaemia O +
type O +
I O +
is O +
caused O +
by O +
a O +
deficiency O +
of O +
fumarylacetoacetate B-Gene +
hydrolase I-Gene +
and O +
mainly O +
affects O +
the O +
liver O -
. O +

This O +
disease O +
is O +
characterized O +
by O +
the O +
presence O +
of O +
a O +
high O +
level O +
of O +
succinylacetone O -
. O +

This O +
metabolite O +
has O +
been O +
used O +
for O +
prenatal O +
diagnosis O +
from O +
amniotic O +
fluid O +
samples O -
. O +

One O +
case O +
with O +
a O +
normal O +
level O +
of O +
succinylacetone O +
in O +
amniotic O +
fluid O +
has O +
recently O +
been O +
described O +
( O -
Grenier O +
et O +
al. O -
, O +
1996 O -
) O -
. O +

Here O -
, O +
we O +
report O +
that O +
this O +
patient O +
is O +
a O +
compound O +
heterozygote O +
for O +
two O +
known O +
mutations O -
: O +
E364X O +
and O +
IVS6 O -
- O -
1g-->t O -
. O +

The O +
low O +
level O +
of O +
succinylacetone O +
can O -
not O +
be O +
explained O +
by O +
these O +
mutations O -
. O +

An O +
aminotransferase B-Gene +
which O +
catalyzes O +
the O +
final O +
step O +
in O +
methionine O +
recycling O +
from O +
methylthioadenosine O -
, O +
the O +
conversion O +
of O +
alpha O -
- O -
ketomethiobutyrate O +
to O +
methionine O -
, O +
has O +
been O +
purified O +
from O +
Klebsiella O +
pneumoniae O +
and O +
characterized O -
. O +

The O +
enzyme B-Gene +
was O +
found O +
to O +
be O +
a O +
homodimer O +
of O +
45-kDa O +
subunits O -
, O +
and O +
it O +
catalyzed O +
methionine O +
formation O +
primarily O +
using O +
aromatic O +
amino O +
acids O +
and O +
glutamate O +
as O +
the O +
amino O +
donors O -
. O +

Histidine O -
, O +
leucine O -
, O +
asparagine O -
, O +
and O +
arginine O +
were O +
also O +
functional O +
amino O +
donors O +
but O +
to O +
a O +
lesser O +
extent O -
. O +

The O +
N O -
- O -
terminal O +
amino O +
acid O +
sequence O +
of O +
the O +
enzyme B-Gene +
was O +
determined O +
and O +
found O +
to O +
be O +
almost O +
identical O +
to O +
the O +
N O -
- O -
terminal O +
sequence O +
of O +
both O +
the O +
Escherichia O +
coli O +
and O +
Salmonella O +
typhimurium O +
tyrosine B-Gene +
aminotransferases I-Gene +
( O -
tyrB B-Gene +
gene O +
products O -
) O -
. O +

The O +
structural O +
gene O +
for O +
the O +
tyrosine B-Gene +
aminotransferase I-Gene +
was O +
cloned O +
from O +
K. O +
pneumoniae O +
and O +
expressed O +
in O +
E. O +
coli O -
. O +

The O +
deduced O +
amino O +
acid O +
sequence O +
displayed O +
83 O -
, O +
80 O -
, O +
38 O -
, O +
and O +
34 O -
% O +
identity O +
to O +
the O +
tyrosine B-Gene +
aminotransferases I-Gene +
from O +
E. O +
coli O -
, O +
S. O +
typhimurium O -
, O +
Paracoccus O +
denitrificans O -
, O +
and O +
Rhizobium O +
meliloti O -
, O +
respectively O -
, O +
but O +
it O +
showed O +
less O +
than O +
13 O -
% O +
identity O +
to O +
any O +
characterized O +
eukaryotic O +
tyrosine B-Gene +
aminotransferase I-Gene -
. O +

Structural O +
motifs O +
around O +
key O +
invariant O +
residues O +
placed O +
the O +
K. O +
pneumoniae O +
enzyme B-Gene +
within O +
the O +
Ia O +
subfamily O +
of O +
aminotransferases B-Gene -
. O +

Kinetic O +
analysis O +
of O +
the O +
aminotransferase B-Gene +
showed O +
that O +
reactions O +
of O +
an O +
aromatic O +
amino O +
acid O +
with O +
alpha O -
- O -
ketomethiobutyrate O +
and O +
of O +
glutamate O +
with O +
alpha O -
- O -
ketomethiobutyrate O +
proceed O +
as O +
favorably O +
as O +
the O +
well O -
- O -
known O +
reactions O +
of O +
tyrosine O +
with O +
alpha O -
- O -
ketoglutarate O +
and O +
tyrosine O +
with O +
oxaloacetate O +
normally O +
associated O +
with O +
tyrosine B-Gene +
aminotransferases I-Gene -
. O +

The O +
aminotransferase B-Gene +
was O +
inhibited O +
by O +
the O +
aminooxy O +
compounds O +
canaline O +
and O +
carboxymethoxylamine O +
but O +
not O +
by O +
substrate O +
analogues O -
, O +
such O +
as O +
nitrotyrosine O +
or O +
nitrophenylalanine O -
. O +

Casimiroa O +
edulis O +
de O +
la O +
Llave O +
and O +
Lexarza O +
( O -
Rutaceae O -
) O -
, O +
commonly O +
known O +
as O +
' O -
zapote O +
blanco O -
' O +
is O +
a O +
tree O +
indigenous O +
to O +
Mexico O -
, O +
used O +
by O +
local O +
herbalists O +
in O +
the O +
treatment O +
of O +
hypertension O +
( O -
Lozoya O +
et O +
al. O -
, O +
1987 O +
) O -
. O +

The O +
hypotensive O +
activity O +
of O +
the O +
plant O +
was O +
first O +
recognized O +
a O +
hundred O +
years O +
ago O +
( O -
Anonymous O -
, O +
1897 O +
) O +
and O +
later O +
confirmed O +
in O +
animals O +
( O -
De O +
Lille O +
1934 O -
, O +
Ramı́rez O +
and O +
Rivero O +
1935 O -
, O +
Lozoya O +
et O +
al. O +
1977 O -
, O +
Magos O +
and O +
Vidrio O +
1991 O +
) O +
and O +
humans O +
( O -
Flores O +
Montalvo O +
1936 O -
, O +
Cruz O +
y O +
Corro O +
1939 O +
) O -
. O +

We O +
recently O +
found O +
that O +
the O +
methanolic O +
extract O +
of O +
' O -
zapote O +
blanco O -
' O +
seeds O +
exerts O +
its O +
hypotensive O +
action O +
apparently O +
by O +
peripheral O +
vasodilation O +
mediated O +
through O +
histamine B-Gene +
H1 I-Gene +
-receptors I-Gene +
and O +
that O +
it O +
also O +
produces O +
α O +
-adrenergic O +
vasoconstriction O +
( O -
Magos O +
and O +
Vidrio O +
1991 O -
, O +
Vidrio O +
and O +
Magos O +
1991 O -
, O +
Magos O +
et O +
al. O +
1995 O +
) O -
. O +

Hypotension O +
produced O +
by O +
' O -
zapote O +
blanco O -
' O +
was O +
previously O +
attributed O +
solely O +
to O +
N O +
, O -
N O +
-dimethylhistamine O +
( O -
Major O +
and O +
Dürsch O +
1958 O -
, O +
Lozoya O +
et O +
al. O +
1978 O +
) O -
, O +
a O +
histamine O +
derivative O +
present O +
in O +
the O +
plant O -
, O +
which O +
shares O +
the O +
hypotensive O +
effects O +
of O +
the O +
parent O +
compound O +
( O -
Vartiainen O +
1935 O -
, O +
Bertaccini O +
and O +
Vitali O +
1964 O +
) O -
. O +

No O +
detailed O +
pharmacology O +
of O +
other O +
possible O +
vasoactive O +
components O +
of O +
the O +
seed O +
has O +
been O +
described O -
. O +

In O +
this O +
work O +
we O +
report O +
the O +
hypotensive O +
effects O +
of O +
several O +
compounds O +
present O +
in O +
the O +
methanolic O +
extract O +
of O +
' O -
zapote O +
blanco O -
' O +
seeds O -
, O +
potentially O +
jointly O +
responsible O +
for O +
the O +
action O +
of O +
the O +
plant O +
on O +
blood O +
pressure O -
. O +

Particular O +
attention O +
is O +
given O +
to O +
the O +
mechanism O +
of O +
action O +
of O +
the O +
above O +
mentioned O +
histamine O +
derivative O -
, O +
as O +
well O +
as O +
of O +
its O +
N O +
-monomethyl O +
analog O -
. O +

Of O +
the O +
other O +
compounds O -
, O +
some O +
were O +
previously O +
reported O +
for O +
this O +
plant O +
and O +
some O +
are O +
described O +
for O +
the O +
first O +
time O -
. O +

Detailed O +
chemical O +
work O +
leading O +
to O +
the O +
structural O +
characterization O +
of O +
these O +
compounds O +
will O +
be O +
published O +
elsewhere O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Plant O +
material O +
Seeds O +
of O +
ripe O +
fruits O +
of O +
C. O +
edulis O +
were O +
collected O +
in O +
Texcoco O -
, O +
Mexico O +
State O -
. O +

The O +
botanical O +
identity O +
of O +
the O +
plant O +
was O +
verified O +
and O +
vouched O +
at O +
the O +
herbarium O +
of O +
the O +
Botanical O +
Center O +
of O +
the O +
Graduate O +
College O +
of O +
Chapingo O -
. O +

The O +
specimen O +
deposited O +
as O +
Collection O +
No. O +
1 O +
of O +
G.A. O +
Magos O -
, O +
was O +
authenticated O +
by O +
José O +
Garcı́a O +
Pérez O -
, O +
botanist O +
in O +
charge O +
of O +
the O +
herbarium O -
. O +

2.2 O +
Sample O +
preparation O +
The O +
dry O +
ground O +
kernels O +
( O -
1 O +
kg O -
) O +
were O +
extracted O +
by O +
maceration O +
at O +
room O +
temperature O +
with O +
methanol O -
. O +

The O +
solvent O +
was O +
eliminated O +
by O +
drying O +
in O +
vacuum O +
and O +
a O +
portion O +
of O +
the O +
extracted O +
material O +
( O -
25 O +
g O -
) O +
was O +
subjected O +
to O +
column O +
chromatography O +
( O -
CC O -
) O +
on O +
silica O +
gel O +
60 O +
( O -
500 O +
g O -
) O -
. O +

Fractions O +
obtained O +
by O +
discontinuous O +
gradient O +
elution O +
with O +
acetonitrile O -
- O -
methanol O +
( O -
60:40 O +
v O -
/ O -
v O -
) O +
and O +
n O -
- O -
propanol O -
- O -
water O +
( O -
100:50 O +
v O -
/ O -
v O -
) O -
, O +
both O +
in O +
1 O -
% O +
ammonium O +
hydroxide O -
, O +
were O +
grouped O +
on O +
the O +
basis O +
of O +
thin O +
layer O +
chromatography O +
( O -
TLC O -
) O +
and O +
hypotensive O +
activity O -
. O +

The O +
active O +
fractions O +
were O +
rechromatographed O +
by O +
CC O +
and O +
preparative O +
TLC O -
. O +

2.3 O +
Compound O +
identification O +
The O +
seven O +
compounds O +
found O +
in O +
the O +
active O +
fractions O +
were O +
identified O +
by O +
IR O -
, O +
NMR O +
and O +
MS O +
spectra O -
. O +

IR O +
spectra O +
were O +
obtained O +
in O +
Kbr O +
or O +
as O +
a O +
film O +
with O +
a O +
Perkin O -
- O -
Elmer O +
283-B O +
or O +
a O +
Nicolet O +
FT O -
- O -
J.RSX O +
spectrometer O -
. O +

1 O +
H O +
NMR O +
spectra O +
were O +
obtained O +
in O +
methanol O +
or O +
D2 O +
O O +
using O +
a O +
Varian O +
XL O +
300 O +
Mhz O +
spectrometer O -
. O +

MS O +
spectra O +
were O +
obtained O +
with O +
a O +
Jeol O +
JMS O -
- O -
SX102A O +
mass O +
spectrometer O +
operating O +
at O +
70 O +
eV. O +
Compounds O +
in O +
the O +
fraction O +
of O +
higher O +
polarity O +
designated O +
as O +
the O +
MP O +
zone O +
( O -
see O +
below O -
) O +
were O +
identified O +
by O +
1 O +
H O +
and O +
DEPT O +
NMR O +
spectra O +
in O +
conjuction O +
with O +
COSY O -
, O +
TOCSY O -
, O +
HMQC O +
and O +
HMBC O +
NMR O +
using O +
a O +
500 O +
Mhz O +
instrument O -
. O +

2.4 O +
Preparation O +
of O +
anesthetized O +
rats O +
and O +
guinea O +
pigs O +
Male O +
Wistar O +
rats O +
weighing O +
250–300 O +
g O +
and O +
male O +
guinea O +
pigs O +
of O +
mixed O +
breed O +
weighing O +
300–400 O +
g O -
, O +
were O +
anesthetized O +
with O +
sodium O +
pentobarbital O +
( O -
30 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O -
. O +

After O +
cannulation O +
of O +
the O +
trachea O +
for O +
artificial O +
respiration O -
, O +
polyethylene O +
cannulas O +
were O +
inserted O +
in O +
a O +
femoral O +
artery O +
and O +
vein O +
in O +
rats O +
or O +
in O +
a O +
carotid O +
artery O +
and O +
a O +
jugular O +
vein O +
in O +
guinea O +
pigs O -
, O +
for O +
continuous O +
recording O +
of O +
blood O +
pressure O +
and O +
drug O +
administration O -
, O +
respectively O -
. O +

Mean O +
arterial O +
pressure O +
( O -
MAP O -
) O +
was O +
recorded O +
with O +
a O +
pressure O +
transducer O +
connected O +
to O +
the O +
arterial O +
cannula O -
. O +

The O +
signal O +
from O +
the O +
transducer O +
was O +
electronically O +
dampened O +
and O +
inscribed O +
on O +
a O +
Model O +
79 O +
Grass O +
polygraph O -
. O +

Heart O +
rate O +
( O -
HR O -
) O +
was O +
recorded O +
with O +
a O +
tachograph O +
driven O +
by O +
the O +
undampened O +
pulse O +
signal O +
of O +
the O +
transducer O -
. O +

In O +
all O +
experiments O -
, O +
groups O +
of O +
six O +
animals O +
were O +
used O +
and O +
pretreatments O +
were O +
carried O +
out O +
i.v O -
. O +

10 O +
min O +
before O +
administration O +
of O +
the O +
test O +
compounds O -
. O +

2.5 O +
Drugs O +
Micronized O +
loratadine O +
was O +
supplied O +
by O +
Schering O +
Plough O -
, O +
Mexico O -
. O +

The O +
hydrochlorides O +
of O +
histamine O -
, O +
prazosin O -
, O +
dl O +
-propranolol O -
, O +
l O +
-phenylephrine O +
and O +
N O +
ω O -
- O -
nitro O -
- O -
l O +
-arginine O +
methyl O +
ester O -
, O +
as O +
well O +
as O +
atropine O +
sulfate O -
, O +
( O -
± O -
) O -
-synephrine O +
and O +
cimetidine O +
free O +
bases O -
, O +
γ O +
-aminobutyric O +
acid O -
, O +
l O +
-proline O +
and O +
N O +
-methyl O -
- O -
l O +
-proline O +
were O +
obtained O +
from O +
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
. O +

Loratadine O +
and O +
casimiroedine O +
were O +
used O +
as O +
resuspensions O +
in O +
distilled O +
water O -
; O +
all O +
other O +
drugs O +
were O +
dissolved O +
in O +
isotonic O +
saline O +
solution O -
. O +

In O +
all O +
cases O +
the O +
volume O +
injected O +
was O +
1 O +
ml O -
/ O -
kg O -
. O +

2.6 O +
Statistical O +
analysis O +
Baseline O +
MAP O +
and O +
HR O +
values O -
, O +
as O +
well O +
as O +
changes O +
in O +
these O +
parameters O +
in O +
response O +
to O +
the O +
test O +
compounds O +
at O +
different O +
doses O +
or O +
times O +
were O +
compared O +
in O +
control O +
and O +
pretreated O +
groups O +
by O +
unpaired O +
or O +
paired O +
Student O -
's O +
t O +
-test O +
as O +
indicated O -
. O +

Comparison O +
of O +
two O +
treatment O +
groups O +
with O +
the O +
same O +
control O +
was O +
carried O +
out O +
by O +
analysis O +
of O +
variance O +
followed O +
by O +
Dunnett O -
's O +
test O -
. O +

A O +
probability O +
level O +
of O +
less O +
than O +
0.05 O +
was O +
considered O +
as O +
indicating O +
statistical O +
significance O +
of O +
the O +
differences O +
observed O -
. O +

3 O +
Results O +
The O +
bioassay O -
- O -
guided O +
fractionation O +
of O +
the O +
methanolic O +
extract O +
of O +
' O -
zapote O +
blanco O -
' O +
seeds O +
led O +
to O +
identification O +
of O +
a O +
chromatographic O +
zone O +
from O +
which O +
several O +
compounds O +
with O +
cardiovascular O +
activity O +
were O +
isolated O -
. O +

These O +
were O +
identified O +
as O +
the O +
histamine O +
( O -
H O -
) O +
derivatives O +
N O +
-momomethylhistamine O +
( O -
MMH O -
) O +
and O +
N O -
, O -
N O +
-dimethylhistamine O +
( O -
DMH O -
) O -
, O +
and O +
the O +
imidazolic O +
glucoalkaloid O +
casimiroedine O +
( O -
CAS O -
) O -
, O +
all O +
producing O +
hypotension O -
, O +
as O +
well O +
as O +
the O +
phenethylamine O +
derivative O +
synephrine O +
acetonide O +
( O -
SA O -
) O -
, O +
which O +
increased O +
MAP O +
and O +
HR O -
. O +

Silica O +
gel O +
rechromatography O +
of O +
the O +
methanolic O +
extract O +
produced O +
in O +
0.09 O -
% O +
yield O +
a O +
homogeneous O +
fraction O +
of O +
higher O +
polarity O +
( O -
MP O +
zone O -
) O +
also O +
eliciting O +
hypotension O -
. O +

High O +
field O +
and O +
bidimensional O +
NMR O +
revealed O +
the O +
presence O +
of O +
the O +
amino O +
acids O +
N O +
-methylproline O +
( O -
MP O -
, O +
70 O -
% O -
) O -
, O +
proline O +
( O -
P O -
, O +
18 O -
% O -
) O -
, O +
γ O +
-aminobutyric O +
acid O +
( O -
GABA O -
, O +
12 O -
% O -
) O +
and O +
other O +
unidentified O +
components O +
( O -
< O -
1 O -
% O -
) O -
. O +

The O +
structures O +
of O +
the O +
seven O +
compounds O +
identified O +
appear O +
in O +
Fig. O +
1 O +
. O +

3.1 O +
Studies O +
of O +
histamine O +
derivatives O +
Both O +
MMH O +
and O +
DMH O -
, O +
as O +
well O +
as O +
H O -
, O +
produced O +
short O -
- O -
lasting O -
, O +
dose O -
- O -
related O +
decreases O +
in O +
MAP O +
( O -
Fig. O +
2 O +
) O -
. O +

The O +
derivatives O +
were O +
respectively O +
two O +
and O +
ten O +
times O +
less O +
potent O +
than O +
H. O +
Responses O +
were O +
significantly O +
inhibited O +
by O +
the O +
peripheral O +
H1 B-Gene +
-antagonist O +
loratadine O +
but O +
not O +
by O +
the O +
H2 B-Gene +
-blocker O +
cimetidine O -
. O +

In O +
contrast O +
to O +
H O -
, O +
which O +
did O +
not O +
modify O +
HR O +
at O +
any O +
dose O -
, O +
both O +
derivatives O +
elicited O +
positive O +
chronotropic O +
effects O +
which O +
were O +
not O +
affected O +
by O +
H1 B-Gene +
- O +
or O +
H2 B-Gene +
-blockade O -
. O +

In O +
another O +
series O -
, O +
dose O -
- O -
response O +
curves O +
to O +
H O -
, O +
MMH O +
and O +
DMH O +
were O +
obtained O +
in O +
rats O +
receiving O +
a O +
continuous O +
infusion O +
of O +
phenylephrine O +
and O +
subsequently O +
pretreated O +
with O +
the O +
nitric O +
oxide O +
synthesis O +
inhibitor O +
Nω O +
-nitro O -
- O -
l O +
-arginine O +
methylester O +
( O -
l O +
-NAME O -
) O -
. O +

Phenylephrine O +
significantly O +
increased O +
MAP O +
from O +
123±2 O +
to O +
155±2 O +
mmHg O +
and O +
decreased O +
HR O +
from O +
427±6 O +
to O +
395±8 O +
beats O -
/ O -
min O -
. O +

These O +
values O +
were O +
not O +
changed O +
further O +
after O +
l O +
-NAME O -
, O +
MAP O +
being O +
156±5 O +
mmHg O +
and O +
HR O +
400±7 O +
beats O -
/ O -
min O -
. O +

Hypotensive O +
responses O +
to O +
H O +
were O +
similar O +
to O +
those O +
of O +
animals O +
not O +
receiving O +
the O +
vasoconstrictor O -
, O +
whereas O +
around O +
10-fold O +
higher O +
doses O +
of O +
the O +
derivatives O +
were O +
required O +
to O +
induce O +
equivalent O +
depressor O +
effects O -
. O +

Additional O +
pretreatment O +
with O +
l O +
-NAME O +
significantly O +
antagonized O +
responses O +
to O +
H O +
and O +
DMH O -
, O +
but O +
not O +
to O +
MMH O -
. O +

In O +
this O +
model O -
, O +
H O +
and O +
its O +
two O +
analogs O +
increased O +
HR O -
; O +
this O +
effect O +
was O +
inhibited O +
by O +
l O +
-NAME O +
only O +
in O +
the O +
case O +
of O +
DMH O +
( O -
Fig. O +
3 O +
) O -
. O +

3.2 O +
Studies O +
of O +
synephrine O +
acetonide O +
All O +
experiments O +
in O +
this O +
series O +
were O +
carried O +
out O +
after O +
pretreatment O +
with O +
atropine O -
, O +
in O +
order O +
to O +
block O +
baroreflex O -
- O -
induced O +
vagal O +
bradycardia O -
. O +

The O +
cyclized O +
phenethylamine O +
derivative O +
SA O +
produced O +
transient O -
, O +
dose O -
- O -
related O +
increases O +
in O +
MAP O +
and O +
HR O +
identical O +
to O +
those O +
elicited O +
by O +
the O +
reference O +
drug O +
synephrine O +
( O -
S O -
, O +
Fig. O +
4 O +
) O -
. O +

Pressor O +
responses O +
to O +
both O +
agents O +
were O +
significantly O +
inhibited O +
by O +
the O +
α O +
-adrenergic O +
antagonist O +
prazosin O -
, O +
but O +
were O +
unaffected O +
by O +
the O +
β O +
-adrenergic O +
blocker O +
propranolol O -
. O +

In O +
contrast O -
, O +
tachycardia O +
after O +
SA O +
and O +
S O +
was O +
partially O +
inhibited O +
by O +
both O +
antagonists O -
. O +

3.3 O +
Studies O +
of O +
the O +
MP O +
zone O +
and O +
casimiroedine O +
The O +
MP O +
zone O -
, O +
tested O +
in O +
rats O +
at O +
a O +
single O +
dose O +
of O +
10 O +
mg O -
/ O -
kg O -
, O +
elicited O +
marked O +
hypotension O +
lasting O +
more O +
than O +
60 O +
min O -
, O +
without O +
affecting O +
HR O +
( O -
Fig. O +
5 O +
A O -
) O -
. O +

The O +
constituent O +
amino O +
acids O -
, O +
administered O +
either O +
separately O +
or O +
as O +
a O +
mixture O -
, O +
had O +
no O +
effects O +
on O +
MAP O +
or O +
HR O +
( O -
results O +
not O +
shown O -
) O -
. O +

The O +
glucoalkaloid O +
CAS O +
lacked O +
hypotensive O +
activity O +
in O +
rats O -
, O +
but O +
produced O +
a O +
prolonged O +
fall O +
in O +
MAP O -
, O +
also O +
with O +
no O +
appreciable O +
change O +
in O +
HR O -
, O +
when O +
tested O +
in O +
guinea O +
pigs O +
( O -
Fig. O +
5 O +
B O -
) O -
. O +

It O +
shoud O +
be O +
noted O +
that O +
baseline O +
MAP O +
in O +
these O +
animals O +
was O +
67±1 O +
mmHg O -
, O +
so O +
that O +
the O +
20 O +
mmHg O +
decrease O +
observed O +
after O +
CAS O +
corresponds O +
to O +
a O +
30 O -
% O +
fall O -
, O +
i.e. O +
similar O +
to O +
that O +
produced O +
in O +
rats O +
by O +
the O +
MP O +
zone O -
. O +

4 O +
Discussion O +
Of O +
the O +
seven O +
compounds O +
identified O +
in O +
the O +
present O +
study O -
, O +
CAS O +
( O -
Power O +
and O +
Callan O -
, O +
1911 O +
) O +
and O +
DMH O +
( O -
Major O +
and O +
Dürsch O -
, O +
1958 O +
) O +
have O +
been O +
reported O +
as O +
constituents O +
of O +
C. O +
edulis O +
. O +

MMH O -
, O +
MP O -
, O +
P O +
and O +
GABA O +
are O +
known O +
compounds O +
not O +
previously O +
described O +
in O +
the O +
plant O -
, O +
while O +
SA O +
is O +
an O +
entirely O +
new O +
chemical O +
entity O -
. O +

The O +
identity O +
of O +
these O +
active O +
compounds O +
was O +
confirmed O +
by O +
comparison O +
of O +
their O +
spectral O +
parameters O +
with O +
those O +
reported O +
in O +
the O +
literature O +
( O -
Panzica O +
and O +
Townsed O +
1973 O -
, O +
Lozoya O +
et O +
al. O +
1978 O -
, O +
Toscano O +
et O +
al. O +
1997 O +
) O -
, O +
as O +
well O +
as O +
by O +
TLC O -
's O +
ran O +
in O +
parallel O +
with O +
standard O +
samples O -
. O +

The O +
new O +
compound O +
SA O +
was O +
also O +
characterized O +
by O +
various O +
physicochemical O +
methods O +
( O -
Enrı́quez O +
et O +
al. O -
, O +
unpublished O -
) O -
. O +

The O +
present O +
results O +
show O +
that O +
in O +
the O +
rat O -
, O +
MMH O +
and O +
DMH O +
elicit O +
transient O +
hypotensive O +
responses O +
lasting O +
less O +
than O +
3 O +
min O +
and O +
entirely O +
similar O +
to O +
those O +
produced O +
by O +
H O -
, O +
thus O +
confirming O +
previous O +
reports O +
( O -
Vartiainen O +
1935 O -
, O +
Bertaccini O +
and O +
Vitali O +
1964 O +
) O -
. O +

These O +
compounds O +
can O -
not O +
therefore O +
be O +
solely O +
responsible O +
for O +
the O +
long O -
- O -
lasting O +
decrease O +
in O +
MAP O +
produced O +
by O +
Casimiroa O +
extracts O -
, O +
a O +
possibility O +
which O +
we O +
have O +
suggested O +
previously O +
( O -
Magos O +
and O +
Vidrio O -
, O +
1991 O +
) O -
. O +

Results O +
of O +
experiments O +
with O +
H O -
- O -
antagonists O +
indicate O +
that O +
hypotension O +
is O +
mediated O +
by O +
activation O +
of O +
peripheral O -
, O +
presumably O +
vascular O -
, O +
H1 B-Gene +
-receptors I-Gene -
; O +
blockade O +
by O +
loratadine O -
, O +
an O +
H1 O +
-antagonist O +
which O +
does O +
not O +
penetrate O +
into O +
the O +
central O +
nervous O +
system O +
( O -
Simons O +
and O +
Simons O -
, O +
1994 O +
) O -
, O +
precludes O +
involvement O +
of O +
central O +
H1 B-Gene +
-receptors I-Gene +
in O +
this O +
response O -
. O +

In O +
contrast O +
to O +
H O -
, O +
which O +
in O +
the O +
rat O +
is O +
devoid O +
of O +
effects O +
on O +
HR O +
( O -
Levi O +
et O +
al. O -
, O +
1982 O +
) O +
and O +
was O +
so O +
found O +
in O +
the O +
present O +
experiments O -
, O +
both O +
MMH O +
and O +
DMH O +
produced O +
tachycardia O -
. O +

This O +
response O +
is O +
apparently O +
not O +
mediated O +
through O +
H1 B-Gene +
- I-Gene +
or O +
H2 B-Gene +
-receptors I-Gene -
, O +
since O +
it O +
is O +
not O +
blocked O +
by O +
the O +
corresponding O +
antagonists O -
. O +

Stimulation O +
of O +
cardiac O +
β B-Gene +
- I-Gene +
adrenegic I-Gene +
receptors I-Gene -
, O +
such O +
as O +
that O +
produced O +
by O +
high O +
concentrations O +
of O +
H O +
in O +
rat O +
atria O +
( O -
Cakici O +
et O +
al. O -
, O +
1992 O +
) O -
, O +
could O +
explain O +
this O +
finding O -
. O +

Since O +
vascular O +
relaxation O +
by O +
H O +
in O +
rat O +
aortic O +
rings O +
is O +
endothelium O -
- O -
dependent O -
( O -
van O +
de O +
Voorde O +
and O +
Leusen O -
, O +
1983 O +
) O -
, O +
the O +
role O +
of O +
nitric O +
oxide O +
as O +
the O +
endothelium O -
- O -
derived O +
relaxing O +
factor O +
in O +
the O +
hypotensive O +
effects O +
of O +
H O -
, O +
MMH O +
and O +
DMH O +
was O +
explored O +
in O +
rats O +
pretreated O +
with O +
the O +
nitric O +
oxide O +
synthesis O +
inhibitor O +
l O +
-NAME O -
. O +

In O +
preliminary O +
experiments O -
, O +
even O +
high O +
doses O +
of O +
this O +
agent O +
did O +
not O +
affect O +
depressor O +
responses O +
to O +
H O -
, O +
a O +
finding O +
similar O +
to O +
that O +
reported O +
by O +
others O +
( O -
Conrad O +
and O +
Whittemore O +
1992 O -
, O +
Nakahara O +
et O +
al. O +
1995 O +
) O -
. O +

Blockade O +
of O +
hypotension O +
induced O +
by O +
acetylcholine O -
, O +
another O +
endothelium O -
- O -
dependent O +
vasodilator O -
, O +
could O +
be O +
achieved O +
by O +
nitric O +
oxide O +
synthesis O +
inhibition O +
in O +
rabbits O +
previously O +
subjected O +
to O +
vasoconstriction O +
with O +
phenylephrine O +
( O -
Rees O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

It O +
was O +
therefore O +
reasoned O +
that O +
an O +
increase O +
in O +
vascular O +
tone O +
would O +
enhance O +
nitric O +
oxide O +
release O +
( O -
Vargas O +
et O +
al. O -
, O +
1990 O +
) O +
and O +
amplify O +
the O +
consequences O +
of O +
nitric O +
oxide O +
synthesis O +
inhibition O -
. O +

Experiments O +
in O +
phenylephrine O -
- O -
vasoconstricted O +
rats O +
show O +
that O +
hypotension O +
induced O +
by O +
H O +
and O +
DMH O -
, O +
but O +
surprisingly O +
not O +
by O +
MMH O -
, O +
is O +
nitric O +
oxide O -
- O -
dependent O -
. O +

In O +
agreement O +
with O +
this O +
finding O -
, O +
preliminary O +
results O +
in O +
rat O +
aortic O +
rigs O +
indicate O +
that O +
removal O +
of O +
endothelium O +
prevents O +
relaxation O +
by O +
H O +
and O +
DMH O -
, O +
but O +
not O +
by O +
MMH O +
( O -
Magos O +
et O +
al. O -
, O +
unpublished O -
) O -
. O +

Taken O +
together O -
, O +
these O +
results O +
suggest O +
that O +
vasodilatation O +
by O +
H O +
and O +
DMH O +
is O +
the O +
result O +
of O +
stimulation O +
of O +
H1 B-Gene +
-receptors I-Gene +
in O +
vascular O +
endothelium O +
( O -
Van O +
de O +
Voorde O +
and O +
Leusen O -
, O +
1983 O +
) O -
, O +
which O +
leads O +
to O +
the O +
release O +
of O +
nitric O +
oxide O +
and O +
vascular O +
smooth O +
muscle O +
relaxation O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
action O +
of O +
MMH O +
appears O +
to O +
be O +
exerted O +
on O +
H1 B-Gene +
-receptors I-Gene +
located O +
in O +
vascular O +
smooth O +
muscle O -
. O +

It O +
should O +
be O +
noted O +
that O +
H O +
elicits O +
endothelium O -
- O -
independent O +
vasodilatation O +
in O +
the O +
rat O +
femoral O +
artery O +
by O +
activation O +
of O +
smooth B-Gene +
muscle I-Gene +
H I-Gene +
receptors I-Gene -
, O +
although O +
these O +
have O +
been O +
identified O +
as O +
H2 B-Gene +
- O +
( O -
Krstic O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
H1 B-Gene +
-relaxation O +
of O +
dog O +
mesenteric O +
and O +
gastroepiploic O +
arteries O +
has O +
been O +
attributed O +
to O +
release O +
of O +
prostaglandin O +
I2 O +
( O -
Toda O +
et O +
al. O -
, O +
1982 O +
) O -
. O +

In O +
any O +
event O -
, O +
further O +
studies O +
are O +
necessary O +
to O +
elucidate O +
the O +
nature O +
of O +
MMH O -
- O -
induced O +
vasodilatation O -
. O +

Tachycardia O +
produced O +
by O +
DMH O -
, O +
but O +
not O +
by O +
H O +
or O +
MMH O -
, O +
was O +
partially O +
inhibited O +
by O +
l O +
-NAME O -
, O +
suggesting O +
involvement O +
of O +
nitric O +
oxide O +
in O +
this O +
response O -
. O +

In O +
keeping O +
with O +
the O +
above O +
postulated O +
β O +
-adrenergic O +
mechanism O +
of O +
DMH O -
- O -
induced O +
tachycardia O -
, O +
l O +
-NAME O +
has O +
been O +
shown O +
to O +
decrease O +
chronotropic O +
responses O +
to O +
β O +
- O +
adrenergic O +
stimulation O +
( O -
Reid O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
as O +
well O +
as O +
to O +
antagonize O +
the O +
facilitation O +
by O +
angiotensin B-Gene +
of O +
norepinephrine O +
release O +
from O +
atrial O +
sympathetic O +
nerve O +
endings O +
( O -
Gironacci O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

The O +
cardiovascular O +
effects O +
of O +
the O +
new O +
compound O +
SA O -
, O +
i.e. O -
, O +
transient O +
hypertension O +
and O +
tachycardia O -
, O +
are O +
identical O +
to O +
those O +
of O +
the O +
reference O +
drug O +
S O -
, O +
which O +
has O +
been O +
described O +
as O +
an O +
adrenergic B-Gene +
receptor I-Gene +
agonsit O +
with O +
much O +
less O +
affinity O +
for O +
β B-Gene +
1 I-Gene +
- O +
than O +
for O +
α B-Gene +
1 I-Gene +
- I-Gene +
receptors I-Gene +
( O -
Jordan O +
et O +
al. O +
1957 O -
, O +
Brown O +
et O +
al. O +
1988 O +
) O -
. O +

The O +
α O +
1 O +
- O +
nature O +
of O +
the O +
pressor O +
effect O +
of O +
SA O +
and O +
S O +
is O +
clearly O +
demonstrated O +
by O +
its O +
blockade O +
by O +
the O +
specific O +
antagonist O +
prazosin O -
, O +
an O +
interaction O +
found O +
previously O +
with O +
crude O +
Casimiroa O +
extract O +
in O +
rat O +
aortic O +
rings O +
( O -
Magos O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

Their O +
positive O +
chronotropic O +
action O +
appears O +
to O +
be O +
mediated O +
by O +
both O +
α B-Gene +
- I-Gene +
and O +
β B-Gene +
-receptors I-Gene -
, O +
since O +
it O +
is O +
partially O +
antagonized O +
by O +
prazosin O +
and O +
propranolol O -
. O +

Tachycardia O +
paradoxically O +
produced O +
by O +
α B-Gene +
-receptor I-Gene +
activation O +
has O +
been O +
reported O +
with O +
phenylephrine O -
, O +
the O +
m O -
- O -
OH O +
isomer O +
of O +
S O +
( O -
Williamson O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

It O +
is O +
interesting O +
that O +
the O +
hypotensive O +
fraction O +
of O +
Casimiroa O +
methanolic O +
extract O +
contains O +
a O +
compound O +
eliciting O +
an O +
opposite O +
effect O +
on O +
MAP O -
, O +
thus O +
theoretically O +
preventing O +
an O +
excessive O +
depressor O +
response O +
to O +
the O +
extract O -
. O +

This O +
constitutes O +
another O +
example O +
of O +
antagonistic O +
actions O +
of O +
constituents O +
of O +
the O +
same O +
plant O +
( O -
Izaddosst O +
and O +
Robinson O -
, O +
1991 O +
) O -
. O +

In O +
contrast O +
to O +
the O +
transient O +
hypotension O +
produced O +
by O +
the O +
H O +
derivatives O -
, O +
the O +
mixture O +
of O +
amino O +
acids O +
designated O +
as O +
the O +
MP O +
zone O +
elicits O +
a O +
long O -
- O -
lasting O +
fall O +
in O +
MAP O +
and O +
could O +
thus O +
be O +
responsible O +
for O +
the O +
persistent O +
hypotensive O +
action O +
of O +
Casimiroa O +
crude O +
extract O +
in O +
the O +
dog O +
( O -
Vidrio O +
and O +
Magos O -
, O +
1991 O +
) O -
. O +

Although O +
peripherally O +
administered O +
GABA O +
lowers O +
blood O +
pressure O +
in O +
the O +
rat O +
( O -
Billingsley O +
and O +
Suria O -
, O +
1982 O +
) O -
, O +
its O +
effects O +
are O +
short O -
- O -
lived O +
and O +
can O -
not O +
account O +
for O +
the O +
prolonged O +
MAP O +
response O +
to O +
the O +
MP O +
zone O -
. O +

The O +
other O +
major O +
components O -
, O +
P O +
and O +
MP O -
, O +
are O +
devoid O +
of O +
hypotensive O +
activity O +
either O +
by O +
themselves O +
or O +
as O +
a O +
mixture O +
with O +
GABA O -
. O +

The O +
nature O +
of O +
the O +
blood O +
pressure O +
effect O +
of O +
the O +
MP O +
zone O +
remains O +
unexplained O -
, O +
although O +
it O +
is O +
possible O +
that O +
the O +
amino O +
acids O +
found O +
are O +
in O +
effect O +
residues O +
of O +
a O +
peptide O +
responsible O +
for O +
this O +
effect O -
. O +

In O +
this O +
connection O -
, O +
it O +
should O +
be O +
mentioned O +
that O +
P O +
is O +
a O +
constituent O +
of O +
the O +
potent O +
vasodilator O +
peptides O +
kallidin O +
and O +
bradykinin O +
( O -
Trifilieff O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

CAS O -
, O +
the O +
main O +
component O +
of O +
Casimiroa O +
seeds O +
( O -
Kincl O +
et O +
al. O -
, O +
1956 O +
) O -
, O +
is O +
devoid O +
of O +
blood O +
pressure O +
effects O +
in O +
rats O -
, O +
but O +
elicits O +
long O -
- O -
lasting O +
hypotension O +
in O +
guinea O +
pigs O +
and O +
could O +
therefore O +
be O +
another O +
constituent O +
of O +
Casimiroa O +
extract O +
contributing O +
to O +
its O +
depressor O +
effect O -
. O +

Although O +
in O +
the O +
present O +
study O +
the O +
mechanism O +
of O +
CAS O +
hypotension O +
was O +
not O +
investigated O -
, O +
stimulation O +
of O +
histaminergic O +
H3 O +
-receptors O +
is O +
an O +
interesting O +
possibility O -
, O +
considering O +
the O +
imidazolic O +
nature O +
of O +
the O +
compound O -
. O +

These O +
receptors O -
, O +
located O +
in O +
sympathetic O +
nerve O +
terminals O -
, O +
inhibit O +
the O +
release O +
of O +
norepinephrine O +
and O +
thus O +
lead O +
to O +
vasodilatation O +
and O +
lowering O +
of O +
blood O +
pressure O +
( O -
McLeod O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

The O +
lack O +
of O +
effect O +
of O +
CAS O +
on O +
the O +
blood O +
pressure O +
of O +
rats O +
as O +
compared O +
to O +
guinea O +
pigs O +
parallels O +
the O +
species O +
differences O +
found O +
for O +
the O +
prototypic O +
H3 B-Gene +
-agonist O +
R O -
- O -
α O +
-methylhistamine O +
( O -
McLeod O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

In O +
conclusion O -
, O +
the O +
present O +
findings O +
indicate O +
that O +
hypotension O +
after O +
C. O +
edulis O +
is O +
due O +
to O +
several O +
active O +
components O -
. O +

Immediate O -
, O +
transitory O +
effects O +
can O +
be O +
attributed O +
to O +
MMH O +
and O +
DMH O -
, O +
acting O +
through O +
H1 B-Gene +
-histaminergic I-Gene +
receptors I-Gene +
located O +
in O +
vascular O +
smooth O +
muscle O +
and O +
vascular O +
endothelium O -
, O +
respectively O -
. O +

More O +
prolonged O +
hypotension O +
would O +
be O +
produced O +
by O +
a O +
mixture O +
of O +
the O +
amino O +
acids O +
MP O -
, O +
P O +
and O +
GABA O +
through O +
an O +
unknown O +
mechanism O -
, O +
as O +
well O +
as O +
by O +
CAS O -
, O +
possibly O +
by O +
activation O +
of O +
H3 B-Gene +
-histaminergic I-Gene +
receptors I-Gene -
. O +

Coexisting O +
with O +
these O +
hypotensive O +
components O +
is O +
SA O -
, O +
which O +
increases O +
blood O +
pressure O +
and O +
heart O +
rate O +
by O +
α B-Gene +
- I-Gene +
and O +
β B-Gene +
- I-Gene +
adrenergic I-Gene +
mechanisms O +
Acknowledgements O +
The O +
authors O +
wish O +
to O +
thank O +
the O +
National O +
University O +
of O +
Mexico O +
for O +
financial O +
support O +
through O +
projects O +
IN214094 O +
and O +
FM-012314 O +
of O +
Dirección O +
General O +
de O +
Asuntos O +
del O +
Personal O +
Académico O +
and O +
Coordinación O +
General O +
de O +
Estudios O +
de O +
Posgrado O -
, O +
respectively O -
. O +

Three O +
novel O +
triterpene O +
alcohols O -
, O +
camelliols O +
A O +
( O -
1 O -
) O -
, O +
B O +
( O -
3 O -
) O -
, O +
and O +
C O +
( O -
5 O -
) O -
, O +
possessing O +
a O +
mono- O -
, O +
bi- O -
, O +
and O +
tricyclic O +
ring O +
system O -
, O +
respectively O -
, O +
have O +
been O +
isolated O -
, O +
along O +
with O +
achilleol O +
A O -
, O +
a O +
known O +
monocyclic O +
triterpene O +
alcohol O -
, O +
from O +
the O +
nonsaponifiable O +
lipids O +
of O +
sasanqua O +
oil O +
( O -
Camellia O +
sasanqua O -
) O -
. O +

The O +
structures O +
of O +
these O +
new O +
alcohols O +
were O +
determined O +
on O +
the O +
basis O +
of O +
spectroscopic O +
methods O -
. O +

A O +
new O +
natural O +
product O -
, O +
4-epifriedelin O +
( O -
1 O -
) O -
, O +
and O +
12 O +
known O +
terpenoids O +
have O +
been O +
isolated O +
from O +
the O +
leaves O +
of O +
Syzygium O +
formosanum O -
. O +

The O +
known O +
compounds O +
include O +
caryophyllene O +
oxide O -
, O +
friedelin O -
, O +
canophyllal O -
, O +
glutinol O -
, O +
alpha O -
- O -
terpineol O -
, O +
phytol O -
, O +
betulinic O +
acid O -
, O +
uvaol O -
, O +
lupeol O -
, O +
betulin O -
, O +
ursolic O +
acid O -
, O +
and O +
oleanolic O +
acid O -
. O +

All O +
of O +
these O +
compounds O +
are O +
reported O +
for O +
the O +
first O +
time O +
from O +
S. O +
formosanum O -
. O +

Two O +
new O +
jaspamide O +
derivatives O +
( O -
1 O +
and O +
2 O -
) O +
along O +
with O +
jaspamide O +
have O +
been O +
isolated O +
from O +
the O +
marine O +
sponge O +
Jaspis O +
splendans O +
collected O +
in O +
Vanuatu O -
. O +

Their O +
chemical O +
structures O +
were O +
determined O +
from O +
1D O +
and O +
2D O +
NMR O +
studies O +
and O +
MS O +
data O -
. O +

These O +
two O +
compounds O +
inhibited O +
the O +
in O +
vitro O +
growth O +
of O +
the O +
NSCLC O -
- O -
N6 O +
human O +
tumor O +
cell O +
lines O +
with O +
IC50 O +
values O +
in O +
the O +
microg O -
/ O -
mL O +
range O -
. O +

7-Epiclusianone O -
, O +
isolated O +
from O +
Rheedia O +
gardneriana O -
, O +
was O +
tested O +
in O +
several O +
biological O +
assays O -
. O +

It O +
was O +
active O +
in O +
vitro O +
against O +
trypomastigotes O +
of O +
Trypanosoma O +
cruzi O +
but O +
inactive O +
in O +
vivo O +
in O +
experimentally O +
infected O +
mice O -
. O +

It O +
was O +
also O +
active O +
against O +
Artemia O +
salina O -
, O +
but O +
inactive O +
against O +
the O +
fungus O +
Cladosporium O +
sphaerospermum O +
and O +
the O +
snail O +
Biomphalaria O +
glabrata O -
. O +

Prolyl B-Gene +
endopeptidase I-Gene +
( O -
PEP B-Gene -
, O +
EC B-Gene +
3.4.21.26 I-Gene -
) O +
is O +
an O +
enzyme B-Gene +
which O +
plays O +
a O +
role O +
in O +
the O +
metabolism O +
of O +
proline O -
- O -
containing O +
neuropeptides O -
, O +
e.g. O -
, O +
vasopressin O -
, O +
substance O +
P O +
and O +
thyrotropin O -
- O -
releasing O +
hormone O +
( O -
TRH O -
) O -
, O +
which O +
have O +
been O +
suggested O +
to O +
be O +
involved O +
in O +
learning O +
and O +
memory O +
processes O -
. O +

In O +
our O +
systematic O +
screening O +
for O +
PEP B-Gene +
inhibitors O +
from O +
traditional O +
Chinese O +
medicines O -
, O +
we O +
found O +
that O +
MeOH O +
extract O +
from O +
the O +
underground O +
part O +
of O +
Rhodiola O +
sacra O +
S. O +
H. O +
Fu O +
shows O +
significant O +
inhibitory O +
activity O +
against O +
PEP B-Gene +
from O +
Flavobacterium O +
meningosepticum O -
. O +

Examination O +
of O +
the O +
constituents O +
of O +
the O +
extract O +
resulted O +
in O +
the O +
isolation O +
of O +
nineteen O +
known O +
compounds O -
, O +
identified O +
as O +
hydroquinone O +
( O -
1 O -
) O -
, O +
4-hydroxybenzoic O +
acid O +
( O -
2 O -
) O -
, O +
caffeic O +
acid O +
( O -
3 O -
) O -
, O +
4-hydroxycinnamic O +
acid O +
( O -
4 O -
) O -
, O +
suberic O +
acid O +
( O -
5 O -
) O -
, O +
protocatechuic O +
acid O +
( O -
6 O -
) O -
, O +
gallic O +
acid O +
( O -
7 O -
) O -
, O +
( O -
- O -
) O -
-epigallocatechin O +
3-O O -
- O -
gallate O +
( O -
8) O -
, O +
2-phenylethyl O +
beta O -
- O -
D O -
- O -
glucopyranoside O +
( O -
9 O -
) O -
, O +
3-O O -
- O -
galloylepigallocatechin- O -
( O -
4beta-->8 O -
) O -
-epigallocatechin+ O +
+ O -
+ O +
3-O O -
- O -
gallate O +
( O -
10 O -
) O -
, O +
2-phenylethyl O +
alpha O -
- O -
L O -
- O -
arabinopyranosyl- O -
( O -
1 O -
- O -
->6 O -
) O -
-beta O -
- O -
D O -
- O -
glucopyranoside O +
( O -
11 O -
) O -
, O +
sacranoside O +
A O +
( O -
12 O -
) O -
, O +
beta O -
- O -
D O -
- O -
glucopyranosyl O +
4-hydroxybenzoate O +
( O -
13 O -
) O -
, O +
rhodiocyanoside O +
A O +
( O -
14 O -
) O -
, O +
rhodiooctanoside O +
( O -
15 O -
) O -
, O +
sarmentosin O +
( O -
16 O -
) O -
, O +
heterodendrin O +
( O -
17 O -
) O -
, O +
arbutin O +
( O -
18 O -
) O +
and O +
4-O- O -
( O -
beta O -
- O -
D O -
- O -
glucopyranosyl O -
) O -
-gallic O +
acid O +
( O -
19 O -
) O -
. O +

Among O +
these O -
, O +
1 O -
, O +
2 O -
, O +
5 O -
, O +
8 O -
- O -
10 O -
, O +
13 O -
, O +
16 O -
, O +
18 O +
and O +
19 O +
have O +
been O +
isolated O +
for O +
the O +
first O +
time O +
from O +
R. O +
sacra O -
, O +
among O +
which O +
5 O -
, O +
9 O -
, O +
10 O -
, O +
13 O -
, O +
16 O -
, O +
18 O +
and O +
19 O +
have O +
been O +
isolated O +
from O +
Rhodiola O +
plants O +
for O +
the O +
first O +
time O -
. O +

On O +
the O +
PEP B-Gene +
inhibition O -
, O +
seven O +
compounds O +
( O -
6 O -
- O -
8 O -
, O +
10 O -
, O +
12 O -
, O +
18 O -
, O +
19 O -
) O +
showed O +
inhibition O +
with O +
an O +
1C50 O +
of O +
27.8 O -
, O +
487 O -
, O +
1.47 O -
, O +
0.437 O -
, O +
348 O -
, O +
391 O +
and O +
215 O +
microM O -
, O +
respectively O -
. O +

The O +
kinetic O +
study O +
of O +
these O +
inhibitors O +
indicated O +
that O +
they O +
are O +
noncompetitive O +
inhibitors O -
, O +
except O +
for O +
6 O +
which O +
is O +
a O +
competitive O +
inhibitor O -
. O +

The O +
growth O -
- O -
promoting O +
effects O +
of O +
estrogens O +
in O +
hormone O -
- O -
dependent O +
tumor O +
tissues O +
involve O +
receptor O -
- O -
mediated O +
pathways O +
that O +
are O +
well O -
- O -
recognized O -
; O +
however O -
, O +
the O +
role O +
of O +
estrogens O +
in O +
tumor O +
initiation O +
remains O +
controversial O -
. O +

Estrogen O +
metabolites O -
, O +
primarily O +
the O +
catechol O +
estrogens O +
( O -
CE O -
's O -
) O -
, O +
have O +
been O +
implicated O +
in O +
tumor O +
initiation O +
via O +
a O +
redox O +
cycling O +
mechanism O -
. O +

We O +
have O +
developed O +
metabolically O +
stable O +
CE O +
analogues O +
for O +
the O +
study O +
of O +
receptor O +
versus O +
redox O +
cycling O +
effects O +
on O +
DNA O +
damage O -
. O +

Comparisons O +
between O +
hydroxy O +
estradiols O +
( O -
HE2 O -
's O -
) O -
, O +
methoxy O +
estradiols O +
( O -
ME2 O -
's O -
) O -
, O +
and O +
hydroxymethyl O +
estradiols O +
( O -
HME2 O -
) O +
in O +
potentiometric O +
and O +
DNA O +
damaging O +
studies O +
were O +
made O -
. O +

DNA O +
damage O +
was O +
assessed O +
in O +
calf O +
thymus O +
DNA O +
using O +
8-oxo-2'-deoxyguanosine O +
( O -
8-oxo O -
- O -
dG O -
) O +
as O +
a O +
genotoxic O +
marker O +
for O +
oxidative O +
stress O -
. O +

Increases O +
in O +
the O +
number O +
of O +
8-oxo O -
- O -
dG O -
/ O -
10 O -
( O -
5 O -
) O +
dG O +
were O +
significant O +
for O +
each O +
2-HE2 O +
and O +
4-HE2 O -
. O +

Cu O -
( O -
II O -
) O -
SO4 O -
, O +
a O +
transition O +
metal O +
known O +
to O +
catalyze O +
the O +
redox O +
cycling O +
of O +
o O -
- O -
quinones O -
, O +
substantially O +
increased O +
the O +
amount O +
of O +
DNA O +
damage O +
caused O +
by O +
both O +
CE O -
's O -
. O +

However O -
, O +
DNA O +
damage O +
was O +
only O +
observed O +
at O +
concentrations O +
of O +
10 O +
microM O +
or O +
higher O -
, O +
much O +
greater O +
than O +
what O +
is O +
found O +
under O +
physiologic O +
conditions O -
. O +

Furthermore O -
, O +
the O +
presence O +
of O +
endogenous O +
antioxidants O +
such O +
as O +
glutathione O -
, O +
SOD B-Gene -
, O +
and O +
catalase B-Gene +
drastically O +
reduced O +
the O +
amount O +
of O +
DNA O +
damage O +
induced O +
by O +
high O +
concentrations O +
of O +
2-HE2 O -
. O +

There O +
was O +
no O +
DNA O +
damage O +
observed O +
for O +
the O +
non O -
- O -
redox O +
cycling O +
HME2 O -
's O -
, O +
making O +
these O +
compounds O +
useful O +
probes O +
in O +
the O +
study O +
of O +
receptor O -
- O -
mediated O +
carcinogenesis O -
. O +

Thus O -
, O +
both O +
2-HE2 O +
and O +
4-HE2 O +
are O +
capable O +
of O +
producing O +
oxidative O +
DNA O +
damage O +
at O +
micromolar O +
concentrations O +
in O +
vitro O -
. O +

However O -
, O +
since O +
the O +
amount O +
of O +
CE O -
's O +
has O +
not O +
been O +
shown O +
to O +
surpass O +
nanomolar O +
levels O +
in O +
vivo O -
, O +
it O +
is O +
unlikely O +
that O +
free O +
radical O +
production O +
via O +
redox O +
cycling O +
of O +
CE O -
's O +
is O +
a O +
causative O +
factor O +
in O +
human O +
tumorigenesis O -
. O +

In O +
addition O +
to O +
effects O +
in O +
the O +
periphery O +
through O +
inhibition O +
of O +
prostaglandin O +
synthesis O -
, O +
several O +
lines O +
of O +
evidence O +
suggest O +
that O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O +
act O +
in O +
the O +
central O +
nervous O +
system O -
. O +

The O +
possibility O +
that O +
the O +
central O +
action O +
of O +
NSAIDs O +
involves O +
regulation O +
of O +
opioid B-Gene +
receptors I-Gene +
was O +
investigated O +
by O +
quantitative O +
autoradiography O +
of O +
mu B-Gene -
, O +
delta B-Gene -
, O +
and O +
kappa B-Gene +
sites B-Gene +
in O +
rat O +
brain O +
slices O -
. O +

Increased O +
( O -
p O +
< O +
0.05 O -
) O +
labeling O +
of O +
mu B-Gene +
receptors I-Gene +
was O +
observed O +
in O +
thalamic O +
nuclei O -
, O +
gyrus O +
dentate O -
, O +
and O +
layers O +
of O +
the O +
parietal O +
cortex O +
of O +
rats O +
treated O +
for O +
10 O +
days O +
with O +
lysine O +
clonixinate O -
. O +

Labeling O +
of O +
delta B-Gene +
receptors I-Gene +
was O +
lower O +
in O +
the O +
lateral O +
septum O -
, O +
and O +
kappa B-Gene +
sites I-Gene +
decreased O +
in O +
thalamic O +
nuclei O -
. O +

These O +
effects O +
were O +
not O +
mediated O +
through O +
direct O +
interaction O +
with O +
opioid B-Gene -
- I-Gene -
binding I-Gene +
sites I-Gene -
, O +
since O +
receptor O -
- O -
binding O +
assays O +
using O +
rat O +
brain O +
membranes O +
confirmed O +
that O +
clonixinate O +
up O +
to O +
1 O +
x O +
10 O -
( O -
-4 O -
) O +
mol O -
/ O -
l O +
does O +
not O +
inhibit O +
mu B-Gene -
, O +
delta B-Gene -
, O +
and O +
kappa B-Gene +
receptor I-Gene +
specific O +
binding O -
. O +

Central O +
effects O +
of O +
NSAIDs O +
might O -
, O +
therefore O -
, O +
involve O +
interaction O +
with O +
the O +
opioid B-Gene +
receptor I-Gene +
system O +
through O +
indirect O +
mechanisms O -
. O +

1 O -
. O +

Quantitative O +
relationships O +
between O +
molecular O +
physico O -
- O -
chemical O +
properties O +
of O +
22 O +
substituted O +
benzoic O +
acids O +
and O +
the O +
extent O +
of O +
excretion O +
of O +
their O +
metabolites O +
in O +
rat O +
urine O +
have O +
been O +
investigated O +
using O +
computational O +
chemistry O +
and O +
multivariate O +
statistics O -
. O +

2 O -
. O +

A O +
data O +
set O +
of O +
34 O +
theoretically O +
derived O +
physico O -
- O -
chemical O +
descriptors O +
calculated O +
was O +
used O +
to O +
classify O +
the O +
benzoic O +
acids O +
according O +
to O +
their O +
predominant O +
urinary O +
metabolic O +
fate O -
. O +

3 O -
. O +

Quantitative O +
structure O -
- O -
metabolism O +
relationships O +
were O +
obtained O +
by O +
linear O +
regression O +
using O +
combinations O +
of O +
physico O -
- O -
chemical O +
descriptors O +
allowing O +
the O +
prediction O +
of O +
% O +
urinary O +
excretion O +
of O +
glycine O +
( O -
r O +
= O +
0.73 O -
) O +
and O +
glucuronide O +
conjugates O +
( O -
r O +
= O +
0.82 O -
) O +
and O +
% O +
urinary O +
excretion O +
of O +
the O +
parent O +
compound O +
( O -
r O +
= O +
0.91 O -
) O -
. O +

A O +
novel O +
phospholipid O +
has O +
been O +
purified O +
from O +
strain O +
Dm O +
28c O +
of O +
Trypanosoma O +
cruzi O -
, O +
and O +
characterized O +
by O +
fast O +
atom O +
bombardment O +
mass O +
spectrometry O +
and O +
nuclear O +
magnetic O +
resonance O +
spectroscopy O +
as O +
a O +
plasmenylethanolamine O +
with O +
a O +
hexadec O -
- O -
l O -
- O -
enyl O +
group O +
in O +
the O +
sn-1 O +
position O +
and O +
an O +
approximately O +
equimolar O +
mixture O +
of O +
octadecenoate O +
and O +
octadecadienoate O +
esterified O +
to O +
the O +
sn-2 O +
hydroxyl O -
. O +

The O +
purified O +
plasmenylethanolamine O +
reacted O +
positively O +
when O +
probed O +
with O +
sera O +
from O +
patients O +
with O +
chronic O +
Chagas O -
' O +
disease O -
. O +

Since O +
plasmenylethanolamines O +
of O +
similar O +
structure O +
are O +
abundant O +
in O +
mammalian O +
cardiac O +
and O +
neuronal O +
tissues O -
, O +
cross O +
reactions O +
between O +
these O +
epitopes O +
may O +
be O +
a O +
factor O +
in O +
the O +
mechanism O +
of O +
autoimmune O +
pathology O +
in O +
the O +
chronic O +
phase O +
of O +
Chagas O -
' O +
disease O -
. O +

Trypanosoma O +
cruzi O +
is O +
the O +
causative O +
agent O +
of O +
Chagas O -
' O +
disease O -
, O +
which O +
is O +
still O +
endemic O +
throughout O +
much O +
of O +
Central O +
and O +
South O +
America O +
[ O -
1 O -
] O +
. O +

The O +
parasite O +
has O +
a O +
complex O +
life O -
- O -
cycle O +
in O +
which O +
several O +
morphologically O +
distinct O +
forms O +
alternate O +
between O +
blood O -
- O -
sucking O +
insects O +
and O +
mammalian O +
hosts O +
[ O -
2,3 O -
] O +
. O +

These O +
various O +
developmental O +
stages O +
are O +
confronted O +
with O +
a O +
range O +
of O +
environments O -
, O +
some O +
extremely O +
hostile O -
. O +

Epimastigotes O +
must O +
resist O +
the O +
hydrolytic O +
action O +
of O +
digestive O +
enzymes B-Gene +
in O +
the O +
insect O +
intestinal O +
tract O -
, O +
bloodstream O +
trypomastigotes O +
have O +
to O +
evade O +
complement O -
- O -
mediated O +
lysis O +
and O +
other O +
immune O +
defence O +
mechanisms O -
, O +
and O +
amastigotes O +
need O +
to O +
survive O +
and O +
replicate O +
inside O +
their O +
host O +
cells O -
. O +

Components O +
of O +
the O +
parasite O +
cell O +
surface O +
provide O +
crucial O +
protection O +
against O +
these O +
hostile O +
environments O -
, O +
and O +
actively O +
mediate O +
processes O +
such O +
as O +
cellular O +
invasion O +
and O +
intracellular O +
survival O +
[ O -
4 O -
] O +
. O +

The O +
immunological O +
properties O +
of O +
surface O +
molecules O +
of O +
T. O +
cruzi O +
are O +
likely O +
to O +
be O +
of O +
particular O +
relevance O -
, O +
since O +
many O +
of O +
the O +
pathological O +
features O +
of O +
chronic O +
Chagas O -
' O +
disease O +
may O +
result O +
from O +
autoimmune O +
processes O -
, O +
perhaps O +
originating O +
from O +
molecular O +
mimicry O +
between O +
parasite O +
antigens O +
and O +
host O +
tissues O +
[ O -
5 O -
] O +
. O +

Surface O +
molecules O +
of O +
T. O +
cruzi O +
which O +
have O +
been O +
characterized O +
include O +
trans B-Gene -
- I-Gene -
sialidase I-Gene +
[ O -
6 O -
] O +
, O +
mucin B-Gene -
- O -
like O +
glycoproteins B-Gene +
[ O -
7 O -
] O +
, O +
glycoinositol O +
phospholipids O +
[ O -
8 O -
] O +
, O +
inositol O +
phosphoceramides O +
[ O -
9 O -
] O +
, O +
and O +
glycosphingolipids O +
[ O -
10 O -
] O +
. O +

Surprisingly O +
little O +
recent O +
attention O +
has O -
, O +
however O -
, O +
been O +
devoted O +
to O +
the O +
phospholipids O +
of O +
Trypanosoma O +
cruzi O +
, O +
even O +
though O +
it O +
is O +
increasingly O +
recognised O +
that O +
membrane O +
lipids O +
are O +
not O +
simply O +
structural O +
components O -
, O +
but O +
are O +
active O +
participants O +
in O +
processes O +
such O +
as O +
signal O +
transduction O +
and O +
are O +
the O +
precursors O +
of O +
biologically O +
active O +
molecules O +
including O +
diacylglycerols O -
, O +
platelet O +
activating O +
factor O +
( O -
PAF O -
) O -
, O +
and O +
eicosanoids O -
. O +

In O +
the O +
present O +
paper O +
we O +
report O +
the O +
characterization O +
of O +
a O +
major O +
phospholipid O +
from O +
the O +
Dm O +
28c O +
clone O +
of O +
T. O +
cruzi O +
by O +
thin O -
- O -
layer O +
chromatography O +
( O -
TLC O -
) O -
, O +
gas O -
- O -
chromatography O +
mass O +
spectrometry O +
( O -
GC O -
/ O -
MS O -
) O -
, O +
fast O +
atom O +
bombardment O +
mass O +
spectrometry O +
( O -
FAB O +
MS O -
) O +
and O +
nuclear O +
magnetic O +
resonance O +
( O -
NMR O -
) O +
spectroscopy O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
All O +
solvents O +
were O +
of O +
reagent O +
grade O +
and O +
were O +
obtained O +
from O +
Merck O +
and O +
re O -
- O -
distilled O +
before O +
use O -
. O +

Phospholipid O +
standards O +
and O +
phospholipase B-Gene +
A2 I-Gene +
were O +
purchased O +
from O +
Sigma O -
. O +

Silica O +
gel O +
60 O +
and O +
high O +
performance O +
thin O -
- O -
layer O +
chromatography O +
( O -
HPTLC O -
) O +
plates O +
were O +
obtained O +
from O +
Merck O -
. O +

Human O +
sera O +
were O +
obtained O +
from O +
five O +
confirmed O +
cases O +
of O +
chronic O +
Chagas O -
' O +
disease O +
and O +
from O +
two O +
healthy O +
controls O -
. O +

2.2 O +
Culture O +
of O +
parasites O +
The O +
Dm O +
28c O +
clone O +
of O +
Trypanosoma O +
cruzi O +
[ O -
11 O -
] O +
was O +
obtained O +
from O +
the O +
Department O +
of O +
Protozoology O -
, O +
FIOCRUZ O -
, O +
Rio O +
de O +
Janeiro O -
, O +
Brazil O -
. O +

Parasites O +
were O +
grown O +
at O +
25 O -
° O -
C O +
in O +
brain O +
heart O +
infusion O +
medium O +
( O -
Becton O +
Dickinson O -
, O +
USA O -
) O -
, O +
supplemented O +
with O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
foetal O +
calf O +
serum O +
( O -
Fazenda O +
Pigue O -
, O +
Brazil O -
) O +
and O +
10 O +
mg O +
l−1 O +
haemin O -
. O +

Epimastigotes O +
were O +
harvested O +
by O +
centrifugation O +
in O +
early O +
stationary O +
phase O +
( O -
7 O +
days O +
growth O -
) O -
, O +
washed O +
three O +
times O +
with O +
isotonic O +
buffered O +
saline O +
and O +
stored O +
at O +
−20 O -
° O -
C O -
. O +

2.3 O +
Extraction O +
and O +
purification O +
of O +
phospholipids O +
Epimastigote O +
cells O +
( O -
100 O +
g O -
, O +
wet O +
weight O -
) O +
were O +
extracted O +
for O +
24 O +
h O +
at O +
−10 O -
° O -
C O +
with O +
100 O +
ml O +
of O +
acetone O -
, O +
then O +
for O +
2 O +
h O +
at O +
room O +
temperature O +
with O +
successive O +
volumes O +
of O +
chloroform O -
/ O -
methanol O +
( O -
2:1 O +
and O +
1:2 O +
v O -
/ O -
v O -
) O -
. O +

Crude O +
lipid O +
was O +
obtained O +
by O +
evaporation O +
of O +
the O +
combined O +
extracts O -
, O +
and O +
was O +
partitioned O +
according O +
to O +
Folch O +
et O +
al. O +
[ O -
12 O -
] O +
. O +

Material O +
recovered O +
from O +
the O +
lower O +
phase O +
was O +
separated O +
by O +
silica O +
gel O +
60 O +
chromatography O +
into O +
neutral O -
, O +
glyco- O +
and O +
phospholipid O +
fractions O +
as O +
previously O +
described O +
[ O -
13 O -
] O +
. O +

The O +
resulting O +
phospholipids O +
were O +
applied O +
to O +
a O +
column O +
of O +
silica O +
gel O +
60 O +
and O +
eluted O +
with O +
200 O +
ml O +
volumes O +
of O +
chloroform O -
/ O -
methanol O +
( O -
95:5 O -
, O +
90:10 O -
, O +
80:20 O -
, O +
and O +
50:50 O +
( O -
v O -
/ O -
v O -
) O +
and O +
finally O +
with O +
methanol O -
. O +

The O +
methanol O +
fractions O +
were O +
pooled O +
and O +
subjected O +
to O +
a O +
final O +
purification O +
on O +
silica O +
gel O +
60 O +
in O +
which O +
the O +
column O +
was O +
sequentially O +
eluted O +
with O +
100 O +
ml O +
portions O +
of O +
chloroform O -
/ O -
methanol O +
( O -
80:20 O +
and O +
50:50 O +
v O -
/ O -
v O -
) O +
and O +
lastly O +
with O +
methanol O -
. O +

Fractions O +
( O -
5 O +
ml O -
) O +
were O +
collected O +
and O +
monitored O +
by O +
TLC O -
. O +

The O +
major O +
phospholipid O +
was O +
obtained O +
as O +
a O +
single O +
component O +
in O +
fractions O +
12 O +
and O +
13 O +
of O +
the O +
50:50 O +
chloroform O -
/ O -
methanol O +
eluate O -
. O +

2.4 O +
Thin O +
layer O +
chromatography O +
Analytical O +
TLC O +
was O +
performed O +
on O +
silica O +
gel O +
G O +
plates O +
( O -
Merck O -
, O +
Darmstadt O -
, O +
Germany O -
) O -
. O +

developed O +
with O +
chloroform O -
/ O -
methanol O -
/ O -
water O +
( O -
65:25:4 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O -
. O +

The O +
separated O +
components O +
were O +
visualized O +
with O +
iodine O +
vapour O -
, O +
ninhydrin O +
[ O -
14 O -
] O +
, O +
and O +
ammonium O +
molybdate O +
reagent O +
[ O -
15 O -
] O +
. O +

For O +
two O +
dimensional O +
TLC O +
the O +
first O +
dimension O +
was O +
developed O +
with O +
chloroform O -
/ O -
methanol O -
/ O -
28 O -
% O +
ammonium O +
hydroxide O +
( O -
65:35:5 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O +
and O +
the O +
second O +
with O +
chloroform O -
: O -
acetone O -
: O -
methanol O -
: O -
acetic O +
acid O -
: O +
water O +
( O -
5:2:1:1:0.5 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
/ O -
v O -
/ O -
v O -
) O +
[ O -
16 O -
] O +
. O +

The O +
separated O +
phospholipids O +
were O +
visualized O +
by O +
spraying O +
with O +
ammonium O +
molybdate O -
. O +

2.5 O +
High O +
performance O +
thin O +
layer O +
chromatography O +
immunostaining O +
The O +
total O +
lipid O +
fraction O +
was O +
separated O +
by O +
HPTLC O +
using O +
chloroform O -
/ O -
methanol O -
/ O -
water O +
( O -
65:25:4 O +
v O -
/ O -
v O -
) O +
as O +
solvent O +
system O -
. O +

The O +
developed O +
plates O +
were O +
soaked O +
in O +
0.5 O -
% O +
polymethacrylate O +
in O +
diethyl O +
ether O -
, O +
blocked O +
for O +
2 O +
h O +
with O +
10 O -
% O +
skimmed O +
milk O +
in O +
phosphate O -
- O -
buffered O +
saline O +
and O +
incubated O +
overnight O +
with O +
sera O +
from O +
either O +
chagasic O +
patients O +
or O +
healthy O +
volunteers O -
, O +
followed O +
by O +
sequential O +
treatment O +
with O +
peroxidase B-Gene -
- O -
conjugated O +
goat O +
anti B-Gene -
- I-Gene -
human I-Gene +
IgG I-Gene +
( O -
2 O +
h O -
) O +
and O +
diaminobenzidine O -
, O +
as O +
described O +
by O +
Straus O +
et O +
al. O +
[ O -
17 O -
] O +
. O +

The O +
reaction O +
was O +
terminated O +
after O +
5 O +
min O +
by O +
washing O +
with O +
distilled O +
water O -
. O +

Reactive O +
components O +
were O +
indicated O +
by O +
the O +
development O +
of O +
brown O +
bands O +
on O +
the O +
HPTLC O +
plates O -
. O +

2.6 O +
Acid O +
methanolysis O +
The O +
purified O +
phospholipid O +
was O +
methanolysed O +
overnight O +
at O +
80 O -
° O -
C O +
in O +
1 O +
M O +
methanol O -
: O +
HCl O +
made O +
10 O +
M O +
with O +
respect O +
to O +
water O +
[ O -
18 O -
] O +
, O +
cooled O +
and O +
extracted O +
twice O +
with O +
an O +
equal O +
volume O +
of O +
hexane O -
. O +

The O +
combined O +
hexane O +
extracts O +
were O +
dried O +
and O +
analysed O +
by O +
GC O -
/ O -
MS O -
. O +

2.7 O +
Phospholipase B-Gene +
A2 I-Gene +
digestion O -
. O +

The O +
purified O +
phospholipid O +
( O -
0.15 O +
mg O -
) O +
was O +
dissolved O +
in O +
2 O +
ml O +
of O +
diethyl O +
ether O -
/ O -
methanol O +
( O -
98:2 O -
) O +
and O +
10 O +
units O +
of O +
Crotalus B-Gene +
atrox I-Gene +
phospholipase I-Gene +
A2 I-Gene +
( O -
Sigma O +
P-3770 O -
) O +
in O +
0.5 O +
ml O +
of O +
borate O +
buffer O +
pH O +
8.9 O +
was O +
added O +
[ O -
19 O -
] O +
. O +

Dipalmitoyl O +
phosphatidylethanolamine O +
was O +
used O +
as O +
a O +
positive O +
control O -
. O +

After O +
incubation O +
overnight O +
( O -
37 O -
° O -
C O -
, O +
with O +
agitation O -
) O +
the O +
ether O +
was O +
removed O +
by O +
vacuum O +
centrifugation O -
, O +
and O +
the O +
digestion O +
products O +
were O +
recovered O +
by O +
Bligh O -
- O -
Dyer O +
extraction O +
and O +
analysed O +
by O +
FAB O +
MS O -
. O +

2.8 O +
Gas O +
chromatography O +
mass O +
spectrometry O +
GC O -
/ O -
MS O +
was O +
performed O +
with O +
a O +
Kratos O +
MS80 O +
RFA O +
spectrometer O +
( O -
Kratos O +
Manchester O -
, O +
UK O -
) O +
interfaced O +
to O +
a O +
Carlo O +
Erba O +
5160 O +
chromatograph O +
fitted O +
with O +
a O +
BPX-5 O +
fused O +
silica O +
column O +
( O -
25 O +
m O +
by O +
0.2 O +
mm O -
; O +
SGE O -
, O +
Milton O +
Keynes O -
, O +
UK O -
) O -
. O +

Helium O +
( O -
0.7 O +
ml O +
min−1 O +
) O +
was O +
the O +
carrier O +
gas O -
, O +
and O +
samples O +
were O +
introduced O +
by O +
' O -
splitless O -
' O +
injection O -
. O +

Electron O +
ionization O +
spectra O +
were O +
recorded O +
at O +
an O +
ionization O +
energy O +
of O +
70 O +
eV O -
, O +
trap O +
current O +
of O +
100 O +
μA O -
, O +
and O +
source O +
temperature O +
of O +
220 O -
° O -
C O -
. O +

Chemical O +
ionization O +
spectra O +
were O +
obtained O +
using O +
isobutane O +
reagent O +
gas O +
and O +
an O +
emission O +
current O +
of O +
250 O +
mA. O +
2.9 O +
Fast O +
atom O +
bombardment O -
- O -
mass O +
spectrometry O +
Fast O +
atom O +
bombardment O +
( O -
FAB O -
) O +
spectra O +
were O +
obtained O +
in O +
positive O +
and O +
negative O +
ion O +
modes O +
with O +
a O +
Kratos O +
MS80 O +
spectrometer O -
, O +
fitted O +
with O +
an O +
IonTech O +
saddle O -
- O -
field O +
atom O +
gun O +
supplied O +
with O +
high O -
- O -
purity O +
xenon O +
gas O -
. O +

Approximately O +
10 O +
μg O +
of O +
sample O +
was O +
loaded O +
into O +
3-nitrobenzyl O +
alcohol O +
matrix O -
. O +

Collision O +
induced O +
dissociation O +
was O +
achieved O +
by O +
admitting O +
helium O +
into O +
a O +
collision O +
cell O +
in O +
the O +
field O -
- O -
free O +
region O +
between O +
source O +
and O +
electrostatic O +
analyser O +
so O +
as O +
to O +
attenuate O +
the O +
ion O +
beam O +
by O +
50 O -
% O -
. O +

Constant O +
neutral O +
loss O +
and O +
daughter O +
ion O +
spectra O +
were O +
recorded O +
by O +
means O +
of O +
computer O +
generated O +
linked O +
scans O -
. O +

2.10 O +
Nuclear O +
magnetic O +
resonance O +
spectroscopy O +
Proton O +
( O -
500 O +
MHz O -
, O +
25 O -
° O -
C O -
) O +
and O +
13 O +
C O +
NMR O +
spectra O +
( O -
125 O +
MHz O -
, O +
25 O -
° O -
C O -
) O +
were O +
acquired O +
on O +
a O +
Varian O +
Unity O +
500 O +
MHz O +
spectrometer O +
using O +
the O +
manufacturer O -
's O +
standard O +
pulse O +
sequences O -
. O +

Samples O +
were O +
dissolved O +
in O +
CDCl3 O +
containing O +
a O +
trace O +
of O +
CD3 O +
OD O +
or O +
CDCl3 O +
and O +
CD3 O +
OD O +
( O -
1:2 O +
v O -
/ O -
v O -
) O -
. O +

1 O +
H O +
and O +
13 O +
C O +
chemical O +
shifts O +
are O +
reported O +
relative O +
to O +
tetramethylsilane O +
at O +
0 O +
ppm O -
. O +

3 O +
Results O +
3.1 O +
Isolation O +
of O +
phospholipids O +
Phospholipids O +
were O +
extracted O +
from O +
epimastigotes O +
of O +
the O +
Dm O +
28c O +
clone O +
of O +
T. O +
cruzi O +
with O +
chloroform O -
/ O -
methanol O -
, O +
and O +
were O +
purified O +
by O +
Folch O +
partition O +
and O +
silica O +
chromatography O -
. O +

Twenty O +
milligrams O +
of O +
purified O +
material O +
were O +
obtained O +
from O +
100 O +
g O +
( O -
wet O +
weight O -
) O +
of O +
biomass O -
. O +

The O +
unknown O +
phospholipid O +
was O +
similar O +
in O +
one O -
- O -
dimensional O +
TLC O +
mobility O +
to O +
a O +
phosphatidylethanolamine O +
( O -
PE O -
) O +
standard O +
( O -
Fig. O +
1 O +
A O +
and O +
B O -
) O +
and O +
stained O +
positively O +
with O +
ninhydrin O -
, O +
iodine O -
, O +
and O +
ammonium O +
molybdate O +
reagents O -
. O +

Two O +
dimensional O +
TLC O -
, O +
however O -
, O +
resolved O +
the O +
compound O +
from O +
phosphatidylethanolamine O +
( O -
Fig. O +
1 O +
C O -
) O -
. O +

The O +
phospholipid O +
was O +
derived O +
from O +
the O +
T. O +
cruzi O +
biomass O -
, O +
since O +
it O +
was O +
not O +
detected O +
in O +
control O +
extractions O +
of O +
the O +
culture O +
medium O +
alone O -
. O +

3.2 O +
Gas O +
chromotography O +
mass O +
spectrometry O +
analysis O +
of O +
the O +
methanolysed O +
phospholipid O +
The O +
phospholipid O +
was O +
methanolysed O +
under O +
acid O +
conditions O -
, O +
and O +
the O +
products O +
were O +
analysed O +
by O +
GC O -
/ O -
MS O -
. O +

Four O +
peaks O +
( O -
I O -
– O -
IV O -
) O +
were O +
observed O +
in O +
the O +
chromatogram O +
in O +
an O +
intensity O +
ratio O +
of O +
≈1:0.2:1:1 O -
; O +
two O +
of O +
these O +
( O -
III O +
and O +
IV O -
) O +
were O +
late O -
- O -
eluting O +
and O +
poorly O +
resolved O +
under O +
the O +
conditions O +
used O -
. O +

The O +
minor O +
peak O +
( O -
II O -
) O +
was O +
intermediate O +
in O +
retention O +
time O +
between O +
peak O +
I O +
and O +
peaks O +
III O +
and O +
IV O -
. O +

The O +
pair O +
of O +
late O -
- O -
eluting O +
peaks O +
had O +
mass O +
spectra O +
typical O +
of O +
methyl O +
esters O +
of O +
unsaturated O +
long O +
chain O +
fatty O +
acids O -
. O +

The O +
earlier O -
- O -
eluting O +
of O +
the O +
two O +
( O -
III O -
) O +
had O +
a O +
molecular O +
ion O +
( O -
M+ O +
) O +
at O +
m O +
/z O +
294 O -
, O +
and O +
an O +
ion O +
at O +
m O +
/z O +
263 O +
( O -
M-31 O -
) O -
, O +
the O +
latter O +
comparable O +
in O +
intensity O +
to O +
M+ O +
. O +

The O +
low O +
mass O +
end O +
of O +
the O +
spectrum O +
was O +
dominated O +
by O +
a O +
series O +
of O +
ions O +
at O +
m O +
/z O +
67 O +
( O -
base O +
peak O -
) O -
, O +
m O +
/z O +
81 O -
, O +
m O +
/z O +
95 O +
etc O -
. O +

The O +
spectrum O +
thus O +
confirmed O +
the O +
identity O +
of O +
this O +
component O +
as O +
octadecadienoic O +
acid O +
[ O -
20 O -
] O +
. O +

Peak O +
IV O +
had O +
an O +
M+ O +
at O +
m O +
/z O +
296 O -
, O +
an O +
M-32 O +
ion O +
at O +
m O +
/z O +
264 O -
, O +
( O -
more O +
abundant O +
than O +
the O +
molecular O +
ion O -
) O -
, O +
and O +
a O +
low O +
mass O +
ion O +
series O +
at O +
m O +
/z O +
55 O +
( O -
base O +
peak O -
) O -
, O +
m O +
/z O +
69 O -
, O +
m O +
/z O +
83 O +
etc O -
. O +

which O +
identified O +
it O +
as O +
octadecenoic O +
acid O -
. O +

No O +
attempt O +
was O +
made O +
to O +
determine O +
the O +
locations O +
of O +
the O +
double O +
bonds O +
in O +
either O +
compound O -
. O +

The O +
spectrum O +
of O +
peak O +
II O +
was O +
consistent O +
with O +
the O +
methyl O +
ester O +
of O +
a O +
saturated O +
fatty O +
acid O +
( O -
M+ O +
at O +
m O +
/z O +
270 O -
, O +
ions O +
at O +
m O +
/z O +
241 O -
, O +
239 O -
, O +
and O +
227 O -
; O +
base O +
peak O +
at O +
m O +
/z O +
74 O -
, O +
and O +
was O +
assigned O +
as O +
methyl O +
hexadecanoate O -
. O +

The O +
mass O +
spectrum O +
of O +
the O +
other O +
major O +
peak O +
in O +
the O +
methanolysate O +
did O +
not O +
resemble O +
that O +
of O +
a O +
fatty O +
acid O +
but O +
was O +
consistent O +
with O +
a O +
long O +
chain O +
aldehyde O +
as O +
would O +
be O +
obtained O +
from O +
hydrolysis O +
of O +
a O +
plasmenyl O +
linkage O +
( O -
Fig. O +
2 O +
A O -
) O -
. O +

A O +
weak O +
ion O +
was O +
observed O +
at O +
m O +
/z O +
240 O -
, O +
the O +
mass O +
of O +
hexadecanal O -
, O +
and O +
was O +
accompanied O +
by O +
fragments O +
at O +
m O +
/z O +
222 O -
, O +
212 O -
, O +
and O +
296 O +
( O -
loss O +
of O +
H2 O +
O O -
, O +
CO O -
, O +
and O +
CH3 O +
CO O -
, O +
respectively O -
) O -
, O +
all O +
fragmentation O +
processes O +
characteristic O +
of O +
aliphatic O +
aldehydes O +
[ O -
21 O -
] O +
. O +

In O +
the O +
corresponding O +
chemical O +
ionization O +
spectrum O -
, O +
the O +
base O +
peak O +
was O +
observed O +
at O +
m O +
/z O +
241 O -
, O +
consistent O +
with O +
the O +
protonated O +
molecule O +
of O +
hexadecanal O +
( O -
Fig. O +
2 O +
B O -
) O -
. O +

The O +
electron O +
ionization O +
and O +
chemical O +
ionizaton O +
spectra O +
obtained O +
from O +
a O +
tetradecanal O +
standard O +
of O +
were O +
similar O +
except O +
that O +
the O +
corresponding O +
protonated O +
molecules O +
and O +
fragment O +
ions O +
were O +
observed O +
28 O +
m O +
/z O +
units O +
lower O +
in O +
mass O -
. O +

3.3 O +
Fast O +
atom O +
bombardment O +
mass O +
spectroscopy O +
analysis O +
A O +
doublet O +
of O +
de O -
- O -
protonated O +
molecules O +
( O -
[ O -
M O -
- O -
H O -
] O -
− O +
) O -
, O +
approximately O +
equal O +
in O +
abundance O -
, O +
was O +
observed O +
at O +
m O +
/z O +
698 O +
and O +
700 O +
in O +
the O +
negative O +
ion O +
FAB O +
spectrum O +
of O +
the O +
intact O +
phospholipid O +
( O -
Fig. O +
3 O +
) O -
, O +
together O +
with O +
a O +
pair O +
of O +
signals O +
at O +
m O +
/z O +
279 O +
and O +
281 O -
, O +
also O +
similar O +
to O +
each O +
other O +
in O +
intensity O -
. O +

The O +
latter O +
were O +
consistent O +
with O +
carboxylate O +
anions O +
derived O +
from O +
octadecenoic O +
( O -
18:1 O -
) O +
and O +
octadecadienoic O +
( O -
18:2 O -
) O +
substituents O -
. O +

In O +
the O +
positive O +
ion O +
FAB O +
spectrum O -
, O +
corresponding O +
[ O -
M+H O -
] O -
+ O +
ions O +
were O +
present O +
at O +
m O +
/z O +
700 O +
and O +
702 O -
, O +
but O +
were O +
accompanied O +
by O +
more O +
abundant O +
[ O -
M+Na O -
] O -
+ O +
and O +
[ O -
M O -
- O -
H+Na2 O +
] O -
+ O +
signals O +
at O +
m O +
/z O +
722 O -
/ O -
744 O -
, O +
and O +
744 O -
/ O -
746 O -
, O +
respectively O -
. O +

A O +
doublet O +
of O +
fragment O +
ions O +
at O +
m O +
/z O +
561 O +
and O +
559 O +
was O +
consistent O +
with O +
loss O +
of O +
an O +
ethanolamine O +
phosphate O +
headgroup O +
( O -
141 O -
) O +
from O +
the O +
protonated O +
molecules O -
. O +

This O +
was O +
verified O +
by O +
a O +
constant O +
neutral O +
loss O +
scan O -
, O +
which O +
confirmed O +
that O +
the O +
peaks O +
at O +
m O +
/z O +
559 O +
and O +
561 O +
originated O +
by O +
elimination O +
of O +
141 O +
from O +
the O +
protonated O +
molecules O +
at O +
m O +
/z O +
700 O +
and O +
702 O -
. O +

The O +
data O +
thus O +
indicate O +
the O +
presence O +
of O +
both O +
phosphoethanolamine O +
and O +
hydroxyester O -
- O -
linked O +
C18:1 O +
and O +
C18:2 O +
fatty O +
acids O -
. O +

The O +
observed O +
[ O -
M+H O -
] O -
+ O +
is O +
not O -
, O +
however O -
, O +
consistent O +
with O +
a O +
phosphatidyl O +
ethanolamine O +
having O +
this O +
substitution O +
pattern O -
, O +
for O +
which O +
the O +
calculated O +
mass O +
would O +
be O +
742 O -
. O +

The O +
spectra O +
are O +
more O +
compatible O +
with O +
a O +
plasmenyl O +
ethanolamine O -
, O +
in O +
which O +
carbon O +
1 O +
of O +
sn O +
-glycero-3-phosphoethanolamine O +
bears O +
an O +
O O +
- O -
( O -
1-hexadecenyl O -
) O +
residue O -
, O +
and O +
the O +
sn O +
-2 O +
position O +
is O +
esterified O +
with O +
a O +
mixture O +
of O +
octadecenoic O +
and O +
octadecadienoic O +
acids O -
. O +

This O +
structure O +
would O +
yield O +
on O +
hydrolysis O +
an O +
equimolar O +
mixture O +
of O +
hexadecanal O -
, O +
octadecanoate O -
, O +
and O +
octadecadienoate O +
acid O -
, O +
in O +
agreement O +
with O +
the O +
results O +
of O +
the O +
GC O -
/ O -
MS O +
experiments O -
. O +

The O +
acid O +
lability O +
of O +
the O +
compound O +
similarly O +
excludes O +
an O +
alkylglycerol O +
structure O -
, O +
which O +
would O +
be O +
stable O +
to O +
the O +
acid O +
hydrolysis O +
conditions O +
employed O -
. O +

When O +
the O +
compound O +
was O +
treated O +
with O +
phospholipase B-Gene +
A2 I-Gene +
, O +
and O +
reanalysed O +
by O +
negative O +
ion O +
FAB O +
MS O -
, O +
the O +
doublet O +
at O +
m O +
/z O +
698 O -
/ O -
700 O +
disappeared O -
, O +
and O +
was O +
replaced O +
by O +
a O +
singlet O +
at O +
m O +
/z O +
436.3 O -
, O +
consistent O +
with O +
removal O +
of O +
octadecanoate O +
and O +
octadecadienoate O -
, O +
thus O +
establishing O +
an O +
sn O +
-1,2-diradyl O +
glycerol O +
stereochemisty O -
. O +

Further O +
confirmation O +
of O +
the O +
structure O +
was O +
provided O +
by O +
the O +
helium O +
collisional O +
activation O +
spectrum O +
of O +
the O +
protonated O +
molecules O +
at O +
m O +
/z O +
700 O +
and O +
702 O +
( O -
both O +
ions O +
fell O +
within O +
the O +
precursor O +
ion O +
window O +
because O +
of O +
the O +
poor O +
parent O -
- O -
ion O +
resolution O +
of O +
the O +
B O -
/ O -
E O +
scan O +
on O +
a O +
two O +
sector O +
instrument O -
) O -
. O +

In O +
addition O +
to O +
daughter O +
ions O +
at O +
m O +
/z O +
559 O +
and O +
561 O -
, O +
attributable O +
to O +
loss O +
of O +
the O +
phosphoethanolamine O +
head O +
group O -
, O +
a O +
further O +
doublet O +
of O +
fragment O +
ions O +
was O +
observed O +
at O +
m O +
/z O +
337 O +
and O +
339 O -
, O +
which O +
were O +
the O +
result O +
of O +
cleavage O +
of O +
the O +
sn O +
-1 O +
O O -
- O -
CH O +
bond O +
( O -
with O +
hydrogen O +
transfer O +
to O +
glycerol O -
) O +
combined O +
with O +
loss O +
of O +
ethanolamine O +
phosphate O -
. O +

Consistent O +
with O +
previous O +
reports O +
of O +
the O +
FAB O +
spectra O +
of O +
plasmalogens O -
, O +
both O +
in O -
- O -
source O +
and O +
collision O -
- O -
induced O +
loss O +
of O +
phosphoethanolamine O +
was O +
considerably O +
less O +
facile O +
than O +
in O +
the O +
spectra O +
of O +
phosphatidylethanolamines O +
[ O -
22,23 O -
] O +
. O +

3.4 O +
Nuclear O +
magnetic O +
resonance O +
analysis O +
of O +
the O +
phospholipid O +
Proton O +
and O +
carbon O +
spectra O +
were O +
assigned O +
using O +
two O -
- O -
dimensional O +
NMR O +
techniques O -
; O +
double O +
quantum O +
filtered O +
correlation O +
spectroscopy O +
( O -
DQCOSY O -
) O +
and O +
total O +
correlation O +
spectroscopy O +
( O -
TOCSY O -
) O +
for O +
the O +
1 O +
H O +
spectrum O +
and O +
heteronuclear O +
multiple O +
quantum O +
correlated O +
spectroscopy O +
( O -
HMQC O -
) O +
for O +
the O +
13 O +
C O +
spectrum O -
. O +

The O +
chemical O +
shifts O +
listed O +
in O +
Table O +
1 O +
were O +
obtained O +
in O +
CDCl3 O +
at O +
25 O -
° O -
C O -
: O +
Both O +
the O +
1 O +
H O +
and O +
13 O +
C O +
spectra O +
are O +
consistent O +
with O +
the O +
structure O +
deduced O +
from O +
the O +
mass O +
spectrometric O +
analysis O +
and O +
the O +
chemical O +
shifts O +
were O +
in O +
agreement O +
with O +
the O +
published O +
values O +
of O +
a O +
synthetic O +
plasmenylcholine O +
model O +
system O +
[ O -
24 O -
] O +
, O +
except O +
for O +
differences O +
attributable O +
to O +
the O +
presence O +
of O +
a O +
phosphoethanolamine O +
rather O +
than O +
a O +
phosphocholine O +
polar O +
head O +
group O -
. O +

The O +
relative O +
positions O +
of O +
the O +
double O +
bonds O +
in O +
octadecadienoic O +
acid O +
are O +
revealed O +
by O +
the O +
chemical O +
shift O +
of O +
signals O +
from O +
protons O +
attached O +
to O +
carbon O +
32 O +
( O -
arbitrary O +
numbering O -
; O +
Fig. O +
4 O +
) O -
, O +
consistent O +
with O +
a O +
bisallylic O +
methylene O -
; O +
which O +
are O +
correlated O +
by O +
COSY O +
cross O -
- O -
peaks O +
to O +
the O +
envelope O +
of O +
methine O +
resonances O +
at O +
5.35 O +
ppm O -
. O +

3.5 O +
High O +
performance O +
thin O +
layer O +
chromatography O +
immunostaining O +
Immunostaining O +
of O +
the O +
HPTLC O -
- O -
separated O +
total O +
lipid O +
extract O +
showed O +
that O +
only O +
the O +
band O +
corresponding O +
to O +
the O +
plasmenyl O +
ethanolamine O +
was O +
recognised O +
by O +
sera O +
from O +
patients O +
with O +
Chagas O -
' O +
disease O +
( O -
Fig. O +
5 O +
) O -
. O +

4 O +
Discussion O +
This O +
study O +
describes O +
the O +
purification O +
and O +
molecular O +
characterization O +
of O +
a O +
novel O +
phospholipid O +
from O +
T. O +
cruzi O +
strain O +
Dm O +
28c O -
, O +
which O +
we O +
show O +
by O +
FAB O +
MS O +
and O +
NMR O +
is O +
a O +
plasmenylethanolamine O +
with O +
a O +
hexadec-1-enyl O +
group O +
in O +
the O +
sn O +
-1 O +
position O +
and O +
an O +
approximately O +
equimolar O +
mixture O +
of O +
octadecenoate O +
and O +
octadecadienoate O +
esterified O +
to O +
the O +
sn O +
-2 O +
hydroxyl O -
. O +

Plasmalogens O +
are O +
a O +
unique O +
class O +
of O +
glycerophospholipids O +
with O +
an O +
alk-1-enyl O +
ether O +
substituent O +
on O +
the O +
sn O +
-1 O +
position O +
of O +
glycerol O +
[ O -
25 O -
] O +
. O +

The O +
molecular O +
geometry O +
of O +
the O +
alk-1-enyl O +
ether O +
linkage O +
is O +
significantly O +
different O +
to O +
that O +
found O +
in O +
diacyl O +
phospholipids O -
, O +
resulting O +
in O +
altered O +
packing O +
within O +
the O +
lipid O +
bilayer O +
[ O -
26 O -
] O +
, O +
and O +
modifying O +
the O +
phase O +
transition O +
behaviour O +
of O +
the O +
membrane O +
[ O -
27 O -
] O +
. O +

In O +
activated O +
neutrophils O +
plasmenylethanolamine O +
catabolism O +
can O +
result O +
in O +
enhanced O +
production O +
of O +
platelet O +
activating O +
factor O +
( O -
PAF O -
) O +
via O +
a O +
novel O +
remodelling O +
pathway O +
[ O -
28 O -
] O +
. O +

Plasmalogen O +
catabolism O +
in O +
activated O +
neutrophils O +
has O +
also O +
been O +
shown O +
to O +
lead O +
to O +
the O +
production O +
of O +
a O +
plasmenyl O +
analogue O +
of O +
PAF O +
[ O -
29 O -
] O +
, O +
though O +
this O +
compound O +
is O +
apparently O +
about O +
five O +
times O +
less O +
active O +
than O +
PAF O +
[ O -
30 O -
] O +
, O +
and O +
its O +
role O +
remains O +
to O +
be O +
determined O -
. O +

Plasmalogens O +
have O +
previously O +
been O +
reported O +
in O +
rumen O +
protozoa O +
[ O -
31–33 O -
] O +
, O +
and O +
in O +
the O +
trypanosomatids O +
Blastocrithidia O +
culicis O +
[ O -
34 O -
] O +
, O +
Leishmania O +
[ O -
35 O -
] O +
, O +
and O +
Trypanosoma O +
brucei O +
[ O -
36 O -
] O +
. O +

In O +
the O +
latter O +
organism O +
≈60 O -
% O +
of O +
the O +
glycerophosphoethanolamine O +
fraction O +
belonged O +
to O +
the O +
alk-1-enyl-2-acyl O +
class O -
, O +
of O +
which O -
, O +
in O +
bloodstream O +
forms O -
, O +
plasmenylethanolamine O +
comprised O +
a O +
single O +
molecular O +
species O -
, O +
which O +
was O +
substituted O +
with O +
octadecanoic O +
and O +
octadecadienoic O +
acids O +
in O +
the O +
sn O +
-1 O +
and O +
sn O +
-2 O +
positions O -
, O +
respectively O +
[ O -
36 O -
] O +
. O +

Most O +
reports O +
of O +
the O +
phospholipid O +
composition O +
of O +
T. O +
cruzi O +
have O +
made O +
no O +
mention O +
of O +
plasmalogens O +
[ O -
37–40 O -
] O +
, O +
though O +
an O +
early O +
paper O +
provided O +
indirect O +
evidence O +
for O +
the O +
presence O +
of O +
plasmenylethanolamine O +
in O +
the O +
Tulahuen O +
strain O +
[ O -
41 O -
] O +
. O +

The O +
present O +
study O +
is O +
therefore O +
the O +
first O +
instance O +
of O +
detailed O +
chemical O +
characterization O +
of O +
plasmalogens O +
from O +
this O +
organism O -
. O +

No O +
convincing O +
function O +
has O +
yet O +
been O +
assigned O +
to O +
the O +
plasmalogens O +
of O +
protozoa O -
. O +

In O +
contrast O +
to O +
mammalian O +
plasmalogens O -
, O +
those O +
of O +
protozoa O +
are O +
not O +
usually O +
enriched O +
in O +
arachidonate O -
, O +
and O +
thus O +
their O +
hydrolysis O +
may O +
not O +
result O +
in O +
the O +
release O +
of O +
biologically O +
active O +
eicosanoids O -
. O +

It O +
may O +
however O +
be O +
significant O +
that O +
plasmenylethanolamine O +
can O +
enhance O +
PAF O +
production O -
, O +
since O +
it O +
has O +
been O +
shown O +
that O +
PAF O +
encourages O +
cell O +
differentiation O +
in O +
T. O +
cruzi O +
strain O +
Dm28c O +
[ O -
42 O -
] O +
and O +
in O +
Herpetomonas O +
muscarum O +
[ O -
43 O -
] O +
, O +
and O +
that O +
both O +
parasites O +
have O +
specific O +
receptors B-Gene +
for O +
PAF O -
. O +

It O +
is O +
possible O +
that O +
parasite O +
plasmalogens O +
have O +
a O +
protective O +
function O -
, O +
since O +
they O +
have O +
been O +
shown O +
to O +
be O +
effective O +
scavengers O +
of O +
reactive O +
oxygen O +
species O +
[ O -
44,45 O -
] O +
and O +
might O +
thus O +
prevent O +
killing O +
by O +
the O +
oxidative O +
burst O -
. O +

In O +
the O +
present O +
study O +
we O +
show O +
that O +
the O +
major O +
plasmenylethanolamine O +
of O +
the O +
Dm28c O +
clone O +
of O +
T. O +
cruzi O +
is O +
recognised O +
by O +
antibodies B-Gene +
in O +
human O +
serum O +
which O +
are O +
present O +
at O +
elevated O +
levels O +
in O +
patients O +
with O +
chronic O +
Chagas O -
' O +
disease O -
. O +

Anti O -
- O -
phospholipid O +
antibodies O +
have O +
been O +
associated O +
with O +
infection O +
[ O -
44 O -
] O +
, O +
inflammation O -
, O +
immunological O +
diseases O -
, O +
and O +
conditions O +
such O +
as O +
pregnancy O +
and O +
ageing O +
[ O -
45 O -
] O +
. O +

In O +
general O +
antibodies B-Gene +
are O +
directed O +
against O +
cardiolipin O -
, O +
or O +
more O +
rarely O +
phosphatidylcholine O +
[ O -
46 O -
] O +
. O +

To O +
our O +
knowledge O +
this O +
is O +
the O +
first O +
report O +
of O +
the O +
detection O +
of O +
anti O -
- O -
plasmenylethanolamine O +
antibodies B-Gene -
. O +

Most O +
morbidity O +
and O +
mortality O +
in O +
Chagas O -
' O +
disease O +
is O +
a O +
consequence O +
of O +
the O +
cardiac O +
myopathy O +
associated O +
with O +
the O +
chronic O +
phase O +
of O +
the O +
disease O -
, O +
which O +
affects O +
20–30 O -
% O +
of O +
seropositive O +
patients O +
years O +
after O +
their O +
initial O +
infection O -
. O +

It O +
has O +
been O +
suggested O +
the O +
mechanism O +
of O +
cardiac O +
damage O +
is O +
autoimmune O +
in O +
nature O -
, O +
as O +
is O +
the O +
associated O +
destruction O +
of O +
the O +
autonomic O +
nerve O +
supply O +
to O +
the O +
affected O +
organs O -
. O +

Cross O +
reactive O +
antibodies B-Gene +
have O +
been O +
described O +
between O +
T. O +
cruzi O +
epitopes O +
and O +
a O +
43 O +
kDa O +
muscle O +
protein B-Gene +
[ O -
47 O -
] O +
, O +
laminin B-Gene +
[ O -
48 O -
] O +
, O +
tubulin B-Gene +
[ O -
49 O -
] O +
, O +
muscle O +
sarcoplasmatic O +
reticulum O +
antigen O +
[ O -
50 O -
] O +
, O +
ribosomal B-Gene +
proteins I-Gene +
[ O -
51 O -
] O +
, O +
antigens O +
of O +
nervous O +
tissues O +
[ O -
52 O -
] O +
cholesterol O +
sulphate O +
[ O -
53 O -
] O +
, O +
cardiac O +
glycosphingolipids O +
[ O -
54 O -
] O +
, O +
and O +
the O +
AAALDK O +
motif O +
of O +
cardiac O +
myosin B-Gene +
heavy O +
chain O +
[ O -
55 O -
] O +
. O +

Many O +
of O +
these O +
are O +
of O +
dubious O +
clinical O +
relevance O -
, O +
because O +
of O +
poor O +
correlation O +
with O +
the O +
different O +
forms O +
of O +
chronic O +
disease O -
, O +
lack O +
of O +
specificity O +
of O +
self O -
- O -
antigen O +
to O +
the O +
target O +
organs O -
, O +
or O +
because O +
the O +
cross O +
reactive O +
antigens O +
are O +
also O +
present O +
in O +
sera O +
from O +
uninfected O +
individuals O -
. O +

The O +
observation O +
that O +
the O +
plasmenylethanolamine O +
characterized O +
in O +
the O +
present O +
study O +
is O +
recognised O +
by O +
chagasic O +
serum O +
is O +
intriguing O -
, O +
because O +
plasmalogens O +
are O +
relatively O +
minor O +
constituents O +
of O +
most O +
mammalian O +
cell O +
types O +
but O +
are O +
abundant O +
in O +
the O +
cardiac O +
and O +
neuronal O +
tissues O +
that O +
are O +
the O +
main O +
sites O +
of O +
damage O +
in O +
chronic O +
Chagas O -
' O +
disease O -
. O +

In O +
most O +
mammalian O +
species O +
heart O +
muscle O +
is O +
markedly O +
enriched O +
in O +
plasmalogens O -
, O +
( O -
over O +
30 O -
% O +
of O +
total O +
phospholipid O +
in O +
ox O -
, O +
rabbit O -
, O +
dog O -
, O +
and O +
humans O +
[ O -
24 O -
] O +
) O -
. O +

In O +
human O +
heart O +
the O +
most O +
abundant O +
plasmalogen O +
species O +
are O +
plasmenylethanolamines O +
with O +
predominantly O +
hexadec-1-enyl O +
substituents O +
in O +
the O +
sn O +
-1 O +
position O +
and O +
a O +
mixture O +
of O +
octadecenoyl O -
, O +
eicosenoyl O -
, O +
and O +
arachidonoyl O +
acyl O +
groups O +
on O +
sn O +
-2 O -
. O +

The O +
presence O +
of O +
these O +
epitopes O +
shared O +
by O +
parasite O +
and O +
host O +
may O +
thus O +
provide O +
an O +
additional O +
route O +
for O +
the O +
development O +
of O +
the O +
characteristic O +
myopathy O +
of O +
chronic O +
Chagas O -
' O +
disease O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
grants O +
from O +
the O +
Conselho O +
Nacional O +
de O +
Desenvolvimento O +
Cientı́fico O +
e O +
Tecnológico O +
( O -
CNPq O -
) O -
, O +
Financiadora O +
de O +
Estudos O +
e O +
Projetos O +
( O -
FINEP O -
) O -
, O +
Conselho O +
de O +
Ensino O +
e O +
Pesquisa O +
da O +
UFRJ O +
( O -
CEPG O -
) O -
, O +
and O +
Programa O +
de O +
Núcleos O +
de O +
Excelência O +
( O -
PRONEX O -
) O -
. O +

We O +
thank O +
Dr O +
Barbara O +
Mulloy O +
( O -
National O +
Institute O +
for O +
Biological O +
Standards O +
and O +
Control O -
, O +
UK O -
) O +
for O +
the O +
NMR O +
spectroscopy O +
and O +
Maria O +
de O +
Fátima O +
Ferreira O +
Soares O +
for O +
technical O +
assistance O -
. O +

The O +
radioligand O +
[ O -
3 O +
H O +
] O +
{ O -
1- O -
[ O -
2- O -
( O -
diphenylmethoxy O -
) O -
ethyl O -
] O -
-4- O -
( O -
3-phenylpropyl O -
) O +
piperazine O +
dihydrochloride O -
} O +
( O -
[ O -
3 O +
H O +
] O -
GBR O +
12935 O -
) O +
labels O +
the O +
neuronal O +
dopamine O +
uptake O +
site O +
and O +
functions O +
as O +
a O +
marker O +
for O +
dopaminergic B-Gene +
neuron I-Gene +
terminals I-Gene +
in O +
brain O -
. O +

[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
also O +
recognizes O +
a O +
` O -
piperazine B-Gene +
acceptor I-Gene +
site I-Gene -
' O +
in O +
brain O -
. O +

The O +
designation O +
implies O +
that O +
this O +
site O +
is O +
recognized O +
by O +
piperazine O +
derivatives O +
such O +
as O +
flupenthixol O +
and O +
piflutixol O +
( O -
Andersen O -
, O +
1987 O +
) O -
. O +

Also O +
in O +
human O +
platelet O +
membranes O -
, O +
the O +
binding O +
of O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
has O +
yielded O +
characteristics O +
indicating O +
that O +
part O +
of O +
the O +
binding O +
is O +
to O +
a O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene +
( O -
Gordon O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

The O +
molecular O +
identity O +
and O +
functional O +
significance O +
of O +
the O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene +
have O +
not O +
yet O +
been O +
established O -
. O +

Some O +
data O +
indicate O +
that O +
there O +
might O +
be O +
an O +
association O +
with O +
the O +
cytochrome B-Gene +
P I-Gene +
-450 I-Gene +
( O -
CYP450 B-Gene -
) O +
system O -
; O +
in O +
canine O +
brain O +
the O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene +
has O +
been O +
identified O +
as O +
CYP4502D1 B-Gene -
, O +
which O +
corresponds O +
to O +
human O +
CYP4502D6 B-Gene +
( O -
Niznik O +
et O +
al. O -
, O +
1990 O +
; O +
Tyndale O +
et O +
al. O -
, O +
1991 O +
) O -
, O +
and O +
in O +
human O +
brain O +
an O +
association O +
between O +
the O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene +
and O +
CYP4502D6 B-Gene +
has O +
been O +
demonstrated O +
( O -
Allard O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

In O +
human O +
platelets O -
, O +
the O +
pharmacological O +
characteristics O +
of O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
were O +
recently O +
investigated O -
. O +

Part O +
of O +
the O +
binding O +
was O +
inhibited O +
by O +
compounds O +
known O +
as O +
inhibitors O +
of O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
to O +
CYP4502D6 B-Gene +
in O +
liver O +
and O +
brain O -
, O +
suggesting O +
that O +
this O +
binding O +
fraction O +
in O +
platelets O +
is O +
associated O +
with O +
CYP4502D6 B-Gene +
( O -
Norlén O +
and O +
Allard O -
, O +
1997 O +
) O -
. O +

In O +
humans O -
, O +
CYP4502D6 B-Gene +
( O -
debrisoquine-4-hydroxylase B-Gene -
) O +
has O +
been O +
demonstrated O +
mainly O +
in O +
liver O -
. O +

The O +
enzyme B-Gene +
is O +
responsible O +
for O +
the O +
metabolism O +
of O +
more O +
than O +
40 O +
different O +
drugs O -
, O +
such O +
as O +
antidepressants O -
, O +
neuroleptics O +
and O +
antiarrhythmics O -
. O +

The O +
CYP4502D6 B-Gene +
gene O +
on O +
human O +
chromosome O +
22 O +
is O +
highly O +
polymorphic O -
. O +

At O +
least O +
20 O +
different O +
alleles O +
have O +
been O +
described O +
( O -
Stüven O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
some O +
of O +
them O +
harbouring O +
mutations O +
leading O +
to O +
the O +
poor O +
metabolizer O +
phenotype O -
. O +

This O +
autosomal O +
recessive O +
metabolic O +
deficiency O +
affects O +
5–10 O -
% O +
of O +
Caucasians O +
and O +
may O +
lead O +
to O +
adverse O +
reactions O +
upon O +
administration O +
of O +
drugs O +
in O +
standard O +
doses O -
. O +

According O +
to O +
our O +
previous O +
study O +
( O -
Norlén O +
and O +
Allard O -
, O +
1997 O +
) O -
, O +
part O +
of O +
the O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
in O +
platelets O +
might O +
be O +
to O +
CYP4502D6 B-Gene -
. O +

Therefore O -
, O +
possible O +
differences O +
in O +
binding O +
characteristics O +
in O +
platelets O +
from O +
CYP4502D6 B-Gene +
poor O +
and O +
extensive O +
metabolizers O +
respectively O -
, O +
were O +
investigated O +
in O +
the O +
present O +
study O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Subjects O +
Thirty O -
- O -
four O +
subjects O +
took O +
part O +
in O +
the O +
investigation O -
, O +
which O +
was O +
approved O +
by O +
the O +
Ethics O +
Committee O +
at O +
the O +
University O +
of O +
Umeå O -
. O +

All O +
subjects O +
were O +
healthy O -
, O +
as O +
assessed O +
by O +
medical O +
history O -
, O +
physical O +
examination O +
and O +
routine O +
blood O +
chemistry O +
tests O -
. O +

They O +
were O +
recruited O +
from O +
a O +
population O +
of O +
more O +
than O +
500 O +
volunteers O +
phenotyped O +
with O +
respect O +
to O +
the O +
CYP4502D6 B-Gene +
polymorphism O +
by O +
means O +
of O +
the O +
test O +
drug O +
dextromethorphan O -
. O +

The O +
34 O +
subjects O +
included O +
16 O +
( O -
11 O +
men O +
and O +
5 O +
women O -
) O +
poor O +
metabolizers O +
of O +
dextromethorphan O +
and O +
18 O +
( O -
10 O +
men O +
and O +
8 O +
women O -
) O +
extensive O +
metabolizers O +
of O +
dextromethorphan O -
. O +

The O +
mean O +
age O +
of O +
the O +
extensive O +
metabolizer O +
group O +
was O +
38±2 O +
years O +
( O -
mean±S.E.M. O -
) O +
( O -
range O +
23–51 O +
years O -
) O +
and O +
of O +
the O +
poor O +
metabolizer O +
group O +
29±2 O +
years O +
( O -
range O +
23–43 O +
years O -
) O +
( O -
P O +
= O -
0.006 O -
) O -
. O +

When O +
dividing O +
the O +
subjects O +
with O +
respect O +
to O +
gender O -
, O +
the O +
mean O +
age O +
of O +
the O +
men O +
was O +
30±2 O +
years O +
( O -
mean±S.E.M. O -
) O +
( O -
range O +
23–50 O +
years O -
) O +
and O +
of O +
the O +
women O +
40±3 O +
years O +
( O -
range O +
23–51 O +
years O -
) O +
( O -
P O +
= O -
0.002 O -
) O -
. O +

The O +
body O +
weight O +
was O +
70±3 O +
kg O +
( O -
mean±S.E.M. O -
) O +
in O +
the O +
extensive O +
metabolizer O +
group O +
and O +
71±3 O +
kg O +
in O +
the O +
poor O +
metabolizer O +
group O -
. O +

As O +
expected O -
, O +
the O +
mean O +
body O +
weight O +
was O +
significantly O +
higher O +
in O +
males O +
than O +
in O +
females O +
( O -
77±2 O +
and O +
60±2 O +
kg O -
, O +
respectively O -
) O +
( O -
P O +
= O -
0.0001 O -
) O -
. O +

All O +
individuals O +
had O +
been O +
entirely O +
drug O -
- O -
free O +
for O +
at O +
least O +
2 O +
weeks O -
. O +

2.2 O +
CYP4502D6 B-Gene +
phenotyping O +
After O +
intake O +
of O +
50 O +
mg O +
dextromethorphan O +
hydrobromide O +
( O -
Tussidyl O +
mixture O -
, O +
2 O +
mg O -
/ O -
ml O -
, O +
TIKA O -
, O +
Lund O -
, O +
Sweden O -
) O -
, O +
urine O +
was O +
collected O +
for O +
10 O +
h. O +
Dextromethorphan O +
and O +
its O +
O O +
-demethylated O +
metabolite O +
dextrorphan O +
were O +
analyzed O +
by O +
a O +
capillary O +
gas O +
chromatography O +
method O +
published O +
earlier O +
( O -
Spigset O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Dextromethorphan O -
/ O -
dextrorphan O +
ratios O +
> O -
0.90 O +
defined O +
the O +
CYP4502D6 B-Gene +
poor O +
metabolizers O -
, O +
whereas O +
ratios O +
< O -
0.90 O +
defined O +
the O +
CYP4502D6 B-Gene +
extensive O +
metabolizers O -
. O +

The O +
poor O +
metabolizers O +
had O +
metabolic O +
ratios O +
between O +
0.92 O +
and O +
77.11 O -
, O +
whereas O +
the O +
extensive O +
metabolizers O +
had O +
metabolic O +
ratios O +
between O +
0.02 O +
and O +
0.86 O -
. O +

2.3 O +
Tissue O +
preparation O +
A O +
total O +
of O +
75 O +
ml O +
whole O +
blood O +
was O +
collected O +
from O +
each O +
individual O -
. O +

The O +
samples O +
were O +
centrifuged O +
at O +
180 O -
× O -
g O +
for O +
15 O +
min O +
at O +
20 O -
° O -
C O -
. O +

Assay O +
buffer O +
( O -
50 O +
mM O +
Tris·HCl O -
, O +
120 O +
mM O +
NaCl O -
, O +
5 O +
mM O +
KCl O -
, O +
pH O +
7.4 O -
) O +
was O +
then O +
added O +
1:1 O +
to O +
the O +
supernatant O -
, O +
which O +
was O +
then O +
centrifuged O +
at O +
3000 O -
× O -
g O +
for O +
20 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
pellets O +
were O +
washed O +
with O +
20 O +
ml O +
of O +
assay O +
buffer O +
and O +
then O +
recentrifuged O +
at O +
3000 O -
× O -
g O +
for O +
10 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
pellets O +
were O +
homogenized O +
with O +
10 O -
+ O -
10 O +
ml O +
of O +
assay O +
buffer O +
using O +
a O +
Kinematica O +
Polytron O +
homogenizer O +
( O -
Luzern O -
, O +
Switzerland O -
) O -
, O +
at O +
a O +
setting O +
of O +
6 O -
, O +
for O +
7 O +
s. O +
The O +
pellets O +
were O +
centrifuged O +
at O +
15 O +
000 O -
× O -
g O +
for O +
10 O +
min O +
at O +
4 O -
° O -
C O +
and O +
frozen O +
at O +
−70 O -
° O -
C O +
until O +
assay O -
. O +

On O +
the O +
day O +
of O +
experiment O -
, O +
the O +
tissue O +
was O +
washed O +
in O +
10 O -
+ O -
10 O +
ml O +
assay O +
buffer O +
and O +
centrifuged O +
at O +
18 O +
000 O -
× O -
g O +
for O +
10 O +
min O -
. O +

The O +
pellets O +
were O +
finally O +
homogenized O +
at O +
a O +
setting O +
of O +
4 O -
, O +
for O +
10 O +
s O -
, O +
and O +
then O +
resuspended O +
in O +
the O +
assay O +
buffer O +
to O +
a O +
mean O +
final O +
protein B-Gene +
concentration O +
of O +
470 O +
μg O +
protein B-Gene -
/ O -
ml O +
( O -
range O +
270–710 O +
μg O +
protein O -
/ O -
ml O -
) O -
. O +

2.4 O +
Compounds O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
( O -
40–45.7 O +
Ci O -
/ O -
mmol O -
) O +
was O +
purchased O +
from O +
New O +
England O +
Nuclear O -
, O +
Boston O -
, O +
MA O -
, O +
USA O -
. O +

cis O +
- O -
( O -
Z O +
) O -
-Flupenthixol O +
was O +
obtained O +
as O +
a O +
gift O +
from O +
H. O +
Lundbeck O -
, O +
Copenhagen O -
, O +
Denmark O -
. O +

2.5 O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
The O +
binding O +
of O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
was O +
carried O +
out O +
for O +
60 O +
min O +
at O +
25 O -
° O -
C O +
in O +
a O +
total O +
volume O +
of O +
2.0 O +
ml O -
. O +

The O +
incubation O +
volume O +
contained O +
250 O +
μl O +
of O +
tissue O +
homogenate O -
, O +
250 O +
μl O +
of O +
radioligand O -
, O +
250 O +
μl O +
of O +
displacing O +
drug O +
or O +
buffer O +
and O +
1250 O +
μl O +
assay O +
buffer O +
( O -
50 O +
mM O +
Tris·HCl O -
, O +
120 O +
mM O +
NaCl O -
, O +
0.01 O -
% O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene -
, O +
pH O +
7.4 O -
) O -
. O +

The O +
concentrations O +
of O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
ranged O +
from O +
0.25 O +
to O +
30 O +
nM. O +
The O +
experiments O +
were O +
carried O +
out O +
in O +
duplicate O -
. O +

After O +
the O +
addition O +
of O +
6 O +
ml O +
of O +
ice O -
- O -
cold O +
assay O +
buffer O -
, O +
the O +
homogenates O +
were O +
filtered O +
through O +
Whatman O +
GF O -
/ O -
C O +
filters O +
using O +
a O +
24-channel O +
cell O +
harvester O +
( O -
Brandel O -
, O +
Gaithersburg O -
, O +
MD O -
, O +
USA O -
) O +
Finally O -
, O +
the O +
filters O +
were O +
washed O +
with O +
three O +
6-ml O +
rinses O +
of O +
the O +
buffer O +
and O +
the O +
radioactivity O +
determined O +
by O +
liquid O +
scintillation O +
spectroscopy O -
. O +

Specific O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
to O +
the O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene +
was O +
defined O +
as O +
the O +
difference O +
between O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
in O +
the O +
absence O +
and O +
presence O +
of O +
0.3 O +
μM O +
cis O +
-flupenthixol O +
( O -
Norlén O +
and O +
Allard O -
, O +
1997 O +
) O -
. O +

Protein B-Gene +
determination O +
was O +
performed O +
according O +
to O +
Markwell O +
et O +
al. O +
( O -
1978 O -
) O +
. O +

2.6 O +
Data O +
analysis O +
and O +
statistics O +
B O +
max O +
and O +
K O +
d O +
values O +
were O +
determined O +
by O +
least O +
squares O +
linear O +
regression O +
analysis O +
of O +
Scatchard O +
plots O +
derived O +
from O +
the O +
saturation O +
experiments O -
. O +

Student O -
's O +
t O +
-test O +
and O +
covariate O +
analysis O +
were O +
used O +
for O +
comparisons O +
between O +
groups O -
. O +

The O +
criterion O +
for O +
statistical O +
significance O +
was O +
P O +
< O -
0.05 O -
. O +

3 O +
Results O +
B O +
max O +
was O +
680±74 O +
fmol O -
/ O -
mg O +
protein B-Gene +
( O -
mean±S.E.M. O -
) O +
in O +
the O +
poor O +
metabolizer O +
group O +
and O +
648±78 O +
fmol O -
/ O -
mg O +
protein B-Gene +
in O +
the O +
extensive O +
metabolizer O +
group O +
( O -
P O +
= O -
0.772 O -
) O -
. O +

K O +
d O +
was O +
5.77±0.81 O +
nM O +
in O +
the O +
poor O +
metabolizer O +
group O +
and O +
4.29±0.52 O +
nM O +
in O +
the O +
extensive O +
metabolizer O +
group O +
( O -
Fig. O +
1 O +
A O -
) O -
, O +
indicating O +
a O +
lower O +
binding O +
affinity O +
in O +
the O +
poor O +
metabolizer O +
group O -
. O +

The O +
difference O +
was O -
, O +
however O -
, O +
not O +
statistically O +
significant O +
( O -
P O +
= O -
0.126 O -
) O -
. O +

Representative O +
Scatchard O +
plots O -
, O +
one O +
from O +
each O +
group O -
, O +
are O +
depicted O +
in O +
Fig. O +
2 O +
. O +

There O +
were O +
no O +
correlations O +
between O +
age O +
and O +
the O +
B O +
max O +
or O +
K O +
d O +
values O +
( O -
r O +
= O -
−0.19 O +
and O +
−0.28 O -
, O +
respectively O -
) O -
. O +

Neither O +
were O +
there O +
any O +
correlations O +
between O +
body O +
weight O +
and O +
the O +
B O +
max O +
or O +
K O +
d O +
values O +
( O -
r O +
= O -
0.25 O +
and O +
0.31 O -
, O +
respectively O -
) O -
. O +

When O +
analyzing O +
possible O +
gender O +
differences O +
in O +
binding O +
parameters O -
, O +
no O +
significant O +
differences O +
in O +
density O +
of O +
binding B-Gene +
sites I-Gene +
were O +
found O -
; O +
in O +
male O +
subjects O +
( O -
poor O +
metabolizers O +
plus O +
extensive O +
metabolizers O -
) O -
, O +
B O +
max O +
was O +
725±78 O +
fmol O -
/ O -
mg O +
protein B-Gene +
and O +
in O +
female O +
subjects O +
( O -
poor O +
metabolizers O +
plus O +
extensive O +
metabolizers O -
) O -
, O +
B O +
max O +
was O +
564±49 O +
fmol O -
/ O -
mg O +
protein B-Gene +
( O -
P O +
= O -
0.144 O -
) O -
. O +

In O +
contrast O -
, O +
significant O +
differences O +
in O +
binding O +
affinity O +
were O +
found O -
; O +
K O +
d O +
for O +
male O +
subjects O +
was O +
5.73±0.66 O +
nM O -
, O +
and O +
for O +
female O +
subjects O +
3.78±0.56 O +
nM O +
( O -
P O +
= O -
0.048 O -
) O +
( O -
Fig. O +
1 O +
B O -
) O -
. O +

After O +
correction O +
for O +
gender O +
using O +
covariance O +
analysis O -
, O +
the O +
differences O +
in O +
K O +
d O +
between O +
the O +
poor O +
metabolizers O +
and O +
the O +
extensive O +
metabolizers O +
remained O +
grossly O +
unchanged O +
( O -
P O +
= O -
0.19 O -
) O -
. O +

There O +
was O +
no O +
correlation O +
between O +
the O +
concentrations O +
of O +
tissue O +
protein B-Gene +
and O +
the O +
K O +
d O +
values O +
( O -
r O +
= O -
−0.28 O -
) O -
. O +

4 O +
Discussion O +
The O +
principal O +
finding O +
in O +
this O +
study O +
was O +
that O +
males O +
had O +
significantly O +
lower O +
binding O +
affinity O +
for O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
than O +
females O -
. O +

This O +
discrepancy O +
seems O +
not O +
to O +
be O +
related O +
to O +
differences O +
in O +
CYP4502D6 B-Gene +
activity O +
since O +
the O +
metabolism O +
of O +
debrisoquine O +
is O +
not O +
affected O +
by O +
gender O +
( O -
Hietanen O +
et O +
al. O -
, O +
1991 O +
; O +
Bock O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

The O +
observed O +
gender O +
difference O +
could O +
imply O +
that O +
the O +
binding O +
is O +
influenced O +
in O +
a O +
competitive O +
manner O +
by O +
hormonal O +
factors O +
not O +
yet O +
identified O -
, O +
or O +
that O +
the O +
properties O +
of O +
the O +
piperazine B-Gene +
acceptor I-Gene +
ligand I-Gene +
binding I-Gene +
sites I-Gene +
are O +
differently O +
developed O +
secondary O +
to O +
unknown O +
gender O -
- O -
related O +
factors O -
. O +

No O +
significant O +
differences O +
in O +
binding O +
parameters O +
were O +
obtained O +
between O +
the O +
poor O +
metabolizer O +
and O +
the O +
extensive O +
metabolizer O +
groups O -
, O +
although O +
higher O +
K O +
d O +
values O +
were O +
found O +
in O +
the O +
poor O +
metabolizer O +
group O -
, O +
a O +
tendency O +
that O +
persisted O +
after O +
correction O +
for O +
gender O -
. O +

Although O +
the O +
difference O +
was O +
not O +
statistically O +
significant O -
, O +
some O +
possibilities O +
favouring O +
that O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
could O +
be O +
associated O +
with O +
CYP4502D6 B-Gene +
can O +
be O +
stated O -
. O +

The O +
reduced O +
binding O +
affinity O +
in O +
poor O +
metabolizers O +
could O +
in O +
fact O +
indicate O +
impairments O +
in O +
enzymatic B-Gene +
function O +
among O +
the O +
poor O +
metabolizers O +
or O -
, O +
alternatively O -
, O +
that O +
CYP4502D6 B-Gene +
is O +
not O +
completely O +
expressed O +
in O +
platelets O -
. O +

Further O +
possibilities O +
that O +
could O +
be O +
accounted O +
for O +
might O +
be O +
that O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binds O +
to O +
CYP450 B-Gene +
isoenzymes B-Gene +
other O +
than O +
CYP4502D6 B-Gene -
, O +
several O +
of O +
which O +
are O +
gender O -
- O -
specific O +
( O -
Fletcher O +
et O +
al. O -
, O +
1994 O +
; O +
Gleiter O +
and O +
Gundert O -
- O -
Remy O -
, O +
1996 O +
) O -
, O +
or O +
that O +
mutant O +
CYP4502D6 B-Gene +
alleles O +
in O +
poor O +
metabolizers O +
might O +
produce O +
enzymes B-Gene +
not O +
metabolically O +
active O +
but O +
still O +
harbouring O +
piperazine B-Gene +
acceptor I-Gene +
sites I-Gene -
. O +

A O +
shortcoming O +
to O +
the O +
study O +
might O +
be O +
the O +
age O +
differences O +
with O +
respect O +
to O +
gender O +
and O +
metabolic O +
capacity O -
; O +
women O +
being O +
significantly O +
older O +
than O +
men O -
, O +
and O +
the O +
extensive O +
metabolizers O +
being O +
significantly O +
older O +
than O +
the O +
poor O +
metabolizers O -
. O +

Age O +
was O -
, O +
however O -
, O +
not O +
significantly O +
correlated O +
to O +
either O +
the O +
K O +
d O +
or O +
the O +
B O +
max O +
values O +
and O -
, O +
consequently O -
, O +
the O +
age O +
differences O +
appear O +
not O +
to O +
influence O +
the O +
binding O +
parameters O -
. O +

The O +
function O +
and O +
significance O +
of O +
the O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene +
are O +
incompletely O +
known O -
. O +

The O +
present O +
study O +
revealed O -
, O +
as O +
a O +
conclusion O -
, O +
that O +
there O +
was O +
a O +
significant O +
gender O +
difference O +
in O +
the O +
affinity O +
of O +
piperazine B-Gene +
acceptor I-Gene +
sites I-Gene +
for O +
the O +
binding O +
of O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O -
. O +

There O +
was O +
also O +
a O +
tendency O +
towards O +
reduced O +
affinity O +
for O +
[ O -
3 O +
H O +
] O -
GBR O +
12935 O +
binding O +
to O +
piperazine B-Gene +
acceptor I-Gene +
sites I-Gene +
among O +
poor O +
metabolizers O +
compared O +
with O +
extensive O +
metabolizers O -
, O +
although O +
the O +
difference O +
was O +
not O +
statistically O +
significant O -
. O +

The O +
association O +
between O +
the O +
piperazine B-Gene +
acceptor I-Gene +
site I-Gene +
and O +
CYP4502D6 B-Gene +
in O +
platelets O +
has O +
not O +
been O +
convincingly O +
demonstrated O -
. O +

If O +
such O +
a O +
connection O +
exists O -
, O +
it O +
should O +
be O +
taken O +
into O +
account O +
that O +
gender O -
- O -
related O +
factors O +
probably O +
exert O +
an O +
important O +
influence O +
upon O +
that O +
link O -
. O +

Acknowledgements O +
The O +
authors O +
would O +
like O +
to O +
thank O +
Professor O +
Svante O +
B. O +
Ross O -
, O +
Astra O -
, O +
Södertälje O -
, O +
Sweden O +
for O +
generous O +
donation O +
of O +
radioligand O -
; O +
H. O +
Lundbeck O -
, O +
Copenhagen O -
, O +
Denmark O +
for O +
generous O +
donation O +
of O +
displacing O +
drug O -
; O +
Kerstin O +
Granberg O +
and O +
Margareta O +
Danielsson O +
for O +
excellent O +
technical O +
assistance O -
. O +

This O +
study O +
was O +
supported O +
by O +
the O +
County O +
Councils O +
of O +
Northern O +
Sweden O -
, O +
Gamla O +
Tjänarinnor O +
Foundation O -
, O +
the O +
Medical O +
Faculty O +
of O +
Umeå O +
University O +
and O +
the O +
Swedish O +
Society O +
for O +
Medicine O -
. O +

We O +
have O +
previously O +
identified O +
two O +
enzyme B-Gene +
activities O +
that O +
transfer O +
the O +
acetyl O +
group O +
from O +
platelet O -
- O -
activating O +
factor O +
( O -
PAF O -
) O +
in O +
a O +
CoA O -
- O -
independent O +
manner O +
to O +
lysoplasmalogen O +
or O +
sphingosine O +
in O +
HL-60 O +
cells O -
, O +
endothelial O +
cells O -
, O +
and O +
a O +
variety O +
of O +
rat O +
tissues O -
. O +

These O +
were O +
termed O +
as O +
PAF B-Gene -
: I-Gene -
lysoplasmalogen I-Gene +
( I-Gene -
lysophospholipid I-Gene -
) I-Gene +
transacetylase I-Gene +
and O +
PAF B-Gene -
: I-Gene -
sphingosine I-Gene +
transacetylase I-Gene -
, O +
respectively O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
have O +
solubilized O +
and O +
purified O +
this O +
PAF B-Gene -
- I-Gene -
dependent I-Gene +
transacetylase I-Gene +
13,700-fold O +
from O +
rat O +
kidney O +
membranes O +
( O -
mitochondrial O +
plus O +
microsomal O +
membranes O -
) O +
based O +
on O +
the O +
PAF B-Gene -
: I-Gene -
lysoplasmalogen I-Gene +
transacetylase I-Gene +
activity O -
. O +

The O +
mitochondria O +
and O +
microsomes O +
were O +
prepared O +
and O +
washed O +
three O +
times O -
, O +
then O +
solubilized O +
with O +
0.04 O -
% O +
Tween O +
20 O +
at O +
a O +
detergent O -
/ O -
protein O +
( O -
w O -
/ O -
w O -
) O +
ratio O +
of O +
0.1 O -
. O +

The O +
solubilized O +
fractions O +
from O +
mitochondria O +
and O +
microsomes O +
were O +
combined O +
and O +
subjected O +
to O +
sequential O +
column O +
chromatographies O +
on O +
DEAE O -
- O -
Sepharose O -
, O +
hydroxyapatite O -
, O +
phenyl O -
- O -
Sepharose O -
, O +
and O +
chromatofocusing O -
. O +

The O +
enzyme B-Gene +
was O +
further O +
purified O +
by O +
native O -
- O -
polyacrylamide O +
gel O +
electrophoresis O +
( O -
PAGE O -
) O +
and O +
affinity O +
gel O +
matrix O +
in O +
which O +
the O +
competitive O +
inhibitor O +
of O +
the O +
enzyme O -
, O +
1-O O -
- O -
hexadecyl-2-N O -
- O -
methylcarbamyl O -
- O -
sn O -
- O -
glycero-3-phosphoethanolamine O +
was O +
covalently O +
attached O +
to O +
the O +
CH O -
- O -
Sepharose O -
. O +

On O +
SDS O -
- O -
PAGE O -
, O +
the O +
purified O +
enzyme B-Gene +
showed O +
a O +
single O +
homogeneous O +
band O +
with O +
an O +
apparent O +
molecular O +
mass O +
of O +
40 O +
kDa O -
. O +

The O +
purified O +
enzyme B-Gene +
catalyzed O +
transacetylation O +
of O +
the O +
acetyl O +
group O +
not O +
only O +
from O +
PAF O +
to O +
lysoplasmalogen O +
forming O +
plasmalogen O +
analogs O +
of O +
PAF O -
, O +
but O +
also O +
to O +
sphingosine O +
producing O +
N O -
- O -
acetylsphingosine O +
( O -
C2-ceramide O -
) O -
. O +

In O +
addition O -
, O +
this O +
enzyme B-Gene +
acted O +
as O +
a O +
PAF B-Gene -
- I-Gene -
acetylhydrolase I-Gene +
in O +
the O +
absence O +
of O +
lipid O +
acceptor O +
molecules O -
. O +

These O +
results O +
suggest O +
that O +
PAF B-Gene -
- I-Gene -
dependent I-Gene +
transacetylase I-Gene +
is O +
an O +
enzyme B-Gene +
that O +
modifies O +
the O +
cellular O +
functions O +
of O +
PAF O +
through O +
generation O +
of O +
other O +
diverse O +
lipid O +
mediators O -
. O +

It O +
has O +
been O +
proposed O +
that O +
cells O +
sense O +
hypoxia O +
by O +
a O +
heme B-Gene +
protein I-Gene -
, O +
which O +
transmits O +
a O +
signal O +
that O +
activates O +
the O +
heterodimeric B-Gene +
transcription I-Gene +
factor I-Gene +
hypoxia I-Gene -
- I-Gene -
inducible I-Gene +
factor I-Gene +
1 I-Gene +
( O -
HIF-1 B-Gene -
) O -
, O +
thereby O +
inducing O +
a O +
number O +
of O +
physiologically O +
relevant O +
genes O +
such O +
as O +
erythropoietin B-Gene +
( O -
Epo O -
) O -
. O +

We O +
have O +
investigated O +
the O +
mechanism O +
by O +
which O +
two O +
heme O -
- O -
binding O +
ligands O -
, O +
carbon O +
monoxide O +
and O +
nitric O +
oxide O -
, O +
affect O +
oxygen O +
sensing O +
and O +
signaling O -
. O +

Two O +
concentrations O +
of O +
CO O +
( O -
10 O +
and O +
80 O -
% O -
) O +
suppressed O +
the O +
activation O +
of O +
HIF-1 B-Gene +
and O +
induction O +
of O +
Epo B-Gene +
mRNA O +
by O +
hypoxia O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

In O +
contrast O -
, O +
CO O +
had O +
no O +
effect O +
on O +
the O +
induction O +
of O +
HIF-1 B-Gene +
activity O +
and O +
Epo B-Gene +
expression O +
by O +
either O +
cobalt O +
chloride O +
or O +
the O +
iron O +
chelator O +
desferrioxamine O -
. O +

The O +
affinity O +
of O +
CO O +
for O +
the O +
putative O +
sensor O +
was O +
much O +
lower O +
than O +
that O +
of O +
oxygen O +
( O -
Haldane O +
coefficient O -
, O +
approximately O +
0.5 O -
) O -
. O +

Parallel O +
experiments O +
were O +
done O +
with O +
100 O +
microM O +
sodium O +
nitroprusside O -
, O +
a O +
nitric O +
oxide O +
donor O -
. O +

Both O +
NO O +
and O +
CO O +
inhibited O +
HIF-1 B-Gene +
DNA O +
binding O +
by O +
abrogating O +
hypoxia O -
- O -
induced O +
accumulation O +
of O +
HIF-1alpha B-Gene +
protein O -
. O +

Moreover O -
, O +
both O +
NO O +
and O +
CO O +
specifically O +
targeted O +
the O +
internal O +
oxygen O -
- O -
dependent O +
degradation O +
domain O +
of O +
HIF-1alpha B-Gene -
, O +
and O +
also O +
repressed O +
the O +
C O -
- O -
terminal O +
transactivation O +
domain O +
of O +
HIF-1alpha B-Gene -
. O +

Thus O -
, O +
NO O +
and O +
CO O +
act O +
proximally O -
, O +
presumably O +
as O +
heme O +
ligands O +
binding O +
to O +
the O +
oxygen O +
sensor O -
, O +
whereas O +
desferrioxamine O +
and O +
perhaps O +
cobalt O +
appear O +
to O +
act O +
at O +
a O +
site O +
downstream O -
. O +

Binding O +
of O +
fluorescent O +
fatty O +
acids O +
to O +
bovine B-Gene +
liver I-Gene +
non I-Gene -
- I-Gene -
specific I-Gene +
lipid I-Gene -
- I-Gene -
transfer I-Gene +
protein I-Gene +
( O -
nsL B-Gene -
- I-Gene -
TP I-Gene -
) O +
was O +
assessed O +
by O +
measuring O +
fluorescence O +
resonance O +
energy O +
transfer O +
( O -
FRET O -
) O +
between O +
the O +
single O +
tryptophan O +
residue O +
of O +
nsL B-Gene -
- I-Gene -
TP I-Gene +
and O +
the O +
fluorophore O -
. O +

Upon O +
addition O +
of O +
pyrene O +
dodecanoic O +
acid O +
( O -
Pyr O -
- O -
C12 O -
) O +
and O +
cis O -
- O -
parinaric O +
acid O +
to O +
nsL B-Gene -
- I-Gene -
TP I-Gene -
, O +
FRET O +
was O +
observed O +
indicating O +
that O +
these O +
fatty O +
acids O +
were O +
accommodated O +
in O +
the O +
lipid B-Gene +
binding I-Gene +
site I-Gene +
closely O +
positioned O +
to O +
the O +
tryptophan O +
residue O -
. O +

Substantial O +
binding O +
was O +
observed O +
only O +
when O +
these O +
fatty O +
acids O +
were O +
presented O +
in O +
the O +
monomeric O +
form O +
complexed O +
to O +
beta O -
- O -
cyclodextrin O -
. O +

As O +
shown O +
by O +
time O -
- O -
resolved O +
fluorescence O +
measurements O -
, O +
translocation O +
of O +
Pyr O -
- O -
C12 O +
from O +
the O +
Pyr O -
- O -
C12-beta O -
- O -
cyclodextrin O +
complex O +
to O +
nsL B-Gene -
- I-Gene -
TP I-Gene +
changed O +
dramatically O +
the O +
direct O +
molecular O +
environment O +
of O +
the O +
pyrene O +
moiety O -
: O +
i.e. O +
the O +
fluorescence O +
lifetime O +
of O +
the O +
directly O +
excited O +
pyrene O +
increased O +
at O +
least O +
by O +
25 O -
% O +
and O +
a O +
distinct O +
rotational O +
correlation O +
time O +
of O +
7 O +
ns O +
was O +
observed O -
. O +

In O +
order O +
to O +
evaluate O +
the O +
affinity O +
of O +
nsL B-Gene -
- I-Gene -
TP I-Gene +
for O +
intermediates O +
of O +
the O +
beta O -
- O -
oxidation O +
pathway O -
, O +
a O +
binding O +
assay O +
was O +
developed O +
based O +
on O +
the O +
ability O +
of O +
fatty O +
acyl O +
derivatives O +
to O +
displace O +
Pyr O -
- O -
C12 O +
from O +
the O +
lipid B-Gene +
binding I-Gene +
site I-Gene +
as O +
reflected O +
by O +
the O +
reduction O +
of O +
FRET O -
. O +

Hexadecanoyl O -
- O -
CoA O +
and O +
2-hexadecenoyl O -
- O -
CoA O +
were O +
found O +
to O +
bind O +
readily O +
to O +
nsL B-Gene -
- I-Gene -
TP I-Gene -
, O +
whereas O +
3-hydroxyhexadecanoyl O -
- O -
CoA O +
and O +
3-ketohexadecanoyl O -
- O -
CoA O +
bound O +
poorly O -
. O +

The O +
highest O +
affinities O +
were O +
observed O +
for O +
the O +
very O -
- O -
long O -
- O -
chain O +
fatty O +
acyl O -
- O -
CoA O +
esters O +
( O -
24:0-CoA O -
, O +
26:0-CoA O -
) O +
and O +
their O +
enoyl O +
derivatives O +
( O -
24:1-CoA O -
, O +
26:1-CoA O -
) O -
. O +

Binding O +
of O +
non O -
- O -
esterified O +
hexadecanoic O +
acid O +
and O +
tetracosanoic O +
acid O +
( O -
24:0 O -
) O +
was O +
negligible O -
. O +

Isatin O +
is O +
an O +
endogenous O +
indole O +
and O +
an O +
inhibitor O +
of O +
atrial B-Gene +
natriuretic I-Gene +
peptide I-Gene +
( O -
ANP B-Gene -
) O +
receptors O +
coupled O +
with O +
particulate O +
guanylyl B-Gene +
cyclase I-Gene +
( O -
GC B-Gene -
) O -
. O +

In O +
this O +
study O -
, O +
several O +
isatin O +
analogues O +
were O +
tested O +
as O +
inhibitors O +
of O +
ANP B-Gene -
- I-Gene -
stimulated I-Gene +
GC I-Gene +
in O +
rat O +
brain O +
and O +
heart O +
membranes O -
. O +

None O +
of O +
these O +
analogues O +
affected O +
activity O +
in O +
the O +
absence O +
of O +
ANP B-Gene -
, O +
or O +
stimulated O +
ANP O -
- O -
induced O +
activity O -
. O +

In O +
both O +
tissues O -
, O +
some O +
5-substituted O +
isatins O +
( O -
5-hydroxyisatin O -
, O +
5-methylisatin O -
, O +
and O +
5-aminoisatin O -
) O +
exhibited O +
more O +
effective O +
inhibitory O +
activity O +
than O +
isatin O +
itself O -
, O +
with O +
IC50 O +
values O +
in O +
the O +
range O +
1.3 O -
- O -
20 O +
microM. O +
The O +
efficacy O +
of O +
other O +
analogues O +
varied O +
and O +
was O +
not O +
consistent O +
between O +
the O +
two O +
tissues O -
, O +
raising O +
the O +
possibility O +
of O +
receptor O +
heterogeneity O +
and O +
relative O +
selectivity O +
of O +
inhibition O -
. O +

Some O +
substituted O +
isatins O +
may O +
have O +
a O +
role O +
as O +
pharmacological O +
tools O +
for O +
investigating O +
the O +
physiological O +
roles O +
of O +
natriuretic B-Gene +
peptides I-Gene +
and O +
their O +
receptors B-Gene -
. O +

It O +
has O +
been O +
shown O +
previously O +
that O +
4-anilino O +
quinazolines O +
compete O +
with O +
the O +
ability O +
of O +
ATP O +
to O +
bind O +
the O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
EGF B-Gene -
- I-Gene -
R I-Gene -
) I-Gene -
, O +
inhibit O +
EGF B-Gene -
- O -
stimulated O +
autophosphorylation O +
of O +
tyrosine O +
residues O +
in O +
EGF B-Gene -
- I-Gene -
R I-Gene -
, O +
and O +
block O +
EGF B-Gene -
- O -
mediated O +
growth O -
. O +

Since O +
millimolar O +
concentrations O +
of O +
ATP O +
in O +
cells O +
could O +
reduce O +
the O +
efficacy O +
of O +
4-anilino O +
quinazolines O +
in O +
cells O +
and O +
the O +
activity O +
of O +
these O +
compounds O +
would O +
not O +
be O +
sustained O +
once O +
they O +
were O +
removed O +
from O +
the O +
body O -
, O +
we O +
reasoned O +
that O +
irreversible O +
inhibitors O +
of O +
EGF B-Gene -
- I-Gene -
R I-Gene +
might O +
improve O +
the O +
activity O +
of O +
this O +
series O +
of O +
compounds O +
in O +
animals O -
. O +

Molecular O +
modeling O +
of O +
the O +
EGF B-Gene -
- I-Gene -
R I-Gene +
kinase I-Gene +
domain B-Gene +
was O +
used O +
to O +
design O +
irreversible O +
inhibitors O -
. O +

We O +
herein O +
describe O +
one O +
such O +
inhibitor O -
: O +
N- O -
[ O -
4- O -
[ O -
( O -
3-bromophenyl O -
) O -
amino O -
] O -
-6-quinazolinyl O -
] O -
2-butynamide O -
, O +
known O +
as O +
CL-387,785 O -
. O +

This O +
compound O +
covalently O +
bound O +
to O +
EGF B-Gene -
- I-Gene -
R. I-Gene +
It O +
also O +
specifically O +
inhibited O +
kinase O +
activity O +
of O +
the O +
protein B-Gene +
( O -
IC50 O +
= O +
370+ O -
/ O -
-120 O +
pM O -
) O -
, O +
blocked O +
EGF B-Gene -
- O -
stimulated O +
autophosphorylation O +
of O +
the O +
receptor O +
in O +
cells O +
( O -
ic50 O +
approximately O +
5 O +
nM O -
) O -
, O +
inhibited O +
cell O +
proliferation O +
( O -
IC50 O +
= O +
31 O -
- O -
125 O +
nM O -
) O +
primarily O +
in O +
a O +
cytostatic O +
manner O +
in O +
cell O +
lines O +
that O +
overexpress O +
EGF B-Gene -
- I-Gene -
R I-Gene +
or O +
c B-Gene -
- I-Gene -
erbB-2 I-Gene -
, O +
and O +
profoundly O +
blocked O +
the O +
growth O +
of O +
a O +
tumor O +
that O +
overexpresses O +
EGF B-Gene -
- I-Gene -
R I-Gene +
in O +
nude O +
mice O +
( O -
when O +
given O +
orally O +
at O +
80 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
10 O +
days O -
, O +
daily O -
) O -
. O +

We O +
conclude O +
that O +
CL-387,785 O +
is O +
useful O +
for O +
studying O +
the O +
interaction O +
of O +
small O +
molecules O +
with O +
EGF B-Gene -
- I-Gene -
R I-Gene +
and O +
may O +
have O +
clinical O +
utility O -
. O +

Ethylene O -
- O -
di O -
- O -
bromide O +
is O +
a O +
popular O +
fumigant O -
. O +

Delayed O +
long O -
- O -
term O +
effects O +
of O +
this O +
chemical O +
include O +
carcinogenicity O +
and O +
genotoxicity O +
in O +
animals O -
. O +

Only O +
a O +
few O +
cases O +
of O +
acute O +
ethylene O -
- O -
di O -
- O -
bromide O +
toxicity O +
have O +
been O +
reported O +
and O +
all O +
of O +
them O +
have O +
resulted O +
in O +
a O +
fatal O +
outcome O -
. O +

We O +
report O +
the O +
first O +
case O +
of O +
ethylene O -
- O -
di O -
- O -
bromide O +
poisoning O +
presenting O +
with O +
acute O +
renal O +
failure O +
and O +
toxic O +
hepatitis O +
that O +
was O +
managed O +
successfully O -
. O +

By O +
using O +
wild O -
- O -
type O +
and O +
deoxystreptamine O -
- O -
negative O +
mutants O +
of O +
Streptomyces O +
fradiae O +
grown O +
in O +
media O +
containing O +
[ O -
6 O -
( O -
-3 O -
) O -
H O -
] O -
glucose O +
or O +
[ O -
U-14C O -
] O -
glucose O -
, O +
and O +
by O +
subsequent O +
hydrolysis O +
of O +
the O +
labelled O +
neomycin O +
produced O -
, O +
neamines O +
labelled O +
with O +
3H O +
in O +
both O +
rings O +
I O +
and O +
II O -
, O +
but O +
with O +
14C O +
in O +
ring O +
I O +
only O -
, O +
were O +
prepared O -
. O +

A O +
mixture O +
of O +
these O +
two O +
forms O +
of O +
neamine O +
was O +
converted O +
by O +
deoxystreptamine O -
- O -
negative O +
Streptomyces O +
rimosus O +
forma O +
paromomycinus O +
into O +
neomycin O +
( O -
not O +
paromomycin O -
) O +
with O +
a O +
30 O -
% O +
yield O -
. O +

The3H O -
: O +
14C O +
ratio O +
in O +
this O +
neomycin O +
was O +
the O +
same O +
as O +
the O +
measured O +
in O +
neamine O +
produced O +
by O +
hydrolysis O +
of O +
the O +
neomycin O -
, O +
and O +
in O +
unused O +
neamine O +
reisolated O +
from O +
the O +
incubation O +
medium O -
. O +

The O +
3H:14C O +
ratio O +
in O +
the O +
neomycin O +
was O +
not O +
affected O +
by O +
the O +
presence O +
of O +
unlabelled O +
deoxystreptamine O +
during O +
the O +
incubation O -
. O +

The O +
radioactivity O +
in O +
the O +
neomycin O +
was O +
associated O +
with O +
rings O +
I O +
and O +
II O +
only O -
. O +

It O +
is O +
concluded O +
that O +
the O +
added O +
neamine O +
is O +
incorporated O +
into O +
antibiotic O +
intact O -
, O +
without O +
initial O +
hydrolysis O -
, O +
and O +
that O +
the O +
probable O +
first O +
step O +
in O +
the O +
subunit O +
assembly O +
of O +
neomycin O +
is O +
the O +
formation O +
of O +
neamine O -
. O +

Extraction O +
with O +
butan-1-ol O +
of O +
freeze O -
- O -
dried O +
microsomal O +
fractions O +
from O +
livers O +
of O +
3-methyl O -
- O -
cholarthrene O -
- O -
pre O -
- O -
treated O +
hamsters O +
removed O +
about O +
90 O -
% O +
of O +
the O +
total O +
lipid O +
content O -
, O +
but O +
the O +
lipid O +
remaining O +
proved O +
sufficient O +
for O +
the O +
cytochrome B-Gene +
P-450 I-Gene +
enzyme O +
system O +
to O +
retain O +
about O +
15 O -
- O -
40 O -
% O +
of O +
its O +
original O +
catalytic O +
activity O +
for O +
dimethylnitrosamine O +
demethylation O -
. O +

Addition O +
of O +
butan-1-ol O -
- O -
extracted O +
total O +
phospholipid O +
or O +
phosphatidylcholine O +
could O +
not O +
restore O +
any O +
activity O -
, O +
whereas O +
the O +
addition O +
of O +
the O +
synthetic O +
phospholipid O +
dilauroyl O +
phosphatidylcholine O +
was O +
able O +
to O +
restore O +
almost O +
complete O +
activity O -
. O +

Synthetic O +
dipalmitoyl O +
or O +
distearoyl O +
phosphatidylcholine O +
was O +
ineffective O +
in O +
restoring O +
the O +
activity O +
in O +
this O +
reconstituted O +
system O -
. O +

The O +
prevention O +
of O +
cerebral O +
palsy O +
and O +
neuroprotection O +
of O +
the O +
immature O +
brain O +
continue O +
to O +
be O +
health O +
care O +
priorities O -
. O +

The O +
pathophysiology O +
of O +
perinatal O +
brain O +
lesions O +
associated O +
with O +
cerebral O +
palsy O +
seems O +
to O +
be O +
multifactorial O +
and O +
includes O +
pre- O +
and O +
perinatal O +
factors O +
such O +
as O +
preconceptional O +
events O -
, O +
hormone O +
and O +
growth O +
factors O +
deficiencies O -
, O +
maternal O +
infections O +
with O +
production O +
of O +
cytokines B-Gene -
, O +
and O +
hypoxic O -
/ O -
ischemic O +
perfusion O +
failures O -
. O +

Excitotoxic O +
cascade O +
could O +
represent O +
a O +
common O +
pathway O +
that O +
leads O +
to O +
neural O +
cell O +
death O +
and O +
subsequent O +
brain O +
damage O -
. O +

Brain O +
injuries O +
induced O +
by O +
ibotenate O -
, O +
a O +
glutamatergic O +
analog O -
, O +
which O +
are O +
essentially O +
mediated O +
through O +
the O +
N B-Gene -
- I-Gene -
methyl I-Gene -
- I-Gene -
D I-Gene -
- I-Gene -
aspartate I-Gene +
receptor I-Gene -
, I-Gene +
mimic O +
some O +
aspects O +
of O +
the O +
white O +
matter O +
cysts O +
and O +
transcortical O +
necrosis O +
observed O +
in O +
human O +
perinatal O +
brain O +
damage O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
assess O +
the O +
protective O +
role O +
of O +
several O +
pharmacological O +
agents O -
, O +
administered O +
in O +
conjunction O +
with O +
ibotenate O -
, O +
against O +
induced O +
excitotoxic O +
lesions O -
. O +

We O +
injected O +
ibotenate O +
in O +
the O +
developing O +
mouse O +
brain O +
5 O +
d O +
postnatally O -
, O +
after O +
the O +
full O +
settlement O +
of O +
neuronal O +
layers O -
. O +

Co O -
- O -
treatment O +
with O +
kynurenic O +
acid O -
, O +
an O +
antagonist O +
of O +
the O +
facilitating O +
glycine O +
site O +
of O +
the O +
N B-Gene -
- I-Gene -
methyl I-Gene -
- I-Gene -
D I-Gene -
- I-Gene -
aspartate I-Gene +
receptor I-Gene -
, O +
or O +
with O +
N O -
( O -
G O -
) O -
-nitro O -
- O -
L O -
- O -
arginine O -
, O +
an O +
inhibitor O +
of O +
nitric O +
oxide O +
synthesis O -
, O +
induced O +
a O +
dose O -
- O -
dependent O +
neuroprotective O +
effect O -
. O +

Conversely O -
, O +
zinc O +
gluconate O -
, O +
a O +
blocking O +
agent O +
of O +
the O +
channel O +
linked O +
to O +
the O +
N B-Gene -
- I-Gene -
methyl I-Gene -
- I-Gene -
D I-Gene -
- I-Gene -
aspartate I-Gene +
receptor I-Gene -
, O +
and O +
a O +
free O +
radical O +
scavenger O +
( O -
U74389F O -
) O -
, O +
were O +
unable O +
to O +
protect O +
the O +
developing O +
brain O +
against O +
excitotoxic O +
attack O -
. O +

These O +
data O +
help O +
to O +
clarify O +
some O +
molecular O +
mechanisms O +
involved O +
in O +
excitotoxic O +
lesions O +
of O +
the O +
developing O +
mouse O +
brain O +
and O +
permit O +
us O +
to O +
envision O +
new O +
strategies O +
in O +
the O +
prevention O +
of O +
cerebral O +
palsy O -
. O +

A O +
novel O +
tricyclic O +
diterpenoid O +
antibiotic O -
, O +
brasilicardin O +
A O -
, O +
was O +
isolated O +
from O +
the O +
culture O +
broth O +
of O +
Nocardia O +
brasiliensis O +
IFM O +
0406 O -
. O +

The O +
antibiotic O +
exhibited O +
immunosuppressive O +
activity O +
in O +
a O +
mouse O +
mixed O +
lymphocyte O +
reaction O +
( O -
MLR O -
) O +
assay O +
system O +
and O +
its O +
IC50 O +
value O +
was O +
0.057 O +
microg O -
/ O -
ml O -
. O +

Although O +
the O +
inhibitory O +
activity O +
of O +
cyclosporin O +
A O +
( O -
CyA O -
) O +
against O +
IL-2 O +
production O +
was O +
confirmed O +
in O +
the O +
MLR O +
assay O +
system O -
, O +
brasilicardin O +
A O +
did O +
not O +
have O +
the O +
activity O -
. O +

The O +
results O +
of O +
in O +
vitro O +
toxicity O +
testing O +
of O +
brasilicardin O +
A O +
against O +
various O +
human O +
cell O +
lines O +
were O +
compared O +
with O +
those O +
of O +
CyA. O +

IC202A O -
, O +
a O +
new O +
immunosuppressive O +
compound O -
, O +
was O +
isolated O +
from O +
the O +
culture O +
filtrate O +
of O +
Streptoalloteichus O +
sp. O +
1454 O -
- O -
19 O -
. O +

It O +
showed O +
a O +
suppressive O +
effect O +
on O +
mixed O +
lymphocyte O +
culture O +
reaction O +
with O +
an O +
IC50 O +
value O +
of O +
3.6 O +
microg O -
/ O -
ml O +
and O +
mitogen O +
induced O +
lymphocyte O +
blastogenesis O +
in O +
vitro O -
. O +

A O +
glutathione B-Gene +
S I-Gene -
- I-Gene -
transferase I-Gene +
( O -
GST B-Gene -
) O +
with O +
activity O +
toward O +
1 O -
, O +
2-epoxy-2-methyl-3-butene O +
( O -
isoprene O +
monoxide O -
) O +
and O +
cis-1 O -
, O +
2-dichloroepoxyethane O +
was O +
purified O +
from O +
the O +
isoprene O -
- O -
utilizing O +
bacterium O +
Rhodococcus O +
sp. O +
strain O +
AD45 O -
. O +

The O +
homodimeric O +
enzyme B-Gene +
( O -
two O +
subunits O +
of O +
27 O +
kDa O +
each O -
) O +
catalyzed O +
the O +
glutathione O +
( O -
GSH O -
) O -
-dependent O +
ring O +
opening O +
of O +
various O +
epoxides O -
. O +

At O +
5 O +
mM O +
GSH O -
, O +
the O +
enzyme B-Gene +
followed O +
Michaelis O -
- O -
Menten O +
kinetics O +
for O +
isoprene O +
monoxide O +
and O +
cis-1 O -
, O +
2-dichloroepoxyethane O -
, O +
with O +
Vmax O +
values O +
of O +
66 O +
and O +
2.4 O +
micromol O +
min-1 O +
mg O +
of O +
protein-1 O +
and O +
Km O +
values O +
of O +
0.3 O +
and O +
0.1 O +
mM O +
for O +
isoprene O +
monoxide O +
and O +
cis-1,2-dichloroepoxyethane O -
, O +
respectively O -
. O +

Activities O +
increased O +
linearly O +
with O +
the O +
GSH O +
concentration O +
up O +
to O +
25 O +
mM. O +
1H O +
nuclear O +
magnetic O +
resonance O +
spectroscopy O +
showed O +
that O +
the O +
product O +
of O +
GSH O +
conjugation O +
to O +
isoprene O +
monoxide O +
was O +
1-hydroxy-2-glutathionyl-2-methyl-3-butene O +
( O -
HGMB O -
) O -
. O +

Thus O -
, O +
nucleophilic O +
attack O +
of O +
GSH O +
occurred O +
on O +
the O +
tertiary O +
carbon O +
atom O +
of O +
the O +
epoxide O +
ring O -
. O +

HGMB O +
was O +
further O +
converted O +
by O +
an O +
NAD+-dependent B-Gene +
dehydrogenase I-Gene -
, O +
and O +
this O +
enzyme B-Gene +
was O +
also O +
purified O +
from O +
isoprene O -
- O -
grown O +
cells O -
. O +

The O +
homodimeric O +
enzyme B-Gene +
( O -
two O +
subunits O +
of O +
25 O +
kDa O +
each O -
) O +
showed O +
a O +
high O +
activity O +
for O +
HGMB O -
, O +
whereas O +
simple O +
primary O +
and O +
secondary O +
alcohols O +
were O +
not O +
oxidized O -
. O +

The O +
enzyme B-Gene +
catalyzed O +
the O +
sequential O +
oxidation O +
of O +
the O +
alcohol O +
function O +
to O +
the O +
corresponding O +
aldehyde O +
and O +
carboxylic O +
acid O +
and O +
followed O +
Michaelis O -
- O -
Menten O +
kinetics O +
with O +
respect O +
to O +
NAD+ O +
and O +
HGMB O -
. O +

The O +
results O +
suggest O +
that O +
the O +
initial O +
steps O +
in O +
isoprene O +
metabolism O +
are O +
a O +
monooxygenase B-Gene -
- O -
catalyzed O +
conversion O +
to O +
isoprene O +
monoxide O -
, O +
a O +
GST O -
- O -
catalyzed O +
conjugation O +
to O +
HGMB O -
, O +
and O +
a O +
dehydrogenase O -
- O -
catalyzed O +
two O -
- O -
step O +
oxidation O +
to O +
2-glutathionyl-2-methyl-3-butenoic O +
acid O -
. O +

This O +
paper O +
reports O +
the O +
preparation O +
and O +
identification O +
of O +
two O +
monoclonal O +
antibodies B-Gene +
against O +
FTB O -
, O +
and O +
the O +
establishment O +
of O +
an O +
indirect O +
competitive O +
ELISA O +
methods O +
for O +
FTB O +
determination O +
in O +
buckwheat O -
, O +
rice O -
, O +
and O +
corn O -
. O +

Two O +
of O +
the O +
hybridoma O +
cell O +
lines O +
( O -
1C9 O +
and O +
2D10 O -
) O -
, O +
which O +
could O +
produce O +
specific O +
antibodies B-Gene +
against O +
fumitremorgin O +
B O -
( O -
FTB O -
) O -
, O +
were O +
selected O +
and O +
developed O -
. O +

The O +
affinity O +
Kaff O +
constants O +
of O +
the O +
monoclonal O +
antibodies O +
with O +
the O +
coating O +
antigen O -
, O +
FTBS O -
- O -
IgG O -
, O +
were O +
found O +
to O +
be O +
6 O +
x O +
10 O -
( O -
8 O -
) O +
M-1 O +
and O +
9.8 O +
x O +
10 O +
M-1 O -
, O +
respectively O -
. O +

The O +
isotypes O +
of O +
the O +
monoclonal O +
antibodies B-Gene +
are O +
of O +
two O +
isotypes O -
, O +
IgG1 O +
and O +
IgM O -
, O +
respectively O -
. O +

The O +
antibody B-Gene +
titers O +
were O +
found O +
around O +
1 O +
x O +
10 O -
( O -
6 O -
) O +
and O +
1.5 O +
x O +
10 O -
( O -
6 O -
) O -
. O +

The O +
standard O +
curves O +
showed O +
that O +
as O +
little O +
as O +
5 O +
pg O +
of O +
FTB O +
in O +
50 O +
mL O +
could O +
be O +
detected O -
, O +
and O +
the O +
linear O +
range O +
of O +
standard O +
curve O +
was O +
from O +
10 O +
pg O +
to O +
1000 O +
pg O +
of O +
standard O +
FTB O -
. O +

There O +
were O +
no O +
cross O -
- O -
reaction O +
for O +
McAbs O +
in O +
the O +
assay O +
system O +
with O +
some O +
mycotoxins O +
tested O -
. O +

The O +
mean O +
recovery O +
rate O +
from O +
buckwheat O +
spiked O +
with O +
10 O -
- O -
60 O +
ng O -
/ O -
g O +
of O +
FTB O +
was O +
78 O -
- O -
88.7 O -
% O -
. O +

The O +
reaction O +
of O +
[ O -
3H O -
] O -
p O -
- O -
nitrophenyl O +
acetate O +
( O -
NPA O -
) O +
or O +
[ O -
14C O -
] O -
methyl O +
acetimidate O +
( O -
MAI O -
) O +
with O +
amino O +
groups O +
of O +
ribosomal O +
pade O +
between O +
the O +
reactivity O +
of O +
the O +
proteins B-Gene +
in O +
situ O +
in O +
the O +
ribosomal O +
subunit O +
with O +
that O +
of O +
isolated O +
protein B-Gene +
mixtures O -
. O +

In O +
the O +
small O +
subunit O +
reactivity O +
compared O +
with O +
the O +
protein B-Gene +
mixture O +
was O +
only O +
10 O -
- O -
65 O -
% O +
in O +
the O +
case O +
of O +
NPA O +
but O +
45 O +
to O +
more O +
than O +
100 O -
% O +
in O +
the O +
case O +
of O +
MAI O -
. O +

In O +
the O +
large O +
subunit O +
reactivity O +
to O +
MAI O +
was O +
10 O -
- O -
60 O -
% O +
that O +
of O +
the O +
isas O +
a O +
denser O +
structure O +
than O +
the O +
small O +
one O -
. O +

In O +
agreement O +
with O +
earlier O +
experiments O +
with O +
iodoacetamide O +
the O +
proteins B-Gene +
S2 O -
, O +
5 O -
, O +
7 O -
, O +
8 O -
, O +
10 O +
and O +
13 O +
of O +
the O +
small O +
subunit O +
and O +
L15 O -
, O +
17 O -
, O +
20 O -
, O +
24 O -
, O +
25 O -
, O +
27 O -
, O +
29 O -
, O +
33 O -
, O +
34 O -
, O +
35 O +
and O +
38 O +
in O +
the O +
large O +
subunit O +
are O +
quite O +
accessible O +
while O +
proteins B-Gene +
S9 O -
, O +
14 O -
, O +
19 O -
, O +
20 O -
, O +
24 O -
, O +
25 O -
, O +
27 O -
, O +
29 O +
and O +
30 O +
of O +
the O +
small O +
subunit O +
and O +
L1 O -
, O +
7 O -
, O +
8 O -
, O +
10 O -
, O +
11 O -
, O +
19 O -
, O +
28 O -
, O +
31 O -
, O +
and O +
32 O +
of O +
the O +
large O +
one O +
are O +
relatively O +
inaccessible O -
. O +

BACKGROUND O -
: O +
Removal O +
and/or O +
" O -
neutralization O -
" O +
of O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
alpha1 I-Gene -
- I-Gene -
3Gal I-Gene +
( B-Gene -
alphaGal I-Gene -
) I-Gene +
antibodies I-Gene +
can O +
prevent O +
or O +
delay O +
the O +
hyperacute O +
rejection O +
of O +
pig O +
organs O +
transplanted O +
into O +
primates O -
. O +

AIM O -
: O +
To O +
determine O +
variations O +
in O +
( O -
1 O -
) O +
cytotoxicity O +
to O +
pig O +
kidney O +
( O -
PK15 O -
) O +
cells O -
, O +
( O -
2 O -
) O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibody I-Gene +
level O -
, O +
and O +
( O -
3 O -
) O +
specificity O +
in O +
adult O +
human O +
( O -
n=46 O -
) O +
and O +
baboon O +
( O -
n=38 O -
) O +
sera O -
. O +

METHODS O -
: O +
Cytotoxicity O +
to O +
PK15 O +
cells O +
was O +
determined O +
by O +
adding O +
rabbit O +
complement O +
to O +
heat O -
- O -
inactivated O +
serum O -
, O +
using O +
a O +
two O -
- O -
color O +
fluorescent O +
dye O +
to O +
distinguish O +
live O +
and O +
dead O +
cells O -
. O +

Anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibody I-Gene +
level O +
was O +
determined O +
by O +
ELISA O +
using O +
alphaGal B-Gene +
trisaccharide I-Gene +
type I-Gene +
2-BSA I-Gene +
glycoconjugate O +
as O +
antigen O +
target O -
. O +

Specificity O +
determined O +
by O +
ELISA O +
using O +
four O +
different O +
alphaGal B-Gene -
- I-Gene -
BSA I-Gene +
glycoconjugates O -
: O +
( O -
disaccharide O -
, O +
trisaccharides O +
type O +
2 O +
and O +
6 O -
, O +
and O +
pentasaccharide O -
) O -
. O +

RESULTS O -
: O +
Cytotoxicity O +
of O +
human O +
AB O +
sera O +
varied O +
from O +
30 O -
- O -
100 O -
% O +
PK15 O +
relative O +
cell O +
damage O +
( O -
% O -
RCD O -
) O -
, O +
although O +
that O +
of O +
baboon O +
sera O +
of O +
all O +
blood O +
groups O +
varied O +
from O +
35 O -
- O -
100 O -
% O +
RCD O -
. O +

In O +
human O +
AB O +
sera O -
, O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibody I-Gene +
level O +
( O -
at O +
a O +
dilution O +
of O +
1:80 O -
) O +
varied O +
from O +
undetectable O +
to O +
0.75 O +
( O -
OD O +
at O +
405 O +
nm O -
) O -
, O +
although O +
in O +
baboon O +
sera O +
of O +
all O +
blood O +
groups O -
, O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibody I-Gene +
level O +
varied O +
from O +
undetectable O +
to O +
> O -
2.0 O -
. O +

There O +
was O +
no O +
correlation O +
between O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibody I-Gene +
level O +
and O +
serum O +
cytotoxicity O +
in O +
either O +
species O -
. O +

Specificity O +
varied O +
among O +
individuals O +
in O +
both O +
human O +
and O +
baboon O +
sera O -
. O +

CONCLUSIONS O -
: O +
These O +
studies O +
have O +
demonstrated O +
( O -
1 O -
) O +
considerable O +
variation O +
in O +
cytotoxicity O +
and O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibody I-Gene +
level O +
in O +
human O +
and O +
baboon O +
sera O -
, O +
but O +
a O +
lack O +
of O +
correlation O +
between O +
these O +
two O +
parameters O -
; O +
( O -
2 O -
) O +
considerable O +
variation O +
in O +
the O +
specificity O +
of O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibodies I-Gene -
; O +
( O -
3 O -
) O +
blood O +
group O +
B O +
human O +
and O +
baboon O +
sera O +
have O +
lower O +
levels O +
of O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibodies I-Gene -
; O +
( O -
4 O -
) O +
no O +
relation O +
between O +
blood O +
group O +
and O +
specificity O +
of O +
anti B-Gene -
- I-Gene -
alphaGal I-Gene +
antibodies I-Gene -
. O +

Although O +
there O +
are O +
minor O +
differences O +
in O +
the O +
parameters O +
measured O -
, O +
baboons O +
would O +
appear O +
to O +
be O +
suitable O +
surrogates O +
for O +
humans O +
in O +
the O +
pig O -
- O -
to O -
- O -
primate O +
xenograft O +
model O -
. O +

Three O +
novel O +
sesquiterpene O +
esters O +
of O +
aristolochic O +
acid O -
, O +
aristoloterpenate O -
- O -
II O +
( O -
2 O -
) O -
, O +
-III O +
( O -
3 O -
) O -
, O +
and O -
- O -
IV O +
( O -
4 O -
) O -
, O +
together O +
with O +
known O +
aristoloterpenate O -
- O -
I O +
( O -
1 O -
) O -
, O +
were O +
isolated O +
and O +
characterized O +
from O +
the O +
root O +
and O +
stem O +
of O +
Aristolochia O +
heterophylla O -
. O +

Their O +
structures O +
were O +
elucidated O +
by O +
spectroscopic O +
methods O -
. O +

The O +
absolute O +
configuration O +
of O +
these O +
compounds O +
at O +
C-4 O -
' O +
was O +
determined O +
as O +
R O +
by O +
circular O +
dichroic O +
studies O -
. O +

These O +
compounds O +
showed O +
cytotoxicity O +
against O +
hepatoma O +
G2 O -
, O +
2 O -
, O +
2 O -
, O +
15 O +
cells O -
. O +

Raloxifene O +
hydrochloride O +
( O -
HCl O -
) O +
is O +
a O +
selective O +
estrogen B-Gene +
receptor I-Gene +
modulator O +
with O +
estrogen O +
agonist O +
effects O +
on O +
bone O +
and O +
lipid O +
metabolism O +
and O +
estrogen O +
antagonist O +
effects O +
on O +
reproductive O +
tissues O -
. O +

Animal O +
studies O +
suggest O +
that O +
raloxifene O +
may O +
affect O +
brain O +
function O +
as O +
well O -
, O +
although O +
the O +
effects O +
of O +
raloxifene O +
on O +
the O +
human O +
brain O +
remain O +
to O +
be O +
established O -
. O +

This O +
paper O +
presents O +
an O +
early O +
safety O +
assessment O +
of O +
raloxifene O +
effects O +
on O +
cognition O +
and O +
mood O +
in O +
postmenopausal O +
women O +
participating O +
in O +
a O +
randomized O -
, O +
double O -
- O -
blind O +
osteoporosis O +
treatment O +
trial O -
. O +

Psychometric O +
test O +
batteries O +
were O +
administered O +
to O +
postmenopausal O +
women O +
at O +
baseline O +
and O +
1 O -
, O +
6 O -
, O +
and O +
12 O +
months O +
after O +
initiating O +
treatment O +
with O +
raloxifene O +
( O -
60 O +
and O +
120 O +
mg O -
/ O -
day O -
) O -
. O +

The O +
Memory O +
Assessment O +
Clinics O +
( O -
MAC O -
) O +
battery O +
and O +
Walter O +
Reed O +
Performance O +
Assessment O +
Battery O +
( O -
PAB O -
) O +
were O +
used O +
to O +
assess O +
multiple O +
and O +
independent O +
aspects O +
of O +
cognitive O +
function O -
, O +
while O +
mood O +
was O +
assessed O +
with O +
the O +
Geriatric O +
Depression O +
Scale O +
( O -
GDS O -
) O -
. O +

After O +
12 O +
months O +
of O +
treatment O -
, O +
there O +
were O +
no O +
significant O +
differences O +
between O +
the O +
raloxifene O +
groups O +
and O +
placebo O +
on O +
performance O +
in O +
either O +
the O +
MAC O +
battery O +
or O +
the O +
PAB O -
. O +

The O +
only O +
significant O +
difference O +
observed O +
was O +
a O +
slight O +
increase O +
in O +
performance O +
favoring O +
the O +
raloxifene O +
120 O +
mg O -
/ O -
day O +
group O +
in O +
an O +
assessment O +
of O +
verbal O +
memory O +
on O +
the O +
MAC O +
battery O +
after O +
1 O +
month O +
of O +
treatment O -
. O +

Scores O +
on O +
the O +
GDS O +
and O +
the O +
self O -
- O -
reported O +
incidence O +
of O +
mood O -
- O -
related O +
events O +
were O +
not O +
different O +
between O +
treatment O +
groups O +
at O +
any O +
of O +
the O +
assessment O +
periods O -
. O +

These O +
data O +
do O +
not O +
suggest O +
that O +
raloxifene O +
impairs O +
cognition O +
or O +
affects O +
mood O +
in O +
postmenopausal O +
women O +
treated O +
for O +
1 O +
year O -
. O +

Studies O +
to O +
further O +
assess O +
the O +
safety O +
and O +
potential O +
efficacy O +
of O +
raloxifene O +
with O +
respect O +
to O +
cognitive O +
function O +
are O +
ongoing O -
. O +

Preclinical O +
studies O +
suggest O +
that O +
estrogenic O +
hormones O +
may O +
affect O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
function O +
( O -
Schneider O +
and O +
Finch O -
, O +
1997 O +
) O -
, O +
enhancing O +
cholinergic O +
and O +
serotonergic O +
mechanisms O +
in O +
the O +
rat O +
brain O -
, O +
modulating O +
the O +
growth O +
and O +
maintenance O +
of O +
neuronal O +
cells O +
in O +
vitro O -
, O +
and O +
ameliorating O +
ovariectomy O -
- O -
induced O +
learning O +
deficits O +
in O +
rats O -
. O +

Nevertheless O -
, O +
the O +
effect O +
of O +
estrogen O +
on O +
cognitive O +
function O +
in O +
humans O +
remains O +
a O +
matter O +
of O +
debate O +
( O -
Haskell O +
et O +
al. O -
, O +
1997 O -
; O +
Plouffe O +
and O +
Schulkin O -
, O +
1998 O -
; O +
Yaffe O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

In O +
postmenopausal O +
women O -
, O +
modest O +
improvements O +
in O +
certain O +
aspects O +
of O +
cognitive O +
function O -
, O +
particularly O +
in O +
verbal O +
memory O -
, O +
have O +
been O +
demonstrated O +
with O +
estrogen O +
in O +
some O +
small O -
- O -
scale O +
randomized O -
, O +
placebo O -
- O -
controlled O +
studies O +
( O -
Hackman O +
and O +
Galbraith O -
, O +
1976 O -
; O +
Sherwin O -
, O +
1988 O -
; O +
Phillips O +
and O +
Sherwin O -
, O +
1992 O +
) O -
, O +
but O +
not O +
others O +
( O -
Rauramo O +
et O +
al. O -
, O +
1975 O -
; O +
Vanhulle O +
and O +
Demol O -
, O +
1976 O -
; O +
Ditkoff O +
et O +
al. O -
, O +
1991 O -
; O +
Erkkola O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Also O -
, O +
several O +
epidemiological O +
studies O +
suggest O +
that O +
estrogen O +
replacement O +
therapy O +
( O -
ERT O -
) O +
may O +
delay O +
the O +
onset O +
of O +
Alzhiemer O -
's O +
disease O +
( O -
Paganini O -
- O -
Hill O +
and O +
Henderson O -
, O +
1996 O -
; O +
Kawas O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
although O +
in O +
other O +
studies O +
no O +
effect O +
was O +
observed O +
( O -
Barrett O -
- O -
Connor O +
and O +
Kritz O -
- O -
Silverstein O -
, O +
1993 O -
; O +
Brenner O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

Thus O -
, O +
confirmation O +
of O +
any O +
positive O +
effect O +
of O +
estrogen O +
on O +
cognition O -
, O +
as O +
well O +
as O +
clarification O +
of O +
its O +
magnitude O +
and O +
clinical O +
significance O -
, O +
must O +
await O +
completion O +
of O +
a O +
large O -
- O -
scale O -
, O +
randomized O -
, O +
placebo O -
- O -
controlled O -
, O +
prospective O +
trial O +
( O -
Yaffe O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Raloxifene O +
is O +
a O +
benzothiophene O +
member O +
of O +
a O +
new O +
class O +
of O +
compounds O +
termed O +
selective O +
estrogen B-Gene +
receptor I-Gene +
modulators O -
, O +
which O +
bind O +
with O +
high O +
affinity O +
to O +
the O +
estrogen B-Gene +
receptor I-Gene -
, O +
and O +
can O +
exert O +
either O +
agonist O +
or O +
antagonist O +
effects O +
in O +
a O +
tissue O -
- O -
dependent O +
manner O +
( O -
Mitlak O +
and O +
Cohen O -
, O +
1997 O +
) O -
. O +

Studies O +
in O +
animals O +
( O -
Black O +
et O +
al. O -
, O +
1994 O +
) O +
and O +
clinical O +
studies O +
in O +
postmenopausal O +
women O +
( O -
Draper O +
et O +
al. O -
, O +
1996 O -
; O +
Delmas O +
et O +
al. O -
, O +
1997 O -
; O +
Walsh O +
et O +
al. O -
, O +
1998 O +
) O +
have O +
demonstrated O +
that O +
raloxifene O +
prevents O +
bone O +
loss O +
caused O +
by O +
loss O +
of O +
endogenous O +
estrogen O -
, O +
favorably O +
alters O +
the O +
serum O +
lipid O +
profile O -
, O +
and O +
does O +
not O +
stimulate O +
breast O +
or O +
uterine O +
tissue O -
. O +

Based O +
on O +
this O +
selective O +
pharmacological O +
profile O -
, O +
raloxifene O +
has O +
been O +
approved O +
for O +
marketing O +
in O +
several O +
countries O +
for O +
the O +
prevention O +
of O +
postmenopausal O +
osteoporosis O -
. O +

Whether O +
raloxifene O +
affects O +
human O +
brain O +
function O +
or O +
cognition O +
is O +
a O +
topic O +
of O +
ongoing O +
research O -
. O +

To O +
test O +
the O +
hypothesis O +
that O +
raloxifene O +
does O +
not O +
adversely O +
affect O +
cognition O +
or O +
mood O +
in O +
postmenopausal O +
women O -
, O +
we O +
assessed O +
cognitive O +
and O +
affective O +
function O +
as O +
secondary O +
safety O +
endpoints O +
in O +
a O +
placebo O -
- O -
controlled O +
osteoporosis O +
treatment O +
study O +
with O +
raloxifene O -
. O +

Computerized O +
neuropsychological O +
test O +
batteries O +
long O -
- O -
used O +
in O +
neuropharmacology O +
research O +
were O +
used O +
to O +
monitor O +
cognition O +
and O +
memory O +
in O +
postmenopausal O +
women O +
treated O +
with O +
raloxifene O +
for O +
1 O +
year O -
. O +

Although O +
the O +
effect O +
of O +
estrogen O +
on O +
these O +
batteries O +
has O +
not O +
been O +
tested O -
, O +
they O +
were O +
chosen O +
based O +
on O +
their O +
reliability O +
( O -
Youngjohn O +
et O +
al. O -
, O +
1992a O +
) O +
and O +
validity O +
( O -
Youngjohn O +
et O +
al. O -
, O +
1992b O +
) O +
in O +
measuring O +
independent O +
aspects O +
of O +
cognition O +
and O +
memory O -
. O +

In O +
addition O -
, O +
a O +
test O +
of O +
affective O +
function O +
designed O +
specifically O +
for O +
mature O +
adults O +
( O -
Yesavage O +
et O +
al. O -
, O +
1983 O +
) O +
was O +
administered O -
. O +

The O +
use O +
of O +
these O +
well O -
- O -
established O +
assessments O +
of O +
cognition O +
and O +
mood O +
is O +
particularly O +
important O -
, O +
because O +
in O +
some O +
previous O +
studies O +
of O +
estrogen O +
and O +
cognition O -
, O +
tests O +
of O +
attention O +
span O +
and O +
reaction O +
time O +
were O +
erroneously O +
used O +
as O +
tests O +
of O +
memory O -
, O +
and O +
potentially O +
important O +
confounding O +
factors O +
such O +
as O +
mood O +
were O +
not O +
assessed O +
( O -
Haskell O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

This O +
report O +
is O +
the O +
first O +
of O +
a O +
series O +
of O +
investigations O +
that O -
, O +
together O -
, O +
will O +
determine O +
the O +
long O -
- O -
term O +
effects O +
of O +
raloxifene O +
on O +
cognitive O +
function O +
and O +
mood O +
in O +
postmenopausal O +
women O -
. O +

2 O +
Methods O +
2.1 O +
Patient O +
population O +
This O +
study O +
included O +
postmenopausal O +
women O +
with O +
established O +
osteoporosis O -
, O +
45–75 O +
years O +
of O +
age O -
, O +
who O +
had O +
their O +
last O +
menstrual O +
periods O +
at O +
least O +
5 O +
years O +
before O +
the O +
beginning O +
of O +
the O +
study O -
. O +

All O +
subjects O +
were O +
studied O +
at O +
Mayo O +
Clinic O +
Rochester O -
, O +
MN O +
or O +
Mayo O +
Clinic O +
Scottsdale O -
, O +
AZ O -
. O +

Patients O +
were O +
eligible O +
if O +
they O +
were O +
in O +
good O +
health O +
except O +
for O +
osteoporosis O -
, O +
free O +
of O +
any O +
serious O +
acute O +
or O +
chronic O +
medical O +
condition O +
that O +
might O +
affect O +
bone O +
or O +
calcium O +
metabolism O -
, O +
and O +
fully O +
ambulatory O -
. O +

Postmenopausal O +
status O +
was O +
confirmed O +
in O +
women O +
less O +
than O +
60 O +
years O +
of O +
age O +
by O +
serum O +
estradiol O +
≤73 O +
pmol O -
/ O -
l O +
and O +
follicle B-Gene +
stimulating I-Gene +
hormone I-Gene +
≥30 O +
IU O -
/ O -
l O -
. O +

Osteoporosis O +
was O +
documented O +
by O +
diagnosis O +
of O +
at O +
least O +
one O +
non O -
- O -
traumatic O +
vertebral O +
fracture O +
and O +
a O +
bone O +
mineral O +
density O +
of O +
the O +
lumbar O +
spine O +
or O +
proximal O +
femur O +
of O +
less O +
than O +
the O +
tenth O +
percentile O +
of O +
normal O +
premenopausal O +
women O -
. O +

Patients O +
with O +
bone O +
disorders O +
other O +
than O +
osteoporosis O -
, O +
clinically O +
significant O +
menopausal O +
symptoms O +
( O -
hot O +
flashes O -
, O +
sweating O -
, O +
etc O -
. O -
) O -
, O +
any O +
history O +
of O +
cancer O +
( O -
except O +
superficial O +
basal O +
or O +
squamous O +
cell O +
carcinoma O +
of O +
the O +
skin O -
) O +
within O +
the O +
previous O +
5 O +
years O -
, O +
acute O +
or O +
chronic O +
liver O +
disease O -
, O +
history O +
of O +
deep O +
vein O +
thrombosis O +
or O +
cerebral O +
vascular O +
accident O -
, O +
or O +
impaired O +
kidney O +
function O +
were O +
not O +
considered O +
for O +
enrollment O +
in O +
the O +
study O -
. O +

Treatment O +
with O +
estrogen O -
, O +
progestin O -
, O +
calcitonin O -
, O +
androgen O -
, O +
or O +
systemic O +
corticosteroid O +
more O +
recently O +
than O +
6 O +
months O +
prior O +
to O +
study O +
was O +
also O +
grounds O +
for O +
exclusion O -
. O +

An O +
informed O +
consent O +
document O +
and O +
study O +
protocol O +
were O +
reviewed O +
and O +
approved O +
by O +
the O +
appropriate O +
ethical O +
review O +
board O +
prior O +
to O +
initiation O +
of O +
the O +
study O -
. O +

Informed O +
consent O +
was O +
obtained O +
from O +
all O +
study O +
participants O +
according O +
to O +
the O +
ethical O +
principles O +
stated O +
in O +
the O +
latest O +
version O +
of O +
the O +
Declaration O +
of O +
Helsinki O -
. O +

2.2 O +
Study O +
design O +

This O +
was O +
a O +
Phase O +
2 O -
, O +
two O -
- O -
site O -
, O +
parallel O +
groups O -
, O +
placebo O -
- O -
controlled O -
, O +
randomized O -
, O +
double O -
- O -
blind O +
study O -
. O +

Patients O +
were O +
randomly O +
assigned O +
to O +
one O +
of O +
three O +
treatment O +
groups O -
; O +
placebo O -
, O +
raloxifene O +
60 O +
mg O -
/ O -
day O -
, O +
or O +
raloxifene O +
120 O +
mg O -
/ O -
day O -
. O +

Outcome O +
measures O +
were O +
recorded O +
at O +
baseline O +
and O +
at O +
1 O -
, O +
6 O -
, O +
and O +
12 O +
months O +
after O +
initiation O +
of O +
treatment O -
. O +

2.3 O +
Outcome O +
measures O +
Outcome O +
measures O +
included O +
ten O +
cognitive O +
assessments O +
and O +
one O +
assessment O +
of O +
mood O -
. O +

Seven O +
of O +
the O +
cognitive O +
outcome O +
measures O +
were O +
derived O +
from O +
the O +
MAC O +
computerized O +
psychometric O +
battery O +
while O +
three O +
were O +
derived O +
from O +
the O +
Walter O +
Reed O +
PAB O -
. O +

Both O +
assessments O +
measure O +
components O +
of O +
cognitive O +
function O +
that O +
have O +
been O +
shown O +
to O +
decline O +
with O +
advancing O +
age O -
. O +

The O +
Geriatric O +
Depression O +
Scale O +
( O -
GDS O -
) O -
, O +
a O +
valid O +
and O +
reliable O +
test O +
designed O +
specifically O +
for O +
the O +
assessment O +
of O +
mood O +
in O +
the O +
elderly O +
( O -
Yesavage O +
et O +
al. O -
, O +
1983 O +
) O -
, O +
was O +
also O +
administered O +
on O +
each O +
patient O +
visit O -
. O +

The O +
individual O +
cognitive O +
assessments O +
within O +
each O +
battery O +
are O +
outlined O +
below O -
. O +

The O +
test O +
batteries O +
have O +
been O +
described O +
in O +
many O +
previous O +
publications O +
( O -
Thorne O +
et O +
al. O -
, O +
1985 O -
; O +
Larrabee O +
and O +
Crook O -
, O +
1988 O -
; O +
Crook O +
et O +
al. O -
, O +
1990 O -
; O +
Crook O -
, O +
1992 O +
) O -
. O +

2.3.1 O +
MAC O +
battery O +
This O +
assessment O +
battery O +
was O +
designed O +
to O +
simulate O +
critical O +
cognitive O +
tasks O +
of O +
everyday O +
life O +
and O +
has O +
been O +
shown O +
to O +
be O +
reliable O +
( O -
Youngjohn O +
et O +
al. O -
, O +
1992a O +
) O +
and O +
valid O +
( O -
Crook O +
and O +
West O -
, O +
1990 O -
; O +
Youngjohn O +
et O +
al. O -
, O +
1992b O +
) O -
. O +

The O +
independent O +
parameters O +
of O +
learning O +
and O +
memory O +
tested O +
by O +
this O +
battery O +
are O +
as O +
follows:• O +
name O -
– O -
face O +
association O -
: O +
delayed O +
recall O +
and O +
total O +
acquisition O +
( O -
Crook O +
and O +
West O -
, O +
1990 O +
) O -
; O +
• O +
first O -
– O -
last O +
names O -
: O +
delayed O +
recall O +
and O +
total O +
acquisition O +
( O -
Youngjohn O +
et O +
al. O -
, O +
1991 O +
) O -
; O +
• O +
facial O +
recognition O -
: O +
number O +
before O +
first O +
error O +
( O -
Crook O +
and O +
Larrabee O -
, O +
1992 O +
) O -
; O +
• O +
telephone O +
number O +
recall O +
( O -
ten O +
digit O -
) O -
: O +
before O +
interference O +
and O +
after O +
interference O +
( O -
West O +
and O +
Crook O -
, O +
1990 O +
) O -
. O +

The O +
name O -
– O -
face O +
association O +
and O +
first O -
– O -
last O +
names O +
recall O +
tests O +
measure O +
primarily O +
verbal O +
memory O -
, O +
the O +
facial O +
recognition O +
test O +
measures O +
primarily O +
visual O +
memory O -
, O +
and O +
the O +
telephone O +
number O +
recall O +
test O +
measures O +
working O +
memory O -
; O +
that O +
is O -
, O +
encoding O +
and O +
manipulation O +
of O +
information O +
for O +
later O +
use O -
. O +

2.3.2 O +
Walter O +
Reed O +
performance O +
assessment O +
battery O +
( O -
PAB O -
) O +

The O +
Walter O +
Reed O +
PAB O +
was O +
developed O +
by O +
the O +
United O +
States O +
Army O +
and O +
provides O +
measures O +
of O +
various O +
aspects O +
of O +
attention O -
, O +
information O +
processing O +
speed O +
and O +
efficiency O -
, O +
and O +
reaction O +
time O +
( O -
Thorne O +
et O +
al. O -
, O +
1985 O +
) O -
. O +

These O +
tests O +
are O +
particularly O +
suited O +
to O +
detect O +
even O +
subtle O +
influences O +
of O +
drugs O +
on O +
attention O -
, O +
vigilance O -
, O +
and O +
information O +
processing O +
( O -
Newhouse O +
et O +
al. O -
, O +
1989 O -
; O +
Snyder O +
and O +
Henningfield O -
, O +
1989 O +
) O -
. O +

The O +
three O +
Walter O +
Reed O +
PAB O +
assessments O +
used O +
in O +
this O +
study O +
were:• O +
two O -
- O -
letter O +
search O -
; O +
• O +
six O -
- O -
letter O +
search O -
; O +
• O +
four O -
- O -
choice O +
serial O +
reaction O +
time O -
. O +

Both O +
assessment O +
batteries O +
were O +
administered O +
by O +
a O +
research O +
assistant O +
in O +
a O +
controlled O +
testing O +
environment O +
and O +
required O +
30–40 O +
min O +
to O +
complete O -
. O +

Multiple O -
, O +
equivalent O +
forms O +
of O +
both O +
the O +
MAC O +
battery O +
( O -
Crook O +
et O +
al. O -
, O +
1992 O +
) O +
and O +
the O +
Walter O +
Reed O +
PAB O +
( O -
Thorne O +
et O +
al. O -
, O +
1985 O +
) O +
were O +
administered O +
such O +
that O +
subjects O +
did O +
not O +
see O +
the O +
same O +
stimuli O +
more O +
than O +
once O -
. O +

2.4 O +
Evaluation O +
of O +
test O +
batteries O +
for O +
sensitivity O +
to O +
cognitive O +
impairment O +
in O +
healthy O +
older O +
adults O +
Both O +
test O +
batteries O +
employed O +
have O +
been O +
used O +
in O +
multiple O +
studies O +
of O +
drug O +
effects O +
on O +
cognition O +
( O -
Newhouse O +
et O +
al. O -
, O +
1989 O -
; O +
Crook O +
and O +
Lakin O -
, O +
1991 O -
; O +
Crook O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

However O -
, O +
many O +
of O +
these O +
studies O +
were O +
conducted O +
in O +
populations O +
with O +
neurologic O +
or O +
psychiatric O +
impairments O -
. O +

To O +
assure O +
sensitivity O +
to O +
cognitive O +
impairment O +
in O +
the O +
population O +
under O +
study O +
with O +
raloxifene O -
, O +
a O +
preliminary O +
sensitivity O +
study O +
was O +
undertaken O +
in O +
a O +
separate O +
cohort O +
of O +
subjects O -
. O +

The O +
ability O +
of O +
diazepam O +
to O +
induce O +
deficits O +
in O +
memory O +
and O +
cognitive O +
performance O +
is O +
well O -
- O -
established O +
and O -
, O +
thus O -
, O +
was O +
considered O +
appropriate O +
for O +
comparison O +
with O +
placebo O +
in O +
this O +
sensitivity O +
study O -
. O +

Healthy O +
subjects O +
of O +
either O +
sex O +
between O +
55 O +
and O +
75 O +
years O +
of O +
age O +
( O -
mean O +
age=63 O -
) O +
were O +
tested O +
with O +
both O +
the O +
MAC O +
battery O +
and O +
Walter O +
Reed O +
PAB O +
at O +
baseline O +
( O -
day O +
1 O -
) O -
. O +

Subjects O +
were O +
treated O +
with O +
diazepam O +
( O -
4 O -
× O -
5 O +
mg O -
/ O -
day O -
) O +
on O +
days O +
2 O +
and O +
3 O -
. O +

On O +
day O +
4 O -
, O +
subjects O +
were O +
retested O +
with O +
both O +
assessment O +
batteries O +
1 O +
h O +
after O +
a O +
morning O +
5 O +
mg O +
dose O +
of O +
diazepam O -
. O +

Scores O +
obtained O +
on O +
the O +
test O +
batteries O +
at O +
baseline O +
and O +
after O +
diazepam O +
therapy O +
were O +
compared O -
. O +

Diazepam O +
induced O +
clear O +
performance O +
deficits O +
in O +
all O +
of O +
the O +
components O +
of O +
the O +
MAC O +
battery O +
( O -
Fig. O +
1 O +
) O -
. O +

Significant O +
performance O +
deficits O +
were O +
also O +
observed O +
in O +
the O +
PAB O +
( O -
data O +
not O +
shown O -
) O -
. O +

Thus O -
, O +
the O +
test O +
batteries O +
used O +
in O +
this O +
study O +
were O +
considered O +
appropriate O +
for O +
detection O +
of O +
negative O +
drug O +
effects O +
in O +
the O +
population O +
being O +
studied O -
. O +

2.5 O +
Data O +
analysis O +
Analysis O +
of O +
drug O +
effects O +
on O +
cognition O +
in O +
this O +
study O +
was O +
based O +
on O +
a O +
univariate O +
analysis O +
of O +
covariance O +
( O -
ANCOVA O -
) O +
in O +
which O +
age O +
and O +
baseline O +
score O +
on O +
each O +
variable O +
were O +
entered O +
as O +
covariates O +
and O +
the O +
single O +
main O +
effect O +
was O +
treatment O -
. O +

Overall O +
ANCOVA O +
comparisons O +
were O +
conducted O +
comparing O +
all O +
three O +
treatment O +
groups O +
on O +
each O +
variable O -
. O +

Data O +
analysis O +
was O +
based O +
on O +
an O +
intent O -
- O -
to O -
- O -
treat O +
principle O -
. O +

Thus O -
, O +
all O +
patients O +
were O +
included O +
in O +
the O +
treatment O +
group O +
to O +
which O +
they O +
were O +
originally O +
randomized O -
. O +

In O +
cases O +
where O +
patients O +
discontinued O +
from O +
the O +
study O +
early O -
, O +
values O +
obtained O +
from O +
the O +
last O +
visit O +
were O +
carried O +
forward O +
to O +
all O +
subsequent O +
analyses O -
. O +

3 O +
Results O +
3.1 O +
Characteristics O +
and O +
disposition O +
of O +
study O +
subjects O +
Selected O +
characteristics O +
of O +
the O +
study O +
subjects O +
are O +
summarized O +
in O +
Table O +
1 O +
. O +

Of O +
the O +
143 O +
patients O +
randomized O -
, O +
48 O +
received O +
placebo O -
, O +
48 O +
received O +
raloxifene O +
HCl O +
60 O +
mg O -
, O +
and O +
47 O +
received O +
raloxifene O +
HCl O +
120 O +
mg O -
. O +

The O +
raloxifene O +
60 O +
mg O +
group O +
was O +
slightly O +
older O +
than O +
the O +
other O +
groups O -
. O +

This O +
difference O +
was O +
controlled O +
by O +
entering O +
age O +
as O +
a O +
covariate O +
in O +
all O +
comparisons O +
among O +
treatment O +
groups O -
. O +

The O +
overall O +
mean O +
age O +
of O +
study O +
subjects O +
was O +
68 O +
years O -
. O +

The O +
incidence O +
of O +
concomitant O +
medication O +
was O +
not O +
significantly O +
different O +
among O +
treatment O +
groups O +
for O +
any O +
specific O +
medication O -
, O +
including O +
benzodiazepines O -
, O +
tricyclic O +
antidepressants O -
, O +
antipsychotics O -
, O +
and O +
selective O +
serotonin O +
reuptake O +
inhibitors O -
. O +

The O +
percentage O +
of O +
women O +
reporting O +
an O +
alcohol O +
consumption O +
of O +
greater O +
than O +
three O +
drinks O +
per O +
week O +
was O +
significantly O +
different O +
among O +
the O +
treatment O +
groups O +
( O -
33 O -
, O +
15 O -
, O +
and O +
20 O -
% O +
in O +
the O +
placebo O -
, O +
raloxifene O +
60 O +
mg O -
, O +
and O +
raloxifene O +
120 O +
mg O -
, O +
respectively O -
; O +
p O +
= O -
.022 O -
) O -
. O +

Thirteen O +
patients O +
( O -
9.1 O -
% O -
) O +
discontinued O +
from O +
the O +
study O +
before O +
completing O +
the O +
12 O +
month O +
treatment O +
period O -
. O +

The O +
number O +
of O +
discontinuations O +
did O +
not O +
differ O +
significantly O +
among O +
the O +
treatment O +
groups O +
and O +
did O +
not O +
alter O +
the O +
age O +
distribution O +
among O +
groups O +
for O +
the O +
intent O -
- O -
to O -
- O -
treat O +
analyses O -
. O +

One O +
women O +
in O +
the O +
raloxifene O +
60 O +
mg O +
group O +
died O +
of O +
unrelated O +
causes O +
( O -
pneumonia O -
) O -
, O +
two O +
discontinued O +
for O +
personal O +
reasons O -
, O +
two O +
for O +
protocol O +
variances O -
, O +
and O +
eight O +
because O +
of O +
adverse O +
events O -
. O +

The O +
percentage O +
of O +
women O +
discontinuing O +
due O +
to O +
an O +
adverse O +
event O +
was O +
not O +
significantly O +
different O +
among O +
treatment O +
groups O +
( O -
6.3 O -
, O +
4.2 O -
, O +
and O +
6.4 O -
% O +
for O +
placebo O -
, O +
raloxifene O +
60 O +
mg O -
, O +
and O +
raloxifene O +
120 O +
mg O -
, O +
respectively O -
; O +
p O +
= O -
.87 O -
) O -
. O +

3.2 O +
Baseline O +
cognitive O +
and O +
mood O +
assessment O +
scores O +
Unadjusted O +
mean O +
baseline O +
scores O +
for O +
the O +
cognitive O +
assessments O +
and O +
GDS O +
are O +
summarized O +
in O +
Table O +
2 O +
. O +

Baseline O +
performance O +
in O +
all O +
assessments O +
was O +
not O +
significantly O +
different O +
between O +
the O +
raloxifene O +
and O +
placebo O +
groups O -
. O +

3.3 O +
Effect O +
of O +
raloxifene O +
on O +
cognitive O +
assessment O +
scores O +
Scores O +
( O -
adjusted O +
for O +
age O +
and O +
baseline O +
performance O -
) O +
for O +
each O +
assessment O +
of O +
the O +
MAC O +
battery O +
at O +
month O +
1 O -
, O +
6 O -
, O +
and O +
12 O -
, O +
are O +
displayed O +
in O +
Fig. O +
2 O +
. O +

After O +
12 O +
months O +
of O +
treatment O +
with O +
raloxifene O -
, O +
there O +
were O +
no O +
significant O +
differences O +
on O +
any O +
of O +
the O +
seven O +
MAC O +
assessments O +
between O +
the O +
raloxifene O +
groups O +
and O +
placebo O -
. O +

Among O +
all O +
assessments O +
and O +
all O +
time O +
points O -
, O +
only O +
one O +
significant O +
difference O +
between O +
the O +
treatment O +
groups O +
was O +
observed O -
: O +
delayed O +
recall O +
of O +
first O -
– O -
last O +
names O +
after O +
1 O +
month O +
of O +
treatment O +
( O -
Fig. O +
2 O +
( O -
B O -
) O -
) O -
. O +

This O +
difference O +
resulted O +
from O +
high O +
scores O +
in O +
the O +
raloxifene O +
120 O +
mg O +
group O -
. O +

There O +
were O +
also O +
no O +
significant O +
differences O +
between O +
treatment O +
groups O +
at O +
any O +
time O +
point O +
on O +
any O +
of O +
the O +
three O +
Walter O +
Reed O +
PAB O +
assessments O +
tested O +
( O -
Table O +
3 O +
) O -
. O +

3.4 O +
Effect O +
of O +
raloxifene O +
on O +
mood O +
Patient O +
scores O +
on O +
the O +
Geriatric O +
Depression O +
Scale O +
are O +
shown O +
for O +
each O +
assessment O +
period O +
in O +
Table O +
4 O +
. O +

There O +
were O +
no O +
significant O +
differences O +
between O +
the O +
raloxifene O +
groups O +
and O +
the O +
placebo O +
group O +
at O +
any O +
of O +
the O +
time O +
points O +
tested O -
. O +

In O +
addition O -
, O +
the O +
only O +
self O -
- O -
reported O +
adverse O +
events O +
related O +
to O +
mood O +
were O +
malaise O +
and O +
anxiety O -
; O +
the O +
incidence O +
of O +
these O +
events O +
was O +
low O +
( O -
< O -
5 O -
% O -
) O +
and O +
not O +
significantly O +
different O +
among O +
treatment O +
groups O -
. O +

The O +
incidence O +
of O +
hot O +
flashes O -
, O +
an O +
event O +
that O +
may O +
have O +
secondary O +
effects O +
on O +
mood O +
in O +
postmenopausal O +
women O -
, O +
was O +
not O +
significantly O +
different O +
among O +
treatment O +
groups O +
( O -
10.4 O -
, O +
14.6 O -
, O +
and O +
12.8 O -
% O +
for O +
placebo O -
, O +
raloxifene O +
60 O +
mg O -
, O +
and O +
raloxifene O +
120 O +
mg O -
, O +
respectively O -
; O +
p O +
= O -
.83 O -
) O -
. O +

4 O +
Discussion O +
This O +
study O +
was O +
done O +
to O +
obtain O +
preliminary O +
safety O +
assessments O +
of O +
possible O +
effects O +
of O +
raloxifene O +
on O +
cognition O +
and O +
mood O +
in O +
women O +
being O +
studied O +
for O +
the O +
treatment O +
of O +
postmenopausal O +
osteoporosis O -
. O +

In O +
this O +
study O -
, O +
two O +
separate O +
computerized O +
batteries O +
yielded O +
ten O +
separate O +
measures O +
of O +
cognitive O +
function O -
. O +

These O +
batteries O +
were O +
administered O +
on O +
three O +
occasions O +
during O +
the O +
course O +
of O +
the O +
study O -
, O +
providing O +
30 O +
separate O +
measures O +
of O +
cognitive O +
abilities O +
for O +
treatment O +
group O +
comparisons O -
. O +

A O +
mood O +
scale O +
brought O +
the O +
total O +
number O +
of O +
comparisons O +
to O +
33 O -
. O +

From O +
these O +
33 O +
comparisons O +
among O +
the O +
three O +
treatment O +
groups O -
, O +
only O +
one O +
significant O +
difference O +
emerged O +
( O -
first O -
– O -
last O +
names O +
delayed O +
recall O +
at O +
1 O +
month O -
) O -
. O +

Beyond O +
that O -
, O +
no O +
consistent O +
or O +
meaningful O +
trends O +
were O +
seen O +
when O +
examining O +
differences O +
among O +
groups O -
. O +

Notably O -
, O +
the O +
only O +
significant O +
difference O +
between O +
raloxifene O +
and O +
placebo O +
observed O +
in O +
this O +
study O +
favored O +
the O +
raloxifene O +
120 O +
mg O +
group O -
, O +
and O +
occurred O +
on O +
the O +
test O +
that O +
appears O +
to O +
be O +
most O +
sensitive O +
to O +
drug O -
- O -
induced O +
impairment O +
( O -
first O -
– O -
last O +
names O -
, O +
delayed O +
recall O -
, O +
Fig. O +
2 O +
( O -
B O -
) O -
) O -
. O +

Together O -
, O +
these O +
data O +
do O +
not O +
support O +
an O +
effect O +
of O +
raloxifene O +
to O +
impair O +
cognitive O +
function O +
in O +
postmenopausal O +
women O +
treated O +
for O +
up O +
to O +
12 O +
months O -
. O +

Assessment O +
of O +
mood O +
by O +
the O +
Geriatric O +
Depression O +
Scale O +
revealed O +
no O +
significant O +
differences O +
between O +
the O +
raloxifene O +
groups O +
and O +
the O +
placebo O +
group O +
at O +
any O +
assessment O +
point O -
. O +

Furthermore O -
, O +
self O -
- O -
reported O +
incidences O +
of O +
adverse O +
events O +
related O +
to O +
mood O +
also O +
did O +
not O +
differ O +
between O +
treatment O +
groups O -
. O +

Mood O +
is O +
known O +
to O +
affect O +
performance O +
on O +
cognitive O +
assessment O +
batteries O +
( O -
Palinkas O +
and O +
Barrett O -
- O -
Connor O -
, O +
1992 O +
) O -
, O +
a O +
factor O +
that O +
was O +
not O +
controlled O +
for O +
in O +
some O +
studies O +
of O +
estrogen O +
and O +
cognitive O +
function O +
( O -
Hackman O +
and O +
Galbraith O -
, O +
1976 O -
; O +
Sherwin O -
, O +
1988 O +
) O -
. O +

Thus O -
, O +
alterations O +
in O +
mood O +
did O +
not O +
confound O +
the O +
assessment O +
of O +
cognitive O +
function O +
in O +
this O +
study O -
. O +

Assessment O +
of O +
cognitive O +
function O +
was O +
a O +
secondary O +
objective O +
in O +
this O +
study O +
with O +
the O +
primary O +
endpoint O +
of O +
determining O +
effects O +
of O +
the O +
raloxifene O +
on O +
bone O +
in O +
osteoporosis O -
. O +

However O -
, O +
the O +
test O +
batteries O +
used O +
to O +
assess O +
cognitive O +
function O +
in O +
this O +
study O +
are O +
well O -
- O -
established O +
and O +
particularly O +
sensitive O +
to O +
impairments O +
in O +
cognitive O +
function O +
( O -
West O +
and O +
Crook O -
, O +
1990 O -
; O +
West O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

Indeed O -
, O +
diazepam O +
induced O +
rapid O +
and O +
significant O +
impairments O +
in O +
performance O +
on O +
the O +
MAC O +
Battery O +
in O +
a O +
patient O +
cohort O +
with O +
similar O +
baseline O +
variability O +
in O +
cognitive O +
performance O -
, O +
confirming O +
the O +
sensitivity O +
of O +
this O +
battery O +
to O +
drug O -
- O -
induced O +
cognitive O +
impairments O -
. O +

The O +
estrogen O +
agonist O +
and O +
antagonist O +
effects O +
of O +
raloxifene O +
in O +
the O +
CNS O +
are O +
under O +
investigation O -
. O +

In O +
ovariectomized O +
rats O -
, O +
raloxifene O +
antagonized O +
both O +
estrogen O -
- O -
induced O +
changes O +
in O +
serum O +
luteinizing B-Gene +
hormone I-Gene +
( O -
LH B-Gene -
) O +
levels O +
( O -
Clemens O +
et O +
al. O -
, O +
1983 O +
) O +
and O +
estrogen O -
- O -
stimulated O +
expression O +
of O +
hypothalamic O +
progesterone B-Gene +
receptor I-Gene +
message O +
( O -
Shughrue O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Although O +
these O +
data O +
suggest O +
that O +
raloxifene O +
may O +
have O +
antiestrogenic O +
activity O +
at O +
the O +
level O +
of O +
the O +
hypothalamus O +
and/or O +
pituitary O +
in O +
the O +
rat O +
brain O -
, O +
its O +
effect O +
on O +
this O +
brain O +
region O +
in O +
humans O +
remains O +
unclear O -
. O +

In O +
premenopausal O +
women O -
, O +
raloxifene O +
increased O +
gonadotropin B-Gene +
levels O +
and O +
decreased O +
prolactin B-Gene +
levels O +
( O -
Baker O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
suggestive O +
of O +
an O +
estrogen O -
- O -
antagonist O +
effect O -
. O +

Although O +
not O +
evident O +
in O +
the O +
present O +
study O -
, O +
raloxifene O +
was O +
reported O +
to O +
increase O +
the O +
incidence O +
of O +
hot O +
flashes O +
in O +
postmenopausal O +
women O +
( O -
Draper O +
et O +
al. O -
, O +
1996 O -
; O +
Walsh O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

However O -
, O +
it O +
has O +
not O +
been O +
established O +
that O +
this O +
effect O +
is O +
related O +
to O +
an O +
antiestrogen O +
action O +
of O +
raloxifene O +
in O +
the O +
hypothalamus O -
. O +

Indeed O -
, O +
raloxifene O +
significantly O +
decreases O +
the O +
serum O +
level O +
of O +
follicle B-Gene +
stimulating I-Gene +
hormone I-Gene +
and O +
had O +
no O +
effect O +
on O +
serum O +
LH B-Gene +
or O +
prolactin B-Gene +
levels O +
in O +
postmenopausal O +
women O +
( O -
unpublished O +
data O -
) O -
, O +
suggestive O +
of O +
either O +
a O +
neutral O +
or O +
weak O +
estrogen O +
agonist O +
effect O +
at O +
the O +
hypothalamic O -
/ O -
pituitary O +
axis O -
. O +

Importantly O -
, O +
preliminary O +
results O +
suggest O +
that O +
benzothiophene O +
SERMs O +
similar O +
to O +
raloxifene O +
increase O +
the O +
expression O +
of O +
trkA B-Gene +
( O -
a O +
nerve B-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
component O -
) O +
and O +
other O +
estrogen O -
- O -
responsive O +
genes O +
in O +
the O +
hippocampus O +
and O +
cortex O +
of O +
ovariectomized O +
rats O -
, O +
and O +
differential O +
display O +
analysis O +
revealed O +
identical O +
patterns O +
of O +
hippocampal O +
mRNA O +
expression O +
induced O +
by O +
treatment O +
of O +
ovariectomized O +
rats O +
with O +
estrogen O +
and O +
benzothiophene O +
analogs O +
of O +
raloxifene O +
( O -
Bryant O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Similar O +
results O +
have O +
also O +
been O +
observed O +
with O +
raloxifene O +
( O -
H.U. O +
Bryant O -
, O +
personal O +
communication O -
) O -
. O +

These O +
data O +
are O +
consistent O +
with O +
an O +
estrogen O +
agonist O -
- O -
like O +
effect O +
of O +
raloxifene O +
in O +
the O +
rat O +
hippocampus O +
and O +
cortex O -
. O +

Thus O -
, O +
the O +
effects O +
of O +
raloxifene O +
on O +
the O +
brain O +
are O +
likely O +
complex O +
and O +
may O +
not O +
be O +
inferred O +
solely O +
from O +
its O +
actions O +
on O +
the O +
hypothalamic O -
/ O -
pituitary O +
axis O -
. O +

The O +
potential O +
of O +
raloxifene O +
to O +
improve O +
cognitive O +
performance O -
, O +
or O +
to O +
alter O +
the O +
time O +
of O +
onset O +
or O +
course O +
of O +
dementing O +
disorders O +
such O +
as O +
Alzheimer O -
's O +
disease O -
, O +
was O +
beyond O +
the O +
scope O +
of O +
this O +
safety O +
study O -
. O +

However O -
, O +
it O +
should O +
be O +
emphasized O +
that O -
, O +
despite O +
many O +
reports O +
in O +
the O +
popular O +
media O +
to O +
the O +
contrary O -
, O +
clinically O +
important O +
effects O +
of O +
estrogen O +
on O +
cognitive O +
function O +
have O +
not O +
been O +
established O +
in O +
clinical O +
trials O +
( O -
Haskell O +
et O +
al. O -
, O +
1997 O -
; O +
Yaffe O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Whereas O +
some O +
observational O +
( O -
Kampen O +
and O +
Sherwin O -
, O +
1994 O +
) O +
and O +
controlled O +
studies O +
( O -
Hackman O +
and O +
Galbraith O -
, O +
1976 O -
; O +
Phillips O +
and O +
Sherwin O -
, O +
1992 O +
) O +
suggest O +
that O +
estrogen O +
may O +
improve O +
certain O +
aspects O +
of O +
cognitive O +
function O +
in O +
postmenopausal O +
women O -
, O +
other O +
studies O +
failed O +
to O +
demonstrate O +
any O +
effect O +
of O +
estrogen O +
( O -
Rauramo O +
et O +
al. O -
, O +
1975 O -
; O +
Vanhulle O +
and O +
Demol O -
, O +
1976 O -
; O +
Ditkoff O +
et O +
al. O -
, O +
1991 O -
; O +
Barrett O -
- O -
Connor O +
and O +
Kritz O -
- O -
Silverstein O -
, O +
1993 O -
; O +
Erkkola O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Many O +
of O +
these O +
studies O +
are O +
difficult O +
to O +
compare O +
due O +
to O +
different O +
methodologies O +
used O +
to O +
assess O +
cognitive O +
function O -
, O +
variation O +
in O +
study O +
populations O -
, O +
and O +
the O +
failure O +
of O +
some O +
studies O +
to O +
consider O +
the O +
positive O +
effects O +
of O +
estrogen O +
on O +
mood O +
as O +
a O +
contributor O +
to O +
improvements O +
in O +
cognitive O +
function O +
observed O -
. O +

Taken O +
together O -
, O +
the O +
literature O +
suggests O +
that O +
estrogen O +
therapy O +
may O +
produce O +
modest O +
improvements O +
in O +
certain O +
aspects O +
of O +
cognitive O +
function O -
, O +
but O +
detecting O +
these O +
effects O +
experimentally O +
may O +
be O +
dependent O +
upon O +
the O +
patient O +
population O +
studied O +
and O +
the O +
techniques O +
used O +
to O +
assess O +
cognition O -
. O +

Studies O +
to O +
further O +
assess O +
the O +
safety O +
and O +
potential O +
efficacy O +
of O +
raloxifene O +
with O +
respect O +
to O +
cognitive O +
function O +
are O +
ongoing O -
. O +

Acknowledgements O +

The O +
authors O +
thank O +
Sushant O +
D. O +
Hardikar O -
, O +
PhD O -
, O +
for O +
critically O +
reviewing O +
the O +
manuscript O -
. O +

A O +
novel O +
series O +
of O +
nonpeptide O +
small O -
- O -
molecular O +
dipeptidyl B-Gene +
peptidase I-Gene +
IV I-Gene +
( O -
DPP B-Gene -
- I-Gene -
IV I-Gene -
) O +
inhibitors O +
with O +
an O +
N O -
- O -
phenylphthalimide O +
skeleton O +
has O +
been O +
developed O -
. O +

Some O +
of O +
the O +
compounds O -
, O +
including O +
4-amino- O -
( O -
2,6-dimethylphenyl O -
) O -
phthalimides O +
( O -
7 O -
) O -
, O +
4- O +
and O +
5-hydroxy- O -
( O -
2,6-diethylphenyl O -
) O -
phthalimide O +
( O -
11 O +
and O +
14 O -
) O -
, O +
4-hydroxy- O -
( O -
2,6-diisopropylphenyl O -
) O -
phthalimide O +
( O -
12 O -
) O -
, O +
and O +
thiocarbonyl O +
analogs O +
of O +
( O -
2,6-diisopropylphenyl O -
) O -
phthalimide O +
and O +
their O +
4,5,6,7-tetrafluorinated O +
derivative O +
( O -
18 O -
, O +
19 O +
and O +
20 O -
) O -
, O +
were O +
more O +
potent O +
than O +
the O +
well O -
- O -
known O +
DPP B-Gene -
- I-Gene -
IV I-Gene -
- O -
specific O +
inhibitor O -
, O +
Pro O -
- O -
boroPro O +
( O -
PBP O -
) O -
. O +

Among O +
them O -
, O +
18 O +
was O +
revealed O +
to O +
be O +
a O +
DPP B-Gene -
- I-Gene -
IV I-Gene -
- O -
specific O +
inhibitor O -
, O +
while O +
the O +
others O +
also O +
showed O +
inhibitory O +
activity O +
toward O +
another O +
peptidase O -
, O +
aminopeptidase B-Gene +
N I-Gene +
( O -
APN B-Gene -
) O -
. O +

Methyl- O +
and O +
hydroxymethyl O +
derivatives O +
of O +
the O +
highly O +
potent O +
glycosidase B-Gene +
inhibitor O +
isofagomine O +
are O +
accessible O +
via O +
aldolase B-Gene -
- O -
catalyzed O +
C O -
- O -
C O +
bond O +
formation O +
and O +
competitively O +
inhibit O +
beta B-Gene -
- I-Gene -
glucosidase I-Gene +
at O +
low O +
micromolar O +
concentrations O -
. O +

A O +
kilogram O -
- O -
scale O +
synthesis O +
of O +
( O -
Z O -
) O -
-3-hexen-1-yl O +
acetate O -
, O +
in O +
hexane O -
, O +
on O +
direct O +
esterification O +
of O +
( O -
Z O -
) O -
-3-hexen-1-ol O +
with O +
acetic O +
acid O +
in O +
the O +
presence O +
of O +
2 O -
% O +
( O -
w O -
/ O -
w O +
reactants O -
) O +
of O +
an O +
immobilized O +
lipase B-Gene +
from O +
Candida O +
antarctica O +
( O -
Novozym B-Gene +
435 I-Gene -
) O +
is O +
reported O -
. O +

Conversion O +
yields O +
ranging O +
from O +
92 O +
to O +
96 O -
% O +
were O +
obtained O +
after O +
optimization O +
of O +
various O +
parameters O -
. O +

In O +
that O +
respect O -
, O +
elimination O +
of O +
the O +
water O +
proved O +
crucial O -
. O +

Using O +
at O +
both O +
the O +
laboratory O +
large O +
scale O +
( O -
preparation O +
of O +
200 O -
- O -
400 O +
g O +
of O +
ester O -
) O +
and O +
the O +
pilot O +
scale O +
( O -
1 O -
- O -
5 O +
kg O -
) O +
a O +
" O -
reflux O -
" O +
rotary O +
evaporator O +
equipped O +
with O +
a O +
graduated O +
decantation O +
flask O -
, O +
we O +
were O +
able O +
to O +
trap O +
the O +
water O +
evolved O +
during O +
esterification O +
while O +
at O +
the O +
same O +
time O +
monitor O +
the O +
time O +
course O +
of O +
the O +
reaction O -
. O +

As O +
a O +
consequence O +
of O +
both O +
an O +
efficient O +
water O +
trapping O +
and O +
of O +
a O +
gentle O +
dispersion O +
of O +
the O +
immobilized O +
lipase B-Gene +
into O +
the O +
reaction O +
medium O -
, O +
the O +
lifetime O +
of O +
the O +
enzyme B-Gene +
was O +
significantly O +
prolonged O -
. O +

At O +
the O +
laboratory O +
large O +
scale O +
( O -
LLS O -
) O -
, O +
the O +
yield O +
was O +
still O +
> O -
/=90 O -
% O +
after O +
seven O +
consecutive O +
utilizations O +
whereas O +
at O +
the O +
pilot O +
scale O +
( O -
PS O -
) O -
, O +
it O +
reached O +
93 O -
% O +
after O +
reusing O +
the O +
enzyme B-Gene +
four O +
times O -
. O +

In O +
those O +
conditions O -
, O +
the O +
amount O +
of O +
immobilized O +
enzyme B-Gene +
necessary O +
to O +
produce O +
1 O +
kg O +
of O +
( O -
Z O -
) O -
-3-hexen-1-yl O +
acetate O +
was O +
18 O +
g O +
( O -
1 O -
. O +
8 O -
% O -
) O +
and O +
60 O +
g O +
( O -
6 O -
% O -
) O +
at O +
the O +
LLS O +
and O +
the O +
PS O -
, O +
respectively O -
. O +

Copyright O +
1998 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Inc. O +

BACKGROUND O -
: O +
Phenylephrine O +
is O +
an O +
alpha1-adrenergic B-Gene +
agonist O +
which O +
causes O +
contraction O +
of O +
human O +
internal O +
anal O +
sphincter O +
muscle O +
in O +
vitro O -
. O +

Its O +
intra O -
- O -
arterial O +
administration O +
in O +
animals O +
has O +
been O +
shown O +
to O +
increase O +
resting O +
sphincter O +
pressure O +
in O +
vivo O -
. O +

In O +
this O +
study O +
the O +
effect O +
of O +
topical O +
application O +
of O +
phenylephrine O +
on O +
resting O +
anal O +
pressure O +
in O +
healthy O +
human O +
volunteers O +
was O +
investigated O -
. O +

METHODS O -
: O +
Twelve O +
healthy O +
volunteers O +
had O +
measurements O +
of O +
maximum O +
resting O +
sphincter O +
pressure O +
( O -
MRP O -
) O +
and O +
anodermal O +
blood O +
flow O +
taken O +
before O +
and O +
after O +
topical O +
application O +
of O +
increasing O +
concentrations O +
of O +
phenylephrine O +
gel O +
to O +
the O +
anus O -
. O +

To O +
determine O +
the O +
duration O +
of O +
effect O +
of O +
the O +
agent O -
, O +
readings O +
were O +
taken O +
throughout O +
the O +
day O +
after O +
a O +
single O +
application O -
. O +

RESULTS O -
: O +
There O +
was O +
a O +
dose O -
- O -
dependent O +
rise O +
in O +
the O +
resting O +
anal O +
sphincter O +
pressure O -
, O +
with O +
a O +
small O +
8 O +
per O +
cent O +
rise O +
after O +
5 O +
per O +
cent O +
phenylephrine O +
( O -
P O +
= O +
0.012 O -
) O +
and O +
a O +
larger O +
33 O +
per O +
cent O +
rise O +
with O +
10 O +
per O +
cent O +
phenylephrine O +
( O -
mean O -
( O -
s.d O -
. O -
) O +

MRP O +
85 O -
( O -
12 O -
) O +
cmH2O O +
before O +
versus O +
127 O -
( O -
12 O -
) O +
cmH2O O +
after O +
treatment O -
, O +
P O +
< O +
0.0001 O -
) O -
. O +

Thereafter O +
no O +
additional O +
response O +
was O +
noted O +
with O +
higher O +
concentrations O +
of O +
phenylephrine O -
. O +

The O +
median O +
duration O +
of O +
action O +
of O +
a O +
single O +
application O +
of O +
10 O +
per O +
cent O +
phenylephrine O +
was O +
7 O +
( O -
range O +
from O +
6 O +
to O +
more O +
than O +
8) O +
h. O +
CONCLUSION O -
: O +
Topical O +
application O +
of O +
10 O +
per O +
cent O +
phenylephrine O +
gel O +
to O +
the O +
anus O +
produces O +
a O +
significant O +
rise O +
in O +
the O +
resting O +
anal O +
sphincter O +
pressure O +
in O +
healthy O +
human O +
volunteers O -
. O +

This O +
represents O +
a O +
potential O +
novel O +
therapeutic O +
approach O +
to O +
the O +
treatment O +
of O +
passive O +
faecal O +
incontinence O +
associated O +
with O +
a O +
low O +
resting O +
anal O +
sphincter O +
pressure O -
. O +

Curcumin O -
, O +
the O +
yellow O +
pigment O +
in O +
turmeric O +
and O +
curry O -
, O +
has O +
antioxidative O +
and O +
anticarcinogenic O +
activities O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
pharmacokinetic O +
properties O +
of O +
curcumin O +
in O +
mice O -
. O +

After O +
i.p O -
. O +

administration O +
of O +
curcumin O +
( O -
0.1 O +
g O -
/ O -
kg O -
) O +
to O +
mice O -
, O +
about O +
2.25 O +
microg O -
/ O -
ml O +
of O +
curcumin O +
appeared O +
in O +
the O +
plasma O +
in O +
the O +
first O +
15 O +
min O -
. O +

One O +
hour O +
after O +
administration O -
, O +
the O +
levels O +
of O +
curcumin O +
in O +
the O +
intestines O -
, O +
spleen O -
, O +
liver O -
, O +
and O +
kidneys O +
were O +
177.04 O -
, O +
26.06 O -
, O +
26.90 O -
, O +
and O +
7.51 O +
microg O -
/ O -
g O -
, O +
respectively O -
. O +

Only O +
traces O +
( O -
0.41 O +
microg O -
/ O -
g O -
) O +
were O +
observed O +
in O +
the O +
brain O +
at O +
1 O +
h. O +
To O +
clarify O +
the O +
nature O +
of O +
the O +
metabolites O +
of O +
curcumin O -
, O +
the O +
plasma O +
was O +
analyzed O +
by O +
reversed O -
- O -
phase O +
HPLC O -
, O +
and O +
two O +
putative O +
conjugates O +
were O +
observed O -
. O +

Treatment O +
of O +
the O +
plasma O +
with O +
beta B-Gene -
- I-Gene -
glucuronidase I-Gene +
resulted O +
in O +
a O +
decrease O +
in O +
the O +
concentrations O +
of O +
these O +
two O +
putative O +
conjugates O +
and O +
the O +
concomitant O +
appearance O +
of O +
tetrahydrocurcumin O +
( O -
THC O -
) O +
and O +
curcumin O -
, O +
respectively O -
. O +

To O +
investigate O +
the O +
nature O +
of O +
these O +
glucuronide O +
conjugates O +
in O +
vivo O -
, O +
the O +
plasma O +
was O +
analyzed O +
by O +
electrospray O -
. O +

The O +
chemical O +
structures O +
of O +
these O +
metabolites O -
, O +
determined O +
by O +
mass O +
spectrometry O -
/ O -
mass O +
spectrometry O +
analysis O -
, O +
suggested O +
that O +
curcumin O +
was O +
first O +
biotransformed O +
to O +
dihydrocurcumin O +
and O +
THC O +
and O +
that O +
these O +
compounds O +
subsequently O +
were O +
converted O +
to O +
monoglucuronide O +
conjugates O -
. O +

Because O +
THC O +
is O +
one O +
of O +
the O +
major O +
metabolites O +
of O +
curcumin O -
, O +
we O +
studied O +
its O +
stability O +
at O +
different O +
pH O +
values O -
. O +

THC O +
was O +
very O +
stable O +
in O +
0.1 O +
M O +
phosphate O +
buffers O +
of O +
various O +
pH O +
values O -
. O +

Moreover O -
, O +
THC O +
was O +
more O +
stable O +
than O +
curcumin O +
in O +
0.1 O +
M O +
phosphate O +
buffer O -
, O +
pH O +
7.2 O +
( O -
37 O +
degrees O +
C O -
) O -
. O +

These O +
results O -
, O +
together O +
with O +
previous O +
findings O -
, O +
suggest O +
that O +
curcumin O -
- O -
glucuronoside O -
, O +
dihydrocurcumin O -
- O -
glucuronoside O -
, O +
THC O -
- O -
glucuronoside O -
, O +
and O +
THC O +
are O +
major O +
metabolites O +
of O +
curcumin O +
in O +
vivo O -
. O +

Forty O -
- O -
eight O +
patients O +
with O +
acute O +
proximal O +
deep O +
vein O +
thrombosis O +
( O -
DVT O -
) O +
were O +
randomised O +
to O +
intravenous O +
infusions O +
for O +
4 O +
to O +
6 O +
days O +
with O +
melagatran O -
, O +
a O +
novel O +
synthetic O +
low O +
molecular O +
weight O +
thrombin B-Gene +
inhibitor O -
, O +
or O +
unfractionated O +
heparin O +
adjusted O +
by O +
the O +
activated O +
partial O +
thromboplastin O +
time O +
( O -
APTT O -
) O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
pharmacokinetics O -
, O +
pharmacodynamics O +
and O +
the O +
safety O +
of O +
melagatran O +
therapy O +
at O +
three O +
different O +
doses O -
. O +

Steady O -
- O -
state O +
plasma O +
concentrations O +
were O +
rapidly O +
achieved O +
and O +
maintained O +
throughout O +
the O +
infusion O +
period O -
. O +

The O +
mean O +
plasma O +
concentrations O +
in O +
the O +
low O -
, O +
medium O +
and O +
high O +
dose O +
groups O +
were O +
0.17 O -
, O +
0.31 O +
and O +
0.53 O +
micromol O -
/ O -
l O -
, O +
respectively O -
. O +

The O +
prolongation O +
of O +
APTT O +
was O +
stable O +
during O +
the O +
melagatran O +
infusions O +
and O +
correlated O +
to O +
the O +
plasma O +
concentration O -
. O +

Phlebographically O +
verified O +
regression O +
of O +
thrombus O +
size O +
measured O +
as O +
decrease O +
in O +
Marder O +
score O +
was O +
seen O +
after O +
4 O +
to O +
6 O +
days O +
in O +
8 O +
of O +
12 O +
patients O -
, O +
6 O +
of O +
12 O +
patients O +
and O +
5 O +
of O +
11 O +
patients O +
in O +
the O +
low O -
, O +
medium O +
and O +
high O +
dose O +
groups O +
of O +
melagatran O +
and O +
in O +
5 O +
of O +
the O +
heparin O -
- O -
treated O +
patients O -
. O +

In O +
the O +
low O +
dose O +
group O +
with O +
melagatran O -
, O +
thrombus O +
extension O +
was O +
seen O +
in O +
one O +
patient O -
. O +

At O +
the O +
dose O +
levels O +
studied O -
, O +
melagatran O +
was O +
well O +
tolerated O +
with O +
no O +
clinically O +
significant O +
bleeding O +
problems O -
, O +
suggesting O +
that O +
melagatran O +
could O +
safely O +
be O +
given O +
to O +
patients O +
suffering O +
from O +
DVT O -
. O +

Bacterial O +
strain O +
LW1 O -
, O +
which O +
belongs O +
to O +
the O +
family O +
Comamonadaceae O -
, O +
utilizes O +
1-chloro-4-nitrobenzene O +
( O -
1C4NB O -
) O +
as O +
a O +
sole O +
source O +
of O +
carbon O -
, O +
nitrogen O -
, O +
and O +
energy O -
. O +

Suspensions O +
of O +
1C4NB O -
- O -
grown O +
cells O +
removed O +
1C4NB O +
from O +
culture O +
fluids O -
, O +
and O +
there O +
was O +
a O +
concomitant O +
release O +
of O +
ammonia O +
and O +
chloride O -
. O +

Under O +
anaerobic O +
conditions O +
LW1 O +
transformed O +
1C4NB O +
into O +
a O +
product O +
which O +
was O +
identified O +
as O +
2-amino-5-chlorophenol O +
by O +
1H O +
and O +
13C O +
nuclear O +
magnetic O +
resonance O +
( O -
NMR O -
) O +
spectroscopy O +
and O +
mass O +
spectrometry O -
. O +

This O +
transformation O +
indicated O +
that O +
there O +
was O +
partial O +
reduction O +
of O +
the O +
nitro O +
group O +
to O +
the O +
hydroxylamino O +
substituent O -
, O +
followed O +
by O +
Bamberger O +
rearrangement O -
. O +

In O +
the O +
presence O +
of O +
oxygen O +
but O +
in O +
the O +
absence O +
of O +
NAD O -
, O +
fast O +
transformation O +
of O +
2-amino-5-chlorophenol O +
into O +
a O +
transiently O +
stable O +
yellow O +
product O +
was O +
observed O +
with O +
resting O +
cells O +
and O +
cell O +
extracts O -
. O +

This O +
compound O +
exhibited O +
an O +
absorption O +
maximum O +
at O +
395 O +
nm O +
and O +
was O +
further O +
converted O +
to O +
a O +
dead O -
- O -
end O +
product O +
with O +
maxima O +
at O +
226 O +
and O +
272 O +
nm O -
. O +

The O +
compound O +
formed O +
was O +
subsequently O +
identified O +
by O +
1H O +
and O +
13C O +
NMR O +
spectroscopy O +
and O +
mass O +
spectrometry O +
as O +
5-chloropicolinic O +
acid O -
. O +

In O +
contrast O -
, O +
when O +
NAD O +
was O +
added O +
in O +
the O +
presence O +
of O +
oxygen O -
, O +
only O +
minor O +
amounts O +
of O +
5-chloropicolinic O +
acid O +
were O +
formed O -
, O +
and O +
a O +
new O +
product O -
, O +
which O +
exhibited O +
an O +
absorption O +
maximum O +
at O +
306 O +
nm O -
, O +
accumulated O -
. O +

In O +
this O +
article O -
, O +
a O +
cost O -
- O -
minimization O +
model O +
was O +
used O +
to O +
make O +
an O +
economic O +
comparison O +
between O +
cefmetazole O +
and O +
cefoxitin O -
-- O -
two O +
drugs O +
with O +
comparable O +
in O +
vitro O +
spectra O +
of O +
activity O -
, O +
clinical O +
efficacy O -
, O +
and O +
safety O +
profiles O -
. O +

Drug O +
acquisition O +
costs O +
were O +
estimated O +
from O +
published O +
information O +
and O +
labor O +
and O +
material O +
costs O +
were O +
calculated O +
based O +
on O +
actual O +
costs O +
at O +
Presbyterian O +
Hospital O +
of O +
Dallas O -
. O +

Costs O +
of O +
the O +
agents O +
were O +
calculated O +
based O +
on O +
the O +
dosage O +
and O +
administration O +
schedules O +
typically O +
used O +
in O +
published O +
clinical O +
trials O +
of O +
cefmetazole O +
and O +
cefoxitin O +
and O +
on O +
the O +
typical O +
dosing O +
patterns O +
of O +
cefoxitin O +
used O +
at O +
Presbyterian O +
Hospital O -
. O +

Results O +
of O +
the O +
cost O +
analysis O +
revealed O +
that O +
an O +
annual O +
savings O +
of O +
$ O -
36,015 O +
to O +
$ O -
59,143 O +
could O +
be O +
realized O +
at O +
Presbyterian O +
Hospital O +
if O +
cefmetazole O +
were O +
used O +
in O +
place O +
of O +
cefoxitin O +
for O +
surgical O +
prophylaxis O -
. O +

Furthermore O -
, O +
use O +
of O +
cefmetazole O +
in O +
place O +
of O +
cefoxitin O +
for O +
wound O +
treatment O +
would O +
yield O +
annual O +
savings O +
of O +
$ O -
33,242 O -
. O +

Aspergillus O +
candidus O +
Link O -
, O +
one O +
of O +
the O +
commonest O +
constituents O +
of O +
cereal O +
mycoflora O -
, O +
produces O +
two O +
kinds O +
of O +
mycotoxins O -
, O +
terphenyllin O +
and O +
xanthoascin O -
, O +
which O +
show O +
different O +
chemical O +
and O +
toxicological O +
properties O -
. O +

The O +
latter O -
, O +
xanthoascin O -
, O +
caused O +
severe O +
hepatic O +
injury O +
with O +
jaundice O +
and O +
focal O +
or O +
confluent O +
necrosis O +
of O +
hepatocytes O -
, O +
when O +
given O +
to O +
mice O +
in O +
doses O +
of O +
6 O +
mg O -
/ O -
kg O +
b.w O -
. O +

or O +
higher O +
by O +
a O +
single O +
subcutaneous O +
injection O -
. O +

With O +
higher O +
doses O +
above O +
15 O +
mg O -
/ O -
kg O -
, O +
myocardial O +
degeneration O +
and O +
necrosis O +
was O +
induced O +
after O +
a O +
week O +
or O +
two O +
in O +
addition O +
to O +
the O +
hepatic O +
injury O -
. O +

Vacuolation O +
of O +
the O +
nuclei O +
of O +
the O +
alveolar O +
interstitial O +
cells O +
of O +
the O +
lung O +
and O +
myocardial O +
interstitial O +
cells O +
was O +
another O +
characteristic O +
lesion O +
caused O +
by O +
this O +
mycotoxin O -
. O +

Other O +
organs O +
including O +
the O +
testicles O +
and O +
thymus O +
were O +
widely O +
involved O -
. O +

The O +
unique O +
nature O +
of O +
lesions O +
in O +
the O +
liver O +
and O +
heart O +
may O +
necessitate O +
further O +
investigations O +
in O +
the O +
field O +
of O +
mycotoxicology O +
in O +
relation O +
to O +
human O +
diseases O +
such O +
as O +
nutritional O +
hepatitis O +
and O +
primary O +
myocardial O +
degeneration O -
. O +

1 O -
. O +

The O +
central O +
depressant O +
effects O +
of O +
bromvaletone O -
, O +
carbromal O +
and O +
six O +
non O -
- O -
bromo O +
analogues O +
were O +
compared O +
in O +
mice O -
. O +

2 O -
. O +

The O +
chloro O +
analogues O +
of O +
bromvaletone O +
and O +
carbromal O +
were O +
slightly O +
less O +
potent O +
as O +
central O +
depressant O +
agents O +
than O +
the O +
bromo O +
compounds O -
. O +

3 O -
. O +

The O +
chloro O +
analogue O +
of O +
bromvaletone O +
had O +
the O +
greatest O +
margin O +
between O +
central O +
depressant O +
and O +
lethal O +
doses O -
. O +

4 O -
. O +
Lipophilicity O +
( O -
octanol O -
- O -
water O +
partition O +
coefficient O -
) O +
did O +
not O +
provide O +
a O +
unifying O +
relationship O +
for O +
potency O +
within O +
this O +
group O +
of O +
eight O +
acylureas O -
. O +

However O -
, O +
within O +
each O +
of O +
the O +
two O +
subsets O +
of O +
compounds O -
, O +
a O +
linear O +
relationship O +
was O +
found O +
between O +
relative O +
potency O +
and O +
lipophilicity O -
. O +

Isoguanine O +
( O -
2 O -
) O +
was O +
found O +
to O +
be O +
an O +
antineoplastic O +
constituent O +
of O +
Prioneris O +
thestylis O +
Dbldy O -
. O +

wings O -
. O +

Three O +
other O +
purine O +
components O +
of O +
the O +
butterfly O +
wings O +
were O +
identified O +
as O +
hypoxanthine O +
( O -
3 O -
) O -
, O +
uric O +
acid O +
( O -
4 O -
) O +
and O +
xanthine O +
( O -
5 O -
) O -
. O +

Isolation O +
of O +
urocanic O +
acid O +
( O -
6 O -
) O +
from O +
the O +
same O +
wing O +
material O +
represented O +
the O +
first O +
detection O +
of O +
this O +
interesting O +
histidine O +
derivative O +
in O +
an O +
arthropod O -
. O +

Antiandrogenic O +
chemicals O +
alter O +
sexual O +
differentiation O +
by O +
a O +
variety O +
of O +
mechanisms O -
, O +
and O +
as O +
a O +
consequence O -
, O +
they O +
induce O +
different O +
profiles O +
of O +
effects O -
. O +

For O +
example O -
, O +
in O +
utero O +
treatment O +
with O +
the O +
androgen B-Gene +
receptor I-Gene +
( O -
AR B-Gene -
) O +
antagonist O -
, O +
flutamide O -
, O +
produces O +
ventral O +
prostate O +
agenesis O +
and O +
testicular O +
nondescent O -
, O +
while O +
in O +
contrast O -
, O +
finasteride O -
, O +
an O +
inhibitor O +
of O +
5 O +
alpha O -
- O -
dihydrotestosterone O +
( O -
DHT O -
) O +
synthesis O -
, O +
rarely O -
, O +
if O +
ever O -
, O +
induces O +
such O +
malformations O -
. O +

In O +
this O +
regard O -
, O +
it O +
was O +
recently O +
proposed O +
that O +
dibutyl O +
phthalate O +
( O -
DBP O -
) O +
alters O +
reproductive O +
development O +
by O +
a O +
different O +
mechanism O +
of O +
action O +
than O +
flutamide O +
or O +
vinclozolin O +
( O -
V O -
) O -
, O +
which O +
are O +
AR B-Gene +
antagonists O -
, O +
because O +
the O +
male O +
offsprings O +
display O +
an O +
unusually O +
high O +
incidence O +
of O +
testicular O +
and O +
epididymal O +
alterations O -
-- O -
effects O +
rarely O +
seen O +
after O +
in O +
utero O +
flutamide O +
or O +
V O +
treatment O -
. O +

In O +
this O +
study O -
, O +
we O +
present O +
original O +
data O +
describing O +
the O +
reproductive O +
effects O +
of O +
10 O +
known O +
or O +
suspected O +
anti O -
- O -
androgens O -
, O +
including O +
a O +
Leydig O +
cell O +
toxicant O +
ethane O +
dimethane O +
sulphonate O +
( O -
EDS O -
, O +
50 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
linuron O +
( O -
L O -
, O +
100 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
p O -
, O -
p'-DDE O +
( O -
100 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
ketoconazole O +
( O -
12 O -
- O -
50 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
procymidone O +
( O -
P O -
, O +
100 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
chlozolinate O +
( O -
100 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
iprodione O +
( O -
100 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
DBP O +
( O -
500 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
diethylhexyl O +
phthalate O +
( O -
DEHP O -
, O +
750 O +
mg O +
kg-1 O +
day-1 O -
) O -
, O +
and O +
polychlorinated O +
biphenyl O +
( O -
PCB O -
) O +
congener O +
no. O +
169 O +
( O -
single O +
dose O +
of O +
1.8 O +
mg O +
kg-1 O -
) O -
. O +

Our O +
analysis O +
indicates O +
that O +
the O +
chemicals O +
discussed O +
here O +
can O +
be O +
clustered O +
into O +
three O +
or O +
four O +
separate O +
groups O -
, O +
based O +
on O +
the O +
resulting O +
profiles O +
of O +
reproductive O +
effects O -
. O +

Vinclozolin O -
, O +
P O -
, O +
and O +
DDE O -
, O +
known O +
AR B-Gene +
ligands O -
, O +
produce O +
similar O +
profiles O +
of O +
toxicity O -
. O +

However O -
, O +
p O -
, O -
p'-DDE O +
is O +
less O +
potent O +
in O +
this O +
regard O -
. O +

DBP O +
and O +
DEHP O +
produce O +
a O +
profile O +
distinct O +
from O +
the O +
above O +
AR B-Gene +
ligands O -
. O +

Male O +
offsprings O +
display O +
a O +
higher O +
incidence O +
of O +
epididymal O +
and O +
testicular O +
lesions O +
than O +
generally O +
seen O +
with O +
flutamide O -
, O +
P O -
, O +
or O +
V O +
even O +
at O +
high O +
dosage O +
levels O -
. O +

Linuron O +
treatment O +
induced O +
a O +
level O +
of O +
external O +
effects O +
consistent O +
with O +
its O +
low O +
affinity O +
for O +
AR B-Gene +
[ O -
reduced O +
anogenital O +
distance O +
( O -
AGD O -
) O -
, O +
retained O +
nipples O -
, O +
and O +
a O +
low O +
incidence O +
of O +
hypospadias O -
] O -
. O +

However O -
, O +
L O +
treatment O +
also O +
induced O +
an O +
unanticipated O +
degree O +
of O +
malformed O +
epididymides O +
and O +
testis O +
atrophy O -
. O +

In O +
fact O -
, O +
the O +
profile O +
of O +
effects O +
induced O +
by O +
L O +
was O +
similar O +
to O +
that O +
seen O +
with O +
DBP O -
. O +

These O +
results O +
suggest O +
that O +
L O +
may O +
display O +
several O +
mechanisms O +
of O +
endocrine O +
toxicity O -
, O +
one O +
of O +
which O +
involves O +
AR B-Gene +
binding O -
. O +

Chlozolinate O +
and O +
iprodione O +
did O +
not O +
produce O +
any O +
signs O +
of O +
maternal O +
or O +
fetal O +
endocrine O +
toxicity O +
at O +
100 O +
mg O +
kg-1 O +
day-1 O -
. O +

EDS O +
produced O +
severe O +
maternal O +
toxicity O +
and O +
a O +
45 O -
% O +
reduction O +
in O +
size O +
at O +
birth O -
, O +
which O +
resulted O +
in O +
the O +
death O +
of O +
all O +
neonates O +
by O +
5 O +
days O +
of O +
age O -
. O +

However O -
, O +
EDS O +
only O +
reduced O +
AGD O +
in O +
male O +
pups O +
by O +
15 O -
% O -
. O +

Ketoconazole O +
did O +
not O +
demasculinize O +
or O +
feminize O +
males O +
but O +
rather O +
displayed O +
anti O -
- O -
hormonal O +
activities O -
, O +
apparently O +
by O +
inhibiting O +
ovarian O +
hormone O +
synthesis O -
, O +
which O +
resulted O +
in O +
delayed O +
delivery O +
and O +
whole O +
litter O +
loss O -
. O +

In O +
summary O -
, O +
the O +
above O +
in O +
vivo O +
data O +
suggest O +
that O +
the O +
chemicals O +
we O +
studied O +
alter O +
male O +
sexual O +
differentiation O +
via O +
different O +
mechanisms O -
. O +

The O +
anti O -
- O -
androgens O +
V O -
, O +
P O -
, O +
and O +
p O -
, O -
p'-DDE O +
produce O +
flutamide O -
- O -
like O +
profiles O +
that O +
are O +
distinct O +
from O +
those O +
seen O +
with O +
DBP O -
, O +
DEHP O -
, O +
and O +
L. O +
The O +
effects O +
of O +
PCB O +
169 O +
bear O +
little O +
resemblance O +
to O +
those O +
of O +
any O +
known O +
anti O -
- O -
androgen O -
. O +

Only O +
in O +
depth O +
in O +
vitro O +
studies O +
will O +
reveal O +
the O +
degree O +
to O +
which O +
one O +
can O +
rely O +
upon O +
in O +
vivo O +
studies O -
, O +
like O +
those O +
presented O +
here O -
, O +
to O +
predict O +
the O +
cellular O +
and O +
molecular O +
mechanisms O +
of O +
developmental O +
toxicity O -
. O +

Lysine O +
clonixinate O +
( O -
LC O -
) O +
is O +
a O +
drug O +
of O +
antiinflammatory O +
antipyretic O +
and O +
analgesic O +
activity O +
that O +
produces O +
minor O +
digestive O +
side O -
- O -
effects O -
. O +

This O +
fact O +
induced O +
us O +
to O +
think O +
that O +
LC O +
is O +
possibly O +
a O +
weak O +
COX-1 B-Gene +
inhibitor O -
. O +

In O +
order O +
to O +
investigate O +
our O +
hypothesis O +
we O +
inhibited O +
cyclooxygenase B-Gene +
activity O +
with O +
LC O +
or O +
indomethacin O +
( O -
INDO O -
) O +
in O +
rat O +
lung O +
and O +
stomach O +
obtained O +
from O +
rats O +
treated O +
with O +
lipopolysacharide O +
( O -
LPS O -
) O +
and O +
control O +
rats O -
. O +

Rat O +
lung O +
preparations O +
incubated O +
with O +
14C O -
- O -
arachidonic O +
acid O +
synthesise O +
mainly O +
PGE2 O -
. O +

LC O +
at O +
2.5 O +
and O +
4.1 O +
x O +
10 O -
( O -
-5 O -
) O +
M O +
does O +
not O +
modify O +
the O +
basal O +
production O +
of O +
PGE2 O +
( O -
probably O +
COX-1 B-Gene -
) O +
but O +
at O +
6.8 O +
x O +
10 O -
( O -
-5 O -
) O +
M O +
significantly O +
inhibited O +
PGE2 O +
production O +
( O -
approximately O +
48.5 O -
% O +
inhibition O -
, O +
P<0.001 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
INDO O +
at O +
10 O -
( O -
-6 O -
) O +
inhibited O +
the O +
basal O +
production O +
of O +
PGE2 O +
by O +
around O +
73 O -
% O -
. O +

In O +
LPS O -
- O -
treated O +
rats O -
, O +
the O +
production O +
of O +
PGE2 O +
was O +
significantly O +
higher O +
than O +
in O +
the O +
lungs O +
of O +
control O +
rats O -
, O +
probably O +
due O +
to O +
the O +
induction O +
of O +
COX-2 B-Gene -
. O +

The O +
addition O +
of O +
LC O +
at O +
2.7 O +
and O +
4.1 O +
x O +
10 O -
( O -
-5 O -
) O +
M O +
recovered O +
the O +
control O +
values O +
of O +
PGE2 O +
inhibiting O -
, O +
probably O +
only O +
from O +
COX-2 B-Gene +
activity O -
. O +

LC O +
at O +
higher O +
concentrations O +
( O -
6.8 O +
x O +
10 O -
( O -
-5 O -
) O +
M O -
) O +
and O +
INDO O +
10 O -
( O -
-6 O -
) O +
M O +
inhibited O +
PGE2 O +
formed O +
by O +
COX-2 B-Gene +
and O +
also O +
partly O +
by O +
COX-1 B-Gene +
activity O -
. O +

The O +
leaves O +
of O +
the O +
composite O +
Solidago O +
canadensis O +
( O -
goldenrod O -
) O +
were O +
shown O +
to O +
contain O +
( B-Gene -
- I-Gene -
) I-Gene -
-alpha I-Gene -
- I-Gene -
gurjunene I-Gene +
synthase I-Gene +
activity O -
. O +

This O +
sesquiterpene O +
is O +
likely O +
to O +
be O +
the O +
precursor O +
for O +
cyclocolorenone O -
, O +
a O +
sesquiterpene O +
ketone O +
present O +
in O +
high O +
amounts O +
in O +
S. O +
canadensis O +
leaves O -
. O +

( B-Gene -
- I-Gene -
) I-Gene -
-alpha I-Gene -
- I-Gene -
Gurjunene I-Gene +
synthase I-Gene +
was O +
purified O +
to O +
apparent O +
homogeneity O +
( O -
741-fold O -
) O +
by O +
anion O -
- O -
exchange O +
chromatography O +
( O -
on O +
several O +
matrices O -
) O -
, O +
dye O +
ligand O +
chromatography O -
, O +
hydroxylapatite O +
chromatography O -
, O +
and O +
gel O +
filtration O -
. O +

Chromatography O +
on O +
a O +
gel O +
filtration O +
matrix O +
indicated O +
a O +
native O +
molecular O +
mass O +
of O +
48 O +
kDa O -
, O +
and O +
SDS O -
- O -
PAGE O +
showed O +
the O +
enzyme B-Gene +
to O +
be O +
composed O +
of O +
one O +
subunit O +
with O +
a O +
denatured O +
mass O +
of O +
60 O +
kDa O -
. O +

Its O +
maximum O +
activity O +
was O +
observed O +
at O +
pH O +
7.8 O +
in O +
the O +
presence O +
of O +
10 O +
mM O +
Mg2 O -
+ O +
and O +
the O +
KM O +
value O +
for O +
the O +
substrate O +
farnesyl O +
diphosphate O +
was O +
5.5 O +
microM. O +
Over O +
a O +
range O +
of O +
purification O +
steps O +
( B-Gene -
- I-Gene -
) I-Gene -
-alpha I-Gene -
- I-Gene -
gurjunene I-Gene +
and O +
( B-Gene -
+ I-Gene -
) I-Gene -
-gamma I-Gene -
- I-Gene -
gurjunene I-Gene +
synthase I-Gene +
activities O +
copurified O -
. O +

In O +
addition O -
, O +
the O +
product O +
ratio O +
of O +
the O +
enzyme O +
activity O +
under O +
several O +
different O +
assay O +
conditions O +
was O +
always O +
91 O -
% O +
( O -
- O -
) O -
-alpha O -
- O -
gurjunene O +
and O +
9 O -
% O +
( O -
+ O -
) O -
-gamma O -
- O -
gurjunene O -
. O +

This O +
suggests O +
that O +
the O +
formation O +
of O +
these O +
two O +
structurally O +
related O +
products O +
is O +
catalyzed O +
by O +
one O +
enzyme B-Gene -
. O +

For O +
further O +
confirmation O -
, O +
we O +
carried O +
out O +
a O +
number O +
of O +
mechanistic O +
studies O +
with O +
( B-Gene -
- I-Gene -
) I-Gene -
-alpha I-Gene -
- I-Gene -
gurjunene I-Gene +
synthase I-Gene -
, I-Gene +
in O +
which O +
an O +
enzyme O +
preparation O +
was O +
incubated O +
with O +
deuterated O +
substrate O +
analogues O -
. O +

Based O +
on O +
mass O +
spectrometry O +
analysis O +
of O +
the O +
products O +
formed O -
, O +
a O +
cyclization O +
mechanism O +
was O +
postulated O +
which O +
makes O +
it O +
plausible O +
that O +
the O +
synthase B-Gene +
catalyzes O +
the O +
formation O +
of O +
both O +
sesquiterpenes O -
. O +

The O +
stereochemistry O +
of O +
the O +
alpha O -
- O -
oxidation O +
of O +
3-methyl O -
- O -
branched O +
fatty O +
acids O +
was O +
studied O +
in O +
rat O +
liver O -
. O +

R- O +
and O +
S-3-methylhexadecanoic O +
acid O +
were O +
equally O +
well O +
alpha O -
- O -
oxidized O +
in O +
intact O +
hepatocytes O +
and O +
homogenates O -
. O +

Subcellular O +
fractionation O +
studies O +
showed O +
that O +
alpha O -
- O -
oxidation O +
of O +
both O +
isomers O +
is O +
confined O +
to O +
peroxisomes O -
. O +

Dehydrogenation O +
of O +
2-methylpentadecanal O -
, O +
the O +
end O -
- O -
product O +
of O +
the O +
peroxisomal O +
alpha O -
- O -
oxidation O +
of O +
3-methylhexadecanoic O +
acid O -
, O +
to O +
2-methylpentadecanoic O +
acid O -
, O +
followed O +
by O +
derivatization O +
with O +
R-1-phenylethylamine O +
and O +
subsequent O +
separation O +
of O +
the O +
stereoisomers O +
by O +
gas O +
chromatography O -
, O +
revealed O +
that O +
the O +
configuration O +
of O +
the O +
methyl O -
- O -
branch O +
is O +
preserved O +
throughout O +
the O +
whole O +
alpha O -
- O -
oxidation O +
process O -
. O +

Metabolism O +
and O +
formation O +
of O +
the O +
2-hydroxy-3-methylhexadecanoyl O -
- O -
CoA O +
intermediate O +
were O +
also O +
investigated O -
. O +

Separation O +
of O +
the O +
methyl O +
esters O +
of O +
the O +
four O +
isomers O +
of O +
2-hydroxy-3-methylhexadecanoic O +
acid O +
was O +
achieved O +
by O +
gas O +
chromatography O +
after O +
derivatization O +
of O +
the O +
hydroxy O +
group O +
with O +
R-2-methoxy-2-trifluoromethylphenylacetic O +
acid O +
chloride O +
and O +
the O +
absolute O +
configuration O +
of O +
the O +
four O +
isomers O +
was O +
determined O -
. O +

Although O +
purified O +
peroxisomes O +
are O +
capable O +
of O +
metabolizing O +
all O +
four O +
isomers O +
of O +
2-hydroxy-3-methylhexadecanoyl O -
- O -
CoA O -
, O +
they O +
can O +
only O +
form O +
the O +
( O -
2S,3R O -
) O +
and O +
the O +
( O -
2R,3S O -
) O +
isomers O -
. O +

Our O +
experiments O +
exclude O +
the O +
racemization O +
of O +
the O +
3-methyl O +
branch O +
during O +
the O +
alpha O -
- O -
oxidation O +
process O -
. O +

The O +
configuration O +
of O +
the O +
3-methyl O +
branch O +
does O +
not O +
influence O +
the O +
rate O +
of O +
alpha O -
- O -
oxidation O -
, O +
but O +
determines O +
the O +
side O +
of O +
the O +
2-hydroxylation O -
, O +
hence O +
the O +
configuration O +
of O +
the O +
2-hydroxy-3-methylacyl O -
- O -
CoA O +
intermediates O +
formed O +
during O +
the O +
process O -
. O +

Mass O +
transport O +
of O +
electrolyte O +
species O +
during O +
the O +
redox O +
reaction O +
of O +
conducting O +
polymers O -
, O +
plays O +
an O +
important O +
role O +
in O +
determining O +
their O +
electrochemical O +
characteristics O -
, O +
and O +
has O +
been O +
extensively O +
investigated O +
by O +
many O +
groups O +
[ O -
1,2 O -
] O +
. O +

In O +
general O -
, O +
the O +
mass O +
transport O +
mechanism O +
is O +
very O +
complex O -
, O +
because O +
dual O +
ion O +
transport O -
, O +
solvent O +
transport O -
, O +
and O +
neutral O +
salt O +
transport O +
are O +
present O +
and O +
they O +
depend O +
on O +
the O +
applied O +
potential O -
. O +

In O +
spite O +
of O +
these O +
complexities O -
, O +
considerable O +
progress O +
has O +
been O +
made O +
in O +
the O +
elucidation O +
of O +
the O +
mass O +
transport O +
mechanism O +
in O +
an O +
aqueous O +
solution O -
. O +

Recently O -
, O +
we O +
reported O +
valuable O +
information O +
on O +
water O +
transport O +
in O +
polypyrrole O +
( O -
PPy O -
) O +
and O +
poly O -
( O -
N O +
-methylpyrrole O -
) O +
( O -
PMPy O -
) O +
films O +
[ O -
3,4 O -
] O +
. O +

We O +
showed O +
that O +
water O +
transport O +
accompanying O +
cation O +
transport O +
in O +
a O +
PPy O +
film O +
depends O +
on O +
the O +
nature O +
and O +
concentration O +
of O +
the O +
electrolyte O +
solution O +
as O +
well O +
as O +
the O +
applied O +
potential O -
. O +

We O +
also O +
showed O +
that O +
water O +
transport O +
during O +
anion O +
transport O +
in O +
a O +
PMPy O +
film O +
does O +
not O +
change O +
extensively O +
with O +
the O +
concentration O +
of O +
the O +
electrolyte O +
solution O +
and O +
the O +
applied O +
potential O -
. O +

Moreover O -
, O +
it O +
was O +
found O +
that O +
the O +
amount O +
of O +
accompanying O +
water O +
per O +
ion O +
affects O +
the O +
ionic O +
conductivity O +
in O +
the O +
film O +
and O +
the O +
morphology O +
change O +
of O +
a O +
film O -
. O +

Although O +
the O +
mass O +
transport O +
study O +
of O +
conducting O +
polymers O +
in O +
polar O +
aprotic O +
solvents O +
has O +
been O +
an O +
important O +
topic O +
because O +
of O +
Li O +
battery O +
application O +
[ O -
5,6 O -
] O +
, O +
the O +
study O +
in O +
such O +
solvents O +
has O +
not O +
been O +
performed O +
as O +
extensively O +
as O +
in O +
aqueous O +
solutions O -
. O +

Daifuku O +
et O +
al. O +
[ O -
7,8 O -
] O +
reported O +
that O +
only O +
anion O +
transport O +
occurs O +
during O +
the O +
redox O +
reaction O +
of O +
polyaniline O +
( O -
PAn O -
) O +
films O +
in O +
acetonitrile O +
( O -
AN O -
) O +
containing O +
LiClO4 O +
. O +

Desilvestro O +
et O +
al. O +
[ O -
9 O -
] O +
showed O +
that O +
some O +
propylene O +
carbonate O +
( O -
PC O -
) O +
molecules O +
move O +
in O +
the O +
same O +
or O +
in O +
the O +
opposite O +
direction O +
with O +
respect O +
to O +
anion O +
transport O +
during O +
the O +
redox O +
reaction O +
of O +
PAn O +
films O +
in O +
a O +
PC O +
solution O -
. O +

Hillman O +
et O +
al. O +
[ O -
10 O -
] O +
insisted O +
that O +
a O +
neutral O +
salt O +
as O +
well O +
as O +
an O +
anion O +
and O +
a O +
solvent O +
take O +
part O +
in O +
mass O +
transport O +
of O +
polybithiophene O +
films O +
in O +
AN O -
. O +

Schiavon O +
et O +
al. O +
[ O -
11 O -
] O +
showed O +
that O +
ion O +
transport O +
is O +
anion O -
- O -
specific O +
in O +
the O +
case O +
of O +
poly O -
( O -
N O +
-alkyl O -
- O -
substituted O +
pyrrole O -
) O +
films O +
in O +
an O +
AN O +
solution O +
and O +
that O +
some O +
AN O +
molecules O +
move O +
in O +
the O +
opposite O +
direction O +
to O +
anion O +
transport O -
. O +

Thus O -
, O +
mass O +
transport O +
in O +
an O +
aprotic O +
solvent O +
is O +
very O +
complex O -
, O +
and O +
its O +
mechanism O +
is O +
still O +
far O +
from O +
being O +
fully O +
understood O -
. O +

In O +
this O +
study O -
, O +
the O +
ion O +
and O +
solvent O +
transport O +
behavior O +
for O +
PPy O +
and O +
PMPy O +
films O +
in O +
AN O +
are O +
investigated O +
by O +
using O +
the O +
cyclic O +
electrochemical O +
quartz O +
crystal O +
microbalance O +
( O -
EQCM O -
) O +
technique O +
[ O -
12,13 O -
] O +
. O +

First O -
, O +
cyclic O +
voltammograms O +
and O +
mass O +
change O +
diagrams O +
are O +
obtained O +
for O +
PPy O +
and O +
PMPy O +
films O +
during O +
the O +
first O +
negative O +
scan O +
as O +
well O +
as O +
the O +
steady O -
- O -
state O +
scan O -
. O +

Second O -
, O +
the O +
identity O +
of O +
charge O +
compensating O +
species O +
in O +
various O +
electrolyte O +
solutions O +
is O +
revealed O +
by O +
quantitative O +
analysis O -
. O +

Finally O -
, O +
the O +
differences O +
in O +
the O +
mass O +
transport O +
behavior O +
between O +
a O +
PPy O +
film O +
and O +
a O +
PMPy O +
film O +
are O +
discussed O +
focusing O +
on O +
solvent O +
transport O -
. O +

2 O +
Experimental O +
2.1 O +
Chemicals O +
Pyrrole O -
, O +
N O +
-methylpyrrole O -
, O +
and O +
AN O +
( O -
anhydrous O -
, O +
99.8 O -
% O -
) O +
were O +
purchased O +
from O +
Aldrich O +
and O +
used O +
as O +
received O -
. O +

All O +
the O +
electrolytes O +
used O +
in O +
this O +
study O +
are O +
of O +
reagent O +
grade O +
and O +
were O +
dried O +
at O +
80 O -
° O -
C O +
under O +
vacuum O +
before O +
use O -
. O +

2.2 O +
Electrochemistry O +
and O +
film O +
preparations O +
A O +
standard O +
three O -
- O -
electrode O +
cell O +
was O +
used O +
for O +
all O +
electrochemical O +
measurement O +
with O +
an O +
Ag O +
| O +
Ag+ O +
( O -
0.01 O +
M O +
AgNO3 O +
in O +
AN O -
) O +
reference O +
electrode O +
and O +
a O +
Pt O +
wire O +
counter O +
electrode O -
. O +

All O +
potentials O +
are O +
quoted O +
against O +
the O +
saturated O +
calomel O +
electrode O +
( O -
SCE O -
) O -
. O +

A O +
6 O +
MHz O +
AT O -
- O -
cut O +
quartz O +
crystal O +
( O -
Inficon O -
, O +
NY O -
) O +
coated O +
with O +
Au O -
, O +
0.32 O +
cm2 O +
in O +
area O -
, O +
served O +
as O +
the O +
working O +
electrode O -
. O +

The O +
electromechanical O +
impedance O +
of O +
the O +
quartz O +
crystal O +
was O +
measured O +
using O +
a O +
Hewlett O -
- O -
Packard O +
4285A O +
LCR O +
meter O -
. O +

The O +
experimental O +
setup O +
for O +
the O +
EQCM O +
and O +
the O +
electromechanical O +
impedance O +
experiment O +
was O +
the O +
same O +
as O +
that O +
reported O +
previously O +
[ O -
3 O -
] O +
. O +

PPy O +
films O +
were O +
prepared O +
galvanostatically O +
at O +
0.2 O +
mA O +
cm−2 O +
in O +
AN O +
containing O +
0.1 O +
M O +
pyrrole O +
and O +
0.1 O +
M O +
electrolyte O -
, O +
and O +
PMPy O +
was O +
polymerized O +
from O +
an O +
AN O +
solution O +
containing O +
0.1 O +
M O +
N O +
-methylpyrrole O +
and O +
0.1 O +
M O +
electrolyte O -
. O +

The O +
electrolyte O +
used O +
in O +
the O +
polymerizations O +
is O +
a O +
salt O +
containing O +
TEA+ O +
and O +
the O +
anion O +
to O +
be O +
used O +
in O +
the O +
cyclic O +
EQCM O +
experiment O -
. O +

The O +
charge O +
consumed O +
during O +
the O +
polymerization O +
was O +
300 O +
mC O +
cm−2 O +
for O +
all O +
the O +
films O -
. O +

After O +
polymerization O -
, O +
the O +
films O +
were O +
washed O +
with O +
pure O +
AN O +
and O +
transferred O +
into O +
an O +
Ar O -
- O -
filled O +
glove O +
box O -
. O +

All O +
the O +
cyclic O +
EQCM O +
experiments O +
were O +
performed O +
in O +
the O +
glove O +
box O -
, O +
and O +
the O +
electromechanical O +
impedance O +
experiments O +
were O +
performed O +
in O +
the O +
atmosphere O +
with O +
a O +
closed O +
cell O -
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Mass O +
transport O +
behavior O +
in O +
the O +
first O +
cathodic O +
scan O +
Fig. O +
1 O +
shows O +
a O +
cyclic O +
voltammogram O +
and O +
a O +
mass O +
change O +
diagram O +
for O +
a O +
PPy O +
film O +
during O +
the O +
first O +
two O +
cycles O +
in O +
AN O +
containing O +
1 O +
M O +
LiClO4 O +
. O +

The O +
first O +
negative O +
scan O +
exhibits O +
a O +
sharp O +
and O +
large O +
peak O +
at O +
a O +
more O +
negative O +
potential O +
than O +
that O +
in O +
the O +
second O +
scan O -
. O +

As O +
shown O +
in O +
Fig. O +
1 O +
b O -
, O +
the O +
mass O +
of O +
a O +
film O +
decreases O +
at O +
first O +
and O +
then O +
increases O +
sharply O +
around O +
the O +
peak O +
potential O +
of O +
the O +
first O +
negative O +
scan O -
. O +

This O +
means O +
that O +
anions O +
initially O +
move O +
out O +
of O +
the O +
film O +
and O +
that O +
cations O +
begin O +
to O +
move O +
into O +
the O +
film O +
around O +
the O +
peak O +
potential O -
. O +

The O +
charge O +
change O +
in O +
the O +
potential O +
region O +
where O +
mass O +
increases O +
is O +
5.6 O +
mC O -
, O +
which O +
would O +
correspond O +
to O +
0.4 O +
μg O +
if O +
only O +
Li+ O +
insertion O +
contributed O +
to O +
the O +
mass O +
increase O -
. O +

However O -
, O +
the O +
actual O +
mass O +
change O +
in O +
this O +
potential O +
region O +
is O +
10.7 O +
μg O -
. O +

This O +
large O +
mass O +
change O +
indicates O +
that O +
there O +
is O +
considerable O +
solvent O +
transport O +
in O +
addition O +
to O +
Li+ O +
transport O +
during O +
the O +
first O +
negative O +
scan O -
. O +

On O +
the O +
contrary O -
, O +
in O +
the O +
case O +
of O +
a O +
PMPy O +
film O -
, O +
there O +
is O +
no O +
significant O +
difference O +
between O +
the O +
first O +
two O +
cycles O +
in O +
both O +
the O +
cyclic O +
voltammogram O +
and O +
the O +
mass O +
change O +
diagram O +
as O +
shown O +
in O +
Fig. O +
2 O +
. O +

Moreover O -
, O +
the O +
mass O +
of O +
a O +
film O +
decreases O +
monotonically O +
in O +
the O +
negative O +
scan O +
and O +
increases O +
in O +
the O +
positive O +
scan O -
. O +

It O +
seems O +
that O +
anion O +
transport O +
is O +
dominant O +
over O +
the O +
whole O +
scan O +
range O -
. O +

The O +
abnormal O +
behavior O +
in O +
the O +
first O +
negative O +
scan O +
has O +
been O +
referred O +
to O +
as O +
the O +
' O -
break O -
- O -
in O +
process O -
. O -
' O +

It O +
is O +
known O +
that O +
the O +
film O +
after O +
its O +
deposition O +
is O +
compact O +
[ O -
14 O -
] O +
. O +

When O +
a O +
cation O +
with O +
some O +
solvent O +
moves O +
into O +
the O +
compact O +
film O +
in O +
the O +
first O +
negative O +
scan O -
, O +
the O +
break O -
- O -
in O +
process O +
occurs O +
[ O -
14,15 O -
] O +
. O +

However O -
, O +
when O +
an O +
anion O +
moves O +
out O +
of O +
the O +
compact O +
film O -
, O +
there O +
is O +
no O +
break O -
- O -
in O +
process O -
. O +

We O +
reported O +
previously O +
that O -
, O +
in O +
aqueous O +
solutions O -
, O +
the O +
break O -
- O -
in O +
process O +
is O +
observed O +
for O +
a O +
PPy O -
/ O -
copper O +
phthalocyaninetetrasulfonate O +
film O +
where O +
cation O +
transport O +
is O +
dominant O +
[ O -
3 O -
] O +
, O +
whereas O +
it O +
is O +
not O +
observed O +
for O +
a O +
PMPy O +
film O +
where O +
anion O +
transport O +
is O +
dominant O +
[ O -
4 O -
] O +
. O +

Thus O -
, O +
the O +
break O -
- O -
in O +
process O +
in O +
AN O +
can O +
be O +
understood O +
in O +
the O +
same O +
way O +
because O +
the O +
break O -
- O -
in O +
process O +
is O +
observed O +
for O +
a O +
PPy O +
film O +
where O +
cation O +
transport O +
is O +
considerable O -
, O +
whereas O +
it O +
is O +
not O +
observed O +
for O +
a O +
PMPy O +
film O +
where O +
only O +
anion O +
transport O +
occurs O -
. O +

3.2 O +
Mass O +
transport O +
behavior O +
in O +
the O +
steady O +
state O +
Fig. O +
3 O +
a O +
shows O +
a O +
cyclic O +
voltammogram O +
and O +
a O +
mass O +
change O +
diagram O +
for O +
a O +
PPy O +
film O +
in O +
LiClO4 O +
after O +
the O +
film O +
has O +
reached O +
its O +
steady O +
state O -
. O +

Similar O +
to O +
the O +
first O +
negative O +
scan O +
( O -
Fig. O +
1 O +
) O -
, O +
the O +
mass O +
of O +
a O +
film O +
decreases O +
at O +
first O +
and O +
then O +
increases O +
around O +
the O +
peak O +
potential O -
. O +

This O +
means O +
that O +
anion O +
transport O +
is O +
dominant O +
in O +
the O +
highly O +
oxidized O +
state O +
of O +
the O +
film O +
and O +
that O +
cation O +
transport O +
is O +
dominant O +
in O +
its O +
lightly O +
oxidized O +
state O -
. O +

Moreover O -
, O +
the O +
extent O +
of O +
mass O +
increase O +
is O +
significantly O +
reduced O +
when O +
it O +
is O +
compared O +
with O +
that O +
observed O +
during O +
the O +
first O +
scan O -
. O +

Fig. O +
3 O +
b O +
shows O +
the O +
result O +
obtained O +
in O +
TBAClO4 O +
. O +

When O +
large O +
TBA+ O +
is O +
used O +
as O +
the O +
electrolyte O +
cation O +
instead O +
of O +
small O +
Li+ O +
, O +
the O +
shape O +
of O +
the O +
cyclic O +
voltammogram O +
is O +
very O +
different O -
. O +

The O +
mass O +
increase O +
is O +
very O +
small O +
in O +
the O +
lower O +
potential O +
region O +
which O +
means O +
that O +
cation O +
transport O +
is O +
severely O +
suppressed O +
in O +
the O +
case O +
of O +
TBAClO4 O +
. O +

Consequently O -
, O +
it O +
is O +
evident O +
that O +
cation O +
transport O +
is O +
considerable O +
during O +
the O +
redox O +
reaction O +
of O +
a O +
PPy O +
film O -
. O +

Fig. O +
4 O +
a O +
shows O +
diagrams O +
for O +
a O +
PMPy O +
film O +
in O +
LiClO4 O +
. O +

The O +
mass O +
of O +
a O +
film O +
decreases O +
monotonically O +
in O +
the O +
negative O +
scan O +
and O +
increases O +
in O +
the O +
positive O +
scan O -
, O +
similarly O +
to O +
that O +
of O +
the O +
first O +
cycle O +
( O -
Fig. O +
2 O +
) O -
. O +

Anion O +
transport O +
seems O +
to O +
be O +
dominant O +
over O +
the O +
whole O +
range O -
, O +
too O -
. O +

Fig. O +

4 O +
b O +
shows O +
the O +
result O +
for O +
a O +
PMPy O +
film O +
in O +
TBAClO4 O +
. O +

Contrary O +
to O +
PPy O +
films O -
, O +
there O +
is O +
no O +
significant O +
change O +
in O +
the O +
cyclic O +
voltammogram O +
or O +
the O +
mass O +
change O +
diagram O +
when O +
TBA+ O +
is O +
used O +
as O +
the O +
electrolyte O +
cation O +
instead O +
of O +
Li+ O +
. O +

Therefore O -
, O +
it O +
is O +
evident O +
that O +
cation O +
transport O +
is O +
negligible O +
during O +
the O +
redox O +
reaction O +
of O +
a O +
PMPy O +
film O -
. O +

3.3 O +
Quantitative O +
analysis O +
The O +
plots O +
of O +
mass O +
change O +
( O -
ΔM O +
) O +
vs. O +
charge O +
change O +
( O -
ΔQ O +
) O +
during O +
the O +
redox O +
reaction O +
of O +
a O +
PPy O +
film O +
( O -
Fig. O +
3 O +
a O -
) O +
and O +
a O +
PMPy O +
film O +
( O -
Fig. O +
4 O +
a O -
) O +
in O +
1 O +
M O +
LiClO4 O +
are O +
shown O +
in O +
Figs. O +
5a O -
, O -
b O +
, O +
respectively O -
. O +

From O +
the O +
slope O +
of O +
the O +
plot O -
, O +
the O +
apparent O +
molar O +
mass O +
( O -
W O +
′ O -
) O +
of O +
charge O +
compensating O +
species O +
can O +
be O +
calculated O +
according O +
to O +
Eq. O +
( O -
1 O -
) O +
: O -
( O -
1 O -
) O +
W′ O +
= O -
− O +
zF O -
( O -
Δ O +
M O -
/ O -
Δ O +
Q O -
) O +
where O +
F O +
is O +
the O +
Faraday O +
constant O +
and O +
z O +
is O +
the O +
electric O +
charge O +
of O +
the O +
charge O +
compensating O +
species O -
. O +

3.3.1 O +
PPy O +
film O +
The O +
ΔM O +
vs. O +
ΔQ O +
plot O +
for O +
a O +
PPy O +
film O +
( O -
Fig. O +
5 O +
a O -
) O +
is O +
V O -
- O -
shaped O +
and O +
exhibits O +
' O -
hysteresis O +
behavior O -
' O -
. O +

Thus O -
, O +
we O +
obtained O +
two O +
W O +
′ O +
values O +
for O +
the O +
oxidized O +
and O +
the O +
reduced O +
state O -
. O +

Because O +
the O +
value O +
for O +
the O +
oxidized O +
state O +
is O +
mainly O +
related O +
to O +
anion O +
transport O -
, O +
we O +
represented O +
it O +
as O +
W O +
′+ O +
. O +

On O +
the O +
contrary O -
, O +
the O +
value O +
for O +
the O +
reduced O +
state O +
is O +
represented O +
as O +
W O +
′− O +
because O +
it O +
is O +
mainly O +
related O +
to O +
cation O +
transport O -
. O +

W O +
′ O +
values O +
obtained O +
in O +
various O +
systems O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

For O +
a O +
PPy O +
film O +
in O +
1 O +
M O +
LiClO4 O +
, O +
W O +
′+ O +
values O +
both O +
in O +
the O +
first O +
scan O +
and O +
in O +
the O +
steady O -
- O -
state O +
scan O +
are O +
much O +
larger O +
than O +
the O +
molar O +
mass O +
of O +
Li+ O +
( O -
W O +
Li+ O +
= O -
7 O -
) O -
. O +

A O +
similar O +
behavior O +
is O +
observed O +
for O +
PPy O +
films O +
in O +
1 O +
and O +
0.1 O +
M O +
TEAClO4 O +
. O +

Two O +
explanations O +
are O +
possible O +
for O +
the O +
difference O +
between O +
the O +
molar O +
mass O +
of O +
the O +
cation O +
( O -
W O +
+ O +
) O +
and O +
the O +
apparent O +
molar O +
mass O +
( O -
W O +
′+ O +
) O -
. O +

One O +
is O +
neutral O +
salt O +
transport O -
, O +
and O +
the O +
other O +
is O +
solvent O +
transport O -
. O +

However O -
, O +
the O +
difference O +
for O +
1 O +
M O +
TEAClO4 O +
in O +
the O +
first O +
scan O +
( O -
177–130=47 O -
) O +
is O +
much O +
smaller O +
than O +
that O +
for O +
1 O +
M O +
LiClO4 O +
( O -
262–7=255 O -
) O -
. O +

The O +
same O +
behavior O +
is O +
observed O +
in O +
the O +
steady O -
- O -
state O +
scan O -
. O +

If O +
neutral O +
salt O +
transport O +
occurred O -
, O +
the O +
differences O +
were O +
larger O +
for O +
TEAClO4 O +
due O +
to O +
its O +
large O +
molar O +
mass O -
. O +

Moreover O -
, O +
the O +
differences O +
in O +
0.1 O +
M O +
TEAClO4 O +
are O +
larger O +
than O +
those O +
in O +
1 O +
M O +
TEAClO4 O +
. O +

However O -
, O +
this O +
would O +
be O +
reversed O +
if O +
neutral O +
salt O +
transport O +
was O +
present O +
because O +
neutral O +
salt O +
transport O +
occurs O +
more O +
extensively O +
in O +
more O +
concentrated O +
electrolyte O +
solutions O -
. O +

Therefore O -
, O +
the O +
difference O +
between O +
W O +
+ O +
and O +
W O +
′+ O +
is O +
likely O +
to O +
be O +
due O +
to O +
solvent O +
transport O -
. O +

If O +
only O +
cation O +
transport O +
and O +
solvent O +
transport O +
occur O -
, O +
W O +
′+ O +
can O +
be O +
expressed O +
as O +
follows: O -
( O -
2 O -
) O +
W′ O +
+ O +
= O -
W+ O +
+ O -
Y+ O +
Ws O +
where O +
W O +
+ O +
and O +
W O +
s O +
are O +
the O +
molar O +
masses O +
of O +
a O +
cation O +
and O +
a O +
solvent O -
, O +
respectively O -
, O +
and O +
Y O +
+ O +
is O +
the O +
number O +
of O +
accompanying O +
solvent O +
molecules O +
per O +
cation O -
. O +

As O +
shown O +
in O +
Table O +
1 O +
, O +
Y O +
+ O +
values O +
for O +
1 O +
M O +
LiClO4 O +
are O +
6.2 O +
and O +
2.7 O +
in O +
the O +
first O +
and O +
in O +
the O +
steady O -
- O -
state O +
scan O -
, O +
respectively O -
. O +

This O +
means O +
the O +
amount O +
of O +
accompanying O +
solvent O +
is O +
larger O +
in O +
the O +
first O +
scan O +
than O +
in O +
the O +
steady O -
- O -
state O +
scan O -
. O +

For O +
1 O +
M O +
TEAClO4 O +
, O +
Y O +
+ O +
values O +
are O +
1.1 O +
and O +
0.1 O -
, O +
which O +
are O +
much O +
smaller O +
than O +
those O +
for O +
LiClO4 O +
This O +
indicates O +
that O +
the O +
amount O +
of O +
accompanying O +
solvent O +
depends O +
on O +
the O +
kind O +
of O +
cation O -
. O +

In O +
addition O -
, O +
the O +
fact O +
that O +
Y O +
+ O +
values O +
for O +
0.1 O +
M O +
TEAClO4 O +
are O +
larger O +
than O +
those O +
for O +
1 O +
M O +
TEAClO4 O +
means O +
that O +
the O +
amount O +
of O +
accompanying O +
solvent O +
depends O +
on O +
the O +
concentration O +
of O +
the O +
electrolyte O +
solution O -
. O +

The O +
increased O +
Y O +
+ O +
in O +
a O +
dilute O +
solution O +
can O +
be O +
explained O +
by O +
the O +
fact O +
that O +
the O +
solvation O +
number O +
of O +
the O +
ion O +
increases O +
due O +
to O +
the O +
increased O +
dielectric O +
constant O +
in O +
a O +
dilute O +
solution O +
[ O -
3 O -
] O +
. O +

In O +
every O +
PPy O +
film O -
, O +
W O +
′− O +
is O +
smaller O +
than O +
W O +
ClO4 O +
− O +
( O -
= O -
99.5 O -
) O +
and O +
varies O +
little O +
in O +
comparison O +
with O +
the O +
variation O +
of O +
W O +
′+ O +
. O +

It O +
is O +
difficult O +
to O +
give O +
a O +
clear O +
explanation O +
for O +
the O +
smaller O +
value O +
of O +
W O +
′− O +
compared O +
to O +
W O +
ClO4 O +
− O +
. O +

In O +
addition O +
to O +
anion O +
transport O -
, O +
cation O +
and O +
solvent O +
transport O +
might O +
occur O +
even O +
in O +
the O +
region O +
where O +
anion O +
transport O +
is O +
dominant O -
. O +

3.3.2 O +
PMPy O +
film O +
The O +
ΔM O +
vs. O +
ΔQ O +
plot O +
for O +
a O +
PMPy O +
film O +
( O -
Fig. O +
5 O +
b O -
) O +
is O +
linear O +
over O +
the O +
whole O +
charge O +
range O -
, O +
and O +
it O +
shows O +
no O +
hysteresis O +
behavior O -
. O +

Since O +
W O +
′− O +
in O +
the O +
first O +
scan O +
is O +
similar O +
to O +
that O +
in O +
the O +
steady O -
- O -
state O +
scan O +
within O +
the O +
experimental O +
error O -
, O +
only O +
W O +
′− O +
in O +
the O +
steady O -
- O -
state O +
scan O +
is O +
obtained O +
( O -
Table O +
2 O +
) O -
. O +

In O +
LiClO4 O +
, O +
W O +
′− O +
is O +
76 O -
, O +
which O +
is O +
smaller O +
than O +
W O +
ClO4 O +
− O +
. O +

All O +
W O +
′− O +
values O +
in O +
other O +
solutions O +
containing O +
ClO4 O +
− O +
are O +
smaller O +
than O +
W O +
ClO4 O +
− O +
, O +
too O -
. O +

Moreover O -
, O +
W O +
′− O +
values O +
are O +
not O +
significantly O +
affected O +
by O +
the O +
kind O +
of O +
cation O +
nor O +
by O +
the O +
concentration O +
of O +
the O +
electrolyte O -
. O +

It O +
shows O +
that O +
cation O +
or O +
neutral O +
salt O +
transport O +
is O +
negligible O +
in O +
ClO4 O +
− O +
-containing O +
solutions O -
. O +

Therefore O -
, O +
the O +
possibility O +
that O +
the O +
smaller O +
W O +
′− O +
is O +
due O +
to O +
cation O +
or O +
neutral O +
salt O +
transport O +
in O +
the O +
opposite O +
direction O +
to O +
anion O +
transport O +
can O +
be O +
excluded O -
. O +

In O +
that O +
case O -
, O +
two O +
possibilities O +
remain O -
. O +

One O +
is O +
that O +
solvent O +
transport O +
occurs O +
in O +
the O +
opposite O +
direction O +
to O +
anion O +
( O -
ClO4 O +
− O +
) O +
transport O -
, O +
and O +
the O +
other O +
is O +
that O +
the O +
morphology O +
change O +
of O +
a O +
film O +
results O +
in O +
a O +
miscalculation O +
of O +
ΔM O +
. O +

In O +
order O +
to O +
examine O +
the O +
latter O +
possibility O -
, O +
the O +
electromechanical O +
impedance O +
[ O -
16–18 O -
] O +
is O +
measured O +
for O +
a O +
PMPy O +
film O +
in O +
1 O +
M O +
TEAClO4 O +
( O -
Fig. O +
6 O +
) O -
. O +

In O +
the O +
electromechanical O +
impedance O +
experiment O -
, O +
the O +
excitation O +
signal O +
( O -
Fig. O +
6 O +
a O -
) O +
consists O +
of O +
successive O +
potential O +
steps O -
. O +

The O +
resonance O +
frequency O +
of O +
a O +
quartz O +
crystal O +
( O -
Δf O +
o O +
) O -
, O +
the O +
maximum O -
- O -
conductance O +
frequency O +
( O -
Δf O +
r O +
) O -
, O +
and O +
the O +
total O +
resistance O +
of O +
a O +
quartz O +
crystal O +
( O -
R O +
t O +
) O +
are O +
measured O +
at O +
every O +
step O +
after O +
steady O +
state O +
is O +
established O -
. O +

It O +
has O +
been O +
known O +
that O +
Δf O +
r O +
depends O +
only O +
on O +
ΔM O +
, O +
and O +
R O +
t O +
depends O +
on O +
the O +
morphology O +
change O +
of O +
a O +
film O -
. O +

We O +
previously O +
reported O +
that O +
the O +
comparison O +
between O +
f O +
o O +
and O +
f O +
r O +
enables O +
one O +
to O +
verify O +
the O +
linear O +
relation O +
between O +
ΔM O +
and O +
Δf O +
o O +
[ O -
3 O -
] O +
. O +

As O +
shown O +
in O +
Fig. O +
6 O +
b O -
, O +
R O +
t O +
varies O +
within O +
about O +
20 O +
Ω O -
, O +
which O +
is O +
very O +
small O +
compared O +
with O +
that O +
for O +
other O +
systems O +
reported O +
previously O +
[ O -
3 O -
] O +
. O +

It O +
indicates O +
that O +
the O +
morphology O +
change O +
is O +
not O +
significant O +
during O +
the O +
redox O +
reaction O +
of O +
a O +
PMPy O +
film O +
in O +
an O +
AN O +
solution O -
. O +

Moreover O -
, O +
the O +
Δf O +
o O +
behavior O +
is O +
very O +
similar O +
to O +
the O +
Δf O +
r O +
behavior O +
as O +
shown O +
in O +
Fig. O +
6 O +

c. O +
Therefore O -
, O +
ΔM O +
can O +
be O +
obtained O +
from O +
Δf O +
o O +
without O +
considering O +
a O +
change O +
in O +
the O +
morphology O +
of O +
the O +
film O +
in O +
this O +
system O -
. O +

Consequently O -
, O +
the O +
smaller O +
value O +
of O +
W O +
′− O +
is O +
related O +
to O +
solvent O +
transport O +
occurring O +
in O +
the O +
opposite O +
direction O +
to O +
anion O +
transport O -
. O +

Assuming O +
that O +
only O +
anion O +
transport O +
and O +
solvent O +
transport O +
take O +
place O -
, O +
W O +
′− O +
can O +
be O +
expressed O +
as O +
below: O -
( O -
3 O -
) O +

W′ O +
− O +
= O -
W− O +
+ O -
Y− O +
Ws O +
where O +
W O +
− O +
and O +
W O +
s O +
are O +
the O +
molar O +
masses O +
of O +
an O +
anion O +
and O +
a O +
solvent O -
, O +
respectively O -
, O +
and O +
Y O +
− O +
is O +
the O +
number O +
of O +
accompanying O +
solvent O +
molecules O +
per O +
anion O -
. O +

As O +
shown O +
in O +
Table O +
2 O +
, O +
Y O +
− O +
for O +
PMPy O +
films O +
in O +
ClO4 O +
− O +
-containing O +
AN O +
is O +
between O +
−0.5 O +
and O +
−0.6 O -
. O +

This O +
means O +
that O +
some O +
AN O +
molecules O +
( O -
about O +
0.5 O +
per O +
ClO4 O +
− O +
) O +
move O +
in O +
the O +
opposite O +
direction O +
to O +
ClO4 O +
− O +
transport O -
. O +

In O +
order O +
to O +
examine O +
the O +
effect O +
of O +
the O +
anion O +
on O +
the O +
mass O +
transport O +
of O +
a O +
PMPy O +
film O -
, O +
cyclic O +
EQCM O +
experiments O +
were O +
performed O +
in O +
solutions O +
containing O +
BF4 O +
− O +
and O +
CF3 O +
SO3 O +
− O +
. O +

The O +
cyclic O +
voltammograms O +
and O +
mass O +
change O +
diagrams O +
are O +
very O +
similar O +
to O +
those O +
of O +
ClO4 O +
− O +
-containing O +
solutions O -
. O +

Table O +
2 O +
shows O +
that O +
the O +
W O +
′− O +
value O +
is O +
67 O +
in O +
both O +
LiBF4 O +
and O +
TBABF4 O +
, O +
and O +
that O +
the O +
value O +
is O +
about O +
110 O +
in O +
both O +
LiCF3 O +
SO3 O +
and O +
TBACF3 O +
SO3 O +
. O +

It O +
shows O +
that O +
W O +
′− O +
values O +
are O +
smaller O +
than O +
W O +
− O +
( O -
W O +
BF4 O +
− O +
= O -
86.8 O +
and O +
W O +
CF3 O +
SO3 O +
− O +
= O -
149 O -
) O +
and O +
independent O +
of O +
the O +
kind O +
of O +
cation O +
in O +
both O +
solutions O +
containing O +
BF4 O +
− O +
and O +
CF3 O +
SO3 O +
− O +
. O +

Thus O -
, O +
it O +
is O +
evident O +
that O +
cation O +
or O +
neutral O +
salt O +
transport O +
is O +
negligible O +
and O +
that O +
counter O +
flux O +
of O +
the O +
solvent O +
occurs O +
in O +
these O +
solutions O -
. O +

4 O +
Conclusions O +
Ion O +
and O +
solvent O +
transport O +
behavior O +
for O +
PPy O +
and O +
PMPy O +
films O +
in O +
AN O +
was O +
investigated O +
with O +
the O +
cyclic O +
EQCM O +
technique O -
. O +

Cations O +
as O +
well O +
as O +
anions O +
take O +
part O +
in O +
ion O +
transport O +
during O +
the O +
redox O +
reaction O +
of O +
PPy O +
films O -
, O +
and O +
AN O +
transport O +
also O +
occurs O +
in O +
the O +
same O +
direction O +
as O +
cation O +
transport O -
. O +

In O +
the O +
first O +
negative O +
scan O -
, O +
the O +
break O -
- O -
in O +
process O +
takes O +
place O +
and O +
AN O +
molecules O +
are O +
inserted O +
into O +
the O +
film O -
. O +

In O +
a O +
TBA+ O +
-containing O +
solution O -
, O +
cation O +
transport O +
is O +
suppressed O +
because O +
of O +
the O +
large O +
cation O -
. O +

On O +
the O +
other O +
hand O -
, O +
anion O +
transport O +
is O +
dominant O +
during O +
the O +
redox O +
reaction O +
of O +
PMPy O +
films O -
. O +

AN O +
transport O +
takes O +
place O +
in O +
the O +
opposite O +
direction O +
to O +
anion O +
transport O -
. O +

Acknowledgements O +
The O +
authors O +
are O +
grateful O +
to O +
the O +
Korea O +
Advanced O +
Institute O +
of O +
Science O +
and O +
Technology O +
for O +
financial O +
support O +
of O +
this O +
research O -
. O +

The O +
stable O +
prostacyclin O +
analogue O -
, O +
iloprost O +
relaxes O +
a O +
variety O +
of O +
blood O +
vessels O +
and O +
increases O +
cyclic O +
AMP O -
, O +
although O +
the O +
relationship O +
between O +
adenosine O +
3 O -
' O -
: O +
5'-cyclic O +
monophosphate O +
( O -
cyclic O +
AMP O -
) O +
and O +
vasorelaxation O +
remains O +
unclear O -
. O +

We O +
therefore O +
investigated O +
the O +
effect O +
of O +
the O +
adenylyl B-Gene +
cyclase I-Gene +
inhibitor O -
, O +
9- O -
( O -
tetrahydro-2-furanyl O -
) O -
-9H O -
- O -
purin-6-amine O +
( O -
SQ22536 O -
) O +
on O +
iloprost O -
- O -
mediated O +
relaxation O +
and O +
cyclic O +
AMP O +
elevation O +
in O +
endothelium O -
- O -
denuded O +
aortic O +
strips O -
. O +

Iloprost O +
( O -
1 O -
- O -
1000 O +
nM O -
) O +
caused O +
a O +
concentration O -
- O -
dependent O +
inhibition O +
of O +
phenylephrine O +
( O -
1 O -
- O -
6 O +
microM O -
) O +
contractions O -
, O +
the O +
responses O +
being O +
unaffected O +
by O +
pre O -
- O -
incubation O +
with O +
SQ22536 O +
( O -
100 O +
microM O -
) O +
for O +
30 O +
min O -
. O +

In O +
other O +
experiments O +
60 O +
nM O +
iloprost O +
caused O +
a O +
64 O -
% O +
inhibition O +
of O +
phenylephrine O +
contractions O +
concomitant O +
with O +
a O +
3 O +
fold O +
rise O +
in O +
cyclic O +
AMP O -
. O +

SQ22536 O +
completely O +
abolished O +
the O +
iloprost O -
- O -
induced O +
elevation O +
in O +
cyclic O +
AMP O +
while O +
having O +
no O +
significant O +
effect O +
on O +
relaxation O -
. O +

Our O +
results O +
therefore O +
strongly O +
suggest O +
that O +
cyclic O +
AMP O -
- O -
independent O +
pathways O +
are O +
responsible O +
for O +
the O +
vasorelaxant O +
effects O +
of O +
iloprost O +
in O +
guinea O -
- O -
pig O +
aorta O -
. O +

The O +
photosynthetic O +
organelles O +
( O -
cyanelles O -
) O +
of O +
the O +
protist O +
Cyanophora O +
paradoxa O +
are O +
surrounded O +
by O +
a O +
peptidoglycan O +
wall O -
, O +
modified O +
through O +
amidation O +
with O +
N O -
- O -
acetylputrescine O -
. O +

Cyanelle O +
envelope O +
membrane O +
preparations O +
were O +
shown O +
to O +
catalyze O +
the O +
lipid O -
- O -
linked O +
steps O +
of O +
peptidoglycan O +
biosynthesis O +
as O +
well O +
as O +
the O +
putrescinylation O +
and O +
subsequent O +
acetylation O -
, O +
occurring O +
at O +
the O +
stage O +
of O +
lipid O +
I O +
and/or O +
lipid O +
II O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
involvement O +
of O +
cyclooxygenase-1 B-Gene +
( O -
COX-1 B-Gene -
) O -
, O +
cyclooxygenase-2 B-Gene +
( O -
COX-2 B-Gene -
) O -
, O +
and O +
tyrosine B-Gene +
kinase I-Gene +
on O +
prostaglandin O +
E2 O +
( O -
PGE2 O -
) O +
production O +
in O +
human O +
gingival O +
fibroblasts O +
stimulated O +
by O +
interleukin-1beta B-Gene +
( O -
IL-1beta B-Gene -
) O +
and/or O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
( O -
EGF B-Gene -
) O -
. O +

The O +
cytokine B-Gene +
IL-1beta I-Gene +
and O +
to O +
a O +
lesser O +
extent O +
EGF B-Gene -
, O +
enhanced O +
COX-2 B-Gene +
mRNA O +
levels O +
in O +
gingival O +
fibroblasts O -
. O +

Simultaneous O +
treatment O +
with O +
EGF B-Gene +
and O +
IL-1beta B-Gene +
resulted O +
in O +
enhanced O +
COX-2 B-Gene +
mRNA O +
levels O +
accompanied O +
by O +
a O +
synergistic O +
stimulation O +
of O +
PGE2 O +
biosynthesis O +
compared O +
to O +
the O +
cells O +
treated O +
with O +
IL-1beta B-Gene +
or O +
EGF B-Gene +
alone O -
. O +

Neither O +
IL-1beta B-Gene +
EGF B-Gene +
nor O +
the O +
combination O +
of O +
IL-1beta B-Gene +
and O +
EGF B-Gene +
enhanced O +
COX-1 B-Gene +
mRNA O +
levels O +
in O +
gingival O +
fibroblasts O -
. O +

The O +
tyrosine B-Gene +
kinase I-Gene +
inhibitors O -
, O +
Herbimycin O +
A O +
and O +
PD O +
153035 O +
hydrochloride O -
, O +
reduced O +
COX-2 O +
mRNA O +
levels O +
as O +
well O +
as O +
PGE2 O +
production O +
induced O +
by O +
IL-1beta B-Gene +
or O +
the O +
combination O +
of O +
IL-1beta B-Gene +
and O +
EGF B-Gene +
whereas O +
COX-1 B-Gene +
mRNA O +
levels O +
were O +
not O +
affected O -
. O +

Furthermore O -
, O +
the O +
COX-2 B-Gene +
specific O +
inhibitor O -
, O +
NS-398 O -
, O +
abolished O +
the O +
PGE2 O +
production O +
induced O +
by O +
IL-1beta B-Gene -
, O +
EGF B-Gene -
, O +
or O +
the O +
combination O -
. O +

These O +
results O +
indicate O +
that O +
the O +
synergy O +
between O +
IL-1beta B-Gene +
and O +
EGF B-Gene +
on O +
PGE2 O +
production O +
is O +
due O +
to O +
an O +
enhanced O +
gene O +
expression O +
of O +
COX-2 B-Gene +
and O +
that O +
tyrosine B-Gene +
kinase I-Gene -
( O -
s O -
) O +
are O +
involved O +
in O +
the O +
signal O +
transduction O +
of O +
COX-2 B-Gene +
in O +
gingival O +
fibroblasts O -
. O +

Phosphorothioate O +
oligonucleotides O +
( O -
S O -
- O -
oligos O -
) O +
are O +
nucleic O +
acid O +
derivatives O +
that O +
are O +
commonly O +
used O +
as O +
antisense O +
agents O -
. O +

These O +
compounds O -
, O +
similar O +
to O +
bacterial O +
DNA O +
and O +
CpG O +
oligonucleotides O -
, O +
display O +
a O +
variety O +
of O +
immunological O +
activities O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

To O +
assess O +
further O +
these O +
activities O -
, O +
the O +
antigenicity O +
of O +
a O +
series O +
of O +
S O -
- O -
oligos O +
was O +
assessed O +
in O +
the O +
solid O +
phase O +
using O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
from O +
sera O +
of O +
patients O +
with O +
systemic O +
lupus O +
erythematosus O -
. O +

By O +
ELISA O -
, O +
S O -
- O -
oligos O +
bound O +
well O +
to O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
under O +
the O +
same O +
conditions O +
as O +
calf B-Gene +
thymus I-Gene +
DNA I-Gene +
antigen I-Gene -
. O +

The O +
specificity O +
for O +
anti O -
- O -
DNA O +
was O +
established O +
by O +
competition O +
assays O +
showing O +
cross O -
- O -
inhibition O +
of O +
binding O +
by O +
DNA O +
and O +
S O -
- O -
oligos O -
. O +

Reactivity O +
with O +
anti O -
- O -
DNA O +
was O +
observed O +
with O +
S O -
- O -
oligos O +
varying O +
in O +
sequence O -
, O +
suggesting O +
interaction O +
with O +
a O +
conserved O +
determinant O +
not O +
strictly O +
dependent O +
on O +
the O +
bases O -
. O +

Furthermore O -
. O +
in O +
comparison O +
with O +
a O +
phosphodiester O +
oligomer O +
of O +
the O +
same O +
sequence O -
, O +
a O +
phosphorothioate O +
showed O +
dramatically O +
increased O +
activity O -
. O +

These O +
findings O +
indicate O +
that O +
structural O +
features O +
associated O +
with O +
the O +
S O -
- O -
oligo O +
backbone O +
promote O +
specific O +
binding O +
to O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
and O +
influence O +
the O +
size O +
requirement O +
for O +
antigenicity O +
in O +
the O +
solid O +
phase O -
. O +

These O +
observations O +
thus O +
extend O +
the O +
immunological O +
properties O +
of O +
S O -
- O -
oligos O +
and O +
suggest O +
uses O +
of O +
these O +
compounds O +
in O +
the O +
diagnosis O +
and O +
treatment O +
of O +
autoimmune O +
disease O -
. O +

Phosphorothioate O +
oligonucleotides O +
( O -
S O -
- O -
oligos O -
) O +
are O +
nucleic O +
acid O +
derivatives O +
commonly O +
used O +
as O +
antisense O +
agents O +
( O -
Milligan O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

These O +
compounds O +
have O +
the O +
replacement O +
of O +
one O +
of O +
non O -
- O -
bridging O +
oxygens O +
by O +
a O +
sulfur O +
in O +
the O +
phosphodiester O +
backbone O -
. O +

While O +
this O +
modification O +
increases O +
nuclease B-Gene +
resistance O -
, O +
it O +
also O +
affects O +
helix O +
stability O +
as O +
well O +
as O +
the O +
charge O +
distribution O +
along O +
the O +
backbone O +
( O -
Iyengar O +
et O +
al. O -
, O +
1984 O +
; O +
Frey O +
and O +
Sammons O -
, O +
1985 O +
; O +
Stein O +
et O +
al. O -
, O +
1988 O +
) O -
. O +

In O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
systems O -
, O +
S O -
- O -
oligos O +
display O +
potent O +
antisense O +
activities O +
and O +
are O +
currently O +
in O +
clinical O +
trials O +
in O +
human O +
disease O +
( O -
Stein O +
and O +
Cheng O -
, O +
1993 O +
; O +
Wagner O -
, O +
1994 O +
, O +
Wagner O -
, O +
1995 O +
) O -
. O +

Despite O +
their O +
effectiveness O +
in O +
blocking O +
gene O +
expression O -
, O +
S O -
- O -
oligos O +
have O +
properties O +
that O +
could O +
affect O +
their O +
use O +
in O +
antisense O +
therapy O -
. O +

These O +
properties O +
include O +
non O -
- O -
specific O +
binding O +
to O +
cellular O +
proteins B-Gene +
as O +
well O +
as O +
powerful O +
immunostimulatory O +
activities O +
( O -
Pisetsky O +
and O +
Reich O -
, O +
1993 O +
, O +
Pisetsky O +
and O +
Reich O -
, O +
1994a O +
; O +
Brown O +
et O +
al. O -
, O +
1994 O +
; O +
Perez O +
et O +
al. O -
, O +
1994 O +
; O +
Zhao O +
et O +
al. O -
, O +
1996 O +
) O -
.These O +

activities O +
include O +
stimulation O +
of O +
lymphocyte O +
proliferation O +
as O +
well O +
as O +
induction O +
of O +
cytokines B-Gene -
, O +
including O +
IL-12 B-Gene -
, O +
IFN B-Gene -
- I-Gene -
α I-Gene -
/ I-Gene -
β I-Gene +
and O +
IL-6 B-Gene +
( O -
Krieg O +
et O +
al. O -
, O +
1995 O +
; O +
Klinman O +
et O +
al. O -
, O +
1996 O +
; O -
Lipford O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

While O +
sequence O +
dependent O -
, O +
these O +
activities O +
are O +
not O +
antisense O +
effects O -
. O +

Rather O -
, O +
immunostimulation O +
by O +
S O -
- O -
oligos O +
resembles O +
that O +
of O +
bacterial O +
DNA O +
as O +
well O +
as O +
synthetic O +
phosphodiester O +
oligonucleotides O +
containing O +
CpG O +
motifs O -
. O +

These O +
findings O +
suggest O +
that O +
S O -
- O -
oligos O +
exert O +
immunological O +
effects O +
by O +
mimicking O +
foreign O +
DNA O +
in O +
its O +
signaling O +
properties O +
( O -
Pisetsky O -
, O +
1996a O +
, O +
Pisetsky O -
, O +
1996b O +
) O -
. O +

In O +
the O +
current O +
study O -
, O +
we O +
have O +
evaluated O +
further O +
the O +
immunological O +
properties O +
of O +
S O -
- O -
oligos O +
by O +
testing O +
their O +
ability O +
to O +
bind O +
to O +
antibodies B-Gene +
to O +
DNA O +
( O -
anti B-Gene -
- I-Gene -
DNA I-Gene -
) O +
in O +
the O +
solid O +
phase O -
. O +

These O +
antibodies B-Gene +
occur O +
prominently O +
in O +
systemic O +
lupus O +
erythematosus O +
( O -
SLE O -
) O -
, O +
a O +
prototypic O +
autoimmune O +
disease O +
characterized O +
by O +
the O +
expression O +
of O +
antibodies B-Gene +
to O +
components O +
of O +
the O +
cell O +
nucleus O +
( O -
Pisetsky O -
, O +
1992 O +
) O -
. O +

Anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
from O +
lupus O +
patients O +
as O +
well O +
as O +
murine O +
models O +
differ O +
in O +
fine O +
specificity O -
. O +

Some O +
antibodies B-Gene +
have O +
preference O +
for O +
certain O +
base O +
sequences O +
and O +
have O +
binding O +
site O +
interactions O +
with O +
exposed O +
bases O -
. O +

Other O +
antibodies B-Gene +
bind O +
to O +
conserved O +
determinants O +
found O +
commonly O +
on O +
all O +
natural O +
DNA O -
, O +
both O +
single O +
stranded O +
( O -
ss O -
) O +
and O +
double O +
stranded O +
( O -
ds O -
) O -
, O +
with O +
much O +
less O +
dependence O +
on O +
base O +
sequence O +
( O -
Stollar O +
et O +
al. O -
, O +
1986 O +
; O +
Sano O +
et O +
al. O -
, O +
1989 O +
; O +
Stollar O -
, O +
1994 O +
; O +
Eilat O +
and O +
Anderson O -
, O +
1994 O +
; O +
Herrmann O +
et O +
al. O -
, O +
1995 O +
; O +
Swanson O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

To O +
investigate O +
the O +
antigenicity O +
of O +
S O -
- O -
oligos O -
, O +
we O +
have O +
tested O +
the O +
reactivity O +
of O +
normal O +
and O +
SLE O +
sera O +
to O +
phosphorothioate O +
compounds O +
up O +
to O +
30 O +
bases O +
in O +
length O -
. O +

In O +
results O +
presented O +
herein O -
, O +
we O +
show O +
that O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
in O +
SLE O +
sera O +
bind O +
phosphorothioate O +
oligonucleotides O +
in O +
a O +
solid O +
phase O +
immunoassay O -
. O +

In O +
their O +
reactivity O -
, O +
S O -
- O -
oligos O +
were O +
more O +
potent O +
than O +
phosphodiester O +
oligonucleotides O +
of O +
similar O +
sequence O -
, O +
suggesting O +
that O +
backbone O +
modifications O +
enhance O +
antigenicity O -
. O +

These O +
findings O +
extend O +
the O +
immunological O +
effects O +
of O +
S O -
- O -
oligos O +
to O +
antibody B-Gene +
binding O +
and O +
suggest O +
the O +
use O +
for O +
phosphorothioates O +
as O +
antigens O +
in O +
immunological O +
testing O -
. O +

2 O +
Experimental O +
2.1 O +
Materials O +
and O +
methods O +
2.1.1 O +
Antigens O +
Oligonucleotides O -
, O +
synthesized O +
using O +
cyanoethyl O +
phosphoramidite O +
chemistry O -
, O +
were O +
purchased O +
from O +
Midland O +
Certified O +
Reagent O +
Company O +
( O -
Midland O -
, O +
TX O -
) O +
and O +
purified O +
by O +
gel O +
filtration O +
and O +
ethanol O +
precipitation O -
. O +

These O +
compounds O +
were O +
dissolved O +
in O +
distilled O +
water O +
to O +
a O +
final O +
concentration O +
of O +
1 O +
mg O -
/ O -
ml O +
and O +
filter O +
sterilized O +
through O +
a O +
Millex O +
GV O +
filter O +
( O -
Millipore O -
, O +
Bedford O +
MA O -
) O +
for O +
storage O +
at O +
4 O -
° O -
C O -
. O +

Calf O +
thymus O +
( O -
CT O -
) O +
DNA O +
was O +
purchased O +
from O +
the O +
Sigma O +
Chemical O +
Co. O +
( O -
St O +
Louis O -
, O +
MO O -
) O +
and O +
further O +
purified O +
by O +
extraction O +
with O +
phenol O +
: O +
chloroform O +
and O +
ethanol O +
precipitation O -
. O +

To O +
prepare O +
ssDNA O +
antigen O -
, O +
the O +
DNA O +
was O +
boiled O +
for O +
10 O +
min O +
and O +
then O +
rapidly O +
cooled O +
in O +
ice O -
. O +

Concentrations O +
were O +
determinated O +
by O +
absorbance O +
at O +
260 O +
nm O +
with O +
OD O +
260 O -
/ O -
280 O +
ratios O +
greater O +
than O +
1.8 O +
for O +
preparations O +
used O -
. O +

2.1.1.1 O +
Sera O +
Sera O +
from O +
patients O +
with O +
systemic O +
lupus O +
erythematosus O +
were O +
obtained O +
from O +
the O +
Clinical O +
Immunology O +
Laboratory O +
of O +
the O +
Duke O +
University O +
Medical O +
Center O +
and O +
were O +
selected O +
on O +
the O +
basis O +
of O +
a O +
high O +
level O +
of O +
anti O -
- O -
DNA O +
in O +
an O +
ELISA O +
for O +
dsDNA O +
( O -
Sanofi O +
Diagnostics O +
Pasteur O -
, O +
Redmond O -
, O +
WA O -
) O -
. O +

Sera O +
from O +
normal O +
human O +
subjects O +
( O -
NHS O -
) O +
were O +
obtained O +
from O +
healthy O +
volunteers O +
at O +
the O +
Durham O +
VA O +
Hospital O -
. O +

2.1.1.2 O +
ELISA O +
For O +
antibody B-Gene +
assays O -
, O +
96 O +
well O +
microtiter O +
plates O +
( O -
Dynatech O +
Laboratories O -
, O +
Chantilly O -
, O +
VA O -
) O +
were O +
coated O +
overnight O +
at O +
4 O -
° O -
C O +
with O +
DNA O +
or O +
oligonucleotides O +
diluted O +
to O +
various O +
concentrations O +
in O +
SSC O +
( O -
0.15 O +
M O +
NaCl O -
, O +
0.1 O +
M O +
Na O +
citrate O +
pH O +
8.0 O -
) O -
. O +

Plates O +
were O +
then O +
washed O +
3 O +
times O +
with O +
phosphate O +
buffered O +
saline O +
( O -
PBS O -
, O +
pH O +
7.3 O -
) O +
containing O +
0.05 O -
% O +
Tween O +
20 O +
( O -
Sigma O -
) O +
( O -
PBS O -
- O -
T O -
) O -
. O +

Sera O +
starting O +
at O +
1 O +
: O +
100 O +
dilution O +
were O +
serially O +
diluted O +
in O +
PBS O -
- O -
T O +
containing O +
1 O -
% O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
Sigma O -
) O +
and O +
then O +
incubated O +
on O +
plates O +
for O +
1 O +
h O +
at O +
room O +
temperature O -
. O +

After O +
washing O +
plates O +
3 O +
times O +
with O +
PBS O -
- O -
T O -
, O +
peroxidase B-Gene -
- O -
conjugated O +
goat O +
anti B-Gene -
- I-Gene -
human I-Gene +
IgG I-Gene +
( O -
gamma O +
chain O +
specific O -
, O +
Sigma O -
) O +
diluted O +
1 O +
: O +
1000 O +
in O +
PBS O -
- O -
T O +
was O +
then O +
added O +
to O +
the O +
wells O +
and O +
incubated O +
for O +
1 O +
h. O +
Plates O +
were O +
then O +
washed O +
3 O +
times O +
with O +
PBS O -
- O -
T O +
and O +
substrate O +
solution O +
containing O +
0.015 O -
% O +
3,3′,5,5′-tetramethylbenzidine O +
( O -
Sigma O -
) O -
, O +
0.01 O -
% O +
hydrogen O +
peroxide O +
in O +
0.1 O +
M O +
sodium O +
citrate O +
buffer O -
. O +

pH O +
4 O +
was O +
added O -
. O +

After O +
a O +
30 O +
min O +
incubation O +
at O +
room O +
temperature O -
, O +
optical O +
densities O +
were O +
determined O +
at O +
380 O +
nm O +
using O +
a O +
Titertek O +
plate O +
reader O +
( O -
Flow O +
Laboratories O -
, O +
McLean O -
, O +
VA O -
) O -
. O +

For O +
competition O +
experiments O -
, O +
sera O +
were O +
initially O +
titrated O +
to O +
determine O +
the O +
concentration O +
producing O +
an O +
OD O +
380 O +
value O +
of O +
approximately O +
1 O +
when O +
uninhibited O -
. O +

This O +
dilution O +
of O +
serum O +
was O +
then O +
mixed O +
with O +
competing O +
oligonucleotides O +
or O +
DNA O +
antigen O +
and O +
incubated O +
for O +
1 O +
h O +
prior O +
to O +
transfer O +
to O +
plates O -
. O +

The O +
ELISA O +
was O +
then O +
performed O +
as O +
described O -
. O +

2.2 O +
Results O +
As O +
a O +
model O +
to O +
investigate O +
the O +
antigenicity O +
of O +
phosphorothioate O +
oligonucleotides O -
, O +
we O +
initially O +
studied O +
the O +
compound O +
1082 O +
which O +
has O +
a O +
sequence O +
complementary O +
to O +
a O +
translation O +
initiation O +
codon O +
region O +
within O +
the O +
UL13 O +
open O +
reading O +
frame O +
of O +
the O +
herpes O +
simplex O +
virus O +
( O -
Table O +
1 O +
) O -
. O +

This O +
compound O +
is O +
21 O +
bases O +
long O +
and O +
has O +
been O +
previously O +
used O +
to O +
assess O +
the O +
immunostimulatory O +
activity O +
of O +
phosphorothioates O +
( O -
Pisetsky O +
and O +
Reich O -
, O +
1994a O +
) O -
. O +

As O +
shown O +
in O +
Fig. O +
1 O +
, O +
this O +
compound O +
shows O +
reactivity O +
with O +
a O +
lupus O +
serum O +
when O +
coated O +
to O +
microtiter O +
plates O +
under O +
the O +
same O +
conditions O +
as O +
CT O +
ssDNA O -
. O +

Optimal O +
antigenic O +
activity O +
was O +
observed O +
with O +
oligonucleotide O +
concentrations O +
of O +
1–5 O +
μg O -
/ O -
ml O -
, O +
a O +
value O +
similar O +
to O +
that O +
of O +
CT O +
ssDNA O -
. O +

Under O +
these O +
conditions O -
, O +
the O +
NHS O +
showed O +
no O +
appreciable O +
reactivity O -
, O +
indicating O +
specificity O +
for O +
antibodies B-Gene +
in O +
the O +
SLE O +
serum O -
. O +

A O +
panel O +
of O +
SLE O +
sera O +
was O +
next O +
tested O +
for O +
reactivity O +
to O +
plates O +
coated O +
with O +
S O -
- O -
oligo O +
1082 O +
at O +
a O +
concentration O +
of O +
5 O +
μg O -
/ O -
ml O -
. O +

Of O +
12 O +
SLE O +
with O +
high O +
levels O +
of O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
binding O +
( O -
OD380 O +
greater O +
than O +
2.0 O +
at O +
a O +
dilution O +
of O +
1 O +
: O +
100 O -
) O -
, O +
all O +
but O +
three O +
produced O +
ELISA O +
values O +
greater O +
than O +
1.0 O +
using O +
1082 O +
as O +
the O +
coating O +
antigen O -
. O +

Fig. O +
2 O +
shows O +
representative O +
data O +
of O +
these O +
titrations O -
. O +

These O +
results O +
suggest O +
that O +
binding O +
to O +
S O -
- O -
oligos O +
is O +
a O +
property O +
of O +
some O +
but O +
not O +
all O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene -
. O +

To O +
demonstrate O +
further O +
that O +
binding O +
to O +
S O -
- O -
oligos O +
is O +
a O +
property O +
of O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene -
, O +
inhibition O +
ELISA O +
were O +
performed O +
using O +
sera O +
that O +
bound O +
both O +
CT O +
ssDNA O +
and O +
1082 O -
. O +

As O +
shown O +
in O +
Fig. O +
3 O +
, O +
soluble O +
S O -
- O -
oligo O +
effectively O +
competed O +
for O +
binding O +
to O +
surface O +
bound O +
CT O +
ssDNA O -
. O +

Conversely O -
, O +
CT O +
ssDNA O +
effectively O +
competed O +
for O +
binding O +
to O +
1082 O +
( O -
Fig. O +
4 O +
) O -
. O +

These O +
results O +
indicate O +
that O +
the O +
free O +
oligonucleotide O +
is O +
antigenic O +
and O +
provide O +
further O +
evidence O +
that O +
S O -
- O -
oligo O +
reactivity O +
reflects O +
anti O -
- O -
DNA O +
binding O -
. O +

The O +
relationship O +
of O +
sequence O +
to O +
antigenicity O +
was O +
next O +
assessed O +
by O +
comparing O +
antibody O +
binding O +
by O +
two O +
SLE O +
sera O +
and O +
an O +
NHS O +
serum O +
to O +
a O +
group O +
of O +
S O -
- O -
oligos O +
( O -
Table O +
1 O +
) O -
. O +

As O +
shown O +
in O +
Table O +
2 O +
, O +
all O +
compounds O +
tested O +
were O +
active O +
in O +
the O +
direct O +
binding O +
ELISA O -
, O +
although O +
the O +
sera O +
varied O +
somewhat O +
in O +
their O +
binding O +
to O +
these O +
compounds O -
; O +
the O +
NHS O +
serum O -
, O +
however O -
, O +
showed O +
binding O +
minimally O +
above O +
background O -
. O +

These O +
results O +
suggest O +
that O +
an O +
important O +
determinant O +
of O +
antigenicity O +
is O +
the O +
phosphorothioate O +
backbone O +
but O +
do O +
not O +
exclude O +
sequence O -
- O -
specific O +
binding O -
. O +

The O +
specificity O +
for O +
backbone O +
determinants O +
was O +
evaluated O +
further O +
by O +
comparing O +
reactivity O +
of O +
phosphorothioate O +
and O +
phosphodiester O +
compounds O +
20 O +
bases O +
long O +
synthesized O +
with O +
all O +
four O +
bases O +
at O +
each O +
position O +
to O +
provide O +
a O +
large O +
set O +
of O +
varying O +
sequences O +
( O -
randomers O -
) O -
. O +

Like O +
S O -
- O -
oligos O +
of O +
other O +
sequences O -
, O +
the O +
S O -
- O -
oligo O +
randomer O +
was O +
active O +
when O +
bound O +
to O +
polystyrene O +
plates O -
. O +

Under O +
the O +
same O +
coating O +
and O +
assay O +
conditions O -
, O +
however O -
, O +
the O +
phosphodiester O +
compound O +
was O +
much O +
less O +
active O +
( O -
Fig. O +
5 O +
) O -
. O +

These O +
findings O +
suggest O +
the O +
importance O +
of O +
the O +
phosphorothioate O +
backbone O +
to O +
antigenicity O -
. O +

This O +
point O +
was O +
further O +
demonstrated O +
by O +
comparing O +
the O +
activity O +
of O +
the O +
phosphorothioate O +
randomer O +
with O +
the O +
phosphodiester O +
randomer O +
as O +
fluid O +
phase O +
inhibitors O -
. O +

Consistent O +
with O +
direct O +
binding O +
results O -
, O +
the O +
phosphorothioate O +
was O +
a O +
much O +
better O +
inhibitor O +
than O +
the O +
phosphodiester O -
. O +

Thus O -
, O +
at O +
a O +
concentration O +
of O +
50 O +
μg O -
/ O -
ml O -
, O +
the O +
phosphorothioate O +
randomer O +
inhibited O +
binding O +
in O +
the O +
ELISA O +
67±12 O -
% O +
compared O +
to O +
17±11 O -
% O +
for O +
the O +
phosphodiester O +
( O -
mean±S.D. O +
for O +
four O +
SLE O +
sera O -
) O -
. O +

In O +
these O +
experiments O -
, O +
the O +
oligonucleotides O +
were O +
all O +
at O +
least O +
18 O +
bases O +
in O +
length O -
. O +

To O +
evaluate O +
whether O +
shorter O +
compounds O +
are O +
also O +
antigenic O -
, O +
the O +
activity O +
of O +
a O +
random O +
sequence O +
10-mer O +
was O +
tested O -
. O +

As O +
shown O +
in O +
Fig. O +
6 O +
, O +
this O +
compound O +
showed O +
only O +
weak O +
antigenicity O +
with O +
only O +
two O +
of O +
four O +
sera O +
tested O +
producing O +
on O +
OD380 O +
value O +
in O +
the O +
ELISA O +
greater O +
than O +
0.5 O -
. O +

These O +
results O +
suggest O +
that O +
a O +
sequence O +
somewhere O +
between O +
10 O +
and O +
20 O +
bases O +
in O +
length O +
is O +
required O +
for O +
antigenicity O +
and O +
that O +
shorter O +
compounds O +
either O +
fail O +
to O +
adhere O +
to O +
plates O +
or O +
present O +
an O +
antigenic O +
epitope O -
. O +

2.3 O +
Discussion O +
Results O +
of O +
these O +
studies O +
demonstrate O +
that O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
in O +
SLE O +
sera O +
can O +
bind O +
solid O +
phase O +
phosphorothioate O +
oligonucleotides O +
in O +
an O +
interaction O +
influenced O +
by O +
the O +
backbone O +
modification O -
. O +

The O +
identity O +
of O +
these O +
antibodies B-Gene +
as O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
is O +
established O +
by O +
both O +
direct O +
binding O +
as O +
well O +
as O +
inhibition O +
assays O -
. O +

Thus O -
, O +
soluble O +
CT O +
ssDNA O +
can O +
block O +
antibody B-Gene +
binding O +
to O +
solid O +
phase O +
S O -
- O -
oligos O +
while O +
S O -
- O -
oligos O +
can O +
block O +
antibody B-Gene +
binding O +
to O +
CT O +
ssDNA O -
. O +

The O +
binding O +
of O +
murine O +
monoclonal O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
to O +
phosphorothoiate O +
DNA O +
has O +
been O +
previously O +
described O -
, O +
although O +
these O +
antibodies B-Gene +
were O +
induced O +
by O +
immunization O +
with O +
modified O +
DNA O +
( O -
Latimer O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

Our O +
data O +
provide O +
the O +
first O +
demonstration O +
that O +
spontaneous O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
in O +
human O +
SLE O +
sera O +
display O +
such O +
reactivity O -
. O +

The O +
binding O +
of O +
lupus O +
sera O +
to O +
S O -
- O -
oligos O +
is O +
notable O +
in O +
view O +
of O +
studies O +
on O +
the O +
influence O +
of O +
DNA O +
size O +
on O +
antigenicity O +
( O -
Papalian O +
et O +
al. O -
, O +
1980 O +
; O +
Ali O +
et O +
al. O -
, O +
1985 O +
) O -
. O +

Although O +
an O +
antibody B-Gene +
binding O +
site O +
can O +
accommodate O +
three O +
to O +
four O +
bases O -
, O +
most O +
SLE O +
sera O +
fail O +
to O +
bind O +
to O +
short O +
oligonucleotides O +
and O +
rather O +
require O +
DNA O +
pieces O +
at O +
least O +
35–45 O +
bases O +
in O +
length O +
in O +
fluid O +
phase O +
assays O -
. O +

These O +
findings O +
suggest O +
that O +
lupus O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
bind O +
to O +
DNA O +
by O +
bivalent O +
or O +
monogamous O +
interaction O -
. O +

In O +
this O +
mode O +
of O +
binding O -
, O +
both O +
Fab O +
combining O +
sites O +
contact O +
antigenic O +
determinants O +
along O +
the O +
same O +
continuous O +
stretch O +
of O +
DNA O -
. O +

Because O +
of O +
the O +
distance O +
between O +
antibody B-Gene +
combining O +
sites O +
( O -
greater O +
than O +
100Å O +
depending O +
on O +
the O +
angle O +
at O +
the O +
hinge O +
region O -
) O -
, O +
the O +
minimum O +
size O +
piece O +
of O +
DNA O +
to O +
span O +
this O +
distance O +
is O +
approximately O +
35–45 O +
bases O +
in O +
length O -
. O +

The O +
requirement O +
for O +
bivalent O +
interaction O +
suggests O +
that O +
the O +
affinity O +
of O +
each O +
Fab O +
combining O +
site O +
is O +
relatively O +
low O +
and O +
insufficient O +
for O +
monovalent O +
binding O -
. O +

The O +
model O +
for O +
bivalent O +
binding O +
is O +
based O +
on O +
studies O +
of O +
fluid O +
phase O +
assays O -
. O +

A O +
recent O +
study O +
assessing O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
binding O +
by O +
ELISA O +
suggested O +
that O +
solid O +
phase O +
interactions O +
impose O +
more O +
drastic O +
requirements O +
for O +
DNA O +
antigenicity O +
( O -
Pisetsky O +
and O +
Reich O -
, O +
1994b O +
) O -
. O +

Thus O -
, O +
ssDNA O +
pieces O +
less O +
than O +
2000 O +
bases O +
showed O +
poor O +
antigenicity O +
when O +
adhered O +
to O +
plastic O +
surfaces O -
, O +
although O +
these O +
fragments O +
were O +
nevertheless O +
active O +
in O +
the O +
fluid O +
phase O -
. O +

These O +
results O +
suggest O +
that O +
solid O +
phase O +
binding O +
may O +
limit O +
antibody B-Gene -
- O -
antigen O +
interactions O +
because O +
of O +
structural O +
constraints O +
imposed O +
on O +
low O +
molecular O +
weight O +
DNA O +
( O -
1000–2000 O +
bases O +
or O +
less O -
) O +
by O +
surface O +
adherence O -
. O +

The O +
surface O +
adherence O +
of O +
DNA O +
in O +
this O +
size O +
range O +
may O +
involve O +
the O +
majority O +
of O +
the O +
molecule O -
; O +
under O +
these O +
conditions O -
, O +
antigenicity O +
may O +
be O +
impaired O +
because O +
extensive O +
surface O +
binding O +
limits O +
the O +
exposure O +
of O +
certain O +
determinants O +
or O +
prevents O +
conformational O +
rearrangements O +
( O -
e.g. O -
, O +
DNA O +
looping O -
) O +
required O +
for O +
antibody B-Gene +
binding O -
. O +

In O +
contrast O -
, O +
high O +
molecular O +
DNA O +
may O +
have O +
greater O +
regions O +
that O +
are O +
free O +
in O +
solution O +
and O +
capable O +
of O +
rearranging O +
for O +
bivalent O +
binding O -
. O +

In O +
contrast O +
to O +
phosphodiester O +
oligonucleotides O -
, O +
phosphorothioate O +
oligonucleotides O +
were O +
antigenically O +
active O +
in O +
solid O +
phase O +
form O -
. O +

The O +
results O +
with O +
the O +
ELISA O +
are O +
particularly O +
striking O +
since O -
, O +
as O +
described O +
above O -
, O +
SLE O +
sera O +
fail O +
to O +
bind O +
appreciably O +
to O +
natural O +
DNA O +
fragments O +
much O +
greater O +
in O +
length O +
or O -
, O +
as O +
shown O +
herein O -
, O +
phosphodiester O +
oligonucleotides O +
of O +
the O +
same O +
sequence O -
. O +

These O +
results O +
suggest O +
that O +
lupus O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
bind O +
much O +
more O +
avidly O +
to O +
phosphorothioates O +
than O +
phosphodiester O +
compounds O +
and O -
, O +
as O +
a O +
result O -
, O +
interact O +
with O +
oligonucleotides O +
in O +
solid O +
phase O +
assays O -
. O +

As O +
shown O +
with O +
phosphorothioates O +
in O +
a O +
number O +
of O +
systems O -
, O +
the O +
presence O +
of O +
phosphorothioate O +
linkages O +
increases O +
non O -
- O -
specific O +
protein B-Gene +
binding O +
( O -
Brown O +
et O +
al. O -
, O +
1994 O +
; O +
Guvakova O +
et O +
al. O -
, O +
1995 O +
; O +
Shoeman O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

In O +
the O +
case O +
of O +
antibodies B-Gene -
, O +
however O -
, O +
binding O +
to O +
phosphorothioates O +
appears O +
to O +
be O +
a O +
specific O +
property O +
of O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene -
. O +

Thus O -
, O +
normal O +
sera O +
showed O +
low O +
reactivity O +
with O +
phosphorothioate O -
- O -
coated O +
plates O +
under O +
conditions O +
in O +
which O +
SLE O +
sera O +
bound O +
well O +
in O +
a O +
fashion O +
inhibited O +
by O +
soluble O +
DNA O -
. O +

Enhanced O +
antigenicity O +
of O +
phosphorothioates O +
could O +
relate O +
to O +
the O +
distribution O +
of O +
charge O +
along O +
the O +
backbone O +
since O +
charge O -
– O -
charge O +
interactions O +
are O +
important O +
for O +
lupus O +
anti B-Gene -
- I-Gene -
DNA I-Gene -
. O +

Alternatively O -
, O +
the O +
presence O +
of O +
phosphorothioate O +
groups O +
may O +
enhance O +
binding O +
by O +
altering O +
backbone O +
geometry O +
or O +
flexibility O +
as O +
well O +
as O +
adherence O +
to O +
solid O +
phase O +
supports O -
. O +

Because O +
of O +
the O +
stereochemistry O +
of O +
phosphorothioate O +
bonds O -
, O +
the O +
structure O +
of O +
these O +
compounds O +
has O +
been O +
difficult O +
to O +
determine O +
precisely O -
. O +

Using O +
current O +
synthetic O +
methods O -
, O +
these O +
compounds O +
have O +
chiral O +
centers O +
since O +
the O +
sulfur O +
atom O +
can O +
occur O +
in O +
either O +
of O +
two O +
orientations O +
( O -
R O +
or O +
S O -
) O +
with O +
respect O +
to O +
the O +
phosphate O +
backbone O +
( O -
Milligan O +
et O +
al. O -
, O +
1993 O +
; O +
Frey O +
and O +
Sammons O -
, O +
1985 O +
) O -
. O +

As O +
a O +
result O -
, O +
S O -
- O -
oligo O +
preparations O +
contain O +
an O +
enormous O +
mixture O +
of O +
stereoisomers O -
, O +
reflecting O +
the O +
occurrence O +
of O +
either O +
isomeric O +
form O +
at O +
every O +
bond O +
position O -
. O +

This O +
complexity O -
, O +
which O +
precludes O +
structural O +
analysis O +
by O +
usual O +
biophysical O +
techniques O -
, O +
also O +
prevents O +
determination O +
of O +
whether O +
enhanced O +
antigenicity O +
characterizes O +
all O +
phosphorothioates O +
or O +
only O +
certain O +
steroisomers O -
. O +

In O +
this O +
regard O -
, O +
we O +
have O +
not O +
as O +
yet O +
tested O +
double O +
stranded O +
oligomers O +
to O +
assess O +
their O +
behavior O +
in O +
these O +
assays O -
; O +
most O +
SLE B-Gene +
anti I-Gene -
- I-Gene -
DNA I-Gene -
, O +
however O -
, O +
crossreact O +
with O +
ss O +
and O +
dsDNA O -
. O +

These O +
findings O +
have O +
implications O +
both O +
for O +
the O +
assessment O +
of O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
as O +
well O +
as O +
the O +
medicinal O +
use O +
of O +
phosphorothioate O +
oligonucleotides O -
. O +

Thus O -
, O +
phosphorothioate O +
oligonucleotides O +
could O +
provide O +
the O +
basis O +
for O +
assays O +
of O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
antibodies I-Gene +
( O -
at O +
least O +
to O +
ssDNA O -
) O +
using O +
short O +
compounds O +
synthesized O +
with O +
defined O +
sequence O -
. O +

The O +
application O +
of O +
synthetic O +
compounds O +
should O +
obviate O +
variations O +
in O +
assays O +
resulting O +
from O +
the O +
use O +
of O +
DNA O +
from O +
various O +
species O +
and O +
possible O +
interference O +
from O +
contaminating O +
non O -
- O -
nucleic O +
acid O +
components O +
( O -
Stollar O +
et O +
al. O -
, O +
1962 O +
; O +
Casperson O +
and O +
Voss O -
, O +
1983 O +
) O -
. O +

The O +
nuclease B-Gene +
resistance O +
of O +
phosphorothioates O +
may O +
also O +
improve O +
stability O +
of O +
antigens O +
in O +
sera O +
and O +
performance O +
characteristics O +
of O +
assays O -
. O +

As O +
shown O +
previously O -
, O +
phosphorothioates O +
have O +
immunostimulatory O +
properties O +
that O +
reflect O +
features O +
of O +
the O +
backbone O +
( O -
Pisetsky O +
and O +
Reich O -
, O +
1993 O +
; O +
Pisetsky O +
and O +
Reich O -
, O +
1994a O +
; O +
Zhao O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

The O +
ability O +
of O +
these O +
compounds O +
to O +
bind O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
suggests O +
that O +
may O +
also O +
have O +
immunogenic O +
potential O +
and O +
promote O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
production O +
in O +
susceptible O +
individuals O -
. O +

This O +
potential O -
, O +
which O +
could O +
reflect O +
their O +
adjuvant O +
properties O -
, O +
nuclease B-Gene +
resistance O +
as O +
well O +
as O +
interactions O +
with O +
surface O +
Ig B-Gene +
receptors I-Gene -
, O +
could O +
limit O +
the O +
use O +
of O +
phosphorothioates O +
in O +
the O +
setting O +
of O +
inflammatory O +
or O +
autoimmune O +
disease O +
( O -
Braun O +
and O +
Lee O -
, O +
1988 O +
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
an O +
S O -
- O -
oligo O +
that O +
bound O +
anti B-Gene -
- I-Gene -
DNA I-Gene +
without O +
exerting O +
immunostimulatory O +
effects O +
could O +
block O +
the O +
pathogenic O +
effects O +
of O +
anti B-Gene -
- I-Gene -
DNA I-Gene -
. O +

Studies O +
are O +
therefore O +
in O +
progress O +
to O +
define O +
further O +
the O +
immunological O +
effects O +
of O +
phosphorothioates O +
binding O +
to O +
antibodies B-Gene +
and O +
structural O +
basis O +
for O +
antibody B-Gene +
interaction O -
. O +

Synthetic O +
benzamide O +
derivatives O +
were O +
investigated O +
for O +
their O +
ability O +
to O +
inhibit O +
histone B-Gene +
deacetylase I-Gene +
( O -
HDA B-Gene -
) O -
. O +

In O +
this O +
study O -
, O +
one O +
of O +
the O +
most O +
active O +
benzamide O +
derivatives O -
, O +
MS-27 O -
- O -
275 O -
, O +
was O +
examined O +
with O +
regard O +
to O +
its O +
biological O +
properties O +
and O +
antitumor O +
efficacy O -
. O +

MS-27 O -
- O -
275 O +
inhibited O +
partially O +
purified O +
human O +
HDA B-Gene +
and O +
caused O +
hyperacetylation O +
of O +
nuclear O +
histones B-Gene +
in O +
various O +
tumor O +
cell O +
lines O -
. O +

It O +
behaved O +
in O +
a O +
manner O +
similar O +
to O +
other O +
HDA B-Gene +
inhibitors O -
, O +
such O +
as O +
sodium O +
butyrate O +
and O +
trichostatin O +
A O -
; O +
MS-27 O -
- O -
275 O +
induced O +
p21 B-Gene -
( I-Gene -
WAF1 I-Gene -
/ I-Gene -
CIP1 I-Gene -
) I-Gene +
and O +
gelsolin B-Gene +
and O +
changed O +
the O +
cell O +
cycle O +
distribution O -
, O +
decrease O +
of O +
S O -
- O -
phase O +
cells O -
, O +
and O +
increase O +
of O +
G1-phase O +
cells O -
. O +

The O +
in O +
vitro O +
sensitivity O +
spectrum O +
of O +
MS-27 O -
- O -
275 O +
against O +
various O +
human O +
tumor O +
cell O +
lines O +
showed O +
a O +
pattern O +
different O +
than O +
that O +
of O +
a O +
commonly O +
used O +
antitumor O +
agent O -
, O +
5-fluorouracil O -
, O +
and O -
, O +
of O +
interest O -
, O +
the O +
accumulation O +
of O +
p21 B-Gene -
( I-Gene -
WAF1 I-Gene -
/ I-Gene -
CIP1 I-Gene -
) I-Gene +
tended O +
to O +
be O +
faster O +
and O +
greater O +
in O +
the O +
cell O +
lines O +
sensitive O +
to O +
MS-27 O -
- O -
275 O -
. O +

MS-27 O -
- O -
275 O +
administered O +
orally O +
strongly O +
inhibited O +
the O +
growth O +
in O +
seven O +
of O +
eight O +
tumor O +
lines O +
implanted O +
into O +
nude O +
mice O -
, O +
although O +
most O +
of O +
these O +
did O +
not O +
respond O +
to O +
5-fluorouracil O -
. O +

A O +
structurally O +
analogous O +
compound O +
to O +
MS-27 O -
- O -
275 O +
without O +
HDA B-Gene -
- O -
inhibiting O +
activity O +
showed O +
neither O +
the O +
biological O +
effects O +
in O +
cell O +
culture O +
nor O +
the O +
in O +
vivo O +
therapeutic O +
efficacy O -
. O +

These O +
results O +
suggest O +
that O +
MS-27 O -
- O -
275 O +
acts O +
as O +
an O +
antitumor O +
agent O +
through O +
HDA B-Gene +
inhibition O +
and O +
may O +
provide O +
a O +
novel O +
chemotherapeutic O +
strategy O +
for O +
cancers O +
insensitive O +
to O +
traditional O +
antitumor O +
agents O -
. O +

Mechanisms O +
leading O +
to O +
down O -
- O -
regulation O +
of O +
activated O +
microglia O +
and O +
astrocytes O +
are O +
poorly O +
understood O -
, O +
in O +
spite O +
of O +
the O +
potentially O +
detrimental O +
role O +
of O +
activated O +
glia O +
in O +
neurodegeneration O -
. O +

Prostaglandins O -
, O +
produced O +
both O +
by O +
neurons O +
and O +
glia O -
, O +
may O +
serve O +
as O +
mediators O +
of O +
glial O +
and O +
neuronal O +
functions O -
. O +

We O +
examined O +
the O +
influence O +
of O +
cyclopentenone O +
prostaglandins O +
and O +
their O +
precursors O +
on O +
activated O +
glia O -
. O +

As O +
models O +
of O +
glial O +
activation O -
, O +
production O +
of O +
inducible B-Gene +
nitric I-Gene -
- I-Gene -
oxide I-Gene +
synthase I-Gene +
( O -
iNOS B-Gene -
) O +
was O +
studied O +
in O +
lipopolysaccharide O -
- O -
stimulated O +
rat O +
microglia O -
, O +
a O +
murine O +
microglial O +
cell O +
line O +
BV-2 O -
, O +
and O +
IL-1beta B-Gene -
- O -
stimulated O +
rat O +
astrocytes O -
. O +

Cyclopentenone O +
prostaglandins O +
were O +
potent O +
inhibitors O +
of O +
iNOS B-Gene +
induction O +
and O +
were O +
more O +
effective O +
than O +
their O +
precursors O -
, O +
prostaglandins O +
E2 O +
and O +
D2 O -
. O +

15-Deoxy O -
- O -
Delta12,14-prostaglandin O +
J2 O +
( O -
15d O -
- O -
PGJ2 O -
) O +
was O +
the O +
most O +
potent O +
prostaglandin O +
among O +
those O +
tested O -
. O +

In O +
activated O +
microglia O -
, O +
15d O -
- O -
PGJ2 O +
suppressed O +
iNOS B-Gene +
promoter O +
activity O -
, O +
iNOS B-Gene +
mRNA O -
, O +
and O +
protein O +
levels O -
. O +

The O +
action O +
of O +
15d O -
- O -
PGJ2 O +
does O +
not O +
appear O +
to O +
involve O +
its O +
nuclear O +
receptor O +
peroxisome B-Gene +
proliferator I-Gene -
- I-Gene -
activated I-Gene +
receptor I-Gene +
gamma I-Gene +
( O -
PPARgamma B-Gene -
) O +
because O +
troglitazone O -
, O +
a O +
specific O +
ligand O +
of O +
PPARgamma B-Gene -
, O +
was O +
unable O +
to O +
inhibit O +
iNOS B-Gene +
induction O -
, O +
and O +
neither O +
troglitazone O +
nor O +
15d O -
- O -
PGJ2 O +
could O +
stimulate O +
the O +
activity O +
of O +
a O +
PPAR B-Gene -
- O -
dependent O +
promoter O +
in O +
the O +
absence O +
of O +
cotransfected O +
PPARgamma B-Gene -
. O +

15d O -
- O -
PGJ2 O +
did O +
not O +
block O +
nuclear O +
translocation O +
or O +
DNA O -
- O -
binding O +
activity O +
of O +
the O +
transcription O +
factor O +
NFkappaB B-Gene -
, O +
but O +
it O +
did O +
inhibit O +
the O +
activity O +
of O +
an O +
NFkappaB B-Gene +
reporter O +
construct O -
, O +
suggesting O +
that O +
the O +
mechanism O +
of O +
suppression O +
of O +
microglial O +
iNOS B-Gene +
by O +
15d O -
- O -
PGJ2 O +
may O +
involve O +
interference O +
with O +
NFkappaB B-Gene +
transcriptional O +
activity O +
in O +
the O +
nucleus O -
. O +

Thus O -
, O +
our O +
data O +
suggest O +
the O +
existence O +
of O +
a O +
novel O +
pathway O +
mediated O +
by O +
cyclopentenone O +
prostaglandins O -
, O +
which O +
may O +
represent O +
part O +
of O +
a O +
feedback O +
mechanism O +
leading O +
to O +
the O +
cessation O +
of O +
inflammatory O +
glial O +
responses O +
in O +
the O +
brain O -
. O +

This O +
ongoing O +
study O +
evaluates O +
the O +
efficacy O +
of O +
oral O +
9-nitrocamptothecin O +
( O -
9NC O -
) O -
, O +
or O +
RFS-2000 O -
, O +
in O +
the O +
treatment O +
of O +
advanced O +
pancreatic O +
cancer O -
. O +

Patients O +
received O +
9NC O +
orally O +
for O +
5 O +
days O -
/ O -
week O -
; O +
8 O +
weeks O +
of O +
therapy O +
is O +
required O +
to O +
achieve O +
minimum O +
effective O +
dose O -
. O +

Starting O +
dose O +
was O +
1.5 O +
mg O -
/ O -
m2 O -
/ O -
day O -
, O +
with O +
adjustments O +
made O +
as O +
necessary O -
. O +

Patients O +
were O +
analyzed O +
for O +
changes O +
in O +
tumor O +
size O +
by O +
CT O +
scan O -
, O +
changes O +
in O +
serum O +
CA O +
19 O -
- O -
9 O +
tumor O +
marker O +
levels O -
, O +
quality O +
of O +
life O -
, O +
and O +
survival O -
. O +

107 O +
consecutive O +
patients O +
with O +
advanced O +
adenocarcinoma O +
of O +
the O +
pancreas O +
were O +
enrolled O +
before O +
November O +
3 O -
, O +
1997 O -
. O +

Of O +
this O +
group O -
, O +
47 O +
patients O +
did O +
not O +
receive O +
the O +
minimum O +
2 O +
courses O +
of O +
treatment O +
necessary O +
to O +
induce O +
response O -
, O +
leaving O +
60 O +
evaluable O +
patients O -
. O +

Primary O +
dose O -
- O -
limiting O +
toxicities O +
were O +
myelosuppression O +
and O +
interstitial O +
cystitis O -
. O +

No O +
deaths O +
were O +
attributed O +
to O +
9NC O -
. O +

Median O +
survival O +
was O +
6.5 O +
months O +
for O +
the O +
107 O +
total O +
patients O +
and O +
8.7 O +
months O +
for O +
the O +
60 O +
evaluable O +
patients O -
, O +
with O +
one O +
patient O +
surviving O +
at O +
44 O -
+ O +
months O -
. O +

Of O +
the O +
60 O +
evaluable O +
patients O -
, O +
31.7 O -
% O +
were O +
responders O +
( O -
median O +
survival O +
18.6 O +
months O -
; O +
range O +
6.5 O -
- O -
44.7 O -
+ O +
months O -
) O -
, O +
31.7 O -
% O +
were O +
stable O +
( O -
median O +
survival O +
9.7 O +
months O -
) O -
, O +
and O +
36.6 O -
% O +
were O +
non O -
- O -
responders O +
( O -
median O +
survival O +
6.8 O +
months O -
) O -
. O +

Fifty O -
- O -
seven O +
previously O +
untreated O +
patients O +
had O +
a O +
median O +
survival O +
of O +
7.3 O +
months O +
compared O +
to O +
4.7 O +
months O +
for O +
the O +
50 O +
previously O +
treated O +
patients O -
. O +

Thirty O -
- O -
three O +
patients O +
who O +
failed O +
gemcitabine O +
therapy O +
prior O +
to O +
9NC O +
treatment O +
had O +
a O +
median O +
survival O +
of O +
4.7 O +
months O -
. O +

9NC O +
is O +
safe O +
and O +
efficacious O +
as O +
first O -
- O -
line O +
therapy O +
for O +
the O +
treatment O +
of O +
advanced O +
pancreatic O +
cancer O -
. O +

It O +
also O +
shows O +
some O +
modest O +
success O +
as O +
second O -
- O -
line O +
therapy O +
in O +
treating O +
gemcitabine O +
failures O -
. O +

An O +
efficient O +
solid O -
- O -
phase O +
synthesis O +
of O +
benzisothiazolone-1,1-dioxide O -
- O -
based O +
serine B-Gene +
protease I-Gene +
inhibitors O +
involving O +
alkylation O +
of O +
carboxylic O +
acids O +
with O +
N- O -
( O -
bromomethyl O -
) O -
benzisothiazolone-1,1-dioxide O +
has O +
been O +
developed O -
. O +

An O +
example O +
using O +
this O +
procedure O +
for O +
preparation O +
of O +
a O +
library O +
of O +
human O +
mast B-Gene +
cell I-Gene +
tryptase I-Gene +
inhibitors O +
is O +
described O -
. O +

We O +
compared O +
effects O +
of O +
alpha O -
- O -
galactosylceramide O +
( O -
alpha O -
- O -
GalCer O -
) O +
and O +
its O +
3alpha- O +
or O +
3beta O -
- O -
galactosylated O +
derivatives O +
on O +
the O +
proliferation O +
of O +
murine O +
spleen O +
cells O -
. O +

The O +
3alpha O -
- O -
galactosylated O +
alpha O -
- O -
GalCer O +
showed O +
stronger O +
proliferative O +
response O +
than O +
the O +
parental O +
alpha O -
- O -
GalCer O -
, O +
but O +
the O +
3beta O -
- O -
galactosylated O +
alpha O -
- O -
GalCer O +
possessed O +
weaker O +
activity O +
than O +
the O +
alpha O -
- O -
GalCer O -
. O +

In O +
addition O -
, O +
alpha O -
- O -
Gal-3-Cer O +
did O +
not O +
show O +
immunostimulatory O +
activity O -
. O +

We O +
previously O +
reported O +
that O +
representative O +
o~-galactosylceramide O +
( O -
oc O -
- O -
GalCer O -
, O +
galactose O +
bound O +
to O +
ceramide O +
in O +
an O +
c~-configuration O -
) O -
, O +
named O +
KRN7000 O +
( O -
1 O -
) O +
( O -
Fig. O +
1 O -
) O -
, O +
has O +
strong O +
immunostimulatory O +
and O +
antitumor O +
activity O -
. O +

1,2 O +
KRN7000 O +
has O +
also O +
drawn O +
researchers O -
' O +
attention O +
as O +
a O +
ligand O +
for O +
mouse O +
and O +
human O +
natural O +
killer O +
T O +
( O -
NKT O -
) O +
cells.3 O -
- O -
8 O +
Our O +
structure O -
- O -
activity O +
relationship O +
study O +
using O +
ct O -
- O -
GalCers O +
with O +
different O +
ceramide O +
moieties O +
indicated O +
that O +
the O +
3 O +
hydroxyl O +
group O +
( O -
3-OH O -
) O +
in O +
the O +
ceramide O +
plays O +
an O +
essential O +
role O +
in O +
the O +
manifestation O +
of O +
immunostimulatory O +
activity O +
induced O +
by O +
0c O -
- O -
GalCers O -
, O +
demonstrating O +
that O +
ot O -
- O -
GalCer O +
with O +
only O +
the O +
3-OH O +
is O +
the O +
minimal O +
structure O +
to O +
stimulate O +
the O +
immune O +
system O +
through O +
the O +
activation O +
of O +
NKT O +
cells O -
. O +

1,3 O +
HO O +
.OH O +
O O +
~ O -
/ O -
( O -
CH2 O -
) O -
24CH3 O +
HO O +
.OH O +
? O +

H O +
OH O +
HO O +
QI~,~ O +
HN O +
. O +

HO6 O +
- O +
v~ O -
( O -
CH2 O -
) O +
I3CH3 O +
v~ O -
( O -
cH2 O -
) O +

I3cH3 O +
OH O +
OH O +
I O +
2 O +
Figure O +
1 O +
Structures O +
of O +
KRN7000 O +
( O -
1 O -
) O +
and O +
AGL-506 O +
( O -
2 O -
) O +
Other O +
researchers O +
also O +
attempted O +
to O +
isolate O +
c~-glycosylceramides O +
from O +
marine O +
sponges O -
, O +
and O +
they O +
succeeded O +
in O +
the O +
isolation O +
of O +
various O +
types O +
of O +
c~-GaICers O -
, O +
monoglycosylated O +
oc O -
- O -
GalCers O -
, O +
and O +
diglycosylated O +
~- O +
0960 O -
- O -
894X O -
/ O -
99 O -
/ O -
$ O +
- O +
see O +
front O +
matter O +
1999 O +
Elsevier O +
Science O +
Ltd. O +
All O +
rights O +
reserved O -
. O +

PII O -
: O +
S0960 O -
- O -
894X O -
( O -
99 O -
) O -
00054 O -
- O -
2 O +
698 O +
T. O +
Sakai O +
et O +
al. O +
I O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
697 O -
- O -
702 O +
GalCers,7 O -
- O -
9 O +
and O +
it O +
has O +
been O +
reported O +
that O +
several O +
mono- O +
or O +
diglycosylated O +
~-GalCers O +
as O +
well O +
as O +
cGalCers O +
possess O +
immunostimulatory O +
effects.12 O -
- O -
14 O +
In O +
these O +
studies O +
using O +
mono- O +
or O +
diglycosylated O +
t~-GalCers O -
, O +
it O +
was O +
demonstrated O +
that O +
the O +
3"-glycosylated O +
~-GalCer O +
have O +
much O +
less O +
immunostimulatory O +
activity O +
than O +
the O +
parental O +
ct O -
- O -
GalCer.13,14 O +
These O +
findings O +
arose O +
a O +
question O +
as O +
to O +
whether O +
the O +
3-glycosylated O +
0~-GalCer O +
also O +
has O +
weaker O +
immunostimulatory O +
activity O +
than O +
the O +
parental O +
ct O -
- O -
GalCer O -
. O +

In O +
order O +
to O +
address O +
this O +
question O -
, O +
we O +
synthesized O +
two O +
kinds O +
of O +
3-galactosylated O +
ct O -
- O -
GalCers O -
, O +
and O +
compared O +
effects O +
among O +
these O +
two O +
compounds O +
and O +
AGL-506 O +
( O -
2 O -
) O +
l O +
( O -
Fig. O +
1 O -
) O -
, O +
the O +
parental O +
ot O -
- O -
GalCer O -
, O +
on O +
the O +
proliferation O +
of O +
murine O +
spleen O +
cells O -
. O +

Chemistry O +
The O +
synthetic O +
procedures O +
of O +
AGL-529 O +
( O -
3 O -
[ O -
3-galactosylated O +
t~-GalCer O -
, O +
3 O -
) O +
and O +
AGL-533 O +
( O -
3a O -
- O -
galactosylated O +
o~- O +
GalCer O -
, O +
4 O -
) O +
are O +
shown O +
in O +
Scheme O +
1 O -
. O +

The O +
synthesis O +
of O +
ceramide O +
( O -
5 O -
) O +
was O +
reported O +
previously.1 O +
The O +
ceramide O +
( O -
5 O -
) O +
was O +
glycosylated O +
with O +
3 O +
eq. O +
galactosyl O +
donor O +
( O -
6 O -
) O +
to O +
give O +
7 O +
and O +
8 O -
. O +

The O +
mixture O +
of O +
7 O +
and O +
8 O +
were O +
directly O +
hydrogenated O +
and O +
subsequent O +
acetylated O +
to O +
give O +
9 O +
and O +
10 O -
. O +

Deacetylation O +
of O +
9 O +
and O +
10 O +
gave O +
AGL-529 O +
( O -
3 O -
) O -
j5 O +
and O +
AGL-533 O +
( O -
4 O -
) O -
,16 O +
respectively O -
. O +

Scheme O +
I O +
OAc O +
OAc O +
BnO O +
OBn O +
OAc O +
BnO O +
/OBn O +
~ O +
- O +
O O +
- O +
L~,~ O -
.. O -
_\ O +
BnO O +
_ O -
OBn O +
: O +
u O +
I O +
( O +
O. O +
/ O -
/ O -
.. O +

L O -
.. O +

_ O -
\~O O +
" O -
" O -
~ O -
( O -
CH2 O -
) O -
21CH3 O +
~'~' O -
( O -
CH2 O -
) O -
2,CH3 O +
BnO~\~F O +
~O O +
" O -
~ O +
" O -
( O -
CH2 O -
) O -
21CH3 O +
BnO~ O -
, O -
.. O +

~t~ O +
HIll O +
Ha O +
60Bn O +
BnO O -
,.~ O -
l,.w O -
,,~ O -
l,~ O +
Ha O +

8n~ O -
/ O +
- O +
7 O +
Bnbl O +
.. O -
= O +
O O +
~ O -
( O -
CH2 O -
) O -
14CH3 O +
HO~ O -
( O -
CH2 O -
) O -
12cH3a O +
O O +
V'~,~v O -
/ O -
( O -
CH2 O -
) O -
'2CH3 O +
+ O +
IO O +
o. O +
5 O +
7 O +
O"~ O +
OBn O +
( O -
) O -
~ O +
8 O +
oB O -
~ O -
OBOn O +
O O -
~ O -
H O +
BnO O +
Bn O +
4 O -
' O +
o O +
Bn O +
BnO O +
AcO O +
/OAc O +
0 O +
? O +

Acc O +
H O +
CH O +
AcO O +
. O -
/ O -
OAc O +
O O +
b. O +

L O -
- O -
o O +
L\ O +
o O +
H. O -
_ O -
' O +
9 O +
X O +
OAc O +
o O +
/~ O +
.OAc O +

10 O +
AcO O +
OAc O +
Ac O -
~ O -
J O +
uAc O +
OH O +
HO O +
.OH O +
_ O -
-- O +
x~ O +
HO~--~ O +
O'~""' O -
( O -
C O +
H2 O -
) O -
210 O +
H3 O +
HO O -
/ O +
HN O +
O~ O -
( O -
CH2 O -
) O -
12CH3 O +
AG O +
L-529 O +
( O -
3 O -
) O +
Oo-~H O +
Scheme O +
1 O -
; O +
Reagents O -
; O +
( O -
a O -
) O +
6 O -
( O -
3eq O -
) O -
, O +
SnCI2 O -
, O +
AgCIO4 O -
, O +
MS4A O +
/ O +
THF O -
, O +
-10 O +
~C- O +
r.t O -
. O -
, O +
2hr O -
, O +
65 O -
% O -
; O +
( O -
b O -
) O +
H2 O -
, O +
Pd O -
- O -
black O +
/ O +
THF O -
, O +
r.t O -
. O -
, O +
24hr O -
, O +
95 O -
% O -
; O +
( O -
c O -
) O -
Ac2O O -
, O +
Et3N O +
/ O +
CH2CI2 O -
, O +
r.t O -
. O -
, O +
5hr O -
, O +
9 O +
( O -
15 O -
% O -
) O -
, O +
10 O +
( O -
33 O -
% O -
) O -
; O +
( O -
d O -
) O +
NaOMe O -
, O +
MeOH O -
, O +
lhr O -
, O +
90 O -
% O -
. O +

b O -
, O -
c O +
OH O +
HO O +
.OH O +
HO O +
~.~ O +
OHN'~ O -
( O -
CH2 O -
) O -
21CH3 O +
d O +
HO O +
/ O +
- O +
Ov O -
/ O -
~ O -
( O -
cH2 O -
) O -
14cH3 O +
AGL-533 O +
( O -
4 O -
) O +
O O -
~ O -
H O +
T. O +
Sakai O +
et O +
al. O -
/ O -
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
697 O -
- O -
702 O +
699 O +
The O +
synthetic O +
procedures O +
of O +
~-Gal O -
- O -
l O -
- O -
Cer O +
( O -
AGL-517 O -
, O +
16 O -
) O +
and O +
~-Gal-3-Cer O +
( O -
AGL-553 O -
, O +
17 O -
) O +
are O +
shown O +
in O +
Scheme O +
2 O -
. O +

Briefly O -
, O +
the O +
synthesis O +
of O +
ceramide O +
11 O +
was O +
reported O +
previously.13 O +
The O +
ceramide O +
11 O +
was O +
directly O +
glycosylated O +
with O +
1.2 O +
eq O +
( O -
6 O -
) O +
to O +
give O +
12 O +
and O +
13 O -
. O +

The O +
mixture O +
of O +
12 O +
and O +
13 O +
were O +
directly O +
acetylated O +
to O +
give O +
14 O +
and O +
15 O -
. O +

Debenzylation O +
and O +
subsequent O +
deacetylation O +
of O +
14 O +
and O +
15 O +
gave O +
AGL-517 O +
( O -
16 O -
) O -
1 O +
and O +
AGL- O +
553 O +
( O -
17 O -
) O -
,17 O +
respectively O -
. O +

Scheme O +
2 O +

O O +
BnO~-~Bn O +
Bn O -
? O +

( O -
... O -
OBn O +
O O +
= O -
O O +
HN"J~ O -
( O -
cH2 O -
) O -
'2OH3 O +
B O +
nO O +
" O -
31~"~"~"~ O +
F O +
BnO~ O +
HN-~ O -
( O -
OH2 O -
) O -
I2CH3 O +
HN"J~ O -
( O -
oH2 O -
) O -
'2OH3 O +
--'- O +
~ O -
_ O +
.:- O +
+ O +
HOv~ O -
( O -
cH2 O -
) O -
14cH3 O +
HO~ O -
( O -
CH2 O -
) O -
14CH3 O +
60Bn O +
BnOo O +
" O -
~"~ O -
( O -
CH2 O -
) O -
14CH3 O +
OH O +
a O +
O O +
/~'IOBn O +
13 O +
11 O +
OH O +
( O -
) O -
~ O +
12 O +
BnOn~,,y O +
OBn O +
BnO O +
_ O -
OBn O +
O O +
BnO O +
HN O -
- O -
JL-. O -
( O -
CH2 O -
) O -
,2CH3 O +
HN"~ O -
( O -
CH2 O -
) O -
mCH3 O +
b O +
" O +
~ O -
( O -
cH2 O -
) O -
'4CH3 O +
+ O +
AcOx"~"~ O -
( O -
CH2 O -
) O -
'4CH30 O +
OAc O +
/~ O +
.OBn O +

O O +
15 O +
14 O +
BnO O -
) O -
~'q'~ O +
l O +
o O +
c O -
, O +
d O +
HN O +
" O -
~ O -
( O -
CH2 O -
) O -
12CH3 O +
HO O +
~OH O +
0 O +
HO~ O +
HN O +
~"' O -
( O -
CH2 O -
) O -
12CH3 O +
HO~ O -
( O -
CH2 O -
) O -
14CH3 O +
HO2 O +
~ O +
o O -
/ O -
~OH O +
O'~oH O -
( O -
CH2 O -
) O -
14CH3 O +
HOo O -
~ O -
OH O +
AGL-517 O +
( O -
16 O -
) O +
AGL-553 O +
( O -
17 O -
) O +
Scheme O +
2 O -
; O +
Reagents O -
; O +
( O -
a O -
) O +
6 O -
( O -
1.2eq O -
) O -
, O +
SnCI2 O -
, O +
AgClO4 O -
, O +
MS4A O +
/ O +
THF O -
, O +
-10 O +
~C- O +
r.t O -
. O -
, O +
2hr O -
, O +
65 O -
% O -
; O +
( O -
b O -
) O +
Ac20 O -
, O +
Et3N O +
/ O +
CH2Cl2 O -
, O +
r.t O -
. O -
, O +
5hr O -
, O +
14 O +
( O -
48 O -
% O -
) O -
, O +
15 O +
( O -
26 O -
% O -
) O -
; O +
( O -
c O -
) O +
H2 O -
, O +
Pd O -
- O -
black O +
/ O +
THF O -
, O +
r.t O -
. O -
, O +
24hr O -
, O +
95 O -
% O -
; O +
( O -
d O -
) O +
NaOMe O -
, O +
MeOH O -
, O +
lhr O -
, O +
90 O -
% O -
. O +

Results O +
and O +
Discussion O +
We O +
compared O +
the O +
effects O +
of O +
AGL-506 O +
( O -
tx O -
- O -
GalCer O -
, O +
2 O -
) O -
, O +
AGL-529 O +
( O -
313-galactosylated O +
~-GalCer O -
, O +
3 O -
) O -
, O +
and O +
AGL-533 O +
( O -
3c~-galactosylated O +
a O -
- O -
GalCer O -
, O +
4 O -
) O +
on O +
the O +
proliferation O +
of O +
mouse O +
spleen O +
cells O -
. O +

As O +
shown O +
in O +
Table O +
l O -
, O +
AGL-506 O +
stimulated O +
the O +
proliferation O +
of O +
spleen O +
cells O +
in O +
a O +
concentration O -
- O -
dependent O +
fashion O -
, O +
and O +
significant O +
stimulatory O +
activity O +
was O +
observed O +
from O +
the O +
concentration O +
of O +
1 O +
ng O -
/ O -
ml O -
. O +

Although O +
AGL-529 O +
showed O +
significant O +
enhancement O +
of O +
the O +
proliferative O +
effect O +
from O +
the O +
concentration O +
of O +
10 O +
ng O -
/ O -
ml O -
, O +
its O +
potency O +
was O +
weaker O +
than O +
that O +
of O +
AGL-506 O -
, O +
the O +
parental O +
o~-GalCer O -
. O +

By O +
contrast O -
, O +
AGL-533 O +
significantly O +
stimulated O +
the O +
proliferation O +
of O +
spleen O +
cells O +
from O +
the O +
concentration O +
of O +
1 O +
ng O -
/ O -
ml O -
, O +
and O +
it O +
appeared O +
that O +
AGL-533 O +
has O +
stronger O +
irnmunostimulatory O +
activity O +
than O +
AGL-506 O -
. O +

It O +
is O +
quite O +
interesting O +
that O +
the O +
configuration O +
of O +
the O +
glycosidic O +
linkage O +
between O +
galactose O +
700 O +
T. O +
Sakai O +
et O +
al. O +
/Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
697 O -
- O -
702 O +
and O +
ceramide O +
in O +
the O +
3-position O +
greatly O +
affects O +
the O +
ct O -
- O -
GalCer O +
induced O +
immunostimulatory O +
effects O -
, O +
i.e. O -
, O +
linkage O +
enhances O +
the O +
immunostimulatory O +
effect O +
of O +
ct O -
- O -
GalCer O -
, O +
but O +
the O +
] O -
3-linkage O +
reduces O +
the O +
activity O -
. O +

Table O +
1 O -
. O +

Effects O +
of O +
AGL-506 O +
( O -
2 O -
) O -
, O +
AGL-529 O +
( O -
3 O -
) O +
and O +
AGL-533 O +
( O -
4 O -
) O +
on O +
the O +
proliferation O +
of O +
murine O +
spleen O +
cells O -
. O +

the O +
( O -
x- O +
3H O -
- O -
TdR O +
incorpolation O +
( O -
cpm O -
) O +
Sample O +
1 O +
n~ O -
/ O -
ml O +
10 O +
ng O -
/ O -
ml O +
100 O +
ng O -
/ O -
ml O +
Vehicle O +
6962 O +
+ O -
_ O +
758 O +
7858 O +
_ O -
+ O +
1065 O +
6280 O +
_ O -
+ O +
823 O +
AGL-506 O +
( O -
2 O -
) O +
9454 O +
_ O -
_ O -
_ O +
844 O -
* O +
20283 O +
_ O -
+ O +
3420 O -
* O +
45966 O +
_ O -
+ O +
2196 O -
" O +
AGL-529 O +
( O -
3 O -
) O +
7892 O +
_ O -
+ O +
1320 O +
13195 O +
_ O -
+ O +
1818 O -
" O +
45036 O +
+ O -
_ O +
231 O -
" O +
AGL-533 O +
( O -
4 O -
) O +
16138 O +
_ O +
944 O -
* O +
34892 O +
+ O +
1259 O -
" O +
44867 O +
_ O -
+ O +
4529 O -
* O +
2.5 O +
x O +
105 O +
cells O -
/ O -
100Bl O -
/ O -
well O +
of O +
spleen O +
cells O +
from O +
BALB O -
/ O -
c O +
mice O +
suspended O +
in O +
10 O +
% O +
FCS O +
RPMI O +
1640 O +
medium O +
were O +
plated O +
on O +
a O +
96-well O +
plate O -
. O +

At O +
the O +
same O +
time O -
, O +
various O +
concentrations O +
of O +
samples O +
( O -
10 O +
Bl O -
/ O -
well O -
) O +
were O +
added O +
into O +
each O +
well O -
, O +
and O +
the O +
cell O +
suspension O +
was O +
cultured O +
at O +
37 O +
, O +
5 O -
% O +
CO2 O +
for O +
2 O +
days O -
. O +

Then O +
0.5 O +
BCi O -
/ O -
well O +
of O +
tritium O -
- O -
thymidine O +
( O -
3H O -
- O -
TdR O -
) O +
was O +
added O +
into O +
each O +
well O -
, O +
and O +
16 O +
hours O +
later O -
, O +
the O +
3H O -
- O -
TdR O +
uptake O +
into O +
the O +
cells O +
was O +
measured O +
by O +
a O +
liquid O +
scintillation O +
counter O -
. O +

Each O +
value O +
shows O +
the O +
mean O +
+ O -
_ O +
S.D. O +
* O -
; O +
p O +
< O +
0.05 O +
( O -
vs. O +
vehicle O +
treated O +
group O -
) O -
. O +

Because O +
3tx O -
- O -
galactosylated O +
~-GalCer O +
( O -
AGL-533 O -
) O +
showed O +
stronger O +
immunostimulatory O +
activity O +
than O +
the O +
parental O +
~-GalCer O +
( O -
AGL-506 O -
) O +
( O -
Table O +
1 O -
) O -
, O +
the O +
result O +
arose O +
a O +
question O +
as O +
to O +
whether O +
c~-galactosyl-3-ceramide O +
( O -
~- O +
Gal-3-Cer O -
, O +
galactose O +
bound O +
to O +
ceramide O +
in O +
the O +
3-position O -
) O +
can O +
stimulate O +
the O +
proliferation O +
of O +
spleen O +
cells O +
as O +
ct- O +
Gal O -
- O -
l O -
- O -
Cers O +
such O +
as O +
KRN7000 O +
and O +
AGL-506 O +
can O +
do O -
. O +

To O +
address O +
this O +
question O -
, O +
we O +
synthesized O +
two O +
kinds O +
of O +
c~-GalCers O +
with O +
only O +
the O +
3-OH O -
, O +
ct O -
- O -
Gal O -
- O -
l O -
- O -
Cer O +
( O -
AGL-517 O -
, O +
16 O -
) O +
and O +
ct O -
- O -
Gal-3-Cer O +
( O -
AGL-553 O -
, O +
17 O -
) O -
, O +
by O +
the O +
methods O +
shown O +
in O +
Scheme O +
2 O -
. O +

Table O +
2 O -
, O +
Effects O +
of O +
AGL-517 O +
( O -
16 O -
) O +
and O +
AGL-553 O +
( O -
17 O -
) O +
on O +
murine O +
spleen O +
cells O -
. O +

3H O -
- O -
TdR O +
incorpolation O +
( O -
cpm O -
) O +
Sample O +
1 O +
n~ O -
/ O -
ml O +
l0 O +
ng O -
/ O -
ml O +
100 O +
ng O -
/ O -
ml O +
Vehicle O +
6962 O +
+ O -
_ O +
758 O +
7858 O +
_ O -
_ O +
1065 O +
6280 O +
_ O -
+ O +
823 O +
AGL-517 O +
( O -
16 O -
) O +
9018 O +
_ O -
+ O +
541 O -
" O +
44395 O +
+ O +
2157 O -
" O +
44395 O +
_ O -
+ O +
2157 O -
" O +
AGL-553 O +
( O -
17 O -
) O +
7722 O +
_ O +
230 O +
7412 O +
_ O -
+ O +
1783 O +
6141 O +
_ O -
_ O +
1040 O +
The O +
speen O +
cell O +
proliferation O +
assay O +
was O +
done O +
by O +
the O +
same O +
method O +
shown O +
in O +
Table O +
1 O -
. O +

Each O +
value O +
shows O +
the O +
mean O +
+ O +
S.D. O +
* O -
; O +
p O +
< O +
0.05 O +
( O -
vs. O +
vehicle O +
treated O +
group O -
) O -
. O +

We O +
compared O +
the O +
effects O +
of O +
ct O -
- O -
Gal O -
- O -
l O -
- O -
Cer O -
, O +
AGL-517 O +
( O -
16 O -
) O -
, O +
and O +
ct O -
- O -
Gal-3-Cer O -
, O +
AGL-553 O +
( O -
17 O -
) O -
, O +
on O +
the O +
proliferation O +
of O +
mouse O +
spleen O +
cells O -
. O +

As O +
shown O +
in O +
Table O +
2 O -
, O +
AGL-517 O +
stimulated O +
the O +
proliferation O +
of O +
spleen O +
cells O +
in O +
a O +
concentration O -
- O -
dependent O +
fashion O -
, O +
and O +
significant O +
stimulatory O +
activity O +
was O +
observed O +
from O +
the O +
concentration O +
of O +
1 O +
ng O -
/ O -
ml O -
. O +

By O +
contrast O -
, O +
AGL-553 O +
did O +
not O +
stimulate O +
the O +
proliferation O +
of O +
spleen O +
cells O +
even O +
at O +
the O +
highest O +
concentration O +
of O +
100 O +
ng O -
/ O -
ml O -
. O +

Although O +
several O +
research O +
groups O +
have O +
published O +
the O +
reports O +
on O +
various O +
types O +
of O +
T. O +
Sakai O +
et O +
al. O +
/ O +
Bioorg O -
. O +

Med O -
. O +

Chem O -
. O +

Lett O -
. O +

9 O +
( O -
1999 O -
) O +
697 O -
- O -
702 O +
701 O +
cz O -
- O -
GalCers O +
and O +
their O +
derivatives O +
which O +
were O +
isolated O +
from O +
marine O +
sponges9 O -
- O -
13,18,19 O +
or O +
were O +
totally O +
synthesized O -
, O -
l,14,20 O +
all O +
compounds O +
are O +
cz O -
- O -
Gal O -
- O -
l O -
- O -
Cers O +
and O +
their O +
derivatives O -
. O +

Since O +
there O +
is O +
no O +
report O +
on O +
cx O -
- O -
Gal-3- O +
Cer O +
as O +
far O +
as O +
we O +
know O -
, O +
this O +
is O +
the O +
first O +
finding O +
that O +
oc O -
- O -
Gal-3-Cer O +
( O -
at O +
least O +
100 O +
ng O -
/ O -
ml O -
) O +
has O +
no O +
immunostimulatory O +
effect O -
. O +

The O +
results O +
shown O +
in O +
Table O +
1 O +
and O +
2 O +
demonstrate O +
that O +
{ O -
x O -
- O -
binding O +
of O +
galactose O +
not O +
in O +
the O +
3-position O +
but O +
in O +
the O +
1-position O +
is O +
essential O +
for O +
the O +
manifestation O +
of O +
immunostimulatory O +
activity O +
by O +
cz O -
- O -
GalCers O -
, O +
and O +
that O +
the O +
3- O +
position O +
is O +
a O +
preferable O +
site O +
to O +
enhance O +
the O +
activity O +
by O +
the O +
glycosylation O -
. O +

It O +
was O +
demonstrated O +
that O +
CDld O -
- O -
transfectant O +
cells O +
pretreated O +
with O +
KRN7000 O +
activate O +
murine O +
Vczl4 O +
positive O +
NKT O +
cell O +
clones O +
and O +
human O +
Vo~24 O +
positive O +
NKT O +
cell O +
clones O -
, O +
suggesting O +
that O +
CDld O +
molecule O +
plays O +
an O +
essential O +
role O +
in O +
the O +
activation O +
of O +
these O +
NKT O +
cells.4 O -
- O -
8 O +
In O +
addition O -
, O +
it O +
was O +
recently O +
proven O +
that O +
radiolabeled O +
KRN700021 O +
and O +
biotinylated O +
o~-GalCers22 O +
actualy O +
bind O +
to O +
mouse O +
CDI O +
and O +
human O +
CDld O +
molecules O -
. O +

These O +
results O +
suggest O +
that O +
the O +
complex O +
of O +
cz O -
- O -
GalCer O +
and O +
CDld B-Gene +
molecule O +
is O +
recognized O +
by O +
Vc~14 B-Gene +
or O +
Vc~24 B-Gene +
T I-Gene +
cell I-Gene +
receptor I-Gene +
on O +
NKT O +
cells O -
. O +

Our O +
computer O -
- O -
aided O +
molecular O +
modeling O +
demonstrated O +
that O +
active O +
compounds O +
such O +
as O +
R O -
- O -
GalCer O +
and O +
~-glucosylceramide O +
( O -
o~-GlcCer O -
) O +
share O +
active O +
conformations O +
which O +
are O +
not O +
accessible O +
to O +
[ O -
3-GalCer O +
and O +
~-GlcCer.23 O +
Furthermore O -
, O +
the O +
crystallographic O +
structure O +
of O +
mouse O +
CD1 B-Gene +
was O +
recently O +
solved O +
by O +
Zeng O +
et O +
al.24 O +
Taken O +
these O +
findings O +
together O -
, O +
it O +
seems O +
to O +
be O +
possible O +
to O +
construct O +
the O +
binding O +
model O +
of O +
CDld B-Gene -
/ O -
o~-GalCer O +
complex O +
using O +
these O +
data O -
. O +

It O +
is O +
considered O +
that O +
the O +
present O +
study O +
using O +
AGL-506 O +
( O -
2 O -
) O -
, O +
AGL-529 O +
( O -
3 O -
) O -
, O +
AGL- O +
533 O +
( O -
4 O -
) O -
, O +
AGL-517 O +
( O -
16 O -
) O +
and O +
AGL-553 O +
( O -
17 O -
) O +
will O +
contribute O +
to O +
the O +
modeling O +
study O +
of O +
CDld B-Gene -
/ O -
cz O -
- O -
GalCer O +
complex O +
and O +
will O +
be O +
useful O +
to O +
investigate O +
the O +
interaction O +
mechanism O +
among O +
CDId B-Gene +
molecules I-Gene -
, O +
R O -
- O -
GalCer O +
and O +
T B-Gene +
cell I-Gene +
receptor I-Gene -
. O +

Zonal O +
elution O +
and O +
high O -
- O -
performance O +
affinity O +
chromatography O +
were O +
used O +
to O +
examine O +
interactions O +
of O +
the O +
drugs O +
digitoxin O +
and O +
acetyldigitoxin O +
with O +
the O +
protein O +
human B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
HSA B-Gene -
) O -
. O +

This O +
was O +
done O +
by O +
injecting O +
small O +
amounts O +
of O +
digitoxin O +
and O +
acetyldigitoxin O +
onto O +
an O +
immobilized O +
HSA B-Gene +
column O +
in O +
the O +
presence O +
of O +
mobile O +
phases O +
that O +
contained O +
various O +
concentrations O +
of O +
digitoxin O -
, O +
acetyldigitoxin O +
or O +
other O +
solutes O +
as O +
competing O +
agents O -
. O +

A O +
fixed O +
concentration O +
of O +
beta O -
- O -
cyclodextrin O +
was O +
also O +
present O +
in O +
the O +
mobile O +
phase O +
as O +
a O +
solubilising O +
agent O -
. O +

It O +
was O +
found O +
that O +
digitoxin O +
and O +
acetyldigitoxin O +
each O +
had O +
strong O +
interactions O +
at O +
a O +
single O +
common O +
binding O +
site O +
on O +
HSA B-Gene -
, O +
but O +
with O +
slightly O +
different O +
equilibrium O +
constants O +
for O +
this O +
region O -
. O +

Neither O +
compound O +
showed O +
any O +
competition O +
with O +
warfarin O +
or O +
L O -
- O -
tryptophan O -
, O +
which O +
were O +
used O +
as O +
probes O +
for O +
binding O +
at O +
the O +
warfarin O -
- O -
azapropazone O +
and O +
indole O -
- O -
benzodiazepine O +
sites O +
of O +
HSA B-Gene -
. O +

These O +
results O +
confirmed O +
the O +
presence O +
of O +
a O +
separate O +
binding O +
region O +
on O +
HSA B-Gene +
for O +
digitoxin O -
- O -
related O +
compounds O -
. O +

Digitoxin O +
is O +
a O +
common O +
cardiovascular O +
drug O +
used O +
for O +
the O +
treatment O +
of O +
individuals O +
with O +
congestive O +
heart O +
failure O +
or O +
atrial O +
fibrillation O +
[ O -
1 O -
] O +
. O +

As O +
shown O +
in O +
Fig. O +
1 O +
, O +
the O +
structure O +
of O +
digitoxin O +
consists O +
of O +
a O +
steroid O +
backbone O +
with O +
a O +
lactone O +
ring O +
at O +
the O +
C-17 O +
position O +
and O +
a O +
linear O +
chain O +
of O +
three O +
digitoxose O +
sugar O +
residues O +
attached O +
at O +
the O +
C-3 O +
carbon O +
[ O -
2 O -
] O +
. O +

A O +
closely O +
related O +
molecule O +
is O +
acetyldigitoxin O +
( O -
or O +
digitoxin O +
monoacetate O -
) O -
, O +
in O +
which O +
an O +
acetyl O +
group O +
replaces O +
one O +
of O +
the O +
hydroxyl O +
groups O +
on O +
the O +
digitoxose O +
residues O -
. O +

Acetyldigitoxin O +
is O +
also O +
used O +
in O +
pharmaceutical O +
preparations O +
as O +
a O +
cardiovascular O +
drug O +
[ O -
3 O -
] O +
. O +

Like O +
many O +
other O +
drugs O -
, O +
both O +
digitoxin O +
and O +
acetyldigitoxin O +
are O +
known O +
to O +
interact O +
with O +
carrier B-Gene +
proteins I-Gene +
in O +
blood O +
[ O -
4–6 O -
] O +
. O +

Such O +
binding O +
can O +
play O +
an O +
important O +
role O +
in O +
controlling O +
the O +
distribution O -
, O +
metabolism O +
and O +
excretion O +
of O +
drugs O +
within O +
the O +
body O +
[ O -
7 O -
] O +
. O +

One O +
important O +
carrier B-Gene +
protein I-Gene +
is O +
human B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
HSA B-Gene -
) I-Gene -
. I-Gene +

HSA B-Gene +
is O +
the O +
most O +
abundant O +
protein B-Gene +
in O +
human O +
blood O +
plasma O +
and O +
is O +
known O +
to O +
bind O +
to O +
a O +
wide O +
range O +
of O +
exogenous O +
and O +
endogenous O +
compounds O -
, O +
including O +
bilirubin O -
, O +
fatty O +
acids O -
, O +
warfarin O -
, O +
tryptophan O +
and O +
benzodiazepines O -
, O +
among O +
others O +
[ O -
8 O -
] O +
. O +

Some O +
previous O +
studies O +
have O +
reported O +
that O +
both O +
digitoxin O +
and O +
acetyldigitoxin O +
bind O +
to O +
HSA B-Gene +
[ O -
4,6,9 O -
] O +
. O +

This O +
was O +
noted O +
in O +
solution O -
- O -
phase O +
radiolabel O +
studies O -
, O +
in O +
which O +
acetyldigitoxin O +
was O +
found O +
to O +
displace O +
digitoxin O +
from O +
HSA B-Gene -
. O +

In O +
the O +
same O +
work O -
, O +
it O +
was O +
found O +
that O +
digitoxin O +
was O +
not O +
displaced O +
from O +
HSA B-Gene +
by O +
other O +
compounds O +
that O +
are O +
known O +
to O +
interact O +
with O +
the O +
major O +
binding O +
regions O +
of O +
HSA B-Gene +
( O -
i.e. O -
, O +
the O +
warfarin B-Gene -
- I-Gene -
azapropazone I-Gene +
and O +
indole B-Gene -
- I-Gene -
benzodiazepine I-Gene +
binding I-Gene +
sites I-Gene -
) O +
[ O -
6 O -
] O +
. O +

It O +
was O +
concluded O +
from O +
these O +
results O +
that O +
a O +
separate O +
binding O +
region O +
exists O +
on O +
HSA B-Gene -
, O +
known O +
as O +
the O +
digitoxin B-Gene +
site I-Gene -
, O +
which O +
is O +
responsible O +
for O +
the O +
interactions O +
of O +
digitoxin O +
and O +
related O +
compounds O +
with O +
this O +
protein B-Gene +
[ O -
6 O -
] O +
. O +

However O -
, O +
the O +
existence O +
of O +
this O +
binding O +
region O +
still O +
remains O +
an O +
area O +
of O +
controversy O +
and O +
little O +
quantitative O +
data O +
is O +
available O +
on O +
the O +
overall O +
strength O +
of O +
binding O +
between O +
digitoxin O +
and O +
acetyldigitoxin O +
with O +
HSA B-Gene +
[ O -
4,6,9 O -
] O +
. O +

The O +
general O +
goal O +
of O +
this O +
study O +
is O +
to O +
perform O +
a O +
detailed O +
examination O +
of O +
the O +
binding O +
between O +
digitoxin O +
and O +
acetyldigitoxin O +
with O +
HSA B-Gene +
by O +
using O +
high O -
- O -
performance O +
affinity O +
chromatography O +
( O -
HPAC O -
) O +
and O +
zonal O +
elution O +
competitive O +
binding O +
experiments O -
. O +

In O +
this O +
approach O -
, O +
HSA B-Gene +
will O +
be O +
immobilized O +
onto O +
a O +
HPLC O -
- O -
based O +
silica O +
support O +
and O +
packed O +
into O +
a O +
column O -
. O +

The O +
immobilized O +
HSA B-Gene +
will O +
then O +
be O +
used O +
as O +
a O +
stationary O +
phase O +
to O +
examine O +
the O +
binding O +
of O +
drugs O +
or O +
other O +
solutes O +
that O +
are O +
applied O +
to O +
the O +
chromatographic O +
system O -
. O +

In O +
previous O +
work O -
, O +
it O +
has O +
been O +
repeatedly O +
shown O +
that O +
there O +
is O +
good O +
correlation O +
between O +
the O +
behaviour O +
observed O +
with O +
these O +
immobilized O +
HSA B-Gene +
supports O +
and O +
that O +
seen O +
for O +
solution O -
- O -
phase O +
HSA B-Gene +
[ O -
10–19 O -
] O +
. O +

However O -
, O +
the O +
chromatographic O +
approach O +
has O +
the O +
advantages O +
of O +
being O +
faster O -
, O +
easier O +
to O +
use O +
and O +
more O +
precise O +
than O +
traditional O +
solution O -
- O -
phase O +
methods O +
for O +
the O +
measurement O +
of O +
drug O -
- O -
protein B-Gene +
interactions O +
[ O -
19 O -
] O +
. O +

The O +
immobilized O +
HSA B-Gene +
columns O +
in O +
this O +
work O +
will O +
be O +
used O +
to O +
examine O +
the O +
retention O +
of O +
digitoxin O +
and O +
acetyldigitoxin O +
in O +
the O +
presence O +
of O +
various O +
competing O +
agents O -
. O +

The O +
competition O +
of O +
each O +
drug O +
with O +
itself O +
will O +
be O +
used O +
to O +
determine O +
the O +
total O +
number O +
of O +
binding O +
regions O +
for O +
these O +
solutes O -
, O +
while O +
the O +
competition O +
of O +
acetyldigitoxin O +
with O +
digitoxin O +
will O +
be O +
used O +
to O +
examine O +
the O +
number O +
of O +
their O +
common O +
binding O +
sites O -
. O +

Other O +
competing O +
agents O -
, O +
such O +
as O +
warfarin O +
and O +
L O -
- O -
tryptophan O -
, O +
will O +
be O +
employed O +
to O +
determine O +
whether O +
or O +
not O +
digitoxin O +
and O +
acetyldigitoxin O +
really O +
do O +
have O +
sites O +
on O +
HSA B-Gene +
that O +
are O +
separate O +
from O +
the O +
major O +
binding O +
regions O +
of O +
this O +
protein B-Gene -
. O +

From O +
these O +
studies O -
, O +
data O +
will O +
be O +
obtained O +
that O +
should O +
allow O +
a O +
more O +
complete O +
picture O +
to O +
be O +
developed O +
for O +
the O +
binding O +
of O +
HSA B-Gene +
to O +
digitoxin O +
and O +
related O +
compounds O -
. O +

2 O +
Theory O +
The O +
binding O +
of O +
digitoxin O +
and O +
acetyldigitoxin O +
to O +
HSA B-Gene +
was O +
studied O +
by O +
using O +
the O +
technique O +
of O +
zonal O +
elution O +
[ O -
19 O -
] O +
. O +

In O +
this O +
method O -
, O +
a O +
known O +
concentration O +
of O +
a O +
competing O +
agent O +
( O -
I O -
) O +
is O +
continuously O +
applied O +
to O +
a O +
column O +
that O +
contains O +
an O +
immobilized O +
ligand O +
( O -
L O -
) O +
( O -
e.g. O -
, O +
HSA B-Gene -
) O +
while O +
injections O +
of O +
a O +
small O +
amount O +
of O +
analyte O +
( O -
A O -
) O +
are O +
made O -
. O +

If O +
I O +
and O +
A O +
compete O +
for O +
a O +
single O +
site O +
on O +
L O -
, O +
and O +
A O +
binds O +
to O +
no O +
other O +
type O +
of O +
site O +
on O +
the O +
support O -
, O +
then O +
the O +
following O +
reactions O +
can O +
be O +
used O +
to O +
describe O +
the O +
binding O +
events O +
that O +
take O +
place O +
in O +
the O +
column. O -
( O -
1 O -
) O +
A+L O +
⇌ O +
KAL O +
A−L O +
( O -
2 O -
) O +
I+L O +
⇌ O +
KIL O +
I−L O +
In O +
these O +
equations O +
K O +
AL O +
and O +
K O +
IL O +
are O +
the O +
association O +
equilibrium O +
constants O +
for O +
the O +
formation O +
of O +
the O +
complexes O +
A−L O +
and O +
I−L O -
, O +
respectively O -
. O +

It O +
was O +
necessary O +
in O +
this O +
study O +
to O +
also O +
use O +
β O -
- O -
cyclodextrin O +
as O +
a O +
mobile O +
phase O +
additive O +
to O +
help O +
complex O +
and O +
dissolve O +
the O +
digitoxin O +
and O +
acetyldigitoxin O +
in O +
solution O -
. O +

If O +
such O +
a O +
solubilising O +
agent O +
( O -
S O -
) O +
has O +
1:1 O +
interactions O +
with O +
A O +
and/or O +
I O -
, O +
then O +
the O +
following O +
additional O +
reactions O +
will O +
occur O +
within O +
the O +
mobile O +
phase O +
during O +
the O +
zonal O +
elution O +
study. O -
( O -
3 O -
) O +
A+S O +
⇌ O +
KAS O +
A−S O +
( O -
4 O -
) O +
I+S O +
⇌ O +
KIS O +
I−S O +
In O +
these O +
reactions O -
, O +
K O +
AS O +
and O +
K O +
IS O +
are O +
the O +
association O +
equilibrium O +
constants O +
for O +
the O +
formation O +
of O +
the O +
complexes O +
A−S O +
and O +
I−S O -
, O +
respectively O -
. O +

For O +
the O +
reaction O +
scheme O +
shown O +
in O +
Eqs. O +
( O -
1 O -
) O -
– O -
( O -
4 O -
) O +
, O +
the O +
following O +
relationship O +
has O +
been O +
previously O +
derived O +
to O +
describe O +
the O +
change O +
in O +
retention O +
for O +
A O +
as O +
the O +
mobile O +
phase O +
concentration O +
of O +
the O +
competing O +
agent O +
is O +
varied O +
[ O -
20 O -
] O +
. O -
( O -
5 O -
) O +
1 O -
/ O -
kA O +
′= O -
( O -
1+KAS O +
CS O +
) O -
( O -
1+KIS O +
CS O +
) O +
KAL O +
CL O +
( O -
1+KIL O +
CS O +
) O +
+ O -
( O -
1+KAS O +
CS O +
) O -
( O -
KIL O +
CI O +
) O +
KAL O +
CL O +
( O -
1+KIL O +
CS O +
) O +
In O +
Eq. O +
( O -
5 O -
) O +
, O +
k O +
A O +
′ O +
is O +
the O +
capacity O +
factor O +
for O +
the O +
injected O +
solute O -
, O +
or O +
k O +
A O +
′= O -
( O -
t O +
r O +
/t O +
m O +
−1 O -
) O -
, O +
where O +
tr O +
is O +
the O +
measured O +
retention O +
time O +
of O +
the O +
analyte O +
and O +
tm O +
is O +
the O +
column O +
void O +
time O -
. O +

The O +
term O +
C O +
L O +
is O +
the O +
total O +
concentration O +
of O +
all O +
active O +
ligand O +
sites O +
in O +
the O +
column O -
, O +
C O +
S O +
is O +
the O +
total O +
mobile O +
phase O +
concentration O +
of O +
the O +
solubilising O +
agent O -
, O +
and O +
C O +
I O +
is O +
the O +
total O +
concentration O +
of O +
competing O +
agent O +
in O +
the O +
mobile O +
phase O -
. O +

It O +
is O +
assumed O +
in O +
Eq. O +
( O -
5 O -
) O +
that O +
the O +
amount O +
of O +
A O +
that O +
is O +
injected O +
is O +
much O +
smaller O +
than O +
the O +
amount O +
of O +
competing O +
agent O +
or O +
immobilized O +
ligand O +
in O +
the O +
column O +
( O -
i.e. O -
, O +
linear O +
elution O +
conditions O +
are O +
present O -
) O -
. O +

It O +
is O +
also O +
assumed O +
that O +
the O +
amount O +
of O +
solubilising O +
agent O +
is O +
much O +
larger O +
than O +
the O +
amount O +
of O +
A O +
or O +
I O +
that O +
is O +
complexed O +
by O +
this O +
agent O +
in O +
the O +
mobile O +
phase O -
. O +

For O +
the O +
1:1 O +
direct O +
competition O +
of O +
A O +
and O +
I O +
for O +
L O -
, O +
Eq. O +
( O -
5 O -
) O +
predicts O +
that O +
a O +
plot O +
of O +
1 O -
/ O -
k O +
A O +
versus O +
C O +
I O +
should O +
yield O +
a O +
linear O +
relationship O -
, O +
with O +
the O +
ratio O +
of O +
the O +
intercept O +
to O +
the O +
slope O +
for O +
this O +
graph O +
giving O +
a O +
value O +
equal O +
to O +
( O -
1+K O +
IS O +
C O +
S O +
) O -
/K O +
IL O +
. O +

The O +
values O +
for O +
some O +
of O +
the O +
equilibrium O +
constants O +
in O +
this O +
system O +
can O +
be O +
determined O +
by O +
preparing O +
a O +
second O +
plot O +
of O +
the O +
intercept O -
/ O -
slope O +
ratio O +
versus O +
the O +
concentration O +
of O +
solubilising O +
agent O +
( O -
C O +
S O +
) O +
that O +
was O +
used O +
in O +
each O +
study O -
. O +

If O +
the O +
test O +
system O +
follows O +
the O +
reaction O +
model O +
shown O +
in O +
Eqs. O +
( O -
1 O -
) O -
– O -
( O -
4 O -
) O +
, O +
then O +
this O +
second O +
plot O +
should O +
give O +
a O +
linear O +
relationship O +
with O +
an O +
intercept O +
equal O +
to O +
1 O -
/ O -
K O +
IL O +
and O +
a O +
slope O +
equal O +
to O +
K O +
IS O +
/K O +
IL O +
. O +

By O +
taking O +
the O +
reciprocal O +
of O +
the O +
intercept O +
obtained O +
for O +
this O +
plot O -
, O +
the O +
association O +
equilibrium O +
constant O +
K O +
IL O +
for O +
the O +
binding O +
of O +
I O +
to O +
L O +
can O +
be O +
determined O +
at O +
the O +
site O +
of O +
competition O +
between O +
A O +
and O +
I O +
on O +
the O +
immobilized O +
ligand O +
[ O -
20 O -
] O +
. O +

3 O +
Experimental O +
3.1 O +
Reagents O +
Digitoxin O +
and O +
acetyldigitoxin O +
( O -
2:1 O +
ratio O +
of O +
α- O +
and O +
β O -
- O -
forms O -
) O -
, O +
β O -
- O -
cyclodextrin O -
, O +
HSA B-Gene +
( O -
Cohn O +
fraction O +
V O -
, O +
99 O -
% O +
globulin B-Gene +
free O -
, O +
fatty O +
acid O +
free O -
) O -
, O +
racemic O +
warfarin O +
and O +
L O -
- O -
tryptophan O +
were O +
obtained O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

The O +
HSA B-Gene +
and O +
diol O -
- O -
bonded O +
silica O +
supports O +
were O +
prepared O +
using O +
Nucleosil O +
Si-300 O +
silica O +
( O -
7μm O +
particle O +
diameter O -
, O +
300 O +
Å O +
pore O -
- O -
size O -
) O +
from O +
Macherey O -
- O -
Nagel O +
( O -
Duren O -
, O +
Germany O -
) O -
. O +

Other O +
chemicals O +
and O +
biochemicals O +
used O +
were O +
of O +
the O +
purest O +
grades O +
available O -
. O +

All O +
aqueous O +
solutions O +
were O +
prepared O +
using O +
water O +
purified O +
by O +
a O +
Nanopure O +
water O +
system O +
( O -
Barnstead O -
, O +
Dubuque O -
, O +
IA O -
, O +
USA O -
) O -
. O +

3.2 O +
Apparatus O +
The O +
chromatographic O +
system O +
consisted O +
of O +
a O +
CM3000 O +
solvent O +
delivery O +
system O +
from O +
Thermoseparations O +
( O -
Riviera O +
Beach O -
, O +
FL O -
, O +
USA O -
) O -
, O +
a O +
Rheodyne O +
7010 O +
injection O +
valve O +
( O -
Cotati O -
, O +
CA O -
, O +
USA O -
) O +
equipped O +
with O +
a O +
20 O +
μL O +
sample O +
loop O -
, O +
and O +
a O +
SM3100 O +
UV O -
– O -
Vis O +
variable O +
wavelength O +
detector O +
from O +
Thermoseparations O -
. O +

A O +
Winner O -
- O -
on O -
- O -
Windows O +
interface O +
from O +
Thermoseparations O +
was O +
used O +
for O +
data O +
collection O -
. O +

Chromatograms O +
were O +
processed O +
by O +
programs O +
written O +
in O +
Microsoft O +
QuickBASIC O +
( O -
Redmond O -
, O +
WA O -
, O +
USA O -
) O -
. O +

All O +
columns O +
and O +
mobile O +
phases O +
were O +
maintained O +
at O +
37±0.2 O -
° O -
C O +
by O +
using O +
an O +
Isotemp O +
9100 O +
water O +
bath O +
( O -
Fisher O +
Scientific O -
, O +
Pittsburgh O -
, O +
PA O -
, O +
USA O -
) O -
. O +

The O +
columns O +
were O +
downward O +
slurry O -
- O -
packed O +
using O +
an O +
HPLC O +
column O +
slurry O +
packer O +
from O +
Alltech O +
( O -
Deerfield O -
, O +
IL O -
, O +
USA O -
) O -
. O +

3.3 O +
Methods O +
Digitoxin O +
and O +
acetyldigitoxin O +
were O +
placed O +
into O +
pH O +
7.4 O -
, O +
0.067 O +
M O +
phosphate O +
buffer O +
by O +
using O +
β O -
- O -
cyclodextrin O +
as O +
a O +
solubilising O +
agent O -
. O +

The O +
concentration O +
of O +
this O +
solubilising O +
agent O +
was O +
varied O +
from O +
1.0–2.6 O +
mM O +
during O +
the O +
zonal O +
elution O +
studies O -
. O +

Both O +
digitoxin O +
and O +
acetyldigitoxin O +
were O +
found O +
to O +
be O +
stable O +
in O +
this O +
solution O +
for O +
over O +
two O +
weeks O +
at O +
room O +
temperature O -
. O +

Diol O -
- O -
bonded O +
silica O +
was O +
prepared O +
as O +
described O +
previously O +
[ O -
21 O -
] O +
. O +

The O +
diol O +
coverage O +
of O +
the O +
final O +
Nucleosil O +
support O +
was O +
230±3μmol O +
( O -
±1 O +
SD O -
) O +
per O +
gram O +
of O +
silica O -
, O +
as O +
determined O +
in O +
duplicate O +
by O +
an O +
iodometric O +
capillary O +
electrophoresis O +
assay O +
[ O -
22 O -
] O +
. O +

The O +
Schiff O +
base O +
immobilisation O +
method O +
was O +
used O +
to O +
couple O +
HSA B-Gene +
to O +
this O +
diol O +
support O +
[ O -
23,24 O -
] O +
. O +

A O +
bicinchoninic O +
acid O +
( O -
BCA O -
) O +
protein O +
assay O +
was O +
performed O +
in O +
triplicate O +
on O +
the O +
HSA B-Gene +
support O +
using O +
HSA B-Gene +
as O +
the O +
standard O +
and O +
diol O -
- O -
bonded O +
silica O +
as O +
the O +
blank O +
[ O -
25 O -
] O +
, O +
according O +
to O +
previous O +
methods O +
[ O -
12 O -
] O +
. O +

The O +
final O +
protein O +
content O +
of O +
the O +
HSA B-Gene +
support O +
was O +
found O +
to O +
be O +
426±2 O +
nmol O +
HSA B-Gene +
per O +
gram O +
of O +
silica O -
. O +

A O +
3 O +
cm O -
× O -
2 O +
mm O +
I.D. O +
stainless O +
steel O +
column O +
was O +
downward O +
slurry O -
- O -
packed O +
at O +
3500 O +
p.s.i O -
. O +

with O +
the O +
immobilized O +
HSA B-Gene +
silica O +
and O +
enclosed O +
in O +
a O +
water O +
jacket O +
for O +
temperature O +
control O -
. O +

A O +
pH O +
7.4 O -
, O +
0.067 O +
M O +
potassium O +
phosphate O +
buffer O +
containing O +
1.0–2.6 O +
mM O +
β O -
- O -
cyclodextrin O +
was O +
used O +
to O +
prepare O +
all O +
mobile O +
phases O -
. O +

To O +
each O +
of O +
these O +
solutions O +
was O +
added O +
0–10 O +
μM O +
of O +
digitoxin O -
, O +
acetyldigitoxin O +
or O +
warfarin O -
, O +
or O +
0–50 O +
μM O +
of O +
L O -
- O -
tryptophan O +
as O +
a O +
competing O +
agent O -
. O +

Linear O +
behaviour O +
in O +
plots O +
made O +
according O +
to O +
Eq. O +
( O -
5 O -
) O +
was O +
observed O +
when O +
using O +
mobile O +
phase O +
concentrations O +
of O +
0–0.5 O +
μM O +
digitoxin O +
or O +
acetyldigitoxin O -
; O +
as O +
discussed O +
later O -
, O +
these O +
were O +
the O +
final O +
conditions O +
selected O +
for O +
use O +
in O +
all O +
equilibrium O +
constant O +
measurements O -
. O +

These O +
concentrations O +
were O +
approximately O +
ten O +
times O +
higher O +
than O +
the O +
therapeutic O +
range O +
of O +
digitoxin O +
( O -
i.e. O -
, O +
26–46 O +
nM O +
) O +
[ O -
26 O -
] O +
, O +
and O +
thus O +
should O +
have O +
provided O +
sufficient O +
amounts O +
of O +
these O +
drugs O +
for O +
the O +
detection O +
of O +
any O +
significant O +
interactions O +
between O +
these O +
compounds O +
and O +
HSA B-Gene +
under O +
conditions O +
of O +
normal O +
use O -
. O +

After O +
preparation O -
, O +
each O +
mobile O +
phase O +
was O +
filtered O +
through O +
a O +
0.22 O +
μm O +
nylon O +
filter O +
and O +
degassed O +
under O +
vacuum O +
for O +
15 O +
min O -
. O +

The O +
samples O +
of O +
acetyldigitoxin O +
or O +
digitoxin O +
to O +
be O +
used O +
as O +
the O +
injected O +
analyte O +
were O +
then O +
prepared O +
in O +
the O +
same O +
mobile O +
phases O +
as O +
employed O +
in O +
each O +
individual O +
zonal O +
elution O +
study O -
. O +

The O +
zonal O +
elution O +
experiments O +
were O +
performed O +
at O +
flow O -
- O -
rates O +
between O +
0.2 O +
and O +
0.5 O +
ml O -
/ O -
min O -
, O +
with O +
the O +
desired O +
analyte O +
being O +
applied O +
in O +
replicate O +
injections O -
. O +

The O +
column O +
back O -
- O -
pressures O +
under O +
these O +
conditions O +
ranged O +
from O +
200–500 O +
p.s.i O -
. O +

The O +
elution O +
of O +
the O +
injected O +
acetyldigitoxin O +
and O +
digitoxin O +
was O +
monitored O +
at O +
221 O +
nm O -
. O +

The O +
retention O +
time O +
of O +
each O +
probe O +
was O +
calculated O +
by O +
using O +
the O +
first O +
statistical O +
moment O +
of O +
its O +
corresponding O +
peak O +
[ O -
27 O -
] O +
. O +

The O +
void O +
time O +
of O +
the O +
column O +
was O +
determined O +
by O +
making O +
similar O +
injections O +
with O +
sodium O +
nitrate O -
, O +
a O +
non O -
- O -
retained O +
compound O -
. O +

Tests O +
for O +
non O -
- O -
specific O +
binding O +
between O +
digitoxin O +
and O +
acetyldigitoxin O +
and O +
the O +
support O +
were O +
performed O +
by O +
injecting O +
these O +
compounds O +
onto O +
a O +
diol O -
- O -
bonded O +
silica O +
column O -
; O +
in O +
each O +
case O -
, O +
only O +
negligible O +
interactions O +
were O +
noted O -
. O +

The O +
capacity O +
factors O +
for O +
the O +
injected O +
probe O +
compounds O +
were O +
determined O +
over O +
sample O +
concentrations O +
of O +
0.1–100 O +
μM O +
, O +
with O +
0.1 O +
μM O +
being O +
the O +
typical O +
level O +
employed O -
. O +

There O +
were O +
no O +
noticeable O +
shifts O +
in O +
the O +
capacity O +
factors O +
over O +
this O +
range O +
of O +
sample O +
concentrations O -
, O +
indicating O +
that O +
linear O +
elution O +
conditions O +
were O +
present O -
, O +
as O +
assumed O +
in O +
Eq. O +
( O -
5 O -
) O +
. O +

4 O +
Results O +
and O +
discussion O +
4.1 O +
General O +
design O +
of O +
zonal O +
elution O +
studies O -
. O +

The O +
binding O +
studies O +
performed O +
in O +
this O +
work O +
were O +
based O +
on O +
the O +
change O +
in O +
retention O +
observed O +
for O +
a O +
small O +
amount O +
of O +
an O +
injected O +
analyte O +
that O +
was O +
passed O +
through O +
an O +
immobilized O +
protein B-Gene +
column O +
in O +
the O +
presence O +
or O +
absence O +
of O +
a O +
fixed O +
concentration O +
of O +
a O +
competing O +
agent O -
. O +

If O +
direct O +
competition O +
occurs O +
between O +
the O +
analyte O +
and O +
competing O +
agent O -
, O +
then O +
a O +
decrease O +
in O +
retention O +
should O +
be O +
obtained O +
for O +
the O +
analyte O +
as O +
the O +
competing O +
agent O -
's O +
concentration O +
is O +
increased O -
. O +

If O +
indirect O +
( O -
or O +
allosteric O -
) O +
competition O +
is O +
present O -
, O +
then O +
either O +
an O +
increase O +
or O +
decrease O +
in O +
analyte O +
retention O +
may O +
be O +
seen O +
at O +
higher O +
concentrations O +
of O +
the O +
competing O +
agent O -
, O +
depending O +
on O +
whether O +
the O +
indirect O +
competition O +
is O +
positive O +
or O +
negative O +
in O +
nature O -
. O +

Examples O +
of O +
typical O +
chromatograms O +
and O +
shifts O +
in O +
retention O +
that O +
are O +
obtained O +
in O +
such O +
studies O +
are O +
provided O +
in O +
[ O -
10–19 O -
] O +
. O +

By O +
analysing O +
the O +
data O +
of O +
these O +
experiments O +
according O +
to O +
equations O +
derived O +
for O +
specific O +
reaction O +
models O +
( O -
e.g. O -
, O +
see O +
Eqs. O +
( O -
1 O -
) O -
– O -
( O -
5 O -
) O +
for O +
direct O +
1:1 O +
competition O -
) O -
, O +
it O +
is O +
possible O +
to O +
not O +
only O +
identify O +
the O +
particular O +
type O +
of O +
interaction O +
that O +
is O +
occurring O +
but O +
also O +
to O +
determine O +
the O +
equilibrium O +
constants O +
that O +
are O +
involved O +
in O +
these O +
binding O +
processes O -
. O +

Several O +
practical O +
factors O +
had O +
to O +
be O +
considered O +
when O +
using O +
these O +
types O +
of O +
zonal O +
elution O +
experiments O +
to O +
examine O +
the O +
interactions O +
of O +
digitoxin O +
and O +
acetyldigitoxin O +
with O +
immobilized O +
HSA B-Gene -
. O +

The O +
first O +
problem O +
encountered O +
was O +
the O +
relatively O +
low O +
water O +
solubility O +
of O +
these O +
drugs O -
, O +
which O +
made O +
it O +
difficult O +
to O +
reliably O +
put O +
enough O +
of O +
these O +
compounds O +
in O +
the O +
mobile O +
phase O +
for O +
detection O +
by O +
a O +
standard O +
HPLC O +
absorbance O +
detector O +
or O +
for O +
use O +
as O +
a O +
competing O +
agent O +
in O +
the O +
zonal O +
elution O +
studies O -
. O +

One O +
possible O +
way O +
of O +
enhancing O +
the O +
solubility O +
of O +
these O +
agents O +
would O +
be O +
to O +
add O +
an O +
organic O +
solvent O +
as O +
a O +
modifier O +
to O +
the O +
mobile O +
phase O -
. O +

However O -
, O +
this O +
would O +
also O +
be O +
likely O +
to O +
cause O +
a O +
change O +
in O +
the O +
binding O +
properties O +
and/or O +
structure O +
of O +
the O +
immobilized O +
HSA B-Gene +
[ O -
28,29 O -
] O +
. O +

An O +
alternative O +
approach O +
has O +
recently O +
been O +
developed O +
in O +
which O +
β O -
- O -
cyclodextrin O -
, O +
or O +
a O +
related O +
compound O +
like O +
α- O +
or O +
γ O -
- O -
cyclodextrin O -
, O +
is O +
used O +
as O +
a O +
mobile O +
phase O +
additive O +
to O +
help O +
solubilise O +
non O -
- O -
polar O +
compounds O +
during O +
HPLC O -
- O -
based O +
binding O +
studies O +
[ O -
20 O -
] O +
. O +

In O +
this O +
present O +
study O +
it O +
was O +
found O +
that O +
a O +
solution O +
of O +
1–2.6 O +
mM O +
β O -
- O -
cyclodextrin O +
could O +
easily O +
dissolve O +
acetyldigitoxin O +
and O +
digitoxin O +
in O +
pH O +
7.4 O -
, O +
0.067 O +
phosphate O +
buffer O +
at O +
concentrations O +
that O +
were O +
compatible O +
with O +
zonal O +
elution O +
experiments O +
( O -
i.e. O -
, O +
0.1–100 O +
μM O +
) O -
. O +

Absorbance O +
and O +
light O -
- O -
scattering O +
measurements O +
indicated O +
that O +
were O +
no O +
apparent O +
changes O +
in O +
the O +
solubility O +
of O +
these O +
acetyldigitoxin O +
or O +
digitoxin O +
solutions O +
when O +
stored O +
for O +
several O +
weeks O +
at O +
4–37 O -
° O -
C O -
, O +
thus O +
indicating O +
that O +
they O +
were O +
sufficiently O +
stable O +
for O +
use O +
as O +
mobile O +
phases O +
in O +
HPLC O +
studies O -
. O +

β O -
- O -
Cyclodextrin O +
was O +
selected O +
as O +
a O +
solubilising O +
agent O +
for O +
acetyldigitoxin O +
and O +
digitoxin O +
since O +
it O +
is O +
known O +
to O +
bind O +
to O +
many O +
small O -
, O +
non O -
- O -
polar O +
compounds O +
and O +
yet O +
it O +
has O +
no O +
measurable O +
binding O +
to O +
HSA B-Gene +
[ O -
20,30 O -
] O +
. O +

This O +
means O +
that O +
the O +
presence O +
of O +
β O -
- O -
cyclodextrin O +
in O +
the O +
mobile O +
phase O +
should O +
not O +
alter O +
the O +
nature O +
or O +
strength O +
of O +
the O +
binding O +
between O +
immobilized O +
HSA B-Gene +
and O +
solutes O +
like O +
acetyldigitoxin O +
and O +
digitoxin O -
. O +

Instead O -
, O +
β O -
- O -
cyclodextrin O +
and O +
HSA B-Gene +
would O +
be O +
expected O +
to O +
act O +
as O +
independent O +
ligands O +
for O +
these O +
drugs O -
, O +
with O +
the O +
β O -
- O -
cyclodextrin O +
being O +
used O +
to O +
merely O +
help O +
keep O +
acetyldigitoxin O +
and O +
digitoxin O +
in O +
the O +
mobile O +
phase O +
through O +
the O +
formation O +
of O +
soluble O +
host O -
: O +
guest O +
complexes O -
. O +

This O +
type O +
of O +
behaviour O +
has O +
been O +
confirmed O +
in O +
earlier O +
HPLC O +
experiments O +
that O +
have O +
examined O +
the O +
interactions O +
of O +
cis O +
- O +
and O +
trans O +
-clomiphene O +
with O +
immobilized O +
HSA B-Gene +
in O +
the O +
presence O +
of O +
soluble O +
β O -
- O -
cyclodextrin O +
[ O -
20 O -
] O +
. O +

A O +
second O +
advantage O +
of O +
using O +
β O -
- O -
cyclodextrin O +
as O +
a O +
complexing O +
agent O +
is O +
that O +
it O +
has O +
no O +
absorbance O +
under O +
the O +
UV O -
/ O -
Vis O +
detection O +
conditions O +
that O +
are O +
commonly O +
employed O +
to O +
monitor O +
injected O +
solutes O +
in O +
HPLC O +
studies O +
of O +
drug O -
- O -
protein B-Gene +
interactions O -
. O +

Although O +
the O +
presence O +
of O +
β O -
- O -
cyclodextrin O +
did O +
help O +
produce O +
sufficient O +
mobile O +
phase O +
concentrations O +
of O +
acetyldigitoxin O +
and O +
digitoxin O +
for O +
HPLC O +
studies O -
, O +
the O +
presence O +
of O +
this O +
secondary O +
ligand O +
did O +
add O +
some O +
complexity O +
to O +
these O +
measurements O -
. O +

This O +
was O +
true O +
even O +
though O +
the O +
β O -
- O -
cyclodextrin O +
did O +
not O +
directly O +
affect O +
the O +
interactions O +
of O +
these O +
compounds O +
with O +
HSA B-Gene -
. O +

For O +
example O -
, O +
it O +
was O +
now O +
necessary O +
to O +
consider O +
how O +
the O +
elution O +
of O +
acetyldigitoxin O +
or O +
digitoxin O +
changed O +
as O +
a O +
function O +
of O +
the O +
concentrations O +
of O +
both O +
the O +
solubilising O +
agent O +
( O -
β O -
- O -
cyclodextrin O -
) O +
and O +
any O +
competing O +
agent O +
that O +
was O +
present O +
in O +
the O +
mobile O +
phase O +
( O -
e.g. O -
, O +
acetyldigitoxin O -
, O +
digitoxin O -
, O +
L O -
- O -
tryptophan O +
or O +
R O -
/ O -
S O -
- O -
warfarin O -
) O -
. O +

The O +
equations O +
and O +
experiments O +
that O +
were O +
used O +
for O +
this O +
purpose O +
are O +
described O +
in O +
detail O +
in O +
[ O -
20 O -
] O +
as O +
well O +
as O +
in O +
the O +
Theory O +
and O +
Sections O +
4.2–4.4 O +
of O +
this O +
current O +
report O -
. O +

A O +
second O +
complication O +
created O +
by O +
the O +
presence O +
of O +
β O -
- O -
cyclodextrin O +
was O +
the O +
relatively O +
small O +
retention O +
and O +
small O +
changes O +
in O +
retention O +
that O +
now O +
occurred O +
during O +
the O +
zonal O +
elution O +
studies O -
. O +

This O +
was O +
caused O +
by O +
the O +
increased O +
time O +
that O +
the O +
acetyldigitoxin O +
and O +
digitoxin O +
spent O +
in O +
the O +
mobile O +
phase O +
because O +
of O +
their O +
complexation O +
to O +
β O -
- O -
cyclodextrin O -
, O +
which O +
in O +
turn O +
led O +
to O +
a O +
decrease O +
in O +
their O +
observed O +
retention O +
times O +
and O +
capacity O +
factors O -
. O +

Most O +
of O +
the O +
capacity O +
factors O +
measured O +
in O +
this O +
work O +
were O +
in O +
the O +
range O +
of O +
0.10–0.25 O -
, O +
with O +
some O +
experimental O +
conditions O +
giving O +
k O +
′ O +
values O +
that O +
were O +
even O +
as O +
low O +
as O +
0.03 O -
. O +

Non O -
- O -
specific O +
binding O +
did O +
not O +
create O +
a O +
problem O +
at O +
these O +
small O +
retention O +
values O +
because O +
neither O +
acetyldigitoxin O +
or O +
digitoxin O +
were O +
found O +
to O +
have O +
any O +
significant O +
interactions O +
with O +
the O +
diol O -
- O -
bonded O +
support O +
that O +
was O +
used O +
for O +
the O +
immobilisation O +
of O +
HSA B-Gene -
. O +

But O +
these O +
small O +
levels O +
of O +
retention O +
did O +
require O +
that O +
several O +
precautions O +
be O +
taken O +
in O +
order O +
to O +
obtain O +
reliable O +
estimates O +
of O +
shifts O +
in O +
k O +
′ O +
values O +
as O +
the O +
experimental O +
conditions O +
were O +
changed O -
. O +

For O +
instance O -
, O +
a O +
low O +
injection O +
flow O +
rate O +
( O -
down O +
to O +
0.2 O +
ml O -
/ O -
min O -
) O +
and O +
a O +
fast O +
data O +
acquisition O +
rate O +
( O -
usually O +
60 O +
points O +
per O +
second O -
) O +
were O +
used O +
to O +
obtain O +
good O +
time O +
resolution O +
in O +
the O +
chromatographic O +
data O +
that O +
were O +
generated O -
. O +

This O -
, O +
combined O +
with O +
the O +
use O +
of O +
replicate O +
moments O +
analysis O +
for O +
determining O +
the O +
true O +
center O +
of O +
each O +
peak O -
, O +
provided O +
an O +
estimated O +
precision O +
of O +
±0.001–0.002 O +
min O +
( O -
or O +
about O +
±0.05–0.10 O +
s O -
) O +
for O +
the O +
retention O +
time O +
measurements O +
performed O +
on O +
any O +
given O +
peak O -
. O +

Replicate O +
injections O +
under O +
each O +
set O +
of O +
experimental O +
conditions O +
gave O +
a O +
typical O +
observed O +
run O -
- O -
to O -
- O -
run O +
variation O +
of O +
±0.002–0.004 O +
min O +
( O -
± O +
1 O +
SD O -
) O -
. O +

When O +
the O +
retention O +
times O +
from O +
these O +
replicate O +
runs O +
were O +
averaged O -
, O +
the O +
resulting O +
precision O +
for O +
the O +
mean O +
retention O +
time O +
became O +
a O +
value O +
of O +
±0.002 O -
/ O -
N O +
to O +
0.004 O -
/ O -
N O +
( O -
or O +
±0.001–0.002 O +
min O +
for O +
N=3 O -
) O -
. O +

This O +
level O +
of O +
precision O +
was O +
found O +
to O +
be O +
sufficient O +
for O +
examining O +
most O +
of O +
the O +
shifts O +
in O +
k O +
′ O +
that O +
occurred O +
throughout O +
this O +
work O -
. O +

In O +
those O +
cases O +
that O +
needed O +
even O +
higher O +
precision O +
( O -
e.g. O -
, O +
the O +
experiments O +
performed O +
at O +
k O +
′=0.03 O -
) O -
, O +
a O +
larger O +
of O +
number O +
of O +
replicate O +
injections O +
were O +
used O +
to O +
further O +
decrease O +
the O +
standard O +
deviations O +
of O +
the O +
mean O +
retention O +
times O +
until O +
the O +
precision O +
of O +
the O +
average O +
capacity O +
factors O +
was O +
at O +
an O +
acceptable O +
level O -
. O +

4.2 O +
Competitive O +
binding O +
studies O +
using O +
digitoxin O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

The O +
first O +
set O +
of O +
zonal O +
elution O +
studies O +
in O +
this O +
study O +
examined O +
the O +
competitive O +
binding O +
of O +
injected O +
digitoxin O +
and O +
acetyldigitoxin O +
in O +
the O +
presence O +
of O +
digitoxin O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

Plots O +
of O +
1 O -
/ O -
k O +
′A O +
versus O +
C O +
I O +
were O +
initially O +
generated O +
in O +
these O +
experiments O +
over O +
a O +
wide O +
range O +
of O +
competing O +
agent O +
concentrations O +
in O +
the O +
mobile O +
phase O -
. O +

When O +
using O +
1.0–2.6 O +
mM O +
β O -
- O -
cyclodextrin O +
as O +
a O +
solubilising O +
agent O -
, O +
a O +
linear O +
region O +
in O +
these O +
plots O +
was O +
generally O +
observed O +
whenever O +
the O +
concentration O +
of O +
digitoxin O +
or O +
acetyldigitoxin O +
in O +
the O +
mobile O +
phase O +
was O +
below O +
0.5 O +
μM O +
( O -
see O +
Fig. O +
2 O +
) O -
. O +

Similar O +
results O +
have O +
been O +
observed O +
in O +
zonal O +
elution O +
studies O +
of O +
clomiphene O +
binding O +
to O +
HSA B-Gene +
in O +
the O +
presence O +
of O +
β B-Gene -
- I-Gene -
cyclodextrin I-Gene +
[ O -
20 O -
] O +
. O +

Since O +
Eq. O +
( O -
5 O -
) O +
assumes O +
that O +
the O +
solubilising O +
agent O +
is O +
present O +
in O +
a O +
large O +
excess O +
versus O +
the O +
competing O +
agent O -
, O +
0–0.5 O +
μM O +
digitoxin O +
or O +
acetyldigitoxin O +
was O +
the O +
mobile O +
phase O +
concentration O +
range O +
used O +
for O +
all O +
later O +
zonal O +
elution O +
studies O +
in O +
this O +
work O -
. O +

When O +
using O +
less O +
than O +
0.5 O +
μM O +
digitoxin O +
as O +
a O +
competing O +
agent O +
and O +
digitoxin O +
as O +
the O +
injected O +
probe O -
, O +
plots O +
of O +
1 O -
/ O -
k O +
A O +
′ O +
versus O +
[ O -
digitoxin O -
] O +
gave O +
linear O +
relationships O -
, O +
as O +
predicted O +
by O +
Eq. O +
( O -
5 O -
) O +
for O +
systems O +
with O +
1:1 O +
competition O -
. O +

The O +
graphs O +
that O +
were O +
obtained O +
are O +
shown O +
in O +
Figs. O +
2 O -
( O -
a O -
) O +
and O +
3 O -
( O -
a O -
– O -
c O -
) O +
. O +

The O +
correlation O +
coefficients O +
for O +
all O +
these O +
plots O +
were O +
0.9999 O +
over O +
the O +
four O +
data O +
points O +
generated O +
at O +
1.0–2.6 O +
mM O +
β O -
- O -
cyclodextrin O -
. O +

A O +
second O +
graph O +
( O -
Fig. O +
4 O +
) O +
was O +
made O +
for O +
the O +
digitoxin O -
/ O -
digitoxin O +
data O +
by O +
taking O +
the O +
ratio O +
of O +
the O +
intercepts O +
and O +
slopes O +
of O +
the O +
best O -
- O -
fit O +
lines O +
and O +
plotting O +
these O +
values O +
versus O +
the O +
total O -
, O +
or O +
analytical O -
, O +
concentration O +
of O +
β O -
- O -
cyclodextrin O +
that O +
was O +
present O +
in O +
the O +
mobile O +
phase O -
. O +

This O +
graph O +
also O +
gave O +
linear O +
behaviour O -
, O +
with O +
a O +
correlation O +
coefficient O +
of O +
0.9974 O +
over O +
the O +
four O +
concentrations O +
of O +
β O -
- O -
cyclodextrin O +
that O +
were O +
used O -
. O +

From O +
the O +
reciprocal O +
of O +
the O +
intercept O +
for O +
the O +
digitoxin O -
/ O -
digitoxin O +
data O +
in O +
Fig. O +
4 O +
, O +
it O +
was O +
possible O +
to O +
obtain O +
the O +
association O +
equilibrium O +
constant O +
for O +
the O +
competition O +
of O +
digitoxin O +
with O +
itself O +
at O +
its O +
binding O +
regions O +
on O +
HSA B-Gene -
. O +

This O +
gave O +
a O +
K O +
IL O +
value O +
for O +
this O +
interaction O +
of O +
5.2 O +
( O -
±0.2 O -
) O -
× O -
104 O +
M−1 O +
. O +

The O +
linearity O +
of O +
the O +
graphs O +
in O +
Figs. O +
2–4 O +
for O +
the O +
competition O +
of O +
digitoxin O +
with O +
itself O +
supports O +
a O +
model O +
in O +
which O +
digitoxin O +
is O +
interacting O +
at O +
only O +
one O +
type O +
of O +
site O +
on O +
HSA B-Gene -
. O +

The O +
size O +
of O +
this O +
association O +
constant O +
is O +
also O +
in O +
good O +
agreement O +
with O +
previous O +
estimates O +
of O +
4–7 O -
× O -
104 O +
M−1 O +
that O +
have O +
been O +
made O +
for O +
the O +
binding O +
of O +
digitoxin O +
to O +
HSA B-Gene +
in O +
solution O +
[ O -
31 O -
] O +
. O +

Similar O +
competitive O +
binding O +
studies O +
were O +
performed O +
between O +
acetyldigitoxin O +
and O +
digitoxin O +
by O +
injecting O +
small O +
amounts O +
of O +
acetyldigitoxin O +
into O +
the O +
presence O +
of O +
digitoxin O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

Plots O +
of O +
1 O -
/ O -
k O +
A O +
′ O +
versus O +
[ O -
digitoxin O -
] O +
for O +
these O +
experiments O +
again O +
gave O +
linear O +
relationships O +
at O +
competing O +
agent O +
concentrations O +
below O +
0.5 O +
μM O +
( O -
see O +
Fig. O +
5 O +
) O -
, O +
with O +
correlation O +
coefficients O +
ranging O +
from O +
0.9994–0.9999 O +
over O +
four O +
data O +
points O +
obtained O +
at O +
each O +
level O +
of O +
β O -
- O -
cyclodextrin O -
. O +

The O +
ratio O +
of O +
the O +
intercepts O +
and O +
slopes O +
from O +
these O +
graphs O +
were O +
then O +
plotted O +
versus O +
the O +
total O +
concentration O +
of O +
β O -
- O -
cyclodextrin O +
in O +
the O +
mobile O +
phase O -
. O +

The O +
result O +
was O +
a O +
linear O +
relationship O +
with O +
a O +
correlation O +
coefficient O +
of O +
0.9988 O +
over O +
four O +
levels O +
of O +
β O -
- O -
cyclodextrin O +
( O -
Fig. O +
4 O +
) O -
. O +

The O +
reciprocal O +
of O +
the O +
intercept O +
from O +
this O +
plot O +
gave O +
an O +
association O +
equilibrium O +
constant O +
of O +
5.4 O +
( O -
±0.2 O -
) O -
× O -
10−4 O +
M−1 O +
for O +
the O +
interaction O +
of O +
digitoxin O +
at O +
the O +
site O +
at O +
which O +
it O +
competes O +
with O +
acetyldigitoxin O +
for O +
HSA B-Gene +
binding O -
. O +

This O +
value O +
was O +
statistically O +
identical O +
to O +
that O +
obtained O +
in O +
the O +
previous O +
experiment O +
for O +
the O +
competition O +
of O +
digitoxin O +
with O +
itself O -
, O +
indicating O +
that O +
the O +
same O +
site O +
on O +
HSA B-Gene +
was O +
involved O +
in O +
both O +
binding O +
processes O -
. O +

Furthermore O -
, O +
the O +
linearity O +
of O +
the O +
acetyldigitoxin O -
/ O -
digitoxin O +
plots O +
in O +
Figs. O +
4–5 O +
indicates O +
that O +
digitoxin O +
and O +
acetyldigitoxin O +
had O +
only O +
one O +
region O +
on O +
HSA B-Gene +
at O +
which O +
they O +
had O +
competitive O +
binding O -
, O +
as O +
observed O +
for O +
the O +
digitoxin O -
/ O -
digitoxin O +
system O +
in O +
Figs. O +
2–4 O +
. O +

4.3 O +
Competitive O +
binding O +
studies O +
using O +
acetyldigitoxin O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

The O +
next O +
group O +
of O +
zonal O +
elution O +
studies O +
examined O +
the O +
binding O +
of O +
acetyldigitoxin O +
in O +
the O +
presence O +
of O +
acetyldigitoxin O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

As O +
seen O +
earlier O +
in O +
the O +
digitoxin O +
studies O -
, O +
linear O +
behaviour O +
was O +
obtained O +
for O +
plots O +
of O +
1 O -
/ O -
k O +
A O +
′ O +
versus O +
[ O -
acetyldigitoxin O -
] O +
at O +
competing O +
agent O +
concentrations O +
below O +
0.5 O +
μM O +
. O +

The O +
linear O +
region O +
of O +
these O +
curves O +
gave O +
correlation O +
coefficients O +
of O +
0.9980–0.9999 O +
over O +
the O +
four O +
data O +
points O +
in O +
this O +
range O -
. O +

The O +
ratio O +
of O +
the O +
intercepts O +
and O +
slopes O +
of O +
these O +
results O +
were O +
then O +
plotted O +
against O +
the O +
concentration O +
of O +
β O -
- O -
cyclodextrin O -
. O +

The O +
result O +
was O +
a O +
linear O +
relationship O +
( O -
correlation O +
coefficient O -
, O +
0.9995 O -
) O -
, O +
indicating O +
the O +
presence O +
of O +
single O -
- O -
site O +
binding O +
between O +
acetyldigitoxin O +
and O +
HSA B-Gene +
( O -
see O +
Fig. O +
4 O +
) O -
. O +

From O +
the O +
reciprocal O +
of O +
the O +
intercept O +
in O +
this O +
graph O -
, O +
an O +
association O +
equilibrium O +
constant O +
of O +
4.8 O +
( O -
±0.2 O -
) O -
× O -
10−4 O +
M−1 O +
was O +
obtained O +
for O +
the O +
competition O +
of O +
acetyldigitoxin O +
with O +
itself O +
at O +
its O +
binding O +
regions O +
on O +
HSA B-Gene -
. O +

Another O +
zonal O +
elution O +
study O +
examined O +
the O +
competition O +
of O +
injected O +
digitoxin O +
in O +
the O +
presence O +
of O +
acetyldigitoxin O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

The O +
plots O +
of O +
1 O -
/ O -
k O +
A O +
′ O +
versus O +
various O +
acetyldigitoxin O +
concentrations O +
below O +
0.5 O +
μM O +
gave O +
linear O +
relationships O +
with O +
correlation O +
coefficients O +
of O +
0.9995–0.9999 O +
over O +
the O +
four O +
data O +
points O +
obtained O +
at O +
each O +
concentration O +
of O +
β O -
- O -
cyclodextrin O -
. O +

The O +
ratio O +
of O +
the O +
intercepts O +
and O +
slopes O +
were O +
plotted O +
against O +
the O +
concentration O +
of O +
β O -
- O -
cyclodextrin O -
, O +
which O +
gave O +
a O +
linear O +
relationship O +
with O +
a O +
correlation O +
coefficient O +
of O +
0.9991 O +
( O -
see O +
Fig. O +
4 O +
) O -
. O +

From O +
the O +
reciprocal O +
of O +
the O +
intercept O +
in O +
this O +
plot O -
, O +
an O +
association O +
equilibrium O +
constant O +
of O +
4.9 O +
( O -
±0.2 O -
) O -
× O -
10−4 O +
M−1 O +
was O +
found O +
for O +
acetyldigitoxin O +
at O +
the O +
site O +
where O +
both O +
it O +
and O +
digitoxin O +
were O +
binding O +
to O +
HSA B-Gene -
. O +

This O +
association O +
equilibrium O +
constant O +
was O +
statistically O +
identical O +
to O +
that O +
seen O +
for O +
acetyldigitoxin O +
at O +
its O +
site O +
of O +
competition O +
with O +
itself O -
, O +
again O +
indicating O +
that O +
these O +
two O +
agents O +
each O +
had O +
just O +
one O +
common O +
binding O +
region O +
on O +
HSA B-Gene -
. O +

4.4 O +
Competitive O +
binding O +
studies O +
using O +
warfarin O +
or O +
L O -
- O -
tryptophan O +
as O +
mobile O +
phase O +
additives O -
. O +

It O +
has O +
previously O +
been O +
proposed O +
in O +
the O +
literature O +
that O +
digitoxin O +
has O +
a O +
distinct O +
site O +
on O +
HSA B-Gene +
that O +
is O +
separate O +
from O +
the O +
warfarin O +
and O +
indole O +
binding O +
regions O +
[ O -
6 O -
] O +
. O +

It O +
has O +
also O +
been O +
reported O +
that O +
digitoxin O +
does O +
not O +
compete O +
with O +
warfarin O +
or O +
diazepam O +
( O -
a O +
marker O +
for O +
the O +
indole B-Gene +
site I-Gene +
of I-Gene +
HSA I-Gene -
) O +
in O +
the O +
presence O +
of O +
rat B-Gene +
α I-Gene -
- I-Gene -
fetoprotein I-Gene -
, O +
which O +
is O +
closely O -
- O -
related O +
to O +
HSA B-Gene +
in O +
its O +
structure O +
[ O -
32 O -
] O +
. O +

The O +
binding O +
( O -
or O +
lack O +
of O +
binding O -
) O +
of O +
digitoxin O +
and O +
acetyldigitoxin O +
at O +
the O +
warfarin B-Gene +
and O +
indole O +
sites B-Gene +
of B-Gene +
HSA I-Gene +
was O +
examined O +
in O +
this O +
study O +
by O +
performing O +
competitive O +
binding O +
zonal O +
elution O +
studies O +
between O +
these O +
drugs O +
and O +
warfarin O +
or O +
L O -
- O -
tryptophan O -
, O +
which O +
are O +
often O +
used O +
as O +
probes O +
for O +
the O +
warfarin B-Gene +
and O +
indole B-Gene +
sites I-Gene +
of I-Gene +
HSA I-Gene -
. O +

The O +
first O +
zonal O +
elution O +
studies O +
in O +
this O +
section O +
involved O +
the O +
injection O +
of O +
digitoxin O +
or O +
acetyldigitoxin O +
into O +
the O +
presence O +
of O +
warfarin O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

In O +
these O +
experiments O -
, O +
only O +
random O +
variations O +
of O +
±2–3 O -
% O +
were O +
noted O +
in O +
k O +
A O +
′ O +
for O +
injections O +
of O +
acetyldigitoxin O +
and O +
digitoxin O +
when O +
0–10 O +
μM O +
warfarin O +
was O +
present O +
in O +
the O +
mobile O +
phase O -
. O +

Furthermore O -
, O +
both O +
acetyldigitoxin O +
and O +
digitoxin O +
gave O +
graphs O +
of O +
1 O -
/ O -
k O +
A O +
′ O +
versus O +
[ O -
warfarin O -
] O +
that O +
had O +
small O +
correlation O +
coefficients O +
( O -
0.1865–0.1942 O +
over O +
seven O +
data O +
points O -
) O +
and O +
best O -
- O -
fit O +
slopes O +
that O +
were O +
statistically O +
equal O +
to O +
zero O +
( O -
i.e. O -
, O +
slopes O +
that O +
overlapped O +
with O +
zero O +
within O +
a O +
range O +
of O +
±1 O +
SD O -
) O -
. O +

These O +
results O +
indicated O +
that O +
no O +
competition O +
existed O +
between O +
these O +
compounds O +
and O +
warfarin O +
for O +
binding B-Gene +
sites I-Gene +
on I-Gene +
HSA I-Gene -
, O +
in O +
agreement O +
with O +
previous O +
observations O +
[ O -
6 O -
] O +
. O +

This O +
confirmed O +
that O +
digitoxin O +
and O +
acetyldigitoxin O +
were O +
not O +
binding O +
at O +
the O +
warfarin B-Gene +
site I-Gene +
of I-Gene +
HSA I-Gene -
. O +

Competitive O +
binding O +
studies O +
between O +
digitoxin O +
or O +
acetyldigitoxin O +
and O +
L O -
- O -
tryptophan O +
produced O +
similar O +
negative O +
results O -
. O +

For O +
these O +
experiments O -
, O +
random O +
variations O +
of O +
±0.3–0.4 O -
% O +
were O +
noted O +
in O +
k O +
A O +
′ O +
for O +
injections O +
of O +
acetyldigitoxin O +
and O +
digitoxin O +
when O +
0–50 O +
μM O +
L O -
- O -
tryptophan O +
was O +
used O +
as O +
a O +
mobile O +
phase O +
additive O -
. O +

The O +
correlation O +
coefficients O +
for O +
plots O +
of O +
1 O -
/ O -
k O +
A O +
′ O +
versus O +
[ O -
L O -
- O -
tryptophan O -
] O +
gave O +
values O +
of O +
only O +
0.0081–0.0417 O +
over O +
seven O +
data O +
points O -
, O +
and O +
the O +
best O -
- O -
fit O +
slopes O +
were O +
again O +
statistically O +
equal O +
to O +
zero O +
within O +
a O +
range O +
of O +
±1 O +
SD O -
. O +

As O +
in O +
the O +
previous O +
solution O -
- O -
phase O +
studies O +
[ O -
6 O -
] O +
, O +
this O +
indicated O +
that O +
digitoxin O +
and O +
acetyldigitoxin O +
were O +
not O +
competing O +
with O +
L O -
- O -
tryptophan O +
and O +
did O +
not O +
have O +
any O +
detectable O +
interactions O +
at O +
the O +
indole B-Gene +
site I-Gene +
of I-Gene +
HSA I-Gene -
. O +

5 O +
Conclusion O +
In O +
this O +
report O -
, O +
HPAC O +
and O +
competitive O +
binding O +
zonal O +
elution O +
studies O +
were O +
used O +
to O +
characterize O +
the O +
binding O +
of O +
digitoxin O +
and O +
acetyldigitoxin O +
to O +
immobilized O +
HSA B-Gene -
, O +
with O +
β O -
- O -
cyclodextrin O +
being O +
used O +
in O +
the O +
mobile O +
phase O +
as O +
a O +
solubilising O +
agent O -
. O +

These O +
experiments O +
indicated O +
that O +
digitoxin O +
and O +
acetyldigitoxin O +
each O +
had O +
a O +
single O +
common O +
binding O +
site O +
on O +
HSA B-Gene -
, O +
but O +
with O +
slightly O +
different O +
equilibrium O +
constants O +
for O +
this O +
region O -
. O +

The O +
association O +
constants O +
that O +
were O +
measured O +
( O -
see O +
Table O +
1 O +
) O +
were O +
in O +
good O +
agreement O +
with O +
earlier O +
solution O -
- O -
phase O +
estimates O +
[ O -
31 O -
] O +
. O +

Neither O +
digitoxin O +
or O +
acetyldigitoxin O +
showed O +
any O +
competition O +
with O +
warfarin O +
or O +
L O -
- O -
tryptophan O -
, O +
which O +
were O +
used O +
as O +
probes O +
for O +
binding O +
at O +
the O +
warfarin B-Gene -
- I-Gene -
azapropazone I-Gene +
and O +
indole B-Gene -
- I-Gene -
benzodiazepine I-Gene +
sites I-Gene +
of I-Gene +
HSA I-Gene -
. O +

Thus O -
, O +
these O +
data O +
support O +
a O +
model O +
in O +
which O +
HSA B-Gene +
has O +
a O +
separate O +
binding O +
region O +
for O +
digitoxin O -
- O -
related O +
compounds O -
, O +
as O +
proposed O +
previously O +
[ O -
6 O -
] O +
. O +

Similar O +
competitive O +
binding O +
studies O +
could O +
be O +
used O +
to O +
examine O +
the O +
binding O +
of O +
other O +
compounds O +
to O +
HSA B-Gene -
, O +
including O +
digitoxin O -
- O -
related O +
cardiovascular O +
drugs O +
or O +
other O +
therapeutic O +
agents O +
that O +
may O +
be O +
co O -
- O -
administered O +
with O +
digitoxin O +
or O +
acetyldigitoxin O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
the O +
National O +
Institutes O +
of O +
Health O +
under O +
grant O +
R01 O +
GM44931 O -
. O +

The O +
cellular O +
responses O +
of O +
plants O +
to O +
numerous O +
extracellular O +
stimuli O +
are O +
mediated O +
by O +
transient O +
elevations O +
in O +
the O +
concentration O +
of O +
cytosolic O +
free O +
calcium O +
( O -
[ O -
Ca2+ O -
] O -
cyt O -
) O -
. O +

We O +
have O +
addressed O +
the O +
question O +
of O +
how O +
cells O +
can O +
use O +
this O +
apparently O +
ubiquitous O +
system O +
to O +
initiate O +
so O +
many O +
specific O +
and O +
appropriate O +
end O +
responses O -
. O +

We O +
show O +
that O +
the O +
pollutant O +
gas O +
ozone O +
elicits O +
a O +
biphasic O +
Ca2 O -
+ O +
response O +
in O +
intact O +
Arabidopsis O +
plants O +
and O +
a O +
subsequent O +
increase O +
in O +
expression O +
of O +
the O +
gene O +
encoding O +
the O +
antioxidant O +
defence O +
enzyme O +
glutathione B-Gene -
- I-Gene -
S I-Gene -
- I-Gene -
transferase I-Gene +
( O -
GST B-Gene -
) O -
. O +

The O +
second O +
of O +
the O +
two O +
[ O -
Ca2+ O -
] O -
cyt O +
peaks O -
, O +
but O +
not O +
the O +
first O -
, O +
could O +
be O +
eliminated O +
either O +
by O +
pre O -
- O -
treatment O +
of O +
plants O +
with O +
lanthanum O +
chloride O -
, O +
or O +
by O +
reducing O +
the O +
duration O +
of O +
ozone O +
fumigation O -
. O +

Under O +
these O +
conditions O -
, O +
ozone O -
- O -
induced O +
GST B-Gene +
expression O +
was O +
abolished O -
. O +

These O +
data O +
provide O +
a O +
functional O +
dissection O +
of O +
the O +
ozone O +
Ca2 O -
+ O +
signalling O +
pathway O +
and O +
indicate O +
that O +
the O +
second O +
ozone O -
- O -
induced O +
[ O -
Ca2+ O -
] O -
cyt O +
peak O +
provides O +
the O +
necessary O +
information O +
to O +
direct O +
expression O +
of O +
GST B-Gene -
. O +

Dipiperon O +
drops O +
30 O -
- O -
180 O +
mg O -
/ O -
day O +
were O +
given O +
for O +
eight O +
weeks O +
to O +
29 O +
children O +
with O +
character O +
neuroses O +
and O +
behavioural O +
disorders O -
. O +

A O +
16-item O +
rating O -
- O -
scale O +
covering O +
several O +
features O +
of O +
behaviour O +
disorder O +
was O +
completed O +
by O +
a O +
psychologist O +
and O +
a O +
teacher O +
independent O +
from O +
each O +
other O -
. O +

The O +
individual O +
number O +
of O +
pathological O +
scores O +
showed O +
a O +
decrease O +
already O +
within O +
the O +
first O +
treatment O +
week O +
and O +
a O +
further O +
decrease O +
by O +
the O +
end O +
of O +
the O +
trial O -
, O +
especially O +
for O +
the O +
items O +
of O +
capriciousness O -
, O +
obstinacy O -
, O +
irritability O +
and O +
restlessness O -
. O +

The O +
therapeutic O +
benefit O +
was O +
not O +
accompanied O +
by O +
an O +
adverse O +
effect O +
on O +
the O +
school O +
performance O +
of O +
the O +
children O -
. O +

No O +
side O -
- O -
effects O +
were O +
reported O +
or O +
observed O -
. O +

In O +
starfish O +
oocytes O -
, O +
maturation O +
is O +
induced O +
by O +
a O +
hormone O -
, O +
1-methyladenine O +
( O -
1-MA O -
) O -
, O +
that O +
binds O +
to O +
the O +
receptors B-Gene +
exposed O +
to O +
the O +
outer O +
surface O +
of O +
the O +
plasma O +
membrane O -
. O +

The O +
signal O +
of O +
1-MA O +
stimulates O +
the O +
heterotrimeric O +
G B-Gene +
protein I-Gene -
, O +
resulting O +
in O +
dissociation O +
of O +
the O +
betagamma O +
subunit O +
of O +
G B-Gene +
protein I-Gene +
( O -
Gbetagamma B-Gene -
) I-Gene +
from O +
a O +
pertussis B-Gene +
toxin I-Gene -
- O -
sensitive O +
Gi O -
- O -
type O +
alpha O +
subunit O -
. O +

To O +
investigate O +
the O +
targets O +
for O +
Gbetagamma B-Gene -
, O +
we O +
analyzed O +
1-MA- O +
or O +
Gbetagamma B-Gene -
- O -
dependent O +
phosphorylation O +
using O +
in O +
vivo O +
and O +
in O +
vitro O +
systems O -
. O +

A O +
62-kDa B-Gene +
protein I-Gene +
was O +
phosphorylated O +
immediately O +
after O +
1-MA O +
treatment O +
in O +
intact O +
oocytes O -
. O +

In O +
the O +
cell O -
- O -
free O +
preparations O -
, O +
the O +
62-kDa B-Gene +
protein I-Gene +
was O +
also O +
phosphorylated O +
on O +
serine O +
residue O -
( O -
s O -
) O +
immediately O +
after O +
addition O +
of O +
1-MA O +
or O +
Gbetagamma B-Gene -
. O +

The O +
Gbetagamma B-Gene -
- O -
dependent O +
phosphorylation O +
of O +
the O +
62-kDa B-Gene +
protein I-Gene +
was O +
inhibited O +
by O +
wortmannin O +
or O +
LY294002 O -
, O +
which O +
are O +
mechanistically O +
different O +
inhibitors O +
of O +
phosphatidylinositol B-Gene +
3-kinase I-Gene +
( O -
PI3 B-Gene -
K I-Gene -
) O -
. O +

LY294002 O +
also O +
inhibited O +
Gbetagamma- B-Gene +
as O +
well O +
as O +
1-MA O -
- O -
induced O +
maturation O +
of O +
oocytes O -
. O +

Taken O +
together O -
, O +
these O +
results O +
indicate O +
that O +
the O +
62-kDa B-Gene +
protein I-Gene +
functions O +
downstream O +
of O +
Gbetagamma B-Gene +
and O +
PI3 B-Gene -
K I-Gene +
in O +
the O +
early O +
signaling O +
pathway O +
of O +
1-MA O -
- O -
induced O +
starfish O +
oocyte O +
maturation O -
. O +

The O +
phosphorylation O +
of O +
the O +
62-kDa B-Gene +
protein I-Gene +
may O +
be O +
required O +
for O +
the O +
activation O +
of O +
maturation O -
- O -
promoting O +
factor O -
. O +

The O +
flavoenzyme B-Gene +
d B-Gene -
- I-Gene -
aspartate I-Gene +
oxidase I-Gene +
from O +
beef O +
kidney O +
( O -
DASPO B-Gene -
, O +
EC B-Gene +
1.4 I-Gene -
. I-Gene +
3.1 I-Gene -
) O +
has O +
been O +
overexpressed O +
in O +
Escherichia O +
coli O -
. O +

A O +
purification O +
procedure O -
, O +
faster O +
than O +
the O +
one O +
used O +
for O +
the O +
enzyme O +
from O +
the O +
natural O +
source O +
( O -
bDASPO B-Gene -
) O -
, O +
has O +
been O +
set O +
up O +
yielding O +
about O +
2 O +
mg O +
of O +
pure O +
recombinant B-Gene +
protein I-Gene +
( O -
rDASPO B-Gene -
) O +
per O +
each O +
gram O +
of O +
wet O +
E. O +
coli O +
paste O -
. O +

rDASPO B-Gene +
has O +
been O +
shown O +
to O +
possess O +
the O +
same O +
general O +
biochemical O +
properties O +
of O +
bDASPO B-Gene -
, O +
except O +
that O +
the O +
former O +
contains O +
only O +
FAD O -
, O +
while O +
the O +
latter O +
is O +
a O +
mixture O +
of O +
two O +
forms O -
, O +
one O +
active O +
containing O +
FAD O +
and O +
one O +
inactive O +
containing O +
6-OH O -
- O -
FAD O +
( O -
9 O -
- O -
20 O -
% O +
depending O +
on O +
the O +
preparation O -
) O -
. O +

This O +
results O +
in O +
a O +
slightly O +
higher O +
specific O +
activity O +
( O -
about O +
15 O -
% O -
) O +
for O +
rDASPO B-Gene +
compared O +
to O +
bDASPO B-Gene +
and O +
in O +
facilitated O +
procedures O +
for O +
apoprotein B-Gene +
preparation O +
and O +
reconstitution O -
. O +

Redox O +
potentials O +
of O +
-97 O +
mV O +
and O +
-157 O +
mV O +
were O +
determined O +
for O +
free O +
and O +
l- O -
( O -
+ O -
) O -
-tartrate O +
complexed O +
DASPO B-Gene -
, O +
respectively O -
, O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
25 O +
degrees O +
C. O +
The O +
large O +
positive O +
shift O +
in O +
the O +
redox O +
potential O +
of O +
the O +
coenzyme O +
compared O +
to O +
free O +
FAD O +
( O -
-207 O +
mV O -
) O +
is O +
in O +
agreement O +
with O +
similar O +
results O +
obtained O +
with O +
other O +
flavooxidases B-Gene -
. O +

rDASPO B-Gene +
has O +
been O +
used O +
to O +
assess O +
a O +
possible O +
oxidative O +
activity O +
of O +
the O +
enzyme B-Gene +
towards O +
a O +
number O +
of O +
compounds O +
used O +
as O +
agonists O +
or O +
antagonists O +
of O +
neurotransmitters O -
, O +
including O +
d O -
- O -
aspartatic O +
acid O -
, O +
d O -
- O -
glutamic O +
acid O -
, O +
N O -
- O -
methyl O -
- O -
d O -
- O -
aspartic O +
acid O -
, O +
d O -
, O -
l O -
- O -
cysteic O +
acid O -
, O +
d O -
- O -
homocysteic O +
acid O -
, O +
d O -
, O +
l-2-amino-3-phosphonopropanoic O +
acid O -
, O +
d O -
- O -
alpha O -
- O -
aminoadipic O +
acid O -
, O +
d O -
- O -
aspartic O +
acid O -
- O -
beta O -
- O -
hydroxamate O -
, O +
glycyl O -
- O -
d O -
- O -
aspartic O +
acid O +
and O +
cis-2 O -
, O +
3-piperidine O +
dicarboxylic O +
acid O -
. O +

Kinetic O +
parameters O +
for O +
each O +
substrate O +
in O +
50 O +
mM O +
KPi O -
, O +
pH O +
7.4 O -
, O +
25 O +
degrees O +
C O +
are O +
reported O -
. O +

LD50 O +
of O +
karminomycin O -
, O +
rubomycin O +
and O +
adriamycin O +
were O +
determined O +
after O +
their O +
single O +
administration O +
or O +
3- O -
, O +
5- O -
, O +
10- O +
and O +
15-fold O +
administration O +
once O +
a O +
day O +
to O +
540 O +
hybrid O +
male O +
mice O +
F1 O -
( O -
C57B1 O +
X O +
CBA O -
) O -
. O +

Comparison O +
of O +
the O +
cumulative O +
indices O +
for O +
these O +
antibiotics O +
showed O +
that O +
after O +
injections O +
they O +
were O +
close O -
. O +

After O +
5 O +
injections O +
the O +
cumulative O +
properties O +
were O +
more O +
pronounced O +
for O +
adriamycin O -
. O +

After O +
10 O +
or O +
15 O +
injections O +
the O +
cumulative O +
properties O +
were O +
less O +
pronounced O +
for O +
karminomycin O -
. O +

We O +
have O +
compared O +
the O +
minimum O +
local O +
analgesic O +
concentrations O +
( O -
MLAC O -
) O +
of O +
levobupivacaine O +
relative O +
to O +
racemic O +
bupivacaine O +
in O +
a O +
prospective O -
, O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
sequential O +
allocation O +
study O -
. O +

Women O +
in O +
labour O +
were O +
given O +
a O +
20-ml O +
bolus O +
of O +
epidural O +
levobupivacaine O +
or O +
bupivacaine O +
diluted O +
to O +
a O +
concentration O +
determined O +
by O +
up O -
- O -
down O +
sequential O +
allocation O -
. O +

The O +
initial O +
concentration O +
was O +
0.07 O -
% O +
w O -
/ O -
v O +
for O +
both O +
drugs O -
. O +

Efficacy O +
was O +
defined O +
using O +
a O +
visual O +
analogue O +
pain O +
score O +
( O -
VAPS O -
) O +
at O +
10 O +
mm O +
or O +
less O +
within O +
30 O +
min O -
. O +

The O +
MLAC O +
of O +
levobupivacaine O +
was O +
0.083 O -
% O +
w O -
/ O -
v O +
( O -
95 O -
% O +
CI O +
0.065 O -
- O -
0.101 O -
) O +
and O +
the O +
MLAC O +
of O +
bupivacaine O +
0.081 O -
% O +
w O -
/ O -
v O +
( O -
95 O -
% O +
CI O +
0.055 O -
- O -
0.108 O -
) O -
. O +

In O +
molar O +
terms O -
, O +
the O +
MLAC O +
of O +
levobupivacaine O +
was O +
2.87 O +
mmol O +
litre-1 O +
( O -
95 O -
% O +
CI O +
2.25 O -
- O -
3.49 O -
) O +
and O +
the O +
MLAC O +
of O +
bupivacaine O +
2.49 O +
mmol O +
litre-1 O +
( O -
95 O -
% O +
CI O +
1.69 O -
- O -
3.32 O -
) O -
. O +

With O +
regard O +
to O +
the O +
commercial O +
preparations O -
, O +
the O +
potency O +
ratio O +
levobupivacaine O -
: O +
bupivacaine O +
was O +
0.98 O +
( O -
95 O -
% O +
CI O +
0.67 O -
- O -
1.41 O -
) O -
, O +
and O +
this O +
is O +
unlikely O +
to O +
be O +
of O +
clinical O +
relevance O -
. O +

In O +
molar O +
terms O -
, O +
the O +
ratio O +
was O +
0.87 O +
( O -
95 O -
% O +
CI O +
0.60 O -
- O -
1.25 O -
) O -
. O +

With O +
regard O +
to O +
toxicity O -
, O +
the O +
evidence O +
should O +
be O +
evaluated O +
in O +
the O +
light O +
of O +
a O +
possible O +
13 O -
% O +
potency O +
difference O +
in O +
molar O +
concentration O +
in O +
favour O +
of O +
racemic O +
bupivacaine O -
. O +

The O +
expression O +
of O +
the O +
sialyl O +
Lewis O +
x O +
antigen O +
( O -
sLe O -
( O -
x O -
) O -
) O +
on O +
surgical O +
specimens O +
of O +
primary O +
gastric O +
cancer O +
correlates O +
with O +
the O +
degree O +
of O +
differentiation O +
and O +
synchronous O +
and O +
metachronous O +
liver O +
metastasis O -
. O +

Multivariate O +
analysis O +
by O +
means O +
of O +
Quantification O +
theory O +
II O +
revealed O +
that O +
sLe O -
( O -
x O -
) O +
expression O +
was O +
an O +
independent O +
risk O +
factor O +
for O +
liver O +
metastasis O +
from O +
gastric O +
cancer O -
. O +

Novel O +
as O +
well O +
as O +
known O +
5'-N O -
- O -
substituted O +
carboxamidoadenosines O +
were O +
prepared O +
via O +
new O +
routes O +
that O +
provided O +
shorter O +
reaction O +
times O +
and O +
good O +
yields O -
. O +

Binding O +
affinities O +
were O +
determined O +
for O +
rat O +
A1 B-Gene +
and O +
A2A B-Gene +
receptors I-Gene +
and O +
human O +
A3 B-Gene +
receptors I-Gene -
. O +

EC50 O +
values O +
were O +
determined O +
for O +
cyclic O +
AMP O +
production O +
in O +
CHO O +
cells O +
expressing O +
human O +
A2B B-Gene +
receptors I-Gene -
. O +

On O +
all O +
receptor O +
subtypes O +
relatively O +
small O +
substituents O +
on O +
the O +
carboxamido O +
moiety O +
were O +
optimal O -
. O +

Selectivity O +
for O +
the O +
A3 B-Gene +
receptor I-Gene +
was O +
found O +
for O +
several O +
analogues O +
( O -
1a O -
, O +
1d O -
, O +
1h O -
, O +
and O +
1k O -
) O -
. O +

On O +
A1 B-Gene +
receptors I-Gene +
a O +
number O +
of O +
compounds O -
, O +
but O +
not O +
5'-N O -
- O -
ethylcarboxamidoadenosine O +
( O -
NECA O -
, O +
1b O -
) O -
, O +
showed O +
small O +
GTP O +
shifts O -
, O +
which O +
could O +
be O +
indicative O +
of O +
lower O +
intrinsic O +
activities O +
at O +
the O +
A1 B-Gene +
receptor I-Gene -
. O +

At O +
the O +
A2B B-Gene +
receptor I-Gene -
, O +
derivatives O +
1i O -
- O -
k O +
with O +
modified O +
ethyl O +
substituents O +
had O +
reduced O +
activities O +
compared O +
to O +
the O +
A2B B-Gene +
reference O +
agonist O +
NECA O +
( O -
1b O -
) O -
. O +

Thiocarboxamido O +
derivatives O +
( O -
8b O +
and O +
8c O -
) O +
displayed O +
considerable O +
although O +
decreased O +
A2B B-Gene +
receptor I-Gene +
activity O -
. O +

The O +
X O -
- O -
ray O +
structure O +
determination O +
of O +
compound O +
8b O +
was O +
carried O +
out O -
. O +

Due O +
to O +
intramolecular O +
hydrogen O +
bonding O +
between O +
the O +
carboxamido O +
NH O +
and O +
the O +
purine O +
N3 O +
in O +
the O +
crystal O +
structure O -
, O +
the O +
ribose O +
moiety O +
of O +
this O +
compound O +
is O +
in O +
a O +
syn O +
conformation O -
. O +

However O -
, O +
theoretical O +
calculations O +
support O +
that O +
NECA O +
( O -
1b O -
) O -
, O +
and O +
less O +
so O +
8b O -
, O +
can O +
readily O +
adopt O +
both O +
the O +
syn O +
and O +
the O +
anti O +
conformation O -
, O +
therefore O +
not O +
excluding O +
the O +
proposed O +
anti O +
mode O +
of O +
binding O +
to O +
the O +
receptor B-Gene -
. O +

Calcitriol O -
, O +
also O +
known O +
as O +
1,25-dihydroxy O -
- O -
vitamin O +
D3 O -
, O +
is O +
a O +
steroid O +
hormone O +
that O +
has O +
been O +
shown O +
to O +
have O +
effects O +
on O +
cytokine B-Gene +
production O +
and O +
lymphocyte O +
proliferation O -
. O +

Coadministration O +
of O +
calcitriol O +
with O +
trivalent O +
influenza O +
vaccine O +
in O +
mice O +
enhanced O +
both O +
mucosal O +
and O +
systemic O +
antibody B-Gene +
responses O -
. O +

We O +
studied O +
the O +
effects O +
of O +
calcitriol O +
coadministered O +
with O +
a O +
commercially O +
available O +
influenza O +
vaccine O +
in O +
175 O +
human O +
volunteers O +
in O +
this O +
double O -
- O -
blind O -
, O +
placebo O +
controlled O +
clinical O +
trial O -
. O +

Subjects O +
that O +
received O +
calcitriol O +
experienced O +
more O +
pain O +
at O +
the O +
injection O +
site O +
compared O +
with O +
placebo O +
recipients O -
. O +

No O +
significant O +
differences O +
in O +
hemagglutination O +
inhibition O +
titers O +
against O +
H1N1 O -
, O +
H3N2 O -
, O +
or O +
influenza O +
B O +
antigens O +
were O +
detected O +
at O +
1 O +
or O +
3 O +
months O +
postvaccination O -
. O +

We O +
conclude O +
that O +
coadministration O +
of O +
1.0 O +
microg O +
of O +
calcitriol O +
at O +
a O +
site O +
adjacent O +
to O +
influenza O +
vaccination O +
does O +
not O +
enhance O +
humoral O +
immunity O +
in O +
human O +
volunteers O -
. O +

Influenza O +
viruses O +
have O +
been O +
responsible O +
for O +
epidemics O +
of O +
febrile O +
respiratory O +
infections O +
for O +
hundreds O +
of O +
years O -
. O +

Individuals O +
with O +
acute O +
influenza O +
A O +
infection O +
characteristically O +
develop O +
the O +
acute O +
onset O +
of O +
fever O -
, O +
myalgias O +
and O +
headache O -
, O +
followed O +
by O +
a O +
severe O +
upper O +
respiratory O +
illness O +
with O +
cough O +
lasting O +
for O +
days O +
or O +
weeks O -
. O +

Some O +
influenza O +
cases O +
progress O +
to O +
a O +
morbid O +
or O +
fatal O +
lower O +
respiratory O +
infection O -
. O +

During O +
the O +
great O +
pandemic O +
of O +
1918–1919 O -
, O +
more O +
persons O +
succumbed O +
to O +
complications O +
of O +
influenza O +
infection O +
than O +
were O +
killed O +
during O +
the O +
four O +
preceding O +
years O +
of O +
World O +
War O +
I O -
[ O -
1 O -
] O +
. O +

The O +
efficacy O +
of O +
vaccination O +
against O +
influenza O +
viruses O +
has O +
been O +
limited O +
by O +
the O +
ability O +
of O +
the O +
virus O +
to O +
alter O +
its O +
antigenic O +
structure O -
, O +
a O +
relatively O +
short O +
duration O +
of O +
immunity O -
, O +
and O +
incomplete O +
protection O +
provided O +
by O +
tolerable O +
doses O +
of O +
these O +
vaccines O -
. O +

1,25-dihydroxy O -
- O -
vitamin O +
D3 O -
, O +
also O +
known O +
as O +
calcitriol O -
, O +
has O +
potent O +
effects O +
on O +
cytokine B-Gene +
production O +
and O +
immune O +
functions O +
in O +
animals O +
and O +
humans O -
[ O -
2–6 O -
] O +
. O +

The O +
addition O +
of O +
calcitriol O +
to O +
a O +
variety O +
of O +
vaccine O +
preparations O +
has O +
been O +
shown O +
to O +
augment O +
induced O +
immunity O +
to O +
herpes O +
simplex O +
virus O -
, O +
tetanus O +
toxoid O -
, O +
hepatitis O +
B O +
surface O +
antigen O +
and O +
HIV O +
gp160 O -
[ O -
7–9 O -
] O +
. O +

Calcitriol O +
coadministered O +
with O +
trivalent O +
influenza O +
vaccine O +
in O +
mice O +
enhanced O +
both O +
mucosal O +
and O +
sytemic O +
antibody B-Gene +
responses O -
[ O -
10 O -
, O +
11 O -
] O +
. O +

Coadministration O +
of O +
calcitriol O +
in O +
this O +
study O +
also O +
enhanced O +
the O +
vaccinated O +
animals O -
' O +
ability O +
to O +
neutralize O +
live O +
influenza O +
virus O +
instilled O +
into O +
the O +
nose O -
. O +

Serum O +
influenza O +
hemagglutination O +
inhibition O +
( O -
HAI O -
) O +
titers O +
reflect O +
the O +
ability O +
of O +
the O +
host O +
immune O +
response O +
to O +
neutralize O +
infectivity O +
of O +
the O +
virus O -
. O +

Most O +
importantly O -
, O +
higher O +
HAI O +
titers O +
are O +
correlated O +
with O +
the O +
protection O +
of O +
humans O +
from O +
influenza O +
virus O +
induced O +
respiratory O +
disease O -
[ O -
12 O -
] O +
. O +

The O +
following O +
prospective O -
, O +
randomized O -
, O +
double O -
- O -
blind O +
clinical O +
trial O +
evaluated O +
calcitriol O +
as O +
a O +
potential O +
vaccine O -
- O -
enhancing O +
agent O +
when O +
coadministered O +
with O +
split O -
- O -
killed O +
influenza O +
vaccine O +
in O +
healthy O +
human O +
volunteers O -
. O +

We O +
hypothesized O +
that O +
calcitriol O +
and O +
influenza O +
vaccine O +
would O +
have O +
a O +
significant O +
enhancing O +
effect O +
on O +
influenza O +
hemagglutination O +
inhibition O +
( O -
HAI O -
) O +
titers O +
compared O +
to O +
a O +
parallel O +
control O +
group O +
that O +
received O +
influenza O +
vaccine O +
and O +
placebo O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Subjects O +
and O +
vaccinations O +
One O -
- O -
hundred O +
seventy O -
- O -
five O +
healthy O +
volunteers O +
were O +
enrolled O +
and O +
vaccinated O +
in O +
the O +
deltoid O +
muscle O +
with O +
0.5 O +
ml O +
1996–1997 O +
trivalent O +
split O -
- O -
killed O +
influenza O +
vaccine O +
( O -
Fluzone O -
, O +
Connaught O +
Laboratories O -
, O +
Inc. O -
, O +
Swiftwater O -
, O +
PA O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
recommendations O -
. O +

At O +
this O +
time O -
, O +
the O +
vaccinees O +
also O +
received O +
1.0 O +
mL O +
( O -
1.0 O +
μg O -
) O +
of O +
intramuscular O +
calcitriol O +
( O -
Calcijex O -
, O +
Abbott O +
Laboratories O -
, O +
North O +
Chicago O -
, O +
IL O -
) O +
or O +
a O +
matching O +
saline O +
placebo O +
at O +
a O +
site O +
adjacent O +
to O +
and O +
1.0 O +
cm O +
distant O +
from O +
the O +
influenza O +
vaccination O +
site O -
. O +

The O +
1.0 O +
cm O +
separation O +
of O +
the O +
two O +
injections O +
was O +
chosen O +
to O +
comply O +
with O +
federal O +
regulations O +
yet O +
still O +
allow O +
the O +
in O +
vivo O +
mixing O +
of O +
the O +
two O +
agents O +
necessary O +
for O +
the O +
immunologic O +
effects O +
of O +
calcitriol O -
. O +

The O +
1.0 O +
μg O +
dose O +
of O +
calcitriol O +
was O +
chosen O +
based O +
on O +
efficacy O +
in O +
preclinical O +
animal O +
studies O +
and O +
on O +
a O +
study O +
showing O +
a O +
lack O +
of O +
toxicity O +
in O +
normal O +
human O +
volunteers O -
[ O -
13 O -
, O +
14 O -
] O +
. O +

The O +
calcitriol O +
or O +
placebo O +
injections O +
were O +
administered O +
in O +
a O +
randomized O -
, O +
double O -
- O -
blind O +
manner O +
at O +
a O +
ratio O +
of O +
1:1 O -
. O +

The O +
subjects O +
were O +
vaccinated O +
and O +
observed O +
in O +
the O +
Clinical O +
Research O +
Center O +
within O +
the O +
University O +
of O +
Utah O +
Medical O +
Center O -
. O +

Serum O +
samples O +
were O +
obtained O +
at O +
the O +
time O +
of O +
vaccination O +
and O +
30 O +
and O +
90 O +
days O +
postvaccination O -
. O +

Serum O +
was O +
stored O +
at O +
−20 O -
° O -
C O -
. O +

before O +
thawing O +
and O +
analysis O -
. O +

The O +
study O +
was O +
reviewed O +
and O +
authorized O +
by O +
the O +
University O +
of O +
Utah O +
Institutional O +
Review O +
Board O +
and O +
by O +
the O +
US O +
Food O +
and O +
Drug O +
Administration O -
. O +

The O +
randomization O +
schedule O +
and O +
study O +
drug O +
were O +
prepared O +
by O +
the O +
University O +
of O +
Utah O +
Investigational O +
Pharmacy O -
. O +

The O +
blind O +
was O +
held O +
there O +
until O +
the O +
dataset O +
was O +
finalized O -
. O +

All O +
the O +
subjects O +
were O +
18–49 O +
years O +
of O +
age O +
( O -
male O +
or O +
female O -
) O -
, O +
in O +
good O +
physical O +
health O +
and O +
willing O +
to O +
provide O +
written O +
informed O +
consent O -
. O +

Female O +
subjects O +
in O +
their O +
childbearing O +
years O +
were O +
willing O +
to O +
perform O +
an O +
effective O +
method O +
of O +
contraception O +
during O +
the O +
study O +
period O -
. O +

Subjects O +
were O +
excluded O +
if O +
they O +
( O -
1 O -
) O +
were O +
pregnant O +
or O +
lactating O -
, O +
( O -
2 O -
) O +
had O +
received O +
an O +
investigational O +
drug O +
within O +
the O +
last O +
30 O +
days O -
, O +
( O -
3 O -
) O +
had O +
a O +
history O +
of O +
malignancy O -
, O +
renal O +
failure O -
, O +
nephrolithiasis O -
, O +
hypercalcemia O -
, O +
hyperparathyroidism O -
, O +
hypervitaminosis O +
D O +
or O +
other O +
serious O +
underlying O +
illnesses O -
, O +
( O -
4 O -
) O +
were O +
using O +
oral O +
steroids O -
, O +
had O +
used O +
oral O +
or O +
IV O +
calcitriol O +
within O +
the O +
past O +
2 O +
months O +
or O +
calcium O +
supplementation O +
in O +
the O +
past O +
2 O +
days O -
, O +
( O -
5 O -
) O +
had O +
already O +
received O +
any O +
1996–1997 O +
influenza O +
vaccine O +
or O +
( O -
6 O -
) O +
had O +
known O +
sensitivity O +
to O +
influenza O +
vaccines O -
, O +
calcitriol O +
or O +
any O +
components O +
of O +
these O +
commercial O +
preparations O -
. O +

Medical O +
histories O +
and O +
physical O +
examinations O +
were O +
performed O +
on O +
all O +
the O +
subjects O +
before O +
inclusion O +
and O +
vaccination O -
. O +

To O +
detect O +
potential O +
hypercalcemia O +
due O +
to O +
intramuscular O +
injection O +
of O +
calcitriol O -
, O +
the O +
first O +
20 O +
subjects O +
had O +
serum O +
calcium O +
and O +
phosphorus O +
determinations O +
at O +
the O +
time O +
of O +
vaccination O +
and O +
24 O +
h O +
later O -
. O +

The O +
subjects O +
were O +
asked O +
to O +
record O +
daily O +
oral O +
temperatures O -
, O +
general O +
symptoms O +
( O -
malaise O -
, O +
fatigue O -
) O +
and O +
local O +
symptoms O +
( O -
redness O -
, O +
swelling O +
and O +
soreness O +
at O +
the O +
injection O +
sites O -
) O +
the O +
day O +
of O +
and O +
for O +
3 O +
days O +
following O +
vaccination O -
. O +

Queries O +
were O +
made O +
about O +
adverse O +
events O +
and O +
concomitant O +
medications O +
at O +
the O +
30- O +
and O +
90-day O +
follow O +
up O +
visits O -
. O +

A O +
brief O +
questionnaire O +
intended O +
to O +
elicit O +
signs O +
and O +
symptoms O +
of O +
clinical O +
influenza O +
was O +
administered O +
at O +
the O +
90-day O +
follow O -
- O -
up O +
visit O -
. O +

2.2 O +
Serologies O +
The O +
primary O +
end O -
- O -
point O +
of O +
this O +
study O +
was O +
the O +
comparison O +
of O +
serum O +
hemagglutination O +
inhibition O +
( O -
HAI O -
) O +
titers O +
in O +
the O +
calcitriol O -
/ O -
vaccine O +
group O +
compared O +
with O +
the O +
placebo O -
/ O -
vaccine O +
group O -
. O +

Sera O +
were O +
thawed O -
, O +
treated O +
overnight O +
at O +
37 O -
° O -
C O +
with O +
receptor B-Gene +
destroying I-Gene +
enzyme I-Gene +
( O -
Sigma O -
, O +
Cat O +
# O -
C8772 O -
) O -
, O +
diluted O +
1:20 O +
and O +
serum O +
HAI O +
titers O +
determined O +
by O +
a O +
standard O +
method O -
[ O -
15 O -
] O +
. O +

Titers O +
are O +
reported O +
as O +
the O +
highest O +
dilution O +
of O +
sera O +
that O +
showed O +
complete O +
inhibition O +
of O +
agglutination O -
. O +

HAI O +
titers O +
for O +
each O +
of O +
the O +
three O +
1996–1997 O +
influenza O +
antigens O -
: O +
H1N1 O -
, O +
H3N2 O +
and O +
B O +
were O +
compared O +
between O +
the O +
groups O +
in O +
two O +
ways O -
: O +
( O -
1 O -
) O +
comparison O +
of O +
the O +
mean O +
and O +
median O +
rises O +
above O +
baseline O +
at O +
30 O +
and O +
90 O +
days O +
( O -
paired O +
analysis O -
) O -
, O +
( O -
2 O -
) O +
comparisons O +
between O +
the O +
groups O +
at O +
0 O +
( O -
baseline O -
) O -
, O +
30 O +
and O +
90 O +
days O +
( O -
unpaired O -
) O -
. O +

Secondary O +
end O -
- O -
points O +
of O +
the O +
trial O +
were O +
comparisons O +
of O +
serum O +
ELISA O +
titers O +
to O +
the O +
influenza O +
antigens O +
H1N1 O -
, O +
H3N2 O +
and O +
B O +
and O +
the O +
presence O +
of O +
clinical O +
influenza O +
syndrome O +
in O +
the O +
subjects O -
. O +

Antibody B-Gene +
to O +
subtype O -
- O -
specific O +
Influenza O +
hemagglutinin B-Gene +
is O +
measured O +
by O +
hemagglutination O +
inhibition O +
according O +
to O +
a O +
standard O +
CDC O +
protocol O +
using O +
each O +
of O +
the O +
above O +
three O +
antigens O +
( O -
H1N1 O -
, O +
H3N2 O +
and O +
B O -
; O +
CDC O -
, O +
Atlanta O -
, O +
GA O -
) O -
. O +

Titers O +
were O +
log2 O +
-transformed O +
for O +
analysis O +
as O +
follows O -
: O +
0 O -
= O -
no O +
hemagglutinating O +
activity O -
, O +
1=1:10 O -
, O +
2=1:20 O -
, O +
3=1 O -
: O +
40 O -
, O +
4=1:80 O -
, O +
etc O -
. O +

2.3 O +
Statistical O +
analysis O +
We O +
estimated O +
that O +
63 O +
evaluable O +
patients O +
per O +
group O +
( O -
126 O +
total O -
) O +
would O +
be O +
required O +
to O +
detect O +
a O +
one O +
log2 O +
( O -
twofold O -
) O +
increase O +
in O +
postvaccination O +
serum O +
HAI O +
titers O +
between O +
the O +
groups O -
. O +

The O +
group O +
size O +
was O +
determined O +
using O +
an O +
estimated O +
mean O +
HAI O +
titer O +
in O +
the O +
control O +
group O +
of O +
4.0 O +
log O +
units O -
, O +
a O +
standard O +
deviation O +
of O +
2.0 O +
log O +
units O -
, O +
significance O +
at O +
the O +
p O +
= O -
0.05 O +
level O +
and O +
a O +
power O +
to O +
detect O +
of O +
80 O -
% O +
( O -
β O +
= O -
0.20 O -
) O -
. O +

Demographic O +
parameters O -
, O +
serologic O +
titers O +
and O +
adverse O +
events O +
were O +
compared O +
using O +
the O +
nonparametric O +
Mann O -
– O -
Whitney O +
( O -
unpaired O -
) O +
or O +
Wilcoxan O +
( O -
paired O -
) O +
tests O -
. O +

3 O +
Results O +
3.1 O +
Demographics O +
A O +
total O +
of O +
175 O +
subjects O +
were O +
enrolled O +
and O +
vaccinated O +
during O +
the O +
influenza O +
season O +
beginning O +
in O +
October O -
, O +
1996 O +
and O +
ending O +
in O +
January O -
, O +
1997 O -
. O +

The O +
distributions O +
of O +
sex O -
, O +
race O +
and O +
age O +
were O +
not O +
significantly O +
different O +
between O +
the O +
placebo O +
and O +
calcitriol O +
groups O +
( O -
Table O +
1 O +
) O -
. O +

Most O +
of O +
the O +
subjects O +
were O +
young O +
and O +
white O -
; O +
many O +
were O +
medical O +
students O +
at O +
the O +
University O +
of O +
Utah O -
. O +

3.2 O +
Safety O +
analysis O +
None O +
of O +
the O +
calcitriol O -
/ O -
vaccine O +
or O +
placebo O +
vaccine O +
recipients O +
experienced O +
laboratory O -
- O -
defined O +
or O +
clinical O +
symptoms O +
of O +
hypercalcemia O -
. O +

There O +
were O +
no O +
significant O +
differences O +
in O +
serum O +
calcium O +
levels O +
between O +
the O +
calcitriol O +
and O +
placebo O +
groups O +
either O +
pretreatment O +
( O -
SCa2 O -
+ O +
= O -
9.6 O +
and O +
9.4 O +
mg O -
/ O -
dl O -
, O +
respectively O -
) O +
or O +
one O +
day O +
postinjection O +
( O -
SCa2 O -
+ O +
= O -
9.5 O +
and O +
9.4 O +
mg O -
/ O -
dl O -
, O +
respectively O -
) O -
. O +

Nearly O +
all O +
the O +
subjects O +
experienced O +
some O +
pain O +
at O +
the O +
injection O +
site O +
which O +
declined O +
rapidly O +
over O +
the O +
following O +
few O +
days O +
( O -
Fig. O +
1 O +
) O -
. O +

Subjects O +
in O +
the O +
calcitriol+flu O +
vaccine O +
group O +
were O +
more O +
likely O +
to O +
still O +
be O +
experiencing O +
pain O +
at O +
the O +
injection O +
site O +
2 O +
and O +
3 O +
days O +
postvaccination O +
compared O +
with O +
the O +
placebo+flu O +
vaccine O +
group O -
. O +

Overall O -
, O +
25–50 O -
% O +
of O +
the O +
subjects O +
reported O +
some O +
generalized O +
malaise O +
or O +
fatigue O +
on O +
the O +
day O +
of O +
or O +
1–3 O +
days O +
after O +
their O +
injections O -
. O +

Those O +
that O +
received O +
calcitriol O +
were O +
more O +
likely O +
to O +
experience O +
malaise O +
and O +
fatigue O +
1–2 O +
days O +
after O +
injection O +
( O -
time O -
- O -
course O +
data O +
not O +
shown O -
) O -
, O +
but O +
the O +
overall O +
frequency O +
of O +
these O +
symptoms O +
were O +
not O +
significantly O +
different O +
between O +
the O +
groups O -
. O +

No O +
significant O +
differences O +
in O +
redness O +
or O +
swelling O +
at O +
the O +
injection O +
site O +
were O +
observed O +
between O +
the O +
groups O +
at O +
any O +
time O -
- O -
point O -
. O +

Only O +
a O +
single O +
subject O +
experienced O +
fever O +
postvaccination O -
. O +

3.3 O +
Efficacy O +
analysis O +
Among O +
the O +
88 O +
subjects O +
enrolled O +
in O +
the O +
placebo O +
group O -
, O +
77 O +
( O -
88 O -
% O -
) O +
followed O +
through O +
and O +
provided O +
serum O +
for O +
analysis O +
28 O +
and O +
90 O +
days O +
postvaccination O -
. O +

In O +
the O +
calcitriol O +
group O +
76 O +
of O +
87 O +
subjects O +
( O -
87 O -
% O -
) O +
provided O +
serum O +
for O +
analysis O +
at O +
the O +
subsequent O +
time O +
points O -
. O +

Baseline O +
( O -
day O +
0 O -
) O +
influenza O +
HAI O +
titers O +
for O +
all O +
three O +
antigens O +
were O +
similar O +
between O +
the O +
calcitriol O +
and O +
placebo O +
groups O +
( O -
Fig. O +
2 O +
) O -
. O +

Including O +
all O +
subjects O +
in O +
both O +
groups O -
, O +
the O +
mean O +
absolute O +
HAI O +
titers O +
prevaccination O +
were O +
H1N1 O +
4.3 O -
, O +
H3N2 O +
2.3 O +
and O +
influenza O +
B O +
3.1 O +
log2 O +
units O +
( O -
Fig. O +
2 O +
) O -
. O +

These O +
titers O +
rose O +
significantly O +
to O +
6.2 O -
, O +
4.8 O +
and O +
4.9 O +
log2 O +
units O -
, O +
respectively O -
, O +
at O +
28 O +
days O +
postvaccination O -
. O +

HAI O +
titers O +
against O +
each O +
antigen O +
decreased O +
slightly O +
between O +
28 O +
and O +
90 O +
days O +
postvaccination O +
but O +
remained O +
above O +
prevaccination O +
levels O -
. O +

Coinjection O +
of O +
calcitriol O +
with O +
the O +
influenza O +
vaccine O +
failed O +
to O +
significantly O +
increase O +
28 O +
day O +
or O +
90 O +
day O +
HAI O +
titers O +
against O +
H1N1 O -
, O +
H3N2 O +
or O +
influenza O +
B O +
antigens O -
. O +

To O +
determine O +
whether O +
preexisting O +
immunity O +
to O +
any O +
of O +
the O +
influenza O +
antigens O +
might O +
influence O +
a O +
calcitriol O +
enhanced O +
response O -
, O +
a O +
censored O +
analysis O +
of O +
the O +
serologic O +
data O +
was O +
performed O -
. O +

Subjects O +
who O +
were O +
relatively O +
naive O +
to O +
influenza O +
antigens O -
, O +
defined O +
as O +
baseline O +
( O -
day O +
0 O -
) O +
H1N1 O -
, O +
H3N2 O +
or O +
influenza O +
B O +
HAI O +
titers O +
≤3 O +
log O +
units O +
( O -
1:40 O +
or O +
less O -
) O +
were O +
included O +
in O +
this O +
subanalysis O -
. O +

The O +
number O +
of O +
subjects O +
available O +
for O +
these O +
subanalyses O +
were O -
: O +
influenza O +
B O -
, O +
N O +
= O -
49 O +
( O -
placebo O -
) O -
, O +
46 O +
( O -
calcitriol O -
) O -
; O +
H1N1 O -
, O +
N O +
= O -
24 O -
, O +
33 O -
; O +
H3N2 O -
, O +
N O +
= O -
58 O -
, O +
58 O -
. O +

HAI O +
titers O +
for O +
each O +
of O +
the O +
influenza O +
antigens O +
in O +
these O +
naive O +
subjects O +
were O +
not O +
significantly O +
different O +
at O +
either O +
28 O +
or O +
90 O +
days O +
postvaccination O +
( O -
data O +
not O +
shown O -
) O -
. O +

Similar O +
nonsignificant O +
results O +
were O +
obtained O +
when O +
responses O +
were O +
analyzed O +
from O +
subjects O +
with O +
baseline O +
HAI O +
titers O +
of O +
≤2 O +
log O +
units O +
( O -
1:20 O +
or O +
less O -
) O -
. O +

4 O +
Discussion O +
This O +
double O +
blind O -
, O +
placebo O -
- O -
controlled O +
study O +
of O +
calcitriol O +
coinjected O +
with O +
a O +
commercial O +
influenza O +
vaccine O +
did O +
not O +
confirm O +
the O +
hypothesized O +
immunologic O +
benefit O +
of O +
this O +
compound O -
. O +

Intramuscular O +
calcitriol O +
coinjection O +
did O +
not O +
significantly O +
enhance O +
subsequent O +
serum O +
HAI O +
titers O +
to O +
any O +
of O +
the O +
vaccine O +
antigens O +
compared O +
to O +
a O +
saline O +
placebo O -
. O +

Calcitriol O +
injection O +
was O +
more O +
painful O +
and O +
resulted O +
in O +
more O +
malaise O +
and O +
fatigue O +
than O +
placebo O +
in O +
our O +
subjects O -
. O +

There O +
are O +
several O +
important O +
limitations O +
to O +
the O +
conclusions O +
which O +
may O +
be O +
drawn O +
from O +
this O +
controlled O +
human O +
study O -
. O +

It O +
should O +
be O +
noted O +
that O +
prior O +
exposure O +
and O +
immunity O +
to O +
influenza O +
viruses O +
within O +
the O +
study O +
population O -
, O +
the O +
manner O +
in O +
which O +
calcitriol O +
and O +
the O +
trivalent O +
influenza O +
vaccines O +
were O +
delivered O -
, O +
and O +
the O +
use O +
of O +
systemic O +
HAI O +
titers O +
as O +
the O +
primary O +
endpoint O +
may O +
all O +
have O +
had O +
a O +
masking O +
effect O +
on O +
the O +
immunomodulatory O +
properties O +
of O +
calcitriol O -
. O +

Since O +
HAI O +
titers O +
rather O +
than O +
ELISA O +
are O +
associated O +
with O +
protection O +
from O +
clinical O +
influenza O +
and O +
HAI O +
analysis O +
failed O +
to O +
show O +
a O +
benefit O +
from O +
calcitriol O -
, O +
ELISA O +
was O +
not O +
performed O +
on O +
the O +
serum O +
specimens O -
. O +

The O +
subjects O +
in O +
this O +
study O +
were O +
young O +
( O -
mean O +
age O +
32 O -
) O +
and O +
predominantly O +
white O -
. O +

Significant O +
baseline O +
HAI O +
titers O +
against O +
each O +
vaccine O +
antigen O +
were O +
detected O +
in O +
nearly O +
all O +
the O +
subjects O +
( O -
Fig. O +
2 O +
) O -
, O +
indicating O +
that O +
the O +
subjects O +
had O +
considerable O +
immunity O +
to O +
influenza O +
before O +
their O +
vaccination O -
. O +

This O +
is O +
understandable O +
in O +
our O +
study O +
population O -
, O +
which O +
included O +
many O +
medical O +
students O +
and O +
members O +
of O +
the O +
hospital O +
staff O +
required O +
to O +
have O +
annual O +
influenza O +
vaccinations O -
. O +

Nevertheless O -
, O +
vaccination O +
of O +
our O +
subjects O +
did O +
result O +
in O +
a O +
4–8-fold O +
( O -
2–3 O +
log2 O +
units O -
) O +
increase O +
in O +
HAI O +
titers O +
measured O +
one O +
month O +
later O -
. O +

The O +
study O +
was O +
designed O +
to O +
detect O +
a O +
twofold O +
difference O +
( O -
one O +
log2 O +
unit O -
) O +
in O +
HAI O +
titers O +
between O +
the O +
treated O +
and O +
control O +
groups O +
postvaccination O -
. O +

It O +
is O +
possible O +
that O +
there O +
was O +
a O +
small O +
positive O +
effect O +
of O +
calcitriol O +
that O +
was O +
undetectable O +
by O +
these O +
methods O -
. O +

However O -
, O +
the O +
nearly O +
identical O +
values O +
of O +
mean O +
HAI O +
titers O +
between O +
the O +
groups O +
at O +
all O +
the O +
timepoints O +
argues O +
against O +
any O +
real O +
effect O +
of O +
calcitriol O +
on O +
humoral O +
immunity O +
in O +
these O +
subjects O -
. O +

Malaise O +
and O +
fatigue O +
were O +
more O +
likely O +
to O +
have O +
been O +
experienced O +
in O +
the O +
calcitriol O -
- O -
injected O +
subjects O +
and O +
were O +
also O +
associated O +
with O +
pain O +
at O +
the O +
injection O +
site O +
2–3 O +
days O +
after O +
injection O -
. O +

Malaise O -
, O +
fatigue O -
, O +
redness O +
and O +
swelling O +
were O +
self O -
- O -
reported O -
, O +
necessarily O +
somewhat O +
subjective O +
and O +
probably O +
overreported O +
by O +
the O +
subjects O -
. O +

Since O +
a O +
sham O -
- O -
vaccine O +
group O +
was O +
not O +
included O +
in O +
this O +
trial O -
, O +
it O +
can O -
not O +
be O +
concluded O +
that O +
the O +
vaccine O +
itself O +
caused O +
these O +
subjective O +
symptoms O -
. O +

The O +
increased O +
pain O +
observed O +
in O +
the O +
calcitriol O -
- O -
injected O +
subjects O +
may O +
be O +
related O +
to O +
the O +
relatively O +
large O +
molecular O +
weight O +
of O +
this O +
compound O +
or O +
to O +
its O +
vehicle O +
formulated O +
for O +
intravenous O +
use O -
. O +

The O +
injection O +
of O +
calcitriol O +
next O +
to O +
but O +
1.0 O +
cm O +
distant O +
from O +
the O +
site O +
of O +
influenza O +
injection O +
may O +
have O +
limited O +
the O +
in O +
vivo O +
contact O +
of O +
calcitriol O +
with O +
influenza O +
antigens O -
. O +

Adjacent O +
injection O +
rather O +
than O +
direct O +
mixing O +
of O +
the O +
two O +
compounds O +
was O +
necessary O +
to O +
comply O +
with O +
federal O +
regulations O +
and O +
gain O +
FDA O +
approval O +
for O +
the O +
study O -
. O +

It O +
is O +
possible O +
that O +
mixing O +
of O +
calcitriol O +
and O +
influenza O +
vaccine O +
in O +
a O +
single O +
syringe O -
, O +
like O +
in O +
the O +
preliminary O +
animal O +
experiments O -
, O +
might O +
also O +
be O +
effective O +
in O +
humans O -
. O +

Finally O -
, O +
serum O +
rather O +
than O +
mucosal O +
antibody B-Gene +
levels O +
were O +
measured O +
in O +
these O +
subjects O -
. O +

Preclinical O +
studies O +
in O +
mice O +
showed O +
that O -
, O +
while O +
serum O +
influenza O +
antibody B-Gene +
levels O +
were O +
enhanced O +
by O +
calcitriol O -
, O +
a O +
much O +
more O +
dramatic O +
effect O +
was O +
seen O +
on O +
mucosal O +
antibodies B-Gene +
in O +
vaginal O +
fluid O -
[ O -
10 O -
, O +
11 O -
] O +
. O +

Future O +
studies O +
which O +
employ O +
calcitriol O +
as O +
a O +
candidate O +
vaccine O +
immunomodulator O +
should O +
incorporate O +
the O +
measurement O +
of O +
nasal O -
, O +
oral O +
or O +
vaginal O +
mucosal O +
antibodies B-Gene -
. O +

In O +
summary O -
, O +
calcitriol O +
had O +
no O +
demonstrable O +
immunologic O +
effects O +
on O +
influenza O +
vaccination O +
at O +
this O +
dose O +
and O +
route O +
in O +
this O +
relatively O +
young O +
healthy O +
population O -
. O +

Side O +
effects O -
, O +
particularly O +
pain O +
at O +
the O +
injection O +
site O -
, O +
were O +
increased O +
by O +
the O +
coadministration O +
of O +
calcitriol O +
with O +
influenza O +
vaccine O -
. O +

Other O +
strategies O +
should O +
be O +
employed O +
to O +
boost O +
the O +
effectiveness O +
and O +
duration O +
of O +
immunity O +
of O +
influenza O +
vaccines O -
. O +

Acknowledgements O +
The O +
authors O +
wish O +
to O +
thank O +
Dr. O +
James O +
Kushner O +
and O +
the O +
staff O +
of O +
the O +
University O +
of O +
Utah O +
Clinical O +
Research O +
Center O +
for O +
the O +
use O +
of O +
their O +
facility O +
and O +
expertise O +
in O +
completing O +
this O +
study O +
and O +
Dr. O +
Raymond O +
A. O +
Daynes O +
for O +
reviewing O +
the O +
manuscript O -
. O +

This O +
investigation O +
was O +
supported O +
by O +
research O +
grant O +
number O +
M01-RR00064 O +
from O +
the O +
National O +
Center O +
for O +
Research O +
Resources O -
, O +
and O +
by O +
Pharmadigm O +
Biosciences O -
, O +
Inc. O -
, O +
Salt O +
Lake O +
City O -
, O +
UT O -
. O +

In O +
intermediary O +
metabolism O -
, O +
lipoic O +
acid O +
( O -
LA O -
; O +
6,8-thioctic O +
acid O -
) O +
serves O +
as O +
a O +
prosthetic O +
group O +
covalently O +
linked O +
to O +
a O +
lysyl O +
residue O +
of O +
three O +
mitochondrial O +
α B-Gene -
- I-Gene -
keto I-Gene +
acid I-Gene +
dehydrogenase I-Gene +
complexes O -
; O +
namely O -
, O +
the O +
pyruvate B-Gene +
dehydrogenase I-Gene +
complex O +
( O -
PDC O -
) O -
, O +
the O +
α B-Gene -
- I-Gene -
ketoglutarate I-Gene +
dehydrogenase I-Gene +
complex O -
, O +
and O +
the O +
branched B-Gene -
- I-Gene -
chain I-Gene +
α I-Gene -
- I-Gene -
keto I-Gene +
acid I-Gene +
dehydrogenase I-Gene +
complex O -
, O +
and O +
also O +
to O +
H B-Gene +
protein I-Gene +
of O +
the O +
glycine B-Gene +
cleavage I-Gene +
system I-Gene +
[ O -
1,2 O -
] O +
. O +

These O +
complexes O +
are O +
involved O +
in O +
the O +
oxidation O +
of O +
carbohydrate O +
and O +
amino O +
acids O +
as O +
well O +
as O +
in O +
cellular O +
oxidative O +
metabolism O +
[ O -
1 O -
] O +
. O +

Reoxidation O +
of O +
reduced O +
lipoyl O +
moieties O +
of O +
these O +
four O +
complexes O +
is O +
carried O +
out O +
by O +
dihydrolipoamide B-Gene +
dehydrogenase I-Gene +
( O -
E3 B-Gene -
) O -
, O +
the O +
common O +
component O +
of O +
the O +
complexes O -
. O +

Additionally O -
, O +
E3 B-Gene +
recognizes O +
free O +
dihydrolipoamide O +
as O +
a O +
substrate O +
and O +
also O +
catalyzes O +
the O +
reverse O +
reaction O +
using O +
lipoamide O +
and O +
NADH O -
. O +

LA O +
itself O +
is O +
a O +
poor O +
substrate O +
for O +
the O +
reverse O +
reaction O +
of O +
E3 B-Gene +
[ O -
3 O -
] O +
. O +

Due O +
to O +
its O +
potent O +
anti O -
- O -
oxidant O +
properties O +
in O +
biological O +
systems O -
, O +
LA O +
has O +
been O +
used O +
as O +
a O +
therapeutic O +
agent O +
against O +
hepatic O +
and O +
neurological O +
disorders O -
. O +

Clinically O -
, O +
decreased O +
levels O +
of O +
endogenous O +
LA O +
were O +
reported O +
in O +
patients O +
with O +
liver O +
cirrhosis O -
, O +
diabetes O +
mellitus O -
, O +
polyneuritis O +
and O +
atherosclerosis O +
[ O -
4 O -
] O +
. O +

LA O +
has O +
been O +
used O +
in O +
therapeutic O +
treatments O +
for O +
the O +
relief O +
of O +
symptoms O +
of O +
diabetic O +
neuropathy O +
and O +
improvements O +
in O +
overall O +
cellular O +
metabolism O -
, O +
probably O +
via O +
the O +
stimulatory O +
effects O +
on O +
glucose O +
uptake O -
, O +
utlization O +
and O +
disposal O +
in O +
various O +
biological O +
tissues O +
[ O -
5–8 O -
] O +
. O +

LA O +
is O +
also O +
used O +
as O +
a O +
preventive O +
agent O +
for O +
calcium O +
oxalate O +
stone O +
formation O +
in O +
animals O +
[ O -
9,10 O -
] O +
. O +

Even O +
though O +
the O +
mechanisms O +
of O +
the O +
actions O +
of O +
LA O +
have O +
not O +
been O +
elucidated O -
, O +
these O +
therapeutic O +
effects O +
might O +
be O +
explained O +
by O +
the O +
free O -
- O -
radical O +
scavenging O +
role O +
of O +
dihydrolipoic O +
acid O +
( O -
DHLA O -
) O -
, O +
formed O +
by O +
intracellular O +
reduction O +
of O +
LA O +
[ O -
11 O -
] O +
, O +
since O +
exogenous O +
DHLA O +
prevented O +
oxidative O +
damage O +
to O +
membranes O -
, O +
low B-Gene +
density I-Gene +
lipoproteins I-Gene -
, O +
and O +
ischemia O +
reperfusion O +
injury O +
of O +
rat O +
heart O +
and O +
brain O +
[ O -
12,13 O -
] O +
. O +

Since O +
R O -
- O -
LA O +
is O +
increasingly O +
used O +
as O +
an O +
antioxidant O -
, O +
it O +
is O +
of O +
interest O +
to O +
evaluate O +
its O +
effects O +
on O +
pyruvate O +
metabolism O +
via O +
PDC B-Gene +
in O +
the O +
cell O -
. O +

Recently O -
, O +
1,2-diselenolane-3-pentanoic O +
acid O +
( O -
Se O -
- O -
LA O -
, O +
diseleno O +
lipoic O +
acid O -
) O -
, O +
a O +
derivative O +
of O +
LA O +
in O +
which O +
two O +
sulfur O +
atoms O +
are O +
substituted O +
with O +
selenium O +
atoms O -
, O +
was O +
also O +
found O +
to O +
be O +
an O +
effective O +
antioxidant O -
. O +

Although O +
both O +
LA O +
and O +
Se O -
- O -
LA O +
have O +
similar O +
chemical O +
structures O +
except O +
for O +
the O +
larger O +
selenium O +
atoms O +
in O +
the O +
1,2-dithiolane O +
ring O +
of O +
Se O -
- O -
LA O -
, O +
they O +
showed O +
remarkably O +
different O +
anti O -
- O -
oxidant O +
properties O +
against O +
various O +
biological O +
systems O +
[ O -
S. O +
Matsugo O -
, O +
L O -
.- O -
J. O +
Yan O -
, O +
H. O +
Ulrich O -
, O +
and O +
L. O +
Packer O +
( O -
unpublished O +
work O -
) O -
] O -
. O +

In O +
that O +
study O -
, O +
Se O -
- O -
LA O +
had O +
no O +
antioxidant O +
effect O +
on O +
protein B-Gene +
oxidative O +
modification O +
of O +
human B-Gene +
low I-Gene +
density I-Gene +
lipoprotein I-Gene -
, O +
but O +
it O +
showed O +
a O +
protective O +
effect O -
, O +
similar O +
to O +
LA O -
, O +
against O +
the O +
formation O +
of O +
lipid O +
peroxidation O +
products O -
. O +

In O +
earlier O +
works O -
, O +
both O +
enantiomers O +
of O +
lipoic O +
acid O +
( O -
R- O +
and O +
S- O +
forms O -
) O +
and O +
lipoic O +
acid O +
homologues O +
( O -
RS-1,2-dithiolane-3-caproic O +
acid O -
, O +
RS O -
- O -
bisnorlipoic O +
acid O +
and O +
RS O -
- O -
tetranorlipoic O +
acid O -
) O +
were O +
studied O +
for O +
the O +
substrate O +
selectivity O +
for O +
E3 B-Gene +
[ O -
14–17 O -
] O +
. O +

Furthermore O -
, O +
the O +
effects O +
of O +
LA O +
enantiomers O +
and O +
their O +
analogs O +
on O +
the O +
activities O +
of O +
PDC B-Gene +
and O +
its O +
catalytic O +
components O +
from O +
different O +
sources O +
have O +
been O +
investigated O +
with O +
variable O +
findings O +
[ O -
17 O -
] O +
, O +
and O +
the O +
possible O +
effects O +
of O +
Se O -
- O -
LA O +
on O +
PDC B-Gene +
have O +
not O +
been O +
reported O -
. O +

In O +
this O +
paper O -
, O +
we O +
report O +
the O +
effects O +
of O +
Se O -
- O -
LA O -
, O +
and O +
both O +
the O +
R- O +
and O +
S- O +
forms O +
of O +
LA O -
, O +
on O +
the O +
reactions O +
catalyzed O +
by O +
mammalian O +
PDC B-Gene +
and O +
its O +
individual O +
catalytic O +
components O +
as O +
well O +
as O +
their O +
effects O +
on O +
pyruvate O +
oxidation O +
by O +
intact O +
HepG2 O +
cells O -
. O +

Materials O +
and O +
methods O +
Materials O +
Porcine O +
heart O +
PDC B-Gene +
and O +
DL O -
- O -
lipoamide O +
were O +
purchased O +
from O +
Sigma O +
Chemical O +
Company O +
( O -
St. O +
Louis O -
, O +
MO O -
) O -
. O +

R O -
- O -
LA O -
, O +
S O -
- O -
LA O -
, O +
and O +
Se O -
- O -
LA O +
were O +
kindly O +
provided O +
by O +
ASTA O +
Medica O +
AG O -
, O +
Frankfurt O -
, O +
Germany O -
. O +

DL O -
- O -
Dihydrolipoamide O +
was O +
chemically O +
produced O +
by O +
the O +
reduction O +
of O +
DL O -
- O -
lipoamide O +
with O +
NaBH4 O +
[ O -
18 O -
] O +
. O +

[ O -
1 O -
- O -
14 O +
C O -
] O -
Acetyl O -
- O -
CoA O +
and O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
pyruvate O +
were O +
from O +
ICN O +
Pharmaceutical O +
Inc. O +
( O -
Costa O +
Mesa O -
, O +
CA O -
) O -
. O +

Other O +
chemicals O +
were O +
commercial O +
grade O -
. O +

Activity O +
measurements O +
of O +
PDC B-Gene +
and O +
its O +
catalytic O +
components O +
For O +
the O +
preparation O +
of O +
lipoic O +
acid O +
stock O +
solutions O -
, O +
R O -
- O -
LA O -
, O +
S O -
- O -
LA O -
, O +
and O +
Se O -
- O -
LA O +
were O +
dissolved O +
to O +
their O +
desired O +
concentrations O +
( O -
up O +
to O +
200 O +
mM O -
) O +
in O +
95 O -
% O +
( O -
v O -
/ O -
v O -
) O +
ethanol O -
, O +
daily O -
. O +

Experimental O +
assays O +
contained O +
5–40 O +
μl O +
of O +
these O +
lipoic O +
compounds O -
, O +
while O +
control O +
assays O +
contained O +
the O +
same O +
volume O +
of O +
95 O -
% O +
( O -
v O -
/ O -
v O -
) O +
ethanol O -
. O +

For O +
all O +
enzymes B-Gene +
in O +
this O +
study O -
, O +
one O +
unit O +
of O +
enzyme B-Gene +
activity O +
is O +
defined O +
as O +
the O +
formation O +
of O +
one O +
μmole O +
of O +
product O +
or O +
utilization O +
of O +
1 O +
μmole O +
of O +
substrate O +
per O +
min O +
at O +
37 O -
° O -
. O +

Porcine O +
heart O +
PDC B-Gene +
activity O +
was O +
assayed O +
by O +
measuring O +
the O +
14 O +
CO2 O +
produced O +
from O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
pyruvate O +
as O +
described O +
previously O +
[ O -
19 O -
] O +
. O +

The O +
reaction O +
was O +
carried O +
out O +
in O +
the O +
presence O +
of O +
0.5 O +
mM O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
pyruvate O +
( O -
200 O +
cpm O -
/ O -
nmole O -
) O -
, O +
0.2 O +
mM O +
thiamine O +
pyrophosphate O -
, O +
0.15 O +
mM O +
coenzyme O +
A O +
and O +
2 O +
mM O +
NAD+ O +
with O +
or O +
without O +
lipoic O +
compounds O +
( O -
0.25– O +
4 O +
mM O -
) O -
. O +

The O +
reaction O +
was O +
initiated O +
by O +
adding O +
3.7 O +
μg O +
of O +
porcine O +
heart O +
PDC B-Gene -
, O +
and O +
stopped O +
with O +
0.1 O +
ml O +
of O +
20 O -
% O +
( O -
W O -
/ O -
V O -
) O +
trichloroacetic O +
acid O +
containing O +
30 O +
mM O +
pyruvate O +
after O +
a O +
4 O +
min O +
reaction O +
at O +
37 O -
° O -
. O +

Released O +
14 O +
CO2 O +
was O +
absorbed O +
in O +
0.2 O +
ml O +
of O +
benzothonium O +
hydroxide O +
( O -
Sigma O +
Chemical O +
Company O -
, O +
St. O +
Louis O -
, O +
MO O -
) O +
for O +
1 O +
h O -
, O +
and O +
the O +
radioactivity O +
was O +
measured O +
in O +
a O +
Beckman O +
LS6500 O +
scintillation O +
counter O -
. O +

As O +
a O +
blank O -
, O +
radioactivity O +
from O +
control O +
assays O +
which O +
contained O +
buffer O +
in O +
place O +
of O +
enzyme B-Gene +
was O +
subtracted O +
from O +
other O +
assays O -
. O +

Recombinant B-Gene +
human I-Gene +
pyruvate I-Gene +
dehydrogenase I-Gene +
( O -
E1 B-Gene -
) O +
was O +
overexpressed O +
and O +
purified O +
according O +
to O +
Korotchkina O +
et O +
al. O +
[ O -
20 O -
] O +
. O +

The O +
activity O +
of O +
E1 B-Gene +
was O +
measured O +
using O +
the O +
artificial O +
electron O +
acceptor O -
, O +
2,6-dichlorophenol O -
- O -
indophenol O +
( O -
Sigma O +
Chemical O +
Company O -
, O +
St. O +
Louis O -
, O +
MO O -
) O -
, O +
in O +
the O +
presence O +
of O +
0–4 O +
mM O +
lipoic O +
compounds O +
with O +
either O +
0.1 O +
or O +
5 O +
mM O +
pyruvate O +
in O +
a O +
final O +
volume O +
of O +
1 O +
ml O +
[ O -
21 O -
] O +
. O +

The O +
change O +
in O +
absorbance O +
at O +
600 O +
nm O +
per O +
minute O +
was O +
measured O +
by O +
a O +
SHIMADZU O +
UV160U O +
spectrophotometer O +
and O +
the O +
μmoles O +
of O +
reduced O +
2,6-dichlorophenol O -
- O -
indo O -
- O -
phenol O +
were O +
calculated O +
using O +
the O +
extinction O +
coefficeint O +
of O +
15,600 O +
M−1 O +
cm−1 O +
. O +

The O +
activity O +
of O +
dihydrolipoamide B-Gene +
acetyltransferase I-Gene +
( O -
E2 B-Gene -
) O +
was O +
measured O +
in O +
the O +
reverse O +
direction O +
[ O -
22 O -
] O +
. O +

The O +
reaction O +
mixture O +
( O -
1 O +
ml O -
) O +
contained O +
43.5 O +
mM O +
MOPS O -
, O +
pH O +
7.4 O -
, O +
0.9 O +
mM O +
dithiothreitol O -
, O +
0.13 O +
mM O +
NADH O -
, O +
13.9 O +
mM O +
DL O -
- O -
dihydrolipoamide O -
, O +
0 O +
to O +
4 O +
mM O +
lipoic O +
compounds O -
, O +
and O +
about O +
320 O +
ng O +
of O +
porcine O +
heart O +
PDC B-Gene -
. O +

After O +
preincubation O +
for O +
3 O +
min O +
at O +
37 O -
° O -
, O +
the O +
reaction O +
was O +
started O +
by O +
the O +
addition O +
of O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
acetyl O -
- O -
CoA O +
( O -
final O +
concentration O +
0.36 O +
mM O -
, O +
43,200 O +
cpm O -
) O -
, O +
and O +
incubated O +
for O +
up O +
to O +
4.5 O +
min O -
. O +

The O +
radioactive O +
product O +
was O +
extracted O +
with O +
benzene O -
, O +
and O +
was O +
counted O +
in O +
a O +
Beckman O +
LS6500 O +
scintillation O +
counter O -
. O +

Radioactivity O +
from O +
control O +
samples O +
without O +
added O +
enzyme B-Gene +
was O +
subtracted O +
as O +
blank O -
. O +

Recombinant B-Gene +
human I-Gene +
E3 I-Gene +
was O +
overexpressed O +
by O +
Escherichia O +
coli O +
XL-1 O +
Blue O +
cells O +
with O +
pPROEX-1 O +
expression O +
vector O +
( O -
Life O +
Technologies O -
, O +
Inc. O -
; O +
Gaithersburg O -
, O +
MD O -
) O +
containing O +
cloned O +
human O +
E3 O +
cDNA O +
( O -
coding O +
region O +
for O +
mature O +
E3 O +
protein O -
) O +
[ O -
Y. O +
S. O +
Hong O +
and O +
M. O +
S. O +
Patel O +
( O -
unpublished O +
work O -
) O -
] O -
. O +

E3 B-Gene +
activities O +
in O +
the O +
forward O +
and O +
reverse O +
directions O +
were O +
measured O +
as O +
described O +
[ O -
3 O -
] O +
. O +

For O +
the O +
forward O +
reaction O -
, O +
the O +
1 O +
ml O +
reaction O +
mixture O +
contained O +
100 O +
mM O +
potassium O +
phosphate O +
buffer O -
, O +
pH O +
8.0 O -
, O +
3 O +
mM O +
DL O -
- O -
dihydrolipoamide O -
, O +
3 O +
mM O +
NAD+ O +
, O +
and O +
1.5 O +
mM O +
EDTA O -
. O +

The O +
reverse O +
reaction O +
contained O +
100 O +
mM O +
potassium O +
phosphate O +
buffer O -
, O +
pH O +
6.3 O -
, O +
3 O +
mM O +
lipoamide O +
( O -
or O +
varying O +
levels O +
of O +
other O +
lipoic O +
compounds O -
) O -
, O +
0.2 O +
mM O +
NAD+ O +
and O +
0.2 O +
mM O +
NADH O -
. O +

NAD+ O +
was O +
needed O +
to O +
eliminate O +
the O +
initial O +
lag O +
period O +
in O +
the O +
reaction O +
[ O -
3 O -
] O +
. O +

The O +
reaction O +
was O +
initiated O +
by O +
the O +
addition O +
of O +
E3 B-Gene -
. O +

The O +
rates O +
of O +
NADH O +
production O +
( O -
forward O -
) O +
or O +
consumption O +
( O -
reverse O -
) O +
per O +
min O +
were O +
measured O +
at O +
340 O +
nm O -
. O +

Km O +
s O +
and O +
Vmax O +
s O +
were O +
obtained O +
from O +
double O +
reciprocal O +
plots O +
of O +
each O +
E3 B-Gene +
reverse O +
reaction O +
obtained O +
by O +
varying O +
concentrations O +
of O +
lipoic O +
compounds O +
( O -
R O -
- O -
LA O -
, O +
0.07–0.3 O +
mM O -
; O +
S O -
- O -
LA O -
, O +
0.5–4 O +
mM O -
; O +
Se O -
- O -
LA O -
, O +
0.18–0.625 O +
mM O -
; O +
DL O -
- O -
dihydrolipoamide O -
, O +
0.48 O -
- O -
1.8 O +
mM O -
) O +
as O +
substrates O -
. O +

k O +
cat O +
, O +
the O +
number O +
of O +
product O +
molecules O +
per O +
active O +
site O +
of O +
the O +
enzyme B-Gene +
per O +
sec O -
, O +
was O +
calculated O +
based O +
on O +
Vmax O +
and O +
2 O +
active O +
sites O +
per O +
E3 O +
dimer O -
. O +

Pyruvate O +
decarboxylation O +
was O +
carried O +
out O +
using O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
pyruvate O +
with O +
cultured O +
HepG2 O +
cells O +
( O -
American O +
Type O +
Culture O +
Collection O -
; O +
Rockville O -
, O +
MD O -
) O -
. O +

HepG2 O +
cells O +
were O +
cultured O +
in O +
minimum O +
essential O +
medium O +
( O -
MEM O -
) O +
containing O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
fetal O +
calf O +
serum O +
[ O -
24 O -
] O +
. O +

Confluent O +
HepG2 O +
cells O +
were O +
harvested O +
by O +
trypsinization O +
and O +
separated O +
by O +
centrifugation O -
, O +
and O +
washed O +
with O +
MEM O +
containing O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
fetal O +
calf O +
serum O -
. O +

To O +
convert O +
inactive O +
phosphorylated B-Gene +
PDC I-Gene +
into O +
the O +
active O +
dephosphorylated O +
form O -
, O +
cells O +
were O +
suspended O +
in O +
MEM O +
with O +
serum O +
containing O +
5 O +
mM O +
dichloroacetic O +
acid O +
and O +
incubated O +
at O +
37 O -
° O +
for O +
15 O +
min O -
. O +

After O +
being O +
collected O +
by O +
centrifugation O -
, O +
cells O +
were O +
washed O +
twice O +
with O +
phosphate O +
buffered O +
saline O +
containing O +
5 O +
mM O +
dichloroacetic O +
acid O +
( O -
inhibitor O +
of O +
E1 B-Gene +
kinases I-Gene -
) O -
. O +

Final O +
cell O +
suspensions O +
were O +
made O +
in O +
2.5 O +
ml O +
of O +
phosphate O +
buffered O +
saline O +
containing O +
5 O +
mM O +
dichloroacetic O +
acid O +
and O +
kept O +
on O +
ice O +
until O +
used O -
. O +

The O +
reaction O +
mixture O +
( O -
100 O +
μl O -
) O +
contained O +
94 O +
μl O +
( O -
5–10 O +
mg O -
/ O -
ml O +
total O +
protein O -
) O +
of O +
HepG2 O +
cell O +
suspensions O -
, O +
5 O +
μl O +
of O +
lipoic O +
compounds O +
( O -
final O +
1–4 O +
mM O +
range O +
where O +
indicated O -
) O -
, O +
and O +
1 O +
μl O +
of O +
50 O +
mM O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
pyruvate O +
( O -
200 O +
cpm O -
/ O -
nmole O -
) O -
. O +

Cells O +
were O +
incubated O +
at O +
37 O -
° O +
for O +
5 O +
min O +
in O +
a O +
sealed O +
test O +
tube O -
, O +
and O +
the O +
pyruvate O +
decarboxylation O +
reaction O +
was O +
terminated O +
by O +
injecting O +
0.1 O +
ml O +
of O +
20 O -
% O +
( O -
w O -
/ O -
v O -
) O +
trichloroacetic O +
acid O +
with O +
30 O +
mM O +
pyruvate O +
to O +
the O +
reaction O +
mixture O -
. O +

To O +
trap O +
the O +
liberated O +
14 O +
CO2 O +
, O +
0.2 O +
ml O +
of O +
benzothonium O +
hydroxide O +
was O +
injected O +
into O +
a O +
hanging O +
plastic O +
cup O +
in O +
a O +
sealed O +
tube O +
with O +
a O +
rubber O +
stopper O -
, O +
and O +
the O +
evolved O +
14 O +
CO2 O +
was O +
absorbed O +
for O +
1 O +
h O +
and O +
the O +
radioactivity O +
was O +
measured O +
in O +
a O +
Beckman O +
LS6500 O +
scintillation O +
counter O -
. O +

Radioactivity O +
from O +
the O +
blank O +
( O -
without O +
cells O +
and O +
lipoic O +
compound O -
) O +
was O +
subtracted O +
from O +
total O +
counts O -
. O +

Pyruvate O +
metabolism O +
via O +
pyruvate B-Gene +
carboxylase I-Gene +
and O +
subsequent O +
oxidation O +
in O +
the O +
tricarboxylic O +
acid O +
cycle O +
was O +
measured O +
using O +
the O +
protocol O +
described O +
for O +
pyruvate O +
decarboxylation O +
except O +
HepG2 O +
cells O +
were O +
treated O +
with O +
1 O +
mM O +
n O -
- O -
octanoic O +
acid O +
instead O +
of O +
dichloroacetic O +
acid O +
in O +
both O +
preincubation O +
and O +
incubation O +
of O +
the O +
cells O -
. O +

The O +
oxidation O +
of O +
n O -
- O -
octanoic O +
acid O +
is O +
shown O +
to O +
stimulate O +
E1 B-Gene +
kinase O +
activity O -
, O +
resulting O +
in O +
the O +
phosphorylation O +
( O -
and O +
hence O +
inactivation O -
) O +
of O +
PDC B-Gene +
[ O -
25 O -
] O +
. O +

Results O +
In O +
a O +
previous O +
study O -
, O +
two O +
enantiomers O +
of O +
LA O +
( O -
R O -
- O -
LA O +
and O +
S O -
- O -
LA O -
) O +
were O +
found O +
to O +
have O +
different O +
effects O +
on O +
the O +
overall O +
activity O +
of O +
PDC B-Gene +
from O +
mammalian O +
and O +
prokaryotic O +
sources O +
[ O -
17 O -
] O +
. O +

We O -
, O +
therefore O -
, O +
reinvestigated O +
the O +
effect O +
of O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
and O +
also O +
investigated O +
the O +
effect O +
of O +
Se O -
- O -
LA O +
on O +
this O +
complex O -
. O +

Overall O +
activity O +
of O +
porcine B-Gene +
heart I-Gene +
PDC I-Gene +
was O +
markedly O +
inhibited O +
by O +
both O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O -
, O +
showing O +
at O +
least O +
80 O -
% O +
inhibition O +
by O +
1 O +
mM O +
or O +
higher O +
concentrations O +
of O +
LA O +
( O -
Fig. O +
1 O -
) O +
. O +

In O +
comparison O -
, O +
Se O -
- O -
LA O -
- O -
mediated O +
PDC B-Gene +
inhibition O +
was O +
weaker O -
, O +
requiring O +
a O +
much O +
higher O +
concentration O +
of O +
Se O -
- O -
LA O +
( O -
4 O +
mM O -
) O +
to O +
achieve O +
about O +
65 O -
% O +
inhibition O +
( O -
Fig. O +
1 O -
) O +
. O +

Since O +
LA O -
- O -
mediated O +
inhibition O +
of O +
overall O +
PDC B-Gene +
activity O +
could O +
be O +
due O +
to O +
the O +
inhibition O +
of O +
one O +
or O +
more O +
catalytic O +
components O +
of O +
the O +
complex O -
, O +
the O +
effects O +
of O +
lipoic O +
compounds O +
were O +
tested O +
on O +
the O +
three O +
catalytic O +
components O +
of O +
mammalian O +
PDC B-Gene -
. O +

In O +
the O +
forward O +
reaction O -
, O +
the O +
E3 B-Gene +
component O +
of O +
the O +
complex O +
reoxidizes O +
exogenous O +
DL O -
- O -
dihydrolipoamide O +
as O +
a O +
substrate O +
[ O -
3 O -
] O +
. O +

The O +
effects O +
of O +
lipoic O +
compounds O +
on O +
the O +
forward O +
reaction O +
of O +
recombinant B-Gene +
human I-Gene +
E3 I-Gene +
were O +
examined O -
. O +

Up O +
to O +
1 O +
mM O -
, O +
Se O -
- O -
LA O +
was O +
more O +
effective O +
as O +
an O +
effector O +
( O -
approximately O +
25 O -
% O +
reduction O -
) O +
than O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
( O -
Fig. O +
2 O -
) O +
. O +

However O -
, O +
at O +
higher O +
concentrations O -
, O +
these O +
three O +
compounds O +
affected O +
E3 B-Gene +
activity O +
similarly O -
, O +
lowering O +
about O +
30–45 O -
% O +
at O +
a O +
concentration O +
of O +
4 O +
mM O +
( O -
Fig. O +
2 O -
) O +
. O +

This O +
low O +
level O +
of O +
E3 B-Gene +
activity O +
by O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
did O +
not O +
account O +
for O +
the O +
observed O +
high O +
level O +
of O +
inhibition O +
seen O +
on O +
the O +
overall O +
activity O +
of O +
PDC B-Gene +
at O +
lower O +
concentrations O +
of O +
these O +
two O +
compounds O +
( O -
Fig. O +
1 O -
) O +
. O +

Also O -
, O +
the O +
low O +
level O +
of O +
apparent O +
inhibition O +
implied O +
that O +
NADH O -
, O +
the O +
product O +
of O +
the O +
forward O +
reaction O -
, O +
was O +
probably O +
used O +
as O +
a O +
substrate O +
for O +
the O +
reverse O +
reaction O +
of O +
E3 B-Gene +
in O +
the O +
presence O +
of O +
added O +
oxidized O +
lipoic O +
compounds O -
. O +

Therefore O -
, O +
the O +
activity O +
of O +
E3 B-Gene +
in O +
the O +
reverse O +
direction O +
with O +
R O -
- O -
LA O -
, O +
S O -
- O -
LA O -
, O +
Se O -
- O -
LA O -
, O +
and O +
DL O -
- O -
lipoamide O +
as O +
a O +
substrate O +
was O +
determined O -
, O +
and O +
the O +
results O +
are O +
summarized O +
in O +
Table O +
1 O +
. O +

E3 B-Gene +
had O +
a O +
significantly O +
higher O +
affinity O +
for O +
R O -
- O -
LA O -
, O +
the O +
natural O +
enantiomer O -
, O +
than O +
S O -
- O -
LA O -
, O +
but O +
k O +
cat O +
was O +
not O +
significantly O +
different O +
for O +
these O +
two O +
compounds O -
. O +

Km O +
for O +
Se O -
- O -
LA O +
was O +
similar O +
to O +
that O +
of O +
R O -
- O -
LA O +
and O +
the O +
calculated O +
k O +
cat O +
value O +
for O +
Se O -
- O -
LA O +
was O +
comparable O +
to O +
that O +
of O +
R O -
- O -
LA O +
or O +
S O -
- O -
LA O -
. O +

In O +
contrast O -
, O +
DL O -
- O -
lipoamide O +
was O +
the O +
preferred O +
substrate O +
for O +
the O +
reverse O +
reaction O +
of O +
E3 B-Gene +
( O -
Table O +
1 O -
) O +
. O +

The O +
catalytic O +
efficiency O +
( O -
k O +
cat O +
/Km O +
) O +
was O +
highest O +
with O +
DL O -
- O -
lipoamide O +
and O +
lowest O +
with O +
S O -
- O -
LA O -
. O +

These O +
findings O +
suggested O +
that O +
these O +
lipoic O +
compounds O +
could O +
account O +
for O +
a O +
partial O +
reoxidation O +
of O +
NADH O +
at O +
higher O +
concentrations O +
but O +
failed O +
to O +
support O +
a O +
high O +
degree O +
of O +
PDC B-Gene +
inhibition O +
observed O +
at O +
lower O +
concentrations O +
of O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
( O -
Fig. O +
1 O -
) O +
. O +

E1 B-Gene +
is O +
the O +
rate O -
- O -
limiting O +
component O +
of O +
the O +
complex O +
[ O -
26 O -
] O +
. O +

Using O +
a O +
dye O +
assay O -
, O +
E1 B-Gene +
activity O +
was O +
determined O +
over O +
a O +
range O +
of O +
pyruvate O +
concentrations O +
( O -
0–5 O +
mM O -
) O +
with O +
a O +
fixed O +
concentration O +
( O -
4 O +
mM O -
) O +
of O +
lipoic O +
compounds O -
. O +

R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
had O +
no O +
significant O +
effect O +
on O +
E1 B-Gene +
activity O +
over O +
a O +
wide O +
range O +
of O +
substrate O +
concentrations O +
( O -
Fig. O +
3A O -
) O +
. O +

In O +
contrast O -
, O +
4 O +
mM O +
Se O -
- O -
LA O +
inhibited O +
E1 B-Gene +
activity O +
by O +
about O +
70 O -
% O +
at O +
0.1 O +
and O +
5 O +
mM O +
pyruvate O -
. O +

When O +
the O +
effect O +
of O +
varying O +
concentrations O +
of O +
lipoic O +
compounds O +
were O +
investigated O +
on O +
E1 B-Gene +
activity O +
at O +
two O +
different O +
pyruvate O +
concentrations O +
( O -
0.1 O +
and O +
5 O +
mM O -
) O -
, O +
only O +
a O +
significant O +
inhibitory O +
effect O +
by O +
Se O -
- O -
LA O +
on O +
E1 B-Gene +
activity O +
was O +
noted O +
( O -
Fig. O +
3B O -
) O +
, O +
consistent O +
with O +
the O +
results O +
seen O +
in O +
Fig. O +
3A O +
. O +

To O +
examine O +
the O +
effect O +
of O +
lipoic O +
compounds O +
on O +
E2 B-Gene +
activity O -
, O +
the O +
activity O +
of O +
porcine B-Gene +
heart I-Gene +
E2 I-Gene +
was O +
measured O +
in O +
the O +
reverse O +
direction O +
using O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
acetyl O -
- O -
CoA O +
and O +
dihydrolipoamide O +
as O +
substrates O -
. O +

Both O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
displayed O +
similar O +
concentration O -
- O -
dependent O +
inhibitory O +
effects O +
on O +
the O +
E2 B-Gene +
activity O +
( O -
Fig. O +
4 O -
) O +
. O +

At O +
0.5 O +
mM O +
and O +
4.0 O +
mM O +
R O -
- O -
LA O +
or O +
S O -
- O -
LA O +
, O +
the O +
E2 B-Gene +
activity O +
was O +
inhibited O +
by O +
approximately O +
45 O -
% O +
and O +
80 O -
% O -
, O +
respectively O +
( O -
Fig. O +
4 O -
) O +
. O +

In O +
a O +
separate O +
experiment O +
in O +
which O +
DL O -
- O -
dihydrolipoamide O +
was O +
omitted O +
from O +
the O +
incubation O +
medium O -
, O +
the O +
acetylation O +
of O +
each O +
lipoic O +
compound O +
added O +
accounted O +
less O +
than O +
10 O -
% O +
of O +
the O +
radioactivity O +
extracted O +
in O +
benzene O +
layer O +
compared O +
to O +
that O +
of O +
control O +
with O +
DL O -
- O -
dihydrolipoamide O -
. O +

A O +
significant O +
inhibition O +
of O +
E2 B-Gene +
activity O +
by O +
R O -
- O -
LA O +
or O +
S O -
- O -
LA O +
at O +
or O +
below O +
0.5 O +
mM O +
could O +
explain O -
, O +
at O +
least O +
in O +
part O -
, O +
the O +
observed O +
inhibition O +
of O +
PDC B-Gene +
activity O +
by O +
R O -
- O -
LA O +
or O +
S O -
- O -
LA O +
( O -
Fig. O +
1 O -
) O +
. O +

At O +
2 O +
mM O -
, O +
Se O -
- O -
LA O +
had O +
no O +
significant O +
inhibitory O +
effect O +
on O +
E2 B-Gene +
activity O -
, O +
and O +
only O +
at O +
higher O +
concentrations O +
( O -
3 O -
- O -
4 O +
mM O -
) O +
it O +
inhibited O +
( O -
about O +
25 O -
% O -
) O +
E2 B-Gene +
activity O +
( O -
Fig. O +
4 O -
) O +
. O +

The O +
findings O +
of O +
the O +
previous O +
studies O +
and O +
the O +
present O +
study O +
show O +
the O +
inhibitory O +
effects O +
of O +
the O +
lipoic O +
compounds O +
on O +
the O +
activities O +
of O +
PDC B-Gene +
and O +
its O +
catalytic O +
components O -
. O +

In O +
light O +
of O +
the O +
inhibitory O +
effects O +
of O +
lipoic O +
compounds O +
on O +
purified O +
PDC B-Gene +
components O -
, O +
it O +
was O +
of O +
interest O +
to O +
examine O +
the O +
possible O +
effects O +
of O +
these O +
compounds O +
on O +
pyruvate O +
decarboxylation O +
via O +
PDC B-Gene +
by O +
intact O +
cells O -
. O +

The O +
inhibition O +
of O +
pyruvate O +
oxidation O +
in O +
intact O +
cells O +
by O +
LA O +
compounds O +
could O +
impair O +
carbohydrate O +
metabolism O -
. O +

It O +
should O +
be O +
noted O +
that O +
the O +
formation O +
of O +
14 O +
CO2 O +
from O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
pyruvate O +
in O +
the O +
intact O +
cells O +
occurs O +
via O +
the O +
action O +
of O +
PDC B-Gene +
as O +
well O +
as O +
the O +
formation O +
of O +
oxaloacetate O +
by O +
pyruvate B-Gene +
carboxylase I-Gene +
and O +
the O +
subsequent O +
metabolism O +
of O +
oxaloacetate O +
via O +
the O +
tricarboxylic O +
acid O +
cycle O -
. O +

The O +
results O +
presented O +
for O +
control O +
cells O +
without O +
the O +
addition O +
of O +
any O +
lipoic O +
compounds O +
( O -
Fig. O +
5A O -
, O +
B O -
) O +
show O +
that O +
the O +
formation O +
of O +
14 O +
CO2 O +
from O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
pyruvate O +
via O +
PDC B-Gene +
accounted O +
for O +
the O +
majority O +
( O -
99 O -
% O -
) O +
of O +
pyruvate O +
oxidation O +
( O -
Fig. O +
5A O -
) O +
, O +
and O +
the O +
14 O +
CO2 O +
production O +
from O +
the O +
metabolism O +
of O +
pyruvate O +
via O +
pyruvate B-Gene +
carboxylase I-Gene +
and O +
the O +
tricarboxylic O +
acid O +
cylce O +
was O +
negligible O +
under O +
our O +
experimental O +
conditions O +
( O -
Fig. O +
5B O -
) O +
. O +

Pyruvate O +
decarboxylation O +
by O +
cultured O +
HepG2 O +
cells O +
was O +
not O +
affected O +
in O +
the O +
presence O +
of O +
1–4 O +
mM O +
R O -
- O -
LA O +
in O +
the O +
incubation O +
medium O +
compared O +
to O +
that O +
of O +
control O +
( O -
Fig. O +
5A O -
) O +
. O +

However O -
, O +
approximately O +
25–30 O -
% O +
decrease O +
in O +
pyruvate O +
decarboxylation O +
was O +
seen O +
in O +
cells O +
treated O +
with O +
either O +
4 O +
mM O +
S O -
- O -
LA O +
or O +
DL O -
- O -
dihydrolipoamide O +
and O +
about O +
75 O -
% O +
reduction O +
in O +
pyruvate O +
decarboxylation O +
was O +
observed O +
with O +
cells O +
treated O +
with O +
4 O +
mM O +
Se O -
- O -
LA O +
( O -
Fig. O +
5A O -
) O +
. O +

Discussion O +
The O +
results O +
presented O +
in O +
this O +
paper O +
for O +
the O +
inhibitory O +
effects O +
of O +
both O +
R- O +
and O +
S O -
- O -
enantiomers O +
of O +
lipoic O +
acid O +
on O +
the O +
overall O +
reaction O +
of O +
PDC B-Gene +
from O +
porcine O +
heart O +
support O +
and O +
extend O +
the O +
inhibitory O +
effects O +
of O +
these O +
two O +
compounds O +
on O +
PDC B-Gene +
from O +
bovine O +
heart O +
[ O -
17 O -
] O +
. O +

The O +
degree O +
of O +
inhibition O -
, O +
however O -
, O +
was O +
more O +
pronounced O +
in O +
the O +
present O +
study O -
. O +

For O +
example O -
, O +
1 O +
mM O +
of O +
either O +
R O -
- O -
LA O +
or O +
S O -
- O -
LA O +
inhibited O +
pig B-Gene +
heart I-Gene +
PDC I-Gene +
by O +
about O +
80 O -
% O +
( O -
Fig. O +
1 O -
) O +
as O +
compared O +
to O +
the O +
reported O +
25 O -
% O +
and O +
41 O -
% O +
inhibition O +
of O +
bovine B-Gene +
heart I-Gene +
PDC I-Gene +
by O +
1 O +
mM O +
of O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O -
, O +
respectively O +
[ O -
17 O -
] O +
. O +

Loffelhardt O +
et O +
al. O +
[ O -
17 O -
] O +
also O +
observed O +
that O +
at O +
low O +
concentrations O +
( O -
less O +
than O +
1 O +
mM O -
) O +
of O +
both O +
enantiomers O +
of O +
LA O -
, O +
the O +
overall O +
reaction O +
of O +
the O +
PDC B-Gene +
from O +
rat O +
kidney O +
was O +
activated O -
. O +

These O +
investigators O +
observed O +
even O +
greater O +
stimulatory O +
effects O +
of O +
these O +
two O +
compounds O +
on O +
the O +
PDC B-Gene +
activity O +
from O +
E. O +
coli O +
[ O -
17 O -
] O +
. O +

These O +
species- O +
and O +
tissue O -
- O -
specific O +
effects O +
of O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
on O +
the O +
PDC B-Gene +
activity O +
are O +
difficult O +
to O +
rationalize O +
at O +
the O +
present O +
time O +
and O +
may O +
require O +
a O +
systematic O +
study O +
of O +
highly O +
purified O +
enzyme B-Gene +
complexes O +
from O +
different O +
species O -
. O +

There O -
, O +
however O -
, O +
are O +
several O +
important O +
differences O +
in O +
the O +
experimental O +
approaches O +
used O +
between O +
the O +
study O +
reported O +
by O +
Loffelhardt O +
et O +
al. O +
[ O -
17 O -
] O +
and O +
the O +
present O +
study O -
. O +

First O -
, O +
Loffelhardt O +
et O +
al. O +
studied O +
PDC B-Gene +
preparations O +
from O +
several O +
sources O +
at O +
different O +
stages O +
of O +
purification O +
[ O -
17 O -
] O +
, O +
whereas O +
we O +
have O +
used O +
highly O +
purified O +
porcine B-Gene +
heart I-Gene +
PDC I-Gene +
and O +
overexpressed O +
PDC B-Gene +
components O +
in O +
the O +
present O +
study O -
. O +

Second O -
, O +
Loffelhardt O +
et O +
al. O +
[ O -
17 O -
] O +
examined O +
the O +
effects O +
of O +
LA O +
and O +
its O +
analogs O +
on O +
the O +
E1 B-Gene +
and O +
E3 B-Gene +
components O +
of O +
PDC B-Gene +
only O +
and O +
did O +
not O +
investigate O +
the O +
effect O +
of O +
lipoic O +
acid O +
enantiomers O +
on O +
the O +
E2 B-Gene +
component O +
of O +
PDC B-Gene -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
observed O +
that O +
both O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
at O +
1 O +
mM O +
concentration O +
exerted O +
higher O +
inhibitory O +
effect O +
on O +
PDC O -
- O -
E2 O +
than O +
on O +
either O +
PDC O -
- O -
E1 O +
or O +
E3 O +
( O -
compare O +
Fig. O +
4 O +
vs O +
Figs. O +
2 O +
or O +
3 O -
) O -
. O +

Third O -
, O +
there O +
are O +
differences O +
in O +
kinetic O +
parameters O +
for O +
mammalian O +
E3 B-Gene +
catalyzing O +
the O +
reverse O +
reaction O +
( O -
oxidation O +
of O +
NADH O -
) O +
between O +
the O +
study O +
of O +
Loffelhardt O +
et O +
al. O +
[ O -
17 O -
] O +
and O +
the O +
present O +
study O -
. O +

In O +
the O +
former O +
study O +
the O +
Km O +
of O +
S O -
- O -
LA O +
was O +
only O +
slightly O +
higher O +
than O +
that O +
of O +
R O -
- O -
LA O +
( O -
5.5 O +
mM O +
vs O +
3.7 O +
mM O -
) O +
whereas O +
in O +
the O +
present O +
study O +
this O +
difference O +
was O +
about O +
17-fold O +
( O -
K O +
m O +
values O +
of O +
9.10 O +
mM O +
and O +
0.53 O +
mM O +
for O +
S O -
- O -
LA O +
and O +
R O -
- O -
LA O -
, O +
respectively O -
; O +
Table O +
1 O +
) O -
. O +

Similarly O -
, O +
the O +
catalytic O +
efficiency O +
( O -
k O +
cat O +
/K O +
m O +
) O +
of O +
R O -
- O -
LA O +
was O +
higher O +
compared O +
to O +
S O -
- O -
LA O +
by O +
a O +
factor O +
of O +
36 O +
in O +
previously O +
reported O +
study O +
[ O -
17 O -
] O +
whereas O +
this O +
factor O +
was O +
153 O +
in O +
the O +
present O +
study O -
. O +

Fourth O -
, O +
E3 B-Gene +
from O +
human O +
renal O +
carcinoma O +
had O +
a O +
Km O +
value O +
of O +
18 O +
mM O +
for O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
was O +
found O +
to O +
be O +
inactive O +
as O +
a O +
substrate O +
by O +
Loffelhardt O +
et O +
al. O +
[ O -
17 O -
] O +
. O +

In O +
contrast O -
, O +
in O +
the O +
present O +
study O +
we O +
observed O +
both O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
are O +
used O +
as O +
substrates O +
( O -
in O +
the O +
reverse O +
reaction O -
) O +
for O +
human B-Gene +
liver I-Gene +
E3 I-Gene +
and O +
Km O +
values O +
for O +
these O +
two O +
enantiomers O +
( O -
0.53 O +
mM O +
for O +
R O -
- O -
LA O +
and O +
9.1 O +
mM O +
for O +
S O -
- O -
LA O -
) O +
are O +
lower O +
than O +
that O +
reported O +
( O -
18 O +
mM O +
for O +
R B-Gene -
- I-Gene -
LA I-Gene -
) O +
for O +
partially O +
purified O +
PDC B-Gene -
- I-Gene -
E3 I-Gene +
from O +
human O +
kidney O +
carcinoma O +
[ O -
17 O -
] O +
. O +

The O +
inhibition O +
of O +
PDC B-Gene -
- I-Gene -
E2 I-Gene +
activity O +
by O +
both O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
was O +
the O +
major O +
contribution O +
to O +
the O +
observed O +
inhibition O +
of O +
PDC B-Gene +
activity O -
. O +

However O -
, O +
much O +
higher O +
levels O +
of O +
LA O +
( O -
0.5–1 O +
mM O -
) O +
than O +
is O +
present O +
physiologically O +
were O +
required O +
to O +
attain O +
a O +
significant O +
inhibition O +
( O -
50 O -
% O -
) O +
of O +
this O +
component O -
's O +
activity O -
. O +

If O +
exogenous O +
lipoic O +
acid O +
is O +
provided O +
in O +
large O +
quantities O +
as O +
a O +
daily O +
supplement O -
, O +
it O +
may O +
be O +
possible O +
that O +
intracellular O +
and O +
more O +
importantly O +
intramitochondrial O +
concentrations O +
of O +
LA O +
could O +
be O +
raised O +
to O +
a O +
range O +
that O +
would O +
influence O +
E2 B-Gene +
activity O +
in O +
the O +
mitochondria O -
. O +

However O -
, O +
the O +
likelihood O +
of O +
this O +
possibility O +
is O +
low O +
( O -
Fig. O +
5 O -
) O +
because O +
LA O +
is O +
reduced O +
to O +
dihydrolipoic O +
acid O +
by O +
the O +
action O +
of O +
E3 B-Gene +
and O +
glutathione B-Gene +
reductase I-Gene -
, O +
and O +
subsequently O +
dihydrolipoic O +
acid O +
is O +
readily O +
transported O +
out O +
of O +
the O +
cell O +
[ O -
11 O -
] O +
Furthermore O -
, O +
since O +
both O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
had O +
no O +
significant O +
effect O +
on O +
the O +
activity O +
of O +
E1 B-Gene -
, O +
the O +
rate O -
- O -
limiting O +
step O +
in O +
the O +
overall O +
reaction O +
of O +
PDC B-Gene -
, O +
it O +
is O +
suggested O +
that O +
a O +
partial O +
inhibition O +
of O +
E2 B-Gene +
and O +
E3 B-Gene +
components O +
may O +
not O +
have O +
any O +
significant O +
effect O +
on O +
the O +
carbon O +
flux O +
through O +
PDC B-Gene +
in O +
the O +
cell O +
( O -
Fig. O +
5 O -
) O +
. O +

This O +
study O +
demonstrated O +
for O +
the O +
first O +
time O +
that O +
the O +
site O +
of O +
Se O -
- O -
LA O -
- O -
mediated O +
inhibition O +
of O +
PDC B-Gene +
activity O +
is O +
different O +
than O +
that O +
of O +
LA O -
. O +

Inhibition O +
of O +
PDC B-Gene +
activity O +
required O +
higher O +
concentrations O +
of O +
Se O -
- O -
LA O +
compared O +
to O +
R O -
- O -
LA O +
or O +
S O -
- O -
LA O +
( O -
Fig. O +
1 O -
) O +
. O +

Although O +
Se O -
- O -
LA O +
was O +
as O +
effective O +
as O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
in O +
the O +
inhibition O +
of O +
E3 B-Gene +
activity O +
in O +
the O +
forward O +
direction O +
( O -
Fig. O +
2 O -
) O +
, O +
it O +
inhibited O +
E2 B-Gene +
activity O +
marginally O +
in O +
comparison O +
to O +
that O +
of O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
( O -
Fig. O +
4 O -
) O +
. O +

Since O +
E1 B-Gene +
is O +
the O +
rate O -
- O -
limiting O +
step O +
in O +
the O +
overall O +
reaction O +
of O +
the O +
PDC B-Gene -
, O +
when O +
there O +
is O +
no O +
inhibition O -
, O +
the O +
rate O +
at O +
which O +
NADH O +
is O +
generated O +
is O +
indirectly O +
controlled O +
by O +
E1 B-Gene +
activity O +
in O +
the O +
complex O -
. O +

Se O -
- O -
LA O +
inhibited O +
the O +
activity O +
of O +
the O +
E1 B-Gene +
component O +
( O -
Fig. O +
3 O -
) O +
, O +
and O +
the O +
extent O +
of O +
inhibition O +
by O +
Se O -
- O -
LA O +
of O +
this O +
component O +
closely O +
paralleled O +
inhibition O +
of O +
the O +
overall O +
activity O +
of O +
PDC B-Gene +
( O -
Fig. O +
1 O -
) O +
, O +
indicating O +
that O +
Se O -
- O -
LA O +
and O +
R- O +
or O +
S O -
- O -
LA O +
act O +
on O +
different O +
components O +
of O +
PDC B-Gene -
. O +

Since O +
Se O -
- O -
LA O +
was O +
recognized O +
as O +
a O +
substrate O +
for O +
the O +
reverse O +
reaction O +
of O +
E3 B-Gene -
, O +
we O +
studied O +
the O +
kinetic O +
aspects O +
of O +
these O +
lipoic O +
compounds O +
on O +
the O +
E3 B-Gene +
reverse O +
direction O -
. O +

Our O +
findings O +
demonstrated O +
that O +
the O +
K O +
m O +
and O +
k O +
cat O +
for O +
DL O -
- O -
lipoamide O +
on O +
the O +
reverse O +
reaction O +
of O +
E3 B-Gene -
, O +
calculated O +
as O +
1.39 O +
mM O +
and O +
719 O +
s−1 O +
, O +
respectively O -
, O +
are O +
in O +
agreement O +
with O +
the O +
previously O +
published O +
results O +
[ O -
3 O -
] O +
. O +

Since O +
a O +
mixture O +
of O +
D- O +
and O +
L O -
- O -
forms O +
of O +
lipoamide O +
was O +
used O +
in O +
both O +
experiments O -
, O +
it O +
was O +
not O +
surprising O +
to O +
find O +
a O +
higher O +
Km O +
than O +
that O +
of O +
R O -
- O -
LA O -
. O +

Furthermore O -
, O +
the O +
approximately O +
70 O +
fold O +
higher O +
k O +
cat O +
with O +
DL O -
- O -
lipoamide O -
, O +
compared O +
to O +
those O +
for O +
the O +
other O +
lipoic O +
compounds O -
, O +
indicates O +
that O +
DL O -
- O -
lipoamide O +
is O +
the O +
preferred O +
substrate O +
for O +
the O +
reverse O +
reaction O +
of O +
E3 B-Gene +
among O +
the O +
lipoic O +
compounds O +
tested O +
( O -
Table O +
1 O -
) O +
. O +

The O +
differential O +
effect O +
of O +
lipoic O +
compounds O +
on O +
pyruvate O +
oxidation O +
by O +
intact O +
HepG2 O +
cells O +
( O -
Fig. O +
5 O -
) O +
suggests O +
that O +
PDC B-Gene +
as O +
well O +
as O +
its O +
catalytic O +
components O +
are O +
affected O +
based O +
on O +
the O +
stereoselectivity O +
of O +
the O +
lipoic O +
compounds O -
. O +

Our O +
findings O +
also O +
indicate O +
that O +
R O -
- O -
LA O +
is O +
not O +
inhibitory O +
at O +
the O +
extracellular O +
level O +
of O +
up O +
to O +
4 O +
mM O +
( O -
Fig. O +
5A O -
) O +
which O +
may O +
not O +
be O +
readily O +
attained O +
by O +
supplementation O +
of O +
R O -
- O -
LA O -
. O +

Blumenthal O +
[ O -
27 O -
] O +
suggested O +
that O +
the O +
addition O +
of O +
free O +
R O -
, O -
S O -
- O -
lipoic O +
acid O +
caused O +
the O +
sequestration O +
of O +
intramitochondrial O +
free O +
CoA O +
by O +
the O +
formation O +
of O +
lipoyl O -
- O -
CoA O +
and O +
reduction O +
in O +
gluconeogenesis O +
from O +
lactate O +
and O +
pyruvate O +
by O +
rat O +
hepatocytes O -
. O +

Our O +
results O -
, O +
however O +
do O +
not O +
support O +
this O +
suggestion O +
because O +
there O +
was O +
no O +
significant O +
decrease O +
in O +
the O +
rate O +
of O +
pyruvate O +
decarboxylation O +
which O +
requires O +
the O +
participation O +
of O +
free O +
CoA O +
by O +
intact O +
HepG2 O +
cells O +
with O +
lipoic O +
acids O +
( O -
Fig. O +
5 O -
) O +
. O +

In O +
summary O -
, O +
the O +
influence O +
of O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
on O +
the O +
activity O +
of O +
mammalian O +
PDC B-Gene +
components O +
differs O +
from O +
that O +
of O +
Se O -
- O -
LA O -
. O +

Since O +
LA O +
( O -
R O +
and O +
S O +
forms O -
) O +
has O +
very O +
little O +
effect O +
on O +
the O +
activity O +
of O +
the O +
E1 B-Gene +
component O +
which O +
is O +
the O +
rate O -
- O -
limiting O +
step O +
of O +
the O +
PDC B-Gene -
, O +
R O -
- O -
LA O -
, O +
the O +
natural O +
enantiomer O -
, O +
would O +
not O +
be O +
expected O +
to O +
exert O +
any O +
significant O +
effect O +
on O +
pyruvate O +
metabolism O +
via O +
PDC B-Gene +
in O +
the O +
cell O -
. O +

Furthermore O -
, O +
the O +
high O +
catalytic O +
efficiency O +
of O +
the O +
E3 B-Gene +
component O +
and O +
its O +
reversible O +
action O +
provides O +
a O +
means O +
for O +
the O +
conversion O +
of O +
exogenous O +
oxidized O +
LA O +
to O +
DHLA O +
which O +
is O +
a O +
potent O +
reductant O +
( O -
redox O +
modulator O -
) O +
and O +
cellular O +
anti O -
- O -
oxidant O -
. O +

The O +
findings O +
of O +
this O +
study O +
are O +
consistent O +
with O +
the O +
observed O +
improvements O +
in O +
glucose O +
utilization O +
by O +
mammalian O +
tissues O +
in O +
the O +
presence O +
of O +
lipoic O +
acid O +
[ O -
6–8 O -
] O +
. O +

Our O +
findings O +
clearly O +
show O +
that O +
in O +
contrast O +
to O +
S O -
- O -
LA O -
, O +
R O -
- O -
LA O +
is O +
a O +
better O +
substrate O +
for O +
E3 B-Gene +
and O +
displays O +
no O +
inhibitory O +
effect O +
on O +
pyruvate O +
decarboxylation O +
by O +
intact O +
cells O -
. O +

It O -
, O +
therefore O -
, O +
is O +
suggested O +
that O +
R O -
- O -
LA O -
, O +
and O +
not O +
a O +
racemic O +
mixture O +
of O +
R- O +
and O +
S O -
- O -
LA O -
, O +
should O +
be O +
considered O +
a O +
choice O +
for O +
therapeutic O +
applications O -
. O +

[ O -
23 O -
] O +
Acknowledgements O +
We O +
thank O +
Dr. O +
Murray O +
Ettinger O +
of O +
State O +
University O +
of O +
New O +
York O +
at O +
Buffalo O +
and O +
Dr. O +
Thomas O +
E. O +
Roche O +
of O +
Kansas O +
State O +
University O +
for O +
their O +
critical O +
reading O +
of O +
the O +
manuscript O -
. O +

This O +
study O +
was O +
supported O +
in O +
part O +
by O +
USPHS O +
Grants O +
DK42885 O +
( O -
MSP O -
) O +
and O +
DK50430 O +
( O -
LP O -
) O -
. O +

1 O -
. O +

The O +
metabolism O +
of O +
loxtidine O +
( O -
1-methyl-5- O -
[ O -
3- O -
[ O -
3- O -
[ O -
( O -
1-piperidinyl O -
) O +
methyl O -
] O +
phenoxy O -
] O +
propyl O -
] O +
amino-1H-1,2,4-triazole-3-methanol O -
) O +
was O +
studied O +
in O +
freshly O +
isolated O +
rat O -
, O +
dog O +
and O +
human O +
hepatocytes O -
. O +

Metabolism O +
in O +
vitro O +
was O +
comparable O +
with O +
previously O +
available O +
in O +
vivo O +
data O +
in O +
all O +
three O +
species O +
with O +
the O +
marked O +
species O +
differences O +
observed O +
in O +
vivo O +
being O +
reproduced O +
in O +
the O +
hepatocyte O +
model O -
. O +

2 O -
. O +

The O +
major O +
route O +
for O +
the O +
metabolism O +
of O +
loxtidine O +
by O +
rat O +
hepatocytes O +
was O +
N O -
- O -
dealkylation O +
to O +
form O +
the O +
propionic O +
acid O +
and O +
hydroxymethyl O +
triazole O +
metabolites O -
. O +

A O +
minor O +
metabolic O +
route O +
was O +
the O +
oxidation O +
of O +
loxtidine O +
to O +
a O +
carboxylic O +
acid O +
metabolite O -
. O +

The O +
major O +
route O +
of O +
metabolism O +
for O +
loxtidine O +
in O +
dog O +
hepatocytes O +
was O +
glucuronidation O +
with O +
oxidation O +
to O +
the O +
carboxylic O +
acid O +
metabolite O +
being O +
of O +
minor O +
importance O -
. O +

Incubation O +
of O +
loxtidine O +
with O +
human O +
hepatocytes O +
resulted O +
in O +
the O +
drug O +
remaining O +
largely O +
unchanged O +
but O +
with O +
the O +
carboxylic O +
acid O +
metabolite O +
being O +
produced O +
in O +
minor O +
amounts O -
. O +

3 O -
. O +

In O +
vitro O +
studies O +
were O +
undertaken O +
with O +
rat O -
, O +
dog O +
and O +
human O +
hepatocytes O +
to O +
determine O +
the O +
Michaelis O -
- O -
Menten O +
parameters O +
Vmax O +
and O +
Km O +
for O +
the O +
sum O +
of O +
all O +
the O +
metabolic O +
pathways O -
. O +

These O +
kinetic O +
parameters O +
were O +
used O +
to O +
calculate O +
the O +
intrinsic O +
clearance O +
of O +
loxtidine O -
. O +

Using O +
appropriate O +
scaling O +
factors O -
, O +
the O +
predicted O +
in O +
vivo O +
hepatic O +
clearance O +
was O +
then O +
calculated O -
. O +

The O +
predicted O +
intrinsic O +
clearances O +
were O +
51.4 O +
+ O -
/- O +

12.4 O -
, O +
8.0 O +
+ O -
/- O +

0.8 O +
and O +
1.0 O +
+ O -
/- O +

0.6 O +
ml O -
/ O -
min O -
/ O -
kg O +
for O +
rat O -
, O +
dog O +
and O +
human O +
hepatocytes O +
respectively O -
. O +

These O +
data O +
were O +
then O +
used O +
to O +
calculate O +
hepatic O +
clearances O +
of O +
24.5 O -
, O +
3.1 O +
and O +
0.2 O +
ml O -
/ O -
min O -
/ O -
kg O +
for O +
rat O -
, O +
dog O +
and O +
man O +
respectively O -
. O +

4 O -
. O +

In O +
vivo O +
hepatic O +
and O +
intrinsic O +
clearances O +
for O +
loxtidine O +
were O +
determined O +
in O +
rat O -
, O +
dog O +
and O +
human O +
volunteers O -
. O +

The O +
hepatic O +
clearances O +
of O +
loxtidine O +
were O +
26.6 O -
, O +
6.6 O +
and O +
0.4 O +
ml O -
/ O -
min O -
/ O -
kg O +
in O +
rat O -
, O +
dog O +
and O +
man O +
respectively O +
and O +
intrinsic O +
clearances O +
were O +
58.5 O -
, O +
18.6 O +
and O +
2.0 O +
ml O -
/ O -
min O -
/ O -
kg O +
in O +
rat O -
, O +
dog O +
and O +
man O +
respectively O -
. O +

5 O -
. O +

The O +
present O +
studies O +
demonstrate O +
that O +
the O +
hepatocyte O +
model O +
may O +
be O +
a O +
valuable O +
in O +
vitro O +
tool O +
for O +
predicting O +
both O +
qualitative O +
and O +
quantitative O +
aspects O +
of O +
the O +
metabolism O +
of O +
a O +
drug O +
in O +
animals O +
and O +
man O +
at O +
an O +
early O +
stage O +
of O +
the O +
drug O +
development O +
process O -
. O +

Our O +
development O +
of O +
vaccines O +
to O +
prevent O +
shigellosis O +
is O +
based O +
on O +
the O +
hypothesis O +
that O +
a O +
critical O +
( O -
protective O -
) O +
level O +
of O +
serum O +
IgG B-Gene +
to O +
the O +
O O -
- O -
specific O +
polysaccharide O +
( O -
O O -
- O -
SP O -
) O +
domain O +
of O +
Shigella O +
lipopolysaccharide O +
( O -
LPS O -
) O +
confers O +
immunity O -
. O +

The O +
O O -
- O -
SP O +
is O +
a O +
hapten O +
and O +
must O +
be O +
conjugated O +
to O +
a O +
protein B-Gene +
to O +
induce O +
serum O +
antibodies B-Gene -
. O +

The O +
O O -
- O -
SP O +
of O +
Shigella O +
dysenteriae O +
type O +
1 O +
( O -
approximately O +
27 O +
tetrasaccharide O +
repeat O +
units O -
) O -
, O +
prepared O +
by O +
acid O +
hydrolysis O +
of O +
the O +
LPS O -
, O +
was O +
bound O +
to O +
human B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
HSA B-Gene -
) O +
by O +
multiple O +
point O +
attachment O +
( O -
O O -
- O -
SP O -
- O -
HSA B-Gene -
) O -
: O +
The O +
molar O +
ratio O +
of O +
HSA B-Gene +
to O +
O O -
- O -
SP O +
was O +
1.0 O -
. O +

Synthetic O +
saccharides O -
, O +
composed O +
of O +
one O +
or O +
multiples O +
of O +
the O +
O O -
- O -
SP O +
tetrasaccharide O -
, O +
equipped O +
with O +
a O +
spacer O +
at O +
their O +
reducing O +
end O -
, O +
were O +
bound O +
to O +
HSA B-Gene +
by O +
a O +
single O +
point O +
attachment O -
: O +
The O +
average O +
molar O +
ratios O +
of O +
the O +
saccharides O +
to O +
HSA B-Gene +
ranged O +
from O +
4 O +
to O +
24 O -
. O +

Serum O +
IgG B-Gene +
anti I-Gene -
- I-Gene -
LPS I-Gene -
, O +
elicited O +
in O +
mice O +
by O +
O O -
- O -
SP O -
- O -
HSA B-Gene +
or O +
synthetic O +
tetra- O -
, O +
octa- O -
, O +
dodeca- O -
, O +
and O +
hexadecasaccharide O +
fragments O -
, O +
was O +
measured O +
by O +
ELISA O -
. O +

Outbred O +
6-week O -
- O -
old O +
female O +
mice O +
were O +
injected O +
s.c O -
. O +

three O +
times O +
at O +
biweekly O +
intervals O +
with O +
2.5 O +
micrograms O +
of O +
saccharide O +
as O +
a O +
conjugate O +
and O +
were O +
bled O +
7 O +
days O +
after O +
the O +
second O +
and O +
third O +
injections O -
. O +

Excepting O +
the O +
tetramer O -
, O +
conjugates O +
of O +
the O +
octamer O -
, O +
dodecamer O +
and O +
hexadecamer O +
elicited O +
IgG B-Gene +
LPS I-Gene +
antibodies I-Gene +
after O +
the O +
second O +
injection O -
, O +
a O +
statistically O +
significant O +
rise O +
( O -
booster O -
) O +
after O +
the O +
third O +
injection O -
, O +
and O +
higher O +
levels O +
than O +
those O +
vaccinated O +
with O +
O O -
- O -
SP O -
- O -
HSA B-Gene +
( O -
P O +
= O +
0.0001 O -
) O -
. O +

The O +
highest O +
geometric O +
mean O +
levels O +
of O +
IgG B-Gene +
anti I-Gene -
- I-Gene -
LPS I-Gene +
were O +
elicited O +
by O +
the O +
hexadecamer O +
with O +
9 O +
chains O +
or O +
9 O +
moles O +
of O +
saccharide O -
/ O -
HSA B-Gene +
( O -
15.5 O +
ELISA O +
units O -
) O +
followed O +
by O +
the O +
octamer O +
with O +
20 O +
chains O +
( O -
11.1 O +
ELISA O +
units O -
) O +
and O +
the O +
dodecamer O +
with O +
10 O +
chains O +
( O -
9.52 O +
ELISA O +
units O -
) O -
. O +

Clinical O +
evaluation O +
of O +
these O +
synthetic O +
saccharides O +
bound O +
to O +
a O +
medically O +
useful O +
carrier O +
is O +
planned O -
. O +

OBJECTIVE O -
: O +
To O +
compare O +
the O +
pharmacokinetics O +
and O +
metabolism O +
of O +
R O -
( O -
+ O -
) O -
- O +
and O +
S O -
( O -
- O -
) O -
- O +
ketorolac O +
in O +
children O -
. O +

METHODS O -
: O +
Children O +
from O +
3 O +
to O +
18 O +
years O +
old O +
received O +
0.6 O +
mg O -
/ O -
kg O +
racemic O +
ketorolac O +
intravenously O -
. O +

Serial O +
blood O +
samples O +
were O +
obtained O +
for O +
12 O +
hours O -
, O +
and O +
urine O +
was O +
collected O +
for O +
12 O +
to O +
24 O +
hours O -
. O +

Racemic O +
ketorolac O +
was O +
measured O +
in O +
plasma O -
, O +
and O +
racemic O +
ketorolac O -
, O +
para O -
- O -
hydroxyketorolac O -
, O +
and O +
ketorolac O +
glucuronide O +
were O +
measured O +
in O +
urine O +
by O +
HPLC O -
. O +

S O -
( O -
- O -
) O -
- O +
and O +
R O -
( O -
+ O -
) O -
-ketorolac O +
were O +
measured O +
in O +
plasma O -
; O +
S O -
( O -
- O -
) O -
- O +
and O +
R O -
( O -
+ O -
) O -
-ketorolac O +
and O +
ketorolac O +
glucuronide O +
were O +
measured O +
in O +
urine O +
by O +
chiral O +
HPLC O +
separation O -
. O +

Plasma O +
pharmacokinetic O +
parameters O +
for O +
racemic O +
drug O +
and O +
both O +
enantiomers O +
were O +
determined O +
for O +
each O +
patient O -
. O +

RESULTS O -
: O +
Clearance O +
of O +
racemic O +
ketorolac O +
in O +
children O +
was O +
approximately O +
2 O +
times O +
the O +
clearance O +
reported O +
in O +
adults O -
. O +

Clearance O +
of O +
the O +
S O -
( O -
- O -
) O +
enantiomer O +
was O +
4 O +
times O +
that O +
of O +
the O +
R O -
( O -
+ O -
) O +
enantiomer O -
. O +

Terminal O +
half O -
- O -
life O +
of O +
S O -
( O -
- O -
) O -
-ketorolac O +
was O +
40 O -
% O +
that O +
of O +
the O +
R O -
( O -
+ O -
) O +
enantiomer O -
, O +
and O +
the O +
apparent O +
volume O +
of O +
distribution O +
of O +
the O +
S O -
( O -
- O -
) O +
enantiomer O +
was O +
greater O +
than O +
that O +
of O +
the O +
R O -
( O -
+ O -
) O +
form O -
. O +

Recovery O +
of O +
S O -
( O -
- O -
) O -
-ketorolac O +
glucuronide O +
was O +
2.3 O +
times O +
that O +
of O +
the O +
R O -
( O -
+ O -
) O +
enantiomer O -
. O +

CONCLUSION O -
: O +
The O +
higher O +
clearance O +
in O +
children O +
suggests O +
that O +
the O +
weight O -
- O -
adjusted O +
dose O +
of O +
ketorolac O +
may O +
have O +
to O +
be O +
greater O +
for O +
children O +
to O +
achieve O +
plasma O +
concentrations O +
comparable O +
to O +
those O +
of O +
adults O -
. O +

Because O +
of O +
the O +
greater O +
clearance O +
and O +
shorter O +
half O -
- O -
life O +
of O +
S O -
( O -
- O -
) O -
-ketorolac O -
, O +
pharmacokinetic O +
predictions O +
based O +
on O +
racemic O +
assays O +
may O +
overestimate O +
the O +
duration O +
of O +
pharmacologic O +
effect O -
. O +

Enantiomeric O +
pharmacokinetic O +
differences O +
are O +
best O +
explained O +
by O +
stereoselective O +
plasma O +
protein B-Gene +
binding O -
. O +

Selective O +
glucuronidation O +
of O +
the O +
S O -
( O -
- O -
) O +
enantiomer O +
suggests O +
that O +
stereoselective O +
metabolism O +
may O +
also O +
be O +
a O +
contributing O +
factor O -
. O +

The O +
antifungal O +
activity O +
of O +
eberconazole O -
, O +
a O +
new O +
imidazole O +
derivative O -
, O +
against O +
124 O +
clinical O +
isolates O +
of O +
Candida O +
comprising O +
eight O +
different O +
species O +
and O +
to O +
34 O +
isolates O +
of O +
Cryptococcus O +
neoformans O +
was O +
compared O +
to O +
those O +
of O +
clotrimazole O +
and O +
ketoconazole O -
. O +

MICs O +
of O +
eberconazole O -
, O +
determined O +
by O +
the O +
National O +
Committee O +
for O +
Clinical O +
Laboratory O +
Standards O +
standardized O +
microbroth O +
method O -
, O +
were O +
equal O +
to O +
or O +
lower O +
than O +
those O +
of O +
other O +
azoles O -
, O +
especially O +
for O +
Candida O +
krusei O +
and O +
Candida O +
glabrata O -
, O +
which O +
are O +
usually O +
resistant O +
to O +
triazoles O -
. O +

Long B-Gene -
- I-Gene -
chain I-Gene +
fatty I-Gene +
acyl I-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
( O -
FACS B-Gene -
) O +
catalyzes O +
esterification O +
of O +
long O -
- O -
chain O +
fatty O +
acids O +
( O -
LCFAs O -
) O +
with O +
coenzyme O +
A O +
( O -
CoA O -
) O -
, O +
the O +
first O +
step O +
in O +
fatty O +
acid O +
metabolism O -
. O +

FACS B-Gene +
has O +
been O +
shown O +
to O +
play O +
a O +
role O +
in O +
LCFA O +
import O +
into O +
bacteria O +
and O +
implicated O +
to O +
function O +
in O +
mammalian O +
cell O +
LCFA O +
import O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
demonstrate O +
that O +
FACS B-Gene +
overexpression O +
in O +
fibroblasts O +
increases O +
LCFA O +
uptake O -
, O +
and O +
overexpression O +
of O +
both O +
FACS B-Gene +
and O +
the O +
fatty B-Gene +
acid I-Gene +
transport I-Gene +
protein I-Gene +
( O -
FATP B-Gene -
) O +
have O +
synergistic O +
effects O +
on O +
LCFA O +
uptake O -
. O +

To O +
explore O +
how O +
FACS B-Gene +
contributes O +
to O +
LCFA O +
import O -
, O +
we O +
examined O +
the O +
subcellular O +
location O +
of O +
this O +
enzyme B-Gene +
in O +
3T3-L1 O +
adipocytes O +
which O +
natively O +
express O +
this O +
protein B-Gene +
and O +
which O +
efficiently O +
take O +
up O +
LCFAs O -
. O +

We O +
demonstrate O +
for O +
the O +
first O +
time O +
that O +
FACS B-Gene +
is O +
an O +
integral O +
membrane O +
protein B-Gene -
. O +

Subcellular O +
fractionation O +
of O +
adipocytes O +
by O +
differential O +
density O +
centrifugation O +
reveals O +
immunoreactive O +
and O +
enzymatically O +
active O +
FACS B-Gene +
in O +
several O +
membrane O +
fractions O -
, O +
including O +
the O +
plasma O +
membrane O -
. O +

Immunofluorescence O +
studies O +
on O +
adipocyte O +
plasma O +
membrane O +
lawns O +
confirm O +
that O +
FACS B-Gene +
resides O +
at O +
the O +
plasma O +
membrane O +
of O +
adipocytes O -
, O +
where O +
it O +
co O -
- O -
distributes O +
with O +
FATP B-Gene -
. O +

Taken O +
together O -
, O +
our O +
data O +
support O +
a O +
model O +
in O +
which O +
imported O +
LCFAs O +
are O +
immediately O +
esterified O +
at O +
the O +
plasma O +
membrane O +
upon O +
uptake O -
, O +
and O +
in O +
which O +
FATP B-Gene +
and O +
FACS B-Gene +
function O +
coordinately O +
to O +
facilitate O +
LCFA O +
movement O +
across O +
the O +
plasma O +
membrane O +
of O +
mammalian O +
cells O -
. O +

On O +
the O +
22nd O +
day O +
of O +
gestation O +
in O +
rats O -
, O +
fetuses O +
of O +
acutely O +
adrenalectomized O +
mothers O +
were O +
injected O +
subcutaneously O +
with O +
0.43 O +
muCi O +
4 O -
- O -
14C O -
- O -
progesterone O +
in O +
0.05 O +
ml O +
saline O -
. O +

Ten O +
and O +
20 O +
min O +
after O +
injection O +
to O +
fetuses O -
, O +
samples O +
were O +
taken O +
to O +
determine O +
the O +
14C O -
- O -
progesterone O +
metabolites O +
in O +
the O +
plasma O +
and O +
adrenal O +
glands O -
. O +

After O +
extraction O +
of O +
the O +
samples O +
taken O -
, O +
the O +
metabolites O +
were O +
separated O +
by O +
two O -
- O -
dimensional O +
thin O -
- O -
layer O +
chromatography O +
and O +
identified O +
by O +
autoradiography O -
. O +

11-deoxycorticosterone O -
, O +
18-hydroxy-11-deoxycorticosterone O -
, O +
corticosterone O +
and O +
11beta O -
- O -
hydroxyprogesterone O +
were O +
identified O +
in O +
the O +
plasma O +
of O +
injected O +
fetuses O -
, O +
and O -
, O +
in O +
far O +
smaller O +
amounts O -
, O +
in O +
the O +
plasma O +
of O +
their O +
mothers O -
. O +

The O +
plasma O +
of O +
noninjected O +
fetuses O +
also O +
contained O +
very O +
small O +
amounts O +
of O +
these O +
corticoids O -
. O +

The O +
fetal O +
adrenal O +
glands O +
contained O +
far O +
smaller O +
amounts O +
of O +
radioactive O +
steroids O +
than O +
the O +
fetal O +
plasma O +
did O -
. O +

The O +
results O +
obtained O +
show O +
that O +
steroids O +
of O +
fetal O +
origin O +
can O +
cross O +
the O +
placenta O +
in O +
and O +
out O -
, O +
constituting O +
evidence O +
that O +
the O +
fetal O +
adrenal O +
glands O +
are O +
the O +
only O +
source O +
of O +
the O +
plasma O +
corticoids O +
of O +
their O +
adrenalectomized O +
mothers O -
. O +

Ozone O -
- O -
oxygen O +
mixture O +
( O -
ozone O +
concentration O +
600 O +
microg O -
/ O -
l O -
) O +
was O +
used O +
in O +
irrigations O +
of O +
the O +
tympanic O +
cavity O +
in O +
52 O +
patients O +
with O +
chronic O +
purulent O +
mesotympanitis O +
( O -
CPM O -
) O -
. O +

The O +
course O +
of O +
the O +
treatment O +
consisted O +
of O +
5 O -
- O -
7 O +
procedures O -
. O +

18 O +
CPM O +
controls O +
received O +
standard O +
treatment O +
without O +
the O +
irrigations O -
. O +

The O +
course O +
of O +
the O +
ozone O -
- O -
oxygen O +
irrigations O +
produced O +
good O +
results O -
: O +
ear O +
discharge O +
and O +
tympanic O +
mucosa O +
inflammation O +
stopped O +
in O +
81 O -
% O +
of O +
the O +
irrigated O +
patients O -
, O +
levels O +
of O +
myeloperoxidase B-Gene +
which O +
marks O +
inflammation O +
reduced O +
significantly O -
, O +
bactericidal O +
effects O +
of O +
the O +
mixture O +
were O +
observed O +
for O +
all O +
the O +
detected O +
pathogens O -
, O +
antibiotic O +
sensitivity O +
of O +
the O +
bacteria O +
rose O -
. O +

Fast O +
antiinflammatory O +
result O +
of O +
ozone O +
therapy O +
was O +
due O +
not O +
only O +
to O +
its O +
bactericidal O +
effect O +
but O +
also O +
via O +
its O +
antihypoxic O +
and O +
immunomodulating O +
mechanisms O -
. O +

Galacto O -
- O -
oligosaccharides O -
, O +
including O +
the O +
oligogalactosylated O +
glucoses O -
, O +
are O +
claimed O +
to O +
be O +
beneficial O +
for O +
human O +
health O +
because O +
they O +
seem O +
to O +
promote O +
the O +
growth O +
of O +
bifidobacteria O +
in O +
the O +
large O +
intestine O +
[ O -
1 O -
] O +
. O +

Several O +
studies O +
suggest O +
that O +
the O +
volatile O +
fatty O +
acids O +
resulting O +
from O +
the O +
fermentation O +
of O +
galacto O -
- O -
oligosaccharides O +
by O +
the O +
intestinal O +
microflora O +
improve O +
the O +
absorption O +
ability O +
of O +
the O +
intestinal O +
epithelium O +
[ O -
2–4 O -
] O +
. O +

Oligogalactosylated O +
glucoses O +
can O +
be O +
prepared O +
from O +
lactose O +
through O +
the O +
transgalactosylating O +
activity O +
of O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
( O -
EC B-Gene +
3.2.1.23 I-Gene -
) O -
. O +

Various O +
parameters O +
such O +
as O +
source O +
of O +
the O +
enzyme B-Gene -
, O +
substrate O +
concentration O -
, O +
pH O -
, O +
and O +
temperature O +
can O +
influence O +
the O +
transgalactosylation O +
and O +
thereby O +
the O +
final O +
yields O +
of O +
the O +
different O +
compounds O +
formed O +
[ O -
5 O -
] O +
. O +

The O +
structures O +
of O +
oligogalactosylated O +
glucoses O +
reported O +
so O +
far O +
range O +
from O +
dimers O +
to O +
pentamers O +
[ O -
1,6–9 O -
] O +
. O +

Depending O +
on O +
the O +
biological O +
origin O +
of O +
the O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
applied O -
, O +
different O +
linkages O +
between O +
Gal O +
and O +
the O +
reducing O +
Glc O +
unit O +
have O +
been O +
identified O -
, O +
namely O -
, O +
β O -
- O -
d O +
-Galp O +
- O -
( O -
1→2 O -
) O -
-d O +
-Glcp O +
, O +
β O -
- O -
d O +
-Galp O +
- O -
( O -
1→3 O -
) O -
-d O +
-Glcp O +
, O +
β O -
- O -
d O +
-Galp O +
- O -
( O -
1→4 O -
) O -
-d O +
-Glcp O +
, O +
and O +
β O -
- O -
d O +
-Galp O +
- O -
( O -
1→6 O -
) O -
-d O +
-Glcp O +
. O +

Branched O +
Glc O +
residues O +
also O +
occur O -
, O +
whereas O +
the O +
oligogalactose O +
fragments O +
contain O +
mainly O +
( O -
1→4 O -
) O +
or O +
( O -
1→6 O -
) O +
linkages O -
. O +

So O +
far O +
oligogalactosylated O +
glucose O +
tetramers O +
and O +
pentamers O +
have O +
rarely O +
been O +
observed O +
in O +
large O +
amounts O -
. O +

Here O -
, O +
we O +
report O +
on O +
a O +
novel O +
transgalactosylating O +
activity O +
of O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
leading O +
to O +
the O +
formation O +
of O +
α O -
- O -
d O +
-Glcp O +
- O -
( O -
1↔1 O -
) O -
-β O -
- O -
d O +
-Galp O +
elements O +
in O +
several O +
oligogalactosylated O +
glucoses O -
. O +

2 O +
2 O -
. O +

Results O +
2.1 O +
Purification O +
of O +
oligosaccharides O +
produced O +
by O +
β O -
- O -
galactosidase O +
The O +
oligogalactosylated O +
glucose O +
sample O +
supplied O +
( O -
Borculo O +
Whey O +
Products O -
) O +
was O +
fractionated O +
by O +
gel O -
- O -
permeation O +
chromatography O +
using O +
Fractogel O +
TSK O +
HW-40 O -
( O -
S O -
) O +
followed O +
by O +
Bio O -
- O -
Gel O +
P-2 O -
. O +

Following O +
this O +
protocol O -
, O +
fractions O +
of O +
different O +
degrees O +
of O +
polymerization O +
were O +
obtained O -
. O +

These O +
pools O +
of O +
oligosaccharides O +
were O +
further O +
fractionated O +
by O +
high O -
- O -
performance O +
anion O -
- O -
exchange O +
chromatography O +
( O -
HPAEC O -
) O -
. O +

In O +
Fig. O +
1 O +
HPAEC O +
profiles O +
of O +
the O +
starting O +
oligogalactosylated O +
glucose O +
sample O +
( O -
upper O +
panel O -
) O +
and O +
of O +
five O +
Bio O -
- O -
Gel O +
P-2 O +
fractions O +
( O -
dimers O +
to O +
hexamers O -
) O +
are O +
shown O -
. O +

The O +
major O +
components O +
[ O -
( O -
β O -
- O -
d O +
-Galp O +
- O -
( O -
1→4 O -
) O -
) O -
n O +
-d O +
-Glcp O +
, O +
and O +
( O -
β O -
- O -
d O +
-Galp O +
- O -
( O -
1→6 O -
) O -
) O -
n O +
-β O -
- O -
d O +
-Galp O +
- O -
( O -
1→4 O -
) O -
-d O +
-Glcp O +
, O +
n O +
= O -
0–5 O -
] O +
in O +
each O +
Bio O -
- O -
Gel O +
P-2 O +
fraction O +
were O +
characterized O +
using O +
HPAEC O +
retention O +
times O +
and O +
1 O +
H O +
NMR O +
spectroscopy O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
oligogalactosylated O +
glucose O +
structures O +
found O +
were O +
in O +
agreement O +
with O +
those O +
reported O +
so O +
far O +
[ O -
5 O -
] O +
. O +

For O +
the O +
NMR O +
analysis O -
, O +
use O +
was O +
made O +
of O +
the O +
chemical O +
shifts O +
of O +
linear O +
β- O -
( O -
1→4 O -
) O -
-linked O +
d O +
-galactobi- O +
to O +
pentaose O +
( O -
see O +
Table O +
1 O +
) O -
. O +

The O +
1 O +
H O +
and O +
13 O +
C O +
chemical O +
shifts O +
of O +
the O +
latter O +
compounds O -
, O +
which O +
have O +
not O +
been O +
reported O +
so O +
far O +
in O +
detail O -
, O +
are O +
shown O +
in O +
Tables O +
1 O +
and O +
2 O +
, O +
respectively O -
. O +

Additionally O +
to O +
the O +
known O +
oligogalactosylated O +
glucoses O -
, O +
each O +
Bio O -
- O -
Gel O +
P-2 O +
fraction O +
contained O +
at O +
least O +
one O +
less O +
retarded O +
component O +
( O -
Fig. O +
1 O +
, O +
indicated O +
by O +
its O +
fraction O +
number O -
) O +
whose O +
structure O +
has O +
not O +
yet O +
been O +
reported O -
. O +

The O +
structural O +
characterization O +
of O +
these O +
compounds O +
is O +
described O +
in O +
the O +
following O +
paragraphs O -
. O +

2.2 O +
Characterization O +
of O +
Fractions O +
2.1 O +
and O +
2.2 O +
The O +
pool O +
of O +
disaccharides O +
contained O -
, O +
according O +
to O +
the O +
HPAEC O +
chromatogram O -
, O +
at O +
least O +
six O +
components O +
( O -
Fig. O +
1 O +
) O -
. O +

The O +
1 O +
H O +
NMR O +
spectrum O +
of O +
Fraction O +
2.2 O +
indicated O +
the O +
presence O +
of O +
free O +
Gal O +
and O +
Glc O +
( O -
data O +
not O +
shown O -
) O -
. O +

Fraction O +
2.1 O +
contained O +
a O +
disaccharide O +
consisting O +
of O +
Glc O +
and O +
Gal O +
in O +
a O +
molar O +
ratio O +
of O +
1:1 O -
. O +

Methylation O +
analysis O +
revealed O +
the O +
presence O +
of O +
equimolar O +
amounts O +
of O +
terminal O +
Galp O +
and O +
terminal O +
Glcp O +
. O +

Electrospray O +
ionization O +
mass O +
spectrometry O +
( O -
ESMS O -
) O +
analysis O +
of O +
the O +
sodium O +
borodeuteride O -
- O -
treated O +
and O +
permethylated O +
Fraction O +
2.1 O +
showed O +
an O +
ion O +
at O +
m O -
/ O -
z O +
477 O +
( O -
data O +
not O +
shown O -
) O -
, O +
corresponding O +
to O +
a O +
sodium O -
- O -
cationized O +
pseudomolecular O +
ion O +
[ O -
M+Na O -
] O -
+ O +
for O +
nonreduced O +
permethylated O +
Hex2 O +
. O +

The O +
[ O -
M+H O -
] O -
+ O +
ion O +
at O +
m O -
/ O -
z O +
455 O -
, O +
observed O +
in O +
the O +
FAB O +
mass O +
spectrum O +
was O +
used O +
for O +
a O +
high O +
energy O +
collision O +
experiment O +
applying O +
fast O +
atom O +
bombardment O +
collision O +
induced O +
dissociation O +
tandem O +
mass O +
spectrometry O +
( O -
FAB O +
CID O +
MS O -
- O -
MS O -
) O -
. O +

The O +
most O +
abundant O +
and O +
the O +
only O +
mass O +
spectrometric O +
sequence O +
ion O +
notable O +
in O +
the O +
tandem O +
mass O +
spectrum O +
was O +
the O +
B1 O +
ion O +
at O +
m O -
/ O -
z O +
219 O +
[ O -
10 O -
] O +
. O +

This O +
ion O +
was O +
accompanied O +
by O +
ions O +
resulting O +
from O +
the O +
loss O +
of O +
one O +
and O +
two O +
methanol O +
molecules O +
from O +
the O +
B1 O +
ion O +
( O -
m O -
/ O -
z O +
187 O +
and O +
155 O -
) O +
and O +
the O +
precursor O +
( O -
m O -
/ O -
z O +
423 O +
and O +
391 O -
) O -
. O +

Although O +
the O +
ion O +
at O +
m O -
/ O -
z O +
423 O +
has O +
the O +
same O +
mass O +
as O +
that O +
expected O +
for O +
a O +
B2 O +
ion O -
, O +
its O +
relatively O +
low O +
abundance O +
is O +
not O +
consistent O +
with O +
its O +
assignment O +
as O +
a O +
B2 O +
ion O -
. O +

All O +
data O +
are O +
thus O +
consistent O +
with O +
the O +
presence O +
of O +
a O +
( O -
1↔1 O -
) O -
-linked O +
disaccharide O -
. O +

1D O +
1 O +
H O +
NMR O +
analysis O +
showed O +
two O +
anomeric O +
signals O +
at O +
δ O +
5.230 O +
and O +
4.571 O +
( O -
Fig. O +
2 O +
( O -
A O -
) O -
, O +
Table O +
3 O +
) O +
in O +
the O +
intensity O +
ratio O +
of O +
1:1 O -
. O +

The O +
signal O +
at O +
δ O +
5.230 O +
( O -
3 O +
J O +
1,2 O +
3.7 O +
Hz O -
) O +
had O +
correlations O +
to O +
H-2,3,4,5,6a,6b O +
in O +
the O +
TOCSY O +
spectrum O -
, O +
identifying O +
the O +
α O -
- O -
Glcp O +
residue O -
. O +

The O +
signal O +
at O +
δ O +
4.571 O +
( O -
3 O +
J O +
1,2 O +
7.6 O +
Hz O -
) O +
only O +
showed O +
TOCSY O +
cross O -
- O -
peaks O +
to O +
H-2,3,4 O -
; O +
combined O +
with O +
the O +
typical O +
peak O +
pattern O +
of O +
H-4 O +
and O +
the O +
resemblance O +
of O +
the O +
chemical O +
shifts O +
with O +
those O +
of O +
the O +
nonreducing O +
residues O +
in O +
1 O +
–4 O +
( O -
Table O +
1 O +
) O -
, O +
the O +
β O -
- O -
Galp O +
residue O +
could O +
be O +
assigned O -
. O +

Due O +
to O +
small O +
3 O +
J O +
3,4 O +
( O -
2 O +
Hz O -
) O +
and O +
3 O +
J O +
4,5 O +
( O -
< O -
1 O +
Hz O -
) O +
couplings O +
no O +
correlations O +
to O +
H-5 O +
could O +
be O +
seen O -
. O +

Consequently O -
, O +
Fraction O +
2.1 O +
contains O +
the O +
following O +
disaccharide: O -
( O -
2.1A O -
) O +
α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p O +

In O +
the O +
ROESY O +
spectrum O +
an O +
intense O +
interresidual O +
contact O +
between O +
the O +
two O +
anomeric O +
protons O +
was O +
visible O -
. O +

The O +
assignments O +
of O +
the O +
carbon O +
atoms O +
as O +
obtained O +
from O +
the O +
seHSQC O +
and O +
HMBC O +
spectra O +
are O +
given O +
in O +
Table O +
4 O +
. O +

Notable O +
are O +
the O +
chemical O +
shift O +
values O +
for O +
C-1 O +
of O +
Gal O +
( O -
δ O +
104.5 O -
) O +
and O +
Glc O +
( O -
δ O +
101.1 O -
) O -
, O +
typical O +
for O +
a O +
terminal O +
β O -
- O -
Gal O +
and O +
a O +
terminal O +
α O -
- O -
Glc O +
residue O -
. O +

The O +
HMBC O +
spectrum O +
showed O +
two O +
interresidual O +
contacts O +
( O -
I O +
H-1,II′ O +
C-1 O +
and O +
II′ O +
H-1,I O +
C-1 O -
) O +
and O +
the O +
H-1 O -
/ O -
C-1 O +
coupling O +
constants O +
( O -
Glc O +
1 O +
J O +
C-1,H-1 O +
174 O +
Hz O -
, O +
Gal O +
1 O +
J O +
C-1,H-1 O +
163 O +
Hz O -
) O -
, O +
confirming O +
structure O +
2.1A O +
. O +

2.3 O +
Characterization O +
of O +
Fraction O +
3.1 O +
HPAEC O +
Fraction O +
3.1 O +
( O -
Fig. O +
1 O +
) O +
contained O +
as O +
the O +
major O +
component O +
compound O +
3.1A O +
: O -
( O -
3.1A O -
) O +
β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p O +
Quantitative O +
monosaccharide O +
analysis O +
of O +
Fraction O +
3.1 O +
revealed O +
Glc O +
and O +
Gal O +
in O +
a O +
molar O +
ratio O +
of O +
1.0:1.9 O -
. O +

Methylation O +
analysis O +
demonstrated O +
the O +
presence O +
of O +
terminal O +
Galp O +
and O +
4-substituted O +
Glcp O +
residues O -
. O +

In O +
the O +
ESMS O +
spectrum O +
of O +
the O +
sodium O +
borodeuteride O -
- O -
treated O +
and O +
permethylated O +
Fraction O +
3.1 O -
, O +
an O +
ion O +
at O +
m O -
/ O -
z O +
681 O +
was O +
observed O -
, O +
corresponding O +
to O +
[ O -
M+Na O -
] O -
+ O +
for O +
a O +
nonreduced O +
permethylated O +
Hex3 O +
. O +

The O +
most O +
abundant O +
ions O +
observed O +
in O +
the O +
tandem O +
mass O +
spectrum O +
obtained O +
from O +
the O +
protonated O +
derivatized O +
oligosaccharide O -
, O +
m O -
/ O -
z O +
659 O -
, O +
were O +
the O +
B1 O +
and O +
B2 O +
ions O +
( O -
m O -
/ O -
z O +
219 O +
and O +
423 O -
) O -
. O +

The O +
intense O +
ion O +
observed O +
at O +
m O -
/ O -
z O +
455 O +
corresponding O +
in O +
mass O +
to O +
fully O +
methylated O +
Hex2 O +
was O +
assigned O +
as O +
resulting O +
from O +
' O -
internal O +
residue O +
loss O -
' O +
[ O -
11 O -
] O +
. O +

The O +
very O +
low O +
abundance O +
of O +
the O +
ion O +
at O +
m O -
/ O -
z O +
627 O +
corresponding O +
to O +
the O +
loss O +
of O +
methanol O +
from O +
the O +
precursor O +
and O +
having O +
the O +
same O +
mass O +
as O +
a O +
B3 O +
ion O +
was O +
consistent O +
with O +
the O +
presence O +
of O +
a O +
( O -
1↔1 O -
) O +
glycosidic O +
linkage O +
in O +
Hex3 O +
. O +

1D O +
1 O +
H O +
NMR O +
analysis O +
of O +
Fraction O +
3.1 O +
( O -
Fig. O +
2 O +
( O -
B O -
) O -
) O +
showed O +
three O -
, O +
equally O +
intense O -
, O +
anomeric O +
signals O +
at O +
δ O +
5.228 O +
( O -
3 O +
J O +
1,2 O +
3.4 O +
Hz O -
, O +
1 O +
J O +
C-1,H-1 O +
173 O +
Hz O -
) O -
, O +
4.576 O +
( O -
3 O +
J O +
1,2 O +
7.0 O +
Hz O -
, O +
1 O +
J O +
C-1,H-1 O +
160 O +
Hz O -
) O -
, O +
and O +
4.443 O +
( O -
3 O +
J O +
1,2 O +
7.9 O +
Hz O -
, O +
1 O +
J O +
C-1,H-1 O +
163 O +
Hz O -
) O -
. O +

Taking O +
into O +
account O +
both O +
the O +
3 O +
J O +
1,2 O +
and O +
1 O +
J O +
C-1,H-1 O +
( O -
from O +
HMBC O -
) O +
coupling O +
constants O -
, O +
the O +
first O +
signal O +
belonged O +
to O +
an O +
α O +
and O +
the O +
other O +
two O +
to O +
β O +
gluco O -
/ O -
galactopyranosyl O +
residues O -
. O +

2D O +
NMR O +
spectroscopy O +
( O -
DQF O +
COSY O -
, O +
TOCSY O -
, O +
and O +
ROESY O -
) O +
together O +
with O +
the O +
chemical O +
shift O +
values O +
of O +
1 O +
–4 O +
allowed O +
the O +
assignment O +
of O +
all O +
proton O +
resonances O -
, O +
as O +
presented O +
in O +
Table O +
3 O +
. O +

In O +
this O +
way O -
, O +
the O +
α O +
anomeric O +
signal O +
could O +
be O +
assigned O +
to O +
the O +
Glcp O +
residue O +
and O +
the O +
β O +
anomeric O +
signals O +
to O +
Galp O +
residues O -
. O +

The O +
linkages O +
between O +
the O +
different O +
monosaccharide O +
units O +
were O +
confirmed O +
by O +
the O +
interresidual O +
ROESY O +
cross O -
- O -
peaks O +
II O +
H-1,I O +
H-4 O +
and O +
I O +
H-1,II′ O +
H-1 O -
, O +
and O +
by O +
the O +
long O +
range O +
HMBC O +
contacts O +
( O -
Fig. O +
3 O +
) O +
II O +
H-1,I O +
C-4 O -
, O +
I O +
H-4,II O +
C-1 O -
, O +
I O +
H-1,II′ O +
C-1 O -
, O +
and O +
II′ O +
H-1,I O +
C-1 O -
. O +

The O +
assignments O +
of O +
the O +
carbon O +
chemical O +
shifts O +
as O +
obtained O +
from O +
the O +
HMBC O +
spectrum O +
are O +
shown O +
in O +
Table O +
4 O +
. O +

They O +
are O +
in O +
agreement O +
with O +
terminal O +
β O -
- O -
Galp O +
( O -
C-1 O -
, O +
δ O +
103.8 O +
and O +
104.4 O -
) O +
and O +
4-substituted O +
α O -
- O -
Glcp O +
( O -
C-1 O -
, O +
δ O +
101.7 O -
; O +
C-4 O -
, O +
δ O +
79.0 O -
) O -
. O +

In O +
the O +
1D O +
1 O +
H O +
NMR O +
spectrum O +
of O +
Fraction O +
3.1 O +
( O -
Fig. O +
2 O +
( O -
B O -
) O -
) O +
some O +
other O +
anomeric O +
signals O +
with O +
much O +
lower O +
intensity O +
( O -
ca O -
. O +
10 O -
% O -
) O +
were O +
visible O +
( O -
δ O +
5.45 O -
, O +
3 O +
J O +
1,2 O +
3.4 O +
Hz O -
; O +
4.62 O -
, O +
7.2 O +
Hz O -
; O +
4.53 O -
, O +
7.0 O +
Hz O -
) O -
, O +
suggesting O +
the O +
presence O +
of O +
compound O +
3.1B O +
: O -
( O -
3.1B O -
) O +
β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→2 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p O +
A O +
series O +
of O +
1 O +
H O +
chemical O +
shift O +
values O +
of O +
low O +
intensity O +
peaks O +
( O -
Table O +
3 O +
) O +
could O +
be O +
assigned O +
from O +
the O +
different O +
2D O +
spectra O +
recorded O +
of O +
Fraction O +
3.1 O -
. O +

Evidence O +
for O +
structure O +
3.1B O +
was O +
found O +
in O +
the O +
ROESY O +
spectrum O -
, O +
showing O +
a O +
strong O +
ROE O +
I O +
H-1,II′ O +
H-1 O +
and O +
a O +
weak O +
ROE O +
II O +
H-1,I O +
H-2 O -
. O +

The O +
substitution O +
of O +
Glc O +
at O +
O-2 O +
is O +
supported O +
by O +
the O +
chemical O +
shift O +
of O +
the O +
anomeric O +
proton O +
of O +
residue O +
I O +
( O -
α O +
H-1 O -
, O +
5.45 O +
ppm O -
) O +
which O +
is O +
characteristic O +
for O +
a O +
2-substituted O +
α O -
- O -
Glc O +
residue O +
[ O -
8 O -
] O +
. O +

No O +
2-substituted O +
hexose O +
was O +
found O +
in O +
the O +
methylation O +
analysis O -
, O +
probably O +
because O +
of O +
the O +
small O +
amount O +
of O +
this O +
compound O +
present O +
in O +
Fraction O +
3.1 O -
. O +

2.4 O +
Characterization O +
of O +
Fraction O +
4.1 O +
Monosaccharide O +
analysis O +
of O +
Fraction O +
4.1 O +
revealed O +
the O +
presence O +
of O +
Glc O +
and O +
Gal O +
in O +
a O +
molar O +
ratio O +
of O +
1.3:2.7 O -
. O +

In O +
the O +
ESMS O +
spectrum O +
of O +
the O +
sodium O +
borodeuteride O -
- O -
treated O +
and O +
permethylated O +
Fraction O +
4.1 O -
, O +
an O +
ion O +
at O +
m O -
/ O -
z O +
885 O +
was O +
observed O -
, O +
corresponding O +
to O +
[ O -
M+Na O -
] O -
+ O +
for O +
a O +
nonreduced O +
permethylated O +
Hex4 O +
. O +

In O +
the O +
1D O +
1 O +
H O +
NMR O +
spectrum O +
of O +
Fraction O +
4.1 O +
( O -
Fig. O +
4 O +
( O -
A O -
) O -
) O +
two O +
almost O +
equally O +
intense O +
H-1α O +
signals O +
around O +
5.22 O +
ppm O +
are O +
present O -
. O +

The O +
TOCSY O +
spectrum O +
showed O +
that O +
both O +
signals O +
belong O +
to O +
Glcp O +
residues O -
. O +

Because O +
these O +
oligosaccharides O +
were O +
synthesized O +
by O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
action O -
, O +
each O +
oligosaccharide O +
can O +
only O +
contain O +
one O +
Glc O +
unit O -
, O +
and O -
, O +
consequently O -
, O +
this O +
fraction O +
contains O +
at O +
least O +
two O +
components O -
. O +

The O +
H-1β O +
signals O +
were O +
assigned O +
to O +
Galp O +
residues O +
based O +
on O +
their O +
TOCSY O +
spin O +
system O -
. O +

The O +
ROESY O +
spectrum O +
showed O +
for O +
each O +
H-1α O +
signal O +
an O +
interresidual O +
contact O +
to O +
a O +
H-1β O +
signal O -
. O +

One O +
of O +
these O +
β O -
- O -
Galp O +
residues O +
( O -
δ O +
4.571 O -
) O +
was O +
not O +
substituted O +
whereas O +
the O +
other O +
( O -
δ O +
4.60 O -
) O +
was O +
substituted O +
at O +
O-4 O +
( O -
H-4 O +
at O +
δ O +
4.18 O +
instead O +
of O +
∼3.90 O -
; O +
see O +
Table O +
1 O +
) O -
. O +

In O +
total O -
, O +
two O +
4-substituted O +
Galp O +
residues O +
were O +
found O +
( O -
H-1 O -
, O +
δ O +
4.478 O +
with O +
H-4 O -
, O +
δ O +
4.18 O -
; O +
H-1 O -
, O +
δ O +
4.60 O +
with O +
H-4 O -
, O +
δ O +
4.18 O -
) O -
. O +

The O +
typical O +
chemical O +
shifts O +
of O +
two O +
H-1β O +
signals O +
below O +
δ O +
4.50 O +
( O -
δ O +
4.478 O +
and O +
4.439 O -
) O +
indicated O +
the O +
presence O +
of O +
two O +
Galp O +
residues O +
linked O +
to O +
O-4 O +
of O +
a O +
Glcp O +
residue O +
[ O -
8,12 O -
] O +
( O -
structure O +
3.1A O +
) O -
. O +

On O +
the O +
basis O +
of O +
the O +
results O +
above O -
, O +
the O +
following O +
two O +
structures O -
, O +
4.1A O +
and O +
4.1B O +
, O +
can O +
be O +
established: O -
( O -
4.1A O -
) O +
β O +
-d O +
-G O +
III O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p O +
( O -
4.1B O -
) O +
β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
III′ O +
al O +
p O +
Specific O +
assignments O +
of O +
the O +
1 O +
H O +
and O +
13 O +
C O +
resonances O +
of O +
these O +
two O +
compounds O -
, O +
as O +
obtained O +
from O +
TOCSY O -
, O +
ROESY O -
, O +
and O +
seHSQC O +
spectra O -
, O +
are O +
shown O +
in O +
Tables O +
3 O +
and O +
4 O +
, O +
respectively O -
. O +

1D O +
1 O +
H O +
NMR O +
analysis O +
of O +
Fraction O +
4.1 O +
shows O +
anomeric O +
signals O +
( O -
δ O +
5.26 O -
, O +
5.25 O -
, O +
4.68 O -
, O +
4.64 O -
, O +
4.56 O -
, O +
and O +
4.52 O -
) O +
of O +
some O +
minor O +
components O +
( O -
ca O -
. O +
10 O -
% O -
) O +
that O +
could O +
not O +
be O +
assigned O +
due O +
to O +
the O +
low O +
amounts O +
of O +
the O +
individual O +
components O -
. O +

2.5 O +
Characterization O +
of O +
Fraction O +
5.1 O +
In O +
view O +
of O +
the O +
foregoing O -
, O +
the O +
presence O +
of O +
different O +
compounds O +
with O +
a O +
( O -
1↔1 O -
) O +
glycosidic O +
linkage O +
in O +
Fraction O +
5.1 O +
can O +
be O +
expected O -
, O +
and O +
evidence O +
is O +
provided O +
for O +
the O +
occurrence O +
of O +
compounds O +
5.1A O +
, O +
5.1B O +
, O +
and O +
5.1C O +
. O -
( O -
5.1A O -
) O +
β O +
-d O +
-G O +
IV O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
III O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p O +
( O -
5.1B O -
) O +
β O +
-d O +
-G O +
III O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
III′ O +
al O +
p O +
( O -
5.1C O -
) O +
β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
III′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
IV′ O +
al O +
p O +
In O +
the O +
ESMS O +
spectrum O +
of O +
the O +
sodium O +
borodeuteride O -
- O -
treated O +
and O +
permethylated O +
Fraction O +
5.1 O -
, O +
an O +
ion O +
at O +
m O -
/ O -
z O +
1089 O +
was O +
observed O -
, O +
corresponding O +
to O +
[ O -
M+Na O -
] O -
+ O +
for O +
a O +
nonreduced O +
permethylated O +
Hex5 O +
. O +

In O +
the O +
1D O +
1 O +
H O +
NMR O +
spectrum O +
( O -
Fig. O +
4 O +
( O -
B O -
) O -
) O +
several O +
groups O +
of O +
anomeric O +
signals O +
are O +
visible O -
. O +

In O +
the O +
H-1α O +
region O +
δ O +
5.21–5.23 O -
, O +
three O +
overlapping O +
doublets O +
( O -
3 O +
J O +
1,2 O +
3–4 O +
Hz O -
) O +
at O +
δ O +
5.216 O -
, O +
5.221 O -
, O +
and O +
5.227 O +
are O +
present O +
in O +
a O +
relative O +
abundance O +
of O +
1:0.7:1 O -
. O +

Based O +
on O +
TOCSY O +
spectra O +
these O +
three O +
doublets O +
were O +
assigned O +
to O +
α O -
- O -
Glcp O +
residues O -
. O +

The O +
resonances O +
in O +
the O +
H-1β O +
region O +
δ O +
4.4–4.5 O +
are O +
indicative O +
of O +
β O -
- O -
Galp O +
residues O +
linked O +
to O +
O-4 O +
of O +
α O -
- O -
Glcp O +
residues O +
( O -
see O +
above O -
) O -
. O +

In O +
the O +
1D O +
600 O +
and O +
750 O +
MHz O +
spectra O +
two O +
doublets O +
are O +
visible O +
at O +
δ O +
4.445 O +
and O +
δ O +
4.484 O -
, O +
respectively O -
, O +
in O +
the O +
relative O +
intensity O +
of O +
1:3 O -
. O +

Comparing O +
the O +
relative O +
intensities O +
of O +
these O +
two O +
anomeric O +
signals O +
with O +
those O +
of O +
the O +
three O +
Glc O +
H-1α O +
resonances O -
, O +
it O +
can O +
be O +
concluded O +
that O +
two O +
signals O +
overlap O +
at O +
δ O +
4.484 O -
, O +
since O +
at O +
least O +
three O +
compounds O +
are O +
present O +
in O +
this O +
fraction O -
. O +

By O +
comparing O +
the O +
chemical O +
shift O +
values O +
of O +
Fraction O +
5.1 O +
with O +
those O +
obtained O +
for O +
Fractions O +
3.1 O +
and O +
4.1 O -
, O +
the O +
signal O +
at O +
δ O +
4.445 O +
was O +
assigned O +
to O +
terminal O +
β O -
- O -
Galp O +
( O -
compound O +
5.1C O +
) O +
and O +
that O +
at O +
δ O +
4.484 O +
to O +
4-substituted O +
β O -
- O -
Galp O +
linked O +
to O +
O-4 O +
of O +
α O -
- O -
Glcp O +
( O -
compounds O +
5.1A O +
and O +
5.1B O +
) O -
. O +

According O +
to O +
the O +
ROESY O +
and O +
TOCSY O +
data O +
only O +
terminal O +
and O +
4-substituted O +
β O -
- O -
Galp O +
residues O +
occur O +
in O +
this O +
fraction O +
( O -
terminal O +
β O -
- O -
Galp O +
H-4 O -
, O +
δ O +
∼3.90 O -
; O +
4-substituted O +
β O -
- O -
Galp O +
H-4 O -
, O +
δ O +
∼4.20 O -
) O -
, O +
and O +
each O +
α O -
- O -
Glc O +
H-1 O +
signal O +
( O -
δ O +
5.216 O -
, O +
5.221 O -
, O +
5.227 O -
; O +
Table O +
3 O +
) O +
has O +
an O +
interresidual O +
ROESY O +
cross O -
- O -
peak O +
to O +
a O +
β O -
- O -
Galp O +
H-1 O +
resonance O -
. O +

The O +
chemical O +
shift O +
of O +
C-1 O +
( O -
δ O +
100.6–100.8 O -
; O +
Table O +
4 O +
) O +
gives O +
supporting O +
evidence O +
for O +
the O +
substitution O +
of O +
the O +
anomeric O +
centers O +
of O +
the O +
α O -
- O -
Glcp O +
residues O -
. O +

Based O +
on O +
the O +
reasoning O +
presented O +
above O -
, O +
the O +
structure O +
with O +
the O +
β O -
- O -
Gal O +
H-1 O +
signal O +
at O +
δ O +
4.445 O +
is O +
5.1C O +
. O +

The O +
α O -
- O -
Glc O +
H-1 O +
doublet O +
at O +
δ O +
5.216 O +
has O +
a O +
ROESY O +
cross O -
- O -
peak O +
with O +
a O +
β O -
- O -
Galp O +
H-1 O +
signal O +
at O +
δ O +
4.58 O -
. O +

According O +
to O +
the O +
TOCSY O +
spectrum O +
this O +
Galp O +
residue O +
occurs O +
in O +
a O +
terminal O +
position O +
( O -
H-4 O -
, O +
δ O +
3.90 O -
) O -
, O +
thereby O +
indicating O +
structure O +
5.1A O +
. O +

The O +
third O +
component O +
has O +
structural O +
similarities O +
with O +
5.1A O +
and O +
5.1C O +
( O -
i.e. O -
, O +
the O +
presence O +
of O +
the O +
following O +
structural O +
elements O -
: O +
β O -
- O -
Galp O +
- O -
( O -
1→4 O -
) O -
-β O -
- O -
Galp O +
and O +
β O -
- O -
Galp O +
- O -
( O -
1→4 O -
) O -
-α O -
- O -
Glcp O +
- O -
( O -
1↔1 O -
) O -
-β O -
- O -
Galp O +
) O +
giving O +
rise O +
to O +
overlap O +
in O +
the O +
NMR O +
spectra O +
( O -
compare O +
Table O +
1 O +
) O -
. O +

These O +
similarities O +
lead O +
to O +
propose O +
the O +
presence O +
of O +
structure O +
5.1B O +
. O +

2.6 O +
Characterization O +
of O +
Fraction O +
6.1 O +
Structural O +
analysis O +
of O +
Fraction O +
6.1 O +
gave O +
evidence O +
for O +
the O +
occurrence O +
of O +
compounds O +
6.1A O +
, O +
6.1B O +
, O +
6.1C O +
, O +
and O +
6.1D O +
. O -
( O -
6.1A O -
) O +

β O +
-d O +
-G O +
V O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
IV O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
III O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O +

-α O +
-d O +
-G O +
I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p O +
( O -
6.1B O -
) O +
β O +
-d O +
-G O +
IV O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
III O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
III′ O +
al O +
p O +
( O -
6.1C O -
) O +
β O +
-d O +
-G O +
III O +
al O +
p- O -
( O -
1→4 O +
) O -
-β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
III′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
IV′ O +
al O +
p O +
( O -
6.1D O -
) O +
β O +
-d O +
-G O +
II O +
al O +
p- O -
( O -
1→4 O +
) O -
-α O +
-d O +
-G O +

I O +
lc O +
p- O -
( O -
1↔1 O +
) O -
-β O +
-d O +
-G O +
II′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
III′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
IV′ O +
al O +
p- O -
( O -
4←1 O +
) O -
-β O +
-d O +
-G O +
V′ O +
al O +
p O +
Monosaccharide O +
analysis O +
revealed O +
the O +
presence O +
of O +
Gal O +
and O +
Glc O +
in O +
a O +
molar O +
ratio O +
of O +
4.9:1.1 O -
. O +

Methylation O +
analysis O +
showed O +
the O +
occurrence O +
of O +
terminal O +
Gal O -
, O +
4-substituted O +
Gal O -
, O +
and O +
4-substituted O +
Glc O -
. O +

In O +
the O +
ESMS O +
spectrum O +
of O +
the O +
sodium O +
borodeuteride O -
- O -
treated O +
and O +
permethylated O +
Fraction O +
6.1 O -
, O +
an O +
ion O +
at O +
m O -
/ O -
z O +
1293 O +
was O +
observed O -
, O +
corresponding O +
to O +
[ O -
M+Na O -
] O -
+ O +
for O +
a O +
nonreduced O +
permethylated O +
Hex6 O +
. O +

TOCSY O -
, O +
ROESY O -
, O +
and O +
seHSQC O +
experiments O +
revealed O +
the O +
presence O +
of O +
the O +
structural O +
elements O +
β O -
- O -
Galp O +
- O -
( O -
1→ O -
, O +
→4 O -
) O -
-β O -
- O -
Galp O +
- O -
( O -
1→ O -
, O +
and O +
→4 O -
) O -
-α O -
- O -
Glcp O +
- O -
( O -
1→. O +
In O +
the O +
1D O +
1 O +
H O +
NMR O +
spectrum O +
of O +
Fraction O +
6.1 O +
( O -
Fig. O +
5 O +
) O +
the O +
doublet O +
at O +
δ O +
4.429 O +
is O +
characteristic O +
for O +
a O +
terminal O +
β O -
- O -
Galp O +
residue O +
( O -
1→4 O -
) O -
-linked O +
to O +
α O -
- O -
Glcp O +
( O -
see O +
compounds O +
5.1C O +
and O +
4.1B O +
) O +
and O +
the O +
doublet O +
with O +
the O +
same O +
intensity O +
at O +
δ O +
3.93 O +
is O +
typical O +
for O +
H-4 O +
of O +
a O +
terminal O +
β O -
- O -
Galp O +
residue O -
, O +
giving O +
rise O +
to O +
structure O +
6.1D O +
. O +

The O +
H-1α O +
region O +
( O -
δ O +
∼5.23 O -
) O +
is O +
composed O +
of O +
three O +
doublets O +
with O +
relative O +
intensities O +
1:2:2 O -
, O +
as O +
indicated O +
in O +
Fig. O +
5 O +
. O +

According O +
to O +
TOCSY O +
and O +
seHSQC O +
data O +
these O +
doublets O +
belong O +
to O +
α O -
- O -
Glcp O +
H-1 O +
atoms O -
. O +

Since O +
each O +
compound O +
can O +
only O +
contain O +
one O +
Glc O +
residue O -
, O +
Fraction O +
6.1 O +
contains O +
at O +
least O +
three O +
compounds O +
( O -
see O +
above O -
) O -
. O +

The O +
doublet O +
of O +
6.1D O +
II O +
H-1 O +
is O +
hidden O +
in O +
the O +
multiplet O +
around O +
δ O +
∼5.23 O -
. O +

Therefore O -
, O +
the O +
presence O +
of O +
four O +
instead O +
of O +
three O +
compounds O +
is O +
suggested O -
. O +

The O +
H-1β O +
signal O +
at O +
δ O +
4.582 O +
is O +
characteristic O +
for O +
terminal O +
β O -
- O -
Galp O +
, O +
( O -
1↔1 O -
) O -
-linked O +
to O +
α O -
- O -
Glcp O +
( O -
H-1 O -
, O +
δ O +
5.238 O -
) O +
leading O +
to O +
structure O +
6.1A O +
. O +

Compounds O +
6.1B O +
and O +
6.1C O +
have O +
structural O +
similarities O +
with O +
parts O +
of O +
6.1A O +
( O -
and O +
the O +
minor O +
component O +
6.1D O +
) O +
and O +
with O +
each O +
other O +
( O -
i.e. O -
, O +
the O +
occurrence O +
of O +
the O +
following O +
structural O +
elements O -
: O +
( O -
β O -
- O -
Galp O +
- O -
( O -
1→4 O -
) O -
) O -
n O +
-β O -
- O -
Galp O +
n O +
= O -
0–2 O +
and O +
β O -
- O -
Galp O +
- O -
( O -
1→4 O -
) O -
-α O -
- O -
Glcp O +
- O -
( O -
1↔1 O -
) O -
-β O -
- O -
Galp O +
) O +
giving O +
rise O +
to O +
overlap O +
in O +
the O +
NMR O +
spectra O -
. O +

By O +
consequence O -
, O +
no O +
complete O +
assignment O +
could O +
be O +
established O -
. O +

Exclusive O +
evidence O +
for O +
their O +
presence O +
is O +
the O +
number O +
of O +
Glc O +
H-1α O +
signals O -
. O +

3 O +
3 O -
. O +

Discussion O +
This O +
structural O +
study O +
of O +
oligosaccharides O +
produced O +
by O +
the O +
transgalactosylation O +
activity O +
of O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
using O +
lactose O +
as O +
a O +
substrate O -
, O +
revealed O +
the O +
formation O +
of O +
a O +
series O +
of O +
nonreducing O +
oligosaccharides O +
containing O +
one O +
α O -
- O -
Glcp O +
unit O +
and O +
a O +
variable O +
number O +
of O +
β O -
- O -
Galp O +
units O +
having O +
the O +
structural O +
motif O +
α O -
- O -
d O +
-Glcp O +
- O -
( O -
1↔1 O -
) O -
-β O -
- O -
d O +
-Galp O +
in O +
common O -
. O +

It O +
would O +
be O +
interesting O +
to O +
investigate O +
the O +
gastrointestinal O +
effect O +
of O +
galactosylated O +
glucoses O +
with O +
respect O +
to O +
the O +
Glc O +
unit O +
being O +
reducing O +
or O +
not O -
. O +

Interestingly O -
, O +
no O +
β O -
- O -
Glcp O +
was O +
found O +
in O +
the O +
nonreducing O +
oligosaccharides O +
described O +
above O -
. O +

This O +
can O +
be O +
explained O +
by O +
the O +
way O +
the O +
enzyme B-Gene +
binds O +
to O +
lactose O +
[ O -
13 O -
] O +
. O +

According O +
to O +
[ O -
13 O -
] O +
lactose O +
can O +
be O +
positioned O +
on O +
the O +
enzyme B-Gene +
via O +
several O +
hydrophobic O +
contacts O +
and O +
intermolecular O +
hydrogen O +
bonds O +
( O -
Fig. O +
6 O +
( O -
A O -
) O -
) O +
to O +
Gal O +
( O -
O-2 O -
, O +
O-4 O -
, O +
and O +
O-6 O -
) O +
and O +
Glc O +
( O -
O-2 O +
and O +
O-3 O -
) O -
. O +

During O +
the O +
transgalactosylation O +
process O -
, O +
the O +
terminal O +
Gal O +
residue O +
of O +
the O +
galactosyl O +
acceptor O +
is O +
located O +
in O +
the O +
same O +
part O +
of O +
the O +
pocket O +
as O +
Glc O +
in O +
a O +
galactosidase B-Gene +
reaction O +
( O -
Fig. O +
6 O +
( O -
B O -
) O -
) O -
. O +

Presumably O +
the O +
same O +
intermolecular O +
hydrogen O +
bonds O +
are O +
present O -
, O +
as O +
Gal O +
is O +
the O +
C-4 O +
epimer O +
of O +
Glc O +
having O +
a O +
similar O +
orientation O +
of O +
O-2 O +
and O +
O-3 O -
. O +

This O +
might O +
explain O +
the O +
preference O +
of O +
the O +
enzyme B-Gene +
for O +
Gal O +
O-4 O +
in O +
transgalactosylation O +
reactions O -
. O +

When O +
the O +
anomeric O +
center O +
of O +
Glc O +
enters O +
the O +
active O +
site O +
as O +
galactosyl O +
acceptor O -
, O +
the O +
orientation O +
of O +
Glc O +
O-1,2,3 O +
( O -
Fig. O +
6 O +
( O -
B O -
) O -
) O +
depends O +
on O +
the O +
anomeric O +
configuration O -
: O +
for O +
α O -
- O -
Glc O +
the O +
orientation O +
is O +
the O +
same O +
as O +
for O +
Gal O +
O-4,3,2 O -
. O +

This O +
is O +
probably O +
the O +
reason O +
for O +
the O +
absence O +
of O +
β O -
- O -
Glc O -
- O -
containing O +
nonreducing O +
oligosaccharides O -
. O +

4 O +
4 O -
. O +

Experimental O +
4.1 O +
Model O +
compounds O +
Galactobiose O +
to O +
pentaose O +
( O -
1 O +
–4 O +
) O +
were O +
generated O +
by O +
a O +
controlled O +
digestion O +
of O +
soy O +
arabinogalactan O +
using O +
endogalactanase B-Gene +
from O +
A. O +
niger O +
[ O -
14 O -
] O +
, O +
then O +
isolated O +
via O +
gel O -
- O -
permeation O +
chromatography O +
on O +
Bio O -
- O -
Gel O +
P-2 O -
, O +
when O +
necessary O +
combined O +
with O +
HPAEC O +
on O +
CarboPac O +
PA-100 O +
[ O -
15 O -
] O +
. O +

4.2 O +
Trans O -
- O -
galacto O -
- O -
oligosaccharides O +
A O +
mixture O +
of O +
galactosylated O +
glucoses O -
, O +
produced O +
by O +
a O +
pure O +
β B-Gene -
- I-Gene -
galactosidase I-Gene +
using O +
lactose O +
as O +
substrate O -
, O +
was O +
a O +
gift O +
of O +
Borculo O +
Whey O +
Products O +
( O -
Borculo O -
, O +
The O +
Netherlands O -
) O -
. O +

The O +
sample O +
supplied O +
stemmed O +
from O +
an O +
incubation O +
mixture O +
from O +
which O +
most O +
of O +
the O +
free O +
Gal O +
and O +
Glc O +
and O +
some O +
di- O +
and O +
trisaccharide O +
material O +
had O +
been O +
removed O +
by O +
charcoal O +
column O +
chromatography O -
. O +

Inspection O +
of O +
the O +
sample O +
using O +
gel O -
- O -
permeation O +
chromatography O +
on O +
Bio O -
- O -
Gel O +
P-2 O +
showed O +
that O +
the O +
material O +
consisted O +
of O +
di- O +
through O +
hexasaccharides O +
in O +
a O +
relative O +
abundance O +
of O +
3 O -
, O +
6 O -
, O +
17 O -
, O +
37 O -
, O +
and O +
26 O -
% O -
, O +
respectively O -
, O +
whereas O +
11 O -
% O +
of O +
the O +
material O +
consisted O +
of O +
larger O +
oligomers O -
. O +

The O +
non O -
- O -
reducing O +
oligosaccharide O -
- O -
containing O +
fractions O +
comprised O +
0.3 O -
, O +
0.3 O -
, O +
0.5 O -
, O +
4.6 O -
, O +
2.6 O -
% O +
of O +
di- O +
through O +
hexasaccharides O -
, O +
respectively O -
, O +
in O +
the O +
total O +
mixture O +
of O +
oligosaccharides O -
. O +

4.3 O +
Purification O +
of O +
the O +
galactosylated O +
glucoses O +
sample O +
The O +
galactosylated O +
glucoses O +
sample O +
was O +
fractionated O +
on O +
two O +
connected O +
columns O +
( O -
each O +
600 O -
× O -
26 O +
mm O -
) O +
packed O +
with O +
Fractogel O +
TSK O +
HW-40 O -
( O -
S O -
) O +
( O -
25–40 O +
μm O -
, O +
E. O +
Merck O -
, O +
Darmstadt O -
, O +
Germany O -
) O -
, O +
thermostated O +
at O +
60 O +
° O -
C O +
and O +
eluted O +
with O +
water O +
( O -
2 O +
mL O -
/ O -
min O -
) O -
, O +
using O +
a O +
Pharmacia O +
Hiload O +
system O +
equipped O +
with O +
a O +
Pharmacia O +
P50 O +
pump O -
. O +

A O +
Shodex O +
RI-72 O +
detector O +
was O +
used O +
to O +
monitor O +
the O +
refractive O +
index O -
. O +

The O +
various O +
fractions O +
were O +
subfractionated O +
on O +
a O +
Bio O -
- O -
Gel O +
P-2 O +
column O +
( O -
100 O -
× O -
2.8 O +
cm O -
) O +
at O +
60 O +
° O -
C O -
, O +
eluted O +
with O +
water O -
; O +
the O +
elution O +
profile O +
was O +
established O +
via O +
an O +
auto O -
- O -
analyser O +
( O -
Skalar O +
Analytical O +
BV O -
, O +
Breda O -
, O +
The O +
Netherlands O -
) O +
using O +
the O +
orcinol O -
– O -
H2 O +
SO4 O +
assay O +
for O +
neutral O +
sugars O +
[ O -
16 O -
] O +
. O +

Further O +
fractionation O +
of O +
Bio O -
- O -
Gel O +
P-2 O +
fractions O +
was O +
performed O +
by O +
HPAEC O +
on O +
a O +
preparative O +
( O -
Fractions O +
2 O -
, O +
3 O -
, O +
and O +
6 O -
) O +
or O +
a O +
semi O -
- O -
analytical O +
( O -
Fractions O +
4 O +
and O +
5 O -
) O +
scale O -
. O +

Preparative O +
HPAEC O +
was O +
performed O +
using O +
a O +
Spectra O +
Physics O +
P4000 O +
pump O +
equipped O +
with O +
a O +
CarboPac O +
PA-100 O +
column O +
( O -
250 O -
× O -
22 O +
mm O -
) O +
and O +
coupled O +
with O +
a O +
Spectra O +
Physics O +
AS3000 O +
autosampler O +
( O -
900 O +
μL O +
samples O -
; O +
flow O +
rate O -
, O +
20 O +
mL O -
/ O -
min O -
) O +
and O +
a O +
pulsed O +
electrochemical O +
detector O +
( O -
PED O -
) O -
. O +

Gradients O +
were O +
optimized O +
for O +
each O +
sample O +
using O +
0.2 O +
M O +
NaOH O -
, O +
2 O +
M O +
NaOAc O +
in O +
0.2 O +
M O +
NaOH O +
and O +
Millipore O +
water O +
as O +
eluents O -
. O +

The O +
effluent O +
actually O +
passing O +
the O +
detector O +
was O +
reduced O +
to O +
1 O +
mL O -
/ O -
min O +
by O +
splitting O +
the O +
effluent O +
post O -
- O -
column O -
, O +
and O +
10 O +
mL O +
fractions O +
were O +
collected O +
and O +
immediately O +
neutralized O +
by O +
on O -
- O -
line O +
addition O +
of O +
1 O +
M O +
HOAc O -
. O +

Relevant O +
fractions O +
were O +
concentrated O +
and O +
desalted O +
on O +
a O +
Sephadex O +
G-10 O +
column O +
( O -
600 O -
× O -
50 O +
mm O -
) O +
using O +
distilled O +
water O +
as O +
eluent O +
( O -
RI O +
detection O -
) O -
. O +

The O +
purity O +
of O +
the O +
oligosaccharides O +
was O +
checked O +
by O +
analytical O +
HPAEC O -
. O +

Semi O -
- O -
preparative O +
HPAEC O +
was O +
performed O +
using O +
a O +
Dionex O +
LC O +
system O +
with O +
pulsed O +
amperometric O +
detection O +
( O -
PAD O -
) O -
, O +
equipped O +
with O +
a O +
CarboPac O +
PA-1 O +
column O +
( O -
250 O +
mm O -
× O -
9 O +
mm O -
) O -
, O +
eluted O +
with O +
a O +
gradient O +
of O +
NaOAc O +
in O +
0.1 O +
M O +
NaOH O +
at O +
a O +
flow O +
rate O +
of O +
4 O +
mL O -
/ O -
min O -
. O +

PAD O -
- O -
detection O +
was O +
carried O +
out O +
with O +
a O +
gold O +
working O +
electrode O +
and O +
triple O -
- O -
pulse O +
amperometry O +
was O +
used O -
. O +

Immediately O +
after O +
collection O -
, O +
fractions O +
were O +
neutralized O +
manually O +
with O +
aq O +
99 O -
% O +
HOAc O -
, O +
followed O +
by O +
desalting O +
on O +
a O +
Dowex O +
AG O +
50W O -
- O -
X12 O +
( O -
100–200 O +
mesh O -
, O +
H+ O +
-form O -
, O +
Bio O -
- O -
Rad O -
) O +
column O +
( O -
RI O +
detection O -
) O +
using O +
distilled O +
water O +
as O +
eluent O -
, O +
and O +
subsequent O +
lyophilization O -
. O +

4.4 O +
Gas O -
– O -
liquid O +
chromatography O +
GLC O +
analyses O +
were O +
performed O +
on O +
a O +
Chrompack O +
CP9002 O +
gas O +
chromatograph O -
, O +
equipped O +
with O +
a O +
CP O -
- O -
Sil O +
5 O +
CB O +
DFc.25 O +
( O -
Chrompack O -
) O +
capillary O +
column O +
( O -
25 O +
m O -
× O -
0.32 O +
mm O -
) O +
using O +
a O +
temperature O +
program O +
of O +
130–230 O +
° O -
C O +
at O +
4 O +
° O -
C O -
/ O -
min O -
. O +

4.5 O +
Monosaccharide O +
analysis O +
Oligosaccharides O +
were O +
subjected O +
to O +
methanolysis O +
( O -
methanolic O +
1 O +
M O +
HCl O -
, O +
18 O +
h O -
, O +
85 O +
° O -
C O -
) O -
, O +
and O +
the O +
resulting O +
mixtures O +
of O +
methyl O +
glycosides O +
were O +
trimethylsilylated O +
with O +
1:1:5 O +
hexamethyldisilazane O -
– O -
trimethylchlorosilane O -
– O -
pyridine O -
, O +
and O +
quantitatively O +
analyzed O +
by O +
GLC O +
[ O -
17 O -
] O +
. O +

4.6 O +
Methylation O +
analysis O +
Samples O +
were O +
dissolved O +
in O +
0.5 O +
M O +
NH4 O +
OH O +
( O -
250 O +
μL O -
) O +
containing O +
NaBD4 O +
( O -
10 O +
mg O -
/ O -
mL O -
) O -
. O +

After O +
1 O +
h O -
, O +
the O +
mixture O +
was O +
neutralized O +
with O +
aq O +
99 O -
% O +
HOAc O -
, O +
then O +
concentrated O -
. O +

Boric O +
acid O +
was O +
removed O +
by O +
repetitive O +
co O -
- O -
evaporation O +
with O +
9:1 O +
MeOH O -
– O -
HOAc O +
and O +
MeOH O -
. O +

Permethylation O +
was O +
carried O +
out O +
essentially O +
as O +
described O +
[ O -
18 O -
] O +
. O +

Briefly O -
, O +
freshly O +
ground O +
NaOH O +
pellets O +
( O -
250 O +
mg O -
) O +
were O +
added O +
to O +
solutions O +
of O +
samples O +
in O +
Me2 O +
SO O +
( O -
200 O +
μL O -
) O -
, O +
and O +
portions O +
of O +
MeI O +
( O -
250 O +
μL O -
) O +
were O +
added O +
after O +
5 O -
, O +
15 O -
, O +
and O +
25 O +
min O -
. O +

The O +
reaction O +
was O +
stopped O +
after O +
20 O +
min O +
by O +
adding O +
aq O +
Na2 O +
S2 O +
O3 O +
( O -
1 O +
mL O -
, O +
100 O +
mg O -
/ O -
mL O -
) O +
and O +
CHCl3 O +
( O -
1 O +
mL O -
) O -
. O +

The O +
chloroform O +
layer O +
was O +
extracted O +
with O +
water O +
( O -
3 O -
× O -
0.5 O +
mL O -
) O -
, O +
then O +
concentrated O -
. O +

After O +
hydrolysis O +
with O +
2 O +
M O +
CF3 O +
COOH O +
( O -
0.3 O +
mL O -
; O +
120 O +
° O -
C O -
, O +
1 O +
h O -
) O -
, O +
reduction O +
( O -
see O +
above O -
) O -
, O +
acetylation O +
with O +
Ac2 O +
O O +
( O -
0.5 O +
mL O -
; O +
120 O +
° O -
C O -
, O +
3 O +
h O -
) O -
, O +
quenching O +
with O +
water O +
( O -
0.5 O +
mL O -
) O -
, O +
and O +
neutralization O +
with O +
NaHCO3 O +
, O +
the O +
partially O +
methylated O +
alditol O +
acetates O +
were O +
extracted O +
with O +
CH2 O +
Cl2 O +
( O -
3 O -
× O -
0.7 O +
mL O -
) O -
. O +

After O +
concentration O +
to O +
about O +
20 O +
μL O +
( O -
N2 O +
) O -
, O +
samples O +
were O +
analyzed O +
by O +
GLC O +
and O +
GLC O -
– O -
EIMS O -
. O +

4.7 O +
Gas O -
– O -
liquid O +
chromatography O -
– O -
electron O +
impact O +
mass O +
spectrometry O +
( O -
GLC O -
– O -
EIMS O -
) O +
GLC O -
– O -
EIMS O +
analyses O +
were O +
carried O +
out O +
on O +
a O +
Fisons O +
MD800 O -
/ O -
8060 O +
system O +
( O -
electron O +
energy O -
, O +
70 O +
eV O -
; O +
carrier O +
gas O -
, O +
He O -
) O +
equipped O +
with O +
a O +
DB-1 O +
fused O -
- O -
silica O +
capillary O +
column O +
( O -
30 O +
m O -
× O -
0.32 O +
mm O -
, O +
J&W O +
Scientific O -
) O +
using O +
a O +
temperature O +
program O +
of O +
110–240 O +
° O -
C O +
at O +
4 O +
° O -
C O -
/ O -
min O +
followed O +
by O +
isothermal O +
elution O +
for O +
3 O +
min O -
. O +

4.8 O +
Mass O +
spectrometry O +
Approximately O +
10–25 O -
% O +
of O +
the O +
total O +
amount O +
of O +
each O +
fraction O +
was O +
used O +
for O +
mass O +
spectrometric O +
analysis O -
. O +

NaBD4 O +
-treated O +
and O +
permethylated O +
carbohydrates O +
were O +
dissolved O +
in O +
1:1 O +
MeOH O -
– O -
aq O +
1 O -
% O +
HCOOH O +
( O -
100 O +
μL O -
) O +
for O +
ESMS O -
. O +

Positive O -
- O -
ion O +
mode O +
ES O +
mass O +
spectra O +
were O +
obtained O +
using O +
a O +
VG O +
Platform O +
II O +
single O +
quadrupole O +
mass O +
spectrometer O -
. O +

Aliquots O +
of O +
10 O +
μL O +
of O +
the O +
samples O +
were O +
infused O +
into O +
a O +
mobile O +
phase O +
of O +
1:1 O +
MeOH O -
– O -
aq O +
1 O -
% O +
HCOOH O +
and O +
introduced O +
into O +
the O +
electrospray O +
source O +
at O +
a O +
flow O +
rate O +
of O +
5 O +
μL O -
/ O -
min O -
. O +

Spectra O +
were O +
scanned O +
at O +
a O +
speed O +
of O +
8 O +
s O +
for O +
m O -
/ O -
z O +
200–2000 O -
, O +
with O +
a O +
cone O +
voltage O +
of O +
95 O +
V O -
, O +
recorded O +
and O +
processed O +
using O +
the O +
MassLynx O +
software O -
, O +
version O +
2.0 O -
. O +

Mass O +
calibration O +
was O +
performed O +
by O +
multiple O -
- O -
ion O +
monitoring O +
of O +
peracetylated O +
malto O -
- O -
oligosaccharides O -
. O +

FABMS O +
was O +
carried O +
out O +
using O +
a O +
Jeol O +
JMS O -
- O -
SX O -
/ O -
SX102A O +
tandem O +
mass O +
spectrometer O +
( O -
BEBE O +
geometry O -
) O +
at O +
10 O +
kV O +
accelerating O +
voltage O -
. O +

A O +
Xe O +
beam O +
of O +
about O +
6 O +
kV O +
translational O +
energy O +
( O -
gun O +
current O +
10 O +
mA O -
) O +
was O +
used O +
for O +
FAB O +
ionization O -
. O +

The O +
CID O +
tandem O +
mass O +
spectra O +
were O +
obtained O +
by O +
using O +
the O +
collision O +
cell O +
in O +
the O +
third O +
field O +
free O +
region O +
of O +
the O +
mass O +
spectrometer O +
with O +
air O +
as O +
collision O +
gas O +
at O +
a O +
pressure O +
sufficient O +
to O +
reduce O +
the O +
intensity O +
of O +
the O +
selected O +
ion O +
beam O +
by O +
50 O -
% O -
. O +

As O +
the O +
collision O +
cell O +
was O +
held O +
at O +
ground O +
potential O -
, O +
the O +
collision O +
energy O +
in O +
the O +
MS O -
- O -
MS O +
experiments O +
was O +
10 O +
keV. O +
Spectra O +
were O +
scanned O +
at O +
a O +
speed O +
of O +
30 O +
s O +
for O +
the O +
full O +
mass O +
range O +
specified O +
by O +
the O +
accelerating O +
voltage O +
used O -
, O +
recorded O +
and O +
averaged O +
using O +
a O +
Hewlett O -
– O -
Packard O +
HP9000 O +
data O +
system O +
running O +
Jeol O +
complement O +
software O -
. O +

NaBD4 O +
-treated O +
and O +
permethylated O +
carbohydrates O +
were O +
dissolved O +
in O +
10 O +
μL O +
MeOH O +
and O +
about O +
1 O +
μL O +
of O +
the O +
solution O +
was O +
mixed O +
with O +
0.8 O +
μL O +
thioglycerol O +
matrix O +
on O +
the O +
probe O +
tip O -
. O +

4.9 O +
NMR O +
spectroscopy O +
Prior O +
to O +
NMR O +
analysis O +
samples O +
were O +
exchanged O +
twice O +
in O +
D2 O +
O O +
( O -
99.9 O +
atom% O +
D O -
, O +
Cambridge O +
Isotope O +
Laboratories O -
, O +
MA O -
, O +
USA O -
) O +
and O +
then O +
dissolved O +
in O +
D2 O +
O O +
( O -
99.96 O +
atom% O +
D O -
, O +
Isotec O -
, O +
USA O -
) O -
. O +

NMR O +
spectra O +
were O +
recorded O +
on O +
Bruker O +
AC-300 O +
( O -
Department O +
of O +
Organic O +
Chemistry O -
, O +
Utrecht O +
University O -
) O -
, O +
Bruker O +
AMX-500 O +
( O -
Bijvoet O +
Center O -
, O +
Utrecht O +
University O -
) O -
, O +
Bruker O +
AMX-600 O +
( O -
Bijvoet O +
Center O -
, O +
Utrecht O +
University O +
or O +
NSR O +
Center O -
, O +
University O +
of O +
Nijmegen O -
) O +
or O +
Varian O +
UNITY O -
- O -
plus O +
750 O +
( O -
Bijvoet O +
Center O -
, O +
Utrecht O +
University O -
) O +
instruments O +
at O +
probe O +
temperatures O +
of O +
27 O +
or O +
5 O +
° O -
C O -
. O +

Chemical O +
shifts O +
for O +
1 O +
H O +
are O +
expressed O +
in O +
ppm O +
relative O +
to O +
internal O +
acetone O +
( O -
δ O +
2.225 O -
) O +
or O +
acetate O +
( O -
δ O +
1.908 O -
) O -
, O +
and O +
for O +
13 O +
C O +
to O +
external O +
glucose O +
( O -
δ O +
Glcp O +
C-1α O +
92.9 O -
, O +
Glcp O +
C-1β O +
96.7 O +
[ O -
12 O -
] O +
. O +

1D O +
1 O +
H O +
NMR O +
spectra O +
were O +
recorded O +
with O +
a O +
sweep O +
width O +
of O +
5000 O +
Hz O +
at O +
500 O +
MHz O +
or O +
6000 O +
Hz O +
at O +
600 O +
MHz O +
in O +
data O +
sets O +
of O +
16,384 O +
points O -
. O +

Suppression O +
of O +
the O +
HOD O +
signal O +
was O +
achieved O +
by O +
applying O +
the O +
WEFT O +
pulse O +
as O +
described O +
[ O -
19 O -
] O +
. O +

Proton O +
decoupled O +
13 O +
C O +
NMR O +
spectra O +
were O +
acquired O +
at O +
75.469 O +
MHz O -
. O +

Typically O -
, O +
50,000 O +
transients O +
of O +
16,384 O +
data O +
points O +
were O +
recorded O -
. O +

All O +
2D O +
NMR O +
spectra O +
employed O +
the O +
time O -
- O -
proportional O +
phase O +
increment O +
( O -
TPPI O -
) O +
method O +
[ O -
20 O -
] O +
. O +

Only O +
seHSQC O +
used O +
the O +
STATES O -
- O -
TPPI O +
method O +
[ O -
21 O -
] O +
. O +

In O +
the O +
2D O +
homonuclear O +
proton O +
NMR O +
spectra O +
the O +
HOD O +
signal O +
was O +
suppressed O +
using O +
presaturation O +
during O +
a O +
relaxation O +
delay O +
for O +
1 O +
s. O +
2D O +
TOCSY O +
spectra O +
were O +
acquired O +
using O +
MLEV O +
17 O +
mixing O +
sequences O +
of O +
20–100 O +
ms O +
preceded O +
by O +
a O +
trim O +
pulse O +
of O +
2.5 O +
ms O -
. O +

The O +
spin O -
- O -
lock O +
field O +
strength O +
corresponded O +
with O +
a O +
90 O -
° O +
pulse O +
of O +
25–30 O +
μs O +
and O +
the O +
spectral O +
width O +
was O +
between O +
4 O +
and O +
6 O +
ppm O +
in O +
each O +
dimension O -
. O +

Typically O -
, O +
400–512 O +
experiments O +
of O +
2048 O +
points O +
were O +
acquired O +
with O +
4–32 O +
scans O +
per O +
increment O -
. O +

2D O +
DQF O -
- O -
COSY O +
spectra O +
were O +
recorded O +
with O +
a O +
spectral O +
width O +
as O +
in O +
the O +
2D O +
TOCSY O +
spectra O -
. O +

Typically O -
, O +
400–512 O +
free O +
induction O +
decays O -
, O +
each O +
acquired O +
as O +
8 O +
or O +
16 O +
transients O +
of O +
2048 O +
data O +
points O +
were O +
recorded O -
. O +

2D O +
ROESY O +
spectra O +
were O +
obtained O +
with O +
a O +
mixing O +
time O +
of O +
200–250 O +
ms O -
. O +

The O +
spin O -
- O -
lock O +
field O +
strength O +
was O +
in O +
accordance O +
with O +
a O +
90 O -
° O +
pulse O +
of O +
100–120 O +
μs O -
. O +

The O +
spectral O +
width O +
corresponded O +
with O +
5–7 O +
ppm O +
in O +
each O +
dimension O -
. O +

Typically O -
, O +
400–512 O +
experiments O +
of O +
2048 O +
points O +
were O +
acquired O +
with O +
32–64 O +
scans O +
per O +
increment O -
. O +

The O +
frequency O +
offset O +
was O +
initially O +
placed O +
on O +
the O +
HOD O +
resonance O +
and O +
switched O +
to O +
about O +
5.7 O +
ppm O +
just O +
before O +
application O +
of O +
the O +
spin O -
- O -
lock O +
pulse O +
thereby O +
reducing O +
the O +
Hartmann O -
– O -
Hahn O +
transfer O +
during O +
the O +
ROE O +
mixing O +
time O +
[ O -
22 O -
] O +
. O +

2D O +
sensitivity O +
enhanced O +
HSQC O +
spectra O +
were O +
proton O +
detected O +
and O +
two O +
gradients O +
were O +
applied O +
for O +
13 O +
C O +
coherence O +
selection O -
. O +

These O +
spectra O +
were O +
acquired O +
with O +
the O +
proton O +
offset O +
at O +
about O +
4.6 O +
ppm O +
and O +
a O +
sweepwidth O +
of O +
about O +
6 O +
ppm O -
. O +

In O +
the O +
13 O +
C O +
dimension O +
the O +
offset O +
was O +
placed O +
around O +
80 O +
ppm O +
and O +
a O +
sweep O +
width O +
of O +
60 O +
ppm O +
was O +
used O -
. O +

Typically O -
, O +
300–350 O +
free O +
induction O +
decays O +
of O +
1024 O +
data O +
points O +
were O +
acquired O +
using O +
128–256 O +
scans O +
per O +
decay O -
. O +

2D O +
HMBC O +
spectra O +
were O +
recorded O +
essentially O +
as O +
the O +
2D O +
seHSQC O +
spectra O -
. O +

The O +
delay O +
for O +
the O +
evolution O +
of O +
the O +
long O +
range O +
couplings O +
was O +
40–50 O +
ms O -
. O +

NMR O +
data O +
sets O +
were O +
processed O +
using O +
Bruker O +
UXNMR O +
software O +
or O +
the O +
Triton O +
NMR O +
software O +
package O +
( O -
Bijvoet O +
Center O -
, O +
Utrecht O +
University O -
) O -
. O +

Briefly O -
, O +
time O +
domain O +
data O +
were O +
multiplied O +
by O +
phase O -
- O -
shifted O +
( O -
squared- O -
) O -
sine O -
- O -
bell O +
functions O +
or O +
with O +
a O +
Lorentzian O -
- O -
to O -
- O -
Gaussian O +
multiplication O -
. O +

After O +
zerofilling O +
and O +
Fourier O +
transformation O +
datasets O +
of O +
1024 O -
× O -
1024 O +
or O +
2048 O -
× O -
1024 O +
points O +
were O +
obtained O -
, O +
which O +
were O +
baseline O +
corrected O +
with O +
a O +
fourth O -
- O -
order O +
polynomial O +
function O +
when O +
necessary O -
. O +

Accurate O +
chemical O +
shift O +
values O +
obtained O +
from O +
1D O +
spectra O +
are O +
represented O +
with O +
three O +
( O -
protons O -
) O +
or O +
two O +
( O -
carbons O -
) O +
decimals O -
, O +
whereas O +
values O +
obtained O +
from O +
2D O +
spectra O +
are O +
depicted O +
with O +
two O +
( O -
protons O -
) O +
or O +
one O +
( O -
carbon O -
) O +
decimals O -
. O +

Acknowledgements O +
The O +
authors O +
thank O +
Dr. O +
R.W. O +
Wechselberger O +
( O -
Bijvoet O +
Center O -
, O +
Department O +
of O +
NMR O +
Spectroscopy O -
, O +
Utrecht O +
University O -
, O +
The O +
Netherlands O -
) O +
for O +
recording O +
the O +
1D O +
1 O +
H O +
NMR O +
spectra O +
using O +
the O +
Varian O +
Unity O +
plus O +
750 O +
instrument O -
. O +

This O +
research O +
was O +
supported O +
by O +
the O +
Dutch O +
Technology O +
Foundation O +
( O -
NWO O -
/ O -
STW O -
) O -
, O +
Gist O -
- O -
brocades O -
, O +
The O +
Product O +
Board O +
for O +
Feeding O +
Stuffs O +
( O -
VVR O -
) O -
, O +
and O +
Borculo O +
Whey O +
Products O -
. O +

Activity O -
- O -
guided O +
fractionation O +
of O +
the O +
roots O +
of O +
Anthriscus O +
sylvestris O +
resulted O +
in O +
the O +
isolation O +
and O +
characterization O +
of O +
five O +
cytotoxic O +
compounds O -
, O +
deoxypodophyllotoxin O +
( O -
1 O -
) O -
, O +
falcarindiol O +
( O -
2 O -
) O -
, O +
and O +
angeloyl O +
podophyllotoxin O +
( O -
5 O -
) O +
from O +
the O +
hexane O +
soluble O +
fraction O +
and O +
morelensin O +
( O -
3 O -
) O -
, O +
bursehernin O +
( O -
4 O -
) O +
from O +
the O +
chloroform O +
soluble O +
fraction O -
. O +

It O +
is O +
the O +
first O +
report O +
of O +
the O +
occurrence O +
of O +
compound O +
5 O +
in O +
nature O -
. O +

BACKGROUND O -
: O +
Vegetarians O +
have O +
lower O +
platelet O +
and O +
plasma O +
concentrations O +
of O +
n-3 O +
polyunsaturated O +
fatty O +
acids O +
( O -
PUFAs O -
) O +
than O +
do O +
omnivores O -
. O +

We O +
recently O +
showed O +
that O +
male O +
vegetarians O +
have O +
higher O +
platelet O +
aggregability O +
than O +
do O +
omnivores O -
. O +

OBJECTIVE O -
: O +
We O +
investigated O +
whether O +
male O +
vegetarians O +
( O -
n O +
= O +
17 O -
) O +
who O +
consumed O +
an O +
increased O +
amount O +
of O +
dietary O +
alpha O -
- O -
linolenic O +
acid O +
( O -
ALA O -
) O +
showed O +
any O +
changes O +
in O +
their O +
tissue O +
profile O +
of O +
PUFAs O -
, O +
plasma O +
thromboxane O +
concentrations O -
, O +
platelet O +
aggregability O -
, O +
or O +
hemostatic O +
factors O -
. O +

DESIGN O -
: O +
During O +
the O +
study O -
, O +
all O +
subjects O +
maintained O +
their O +
habitual O +
vegetarian O +
diets O +
except O +
that O +
a O +
proportion O +
of O +
dietary O +
fat O +
was O +
replaced O +
with O +
vegetable O +
oils O +
and O +
margarines O +
that O +
were O +
provided O -
. O +

Initially O -
, O +
all O +
subjects O +
consumed O +
a O +
low O -
- O -
ALA O +
diet O +
( O -
containing O +
safflower O +
oil O +
and O +
safflower O +
oil O -
- O -
based O +
margarine O -
) O +
for O +
14 O +
d O -
; O +
they O +
then O +
consumed O +
either O +
a O +
moderate O -
- O -
ALA O +
diet O +
( O -
containing O +
canola O +
oil O +
and O +
canola O +
oil O -
- O -
based O +
margarine O -
) O +
or O +
a O +
high O -
- O -
ALA O +
diet O +
( O -
containing O +
linseed O +
oil O +
and O +
linseed O +
oil O -
- O -
based O +
margarine O -
) O +
for O +
28 O +
d. O +
Blood O +
samples O +
were O +
collected O +
at O +
day O +
0 O +
( O -
baseline O -
) O -
, O +
day O +
14 O -
, O +
and O +
day O +
42 O -
. O +

RESULTS O -
: O +
Eicosapentaenoic O +
acid O -
, O +
docosapentaenoic O +
acid O -
, O +
total O +
n-3 O +
PUFAs O -
, O +
and O +
the O +
ratio O +
of O +
n-3 O +
to O +
n-6 O +
PUFAs O +
were O +
significantly O +
increased O +
( O -
P O +
< O +
0.05 O -
) O -
, O +
whereas O +
the O +
ratio O +
of O +
arachidonic O +
acid O +
to O +
eicosapentaenoic O +
acid O +
was O +
decreased O +
( O -
P O +
< O +
0.05 O -
) O -
, O +
in O +
platelet O +
phospholipids O -
, O +
plasma O +
phospholipids O -
, O +
and O +
triacylglycerols O +
after O +
either O +
the O +
moderate O -
- O -
ALA O +
or O +
high O -
- O -
ALA O +
diet O +
compared O +
with O +
the O +
low O -
- O -
ALA O +
diet O -
. O +

No O +
significant O +
differences O +
were O +
observed O +
in O +
thrombotic O +
risk O +
factors O -
. O +

CONCLUSION O -
: O +
ALA O +
from O +
vegetable O +
oils O +
( O -
canola O +
and O +
linseed O -
) O +
has O +
a O +
beneficial O +
effect O +
on O +
n-3 O +
PUFA O +
concentrations O +
of O +
platelet O +
phospholipids O +
and O +
plasma O +
lipids O +
in O +
vegetarian O +
males O -
. O +

Organic O +
nitrate O +
esters O -
, O +
such O +
as O +
glyceryl O +
trinitrate O +
and O +
isosorbide O +
dinitrate O -
, O +
are O +
a O +
class O +
of O +
compounds O +
used O +
to O +
treat O +
a O +
variety O +
of O +
vascular O +
ailments O -
. O +

Their O +
effectiveness O +
relies O +
on O +
their O +
ability O +
to O +
be O +
bioactivated O +
to O +
nitric O +
oxide O +
( O -
NO O -
) O +
which O -
, O +
in O +
turn O -
, O +
relaxes O +
vascular O +
smooth O +
muscle O -
. O +

Although O +
there O +
have O +
been O +
many O +
biological O +
studies O +
that O +
indicate O +
that O +
NO O +
can O +
be O +
formed O +
from O +
organic O +
nitrate O +
esters O +
in O +
a O +
biological O +
environment O -
, O +
the O +
chemical O +
mechanism O +
by O +
which O +
this O +
occurs O +
has O +
yet O +
to O +
be O +
established O -
. O +

Previous O +
studies O +
have O +
implicated O +
both O +
flavins O +
and O +
thiols O +
in O +
organic O +
nitrate O +
ester O +
bioactivation O -
. O +

Thus O -
, O +
we O +
examined O +
the O +
chemical O +
interactions O +
of O +
flavins O +
and O +
thiols O +
with O +
organic O +
nitrate O +
esters O +
as O +
a O +
means O +
of O +
determining O +
the O +
role O +
these O +
species O +
may O +
play O +
in O +
NO O +
production O -
. O +

Based O +
on O +
these O +
studies O +
we O +
concluded O +
that O +
a O +
reasonable O +
chemical O +
mechanism O +
for O +
organic O +
nitrate O +
ester O +
bioactivation O +
involves O +
reduction O +
to O +
the O +
organic O +
nitrite O +
ester O +
followed O +
by O +
conversion O +
to O +
a O +
nitrosothiol O -
. O +

The O +
release O +
of O +
NO O +
from O +
nitrosothiols O +
can O +
occur O +
via O +
a O +
variety O +
of O +
processes O +
including O +
reaction O +
with O +
dihydroflavins O +
and O +
NADH O -
. O +

Plant O +
cell O +
suspension O +
cultures O +
of O +
Rauwolfia O +
produce O +
within O +
1 O +
week O +
approximately O +
250 O +
nkat O -
/ O -
l O +
of O +
raucaffricine B-Gene -
- I-Gene -
O I-Gene -
- I-Gene -
beta I-Gene -
- I-Gene -
D I-Gene -
- I-Gene -
glucosidase I-Gene -
. O +

A O +
five O +
step O +
procedure O +
using O +
anion O +
exchange O +
chromatography O -
, O +
chromatography O +
on O +
hydroxylapatite O -
, O +
gel O +
filtration O +
and O +
FPLC O -
- O -
chromatography O +
on O +
Mono O +
Q O +
and O +
Mono O +
P O +
delivered O +
in O +
a O +
yield O +
of O +
0.9 O -
% O +
approximately O +
1200-fold O +
enriched O +
glucosidase B-Gene -
. O +

A O +
short O +
protocol O +
employing O +
DEAE O +
sepharose O -
, O +
TSK O +
55 O +
S O +
gel O +
chromatography O +
and O +
purification O +
on O +
Mono O +
Q O +
gave O +
a O +
5 O -
% O +
recovery O +
of O +
glucosidase B-Gene +
which O +
was O +
340-fold O +
enriched O -
. O +

SDS O -
- O -
PAGE O +
showed O +
a O +
Mr O +
for O +
the O +
enzyme B-Gene +
of O +
61 O +
kDa O -
. O +

The O +
enzyme B-Gene +
is O +
not O +
glycosylated O -
. O +

Structural O +
investigation O +
of O +
the O +
enzyme O +
product O -
, O +
vomilenine O -
, O +
demonstrated O +
that O +
the O +
alkaloid O +
exists O +
in O +
aqueous O +
solutions O +
in O +
an O +
equilibrium O +
of O +
21 O -
( O -
R O -
) O -
- O +
and O +
21 O -
( O -
S O -
) O -
-vomilenine O +
in O +
a O +
ratio O +
of O +
3.4:1 O -
. O +

Proteolysis O +
of O +
the O +
pure O +
enzyme B-Gene +
with O +
endoproteinase B-Gene +
Lys I-Gene +
C I-Gene +
revealed O +
six O +
peptide O +
fragments O +
with O +
6 O -
- O -
24 O +
amino O +
acids O +
which O +
were O +
sequenced O -
. O +

The O +
two O +
largest O +
fragments O +
showed O +
sequences O -
, O +
of O +
which O +
the O +
motif O +
Val O -
- O -
Thr O -
- O -
Glu O -
- O -
Asn O -
- O -
Gly O +
is O +
typical O +
for O +
beta B-Gene -
- I-Gene -
glucosidases I-Gene -
. O +

Sequence O +
alignment O +
of O +
these O +
fragments O +
demonstrated O +
high O +
homologies O +
to O +
linamarase B-Gene +
from O +
Manihot O +
esculenta O +
( O -
81 O -
% O +
identity O -
) O +
or O +
to O +
beta B-Gene -
- I-Gene -
glucosidase I-Gene +
from O +
Prunus O +
avium O +
( O -
79 O -
% O +
identity O -
) O -
. O +

Raucaffricine B-Gene -
- I-Gene -
O I-Gene -
- I-Gene -
beta I-Gene -
- I-Gene -
D I-Gene -
- I-Gene -
glucosidase I-Gene +
seems O +
to O +
be O +
a O +
new O +
member O +
of O +
the O +
family O +
1 O +
of O +
glycosyl B-Gene +
hydrolases I-Gene -
. O +

Glucosidases B-Gene +
belong O +
to O +
a O +
group O +
of O +
enzymes B-Gene +
which O +
are O +
of O +
widespread O +
distribution O +
and O +
for O +
a O +
long O +
time O +
have O +
been O +
extensively O +
studied O +
from O +
several O +
points O +
of O +
view O -
. O +

These O +
enzymes B-Gene +
were O +
investigated O +
not O +
only O +
because O +
of O +
their O +
significant O +
role O +
in O +
cellulose O +
degradation O +
( O -
Beguin O -
, O +
1990 O +
) O -
, O +
their O +
involvement O +
in O +
plant O +
defence O +
reactions O +
( O -
Poulton O -
, O +
1990 O +
) O +
and O +
activation O +
of O +
phytohormones O +
( O -
Brzobohaty O +
et O +
al. O -
, O +
1993 O +
) O -
, O +
but O +
also O +
to O +
elucidate O +
their O +
still O +
unrevealed O +
reaction O +
mechanisms O +
( O -
Withers O +
and O +
Street O -
, O +
1988 O +
; O +
Sinnot O -
, O +
1990 O +
) O +
or O +
to O +
assign O +
them O +
to O +
the O +
appropriate O +
glycosyl B-Gene +
hydrolase I-Gene +
families O +
( O -
Henrissat O -
, O +
1991 O +
; O +
Henrissat O +
and O +
Bairoch O -
, O +
1993 O +
) O -
. O +

Consequently O +
many O +
attempts O +
have O +
been O +
directed O +
towards O +
the O +
purification O +
and O +
characterization O +
of O +
glucosidases B-Gene +
from O +
quite O +
different O +
origins O +
and O +
especially O +
in O +
order O +
to O +
gain O +
insight O +
into O +
their O +
substrate O +
acceptance O +
as O +
unspecific O +
and O +
specific O +
enzymes B-Gene -
. O +

The O +
use O +
of O +
unnatural O +
substrates O -
, O +
like O +
p O +
-nitrophenyl O +
glucoside O -
, O +
for O +
the O +
enrichment O +
of O +
glucosidases B-Gene +
hampered O +
detailed O +
studies O +
of O +
their O +
real O +
substrate O +
specificities O +
and O +
was O +
criticized O +
several O +
times O +
in O +
the O +
literature O +
( O -
Hemscheidt O +
and O +
Zenk O -
, O +
1980 O +
; O +
Conn O -
, O +
1993 O +
) O -
. O +

Very O +
recent O +
work O -
, O +
however O -
, O +
describes O +
a O +
number O +
of O +
more O +
or O +
less O +
substrate O +
specific O +
plant O +
glucosidases B-Gene +
( O -
Gus O -
- O -
Mayer O +
et O +
al. O -
, O +
1994 O +
; O +
Falk O +
and O +
Rask O -
, O +
1995 O +
) O +
and O +
among O +
them O +
the O +
well O +
characterized O +
β B-Gene +
-glucosidases I-Gene +
hydrolyzing O +
cyanogenic O +
glucosides O +
( O -
Oxtoby O +
et O +
al. O -
, O +
1991 O +
; O +
Li O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

Although O +
glucosidases B-Gene +
are O +
involved O +
in O +
the O +
metabolism O +
of O +
a O +
broad O +
variety O +
of O +
plant O +
natural O +
products O +
it O +
seems O +
that O +
this O +
type O +
of O +
enzyme B-Gene +
has O +
no O +
general O +
significance O +
in O +
alkaloid O +
biosynthesis O +
and O +
this O +
is O +
especially O +
true O +
for O +
one O +
of O +
the O +
largest O +
alkaloid O +
groups O -
, O +
containing O +
the O +
so O +
far O +
known O +
2000 O +
monoterpenoid O +
indole O +
alkaloids O -
. O +

Among O +
them O +
less O +
than O +
40 O +
are O +
glucoalkaloids O +
( O -
Ruyter O +
et O +
al. O -
, O +
1988 O +
) O -
. O +

From O +
two O +
of O +
these O +
glucoalkaloids O +
only O +
the O +
corresponding O +
glucosidases B-Gene +
were O +
detected O +
and O +
could O +
be O +
partially O +
characterized O +
from O +
plant O +
cell O +
suspension O +
cultures O +
of O +
Catharanthus O +
roseus O +
G. O +
Don O +
and O +
Rauwolfia O +
serpentina O +
Benth O -
. O +

ex O +
Kurz O +
( O -
Hemscheidt O +
and O +
Zenk O -
, O +
1980 O +
; O +
Schubel O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

Both O +
of O +
them O -
, O +
the O +
alkaloidal O +
glucoside O +
strictosidine O +
( O -
3 O +
) O +
and O +
the O +
alkaloid O +
raucaffricine O +
( O -
6 O +
) O +
are O -
, O +
however O -
, O +
of O +
great O +
interest O +
( O -
Fig. O +
1 O +
) O -
. O +

Strictosidine O +
( O -
3 O +
) O -
, O +
which O +
is O +
the O +
condensation O +
product O +
of O +
the O +
monoterpene O +
glucoside O +
secologanin O +
( O -
2 O +
) O +
and O +
the O +
amine O +
tryptamine O +
( O -
1 O +
) O -
, O +
occupies O +
a O +
crucial O +
biosynthetic O +
role O +
( O -
Kutchan O -
, O +
1993 O +
) O -
. O +

It O +
is O +
most O +
probably O +
the O +
biogenetic O +
progenitor O +
of O +
all O +
monoterpenoid O +
indole O +
alkaloids O +
in O +
nature O -
. O +

This O +
glucoside O +
is O +
therefore O +
an O +
extraordinary O +
example O +
because O +
glucosides O +
of O +
natural O +
products O +
are O +
usually O +
located O +
at O +
the O +
end O +
of O +
biosynthetic O +
routes O +
as O +
water O +
soluble O +
compounds O -
. O +

3 O +
is O -
, O +
however O -
, O +
situated O +
at O +
the O +
beginning O +
of O +
pathways O +
and O +
becomes O +
a O +
highly O +
activated O +
and O +
reactive O +
alkaloid O +
precursor O +
on O +
entering O +
these O +
routes O +
after O +
the O +
splitting O +
off O +
the O +
glucosidic O +
bond O +
by O +
strictosidine B-Gene +
glucosidase I-Gene +
( O -
Hemscheidt O +
and O +
Zenk O -
, O +
1980 O +
) O -
. O +

In O +
contrast O -
, O +
the O +
second O +
glucoside O -
, O +
6 O +
, O +
might O +
well O +
belong O +
to O +
a O +
group O +
of O +
storage O +
compounds O +
but O +
its O +
precise O +
biosynthetic O +
role O +
is O +
not O +
yet O +
known O +
( O -
Stockigt O -
, O +
1995 O +
) O -
. O +

The O +
deglucosylation O +
of O +
6 O +
catalyzed O +
by O +
raucaffricine B-Gene +
glucosidase I-Gene +
( O -
RG B-Gene -
; O +
EC B-Gene +
3.2.1.125 I-Gene -
) O +
leads O +
to O +
its O +
aglycone O +
vomilenine O +
( O -
4 O +
) O -
. O +

The O +
latter O +
alkaloid O +
is O +
a O +
direct O +
intermediate O +
in O +
the O +
biosynthetic O +
pathway O +
of O +
the O +
antiarrhythmic O +
alkaloid O +
ajmaline O +
( O -
5 O +
) O +
( O -
Stockigt O -
, O +
1995 O +
) O -
. O +

RG B-Gene -
, O +
therefore O -
, O +
might O +
have O +
a O +
fascinating O +
biochemical O +
function O -
, O +
e.g. O +
by O +
channeling O +
a O +
biogenetic O +
precursor O +
into O +
the O +
late O +
stages O +
of O +
ajmaline O +
biosynthesis O -
. O +

Moreover O +
the O +
glucosidase B-Gene +
has O +
never O +
been O +
detected O +
in O +
other O +
plants O +
or O +
cell O +
suspension O +
cultures O +
than O +
Rauwolfia O +
and O +
is O +
obviously O +
unique O +
to O +
the O +
co O -
- O -
occurrence O +
of O +
ajmaline O +
type O +
alkaloids O -
. O +

Therefore O -
, O +
for O +
its O +
further O +
investigation O -
, O +
e.g. O +
the O +
elucidation O +
of O +
its O +
reaction O +
mechanism O -
, O +
a O +
pure O +
enzyme B-Gene +
and O +
information O +
on O +
its O +
amino O +
acid O +
sequence O +
would O +
be O +
advantageous O -
. O +

The O +
present O +
paper O +
describes O +
the O +
purification O -
, O +
partial O +
sequencing O -
, O +
the O +
structure O +
of O +
the O +
enzyme B-Gene +
product O +
4 O +
and O +
a O +
comparison O +
of O +
this O +
exceptional O +
enzyme B-Gene +
in O +
alkaloid O +
biosynthesis O +
to O +
other O +
plant O +
glucosidases B-Gene -
. O +

2 O +
Results O +
2.1 O +
Cell O +
growth O +
and O +
glucosidase B-Gene +
activity O +
Cell O +
growth O -
, O +
protein B-Gene +
amount O +
and O +
RG B-Gene +
activity O +
of O +
cultivated O +
Rauwolfia O +
cells O +
were O +
dependent O +
on O +
cultivation O +
time O -
. O +

Enzyme B-Gene +
activity O +
( O -
nkat O -
/ O -
l O +
cell O +
suspension O -
) O +
and O +
protein B-Gene +
content O +
( O -
g O -
/ O -
l O -
) O +
increased O +
up O +
to O +
the O +
5th O -
/ O -
6th O +
day O +
from O +
100 O +
to O +
270 O +
nkat O +
and O +
0.3 O +
to O +
0.6 O +
g O +
protein B-Gene -
, O +
respectively O -
. O +

Optimum O +
conditions O +
were O +
around O +
5–6 O +
days O -
. O +

For O +
cultivation O +
of O +
the O +
Rauwolfia O +
cells O +
usually O +
1 O +
week O +
growth O +
period O +
is O +
applied O +
routinely O -
. O +

Because O +
at O +
that O +
time O +
only O +
slight O +
decrease O +
of O +
enzyme B-Gene +
activity O +
from O +
270 O +
to O +
250 O +
nkat O -
/ O -
l O +
occurs O -
, O +
cells O +
for O +
isolation O +
of O +
RG B-Gene +
were O +
harvested O +
after O +
7 O +
days O +
of O +
growth O -
. O +

2.2 O +
Purification O +
of O +
RG B-Gene +
The O +
results O +
of O +
a O +
typical O +
purification O +
procedure O +
of O +
RG B-Gene +
are O +
shown O +
in O +
Table O +
1 O +
. O +

The O +
combination O +
of O +
five O +
different O +
steps O +
of O +
enzyme B-Gene +
enrichment O +
including O +
HPLC O +
chromatography O +
resulted O +
finally O +
in O +
over O +
1000-fold O +
enzyme B-Gene +
purification O -
. O +

The O +
crude O +
protein B-Gene +
extract O +
obtained O +
from O +
the O +
Rauwolfia O +
cells O +
was O +
subjected O +
to O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
fractionation O +
followed O +
by O +
anion O +
exchange O +
chromatography O +
on O +
DEAE O +
Sephacel O +
( O -
Fig. O +
2 O +
A O -
) O -
. O +

At O +
this O +
stage O +
a O +
3.5-fold O +
enzyme B-Gene +
enrichment O +
with O +
an O +
overall O +
yield O +
of O +
43 O -
% O +
was O +
obtained O -
. O +

For O +
further O +
purification O +
the O +
glucosidase B-Gene -
- O -
containing O +
fractions O +
were O +
added O +
to O +
a O +
hydroxylapatite O +
column O +
which O -
, O +
after O +
elution O +
with O +
a O +
linear O +
KPi O +
gradient O -
, O +
gave O +
a O +
10-fold O +
purification O +
of O +
the O +
RG B-Gene +
activity O +
with O +
a O +
specific O +
activity O +
of O +
3.9 O +
nkat O -
/ O -
mg O -
. O +

As O +
Fig. O +
2 O +
( O -
B O -
) O +
illustrates O -
, O +
maximum O +
enzyme B-Gene +
activity O +
was O +
separated O +
from O +
the O +
bulk O +
of O +
the O +
protein B-Gene +
and O +
this O +
enzyme B-Gene +
preparation O +
was O +
then O +
subjected O +
to O +
size O +
exclusion O +
chromatography O +
applying O +
AcA O +
54 O +
material O +
after O +
it O +
had O +
been O +
concentrated O +
by O +
ultrafiltration O -
. O +

The O +
maximum O +
glucosidase B-Gene +
activity O +
was O +
eluted O +
under O +
the O +
applied O +
conditions O +
after O +
75 O +
ml O +
corresponding O +
to O +
a O +
M O +
r O +
of O +
63 O +
kDa±10 O -
% O +
( O -
Fig. O +
2 O +
C O -
) O -
. O +

The O +
remaining O +
glucosidase B-Gene +
fractions O +
did O +
not O +
contain O +
the O +
well O +
known O +
Rauwolfia O +
enzyme O +
polyneuridine B-Gene +
aldehyde I-Gene +
esterase I-Gene +
( O -
PNA B-Gene +
esterase I-Gene -
, O +
data O +
not O +
shown O +
( O -
Pfitzner O +
and O +
Stockigt O -
, O +
1983 O +
) O -
) O +
indicating O +
its O +
further O +
purification O -
, O +
which O +
corresponded O +
to O +
a O +
133-fold O +
enrichment O -
. O +

Fractions O +
with O +
the O +
highest O +
enzyme B-Gene +
activity O +
were O +
combined O -
, O +
concentrated O +
and O +
were O +
used O +
for O +
the O +
next O +
purification O +
step O +
based O +
on O +
the O +
second O +
ion O +
exchange O +
chromatography O +
in O +
this O +
protocol O -
, O +
on O +
the O +
Mono O +
Q O +
anion O +
exchanger O -
. O +

Although O +
this O +
step O +
did O +
not O +
efficiently O +
resolve O +
the O +
enzyme B-Gene +
activity O +
from O +
the O +
major O +
protein B-Gene +
peaks O +
( O -
Fig. O +
2 O +
D O -
) O -
, O +
the O +
resulting O +
enzyme B-Gene +
solution O +
obtained O +
by O +
KCl O +
elution O +
showed O +
a O +
∼600-fold O +
enrichment O +
with O +
a O +
specific O +
enzyme B-Gene +
activity O +
of O +
240 O +
nkat O -
/ O -
mg O -
. O +

Compared O +
with O +
the O +
starting O +
protein B-Gene +
amount O +
at O +
this O +
stage O +
a O +
yield O +
of O +
∼4 O -
% O +
was O +
determined O -
. O +

After O +
concentration O +
of O +
the O +
protein B-Gene +
solution O -
, O +
the O +
remaining O +
enzyme B-Gene +
could O +
be O +
finally O +
purified O +
by O +
FPLC O +
isoelectric O +
focusing O +
on O +
a O +
Mono O +
P O +
column O +
( O -
Fig. O +
2 O +
E O -
) O -
. O +

The O +
maximum O +
catalytic O +
activity O +
of O +
RG B-Gene +
corresponds O +
to O +
an O +
isoelectric O +
point O +
of O +
5.8 O -
. O +

In O +
summary O -
, O +
the O +
enzyme B-Gene +
was O +
∼1200-fold O +
purified O +
and O +
showed O +
a O +
specific O +
activity O +
of O +
∼470 O +
nkat O -
/ O -
mg O +
with O +
a O +
0.9 O -
% O +
recovery O +
from O +
the O +
crude O +
protein B-Gene +
extract O -
. O +

Only O +
about O +
10 O +
mg O +
of O +
the O +
enzyme B-Gene +
remained O -
. O +

Based O +
on O +
these O +
data O +
a O +
shorter O +
purification O +
protocol O +
for O +
RG B-Gene +
could O +
be O +
developed O +
with O +
the O +
aim O +
of O +
obtaining O +
sufficient O +
pure O +
enzyme B-Gene +
amounts O +
for O +
protein B-Gene +
digestion O +
and O +
partial O +
sequencing O -
. O +

This O +
procedure O +
finally O +
was O +
similar O +
to O +
the O +
just O +
described O +
one O +
but O +
only O +
3 O +
steps O +
of O +
column O +
chromatography O +
were O +
applied O -
; O +
DEAE O +
Sepharose O +
( O +
fast O +
flow O -
) O -
, O +
size O +
exclusion O +
on O +
TSK O +
55 O +
S O +
and O +
Mono O +
Q O +
chromatography O +
resulted O +
in O +
an O +
enzyme B-Gene +
preparation O +
with O +
a O +
specific O +
activity O +
of O +
136 O +
nkat O -
/ O -
mg O +
which O +
was O +
340-fold O +
enriched O +
with O +
a O +
total O +
recovery O +
of O +
5 O -
% O -
. O +

2.3 O +
Purity O -
, O +
molecular O +
weight O +
and O +
sugar O +
content O +
of O +
RG B-Gene +
The O +
340-fold O +
enriched O +
enzyme B-Gene +
preparation O +
showed O +
on O +
SDS O -
- O -
PAGE O +
( O -
Fig. O +
3 O +
A O -
, O +
lane O +
A O -
) O +
after O +
Coomassie O +
Blue O +
staining O +
several O +
bands O +
with O +
a O +
major O +
protein B-Gene +
at O +
61 O +
kDa O -
. O +

Previous O +
determination O +
of O +
M O +
r O +
by O +
gel O +
chromatography O +
on O +
Fractogel O +
TSK O +
3000 O +
indicated O +
66 O +
kDa O +
( O -
±5 O -
% O -
) O +
for O +
the O +
enzyme B-Gene +
( O -
Schubel O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

In O +
order O +
to O +
finally O +
assign O +
the O +
glucosidase B-Gene +
to O +
one O +
of O +
the O +
bands O +
on O +
SDS O -
- O -
PAGE O -
, O +
the O +
same O +
enzyme B-Gene +
preparation O +
was O +
subjected O +
three O +
times O +
( O -
lane O +
A O -
– O -
C O -
) O +
to O +
basic O +
native O +
electrophoresis O +
( O -
BNE O -
, O +
Fig. O +
3 O +
B O -
) O -
. O +

Lane O +
A O +
was O +
separated O +
and O +
stained O +
with O +
Coomassie O +
Blue O -
, O +
indicating O +
three O +
different O +
protein B-Gene +
regions O -
, O +
with O +
one O +
major O +
( O -
a O -
) O +
and O +
with O +
two O +
minor O +
protein B-Gene +
amounts O +
( O -
b O -
) O +
and O +
( O -
c O -
) O -
. O +

From O +
the O +
unstained O +
lane O +
B O +
the O +
corresponding O +
regions O +
( O -
a O -
) O -
, O +
( O -
b O -
) O +
and O +
( O -
c O -
) O +
were O +
scraped O +
off O +
and O +
analyzed O +
for O +
enzyme B-Gene +
activity O -
. O +

Only O +
the O +
major O +
protein B-Gene +
band O +
( O -
a O -
) O +
showed O +
RG B-Gene +
activity O -
. O +

The O +
third O +
lane O +
C O +
was O +
treated O +
accordingly O -
, O +
but O +
used O +
finally O +
for O +
SDS O -
- O -
PAGE O -
. O +

After O +
staining O -
, O +
this O +
gel O +
clearly O +
exhibited O +
only O +
one O +
protein B-Gene +
band O +
at O +
61 O +
kDa O +
( O -
Fig. O +
3 O +
A O -
, O +
lane O +
B O -
) O +
which O +
was O +
the O +
same O +
as O +
that O +
dominating O +
in O +
the O +
original O +
SDS O -
- O -
PAGE O +
of O +
the O +
340-fold O +
enriched O +
enzyme B-Gene +
preparation O +
( O -
Fig. O +
3 O +
A O -
, O +
lane O +
A O -
) O -
. O +

Silver O +
staining O +
of O +
this O +
gel O +
also O +
showed O +
only O +
one O +
protein B-Gene +
band O -
. O +

This O +
protein B-Gene -
, O +
therefore O -
, O +
could O +
be O +
clearly O +
assigned O +
as O +
RG B-Gene -
. O +

To O +
obtain O +
knowledge O +
of O +
a O +
glycosylation O +
of O +
this O +
enzyme B-Gene -
, O +
an O +
enriched O +
glucosidase B-Gene +
fraction O +
( O -
340-fold O -
) O +
was O +
separated O +
on O +
SDS O -
- O -
PAGE O +
with O +
the O +
reference O +
proteins B-Gene -
, O +
transferrin B-Gene +
as O +
a O +
glycoprotein B-Gene +
and O +
creatinase B-Gene +
as O +
a O +
non B-Gene -
- I-Gene -
glycosidic I-Gene +
protein I-Gene -
. O +

The O +
gel O +
exhibited O -
, O +
after O +
blotting O +
on O +
nitrocellulose O +
membranes O +
and O +
staining O +
with O +
the O +
Dig O +
Glycan O +
Detection O +
Kit O -
, O +
only O +
staining O +
of O +
the O +
glycoprotein B-Gene +
transferrin B-Gene +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
RG B-Gene +
is O +
therefore O +
most O +
probably O +
a O +
sugar O -
- O -
free O +
enzyme B-Gene -
. O +

2.4 O +
MS O +
and O +
NMR O +
identification O +
of O +
the O +
glucosidase B-Gene +
product O +
vomilenine O +
The O +
enzyme B-Gene +
product O +
4 O +
showed O +
identical O +
MS O -
- O -
fragmentation O +
when O +
analyzed O +
by O +
EIMS O +
and O +
the O +
same O +
behaviour O +
as O +
a O +
reference O +
sample O +
when O +
analyzed O +
by O +
coupled O +
GC O -
– O -
MS O -
. O +

When O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
the O +
purified O +
enzyme B-Gene +
product O +
4 O +
was O +
measured O +
in O +
DMSO O -
- O -
d6 O +
several O +
protons O +
appeared O +
as O +
double O +
signals O +
in O +
a O +
ratio O +
3.4:1 O -
, O +
like O +
the O +
quartet O +
for O +
H-19 O -
, O +
the O +
singlet O +
of O +
H-21 O +
or O +
the O +
singlet O +
of O +
H-17 O -
. O +

Vomilenine O +
obviously O +
occurs O +
as O +
a O +
mixture O +
of O +
isomers O -
. O +

Analysis O +
of O +
the O +
NMR O +
data O +
indicates O +
that O +
the O +
mixed O +
spectrum O +
consists O +
of O +
the O +
signals O +
for O +
a O +
21a O +
( O -
S O +
) O -
- O +
and O +
a O +
21β O +
( O -
R O +
) O -
-isomer O +
of O +
4 O +
, O +
the O +
latter O +
being O +
the O +
main O +
product O -
, O +
but O +
exhibiting O +
the O +
reverse O +
configuration O +
when O +
compared O +
with O +
the O +
enzyme B-Gene +
substrate O +
6 O +
or O +
with O +
5 O +
and O +
all O +
of O +
its O +
natural O +
derivatives O -
. O +

The O +
stability O +
of O +
4 O +
can O +
be O +
low O +
due O +
to O +
its O +
carbinol O +
( O -
aminal O -
) O +
structure O -
. O +

Structures O +
could O +
exist O +
in O +
an O +
equilibrium O +
through O +
the O +
open O +
form O +
( O -
aldehyde O +
and O +
free O +
amino O +
group O -
) O +
which O +
leads O +
to O +
the O +
21a- O +
( O -
4b O +
) O +
and O +
21β O +
-isomers O +
( O -
4a O +
) O -
, O +
respectively O +
( O -
Fig. O +
4 O +
) O -
. O +

NMR O +
experiments O +
were O +
performed O -
, O +
by O +
measuring O +
1 O +
H O +
of O +
4 O +
in O +
DMSO O -
- O -
d6 O +
in O +
the O +
presence O +
of O +
increasing O +
amounts O +
of O +
D2 O +
O. O +
In O +
this O +
series O +
the O +
1 O +
H O +
signals O +
of O +
H-17 O +
and O +
H-21 O +
were O +
measured O +
in O +
DMSO O -
- O -
d6 O +
/D2 O +
O O +
ratios O +
of O +
100:0 O -
, O +
75:25 O -
, O +
65:35 O +
and O +
50:50 O +
( O -
Fig. O +
5 O +
) O -
. O +

With O +
increasing O +
amounts O +
of O +
D2 O +
O O +
the O +
signal O +
distances O +
of O +
the O +
appropriate O +
proton O +
signals O +
( O -
H-17 O -
, O +
H-21 O -
) O +
of O +
each O +
isomer O +
decreased O +
and O +
signals O +
overlapped O +
completely O +
at O +
50 O -
% O +
D2 O +
O. O +
In O +
the O +
presence O +
of O +
water O +
a O +
fast O +
equilibrium O +
between O +
both O +
configuration O +
isomers O +
exists O +
and O +
one O +
spectrum O +
only O +
is O +
obtained O +
due O +
to O +
a O +
short O +
life O +
time O +
of O +
the O +
isomers O +
compared O +
to O +
the O +
NMR O -
- O -
time O +
scale O -
. O +

2.5 O +
Partial O +
amino O +
acid O +
sequence O +
of O +
RG B-Gene +
Degradation O +
of O +
the O +
enzyme B-Gene +
by O +
endoproteinase B-Gene +
Lys I-Gene +
C I-Gene -
, O +
HPLC O -
- O -
analysis O +
of O +
the O +
resultant O +
peptide O +
fragments O +
( O -
PF O -
) O +
and O +
their O +
sequencing O +
delivered O +
6 O +
peptide O +
sequences O +
with O +
6 O +
to O +
24 O +
amino O +
acids O +
( O -
Table O +
2 O +
) O -
. O +

Comparison O +
of O +
the O +
six O +
peptide O +
sequences O +
against O +
a O +
protein B-Gene +
database O +
( O -
SwissProt O -
) O +
showed O +
a O +
high O +
homology O +
of O +
PF O +
37 O +
and O +
PF O +
47 O +
with O +
different O +
β B-Gene +
-glucosidases I-Gene +
from O +
various O +
sources O +
( O -
Table O +
3 O +
) O +
while O +
for O +
the O +
other O +
peptides O +
no O +
significant O +
homologies O +
could O +
be O +
found O -
. O +

PF O +
37 O +
showed O +
the O +
highest O +
homology O +
( O -
81 O -
% O -
) O +
to O +
linamarase B-Gene +
from O +
Manihot O +
esculenta O +
( O -
Hughes O +
et O +
al. O -
, O +
1992 O +
) O +
while O +
PF O +
47 O +
had O +
a O +
79 O -
% O +
identity O +
to O +
β B-Gene +
-glucosidase I-Gene +
from O +
Prunus O +
avium O +
( O -
Wiersma O +
and O +
Fils O -
- O -
Lycaon O -
, O +
1995 O +
) O -
. O +

3 O +
Discussion O +
The O +
monoterpenoid O +
Rauwolfia O +
alkaloid O +
ajmaline O +
( O -
Gilurytmal O -
® O -
) O +
and O +
its O +
synthetic O +
derivative O +
prajmalium O +
( O -
Neo O -
- O -
Gilurytmal O -
® O -
) O +
are O +
well O +
established O +
in O +
the O +
therapy O +
of O +
heart O +
rhythm O +
disorders O -
. O +

Because O +
of O +
their O +
pronounced O +
quinine O +
related O +
activity O +
they O +
belong O +
to O +
class O +
Ia O +
of O +
antiarrhythmic O +
drugs O -
. O +

Ajmaline O +
( O -
5 O +
) O +
has O +
a O +
complicated O +
hexacyclic O +
structure O +
possessing O +
nine O +
chiral O +
carbon O +
centers O -
. O +

For O +
commercial O +
use O +
5 O +
is O +
therefore O +
not O +
synthesized O +
but O +
still O +
isolated O +
from O +
Rauwolfia O +
roots O -
. O +

In O +
order O +
to O +
understand O +
the O +
formation O +
of O +
this O +
alkaloid O +
in O +
plant O +
cells O +
we O +
have O +
investigated O +
its O +
biosynthesis O +
in O +
plant O +
cell O +
suspension O +
cultures O +
at O +
the O +
enzyme O +
level O +
and O +
have O +
elucidated O +
the O +
major O +
biochemical O +
reactions O +
of O +
this O +
multi O -
- O -
step O +
pathway O +
( O -
Stockigt O -
, O +
1995 O +
) O -
. O +

Enzymatic O +
and O +
phytochemical O +
analysis O +
of O +
Rauwolfia O +
plants O +
and O +
cell O +
suspension O +
cultures O +
showed O +
greater O +
activities O +
of O +
vomilenine O +
UDP B-Gene +
glucose I-Gene +
transferase I-Gene +
and O +
RG B-Gene +
when O +
compared O +
with O +
the O +
differentiated O +
tissue O +
( O -
data O +
not O +
shown O -
) O +
and O +
a O +
much O +
higher O +
content O +
of O +
the O +
glucoalkaloid O +
6 O +
in O +
the O +
in O +
vitro O +
cell O +
systems O +
exceeding O +
that O +
of O +
the O +
differentiated O +
R. O +
serpentina O +
plant O +
by O +
a O +
factor O +
of O +
67 O +
( O -
Ruyter O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

The O +
results O +
obtained O +
up O +
to O +
the O +
present O +
point O +
to O +
the O +
most O +
important O +
branchpoint O +
in O +
the O +
ajmaline O +
pathway O +
involving O +
the O +
intermediate O +
4 O +
, O +
apart O +
from O +
a O +
number O +
of O +
side O +
routes O +
delivering O +
only O +
minor O +
alkaloid O +
amounts O -
. O +

Both O +
enzymes B-Gene -
, O +
the O +
vomilenine O +
glucosylating O +
protein B-Gene +
and O +
the O +
glucosidase B-Gene +
hydrolyzing O +
raucaffricine O +
( O -
vomilenine O -
- O -
β O +
-d O +
-glucoside O -
) O -
, O +
are O +
therefore O +
of O +
extraordinary O +
interest O +
( O -
Fig. O +
1 O +
) O -
. O +

To O +
get O +
a O +
more O +
detailed O +
insight O +
into O +
the O +
properties O -
, O +
structure O +
and O +
mechanism O +
of O +
this O +
outstanding O +
glucosidase B-Gene +
in O +
the O +
biosynthesis O +
of O +
Rauwolfia O +
alkaloids O +
we O +
purified O +
the O +
enzyme B-Gene -
, O +
investigated O +
the O +
structure O +
of O +
the O +
enzyme B-Gene +
product O +
vomilenine O +
and O +
made O +
amino O +
acid O +
sequence O +
alignments O +
of O +
peptide O +
fragments O +
obtained O +
by O +
hydrolyzing O +
the O +
glucosidase B-Gene -
. O +

A O +
relatively O +
long O +
purification O +
protocol O +
employing O +
5 O +
steps O +
permitted O +
the O +
enrichment O +
of O +
RG B-Gene +
to O +
near O +
homogeneity O -
. O +

But O +
in O +
general O +
from O +
1 O +
kg O +
of O +
fresh O +
Rauwolfia O +
cell O +
suspension O +
cells O +
only O +
10 O +
mg O +
RG B-Gene +
remained O -
, O +
an O +
inefficient O +
procedure O +
which O +
did O +
not O +
deliver O +
enough O +
material O +
to O +
allow O +
successful O +
protein B-Gene +
sequencing O -
. O +

The O +
whole O +
purification O +
procedure O +
could O -
, O +
however O -
, O +
be O +
optimized O +
with O +
only O +
3 O +
steps O +
of O +
column O +
chromatography O -
, O +
including O +
the O +
efficient O +
purification O +
on O +
Mono O +
Q O +
material O -
, O +
to O +
yield O +
enough O +
enzyme B-Gene +
( O -
∼550 O +
mg O +
protein B-Gene -
) O +
but O +
of O +
lower O +
purity O -
. O +

With O +
the O +
higher O +
amount O +
of O +
enzyme B-Gene +
several O +
experiments O +
could O +
be O +
performed O -
, O +
like O +
the O +
testing O +
of O +
the O +
enzyme B-Gene +
for O +
sugar O +
residues O -
. O +

The O +
result O +
that O +
RG B-Gene +
is O +
most O +
probably O +
not O +
glycosylated O +
might O +
be O +
an O +
important O +
prerequisite O +
for O +
a O +
heterologous O +
expression O +
of O +
RG B-Gene +
in O +
procaryotic O +
systems O +
in O +
future O -
. O +

Part O +
of O +
the O +
enzyme B-Gene +
from O +
an O +
enriched O +
preparation O +
was O +
used O +
to O +
generate O +
the O +
aglycone O +
4 O +
from O +
6 O +
which O +
was O +
then O +
analysed O +
by O +
MS O +
and O +
NMR O +
spectroscopy O -
. O +

Our O +
previous O +
isolation O +
of O +
this O +
alkaloid O +
from O +
cell O +
suspensions O +
has O +
pointed O +
to O +
the O +
occurrence O +
of O +
an O +
isomer O +
mixture O +
( O -
Stockigt O +
et O +
al. O -
, O +
1981 O +
) O +
which O +
is O +
in O +
contrast O +
to O +
the O +
vomilenine O +
structure O +
discussed O +
in O +
earlier O +
literature O +
( O -
Taylor O +
et O +
al. O -
, O +
1962 O +
) O -
. O +

A O +
careful O +
and O +
complete O +
analysis O +
of O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
4 O +
( O -
the O +
appropriate O +
data O +
only O +
are O +
shown O -
) O +
suggested O +
two O +
C-21 O +
epimers O -
. O +

The O +
major O +
epimer O +
exhibited O +
the O +
C-21 O +
β O +
-hydroxygroup O +
( O -
S O +
-isomer O -
) O +
whereas O +
the O +
minor O +
showed O +
the O +
C-21 O +
a O +
OH O -
. O +

Both O +
( O -
S O +
) O -
- O +
and O +
( O -
R O +
) O -
-isomers O +
occurred O +
in O +
a O +
constant O +
ratio O +
of O +
∼3:1 O +
when O +
measured O +
in O +
dry O +
DMSO O -
- O -
d6 O +
or O +
pyridine O -
- O -
d5 O +
. O +

Since O +
the O +
naturally O +
occurring O +
alkaloids O +
with O +
ajmaline O +
structure O +
are O +
all O +
( O -
R O +
) O -
-configurated O +
at O +
C-21 O -
, O +
an O +
equilibrium O +
between O +
both O +
vomilenine O +
isomers O +
can O +
be O +
assumed O -
, O +
from O +
which O +
by O +
enzymatic O +
reduction O +
of O +
two O +
double O +
bonds O +
exclusively O +
( O -
R O +
) O -
-vomilenine O +
is O +
removed O +
leading O +
finally O +
to O +
5 O +
. O +

In O +
fact O -
, O +
the O +
existence O +
of O +
such O +
an O +
equilibrium O +
became O +
evident O +
by O +
dynamic O +
NMR O +
experiments O -
. O +

When O +
water O +
( O -
D2 O +
O O -
) O +
was O +
added O +
to O +
the O +
NMR O +
sample O +
the O +
interconversion O +
of O +
both O +
isomers O +
became O +
very O +
fast O +
because O +
the O +
signals O +
corresponding O +
to O +
both O +
C-21 O +
isomers O +
moved O +
toward O +
each O +
other O +
and O +
finally O +
overlapped O -
. O +

It O +
therefore O +
seems O +
quite O +
clear O +
that O +
the O +
existence O +
of O +
the O +
isomeric O +
4 O +
mixture O +
being O +
in O +
equilibrium O +
has O +
no O +
real O +
influence O +
on O +
ajmaline O +
biosynthesis O -
. O +

The O +
comparison O +
of O +
the O +
two O +
longest O +
peptide O +
sequences O +
resulted O +
in O +
the O +
detection O +
of O +
surprisingly O +
high O +
sequence O +
homologies O +
( O +
from O +
73 O +
to O +
80 O -
% O -
) O +
to O +
more O +
than O +
10 O +
plant O +
β B-Gene +
-glucosidases I-Gene +
such O +
as O +
linamarase B-Gene +
from O +
Cassava O +
( O -
Manihot O +
esculenta O +
Crantz O -
, O +
( O -
Hughes O +
et O +
al. O -
, O +
1992 O +
) O -
) O -
, O +
which O +
is O +
a O +
major O +
crop O +
plant O +
of O +
tropical O +
Africa O +
or O +
the O +
well O +
investigated O +
amygdalin B-Gene +
and O +
prunasin B-Gene +
hydrolases I-Gene +
from O +
black O +
cherry O +
( O -
Prunus O +
serotina O +
, O +
( O -
Zheng O +
and O +
Poulton O -
, O +
1995 O +
) O -
) O +
and O +
dhurrinase B-Gene +
from O +
mustard O +
( O -
Sinapis O +
alba O +
, O +
( O -
Xue O +
et O +
al. O -
, O +
1992 O +
) O -
) O -
. O +

The O +
amino O +
acid O +
motif O +
Val O -
– O -
Thr O -
– O -
Glu O -
– O -
Asn O -
– O -
Gly O +
in O +
PF O +
37 O +
is O +
remarkably O +
similar O +
to O +
conserved O +
sequence O +
motifs O +
in O +
β B-Gene +
-glucosidases I-Gene +
( O -
Withers O +
et O +
al. O -
, O +
1990 O +
; O +
Trimbur O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

In O +
some O +
cases O +
the O +
glutamic O +
acid O +
in O +
this O +
motif O +
was O +
identified O +
as O +
the O +
active O +
site O +
nucleophil O -
, O +
e.g. O +
in O +
β B-Gene +
-glucosidase I-Gene +
from O +
Agrobacterium O +
faecalis O +
( O -
Trimbur O +
et O +
al. O -
, O +
1992 O +
) O +
or O +
sweet O +
almond O +
( O -
He O +
and O +
Withers O -
, O +
1997 O +
) O -
. O +

From O +
these O +
data O -
, O +
in O +
addition O +
to O +
the O +
catalyzed O +
reaction O +
( O -
chemical O +
identification O +
of O +
the O +
conversion O +
of O +
6 O +
to O +
4 O +
) O -
, O +
it O +
became O +
evident O +
that O +
the O +
here O +
isolated O +
and O +
purified O +
enzyme B-Gene +
was O +
indeed O +
a O +
glucosidase B-Gene -
. O +

Moreover O +
its O +
relation O +
to O +
other O +
glucosidases B-Gene +
is O +
obvious O +
although O +
the O +
substrate O +
specificity O +
of O +
RG B-Gene +
which O +
has O +
been O +
published O +
earlier O +
( O -
Schubel O +
et O +
al. O -
, O +
1986 O +
) O +
is O +
completely O +
different O +
to O +
the O +
above O +
mentioned O +
hydrolases B-Gene -
. O +

RG B-Gene +
is O +
exclusively O +
active O +
towards O +
glucosides O +
derived O +
from O +
6 O +
like O +
1.2-dihydro- O +
and O +
1.2.19.20-tetrahydroraucaffricine O +
( O -
Schubel O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

Obviously O +
a O +
glucosidic O +
ajmalan O -
- O -
type O +
skeleton O +
is O +
a O +
prerequisite O +
for O +
a O +
glucoside O +
being O +
hydrolyzed O +
by O +
this O +
specific O +
glucosidase B-Gene -
. O +

In O +
fact O -
, O +
15 O +
other O +
glucosides O +
including O +
the O +
alkaloidal O +
glucosides O +
strictosidine O -
, O +
strictosidine O +
lactam O -
, O +
monoterpenoid O +
glucosides O +
or O +
artificial O +
glucosides O +
used O +
frequently O +
for O +
glucosidase B-Gene +
purification O +
( O -
nitrophenyl O +
glucosides O -
) O +
were O +
not O +
accepted O +
by O +
RG B-Gene +
( O -
Schubel O +
et O +
al. O -
, O +
1986 O +
) O -
. O +

The O +
appropriate O +
binding O +
site O +
at O +
the O +
enzyme B-Gene +
is O -
, O +
however O -
, O +
not O +
yet O +
known O -
. O +

The O +
obtained O +
data O +
so O +
far O +
suggest O +
that O +
RG B-Gene +
is O +
a O +
new O +
member O +
of O +
the O +
family O +
1 O +
of O +
glycosyl B-Gene +
hydrolases I-Gene +
for O +
which O +
the O +
substrate O +
specificity O +
for O +
β B-Gene +
-glucosides I-Gene +
and O +
the O +
above O +
mentioned O +
amino O +
acid O +
motif O +
found O +
in O +
PF O +
37 O +
are O +
characteristic O -
. O +

On O +
the O +
other O +
hand O +
such O +
sequence O +
information O +
might O +
be O +
very O +
useful O +
in O +
the O +
future O +
search O +
for O +
the O +
corresponding O +
gene O +
in O +
Rauwolfia O +
plant O +
cells O +
and O +
in O +
obtaining O +
enough O +
enzyme B-Gene +
by O +
heterologous O +
expression O +
for O +
a O +
much O +
more O +
detailed O +
analysis O +
of O +
this O +
protein B-Gene -
. O +

In O +
addition O +
it O +
will O +
be O +
of O +
future O +
interest O +
to O +
further O +
investigate O +
not O +
only O +
the O +
molecular O +
structure O +
of O +
RG B-Gene +
but O +
also O +
to O +
extent O +
our O +
understanding O +
of O +
the O +
biochemical O +
and O +
physiological O +
function O +
of O +
the O +
soluble O +
RG B-Gene +
especially O +
in O +
connection O +
with O +
the O +
membrane O +
bound O +
vomilenine O +
UDP B-Gene -
- I-Gene -
glucose I-Gene +
transferase I-Gene +
( O -
Ruyter O +
and O +
Stockigt O -
, O +
1991 O +
) O +
catalyzing O +
the O +
reverse O +
reaction O +
of O +
the O +
glucosidase B-Gene -
. O +

Moreover O +
it O +
would O +
be O +
most O +
interesting O +
to O +
find O +
out O +
whether O +
RG B-Gene +
can O +
exert O +
direct O +
influence O +
on O +
the O +
biosynthesis O +
of O +
the O +
target O +
compound O +
ajmaline O -
, O +
e.g. O +
by O +
channelling O +
the O +
aglycone O +
4 O +
into O +
the O +
biosynthetic O +
pathway O +
or O +
to O +
block O +
the O +
enzyme B-Gene +
or O +
the O +
corresponding O +
gene O +
and O +
to O +
analyze O +
the O +
remaining O +
biosynthetic O +
potency O +
of O +
the O +
cells O +
to O +
perform O +
alkaloid O +
biosynthesis O +
( O -
Fig. O +
1 O +
) O -
. O +

Appropriate O +
work O +
is O +
now O +
in O +
progress O -
. O +

4 O +
Experimental O +
4.1 O +
Cell O +
material O +
Cell O +
material O +
used O +
in O +
this O +
report O +
was O +
obtained O +
from O +
cell O +
suspension O +
cultures O +
of O +
R. O +
serpentina O +
grown O +
in O +
1 O +
l O +
Erlenmeyer O +
flasks O +
in O +
Linsmair O +
and O +
Skoog O +
medium O +
( O -
Linsmaier O +
and O +
Skoog O -
, O +
1965 O +
) O +
for O +
7 O +
days O +
under O +
the O +
following O +
conditions O -
; O +
24±2 O -
° O -
C O -
, O +
under O +
continuous O +
light O +
( O -
600 O +
lx O -
) O +
and O +
shaking O +
( O -
100 O +
rpm O -
) O -
. O +

For O +
optimization O +
of O +
enzyme O +
isolation O +
after O +
the O +
transfer O +
of O +
Rauwolfia O +
cells O +
to O +
new O +
nutrition O +
medium O -
, O +
the O +
RG B-Gene +
activity O +
and O +
the O +
protein B-Gene +
content O +
were O +
measured O +
every O +
day O +
for O +
2 O +
weeks O -
. O +

4.2 O +
Enzyme B-Gene +
assay O +
for O +
RG B-Gene +
activity O +
20 O +
nmol O +
6 O +
( O -
solved O +
in O +
10 O +
ml O +
EtOH O -
) O +
and O +
appropriate O +
amounts O +
of O +
enzyme B-Gene +
solution O +
( O -
RG B-Gene +
with O +
an O +
activity O +
of O +
1–5 O +
pkat O -
) O +
were O +
incubated O +
in O +
a O +
total O +
of O +
0.1 O +
ml O +
of O +
citrate O -
/ O -
NaOH O +
buffer O +
( O -
0.1 O +
M O -
, O +
pH O +
5.0 O -
) O +
for O +
30 O +
min O +
at O +
30 O -
° O -
C O +
under O +
shaking O +
( O -
100 O +
rpm O -
) O -
. O +

The O +
enzyme B-Gene +
reaction O +
was O +
terminated O +
by O +
addition O +
of O +
0.2 O +
ml O +
MeOH O -
. O +

After O +
centrifugation O +
at O +
18000 O -
× O -
g O +
for O +
5 O +
min O +
the O +
supernatant O +
was O +
quantitatively O +
analyzed O +
by O +
HPLC O -
, O +
using O +
a O +
Lichrospher O +
RP O -
- O -
select O +
B O +
column O +
( O -
125 O -
× O -
4 O +
mm O -
) O +
equipped O +
with O +
a O +
4 O -
× O -
4 O +
mm O +
pre O -
- O -
column O +
of O +
the O +
same O +
type O +
( O -
Merck O -
, O +
Darmstadt O -
) O -
; O +
solvent O +
system O +
was O +
( O -
a O -
) O +
CH3 O +
CN O +
and O +
( O -
b O -
) O +
KPi O +
buffer O +
( O -
20 O +
mM O -
, O +
pH O +
4.0 O -
) O +
with O +
a O +
gradient O +
of O +
25 O -
% O +
( O -
a O -
) O +
at O +
0 O +
min O -
, O +
35 O -
% O +
( O -
a O -
) O +
at O +
3.0 O +
min O -
, O +
80 O -
% O +
( O -
a O -
) O +
at O +
3.5–4.5 O +
min O +
and O +
25 O -
% O +
( O -
a O -
) O +
from O +
5–7 O +
min O -
, O +
flow O +
rate O +
was O +
1.5 O +
ml O -
/ O -
min O +
and O +
detection O +
was O +
at O +
258 O +
nm O -
. O +

The O +
substrate O +
6 O +
( O -
R O +
t O +
= O -
1 O +
min O +
44 O +
s O -
) O +
and O +
the O +
enzyme B-Gene +
product O +
4 O +
( O -
R O +
t O +
= O -
2 O +
min O +
41 O +
s O -
) O +
were O +
completely O +
separated O +
and O +
quantified O +
using O +
6 O +
as O +
an O +
external O +
standard O -
. O +

The O +
used O +
6 O +
was O +
isolated O +
from O +
cell O +
suspension O +
cultures O +
of O +
R. O +
serpentina O +
according O +
to O +
a O +
published O +
procedure O +
( O -
Schubel O +
and O +
Stockigt O -
, O +
1984 O +
) O -
. O +

4.3 O +
Protein B-Gene +
determination O +
Protein B-Gene +
concentrations O +
were O +
determined O +
as O +
described O +
by O +
Bradford O +
( O -
1976 O -
) O +
using O +
Coomassie O +
solution O -
. O +

4.4 O +
SDS O -
- O -
Polyacrylamide O +
gel O +
electrophoresis O -
- O -
protein O +
staining O +
SDS O +
gels O +
were O +
stained O +
with O +
Coomassie O +
solution O +
( O -
0.25 O -
% O +
Coomasie O +
Brilliant O +
Blue O +
R-250 O -
, O +
45 O -
% O +
MeOH O +
and O +
9 O -
% O +
HOAc O +
in O +
water O -
) O -
; O +
destaining O +
of O +
backgrounds O +
were O +
performed O +
with O +
a O +
solution O +
of O +
5 O -
% O +
MeOH O +
and O +
7.5 O -
% O +
HOAc O +
in O +
water O -
. O +

Silver O +
staining O +
was O +
performed O +
as O +
published O +
previously O +
( O -
Heukeshoven O +
and O +
Dernick O -
, O +
1985 O +
) O -
. O +

Enzyme B-Gene +
enrichment O +
during O +
the O +
purification O +
of O +
the O +
glucosidase B-Gene +
was O +
followed O +
by O +
SDS O -
- O -
PAGE O +
under O +
denaturing O +
conditions O +
using O +
10 O -
% O +
acrylamide O -
. O +

Marker O +
proteins B-Gene +
used O +
were O +
the O +
LMW O +
marker O +
mixture O +
( O -
Pharmacia O -
) O -
. O +

4.5 O +
Buffers O +
Buffer O +
A O -
: O +
0.1 O +
M O +
Tris O -
– O -
HCl O -
, O +
pH O +
7.5 O -
, O +
1 O +
mM O +
EDTA O -
, O +
20 O +
mM O +
β O +
-mercaptoethanol O +
( O -
EtSH O -
) O -
. O +

Buffer O +
B O -
: O +
as O +
for O +
A O +
but O +
20 O +
mM O +
Tris O -
– O -
HCl O +
and O +
10 O +
mM O +
EtSH O -
. O +

Buffer O +
C O -
: O +
as O +
for O +
B O +
but O +
20 O +
mM O +
KPi O -
. O +

Buffer O +
D O -
: O +
20 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
7.0 O -
, O +
10 O +
mM O +
EtSH O -
. O +

Buffer O +
E O -
: O +
20 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
8.0 O -
, O +
0.1 O +
M O +
KCl O -
, O +
10 O +
mM O +
EtSH O -
. O +

Buffer O +
F O -
: O +
as O +
for O +
buffer O +
D O -
, O +
but O +
pH O +
was O +
7.5 O -
. O +

Buffer O +
G O -
: O +
25 O +
mM O +
Bis O -
– O -
Tris O +
set O +
to O +
pH O +
7.1 O +
with O +
saturated O +
iminodiacetic O +
acid O -
, O +
10 O +
mM O +
EtSH O -
. O +

Buffer O +
H O -
: O +
10 O -
% O +
polybuffer O +
74 O +
( O -
Pharmacia O -
) O +
at O +
pH O +
4.0 O +
adjusted O +
with O +
satd O -
. O +

iminodiacetic O +
acid O -
, O +
10 O +
mM O +
EtSH O -
. O +

Buffer O +
I O -
: O +
0.1 O +
M O +
Tris O -
– O -
HCl O -
, O +
pH O +
7.5 O -
, O +
20 O +
mM O +
EtSH O -
. O +

Buffer O +
K O -
: O +
20 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
8.0 O -
, O +
10 O +
mM O +
EtSH O -
. O +

Buffer O +
L O -
: O +
39 O +
mM O +
glycine O -
, O +
48 O +
mM O +
Tris O -
– O -
HCl O -
, O +
0.0375 O -
% O +
SDS O -
, O +
20 O -
% O +
MeOH O -
. O +

Buffer O +
M O -
: O +
10 O +
mM O +
CAPS O -
, O +
pH O +
11 O -
, O +
10 O -
% O +
MeOH O -
. O +

4.6 O +
MS O +
and O +
GC O -
– O -
MS O +
A O +
Finnigan O +
MAT O +
44S O +
quadrupole O +
instrument O +
was O +
used O -
. O +

Direct O +
inlet O +
mass O +
spectra O +
were O +
obtained O +
under O +
EI O -
- O -
conditions O +
( O -
70 O +
eV O -
) O +
at O +
an O +
ion O +
source O +
temperature O +
of O +
200 O -
° O -
C O +
and O +
a O +
temperature O +
gradient O +
of O +
50 O -
° O -
C O -
/ O -
min O -
. O +

GC O -
– O -
MS O +
analyses O +
were O +
performed O +
with O +
the O +
same O +
instrument O +
coupled O +
to O +
a O +
Varian O +
Gaschromatograph O +
type O +
3700 O -
, O +
which O +
was O +
equipped O +
with O +
a O +
30 O +
m O -
× O -
0.32 O +
mm O +
Durabond O +
DB1 O +
column O -
. O +

GC O -
– O -
MS O +
analyses O +
for O +
identification O +
of O +
4 O +
were O +
carried O +
out O +
with O +
a O +
gas O +
flow O +
of O +
10 O +
ml O -
/ O -
min O +
under O +
isocratic O +
conditions O +
( O -
320 O -
° O -
C O -
) O -
. O +

4.7 O +
NMR O +
measurements O +
NMR O +
spectra O +
were O +
recorded O +
on O +
Bruker O +
360 O +
MHz O +
( O -
360 O +
AM O -
) O +
and O +
400 O +
MHz O +
( O -
400 O +
ARX O -
) O +
instruments O +
using O +
Bruker O +
standard O +
software O +
and O +
5 O +
mm O +
NMR O +
tubes O +
with O +
DMSO O -
- O -
d6 O +
; O +
for O +
dynamic O +
NMR O +
spectroscopy O +
mixtures O +
of O +
DMSO O -
- O -
d6 O +
and O +
D2 O +
O O +
were O +
used O -
. O +

4.8 O +
Purification O +
of O +
RG B-Gene +
All O +
purification O +
steps O +
were O +
carried O +
out O +
at O +
4 O -
° O -
C O -
. O +

4.9 O +
Preparation O +
of O +
crude O +
protein B-Gene +
extracts O +
Cells O +
of O +
R. O +
serpentina O +
cell O +
suspensions O +
( O -
1.0 O +
kg O -
, O +
fr O -
. O +

wt O -
) O +
were O +
frozen O +
with O +
liquid O +
nitrogen O -
, O +
added O +
to O +
1300 O +
ml O +
buffer O +
A O +
and O +
the O +
mixture O +
was O +
stirred O +
at O +
35 O -
° O -
C O +
until O +
thawed O -
. O +

The O +
mixture O +
was O +
then O +
homogenized O +
in O +
an O +
ultraturrax O +
for O +
2 O +
min O +
and O +
filtered O +
through O +
cheese O +
cloth O -
. O +

The O +
resultant O +
solution O +
was O +
centrifuged O +
at O +
10,000 O -
× O -
g O +
for O +
30 O +
min O +
and O +
the O +
supernatant O +
( O -
1.8 O +
l O -
) O +
used O +
for O +
the O +
next O +
purification O +
step O -
. O +

4.10 O +
Fractional O +
precipitation O +
with O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
The O +
protein O +
in O +
the O +
resulting O +
supernatant O +
was O +
subjected O +
to O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
precipitation O -
. O +

The O +
precipitated O +
protein O +
between O +
30–75 O -
% O +
saturation O +
was O +
collected O +
after O +
centrifugation O +
( O -
30 O +
min O -
, O +
10,000 O -
× O -
g O +
) O -
, O +
solubilized O +
in O +
150 O +
ml O +
buffer O +
B O -
, O +
centrifuged O +
and O +
the O +
supernatant O +
dialyzed O +
overnight O +
against O +
10 O +
l O +
of O +
buffer O +
B. O +
Centrifugation O +
( O -
20 O +
min O -
, O +
10,000 O -
× O -
g O +
) O +
yielded O +
the O +
soluble O +
protein B-Gene +
fraction O +
( O -
∼200 O +
ml O -
, O +
4.2 O +
mg O -
/ O -
ml O -
) O -
. O +

4.11 O +
Anion O +
exchange O +
chromatography O +
on O +
DEAE O -
- O -
Sephacel O +
The O +
protein B-Gene +
solution O +
so O +
obtained O +
was O +
added O +
at O +
a O +
rate O +
of O +
1.5 O +
ml O -
/ O -
min O +
to O +
a O +
DEAE O -
- O -
Sephacel O +
column O +
( O -
7.8 O -
× O -
5 O +
cm O -
, O +
XK O +
50 O -
/ O -
20-column O -
, O +
Pharmacia O -
) O +
which O +
was O +
pre O -
- O -
equilibrated O +
with O +
buffer O +
B. O +
After O +
washing O +
the O +
column O +
with O +
buffer O +
B O +
for O +
200 O +
min O +
the O +
enzyme B-Gene +
activity O +
was O +
fractionated O +
( O -
10 O +
ml O +
per O +
fraction O -
) O +
with O +
a O +
linear O +
KCl O +
gradient O +
( O -
0–0.4 O +
M O -
) O +
prepared O +
from O +
buffer O +
B O +
and O +
KCl O +
and O +
applied O +
with O +
the O +
rate O +
of O +
1.5 O +
ml O -
/ O -
min O -
. O +

Enzyme O +
activity O +
appeared O +
at O +
around O +
0.3 O +
M O +
KCl O -
. O +

Fractions O +
containing O +
glucosidase B-Gene +
activity O +
> O -
1.3 O +
nkat O -
/ O -
mg O +
were O +
combined O +
and O +
dialyzed O +
overnight O +
against O +
5 O +
l O +
buffer O +
C. O +
4.12 O +
Biogel O +
HT O -
- O -
hydroxylapatite O +
chromatography O +
The O +
remaining O +
protein B-Gene +
solution O +
from O +
the O +
anion O +
exchange O +
chromatography O +
was O +
added O +
to O +
the O +
top O +
of O +
a O +
Biogel O +
HT O -
- O -
column O +
( O -
1.6 O -
× O -
15 O +
cm O -
) O +
with O +
a O +
flow O +
rate O +
of O +
0.5 O +
ml O -
/ O -
min O -
. O +

After O +
washing O +
the O +
column O +
for O +
50 O +
min O +
with O +
buffer O +
D O +
( O -
0.5 O +
ml O -
/ O -
min O -
) O +
proteins B-Gene +
were O +
eluted O +
with O +
a O +
gradient O +
of O +
KPi O +
( O -
buffer O +
D O +
and O +
20–500 O +
mM O +
KPi O -
) O +
within O +
200 O +
min O -
. O +

Fractions O +
of O +
2.5 O +
ml O +
were O +
collected O +
and O +
assayed O +
for O +
glucosidase B-Gene +
activity O -
. O +

Fractions O +
containing O +
> O -
3.5 O +
nkat O -
/ O -
mg O +
enzyme B-Gene +
were O +
combined O +
( O -
35 O +
ml O -
) O +
and O +
conc O -
. O +

to O +
5 O +
ml O +
by O +
ultra O -
- O -
filtration O +
( O -
membrane O +
pore O +
size O +
< O -
20 O +
kDa O -
, O +
0.1–0.2 O +
MPa O -
) O -
. O +

4.13 O +
Gel O +
filtration O +
on O +
Ultrogel O +
AcA O +
54 O +
For O +
gel O +
filtration O +
the O +
above O +
enzyme B-Gene +
solution O +
was O +
chromatographed O +
on O +
a O +
2 O -
× O -
90 O +
cm O +
column O +
containing O +
the O +
AcA O +
54 O +
material O +
( O -
Pharmacia O -
) O -
, O +
which O +
had O +
been O +
equilibrated O +
earlier O +
with O +
buffer O +
E. O +
The O +
same O +
buffer O +
was O +
used O +
for O +
the O +
fractionation O +
of O +
the O +
protein B-Gene +
solution O +
( O -
0.33 O +
ml O -
/ O -
min O -
, O +
3 O +
ml O -
/ O +
fraction O -
) O -
. O +

Fractions O +
exhibiting O +
glucosidase B-Gene +
activity O +
of O +
> O -
47 O +
nkat O -
/ O -
mg O +
were O +
combined O +
( O -
10 O +
ml O +
total O -
) O +
and O +
conc O -
. O +

to O +
0.5 O +
ml O +
by O +
filtration O +
through O +
Centrisat O +
I O +
filters O +
( O -
20–30 O +
min O -
, O +
2000 O -
× O -
g O +
, O +
pore O +
size O +
< O -
20 O +
kDa O -
) O -
. O +

4.14 O +
Mono O +
Q O +
HR O +
5 O -
/ O -
5 O +
ion O +
exchange O +
chromatography O +
The O +
Mono O +
Q O +
column O +
( O -
0.5 O -
× O -
5 O +
cm O -
) O +
was O +
equilibrated O +
with O +
buffer O +
F O +
and O +
the O +
above O +
mentioned O +
enzyme B-Gene +
solution O +
added O +
to O +
the O +
column O -
. O +

For O +
elution O +
of O +
the O +
enzyme B-Gene +
a O +
KCl O +
gradient O +
( O -
prepared O +
by O +
mixing O +
buffer O +
F O +
and O +
buffer O +
G O +
containing O +
1 O +
M O +
KCl O -
) O +
was O +
applied O +
( O -
0.5 O +
ml O -
/ O -
min O -
) O -
: O +
0–5 O +
ml O +
buffer O +
F O -
: O -
G=100:0 O -
; O +
0.32 O +
ml O +
buffer O +
F O -
: O -
G=50:50 O -
, O +
35 O +
ml O +
buffer O +
F O -
: O -
G=25:75 O -
, O +
36 O +
ml O +
buffer O +
F O -
: O -
G=100:0 O -
. O +

Fractions O +
of O +
0.75 O +
ml O +
were O +
collected O +
and O +
were O +
combined O +
with O +
specific O +
glucosidase B-Gene +
activities O +
of O +
> O -
220 O +
nkat O -
/ O -
mg O -
. O +

This O +
enzyme B-Gene +
solution O +
was O +
concentrated O +
to O +
0.25 O +
ml O +
and O +
equilibrated O +
with O +
the O +
starting O +
buffer O +
of O +
the O +
next O +
step O +
( O -
buffer O +
G O -
) O -
. O +

4.15 O +
FPLC O -
- O -
chromatofocusing O +
with O +
Mono O +
P O +
column O +
The O +
protein B-Gene +
solution O +
obtained O +
by O +
chromatography O +
on O +
Mono O +
Q O +
was O +
added O +
to O +
the O +
Mono O +
P O +
HR O +
515 O +
column O -
. O +

Proteins B-Gene +
were O +
fractionated O +
( O -
0.5 O +
ml O -
) O +
with O +
20 O +
ml O +
buffer O +
H O +
at O +
a O +
flow O +
rate O +
of O +
0.25 O +
ml O -
/ O -
min O +
generating O +
a O +
pH O +
gradient O +
from O +
pH O +
7.1 O +
to O +
4.0 O -
. O +

The O +
enzyme B-Gene +
was O +
eluted O +
after O +
10 O +
ml O +
of O +
buffer O +
H. O +
4.16 O +
Short O +
procedure O +
for O +
RG B-Gene +
purification O +
A O +
short O +
procedure O +
for O +
the O +
enrichment O +
of O +
RG B-Gene +
in O +
higher O +
concentration O +
for O +
proteinase B-Gene -
- O -
catalyzed O +
sequencing O +
included O +
the O +
following O +
steps O -
. O +

From O +
1 O +
kg O +
frozen O +
R. O +
serpentina O +
cells O +
stirred O +
for O +
ca O -
. O +

60 O +
min O +
in O +
buffer O +
I O +
a O +
crude O +
protein B-Gene +
solution O +
of O +
1.8 O +
l O +
( O -
0.8 O +
mg O +
protein O -
/ O -
ml O -
) O +
was O +
obtained O +
with O +
a O +
specific O +
enzyme B-Gene +
activity O +
of O +
0.4 O +
nkat O -
/ O -
mg O -
. O +

( O -
NH4 O +
) O -
2 O +
SO4 O +
precipitation O +
( O -
30–75 O -
% O -
) O +
and O +
solubilisation O +
of O +
the O +
ppt O -
. O +

in O +
180 O +
ml O +
buffer O +
F O +
gave O +
a O +
protein O +
concentration O +
of O +
5.6 O +
mg O -
/ O -
ml O -
. O +

After O +
dialysis O +
against O +
10 O +
l O +
buffer O +
F O +
the O +
final O +
solution O +
of O +
250 O +
ml O +
contained O +
4.0 O +
mg O -
/ O -
ml O +
protein O +
with O +
a O +
specific O +
activity O +
of O +
0.49 O +
nkat O -
/ O -
mg O -
. O +

This O +
protein B-Gene +
solution O +
was O +
added O +
to O +
a O +
15.3 O -
× O -
5 O +
cm O +
column O +
of O +
DEAE O +
sepharose O +
( O +
fast O +
flow O -
) O -
. O +

After O +
washing O +
the O +
column O +
with O +
900 O +
ml O +
buffer O +
B O -
, O +
proteins B-Gene +
were O +
fractionated O +
with O +
a O +
linear O +
KCl O +
gradient O +
( O -
0–0.5 O +
M O -
, O +
1.5 O +
ml O -
/ O -
min O -
) O -
. O +

Glucosidase B-Gene +
activity O +
appeared O +
between O +
0.2–0.3 O +
M O +
KCl O -
. O +

The O +
combined O +
active O +
fractions O +
( O -
190 O +
ml O -
) O +
contained O +
200 O +
mg O +
protein B-Gene +
with O +
a O +
specific O +
activity O +
of O +
1.72 O +
nkat O -
/ O -
mg O +
( O -
4.3-fold O +
enrichment O -
) O -
. O +

This O +
solution O +
was O +
concentrated O +
to O +
6 O +
ml O +
by O +
ultrafiltration O +
( O -
cellulose O +
triacetate O +
membrane O +
< O -
20 O +
kDa O -
, O +
0.1–0.2 O +
MPa O -
) O +
and O +
was O +
then O +
applied O +
to O +
a O +
TSK O +
55 O +
S O +
size O +
exclusion O +
chromatography O +
column O +
( O -
2.5 O -
× O -
47 O +
cm O -
) O -
. O +

Protein B-Gene +
was O +
eluted O +
with O +
buffer O +
K O +
at O +
a O +
flow O +
rate O +
of O +
15 O +
ml O -
/ O -
h O -
. O +

Fractions O +
between O +
95–115 O +
ml O +
were O +
combined O +
and O +
yielded O +
7.6 O +
mg O +
protein B-Gene +
with O +
a O +
specific O +
activity O +
of O +
18.3 O +
nkat O -
/ O -
mg O +
( O -
46-fold O +
enrichment O -
) O -
. O +

After O +
concentration O +
of O +
this O +
solution O +
by O +
centriprep O +
( O -
Amicon O -
/ O -
Witten O -
) O +
it O +
was O +
added O +
to O +
a O +
Mono O +
Q O +
column O +
which O +
was O +
eluted O +
as O +
described O +
above O -
. O +

Maximum O +
enzyme B-Gene +
activity O +
appeared O +
at O +
0.28 O +
M O +
KCl O -
. O +

Fractions O +
from O +
23 O +
to O +
25.5 O +
ml O -
, O +
showing O +
highest O +
enzyme B-Gene +
activity O -
, O +
were O +
combined O -
, O +
resulting O +
in O +
2.5 O +
ml O +
enzyme B-Gene +
solution O +
( O -
0.55 O +
mg O +
glucosidase B-Gene +
exhibiting O +
a O +
specific O +
activity O +
of O +
136 O +
nkat O -
/ O -
mg O -
) O -
. O +

The O +
total O +
yield O +
of O +
enzyme B-Gene +
isolated O +
was O +
5.2 O -
% O -
. O +

4.17 O +
Basic O -
- O -
native O -
- O -
electrophoresis O +
of O +
the O +
enriched O +
RG B-Gene +
Polyacrylamide O +
gels O +
( O -
Clean O +
Gel O +
, O +
Pharmacia O -
) O +
were O +
treated O +
according O +
to O +
the O +
manufacturers O +
instructions O -
. O +

Electrophoresis O +
was O +
carried O +
out O +
under O +
the O +
following O +
conditions O -
: O +
for O +
10 O +
min O +
continuous O +
300 O +
V O +
( O -
9 O +
mA O -
) O +
reaching O +
after O +
60 O +
min O +
900 O +
V O +
( O -
25 O +
mA O -
) O -
. O +

The O +
gel O +
was O +
cut O +
into O +
several O +
bands O -
; O +
one O +
was O +
used O +
for O +
Coomassie O +
staining O -
, O +
one O +
for O +
cutting O +
into O +
small O +
samples O +
which O +
were O +
eluted O +
and O +
concentrated O +
( O -
Microcon O +
10 O -
, O +
Micropur O +
22 O -
; O +
gel O +
nebulizer O -
, O +
Amicon O -
) O +
and O +
some O +
gel O +
strips O +
were O +
used O +
directly O +
for O +
enzyme B-Gene +
assay O +
revealing O +
the O +
glucosidase B-Gene +
activity O -
. O +

The O +
protein B-Gene +
band O +
corresponding O +
to O +
ca O -
. O +

61 O +
kDa O +
showed O +
RG B-Gene +
activity O -
. O +

4.18 O +
Protein B-Gene +
blotting O +
SDS O -
- O -
gels O +
were O +
blotted O +
by O +
the O +
semi O +
dry O +
blotting O +
procedure O +
( O -
Kyhse O -
- O -
Andersen O -
, O +
1984 O +
) O +
for O +
60 O +
min O +
at O +
20 O +
V. O +
For O +
nitrocellulose O +
membrane O +
blotting O +
the O +
transfer O +
buffer O +
L O +
was O +
applied O +
and O +
for O +
blotting O +
on O +
PVDF O +
membranes O +
buffer O +
M O +
was O +
used O -
. O +

The O +
PVDF O +
membranes O +
had O +
been O +
washed O +
first O +
for O +
1 O +
min O +
with O +
MeOH O +
and O +
then O +
equilibrated O +
with O +
buffer O +
M O +
for O +
20 O +
min O -
. O +

4.19 O +
Investigation O +
of O +
RG B-Gene +
for O +
glycosylation O +
A O +
fraction O +
of O +
∼300-fold O +
enriched O +
RG B-Gene +
from O +
Mono O +
Q O +
chromatography O +
was O +
separated O +
by O +
SDS O -
- O -
PAGE O -
. O +

The O +
gel O +
was O +
then O +
blotted O +
to O +
a O +
nitrocellulose O +
membrane O -
, O +
which O +
was O +
processed O +
as O +
described O +
in O +
the O +
Dig O +
Glycan O +
Detection O +
Kit O +
( O -
Boehringer O +
Mannheim O -
) O +
for O +
the O +
detection O +
of O +
glycosylated B-Gene +
proteins I-Gene -
. O +

4.20 O +
Formation O +
of O +
the O +
enzyme B-Gene +
product O +
vomilenine O +
2 O +
mg O +
( O -
3.9 O +
mmol O -
) O +
of O +
6 O +
were O +
dissolved O +
in O +
0.5 O +
ml O +
of O +
100 O +
mM O +
KPi O +
buffer O +
( O -
pH O +
8.0 O -
) O -
. O +

Purified O +
RG B-Gene +
( O -
0.01 O +
ml O -
) O +
was O +
added O +
and O +
the O +
mixture O +
was O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
2 O +
h. O +
The O +
mixture O +
was O +
freeze O +
dried O +
and O +
1 O +
ml O +
KPi O +
buffer O +
and O +
1 O +
ml O +
CH2 O +
Cl2 O +
were O +
added O +
and O +
mixed O -
. O +

The O +
organic O +
solvent O +
was O +
separated O +
and O +
after O +
repeating O +
the O +
procedure O +
and O +
combining O +
the O +
CH2 O +
Cl2 O +
fractions O +
the O +
organic O +
layer O +
was O +
dried O -
, O +
resulting O +
in O +
0.9 O +
mg O +
( O -
2.57 O +
mmol O -
, O +
yield O +
66 O -
% O -
) O +
vomilenine O -
. O +

4.21 O +
Sequencing O +
of O +
RG B-Gene +
and O +
peptide O +
sequence O +
alignment O +
An O +
enriched O +
protein B-Gene +
fraction O +
from O +
step O +
three O +
of O +
the O +
short O +
enzyme B-Gene +
purification O +
protocol O +
was O +
separated O +
on O +
SDS O +
and O +
blotted O +
on O +
a O +
PVDF O +
membrane O +
by O +
the O +
semi O +
dry O +
blotting O +
method O -
. O +

Using O +
the O +
Edman O +
degradation O +
several O +
attempts O +
to O +
sequence O +
RG B-Gene +
were O +
unsuccessful O -
. O +

The O +
enzyme B-Gene -
, O +
therefore O -
, O +
was O +
digested O +
with O +
the O +
endoproteinase B-Gene +
Lys O +
C O +
directly O +
in O +
the O +
gel O -
. O +

After O +
separation O +
and O +
fractionation O +
of O +
formed O +
peptide O +
fragments O +
by O +
HPLC O +
on O +
a O +
Supersphere O +
60 O +
RP O +
select O +
B O +
column O +
( O -
Merck O -
, O +
Darmstadt O -
) O -
, O +
the O +
peptides O +
were O +
sequenced O -
. O +

Two O +
of O +
the O +
obtained O +
peptide O +
sequences O -
, O +
named O +
peptide O +
37 O +
and O +
peptide O +
47 O -
, O +
of O +
RG B-Gene +
were O +
used O +
for O +
screening O +
the O +
SwissProt O +
protein B-Gene +
sequences O +
library O +
by O +
the O +
sequence O +
analysis O +
program O +
BLAST O -
. O +

Acknowledgements O +
We O +
are O +
indebted O +
to O +
Professor O +
Dr. O +
F. O +
Lottspeich O -
, O +
Max O +
Planck O +
Institut O +
für O +
Biochemie O +
( O -
Martinsried O -
, O +
Germany O -
) O +
for O +
performing O +
the O +
amino O +
acid O +
sequencing O +
of O +
the O +
enzyme B-Gene +
and O +
Professor O +
Dr. O +
W.E. O +
Court O +
( O -
Mold O -
, O +
Wales O -
) O +
for O +
correcting O +
the O +
English O +
version O +
of O +
the O +
manuscript O -
. O +

We O +
also O +
acknowledge O +
very O +
much O +
the O +
kind O +
support O +
provided O +
by O +
the O +
Deutsche O +
Forschungsgemeinschaft O +
( O -
Bonn O -
- O -
Bad O +
Godesberg O -
, O +
Germany O -
) O +
and O +
by O +
the O +
Fonds O +
der O +
Chemischen O +
Industrie O +
( O -
Frankfurt O -
/ O -
Main O -
, O +
Germany O -
) O -
. O +

It O +
is O +
shown O +
that O +
6-ketoderivatives O +
of O +
natural O +
sapogenins O -
, O +
viz O -
. O +

agigenin O -
, O +
diosgenin O +
and O +
alliogenin O -
, O +
display O +
the O +
anabolic O +
activity O +
and O +
do O +
not O +
manifest O +
any O +
androgenic O +
properties O -
. O +

The O +
compoud O +
IV O -
/ O -
( O -
25 O +
R O -
) O -
-5alpha O -
- O -
spirostan-2alpha O -
, O +
3beta O -
, O +
5alpha O -
- O -
triol-6-OH O -
/ O -
produces O +
an O +
accelerated O +
gain O +
of O +
weight O +
in O +
rats O -
, O +
and O +
also O +
an O +
increase O +
in O +
the O +
weight O +
of O +
the O +
liver O -
, O +
heart O -
, O +
kidneys O -
, O +
musculus O +
tibiliasis O +
anterior O +
and O +
augments O +
the O +
total O +
amount O +
of O +
protein B-Gene +
therein O -
. O +

All O +
of O +
the O +
above O -
- O -
mentioned O +
changes O +
become O +
more O +
pronounced O +
with O +
the O +
study O +
substance O +
introduced O +
to O +
young O +
animals O -
. O +

Castration O +
of O +
sexually O +
immature O +
rats O +
greatly O +
mitigates O +
the O +
anabolic O +
effect O +
of O +
the O +
compound O +
IV O -
. O +

Three O +
triterpenoid O +
saponins O +
were O +
isolated O +
from O +
the O +
methanol O +
extract O +
of O +
the O +
stem O +
bark O +
of O +
Kalopanax O +
pictum O +
Nakai O +
var O -
. O +

magnificum O +
( O -
Araliaceae O -
) O -
. O +

The O +
structures O +
of O +
these O +
saponins O +
were O +
identified O +
as O +
hederagenin O +
3-O O -
- O -
alpha O -
- O -
L O -
- O -
arabinopyranoside O -
, O +
hederagenin-3-O O -
- O -
alpha O -
- O -
L O -
- O -
rhamnopyranosyl O -
( O -
1 O -
- O -
->2 O -
) O -
-alpha O -
- O -
L O -
- O -
arabinop O +
yranoside O +
and O +
3-O O -
- O -
alpha O -
- O -
L O -
- O -
rhamnopyranosyl O -
( O -
1 O -
- O -
->2 O -
) O -
-alpha O -
- O -
L O -
- O -
arabinopyranosyl O +
hederagenin O +
28-O O -
- O -
alpha O -
- O -
L O -
- O -
rhamnopyranosyl O -
( O -
1 O -
- O -
->4 O -
) O -
-beta O -
- O -
D- O +
glucopyranosyl O -
( O -
1 O -
- O -
->6 O -
) O -
-beta O -
- O -
D O -
- O -
glucopyranosyl O +
ester O -
. O +

A O +
key O +
step O +
in O +
fungal O +
biosynthesis O +
of O +
lysine O -
, O +
enzymatic O +
reduction O +
of O +
alpha O -
- O -
aminoadipate O +
at O +
C6 O +
to O +
the O +
semialdehyde O -
, O +
requires O +
two O +
gene O +
products O +
in O +
Saccharomyces O +
cerevisiae O -
, O +
Lys2 B-Gene +
and O +
Lys5 B-Gene -
. O +

Here O -
, O +
we O +
show O +
that O +
the O +
31-kDa O +
Lys5 B-Gene +
is O +
a O +
specific O +
posttranslational O +
modification O +
catalyst O -
, O +
using O +
coenzyme O +
A O +
( O -
CoASH O -
) O +
as O +
a O +
cosubstrate O +
to O +
phosphopantetheinylate O +
Ser880 O +
of O +
the O +
155-kDa O +
Lys2 B-Gene +
and O +
activate O +
it O +
for O +
catalysis O -
. O +

Lys2 B-Gene +
was O +
subcloned O +
from O +
S. O +
cerevisiae O +
and O +
expressed O +
in O +
and O +
purified O +
from O +
Escherichia O +
coli O +
as O +
a O +
full O -
- O -
length O +
155-kDa O +
enzyme B-Gene -
, O +
as O +
a O +
105-kDa O +
adenylation B-Gene -
/ I-Gene -
peptidyl I-Gene +
carrier I-Gene +
protein I-Gene +
( O -
A B-Gene -
/ I-Gene -
PCP I-Gene -
) O +
fragment O +
( O -
residues O +
1 O -
- O -
924 O -
) O -
, O +
and O +
as O +
a O +
14-kDa O +
PCP B-Gene +
fragment O +
( O -
residues O +
809 O -
- O -
924 O -
) O -
. O +

The O +
apo B-Gene -
- I-Gene -
PCP I-Gene +
fragment O +
was O +
covalently O +
modified O +
to O +
phosphopantetheinylated B-Gene +
holo I-Gene -
- I-Gene -
PCP I-Gene +
by O +
pure O +
Lys5 B-Gene +
and O +
CoASH O +
with O +
a O +
Km O +
of O +
1 O +
microM O +
and O +
kcat O +
of O +
3 O +
min-1 O +
for O +
both O +
the O +
PCP B-Gene +
and O +
CoASH O +
substrates O -
. O +

The O +
adenylation O +
domain O +
of O +
the O +
A B-Gene -
/ I-Gene -
PCP I-Gene +
fragment O +
activated O +
S O -
- O -
carboxymethyl O -
- O -
L O -
- O -
cysteine O +
( O -
kcat O -
/ O -
Km O +
= O +
840 O +
mM-1 O +
min-1 O -
) O +
at O +
16 O -
% O +
the O +
efficiency O +
of O +
L O -
- O -
alpha O -
- O -
aminoadipate O +
in O +
[ O -
32P O -
] O -
PPi O -
/ O -
ATP O +
exchange O +
assays O -
. O +

The O +
holo O +
form O +
of O +
the O +
A B-Gene -
/ I-Gene -
PCP I-Gene +
105-kDa O +
fragment O +
of O +
Lys2 B-Gene +
covalently O +
aminoacylated O +
itself O +
with O +
[ O -
35S O -
] O -
S O -
- O -
carboxymethyl O -
- O -
L O -
- O -
cysteine O -
. O +

Addition O +
of O +
NADPH O +
discharged O +
the O +
covalent O +
acyl B-Gene -
- I-Gene -
S I-Gene -
- I-Gene -
PCP I-Gene +
Lys2 I-Gene -
, O +
consistent O +
with O +
a O +
reductive O +
cleavage O +
of O +
the O +
acyl B-Gene -
- I-Gene -
S I-Gene -
- I-Gene -
enzyme I-Gene +
intermediate O -
. O +

These O +
results O +
identify O +
the O +
Lys5 B-Gene -
/ O -
Lys2 B-Gene +
pair O +
as O +
a O +
two O -
- O -
component O +
system O +
in O +
which O +
Lys5 B-Gene +
covalently O +
primes O +
Lys2 B-Gene -
, O +
allowing O +
alpha B-Gene -
- I-Gene -
aminoadipate I-Gene +
reductase I-Gene +
activity O +
by O +
holo B-Gene -
- I-Gene -
Lys2 I-Gene +
with O +
catalytic O +
cycles O +
of O +
autoaminoacylation O +
and O +
reductive O +
cleavage O -
. O +

This O +
is O +
a O +
novel O +
mechanism O +
for O +
a O +
fungal O +
enzyme B-Gene +
essential O +
for O +
amino O +
acid O +
metabolism O -
. O +

Rat O +
liver O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
catalyzes O +
not O +
only O +
the O +
hydrolysis O +
of O +
1-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O -
, O +
but O +
also O +
the O +
transfer O +
of O +
its O +
acyl O +
chain O +
to O +
a O +
second O +
molecule O +
of O +
1-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O +
to O +
form O +
phosphatidylcholine O +
( O -
H. O +
Sugimoto O -
, O +
S. O +
Yamashita O -
, O +
J. O +
Biol O -
. O +

Chem O -
. O +
269 O +
( O -
1994 O -
) O +
6252 O -
- O -
6258 O -
) O -
. O +

Here O +
we O +
report O +
the O +
detailed O +
characterization O +
of O +
the O +
transacylase B-Gene +
activity O +
of O +
the O +
enzyme B-Gene -
. O +

The O +
enzyme B-Gene +
mediated O +
three O +
types O +
of O +
acyl O +
transfer O +
between O +
donor O +
and O +
acceptor O +
lipids O -
, O +
transferring O +
acyl O +
residues O +
from O -
: O +
( O -
1 O -
) O +
the O +
sn-1 O +
to O +
-1 O -
( O -
3 O -
) O -
; O +
( O -
2 O -
) O +
sn-1 O +
to O +
-2 O -
; O +
and O +
( O -
3 O -
) O +
sn-2 O +
to O +
-1 O +
positions O -
. O +

In O +
the O +
sn-1 O +
to O +
-1 O -
( O -
3 O -
) O +
transfer O -
, O +
the O +
sn-1 O +
acyl O +
residue O +
of O +
1-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O +
was O +
transferred O +
to O +
the O +
sn-1 O -
( O -
3 O -
) O +
positions O +
of O +
glycerol O +
and O +
2-acyl O -
- O -
sn O -
- O -
glycerol O -
, O +
producing O +
1 O -
( O -
3 O -
) O -
-acyl O -
- O -
sn O -
- O -
glycerol O +
and O +
1,2-diacyl O -
- O -
sn O -
- O -
glycerol O -
, O +
respectively O -
. O +

In O +
the O +
sn-1 O +
to O +
-2 O +
transfer O -
, O +
the O +
sn-1 O +
acyl O +
residue O +
of O +
1-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O +
was O +
transferred O +
to O +
not O +
only O +
the O +
sn-2 O +
positions O +
of O +
1-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O -
, O +
but O +
also O +
1-acyl O -
- O -
sn O -
- O -
glycero-3-phosphoethanolamine O -
, O +
producing O +
phosphatidylcholine O +
and O +
phosphatidylethanolamine O -
, O +
respectively O -
. O +

1-Acyl O -
- O -
sn O -
- O -
glycero-3-phospho O -
- O -
myo O -
- O -
inositol O +
and O +
1-acyl O -
- O -
sn O -
- O -
glycero-3-phosphoserine O +
were O +
much O +
less O +
effectively O +
transacylated O +
by O +
the O +
enzyme B-Gene -
. O +

In O +
the O +
sn-2 O +
to O +
-1 O +
transfer O -
, O +
the O +
sn-2 O +
acyl O +
residue O +
of O +
2-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O +
was O +
transferred O +
to O +
the O +
sn-1 O +
position O +
of O +
2-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O +
and O +
2-acyl O -
- O -
sn O -
- O -
glycero-3-phosphoethanolamine O -
, O +
producing O +
phosphatidylcholine O +
and O +
phosphatidylethanolamine O -
, O +
respectively O -
. O +

Consistently O -
, O +
the O +
enzyme B-Gene +
hydrolyzed O +
the O +
sn-2 O +
acyl O +
residue O +
from O +
2-acyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O -
. O +

By O +
the O +
sn-2 O +
to O +
-1 O +
transfer O +
activity O -
, O +
arachidonic O +
acid O +
was O +
transferred O +
from O +
the O +
sn-2 O +
position O +
of O +
donor O +
lipids O +
to O +
the O +
sn-1 O +
position O +
of O +
acceptor O +
lipids O -
, O +
thus O +
producing O +
1-arachidonoyl O +
phosphatidylcholine O -
. O +

When O +
2-arachidonoyl O -
- O -
sn O -
- O -
glycero-3-phosphocholine O +
was O +
used O +
as O +
the O +
sole O +
substrate O -
, O +
diarachidonoyl O +
phosphatidylcholine O +
was O +
synthesized O +
at O +
a O +
rate O +
of O +
0.23 O +
micromol O -
/ O -
min O -
/ O -
mg O +
protein O -
. O +

Thus O -
, O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
may O +
play O +
a O +
role O +
in O +
the O +
synthesis O +
of O +
1-arachidonoyl O +
phosphatidylcholine O +
needed O +
for O +
important O +
cell O +
functions O -
, O +
such O +
as O +
anandamide O +
synthesis O -
. O +

Erbland O +
and O +
Marinetti O +
[ O -
1 O -
] O +
first O +
demonstrated O +
the O +
presence O +
of O +
transacylase B-Gene +
activity O +
in O +
liver O +
supernatant O +
to O +
transfer O +
the O +
acyl O +
group O +
from O +
1-acyl O -
- O -
sn O +
-glycero-3-phosphocholine O +
( O -
1-acyl O -
- O -
GPC O -
) O +
to O +
a O +
second O +
molecule O +
of O +
1-acyl O -
- O -
GPC O -
, O +
producing O +
phosphatidylcholine O +
( O -
PC O -
) O -
. O +

By O +
purifying O +
the O +
enzyme B-Gene +
from O +
rat O +
lung O -
, O +
Brumley O +
and O +
van O +
den O +
Bosch O +
[ O -
2 O -
] O +
demonstrated O +
that O +
the O +
transacylase B-Gene +
activity O +
was O +
a O +
second O +
activity O +
of O +
lysophospholipase B-Gene +
and O +
responsible O +
for O +
the O +
synthesis O +
of O +
disaturated O +
PC O -
, O +
abundantly O +
found O +
in O +
lung O +
surfactant O +
[ O -
3 O -
] O +
. O +

Transacylation O +
activity O +
is O +
not O +
associated O +
with O +
all O +
lysophospholipases B-Gene -
, O +
but O +
one O +
class O +
of O +
isoform O +
with O +
molecular O +
masses O +
of O +
about O +
60 O +
kDa O -
, O +
called O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene -
. O +

The O +
activity O +
is O +
thought O +
to O +
be O +
due O +
to O +
the O +
intermediate O +
formation O +
of O +
the O +
acyl B-Gene -
- I-Gene -
enzyme I-Gene +
during O +
the O +
enzyme B-Gene +
reaction O -
. O +

Lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
was O +
purified O +
from O +
various O +
tissues O -
, O +
such O +
as O +
liver O +
[ O -
4 O -
] O +
, O +
heart O +
[ O -
5 O -
] O +
, O +
and O +
lung O +
[ O -
2 O -
] O +
. O +

We O +
recently O +
cloned O +
cDNA O +
for O +
the O +
hepatic O +
enzyme B-Gene +
and O +
showed O +
that O +
it O +
comprised O +
564 O +
amino O +
acid O +
residues O +
[ O -
6 O -
] O +
. O +

The O +
amino O -
- O -
terminal O +
two O -
- O -
thirds O +
of O +
the O +
molecule O +
resembled O +
Escherichia O +
coli O +
asparaginase B-Gene +
I I-Gene +
[ O -
7 O -
] O +
with O +
the O +
putative O +
catalytic O +
triad O +
Thr O -
- O -
Asp O -
- O -
Lys O -
, O +
followed O +
by O +
the O +
leucine O +
zipper O +
motif O -
. O +

The O +
carboxyl O -
- O -
terminal O +
region O +
contained O +
the O +
ankyrin B-Gene +
repeat O +
[ O -
8,9 O -
] O +
. O +

This O +
structure O +
is O +
markedly O +
different O +
from O +
the O +
other O +
class O +
of O +
lysophospholipase B-Gene +
lacking O +
transacylase B-Gene +
activity O +
with O +
a O +
molecular O +
mass O +
of O +
about O +
25 O +
kDa O -
, O +
comprising O +
230 O +
amino O +
acids O +
with O +
the O +
Gly B-Gene -
- I-Gene -
X I-Gene -
- I-Gene -
Ser I-Gene -
- I-Gene -
X I-Gene -
- I-Gene -
Gly I-Gene +
esterase I-Gene -
/ I-Gene -
lipase I-Gene +
consensus O +
and O +
the O +
catalytic O +
triad O +
Ser119 O +
-Asp174 O +
-His208 O +
[ O -
10–12 O -
] O +
. O +

In O +
the O +
previous O +
study O -
, O +
we O +
showed O +
that O +
rat O +
liver O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
transferred O +
the O +
palmitoyl O +
residue O +
from O +
1-palmitoyl O -
- O -
GPC O +
to O +
a O +
second O +
molecule O +
of O +
1-palmitoyl O -
- O -
GPC O -
, O +
and O +
also O +
to O +
2-palmitoyl O -
- O -
sn O +
-glycerol O +
( O -
hereafter O +
2-palmitoylglycerol O -
) O -
, O +
producing O +
1,2-dipalmitoyl O -
- O -
GPC O +
and O +
1,2-dipalmitoylglycerol O -
, O +
respectively O +
[ O -
4 O -
] O +
. O +

To O +
extend O +
these O +
findings O -
, O +
we O +
characterized O +
the O +
transacylation O +
activity O +
of O +
the O +
enzyme B-Gene +
in O +
more O +
detail O -
. O +

The O +
obtained O +
results O +
indicate O +
that O +
the O +
enzyme B-Gene +
can O +
transfer O +
saturated O +
and O +
unsaturated O +
fatty O +
acyl O +
chains O +
from O +
1-acyl O -
- O -
GPC O +
to O +
the O +
sn O +
-1 O -
( O -
3 O -
) O +
and O +
sn O +
-2 O +
positions O +
of O +
acyl O +
acceptors O +
and O +
also O +
from O +
2-acyl O -
- O -
GPC O +
to O +
the O +
sn O +
-1 O +
position O +
of O +
acyl O +
acceptors O -
. O +

Notably O -
, O +
the O +
enzyme B-Gene +
transferred O +
the O +
arachidonoyl O +
residue O +
from O +
the O +
sn O +
-2 O +
position O +
of O +
the O +
donor O +
lipid O +
to O +
the O +
sn O +
-1 O +
position O +
of O +
the O +
acceptor O +
lipid O -
. O +

When O +
the O +
enzyme B-Gene +
was O +
incubated O +
with O +
2-arachidonoyl O -
- O -
GPC O -
, O +
arachidonic O +
acid O +
was O +
transferred O +
from O +
one O +
molecule O +
of O +
2-arachidonoyl O -
- O -
GPC O +
to O +
another O +
molecule O +
of O +
2-arachidonoyl O -
- O -
GPC O -
, O +
producing O +
1,2-diarachidonoyl O -
- O -
GPC O -
. O +

The O +
present O +
results O +
suggest O +
that O +
60-kDa O +
lysophospholipase O -
- O -
transacylase O +
mediates O +
the O +
synthesis O +
of O +
1-arachidonoyl O +
PC O -
, O +
an O +
important O +
precursor O +
of O +
the O +
intrinsic O +
cannabinol B-Gene +
receptor I-Gene +
ligand O -
, O +
anandamide O +
[ O -
13,14 O -
] O +
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
1-Palmitoyl O -
- O -
GPC O +
was O +
obtained O +
from O +
Bachem O +
Feinchemikalien O +
AG O +
( O -
Bubendorf O -
, O +
Switzerland O -
) O -
. O +

1-Palmitoyl O -
- O -
sn O +
-glycero-3-phosphoethanolamine O +
( O -
1-palmitoyl O -
- O -
GPE O -
) O -
, O +
1-acyl O -
- O -
sn O +
-glycero-3-phospho O -
- O -
myo O +
-inositol O +
( O -
1-acyl O -
- O -
GPI O -
) O -
, O +
and O +
1-acyl O -
- O -
sn O +
-glycero-3-phosphoserine O +
( O -
1-acyl O -
- O -
GPS O -
) O +
were O +
from O +
Avanti O +
Polar O +
Lipids O +
( O -
Alabaster O -
, O +
AL O -
, O +
USA O -
) O -
. O +

1-Stearoyl-2-arachidonoyl O -
- O -
GPC O +
and O +
1 O -
( O -
3 O -
) O -
- O +
and O +
2-palmitoylglycerol O +
were O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

Glycerol O +
was O +
purchased O +
from O +
Wako O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

1- O -
[ O -
14 O +
C O -
] O -
Palmitoyl O -
- O -
GPC O +
( O -
55 O +
mCi O -
/ O -
mmol O -
) O -
, O +
1-stearoyl-2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
( O -
55 O +
mCi O -
/ O -
mmol O -
) O -
, O +
and O +
1-palmitoyl-2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
( O -
55 O +
mCi O -
/ O -
mmol O -
) O +
were O +
from O +
Amersham O +
( O -
UK O -
) O -
. O +

Silica O +
Gel O +
60 O +
plates O +
were O +
obtained O +
from O +
Merck O +
( O -
Darmstadt O -
, O +
Germany O -
) O -
. O +

Rhizopus B-Gene +
arrhizus I-Gene +
lipase I-Gene +
was O +
from O +
Boehringer O +
Mannheim O +
( O -
Germany O -
) O -
. O +

2.2 O +
Preparation O +
of O +
2- O -
[ O -
14 O +
C O -
] O -
palmitoyl- O +
and O +
2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
Two O +
hundred O +
nanomoles O +
of O +
1-palmitoyl-2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
( O -
21.6 O +
dpm O -
/ O -
pmol O -
) O +
or O +
1-stearoyl-2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
( O -
17.7 O +
dpm O -
/ O -
pmol O -
) O +
was O +
treated O +
with O +
R. B-Gene +
arrhizus I-Gene +
lipase I-Gene +
for O +
30 O +
min O +
at O +
37 O -
° O -
C O +
in O +
the O +
presence O +
of O +
2 O +
mM O +
CaCl2 O +
and O +
0.02 O -
% O +
Triton O +
X-100 O +
in O +
a O +
total O +
volume O +
of O +
0.6 O +
ml O -
. O +

2- O -
[ O -
14 O +
C O -
] O -
Palmitoyl- O +
and O +
2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
produced O +
were O +
extracted O +
with O +
chloroform O -
/ O -
methanol O +
( O -
2:1 O -
, O +
by O +
volume O -
) O +
and O +
separated O +
by O +
two O -
- O -
dimensional O +
thin O -
- O -
layer O +
chromatography O +
( O -
TLC O -
) O +
using O +
chloroform O -
/ O -
methanol O -
/ O -
ammonia O -
/ O -
water O +
( O -
65:25:4:1 O -
, O +
by O +
volume O -
) O +
as O +
the O +
first O +
solvent O +
and O +
chloroform O -
/ O -
acetone O -
/ O -
methanol O -
/ O -
acetic O +
acid O -
/ O -
water O +
( O -
30:40:10:7:5 O -
, O +
by O +
volume O -
) O +
as O +
the O +
second O +
solvent O -
. O +

The O +
TLC O +
band O +
containing O +
2- O -
[ O -
14 O +
C O -
] O -
palmitoyl- O +
or O +
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
was O +
located O +
by O +
autoradiography O -
, O +
scraped O +
off O -
, O +
extracted O +
with O +
methanol O -
, O +
and O +
dispersed O +
in O +
90 O +
μl O +
of O +
distilled O +
water O +
using O +
a O +
Branson O +
B-220 O +
sonifier O +
for O +
20 O +
s O +
at O +
an O +
output O +
of O +
125 O +
W O -
, O +
and O +
then O +
immediately O +
used O +
to O +
minimize O +
acyl O +
migration O -
. O +

2.3 O +
Enzyme B-Gene +
purification O +
Sixty O -
- O -
kiloDalton O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
was O +
purified O +
from O +
rat O +
liver O +
as O +
described O +
previously O +
[ O -
4 O -
] O +
with O +
some O +
modification O -
. O +

We O +
found O +
that O +
the O +
G O -
- O -
butyl O +
column O +
chromatography O +
step O +
sometimes O +
gave O +
a O +
poor O +
yield O +
of O +
the O +
enzyme B-Gene -
, O +
but O +
could O +
be O +
removed O +
without O +
any O +
serious O +
effect O +
on O +
the O +
purity O +
of O +
the O +
final O +
enzyme B-Gene +
preparation O -
. O +

Glycerol O +
( O -
10 O -
% O -
) O +
was O +
used O +
instead O +
of O +
dimethylsulfoxide O +
in O +
S-200 O +
column O +
chromatography O -
. O +

2.4 O +
Lysophospholipase B-Gene +
assay O +
The O +
activity O +
was O +
isotopically O +
assayed O +
as O +
described O +
previously O +
[ O -
4 O -
] O +
. O +

2.5 O +
Acyl O +
transfer O +
from O +
the O +
sn-1 O +
to O +
the O +
sn-1 O -
( O -
3 O -
) O +
position O +
The O +
purified O +
enzyme B-Gene +
was O +
incubated O +
for O +
40 O +
min O +
at O +
37 O -
° O -
C O +
in O +
0.1-ml O +
of O +
the O +
indicated O +
buffer O +
containing O +
0.2 O +
mM O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
( O -
3 O +
500 O +
dpm O -
/ O -
nmol O -
) O +
as O +
acyl O +
donor O -
, O +
and O +
the O +
indicated O +
concentration O +
of O +
glycerol O +
or O +
2-palmitoylglycerol O +
as O +
acyl O +
acceptor O -
. O +

The O +
reaction O +
was O +
terminated O +
by O +
adding O +
3 O +
ml O +
of O +
chloroform O -
/ O -
methanol O +
( O -
2:1 O -
, O +
by O +
volume O -
) O -
, O +
followed O +
by O +
the O +
addition O +
of O +
0.6 O +
ml O +
of O +
distilled O +
water O -
. O +

The O +
mixture O +
was O +
shaken O +
vigorously O +
and O +
centrifuged O +
at O +
2000 O -
× O -
g O +
for O +
5 O +
min O -
. O +

The O +
lower O +
phase O +
was O +
evaporated O +
to O +
dryness O +
in O +
a O +
CVE-100 O +
centrifugal O +
vaporizer O +
( O -
Tokyo O +
Rika O -
, O +
Tokyo O -
, O +
Japan O -
) O -
, O +
dissolved O +
in O +
a O +
minimum O +
volume O +
of O +
chloroform O -
/ O -
methanol O +
( O -
2:1 O -
, O +
by O +
volume O -
) O +
and O +
separated O +
by O +
two O -
- O -
dimensional O +
TLC O -
. O +

The O +
acylation O +
product O +
of O +
glycerol O +
was O +
developed O +
with O +
solvent O +
system O +
I O +
( O -
first O +
dimension O -
, O +
chloroform O -
/ O -
methanol O -
/ O -
ammonia O -
/ O -
water O +
( O -
65:25:4:1 O -
, O +
by O +
volume O -
) O -
; O +
second O +
dimension O -
, O +
chloroform O -
/ O -
acetone O -
/ O -
methanol O -
/ O -
acetic O +
acid O -
/ O -
water O +
( O -
30:40:10:7:5 O -
, O +
by O +
volume O -
) O -
) O -
. O +

The O +
acylation O +
product O +
of O +
2-palmitoylglycerol O +
was O +
separated O +
with O +
solvent O +
system O +
II O +
( O -
first O +
dimension O -
, O +
n O +
-hexane O -
/ O -
diethyl O +
ether O -
/ O -
acetic O +
acid O +
( O -
80:20:1 O -
, O +
by O +
volume O -
) O -
; O +
second O +
dimension O -
, O +
chloroform O -
/ O -
methanol O -
/ O -
ammonia O -
/ O -
water O +
( O -
65:25:4:1 O -
, O +
by O +
volume O -
) O -
) O -
. O +

The O +
lipids O +
were O +
located O +
by O +
autoradiography O -
, O +
scraped O +
off O +
the O +
plate O -
, O +
and O +
quantitated O +
by O +
counting O +
in O +
a O +
toluene O -
/ O -
Triton O +
X-100 O +
scintillant O -
. O +

The O +
identity O +
of O +
each O +
TLC O +
spot O +
was O +
ascertained O +
by O +
co O -
- O -
chromatography O +
with O +
authentic O +
samples O -
. O +

Steric O +
isomers O +
of O +
palmitoylglycerol O +
were O +
identified O +
on O +
a O +
borate O -
- O -
impregnated O +
silica O +
gel O +
H O +
plate O +
with O +
chloroform O -
/ O -
acetone O +
( O -
1:1 O -
, O +
by O +
volume O -
) O +
as O +
the O +
developing O +
solvent O +
[ O -
15 O -
] O +
. O +

2.6 O +
Acyl O +
transfer O +
from O +
the O +
sn-1 O +
to O +
the O +
sn-2 O +
position O +
The O +
enzyme O +
was O +
incubated O +
with O +
0.2 O +
mM O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
as O +
acyl O +
donor O +
and O +
0.2 O +
mM O +
1-palmitoyl O -
- O -
GPE O -
, O +
1-acyl O -
- O -
GPI O -
, O +
or O +
1-acyl O -
- O -
GPS O +
as O +
acyl O +
acceptor O -
. O +

The O +
other O +
conditions O +
were O +
as O +
described O +
above O -
. O +

The O +
product O +
lipids O +
were O +
extracted O +
and O +
separated O +
by O +
two O -
- O -
dimensional O +
TLC O +
using O +
the O +
solvent O +
system O +
I O +
and O +
counted O +
as O +
above O -
. O +

2.7 O +
Acyl O +
transfer O +
from O +
the O +
sn-2 O +
to O +
the O +
sn-1 O +
position O +
Two O +
methods O +
were O +
used O -
. O +

In O +
method O +
I O -
, O +
the O +
enzyme B-Gene +
was O +
incubated O +
with O +
0.2 O +
mM O +
2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
( O -
21 O +
600 O +
dpm O -
/ O -
nmol O -
) O +
or O +
2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
( O -
17 O +
700 O +
dpm O -
/ O -
nmol O -
) O -
, O +
and O +
the O +
reaction O +
product O +
was O +
extracted O -
, O +
separated O +
on O +
TLC O +
with O +
the O +
solvent O +
system O +
I O -
, O +
and O +
then O +
quantitated O +
as O +
above O -
. O +

In O +
method O +
II O -
, O +
10 O +
nmol O +
each O +
of O +
1-stearoyl-2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
( O -
20 O +
000 O +
dpm O -
) O +
and O +
1,2-dioleoyl O -
- O -
GPE O +
were O +
preincubated O +
with O +
12.5 O +
U O +
of O +
R. B-Gene +
arrhizus I-Gene +
lipase I-Gene +
at O +
37 O -
° O -
C O +
in O +
a O +
total O +
volume O +
of O +
50 O +
μl O +
containing O +
10 O +
mM O +
Tris O -
- O -
HCl O +
( O -
pH O +
7.5 O -
) O -
, O +
2 O +
mM O +
CaCl2 O +
, O +
and O +
0.02 O -
% O +
Triton O +
X-100 O -
. O +

After O +
20 O +
min O +
of O +
incubation O -
, O +
0.1 O +
μg O +
of O +
purified O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
and O +
2.5 O +
μmol O +
of O +
phosphate O +
buffer O +
( O -
pH O +
6.0 O -
) O +
were O +
added O +
and O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
40 O +
min O +
in O +
a O +
total O +
volume O +
of O +
100 O +
μl O -
. O +

Lipids O +
were O +
extracted O -
, O +
separated O +
with O +
the O +
solvent O +
system O +
I O -
, O +
and O +
then O +
quantitated O +
as O +
described O +
above O -
. O +

All O +
the O +
data O +
presented O +
herein O +
were O +
repeated O +
at O +
least O +
twice O +
and O +
the O +
representative O +
data O +
are O +
shown O -
. O +

3 O +
Results O +
3.1 O +
Acylation O +
of O +
glycerol O +
and O +
2-acylglycerol O +
with O +
1-acyl O -
- O -
GPC O +
( O -
sn-1 O +
to O +
-1 O -
( O -
3 O -
) O +
transfer O -
) O +
When O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
was O +
incubated O +
with O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O -
, O +
we O +
noted O +
the O +
spot O +
of O +
monoacylglycerol O +
on O +
a O +
two O -
- O -
dimensional O +
TLC O +
plate O +
in O +
addition O +
to O +
those O +
of O +
palmitic O +
acid O +
and O +
dipalmitoyl O -
- O -
GPC O +
( O -
data O +
not O +
shown O -
) O -
. O +

Since O +
the O +
enzyme B-Gene +
contained O +
10 O -
% O +
glycerol O +
as O +
the O +
stabilizing O +
agent O -
, O +
we O +
thought O +
that O +
the O +
monoacylglycerol O +
was O +
derived O +
from O +
the O +
acylation O +
of O +
glycerol O +
contained O +
in O +
the O +
enzyme B-Gene +
preparation O -
. O +

To O +
confirm O +
this O -
, O +
increasing O +
concentrations O +
of O +
glycerol O +
were O +
supplemented O +
to O +
the O +
incubation O +
and O +
monoacylglycerol O +
synthesis O +
was O +
examined O -
. O +

As O +
shown O +
in O +
Fig. O +
1 O +
, O +
monoacylglycerol O +
synthesis O +
was O +
stimulated O +
by O +
the O +
substrate O +
glycerol O -
, O +
but O +
inhibited O +
at O +
high O +
concentrations O -
. O +

The O +
optimum O +
pH O +
of O +
monoacylglycerol O +
synthesis O +
was O +
9.0 O -
. O +

However O -
, O +
the O +
glycerol O +
concentration O +
required O +
for O +
the O +
maximal O +
monoacylglycerol O +
synthesis O +
( O -
40 O -
% O -
) O +
was O +
much O +
higher O +
than O +
the O +
reported O +
glycerol O +
content O +
of O +
rat O +
liver O +
( O -
2.7 O +
μg O -
/ O -
g O +
wet O +
weight O -
) O +
[ O -
16 O -
] O +
. O +

Thus O -
, O +
the O +
acylation O +
of O +
glycerol O +
by O +
lysoPC O +
may O +
not O +
have O +
physiological O +
significance O +
in O +
the O +
liver O -
. O +

To O +
determine O +
which O +
carbon O +
of O +
the O +
glycerol O +
backbone O +
was O +
acylated O -
, O +
we O +
separated O +
the O +
palmitoylglycerol O +
formed O +
from O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
and O +
glycerol O +
on O +
a O +
borate O -
- O -
impregnated O +
silicic O +
acid O +
plate O +
[ O -
15 O -
] O +
to O +
separate O +
sn O +
-1 O -
( O -
3 O -
) O -
- O +
and O +
2-isomer O -
. O +

1 O -
( O -
3 O -
) O -
-Palmitoylglycerol O +
migrated O +
more O +
slowly O +
than O +
2-palmitoylglycerol O +
because O +
boric O +
acid O +
complexed O +
with O +
vicinal O +
hydroxy O +
groups O -
. O +

As O +
shown O +
in O +
Fig. O +
2 O +
, O +
the O +
product O +
from O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
and O +
glycerol O +
was O +
identified O +
as O +
the O +
1 O -
( O -
3 O -
) O -
-palmitoylglycerol O -
. O +

Thus O +
glycerol O +
was O +
acylated O +
in O +
a O +
regiospecific O +
manner O +
by O +
the O +
enzyme B-Gene -
. O +

When O +
2-palmitoylglycerol O +
was O +
used O +
as O +
acyl O +
acceptor O -
, O +
1,2-dipalmitoylglycerol O +
was O +
produced O +
( O -
Fig. O +
3 O +
) O -
. O +

1,3-Dipalmitoylglycerol O +
was O +
not O +
produced O +
( O -
data O +
not O +
shown O -
) O -
. O +

1,2-Dipalmitoylglycerol O +
formation O +
was O +
maximal O +
with O +
0.4 O +
mM O +
2-palmitoylglycerol O +
with O +
optimum O +
pH O +
at O +
6.0 O -
. O +

The O +
transacylation O +
was O +
slightly O +
stimulated O +
( O -
25 O -
% O -
) O +
by O +
2 O +
mM O +
Mg2 O -
+ O +
. O +

In O +
the O +
presence O +
of O +
0.4 O +
mM O +
2-palmitoylglycerol O +
and O +
2 O +
mM O +
Mg2 O -
+ O +
at O +
pH O +
6.0 O -
, O +
1,2-diacylglycerol O +
formation O +
was O +
40 O -
% O +
of O +
PC O +
formation O -
. O +

Thus O -
, O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
catalyzed O +
the O +
following O +
sn O +
-1 O +
to O +
-1 O +
acyl O +
transfer O +
reactions:1-acyl O -
- O -
GPC+glycerol→1 O -
( O -
3 O -
) O -
-acylglycerol+GPC O +
1-acyl O -
- O -
GPC+2-acylglycerol→1,2-diacylglycerol+GPC O +
. O +

3.2 O +
Acylation O +
of O +
1-acyl O +
lysophospholipids O +
with O +
1-acyl O -
- O -
GPC O +
( O -
sn-1 O +
to O +
-2 O +
transfer O -
) O +
We O +
examined O +
whether O +
or O +
not O +
the O +
enzyme B-Gene +
was O +
able O +
to O +
utilize O +
different O +
1-acyl O +
lysophospholipids O +
as O +
acyl O +
acceptor O -
. O +

The O +
purified O +
enzyme B-Gene +
was O +
incubated O +
with O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
and O +
0.2 O +
mM O +
1-acyl O +
lysophospholipids O +
( O -
1-palmitoyl O -
- O -
GPE O -
, O +
1-acyl O -
- O -
GPI O -
, O +
or O +
1-acyl O -
- O -
GPS O -
) O +
at O +
pH O +
6.0 O -
, O +
and O +
the O +
radioactive O +
products O +
were O +
separated O +
by O +
two O -
- O -
dimensional O +
TLC O +
and O +
quantitated O -
. O +

When O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
was O +
used O +
as O +
the O +
sole O +
substrate O -
, O +
radioactive O +
product O +
was O +
[ O -
14 O +
C O -
] O -
dipalmitoyl O -
- O -
GPC O +
( O -
Fig. O +
3 O +
) O -
. O +

However O -
, O +
when O +
1- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
was O +
incubated O +
with O +
1-palmitoyl O -
- O -
GPE O -
, O +
1-acyl O -
- O -
GPI O -
, O +
or O +
1-acyl O -
- O -
GPS O -
, O +
[ O -
14 O +
C O -
] O -
PC O +
was O +
decreased O -
, O +
and O +
varying O +
amounts O +
of O +
1-palmitoyl-2 O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPE O -
, O +
1-acyl-2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPI O -
, O +
and O +
1-acyl-2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPS O +
were O +
produced O -
. O +

The O +
total O +
acyl O +
transfer O +
( O -
PC+PE O -
, O +
PC+PI O -
, O +
and O +
PC+PS O +
syntheses O -
) O +
varied O +
with O +
the O +
lysophospholipids O +
used O -
, O +
suggesting O +
the O +
modulation O +
of O +
transferase B-Gene +
activity O +
by O +
lysophospholipids O -
. O +

The O +
amount O +
of O +
[ O -
14 O +
C O -
] O -
PE O +
produced O +
was O +
about O +
half O +
the O +
amount O +
of O +
[ O -
14 O +
C O -
] O -
PC O -
, O +
indicating O +
that O +
1-palmitoyl O -
- O -
GPE O +
was O +
a O +
fairly O +
good O +
acyl O +
acceptor O -
. O +

However O -
, O +
when O +
1-acyl O -
- O -
GPI O +
and O +
1-acyl O -
- O -
GPS O +
were O +
used O +
as O +
acyl O +
acceptor O -
, O +
only O +
low O +
levels O +
of O +
[ O -
14 O +
C O -
] O -
PI O +
and O +
[ O -
14 O +
C O -
] O -
PS O +
were O +
produced O -
, O +
indicating O +
that O +
1-acyl O -
- O -
GPI O +
and O +
1-acyl O -
- O -
GPS O +
were O +
rather O +
poor O +
acyl O +
acceptors O +
although O +
the O +
former O +
was O +
somewhat O +
better O +
than O +
the O +
latter O -
. O +

Thus O -
, O +
the O +
effectiveness O +
of O +
lysophospholipids O +
as O +
acyl O +
acceptor O +
was O +
in O +
the O +
order O -
: O +
1-palmitoyl O -
- O -
GPC>1-palmitoyl O -
- O -
GPE>1-acyl O -
- O -
GPI>1-acyl O -
- O -
GPS O -
. O +

This O +
order O +
agreed O +
fairly O +
well O +
with O +
the O +
specificity O +
of O +
the O +
hydrolytic O +
activity O +
of O +
the O +
enzyme B-Gene +
[ O -
4 O -
] O +
. O +

Thus O -
, O +
the O +
enzyme B-Gene +
catalyzed O +
the O +
following O +
sn O +
-1 O +
to O +
-2 O +
transacylation:1-acyl O -
- O -
GPC+1-acyl O -
- O -
GPX O +
( O -
GPC O -
> O -
GPE O -
> O -
GPI O -
> O -
GPS O -
) O -
→1,2-diacyl O -
- O -
GPX O +
( O -
GPC O -
> O -
GPE O -
> O -
GPI O -
> O -
GPS O -
) O -
+GPX O +
( O -
GPC O -
> O -
GPE O -
> O -
GPI O -
> O -
GPS O -
) O +
. O +

3.3 O +
Acylation O +
of O +
2-acyl O -
- O -
GPC O +
with O +
2-acyl O -
- O -
GPC O +
( O -
sn-2 O +
to O +
-1 O +
transfer O -
) O +
We O +
next O +
examined O +
whether O +
or O +
not O +
the O +
enzyme B-Gene +
utilized O +
2-acyl O -
- O -
GPC O +
as O +
the O +
substrate O -
. O +

We O +
prepared O +
2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl- O +
and O +
2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
from O +
1-stearoyl-2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
and O +
1-palmitoyl-2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O -
, O +
respectively O -
, O +
by O +
treatment O +
with O +
R. B-Gene +
arrhizus I-Gene +
lipase I-Gene +
that O +
specifically O +
cleaved O +
the O +
sn O +
-1 O +
acyl O +
residue O +
of O +
phospholipids O -
. O +

The O +
2-acyl O -
- O -
GPCs O +
thus O +
prepared O +
were O +
separated O +
by O +
two O -
- O -
dimensional O +
TLC O -
. O +

Since O +
2-acyl O -
- O -
GPC O +
is O +
known O +
to O +
be O +
gradually O +
converted O +
to O +
the O +
1-acyl O +
isomer O +
via O +
acyl O +
migration O +
in O +
vitro O +
[ O -
12,17 O -
] O +
, O +
the O +
2-acyl O -
- O -
GPC O +
extracted O +
was O +
immediately O +
used O +
for O +
the O +
assay O -
. O +

The O +
enzyme B-Gene +
was O +
incubated O +
with O +
2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
or O +
2- O -
[ O -
14 O +
C O -
] O -
palmitoyl O -
- O -
GPC O +
at O +
pH O +
6.0 O -
, O +
and O +
the O +
reaction O +
products O +
were O +
analyzed O +
by O +
two O -
- O -
dimensional O +
TLC O -
. O +

As O +
shown O +
in O +
Fig. O +
4 O +
, O +
free O +
fatty O +
acid O +
was O +
released O +
from O +
each O +
substrate O -
, O +
indicating O +
that O +
the O +
enzyme B-Gene +
can O +
hydrolyze O +
the O +
ester O +
bond O +
at O +
the O +
sn O +
-2 O +
position O -
. O +

The O +
hydrolytic O +
rate O +
for O +
2-palmitoyl O -
- O -
GPC O +
was O +
0.57 O +
μmol O -
/ O -
min O -
/ O -
mg O -
, O +
about O +
one O -
- O -
third O +
the O +
rate O +
for O +
the O +
sn O +
-1 O +
isomer O -
. O +

2-Arachidonoyl O -
- O -
GPC O +
was O +
cleaved O +
at O +
a O +
rate O +
of O +
0.4 O +
μmol O -
/ O -
min O -
/ O -
mg O -
. O +

In O +
addition O +
to O +
fatty O +
acid O -
, O +
PC O +
and O +
monoacylglycerol O +
were O +
observed O +
on O +
TLC O -
, O +
indicating O +
that O +
transacylation O +
occurred O +
from O +
2-acyl O -
- O -
GPC O +
to O +
a O +
second O +
molecule O +
of O +
2-acyl O -
- O -
GPC O -
. O +

Monoacylglycerol O +
was O +
formed O +
by O +
transacylation O +
from O +
2-acyl O -
- O -
GPC O +
to O +
glycerol O +
contained O +
in O +
the O +
enzyme B-Gene -
. O +

1,2-Diarachidonoyl O +
PC O +
was O +
synthesized O +
from O +
two O +
molecules O +
of O +
2-arachidonoyl O -
- O -
GPC O +
at O +
a O +
rate O +
of O +
0.23 O +
μmol O -
/ O -
min O -
/ O -
mg O -
, O +
almost O +
three O +
times O +
greater O +
than O +
the O +
rate O +
of O +
dipalmitoyl O +
PC O +
synthesis O +
( O -
0.082 O +
μmol O -
/ O -
min O -
/ O -
mg O -
) O -
. O +

To O +
confirm O +
the O +
above O +
results O -
, O +
we O +
used O +
an O +
alternative O +
method O -
, O +
lipase B-Gene -
- O -
coupling O +
assay O -
, O +
to O +
determine O +
the O +
sn O +
-2 O +
to O +
-1 O +
transacylase B-Gene +
activity O +
of O +
the O +
enzyme B-Gene -
. O +

This O +
method O +
utilized O +
the O +
2-acyl O -
- O -
GPC- O +
and O +
2-acyl O -
- O -
GPE O -
- O -
generating O +
systems O +
as O +
acyl O +
donor O +
and O +
acceptor O -
, O +
respectively O -
. O +

Briefly O -
, O +
1-stearoyl-2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
and O +
1,2-dioleoyl O -
- O -
GPE O +
were O +
mixed O +
with O +
Rhizopus B-Gene +
lipase I-Gene +
and O +
purified O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
and O +
incubated O -
. O +

Radioactive O +
lipid O +
products O +
were O +
separated O +
by O +
two O -
- O -
dimensional O +
TLC O +
and O +
analyzed O -
. O +

We O +
expected O +
that O +
radioactive O +
PE O -
, O +
easily O +
separable O +
from O +
the O +
substrate O +
PC O -
, O +
would O +
be O +
produced O +
by O +
transacylation O +
from O +
2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
to O +
2-oleoyl O -
- O -
GPE O +
generated O +
from O +
the O +
added O +
PC O +
and O +
PE O -
. O +

Fig. O +
5 O +
shows O +
that O +
radioactive O +
PE O +
was O +
indeed O +
formed O +
in O +
the O +
presence O +
of O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
and O +
lipase O -
. O +

However O -
, O +
when O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
was O +
omitted O -
, O +
radioactive O +
PE O +
was O +
not O +
produced O -
. O +

These O +
results O +
confirm O +
the O +
above O +
results O +
that O +
the O +
enzyme B-Gene +
mediated O +
the O +
sn O +
-2 O +
to O +
-1 O +
acyl O +
transfer O -
. O +

Furthermore O -
, O +
the O +
autoradiogram O +
shows O +
that O +
much O +
more O +
[ O -
14 O +
C O -
] O -
arachidonic O +
acid O +
was O +
released O +
from O +
1-stearoyl-2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
by O +
the O +
combined O +
action O +
of O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
and O +
Rhizopus B-Gene +
lipase I-Gene +
than O +
lipase B-Gene +
alone O -
. O +

Fig. O +
6 O +
shows O +
the O +
time O +
course O +
of O +
arachidonic O +
acid O +
release O +
from O +
1-stearoyl-2- O -
[ O -
14 O +
C O -
] O -
arachidonoyl O -
- O -
GPC O +
in O +
the O +
presence O +
of O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
and O +
Rhizopus B-Gene +
lipase I-Gene -
. O +

When O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
was O +
omitted O -
, O +
arachidonic O +
acid O +
release O +
decreased O +
greatly O -
. O +

These O +
results O +
are O +
consistent O +
with O +
the O +
above O +
findings O +
that O +
the O +
60-kDa O +
enzyme B-Gene +
mediated O +
the O +
cleavage O +
of O +
not O +
only O +
the O +
sn O +
-1 O -
, O +
but O +
also O +
sn O +
-2 O +
ester O +
bonds O -
. O +

Taken O +
together O -
, O +
the O +
results O +
indicate O +
that O +
rat O +
liver O +
60-kDa O +
lysophospholipase B-Gene +
catalyzes O +
the O +
following O +
reactions:2-arachidonoyl O +
( O -
or O +
palmitoyl O -
) O -
-GPC+H2 O +
O→arachidonic O +
acid O +
( O -
or O +
palmitic O +
acid O -
) O -
+GPC O -
, O +
2-arachidonoyl O +
or O +
( O -
palmitoyl O -
) O -
-GPC+2-arachidonoyl O +
( O -
or O +
palmitoyl O -
) O -
-GPC→1,2-diarachidonoyl O +
( O -
or O +
dipalmitoyl O -
) O -
-GPC+GPC O -
, O +
2-arachidonoyl O +
( O -
or O +
palmitoyl O -
) O -
-GPC+glycerol→arachidonoylglycerol O +
( O -
or O +
palmitoylglycerol O -
) O -
+GPC O -
, O +
2-arachidonoyl O -
- O -
GPC+2-acyl O -
- O -
GPE→1-arachidonoyl-2-acyl O -
- O -
GPE+GPC O +
. O +

4 O +
Discussion O +
Erbland O +
and O +
Marinetti O +
[ O -
1 O -
] O +
first O +
described O +
the O +
production O +
of O +
PC O +
from O +
two O +
molecules O +
of O +
lysoPC O +
in O +
liver O +
supernatant O -
. O +

This O +
activity O +
was O +
ascribed O +
to O +
a O +
second O +
activity O +
of O +
lysophospholipase B-Gene +
by O +
partial O +
purification O +
of O +
the O +
lung O +
enzyme B-Gene +
[ O -
2 O -
] O +
. O +

We O +
previously O +
observed O +
that O +
the O +
lysophospholipase B-Gene +
activity O +
of O +
liver O +
supernatant O +
was O +
separated O +
into O +
three O +
peaks O +
by O +
DEAE O -
- O -
cellulose O +
chromatography O -
. O +

The O +
first O +
and O +
second O +
peaks O +
exhibited O +
only O +
hydrolase B-Gene +
activity O -
, O +
but O +
the O +
third O +
peak O +
exhibited O +
not O +
only O +
lysophospholipase B-Gene -
, O +
but O +
also O +
transacylase B-Gene +
activities O +
[ O -
4 O -
] O +
. O +

We O +
purified O +
and O +
cloned O +
all O +
three O +
enzyme B-Gene +
peaks O +
[ O -
6,10,18 O -
] O +
. O +

The O +
lysophospholipase B-Gene +
exhibiting O +
transacylase B-Gene -
, O +
named O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene -
, O +
comprised O +
564 O +
amino O +
acid O +
residues O +
with O +
a O +
molecular O +
mass O +
of O +
60 O +
794 O +
Da O -
. O +

The O +
present O +
investigation O +
showed O +
that O +
the O +
enzyme B-Gene +
can O +
catalyze O +
three O +
types O +
of O +
transacylation O +
reactions O -
: O +
( O -
1 O -
) O +
acyl O +
transfer O +
from O +
1-acyl O -
- O -
GPC O +
to O +
the O +
sn O +
-1 O -
( O -
3 O -
) O +
positions O +
of O +
glycerol O +
and O +
2-acylglycerol O +
( O -
sn O +
-1 O +
to O +
-1 O -
( O -
3 O -
) O +
transfer O -
) O -
; O +
( O -
2 O -
) O +
acyl O +
transfer O +
from O +
1-acyl O -
- O -
GPC O +
to O +
the O +
sn O +
-2 O +
positions O +
of O +
1-acyl O -
- O -
GPC O -
, O +
1-acyl O -
- O -
GPE O -
, O +
and O +
other O +
lysophospholipids O +
( O -
sn O +
-1 O +
to O +
-2 O +
transfer O -
) O -
; O +
and O +
( O -
3 O -
) O +
acyl O +
transfer O +
from O +
2-acyl O -
- O -
GPC O +
to O +
the O +
sn O +
-1 O +
position O +
of O +
2-acyl O -
- O -
GPC O +
and O +
2-acyl O -
- O -
GPE O +
( O -
sn O +
-2 O +
to O +
-1 O +
transfer O -
) O -
. O +

The O +
sn O +
-1 O +
to O +
-2 O +
transfer O +
from O +
1-acyl O +
lysophospholipid O +
to O +
a O +
second O +
molecule O +
of O +
1-acyl O +
lysophospholipid O +
is O +
a O +
well O -
- O -
known O +
activity O +
of O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
[ O -
1,2,4,5 O -
] O +
. O +

Since O +
fatty O +
acid O +
esterified O +
at O +
the O +
sn O +
-1 O +
position O +
is O +
normally O +
saturated O +
[ O -
19 O -
] O +
, O +
this O +
activity O +
was O +
thought O +
to O +
be O +
important O +
for O +
the O +
synthesis O +
of O +
disaturated O +
species O +
of O +
phospholipids O +
abundantly O +
found O +
in O +
pulmonary O +
surfactant O +
[ O -
3,19 O -
] O +
. O +

The O +
other O +
two O +
activities O -
, O +
the O +
sn O +
-1 O +
to O +
-1 O -
( O -
3 O -
) O +
and O +
sn O +
-2 O +
to O +
-1 O +
transfers O -
, O +
had O +
not O +
been O +
previously O +
described O +
for O +
lysophospholipase B-Gene -
. O +

It O +
is O +
interesting O +
to O +
note O +
that O +
cytoplasmic O +
phospholipase O +
A2 O +
, O +
which O +
also O +
exhibits O +
lysophospholipase B-Gene +
activity O -
, O +
was O +
reported O +
to O +
mediate O +
a O +
similar O +
transacylation O +
reaction O -
, O +
the O +
acylation O +
of O +
glycerol O +
with O +
1-palmitoyl O -
- O -
GPC O +
[ O -
20 O -
] O +
. O +

The O +
sn O +
-2 O +
to O +
-1 O +
transfer O +
activity O +
of O +
60-kDa O +
lysophospholipase B-Gene +
is O +
of O +
special O +
interest O -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
this O +
activity O +
had O +
not O +
been O +
reported O +
for O +
any O +
other O +
transacylases B-Gene -
. O +

Mammalian O +
cells O +
possess O +
the O +
phospholipid O +
remodeling O +
system O +
to O +
modify O +
the O +
fatty O +
acid O +
composition O +
of O +
the O +
newly O +
synthesized O +
phospholipids O -
. O +

Arachidonic O +
acid O +
is O +
incorporated O +
into O +
phospholipids O +
by O +
such O +
remodeling O +
systems O +
at O +
the O +
sn O +
-2 O +
position O +
of O +
the O +
glycerol O +
backbone O -
. O +

All O +
the O +
known O +
transacylases B-Gene +
involved O +
in O +
phospholipid O +
remodeling O +
introduce O +
arachidonic O +
acid O +
into O +
the O +
sn O +
-2 O +
position O +
to O +
form O +
2-arachidonoyl O +
phospholipids O -
. O +

Lysophospholipid O +
acyltransferase B-Gene +
acylates O +
the O +
sn O +
-2 O +
position O +
of O +
1-acyl O +
lysophospholipids O +
with O +
arachidonoyl O -
- O -
CoA O +
[ O -
21,22 O -
] O +
. O +

CoA O -
- O -
dependent O +
transacylase B-Gene +
which O +
utilizes O +
the O +
existing O +
diacyl O +
phospholipids O +
as O +
acyl O +
donor O +
also O +
transfers O +
arachidonic O +
acid O +
to O +
the O +
sn O +
-2 O +
position O +
of O +
1-acyl O +
lysophospholipids O +
[ O -
23,24 O -
] O +
. O +

CoA O -
- O -
independent O +
transacylase B-Gene +
catalyzes O +
the O +
incorporation O +
of O +
arachidonic O +
acid O +
from O +
the O +
sn O +
-2 O +
position O +
of O +
phospholipid O +
to O +
the O +
sn O +
-2 O +
position O +
of O +
1-alkyl O -
- O -
GPC O +
[ O -
25 O -
] O +
or O +
1-alkenyl O -
- O -
GPE O +
[ O -
26 O -
] O +
. O +

Thus O -
, O +
60-kDa O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene +
is O +
unique O +
in O +
its O +
ability O +
to O +
synthesize O +
1-arachidonoyl O +
species O +
of O +
phospholipids O +
by O +
transferring O +
the O +
arachidonoyl O +
residue O +
from O +
2-arachidonoyl O +
lysophospholipid O +
to O +
the O +
sn O +
-1 O +
position O +
of O +
2-acyl O +
lysophospholipid O -
. O +

Although O +
1-arachidonoyl O +
species O +
of O +
phospholipids O +
are O +
rather O +
rare O +
in O +
mammalian O +
tissues O -
, O +
they O +
may O +
play O +
important O +
roles O +
in O +
cellular O +
functions O -
. O +

For O +
example O -
, O +
1-arachidonoyl O +
PC O +
is O +
required O +
for O +
the O +
synthesis O +
of O +
the O +
intrinsic O +
cannabinol B-Gene +
receptor I-Gene +
ligand O -
, O +
arachidonoylethanolamide O +
or O +
anandamide O +
which O +
plays O +
crucial O +
roles O +
in O +
brain O +
and O +
other O +
tissues O +
[ O -
27 O -
] O +
. O +

Anandamide O +
is O +
produced O +
from O +
N O +
-arachidonoyl O -
- O -
PE O +
by O +
the O +
phospholipase B-Gene +
D I-Gene -
- O -
mediated O +
phosphodiester O +
bond O +
cleavage O +
[ O -
13,14,28 O -
] O +
. O +

N O +
-Arachidonoyl O -
- O -
PE O +
is O +
synthesized O +
by O +
the O +
transfer O +
of O +
the O +
arachidonoyl O +
residue O +
from O +
1-arachidonoyl O +
PC O +
to O +
the O +
ethanolamine O +
moiety O +
of O +
PE O +
[ O -
13,29 O -
] O +
. O +

However O -
, O +
the O +
mechanism O +
of O +
1-arachidonoyl O +
PC O +
formation O +
had O +
not O +
been O +
clarified O -
. O +

The O +
present O +
study O +
showed O +
that O +
1-arachidonoyl O +
PC O +
can O +
be O +
produced O +
from O +
2-arachidonoyl O -
- O -
GPC O +
by O +
the O +
sn O +
-2 O +
to O +
-1 O +
transacylation O +
activity O +
of O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene -
. O +

Pete O +
et O +
al. O +
[ O -
30,31 O -
] O +
showed O +
that O +
the O +
brain O +
tissue O +
contained O +
a O +
high O +
level O +
of O +
phospholipase B-Gene +
A1 I-Gene +
and O +
possessed O +
the O +
PC O +
degradation O +
pathway O +
by O +
which O +
PC O +
was O +
sequentially O +
deacylated O +
first O +
by O +
phospholipase B-Gene +
A1 I-Gene +
and O +
then O +
by O +
lysophospholipase B-Gene -
. O +

Thus O -
, O +
it O +
is O +
very O +
likely O +
that O +
2-arachidonoyl O -
- O -
GPC O +
is O +
formed O +
as O +
the O +
intermediate O +
of O +
PC O +
degradation O +
in O +
brain O +
and O +
probably O +
in O +
other O +
tissues O +
as O +
well O -
, O +
and O +
utilized O +
for O +
the O +
synthesis O +
of O +
1-arachidonoyl O +
species O +
of O +
PC O +
by O +
lysophospholipase B-Gene -
- I-Gene -
transacylase I-Gene -
. O +

A O +
highly O +
sensitive O +
and O +
specific O +
fluorimetric O +
method O +
was O +
developed O +
for O +
the O +
determination O +
of O +
oxamniquine O +
in O +
biological O +
fluids O +
( O -
urine O +
and O +
plasma O -
) O -
. O +

The O +
proposed O +
method O +
is O +
based O +
on O +
the O +
reduction O +
of O +
oxamniquine O +
using O +
zinc O -
/ O -
calcium O +
chloride O +
to O +
obtain O +
its O +
nitroso O +
derivative O -
. O +

The O +
latter O +
is O +
then O +
allowed O +
to O +
react O +
with O +
2-cyanoacetamide O +
to O +
get O +
a O +
highly O +
fluorescent O +
product O -
. O +

The O +
different O +
experimental O +
parameters O +
affecting O +
the O +
intensity O +
of O +
the O +
fluorescence O +
were O +
carefully O +
studied O +
and O +
incorporated O +
into O +
the O +
procedure O -
. O +

Under O +
the O +
described O +
conditions O -
, O +
the O +
method O +
is O +
applicable O +
over O +
the O +
concentration O +
range O +
of O +
0.08 O -
- O -
0.88 O +
microgram O -
/ O -
ml O +
with O +
a O +
minimum O +
detectability O +
( O -
S O -
/ O -
N O +
= O +
2 O -
) O +
of O +
8 O +
ng O -
/ O -
ml O -
. O +

The O +
percentage O +
recoveries O +
from O +
spiked O +
urine O +
and O +
plasma O +
were O +
99.75 O +
+ O -
/- O +

1.58 O +
and O +
97.46 O +
+ O -
/- O +

0.44 O -
% O -
, O +
respectively O -
. O +

Up O +
to O +
now O -
, O +
different O +
methods O +
in O +
guinea O +
pig O +
sensitization O +
were O +
used O -
, O +
to O +
assess O +
contact O +
sensitization O +
potential O +
of O +
low O +
molecular O +
weight O +
chemicals O -
. O +

In O +
order O +
to O +
compare O +
the O +
efficiency O +
of O +
the O +
epicutaneous O -
, O +
intradermal O +
and O +
combined O +
sensitization O +
methods O -
, O +
two O +
stronger O +
sensitizers O -
, O +
the O +
water O +
soluble O +
chlormethylimidazoline O +
hydrochloride O +
( O -
CMI O -
) O +
and O +
the O +
lipid O +
soluble O +
1,3-dinitrochlorobenzene O +
( O -
DNCB O -
) O +
were O +
used O +
for O +
the O +
experiments O -
. O +

Eleven O +
modified O +
sensitization O +
methods O +
were O +
performed O -
. O +

In O +
a O +
first O +
trial O +
each O +
substance O +
was O +
tested O +
on O +
10 O +
animals O -
. O +

In O +
a O +
further O +
study O +
those O +
techniques O +
which O +
had O +
produced O +
the O +
best O +
results O -
, O +
that O +
is O +
the O +
highest O +
degree O +
of O +
sensitization O -
, O +
were O +
applied O +
to O +
25 O +
to O +
30 O +
animals O -
. O +

For O +
comparison O +
of O +
the O +
results O +
of O +
the O +
various O +
methods O -
, O +
a O +
mean O +
sensitization O +
index O +
was O +
calculated O -
. O +

The O +
best O +
results O +
were O +
achieved O +
with O +
the O +
Maximization O +
Test O +
of O +
Magnusson O +
& O +
Kligman O +
( O -
1969 O -
) O +
and O +
the O +
Split O +
Adjuvant O +
Technique O +
of O +
Maguire O +
& O +
Chase O +
( O -
1967 O -
) O -
. O +

Cytochromes B-Gene +
P-450 I-Gene +
( O -
P450 O -
) O +
catalyse O +
terminal O +
( O -
ω O +
) O +
and O +
subterminal O +
( O -
ω O +
-1 O +
to O +
ω O +
-6 O -
) O +
hydroxylations O +
of O +
fatty O +
acids O +
in O +
microorganisms O -
, O +
plants O -
, O +
insects O -
, O +
non O -
- O -
mammalian O +
vertebrates O -
, O +
and O +
mammals O -
. O +

These O +
activities O +
are O +
mediated O +
by O +
several O +
members O +
of O +
the O +
CYP4 B-Gene +
family O +
in O +
mammals O +
[ O -
16 O -
] O +
. O +

In O +
addition O -
, O +
some O +
CYP2 B-Gene +
isoforms O +
are O +
involved O +
in O +
lauric O +
acid O +
subterminal O +
hydroxylations O +
in O +
fish O +
[ O -
4 O -
] O +
. O +

The O +
CYP4 B-Gene +
isozymes B-Gene +
have O +
been O +
characterized O +
in O +
several O +
organs O +
such O +
as O +
liver O -
, O +
kidney O -
, O +
lung O -
, O +
colon O -
, O +
and O +
small O +
intestine O -
. O +

Cloning O +
and O +
heterologous O +
expression O +
of O +
many O +
of O +
them O +
demonstrate O +
their O +
involvement O +
in O +
the O +
oxidation O +
of O +
fatty O +
acids O -
, O +
prostaglandins O +
and O +
leukotrienes O -
, O +
mainly O +
at O +
the O +
ω O +
position O +
in O +
mammals O +
[ O -
16 O -
] O +
. O +

The O +
physiological O +
role O +
of O +
fatty B-Gene +
acid I-Gene +
hydroxylases I-Gene +
remains O +
unclear O -
. O +

Several O +
lines O +
of O +
evidence O +
indicate O +
that O +
oxygenated O +
polyunsaturated O +
fatty O +
acids O +
act O +
as O +
modulators O +
of O +
various O +
cell O +
functions O +
[ O -
24 O -
] O +
. O +

Ortiz O +
de O +
Montellano O +
and O +
Reich O +
[ O -
25 O -
] O +
described O +
fatty O +
acid O +
acetylenic O +
analogues O +
which O +
selectively O +
inhibit O +
P450 B-Gene +
activities O +
based O +
on O +
their O +
substrate O +
specificity O -
. O +

Such O +
inhibitors O +
have O +
been O +
used O +
successfully O +
to O +
investigate O +
the O +
functional O +
role O +
of O +
several O +
fatty B-Gene +
acid I-Gene +
hydroxylases I-Gene +
[ O -
9,40 O -
] O +
. O +

P450 B-Gene +
expression O +
is O +
induced O +
by O +
numerous O +
drugs O +
and O +
chemicals O +
[ O -
22 O -
] O +
. O +

Peroxisome O +
proliferators O -
, O +
such O +
as O +
hypolipidemic O +
drugs O +
( O -
fibrates O -
) O -
, O +
herbicides O +
( O -
2,4-dichlorophenoxyacetic O +
acid O -
) O -
, O +
and O +
phthalate O +
ester O +
plasticizers O +
( O -
DEHP O -
) O +
induce O +
ω O +
-hydroxylation O +
of O +
fatty O +
acids O +
in O +
rodents O +
and O +
increase O +
expression O +
of O +
several O +
mammalian O +
CYP4 B-Gene +
genes O +
[ O -
2,22,23 O -
] O +
. O +

Fatty B-Gene +
acid I-Gene +
hydroxylase I-Gene +
activities O +
from O +
other O +
organisms O -
, O +
such O +
as O +
plants O +
[ O -
26 O -
] O +
and O +
bacteria O +
[ O -
6 O -
] O +
, O +
are O +
also O +
sensitive O +
to O +
peroxisome O +
proliferators O -
. O +

Most O +
of O +
the O +
CYP2 B-Gene +
isozymes B-Gene +
are O +
not O +
induced O +
by O +
peroxisome O +
proliferators O -
, O +
but O +
by O +
other O +
class O +
of O +
xenobiotics O +
such O +
as O +
phenobarbital O +
[ O -
22 O -
] O +
. O +

Most O +
investigations O +
involving O +
fish O +
P450 B-Gene +
have O +
concerned O +
activities O +
toward O +
environmental O +
pollutants O -
, O +
such O +
as O +
polycyclic O +
aromatic O +
hydrocarbons O +
( O -
PAHs O -
) O +
and O +
polychlorobiphenyls O +
( O -
PCBs O -
) O -
, O +
or O +
endogenous O +
substrates O +
( O -
steroids O -
) O -
. O +

Limited O +
information O +
is O +
available O +
about O +
LAH O +
activities O +
in O +
fish O -
. O +

Previous O +
studies O +
by O +
Lemaire O +
et O +
al. O +
[ O -
17 O -
] O +
have O +
shown O +
that O +
starvation O +
increases O +
LAH O +
activities O +
in O +
sea O +
bass O +
liver O -
, O +
as O +
reported O +
for O +
rat O +
[ O -
11 O -
] O +
. O +

A O +
recent O +
report O +
by O +
Buhler O +
et O +
al. O +
[ O -
4 O -
] O +
indicates O +
that O +
both O +
trout O +
liver O +
microsomes O +
and O +
purified O +
CYP2K1 B-Gene +
protein I-Gene +
hydroxylate O +
lauric O +
acid O +
at O +
several O +
subterminal O +
positions O -
. O +

A O +
cDNA O +
fragment O +
was O +
recently O +
isolated O +
from O +
rainbow O +
trout O +
liver O +
and O +
classified O +
in O +
the O +
CYP4 B-Gene +
gene O +
family O +
( O -
CYP4T1 O -
, O +
[ O -
7 O -
] O +
) O -
. O +

Surprisingly O -
, O +
Scarano O +
et O +
al. O +
[ O -
28 O -
] O +
, O +
and O +
Miranda O +
et O +
al. O +
[ O -
18 O -
] O +
reported O +
that O +
rainbow O +
trout O +
was O +
insensitive O +
to O +
peroxisome O +
proliferators O +
( O -
gemfibrozil O -
, O +
dehydroepiandrosterone O -
) O -
, O +
compounds O +
which O +
are O +
known O +
to O +
induce O +
P450-dependent B-Gene +
hydroxylation O +
of O +
fatty O +
acids O +
and O +
peroxisome O +
proliferation O +
in O +
rodents O +
[ O -
37 O -
] O +
. O +

With O +
the O +
aim O +
of O +
developing O +
new O +
biological O +
markers O +
specific O +
for O +
another O +
class O +
of O +
chemical O +
pollutants O +
( O -
peroxisome O +
proliferators O -
, O +
especially O +
the O +
phthalates O -
) O -
, O +
we O +
have O +
studied O +
the O +
effect O +
of O +
these O +
compounds O +
on O +
the O +
cytochrome B-Gene +
P450-dependent I-Gene +
LAH O +
activities O +
in O +
sea O +
bass O +
( O -
Dicentrarchus O +
labrax O -
) O +
tissues O -
. O +

LAH O +
activities O +
and O +
the O +
ratios O +
of O +
each O +
metabolite O +
formed O +
were O +
compared O +
for O +
liver O -
, O +
kidney O +
and O +
small O +
intestine O +
microsomes O +
from O +
control O +
or O +
fish O +
treated O +
with O +
peroxisome O -
- O -
proliferators O +
( O -
clofibrate O +
and O +
DEHP O -
) O -
. O +

In O +
addition O -
, O +
microsomes O +
from O +
liver O +
and O +
kidney O +
were O +
incubated O +
with O +
a O +
series O +
of O +
lauric O +
acid O +
analogues O +
containing O +
terminal O +
and O +
internal O +
acetylenes O -
, O +
9-dodecynoic O +
( O -
9-DDYA O -
) O -
, O +
10-dodecynoic O +
( O -
10-DDYA O -
) O +
and O +
11-dodecynoic O +
( O -
11-DDYA O -
) O +
acids O -
, O +
in O +
order O +
to O +
compare O +
inactivation O +
kinetics O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Chemicals O +
Clofibrate O -
, O +
DEHP O -
, O +
NADPH O -
, O +
glucose-6-phosphate O +
( O -
G-6-P O -
) O -
, O +
and O +
yeast O +
glucose-6-phosphate B-Gene +
dehydrogenase I-Gene +
( O -
G-6-PDH B-Gene -
) O +
were O +
purchased O +
from O +
Sigma O -
– O -
Aldrich O +
Chimie O +
( O -
France O -
) O -
. O +

[ O -
1 O -
- O -
14 O +
C O -
] O -
lauric O +
acid O +
( O -
2.19 O -
× O -
1012 O +
Bq O +
mol−1 O +
) O +
was O +
from O +
the O +
Commissariat O +
à O +
l'Energie O +
Atomique O +
( O -
CEA O -
, O +
Gif O +
sur O +
Yvette O -
, O +
France O -
) O -
. O +

Acetonitrile O +
( O -
HPLC O +
grade O -
) O +
and O +
silica O +
gel O +
plates O +
were O +
from O +
Merck O +
( O -
Darmstadt O -
, O +
Germany O -
) O -
. O +

11-DDYA O -
, O +
10-DDYA O +
and O +
9-DDYA O +
were O +
synthesized O +
from O +
1-bromo-6-hexanol O -
, O +
1-bromo-7-heptanol O +
and O +
1-bromo-9-nonanol O -
, O +
respectively O -
, O +
according O +
to O +
Alayrac O +
et O +
al. O +
[ O -
1 O -
] O +
. O +

2.2 O +
Fish O +
Sexually O +
immature O +
sea O +
bass O +
( O -
D. O +
labrax O +
, O +
100–200 O +
g O -
) O +
were O +
obtained O +
from O +
the O +
fish O +
farm O +
' O -
Théoule O +
Aquaculture O -
' O +
( O -
France O -
) O +
and O +
placed O +
in O +
aquaria O +
containing O +
120 O +
l O +
of O +
artificial O +
sea O +
water O +
( O -
salinity O +
28‰ O -
) O +
at O +
18 O -
° O -
C O -
. O +

An O +
acclimation O +
period O +
of O +
at O +
least O +
2 O +
weeks O +
was O +
needed O +
to O +
reduce O +
stress O -
- O -
related O +
responses O -
. O +

Three O +
groups O +
of O +
ten O +
fish O +
were O +
treated O +
for O +
3 O +
days O +
by O +
daily O +
intraperitoneal O +
injection O +
of O +
clofibrate O +
( O -
100 O +
mg O +
( O -
kg O +
body O +
weight O -
) O -
−1 O +
day−1 O +
, O +
in O +
NaCl O +
0.9 O -
% O -
) O -
, O +
DEHP O +
( O -
1.5 O +
g O +
( O -
kg O +
body O +
weight O -
) O -
−1 O +
day−1 O +
, O +
in O +
NaCl O +
0.9 O -
% O -
) O +
or O +
NaCl O +
0.9 O -
% O +
( O -
control O -
) O -
. O +

2.3 O +
Sample O +
preparation O +
Fish O +
were O +
sacrificed O +
by O +
severing O +
their O +
spinal O +
cord O -
, O +
and O +
liver O -
, O +
kidney O -
, O +
and O +
intestinal O +
mucosa O +
were O +
collected O +
and O +
rinsed O +
in O +
ice O -
- O -
cold O +
150 O +
mM O +
KCl O -
. O +

Tissues O +
were O +
homogenized O +
in O +
5 O +
vol O -
. O +

of O +
buffer O +
A O +
( O -
250 O +
mM O +
sucrose O -
, O +
10 O +
mM O +
Hepes O -
, O +
pH O +
7.4 O -
) O -
, O +
containing O +
1 O +
mM O +
EDTA O -
, O +
1 O +
mM O +
PMSF O +
and O +
1 O +
mM O +
DTT O -
. O +

Homogenates O +
were O +
centrifuged O +
at O +
9000 O -
× O -
g O +
for O +
15 O +
min O +
at O +
4 O -
° O -
C O -
. O +

Resulting O +
supernatants O +
were O +
then O +
centrifuged O +
at O +
100 O +
000 O -
× O -
g O +
for O +
90 O +
min O +
at O +
4 O -
° O -
C O -
. O +

Microsomal O +
pellets O +
were O +
resuspended O +
in O +
buffer O +
A O +
containing O +
20 O -
% O +
glycerol O +
( O -
v O -
/ O -
v O -
) O -
, O +
and O +
stored O +
at O +
−70 O -
° O -
C O -
. O +

Protein B-Gene +
concentrations O +
were O +
determined O +
according O +
to O +
the O +
Bradford O -
's O +
method O -
, O +
with O +
BSA B-Gene +
as O +
a O +
standard O -
. O +

2.4 O +
Enzyme B-Gene +
activities O +
LAH B-Gene +
activities O +
were O +
measured O +
as O +
previously O +
described O +
by O +
Weissbart O +
et O +
al. O +
[ O -
35 O -
] O +
. O +

All O +
assays O +
were O +
carried O +
out O +
at O +
28 O -
° O -
C O +
in O +
a O +
final O +
reaction O +
mixture O +
of O +
0.2 O +
ml O +
containing O +
50 O +
μM O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
lauric O +
acid O -
, O +
0.02 O +
M O +
sodium O +
phosphate O +
buffer O +
pH O +
7.4 O -
, O +
0.1–0.2 O +
mg O +
microsomal O +
proteins B-Gene -
, O +
and O +
1 O +
mM O +
NADPH O +
plus O +
a O +
regenerating O +
system O +
( O -
consisting O +
of O +
1 O +
mM O +
β O +
-NADP O -
, O +
6.7 O +
mM O +
G-6-P O -
, O +
and O +
0.4 O +
IU O +
of O +
G-6-PDH B-Gene +
final O +
concentrations O -
) O -
. O +

The O +
reaction O +
was O +
stopped O +
after O +
20 O +
min O +
by O +
addition O +
of O +
0.2 O +
ml O +
of O +
ice O -
- O -
cold O +
acetonitrile O +
containing O +
0.2 O -
% O +
acetic O +
acid O -
. O +

Proteins B-Gene +
were O +
pelleted O +
by O +
rapid O +
centrifugation O +
( O -
13 O +
000 O -
× O -
g O +
, O +
2 O +
min O -
) O +
and O +
0.1 O +
ml O +
of O +
supernatant O +
was O +
injected O +
into O +
a O +
RP O -
- O -
HPLC O +
column O +
or O +
spotted O +
on O +
silica O +
gel O +
plates O -
. O +

Total O +
specific O +
activity O +
( O -
nmol O +
min−1 O +
mg−1 O +
of O +
microsomal O +
proteins B-Gene -
) O +
was O +
calculated O +
by O +
adding O +
the O +
amounts O +
of O +
each O +
metabolite O +
formed O -
. O +

2.5 O +
Inactivation O +
with O +
mechanism O -
- O -
based O +
inhibitors O +
Five O +
livers O +
or O +
kidneys O +
from O +
DEHP- O +
or O +
clofibrate O -
- O -
treated O +
fish O +
were O +
pooled O +
and O +
homogenized O +
prior O +
to O +
microsomes O +
preparation O -
. O +

Microsomes O +
were O +
first O +
preincubated O +
at O +
28 O -
° O -
C O +
with O +
1 O +
mM O +
NADPH O +
and O +
the O +
regenerating O +
system O +
described O +
above O -
, O +
in O +
the O +
presence O +
of O +
various O +
concentrations O +
( O -
20 O -
, O +
40 O -
, O +
60 O +
or O +
80 O +
μM O -
) O +
of O +
inhibitor O +
( O -
9-DDYA O -
, O +
10-DDYA O +
or O +
11-DDYA O -
) O +
as O +
described O +
by O +
Salaün O +
et O +
al. O +
[ O -
27 O -
] O +
. O +

Mixtures O +
containing O +
no O +
n O -
- O -
DDYA O +
or O +
no O +
NADPH O +
served O +
as O +
controls O -
. O +

One O +
hundred O +
microliters O +
of O +
aliquots O +
of O +
preincubated O +
microsomes O +
were O +
removed O +
at O +
different O +
intervals O +
( O -
0 O -
, O +
6 O -
, O +
10 O -
, O +
20 O +
and O +
30 O +
min O -
) O +
and O +
transferred O +
to O +
incubation O +
mixtures O +
containing O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
lauric O +
acid O -
, O +
as O +
described O +
above O -
, O +
in O +
a O +
final O +
volume O +
of O +
0.2 O +
ml O -
. O +

Mixtures O +
were O +
further O +
incubated O +
at O +
28 O -
° O -
C O +
for O +
5 O +
min O +
to O +
measure O +
residual O +
activities O +
of O +
lauric O +
acid O +
hydroxylation O -
, O +
and O +
the O +
reactions O +
were O +
stopped O +
by O +
adding O +
0.2 O +
ml O +
of O +
ice O -
- O -
cold O +
acetonitrile O +
containing O +
0.2 O -
% O +
acetic O +
acid O -
. O +

Metabolites O +
( O -
100 O +
μl O +
aliquots O -
) O +
were O +
resolved O +
by O +
silica O +
thin O -
- O -
layer O +
chromatography O +
developed O +
with O +
diethyl O +
ether O -
/ O -
light O +
petroleum O +
( O -
bp O +
40–60 O -
° O -
) O -
/ O -
formic O +
acid O +
( O -
70:30:1 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O -
. O +

Radioactive O +
products O +
were O +
located O +
by O +
autoradiography O -
, O +
scraped O +
into O +
counting O +
vials O -
, O +
and O +
the O +
radioactivity O +
was O +
measured O +
with O +
a O +
liquid O +
scintillation O +
counter O +
( O -
Wallac O +
1410 O -
, O +
EG&G O -
) O -
. O +

2.6 O +
HPLC O +
conditions O +
RP O -
- O -
HPLC O +
analysis O +
was O +
performed O +
using O +
an O +
Alltima O +
C18 O +
column O +
( O -
15 O +
cm O -
× O -
4.6 O +
mm O -
, O +
Alltech O -
) O +
at O +
1.5 O +
ml O +
min−1 O +
with O +
acetic O +
acid O -
/ O -
0.2 O -
% O +
water O +
and O +
a O +
linear O +
gradient O +
of O +
acetonitrile O +
from O +
44 O -
% O +
to O +
97 O -
% O +
over O +
a O +
37-min O +
period O -
. O +

The O +
HPLC O +
eluate O +
containing O +
radioactive O +
metabolites O +
was O +
passed O +
through O +
a O +
Flow O -
- O -
One O +
Beta O +
radioactive O +
flow O +
detector O +
( O -
Radiomatic O -
) O +
to O +
quantify O +
each O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
hydroxylated O +
product O +
formed O -
. O +

2.7 O +
GC O -
/ O -
MS O +
analysis O +
Compounds O +
isolated O +
by O +
RP O -
- O -
HPLC O +
were O +
chemically O +
hydrogenated O +
( O -
H2 O +
and O +
Pd O -
/ O -
charcoal O -
) O +
as O +
described O +
by O +
Weissbart O +
et O +
al. O +
[ O -
35 O -
] O +
, O +
and O +
reanalysed O +
by O +
RP O -
- O -
HPLC O +
to O +
verify O +
peak O +
collection O +
before O +
mass O +
spectra O +
analysis O -
. O +

GC O +
and O +
electron O +
impact O +
( O -
70 O +
eV O -
) O +
ionization O +
mass O +
spectrometry O +
analyses O +
were O +
performed O +
as O +
described O +
elsewhere O +
[ O -
35 O -
] O +
. O +

Characteristic O +
fragment O +
ions O +
generated O +
from O +
positional O +
isomers O +
of O +
n O -
- O -
monohydroxylated O +
lauric O +
acids O +
were O +
identified O +
as O +
previously O +
described O +
[ O -
9,17 O -
] O +
. O +

2.8 O +
Statistical O +
analysis O +
Significance O +
of O +
differences O +
( O -
for O +
each O +
metabolite O +
formed O -
) O +
between O +
controls O +
and O +
treated O +
fish O +
groups O +
was O +
evaluated O +
using O +
the O +
non O -
- O -
parametric O +
Kruskal O -
– O -
Wallis O +
test O +
[ O -
15 O -
] O +
at O +
P O +
< O -
0.005 O +
level O -
. O +

Groups O +
were O +
then O +
compared O +
by O +
pairs O +
using O +
the O +
Mann O -
– O -
Whitney O +
test O +
( O -
P O +
< O -
0.05 O -
) O -
. O +

3 O +
Results O +
3.1 O +
Characterization O +
of O +
lauric B-Gene +
acid I-Gene +
hydroxylase I-Gene +
activities O +
from O +
liver O -
, O +
kidney O -
, O +
and O +
intestinal O +
microsomes O +
Microsomal O +
LAH O +
activities O +
from O +
liver O -
, O +
kidney O -
, O +
and O +
intestinal O +
mucosa O +
were O +
O2 O +
- O +
and O +
NADPH O -
- O -
dependent O +
and O +
were O +
inhibited O +
in O +
the O +
presence O +
of O +
a O +
CO O -
/ O -
O2 O +
mixture O +
suggesting O +
the O +
involvement O +
of O +
cytochrome B-Gene +
P-450 I-Gene +
in O +
these O +
reactions O +
( O -
data O +
not O +
shown O -
) O -
. O +

Products O +
of O +
lauric O +
acid O +
hydroxylation O +
were O +
resolved O +
by O +
RP O -
- O -
HPLC O +
analysis O +
into O +
five O +
radiolabelled O +
metabolites O -
. O +

Retention O +
times O +
were O +
compared O +
with O +
those O +
of O +
standards O +
and O +
methylester O +
trimethylsilylether O +
derivatives O +
of O +
metabolites O +
were O +
further O +
identified O +
by O +
a O +
GC O -
- O -
MS O +
analysis O +
( O -
previously O +
reported O +
by O +
Lemaire O +
et O +
al. O +
[ O -
17 O -
] O +
) O +
as O +
( O -
ω O +
-1 O -
) O -
- O -
, O +
( O -
ω O +
-2 O -
) O -
- O -
, O +
( O -
ω O +
-3 O -
) O -
- O -
, O +
( O -
ω O +
-4 O -
) O -
- O +
and O +
ω O +
-hydroxylauric O +
acids O -
, O +
respectively O -
. O +

Mass O +
spectra O +
of O +
the O +
methyl O +
ester O +
and O +
trimethylsilyl O +
( O -
TMS O -
) O +
derivatives O +
showed O +
typical O +
fragment O +
ions O +
expected O +
from O +
monohydroxylated O +
fatty O +
acids O +
at O +
m O -
/ O -
z O +
†287 O +
[ O -
M-15 O -
] O -
+ O +
, O +
m O -
/ O -
z O +
271 O +
[ O -
M-31 O -
] O -
+ O +
, O +
m O -
/ O -
z O +
255 O +
[ O -
M-47 O -
] O -
+ O +
, O +
m O -
/ O -
z O +
146 O +
[ O -
CH2 O +
= O -
C O -
( O -
OSi- O -
( O -
CH3 O +
) O -
3 O +
) O -
OCH3 O +
] O -
+ O +
, O +
m O -
/ O -
z O +
159 O +
[ O -
( O -
CH3 O +
O O -
= O -
C O -
( O -
OSi- O -
( O -
CH3 O +
) O -
3 O +
) O -
CH O -
= O -
CH2 O +
] O -
+ O +
, O +
and O +
the O +
base O +
peak O +
at O +
m O -
/ O -
z O +
73 O +
( O -
TMS O -
) O -
, O +
which O +
were O +
commonly O +
present O +
in O +
all O +
hydroxylated O +
lauric O +
acid O +
metabolites O -
. O +

The O +
same O +
results O +
were O +
obtained O +
for O +
metabolites O +
generated O +
by O +
the O +
three O +
organs O +
from O +
untreated O +
or O +
clofibrate- O +
and O +
DEHP O -
- O -
treated O +
fish O -
. O +

In O +
all O +
cases O -
, O +
all O +
five O +
hydroxylauric O +
acids O +
are O +
generated O -
, O +
indicating O +
that O +
the O +
site O -
- O -
specific O +
oxidative O +
attack O +
of O +
lauric O +
acid O +
remains O +
unchanged O -
. O +

Only O +
the O +
relative O +
proportion O +
of O +
metabolites O +
was O +
changed O +
in O +
terms O +
of O +
organs O +
and O +
fish O +
treatments O -
. O +

Hence O -
, O +
microsomes O +
from O +
liver O -
, O +
kidney O -
, O +
and O +
intestine O +
catalyzed O +
mainly O +
( O -
ω O +
-1 O -
) O -
- O +
and O +
( O -
ω O +
-2 O -
) O -
-hydroxylations O +
of O +
lauric O +
acid O +
( O -
Table O +
1 O +
) O -
. O +

In O +
intestine O -
, O +
( O -
ω O +
-1 O -
) O -
-hydroxylauric O +
acid O +
represents O +
up O +
to O +
72 O -
% O +
of O +
the O +
metabolites O -
. O +

Three O +
other O +
metabolites O +
including O +
ω- O +
, O +
( O -
ω O +
-3 O -
) O -
- O +
and O +
( O -
ω O +
-4 O -
) O -
-hydroxylauric O +
acids O +
were O +
produced O +
to O +
a O +
lesser O +
extent O +
in O +
all O +
tissues O -
. O +

3.2 O +
Tissue O -
- O -
specific O +
induction O +
of O +
LAH B-Gene +
activities O +
by O +
clofibrate O +
and O +
DEHP O +
The O +
microsomal O +
LAH B-Gene +
activities O +
from O +
the O +
three O +
organs O +
were O +
measured O +
in O +
clofibrate- O +
and O +
DEHP O -
- O -
treated O +
sea O +
bass O +
and O +
compared O +
to O +
activities O +
measured O +
in O +
control O +
fish O -
. O +

Intestinal O +
LAH B-Gene +
activity O +
was O +
not O +
induced O +
by O +
clofibrate O +
or O +
DEHP O +
( O -
data O +
not O +
shown O -
) O -
. O +

In O +
liver O +
( O -
Fig. O +
1 O +
( O -
A O -
) O -
) O -
, O +
clofibrate O +
had O +
no O +
statistically O +
significant O +
effect O +
on O +
metabolites O +
generated O +
from O +
lauric O +
acid O -
. O +

A O +
significant O +
effect O +
was O +
found O +
in O +
hepatic O +
microsomes O +
from O +
DEHP O -
- O -
treated O +
fish O -
: O +
the O +
production O +
of O +
( O -
ω O +
-1 O -
) O -
- O -
, O +
( O -
ω O +
-2 O -
) O -
- O -
, O +
and O +
( O -
ω O +
-3 O -
) O -
-hydroxylauric O +
acid O +
was O +
increased O +
1.9- O -
, O +
2- O +
and O +
2.7-fold O -
, O +
respectively O -
. O +

In O +
contrast O -
, O +
LAH B-Gene +
activities O +
of O +
kidney O +
microsomes O +
were O +
strongly O +
affected O -
, O +
especially O +
by O +
a O +
DEHP O +
treatment O -
. O +

As O +
in O +
liver O +
microsomes O -
, O +
the O +
production O +
of O +
( O -
ω O +
-1 O -
) O -
, O +
( O -
ω O +
-2 O -
) O -
, O +
and O +
( O -
ω O +
-3 O -
) O -
-hydroxylauric O +
acid O +
was O +
increased O -
, O +
but O +
to O +
higher O +
levels O +
( O -
5.3- O -
, O +
4- O +
and O +
4.9-fold O -
, O +
respectively O -
) O -
. O +

After O +
clofibrate O +
treatment O -
, O +
only O +
the O +
production O +
of O +
( O -
ω O +
-1 O -
) O -
-hydroxylauric O +
acid O +
was O +
increased O +
( O -
2.6-fold O -
) O -
. O +

3.3 O +
Inactivation O +
of O +
lauric B-Gene +
acid I-Gene +
hydroxylases I-Gene +
by O +
suicide O -
- O -
substrates O +
In O +
order O +
to O +
study O +
the O +
substrate O +
selectivity O +
of O +
sea O +
bass O +
P450s B-Gene +
involved O +
in O +
the O +
oxidation O +
of O +
lauric O +
acid O -
, O +
we O +
have O +
evaluated O +
the O +
effects O +
on O +
microsomal O +
LAH B-Gene +
activities O +
of O +
three O +
lauric O +
acid O +
analogues O +
containing O +
a O +
triple O +
bond O +
in O +
the O +
vicinity O +
of O +
the O +
carbons O +
preferentially O +
attacked O +
( O -
C10 O +
and O +
C11 O -
) O -
. O +

Liver O +
microsomes O +
were O +
incubated O +
with O +
9-DDYA O -
, O +
10-DDYA O +
or O +
11-DDYA O -
. O +

10-DDYA O +
was O +
the O +
only O +
analogue O +
tested O +
on O +
sea O +
bass O +
kidney O +
microsomes O +
because O +
of O +
the O +
low O +
amount O +
of O +
biological O +
material O +
obtained O +
from O +
this O +
organ O -
. O +

Preincubation O +
of O +
liver O +
microsomes O +
with O +
10-DDYA O +
resulted O +
in O +
a O +
drastic O +
decrease O +
in O +
total O +
LAH B-Gene +
activity O -
. O +

This O +
loss O +
of O +
activity O +
was O +
dependent O +
on O +
incubation O +
time O +
and O +
on O +
the O +
concentration O +
of O +
inhibitor O +
and O +
it O +
occured O +
only O +
in O +
the O +
presence O +
of O +
NADPH O -
. O +

LAH B-Gene +
inactivation O +
fitted O +
pseudo O -
- O -
first O -
- O -
order O +
kinetics O +
( O -
Fig. O +
2 O +
) O -
. O +

A O +
plot O +
of O +
half O -
- O -
life O +
values O +
( O -
t O +
1 O -
/ O -
2 O +
) O +
against O +
the O +
reciprocal O +
concentrations O +
of O +
inhibitor O +
( O -
Fig. O +
3 O +
) O +
allowed O +
for O +
the O +
determination O +
of O +
the O +
apparent O +
binding O +
constant O +
( O -
K O +
i O +
) O +
and O +
half O -
- O -
life O +
of O +
LAH B-Gene +
activity O +
at O +
saturating O +
concentration O +
of O +
inhibitor O +
( O -
T O +
1 O -
/ O -
2 O +
) O -
. O +

A O +
pseudo O -
- O -
first O -
- O -
order O +
inactivation O +
constant O +
( O -
k O +
inact O +
) O +
was O +
calculated O +
from O +
the O +
T1 O -
/ O -
2 O +
. O +

The O +
different O +
parameters O +
obtained O +
with O +
10-DDYA O +
and O +
11-DDYA O +
are O +
recapitulated O +
in O +
Table O +
2 O +
. O +

On O +
the O +
other O +
hand O -
, O +
80 O +
μM O +
of O +
9-DDYA O +
caused O +
only O +
a O +
slight O +
loss O +
of O +
activity O +
( O -
4 O -
% O -
) O +
after O +
a O +
30-min O +
preincubation O +
time O +
( O -
data O +
not O +
shown O -
) O -
, O +
indicating O +
that O +
9-DDYA O +
is O +
a O +
weak O +
inhibitor O +
of O +
LAH B-Gene +
activities O +
in O +
liver O +
microsomes O -
. O +

4 O +
Discussion O +
The O +
involvement O +
of O +
several O +
mammalian O +
CYP4 B-Gene +
members O +
in O +
lauric O +
acid O +
hydroxylation O +
is O +
now O +
well O +
documented O -
, O +
but O +
only O +
limited O +
informations O +
are O +
available O +
for O +
fish O -
. O +

Most O +
of O +
the O +
investigations O +
in O +
fish O +
have O +
focused O +
on O +
hepatic O +
P450 B-Gene +
isoforms O -
. O +

The O +
ω O +
- O +
to O +
( O -
ω O +
-6 O -
) O -
-hydroxylation O +
of O +
lauric O +
acid O +
in O +
liver O +
of O +
rainbow O +
trout O +
has O +
been O +
reported O -
, O +
but O +
only O +
CYP2-mediated B-Gene +
activities O +
were O +
investigated O +
[ O -
4,39 O -
] O +
. O +

Very O +
recently O -
, O +
a O +
partial O +
cDNA O +
sequence O +
isolated O +
from O +
rainbow O +
trout O +
liver O +
was O +
identified O +
as O +
a O +
CYP4 O +
gene O +
[ O -
7 O -
] O +
, O +
indicating O +
the O +
existence O +
of O +
a O +
P450 O +
belonging O +
to O +
this O +
family O +
in O +
fish O -
. O +

As O +
a O +
first O +
step O +
to O +
develop O +
new O +
biomarkers O +
specific O +
for O +
other O +
classes O +
of O +
marine O +
pollutants O +
( O -
phthalates O -
) O -
, O +
we O +
focused O +
our O +
study O +
on O +
the O +
effect O +
of O +
several O +
CYP4 B-Gene +
inducers O +
on O +
the O +
cytochrome B-Gene +
P450-dependent I-Gene +
LAH B-Gene +
activities O +
in O +
sea O +
bass O +
tissues O -
. O +

Microsomes O +
from O +
liver O -
, O +
kidney O +
or O +
intestinal O +
mucosa O +
of O +
sea O +
bass O +
catalyzed O +
mainly O +
in O -
- O -
chain O +
hydroxylation O +
( O -
especially O +
( O -
ω O +
-1 O -
) O -
- O +
and O +
( O -
ω O +
-2 O -
) O -
-hydroxylations O -
) O +
of O +
lauric O +
acid O -
. O +

Such O +
an O +
in O -
- O -
chain O +
hydroxylation O +
of O +
fatty O +
acids O +
( O -
ω O +
-1 O +
to O +
ω O +
-4 O -
) O +
is O +
also O +
found O +
in O +
bacteria O +
[ O -
20 O -
] O +
, O +
yeast O +
[ O -
29 O -
] O +
, O +
fungi O +
[ O -
33 O -
] O +
, O +
and O +
some O +
plants O +
[ O -
27 O -
] O +
. O +

In O +
contrast O -
, O +
hydroxylation O +
of O +
fatty O +
acids O +
occurs O +
mainly O +
at O +
the O +
ω O +
position O +
in O +
mammals O +
[ O -
16 O -
] O +
, O +
amphibians O +
[ O -
21 O -
] O +
, O +
insects O +
[ O -
5 O -
] O +
, O +
yeast O +
[ O -
29 O -
] O +
, O +
and O +
Leguminosae O +
[ O -
26 O -
] O +
. O +

Kidney O +
microsomes O +
catalyzed O +
lauric O +
acid O +
hydroxylation O +
more O +
efficiently O +
than O +
liver O +
microsomes O -
, O +
as O +
was O +
observed O +
in O +
the O +
trout O +
[ O -
36 O -
] O +
and O +
in O +
the O +
rat O +
[ O -
10 O -
] O +
. O +

These O +
results O +
suggests O +
that O +
these O +
P450 B-Gene +
systems O +
from O +
kidney O +
are O +
rather O +
specialized O +
for O +
fatty O +
acid O +
( O -
ω O +
-1 O -
) O -
-hydroxylation O -
. O +

The O +
hydroxylation O +
of O +
lauric O +
acid O +
at O +
different O +
positions O +
in O +
sea O +
bass O +
could O +
be O +
explained O +
both O +
by O +
several O +
CYP2 B-Gene +
[ O -
4,19 O -
] O +
and O +
CYP4 B-Gene +
gene O -
- O -
mediated O +
activities O -
. O +

Buhler O +
et O +
al. O +
[ O -
4 O -
] O +
have O +
reported O +
that O +
CYP2M1 B-Gene +
and O +
CYP2K1 B-Gene +
catalyse O +
some O +
of O +
the O +
lauric O +
acid O +
( O -
ω O +
-1 O -
) O -
- O +
to O +
( O -
ω O +
-6 O -
) O -
-hydroxylations O +
but O +
several O +
other O +
CYP B-Gene +
isozymes B-Gene +
may O +
also O +
contribute O +
to O +
this O +
regiospecific O +
fatty O +
acid O +
metabolism O -
. O +

Indeed O -
, O +
a O +
CYP4T1 B-Gene +
gene O +
has O +
been O +
isolated O +
in O +
trout O +
[ O -
7 O -
] O +
, O +
and O +
four O +
CYP4A B-Gene +
isozymes B-Gene +
have O +
been O +
characterized O +
in O +
rat O +
liver O -
. O +

CYP4A2 B-Gene +
catalyses O +
only O +
ω O +
-hydroxylation O +
whereas O +
CYP4A1 B-Gene +
and O +
CYP4A3 B-Gene +
catalyses O +
both O +
ω O +
- O +
and O +
( O -
ω O +
-1 O -
) O -
-hydroxylations O +
of O +
lauric O +
acid O +
[ O -
13,14 O -
] O +
. O +

CYP4A1 B-Gene +
protein B-Gene +
could O +
play O +
two O +
alternative O +
functional O +
roles O +
both O +
in O +
a O +
catabolic O +
process O +
[ O -
32 O -
] O +
and O +
in O +
the O +
conversion O +
of O +
arachidonate O +
to O +
signal O +
metabolites O +
[ O -
30 O -
] O +
. O +

The O +
long O -
- O -
chain O +
dicarboxylic O +
acids O +
formed O +
via O +
the O +
CYP4A1 B-Gene +
pathway O +
seems O +
to O +
regulate O +
the O +
peroxisomal O +
β O +
-oxidation O +
enzymes B-Gene +
[ O -
12 O -
] O +
. O +

Moreover O -
, O +
CYP4A1 B-Gene +
is O +
regulated O +
by O +
the O +
same O +
mechanism O +
that O +
controls O +
the O +
peroxisomal O +
β O +
-oxidation O +
enzymes B-Gene -
: O +
CYP4A1 B-Gene +
expression O +
is O +
modified O +
by O +
starvation O +
[ O -
11 O -
] O +
. O +

Lemaire O +
et O +
al. O +
[ O -
17 O -
] O +
have O +
shown O +
that O +
sea O +
bass O +
starvation O +
also O +
increases O +
LAH B-Gene +
activities O -
. O +

However O -
, O +
the O +
physiological O +
significance O +
of O +
in O -
- O -
chain O +
hydroxylation O +
by O +
P450 B-Gene +
systems O +
in O +
fish O +
is O +
still O +
unknown O -
. O +

Because O +
lipids O +
are O +
a O +
preferential O +
energy O +
source O +
in O +
fish O -
, O +
fatty O +
acid O +
metabolism O +
is O +
a O +
very O +
important O +
biological O +
process O +
for O +
fish O +
[ O -
34 O -
] O +
. O +

This O +
could O +
explain O +
the O +
great O +
diversity O +
of O +
metabolites O +
formed O +
in O +
sea O +
bass O +
and O +
trout O +
[ O -
4 O -
] O +
. O +

Several O +
mechanism O -
- O -
based O +
inhibitors O +
of O +
P450 B-Gene +
which O +
selectively O +
inhibit O +
P450 B-Gene +
isozymes B-Gene +
have O +
been O +
previously O +
described O -
: O +
rat O +
hepatic O +
ω B-Gene +
-hydroxylases I-Gene +
are O +
inactivated O +
by O +
11-DDYA O +
[ O -
25 O -
] O +
. O +

The O +
experimental O +
use O +
in O +
vivo O +
of O +
such O +
fatty O +
acid O +
analogues O +
has O +
clarified O +
the O +
functional O +
role O +
of O +
several O +
fatty B-Gene +
acid I-Gene +
hydroxylases I-Gene +
in O +
rat O +
[ O -
40 O -
] O +
and O +
in O +
plant O +
[ O -
9 O -
] O +
. O +

Preincubations O +
of O +
liver O +
or O +
kidney O +
microsomes O +
with O +
11-DDYA O +
or O +
10-DDYA O +
in O +
the O +
presence O +
of O +
NADPH O +
resulted O +
in O +
time- O +
and O +
concentration O -
- O -
dependent O +
inhibitions O +
described O +
by O +
pseudo O -
- O -
first O +
order O +
kinetics O -
, O +
which O +
is O +
characteristic O +
of O +
mechanism O -
- O -
based O +
inhibition O -
. O +

9-DDYA O +
was O +
a O +
very O +
weak O +
inhibitor O -
. O +

These O +
data O +
agree O +
with O +
the O +
highly O +
selective O +
oxidation O +
of O +
lauric O +
acid O +
at O +
the O +
subterminal O +
position O +
by O +
sea O +
bass O +
microsomes O +
whatever O +
the O +
tissue O -
. O +

Yang O +
et O +
al. O +
[ O -
38 O -
] O +
have O +
demonstrated O +
that O +
ciprofibrate O +
induces O +
peroxisome O +
proliferation O +
in O +
rainbow O +
trout O +
liver O -
, O +
but O +
such O +
a O +
response O +
was O +
not O +
observed O +
with O +
gemfibrozil O +
[ O -
28 O -
] O +
or O +
dehydroepiandrosterone O +
[ O -
18 O -
] O +
, O +
whereas O +
these O +
compounds O +
are O +
LAH B-Gene +
inducers O +
in O +
rodents O +
[ O -
24 O -
] O +
. O +

Haasch O +
[ O -
8 O -
] O +
has O +
reported O +
that O +
catfish O -
's O +
and O +
bluegill O -
's O +
liver O +
and O +
kidney O +
showed O +
increased O +
CYP2K1 B-Gene +
and O +
CYP2M1 B-Gene +
P450 B-Gene +
ortholog O +
expression O +
after O +
treatment O +
with O +
fibrates O +
( O -
clofibrate O +
and O +
ciprofibrate O -
) O -
. O +

We O +
have O +
studied O +
the O +
effects O +
of O +
clofibrate O +
and O +
DEHP O +
on O +
liver O -
, O +
kidney O -
, O +
and O +
intestinal O +
LAH B-Gene +
activities O +
of O +
sea O +
bass O -
. O +

Lauric O +
acid O +
( O -
ω O +
-1 O -
) O -
-hydroxylation O +
is O +
strongly O +
induced O +
in O +
sea O +
bass O +
kidney O +
treated O +
with O +
DEHP O -
. O +

The O +
amount O +
of O +
ω O +
-hydroxylauric O +
acid O +
remained O +
unchanged O +
in O +
liver O +
and O +
kidney O +
of O +
clofibrate O +
and O +
DEHP O -
- O -
treated O +
fish O +
as O +
compared O +
to O +
control O -
, O +
although O +
this O +
metabolite O +
is O +
strongly O +
increased O +
in O +
rodents O +
treated O +
with O +
peroxisome O +
proliferators O +
[ O -
31 O -
] O +
. O +

Thus O -
, O +
the O +
site O -
- O -
specificity O +
of O +
lauric O +
acid O +
oxidative O +
attack O +
in O +
sea O +
bass O +
microsomes O +
was O +
not O +
modified O +
by O +
a O +
treatment O +
with O +
peroxisome O +
proliferators O -
. O +

Methylclofenapate O +
( O -
an O +
hypolipidemic O +
drug O -
, O +
such O +
as O +
clofibrate O -
) O +
induced O +
CYP4A B-Gene +
mRNA O +
in O +
mice O +
and O +
rat O +
liver O -
, O +
and O +
to O +
a O +
lesser O +
extent O +
in O +
kidney O +
[ O -
3 O -
] O +
. O +

In O +
contrast O -
, O +
there O +
was O +
no O +
significant O +
induction O +
of O +
CYP4A B-Gene +
in O +
the O +
liver O +
or O +
kidney O +
of O +
guinea O -
- O -
pigs O +
exposed O +
to O +
methylclofenapate O +
[ O -
3 O -
] O +
. O +

These O +
data O +
suggested O +
that O +
there O +
is O +
species O +
difference O +
in O +
response O +
to O +
peroxisome O +
proliferators O +
between O +
rodents O +
and O +
guinea O +
pig O -
. O +

As O +
in O +
guinea O -
- O -
pig O -
, O +
LAH B-Gene +
activities O +
from O +
clofibrate O -
- O -
treated O +
sea O +
bass O +
showed O +
no O +
significant O +
induction O +
in O +
liver O -
. O +

Both O +
clofibrate O +
( O -
and O +
several O +
other O +
fibrates O -
) O +
and O +
phthalates O +
are O +
potent O +
peroxisome O +
proliferators O +
and O +
CYP4 B-Gene +
inducers O +
in O +
rodent O +
liver O +
[ O -
3 O -
] O +
. O +

In O +
contrast O -
, O +
the O +
induction O +
of O +
LAH B-Gene +
activity O +
in O +
sea O +
bass O +
is O +
more O +
important O +
in O +
kidney O +
than O +
in O +
liver O -
, O +
and O +
DEHP O +
is O +
by O +
far O +
a O +
more O +
potent O +
inducer O +
of O +
LAH B-Gene +
activities O +
than O +
clofibrate O -
. O +

Together O -
, O +
our O +
results O +
are O +
much O +
in O +
favor O +
of O +
the O +
involvement O +
of O +
several O +
P450s B-Gene +
in O +
LAH B-Gene +
activities O +
in O +
sea O +
bass O -
. O +

Furthermore O -
, O +
we O +
have O +
shown O +
that O +
LAH B-Gene +
activities O +
are O +
induced O +
in O +
sea O +
bass O +
kidney O +
by O +
peroxisome O +
proliferators O -
, O +
especially O +
phthalates O -
. O +

Considering O +
that O +
phthalate O +
ester O +
plasticizers O +
represent O +
widely O -
- O -
distributed O +
environmental O +
contaminants O -
, O +
the O +
induction O +
of O +
LAH B-Gene +
activities O +
in O +
fish O +
kidney O +
by O +
phthalates O +
could O +
be O +
a O +
first O +
step O +
in O +
the O +
development O +
of O +
efficient O +
biomarkers O +
for O +
this O +
class O +
of O +
marine O +
pollutants O -
. O +

The O +
use O +
of O +
such O +
a O +
biomarker O +
to O +
detect O +
phthalates O +
in O +
sea O +
water O +
will O +
be O +
easier O +
and O +
cheaper O +
than O +
chemical O +
analysis O -
. O +

Moreover O -
, O +
further O +
isolation O +
and O +
cloning O +
of O +
sea O +
bass O +
CYP4 B-Gene +
genes O +
from O +
this O +
tissue O +
are O +
currently O +
under O +
way O +
to O +
develop O +
molecular O +
tools O -
. O +

Acknowledgements O +
This O +
research O +
was O +
supported O +
by O +
a O +
EEC O +
grant O +
( O -
CEE O -
- O -
BIOMAR O +
EV5V O -
- O -
CT94 O -
- O -
0550 O -
) O -
. O +

We O +
are O +
very O +
grateful O +
to O +
Drs O +
David O +
Pauron O +
( O -
INRA O -
, O +
Antibes O -
) O +
and O +
René O +
Feyereisen O +
( O -
University O +
of O +
Arizona O -
, O +
Tucson O -
) O +
for O +
critically O +
reading O +
this O +
manuscript O -
. O +

We O +
would O +
like O +
to O +
thank O +
Dr O +
Charles O +
Mioskowski O +
( O -
CNRS O -
- O -
Faculté O +
de O +
Pharmacie O -
, O +
Strasbourg O -
) O +
for O +
providing O +
us O +
with O +
dodecynoic O +
acids O -
. O +

A O +
novel O +
type O +
of O +
NADPH B-Gene -
- I-Gene -
dependent I-Gene +
sepiapterin I-Gene +
reductase I-Gene -
, O +
which O +
catalysed O +
uniquely O +
the O +
reduction O +
of O +
sepiapterin O +
to O +
l O -
- O -
threo O -
- O -
dihydrobiopterin O -
, O +
was O +
purified O +
533-fold O +
from O +
the O +
cytosolic O +
fraction O +
of O +
Chlorobium O +
tepidum O -
, O +
with O +
an O +
overall O +
yield O +
of O +
3 O -
% O -
. O +

The O +
native B-Gene +
enzyme I-Gene +
had O +
a O +
molecular O +
mass O +
of O +
55 O +
kDa O +
and O +
SDS O -
/ O -
PAGE O +
revealed O +
that O +
the O +
enzyme B-Gene +
consists O +
of O +
two O +
subunits O +
with O +
a O +
molecular O +
mass O +
of O +
26 O +
kDa O -
. O +

The O +
enzyme B-Gene +
was O +
optimally O +
active O +
at O +
pH8.8 O +
and O +
50 O +
degrees O +
C. O +
Apparent O +
Km O +
values O +
for O +
sepiapterin O +
and O +
NADPH O +
were O +
21 O +
and O +
6.2 O +
microM O -
, O +
respectively O -
, O +
and O +
the O +
kcat O +
value O +
was O +
5.0 O +
s-1 O -
. O +

Diacetyl O +
could O +
also O +
serve O +
as O +
a O +
substrate O -
, O +
with O +
a O +
Km O +
of O +
4.0 O +
mM. O +
The O +
inhibitory O +
effects O +
of O +
N O -
- O -
acetylserotonin O -
, O +
N O -
- O -
acetyldopamine O +
and O +
melatonin O +
were O +
very O +
weak O -
. O +

The O +
Ki O +
value O +
of O +
N O -
- O -
acetyldopamine O +
was O +
measured O +
as O +
400 O +
microM. O +
The O +
N O -
- O -
terminal O +
amino O +
acid O +
sequence O +
was O +
revealed O +
as O +
Met O -
- O -
Lys O -
- O -
His O -
- O -
Ile O -
- O -
Leu O -
- O -
Leu O -
- O -
Ile O -
- O -
Thr O -
- O -
Gly O -
- O -
Ala O -
- O -
Xaa O -
- O -
Lys O +
- O +
Lys O +
- O +
Ile O +
- O +
Xaa O +
- O +
Arg O +
- O +
Ala O +
- O +
Ile O +
- O +
Ala O +
- O +
Leu O +
- O +
Glu O +
- O +
Xaa O +
- O +
Ala O +
- O +
Arg O +
- O +
Xaa O -
- O -
Xaa O -
- O -
Xaa O -
- O -
His O -
- O -
His O -
- O -
His- O -
, O +
which O +
shared O +
relatively O +
high O +
sequence O +
similarity O +
with O +
other O +
sepiapterin B-Gene +
reductases I-Gene -
. O +

Stachyose B-Gene +
synthase I-Gene +
( O -
STS B-Gene -
) O +
( O -
EC B-Gene +
2.4.1.67 I-Gene -
) O +
was O +
purified O +
313-fold O +
from O +
mature O +
seeds O +
of O +
lentil O -
. O +

The O +
final O +
preparation O +
had O +
a O +
specific O +
activity O +
of O +
9.09 O +
nkat O +
stachyose O +
formed O +
per O +
milligram O +
of O +
protein B-Gene -
. O +

The O +
enzyme B-Gene +
was O +
a O +
monomeric B-Gene +
protein I-Gene +
with O +
a O +
molecular O +
mass O +
of O +
88.6 O +
kDa O +
( O -
SDS O -
- O -
PAGE O -
) O +
and O +
an O +
isoelectric O +
point O +
of O +
4.8 O +
( O -
chromatofocusing O -
) O -
. O +

Western O +
analysis O +
revealed O +
cross O -
- O -
reactivity O +
of O +
polyclonal B-Gene +
antibodies I-Gene +
raised O +
against O +
STS O +
from O +
adzuki O +
bean O +
with O +
the O +
lentil O +
enzyme B-Gene -
. O +

The O +
purified O +
enzyme B-Gene +
catalyzed O +
a O +
range O +
of O +
different O +
galactosyl O +
transfer O +
reactions O -
. O +

In O +
addition O +
to O +
the O +
genuine O +
STS B-Gene +
reaction O +
( O -
raffinose O +
+ O +
galactinol O +
-- O -
> O +
stachyose O +
+ O +
myo O -
- O -
inositol O -
) O -
, O +
the O +
enzyme B-Gene +
catalyzed O +
the O +
reversible O +
galactosyl O +
transfer O +
from O +
galactinol O +
to O +
d O -
- O -
pinitol O +
( O -
1d-3-O O -
- O -
methyl O -
- O -
chiro O -
- O -
inositol O -
) O -
, O +
yielding O +
galactopinitol O +
A O +
( O -
O O -
- O -
alpha O -
- O -
d O -
- O -
galactopyranosyl- O -
( O -
1 O +
-- O -
> O +
2 O -
) O -
-4-O O -
- O -
methyl O -
- O -
d O -
- O -
chiro O -
- O -
inositol O -
) O +
and O +
myo O -
- O -
inositol O -
. O +

Galactopinitol O +
A O +
could O +
be O +
further O +
galactosylated O +
by O +
STS B-Gene +
to O +
give O +
ciceritol O +
( O -
O O -
- O -
alpha O -
- O -
d O -
- O -
galactopyranosyl- O -
( O -
1 O +
-- O -
> O +
6 O -
) O -
-O O -
- O -
alpha O -
- O -
d O -
- O -
galactopyranosyl- O -
( O -
1 O +
-- O -
> O +
2 O -
) O -
-4-O O -
- O -
methyl O -
- O -
d O -
- O -
chiro O -
- O -
inositol O -
) O -
. O +

Enzymatic O +
synthesis O +
of O +
galactopinitol O +
A O +
and O +
ciceritol O +
is O +
a O +
new O +
observation O -
. O +

However O -
, O +
STS B-Gene +
was O +
not O +
only O +
able O +
to O +
utilize O +
galactopinitol O +
A O +
as O +
galactosyl O +
acceptor O -
, O +
but O +
also O +
as O +
galactosyl O +
donor O +
to O +
form O +
stachyose O +
from O +
raffinose O -
. O +

The O +
role O +
of O +
STS B-Gene +
in O +
the O +
metabolism O +
of O +
galactosyl O +
cyclitols O +
and O +
oligosaccharides O +
in O +
plant O +
seeds O +
is O +
discussed O -
. O +

We O +
have O +
identified O +
a O +
series O +
of O +
novel O +
inhibitors O +
of O +
human O +
immunodeficiency B-Gene +
virus I-Gene +
type I-Gene +
1 I-Gene +
( O -
HIV-1 B-Gene -
) O +
integrase B-Gene +
by O +
randomly O +
screening O +
natural O +
product O +
extracts O +
using O +
an O +
in O +
vitro O +
biochemical O +
assay O +
designed O +
to O +
identify O +
inhibitors O +
of O +
integrase B-Gene -
- O -
catalysed O +
strand O +
transfer O -
. O +

Equisetin O +
recovered O +
from O +
the O +
fungus O +
Fusarium O +
heterosporum O +
and O +
a O +
novel O +
enantiomeric O +
homologue O +
of O +
equisetin O +
from O +
Phoma O +
sp. O +
were O +
isolated O +
as O +
inhibitors O +
of O +
HIV-1 B-Gene +
integrase I-Gene +
in O +
vitro O -
. O +

Two O +
additional O +
analogues O -
, O +
a O +
novel O +
decalin O +
derivative O -
, O +
integric O +
acid O -
, O +
and O +
oteromycin O +
were O +
also O +
discovered O +
to O +
be O +
inhibitors O +
of O +
integrase B-Gene -
. O +

Equisetin O +
and O +
related O +
compounds O +
inhibit O +
3 O -
' O +
end O -
- O -
processing O +
and O +
strand O +
transfer O +
as O +
well O +
as O +
disintegration O +
catalysed O +
by O +
either O +
the O +
full O -
- O -
length O +
enzyme B-Gene +
or O +
the O +
truncated O +
integrase B-Gene +
core O +
domain O +
( O -
amino O +
acids O +
50 O -
- O -
212 O -
) O -
. O +

These O +
compounds O +
also O +
inhibit O +
strand O +
transfer O +
reactions O +
catalysed O +
by O +
stable O +
complexes O +
assembled O +
in O +
vitro O +
and O +
integration O +
reactions O +
catalysed O +
by O +
pre O -
- O -
integration O +
complexes O +
isolated O +
from O +
HIV-1-infected B-Gene +
cells O -
. O +

The O +
compounds O +
described O +
in O +
this O +
report O +
are O +
structurally O +
novel O +
and O +
mechanistically O +
distinct O +
from O +
many O +
previously O +
described O +
inhibitors O +
of O +
HIV-1 B-Gene +
integrase I-Gene -
. O +

These O +
results O +
demonstrate O +
the O +
utility O +
of O +
using O +
an O +
appropriately O +
configured O +
assay O +
to O +
identify O +
compounds O +
that O +
are O +
effective O +
post O -
- O -
assembly O +
and O +
the O +
potential O +
of O +
isolating O +
novel O +
integrase B-Gene +
inhibitors O +
from O +
complex O +
natural O +
product O +
extracts O -
. O +

AIMS O -
: O +
The O +
present O +
study O +
was O +
conducted O +
to O +
evaluate O +
metabolism O +
of O +
the O +
enantiomers O +
of O +
verapamil O +
and O +
norverapamil O +
using O +
a O +
broad O +
range O +
of O +
cytochrome B-Gene +
P450 I-Gene +
isoforms O +
and O +
measure O +
the O +
kinetic O +
parameters O +
of O +
these O +
processes O -
. O +

METHODS O -
: O +
Cytochrome B-Gene +
P450 I-Gene +
cDNA O -
- O -
expressed O +
cells O +
and O +
microsomes O +
from O +
a O +
P450-expressed B-Gene +
lymphoblastoid O +
cell O +
line O +
were O +
incubated O +
with O +
40 O +
microm O +
concentrations O +
of O +
R- O +
or O +
S O -
- O -
verapamil O +
and O +
R- O +
or O +
S O -
- O -
norverapamil O +
and O +
metabolite O +
formation O +
measured O +
by O +
h.p.l.c O -
. O +

as O +
an O +
initial O +
screening O -
. O +

Those O +
isoforms O +
exhibiting O +
substantial O +
activity O +
were O +
then O +
studied O +
over O +
a O +
range O +
of O +
substrate O +
concentrations O +
( O -
2.5 O -
- O -
450 O +
microm O +
) O +
to O +
estimate O +
the O +
kinetic O +
parameters O +
for O +
metabolite O +
formation O -
. O +

RESULTS O -
: O +
P450s B-Gene +
3A4 B-Gene -
, O +
3A5 B-Gene -
, O +
2C8 B-Gene +
and O +
to O +
a O +
minor O +
extent O +
2E1 B-Gene +
were O +
involved O +
in O +
the O +
metabolism O +
of O +
the O +
enantiomers O +
of O +
verapamil O -
. O +

Estimated O +
Km O +
values O +
for O +
the O +
production O +
of O +
D-617 O +
and O +
norverapamil O +
by O +
P450 B-Gene +
s O +
3A4 B-Gene +
and O +
3A5 B-Gene +
were O +
similar O +
( O -
range=60 O -
- O -
127 O +
microm O +
) O +
regardless O +
of O +
the O +
enantiomer O +
of O +
verapamil O +
studied O +
while O +
the O +
Vmax O +
estimates O +
were O +
also O +
similar O +
( O -
range=4 O -
- O -
8 O +
pmol O +
min-1 O +
pmol-1 O +
P450 B-Gene -
) O -
. O +

Only O +
nominal O +
production O +
of O +
D-620 O +
by O +
these O +
isoforms O +
was O +
noted O -
. O +

Interestingly O -
, O +
P450 B-Gene +
2C8 I-Gene +
readily O +
metabolized O +
both O +
S- O +
and O +
R O -
- O -
verapamil O +
to O +
D-617 O -
, O +
norverapamil O +
and O +
PR-22 O +
with O +
only O +
slightly O +
higher O +
Km O +
values O +
than O +
noted O +
for O +
P450s B-Gene +
3A4 B-Gene +
and O +
3A5 B-Gene -
. O +

However O -
, O +
the O +
Vmax O +
estimates O +
for O +
P450 B-Gene +
2C8 I-Gene +
metabolism O +
of O +
S- O +
and O +
R O -
- O -
verapamil O +
were O +
in O +
general O +
greater O +
( O -
range=8 O -
- O -
15 O +
pmol O +
min-1 O +
pmol-1 O +
P450 B-Gene -
) O +
than O +
those O +
noted O +
for O +
P450 B-Gene +
s O +
3A4 B-Gene +
and O +
3A5 B-Gene +
with O +
preference O +
noted O +
for O +
metabolism O +
of O +
the O +
S O -
- O -
enantiomer O -
. O +

Similarly O -
, O +
P450 B-Gene +
s O +
3A4 B-Gene -
, O +
3A5 B-Gene +
and O +
2C8 B-Gene +
also O +
mediated O +
the O +
metabolism O +
of O +
the O +
enantiomers O +
of O +
norverapamil O +
with O +
minor O +
contributions O +
by O +
P450 B-Gene +
s O +
2D6 B-Gene +
and O +
2E1 B-Gene -
. O +

P450s B-Gene +
3A4 B-Gene +
and O +
3A5 B-Gene +
readily O +
formed O +
the O +
D-620 O +
metabolite O +
with O +
generally O +
a O +
lower O +
Km O +
and O +
higher O +
Vmax O +
for O +
S O -
- O -
norverapamil O +
than O +
for O +
the O +
R O -
- O -
enantiomer O -
. O +

In O +
contrast O -
, O +
P450 B-Gene +
2C8 I-Gene +
produced O +
both O +
the O +
D-620 O +
and O +
PR-22 O +
metabolites O +
from O +
the O +
enantiomers O +
of O +
norverapamil O -
, O +
again O +
with O +
stereoselective O +
preference O +
seen O +
for O +
the O +
S O -
- O -
enantiomer O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
confirm O +
that O +
P450s B-Gene +
3A4 B-Gene -
, O +
3A5 B-Gene +
and O +
2C8 B-Gene +
play O +
a O +
major O +
role O +
in O +
verapamil O +
metabolism O +
and O +
demonstrate O +
that O +
norverapamil O +
can O +
also O +
be O +
further O +
metabolized O +
by O +
the O +
P450s B-Gene -
. O +

Phenylacetic O +
acids O +
are O +
common O +
intermediates O +
in O +
the O +
microbial O +
metabolism O +
of O +
various O +
aromatic O +
substrates O +
including O +
phenylalanine O -
. O +

In O +
the O +
denitrifying O +
bacterium O +
Thauera O +
aromatica O +
phenylacetate O +
is O +
oxidized O -
, O +
under O +
anoxic O +
conditions O -
, O +
to O +
the O +
common O +
intermediate O +
benzoyl O -
- O -
CoA O +
via O +
the O +
intermediates O +
phenylacetyl O -
- O -
CoA O +
and O +
phenylglyoxylate O +
( O -
benzoylformate O -
) O -
. O +

The O +
enzyme B-Gene +
that O +
catalyzes O +
the O +
four O -
- O -
electron O +
oxidation O +
of O +
phenylacetyl O -
- O -
CoA O +
has O +
been O +
purified O +
from O +
this O +
bacterium O +
and O +
studied O -
. O +

The O +
enzyme B-Gene +
preparation O +
catalyzes O +
the O +
reaction O +
phenylacetyl O -
- O -
CoA O +
+ O +
2 O +
quinone O +
+ O +
2 O +
H2O O +
-- O -
> O +
phenylglyoxylate O +
+ O +
2 O +
quinone O +
H2 O +
+ O +
CoASH O -
. O +

Phenylacetyl B-Gene -
- I-Gene -
CoA I-Gene -
: I-Gene -
acceptor I-Gene +
oxidoreductase I-Gene +
is O +
a O +
membrane O -
- O -
bound O +
molybdenum B-Gene -
- I-Gene -
iron I-Gene -
- I-Gene -
sulfur I-Gene +
protein I-Gene -
. I-Gene +

The O +
purest O +
preparations O +
contained O +
three O +
subunits O +
of O +
93 O -
, O +
27 O -
, O +
and O +
26 O +
kDa O -
. O +

Ubiquinone O +
is O +
most O +
likely O +
to O +
act O +
as O +
the O +
electron O +
acceptor O -
, O +
and O +
the O +
oxygen O +
atom O +
introduced O +
into O +
the O +
product O +
is O +
derived O +
from O +
water O -
. O +

The O +
protein B-Gene +
preparations O +
contained O +
0.66 O +
mol O +
Mo O -
, O +
30 O +
mol O +
Fe O -
, O +
and O +
25 O +
mol O +
acid O -
- O -
labile O +
sulfur O +
per O +
mol O +
of O +
native B-Gene +
enzyme I-Gene -
, O +
assuming O +
a O +
native O +
molecular O +
mass O +
of O +
280 O +
kDa O -
. O +

Phenylglyoxylyl O -
- O -
CoA O -
, O +
but O +
not O +
mandelyl O -
- O -
CoA O -
, O +
was O +
observed O +
as O +
a O +
free O +
intermediate O -
. O +

All O +
enzyme B-Gene +
preparations O +
also O +
catalyzed O +
the O +
subsequent O +
hydrolytic O +
release O +
of O +
coenzyme O +
A O +
from O +
phenylglyoxylyl O -
- O -
CoA O +
but O +
not O +
from O +
phenylacetyl O -
- O -
CoA. O +
The O +
enzyme B-Gene +
is O +
reversibly O +
inactivated O +
by O +
a O +
low O +
concentration O +
of O +
cyanide O -
, O +
but O +
is O +
remarkably O +
stable O +
with O +
respect O +
to O +
oxygen O -
. O +

This O +
new O +
member O +
of O +
the O +
molybdoproteins B-Gene +
represents O +
the O +
first O +
example O +
of O +
an O +
enzyme B-Gene +
which O +
catalyzes O +
the O +
alpha O -
- O -
oxidation O +
of O +
a O +
CoA O -
- O -
activated O +
carboxylic O +
acid O +
without O +
utilizing O +
molecular O +
oxygen O -
. O +

Phlorisovalerophenone B-Gene +
synthase I-Gene +
( O -
VPS B-Gene -
) O -
, O +
a O +
novel O +
aromatic B-Gene +
polyketide I-Gene +
synthase I-Gene -
, O +
was O +
purified O +
to O +
homogeneity O +
from O +
4.2 O +
mg O +
protein B-Gene +
extract O +
obtained O +
from O +
hop O +
( O -
Humulus O +
lupulus O +
L. O -
) O +
cone O +
glandular O +
hairs O -
. O +

The O +
enzyme B-Gene +
uses O +
isovaleryl O -
- O -
CoA O +
or O +
isobutyryl O -
- O -
CoA O +
and O +
three O +
molecules O +
of O +
malonyl O -
- O -
CoA O +
to O +
form O +
phlorisovalerophenone O +
or O +
phlorisobutyrophenone O -
, O +
intermediates O +
in O +
the O +
biosynthesis O +
of O +
the O +
hop O +
bitter O +
acids O +
( O -
alpha- O +
and O +
beta O -
- O -
acids O -
) O -
. O +

VPS B-Gene +
is O +
an O +
homodimeric O +
enzyme B-Gene -
, O +
with O +
subunits O +
of O +
45 O +
kDa O -
. O +

The O +
pI O +
of O +
the O +
enzyme B-Gene +
was O +
6.1 O -
. O +

Km O +
values O +
of O +
4 O +
microm O +
for O +
isovaleryl O -
- O -
CoA O -
, O +
10 O +
microm O +
for O +
isobutyryl O -
- O -
CoA O +
and O +
33 O +
microm O +
for O +
malonyl B-Gene -
- I-Gene -
CoA I-Gene -
, I-Gene +
were O +
found O -
. O +

The O +
amino O -
- O -
acid O +
sequences O +
of O +
two O +
peptides O -
, O +
obtained O +
by O +
digestion O +
of O +
VPS B-Gene -
, O +
showed O +
that O +
the O +
enzyme B-Gene +
is O +
highly O +
homologous O +
to O +
plant B-Gene +
chalcone I-Gene +
synthases I-Gene -
. O +

The O +
functional O +
and O +
structural O +
relationship O +
between O +
VPS B-Gene +
and O +
other O +
aromatic B-Gene +
polyketide I-Gene +
synthases I-Gene +
is O +
discussed O -
. O +

Supplementation O +
of O +
vegetable B-Gene +
proteins I-Gene +
with O +
various O +
essential O +
amino O +
acids O +
is O +
an O +
effective O +
means O +
of O +
improving O +
proteins B-Gene +
quality O -
. O +

Unfortunately O -
, O +
simple O +
amino O +
acid O +
additions O +
to O +
foods O +
which O +
must O +
be O +
heat O +
processed O +
and O +
cooked O +
is O +
not O +
without O +
consequences O -
. O +

Under O +
these O +
conditions O -
, O +
methionine O +
interacts O +
with O +
reducing O +
sugars O +
yielding O +
methional O +
through O +
the O +
Strecker O +
degradation O +
reaction O -
. O +

This O +
generation O +
of O +
methional O +
during O +
heat O +
treatment O +
imparts O +
undesirable O +
sulfur O +
odors O +
and O +
flavors O +
to O +
the O +
food O +
rendering O +
it O +
organoleptically O +
unacceptable O -
. O +

Similarly O -
, O +
threonine O +
and O +
lysine O +
are O +
also O +
susceptible O +
to O +
interaction O +
with O +
reducing O +
sugars O +
rendering O +
them O +
nutritionally O +
unavailable O -
. O +

Acetylated O +
derivatives O +
of O +
methionine O -
, O +
threonine O +
and O +
lysine O +
have O +
been O +
studied O +
to O +
determine O +
their O +
utility O +
in O +
overcoming O +
the O +
inherent O +
problems O +
associated O +
with O +
each O +
amino O +
acid O -
. O +

To O +
this O +
end O -
, O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
methionine O +
and O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
threonine O +
were O +
found O +
to O +
be O +
fully O +
available O +
to O +
promote O +
growth O +
of O +
rats O -
. O +

To O +
the O +
contrary O -
, O +
neither O +
the O +
alpha O +
nor O +
the O +
epsilon O -
, O +
monoacetylated O +
derivative O +
of O +
L O -
- O -
Lysine O +
nor O +
the O +
alpha O -
, O +
epsilon O +
diacetyl O +
derivative O +
of O +
L O -
- O -
Lysine O +
were O +
effective O +
in O +
significantly O +
promoting O +
the O +
growth O +
of O +
rats O -
. O +

Utilization O +
of O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
methionine O +
by O +
humans O +
has O +
also O +
been O +
studied O +
and O +
shown O +
to O +
be O +
as O +
effective O +
as O +
methionine O +
in O +
improving O +
the O +
quality O +
of O +
vegetable B-Gene +
proteins I-Gene +
deficient O +
in O +
sulfur O +
amino O +
acids O -
. O +

Nigericin O +
is O +
an O +
ionophore O +
commonly O +
used O +
at O +
the O +
end O +
of O +
experiments O +
to O +
calibrate O +
intracellularly O +
trapped O +
pH O -
- O -
sensitive O +
dyes O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
explore O +
the O +
possibility O +
that O +
residual O +
nigericin O +
from O +
dye O +
calibration O +
in O +
one O +
experiment O +
might O +
interfere O +
with O +
intracellular O +
pH O +
( O -
pHi O -
) O +
changes O +
in O +
the O +
next O -
. O +

Using O +
the O +
pH O -
- O -
sensitive O +
fluorescent O +
dye O +
2 O -
' O -
, O +
7'-bis O -
( O -
carboxyethyl O -
) O -
-5,6-carboxyfluorescein O +
( O -
BCECF O -
) O -
, O +
we O +
measured O +
pHi O +
in O +
cultured O +
rat O +
renal O +
mesangial O +
cells O -
. O +

Nigericin O +
contamination O +
caused O -
: O +
( O -
i O -
) O +
an O +
increase O +
in O +
acid O +
loading O +
during O +
the O +
pHi O +
decrease O +
elicited O +
by O +
removing O +
extracellular O +
Na+ O -
, O +
( O -
ii O -
) O +
an O +
increase O +
in O +
acid O +
extrusion O +
during O +
the O +
pHi O +
increase O +
caused O +
by O +
elevating O +
extracellular O +
[ O -
K+ O -
] O -
, O +
and O +
( O -
iii O -
) O +
an O +
acid O +
shift O +
in O +
the O +
pHi O +
dependence O +
of O +
the O +
background O +
intracellular O +
acid O +
loading O +
unmasked O +
by O +
inhibiting O +
Na O -
- O -
H O +
exchange O +
with O +
ethylisopropylamiloride O +
( O -
EIPA O -
) O -
. O +

However O -
, O +
contamination O +
had O +
no O +
effect O +
on O +
the O +
pHi O +
dependence O +
of O +
Na O -
- O -
H O +
exchange O -
, O +
computed O +
by O +
adding O +
the O +
pHi O +
dependencies O +
of O +
total O +
acid O +
extrusion O +
and O +
background O +
acid O +
loading O -
. O +

Nigericin O +
contamination O +
can O +
be O +
conveniently O +
minimized O +
by O +
using O +
a O +
separate O +
line O +
to O +
deliver O +
nigericin O +
to O +
the O +
cells O -
, O +
and O +
by O +
briefly O +
washing O +
the O +
tubing O +
with O +
ethanol O +
and O +
water O +
after O +
each O +
experiment O -
. O +

The O +
fatty O +
acid O +
composition O +
of O +
caprine O +
milk O +
fat O +
was O +
studied O +
using O +
capillary O +
gas O +
chromatography O -
. O +

Milk O +
was O +
obtained O +
from O +
five O +
goat O +
herds O +
belonging O +
to O +
different O +
breeders O +
in O +
the O +
Murcia O +
region O +
( O -
Spain O -
) O +
and O +
collected O +
monthly O +
( O -
from O +
November O +
to O +
May O -
) O -
. O +

The O +
results O +
showed O +
significant O +
differences O +
among O +
herds O +
mainly O +
in O +
long O -
- O -
chain O +
fatty O +
acids O +
( O -
C16:0 O -
, O +
C18:0 O -
, O +
and O +
C18:2 O -
) O -
. O +

There O +
were O +
five O +
branched O -
- O -
chain O +
fatty O +
acids O +
( O -
iso- O +
and O +
anteiso O -
- O -
C15:0 O -
, O +
iso- O +
and O +
anteiso O -
- O -
C17:0 O -
, O +
and O +
iso O -
- O -
C16:0 O -
) O +
with O +
> O +
0.1 O -
% O +
of O +
the O +
total O +
fatty O +
acid O +
methyl O +
esters O +
and O +
another O +
31 O +
( O -
the O +
most O +
monomethylated O -
) O +
with O +
< O +
0.1 O -
% O -
, O +
including O +
4-ethyloctanoate O -
, O +
which O +
is O +
implicated O +
in O +
goat O -
- O -
like O +
flavors O -
. O +

To O +
study O +
the O +
content O +
of O +
trans O +
unsaturated O +
fatty O +
acids O -
, O +
the O +
fatty O +
acid O +
methyl O +
esters O +
were O +
previously O +
fractionated O +
by O +
AgNO3-thin O +
layer O +
chromatography O -
. O +

The O +
mean O +
contents O +
of O +
trans O -
- O -
C16:1 O +
and O +
trans O -
- O -
C18:1 O +
were O +
0.16 O +
and O +
2.12 O -
% O -
, O +
respectively O -
. O +

The O +
distribution O +
profile O +
of O +
trans O -
- O -
C18:1 O +
was O +
also O +
studied O -
. O +

The O +
nor O +
mutant O +
of O +
Aspergillus O +
flavus O +
has O +
a O +
defective O +
norsolorinic B-Gene +
acid I-Gene +
reductase I-Gene -
, O +
and O +
thus O +
the O +
aflatoxin O +
biosynthetic O +
pathway O +
is O +
blocked O -
, O +
resulting O +
in O +
the O +
accumulation O +
of O +
norsolorinic O +
acid O -
, O +
a O +
bright O +
red O -
- O -
orange O +
pigment O -
. O +

We O +
developed O +
a O +
visual O +
agar O +
plate O +
assay O +
to O +
monitor O +
yeast O +
strains O +
for O +
their O +
ability O +
to O +
inhibit O +
aflatoxin O +
production O +
by O +
visually O +
scoring O +
the O +
accumulation O +
of O +
this O +
pigment O +
of O +
the O +
nor O +
mutant O -
. O +

We O +
identified O +
yeast O +
strains O +
that O +
reduced O +
the O +
red O -
- O -
orange O +
pigment O +
accumulation O +
in O +
the O +
nor O +
mutant O -
. O +

These O +
yeasts O +
also O +
reduced O +
aflatoxin O +
accumulation O +
by O +
a O +
toxigenic O +
strain O +
of O +
A. O +
flavus O -
. O +

These O +
yeasts O +
may O +
be O +
useful O +
for O +
reducing O +
aflatoxin O +
contamination O +
of O +
food O +
commodities O -
. O +

During O +
the O +
course O +
of O +
our O +
screening O +
program O +
for O +
low O +
molecular O +
natural O +
products O +
with O +
their O +
ability O +
to O +
potentiate O +
and/or O +
mimic O +
neurotrophic O +
effect O +
of O +
NGF B-Gene -
, O +
a O +
novel O +
fungal O +
metabolite O -
, O +
phenylacetic O +
acid O +
hydrazide O +
derivative O +
NG-061 O +
was O +
isolated O +
from O +
the O +
fermentation O +
broth O +
of O +
Penicillium O +
minioluteum O +
F-4627 O -
. O +

NG-061 O +
enhanced O +
and O +
mimicked O +
neurotrophic O +
effect O +
of O +
NGF B-Gene +
on O +
neurite O +
outgrowth O +
in O +
a O +
rat O +
pheochromocytoma O +
cell O +
line O +
PC12 O -
. O +

The O +
structure O +
of O +
NG-061 O -
, O +
a O +
new O +
potentiator O +
of O +
nerve B-Gene +
growth I-Gene +
factor I-Gene +
( O -
NGF B-Gene -
) O +
isolated O +
from O +
Penicillium O +
minioluteum O +
F-4627 O -
, O +
was O +
determined O +
by O +
spectroscopic O +
analysis O +
and O +
X O -
- O -
ray O +
diffraction O +
method O +
to O +
be O +
phenylacetic O +
acid O +
2- O -
( O -
2-methoxy-4-oxocyclohexa-2,4-dienylidene O -
) O -
-hydrazide O -
. O +

A O +
new O +
antitumor O +
antibiotic O +
gilvusmycin O +
was O +
isolated O +
from O +
the O +
culture O +
broth O +
of O +
Streptomyces O +
sp. O +
QM16 O -
. O +

The O +
structure O +
of O +
gilvusmycin O +
was O +
related O +
to O +
CC-1065 O +
and O +
determined O +
by O +
NMR O +
spectral O +
analysis O -
. O +

Gilvusmycin O +
exhibited O +
antitumor O +
activity O +
against O +
murine O +
leukemia O +
P388 O +
in O +
vivo O -
. O +

Ethylene O +
glycol O +
is O +
a O +
serious O +
toxin O +
that O +
children O +
frequently O +
ingest O -
. O +

Diagnosis O +
and O +
treatment O +
of O +
this O +
poisoning O +
are O +
challenging O +
and O +
frequently O +
involve O +
the O +
use O +
of O +
novel O +
therapies O -
. O +

In O +
the O +
past O +
year O -
, O +
fomepizole O +
( O -
4-methylpyrazole O -
) O +
has O +
been O +
approved O +
for O +
use O +
as O +
an O +
antidote O +
in O +
the O +
treatment O +
of O +
ethylene O +
glycol O +
poisoning O +
in O +
adults O -
, O +
and O +
the O +
first O +
article O +
reporting O +
the O +
use O +
of O +
fomepizole O +
in O +
a O +
pediatric O +
ethylene O +
glycol O +
exposure O +
was O +
published O -
. O +

As O +
a O +
result O -
, O +
the O +
therapy O +
of O +
ethylene O +
glycol O +
poisoning O +
in O +
children O +
is O +
likely O +
to O +
change O +
from O +
the O +
traditional O +
approach O +
of O +
ethanol O +
administration O +
coupled O +
with O +
hemodialysis O +
to O +
the O +
administration O +
of O +
fomepizole O +
with O +
or O +
without O +
hemodialysis O -
. O +

It O +
was O +
studied O +
the O +
amino O +
acids O +
pattern O +
in O +
serum O +
and O +
cerebrospinal O +
fluid O +
of O +
12 O +
and O +
8 O +
patients O -
, O +
respectively O -
, O +
suffering O +
from O +
optic O +
epidemic O +
neuropathy O +
diagnosed O +
between O +
1995 O +
and O +
1997 O +
( O -
endemic O +
period O -
) O -
. O +

The O +
cerebrospinal O +
fluid O +
of O +
16 O +
patients O +
diagnosed O +
during O +
the O +
epidemic O +
( O -
1992 O -
) O +
was O +
also O +
studied O -
. O +

The O +
analysis O +
of O +
amino O +
acids O +
in O +
serum O +
and O +
cerebrospinal O +
fluid O +
was O +
made O +
by O +
high O +
resolution O +
liquid O +
chromatography O +
with O +
fluorescent O +
detection O -
, O +
previous O +
derivation O +
with O +
orthofthallic O +
aldehyde O -
. O +

As O +
in O +
the O +
previous O +
study O -
, O +
no O +
important O +
deficiencies O +
of O +
the O +
essential O +
amino O +
acids O +
were O +
observed O +
in O +
the O +
serum O +
of O +
the O +
studied O +
patients O -
. O +

Lower O +
concentrations O +
of O +
threonine O -
, O +
aspartic O +
acid O +
and O +
taurine O +
were O +
found O +
in O +
the O +
serum O +
of O +
patients O +
with O +
epidemic O +
optic O +
neuropathy O +
diagnosed O +
in O +
the O +
endemic O +
period O -
. O +

Taurine O +
plays O +
an O +
important O +
role O +
in O +
the O +
structure O +
and O +
function O +
of O +
photoreceptors O +
of O +
the O +
retina O -
. O +

It O +
is O +
synthesized O +
in O +
the O +
necessary O +
amounts O +
in O +
man O -
, O +
so O +
it O +
must O +
be O +
supplied O +
in O +
the O +
diet O -
. O +

As O +
it O +
is O +
only O +
present O +
in O +
food O +
of O +
animal O +
origin O -
, O +
it O +
is O +
considered O +
that O +
the O +
deficiency O +
of O +
taurine O +
may O +
contribute O +
to O +
the O +
development O +
of O +
optic O +
epidemic O +
neuritis O +
in O +
our O +
patients O -
. O +

Samples O +
of O +
cerebrospinal O +
fluid O +
were O +
analyzed O +
during O +
the O +
epidemic O +
and O +
endemic O +
periods O +
and O +
it O +
was O +
observed O +
an O +
increase O +
of O +
the O +
glutamic O +
and O +
aspartic O +
acid O +
in O +
the O +
epidemic O +
period O +
and O +
of O +
glutamic O +
acid O +
during O +
the O +
endemic O -
. O +

The O +
excess O +
of O +
excitotoxic O +
amino O +
acids O +
in O +
the O +
cerebrospinal O +
fluid O +
supports O +
the O +
previous O +
neurocognitive O +
studies O +
that O +
suggested O +
the O +
affection O +
of O +
the O +
central O +
nervous O +
system O +
in O +
these O +
patients O -
. O +

The O +
kinetic O +
properties O +
of O +
bacterial O +
and O +
rat O +
liver O +
glutathione B-Gene +
S I-Gene -
- I-Gene -
transferases I-Gene +
( O -
GST B-Gene -
) O +
active O +
with O +
dichloromethane O +
( O -
DCM O -
) O +
were O +
compared O -
. O +

The O +
theta B-Gene +
class I-Gene +
glutathione I-Gene +
S I-Gene -
- I-Gene -
transferase I-Gene +
( O -
rGSTTI-1 B-Gene -
) O +
from O +
rat O +
liver O +
had O +
an O +
affinity O +
for O +
dihalomethanes O +
lower O +
by O +
three O +
orders O +
of O +
magnitude O +
( O -
K O -
( O -
app O -
) O +
> O +
50 O +
mM O -
) O +
than O +
the O +
bacterial O +
DCM B-Gene +
dehalogenase I-Gene -
/ O -
GST B-Gene +
from O +
Methylophilus O +
sp. O +
DM11 O -
. O +

Unlike O +
the O +
bacterial O +
DCM B-Gene +
dehalogenase I-Gene -
, O +
the O +
rat O +
enzyme B-Gene +
was O +
unable O +
to O +
support O +
growth O +
of O +
the O +
dehalogenase B-Gene +
minus O +
Methylobacterium O +
sp. O +
DM4 O -
- O -
2cr O +
mutant O +
with O +
DCM O -
. O +

Moreover O -
, O +
the O +
presence O +
of O +
DCM O +
inhibited O +
growth O +
with O +
methanol O +
of O +
the O +
DM4 B-Gene -
- I-Gene -
2cr I-Gene +
transconjugant O +
expressing O +
the O +
rat O +
liver O +
GSTT1 B-Gene -
- I-Gene -
1 I-Gene -
. O +

In O +
Salmonella O +
typhimurium O +
TA1535 O -
, O +
expression O +
of O +
rat O +
and O +
bacterial O +
DCM O -
- O -
active O +
GST B-Gene +
from O +
a O +
plasmid O +
in O +
the O +
presence O +
of O +
DCM O +
yielded O +
up O +
to O +
5.3 O +
times O +
more O +
reversions O +
to O +
histidine O +
prototrophy O +
in O +
the O +
transconjugant O +
expressing O +
the O +
rat O +
enzyme B-Gene -
. O +

Under O +
the O +
same O +
conditions O -
, O +
however O -
, O +
GST B-Gene -
- O -
mediated O +
conversion O +
of O +
DCM O +
to O +
formaldehyde O +
was O +
lower O +
in O +
cell O -
- O -
free O +
extracts O +
of O +
the O +
transconjugant O +
expressing O +
the O +
rat O +
GSTT1 B-Gene +
than O +
in O +
the O +
corresponding O +
strain O +
expressing O +
the O +
bacterial O +
DCM B-Gene +
dehalogenase I-Gene -
. O +

This O +
provided O +
new O +
evidence O +
that O +
formaldehyde O +
was O +
not O +
the O +
main O +
toxicant O +
associated O +
with O +
GST B-Gene -
- O -
mediated O +
DCM O +
conversion O -
, O +
and O +
indicated O +
that O +
an O +
intermediate O +
in O +
the O +
transformation O +
of O +
DCM O +
by O +
GST B-Gene -
, O +
presumably O +
S O -
- O -
chloromethylglutathione O -
, O +
was O +
responsible O +
for O +
the O +
observed O +
effects O -
. O +

The O +
marked O +
differences O +
in O +
substrate O +
affinity O +
of O +
rat O +
and O +
bacterial O +
DCM B-Gene -
- I-Gene -
active I-Gene +
GST I-Gene -
, O +
as O +
well O +
as O +
in O +
the O +
toxicity O +
and O +
genotoxicity O +
associated O +
with O +
expression O +
of O +
these O +
enzymes B-Gene +
in O +
bacteria O -
, O +
suggest O +
that O +
bacterial O +
DCM B-Gene +
dehalogenases I-Gene -
/ O -
GST B-Gene +
have O +
evolved O +
to O +
minimise O +
the O +
toxic O +
effects O +
associated O +
with O +
glutathione O -
- O -
mediated O +
catalysis O +
of O +
DCM O +
conversion O -
. O +

Emotional O +
or O +
social O +
stress O +
is O +
consistently O +
viewed O +
as O +
an O +
important O +
factor O +
in O +
voluntary O +
ethanol O +
consumption O -
. O +

Isolation O +
stress O +
was O +
shown O +
to O +
be O +
one O +
of O +
the O +
factors O +
determining O +
the O +
inclination O +
to O +
voluntary O +
ethanol O +
intake O -
. O +

Furthermore O -
, O +
the O +
level O +
of O +
alcohol O +
motivation O +
directly O +
correlated O +
with O +
the O +
degree O +
of O +
stress O +
( O -
1 O -
) O -
. O +

Early O +
maternal O +
deprivation O +
may O +
predispose O +
animals O +
to O +
increased O +
ethanol O +
consumption O +
as O +
adults O +
( O -
2 O -
) O -
. O +

Also O -
, O +
adult O +
isolated O +
rats O +
drank O +
significantly O +
more O +
alcohol O +
than O +
control O +
rats O +
( O -
3 O -
) O -
. O +

Social O +
isolation O +
and O +
loneliness O +
may O +
contribute O +
to O +
ethanol O +
consumption O +
in O +
aged O +
humans O -
. O +

Late O -
- O -
onset O +
drinking O -
, O +
defined O +
as O +
onset O +
of O +
the O +
first O +
alcohol O +
problem O +
at O +
or O +
after O +
age O +
60 O -
, O +
is O +
believed O +
to O +
be O +
related O +
to O +
life O +
and O +
social O +
stress O +
of O +
aging O +
particularly O +
when O +
coping O +
with O +
resources O +
or O +
social O +
supports O +
are O +
inadequate O +
( O -
4 O -
- O -
5 O -
) O +
and O +
was O +
not O +
uncommon O +
( O -
6 O -
) O -
. O +

A O +
long O -
- O -
debated O +
" O -
tension O +
reduction O -
" O +
hypothesis O +
postulates O +
anti O -
- O -
anxiety O +
effects O +
to O +
be O +
important O +
for O +
ethanol O +
reward O -
, O +
and O +
states O +
that O +
elevated O +
anxiety O +
levels O +
might O +
predispose O +
to O +
ethanol O +
consumption O +
and O +
addiction O +
( O -
7 O -
) O -
. O +

Exposure O +
to O +
stress O +
can O +
increase O +
ethanol O +
consumption O +
and O +
ethanol O +
can O +
attenuate O +
the O +
behavioural O +
and O +
biochemical O +
effects O +
of O +
stress O +
( O -
8) O -
. O +

Furthermore O -
, O +
there O +
is O +
a O +
relationship O +
between O +
voluntary O +
ethanol O +
intake O +
and O +
escape O +
from O +
the O +
consequences O +
of O +
stress O +
( O -
9- O +
10 O -
) O -
. O +

In O +
rats O -
, O +
previous O +
reports O +
( O -
7 O -
) O +
support O +
a O +
relation O +
between O +
experimental O +
anxiety O +
and O +
voluntary O +
alcohol O +
consumption O -
. O +

Since O +
previous O +
reports O +
showed O +
that O +
alprazolam O -
, O +
a O +
benzodiazepine O +
anxiolytic O +
drug O -
, O +
partially O +
reversed O +
many O +
effects O +
of O +
stress O +
in O +
rodents O +
( O -
11 O -
- O -
15 O -
) O -
, O +
we O +
then O +
postulated O +
that O +
this O +
drug O +
should O +
affect O +
Corresponding O +
Author O -
: O +
Maria O +
J. O +
Nunez O -
. O +

Department O +
of O +
Nursing O -
. O +

E.U.E. O +
Universidad O +
de O +
Santiago O +
de O +
Compostela O -
. O +

Campus O +
Norte O -
. O +

Avda O -
. O +

Xoan O +
XXIII O -
, O +
s O -
/ O -
n O -
. O +

15075-Santiago O +
de O +
Compostela O -
. O +

SPAIN O +
PL-214 O +
Alprazolam O -
, O +
Ethanol O +
Consumption O +
and O +
Stress O +
Vol O -
. O +

64 O -
, O +
No. O +
20,1999 O +
the O +
free O -
- O -
choice O +
alcohol O +
consumption O +
in O +
aged O +
rats O +
exposed O +
to O +
stress O -
. O +

Therefore O -
, O +
in O +
the O +
present O +
report O +
we O +
study O +
the O +
effect O +
of O +
alprazolam O +
on O +
the O +
voluntary O +
alcohol O +
consumption O +
in O +
Sprague- O +
Dawley O +
aged O +
rats O +
exposed O +
to O +
isolation O +
stress O -
. O +

Methods O +
Rats O +
Aged O +
( O -
18 O +
months O -
) O +
female O +
rats O +
( O -
240 O +
10 O +
g O -
) O +
of O +
the O +
Sprague O -
- O -
Dawley O +
strain O +
( O -
Interfauna O +
Ibica O +
S.A. O -
, O +
Barcelona O -
, O +
Spain O -
) O +
were O +
used O -
. O +

They O +
were O +
housed O -
, O +
7 O +
days O +
before O +
experiments O -
, O +
five O +
per O +
cage O +
in O +
a O +
temperature O +
( O -
22 O -
- O -
24C O -
) O +
and O +
humidity O +
controlled O +
animal O +
room O -
, O +
with O +
an O +
alternating O +
12-hr O +
light O -
- O -
dark O +
cycle O +
( O -
lights O +
on O +
at O +
0600 O -
, O +
lights O +
off O +
at O +
1800 O -
) O -
, O +
with O +
food O +
( O -
Ultrasorb O -
, O +
PANLAB O -
, O +
Barcelona O -
, O +
Spain O -
) O +
and O +
drink O +
ad O +
libitum O -
. O +

Procedure O +
Twenty O +
five O +
rats O +
were O +
randomly O +
assigned O -
, O +
five O +
per O +
group O -
, O +
in O +
the O +
following O +
groups O +
according O +
to O +
the O +
treatment O +
they O +
were O +
submitted O +
to O -
: O +
GROUP O +
A. O +
unstimulated O +
controls O -
, O +
GROUP O +
B. O +
unstimulated O +
rats O +
injected O +
with O +
placebo O -
, O +
GROUP O +
C. O +
unstimulated O +
rats O +
injected O +
with O +
alprazolam O -
, O +
GROUP O +
D. O +
stressed O +
rats O +
injected O +
with O +
placebo O -
, O +
GROUP O +
E. O +
stressed O +
rats O +
injected O +
with O +
alprazolam O -
. O +

Drinking O +
solutions O +
Two O +
drinking O +
solutions O +
were O +
used O -
. O +

One O +
consisted O +
of O +
a O +
0.2 O -
% O +
saccharin O +
solution O +
and O +
the O +
other O +
consisted O +
of O +
the O +
same O +
solution O +
containing O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
ethanol O -
. O +

The O +
solutions O +
were O +
prepared O +
on O +
alternate O +
days O +
and O +
stored O +
in O +
air O -
- O -
tight O +
containers O +
until O +
used O -
. O +

Induction O +
of O +
stress O +
Isolation O +
stress O +
( O -
ISOL O -
) O +
was O +
conducted O +
by O +
placing O +
the O +
animals O +
alone O +
in O +
a O +
novel O +
environment O +
alone O -
. O +

Stress O +
periods O +
ranged O +
from O +
1 O +
to O +
4 O +
hours O +
on O +
a O +
random O +
unpredictable O +
schedule O +
distributed O +
throughout O +
during O +
the O +
day O -
. O +

The O +
total O +
amount O +
of O +
exposure O +
to O +
ISOL O +
was O +
of O +
12 O +
hours O -
. O +

Unstimulated O +
rats O +
were O +
exposed O +
only O +
to O +
the O +
normal O +
activity O +
of O +
the O +
animal O +
room O -
. O +

Groups O +
D O +
and O +
E O +
were O +
submitted O +
to O +
the O +
same O +
ISOL O +
exposure O -
. O +

Following O +
a O +
10 O +
day O +
baseline O +
period O -
, O +
the O +
animals O +
were O +
given O +
4 O +
day O +
of O +
ISOL O +
on O +
an O +
unpredictable O +
schedule O -
, O +
followed O +
by O +
4 O +
day O +
recovery O +
period O +
( O -
16 O -
) O -
. O +

Cages O +
( O -
Cage O +
FI O -
, O +
Iffa O -
- O -
Credo O -
, O +
Griffa O +
SA O -
, O +
Barcelona O -
, O +
Spain O -
) O +
of O +
305 O +
mm O +
depth O +
x O +
180 O +
mm O +
width O +
x O +
184 O +
mm O +
height O +
internal O +
dimensions O +
were O +
used O +
both O +
for O +
control O +
housing O +
conditions O +
and O +
ISOL O -
. O +

They O +
were O +
always O +
placed O +
in O +
the O +
same O +
animal O +
room O -
. O +

Quantification O +
of O +
alcohol O +
consumption O +
During O +
days O +
1 O -
- O -
7 O -
, O +
the O +
saccharin O +
solution O +
was O +
presented O +
in O +
both O +
tubes O -
. O +

Following O +
this O -
, O +
saccharin O +
was O +
presented O +
in O +
one O +
tube O +
and O +
ethanol O -
- O -
saccharin O +
in O +
the O +
other O +
tube O +
for O +
the O +
duration O +
of O +
the O +
study O -
. O +

The O +
volumes O +
remaining O +
in O +
each O +
tube O +
were O +
recorded O +
daily O +
during O +
the O +
period O +
11.00 O -
- O -
13.00 O +
hours O -
, O +
the O +
tubes O +
were O +
refilled O +
and O +
their O +
positions O +
( O -
left O -
- O -
right O -
) O +
alternated O +
to O +
prevent O +
the O +
development O +
of O +
positional O +
preference O +
( O -
16 O -
) O -
. O +

Daily O +
fluid O +
consumption O +
( O -
both O +
ethanol O +
and O +
saccharin O -
) O +
and O +
body O +
weight O +
were O +
monitored O +
and O +
daily O +
ethanol O +
intake O +
in O +
g O -
/ O -
Kg O +
per O +
day O +
were O +
calculated O +
( O -
17 O -
) O -
. O +

Low O -
, O +
medium O +
and O +
high O +
ethanol O +
consumption O +
were O +
defined O +
by O +
the O +
means O +
of O +
daily O +
ethanol O +
consumption O +
( O -
1.5 O -
- O -
2.5 O -
; O +
2.5- O +
4.5 O -
; O +
4.5 O -
- O -
6.0 O +
g O -
/ O -
Kg O -
/ O -
day O -
, O +
respectively O -
) O +
( O -
18 O -
) O -
. O +

Drug O +
treatments O +
Alprazolam O +
was O +
intraperitoneally O +
injected O +
at O +
1 O +
mg O -
/ O -
Kg O -
, O +
in O +
a O +
volume O +
of O +
1 O +
ml O -
/ O -
kg O +
of O +
1 O -
% O +
aqueous O +
solution O +
of O +
carboxymethylcellulose O +
as O +
vehicle O -
. O +

The O +
same O +
volume O +
of O +
diluent O +
was O +
used O +
as O +
placebo O -
. O +

Drugs O +
were O +
daily O +
administerd O +
at O +
09.30 O +
a.m. O +
Statistical O +
analysis O +
Mean O +
24 O +
hour O +
fluid O +
consumption O +
for O +
each O +
group O +
of O +
animals O +
was O +
computed O +
in O +
g O -
/ O -
Kg O +
body O +
weight O +
SEM O -
. O +

Statistical O +
analysis O +
was O +
performed O +
using O +
the O +
ANOVA O +
with O +
grouping O +
of O +
means O +
by O +
Student O +
Newman O -
- O -
Keuls O +
multiple O +
range O +
tests O +
with O +
significance O +
set O +
at O +
p O +
< O +
0.05 O +
( O -
16 O -
) O -
. O +

Vol O -
. O +

64 O -
, O +
No. O +
20 O -
, O +
1999 O +
Alprazolam O -
, O +
Ethanol O +
Consumption O +
and O +
Stress O +
PL-215 O +
Results O +
Table O +
1 O +
summarizes O +
the O +
data O +
from O +
the O +
study O -
. O +

Isolation O +
stress O +
significantly O +
increased O +
the O +
ethanol O +
consumption O +
of O +
the O +
Sprague O -
- O -
Dawley O +
aged O +
rats O -
. O +

Stress O +
induced O +
high O +
ethanol O +
consumption O +
compared O +
to O +
those O +
of O +
the O +
control O +
and O +
unstressed O +
group O +
rats O -
, O +
which O +
exhibited O +
a O +
medium O +
ethanol O +
intake O -
. O +

Also O -
, O +
at O +
the O +
post O -
- O -
stress O +
period O +
stressed O +
animals O +
exhibited O +
a O +
significantly O +
greater O +
ethanol O +
consumption O +
than O +
control O +
and O +
non O -
- O -
stressed O +
groups O -
. O +

Treatment O +
with O +
alprazolam O +
( O -
1 O +
mg O -
/ O -
Kg O -
) O +
partially O +
reversed O +
that O +
adverse O +
effect O +
of O +
stress O -
. O +

Treatment O +
with O +
drugs O +
did O +
not O +
affect O +
the O +
free- O +
choice O +
ethanol O +
consumption O +
in O +
unstressed O +
rats O -
. O +

Saccharin O +
consumption O +
was O +
not O +
influenced O +
by O +
ISOL O +
stress O -
. O +

Total O +
fluid O +
consumption O +
was O +
significantly O +
increased O +
in O +
stressed O +
rats O -
, O +
because O +
of O +
the O +
significant O +
increase O +
in O +
ethanol O +
consumption O +
in O +
stressed O +
rats O +
as O +
compared O +
to O +
control O +
and O +
unstressed O +
groups O +
( O -
Table O +
II O -
) O -
. O +

TABLE O +
I O +
Effects O +
of O +
alprazolam O +
on O +
ethanol O +
consumption O +
in O +
stressed O +
rats O -
. O +

Control O +
3.6 O +
0.2 O +
Placebo O +
Alprazolam O +
Stress O +
+ O +
placebo O +
Stress O +
+ O +
alprazolam O +
Baseline O +
Isolation O +
Recovery O +
3.4 O +
.2 O +
3.7 O +
.2 O +
3.6 O +
.3 O +
3.8 O +
.3 O +
3.9 O +
.3 O +
3.7 O +
0.6 O +
3.6 O +
.1 O +
8.2 O +
.9 O -
' O +

* O +
7.0 O +
.2 O -
" O -
* O +
3.4 O +
.4 O +
5.4.2 O -
" O +
5.5.3 O -
' O -
* O +
Each O +
value O +
represents O +
the O +
mean O +
24 O +
hour O +
consumption O +
value O +
( O -
g O -
/ O -
Kg O +
SD O -
) O +
of O +
5 O +
rats O +
over O +
4 O +
day O +
periods O -
. O +

Statistical O +
analysis O +
was O +
performed O +
using O +
the O +
ANOVA O +
with O +
grouping O +
of O +
means O +
by O +
Student O +
Newman O -
- O -
Keuls O +
multiple O +
range O +
tests O +
with O +
significance O +
set O +
at O +
p O +
< O +
0.05 O +
( O -
14 O -
) O -
. O +
" O +

Significant O +
difference O +
from O +
control O +
rats O +
( O -
p O +
< O +
0.01 O -
) O -
. O +

* O +
Differences O +
between O +
placebo O +
and O +
alprazolam O +
significant O +
at O +
p O +
< O +
0.01 O -
. O +

TABLE O +
II O +
Effects O +
of O +
alprazolam O +
on O +
fluid O +
consumption O +
in O +
stressed O +
rats O -
. O +

Control O +
S O +
11.8 O +
.6 O +
T O +
15.4 O +
.8 O +
Baseline O +
Isolation O +
Recovery O +
Placebo O +
S O +
11.5 O +
.5 O +
12.0 O +
.3 O +
11.1 O +
.5 O +
T O +
14.9 O +
.7 O +
15.7 O +
.5 O +
14.7 O +
.8 O +
Alprazolam O +
S O +
12.2 O +
.2 O +
12.3 O +
.4 O +
12.0 O +
.1 O +
T O +
16.0 O +
.5 O +
16.2 O +
.7 O +
15.7 O +
.7 O +
Stress O +
+ O +
placebo O +
S O +
12.8 O +
.1 O +
12.6 O +
.7 O +
13.0 O +
.4 O +
T O +
16.4 O +
.2 O +
20.8 O +
.6 O -
' O +

* O +

20.0 O +
.6 O -
" O -
' O +
Stress O +
+ O +
alprazolam O +
S O +
12.4 O +
.3 O +

11.2 O +
.4 O +
11.5 O +
.7 O +

T O +
15.8 O +
.7 O +
16.6 O +
.6 O -
' O +

* O +
17.0 O +
1.0'- O +
Each O +
value O +
represents O +
the O +
mean O +
24 O +
hour O +
consumption O +
value O +
( O -
g O -
/ O -
Kg O +
SD O -
) O +
of O +
5 O +
rats O +
over O +
4 O +
day O +
periods O -
. O +

Statistical O +
analysis O +
was O +
performed O +
using O +
the O +
ANOVA O +
with O +
grouping O +
of O +
means O +
by O +
Student O +
Newman O -
- O -
Keuls O +
multiple O +
range O +
tests O +
with O +
significance O +
set O +
at O +
p O +
< O +
0.05 O +
( O -
14 O -
) O -
. O +
' O +

Significant O +
difference O +
from O +
control O +
rats O +
( O -
p O +
< O +
0.01 O -
) O -
. O +

* O -
Differences O +
between O +
placebo O +
and O +
alprazolam O +
significant O +
at O +
p O +
< O +
0.01 O -
. O +

( O -
S O -
: O +
Saccharine O -
; O +
T O -
: O +
Total O -
) O +
PL-216 O +
Alprazolam O -
, O +
Ethanol O +
Consumption O +
and O +
Stress O +
Vol O -
. O +

64 O -
, O +
No. O +
20 O -
, O +
1999 O +

Discussion O +
The O +
presented O +
data O +
shows O +
that O +
isolation O +
stress O +
powerfully O +
increased O +
the O +
voluntary O +
ethanol O +
consumption O +
in O +
aged O +
rats O -
. O +

Our O +
data O +
is O +
in O +
good O +
agreement O +
with O +
those O +
previously O +
reported O +
in O +
young O +
and O +
adult O +
rats O +
( O -
2 O -
, O +
3 O -
, O +
7 O -
, O +
19 O -
) O -
. O +

Stress O +
activates O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenocortical O +
( O -
HPA O -
) O +
axis O -
. O +

At O +
least O +
one O +
of O +
the O +
neuroendocrine O +
responses O +
to O +
stress O -
, O +
i.e. O +
the O +
adrenal O +
corticosterone O +
hypersrion O +
via O +
ACTH B-Gene +
secretion O -
, O +
has O +
been O +
shown O +
to O +
modulate O +
stress O +
increased O +
ethanol O +
consumption O +
( O -
20 O -
- O -
22 O -
) O -
. O +

Firstly O -
, O +
adrenalectomized O +
rats O +
showed O +
neither O +
evidence O +
of O +
enhancement O +
( O -
21 O -
) O +
nor O +
did O +
decrease O +
their O +
ethanol O +
intake O +
compared O +
to O +
the O +
sham O -
- O -
operated O +
controls O +
( O -
22 O -
) O -
, O +
and O +
the O +
treatment O +
with O +
corticosterone O +
restored O +
the O +
intake O +
of O +
ethanol O +
to O +
the O +
preoperative O +
level O +
( O -
22 O -
) O -
. O +

In O +
contrast O -
, O +
treatment O +
with O +
aldosterone O +
had O +
no O +
effect O +
on O +
ethanol O +
intake O +
( O -
22 O -
) O -
. O +

Secondly O -
, O +
treatment O +
of O +
stressed O +
rats O +
with O +
the O +
enzyme B-Gene +
inhibitor O +
cyanoketone O -
, O +
which O +
blocks O +
stress O -
- O -
induced O +
but O +
not O +
basal O +
corticosterone O +
secretion O -
, O +
at O +
least O +
partially O +
prevented O +
the O +
stress O -
- O -
induced O +
increase O +
in O +
ethanol O +
drinking O +
( O -
21 O -
) O -
. O +

Also O -
, O +
exposure O +
to O +
repetitive O +
unpredictable O +
stressful O +
stimuli O +
did O +
not O +
induce O +
the O +
free O -
- O -
choice O +
post O -
- O -
stress O +
consumption O +
of O +
ethanol O +
either O +
in O +
hypophysectomized O +
rats O +
or O +
chronic O +
dexamentasone O +
treated O +
rats O +
( O -
20 O -
) O -
. O +

Aged O +
rats O +
exposed O +
to O +
unpredictable O +
stressful O +
stimuli O +
increased O +
their O +
ethanol O +
intake O +
during O +
the O +
stress O +
period O +
and O +
maintained O +
this O +
increase O +
throughout O +
the O +
entire O +
post O -
- O -
stress O +
period O +
as O +
compared O +
to O +
non O -
- O -
stressed O +
animals O -
. O +

There O +
is O +
an O +
age O -
- O -
related O +
deficiency O +
in O +
HPA O +
response O +
to O +
stress O +
as O +
well O +
as O +
decline O +
in O +
negative O +
feed O -
- O -
back O +
sensitivity O +
to O +
glucocorticoids O +
( O -
23 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
ethanol O +
stimulates O +
corticosterone O +
secretion O +
in O +
rats O +
( O -
24 O -
) O -
. O +

But O -
, O +
whereas O +
young O +
rats O +
exhibit O +
complete O +
tolerance O +
to O +
the O +
stimulatory O +
effects O +
of O +
ethanol O +
on O +
corticosterone O +
levels O -
, O +
impaired O +
adaptation O +
of O +
the O +
hypotalamic O -
- O -
pituitary O -
- O -
adrenal O +
axis O +
to O +
ethanol O +
in O +
aged O +
rats O +
was O +
reported O +
( O -
24 O -
) O -
. O +

Thus O -
, O +
the O +
loss O +
in O +
the O +
ability O +
to O +
down O -
- O -
regulate O +
both O -
, O +
stress O +
and O +
ethanol O +
responses O -
, O +
and O +
the O +
elevated O +
glucocorticoids O +
might O +
induce O +
increased O +
ethanol O +
consumption O +
during O +
post O -
- O -
stress O +
period O +
noted O +
in O +
our O +
study O -
. O +

Alprazolam O +
partially O +
reversed O +
the O +
adverse O +
effect O +
of O +
stress O +
on O +
the O +
free O -
- O -
choice O +
alcohol O +
consumption O -
. O +

It O +
has O +
been O +
reported O +
that O +
anxiolytics O +
reduced O +
the O +
response O +
of O +
CRF B-Gene -
, O +
ACTH B-Gene +
and O +
corticosterone O +
to O +
stress O +
( O -
11 O -
, O +
25 O -
- O -
26 O -
) O -
; O +
so O +
this O +
might O +
be O +
one O +
of O +
the O +
reasons O +
to O +
reverse O +
the O +
increase O +
in O +
alcohol O +
consumption O +
induced O +
by O +
stress O +
This O +
is O +
a O +
benzodiazepine O +
agonist O +
with O +
well O -
- O -
known O +
anxiolytic O +
properties O +
which O +
was O +
found O +
to O +
reduce O +
the O +
stress O -
- O -
induced O +
decrease O +
in O +
the O +
immune O +
function O +
( O -
12 O -
- O -
14 O -
) O -
, O +
which O +
was O +
associated O +
with O +
a O +
proportional O +
suppression O +
of O +
the O +
stress O -
- O -
induce O +
a O +
increase O +
in O +
plasma O +
ACTH B-Gene +
levels O +
( O -
27 O -
) O +
which O +
were O +
attributed O +
to O +
activation O +
of O +
GABA O -
- O -
linked O +
BZD B-Gene +
receptors I-Gene +
in O +
the O +
CNS O -
. O +

Central O +
pharmacological O +
effects O +
related O +
to O +
the O +
central O +
type O +
benzodiazepine O +
( O -
BZD O -
) O +
acting O +
by O +
facilitating O +
inhibitory O +
GABA O +
neurotransmission O +
in O +
CNS O +
may O +
regulate O +
the O +
release O +
of O +
neuroendocrine O +
hormones O +
involved O +
in O +
the O +
response O +
to O +
stress O -
. O +

In O +
summary O -
, O +
the O +
present O +
results O +
suggest O +
that O +
exposure O +
to O +
unpredictable O +
isolation O +
stress O +
produces O +
enhancement O +
of O +
ethanol O +
consumption O +
at O +
the O +
stress O +
and O +
post O -
- O -
stress O +
periods O -
, O +
which O +
are O +
partially O +
reversed O +
by O +
alprazolam O -
. O +

Acknowledgements O +
. O +

To O +
J.A. O +
Veira O +
for O +
his O +
comments O +
on O +
the O +
manuscript O -
. O +

We O +
investigated O +
the O +
effect O +
of O +
tetrahydroswertianolin O +
( O -
THS O -
) O -
, O +
a O +
hepatoprotective O +
agent O +
from O +
Swertia O +
japonica O -
, O +
on O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene -
- I-Gene -
alpha I-Gene +
( O -
TNF B-Gene -
- I-Gene -
alpha I-Gene -
) O -
-dependent O +
hepatic O +
apoptosis O +
induced O +
by O +
D O -
- O -
galactosamine O +
( O -
D O -
- O -
GalN O -
) O +
( O -
700 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
and O +
lipopolysaccharide O +
( O -
LPS O -
) O +
( O -
10 O +
microg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
in O +
mice O -
. O +

Apoptotic O +
symptoms O +
were O +
observed O +
at O +
the O +
initial O +
stage O +
of O +
liver O +
damage O -
. O +

By O +
5 O +
hr O +
after O +
intoxication O -
, O +
hepatic O +
DNA O +
fragmentation O +
had O +
risen O +
to O +
2123 O -
% O -
, O +
with O +
the O +
value O +
in O +
untreated O +
mice O +
set O +
at O +
100 O -
% O -
, O +
without O +
a O +
significant O +
elevation O +
of O +
serum B-Gene +
alanine I-Gene +
transaminase I-Gene +
( O -
ALT B-Gene -
) O +
activity O -
. O +

There O +
was O +
a O +
parallel O +
increase O +
in O +
hepatocytes O +
undergoing O +
chromatin O +
condensation O +
and O +
apoptotic O +
body O +
formation O -
. O +

By O +
8 O +
hr O +
after O +
intoxication O -
, O +
serum O +
ALT B-Gene +
activity O +
had O +
risen O +
to O +
3707 O +
U O -
/ O -
L. O +
Pretreatment O +
with O +
THS O +
( O -
50 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
) O +
at O +
18 O +
and O +
2 O +
hr O +
before O +
intoxication O +
significantly O +
reduced O +
DNA O +
fragmentation O +
to O +
821 O -
% O +
of O +
that O +
in O +
untreated O +
mice O +
and O +
prevented O +
the O +
emergence O +
of O +
chromatin O +
condensation O +
and O +
apoptotic O +
body O +
formation O -
. O +

A O +
significant O +
and O +
dose O -
- O -
dependent O +
reduction O +
in O +
serum O +
ALT B-Gene +
activity O +
at O +
8 O +
hr O +
also O +
was O +
observed O +
with O +
THS O +
pretreatment O -
. O +

These O +
effects O +
of O +
THS O +
were O +
different O +
from O +
those O +
observed O +
from O +
pretreatment O +
with O +
glycyrrhizin O +
( O -
GCR O -
) O -
, O +
which O +
is O +
a O +
clinically O +
used O +
hepatoprotective O +
agent O +
with O +
membrane O -
- O -
stabilizing O +
activity O -
. O +

GCR O +
pretreatment O +
( O -
100 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
) O +
did O +
not O +
inhibit O +
hepatic O +
DNA O +
fragmentation O +
( O -
1588 O -
% O +
of O +
untreated O +
mice O -
) O -
, O +
although O +
this O +
compound O +
significantly O +
protected O +
against O +
serum O +
ALT B-Gene +
elevation O +
( O -
1463 O +
U O -
/ O -
L O -
) O -
. O +

These O +
data O +
suggest O +
that O +
an O +
inhibitory O +
effect O +
on O +
the O +
progression O +
of O +
hepatic O +
apoptosis O +
prior O +
to O +
liver O +
injury O +
may O +
be O +
involved O +
in O +
the O +
hepatoprotective O +
mechanisms O +
of O +
THS O -
, O +
whereas O +
it O +
appears O +
that O +
GCR O +
affects O +
the O +
processes O +
after O +
apoptosis O -
. O +

In O +
a O +
separate O +
experiment O -
, O +
we O +
found O +
that O +
the O +
concentration O +
of O +
serum O +
TNF B-Gene -
- I-Gene -
alpha I-Gene +
rose O +
to O +
2016 O +
pg O -
/ O -
mL O +
at O +
1 O +
hr O +
after O +
intoxication O +
of O +
mice O +
with O +
D O -
- O -
GalN O +
and O +
LPS O -
, O +
but O +
this O +
increase O +
was O +
suppressed O +
by O +
THS O +
pretreatment O +
( O -
10 O -
, O +
50 O -
, O +
or O +
200 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
) O +
to O +
716 O -
, O +
454 O -
, O +
or O +
406 O +
pg O -
/ O -
mL O -
, O +
respectively O -
. O +

Further O +
study O +
with O +
a O +
reverse B-Gene +
transcriptase I-Gene -
- I-Gene -
polymerase I-Gene +
chain O +
reaction O +
method O +
showed O +
that O +
THS O +
blocked O +
TNF B-Gene -
- I-Gene -
alpha I-Gene +
production O +
at O +
the O +
transcriptional O +
level O -
. O +

Because O +
TNF B-Gene -
- I-Gene -
alpha I-Gene +
is O +
a O +
critical O +
mediator O +
to O +
elicit O +
apoptosis O +
in O +
this O +
model O -
, O +
the O +
property O +
of O +
suppressing O +
TNF B-Gene -
- I-Gene -
alpha I-Gene +
production O +
may O +
be O +
of O +
prime O +
importance O +
for O +
THS O +
inhibition O +
of O +
hepatic O +
apoptosis O -
. O +

Dinucleoside O +
polyphosphates O +
( O -
Npn O +
N O -
) O +
are O +
molecules O +
of O +
crescent O +
interest O +
in O +
metabolic O +
regulation O +
and O +
cell O +
signaling O +
[ O -
1–3 O -
] O +
. O +

Diadenosine O +
tetraphosphate O +
( O -
Ap4 O +
A O -
) O +
is O +
present O +
at O +
( O -
sub O -
) O -
micromolar O +
concentration O +
in O +
all O +
the O +
prokaryotic O +
and O +
eukaryotic O +
tissues O +
examined O +
[ O -
4 O -
] O +
. O +

The O +
occurrence O +
of O +
Ap4 O +
A O -
, O +
Ap5 O +
A O +
and O +
Ap6 O +
A O +
has O +
been O +
reported O +
in O +
the O +
dense O +
granules O +
of O +
human O +
blood O +
platelets O +
[ O -
5–7 O -
] O +
, O +
in O +
some O +
rat O +
brain O +
synaptic O +
terminals O +
[ O -
8 O -
, O +
9 O -
] O +
and O +
in O +
chromaffin O +
granules O +
of O +
bovine O +
adrenal O +
medullary O +
gland O +
[ O -
10–13 O -
] O +
. O +

The O +
concentration O +
of O +
ATP O +
in O +
both O +
the O +
total O +
adrenal O +
medullary O +
tissue O +
and O +
in O +
chromaffin O +
granules O +
is O +
three O +
orders O +
of O +
magnitude O +
higher O +
than O +
that O +
of O +
Ap4 O +
A O +
[ O -
13 O -
] O +
. O +

Upon O +
liberation O +
from O +
the O +
adrenal O +
medulla O -
, O +
after O +
an O +
appropriate O +
stimulus O -
, O +
the O +
rate O +
of O +
hydrolysis O +
of O +
the O +
secreted O +
ATP O +
is O +
so O +
high O +
that O +
less O +
than O +
1 O -
% O +
remains O +
as O +
ATP O -
, O +
whereas O +
the O +
secreted O +
Ap4 O +
A O +
was O +
apparently O +
degraded O +
at O +
a O +
much O +
slower O +
rate O +
[ O -
12 O -
, O +
13 O -
] O +
. O +

Probably O +
both O +
ATP O +
and O +
Ap4 O +
A O +
are O +
hydrolyzed O +
by O +
phosphodiesterases B-Gene +
[ O -
14–16 O -
] O +
( O -
and O +
phosphatases B-Gene +
and O +
nucleotidases B-Gene +
for O +
ATP O -
) O +
located O +
in O +
the O +
outer O +
aspect O +
of O +
cell O +
plasma O +
membranes O +
and O +
the O +
ATP O +
itself O +
could O +
be O +
a O +
competitive O +
inhibitor O +
of O +
the O +
degradation O +
of O +
Ap4 O +
A O +
in O +
the O +
extracellular O +
fluid O +
[ O -
12 O -
] O +
. O +

For O +
that O +
reason O -
, O +
the O +
use O +
of O +
Ap4 O +
A O +
monitoring O +
as O +
a O +
reliable O +
index O +
of O +
true O +
secretion O +
from O +
chromaffin O +
granules O +
was O +
suggested O +
[ O -
12 O -
] O +
. O +

The O +
secreted O +
ATP O -
, O +
the O +
diadenosine O +
polyphosphates O -
, O +
and O +
their O +
products O +
of O +
hydrolysis O +
may O +
interact O +
with O +
not O +
yet O +
well O +
defined O +
purine B-Gene +
receptors I-Gene -
, O +
P2X B-Gene +
, O +
P2Y B-Gene +
, O +
P2D B-Gene +
, O +
P4 B-Gene +
and O +
P1 B-Gene +
[ O -
17–20 O -
] O +
, O +
and O +
modulate O +
a O +
variety O +
of O +
processes O +
such O +
as O +
vascular O +
tone O +
[ O -
6 O -
, O +
21–23 O -
] O +
, O +
cell O +
proliferation O +
[ O -
24 O -
, O +
25 O -
] O +
, O +
cardiac O +
function O +
[ O -
26 O -
] O +
, O +
neurotransmission O +
[ O -
17 O -
, O +
27 O -
] O +
, O +
platelet O +
aggregation O +
[ O -
28 O -
] O +
, O +
glucose O +
metabolism O +
[ O -
29 O -
, O +
30 O -
] O +
, O +
cellular O +
pH O +
[ O -
31 O -
] O +
and O +
neutrophil O +
function O +
[ O -
32 O -
] O +
. O +

The O +
potential O +
implication O +
of O +
dinucleoside O +
polyphosphates O +
in O +
the O +
pathogenesis O +
of O +
hypertension O +
and O +
atherosclerosis O +
has O +
been O +
suggested O +
[ O -
7 O -
, O +
23 O -
] O +
and O +
their O +
longer O +
stability O +
in O +
vivo O +
in O +
relation O +
to O +
ATP O +
have O +
inspired O +
basic O +
research O +
on O +
the O +
potential O +
clinical O +
utility O +
of O +
some O +
chemical O +
analogues O +
[ O -
33 O -
] O +
. O +

Of O +
special O +
interest O +
in O +
relation O +
to O +
this O +
paper O +
is O +
the O +
strong O +
vasoconstrictor O +
effect O +
reported O +
for O +
diadenosine O +
hexaphosphate O +
( O -
Ap6 O +
A O -
) O +
and O +
diadenosine O +
pentaphosphate O +
( O -
Ap5 O +
A O -
) O +
in O +
the O +
isolated O +
perfused O +
rat O +
kidney O +
at O +
concentrations O +
as O +
low O +
as O +
1 O +
nM O +
[ O -
6 O -
] O +
. O +

The O +
synthesis O +
of O +
both O +
Ap6 O +
A O +
and O +
Ap5 O +
A O +
catalyzed O +
by O +
firefly O +
luciferase B-Gene +
has O +
been O +
previously O +
reported O +
[ O -
34 O -
] O +
. O +

However O -
, O +
this O +
enzyme B-Gene +
apparently O +
only O +
exists O +
in O +
the O +
lanterns O +
of O +
fireflies O +
and O +
not O +
in O +
mammals O -
. O +

The O +
synthesis O +
of O +
a O +
variety O +
of O +
mono- O +
and O +
dinucleoside O +
polyphosphates O -
, O +
including O +
adenosine O +
tetraphosphate O +
( O -
p4 O +
A O -
) O -
, O +
adenosine O +
pentaphosphate O +
( O -
p5 O +
A O -
) O -
, O +
Ap4 O +
A O -
, O +
Ap5 O +
A O -
, O +
and O +
various O +
heterodinucleoside O +
tetraphosphates O +
( O -
Ap4 O +
N O -
) O +
by O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
from O +
Pseudomonas O +
fragi O +
has O +
been O +
recently O +
reported O +
[ O -
35 O -
] O +
. O +

The O +
objet O +
of O +
this O +
report O +
is O +
to O +
present O +
evidence O +
that O +
this O +
enzyme B-Gene +
also O +
catalyzes O +
the O +
synthesis O +
of O +
the O +
strong O +
vasoactive O +
diadenosine O +
hexaphosphate O +
( O -
Ap6 O +
A O -
) O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
The O +
commercial O +
preparation O +
of O +
Pseudomonas O +
fragi O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
was O +
from O +
Boehringer O +
Mannheim O +
( O -
catalogue O +
no. O +
1002406 O -
; O +
lot O -
: O +
94110725 O -
) O -
. O +

The O +
lyophilyzed O +
powders O +
were O +
dissolved O +
( O -
3.62 O +
mg O -
/ O -
mL O -
) O +
in O +
25 O +
mM O +
Hepes O -
/ O -
KOH O +
( O -
pH O +
7.6 O -
) O -
, O +
0.1 O +
mM O +
dithiothreitol O -
, O +
5 O -
% O +
glycerol O +
and O +
0.1 O -
% O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene -
. O +

Dithiothreitol O -
, O +
ammonium O +
tetrapolyphosphate O +
( O -
P4 O +
) O +
and O +
nucleotides O +
were O +
from O +
Sigma O -
. O +

Bovine B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
fraction O +
V O -
; O +
fatty O +
acids O +
free O -
) O -
, O +
phosphodiesterase B-Gene +
from O +
Crotalus O +
durissus O +
( O -
catalogue O +
no. O +
108260 O -
) O -
, O +
alkaline B-Gene +
phosphatase I-Gene +
( O -
EC O +
3.1.3.1 O -
) O +
from O +
calf O +
intestine O +
( O -
catalogue O +
no. O +
108138 O -
) O +
and O +
inorganic O +
pyrophosphatase O +
( O -
EC O +
3.6.1.1 O -
) O +
from O +
yeast O +
( O -
catalogue O +
no. O +
108987 O -
) O +
were O +
purchased O +
from O +
Boehringer O +
Mannheim O -
. O +

Asymmetrical O +
dinucleoside B-Gene +
tetraphosphatase I-Gene +
was O +
purified O +
from O +
rat O +
liver O +
as O +
described O +
by O +
Sillero O +
et O +
al. O +
[ O -
36 O -
] O +
. O +

Pyrophosphatase B-Gene +
was O +
desalted O +
by O +
ultrafiltration O +
using O +
microconcentrators O +
with O +
exclusion O +
limit O +
membranes O +
of O +
30 O +
kDa O +
( O -
from O +
Vivascience O -
) O +
[ O -
35 O -
] O +
. O +

HPLC O +
chromatographs O +
were O +
from O +
Hewlett O +
Packard O +
or O +
from O +
Waters O -
. O +

The O +
Hypersil O +
ODS O +
and O +
Mono O +
Q O +
columns O +
were O +
from O +
Hewlett O +
Packard O +
and O +
Pharmacia O -
, O +
respectively O -
. O +

2.2 O +
Methods O +
All O +
the O +
incubations O +
were O +
performed O +
at O +
30 O +
° O -
C O -
. O +

2.3 O +
Synthesis O +
of O +
Ap6 O +
A O +
using O +
ATP O +
and O +
P4 O +
as O +
substrates O +
of O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
The O +
reaction O +
mixture O +
( O -
0.4 O +
mL O -
) O +
contained O +
50 O +
mM O +
MES O -
- O -
KOH O +
( O -
pH O +
5.5 O -
) O -
, O +
0.1 O +
mM O +
dithiothreitol O -
, O +
10 O +
mM O +
MgCl2 O +
, O +
4.4 O +
mM O +
ATP O -
, O +
5 O +
mM O +
P4 O +
, O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
from O +
Pseudomonas O +
fragi O +
( O -
0.325 O +
mg O +
protein O -
/ O -
mL O -
) O +
and O +
desalted O +
pyrophosphatase O +
( O -
1.2 O -
% O -
; O +
v O -
/ O -
v O -
) O -
. O +

20 O +
μL O +
aliquots O +
were O +
withdrawn O +
at O +
various O +
times O +
of O +
incubation O +
at O +
30 O +
° O -
C O -
, O +
diluted O +
with O +
180 O +
μL O +
of O +
water O -
, O +
kept O +
at O +
100 O +
° O -
C O +
for O +
90 O +
s O -
, O +
chilled O -
, O +
filtered O +
and O +
analyzed O +
by O +
HPLC O +
using O +
an O +
Hypersil O +
ODS O +
column O +
( O -
100 O +
mm O +
× O +
2.1 O +
mm O -
) O -
. O +

Elutions O +
were O +
performed O +
at O +
a O +
constant O +
flow O +
rate O +
( O -
0.5 O +
mL O +
/min O -
) O +
with O +
a O +
20-min O +
linear O +
gradient O +
( O -
5–30 O +
mM O -
) O +
of O +
sodium O +
phosphate O +
( O -
pH O +
7.5 O -
) O +
in O +
20 O +
mM O +
tetrabutylammonium O +
bromide O -
/ O -
20 O -
% O +
methanol O +
( O -
buffer O +
A O -
) O -
, O +
followed O +
by O +
a O +
10-min O +
linear O +
gradient O +
( O -
30–100 O +
mM O -
) O +
of O +
sodium O +
phosphate O +
( O -
pH O +
7.5 O -
) O +
in O +
buffer O +
A. O +
2.4 O +
Purification O +
of O +
the O +
synthesized O +
Ap6 O +
A O +
Reaction O +
mixtures O +
were O +
set O +
up O +
as O +
described O +
above O -
. O +

After O +
incubation O +
for O +
40 O +
h O +
they O +
were O +
heated O +
at O +
100 O +
° O -
C O +
for O +
90 O +
s O -
, O +
centrifuged O -
, O +
the O +
supernatant O +
brought O +
to O +
pH O +
7.8 O +
with O +
HEPES O -
- O -
KOH O +
mM O +
and O +
treated O +
with O +
25 O +
μg O +
of O +
protein B-Gene -
/ O -
mL O +
alkaline O +
phosphatase O +
during O +
2 O +
h. O +
At O +
the O +
end O +
of O +
the O +
incubation O -
, O +
the O +
mixtures O +
were O +
heated O +
at O +
100 O +
° O -
C O +
for O +
90 O +
s O -
, O +
centrifuged O +
and O +
all O +
the O +
supernatant O +
injected O +
into O +
a O +
Mono O +
Q O +
column O +
( O -
0.5 O +
cm O +
× O +
5 O +
cm O -
) O +
( O -
Pharmacia O -
) O +
and O +
eluted O +
( O -
HPLC O -
) O +
with O +
40 O +
min O +
linear O +
NH4 O +
HCO3 O +
gradient O +
( O -
0.5–0.7 O +
M O -
) O -
. O +

The O +
fractions O +
containing O +
the O +
presumed O +
Ap6 O +
A O +
were O +
pooled O -
, O +
an O +
aliquot O +
was O +
rechromatographed O +
in O +
the O +
same O +
conditions O +
to O +
establish O +
the O +
purity O +
of O +
the O +
pool O -
, O +
and O +
the O +
rest O +
concentrated O +
by O +
lyophilization O -
. O +

2.5 O +
Characterization O +
of O +
the O +
synthesized O +
Ap6 O +
A. O +
Phosphodiesterase B-Gene +
treatment O +
The O +
reaction O +
mixture O +
( O -
0.17 O +
mL O -
) O +
contained O +
15 O +
μM O +
of O +
purified O +
Ap6 O +
A O -
, O +
50 O +
mM O +
HEPES O -
- O -
KOH O +
( O -
pH O +
7.2 O -
) O +
and O +
commercial O +
phosphodiesterase B-Gene +
of O +
Crotalus O +
durissus O +
( O -
2.4 O +
μg O +
of O +
protein O -
/ O -
mL O -
) O -
. O +

Asymmetrical O +
dinucleoside B-Gene +
tetraphosphatase I-Gene +
treatment O -
: O +
the O +
reaction O +
mixture O +
( O -
0.28 O +
mL O -
) O +
contained O +
12 O +
μM O +
of O +
purified O +
Ap6 O +
A O -
, O +
50 O +
mM O +
Tris O -
- O -
HCl O +
( O -
pH O +
7.5 O -
) O -
, O +
1 O +
mM O +
MgCl2 O +
and O +
rat O +
liver O +
asymmetrical O +
dinucleoside B-Gene +
tetraphosphatase I-Gene +
( O -
0.04 O +
mU O -
/ O -
mL O -
) O -
. O +

Aliquots O +
were O +
taken O +
at O +
various O +
times O +
of O +
incubation O +
and O +
analyzed O +
by O +
HPLC O +
using O +
an O +
Hypersil O +
ODS O +
column O +
( O -
100 O +
mm O +
× O +
4.6 O +
mm O -
) O +
and O +
eluting O +
with O +
30 O +
mM O +
sodium O +
phosphate O +
( O -
pH O +
7.5 O -
) O +
in O +
20 O +
mM O +
tetrabutylammonium O +
bromide O -
/ O -
20 O -
% O +
methanol O -
. O +

The O +
products O +
have O +
been O +
identified O +
by O +
co O -
- O -
elution O +
with O +
appropriate O +
standards O -
. O +

3 O +
Results O +
and O +
discussion O +
Although O +
in O +
our O +
view O +
the O +
mechanism O +
of O +
reaction O +
of O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
is O +
not O +
yet O +
completely O +
clarified O -
, O +
here O +
it O +
is O +
assumed O +
that O +
the O +
synthesis O +
of O +
Ap4 O +
N O +
takes O +
place O +
through O +
reactions O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O -
, O +
with O +
the O +
trace O +
amounts O +
of O +
fatty O +
acid O +
needed O +
being O +
supplied O +
by O +
the O +
proper O +
enzyme B-Gene +
preparation O +
or O +
by O +
other O +
component O +
of O +
the O +
reaction O +
mixture O +
( O -
see O +
reference O +
[ O -
35 O -
] O +
) O -
. O +

E O +
+ O +
RCOOH O +
+ O +
ATP O +
→ O +
E.RCO O -
- O -
AMP O +
+ O +
Ppi O +
( O -
1 O -
) O +
E.RCO O -
- O -
AMP O +
+ O +
NTP O +
→ O +
E O +
+ O +
RCOOH O +
+ O +
Ap4 O +
N O +
( O -
2 O -
) O +
ATP O +
is O +
the O +
preferred O +
substrate O +
for O +
reaction O +
( O -
1 O -
) O +
[ O -
35 O -
] O +
. O +

The O +
second O +
step O +
is O +
rather O +
unspecific O +
and O +
all O +
the O +
nucleoside B-Gene +
triphosphates I-Gene +
tested O +
were O +
acceptors O +
of O +
the O +
AMP O +
moiety O +
of O +
the O +
intermediate O +
complex O +
giving O +
rise O +
to O +
a O +
variety O +
of O +
heterodinucleoside O +
polyphosphates O +
( O -
Ap4 O +
N O -
) O +
[ O -
35 O -
] O +
. O +

Tri- O +
and O +
tetrapolyphosphates O +
( O -
P3 O +
and O +
P4 O +
) O +
are O +
also O +
acceptor O +
substrates O +
for O +
the O +
synthesis O +
of O +
p4 O +
A O +
and O +
p5 O +
A O -
, O +
respectively O +
[ O -
35 O -
] O +
. O +

The O +
synthesis O +
of O +
Ap6 O +
A O +
could O +
be O +
approached O +
using O +
ATP O +
and O +
p5 O +
A O +
as O +
donor O +
and O +
acceptor O +
of O +
AMP O -
, O +
respectively O -
. O +

Unfortunately O -
, O +
p5 O +
A O +
is O +
not O +
commercially O +
available O -
. O +

However O -
, O +
as O +
the O +
enzyme B-Gene +
synthesizes O +
p5 O +
A O +
from O +
ATP O +
and O +
P4 O +
[ O -
35 O -
] O +
, O +
a O +
reaction O +
mixture O +
containing O +
ATP O +
and O +
P4 O +
was O +
set O +
up O +
as O +
described O +
in O +
Materials O +
and O +
methods O +
and O +
analyzed O +
by O +
HPLC O +
after O +
different O +
periods O +
of O +
incubation O -
. O +

As O +
expected O -
, O +
a O +
compound O +
corresponding O +
to O +
p5 O +
A O +
( O +
figure O +
1 O +
, O +
peak O +
5 O -
) O +
was O +
firstly O +
synthesized O +
increasing O +
in O +
the O +
first O +
24 O +
h O +
of O +
reaction O +
and O +
decreasing O +
thereafter O -
. O +

In O +
the O +
first O +
12 O +
h O +
of O +
incubation O +
the O +
average O +
rate O +
of O +
synthesis O +
of O +
p5 O +
A O +
was O +
4.2 O +
mU O -
/ O -
mg O +
of O +
protein O -
; O +
its O +
concentration O +
was O +
1.0 O +
mM O +
and O +
1.3 O +
mM O +
at O +
time O +
12 O +
h O +
and O +
24 O +
h O -
, O +
respectively O -
. O +

A O +
new O +
peak O +
( O -
peak O +
d6 O -
) O -
, O +
corresponding O +
presumably O +
to O +
Ap6 O +
A O -
, O +
appeared O +
along O +
the O +
time O +
of O +
incubation O -
. O +

Between O +
time O +
12 O +
h O +
and O +
24 O +
h O +
of O +
incubation O +
the O +
average O +
rate O +
of O +
synthesis O +
of O +
Ap6 O +
A O +
was O +
0.40 O +
mU O -
/ O -
mg O +
of O +
protein B-Gene +
and O +
its O +
concentration O +
increased O +
from O +
51 O +
μM O +
to O +
144 O +
μM O +
during O +
that O +
time O -
. O +

Synthesis O +
of O +
Ap4 O +
A O +
( O -
peak O +
d4 O -
) O +
was O +
also O +
observed O +
due O +
to O +
the O +
dual O +
role O +
of O +
ATP O +
as O +
donor O +
and O +
acceptor O +
of O +
adenylate O +
( O -
figure O +
1 O -
) O +
. O +

p4 O +
A O +
( O -
peak O +
4 O -
) O +
and O +
Ap5 O +
A O +
( O -
d5 O -
) O +
were O +
also O +
synthesized O +
due O +
to O +
the O +
P3 O +
present O +
as O +
product O +
of O +
hydrolysis O +
or O +
contaminating O +
the O +
P4 O +
preparations O +
( O -
figure O +
1 O -
) O +
. O +

In O +
a O +
control O +
without O +
enzyme B-Gene +
only O +
a O +
partial O +
hydrolysis O +
of O +
ATP O +
into O +
ADP O +
( O -
peak O +
2 O -
) O +
and O +
AMP O +
( O -
peak O +
1 O -
) O +
was O +
observed O +
( O -
results O +
not O +
shown O -
) O -
. O +

The O +
synthesized O +
Ap6 O +
A O +
was O +
characterized O +
by O +
its O +
UV O +
spectrum O -
, O +
co O -
- O -
elution O +
with O +
commercial O +
Ap6 O +
A O +
and O +
by O +
treatment O +
with O +
hydrolytic O +
enzymes B-Gene -
. O +

For O +
that O -
, O +
reaction O +
mixtures O +
similar O +
to O +
the O +
one O +
reported O +
above O +
were O +
treated O +
with O +
alkaline B-Gene +
phosphatase I-Gene +
and O -
, O +
by O +
chromatography O +
on O +
a O +
Mono O +
Q O +
column O +
( O -
see O +
Materials O +
and O +
methods O +
) O -
, O +
peaks O +
corresponding O +
to O +
adenosine O -
, O +
Ap4 O +
A O -
, O +
Ap5 O +
A O +
and O +
Ap6 O +
A O +
were O +
separated O +
( O -
not O +
shown O -
) O -
. O +

Fractions O +
containing O +
the O +
presumed O +
Ap6 O +
A O +
were O +
joined O +
and O +
the O +
purity O +
of O +
the O +
pool O +
checked O +
as O +
described O +
in O +
Materials O +
and O +
methods O +
. O +

The O +
remaining O +
of O +
the O +
pool O +
was O +
frozen O -
, O +
dried O +
in O +
vacuum O -
, O +
and O +
a O +
volume O +
of O +
0.23 O +
mL O +
of O +
146 O +
μM O +
Ap6 O +
A O +
was O +
obtained O -
. O +

The O +
purified O +
Ap6 O +
A O +
was O +
treated O +
with O +
commercial O +
phosphodiesterase B-Gene +
from O +
Crotalus O +
durissus O +
or O +
with O +
asymmetrical O +
dinucleoside B-Gene +
tetraphosphatase I-Gene +
( O -
see O +
Materials O +
and O +
methods O +
) O -
. O +

Upon O +
phosphodiesterase B-Gene +
treatment O +
formation O +
of O +
AMP O +
and O +
p5 O +
A O +
was O +
firstly O +
observed O +
and O +
upon O +
asymmetrical O +
dinucleoside B-Gene +
tetraphosphatase I-Gene +
treatment O +
the O +
only O +
product O +
of O +
hydrolysis O +
was O +
ATP O +
( O -
figure O +
2 O -
) O +
. O +

Here O +
we O +
have O +
shown O +
that O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
from O +
Pseudomonas O +
fragi O +
catalyzes O -
, O +
in O +
vitro O -
, O +
the O +
synthesis O +
of O +
Ap6 O +
A O -
, O +
Ap5 O +
A O +
and O +
Ap4 O +
A. O +
It O +
has O +
been O +
hypothesized O +
that O +
the O +
enzymes B-Gene +
( O -
mainly O +
synthetases B-Gene +
and O +
some O +
transferases B-Gene -
) O +
able O +
to O +
form O +
an O +
adenylyl O +
intermediate O +
with O +
simultaneous O +
liberation O +
of O +
PPi O +
in O +
the O +
course O +
of O +
the O +
enzyme B-Gene +
mechanism O +
would O +
be O +
able O +
to O +
synthesize O +
Ap4 O +
N O +
[ O -
37 O -
] O +
. O +

Probably O -
, O +
these O +
enzymes B-Gene +
could O +
also O +
be O +
able O +
to O +
catalyze O -
, O +
at O +
least O +
in O +
vitro O -
, O +
the O +
synthesis O +
of O +
p4 O +
A O -
, O +
p5 O +
A O -
, O +
Ap5 O +
A O +
and O +
Ap6 O +
A. O +
It O +
is O +
known O +
since O +
1966 O +
that O +
certain O +
aminoacyl B-Gene -
- I-Gene -
tRNA I-Gene +
synthetases I-Gene +
catalyze O +
the O +
synthesis O +
of O +
Ap4 O +
A O +
using O +
ATP O +
as O +
adenylyl O +
donor O +
and O +
acceptor O +
[ O -
38 O -
] O +
; O +
it O +
has O +
also O +
been O +
reported O +
that O +
in O +
the O +
presence O +
of O +
ATP O +
and O +
P3 O +
lysil B-Gene -
- I-Gene -
tRNA I-Gene +
synthetase I-Gene +
from O +
E. O +
coli O +
can O +
catalyze O +
the O +
synthesis O +
of O +
p4 O +
A O +
[ O -
39 O -
] O +
. O +

The O +
synthesis O +
of O +
p4 O +
A O +
or O +
p5 O +
A O +
from O +
ATP O +
and O +
P3 O +
or O +
P4 O +
, O +
respectively O -
, O +
has O +
been O +
shown O +
to O +
be O +
catalyzed O +
by O +
yeast O +
acetyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
[ O -
40 O -
] O +
and O +
firefly O +
luciferase B-Gene +
[ O -
34 O -
] O +
. O +

The O +
possibility O +
that O -
, O +
in O +
vivo O -
, O +
the O +
synthesis O +
of O +
Ap5 O +
A O +
and O +
Ap6 O +
A O +
takes O +
place O +
through O +
the O +
mechanism O +
shown O +
to O +
be O +
possible O +
in O +
vitro O +
( O -
this O +
work O -
) O +
is O -
, O +
at O +
present O -
, O +
somewhat O +
speculative O +
and O +
implies O +
the O +
simultaneous O +
presence O +
of O +
those O +
enzymes B-Gene -
, O +
the O +
adequate O +
adenylyl O +
donor O +
ATP O +
and O +
an O +
adequate O +
adenylyl O +
acceptor O +
( O -
p4 O +
A O +
and O +
p5 O +
A O +
or O +
P3 O +
and O +
P4 O +
) O +
in O +
a O +
particular O +
microenvironment O +
of O +
the O +
cell O -
. O +

Actually O -
, O +
p4 O +
A O +
is O +
present O +
in O +
horse O +
and O +
rabbit O +
muscle O +
[ O -
41 O -
] O +
and O +
in O +
adrenal O +
medullary O +
gland O +
[ O -
13 O -
] O +
. O +

The O +
occurrence O +
of O +
polyphosphates O +
in O +
mammalian O +
tissues O +
has O +
also O +
been O +
reported O +
[ O -
42 O -
, O +
43 O -
] O +
. O +

The O +
in O +
vivo O +
relative O +
contributions O +
to O +
the O +
synthesis O +
of O +
Ap6 O +
A O +
of O +
the O +
different O +
enzymes B-Gene +
able O +
to O +
catalyze O +
in O +
vitro O +
the O +
synthesis O +
dinucleoside B-Gene +
polyphosphates I-Gene +
is O +
beyond O +
the O +
objectives O +
of O +
this O +
paper O -
. O +

From O +
data O +
presented O +
above O +
and O +
in O +
a O +
previous O +
paper O +
[ O -
35 O -
] O +
it O +
can O +
be O +
inferred O +
that O +
the O +
activity O +
of O +
synthesis O +
of O +
Ap6 O +
A O +
catalyzed O +
by O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetase I-Gene +
from O +
Pseudomonas O +
fragi O +
would O +
be O +
three O +
to O +
four O +
orders O +
of O +
magnitude O +
lower O +
than O +
the O +
activity O +
of O +
synthesis O +
of O +
palmitoyl O -
- O -
CoA. O +
Similar O +
orders O +
of O +
magnitude O +
for O +
the O +
synthesis O +
of O +
Ap4 O +
A O +
compared O +
to O +
that O +
of O +
aminoacyl O -
- O -
tRNA O +
has O +
also O +
been O +
observed O +
in O +
the O +
cases O +
of O +
valyl B-Gene +
and O +
methionyl B-Gene -
- I-Gene -
tRNA I-Gene +
synthetases I-Gene +
from O +
E. O +
coli O +
and O -
, O +
however O -
, O +
this O +
low O +
activity O +
did O +
not O +
precluded O +
the O +
induction O +
of O +
in O +
vivo O +
increase O +
concentration O +
of O +
Ap4 O +
N O +
by O +
over O +
expression O +
of O +
these O +
enzymes B-Gene +
[ O -
44 O -
] O +
. O +

Acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetases I-Gene +
have O +
been O +
described O +
in O +
the O +
membranes O +
of O +
rat O +
liver O +
peroxisomes O -
, O +
endoplasmic O +
reticulum O +
and O +
mitochondria O +
[ O -
45–47 O -
] O +
. O +

The O +
association O +
of O +
acyl B-Gene -
- I-Gene -
CoA I-Gene +
synthetases I-Gene +
with O +
membranous O +
material O +
supports O +
the O +
speculation O +
that O +
these O +
enzymes B-Gene +
could O +
be O +
involved O +
in O +
the O +
synthesis O +
of O +
diadenosine O +
polyphosphates O +
in O +
chromaffin O +
granules O +
and O +
in O +
synaptic O +
terminals O +
of O +
the O +
nervous O +
system O -
. O +

Acknowledgements O +

We O +
thank O +
Isabel O +
de O +
Diego O +
for O +
very O +
able O +
technical O +
assistance O -
. O +

This O +
work O +
was O +
supported O +
by O +
a O +
grant O +
from O +
the O +
Dirección O +
General O +
de O +
Investigación O +
Científica O +
y O +
Técnica O +
( O -
PM95 O -
/ O -
13 O -
) O -
. O +

R.F. O +
was O +
supported O +
by O +
a O +
Fellowship O +
from O +
Junta O +
Nacional O +
de O +
Investigação O +
Científica O +
e O +
Tecnológica O +
( O -
Portugal O -
) O -
. O +

3-Deoxy O -
- O -
d O +
-glycero O +
-d O +
-galacto O +
-2-nonulosonic O +
acid O +
( O -
Kdn O -
) O +
is O +
a O +
unique O +
deaminated O +
analogue O +
of O +
sialic O +
acid O +
that O +
has O +
recently O +
been O +
isolated O +
from O +
the O +
rainbow O +
trout O +
egg O +
polysialoglycoprotein B-Gene +
( O -
PSGP B-Gene -
) O +
[ O -
1 O -
] O +
. O +

Kdn O +
has O +
several O +
forms O +
of O +
glycosylic O +
linkages O -
, O +
such O +
as O +
α- O -
( O -
2→3 O -
) O -
, O +
α- O -
( O -
2→6 O -
) O +
and O +
α- O -
( O -
2→8 O -
) O +
and O +
has O +
been O +
found O +
in O +
a O +
variety O +
of O +
tissues O +
such O +
as O +
fish O +
egg O -
, O +
sperm O -
, O +
amphibian O +
egg O -
, O +
and O +
bacteria O +
[ O -
2–5 O -
] O +
. O +

To O +
date O -
, O +
in O +
order O +
to O +
investigate O +
the O +
role O +
of O +
the O +
Kdn O -
, O +
several O +
studies O +
have O +
been O +
carried O +
out O +
[ O -
6 O -
] O +
, O +
and O +
consequently O -
, O +
it O +
was O +
deduced O +
that O +
the O +
Kdn O +
may O +
play O +
a O +
role O +
in O +
protecting O +
against O +
sialidase B-Gene +
digestion O +
[ O -
6 O -
] O +
. O +

In O +
order O +
to O +
investigate O +
its O +
further O +
roles O -
, O +
enzymatic O +
incorporation O +
of O +
Kdn O +
and O +
its O +
analogues O +
into O +
intact O +
oligosaccharides O +
in O +
vivo O +
is O +
a O +
potential O +
method O +
as O +
has O +
been O +
demonstrated O +
in O +
the O +
research O +
on O +
N O +
-acetylneuraminic O +
acid O +
( O -
NeuAc O -
) O +
[ O -
7 O -
] O +
. O +

Although O +
activities O +
of O +
Kdn B-Gene -
- I-Gene -
transferase I-Gene +
have O +
been O +
identified O +
[ O -
6 O -
] O +
, O +
purification O +
of O +
Kdn B-Gene -
- I-Gene -
transferase I-Gene +
has O +
not O +
been O +
accomplished O +
on O +
a O +
practical O +
scale O -
. O +

On O +
the O +
other O +
hand O -
, O +
a O +
variety O +
of O +
sialyltransferases B-Gene +
have O +
been O +
purified O +
and O +
used O +
in O +
enzymatic O +
syntheses O +
of O +
sialoside O -
, O +
its O +
analogues O +
[ O -
8 O -
] O +
, O +
and O +
Kdn O -
- O -
α- O -
( O -
2→3 O -
) O -
-Gal O -
- O -
β- O -
( O -
1→4 O -
) O -
-Glc O -
- O -
β-1-OAll O +
[ O -
9 O -
] O +
. O +

Recently O -
, O +
bacterial O +
α- B-Gene -
( I-Gene -
2→6 I-Gene -
) I-Gene +
sialyltransferase I-Gene +
[ O -
EC O +
2.4.99.1 O -
] O -
, O +
which O +
catalyzes O +
the O +
transfer O +
of O +
NeuAc O +
to O +
a O +
variety O +
of O +
sialyl O +
acceptors O -
, O +
has O +
been O +
isolated O +
[ O -
10 O -
] O +
. O +

Since O +
this O +
enzyme B-Gene +
has O +
broad O +
substrate O +
specificity O +
[ O -
11 O -
] O +
, O +
it O +
is O +
expected O +
to O +
be O +
useful O +
for O +
the O +
syntheses O +
of O +
Kdn O +
oligosaccharides O +
or O +
their O +
analogues O -
. O +

If O +
this O +
enzyme B-Gene +
can O +
transfer O +
Kdn O +
from O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
to O +
the O +
corresponding O +
sialyl O +
acceptor O -
, O +
modification O +
of O +
oligosaccharide O +
by O +
Kdn O +
or O +
its O +
analogues O +
in O +
vivo O +
will O +
be O +
developed O -
. O +

We O +
report O +
here O +
enzymatic O +
transfer O +
of O +
Kdn O +
to O +
methyl O +
N O +
-acetyl O -
- O -
β O -
- O -
d O +
-lactosaminide O +
and O +
4-methylumbelliferyl O +
β O -
- O -
d O +
-lactoside O +
by O +
bacterial O +
α- B-Gene -
( I-Gene -
2→6 I-Gene -
) I-Gene -
-sialyltransferase I-Gene -
. O +

2 O +
. O +

Results O +
and O +
discussion O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
was O +
prepared O +
by O +
our O +
previously O +
reported O +
method O +
( O -
Scheme O +
1 O +
) O +
[ O -
12 O -
] O +
. O +

This O +
synthetic O +
route O -
, O +
however O -
, O +
afforded O +
a O +
mixture O +
of O +
four O +
isomers O +
of O +
4 O +
. O +

The O +
derivatives O +
were O +
rationalized O +
as O +
1:1:0.8:0.8 O -
, O +
and O +
this O +
ratio O +
is O +
reproducible O -
. O +

1 O +
H O +
NMR O +
data O +
suggested O +
that O +
the O +
phosphite O +
derivatives O +
consist O +
of O +
an O +
anomeric O +
mixture O +
of O +
Kdn O +
because O +
both O +
H-3′ O +
and O +
H-4′ O +
in O +
the O +
Kdn O +
unit O +
were O +
observed O +
with O +
reasonable O +
chemical O +
shifts O +
( O -
Table O +
2 O +
in O +
Ref O -
. O +

[ O -
13 O -
] O +
) O -
. O +

Since O +
separation O +
of O +
each O +
product O +
proved O +
to O +
be O +
difficult O +
due O +
to O +
their O +
lability O +
on O +
purification O -
, O +
the O +
phosphite O +
4 O +
was O +
then O +
used O +
in O +
the O +
next O +
step O +
without O +
further O +
purification O -
. O +

Oxidation O +
of O +
4 O +
also O +
afforded O +
a O +
mixture O +
of O +
four O +
kinds O +
of O +
phosphate O +
5 O +
in O +
88 O -
% O +
yield O -
. O +

After O +
deprotection O -
, O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
the O +
crude O +
product O +
showed O +
that O +
the O +
desired O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
6 O +
was O +
obtained O +
in O +
60 O -
% O +
purity O -
, O +
and O +
no O +
CMP O -
- O -
α O -
- O -
d O +
-Kdn O +
was O +
observed O +
at O +
all O -
. O +

These O +
results O +
indicated O +
that O +
CMP O -
- O -
α O -
- O -
d O +
-Kdn O +
might O +
be O +
more O +
labile O +
than O +
6 O +
. O +

Purification O +
with O +
a O +
gel O -
- O -
permeation O +
column O +
( O -
5 O +
mM O +
NH4 O +
OH O -
) O +
afforded O +
pure O +
compound O +
6 O +
in O +
30 O -
% O +
yield O -
, O +
and O +
its O +
1 O +
H O +
NMR O +
data O +
are O +
in O +
good O +
agreement O +
with O +
reported O +
data O +
[ O -
4,9,14 O -
] O +
. O +

Enzymatic O +
synthesis O +
of O +
Kdn O -
- O -
oligosaccharide O +
8 O +
using O +
the O +
bacterial O +
α- B-Gene -
( I-Gene -
2→6 I-Gene -
) I-Gene -
-sialyltransferase I-Gene +
was O +
performed O +
under O +
the O +
reported O +
conditions O +
[ O -
11 O -
] O +
for O +
the O +
preparation O +
of O +
sialoside O -
, O +
except O +
that O +
the O +
pH O +
was O +
adjusted O +
to O +
7.5 O -
. O +

The O +
enzyme B-Gene +
catalyzed O +
the O +
transfer O +
of O +
Kdn O +
to O +
methyl O +
β O -
- O -
d O +
-N O +
-acetyllactosaminide O +
( O -
7 O +
) O +
and O +
afforded O +
the O +
desired O +
Kdn O -
- O -
N O +
-acetyl O -
- O -
β O -
- O -
d O +
-lactosaminide O +
8 O +
in O +
77 O -
% O +
yield O +
( O -
Scheme O +
2 O +
) O -
. O +

The O +
structure O +
was O +
identified O +
by O +
1 O +
H O +
and O +
related O +
2D O +
NMR O +
spectra O -
. O +

Enzyme B-Gene +
assay O +
using O +
4-methylumbelliferyl O +
β O -
- O -
d O +
-lactoside O +
indicated O +
that O +
the O +
apparent O +
K O +
m O +
value O +
of O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
is O +
880 O +
μM O -
, O +
which O +
is O +
27 O +
times O +
larger O +
than O +
that O +
of O +
CMP O -
- O -
β O -
- O -
d O +
-NeuAc O +
( O -
33 O +
μM O -
) O -
. O +

In O +
addition O -
, O +
the O +
V O +
max O +
value O +
of O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
is O +
15 O -
% O +
larger O +
than O +
that O +
of O +
CMP O -
- O -
β O -
- O -
d O +
-NeuAc O -
. O +

Despite O +
the O +
fact O +
that O +
substitution O +
of O +
the O +
acetamido O +
group O +
with O +
a O +
hydroxyl O +
group O +
resulted O +
in O +
a O +
decrease O +
of O +
both O +
binding O +
affinity O +
and O +
transfer O +
velocity O -
, O +
practical O +
enzymatic O +
synthesis O +
could O +
still O +
afford O +
Kdn O -
- O -
N O +
-acetyl O -
- O -
β O -
- O -
d O +
-lactosaminide O +
in O +
good O +
yield O -
. O +

In O +
general O -
, O +
mammalian O +
α- B-Gene -
( I-Gene -
2→6 I-Gene -
) I-Gene -
-sialyltransferase I-Gene +
can O -
not O +
catalyze O +
transfer O +
of O +
NeuAc O +
to O +
both O +
lactose O +
and O +
N O +
-acetyl O -
- O -
β O -
- O -
d O +
-lactosamine O -
. O +

However O -
, O +
bacterial O +
sialyltransferase B-Gene +
can O +
transfer O +
even O +
Kdn O +
to O +
both O +
lactose O +
and O +
N O +
-acetyl O -
- O -
β O -
- O -
d O +
-lactosamine O -
. O +

This O +
finding O +
would O +
be O +
useful O +
for O +
the O +
synthesis O +
of O +
several O +
Kdn O +
oligosaccharides O -
. O +

In O +
summary O -
, O +
we O +
found O +
bacterial O +
sialyltransferase B-Gene +
catalyzes O +
the O +
transfer O +
of O +
Kdn O +
to O +
both O +
methyl O +
N O +
-acetyl O -
- O -
β O -
- O -
d O +
-lactosaminide O +
and O +
4-methylumbelliferyl O +
β O -
- O -
d O +
-lactoside O -
. O +

A O +
previous O +
report O +
[ O -
11,15 O -
] O +
showed O +
that O +
this O +
enzyme B-Gene +
has O +
broad O +
substrate O +
specificity O +
toward O +
disaccharides O +
and O +
monosaccharides O -
. O +

In O +
addition O -
, O +
the O +
enzyme B-Gene +
is O +
now O +
available O +
in O +
large O +
quantity O +
[ O -
15 O -
] O +
. O +

Therefore O -
, O +
enzymatic O +
synthesis O +
using O +
CMP O -
- O -
modified O -
- O -
Kdn O +
and O +
bacterial O +
sialyltransferase B-Gene +
would O +
afford O +
Kdn O -
- O -
oligosaccharide O +
analogues O +
which O +
can O +
be O +
expected O +
to O +
clarify O +
the O +
role O +
of O +
Kdn O -
. O +

Since O +
the O +
Kdn O +
may O +
be O +
resistant O +
to O +
sialidase B-Gene +
digestion O -
, O +
the O +
Kdn O +
or O +
its O +
analogues O +
will O +
be O +
expected O +
to O +
be O +
used O +
for O +
masking O +
of O +
galactosides O +
at O +
the O +
nonreducing O +
end O +
of O +
the O +
glycoprotein B-Gene +
in O +
order O +
to O +
change O +
the O +
biological O +
response O -
, O +
such O +
as O +
blocking O +
the O +
hepatic O +
clearance O +
[ O -
16 O -
] O +
. O +

3 O +
. O +

Experimental O +
3.1 O +
General O +
procedure O +
1 O +
H O +
NMR O +
spectra O +
were O +
recorded O +
with O +
either O +
a O +
JEOL O +
EX O +
270 O +
or O +
Bruker O +
DMX O +
500 O +
instrument O -
. O +

31 O +
P O +
NMR O +
spectra O +
were O +
recorded O +
with O +
Bruker O +
DMX O +
500 O +
or O +
AC O +
300 O +
instrument O -
, O +
and O +
chemical O +
shifts O +
are O +
expressed O +
in O +
ppm O +
and O +
referenced O +
to O +
H3 O +
PO4 O +
( O -
0 O +
ppm O -
) O +
as O +
the O +
external O +
standard O -
. O +

Optical O +
rotations O +
were O +
measured O +
with O +
a O +
JASCO O +
DIP-4 O -
. O +

High O -
- O -
resolution O +
mass O +
spectra O +
were O +
recorded O +
using O +
a O +
Shimazu O -
/ O -
Kratos O +
concept O -
- O -
IIH O +
under O +
FAB O +
conditions O -
. O +

All O +
reactions O +
were O +
monitored O +
by O +
TLC O +
( O -
Silica O +
Gel O +
60-F254 O +
, O +
E. O +
Merck O -
) O +
by O +
charring O +
after O +
spraying O +
with O +
5 O -
% O +
H2 O +
SO4 O +
in O +
MeOH O -
. O +

3.2 O +
Methyl O +
4,5,7,8,9-penta O -
- O -
O O -
- O -
acetyl-3-deoxy O -
- O -
d O +
-glycero O -
- O -
β O -
- O -
d O +
-galacto-2-nonulopyranosonate O +
( O -
2 O +
) O +
To O +
a O +
solution O +
of O +
thiophenyl O +
glycoside O +
1 O +
[ O -
13 O -
] O +
( O -
682 O +
mg O -
, O +
1.17 O +
mmol O -
) O +
in O +
10:3 O +
acetone O -
– O -
H2 O +
O O +
( O -
26 O +
mL O -
) O +
was O +
added O +
NBS O +
( O -
609 O +
mg O -
) O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
at O +
0 O +
° O -
C O -
. O +

After O +
2 O +
h O +
the O +
mixture O +
was O +
diluted O +
with O +
EtOAc O +
and O +
washed O +
with O +
a O +
solution O +
of O +
NaHCO3 O +
( O -
2 O -
× O -
) O -
. O +

The O +
organic O +
phase O +
was O +
dried O +
with O +
MgSO4 O +
and O +
was O +
concentrated O +
in O +
vacuo O -
. O +

Purification O +
of O +
the O +
residue O +
by O +
flash O +
column O +
chromatography O +
( O -
2:1→1:1 O +
n O +
-hexane O -
– O -
EtOAc O -
) O +
afforded O +
2 O +
( O -
96 O -
% O -
, O +
546 O +
mg O -
) O -
: O +
[ O -
α O -
] O -
D O +
26 O +
−1.2 O -
° O +
( O -
c O +
0.83 O -
, O +
CHCl3 O +
) O -
; O +
mp O +
106–108 O +
° O -
C O -
; O +
1 O +
H O +
NMR O +
( O -
270 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.34–7.52 O +
( O -
m O -
, O +
5 O +
H O -
, O +
SPh O -
) O -
, O +
5.20 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-7 O -
) O -
, O +
5.04 O +
( O -
ddd O -
, O +
1 O +
H O -
, O +
J O +
7.4 O +
Hz O -
, O +
H-8 O -
) O -
, O +
5.09 O +
( O -
ddd O -
, O +
1 O +
H O -
, O +
J O +
11.8 O +
Hz O -
, O +
H-4 O -
) O -
, O +
4.79 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
7.4 O +
Hz O -
, O +
H-5 O -
) O -
, O +
4.21 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2.9 O +
Hz O -
, O +
H-9 O -
) O -
, O +
4.19 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
10.3 O -
, O +
2.1 O +
Hz O -
, O +
H-6 O -
) O -
, O +
3.97 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
12.4 O -
, O +
6.0 O +
Hz O -
, O +
H-9 O -
) O -
, O +
3.66 O +
( O -
s O -
, O +
3H O -
, O +
COOMe O -
) O -
, O +
2.15 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
5.1 O -
, O +
12.8 O +
Hz O -
, O +
H-3eq O -
) O -
, O +
1.83–1.93 O +
( O -
m O -
, O +
16 O +
H O -
, O +
OAc O -
, O +
H-3ax O -
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C20 O +
H28 O +
O14 O +
: O +
C O -
, O +
48.78 O -
; O +
H O -
, O +
5.73 O -
. O +

Found O -
: O +
C O -
, O +
49.10 O -
; O +
H O -
, O +
5.50 O -
. O +

3.3 O +
2-Cyanoethyl O +
( O -
2′,3′-di O -
- O -
O O -
- O -
acetyl O -
- O -
N4 O +
-acetylcytidine-5′-yl O -
) O +
( O -
methyl O +
4,5,7,8,9-penta O -
- O -
O O -
- O -
acetyl-3-deoxy O -
- O -
β O -
- O -
d O +
-glycero O -
- O -
β O -
- O -
d O +
-galacto-2-non O -
- O -
ulopyranosid-2′′-yl O -
) O +
phosphite O +
( O -
4 O +
) O +
The O +
pentaacetyl O -
- O -
Kdn O +
( O -
2 O +
, O +
229 O +
mg O -
, O +
470 O +
μmol O -
) O +
and O +
cytidine O +
5′-O O +
-amidite O +
( O -
3 O +
, O +
784 O +
mg O -
, O +
14.0 O +
mmol O -
) O +
were O +
separately O +
dried O +
by O +
coevaporating O +
twice O +
with O +
dry O +
toluene O -
. O +

They O +
were O +
then O +
combined O +
in O +
freshly O +
prepared O +
dry O +
MeCN O +
( O -
2.0 O +
mL O -
) O -
. O +

To O +
this O +
mixture O +
was O +
added O +
[ O -
1H O +
] O -
-tetrazole O +
( O -
59 O +
mg O -
, O +
840 O +
μmol O -
) O +
at O +
−40 O +
° O -
C O +
under O +
an O +
argon O +
atmosphere O -
. O +

After O +
5 O +
min O -
, O +
the O +
cold O +
bath O +
was O +
removed O -
. O +

The O +
mixture O +
was O +
further O +
stirred O +
for O +
30 O +
min O +
at O +
room O +
temperature O +
( O -
rt O -
) O -
, O +
and O +
then O +
the O +
mixture O +
was O +
diluted O +
with O +
EtOAc O -
. O +

The O +
organic O +
phase O +
was O +
washed O +
with O +
NaHCO3 O +
solution O -
, O +
dried O +
with O +
MgSO4 O +
, O +
and O +
concentrated O +
in O +
vacuo O +
at O +
40 O +
° O -
C O -
. O +

Purification O +
of O +
the O +
residue O +
by O +
gel O -
- O -
permeation O +
column O +
chromatography O +
twice O +
( O -
Sephadex O +
LH-20 O -
, O +
2 O -
× O -
60 O +
cm O -
, O +
MeOH O -
, O -
) O +
afforded O +
phosphite O +
4 O +
( O -
403 O +
mg O -
, O +
88 O -
% O -
, O +
four O +
diastereomers O -
, O +
1:1:0.8:0.8 O -
) O -
. O +

1 O +
H O +
NMR O +
chemical O +
shifts O +
are O +
summarized O +
in O +
Table O +
1 O +
. O +

31 O +
P O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
135.0 O -
, O +
135.9 O -
, O +
137.2 O -
, O +
137.3 O -
. O +

HRFABMS O -
: O +
Calcd O +
for O +
C38 O +
H50 O +
N4 O +
O23 O +
P O -
, O +
961.2604 O +
( O -
M+H O -
) O -
; O +
Found O -
: O +
961.2611 O -
. O +

Anal O -
. O +

Calcd O +
for O +
C38 O +
H49 O +
N4 O +
O23 O +
P O -
: O +
C O -
, O +
47.50 O -
; O +
H O -
, O +
5.14 O -
; O +
N O -
, O +
5.83 O -
, O +
Found O -
: O +
C O -
, O +
47.09 O -
; O +
H O -
, O +
5.02 O -
; O +
N O -
, O +
6.09 O -
. O +
3.4 O +
2-Cyanoethyl O +
( O -
2′,3′-di O -
- O -
O O -
- O -
acetyl O -
- O -
N4 O +
-acetylcytidine O +
5′-yl O -
) O +
( O -
methyl O +
4,5,7,8,9-penta O -
- O -
O O -
- O -
acetyl-3-deoxy O -
- O -
β O -
- O -
d O +
-glycero O -
- O -
d O +
-galacto-2-nonulo O -
- O -
pyranosid O +
2′′-yl O -
) O +
phosphate O +
( O -
5 O +
) O +
To O +
a O +
solution O +
of O +
phosphite O +
4 O +
( O -
108 O +
mg O -
, O +
110 O +
μmol O -
) O +
in O +
MeCN O +
( O -
1.0 O +
mL O -
) O +
was O +
added O +
tert O +
-BuOOH O +
( O -
2.5 O +
M O +
in O +
toluene O -
, O +
218 O +
μL O -
) O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
30 O +
min O -
, O +
the O +
mixture O +
was O +
diluted O +
with O +
EtOAc O +
and O +
washed O +
with O +
NaHCO3 O +
solution O -
. O +

After O +
drying O +
with O +
MgSO4 O +
, O +
the O +
organic O +
phase O +
was O +
concentrated O +
in O +
vacuo O +
at O +
40 O +
° O -
C O -
. O +

Purification O +
of O +
the O +
residue O +
by O +
gel O -
- O -
permeation O +
column O +
chromatography O +
( O -
Sephadex O +
LH-20 O -
, O +
CH2 O +
Cl2 O +
) O +
afforded O +
phosphate O +
5 O +
( O -
99 O +
mg O -
, O +
90 O -
% O -
, O +
four O +
diastereomers O -
) O -
. O +

1 O +
H O +
NMR O -
: O +
δ O +
9.64 O +
( O -
NHAc O -
) O -
, O +
8.00–8.25 O +
( O -
H-6 O -
) O -
, O +
7.39–7.50 O +
( O -
H-5 O -
) O -
, O +
6.08–6.20 O +
( O -
H-1′ O -
) O -
, O +
3.89 O +
( O -
COOMe O -
) O -
, O +
2.78–2.88 O +
( O -
H-3′′eq O -
) O -
, O +
2.24 O +
( O -
NAc O -
) O -
, O +
1.98–2.11 O +
( O -
OAc O -
) O -
; O +
31 O +
P O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
−6.33 O -
, O +
−6.23 O -
, O +
−6.23 O -
, O +
−6.14 O -
. O +

HRFABMS O -
: O +
Calcd O +
for O +
C38 O +
H50 O +
N4 O +
O24 O +
P O -
, O +
977.2553 O +
( O -
M+H O -
) O -
; O +
Found O -
: O +
977.2552 O -
. O +

3.5 O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
( O -
6 O +
) O +
To O +
a O +
solution O +
of O +
protected O +
CMP O -
- O -
Kdn O +
5 O +
( O -
96 O +
mg O -
, O +
100 O +
μmol O -
) O +
in O +
THF O +
( O -
3.0 O +
mL O -
) O +
was O +
added O +
1,8-diazabicyclo- O -
[ O -
5.4.0 O -
] O -
-7-undecene O +
( O -
2.3 O +
mg O -
, O +
15.2 O +
μmol O -
) O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
5 O +
min O -
, O +
NaOMe O +
( O -
174 O +
mg O -
, O +
3.24 O +
mmol O -
) O +
and O +
MeOH O -
– O -
H2 O +
O O +
( O -
1.2–5.1 O +
mL O -
) O +
were O +
added O +
to O +
this O +
mixture O -
. O +

After O +
16 O +
h O +
the O +
mixture O +
was O +
lyophilized O -
. O +

Purification O +
of O +
the O +
residue O +
by O +
gel O -
- O -
permeation O +
column O +
chromatography O +
( O -
Sephadex O +
G-15 O -
, O +
3 O -
× O -
100 O +
cm O -
, O +
5 O +
mM O +
NH4 O +
OH O -
, O +
4 O +
° O -
C O -
) O +
afforded O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
6 O +
( O -
19 O +
mg O +
30 O -
% O -
) O -
. O +

1 O +
H O +
NMR O +
( O -
HOD=4.81 O +
ppm O -
) O -
: O +
δ O +
7.96 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
7.5 O +
Hz O -
, O +
H-6 O -
) O -
, O +
6.10 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
7.5 O +
Hz O -
, O +
H-5 O -
) O -
, O +
5.97 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
4.5 O +
Hz O -
, O +
H-1′′ O -
) O -
, O +
4.33 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-4′ O -
) O -
, O +
4.27 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2′ O -
) O -
, O +
4.21 O +
( O -
d O -
, O +
3 O +
H O -
, O +
H-3′ O -
, O +
5′a O -
, O +
5′b O -
) O -
, O +
4.06 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
9.6 O +
Hz O -
, O +
H-6′′ O -
) O -
, O +
4.00 O +
( O -
ddd O -
, O +
1 O +
H O -
, O +
J O +
4.9 O -
, O +
9.6 O -
, O +
12.4 O +
Hz O -
, O +
H-4′′ O -
) O -
, O +
3.92 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
12.1 O +
Hz O -
, O +
H-9′′a O -
) O -
, O +
3.88 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-7′′ O -
) O -
, O +
3.72 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-8′′ O -
) O -
, O +
3.65 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
6.8 O -
, O +
12.1 O +
Hz O -
, O +
H-9′′b O -
) O -
, O +
3.57 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
9.6 O -
, O +
9.6 O +
Hz O -
, O +
H-5′′ O -
) O -
, O +
2.41 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
4.9 O -
, O +
12.4 O +
Hz O -
) O -
, O +
1.57 O +
( O -
ddd O -
, O +
1 O +
H O -
, O +
J O +
5.9 O -
, O +
12.4 O -
, O +
12.4 O +
Hz O -
, O +
H-3ax O -
) O -
; O +
31 O +
P O +
NMR O +
( O -
D2 O +
O O -
) O -
: O +
δ O +
−4.43 O -
. O +

HRFABMS O -
: O +
Calcd O +
for O +
C18 O +
H26 O +
N3 O +
O16 O +
PNa3 O +
( O -
M+Na+ O +
) O -
, O +
640.0745 O -
; O +
Found O -
: O +
640.0754 O -
. O +

3.6 O +
Methyl O +
( O -
3-deoxy O -
- O -
d O +
-glycero O -
- O -
α O -
- O -
d O +
-galacto-2-nonulopyranosylonic O +
acid O -
) O -
- O -
( O -
2→6 O -
) O -
- O -
( O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-2-acetoamido-2-deoxy O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
8 O +
) O +
A O +
solution O +
containing O +
the O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
( O -
6.5 O +
mg O -
, O +
10.2 O +
μmol O -
, O +
2 O +
sodium O +
salt O -
) O -
, O +
methyl O +
β O -
- O -
d O +
-lactosaminide O +
7 O +
( O -
3.5 O +
mg O -
, O +
8.1 O +
μmol O -
) O -
, O +
BSA O +
( O -
2 O +
mg O -
) O -
, O +
alkaline B-Gene +
phosphatase I-Gene +
( O -
25 O +
u O -
) O -
, O +
purified O +
sialyltransferase B-Gene +
( O -
80 O +
mu O -
) O +
in O +
HEPES O +
buffer O +
( O -
100 O +
mM O -
, O +
pH O +
7.5 O -
, O +
200 O +
μL O -
) O +
was O +
incubated O +
at O +
37 O +
° O -
C O +
for O +
12 O +
h. O +
The O +
mixture O +
was O +
concentrated O +
in O +
vacuo O -
. O +

The O +
residue O +
was O +
purified O +
by O +
silica O +
gel O +
column O +
chromatography O +
( O -
Kanto O +
Kagaku O +
Co. O -
, O +
Silica O +
Gel O +
60 O -
, O +
Spherical O -
, O +
1 O -
× O -
10 O +
cm O -
, O +
7:3:1 O +
n O +
-PrOH O -
– O -
H2 O +
O O -
– O -
NH4 O +
OH O -
) O -
, O +
and O +
then O +
the O +
product O +
was O +
further O +
purified O +
on O +
a O +
column O +
of O +
Sephadex O +
G-15 O +
( O -
1 O -
× O -
50 O +
cm O -
, O +
water O -
) O +
to O +
give O +
8 O +
( O -
4.0 O +
mg O -
, O +
77 O -
% O -
) O -
. O +

1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
D2 O +
O O -
) O -
: O +
δ O +
4.47 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
8.1 O +
Hz O -
, O +
H-1 O -
) O -
, O +
4.43 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
7.9 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
3.99 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2.1 O -
, O +
13.0 O +
Hz O -
, O +
H-6 O -
) O -
, O +
3.98 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
9.5 O -
, O +
9.5 O +
Hz O -
, O +
H-6′ O -
) O -
, O +
3.91 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3.4 O +
Hz O -
, O +
H-4′ O -
) O -
, O +
3.82 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
5.6 O -
, O +
13.0 O +
Hz O -
, O +
H-6 O -
) O -
, O +
3.52 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
8.0 O -
, O +
10.4 O +
Hz O -
, O +
H-2′ O -
) O -
, O +
3.50 O +
( O -
s O -
, O +
3 O +
H O -
, O +
OMe O -
) O -
, O +
3.47 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
9.4 O -
, O +
9.4 O +
Hz O -
, O +
H-5′′ O -
) O -
, O +
2.61 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
4.6 O -
, O +
12.4 O +
Hz O -
, O +
H-3′′eq O -
) O -
, O +
2.05 O +
( O -
s O -
, O +
3 O +
H O -
, O +
Ac O -
) O -
, O +
1.67 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
12.4 O -
, O +
12.4 O +
Hz O -
, O +
H-3′′ax O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
D2 O +
O O -
, O +
dioxane=67.48 O +
ppm O -
) O -
: O +
δ O +
175.39 O -
, O +
174.36 O -
, O +
174.16 O -
, O +
104.22 O -
, O +
102.51 O -
, O +
100.66 O -
, O +
81.35 O -
, O +
75.39 O -
, O +
74.61 O -
, O +
74.44 O -
, O +
73.36 O -
, O +
73.20 O -
, O +
72.86 O -
, O +
71.52 O -
, O +
70.85 O -
, O +
69.29 O -
, O +
69.00 O -
, O +
64.45 O -
, O +
63.59 O -
, O +
61.12 O -
, O +
57.89 O -
, O +
55.66 O -
, O +
40.45 O -
, O +
23.16 O -
. O +

HRFABMS O -
: O +
Calcd O +
for O +
C24 O +
H41 O +
NO19 O +
Na O +
( O -
M+H O -
) O -
, O +
670.2171 O -
; O +
Found O -
: O +
670.2205 O -
. O +

3.7 O +
Enzyme B-Gene +
assay O +
Sialyltransferase O +
assays O +
were O +
performed O +
with O +
a O +
HEPES O +
buffer O +
solution O +
( O -
pH O +
7.5 O -
, O +
100 O +
mM O -
, O +
25 O +
μL O -
) O +
containing O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O +
( O -
1.5 O -
, O +
3.0 O -
, O +
5.0 O +
and O +
10.0 O +
mM O -
) O +
or O +
CMP O -
- O -
β O -
- O -
d O +
-NeuAc O +
( O -
75.0 O -
, O +
100 O -
, O +
150 O -
, O +
and O +
280 O +
μM O -
) O -
, O +
4-methylumbelliferyl O +
β O -
- O -
d O +
-lactoside O +
( O -
1.0 O +
mM O -
) O -
, O +
BSA O +
( O -
1 O +
μg O -
) O -
, O +
Triton O +
X100 O +
( O -
0.02 O -
% O -
) O +
and O +
sialyltransferase B-Gene +
( O -
for O +
CMP O -
- O -
β O -
- O -
d O +
-Kdn O -
: O +
8.3 O +
mU O -
; O +
for O +
CMP O -
- O -
β O -
- O -
d O +
-NeuAc O -
: O +
0.1 O +
mU O -
) O -
. O +

The O +
mixture O +
was O +
incubated O +
at O +
37 O +
° O -
C O -
. O +

The O +
reaction O +
was O +
followed O +
up O +
to O +
15 O -
% O +
consumption O +
of O +
donor O +
substrate O -
. O +

After O +
incubation O -
, O +
the O +
mixture O +
was O +
allowed O +
to O +
cool O +
with O +
dry O +
ice O -
/ O -
acetone O -
, O +
and O +
then O +
Kdn O +
or O +
NeuAc O +
transferred O +
were O +
quantitated O +
with O +
HPLC O +
( O -
C18-column O -
: O +
1 O -
× O -
25 O +
cm O -
, O +
1:4 O +
MeCN O -
– O -
H2 O +
O O -
) O +
equipped O +
with O +
fluorescence O +
detector O +
( O -
excitation O -
: O +
325 O +
nm O -
, O +
emission O -
: O +
378 O +
nm O -
) O -
. O +

K O +
m O +
and O +
V O +
max O +
values O +
were O +
estimated O +
using O +
a O +
Lineweaver O -
– O -
Burk O +
plot O -
. O +

The O +
data O +
points O +
are O +
the O +
averages O +
of O +
at O +
least O +
duplicate O +
values O -
. O +

Acknowledgements O +
The O +
authors O +
would O +
like O +
to O +
thank O +
Masayosi O +
Kusama O +
for O +
the O +
mass O +
spectroscopic O +
analyses O -
. O +

The O +
cyclic O +
hydroxamic O +
acids O +
DIBOA O +
( O -
2,4-dihydroxy-1,4-benzoxazin-3-one O -
) O +
and O +
DIMBOA O +
( O -
2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one O -
) O +
play O +
an O +
important O +
role O +
in O +
the O +
chemical O +
defense O +
of O +
cereals O +
against O +
deleterious O +
pests O +
such O +
as O +
insects O -
, O +
pathogenic O +
fungi O +
and O +
bacteria O -
[ O -
1 O -
] O +
. O +

DIBOA O +
is O +
the O +
main O +
hydroxamic O +
acid O +
in O +
rye O -
, O +
whereas O +
its O +
methoxy O +
derivative O +
DIMBOA O +
is O +
the O +
predominant O +
form O +
in O +
maize O +
and O +
wheat O -
. O +

In O +
maize O -
, O +
a O +
series O +
of O +
five O +
genes O +
that O +
are O +
clustered O +
on O +
the O +
short O +
arm O +
of O +
chromosome O +
four O -
, O +
is O +
sufficient O +
to O +
encode O +
the O +
enzymes B-Gene +
to O +
synthesise O +
DIBOA O -
[ O -
2 O -
] O +
. O +

The O +
first O +
gene O +
in O +
the O +
pathway O -
, O +
Bx1 O +
, O +
encodes O +
an O +
enzyme B-Gene +
resembling O +
a O +
tryptophan B-Gene +
synthase I-Gene +
α I-Gene +
subunit I-Gene -
[ O -
2 O -
, O +
3 O -
] O +
that O +
catalyses O +
the O +
formation O +
of O +
free O +
indole O -
[ O -
2 O -
] O +
and O +
thereby O +
establishes O +
the O +
branchpoint O +
that O +
leads O +
to O +
the O +
secondary O +
metabolites O +
DIBOA O +
and O +
DIMBOA O -
. O +

The O +
next O +
four O +
genes O -
, O +
Bx2–Bx5 O +
, O +
encode O +
cytochrome B-Gene +
P450-dependent I-Gene +
monooxygenases I-Gene +
of O +
the O +
CYP71C B-Gene +
subfamily O -
[ O -
4 O -
] O +
, O +
that O +
catalyse O +
four O +
consecutive O +
hydroxylations O +
including O +
one O +
ring O -
- O -
expansion O +
to O +
form O +
the O +
defense O +
compound O +
DIBOA O +
( O -
Fig. O +
1 O +
; O -
[ O -
2 O -
] O +
) O -
. O +

The O +
classic O +
forms O +
of O +
cytochrome B-Gene +
P450 I-Gene +
monooxygenases I-Gene +
are O +
membrane O -
- O -
bound O +
heme O -
- O -
containing O +
mixed O +
function O +
oxidases B-Gene -
. O +

They O +
utilise O +
NADPH O +
or O +
NADH O +
to O +
reductively O +
cleave O +
molecular O +
oxygen O +
to O +
produce O +
functionalised O +
organic O +
products O +
and O +
a O +
molecule O +
of O +
water O -
. O +

In O +
this O +
generalised O +
reaction O -
, O +
reducing O +
equivalents O +
from O +
NADPH O +
are O +
transferred O +
to O +
the O +
P450 B-Gene +
enzyme B-Gene +
via O +
a O +
flavin B-Gene -
- I-Gene -
containing I-Gene +
NADPH I-Gene -
- I-Gene -
P450 I-Gene +
reductase I-Gene +
( O -
CPR B-Gene -
) O -
. O +

In O +
plants O -
, O +
P450 B-Gene +
enzymes B-Gene +
are O +
involved O +
mainly O +
in O +
hydroxylation O +
or O +
oxidative O +
demethylation O +
reactions O -
[ O -
5 O -
] O +
of O +
a O +
large O +
variety O +
of O +
primary O +
and O +
secondary O +
metabolites O +
including O +
hormones O -
, O +
phytoalexins O -
, O +
xenobiotics O +
and O +
pharmaceutically O +
relevant O +
compounds O -
. O +

The O +
close O +
genetic O +
linkage O +
and O +
the O +
sequence O +
similarity O +
of O +
the O +
DIBOA O -
- O -
specific O +
P450 B-Gene +
genes O -
[ O -
4 O -
] O +
, O +
indicate O +
that O +
these O +
genes O +
most O +
probably O +
arose O +
from O +
gene O +
duplication O +
events O -
. O +

Evolution O +
of O +
these O +
genes O +
generated O +
enzymes B-Gene +
of O +
the O +
CYP71C B-Gene +
P450 I-Gene +
subfamily O +
that O +
catalyse O +
consecutive O +
reactions O +
in O +
the O +
pathway O +
leading O +
to O +
DIBOA O -
. O +

In O +
this O +
report O +
we O +
show O +
that O +
this O +
process O +
has O +
resulted O +
in O +
rather O +
specific O +
P450 B-Gene +
enzymes B-Gene +
that O +
predominantly O +
catalyse O +
only O +
one O +
reaction O +
in O +
the O +
DIBOA O +
pathway O -
. O +

The O +
question O +
of O +
enzyme B-Gene +
specificity O +
was O +
addressed O +
by O +
heterologous O +
expression O +
of O +
the O +
P450 B-Gene +
genes O +
in O +
yeast O -
. O +

In O +
this O +
system O +
we O +
also O +
investigated O +
the O +
interaction O +
of O +
the O +
maize O +
P450 B-Gene +
enzymes B-Gene +
with O +
one O +
CPR B-Gene +
of O +
yeast O +
and O +
two O +
CPRs B-Gene +
of O +
Arabidopsis O -
, O +
indicating O +
that O +
the O +
availability O +
of O +
CPR B-Gene +
may O +
limit O +
P450 B-Gene +
enzyme B-Gene +
activity O +
in O +
plants O -
. O +

In O +
order O +
to O +
test O +
whether O +
the O +
DIBOA O +
pathway O +
of O +
maize O +
can O +
be O +
generalised O +
in O +
grasses O -
, O +
microsomes O +
derived O +
from O +
rye O +
and O +
barley O +
seedlings O +
were O +
assayed O +
for O +
the O +
BX2–BX5 B-Gene +
specific O +
reactions O -
. O +

In O +
rye O +
( O -
high O +
DIBOA O +
content O -
) O +
the O +
enzyme B-Gene +
activities O +
were O +
identical O +
with O +
those O +
in O +
maize O -
, O +
whereas O +
in O +
barley O +
( O -
no O +
detectable O +
DIBOA O +
or O +
DIMBOA O -
) O +
no O +
enzymatic O +
activities O +
were O +
observed O -
. O +

2 O +
Results O +
2.1 O +
Characterization O +
of O +
the O +
enzymatic O +
properties O +
of O +
BX2–BX5 B-Gene +
by O +
heterologous O +
expression O +
in O +
yeast O +
The O +
cytochrome B-Gene +
P450-dependent I-Gene +
monooxygenases I-Gene +
BX2–BX5 B-Gene +
convert O +
indole O +
to O +
DIBOA O +
by O +
catalysing O +
a O +
series O +
of O +
four O +
hydroxylations O +
( O -
Fig. O +
1 O +
; O -
[ O -
2 O -
] O +
) O -
. O +

These O +
P450 B-Gene +
enzymes B-Gene +
were O +
expressed O +
in O +
yeast O +
in O +
order O +
to O +
characterise O +
their O +
catalytic O +
properties O +
in O +
more O +
detail O -
. O +

For O +
expression O -
, O +
the O +
Bx2–Bx5 B-Gene +
cDNAs O +
were O +
inserted O +
into O +
the O +
pYeDP60 O +
vector O +
under O +
the O +
control O +
of O +
the O +
galactose O +
inducible O +
GAL10-CYC1 O +
promotor O -
[ O -
6 O -
] O +
. O +

The O +
P450 B-Gene +
genes O +
were O +
expressed O +
in O +
four O +
different O +
Saccharomyces O +
cerevisiae O +
strains O +
that O +
were O +
isogenic O +
except O +
for O +
their O +
CPR B-Gene +
gene O +
locus O -
. O +

Strain O +
W O -
( O -
N O -
) O +
has O +
wild O +
type O +
yeast O +
CPR B-Gene +
levels O -
, O +
W O -
( O -
R O -
) O +
overexpresses O +
yeast O +
CPR B-Gene +
after O +
induction O +
with O +
galactose O -
[ O -
7 O -
] O +
. O +

In O +
WAT11 O +
and O +
WAT21 O +
galactose O +
inducible O +
Arabidopsis O +
thaliana O +
CPRs B-Gene +
( O -
ATR1 B-Gene +
and O +
ATR2 B-Gene +
, O +
respectively O -
) O +
replace O +
the O +
yeast O +
reductase B-Gene +
in O +
the O +
genome O -
[ O -
6 O -
, O +
8 O -
] O +
. O +

Microsomes O +
were O +
isolated O +
from O +
the O +
transgenic O +
yeast O +
strains O +
and O +
tested O +
for O +
the O +
four O +
specific O +
reactions O +
of O +
the O +
DIBOA O +
pathway O +
by O +
HPLC O +
analysis O -
. O +

The O +
concentration O +
of O +
the O +
maize O +
P450 B-Gene +
proteins B-Gene +
in O +
the O +
microsomes O +
was O +
determined O +
by O +
quantitative O +
Western O +
analysis O +
( O -
Table O +
1 O +
) O -
. O +

CPR B-Gene +
activities O +
were O +
analysed O +
by O +
cytochrome B-Gene +
c I-Gene +
reduction O -
[ O -
9 O -
] O +
. O +

The O +
CPR B-Gene +
activity O +
was O +
basically O +
independent O +
of O +
the O +
heterologous O +
P450 B-Gene +
gene O +
and O +
similar O +
to O +
the O +
values O +
obtained O +
by O +
Pompon O +
et O +
al. O -
[ O -
5 O -
] O +
. O +

In O +
W O -
( O -
R O -
) O +
overexpression O +
of O +
the O +
yeast O +
CPR B-Gene +
results O +
in O +
a O +
20-fold O +
stimulation O +
of O +
the O +
basal O +
CPR B-Gene +
activity O -
. O +

Overexpression O +
of O +
the O +
CPRs B-Gene +
from O +
Arabidopsis O +
leads O +
to O +
a O +
4 O -
- O -
5-fold O +
increase O +
over O +
the O +
basal O +
level O -
. O +

The O +
concentration O +
of O +
the O +
maize O +
P450 B-Gene +
proteins B-Gene +
in O +
the O +
transgenic O +
yeast O +
microsomes O +
was O +
in O +
the O +
range O +
of O +
0.2–2.6 O +
μ O +
g O -
/ O -
mg O +
microsomes O +
( O -
Table O +
1 O +
) O -
. O +

Except O +
for O +
BX2 B-Gene -
, O +
these O +
expression O +
levels O +
are O +
lower O +
than O +
in O +
maize O +
microsomes O -
. O +

It O +
is O +
possible O +
that O +
the O +
relative O +
high O +
GC O +
content O +
( O -
65 O -
% O -
) O +
of O +
the O +
maize O +
genes O -
[ O -
4 O -
] O +
does O +
not O +
permit O +
efficient O +
expression O +
in O +
the O +
yeast O +
system O -
. O +

Heterologous O +
expression O +
of O +
the O +
cinnamate-4-hydroxylase B-Gene +
gene O +
from O +
Helianthus O +
tuberosus O +
( O -
48 O -
% O +
GC O -
) O -
[ O -
10 O -
] O +
in O +
the O +
same O +
system O +
resulted O +
in O +
protein B-Gene +
expression O +
levels O +
that O +
were O +
in O +
the O +
range O +
of O +
4 O +
to O +
10 O +
μ O +
g O -
/ O -
mg O +
microsomal O +
protein B-Gene -
[ O -
11 O -
] O +
. O +

In O +
general O -
, O +
similar O +
P450 B-Gene +
activities O +
can O +
be O +
obtained O +
in O +
microsomal O +
preparations O +
derived O +
from O +
the O +
yeast O +
strains O +
as O +
with O +
maize O +
microsomes O -
. O +

The O +
specific O +
activity O +
of O +
the O +
P450 B-Gene +
enzymes B-Gene +
is O +
dependent O +
on O +
the O +
amount O +
and O +
to O +
a O +
certain O +
extend O +
on O +
the O +
nature O +
of O +
the O +
CPRs B-Gene +
present O +
in O +
the O +
microsomes O +
( O -
Table O +
1 O +
) O -
. O +

In O +
this O +
respect O -
, O +
some O +
individual O +
features O +
were O +
observed O -
. O +

BX2 B-Gene +
shows O +
little O +
preference O +
for O +
one O +
of O +
the O +
CPRs B-Gene +
and O +
has O +
a O +
similar O +
specific O +
activity O +
in O +
all O +
yeast O +
strains O +
which O +
is O +
highest O +
in O +
W O -
( O -
R O -
) O -
. O +

In O +
contrast O -
, O +
the O +
specific O +
activity O +
of O +
BX3 B-Gene +
is O +
about O +
8 O +
times O +
higher O +
in O +
WAT11 O +
than O +
in O +
maize O +
microsomes O -
. O +

This O +
suggests O +
a O +
productive O +
interaction O +
of O +
BX3 B-Gene +
and O +
ATR1 B-Gene +
and O +
indicates O +
that O +
in O +
this O +
case O +
the O +
amount O +
of O +
CPR B-Gene +
limits O +
the O +
in O +
vivo O +
activity O +
of O +
BX3 B-Gene -
. O +

According O +
to O +
their O +
specific O +
activities O -
, O +
BX4 B-Gene +
and O +
BX5 B-Gene +
show O +
a O +
preference O +
for O +
the O +
maize O +
CPR B-Gene -
( O -
s O -
) O -
. O +

The O +
question O +
of O +
enzyme B-Gene +
specificity O +
was O +
addressed O +
with O +
the O +
yeast O +
expression O +
system O -
. O +

The O +
intermediate O +
metabolites O +
of O +
the O +
DIBOA O +
pathway O +
indole O -
, O +
indolin-2-one O -
, O +
3-hydroxy O -
- O -
indolin-2-on O -
, O +
and O +
HBOA O -
[ O -
2 O -
] O +
were O +
incubated O +
with O +
microsomal O +
preparations O +
each O +
containing O +
one O +
of O +
the O +
P450 B-Gene +
enzymes B-Gene -
. O +

Enzymatic O +
conversions O +
occured O +
only O +
in O +
the O +
known O +
productive O +
combinations O -
[ O -
2 O -
] O +
( O -
Fig. O +
1 O +
) O -
, O +
no O +
conversions O +
were O +
detectable O +
( O -
the O +
detection O +
limit O +
is O +
0.002 O +
nmol O -
× O -
mg−1 O +
×min−1 O +
) O +
in O +
the O +
other O +
combinations O -
. O +

Each O +
enzyme B-Gene +
is O +
therefore O +
specific O +
for O +
the O +
introduction O +
of O +
only O +
one O +
of O +
the O +
oxygen O +
atoms O +
of O +
the O +
DIBOA O +
molecule O -
. O +

In O +
addition O +
to O +
the O +
reactions O +
described O +
above O -
, O +
benzoxazin-3-one O +
and O +
2-hydroxy-7-methoxy-1,4-benzoxazin-3-one O +
( O -
HMBOA O -
, O +
Fig. O +
1 O +
) O +
were O +
tested O +
as O +
possible O +
substrates O +
for O +
BX2–BX5 B-Gene -
. O +

The O +
hydroxylation O +
of O +
benzoxazin-3-one O +
to O +
HBOA O +
( O -
Fig. O +
1 O +
) O +
was O +
previously O +
described O +
for O +
maize O +
microsomes O -
[ O -
12 O -
] O +
. O +

Of O +
the O +
four O +
P450 B-Gene +
enzymes B-Gene +
tested O -
, O +
only O +
BX3 B-Gene +
catalyses O +
this O +
reaction O -
. O +

Hydroxylation O +
of O +
benzoxazin-3-one O +
is O +
approximately O +
half O +
as O +
efficient O +
as O +
the O +
hydroxylation O +
of O +
indolin-2-one O +
( O -
Table O +
1 O +
) O -
. O +

In O +
both O +
cases O +
a O +
C O +
atom O +
at O +
an O +
equivalent O +
position O +
is O +
hydroxylated O +
( O -
Fig. O +
1 O +
) O -
. O +

In O +
contrast O -
, O +
for O +
HMBOA O -
, O +
a O +
derivative O +
present O +
in O +
maize O +
seedlings O -
[ O -
13 O -
] O +
, O +
no O +
enzymatic O +
conversions O +
are O +
detectable O +
with O +
BX2–BX5 B-Gene +
expressed O +
in O +
yeast B-Gene +
or O +
with O +
maize B-Gene +
microsomes O -
. O +

In O +
particular O -
, O +
HMBOA O +
is O +
not O +
N O -
- O -
hydroxylated O +
by O +
BX5 B-Gene -
. O +

This O +
indicates O +
that O +
the O +
7-methoxy O +
group O +
of O +
HMBOA O +
would O +
interfere O +
with O +
BX5 B-Gene +
action O -
. O +

In O +
a O +
number O +
of O +
species O +
the O +
demethylation O +
of O +
the O +
artificial O +
substrate O +
p O +
-chloro O -
- O -
N O +
-methylaniline O +
( O -
pCMA O -
) O +
in O +
a O +
P450 B-Gene +
specific O +
reaction O +
has O +
been O +
described O -
. O +

This O +
activity O +
is O +
associated O +
with O +
the O +
first O +
plant O +
P450 B-Gene +
enzyme B-Gene +
that O +
was O +
purified O +
and O +
cloned O -
[ O -
14 O -
] O +
. O +

This O +
enzyme B-Gene +
from O +
avocado O +
( O -
Persea O +
americana O +
) O -
, O +
for O +
which O +
the O +
natural O +
substrate O +
is O +
still O +
unknown O -
, O +
was O +
designated O +
CYP71A1 B-Gene +
and O +
established O +
the O +
CYP71A B-Gene +
subfamily O -
[ O -
15 O -
] O +
. O +

CYP73A1 B-Gene -
, O +
the O +
cinnamate-4-hydroxylase B-Gene +
from O +
Heliantus O +
tuberosus O +
shows O +
also O +
pCMA B-Gene +
demetylase I-Gene +
activity O -
[ O -
16 O -
] O +
. O +

Since O +
BX2–BX5 B-Gene +
have O +
been O +
grouped O +
into O +
the O +
CYP71 B-Gene +
family O -
[ O -
4 O -
] O +
, O +
they O +
were O +
tested O +
for O +
pCMA B-Gene +
demethylase I-Gene +
activity O -
. O +

While O +
BX3–BX5 B-Gene +
expressed O +
in O +
WAT11 O +
show O +
low O +
pCMA B-Gene +
demethylase I-Gene +
activity O +
( O -
0.02–0.04 O +
nmol O -
× O -
min−1 O +
×mg−1 O +
microsomes O -
) O +
WAT11 O +
yeast O +
microsomes O +
containing O +
the O +
BX2 B-Gene +
enzyme B-Gene +
convert O +
pCMA O +
to O +
p O +
-chloro O -
- O -
aniline O +
with O +
a O +
specific O +
activity O +
of O +
0.74 O +
nmol O -
× O -
min−1 O +
×mg−1 O +
microsomes O -
. O +

This O +
value O +
is O +
about O +
three O +
times O +
the O +
pCMA B-Gene +
demethylase I-Gene +
activity O +
of O +
CYP71A1 B-Gene +
expressed O +
in O +
wild O +
type O +
yeast O -
[ O -
17 O -
] O +
and O +
one O +
third O +
of O +
the O +
activity O +
of O +
CYP73A1 B-Gene +
expressed O +
in O +
W O -
( O -
R O -
) O -
[ O -
16 O -
] O +
. O +

The O +
KM O +
values O +
for O +
BX2–BX5 B-Gene +
are O +
in O +
the O +
range O +
5–38 O +
μ O +
M. O +
The O +
concentrations O +
determined O +
for O +
the O +
yeast O -
- O -
expressed O +
enzymes B-Gene +
are O +
nearly O +
identical O +
to O +
the O +
values O +
measured O +
in O +
maize O +
microsomes O +
( O -
Table O +
2 O +
) O -
. O +

This O +
is O +
an O +
indication O +
for O +
the O +
native O +
conformation O +
of O +
the O +
heterologously O +
expressed O +
P450 B-Gene +
enzymes B-Gene -
. O +

KM O +
values O +
for O +
other O +
plant O +
P450 B-Gene +
enzymes B-Gene +
are O +
in O +
the O +
range O +
of O +
2 O +
μ O +
M O +
for O +
protopin-6-hydroxylase B-Gene -
[ O -
18 O -
] O +
and O +
350 O +
μ O +
M O +
for O +
tyrosin B-Gene -
- I-Gene -
N I-Gene +
-hydroxylase I-Gene -
[ O -
19 O -
] O +
. O +

2.2 O +
DIBOA O +
biosynthetic O +
enzymes B-Gene +
in O +
other O +
cereals O +
The O +
hydroxamic O +
acids O +
are O +
widely O +
distributed O +
in O +
grasses O -
[ O -
1 O -
] O +
, O +
suggesting O +
that O +
the O +
aquisation O +
of O +
this O +
pathway O +
occured O +
relatively O +
early O +
in O +
the O +
evolution O +
of O +
the O +
Gramineae O -
. O +

The O +
activity O +
of O +
the O +
DIBOA O +
specific O +
P450 B-Gene +
enzymes B-Gene +
was O +
assayed O +
in O +
two O +
other O +
cereals O -
, O +
rye O +
( O -
containing O +
hydroxamic O +
acids O -
) O +
and O +
barley O +
( O -
without O +
hydroxamic O +
acids O -
) O -
[ O -
1 O -
] O +
. O +

These O +
two O +
species O +
are O +
much O +
closer O +
related O +
to O +
each O +
other O +
than O +
either O +
is O +
to O +
maize O -
[ O -
20 O -
] O +
. O +

The O +
major O +
cyclic O +
hydroxamic O +
acid O +
of O +
rye O +
is O +
DIBOA O -
. O +

As O +
in O +
maize O -
, O +
there O +
are O +
relatively O +
high O +
concentrations O +
( O -
up O +
to O +
1 O +
mg O -
/ O -
g O +
fresh O +
weight O -
) O -
[ O -
21 O -
] O +
present O +
in O +
the O +
rye O +
seedling O -
. O +

In O +
order O +
to O +
investigate O +
whether O +
identical O +
cytochrome B-Gene +
P450-dependent I-Gene +
reactions O +
are O +
associated O +
with O +
DIBOA O +
biosynthesis O +
in O +
rye O -
, O +
microsomes O +
were O +
isolated O +
from O +
seedlings O -
. O +

The O +
CPR B-Gene +
activity O +
in O +
rye O +
microsomes O +
is O +
about O +
1.8 O +
times O +
higher O +
than O +
in O +
maize O -
. O +

All O +
five O +
substrates O +
tested O +
( O -
Table O +
3 O +
) O +
were O +
converted O +
to O +
products O +
that O +
were O +
identical O +
to O +
the O +
products O +
obtained O +
with O +
maize O +
microsomes O -
. O +

No O +
additional O +
products O +
were O +
detected O -
. O +

The O +
reactions O +
were O +
strictly O +
dependent O +
on O +
NADPH O +
( O -
data O +
not O +
shown O -
) O +
indicating O +
true O +
cytochrome B-Gene +
P450 I-Gene +
enzyme B-Gene +
reactions O -
. O +

The O +
specific O +
activities O +
determined O +
for O +
the O +
rye O +
microsomes O +
were O +
very O +
similar O +
to O +
the O +
values O +
detected O +
with O +
maize O +
microsomes O +
for O +
the O +
first O +
three O +
reactions O +
in O +
the O +
pathway O -
. O +

The O +
conversion O +
of O +
HBOA O +
to O +
DIBOA O +
was O +
reproducibly O +
lower O +
( O -
a O +
factor O +
of O +
two O -
) O +
in O +
rye O +
microsomes O -
. O +

The O +
identity O +
of O +
the O +
reactions O +
in O +
maize O +
and O +
in O +
rye O +
suggests O +
identical O +
DIBOA O +
biosynthetic O +
pathways O +
for O +
both O +
species O -
. O +

In O +
microsomes O +
prepared O +
from O +
barley O +
seedlings O -
, O +
no O +
activities O +
of O +
the O +
P450 B-Gene +
enzymes B-Gene +
of O +
the O +
DIBOA O +
pathway O +
were O +
detectable O -
, O +
although O +
a O +
total O +
P450 B-Gene +
content O +
of O +
3 O +
μ O +
g O -
/ O -
mg O +
microsomal O +
protein B-Gene +
and O +
a O +
CPR B-Gene +
activity O +
of O +
29 O +
nmol O -
× O -
mg−1 O +
×min−1 O +
was O +
determined O +
( O -
Table O +
3 O +
) O -
. O +

3 O +
Discussion O +
Heterologous O +
expression O +
in O +
yeast O +
strains O +
overexpressing O +
plant O +
CPRs B-Gene +
is O +
a O +
powerful O +
tool O +
for O +
the O +
functional O +
analysis O +
of O +
plant O +
cytochrome B-Gene +
P450 I-Gene +
enzymes B-Gene -
[ O -
11 O -
] O +
. O +

Using O +
this O +
system O +
it O +
was O +
possible O +
to O +
determine O +
the O +
enzymatic O +
properties O +
for O +
BX2–BX5 B-Gene +
without O +
using O +
radioactively O +
labelled O +
substrates O -
. O +

3.1 O +
Enzymatic O +
properties O +
of O +
BX2–BX5 B-Gene +
Bx2–Bx5 B-Gene +
have O +
probably O +
evolved O +
by O +
gene O +
duplication O +
events O +
as O +
indicated O +
by O +
clustering O +
of O +
the O +
genes O +
on O +
the O +
short O +
arm O +
of O +
chromosome O +
four O +
and O +
the O +
sequence O +
similarity O +
between O +
these O +
genes O -
. O +

They O +
have O +
been O +
grouped O +
into O +
the O +
CYP71C B-Gene +
subfamily O -
[ O -
4 O -
] O +
of O +
cytochrome B-Gene +
P450-dependent I-Gene +
monooxygenases I-Gene -
. O +

The O +
BX3–BX5 B-Gene +
proteins O +
share O +
an O +
average O +
amino O +
acid O +
identity O +
and O +
similarity O +
of O +
58 O -
% O +
and O +
77 O -
% O -
, O +
respectively O -
, O +
while O +
the O +
average O +
identity O +
and O +
similarity O +
of O +
these O +
P450 B-Gene +
enzymes B-Gene +
to O +
BX2 O +
is O +
only O +
49 O -
% O +
and O +
70 O -
% O +
respectively O -
[ O -
4 O -
] O +
. O +

BX2 B-Gene +
is O +
also O +
distinct O +
in O +
that O +
its O +
expression O +
levels O +
in O +
the O +
yeast O +
strains O +
are O +
much O +
higher O +
than O +
that O +
of O +
the O +
other O +
subfamiliy O +
members O +
( O -
Table O +
1 O +
) O -
. O +

In O +
addition O -
, O +
the O +
interaction O +
of O +
BX2 B-Gene +
with O +
different O +
CPRs B-Gene +
seems O +
to O +
be O +
less O +
selective O +
than O +
that O +
of O +
BX3–BX5 B-Gene -
. O +

The O +
specific O +
activity O +
of O +
BX2 B-Gene +
in O +
the O +
microsomes O +
prepared O +
from O +
transgenic O +
W O -
( O -
R O -
) O +
and O +
WAT11 O +
strains O +
are O +
quite O +
similar O -
. O +

In O +
contrast O -
, O +
BX3 B-Gene +
shows O +
a O +
clear O +
preference O +
for O +
the O +
CPR B-Gene +
of O +
Arabidopsis O +
thaliana O +
( O -
ATR1 B-Gene -
) O +
present O +
in O +
the O +
WAT11 O +
yeast O +
strain O -
. O +

BX4 B-Gene +
and O +
BX5 B-Gene +
also O +
seem O +
to O +
interact O +
relatively O +
well O +
with O +
ATR1 B-Gene -
, O +
although O +
their O +
specific O +
activities O +
are O +
lower O +
than O +
in O +
maize O +
microsomes O -
. O +

All O +
heterologous O +
CPRs B-Gene -
, O +
however O -
, O +
show O +
a O +
productive O +
interaction O +
with O +
the O +
maize O +
P450 B-Gene +
enzymes B-Gene -
. O +

This O +
is O +
further O +
proof O +
for O +
the O +
well O +
established O +
structural O +
conservation O +
of O +
the O +
interaction O +
of O +
P450 B-Gene +
enzymes B-Gene +
and O +
CPRs B-Gene -
[ O -
22 O -
] O +
. O +

The O +
turn O -
- O -
over O +
rate O +
of O +
BX3 B-Gene +
expressed O +
in O +
WAT11 O +
is O +
about O +
eight O +
times O +
higher O +
than O +
in O +
maize O +
microsomes O -
. O +

This O +
indicates O +
that O +
CPR B-Gene +
is O +
a O +
limiting O +
factor O +
for O +
BX3 B-Gene +
activity O +
in O +
vivo O +
. O +

Overexpression O +
of O +
CPRs B-Gene +
in O +
the O +
plant O +
could O +
therefore O +
result O +
in O +
significantly O +
higher O +
enzymatic O +
activities O -
. O +

This O +
could O +
be O +
important O +
for O +
the O +
engineering O +
of O +
metabolic O +
pathways O +
that O +
involve O +
P450 B-Gene +
enzymes B-Gene -
. O +

3.2 O +
Specificity O +
of O +
BX2–BX5 B-Gene +
BX2–BX5 B-Gene +
show O +
high O +
substrate O +
specificity O -
. O +

Each O +
of O +
the O +
DIMBOA O +
specific O +
enzymatic O +
conversions O +
can O +
be O +
performed O +
only O +
by O +
one O +
enzyme B-Gene +
of O +
the O +
subfamily O -
. O +

Such O +
a O +
finding O +
seems O +
to O +
support O +
the O +
idea O +
that O +
plant O +
P450s B-Gene +
generally O +
have O +
a O +
much O +
greater O +
substrate O +
specificity O +
than O +
their O +
animal O +
homologues O -
[ O -
23 O -
] O +
. O +

However O -
, O +
there O +
is O +
emerging O +
evidence O +
that O +
plant O +
P450s B-Gene +
in O +
addition O +
to O +
their O +
normal O +
physiological O +
function O -
, O +
can O +
also O +
convert O +
certain O +
xenobiotics O +
with O +
varying O +
efficiencies O -
. O +

The O +
hydroxylation O +
of O +
the O +
herbicide O +
diclofop O +
was O +
shown O +
to O +
occur O +
by O +
a O +
wheat O +
P450 B-Gene +
enzyme B-Gene -
[ O -
24 O -
] O +
. O +

Other O +
examples O +
include O +
the O +
demethylation O +
of O +
pCMA O +
by O +
CYP71A1 B-Gene -
[ O -
17 O -
] O +
and O +
by O +
CYP73A1 B-Gene -
[ O -
16 O -
] O +
. O +

The O +
natural O +
substrate O +
for O +
CYP71A1 B-Gene +
is O +
not O +
known O -
, O +
although O +
geraniol O +
and O +
nerol O +
have O +
been O +
reported O +
as O +
substrates O -
[ O -
25 O -
] O +
. O +

CYP73A1 B-Gene +
catalyzes O +
the O +
4-hydroxylation O +
of O +
cinnamic O +
acid O -
, O +
the O +
first O +
oxidative O +
step O +
in O +
the O +
phenylpropan O +
pathway O -
. O +

For O +
CYP73A1 B-Gene +
the O +
conversion O +
of O +
extra O +
substrates O +
has O +
been O +
investigated O +
in O +
great O +
detail O -
[ O -
23 O -
] O +
. O +

Furthermore O -
, O +
plant O +
P450 B-Gene +
enzymes B-Gene +
can O +
convert O +
different O +
natural O +
substrates O -
. O +

Two O +
P450 B-Gene +
enzymes B-Gene +
of O +
sorghum O +
that O +
belong O +
to O +
the O +
CYP79 B-Gene +
family O +
and O +
the O +
CYP71E B-Gene +
subfamily O +
respectively O -
[ O -
26 O -
] O +
are O +
involved O +
in O +
the O +
biosynthesis O +
of O +
the O +
cyanogenic O +
glucoside O +
dhurrin O -
. O +

These O +
enzymes B-Gene +
are O +
multifunctional O +
and O +
catalyse O +
four O +
distinct O +
steps O -
[ O -
27 O -
, O +
28 O -
] O +
. O +

Indole O +
appears O +
as O +
the O +
natural O +
substrate O +
for O +
2-hydroxylation O +
by O +
BX2 B-Gene -
. O +

In O +
addition O -
, O +
BX2 B-Gene +
shows O +
pCMA B-Gene +
demethylase I-Gene +
activity O +
like O +
CYP71A1 B-Gene +
and O +
CYP73A1 B-Gene -
. O +

Since O +
the O +
other O +
substrates O +
of O +
these O +
P450 B-Gene +
enzymes B-Gene +
have O +
no O +
structural O +
similarity O -
, O +
it O +
is O +
likely O +
that O +
pCMA O +
is O +
a O +
quite O +
reactive O +
molecule O +
in O +
the O +
context O +
of O +
P450 B-Gene +
catalysed O +
reactions O -
, O +
even O +
if O +
binding O +
of O +
pCMA O +
is O +
not O +
optimal O -
. O +

This O +
is O +
underlined O +
by O +
the O +
fact O +
that O +
demetylation O +
of O +
pCMA O +
is O +
also O +
catalysed O +
by O +
several O +
animal O +
P450 B-Gene +
enzymes B-Gene -
[ O -
29 O -
] O +
. O +

The O +
structural O +
analogy O +
between O +
2-naphthoic O +
acid O +
and O +
trans O +
-cinnamic O +
acid O +
was O +
shown O +
to O +
be O +
sufficient O +
such O +
that O +
2-naphthoic O +
acid O +
can O +
serve O +
as O +
an O +
excellent O +
substrate O +
for O +
CYP73A1 B-Gene -
[ O -
23 O -
] O +
. O +

We O +
have O +
probably O +
observed O +
a O +
similar O +
case O +
for O +
BX3 B-Gene +
that O +
hydroxylates O +
indolin-2-one O +
and O +
1,4-benzoxazin-3-one O +
at O +
an O +
equivalent O +
carbon O +
atom O -
. O +

Although O +
indolin-2-one O +
is O +
converted O +
about O +
2-fold O +
more O +
efficiently O -
, O +
it O +
seems O +
that O +
1,4-benzoxazin-3-one O +
mimics O +
indolin-2-one O +
in O +
the O +
active O +
site O +
of O +
BX3 B-Gene -
. O +

HMBOA O +
was O +
found O +
in O +
maize O +
seedlings O -
[ O -
13 O -
] O +
. O +

It O +
is O +
neither O +
a O +
substrate O +
for O +
BX5 B-Gene +
nor O +
can O +
it O +
be O +
N O -
- O -
hydroxylated O +
in O +
maize O +
microsomes O -
[ O -
30 O -
] O +
. O +

It O +
is O +
probably O +
the O +
presence O +
of O +
the O +
7-methoxy O +
group O +
that O +
excludes O +
HMBOA O +
as O +
a O +
substrate O +
for O +
BX5 B-Gene -
. O +

HMBOA O +
could O +
represent O +
a O +
side O +
product O +
of O +
the O +
DIMBOA O +
pathway O -
, O +
in O +
which O +
the O +
C7-methoxy O +
group O +
was O +
introduced O +
prior O +
to O +
N O -
- O -
hydroxylation O +
by O +
BX5 B-Gene -
. O +

3.3 O +
Evolution O +
of O +
the O +
DIBOA O +
pathway O +
For O +
maize O +
and O +
rye O -
, O +
two O +
distant O +
species O +
among O +
the O +
Gramineae O -
, O +
the O +
same O +
DIBOA O +
biosynthetic O +
pathway O +
exists O +
and O +
therefore O +
a O +
set O +
of O +
proteins B-Gene +
homologous O +
to O +
BX2–BX5 B-Gene +
can O +
be O +
proposed O -
. O +

If O +
this O +
were O +
the O +
case O -
, O +
the O +
duplications O +
responsible O +
for O +
the O +
evolution O +
of O +
the O +
Bx2–Bx5 B-Gene +
gene O +
cluster O +
must O +
have O +
occurred O +
early O +
in O +
the O +
development O +
of O +
the O +
Gramineae O -
. O +

In O +
maize O -
, O +
the O +
Bx1 B-Gene +
gene O +
is O +
included O +
in O +
this O +
cluster O -
[ O -
2 O -
] O +
. O +

Bx1 B-Gene +
encodes O +
a O +
protein B-Gene +
with O +
homology O +
to O +
the O +
trypthophan B-Gene +
sythase I-Gene +
α I-Gene +
subunit O +
that O +
catalyses O +
the O +
first O +
step O +
in O +
DIMBOA O +
biosynthesis O -
. O +

The O +
isolation O +
of O +
genes O +
homologues O +
to O +
Bx1–Bx5 B-Gene +
from O +
rye O +
and O +
other O +
grasses O +
could O +
give O +
insight O +
into O +
the O +
evolution O +
of O +
the O +
Bx O +
gene O +
cluster O -
. O +

Barley O +
microsomes O +
show O +
no O +
significant O +
DIBOA O +
specific O +
P450 B-Gene +
activities O -
. O +

It O +
remains O +
to O +
be O +
shown O +
whether O +
the O +
loss O +
of O +
enzyme B-Gene +
activity O +
is O +
due O +
to O +
gene O +
inactivation O -
, O +
or O +
whether O +
the O +
whole O +
Bx2–Bx5 B-Gene +
cluster O +
has O +
been O +
lost O -
. O +

This O +
might O +
have O +
occured O +
during O +
agricultural O +
breeding O +
from O +
wild O +
barley O +
varieties O +
in O +
which O +
DIMBOA O +
is O +
still O +
present O -
[ O -
1 O -
] O +
. O +

A O +
similar O +
loss O +
of O +
enzyme B-Gene +
activity O +
has O +
been O +
observed O +
for O +
the O +
UDP B-Gene -
- I-Gene -
glucose I-Gene -
: I-Gene -
DIBOA I-Gene +
glycosyltransferase I-Gene -
. O +

Glycosylation O +
is O +
required O +
for O +
transport O +
of O +
DIBOA O +
into O +
the O +
vacuole O -
. O +

Glycosyltransferase B-Gene +
activity O +
present O +
in O +
wild O +
varieties O -
, O +
was O +
lost O +
during O +
barley O +
cultivation O -
[ O -
30 O -
] O +
. O +

4 O +
Experimental O +
4.1 O +
Chemicals O +
DIBOA O +
and O +
HBOA O +
were O +
isolated O +
from O +
etiolated O +
rye O +
seedlings O -
[ O -
31 O -
] O +
and O +
further O +
purified O +
by O +
HPLC O +
using O +
a O +
Merck O +
LiChroCART O +
RP-18 O +
column O +
( O -
10 O -
× O -
250 O +
mm O -
) O -
. O +

The O +
eluent O +
contained O +
9 O -
% O +
HOAc O +
and O +
10 O -
% O +
MeOH O +
in O +
H2 O +
O O +
( O -
v O -
/ O -
v O -
) O -
. O +

4.2 O +
Plant O +
materials O +
The O +
maize O +
hybrid O +
Blizzard O +
( O -
Ciba O +
Geigy O -
) O -
, O +
rye O +
seeds O +
Halo O +
( O -
Lochow O -
- O -
Petkus O -
, O +
Germany O -
) O +
and O +
the O +
barley O +
seeds O +
Dissa O +
( O -
original O +
source O +
Seed O +
Union O -
, O +
Germany O -
) O +
were O +
used O +
for O +
preparation O +
of O +
microsomes O -
. O +

Seeds O +
were O +
germinated O +
in O +
the O +
dark O +
on O +
wet O +
filter O +
paper O +
for O +
3 O +
( O -
maize O -
) O +
or O +
4 O +
( O -
rye O +
and O +
barley O -
) O +
days O -
. O +

Whole O +
seedlings O +
were O +
utilised O +
for O +
microsomal O +
preparations O -
. O +

4.3 O +
Expression O +
of O +
BX2–BX5 B-Gene +
proteins B-Gene +
in O +
E. O +
coli O +
and O +
preparation O +
of O +
antibodies B-Gene +
The O +
coding O +
region O +
of O +
the O +
four O +
P450 B-Gene +
genes O +
was O +
obtained O +
by O +
PCR B-Gene +
amplification O +
using O +
the O +
cDNA O +
clones O -
[ O -
4 O -
] O +
as O +
templates O -
. O +

The O +
PCR B-Gene +
fragments O +
were O +
inserted O +
into O +
the O +
pET3a O +
expression O +
vector O +
and O +
expressed O +
in O +
E. O +
coli O +
strain O +
BL21 O +
( O -
DE3 O -
) O -
[ O -
32 O -
] O +
. O +

1 O +
l O +
cultures O +
were O +
harvested O -
, O +
lysed O +
and O +
the O +
overexpressed O +
proteins B-Gene +
were O +
recovered O +
as O +
inclusion B-Gene +
bodies I-Gene +
using O +
a O +
modified O +
protocol O +
of O +
Ito O +
et O +
al. O -
[ O -
33 O -
] O +
. O +

Final O +
purification O +
was O +
achieved O +
by O +
preparative O +
SDS O -
/ O -
PAGE O +
on O +
a O +
BioRad O +
model O +
491 O +
Prep O +
Cell O +
using O +
10 O -
% O +
SDS O -
/ O -
PAGE O +
according O +
to O +
the O +
recommendations O +
of O +
the O +
supplier O -
. O +

Immunisation O +
of O +
rabbits O +
was O +
carried O +
out O +
by O +
EUROGENTECH O +
( O -
Belgium O -
) O +
using O +
0.3 O +
mg O +
of O +
the O +
purified O +
proteins B-Gene +
per O +
immunisation O -
. O +

4.4 O +
Expression O +
of O +
P450 B-Gene +
proteins O +
in O +
yeast O +
The O +
yeast O +
strains O +
W O -
( O -
N O -
) O -
, O +
W O -
( O -
R O -
) O -
[ O -
6 O -
] O +
, O +
WAT11 O +
and O +
WAT21 O -
[ O -
6 O -
, O +
8 O -
] O +
and O +
the O +
plasmid O +
pYeDP60 O -
[ O -
11 O -
] O +
were O +
obtained O +
from O +
P. O +
Urban O -
. O +

The O +
DNA O +
coding O +
sequences O +
for O +
BX2–BX5 B-Gene +
were O +
excised O +
from O +
the O +
pET3a O +
constructs O +
by O +
cleavage O +
with O +
NdeI B-Gene +
and O +
EcoRI B-Gene -
. O +

The O +
NdeI B-Gene +
site O +
contains O +
the O +
AUG O +
start O +
codon O +
of O +
the O +
genes O -
. O +

The O +
DNA O +
fragments O +
were O +
inserted O +
into O +
pYeDP60 O +
which O +
was O +
linearized O +
with O +
EcoRI B-Gene +
and O +
BamHI B-Gene +
by O +
using O +
an O +
adapter O +
( O -
5′-GATCCAGGTGTCCA-3′ O -
, O +
5́-TATGGACACCTG-3́ O -
) O -
. O +

Yeast O +
cells O +
were O +
transformed O +
by O +
electroporation O -
[ O -
34 O -
] O +
and O +
cell O +
culture O +
was O +
performed O +
as O +
described O +
by O +
Urban O +
et O +
al. O -
[ O -
11 O -
] O +
. O +

4.5 O +
Enzyme O +
assays O +
Plant O +
microsomes O +
were O +
prepared O +
according O +
to O +
Bailey O +
and O +
Larson O -
[ O -
35 O -
] O +
. O +

Yeast O +
microsomes O +
were O +
prepared O +
as O +
described O -
[ O -
11 O -
] O +
. O +

The O +
total O +
P450 B-Gene +
content O +
of O +
plant O +
microsomes O +
was O +
measured O +
by O +
carbon O +
monoxide O +
differential O +
spectroscopy O -
[ O -
36 O -
] O +
. O +

pCMA B-Gene +
demethylase I-Gene +
activity O +
was O +
determined O +
with O +
NADPH O +
as O +
co O -
- O -
substrate O +
as O +
described O -
[ O -
37 O -
] O +
. O +

Other O +
hydroxylase B-Gene +
assays O +
were O +
performed O +
using O +
a O +
0.2 O +
ml O +
reaction O +
mixture O +
containing O +
50 O +
mM O +
K O -
- O -
Pi O +
pH O +
7.5 O -
, O +
0.8 O +
mM O +
NADPH O -
, O +
5 O +
μ O +
M O +
to O +
1 O +
mM O +
of O +
substrate O +
and O +
1 O +
mg O +
microsomes O +
( O -
according O +
to O +
the O +
protein B-Gene +
content O +
as O +
determined O +
by O +
Bradford O -
) O -
. O +

After O +
10 O +
min O +
incubation O +
at O +
25 O -
° O -
C O +
the O +
assays O +
were O +
terminated O +
by O +
the O +
addition O +
of O +
0.2 O +
ml O +
MeOH O +
and O +
centrifuged O +
for O +
5 O +
min O -
. O +

The O +
supernatant O +
was O +
acidified O +
with O +
0.5 O +
ml O +
0.1 O +
M O +
HOAc O +
and O +
extracted O +
three O +
times O +
with O +
0.4 O +
ml O +
EtOAc O -
. O +

The O +
extracts O +
were O +
lyophilised O -
, O +
dissolved O +
in O +
0.1 O +
ml O +
MeOH O +
and O +
an O +
aliquot O +
was O +
loaded O +
onto O +
a O +
Merck O +
LiChroCART O +
RP-18 O +
HPLC O +
column O +
( O -
4 O -
× O -
125 O +
mm O -
) O +
and O +
eluted O +
for O +
5 O +
min O +
in O +
isocratic O +
conditions O +
with O +
solvent O +
A O +
( O -
H2 O +
O O -
– O -
HOAc O -
, O +
9:1 O -
) O +
followed O +
by O +
a O +
linear O +
gradient O +
from O +
solvent O +
A O +
to O +
B O +
( O -
MeOH O -
– O -
H2 O +
O O -
– O -
HOAc O -
, O +
70:27:3 O -
) O +
for O +
7 O +
min O -
. O +

Analytes O +
were O +
detected O +
at O +
254 O +
nm O -
. O +

Microsomal O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
c I-Gene +
reductase I-Gene +
( O -
CPR B-Gene -
) O +
activity O +
was O +
measured O +
as O +
previously O +
described O -
[ O -
38 O -
] O +
. O +

4.6 O +
Determination O +
of O +
BX2–BX5 B-Gene +
concentration O +
in O +
microsomes O +
Microsomal O +
proteins O +
were O +
separated O +
by O +
10 O -
% O +
SDS O -
/ O -
PAGE O +
and O +
transferred O +
to O +
nitro O -
- O -
cellulose O +
membranes O +
according O +
to O +
the O +
recommendations O +
of O +
the O +
manufacturer O +
( O -
Amersham O -
) O -
. O +

For O +
immunostaining O -
, O +
the O +
rabbit O +
polyclonal O +
antibodies B-Gene +
specific O +
for O +
BX2–BX5 B-Gene +
were O +
used O -
. O +

The O +
blot O +
was O +
stained O +
with O +
anti O -
- O -
rabbit O +
antibodies O +
linked O +
with O +
Cy5 O +
fluorescent O +
dye O +
( O -
Amersham O -
) O -
. O +

The O +
fluorescent O +
signal O +
was O +
quantified O +
using O +
a O +
Storm O +
860 O +
imager O +
( O -
Molecular O +
Dynamics O -
) O -
. O +

Purified O +
recombinant O +
P450 B-Gene +
proteins B-Gene +
were O +
used O +
as O +
a O +
reference O +
for O +
quantification O -
. O +

Acknowledgements O +

We O +
thank O +
P. O +
Urban O +
and O +
D. O +
Pompon O +
for O +
the O +
yeast O +
expression O +
system O +
and O +
D. O +
Werck O -
- O -
Reichhart O +
for O +
suggestions O -
. O +

This O +
work O +
was O +
supported O +
by O +
grants O +
from O +
the O +
Deutsche O +
Forschungsgemeinschaft O +
( O -
SFB O +
369 O -
) O +
and O +
the O +
Fonds O +
der O +
Chemischen O +
Industrie O -
. O +

Neu2en5Ac O +
( O -
5-acetamido-2,6-anhydro-3,5-dideoxy O -
- O -
d O +
-glycero O +
-d O +
-galacto O +
-non-2-enonic O +
acid O -
, O +
2,3-dehydro-2-deoxy O -
- O -
N O +
-acetylneuraminic O +
acid O +
( O -
1 O +
) O +
is O +
a O +
transition O -
- O -
state O +
analog O +
of O +
the O +
hydrolysis O +
of O +
sialoglycoconjugates O +
( O -
2 O +
) O +
that O +
liberates O +
Neu5Ac O +
( O -
N O +
-acetylneuraminic O +
acid O +
( O -
3 O +
) O +
by O +
sialidase B-Gene -
; O +
it O +
acts O +
as O +
an O +
inhibitor O +
against O +
sialidase B-Gene +
[ O -
1–5 O -
] O +
. O +

Neu2en5Ac O +
was O +
first O +
detected O +
in O +
the O +
urine O -
, O +
saliva O -
, O +
and O +
blood O +
of O +
a O +
patient O +
with O +
sialuria O +
[ O -
6 O -
] O +
. O +

After O +
that O -
, O +
it O +
was O +
found O +
in O +
low O +
concentrations O +
in O +
the O +
serum O -
, O +
saliva O -
, O +
and O +
urine O +
of O +
healthy O +
individuals O +
[ O -
7 O -
] O +
and O +
was O +
further O +
detected O +
as O +
a O +
metabolite O +
in O +
mammalian O +
brain O +
[ O -
8 O -
] O +
. O +

Current O +
methods O +
of O +
detecting O +
Neu2en5Ac O +
rely O +
on O +
chemical O +
analysis O -
, O +
TLC O -
, O +
GC O +
or O +
MS O +
[ O -
9,10 O -
] O +
. O +

If O +
a O +
specific O +
antibody B-Gene +
to O +
Neu2en5Ac O +
could O +
be O +
produced O -
, O +
it O +
might O +
facilitate O +
the O +
detection O +
and O +
analysis O +
of O +
Neu2en5Ac O +
in O +
various O +
organisms O -
, O +
and O +
it O +
might O +
also O +
be O +
used O +
for O +
screening O +
for O +
sialuria O -
. O +

Here O -
, O +
we O +
describe O +
the O +
synthesis O +
of O +
an O +
effective O +
hapten O +
that O +
induces O +
antibodies B-Gene +
to O +
Neu2en5Ac O +
and O +
the O +
finding O +
of O +
a O +
MAb B-Gene +
that O +
recognizes O +
Neu2en5Ac O +
in O +
a O +
specific O +
manner O -
. O +

2 O +
. O +

Results O +
and O +
discussion O +
2.1 O +
Synthesis O +
of O +
hapten O +
The O +
carboxylate O +
group O +
of O +
Neu5Ac O +
has O +
the O +
special O +
characteristic O +
of O +
exhibiting O +
a O +
negative O +
charge O -
. O +

In O +
order O +
to O +
synthesize O +
a O +
potential O +
hapten O -
, O +
a O +
linker O +
was O +
attached O +
at O +
the O +
9 O +
position O -
, O +
which O +
is O +
remote O +
and O +
may O +
have O +
no O +
relation O +
to O +
the O +
characteristic O +
functional O +
group O -
. O +

Hapten O +
8 O +
was O +
synthesized O +
from O +
methyl O +
5-acetamido-4,7,8,9-tetra O -
- O -
O O +
-acetyl-2,6-anhydro-3,5-dideoxy O -
- O -
d O +
-glycero O +
-d O +
-galacto O +
-non-2-enonate O +
( O -
4 O +
) O +
[ O -
11 O -
] O +
( O -
Scheme O +
1 O +
) O -
. O +

Compound O +
4 O +
was O +
treated O +
with O +
NaOMe O +
and O +
then O +
with O +
p O +
-toluenesulfonyl O +
chloride O +
to O +
produce O +
tosyl O +
derivative O +
5 O +
in O +
42 O -
% O +
yield O -
. O +

Compound O +
5 O +
was O +
converted O +
to O +
azide O +
derivative O +
6 O +
by O +
treatment O +
with O +
sodium O +
azide O -
, O +
and O +
then O +
saponificated O +
( O -
78 O -
% O +
yield O -
) O -
. O +

The O +
reduction O +
of O +
azide O +
derivative O +
6 O +
by O +
triphenylphosphine O +
produced O +
amino O +
derivative O +
7 O +
in O +
59 O -
% O +
yield O -
. O +

In O +
order O +
to O +
attach O +
a O +
linker O +
at O +
C-9 O -
, O +
amino O +
derivative O +
7 O +
was O +
treated O +
with O +
glutaric O +
anhydride O +
to O +
produce O +
hapten O +
8 O +
( O -
59 O -
% O -
) O -
. O +

For O +
the O +
coupling O +
of O +
hapten O +
8 O +
with O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
BSA B-Gene -
) O +
or O +
keyhole O +
limpet O +
hemocyanin B-Gene +
( O -
KLH B-Gene -
) O -
, O +
a O +
mixture O +
of O +
hapten O +
8 O +
and O +
either O +
BSA B-Gene +
or O +
KLH B-Gene +
was O +
treated O +
with O +
1-ethyl-3- O -
( O -
3-diaminopropyl O -
) O -
carbodiimide O +
HCl O +
salt O +
( O -
EDC·HCl O -
) O -
. O +

The O +
conjugate O +
was O +
purified O +
by O +
gel O +
permeation O +
chromatography O -
. O +

2.2 O +
Hybridoma O +
Spleen O +
cells O +
from O +
mice O +
immunized O +
with O +
conjugate B-Gene +
10 I-Gene +
were O +
hybridized O +
with O +
myeloma O +
X63-Ag8.653 O +
cells O +
[ O -
12 O -
] O +
and O +
plated O +
directly O +
on O +
0.5 O -
% O +
agar O +
plates O +
containing O +
a O +
culture O +
medium O +
with O +
HAT O +
( O -
hypoxanthine O -
, O +
aminopterin O -
, O +
and O +
thymidine O -
) O +
[ O -
13 O -
] O +
. O +

Colonies O +
grown O +
on O +
the O +
agar O +
plates O +
were O +
isolated O +
and O +
the O +
culture O +
supernatant O +
was O +
assayed O +
by O +
enzyme B-Gene -
- O -
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O +
using O +
both O +
conjugate B-Gene +
9 I-Gene +
and O +
fetuin B-Gene +
as O +
screening O +
antigens O -
. O +

From O +
394 O +
clones O +
isolated O +
from O +
the O +
agar O +
plates O +
of O +
three O +
hybridization O +
trials O -
, O +
24 O +
hybridomas O +
were O +
obtained O +
that O +
produced O +
ELISA O -
- O -
positive O +
monoclonal B-Gene +
antibodies I-Gene +
( O -
MAbs B-Gene -
) O -
. O +

Most O +
of O +
the O +
positive O +
clones O +
produced O +
antibodies B-Gene +
that O +
also O +
bound O +
to O +
fetuin B-Gene +
as O +
well O -
. O +

However O -
, O +
one O +
clone O +
named O +
SIC172 B-Gene +
produced O +
an O +
antibody B-Gene +
that O +
bound O +
strongly O +
to O +
conjugate B-Gene +
9 I-Gene +
but O +
weakly O +
to O +
fetuin B-Gene -
. O +

Therefore O -
, O +
SIC172 B-Gene +
was O +
selected O +
for O +
further O +
study O -
. O +

The O +
SIC172 B-Gene +
MAb B-Gene +
was O +
IgG3 B-Gene -
( O -
κ O -
) O -
. O +

The O +
recloning O +
of O +
the O +
SIC172 B-Gene +
hybridoma O +
produced O +
subclones O +
essentially O +
similar O +
to O +
the O +
mother O +
clone O -
: O +
22 O +
subclones O +
out O +
of O +
23 O +
subclones O -
, O +
isolated O +
as O +
colonies O +
grown O +
on O +
an O +
agar O +
plate O -
, O +
produced O +
MAbs B-Gene +
that O +
bound O +
strongly O +
to O +
conjugate B-Gene +
9 I-Gene +
but O +
weakly O +
to O +
fetuin B-Gene -
. O +

2.3 O +
SIC172 B-Gene +
MAb B-Gene +
in O +
culture O +
supernatant O +
Fig. O +
1 O +
shows O +
the O +
binding O +
activities O +
of O +
SIC172 B-Gene +
MAb B-Gene +
at O +
various O +
dilutions O +
to O +
conjugate B-Gene +
9 I-Gene +
and O +
fetuin B-Gene -
. O +

For O +
comparison O -
, O +
data O +
obtained O +
with O +
SIC4 B-Gene +
MAb B-Gene +
that O +
bound O +
strongly O +
to O +
conjugate B-Gene +
both O +
9 B-Gene +
and O +
fetuin B-Gene +
are O +
included O -
. O +

SIC172 B-Gene +
MAb B-Gene +
shows O +
strong O +
binding O +
to O +
conjugate B-Gene +
9 I-Gene -
, O +
and O +
in O +
a O +
7-level O +
dilution O +
series O +
( O -
i.e. O -
, O +
dilutions O +
of O +
1:1–1:64 O -
) O -
, O +
it O +
is O +
beyond O +
the O +
upper O +
limit O +
of O +
the O +
assay O +
( O -
A O +
490 O +
of O +
about O +
6 O -
) O -
. O +

But O +
it O +
binds O +
a O +
little O +
to O +
fetuin B-Gene -
, O +
and O +
no O +
increase O +
is O +
found O +
after O +
dilution O -
, O +
which O +
might O +
dilute O +
out O +
some O +
interfering O +
materials O -
, O +
as O +
seen O +
in O +
the O +
case O +
of O +
the O +
binding O +
of O +
SIC4 B-Gene +
MAb O +
in O +
both O +
conjugate B-Gene +
9 I-Gene +
and O +
fetuin B-Gene -
. O +

The O +
effects O +
of O +
Neu2en5Ac O +
and O +
Neu5Ac O +
on O +
the O +
binding O +
of O +
SIC172 B-Gene +
MAb B-Gene +
in O +
culture O +
supernatant O +
to O +
conjugate B-Gene +
9 I-Gene +
were O +
examined O +
to O +
see O +
if O +
Neu2en5A O +
competes O +
specifically O +
with O +
conjugate B-Gene +
9 I-Gene +
( O -
Fig. O +
2 O +
) O -
. O +

High O +
doses O +
of O +
Neu2en5Ac O +
of O +
over O +
10 O +
μg O -
/ O -
well O +
( O -
0.34 O +
mM O -
) O +
interfered O +
with O +
the O +
binding O -
, O +
as O +
expected O -
, O +
and O +
at O +
100 O +
μg O -
/ O -
well O -
, O +
it O +
almost O +
completely O +
suppressed O +
the O +
binding O -
. O +

However O -
, O +
low O +
doses O +
of O +
Neu2en5Ac O -
, O +
such O +
as O +
1 O +
μg O -
/ O -
well O -
, O +
increased O +
the O +
binding O +
of O +
SIC172 B-Gene +
MAb B-Gene +
to O +
conjugate B-Gene +
9 I-Gene +
. O +

As O +
for O +
Neu5Ac O -
, O +
it O +
had O +
little O +
effect O +
on O +
binding O -
; O +
and O +
at O +
100 O +
μg O -
/ O -
well O +
( O -
3.2 O +
mM O -
) O +
it O +
slightly O +
increased O +
the O +
binding O -
, O +
just O +
like O +
a O +
low O +
dose O +
of O +
Neu2en5Ac O -
. O +

The O +
increased O +
binding O +
of O +
SIC172 B-Gene +
MAb B-Gene +
to O +
conjugate B-Gene +
9 I-Gene +
at O +
low O +
doses O +
of O +
Neu2en5Ac O +
may O +
be O +
due O +
to O +
the O +
presence O -
, O +
in O +
culture O +
supernatant O -
, O +
of O +
large O +
amounts O +
of O +
materials O +
that O +
can O +
cross O -
- O -
react O +
with O +
the O +
MAb B-Gene -
. O +

Since O +
high O +
doses O +
of O +
Neu5Ac O +
also O +
produce O +
a O +
similar O +
phenomenon O -
, O +
sialic O +
acid O -
- O -
containing O +
materials O -
, O +
which O +
might O +
be O +
abundant O +
in O +
culture O +
supernatant O -
, O +
may O +
be O +
the O +
ones O -
— O -
they O +
would O +
trap O +
some O +
of O +
the O +
SIC172 B-Gene +
MAb B-Gene +
in O +
culture O +
supernatant O -
. O +

Low O +
doses O +
of O +
Neu2en5Ac O +
may O +
release O +
such O +
trapped O +
MAb B-Gene +
and O +
increase O +
the O +
opportunity O +
to O +
bind O +
to O +
an O +
ELISA O +
antigen O +
plate O -
. O +

Therefore O +
the O +
purification O +
of O +
MAb B-Gene +
should O +
eliminate O +
such O +
contradictory O +
effects O +
of O +
hapten O -
; O +
this O +
was O +
found O +
to O +
be O +
true O -
, O +
as O +
described O +
below O -
. O +

2.4 O +
Purified O +
SIC172 B-Gene +
MAb B-Gene +
To O +
clarify O +
the O +
binding O +
activity O +
of O +
SIC172 B-Gene +
MAb B-Gene -
, O +
it O +
was O +
purified O +
by O +
using O +
a O +
protein B-Gene +
A O -
/ O -
G O +
plus O -
- O -
agarose O +
affinity O +
column O -
. O +

The O +
binding O +
activity O +
of O +
the O +
purified O +
SIC172 B-Gene +
MAb B-Gene +
with O +
regard O +
to O +
conjugate B-Gene +
9 I-Gene +
and O +
to O +
fetuin B-Gene +
is O +
shown O +
in O +
Fig. O +
3 O +
. O +

Purified O +
MAb B-Gene +
bound O +
to O +
conjugate B-Gene +
9 I-Gene +
strongly O +
just O +
as O +
MAb B-Gene +
in O +
culture O +
supernatant O +
( O -
Fig. O +
3 O +
( O -
a O -
) O -
) O -
. O +

Furthermore O -
, O +
as O +
is O +
clearly O +
seen O +
in O +
Fig. O +
3 O +
( O -
b O -
) O -
, O +
it O +
also O +
bound O +
well O +
to O +
fetuin B-Gene -
. O +

The O +
binding O +
to O +
fetuin B-Gene +
is O -
, O +
however O -
, O +
weaker O +
than O +
that O +
to O +
conjugate B-Gene +
9 I-Gene +
, O +
as O +
seen O +
at O +
higher O +
dilutions O -
. O +

The O +
effects O +
of O +
haptens O +
on O +
the O +
binding O +
of O +
purified O +
SIC172 B-Gene +
MAb B-Gene +
both O +
to O +
conjugate B-Gene +
9 I-Gene +
and O +
to O +
fetuin B-Gene +
were O +
then O +
examined O -
. O +

In O +
binding O +
to O +
conjugate B-Gene +
9 I-Gene +
( O -
Fig. O +
4 O +
( O -
a O -
, O -
b O -
) O +
) O -
, O +
at O +
a O +
high O +
dose O +
( O -
1 O +
mM O +
or O +
more O -
) O +
Neu2en5Ac O +
competes O +
strongly O +
with O +
purified O +
SIC172 B-Gene +
MAb B-Gene -
, O +
but O +
Neu5Ac O +
does O +
not O -
. O +

This O +
clearly O +
shows O +
that O +
the O +
binding O +
is O +
specific O +
to O +
Neu2en5Ac O -
. O +

In O +
binding O +
to O +
fetuin B-Gene +
( O -
Fig. O +
4 O +
( O -
c O -
, O -
d O -
) O -
) O -
, O +
on O +
the O +
other O +
hand O -
, O +
both O +
Neu2en5Ac O +
and O +
Neu5Ac O +
compete O +
with O +
the O +
MAb B-Gene -
. O +

But O +
the O +
effect O +
of O +
Neu2en5Ac O +
appears O +
at O +
doses O +
as O +
low O +
as O +
0.01 O +
mM O -
, O +
while O +
that O +
of O +
Neu5Ac O +
appears O +
at O +
above O +
0.3 O +
mM. O +
To O +
determine O +
more O +
precisely O +
the O +
effect O +
of O +
low O +
doses O +
of O +
haptens O +
on O +
binding O +
to O +
fetuin B-Gene -
, O +
IgG B-Gene +
and O +
haptens O +
were O +
preincubated O +
with O +
shaking O +
and O +
applied O +
to O +
an O +
ELISA O +
plate O +
( O -
Fig. O +
5 O +
) O -
. O +

The O +
BSA B-Gene +
used O +
here O +
for O +
the O +
dilution O +
of O +
IgG B-Gene +
and O +
the O +
blocking O +
of O +
a O +
fetuin B-Gene -
- O -
coated O +
plate O +
was O +
pretreated O +
with O +
dilute O +
HCl O +
in O +
order O +
to O +
remove O +
sialic O +
acids O +
from O +
any O +
sialo O -
- O -
compounds O +
contaminating O +
the O +
BSA B-Gene -
. O +

Neu2en5Ac O +
competes O +
strongly O +
and O +
as O +
little O +
as O +
3 O +
μM O +
of O +
it O +
had O +
a O +
significant O +
effect O -
, O +
while O +
300 O +
μM O +
or O +
more O +
of O +
Neu5Ac O +
was O +
required O +
to O +
get O +
a O +
similar O +
result O -
, O +
as O +
before O -
. O +

The O +
purification O +
of O +
SIC172 B-Gene +
MAb B-Gene +
thus O +
revealed O +
its O +
ability O +
to O +
bind O +
to O +
fetuin B-Gene -
. O +

Since O +
it O +
competes O +
with O +
Neu5Ac O -
, O +
SIC172 B-Gene +
MAb B-Gene +
recognizes O +
the O +
Neu5Ac O +
residues O +
present O +
in O +
fetuin B-Gene -
. O +

Neu2en5Ac O +
competes O +
about O +
100–300 O +
times O +
more O +
strongly O +
than O +
Neu5Ac O -
, O +
indicating O +
that O +
SIC172 B-Gene +
MAb B-Gene +
has O +
more O +
affinity O +
to O +
Neu2en5Ac O +
than O +
to O +
Neu5Ac O -
. O +

Since O +
concentrations O +
of O +
Neu2en5Ac O +
as O +
low O +
as O +
3 O +
μM O +
can O +
be O +
detected O +
by O +
this O +
MAb B-Gene +
as O +
a O +
competitor O +
in O +
binding O +
to O +
fetuin B-Gene -
, O +
this O +
MAb B-Gene +
may O +
be O +
useful O +
for O +
the O +
detection O +
of O +
a O +
small O +
amount O +
of O +
Neu2en5Ac O +
in O +
natural O +
biological O +
samples O -
, O +
though O +
adequate O +
separation O +
of O +
Neu2en5Ac O +
from O +
Neu5Ac O -
, O +
such O +
as O +
by O +
TLC O +
on O +
silica O +
gel O +
[ O -
7 O -
] O +
, O +
is O +
necessary O +
to O +
eliminate O +
possible O +
cross O +
reactions O +
with O +
Neu5Ac O -
, O +
which O +
is O +
usually O +
present O +
at O +
much O +
higher O +
levels O +
than O +
Neu2en5Ac O -
. O +

It O +
is O +
interesting O +
that O +
a O +
terminal O +
Neu5Ac O +
residue O -
, O +
bound O +
to O +
the O +
next O +
residue O +
at O +
the O +
C-2 O +
position O -
, O +
in O +
a O +
carbohydrate O +
moiety O +
of O +
fetuin B-Gene +
can O +
be O +
recognized O +
by O +
SIC172 B-Gene +
MAb B-Gene -
, O +
which O +
was O +
generated O +
by O +
immunization O +
with O +
Neu2en5Ac O +
that O +
was O +
bound O +
to O +
a O +
linker O +
at O +
the O +
C-9 O +
position O -
. O +

Determination O +
of O +
the O +
amino O +
acid O +
sequence O +
of O +
SIC172 B-Gene +
MAb B-Gene +
and O +
3-D O +
modeling O +
of O +
the O +
MAb B-Gene +
molecule O +
would O +
offer O +
some O +
clues O +
to O +
this O +
problem O -
. O +

3 O +
. O +

Experimental O +
3.1 O +
General O +
procedure O +
1 O +
H O +
NMR O +
spectra O +
were O +
recorded O +
with O +
a O +
Jeol O +
EX O +
270 O +
( O -
Japan O -
) O +
or O +
Bruker O +
DMX O +
500 O +
( O -
Germany O -
) O +
instrument O +
at O +
298 O +
K. O +
Chemical O +
shifts O +
are O +
expressed O +
in O +
ppm O +
and O +
referenced O +
to O +
HOD O +
( O -
4.81 O +
ppm O -
) O +
as O +
an O +
internal O +
standard O -
. O +

Optical O +
rotations O +
were O +
measured O +
with O +
a O +
Jasco O +
DIP-4 O +
( O -
Japan O -
) O +
polarimeter O -
. O +

High O -
- O -
resolution O +
mass O +
spectra O +
( O -
HR O -
- O -
MS O -
) O +
were O +
recorded O +
on O +
a O +
Shimadzu O -
/ O -
Kratos O +
concept O -
- O -
IIH O +
( O -
Japan O -
/ O -
UK O -
) O +
instrument O +
under O +
Fab O +
conditions O -
. O +

All O +
reactions O +
were O +
monitored O +
by O +
TLC O +
( O -
Silica O +
Gel O +
60-F254 O +
, O +
E. O +
Merck O -
, O +
Germany O -
) O +
by O +
charring O +
after O +
spraying O +
with O +
5 O -
% O +
H2 O +
SO4 O +
in O +
MeOH O -
. O +

3.2 O +
Chemicals O +
5-Acetamido-2,6-anhydro-3,5-dideoxy O -
- O -
d O +
-glycero O +
-d O +
-galacto O +
-non-2-enonic O +
acid O -
, O +
Neu2en5Ac O -
, O +
Neu5Ac O -
, O +
and O +
fetuin B-Gene +
were O +
purchased O +
from O +
Sigma O +
( O -
USA O -
) O -
. O +

3.3 O +
Methyl O +
5-acetamido-2,6-anhydro-3,5-dideoxy-9-p O -
- O -
toluenesulfonyl O -
- O -
d O +
-glycero O -
- O -
d O +
-galacto O -
- O -
non-2-enonate O +
( O -
5 O +
) O +
To O +
a O +
solution O +
of O +
methyl O +
5-acetamido-4,7,8,9-tetra O -
- O -
O O +
-acetyl-2,6-anhydro-3,5-dideoxy O -
- O -
d O +
-glycero O +
-d O +
-galacto O +
-non-2-enonate O +
( O -
4 O +
) O +
( O -
1.12 O +
g O -
, O +
2.36 O +
mmol O -
) O +
[ O -
11 O -
] O +
in O +
dry O +
MeOH O +
( O -
10 O +
mL O -
) O +
was O +
added O +
NaOMe O +
( O -
13 O +
mg O -
, O +
0.25 O +
mmol O -
) O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
for O +
1 O +
h O +
at O +
room O +
temperature O -
. O +

The O +
mixture O +
was O +
neutralized O +
by O +
the O +
addition O +
of O +
Dowex O +
50W O -
× O -
8 O +
resin O -
. O +

To O +
this O +
mixture O +
was O +
added O +
water O +
( O -
2 O +
mL O -
) O -
, O +
and O +
then O +
the O +
mixture O +
was O +
filtered O +
and O +
concentrated O -
. O +

The O +
residue O +
was O +
dried O +
in O +
a O +
desiccator O +
overnight O -
. O +

To O +
a O +
solution O +
of O +
this O +
residue O +
in O +
pyridine O +
( O -
20 O +
mL O -
) O +
was O +
added O +
p O +
-toluenesulfonyl O +
chloride O +
( O -
415 O +
mg O -
, O +
2.17 O +
mmol O -
) O +
at O +
room O +
temperature O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
for O +
4 O +
h. O +
Next O +
MeOH O +
( O -
5 O +
mL O -
) O +
was O +
added O +
to O +
the O +
mixture O -
, O +
which O +
was O +
then O +
concentrated O +
in O +
vacuo O -
. O +

Purification O +
of O +
the O +
residue O +
on O +
a O +
column O +
of O +
silica O +
gel O +
( O -
19:1 O +
EtOAc O -
– O -
MeOH O -
) O +
yielded O +
5 O +
( O -
460 O +
mg O -
, O +
42 O -
% O -
) O -
; O +
[ O -
α O +
] O -
D O +
25 O +
−12.0 O -
° O +
( O -
c O +
0.5 O -
, O +
MeOH O -
) O -
; O +
HR O -
- O -
MS O +
m O +
/z O +
Anal O -
. O +

Calcd O +
for O +
C19 O +
H25 O +
NO10 O +
SNa O -
: O +
482.1097 O +
[ O -
M+Na O -
] O -
+ O +
, O +
Found O -
: O +
482.1109 O -
. O +

1 O +
H O +
NMR O +
data O +
of O +
this O +
and O +
some O +
other O +
compounds O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

3.4 O +
5-Acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy O -
- O -
d O +
-glycero O -
- O -
d O +
-galacto O -
- O -
non-2-enonic O +
acid O +
( O -
6 O +
) O +
To O +
a O +
solution O +
of O +
5 O +
( O -
450 O +
mg O -
, O +
0.98 O +
mmol O -
) O +
in O +
DMF O +
( O -
2 O +
mL O -
) O +
was O +
added O +
sodium O +
azide O +
( O -
241 O +
mg O -
, O +
3.71 O +
mmol O -
) O +
and O +
the O +
mixture O +
was O +
stirred O +
at O +
70 O +
° O -
C O -
. O +

After O +
7 O +
h O -
, O +
it O +
was O +
allowed O +
to O +
cool O +
to O +
room O +
temperature O -
. O +

Purification O +
of O +
the O +
mixture O +
on O +
a O +
column O +
of O +
silica O +
gel O +
( O -
49:1 O +
EtOAc O -
– O -
MeOH O -
) O +
yielded O +
azide O +
derivative O +
6 O +
( O -
280 O +
mg O -
) O -
, O +
{ O -
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O -
: O +
δ O +
5.91 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
2.64 O +
Hz O -
, O +
H-3 O -
) O -
, O +
3.76 O +
( O -
s O -
, O +
3 O +
H O -
, O +
OMe O -
) O -
, O +
3.54 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2.64 O -
, O +
13.2 O +
Hz O -
, O +
H-9a O -
) O -
, O +
3.37 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
6.6 O -
, O +
13.2 O +
Hz O -
, O +
H-9b O -
) O -
, O +
2.03 O +
( O -
s O -
, O +
3 O +
H O -
, O +
Ac O -
) O -
} O -
. O +
The O +
azide O +
derivative O +
was O +
dissolved O +
in O +
1:1 O +
0.3 O +
M O +
NaOH O -
– O -
MeOH O +
( O -
8 O +
mL O -
) O +
and O +
the O +
mixture O +
was O +
stirred O +
for O +
2 O +
h O +
at O +
room O +
temperature O -
. O +

The O +
mixture O +
was O +
neutralized O +
by O +
the O +
addition O +
of O +
Dowex O +
50 O +
W O -
× O -
8 O +
resin O -
, O +
then O +
filtered O -
. O +

The O +
filtrate O +
was O +
concentrated O +
in O +
vacuo O -
. O +

Purification O +
of O +
the O +
residue O +
on O +
a O +
column O +
of O +
silica O +
gel O +
( O -
1:1 O +
EtOAc O -
– O -
MeOH O -
) O +
yielded O +
6 O +
( O -
241 O +
mg O -
, O +
78 O -
% O -
) O -
; O +
[ O -
α O +
] O -
D O +
25 O +
+ O -
33.1 O -
° O +
( O -
c O +
0.87 O -
, O +
MeOH O -
) O -
; O +
HR O -
- O -
MS O +
m O +
/z O +
Anal O -
. O +

Calcd O +
for O +
C11 O +
H16 O +
N4 O +
O7 O +
Na O +
( O -
Na O +
salt O -
) O -
: O +
339.0917 O +
[ O -
M+H O -
] O -
+ O +
, O +
Found O -
: O +
339.0944 O -
. O +

3.5 O +
5-Acetamido-9-amino-2,6-anhydro-3,5,9-trideoxy O -
- O -
d O +
-glycero O -
- O -
d O +
-galacto O -
- O -
non-2-enonic O +
acid O +
( O -
7 O +
) O +
To O +
a O +
solution O +
of O +
azide O +
derivative O +
6 O +
( O -
22 O +
mg O -
, O +
70 O +
μmol O -
) O +
in O +
4:3:1 O +
dioxane O -
– O -
MeOH O -
– O -
H2 O +
O O +
( O -
400 O +
μL O -
) O +
was O +
added O +
triphenylphosphine O +
( O -
27 O +
mg O -
, O +
104 O +
μmol O -
) O +
and O +
the O +
mixture O +
was O +
stirred O +
at O +
room O +
temperature O -
. O +

After O +
12 O +
h O -
, O +
the O +
mixture O +
was O +
concentrated O +
in O +
vacuo O -
. O +

Purification O +
of O +
this O +
residue O +
on O +
a O +
column O +
of O +
silica O +
gel O +
( O -
3:2:1 O +
EtOAc O -
– O -
MeOH O -
– O -
H2 O +
O O -
) O +
yielded O +
amino O +
derivative O +
7 O +
( O -
16 O +
mg O -
, O +
80 O -
% O -
) O -
; O +
[ O -
α O +
] O -
D O +
25 O +
+ O -
30.0 O -
° O +
( O -
c O +
0.6 O -
, O +
H2 O +
O O -
) O -
; O +
HR O -
- O -
MS O +
m O +
/z O +
Anal O -
. O +

Calcd O +
for O +
C11 O +
H19 O +
N2 O +
O7 O +
: O +
291.1192 O +
[ O -
M+H O -
] O -
+ O +
, O +
Found O -
: O +
291.1206 O -
. O +

3.6 O +
5-Acetamido-2,6-anhydro-9-glutaramido-3,5,9-trideoxy O -
- O -
d O +
-glycero O -
- O -
d O +
-galacto O -
- O -
non-2-enonic O +
acid O +
( O -
8 O +
) O +
To O +
a O +
solution O +
of O +
amino O +
derivative O +
7 O +
( O -
5 O +
mg O -
, O +
17 O +
μmol O -
) O +
in O +
300:100:3 O +
MeOH O -
– O -
H2 O +
O O -
– O -
Et3 O +
N O +
( O -
403 O +
μL O -
) O +
was O +
added O +
glutaric O +
acid O +
anhydride O +
( O -
3.5 O +
mg O -
, O +
30 O +
μmol O -
) O +
and O +
the O +
mixture O +
was O +
stirred O +
at O +
room O +
temperature O -
. O +

After O +
20 O +
min O +
the O +
mixture O +
was O +
concentrated O +
in O +
vacuo O -
. O +

Purification O +
of O +
this O +
residue O +
on O +
a O +
column O +
of O +
silica O +
gel O +
( O -
3:2:1 O +
EtOAc O -
– O -
MeOH O -
– O -
H2 O +
O O -
) O +
yielded O +
amino O +
derivative O +
8 O +
( O -
4 O +
mg O -
, O +
59 O -
% O -
) O -
; O +
[ O -
α O +
] O -
D O +
25 O +
+ O -
25.5 O -
° O +
( O -
c O +
0.4 O -
, O +
MeOH O -
) O -
; O +
HR O -
- O -
MS O +
m O +
/z O +
Anal O -
. O +

Calcd O +
for O +
C16 O +
H24 O +
N2 O +
O10 O +
Na O +
( O -
Na O +
salt O -
) O -
: O +
427.1329 O +
[ O -
M+H O -
] O -
+ O +
, O +
Found O -
: O +
427.1354 O -
. O +

3.7 O +
Conjugate B-Gene +
9 I-Gene +
The O +
reaction O +
was O +
carried O +
out O +
in O +
a O +
centricon O +
tube O -
. O +

Compound O +
8 O +
( O -
4 O +
mg O -
, O +
10 O +
μmol O -
) O +
was O +
dissolved O +
in O +
H2 O +
O O +
( O -
250 O +
μL O -
) O -
, O +
and O +
the O +
pH O +
of O +
this O +
solution O +
was O +
adjusted O +
to O +
6.0 O +
by O +
the O +
addition O +
of O +
aq O +
NaHCO3 O +
. O +

To O +
this O +
solution O +
was O +
added O +
BSA B-Gene +
( O -
15 O +
mg O -
, O +
ca O +
0.2 O +
μmol O -
) O +
and O +
EDC·HCl O +
( O -
3 O +
mg O -
, O +
16.5 O +
μmol O -
) O -
, O +
and O +
the O +
mixture O +
was O +
incubated O +
at O +
room O +
temperature O -
. O +

After O +
12 O +
h O -
, O +
the O +
mixture O +
was O +
directly O +
loaded O +
onto O +
a O +
gel O +
permeation O +
column O +
( O -
Sephadex O +
G-50 O -
, O +
H2 O +
O O -
) O -
. O +

The O +
fraction O +
containing O +
BSA B-Gene +
was O +
pooled O +
and O +
lyophilized O -
. O +

3.8 O +
Conjugate O +
10 O +
Prior O +
to O +
the O +
reaction O -
, O +
KLH B-Gene +
was O +
dissolved O +
in O +
H2 O +
O O +
( O -
100 O +
mg O -
/ O -
0.5 O +
mL O -
) O -
, O +
and O +
the O +
precipitate O +
was O +
removed O +
by O +
filtration O -
. O +

The O +
filtrate O +
containing O +
KLH B-Gene +
was O +
lyophilized O +
and O +
used O +
for O +
the O +
synthesis O +
of O +
conjugate B-Gene +
10 I-Gene +
. O +

The O +
conditions O +
for O +
the O +
reaction O +
were O +
the O +
same O +
as O +
those O +
for O +
conjugate B-Gene +
9 I-Gene +
. O +

3.9 O +
Hybridoma O +
Conjugate B-Gene +
10 I-Gene +
( O -
390 O +
μg O -
) O +
was O +
dissolved O +
in O +
1 O +
mL O +
of O +
PBS O +
and O +
mixed O +
into O +
one O +
vial O +
of O +
GERBU O +
adjuvant O +
containing O +
10 O +
μg O +
of O +
GMDP O -
, O +
40 O +
μg O +
of O +
N O -
, O -
N O +
′-dimethyl O -
- O -
N O -
, O -
N O +
-dioctadecylammonium O +
chloride O -
, O +
and O +
1.68 O +
mg O +
of O +
Zn O -
- O -
proline O +
complex O +
( O -
Gerbu O +
Biotechnik O -
, O +
Germany O -
) O -
. O +

Female O +
MRL O -
/ O -
MpJ O -
- O -
lpr O -
/ O -
lpr O +
mice O +
[ O -
10 O -
] O +
( O -
Nihon O +
Slc O -
, O +
Japan O -
) O -
, O +
8-weeks O -
- O -
old O -
, O +
were O +
each O +
immunized O +
subcutaneously O +
with O +
50 O +
μL O +
of O +
the O +
antigen O -
– O -
adjuvant O +
mixture O -
, O +
which O +
contained O +
19.5 O +
μg O +
of O +
conjugate B-Gene +
10 I-Gene +
. O +

The O +
mice O +
were O +
further O +
immunized O +
with O +
the O +
same O +
dose O +
at O +
2 O -
, O +
5 O -
, O +
and O +
8 O +
weeks O +
after O +
the O +
first O +
immunization O -
. O +

The O +
titer O +
of O +
antibodies B-Gene +
that O +
bound O +
to O +
conjugate B-Gene +
9 I-Gene +
, O +
as O +
detected O +
by O +
ELISA O -
, O +
increased O +
gradually O +
after O +
2 O +
weeks O +
in O +
all O +
the O +
mice O +
immunized O -
. O +

Three O +
or O +
4 O +
days O +
after O +
immunization O +
at O +
5 O +
or O +
8 O +
weeks O -
, O +
spleen O +
cells O +
from O +
two O +
or O +
three O +
mice O +
were O +
obtained O +
and O +
hybridized O +
with O +
myeloma O +
X63-Ag8.653 O +
cells O +
[ O -
12 O -
] O +
by O +
using O +
polyethylene O +
glycol O +
6000 O -
, O +
and O +
were O +
plated O +
on O +
0.5 O -
% O +
agar O +
plates O +
containing O +
RPMI O +
medium O +
( O -
in O +
a O +
later O +
experiment O -
, O +
DMEM O +
medium O +
with O +
a O +
high O +
glucose O +
level O +
was O +
used O +
instead O +
of O +
RPMI O +
medium O -
) O -
, O +
HAT O +
( O -
0.1 O +
mM O +
hypoxanthine O -
, O +
0.4 O +
μM O +
aminopterin O -
, O +
and O +
16 O +
μM O +
thymidine O -
, O +
Sigma O -
, O +
USA O -
) O +
and O +
20 O -
% O +
FBS O +
[ O -
13 O -
] O +
. O +

From O +
2 O +
weeks O +
to O +
1 O +
month O +
later O -
, O +
colonies O +
grown O +
on O +
the O +
agar O +
plates O +
were O +
isolated O +
in O +
liquid O +
culture O +
medium O +
containing O +
HT O +
( O -
0.1 O +
mM O +
hypoxanthine O +
and O +
16 O +
μM O +
thymidine O -
, O +
Sigma O -
, O +
USA O -
) O -
. O +

Culture O +
supernatants O +
were O +
assayed O +
by O +
ELISA O +
for O +
the O +
presence O +
of O +
MAb B-Gene +
that O +
can O +
bind O +
to O +
conjugate B-Gene +
9 I-Gene +
and/or O +
to O +
fetuin B-Gene -
. O +

ELISA O -
- O -
positive O +
clones O +
were O +
selected O +
and O +
transfered O +
to O +
normal O +
medium O +
for O +
further O +
study O -
. O +

3.10 O +
Typing O +
of O +
immunoglobulin B-Gene +
subclass O +
This O +
was O +
done O +
by O +
using O +
a O +
Mouse O +
MonoAB O +
ID O +
Kit O +
( O -
Zymed O -
, O +
USA O -
) O -
. O +

3.11 O +
Affinity O +
purification O +
of O +
IgG B-Gene +
IgG B-Gene +
in O +
the O +
culture O +
supernatant O +
was O +
precipitated O +
with O +
ammonium O +
sulfate O +
at O +
50 O -
% O -
, O +
dissolved O +
and O +
dialysed O +
against O +
the O +
application O -
/ O -
binding O +
buffer O -
, O +
and O +
applied O +
to O +
a O +
protein B-Gene +
A O -
/ O -
G O +
plus O -
- O -
agarose O +
affinity O +
column O +
( O -
Calbiochem O -
. O -
, O +
USA O -
) O -
. O +

IgG B-Gene +
was O +
eluted O +
with O +
acetate O +
buffer O +
( O -
pH O +
3.0 O -
) O +
and O +
glycine O -
– O -
HCl O +
buffer O +
( O -
pH O +
3.0 O -
) O -
, O +
and O +
adjusted O +
to O +
a O +
pH O +
of O +
7.0 O +
with O +
Tris O +
base O -
. O +

3.12 O +
ELISA O +
A O +
total O +
of O +
100 O +
μg O +
of O +
conjugate B-Gene +
9 I-Gene +
, O +
or O +
200 O +
μg O +
( O -
145 O +
μg O +
in O +
a O +
later O +
experiment O -
) O +
of O +
fetuin B-Gene +
containing O +
5.5 O -
% O +
Neu5Ac O -
, O +
was O +
dissolved O +
in O +
1 O +
mL O +
of O +
PBS O -
; O +
100 O +
μL O +
of O +
the O +
solution O +
was O +
used O +
to O +
coat O +
each O +
well O +
of O +
a O +
96-well O +
test O +
plate O +
at O +
room O +
temperature O +
for O +
2 O +
h. O +
Antigen O -
- O -
coated O +
plates O +
were O +
blocked O +
with O +
1 O -
% O +
BSA B-Gene +
in O +
PBS O -
, O +
washed O +
with O +
0.1 O -
% O +
Tween O +
20 O +
in O +
PBS O -
, O +
and O +
used O +
for O +
ELISA O -
. O +

The O +
culture O +
supernatant O +
of O +
hybridoma O +
or O +
purified O +
IgG B-Gene -
, O +
undiluted O +
or O +
diluted O +
with O +
0.1 O -
% O +
BSA B-Gene +
in O +
PBS O -
, O +
was O +
used O +
as O +
the O +
source O +
of O +
MAb B-Gene -
. O +

In O +
some O +
experiments O -
, O +
as O +
shown O +
in O +
Fig. O +
5 O +
, O +
the O +
BSA B-Gene +
used O +
to O +
dilute O +
samples O +
and O +
block O +
ELISA O +
plates O +
was O +
pretreated O +
with O +
0.1 O +
M O +
HCl O +
for O +
1 O +
h O +
at O +
80 O +
° O -
C O -
, O +
and O +
neutralized O +
and O +
dialysed O +
against O +
PBS O +
to O +
remove O +
any O +
sialic O +
acids O +
from O +
sialo O -
- O -
compounds O +
contaminating O +
the O +
BSA B-Gene -
. O +

To O +
test O +
the O +
effects O +
of O +
Neu2en5Ac O +
and O +
Neu5Ac O -
, O +
they O +
were O +
dissolved O +
in O +
PBS O -
; O +
and O +
the O +
solution O +
was O +
adjusted O +
to O +
a O +
pH O +
of O +
7.2–7.5 O +
with O +
0.1 O +
M O +
NaOH O +
by O +
using O +
pHBOY O -
- O -
P2 O +
( O -
Shindengen O -
, O +
Japan O -
) O -
, O +
and O +
diluted O +
with O +
PBS O -
. O +

Culture O +
supernatant O -
, O +
purified O +
IgG B-Gene -
, O +
or O +
their O +
diluted O +
solutions O +
were O +
preincubated O +
with O +
various O +
concentrations O +
of O +
either O +
Neu2en5Ac O +
or O +
Neu5Ac O +
at O +
37 O +
° O -
C O +
for O +
1 O +
h O +
( O -
or O +
at O +
room O +
temperature O +
with O +
shaking O +
in O +
the O +
experiments O +
for O +
Fig. O +
5 O +
) O -
, O +
and O +
then O +
the O +
mixture O +
was O +
applied O +
to O +
an O +
antigen O -
- O -
coated O +
well O -
. O +

POD O -
- O -
labeled O +
sheep O +
anti O -
- O -
mouse O -
- O -
immunoglobulins B-Gene +
antibody B-Gene +
was O +
used O +
as O +
a O +
secondary O +
antibody B-Gene -
. O +

Peroxidase B-Gene +
activity O +
was O +
detected O +
with O +
o O +
-phenylenediamine O +
and O +
H2 O +
O2 O +
. O +

The O +
absorbance O +
at O +
490 O +
nm O -
, O +
A O +
490 O +
, O +
was O +
read O +
on O +
a O +
microplate O +
reader O +
( O -
Thermo O +
max O -
, O +
Molecular O +
Devices O -
, O +
USA O -
) O -
. O +

Assays O +
were O +
carried O +
out O +
in O +
duplicate O -
. O +

Acknowledgements O +
The O +
authors O +
would O +
like O +
to O +
thank O +
Mr O +
Masayosi O +
Kusama O +
for O +
the O +
mass O +
spectroscopic O +
analyses O -
. O +

This O +
work O +
was O +
performed O +
as O +
part O +
of O +
the O +
R&D O +
Project O +
of O +
the O +
Industrial O +
Science O +
and O +
Technology O +
Frontier O +
Program O +
supported O +
by O +
NEDO O +
( O -
New O +
Energy O +
and O +
Industrial O +
Technology O +
Development O +
Organization O -
) O -
. O +

LoVoDx O +
cells O +
are O +
derived O +
from O +
initially O +
highly O +
doxorubicin O -
- O -
sensitive O +
LoVo O +
adenocarcinoma O +
cells O +
by O +
incubation O +
and O +
selection O +
on O +
increasing O +
doxorubicin O +
concentrations O +
( O -
Grandi O +
et O +
al. O -
, O +
1986 O -
; O +
Rivoltini O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

Resistance O +
is O +
based O +
on O +
the O +
expression O +
of O +
multidrug O +
resistance O +
( O -
MDR1 O -
) O +
phenotype O +
mediated O +
by O +
the O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
drug O +
extrusion O +
mechanism O +
( O -
Rivoltini O +
et O +
al. O -
, O +
1990 O -
; O +
Bertram O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

Okadaic O +
acid O +
and O +
cantharidic O +
acid O +
are O +
selective O +
inhibitors O +
of O +
ser B-Gene -
/ I-Gene -
thr I-Gene +
phosphatases I-Gene +
1 B-Gene +
and O +
2A B-Gene +
( O -
Cohen O -
, O +
1989 O -
; O +
Honkanen O -
, O +
1993 O -
; O +
Honkanen O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

Via O +
the O +
inhibition O +
of O +
these O +
enzymes B-Gene +
both O +
agents O +
have O +
been O +
shown O +
to O +
induce O +
apoptosis O +
in O +
many O +
human O +
and O +
non O -
- O -
human O +
cell O +
lines O +
( O -
Bøe O +
et O +
al. O -
, O +
1991 O -
; O +
Kiguchi O +
et O +
al. O -
, O +
1994 O -
; O +
Morana O +
et O +
al. O -
, O +
1996 O -
; O +
Laidley O +
et O +
al. O -
, O +
1997 O -
; O +
Tergau O +
et O +
al. O -
, O +
1997 O -
; O +
von O +
Zezschwitz O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

By O +
selection O +
techniques O +
cells O +
could O +
be O +
isolated O +
that O +
were O +
resistant O +
to O +
okadaic O +
acid O +
( O -
Takeda O +
et O +
al. O -
, O +
1994 O -
; O +
Ritz O +
et O +
al. O -
, O +
1997 O +
) O +
as O +
well O +
as O +
cantharidic O +
acid O +
( O -
Richter O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

In O +
some O +
resistant O +
lines O -
, O +
at O +
least O +
in O +
the O +
case O +
of O +
okadaic O +
acid O -
, O +
observations O +
suggested O +
that O +
MDR1 O +
expression O +
might O +
be O +
involved O +
( O -
Tohda O +
et O +
al. O -
, O +
1994 O -
, O +
1997 O -
; O +
Zheng O +
et O +
al. O -
, O +
1994 O -
; O +
Wang O +
et O +
al. O -
, O +
1995 O -
; O +
Ritz O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

In O +
the O +
present O +
study O +
we O +
first O +
tested O +
whether O +
LoVo O +
cells O +
respond O +
with O +
apoptosis O +
when O +
they O +
were O +
treated O +
with O +
the O +
phosphatase B-Gene +
inhibitors O +
okadaic O +
or O +
cantharidic O +
acid O -
. O +

Next O -
, O +
we O +
compared O +
the O +
response O +
of O +
these O +
cells O +
with O +
that O +
observed O +
in O +
doxorubicin O -
- O -
resistant O +
LoVoDx O +
cells O -
. O +

While O +
okadaic O +
and O +
cantharidic O +
acid O +
effectively O +
killed O +
LoVo O +
cells O -
, O +
LoVoDx O +
cells O +
were O +
resistant O +
to O +
doxorubicin O +
as O +
well O +
as O +
to O +
okadaic O +
acid O -
. O +

On O +
the O +
other O +
hand O -
, O +
LoVoDx O +
cells O +
seemed O +
to O +
be O +
even O +
more O +
sensitive O +
to O +
cantharidic O +
acid O -
. O +

Comparable O +
results O +
were O +
obtained O +
with O +
rat O +
pituitary O +
GH3 O +
cells O +
made O +
resistant O +
to O +
150 O +
nM O +
okadaic O +
acid O -
. O +

Incubation O +
of O +
LoVoDx O +
cells O +
in O +
medium O +
devoid O +
of O +
doxorubicin O +
for O +
several O +
months O +
resulted O +
in O +
the O +
loss O +
of O +
okadaic O +
acid O +
and O +
doxorubicin O +
resistance O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Doxorubicin O +
was O +
from O +
Sigma O +
( O -
Deisenhofen O -
, O +
Germany O -
) O -
. O +

Okadaic O +
acid O +
and O +
cantharidic O +
acid O +
were O +
purchased O +
from O +
Calbiochem O +
( O -
Bad O +
Soden O -
, O +
Germany O -
) O -
. O +

Cell O +
culture O +
reagents O +
and O +
fetal B-Gene +
bovine I-Gene +
serum I-Gene +
were O +
from O +
Life O +
Technologies O +
( O -
Eggenstein O -
, O +
Germany O -
) O -
. O +

Caspase B-Gene +
substrate O +
Ac O -
- O -
DEVD O -
- O -
pNA O +
and O +
the O +
inhibitor O +
Ac O -
- O -
DEVD O -
- O -
CHO O +
were O +
obtained O +
from O +
Bachem O +
( O -
Heidelberg O -
, O +
Germany O -
) O -
. O +

2.2 O +
Cell O +
culture O +
and O +
selection O +
of O +
resistant O +
cells O +
LoVo O +
and O +
GH3 O +
rat O +
pituitary O +
cells O +
were O +
maintained O +
in O +
monolayer O +
in O +
Dulbecco O -
's O +
modified O +
Eagle O -
's O +
medium O +
supplemented O +
with O +
8 O -
% O +
fetal B-Gene +
calf I-Gene +
serum I-Gene -
, O +
streptomycin O +
and O +
penicillin O +
at O +
37 O -
° O -
C O +
in O +
5 O -
% O +
CO2 O +
. O +

LoVoDx O +
cells O +
( O -
Rivoltini O +
et O +
al. O -
, O +
1990 O +
) O +
were O +
cultured O +
under O +
the O +
same O +
conditions O +
and O +
fed O +
once O +
a O +
week O +
with O +
1 O +
μg O -
/ O -
ml O +
doxorubicin O -
. O +

Okadaic O +
acid O -
- O -
resistant O +
GH3 O +
cells O +
were O +
selected O +
by O +
culturing O +
partially O +
resistant O +
cells O +
( O -
Ritz O +
et O +
al. O -
, O +
1997 O +
) O +
for O +
an O +
additional O +
12 O +
months O +
in O +
stepwise O +
raised O +
okadaic O +
acid O +
concentrations O +
with O +
subsequent O +
survival O +
at O +
150 O +
nM. O +
Okadaic O +
acid O +
( O -
150 O +
nM O -
) O +
was O +
added O +
once O +
a O +
week O +
to O +
the O +
incubation O +
medium O -
. O +

2.3 O +
Viability O +
assay O +
( O -
MTT O +
conversion O +
assay O -
) O +
Cell O +
suspensions O +
( O -
100 O +
μl O -
; O +
7.5–10 O -
× O -
103 O +
cells O -
/ O -
well O -
) O +
were O +
seeded O +
into O +
a O +
96-well O +
microtiter O +
plate O +
and O +
incubated O +
for O +
24 O +
h. O +
Then O +
cells O +
were O +
incubated O +
for O +
24–72 O +
h O +
with O +
various O +
drug O +
concentrations O +
in O +
serum B-Gene -
- O -
free O +
insulin B-Gene -
– O -
transferrin B-Gene -
– O -
selenite O +
medium O +
followed O +
by O +
the O +
addition O +
of O +
10 O +
μl O +
MTT O +
solution O +
( O -
5 O +
mg O -
/ O -
ml O -
) O +
and O +
incubation O +
for O +
60 O +
min O -
. O +

After O +
addition O +
of O +
100 O +
μl O +
20 O -
% O +
SDS O +
in O +
0.02 O +
N O +
HCl O +
cells O +
were O +
incubated O +
for O +
24 O +
h O +
and O +
MTT O +
conversion O +
was O +
measured O +
at O +
550 O +
and O +
650 O +
nm O +
using O +
a O +
Molecular O +
Devices O +
UV O +
max O +
microplate O +
reader O +
( O -
Ritz O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

2.4 O +
Measurement O +
of O +
caspase-3 B-Gene +
like O +
activity O +
In O +
order O +
to O +
evaluate O +
if O +
cytotoxicity O +
of O +
the O +
tested O +
drugs O +
is O +
apoptotic O +
and O +
therefore O +
associated O +
with O +
the O +
activation O +
of O +
caspases B-Gene -
, O +
cells O +
( O -
2–3 O -
× O -
106 O +
) O +
were O +
plated O +
on O +
10-cm O +
culture O +
dishes O -
. O +

After O +
24-h O +
incubation O +
with O +
complete O +
medium O -
, O +
cells O +
were O +
incubated O +
for O +
an O +
additional O +
24 O +
h O +
with O +
the O +
indicated O +
treatments O +
in O +
serum B-Gene -
- O -
free O +
medium O -
. O +

Cells O +
were O +
harvested O +
after O +
the O +
addition O +
of O +
20 O +
μl O +
PMSF O +
( O -
100 O +
mM O -
) O +
per O +
1 O +
ml O +
medium O -
, O +
and O +
centrifuged O +
at O +
360 O -
× O -
g O +
for O +
5 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
pellet O +
was O +
transferred O +
to O +
a O +
second O +
vial O -
, O +
washed O +
with O +
PBS O +
supplemented O +
with O +
PMSF O +
( O -
20 O +
μl O -
/ O -
ml O -
) O -
. O +

After O +
a O +
second O +
centrifugation O +
( O -
600 O -
× O -
g O +
, O +
5 O +
min O -
, O +
4 O -
° O -
C O -
) O +
600 O +
μl O +
reaction O +
buffer O +
( O -
10 O +
mM O +
HEPES O -
, O +
1 O -
% O +
NP-40 O -
, O +
Aprotinin B-Gene +
10 I-Gene +
μg O -
/ O -
ml O +
at O +
pH O +
7.4 O -
) O +
was O +
added O +
and O +
the O +
resuspended O +
pellet O +
frozen O +
in O +
liquid O +
nitrogen O -
. O +

The O +
frozen O +
pellet O +
was O +
stored O +
at O +
−20 O -
° O -
C O +
until O +
the O +
assay O +
was O +
performed O -
. O +

After O +
thawing O +
cell O +
disruption O +
was O +
completed O +
by O +
two O +
additional O +
freeze O -
– O -
thaw O +
cycles O -
. O +

Following O +
a O +
centrifugation O +
at O +
5000 O -
× O -
g O +
for O +
10 O +
min O +
at O +
4 O -
° O -
C O +
the O +
supernatant O +
was O +
used O +
for O +
protein B-Gene +
determination O +
with O +
the O +
BCA O +
assay O +
( O -
Pierce O -
, O +
Heidelberg O -
, O +
Germany O -
) O -
. O +

Protein B-Gene +
was O +
adjusted O +
to O +
50 O +
μg O -
/ O -
100 O +
μl O -
. O +

Reactions O +
were O +
performed O +
with O +
100 O +
μg O +
protein B-Gene +
in O +
a O +
final O +
volume O +
of O +
350 O +
μl O +
after O +
addition O +
of O +
DTT O +
( O -
final O +
concentration O +
5 O +
mM O -
) O +
at O +
37 O -
° O -
C O -
. O +

Reactions O +
were O +
started O +
by O +
the O +
addition O +
of O +
the O +
substrate O +
peptide O +
Ac O -
- O -
DEVD O -
- O -
pNA O +
( O -
final O +
concentration O +
25 O +
μM O -
) O -
. O +

Caspase-3 B-Gene +
like O +
activity O +
was O +
quantified O +
by O +
measuring O +
the O +
release O +
of O +
p O +
-nitroanilide O +
at O +
405 O +
nm O +
in O +
a O +
microplate O +
reader O -
. O +

Enzyme O +
activity O +
was O +
calculated O +
and O +
expressed O +
as O +
U O -
/ O -
mg O +
protein B-Gene -
. O +

To O +
account O +
for O +
non O -
- O -
specific O +
proteolytic O +
activity O +
the O +
values O +
presented O +
are O +
the O +
difference O +
of O +
the O +
absolute O +
conversion O +
minus O +
the O +
activity O +
not O +
suppressible O +
by O +
100 O +
nM O +
of O +
the O +
DEVDase B-Gene +
inhibitor O +
peptide O +
Ac O -
- O -
DEVD O -
- O -
CHO O -
. O +

3 O +
Results O +
When O +
LoVo O +
cells O +
were O +
incubated O +
with O +
okadaic O +
acid O +
( O -
100 O +
nM O -
) O +
and O +
cantharidic O +
acid O +
( O -
10 O +
μM O -
) O +
for O +
24 O +
h O -
, O +
both O +
treatments O +
resulted O +
in O +
morphological O +
features O +
like O +
rounding O +
of O +
cells O +
that O +
are O +
indicative O +
of O +
the O +
induction O +
of O +
apoptotic O +
cell O +
death O -
. O +

This O +
hypothesis O +
was O +
confirmed O +
by O +
measuring O +
and O +
comparing O +
caspase B-Gene +
activity O +
as O +
evidenced O +
by O +
the O +
cleavage O +
of O +
the O +
substrate O +
Ac O -
- O -
DEVD O -
- O -
pNA O +
with O +
the O +
two O +
phosphatase B-Gene +
inhibitors O +
as O +
well O +
as O +
doxorubicin O +
( O -
1 O +
μg O -
/ O -
ml O -
) O -
. O +

This O +
tetrapeptide O +
is O +
supposed O +
to O +
be O +
mainly O +
a O +
substrate O +
of O +
caspases-3 B-Gene +
and O +
-7 B-Gene -
. O +

All O +
treatment O +
regimens O +
resulted O +
in O +
a O +
significant O +
stimulation O +
of O +
DEVDase B-Gene +
activity O +
with O +
activity O +
ratios O +
of O +
threefold O +
( O -
doxorubicin O +
1 O +
μg O -
/ O -
ml O -
) O -
, O +
fivefold O +
( O -
okadaic O +
acid O +
100 O +
nM O -
) O +
and O +
sixfold O +
( O -
cantharidic O +
acid O +
10 O +
μM O -
) O +
( O -
Fig. O +
1 O +
A O -
) O -
. O +

Thus O -
, O +
like O +
many O +
other O +
tumour O +
cells O +
LoVo O +
cells O +
respond O +
with O +
apoptosis O +
when O +
ser B-Gene -
/ I-Gene -
thr I-Gene +
phosphatases I-Gene +
1 B-Gene +
and O +
2A B-Gene -
, O +
the O +
enzymes B-Gene +
predominantly O +
inhibited O +
by O +
okadaic O +
acid O +
and O +
cantharidic O +
acid O +
at O +
these O +
concentrations O -
, O +
are O +
inhibited O +
for O +
a O +
longer O +
period O +
of O +
time O +
( O -
> O -
12 O +
h O -
) O -
. O +

Next O +
we O +
tested O +
for O +
the O +
viability O +
loss O +
of O +
LoVo O +
cells O +
treated O +
for O +
24 O +
h O +
with O +
doxorubicin O +
( O -
0.33–10 O +
μg O -
/ O -
ml O -
) O -
, O +
okadaic O +
acid O +
( O -
25–300 O +
nM O -
) O +
and O +
cantharidic O +
acid O +
( O -
1–25 O +
μM O -
) O +
( O -
Fig. O +
2 O +
A O -
– O -
C O -
, O +
filled O +
symbols O -
) O -
. O +

At O +
the O +
most O +
effective O +
concentrations O +
these O +
agents O +
induced O +
a O +
loss O +
in O +
viability O +
of O +
about O +
40–60 O -
% O -
. O +

This O +
effect O +
was O +
achieved O +
with O +
10 O +
μg O -
/ O -
ml O +
doxorubicin O -
, O +
300 O +
nM O +
okadaic O +
acid O +
and O +
25 O +
μM O +
cantharidic O +
acid O -
. O +

When O +
cells O +
were O +
treated O +
for O +
up O +
to O +
72 O +
h O +
( O -
Fig. O +
2 O +
A O -
– O -
C O -
, O +
open O +
symbols O -
) O +
toxicity O +
observed O +
with O +
all O +
three O +
agents O +
was O +
significantly O +
more O +
pronounced O +
resulting O +
in O +
overall O +
death O +
rates O +
of O +
80–90 O -
% O +
compared O +
to O +
maximally O +
40–60 O -
% O +
cells O +
that O +
died O +
after O +
24 O +
h O +
( O -
Fig. O +
2 O +
B O -
) O -
. O +

With O +
doxorubicin O +
and O +
okadaic O +
acid O +
40 O -
% O +
viability O +
loss O +
was O +
observed O +
with O +
1 O +
μg O -
/ O -
ml O +
and O +
25 O +
nM O -
, O +
respectively O -
, O +
while O +
cantharidic O +
acid O +
was O +
about O +
2.5 O +
times O +
more O +
effective O +
with O +
40 O -
% O +
of O +
cells O +
dying O +
between O +
5 O +
and O +
10 O +
μM O +
after O +
72 O +
h O +
compared O +
to O +
40 O -
% O +
of O +
cells O +
dying O +
at O +
25 O +
μM O +
after O +
24 O +
h. O +
Sensitivity O +
of O +
different O +
strains O +
of O +
tumour O +
cells O +
to O +
the O +
cytotoxicity O +
induced O +
by O +
phosphatase B-Gene +
inhibitors O +
was O +
shown O +
to O +
differ O +
substantially O +
( O -
Sakurada O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

In O +
order O +
to O +
investigate O +
these O +
aspects O +
in O +
more O +
detail O -
, O +
we O +
studied O +
toxicity O +
of O +
these O +
agents O +
in O +
LoVoDx O +
cells O +
which O +
had O +
become O +
at O +
least O +
10-fold O +
less O +
responsive O +
to O +
doxorubicin O +
( O -
Rivoltini O +
et O +
al. O -
, O +
1990 O +
) O +
by O +
culture O +
in O +
increasing O +
concentrations O +
of O +
doxorubicin O -
. O +

Resistance O +
of O +
these O +
cells O +
is O +
mediated O +
via O +
the O +
enhanced O +
expression O +
of O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
( O -
Rivoltini O +
et O +
al. O -
, O +
1990 O -
; O +
Bertram O +
et O +
al. O -
, O +
1995 O +
) O +
resulting O +
in O +
MDR1 O +
phenotype O +
( O -
Gottesmann O +
and O +
Pastan O -
, O +
1993 O +
) O -
. O +

When O +
either O +
LoVo O +
or O +
LoVoDx O +
cells O +
were O +
cultured O +
for O +
72 O +
h O +
with O +
the O +
three O +
drugs O +
we O +
observed O +
substantially O +
different O +
behaviours O -
. O +

While O +
as O +
expected O +
LoVoDx O +
cells O +
were O +
more O +
than O +
10-fold O +
less O +
sensitive O +
to O +
doxorubicin O +
resulting O +
in O +
a O +
rightward O +
shift O +
of O +
the O +
toxicity O +
curve O +
( O -
Fig. O +
3 O +
A O -
) O -
, O +
cells O +
treated O +
with O +
okadaic O +
acid O +
also O +
showed O +
such O +
a O +
rightward O +
shift O -
, O +
albeit O +
toxicity O +
was O +
only O +
reduced O +
by O +
a O +
factor O +
of O +
about O +
6–8 O +
( O -
Fig. O +
3 O +
B O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
LoVoDx O +
cells O +
treated O +
with O +
cantharidic O +
acid O +
displayed O +
a O +
leftward O +
shift O +
of O +
the O +
toxicity O +
curve O +
since O +
these O +
resistant O +
cells O +
were O +
about O +
2- O +
to O +
2.5-fold O +
more O +
sensitive O +
to O +
this O +
agent O +
( O -
Fig. O +
3 O +
C O -
) O +
with O +
80 O -
% O +
of O +
LoVoDx O +
cells O +
killed O +
at O +
10 O +
μM O +
vs. O +
80 O -
% O +
LoVo O +
cells O +
killed O +
at O +
25 O +
μM. O +
This O +
different O +
behaviour O +
with O +
respect O +
to O +
the O +
response O +
to O +
cantharidic O +
acid O +
vs. O +
that O +
to O +
doxorubicin O +
and O +
okadaic O +
acid O +
was O +
confirmed O +
by O +
measurements O +
of O +
Ac O -
- O -
DEVD O -
- O -
pNA O +
conversion O +
in O +
LoVoDx O +
cells O +
treated O +
with O +
the O +
three O +
agents O -
. O +

While O +
in O +
these O +
cells O +
doxorubicin O +
and O +
okadaic O +
acid O +
showed O +
no O +
increase O +
of O +
caspase B-Gene +
3-like I-Gene +
activity O +
when O +
compared O +
to O +
untreated O +
LoVoDx O +
cells O +
( O -
Fig. O +
1 O +
B O -
) O -
, O +
only O +
in O +
extracts O +
of O +
cantharidic O +
acid O -
- O -
treated O +
cells O +
was O +
caspase B-Gene +
activity O +
higher O +
than O +
in O +
extracts O +
from O +
untreated O +
cells O +
( O -
Fig. O +
1 O +
B O -
) O -
. O +

Caspase B-Gene +
activity O +
in O +
untreated O +
LoVoDx O +
cells O +
was O +
about O +
5.5-fold O +
that O +
observed O +
in O +
untreated O +
LoVo O +
cells O -
. O +

From O +
these O +
observations O +
we O +
conclude O +
that O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene -
- O -
mediated O +
MDR O +
can O +
protect O +
LoVoDx O +
cells O +
not O +
only O +
from O +
doxorubicin O +
but O +
also O -
, O +
albeit O +
to O +
a O +
lesser O +
extent O +
from O +
okadaic O +
acid O +
toxicity O -
. O +

This O +
is O +
in O +
accordance O +
with O +
observations O +
by O +
various O +
groups O +
( O -
Tohda O +
et O +
al. O -
, O +
1994 O -
, O +
1997 O -
; O +
Zheng O +
et O +
al. O -
, O +
1994 O -
; O +
Wang O +
et O +
al. O -
, O +
1995 O -
; O +
Ritz O +
et O +
al. O -
, O +
1997 O +
) O +
obtained O +
with O +
okadaic O +
acid O -
- O -
resistant O +
cells O +
selected O +
on O +
increasing O +
concentrations O +
of O +
okadaic O +
acid O +
in O +
the O +
culture O +
medium O -
. O +

This O +
protection O +
has O +
been O +
shown O +
by O +
functional O +
and O +
biochemical O +
data O +
to O +
be O +
the O +
consequence O +
of O +
overexpression O +
of O +
the O +
MDR1 O +
mediating O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene -
. O +

On O +
the O +
other O +
hand O -
, O +
cells O +
which O +
showed O +
a O +
reduced O +
sensitivity O +
to O +
okadaic O +
acid O +
mainly O +
by O +
overexpression O +
of O +
the O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
displayed O +
no O +
cross O +
resistance O +
to O +
cantharidic O +
acid O +
( O -
Ritz O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Similar O +
results O +
are O +
shown O +
for O +
a O +
okadaic O +
acid O -
- O -
resistant O +
subline O +
of O +
rat O +
pituitary O +
GH3 O +
cells O +
that O +
proliferated O +
at O +
150 O +
nM O +
okadaic O +
acid O +
which O +
is O +
about O +
15-fold O +
the O +
initially O +
lethal O +
concentration O +
( O -
Fig. O +
4 O +
) O -
. O +

In O +
this O +
subline O +
significant O +
okadaic O +
acid O +
toxicity O +
after O +
72 O +
h O +
was O +
only O +
seen O +
with O +
a O +
concentration O +
of O +
300 O +
nM O -
, O +
while O +
nearly O +
50 O -
% O +
of O +
parental O +
cells O +
had O +
already O +
died O +
at O +
25 O +
nM O +
okadaic O +
acid O +
( O -
Fig. O +
4 O +
B O -
) O -
. O +

In O +
agreement O +
with O +
the O +
hypothesis O +
that O +
MDR1 O +
is O +
underlying O +
this O +
loss O +
in O +
sensitivity O -
, O +
these O +
cells O +
were O +
also O +
about O +
10-fold O +
more O +
resistant O +
to O +
doxorubicin O +
toxicity O +
with O +
75 O -
% O +
of O +
cells O +
killed O +
at O +
1 O +
μg O -
/ O -
ml O +
in O +
parental O +
vs. O +
75 O -
% O +
killed O +
at O +
10 O +
μg O -
/ O -
ml O +
in O +
the O +
okadaic O +
acid O -
- O -
resistant O +
cells O +
( O -
Fig. O +
4 O +
A O -
) O -
. O +

In O +
accordance O +
with O +
our O +
observations O +
with O +
the O +
LoVo O +
lines O +
cantharidic O +
acid O +
( O -
15 O +
μM O -
) O +
toxicity B-Gene +
was O +
increased O +
in O +
the O +
resistant O +
GH3 O +
lines O +
with O +
only O +
20 O -
% O +
of O +
cells O +
surviving O +
after O +
72 O +
h O +
compared O +
to O +
about O +
45 O -
% O +
in O +
the O +
parental O +
line O +
( O -
Fig. O +
4 O +
C O -
) O -
. O +

To O +
further O +
supplement O +
our O +
observations O +
on O +
the O +
responsiveness O +
of O +
LoVo O +
cells O +
and O +
lines O +
derived O +
from O +
these O +
cells O +
we O +
studied O +
the O +
loss O +
of O +
drug O +
resistance O +
by O +
omission O +
of O +
doxorubicin O +
from O +
the O +
culture O +
medium O -
. O +

Four O +
months O +
after O +
removal O +
of O +
doxorubicin O +
the O +
toxicity O +
of O +
okadaic O +
acid O +
and O +
doxorubicin O +
was O +
compared O +
between O +
these O +
cells O +
and O +
LoVoDx O +
as O +
well O +
as O +
parental O +
LoVo O +
cells O -
. O +

Interestingly O -
, O +
sensitivity O +
of O +
these O +
revertant O +
cells O +
for O +
doxorubicin O +
was O +
in O +
between O +
that O +
observed O +
with O +
LoVoDx O +
and O +
LoVo O +
cells O +
( O -
Fig. O +
5 O +
A O -
) O -
. O +

Resistance O +
to O +
okadaic O +
acid O +
was O +
completely O +
lost O +
in O +
these O +
revertants O -
, O +
only O +
at O +
the O +
lowest O +
concentrations O +
tested O +
( O -
25 O +
nM O -
) O +
was O +
survival O +
slightly O +
higher O +
than O +
in O +
parental O +
LoVo O +
cells O +
( O -
Fig. O +
5 O +
B O -
) O -
. O +

Loss O +
of O +
MDR O +
in O +
these O +
cells O +
was O +
also O +
confirmed O +
by O +
measuring O +
the O +
accumulation O +
of O +
the O +
fluorescent O +
dye O +
rhodamine O +
123 O +
which O +
as O +
a O +
substrate O +
of O +
the O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
achieves O +
lower O +
steady O +
state O +
levels O +
in O +
resistant O +
cells O -
. O +

Omission O +
of O +
doxorubicin O +
in O +
the O +
culture O +
medium O +
resulted O +
in O +
normalization O +
of O +
dye O +
accumulation O +
( O -
data O +
not O +
shown O -
) O -
. O +

4 O +
Discussion O +
The O +
data O +
presented O +
in O +
this O +
study O +
confirm O +
our O +
earlier O +
observations O +
as O +
well O +
as O +
those O +
of O +
other O +
groups O +
that O +
inhibition O +
of O +
ser B-Gene -
/ I-Gene -
thr I-Gene +
phosphatases I-Gene -
, O +
especially O +
PP1 B-Gene +
and O +
2A B-Gene -
, O +
by O +
selective O +
inhibitors O +
like O +
okadaic O +
acid O +
and O +
cantharidic O +
acid O -
, O +
can O +
be O +
considered O +
a O +
new O +
cytotoxic O +
principle O +
for O +
tumour O +
cells O +
( O -
Bøe O +
et O +
al. O -
, O +
1991 O -
; O +
Kiguchi O +
et O +
al. O -
, O +
1994 O -
; O +
Morana O +
et O +
al. O -
, O +
1996 O -
; O +
Laidley O +
et O +
al. O -
, O +
1997 O -
; O +
Tergau O +
et O +
al. O -
, O +
1997 O -
; O +
von O +
Zezschwitz O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Like O +
doxorubicin O -
, O +
the O +
two O +
tested O +
agents O -
, O +
okadaic O +
acid O +
and O +
cantharidic O +
acid O -
, O +
induced O +
apoptosis O +
in O +
LoVo O +
cells O -
. O +

The O +
extent O +
of O +
cell O +
death O +
was O +
comparable O +
between O +
the O +
three O +
agents O -
. O +

Different O +
cell O +
lines O +
can O +
develop O +
resistance O +
to O +
okadaic O +
acid O -
- O -
induced O +
apoptosis O +
by O +
the O +
development O +
of O +
a O +
MDR1 O +
phenotype O +
( O -
Tohda O +
et O +
al. O -
, O +
1994 O -
, O +
1997 O -
; O +
Zheng O +
et O +
al. O -
, O +
1994 O -
; O +
Wang O +
et O +
al. O -
, O +
1995 O -
; O +
Ritz O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Here O +
we O +
could O +
show O +
that O +
MDR1 O +
expressing O +
LoVo O +
cells O +
resistant O +
to O +
doxorubicin O +
( O -
LoVoDx O -
) O +
displayed O +
a O +
comparable O +
cross O +
resistance O +
to O +
okadaic O +
acid O +
which O +
was O +
further O +
confirmed O +
by O +
the O +
observation O +
that O +
an O +
okadaic O +
acid O -
- O -
resistant O +
GH3 O +
line O +
revealed O +
a O +
comparably O +
reduced O +
sensitivity O +
to O +
doxorubicin O -
. O +

In O +
accordance O +
with O +
this O +
conclusion O +
reduction O +
of O +
doxorubicin O +
resistance O +
in O +
a O +
revertant O +
LoVoDx O +
line O +
is O +
associated O +
with O +
the O +
loss O +
of O +
okadaic O +
acid O +
resistance O -
. O +

Thus O -
, O +
okadaic O +
acid O +
can O +
be O +
considered O +
a O +
drug O +
that O +
is O +
a O +
substrate O +
of O +
the O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene -
- O -
mediating O +
MDR1 O -
. O +

Studying O +
toxicity O +
of O +
this O +
agent O +
and O +
structurally O +
related O +
derivatives O +
should O +
consider O +
the O +
contribution O +
of O +
this O +
drug O +
extrusion O +
mechanism O +
for O +
the O +
correct O +
interpretation O +
of O +
the O +
results O -
. O +

On O +
the O +
other O +
hand O -
, O +
cytotoxicity O +
of O +
cantharidic O +
acid O -
, O +
an O +
inhibitor O +
of O +
PP1 B-Gene +
and O +
PP2A B-Gene +
comparable O +
to O +
okadaic O +
acid O -
, O +
is O +
not O +
reduced O +
but O +
is O +
even O +
slightly O +
enhanced O +
in O +
LoVoDx O +
cells O -
. O +

The O +
potential O +
increased O +
sensitivity O +
of O +
LoVoDx O +
cells O +
was O +
confirmed O +
with O +
the O +
okadaic B-Gene +
acid I-Gene -
- O -
resistant O +
GH3 O +
cells O +
but O +
should O +
be O +
confirmed O +
with O +
other O +
MDR O +
lines O +
before O +
general O +
conclusions O +
can O +
be O +
drawn O -
. O +

Thus O -
, O +
cantharidic O +
acid O +
does O +
not O +
seem O +
to O +
be O +
a O +
substrate O +
of O +
the O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
and O +
might O +
therefore O +
be O +
the O +
drug O +
of O +
choice O +
for O +
testing O +
the O +
new O +
cytotoxic O +
principle O +
of O +
ser B-Gene -
/ I-Gene -
thr I-Gene +
phosphatase I-Gene +
inhibition O +
in O +
MDR1 O +
expressing O +
tumour O +
cells O -
. O +

Acknowledgements O +

We O +
thank O +
Dr O +
J. O +
Bertram O +
for O +
providing O +
us O +
with O +
LoVo O +
and O +
LoVoDx O +
cells O -
. O +

This O +
work O +
was O +
supported O +
by O +
a O +
grant O +
from O +
the O +
Deutsche O +
Forschungsgemeinschaft O +
to O +
HJS O +
( O -
Ste O +
422 O -
/ O -
4 O -
- O -
2 O -
) O -
. O +

Inborn O +
errors O +
of O +
metabolism O +
can O +
in O +
many O +
cases O +
be O +
identified O +
by O +
the O +
presence O +
of O +
abnormal O +
metabolites O +
in O +
the O +
urine O -
. O +

These O +
compounds O +
are O +
either O +
not O +
present O +
or O +
are O +
present O +
in O +
only O +
very O +
small O +
concentrations O +
in O +
the O +
urine O +
of O +
normal O +
individuals O -
. O +

Many O +
organic O +
acidemias O +
show O +
similar O +
clinical O +
manifestations O +
and O +
a O +
definitive O +
diagnosis O +
can O +
only O +
be O +
made O +
by O +
identification O +
of O +
the O +
abnormal O +
metabolites O -
. O +

The O +
method O +
generally O +
applied O +
is O +
capillary O +
gas O +
chromatography O -
/ O -
mass O +
spectrometry O +
( O -
GC O -
/ O -
MS O -
) O -
. O +

One O +
of O +
the O +
drawbacks O +
of O +
this O +
technique O +
is O +
the O +
relatively O +
long O +
time O +
required O +
for O +
sample O +
preparation O +
and O +
analysis O -
. O +

In O +
sick O +
patients O +
it O +
is O +
sometimes O +
desirable O +
to O +
make O +
a O +
diagnosis O +
within O +
a O +
short O +
period O +
of O +
time O -
. O +

To O +
address O +
these O +
needs O -
, O +
we O +
developed O +
a O +
fast O +
solid O -
- O -
phase O +
extraction O +
method O +
for O +
sample O +
preparation O +
and O +
a O +
GC O -
/ O -
MS O -
/ O -
MS O +
screening O +
method O +
for O +
14 O +
diagnostic O +
marker O +
compounds O -
. O +

MS O -
/ O -
MS O +
or O +
tandem O +
mass O +
spectrometry O +
methods O +
are O +
characterized O +
by O +
high O +
specificity O +
and O +
sensitivity O +
due O +
to O +
the O +
effective O +
exclusion O +
of O +
interfering O +
matrix O +
compounds O -
. O +

While O +
to O +
date O -
, O +
in O +
the O +
majority O +
of O +
analytical O +
applications O +
a O +
tandem O -
- O -
in O -
- O -
space O +
MS O +
approach O +
with O +
triple O +
quadrupole O +
or O +
sector O +
MS O -
/ O -
MS O +
instruments O +
is O +
used O -
, O +
we O +
applied O +
a O +
tandem O -
- O -
in O -
- O -
time O +
technique O -
, O +
using O +
a O +
bench O -
- O -
top O +
ion O +
trap O -
. O +

In O +
tandem O -
- O -
in O -
- O -
time O +
instruments O -
, O +
the O +
sequential O +
events O +
of O +
tandem O +
MS O -
, O +
i.e. O +
electron O +
impact O +
ionization O +
of O +
the O +
sample O +
molecules O -
, O +
the O +
mass O +
selection O +
of O +
the O +
precursor O +
ions O -
, O +
the O +
collision O -
- O -
induced O +
dissociation O +
( O -
CID O -
) O +
of O +
the O +
precursor O +
ions O +
with O +
neutral O +
gas O +
molecules O -
, O +
and O +
the O +
mass O +
analysis O +
of O +
the O +
product O +
ions O -
, O +
occur O +
in O +
the O +
same O +
space O -
, O +
the O +
ion O +
trap O -
, O +
and O +
are O +
separated O +
by O +
time O +
[ O -
1 O -
] O +
. O +

With O +
the O +
introduction O +
of O +
the O +
wave O -
- O -
board O +
technology O +
into O +
bench O -
- O -
top O +
ion O +
trap O +
instruments O +
[ O -
2–4 O -
] O +
, O +
MS O -
/ O -
MS O +
experiments O +
can O +
be O +
performed O +
at O +
relatively O +
low O +
cost O -
. O +

Compared O +
to O +
screening O +
methods O +
using O +
quadrupole O +
GC O -
/ O -
MS O +
instruments O +
operated O +
in O +
the O +
selected O +
ion O +
monitoring O +
mode O -
, O +
as O +
described O +
by O +
Tuchman O +
et O +
al. O +
[ O -
5 O -
] O +
for O +
the O +
screening O +
of O +
organic O +
acids O -
, O +
the O +
tandem O +
MS O +
approach O +
described O +
here O +
provides O +
increased O +
specificity O -
. O +

With O +
the O +
help O +
of O +
the O +
Saturn O +
Automatic O +
Method O +
Development O +
( O -
AMD O -
) O +
editor O -
, O +
the O +
development O +
and O +
optimization O +
of O +
tandem O +
MS O +
methods O +
is O +
relatively O +
easy O -
. O +

In O +
this O +
paper O -
, O +
we O +
report O +
methods O +
for O +
the O +
sample O +
preparation O +
and O +
GC O -
/ O -
MS O -
/ O -
MS O +
organic O +
acid O +
screening O -
. O +

We O +
also O +
show O +
examples O +
of O +
how O +
diagnostic O +
marker O +
compounds O +
can O +
be O +
identified O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Instrumentation O +
A O +
Varian O +
3400 O -
/ O -
Saturn O +
2 O +
ion O +
trap O +
GC O -
/ O -
MS O +
system O +
( O -
Varian O -
, O +
Walnut O +
Creek O -
, O +
CA O -
) O -
, O +
equipped O +
with O +
an O +
MS O -
/ O -
MS O +
and O +
SIS O +
( O -
selective O +
ion O +
storage O -
) O +
wave O -
- O -
board O -
, O +
is O +
used O -
. O +

A O +
DB-1 O +
fused O -
- O -
silica O +
capillary O +
column O +
( O -
30 O +
m O -
× O -
0.25 O +
mm O -
× O -
0.25 O +
μm O -
) O +
( O -
Alltech O -
, O +
Deerfield O -
, O +
IL O -
) O +
is O +
used O -
. O +

The O +
column O +
is O +
equilibrated O +
at O +
60 O -
° O -
C O -
, O +
the O +
temperature O +
is O +
increased O +
to O +
300 O -
° O -
C O +
at O +
a O +
rate O +
of O +
24 O -
° O -
C O -
/ O -
min O -
. O +

The O +
total O +
run O +
time O +
is O +
10.0 O +
min O -
. O +

Helium O +
is O +
used O +
as O +
the O +
carrier O +
gas O +
with O +
controlled O +
pressure O +
set O +
at O +
12.5 O +
psi O -
. O +

Data O +
is O +
collected O +
from O +
3.40 O +
to O +
8.50 O +
min O -
. O +

The O +
injector O +
used O +
is O +
a O +
1078 O +
Universal O +
Capillary O +
Injector O +
( O -
Varian O -
) O +
with O +
0.34 O +
mm O +
I.D. O +
injector O +
port O +
liner O -
. O +

The O +
injection O +
is O +
splitless O +
with O +
no O +
temperature O +
program O -
. O +

The O +
injector O +
temperature O +
is O +
300 O -
° O -
C O -
. O +

The O +
split O +
valve O +
is O +
closed O +
at O +
0.01 O +
min O +
and O +
reopened O +
at O +
0.30 O +
min O +
( O -
split O +
mode O -
, O +
50:1 O -
) O -
. O +

A O +
total O +
of O +
2 O +
μl O +
of O +
the O +
sample O +
is O +
injected O -
. O +

The O +
transfer O +
line O +
is O +
held O +
at O +
260 O -
° O -
C O -
. O +

2.2 O +
Chemicals O +
The O +
organic O +
acids O +
were O +
obtained O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
) O +
or O +
Aldrich O +
( O -
Milwaukee O -
, O +
WI O -
) O -
. O +

The O +
acylglycines O +
were O +
synthesized O +
from O +
glycine O +
and O +
acylanhydrides O +
or O +
acylchlorides O +
as O +
described O +
in O +
[ O -
6,7 O -
] O +
. O +

N O +
, O -
O O +
-Bis O -
( O -
trimethylsilyl O -
) O -
trifluoroacetamide O +
( O -
BSTFA O -
) O +
with O +
1 O -
% O +
trimethylchlorosilane O +
( O -
TMCS O -
) O +
was O +
obtained O +
from O +
Alltech O -
. O +

2.3 O +
Solid O -
- O -
phase O +
extraction O +
columns O +
CHEMELUT O +
extraction O +
columns O +
were O +
obtained O +
from O +
Varian O +
( O -
Harbor O +
City O -
, O +
CA O -
) O -
. O +

A O +
specially O +
modified O +
form O +
of O +
diatomaceous O +
earth O -
, O +
that O +
provides O +
large O +
surface O +
area O +
between O +
the O +
aqueous O +
and O +
the O +
organic O +
phase O -
, O +
was O +
utilized O +
as O +
the O +
packing O +
material O -
. O +

The O +
extraction O +
columns O +
were O +
conditioned O +
on O +
a O +
vacuum O +
manifold O +
with O +
the O +
vacuum O +
pressure O +
set O +
at O +
15 O +
mm O +
Hg O +
by O +
sequentially O +
adding O +
2 O +
ml O +
of O +
3 O +
N O +
HCl O +
saturated O +
with O +
NaCl O -
, O +
10 O +
ml O +
of O +
deionized O +
water O -
, O +
5 O +
ml O +
of O +
methanol O -
, O +
and O +
5 O +
ml O +
of O +
ethylactate O -
. O +

The O +
columns O +
were O +
then O +
dried O +
for O +
approximately O +
30 O +
min O -
. O +

2.4 O +
Sample O +
preparation O +
Urine O +
equivalent O +
to O +
2.5 O +
μmol O +
creatinine O +
is O +
used O -
. O +

If O +
the O +
calculated O +
urine O +
volume O +
exceeds O +
2.0 O +
ml O -
, O +
only O +
one O -
- O -
half O +
of O +
the O +
volume O +
is O +
used O +
( O -
internal O +
standard O +
and O +
final O +
volume O +
are O +
also O +
cut O +
into O +
half O -
) O -
. O +

If O +
the O +
urine O +
volume O +
is O +
less O +
than O +
1.0 O +
ml O -
, O +
the O +
volume O +
is O +
brought O +
up O +
to O +
1.0 O +
ml O +
with O +
deionized O +
water O -
. O +

Fifty O +
μl O +
internal O +
standard O +
2-ketocaproic O +
acid O +
( O -
1 O +
mg O -
/ O -
ml O -
) O +
and O +
200 O +
μl O +
hydroxylamine O +
hydrochloride O +
( O -
7.5 O +
mg O -
/ O -
dl O -
) O +
are O +
added O +
and O +
the O +
sample O +
is O +
incubated O +
at O +
60 O -
° O -
C O +
for O +
20 O +
min O -
. O +

Five O +
hundred O +
μl O +
of O +
3 O +
N O +
HCl O +
are O +
added O -
. O +

The O +
sample O +
is O +
vortexed O +
for O +
1 O +
min O +
and O +
applied O +
to O +
the O +
column O -
. O +

Ten O +
ml O +
ethylacetate O +
is O +
added O -
. O +

Water O +
is O +
removed O +
from O +
the O +
eluate O +
with O +
sodium O +
sulfate O -
, O +
it O +
is O +
dried O +
under O +
a O +
flow O +
of O +
nitrogen O +
at O +
40 O -
° O -
C O -
, O +
derivatized O +
with O +
50 O +
μl O +
BSTFA+1%TMCS O +
for O +
10 O +
min O +
at O +
60 O -
° O -
C O +
and O +
the O +
final O +
volume O +
is O +
brought O +
up O +
to O +
1.0 O +
ml O +
with O +
hexane O -
. O +

2.5 O +
MS O -
/ O -
MS O +
method O +
development O +
The O +
following O +
steps O +
were O +
performed O +
for O +
each O +
analyte:1 O -
. O +

In O +
the O +
full O +
scan O +
electron O +
ionization O +
mode O -
, O +
the O +
retention O +
time O +
was O +
determined O +
and O +
the O +
identity O +
of O +
the O +
compound O +
was O +
confirmed O +
by O +
comparison O +
of O +
the O +
full O +
scan O +
electron O +
impact O +
with O +
the O +
library O +
spectra O +
( O -
The O +
MS O +
library O +
used O +
was O +
a O +
gift O +
by O +
Denis O +
C. O +
Lehotay O +
from O +
the O +
Hospital O +
for O +
Sick O +
Children O +
Toronto O -
) O -
. O +

2 O -
. O +

The O +
candidate O +
precursor O +
ion O -
, O +
which O +
in O +
most O +
cases O +
was O +
the O +
most O +
abundant O +
ion O -
, O +
was O +
isolated O +
in O +
the O +
ion O +
trap O +
without O +
applying O +
a O +
CID O +
voltage O -
. O +

3 O -
. O +

If O +
the O +
candidate O +
precursor O +
ion O +
could O +
be O +
isolated O +
successfully O -
, O +
the O +
AMD O +
editor O +
was O +
used O +
to O +
determine O +
the O +
required O +
CID O +
voltage O +
for O +
fragmentation O +
by O +
increasing O +
the O +
voltage O +
in O +
5 O +
or O +
0.05 O +
V O +
steps O +
for O +
the O +
non O -
- O -
resonant O +
or O +
resonant O +
mode O -
, O +
respectively O +
( O -
Figs. O +
1 O +
and O +
2 O +
) O -
. O +

The O +
voltage O +
that O +
gave O +
the O +
highest O +
intensity O +
for O +
the O +
product O +
ions O +
was O +
selected O -
. O +

This O +
was O +
done O +
in O +
the O +
non O -
- O -
resonant O +
mode O +
first O -
. O +

If O +
the O +
fragmentation O +
was O +
not O +
satisfying O -
, O +
the O +
resonant O +
mode O +
was O +
chosen O +
or O +
a O +
different O +
precursor O +
ion O +
was O +
selected O -
. O +

4 O -
. O +

If O +
the O +
fragmentation O +
pattern O +
was O +
satisfying O -
, O +
but O +
the O +
intensity O +
of O +
the O +
product O +
ion O +
spectrum O +
was O +
relatively O +
low O -
, O +
the O +
storage O +
level O +
of O +
the O +
radiofrequency O +
trapping O +
field O +
and O +
the O +
CID O +
voltage O +
were O +
increased O +
to O +
improve O +
ion O +
intensity O -
. O +

5 O -
. O +

A O +
product O +
ion O -
, O +
that O +
was O +
abundant O +
and O +
specific O -
, O +
was O +
selected O +
for O +
analyte O +
detection O -
. O +

3 O +
Results O +
Fourteen O +
urinary O +
organic O +
acids O +
that O +
are O +
indicative O +
of O +
various O +
inherited O +
metabolic O +
diseases O +
were O +
chosen O +
for O +
the O +
GC O -
/ O -
MS O -
/ O -
MS O +
screening O +
( O -
Table O +
1 O +
) O -
. O +

The O +
automatic O +
method O +
development O +
( O -
AMD O -
) O +
is O +
illustrated O +
in O +
Figs. O +
1 O +
and O +
2 O +
for O +
2-ketoisocaproic O +
acid O -
. O +

Fig. O +
1A O -
– O -
D O +
shows O +
the O +
product O +
ion O +
spectra O +
at O +
increasing O +
CID O +
voltages O -
. O +

The O +
ion O +
at O +
m O +
/z O +
200 O +
was O +
chosen O +
as O +
the O +
precursor O +
ion O -
. O +

With O +
increasing O +
CID O +
voltage O -
, O +
the O +
precursor O +
ion O +
signal O +
decreases O -
, O +
while O +
the O +
product O +
ions O +
become O +
more O +
abundant O -
. O +

This O +
is O +
further O +
illustrated O +
in O +
the O +
breakdown O +
curve O +
in O +
Fig. O +
2 O +
, O +
where O +
the O +
ion O +
intensities O +
of O +
the O +
precursor O +
ion O +
m O +
/z O +
200 O +
and O +
the O +
most O +
abundant O +
product O +
ion O +
m O +
/z O +
110 O +
are O +
plotted O +
against O +
the O +
CID O +
voltage O -
. O +

It O +
can O +
be O +
concluded O +
that O +
0.30 O +
V O +
results O +
in O +
the O +
highest O +
intensity O +
of O +
the O +
product O +
ion O +
m O +
/z O +
110 O +
and O +
is O +
therefore O +
the O +
optimum O +
voltage O +
to O +
monitor O +
the O +
product O +
ion O -
. O +

The O +
optimum O +
conditions O +
of O +
the O +
CID O +
process O +
for O +
the O +
other O +
analytes O +
were O +
determined O +
analogously O -
. O +

Table O +
2 O +
lists O +
for O +
each O +
of O +
the O +
fourteen O +
analytes O +
the O +
precursor O +
ion O -
, O +
the O +
product O +
ion O +
that O +
was O +
chosen O +
for O +
the O +
detection O -
, O +
and O +
the O +
determined O +
optimum O +
CID O +
conditions O -
, O +
i.e. O +
the O +
CID O +
mode O +
( O -
non O -
- O -
resonant O +
or O +
resonant O +
excitation O -
) O -
, O +
the O +
CID O +
voltage O +
and O +
the O +
excitation O +
storage O +
level O -
. O +

Table O +
3 O +
shows O +
the O +
determined O +
response O +
factors O +
and O +
the O +
range O +
of O +
linearity O -
. O +

The O +
response O +
factors O +
were O +
measured O +
as O +
the O +
ratio O +
of O +
the O +
intensity O +
of O +
the O +
product O +
ions O +
and O +
the O +
intensity O +
of O +
the O +
peak O +
of O +
the O +
respective O +
analyte O +
in O +
the O +
full O +
scan O +
chromatogram O -
, O +
based O +
on O +
internal O +
standards O -
. O +

The O +
response O +
factors O +
vary O +
widely O +
because O +
of O +
different O +
ionization O +
and O +
fragmentation O +
efficiencies O +
for O +
the O +
analytes O -
. O +

The O +
linearity O +
of O +
the O +
standard O +
curves O -
, O +
tested O +
for O +
over O +
the O +
range O +
from O +
0.1 O +
to O +
10 O +
ng O -
/ O -
μl O -
, O +
varied O +
between O +
the O +
analytes O -
. O +

For O +
the O +
sample O +
preparation O +
a O +
fast O +
solid O -
- O -
phase O +
extraction O +
that O +
was O +
previously O +
described O +
for O +
the O +
extraction O +
of O +
methylmalonic O +
acid O +
[ O -
8 O -
] O +
was O +
chosen O -
. O +

The O +
measured O +
extraction O +
efficiencies O +
for O +
the O +
14 O +
organic O +
acid O +
markers O +
are O +
between O +
57 O -
% O +
( O -
propionylglycine O -
) O +
and O +
106 O -
% O +
( O -
glutaric O +
acid O -
) O +
( O -
data O +
not O +
shown O -
) O -
. O +

When O +
the O +
extraction O +
efficiency O +
of O +
the O +
solid O +
phase O +
extraction O +
was O +
compared O +
using O +
a O +
liquid O -
– O -
liquid O +
extraction O +
two O +
times O +
with O +
5 O +
ml O +
ethylacetate O -
, O +
the O +
ratios O +
in O +
percent O +
of O +
the O +
area O +
counts O +
after O +
solid O +
phase O +
versus O +
liquid O -
– O -
liquid O +
extraction O +
were O +
between O +
89 O +
and O +
145 O -
% O +
for O +
the O +
14 O +
analytes O -
. O +

For O +
all O +
organic O +
acid O +
markers O +
except O +
sebacic O +
acid O +
the O +
solid O -
- O -
phase O +
extraction O +
showed O +
a O +
higher O +
efficiency O +
compared O +
with O +
the O +
liquid O -
– O -
liquid O +
extraction O -
. O +

In O +
order O +
to O +
test O +
the O +
sensitivity O +
and O +
to O +
establish O +
reference O +
values O -
, O +
we O +
determined O +
the O +
areas O +
of O +
the O +
characteristic O +
product O +
ion O +
peaks O +
for O +
each O +
of O +
the O +
14 O +
analytes O +
in O +
30 O +
normal O +
urine O +
samples O -
. O +

The O +
samples O +
were O +
run O +
over O +
a O +
period O +
of O +
3 O +
days O -
. O +

The O +
averages O -
, O +
expressed O +
as O +
the O +
ratio O +
of O +
the O +
area O +
of O +
the O +
analyte O +
over O +
the O +
area O +
of O +
the O +
internal O +
standard O -
, O +
2-ketocaproic O +
acid O -
, O +
and O +
the O +
standard O +
deviations O +
are O +
listed O +
in O +
Table O +
4 O +
. O +

All O +
analytes O +
were O +
detected O +
in O +
at O +
least O +
24 O +
of O +
the O +
30 O +
samples O -
. O +

Fig. O +
3 O +
illustrates O +
how O +
elevations O +
in O +
organic O +
acids O +
can O +
be O +
detected O -
. O +

The O +
product O +
ion O +
chromatograms O +
for O +
all O +
14 O +
analytes O +
in O +
a O +
normal O +
urine O +
sample O +
that O +
was O +
spiked O +
with O +
five O +
organic O +
acids O +
are O +
shown O +
( O -
see O +
legend O +
to O +
Fig. O +
3 O +
) O -
. O +

The O +
elevations O +
in O +
the O +
five O +
organic O +
acids O +
could O +
all O +
be O +
detected O -
. O +

Table O +
5 O +
shows O +
the O +
results O +
from O +
nine O +
patients O +
with O +
various O +
known O +
metabolic O +
diseases O +
that O +
were O +
tested O -
. O +

The O +
elevations O +
in O +
the O +
characteristic O +
analytes O +
were O +
easily O +
detectable O -
. O +

The O +
upper O +
limit O +
of O +
the O +
normal O +
range O +
is O +
considered O +
to O +
be O +
the O +
average O +
of O +
the O +
ratios O +
of O +
the O +
area O +
of O +
the O +
analyte O +
over O +
the O +
area O +
of O +
the O +
internal O +
standard O +
in O +
30 O +
normal O +
controls O +
plus O +
two O +
standard O +
deviations O -
. O +

All O +
analytes O +
that O +
are O +
characteristic O +
for O +
the O +
particular O +
disorder O +
were O +
at O +
least O +
five O +
times O +
higher O +
than O +
the O +
upper O +
limit O +
of O +
the O +
normal O +
range O -
. O +

For O +
the O +
diagnosis O +
of O +
fatty O +
acid O +
oxidation O +
disorders O +
it O +
is O +
necessary O +
to O +
compare O +
the O +
relative O +
quantities O +
of O +
adipic O -
, O +
suberic O +
and O +
sebacic O +
acid O -
. O +

Due O +
to O +
different O +
response O +
factors O +
( O -
see O +
Table O +
3 O +
) O +
this O +
can O +
only O +
be O +
done O +
by O +
dividing O +
the O +
areas O +
by O +
the O +
response O +
factor O -
. O +

The O +
results O +
for O +
adipic O -
, O +
suberic O +
and O +
sebacic O +
acid O +
in O +
the O +
last O +
patient O +
in O +
Table O +
5 O +
are O +
2.0 O -
, O +
4.2 O +
and O +
14.6 O -
, O +
respectively O -
, O +
and O +
are O +
consistent O +
with O +
dietary O +
medium O +
chain O +
triglycerides O -
. O +

4 O +
Discussion O +
The O +
GC O -
/ O -
MS O -
/ O -
MS O +
screening O +
method O +
was O +
developed O +
as O +
a O +
fast O +
and O +
simple O +
method O +
to O +
identify O +
organic O +
acidurias O +
with O +
high O +
sensitivity O +
and O +
specificity O +
in O +
situations O +
where O +
a O +
fast O +
diagnosis O +
is O +
desirable O -
. O +

Fourteen O +
analytes O -
, O +
that O +
are O +
indicative O +
of O +
treatable O +
inborn O +
errors O +
of O +
metabolism O +
( O -
with O +
the O +
exception O +
of O +
fumarase B-Gene +
deficiency O -
) O -
, O +
were O +
chosen O +
for O +
the O +
screening O -
. O +

The O +
list O +
of O +
analytes O +
could O +
possibly O +
be O +
expanded O +
to O +
screen O +
for O +
other O +
disorders O -
. O +

A O +
GC O -
/ O -
MS O +
run O +
in O +
the O +
full O +
scan O +
mode O +
is O +
performed O +
at O +
a O +
later O +
point O +
to O +
confirm O +
the O +
findings O +
of O +
the O +
screening O +
test O -
. O +

The O +
solid O -
- O -
phase O +
extraction O +
method O +
used O +
allows O +
sample O +
preparation O +
within O +
a O +
relatively O +
short O +
time O +
with O +
a O +
good O +
extraction O +
efficiency O +
for O +
all O +
marker O +
compounds O -
. O +

The O +
entire O +
sample O +
preparation O +
including O +
oximation O +
and O +
derivatization O +
can O +
be O +
accomplished O +
in O +
less O +
than O +
90 O +
min O -
. O +

The O +
solid O -
- O -
phase O +
extraction O +
method O +
is O +
superior O +
to O +
a O +
liquid O -
– O -
liquid O +
extraction O +
with O +
ethylacetate O +
with O +
respect O +
to O +
both O +
time O +
and O +
extraction O +
efficiency O -
. O +

The O +
total O +
run O +
time O +
for O +
one O +
sample O +
is O +
10 O +
min O -
. O +

Despite O +
the O +
short O +
run O +
time O -
, O +
the O +
method O +
achieves O +
high O +
specificity O -
. O +

A O +
high O +
specificity O +
is O +
inherent O +
to O +
tandem O +
MS O +
methods O -
, O +
due O +
to O +
the O +
isolation O +
of O +
a O +
characteristic O +
precursor O +
ion O +
in O +
the O +
first O +
step O -
, O +
that O +
gives O +
rise O +
to O +
characteristic O +
product O +
ions O +
in O +
the O +
second O +
step O -
. O +

Only O +
in O +
the O +
case O +
of O +
3-methylcrotonylglycine O +
and O +
tiglylglycine O -
, O +
which O +
are O +
structural O +
isomers O -
, O +
the O +
same O +
precursor O +
ion O +
had O +
to O +
be O +
chosen O +
because O +
of O +
very O +
similar O +
mass O +
spectra O +
of O +
the O +
two O +
compounds O -
. O +

The O +
product O +
ion O +
spectra O +
of O +
the O +
precursor O +
ion O +
m O +
/z O +
170 O +
are O +
also O +
very O +
similar O +
for O +
both O +
organic O +
acids O -
. O +

The O +
most O +
abundant O +
ion O +
in O +
the O +
product O +
ion O +
spectrum O -
, O +
which O +
was O +
for O +
both O +
analytes O +
m O +
/z O +
96 O -
, O +
was O +
chosen O +
for O +
the O +
detection O +
of O +
the O +
compounds O -
. O +

The O +
retention O +
time O +
in O +
comparison O +
to O +
the O +
standard O +
mixture O +
that O +
is O +
run O +
prior O +
to O +
the O +
patient O +
samples O +
has O +
to O +
be O +
used O +
for O +
the O +
identification O +
of O +
the O +
analyte O +
in O +
this O +
case O -
. O +

When O +
the O +
standard O +
mixture O +
is O +
run O -
, O +
the O +
two O +
peaks O +
are O +
always O +
clearly O +
distinguishable O -
. O +

A O +
high O +
sensitivity O +
is O +
also O +
achieved O +
by O +
MS O -
/ O -
MS O -
. O +

Although O +
some O +
analytes O +
have O +
low O +
response O +
factors O -
, O +
this O +
is O +
more O +
than O +
compensated O +
for O +
by O +
the O +
exclusion O +
of O +
the O +
interfering O +
matrix O +
resulting O +
in O +
a O +
high O +
signal O +
to O +
noise O +
ratio O -
. O +

High O +
sensitivity O +
is O +
apparent O +
for O +
all O +
analytes O +
from O +
Table O +
4 O +
. O +

All O +
14 O +
organic O +
acid O +
markers O +
could O +
be O +
detected O +
in O +
the O +
majority O +
of O +
the O +
normal O +
control O +
samples O -
. O +

The O +
range O +
of O +
linearity O +
varies O +
for O +
the O +
14 O +
compounds O -
. O +

While O +
the O +
majority O +
of O +
the O +
organic O +
acid O +
markers O +
showed O +
linearity O +
between O +
0.1 O +
and O +
5 O +
or O +
10 O +
ng O -
/ O -
μl O -
, O +
fumaric O +
acid O -
, O +
glutaric O +
acid O -
, O +
butyrylglycine O +
and O +
adipic O +
acid O +
gave O +
linear O +
standard O +
curves O +
only O +
up O +
to O +
1 O +
ng O -
/ O -
μl O -
. O +

The O +
limitations O +
in O +
some O +
of O +
the O +
linearity O +
ranges O +
is O +
not O +
surprising O +
since O +
the O +
standard O +
curves O +
were O +
obtained O +
over O +
a O +
concentration O +
range O +
of O +
four O +
orders O +
of O +
magnitude O -
. O +

They O +
are O +
in O +
part O +
due O +
to O +
the O +
different O +
response O +
factors O -
. O +

Therefore O -
, O +
at O +
the O +
same O +
analyte O +
concentration O +
different O +
amounts O +
of O +
product O +
ions O +
will O +
be O +
generated O +
and O +
detected O +
and O +
saturation O +
occurs O +
at O +
different O +
concentrations O -
. O +

For O +
the O +
screening O +
method O -
, O +
however O -
, O +
linear O +
standard O +
curves O +
are O +
not O +
necessarily O +
required O +
because O +
it O +
is O +
a O +
semiquantitative O +
method O -
. O +

Data O +
analysis O +
can O +
be O +
accomplished O +
quickly O -
, O +
by O +
simply O +
monitoring O +
the O +
characteristic O +
product O +
ion O +
chromatogram O +
for O +
each O +
of O +
the O +
14 O +
organic O +
acid O +
markers O -
, O +
and O +
determining O +
the O +
peak O +
areas O +
and O +
retention O +
times O +
of O +
the O +
product O +
ion O +
peaks O -
. O +

The O +
retention O +
times O +
are O +
compared O +
with O +
the O +
retention O +
times O +
of O +
a O +
standard O +
mixture O +
that O +
includes O +
all O +
14 O +
analytes O +
to O +
confirm O +
the O +
identity O +
of O +
the O +
detected O +
compound O -
. O +

The O +
determined O +
peak O +
areas O +
are O +
expressed O +
as O +
the O +
ratios O +
over O +
the O +
internal O +
standard O +
2-ketocaproic O +
acid O -
, O +
which O +
can O +
be O +
accomplished O +
with O +
the O +
fully O +
automated O +
software O +
version O +
for O +
Saturn O +
2000 O +
GC O -
/ O -
MS O +
instruments O -
, O +
and O +
are O +
then O +
compared O +
with O +
the O +
established O +
reference O +
values O -
. O +

Although O +
2-ketocaproic O +
acid O +
may O +
not O +
be O +
an O +
optimal O +
internal O +
standard O +
for O +
all O +
the O +
analytes O +
for O +
quantitative O +
purposes O -
, O +
it O +
is O +
a O +
satisfying O +
internal O +
standard O +
in O +
our O +
semiquantitative O +
method O -
. O +

There O +
is O +
very O +
good O +
reproducibility O +
from O +
one O +
injection O +
to O +
the O +
other O +
and O +
reasonable O +
reproducibility O +
from O +
one O +
extraction O +
to O +
the O +
other O -
. O +

We O +
determined O +
the O +
variation O +
coefficients O +
using O +
three O +
aliquots O +
of O +
a O +
standard O +
mixture O +
that O +
were O +
extracted O +
and O +
injected O +
on O +
the O +
same O +
day O +
or O +
on O +
different O +
days O -
. O +

The O +
same O +
day O +
variation O +
for O +
the O +
14 O +
organic O +
acid O +
markers O +
was O +
between O +
0.5 O +
and O +
8.5 O -
% O -
, O +
the O +
day O +
to O +
day O +
variation O +
between O +
14.9 O +
and O +
44.5 O -
% O -
. O +

If O +
the O +
internal O +
standard O +
is O +
used O +
to O +
correct O +
for O +
variation O +
of O +
injection O +
and O +
extraction O -
, O +
the O +
day O +
to O +
day O +
variation O +
amounted O +
to O +
between O +
4.1 O +
and O +
34.7 O -
% O +
( O -
data O +
not O +
shown O -
) O -
. O +

Fig. O +
3 O +
and O +
Table O +
5 O +
show O +
that O +
organic O +
acidurias O +
can O +
be O +
easily O +
detected O +
with O +
this O +
method O -
. O +

We O +
therefore O +
conclude O +
that O +
the O +
method O +
can O +
be O +
used O +
as O +
a O +
quick O +
metabolic O +
screen O +
for O +
very O +
sick O +
patients O +
in O +
whom O +
there O +
is O +
concern O +
regarding O +
the O +
possibility O +
of O +
a O +
treatable O +
metabolic O +
disorder O -
. O +

Acknowledgements O +
TH O +
was O +
a O +
visiting O +
scientist O +
supported O +
by O +
a O +
postdoctoral O +
fellowship O +
grant O +
by O +
the O +
Deutsche O +
Forschungsgemeinschaft O -
. O +

We O +
greatly O +
appreciate O +
the O +
advice O +
and O +
support O +
of O +
Frederic O +
C. O +
Glisson O +
from O +
Varian O -
. O +

A O +
clearer O +
understanding O +
of O +
the O +
role O +
of O +
vitamin O +
A O +
( O -
retinol O -
) O +
in O +
growth O +
and O +
development O +
was O +
achieved O +
when O +
it O +
was O +
discovered O +
that O +
retinoic O +
acid O -
, O +
the O +
carboxylic O +
acid O +
derivative O +
of O +
retinol O -
, O +
functions O +
as O +
a O +
ligand O +
controlling O +
a O +
nuclear O +
receptor B-Gene +
signaling O +
pathway O +
[ O -
1,2 O -
] O +
. O +

However O -
, O +
a O +
full O +
understanding O +
of O +
retinoid O +
signaling O +
will O +
only O +
come O +
when O +
the O +
mechanisms O +
regulating O +
conversion O +
of O +
retinol O +
to O +
the O +
active O +
ligand O +
retinoic O +
acid O +
are O +
elucidated O -
. O +

Enzyme B-Gene +
families O +
able O +
to O +
participate O +
in O +
retinol O +
metabolism O +
have O +
been O +
discovered O +
( O -
reviewed O +
in O +
[ O -
3 O -
] O +
) O -
. O +

In O +
particular O -
, O +
some O +
members O +
of O +
the O +
alcohol B-Gene +
dehydrogenase I-Gene +
( O -
ADH B-Gene -
) O +
and O +
short B-Gene -
- I-Gene -
chain I-Gene +
dehydrogenase I-Gene -
/ I-Gene -
reductase I-Gene +
( O -
SDR B-Gene -
) O +
enzyme B-Gene +
families O +
are O +
capable O +
of O +
catalyzing O +
the O +
oxidation O +
of O +
retinol O +
to O +
retinal O -
, O +
and O +
some O +
forms O +
of O +
aldehyde B-Gene +
dehydrogenase I-Gene +
( O -
ALDH B-Gene -
) O +
and O +
cytochrome B-Gene +
P I-Gene +
-450 I-Gene +
( O -
CYP B-Gene -
) O +
can O +
oxidize O +
retinal O +
to O +
retinoic O +
acid O -
. O +

Retinol O +
oxidation O +
is O +
catalyzed O +
by O +
several O +
distinct O +
classes O +
of O +
cytosolic O +
ADH B-Gene +
[ O -
4–9 O -
] O +
as O +
well O +
as O +
several O +
different O +
microsomal O +
SDRs B-Gene +
[ O -
10–12 O -
] O +
. O +

Further O +
studies O +
on O +
these O +
enzyme B-Gene +
families O +
should O +
reveal O +
the O +
mechanisms O +
of O +
retinol O +
oxidation O +
needed O +
to O +
properly O +
supply O +
retinoic O +
acid O +
for O +
retinoid O +
signaling O -
. O +

Vertebrate O +
ADH B-Gene +
( O -
EC B-Gene +
1.1.1.1 I-Gene -
) O +
consists O +
of O +
a O +
family O +
of O +
cytosolic O -
, O +
NAD B-Gene -
- I-Gene -
dependent I-Gene -
, I-Gene +
zinc I-Gene -
- I-Gene -
containing I-Gene +
enzymes I-Gene +
[ O -
13 O -
] O +
and O +
a O +
nomenclature O +
based O +
upon O +
class O +
distinctions O +
has O +
been O +
described O +
[ O -
14 O -
] O +
. O +

ADHs B-Gene +
are O +
capable O +
of O +
oxidizing O +
a O +
wide O +
variety O +
of O +
aliphatic O +
alcohols O +
to O +
their O +
corresponding O +
aldehydes O +
[ O -
4,15,16 O -
] O +
, O +
and O +
these O +
aldehyde O +
products O +
act O +
as O +
substrates O +
for O +
members O +
of O +
the O +
ALDH B-Gene +
family O +
which O +
oxidize O +
them O +
to O +
their O +
corresponding O +
carboxylic O +
acids O +
[ O -
17 O -
] O +
. O +

The O +
ability O +
of O +
liver O +
ADH B-Gene -
, O +
now O +
known O +
to O +
consist O +
primarily O +
of O +
class B-Gene +
I I-Gene +
ADH I-Gene +
( O -
ADH1 B-Gene -
) O -
, O +
to O +
utilize O +
retinol O +
as O +
a O +
substrate O +
has O +
been O +
appreciated O +
for O +
many O +
years O +
[ O -
18,19 O -
] O +
. O +

However O -
, O +
recent O +
studies O +
have O +
shown O +
that O +
human O +
class B-Gene +
IV I-Gene +
ADH I-Gene +
( O -
ADH4 B-Gene -
) O +
has O +
even O +
higher O +
retinol O -
- O -
oxidizing O +
activity O +
than O +
human O +
ADH1 B-Gene +
[ O -
5,7–9 O -
] O +
. O +

As O +
further O +
evidence O +
that O +
ADH1 B-Gene +
and O +
ADH4 B-Gene +
play O +
a O +
role O +
in O +
retinoid O +
signaling O -
, O +
the O +
mouse O +
homologs O +
for O +
these O +
enzymes B-Gene +
have O +
been O +
localized O +
in O +
numerous O +
retinoid O -
- O -
responsive O +
tissues O +
including O +
epidermis O +
[ O -
20 O -
] O +
, O +
testis O +
[ O -
21 O -
] O +
, O +
genitourinary O +
tract O +
[ O -
22 O -
] O +
, O +
digestive O +
tract O +
[ O -
23 O -
] O +
and O +
neurula O -
- O -
stage O +
embryos O +
[ O -
24,25 O -
] O +
. O +

ADH B-Gene +
may O +
also O +
participate O +
in O +
the O +
production O +
of O +
retinoic O +
acid O +
as O +
an O +
endocrine O +
hormone O +
as O +
demonstrated O +
by O +
the O +
discovery O +
of O +
high O +
levels O +
of O +
ADH1 B-Gene -
, O +
ADH4 B-Gene -
, O +
and O +
retinoic O +
acid O +
in O +
the O +
adrenal O +
cortex O +
[ O -
26,27 O -
] O +
. O +

In O +
addition O +
to O +
all O -
- O -
trans O +
-retinol O +
( O -
vitamin O +
A1 O +
) O +
which O +
is O +
the O +
most O +
abundant O +
form O +
of O +
vitamin O +
A O +
in O +
mammals O +
it O +
has O +
been O +
demonstrated O +
that O +
several O +
additional O +
alcohol O +
forms O +
exist O +
which O +
play O +
biological O +
roles O +
in O +
retinoid O +
signaling O +
( O -
Fig. O +
1 O +
) O -
. O +

In O +
human O +
epidermis O +
3,4-didehydroretinol O +
( O -
vitamin O +
A2 O +
) O +
is O +
present O +
at O +
25 O -
% O +
the O +
level O +
of O +
all O -
- O -
trans O +
-retinol O +
[ O -
28 O -
] O +
, O +
and O +
in O +
chick O +
embryos O +
[ O -
29 O -
] O +
and O +
Xenopus O +
embryos O +
[ O -
30 O -
] O +
the O +
level O +
of O +
3,4-didehydroretinol O +
is O +
comparable O +
to O +
that O +
of O +
all O -
- O -
trans O +
-retinol O -
. O +

Its O +
carboxylic O +
acid O +
derivative O +
3,4-didehydroretinoic O +
acid O +
is O +
produced O +
in O +
chick O +
embryos O +
[ O -
29,31 O -
] O +
and O +
Xenopus O +
embryos O +
[ O -
32 O -
] O +
, O +
and O +
has O +
been O +
shown O +
to O +
activate O +
retinoic B-Gene +
acid I-Gene +
receptors I-Gene +
[ O -
33 O -
] O +
and O +
have O +
biological O +
activity O +
[ O -
34,35 O -
] O +
. O +

Another O +
form O +
of O +
retinol O +
is O +
9-cis O +
-retinol O +
which O +
has O +
been O +
identified O +
in O +
rat O +
kidney O +
[ O -
36 O -
] O +
. O +

Its O +
carboxylic O +
acid O +
derivative O +
9-cis O +
-retinoic O +
acid O +
has O +
been O +
demonstrated O +
to O +
activate O +
retinoic B-Gene +
acid I-Gene +
receptors I-Gene +
as O +
well O +
as O +
retinoid B-Gene +
X I-Gene +
receptors I-Gene +
[ O -
37,38 O -
] O +
and O +
has O +
been O +
shown O +
to O +
have O +
biological O +
activity O +
[ O -
39 O -
] O +
. O +

In O +
addition O -
, O +
4-hydroxy O -
- O -
retinol O +
and O +
4-oxo O -
- O -
retinol O +
represent O +
two O +
additional O +
natural O +
forms O +
of O +
retinol O +
[ O -
40 O -
] O +
, O +
and O +
these O +
plus O +
4-oxo O -
- O -
retinal O +
and O +
4-oxo O -
- O -
retinoic O +
acid O +
have O +
been O +
demonstrated O +
to O +
activate O +
retinoic B-Gene +
acid I-Gene +
receptors I-Gene +
[ O -
40,41 O -
] O +
and O +
have O +
biological O +
activity O +
[ O -
42,43 O -
] O +
. O +

Little O +
is O +
known O +
about O +
the O +
enzymes B-Gene +
able O +
to O +
metabolize O +
these O +
additional O +
natural O +
retinols O +
except O +
in O +
the O +
case O +
of O +
9-cis O +
-retinol O +
which O +
is O +
a O +
substrate O +
for O +
ADH4 B-Gene +
[ O -
8 O -
] O +
and O +
some O +
forms O +
of O +
SDR B-Gene +
[ O -
12,44,45 O -
] O +
. O +

X O -
- O -
Ray O +
crystallographic O +
structures O +
of O +
horse O +
class B-Gene +
I I-Gene +
ADH I-Gene +
EE I-Gene +
( O -
ADH1E B-Gene -
) O +
[ O -
46 O -
] O +
, O +
human O +
class B-Gene +
I I-Gene +
ADH I-Gene +
ββ I-Gene +
( O -
ADH1B B-Gene -
) O +
[ O -
47,48 O -
] O +
, O +
codfish O +
class B-Gene +
I I-Gene +
ADH I-Gene +
( O -
ADH1 B-Gene -
) O +
[ O -
49 O -
] O +
, O +
human O +
class B-Gene +
III I-Gene +
ADH I-Gene +
( O -
ADH3 B-Gene -
) O +
[ O -
50 O -
] O +
, O +
and O +
human O +
class B-Gene +
IV I-Gene +
ADH I-Gene +
( O -
ADH4 B-Gene -
) O +
[ O -
51 O -
] O +
have O +
provided O +
several O +
well O -
- O -
defined O +
ADH B-Gene +
active O +
sites O -
. O +

The O +
structural O +
determinants O +
of O +
substrate O +
recognition O +
indicate O +
that O +
vertebrate O +
ADHs B-Gene +
are O +
best O +
suited O +
for O +
the O +
oxidation O +
of O +
long O -
- O -
chain O +
aliphatic O +
alcohols O -
. O +

Docking O +
studies O +
with O +
human O +
ADH1B B-Gene +
and O +
ADH4 B-Gene -
, O +
which O +
share O +
69 O -
% O +
amino O +
acid O +
sequence O +
identity O -
, O +
have O +
shown O +
that O +
the O +
active O +
sites O +
of O +
both O +
enzymes B-Gene +
can O +
accommodate O +
all O -
- O -
trans O +
-retinol O -
, O +
a O +
compound O +
containing O +
a O +
long O -
- O -
chain O +
aliphatic O +
alcohol O +
group O +
[ O -
51–54 O -
] O +
. O +

When O +
compared O +
with O +
the O +
crystal O +
structure O +
of O +
the O +
human O +
ADH1B B-Gene +
active O +
site O -
, O +
models O +
of O +
the O +
human O +
ADH4 B-Gene +
active O +
site O +
( O -
prior O +
to O +
determination O +
of O +
its O +
crystal O +
structure O -
) O +
were O +
found O +
to O +
be O +
more O +
well O +
suited O +
for O +
binding O +
of O +
all O -
- O -
trans O +
-retinol O +
due O +
to O +
alterations O +
in O +
a O +
loop O +
from O +
amino O +
acid O +
residues O +
114 O +
to O +
120 O +
including O +
deletion O +
of O +
Gly117 O +
which O +
increases O +
the O +
width O +
of O +
the O +
active O +
site O +
[ O -
52,54 O -
] O +
. O +

In O +
order O +
to O +
gain O +
further O +
insight O +
into O +
the O +
role O +
of O +
ADHs B-Gene +
in O +
retinol O +
metabolism O +
we O +
have O +
taken O +
advantage O +
of O +
the O +
recently O +
determined O +
crystal O +
structure O +
of O +
human O +
ADH4 B-Gene +
which O +
can O +
now O +
be O +
directly O +
compared O +
with O +
the O +
previously O +
known O +
crystal O +
structure O +
of O +
human O +
ADH1B B-Gene -
. O +

We O +
have O +
developed O +
a O +
computer O -
- O -
aided O +
molecular O +
docking O +
strategy O +
to O +
gauge O +
the O +
ability O +
of O +
all O +
five O +
natural O +
retinols O +
discussed O +
above O +
to O +
successfully O +
dock O +
to O +
the O +
human O +
ADH1B B-Gene +
and O +
ADH4 B-Gene +
active O +
sites O -
. O +

These O +
binding O +
models O +
suggest O +
that O +
ADH B-Gene +
active O +
sites O +
are O +
well O +
suited O +
to O +
play O +
a O +
role O +
in O +
the O +
metabolism O +
of O +
a O +
wide O +
variety O +
of O +
natural O +
retinols O -
, O +
and O +
support O +
a O +
broad O +
role O +
for O +
ADH B-Gene +
in O +
retinoid O +
signaling O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Structural O +
preparation O +
Modeling O +
took O +
place O +
in O +
a O +
Silicon O +
Graphics O +
Power O +
Indigo O +
R8000 O -
, O +
and O +
the O +
simulations O +
were O +
performed O +
in O +
a O +
Silicon O +
Graphics O +
Challenge O +
DM O +
4xR10000 O -
. O +

All O +
structures O +
were O +
visually O +
inspected O +
using O +
molecular O +
modeling O +
program O +
QUANTA O +
version O +
97.0711 O +
( O -
Molecular O +
Simulations O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
. O +

The O +
structural O +
preparation O +
of O +
ADH1B B-Gene -
, O +
ADH4 B-Gene -
, O +
and O +
cellular O +
retinol B-Gene -
- I-Gene -
binding I-Gene +
protein I-Gene +
II I-Gene +
( O -
CRBPII B-Gene -
) O +
needed O +
to O +
perform O +
docking O +
simulations O +
was O +
based O +
upon O +
molecular O +
docking O +
computational O +
methods O +
( O -
DOCK O +
3.5 O -
) O +
developed O +
by O +
Kuntz O +
and O +
co O -
- O -
workers O +
[ O -
55,56 O -
] O +
. O +

Starting O +
with O +
the O +
crystal O +
structures O +
of O +
human O +
ADH1B B-Gene +
( O -
i.e. O +
the O +
β1 O +
β1 O +
variant O -
) O +
[ O -
48 O -
] O +
, O +
human O +
ADH4 B-Gene +
[ O -
51 O -
] O +
, O +
and O +
rat O +
CRBPII B-Gene +
[ O -
57 O -
] O +
, O +
ligands O +
and O +
all O +
water O +
molecules O +
were O +
removed O +
from O +
the O +
binding O +
pockets O +
except O +
for O +
the O +
structural O +
waters O +
that O +
are O +
part O +
of O +
the O +
binding O +
site O +
in O +
CRBPII B-Gene -
, O +
and O +
except O +
for O +
the O +
bound O +
coenzyme O +
NAD O +
and O +
catalytic O +
zinc O +
which O +
are O +
part O +
of O +
the O +
active O +
sites O +
of O +
ADH1B B-Gene +
and O +
ADH4 B-Gene -
. O +

Amino O +
acid O +
residues O +
surrounding O +
the O +
active O +
site O +
( O -
ADHs B-Gene -
) O +
or O +
binding O +
site O +
( O -
CRBPII B-Gene -
) O +
were O +
extracted O +
using O +
DOCK3.5 O -
. O +

These O +
truncated O +
structures O +
were O +
used O +
for O +
all O +
further O +
computational O +
work O -
. O +

A O +
Connolly O +
molecular O +
surface O +
for O +
each O +
binding O +
pocket O +
was O +
calculated O +
to O +
identify O +
grooves O +
and O +
invaginations O +
[ O -
58 O -
] O +
. O +

The O +
molecular O +
surfaces O +
of O +
each O +
binding O +
pocket O +
were O +
filled O +
with O +
a O +
set O +
of O +
overlapping O +
spheres O +
of O +
different O +
radii O +
using O +
DOCK3.5 O -
. O +

These O +
sphere O +
centers O +
( O -
approx O -
. O +

60–80 O +
spheres O +
per O +
binding O +
site O -
) O +
represented O +
the O +
negative O +
image O +
of O +
the O +
target O +
site O +
where O +
docking O +
simulations O +
and O +
evaluation O +
of O +
quality O +
of O +
fit O +
took O +
place O -
. O +

All O +
dockings O +
were O +
performed O +
with O +
the O +
protein B-Gene +
binding O +
site O +
as O +
described O +
above O +
remaining O +
rigid O -
. O +

Structures O +
for O +
all O -
- O -
trans O +
-retinol O -
, O +
9-cis O +
-retinol O -
, O +
3,4-didehydroretinol O -
, O +
4-oxo O -
- O -
retinol O -
, O +
and O +
4-hydroxy O -
- O -
retinol O +
were O +
also O +
modeled O -
. O +

To O +
overcome O +
the O +
rigid O -
- O -
body O +
docking O +
constraint O -
, O +
we O +
generated O +
different O +
conformations O +
of O +
each O +
retinol O +
as O +
follows O -
. O +

The O +
initial O +
structures O +
were O +
modeled O +
after O +
the O +
crystallographic O +
coordinates O +
of O +
all O -
- O -
trans O +
-retinol O +
in O +
holo B-Gene -
- I-Gene -
CRBPII I-Gene +
[ O -
57 O -
] O +
using O +
the O +
Quanta O +
molecular O +
editor O +
module O -
. O +

Partial O +
charges O +
were O +
calculated O +
and O +
the O +
structures O +
were O +
then O +
optimized O +
using O +
the O +
molecular O +
modeling O +
system O +
InsightII O +
version O +
97.0 O +
builder O +
module O +
( O -
Molecular O +
Simulations O -
) O +
by O +
minimizing O +
the O +
initial O +
structure O +
applying O +
Steepest O +
Descents O +
and O +
Quasi O +
Newton O +
methods O +
( O -
1000 O +
steps O -
) O -
. O +

The O +
optimized O +
retinols O +
were O +
then O +
used O +
as O +
the O +
initial O +
structures O +
to O +
generate O +
different O +
conformations O +
throughout O +
a O +
series O +
of O +
Monte O +
Carlo O +
random O +
sampling O +
runs O +
using O +
QUANTA O -
. O +

A O +
set O +
of O +
conformations O +
for O +
each O +
retinol O +
structure O +
was O +
saved O +
in O +
protein B-Gene +
databank O +
format O +
( O -
PDB O -
) O +
and O +
then O +
converted O +
into O +
DOCK3.5 O +
format O -
. O +

2.2 O +
Docking O +
simulations O +
In O +
order O +
to O +
evaluate O +
the O +
goodness O +
of O +
fit O +
subsequent O +
to O +
docking O -
, O +
each O +
orientation O +
was O +
evaluated O +
based O +
on O +
its O +
shape O +
complementary O +
( O -
contact O +
score O -
) O +
and O +
molecular O +
mechanics O +
interaction O +
energy O +
( O -
force O +
field O +
score O -
) O -
. O +

Contact O +
scoring O +
uses O +
a O +
loose O +
approximation O +
to O +
the O +
Lennard O -
- O -
Jones O +
potential O -
, O +
and O +
force O +
field O +
scoring O +
uses O +
the O +
AMBER O +
potential O -
. O +

For O +
all O +
our O +
experiments O -
, O +
we O +
used O +
both O +
scoring O +
functions O +
and O +
applied O +
the O +
DOCK3.5 O +
rigid O -
- O -
body O +
minimization O +
algorithm O +
to O +
optimize O +
the O +
interaction O +
energies O -
. O +

Therefore O -
, O +
grids O +
containing O +
contact O +
limits O -
, O +
electrostatic O +
values O -
, O +
Van O +
der O +
Waals O +
attraction O +
and O +
repulsion O +
values O +
were O +
calculated O -
. O +

For O +
the O +
AMBER O +
force O -
- O -
field O +
potentials O +
of O +
coenzyme O +
NAD O -
, O +
the O +
explicit O +
parameters O +
of O +
each O +
atom O +
in O +
NAD O +
were O +
added O +
to O +
the O +
DOCK O +
AMBER O +
parameters O +
based O +
on O +
previous O +
studies O +
[ O -
59,60 O -
] O +
. O +

Additional O +
programs O +
in O +
the O +
DOCK O +
suite O +
allowed O +
us O +
to O +
calculate O +
root O -
- O -
mean O -
- O -
square O +
deviation O +
( O -
rmsd O -
) O +
and O +
least O -
- O -
squares O +
rmsd O +
values O -
, O +
close O +
contacts O -
, O +
number O +
of O +
bumps O -
, O +
and O +
to O +
recalculate O +
contact O +
scores O +
for O +
rigid O -
- O -
body O +
minimized O +
orientations O -
. O +

Initial O +
docking O +
was O +
performed O +
in O +
the O +
search O +
mode O +
for O +
each O +
retinol O +
using O +
the O +
set O +
of O +
different O +
conformations O +
generated O +
as O +
described O +
above O -
. O +

For O +
each O +
search O +
run O +
the O +
same O +
parameters O +
were O +
used O +
in O +
addition O +
to O +
the O +
usage O +
of O +
critical O +
clusters O -
, O +
rigid O -
- O -
body O +
minimization O -
, O +
contact O +
scoring O -
, O +
and O +
force O +
field O +
scoring O -
. O +

We O +
used O +
critical O +
clusters O +
to O +
define O +
critical O +
binding O +
regions O -
, O +
thus O +
constraining O +
DOCK O +
to O +
focus O +
on O +
the O +
site O +
near O +
the O +
catalytic O +
zinc O +
in O +
ADH B-Gene -
, O +
or O +
the O +
region O +
near O +
Glu108 O +
in O +
CRBPII B-Gene -
. O +

In O +
order O +
to O +
define O +
critical O +
clusters O -
, O +
the O +
closest O +
sphere O +
center O +
to O +
the O +
catalytic O +
zinc O +
( O -
ADH B-Gene -
) O +
or O +
Glu108 O +
( O -
CRBPII B-Gene -
) O +
was O +
assigned O +
as O +
the O +
critical O +
cluster O +
and O +
for O +
each O +
retinol O +
C-15 O +
was O +
designated O +
the O +
critical O +
atom O -
. O +

Utilizing O +
critical O +
clusters O +
DOCK O +
eliminated O +
all O +
conformations O +
that O +
failed O +
to O +
achieve O +
a O +
distance O +
of O +
at O +
least O +
1.5 O +
Å O +
between O +
the O +
critical O +
cluster O +
and O +
retinol O +
C-15 O -
. O +

In O +
ADH1B B-Gene +
the O +
critical O +
region O +
was O +
equivalent O +
to O +
the O +
area O +
where O +
a O +
water O +
molecule O +
is O +
coordinated O +
by O +
the O +
catalytic O +
zinc O +
in O +
the O +
crystal O +
structure O +
[ O -
47 O -
] O +
. O +

For O +
retinol O +
orientations O +
having O +
a O +
contact O +
score O +
> O -
0 O +
and O +
a O +
force O +
field O +
score O +
< O -
10 O +
kcal O -
/ O -
mol O -
, O +
the O +
orientation O +
was O +
rigid O -
- O -
body O +
minimized O +
and O +
evaluated O +
again O +
for O +
the O +
contact O +
score O +
and O +
force O +
field O +
score O -
. O +

Also O -
, O +
for O +
dockings O +
with O +
ADH1B B-Gene +
and O +
ADH4 B-Gene -
, O +
the O +
NAD O -
, O +
zinc O -
, O +
and O +
Thr48 O +
distances O +
were O +
calculated O -
, O +
i.e. O +
NAD O +
C-4 O +
to O +
retinol O +
C-15 O -
, O +
catalytic O +
zinc B-Gene +
to O +
retinol O +
hydroxyl O +
group O -
, O +
and O +
Thr48 O +
hydroxyl O +
group O +
to O +
retinol O +
hydroxyl O +
group O -
, O +
respectively O -
. O +

In O +
the O +
case O +
of O +
CRBPII B-Gene +
dockings O -
, O +
the O +
Glu108 O +
distance O +
was O +
calculated O -
, O +
i.e. O +
Glu108 O +
amide O +
group O +
to O +
retinol O +
hydroxyl O +
group O -
. O +

The O +
results O +
were O +
analyzed O +
using O +
program O +
X O -
- O -
Motif O +
Graphics O +
to O +
determinate O +
which O +
retinol O +
conformation O +
achieved O +
the O +
best O +
orientation O +
for O +
each O +
protein B-Gene +
examined O -
. O +

Potential O +
candidates O +
were O +
visually O +
inspected O +
to O +
identify O +
location O +
of O +
bumps O +
and O +
potential O +
hydrogen O +
bonds O +
if O +
any O -
. O +

The O +
selected O +
retinol O +
conformation O +
with O +
the O +
best O +
orientation O +
inside O +
the O +
active O +
site O +
was O +
energy O +
minimized O +
using O +
QUANTA O +
CHARMm O +
module O -
. O +

To O +
do O +
this O +
we O +
constrained O +
all O +
non O -
- O -
hydrogen O +
atoms O +
in O +
the O +
protein B-Gene -
, O +
and O +
allowed O +
the O +
selected O +
conformation O +
to O +
be O +
optimized O +
by O +
applying O +
Steepest O +
Descents O +
( O -
1000 O +
steps O -
) O -
. O +

As O +
a O +
final O +
step O +
the O +
optimized O +
conformation O +
determined O +
for O +
each O +
retinol O +
was O +
re O -
- O -
docked O +
to O +
gain O +
more O +
information O +
about O +
potential O +
orientations O +
within O +
each O +
protein B-Gene +
binding O +
site O -
. O +

The O +
final O +
docking O +
was O +
performed O +
using O +
single O +
mode O -
, O +
critical O +
clusters O -
, O +
rigid O -
- O -
body O +
minimization O -
, O +
contact O +
scoring O -
, O +
and O +
force O +
field O +
scoring O -
. O +

In O +
this O +
run O +
DOCK3.5 O +
was O +
constrained O +
to O +
select O +
only O +
those O +
orientations O +
achieving O +
a O +
force O +
field O +
score O +
≤0 O +
kcal O -
/ O -
mol O +
and O +
no O +
more O +
than O +
one O +
bump O +
per O +
orientation O -
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Test O +
of O +
retinol O +
docking O +
strategy O +
The O +
three O -
- O -
dimensional O +
structure O +
of O +
a O +
high O -
- O -
affinity O +
complex O +
between O +
all O -
- O -
trans O +
-retinol O +
and O +
cellular O +
retinol B-Gene -
- I-Gene -
binding I-Gene +
protein I-Gene +
type I-Gene +
II I-Gene +
( O -
holo B-Gene -
- I-Gene -
CRBPII I-Gene -
) O +
has O +
been O +
determined O +
to O +
a O +
resolution O +
of O +
1.9 O +
Å O +
[ O -
57 O -
] O +
. O +

As O +
a O +
test O +
of O +
our O +
molecular O +
docking O +
strategy O +
( O -
see O +
Section O +
2 O +
) O +
all O -
- O -
trans O +
-retinol O +
was O +
removed O +
from O +
the O +
complex O +
and O +
docking O +
experiments O +
between O +
it O +
and O +
CRBPII B-Gene +
were O +
performed O +
using O +
DOCK3.5 O -
. O +

The O +
unchanged O +
conformation O +
of O +
all O -
- O -
trans O +
-retinol O +
derived O +
from O +
the O +
crystal O +
structure O +
was O +
successfully O +
docked O +
to O +
CRBPII B-Gene +
as O +
determined O +
by O +
achieving O +
a O +
rmsd O +
of O +
0.19 O +
Å O +
compared O +
to O +
the O +
crystal O +
structure O +
which O +
was O +
resolved O +
to O +
1.9 O +
Å. O +
A O +
set O +
of O +
all O -
- O -
trans O +
-retinol O +
conformations O +
derived O +
by O +
Monte O +
Carlo O +
random O +
sampling O +
were O +
also O +
docked O +
to O +
CRBPII B-Gene -
, O +
resulting O +
in O +
an O +
orientation O +
with O +
a O +
rmsd O +
value O +
of O +
0.39 O +
Å O +
relative O +
to O +
the O +
crystal O +
structure O -
. O +

The O +
conformation O +
of O +
all O -
- O -
trans O +
-retinol O +
present O +
in O +
this O +
latter O +
docked O +
orientation O +
was O +
quite O +
similar O +
to O +
that O +
in O +
the O +
crystal O +
structure O +
as O +
shown O +
by O +
a O +
least O -
- O -
squares O +
rmsd O +
value O +
of O +
0.37 O +
Å. O +
Docking O +
to O +
CRBPII B-Gene +
was O +
also O +
performed O +
with O +
a O +
set O +
of O +
Monte O +
Carlo O +
random O +
sampling O +
conformations O +
generated O +
for O +
9-cis O +
-retinol O -
, O +
3,4-didehydroretinol O -
, O +
4-oxo O -
- O -
retinol O -
, O +
and O +
4-hydroxy O -
- O -
retinol O -
, O +
and O +
the O +
results O +
were O +
compared O +
to O +
those O +
for O +
all O -
- O -
trans O +
-retinol O +
( O -
Fig. O +
1 O +
) O -
. O +

The O +
most O +
favorable O +
conformation O +
and O +
docked O +
orientation O +
for O +
each O +
retinol O +
structure O +
were O +
selected O +
using O +
the O +
criteria O +
of O +
force O +
field O +
score O -
, O +
contact O +
score O -
, O +
and O +
distance O +
to O +
amino O +
acid O +
residue O +
Gln108 O +
( O -
Table O +
1 O +
) O -
. O +

A O +
critical O +
measure O +
of O +
the O +
docking O +
efficiency O +
was O +
the O +
attainment O +
of O +
a O +
distance O +
of O +
2.98 O +
Å O +
between O +
the O +
hydroxyl O +
group O +
of O +
all O -
- O -
trans O +
-retinol O +
and O +
the O +
side O +
chain O +
amide O +
group O +
of O +
Gln108 O +
in O +
CRBPII B-Gene -
, O +
a O +
distance O +
nearly O +
identical O +
to O +
that O +
in O +
the O +
crystal O +
structure O +
of O +
holo B-Gene -
- I-Gene -
CRBPII I-Gene +
( O -
3.02 O +
Å O -
) O -
. O +

This O +
close O +
proximity O +
allows O +
the O +
formation O +
of O +
a O +
hydrogen O +
bond O +
important O +
for O +
high O +
affinity O +
binding O +
in O +
holo B-Gene -
- I-Gene -
CRBPII I-Gene +
[ O -
57 O -
] O +
. O +

Also O -
, O +
the O +
docked O +
all O -
- O -
trans O +
-retinol O +
had O +
a O +
force O +
field O +
score O +
of O +
−29.9 O +
kcal O -
/ O -
mol O +
and O +
a O +
contact O +
score O +
of O +
110 O -
, O +
values O +
nearly O +
identical O +
to O +
those O +
observed O +
in O +
the O +
holo B-Gene -
- I-Gene -
CRBPII I-Gene +
crystal O +
structure O +
( O -
−27.0 O +
kcal O -
/ O -
mol O +
and O +
105 O -
, O +
respectively O -
) O +
( O -
Table O +
1 O +
) O -
. O +

The O +
most O +
favorable O +
docking O +
obtained O +
with O +
9-cis O +
-retinol O +
gave O +
a O +
hydroxyl O -
- O -
Gln108 O +
distance O +
of O +
3.52 O +
Å O +
( O -
too O +
large O +
for O +
a O +
hydrogen O +
bond O -
) O -
, O +
whereas O +
the O +
most O +
favorable O +
docking O +
achieved O +
for O +
3,4-didehydroretinol O +
gave O +
a O +
hydroxyl O -
- O -
Gln108 O +
distance O +
of O +
3.00 O +
Å O -
, O +
nearly O +
identical O +
to O +
that O +
for O +
all O -
- O -
trans O +
-retinol O +
( O -
Table O +
1 O +
) O -
. O +

Also O -
, O +
the O +
docked O +
9-cis O +
-retinol O +
had O +
a O +
significantly O +
higher O +
force O +
field O +
score O +
( O -
−21.0 O +
kcal O -
/ O -
mol O -
) O +
than O +
that O +
observed O +
for O +
3,4-didehydroretinol O +
( O -
−27.9 O +
kcal O -
/ O -
mol O -
) O +
or O +
all O -
- O -
trans O +
-retinol O +
( O -
−29.9 O +
kcal O -
/ O -
mol O -
) O -
, O +
further O +
indicating O +
that O +
the O +
9-cis O +
conformation O +
is O +
unfavorable O +
for O +
reaching O +
the O +
CRBPII B-Gene +
binding O +
site O -
. O +

These O +
results O +
provide O +
another O +
validation O +
of O +
our O +
docking O +
strategy O +
since O +
previous O +
in O +
vitro O +
binding O +
studies O +
have O +
clearly O +
shown O +
that O +
9-cis O +
-retinol O +
has O +
no O +
detectable O +
binding O +
to O +
CRBPII B-Gene +
whereas O +
3,4-didehydroretinol O +
does O +
bind O +
with O +
high O +
affinity O +
similar O +
to O +
all O -
- O -
trans O +
-retinol O +
[ O -
61 O -
] O +
. O +

Docking O +
of O +
4-oxo O -
- O -
retinol O +
and O +
4-hydroxy O -
- O -
retinol O +
to O +
CRBPII B-Gene +
resulted O +
in O +
hydroxyl O -
- O -
Gln108 O +
distances O +
of O +
2.91 O +
Å O +
and O +
2.90 O +
Å O -
, O +
respectively O -
, O +
and O +
force O +
field O +
scores O +
of O +
−28.7 O +
kcal O -
/ O -
mol O +
and O +
−30.2 O +
kcal O -
/ O -
mol O -
, O +
respectively O +
( O -
Table O +
1 O +
) O -
. O +

Thus O -
, O +
docking O +
of O +
these O +
two O +
oxygenated O +
retinols O +
is O +
quite O +
favorable O -
. O +

No O +
in O +
vitro O +
binding O +
data O +
for O +
CRBPII B-Gene +
with O +
either O +
4-oxo O -
- O -
retinol O +
or O +
4-hydroxy O -
- O -
retinol O +
was O +
found O +
in O +
the O +
literature O -
. O +

Our O +
docking O +
models O +
predict O +
that O +
4-oxo O -
- O -
retinol O +
and O +
4-hydroxy O -
- O -
retinol O -
, O +
like O +
all O -
- O -
trans O +
-retinol O +
and O +
3,4-didehydroretinol O -
, O +
will O +
demonstrate O +
high O +
affinity O +
binding O +
to O +
CRBPII B-Gene -
. O +

3.2 O +
Docking O +
of O +
retinols O +
to O +
human O +
ADH1B B-Gene +
and O +
ADH4 B-Gene +
The O +
docking O +
methods O +
discussed O +
above O -
, O +
which O +
proved O +
successful O +
for O +
CRBPII B-Gene -
, O +
were O +
used O +
to O +
dock O +
all O -
- O -
trans O +
-retinol O -
, O +
9-cis O +
-retinol O -
, O +
3,4-didehydroretinol O -
, O +
4-oxo O -
- O -
retinol O -
, O +
and O +
4-hydroxy O -
- O -
retinol O +
to O +
the O +
active O +
sites O +
of O +
human O +
ADH1B B-Gene +
and O +
ADH4 B-Gene -
. O +

The O +
three O -
- O -
dimensional O +
structures O +
for O +
each O +
active O +
site O +
were O +
based O +
upon O +
recent O +
X O -
- O -
ray O +
crystallographic O +
studies O +
of O +
ADH1B B-Gene +
determined O +
to O +
a O +
resolution O +
of O +
2.5 O +
Å O +
[ O -
48 O -
] O +
and O +
ADH4 B-Gene +
determined O +
to O +
a O +
resolution O +
of O +
3.0 O +
Å O +
[ O -
51 O -
] O +
. O +

Docking O +
was O +
performed O +
with O +
the O +
same O +
set O +
of O +
Monte O +
Carlo O +
random O +
sampling O +
conformations O +
generated O +
for O +
each O +
retinol O +
structure O +
above O -
. O +

In O +
order O +
to O +
obtain O +
an O +
unbiased O +
view O +
of O +
the O +
success O +
of O +
docking O -
, O +
all O +
docked O +
orientations O +
with O +
force O +
field O +
scores O +
0 O +
kcal O -
/ O -
mol O +
and O +
contact O +
scores O +
> O -
0 O +
were O +
examined O +
for O +
their O +
proximity O +
to O +
the O +
catalytic O +
zinc O +
atom O +
( O -
which O +
functions O +
in O +
orientation O +
of O +
the O +
alcohol O +
group O -
) O +
and O +
bound O +
NAD O +
coenzyme O +
( O -
which O +
functions O +
in O +
hydride O +
transfer O +
during O +
alcohol O +
oxidation O -
) O +
[ O -
48,51 O -
] O +
. O +

The O +
orientations O +
obtained O +
for O +
each O +
retinol O +
substrate O +
inside O +
the O +
active O +
sites O +
of O +
either O +
ADH1B B-Gene +
or O +
ADH4 B-Gene +
were O +
plotted O +
with O +
respect O +
to O +
the O +
distances O +
between O +
the O +
catalytic O +
zinc O +
and O +
the O +
substrate O +
hydroxyl O +
oxygen O +
( O -
zinc O +
distance O -
) O +
versus O +
the O +
distances O +
between O +
NAD O +
C-4 O +
and O +
substrate O +
C-15 O +
which O +
donates O +
the O +
hydrogen O +
to O +
NAD O +
during O +
hydride O +
transfer O +
( O -
NAD O +
distance O -
) O -
. O +

Linear O +
regression O +
analysis O +
of O +
these O +
results O +
show O +
that O +
all O +
retinols O +
examined O +
( O -
each O +
approx O -
. O +

15 O +
Å O +
in O +
length O -
) O +
can O +
enter O +
and O +
dock O +
along O +
at O +
least O +
some O +
portion O +
of O +
the O +
ADH1B B-Gene +
and O +
ADH4 B-Gene +
active O +
sites O -
, O +
both O +
of O +
which O +
stretch O +
approx O -
. O +

16 O +
Å O +
from O +
the O +
enzyme B-Gene +
surface O +
to O +
the O +
catalytic O +
zinc O +
( O -
Fig. O +
2 O +
) O -
. O +

These O +
results O +
demonstrate O +
that O +
9-cis O +
-retinol O +
and O +
3,4-didehydroretinol O +
are O +
unable O +
to O +
dock O +
close O +
to O +
the O +
catalytic O +
zinc O +
of O +
ADH1B B-Gene +
since O +
their O +
closest O +
zinc O +
distances O +
ranged O +
from O +
5.3 O +
to O +
5.9 O +
Å O +
and O +
their O +
closest O +
NAD O +
distances O +
ranged O +
from O +
4.5 O +
to O +
4.7 O +
Å O +
( O -
Fig. O +
2B O -
, O -
C O +
) O -
. O +

However O -
, O +
all O +
other O +
retinol O -
- O -
ADH B-Gene +
combinations O +
underwent O +
much O +
more O +
favorable O +
docking O +
since O +
the O +
closest O +
zinc O +
distances O +
ranged O +
from O +
1.9 O +
to O +
2.4 O +
Å O +
and O +
the O +
closest O +
NAD O +
distances O +
ranged O +
from O +
3.2 O +
to O +
3.6 O +
Å O +
( O -
Fig. O +
2A O -
, O -
D O -
, O -
E O +
) O -
. O +

These O +
latter O +
distances O +
would O +
place O +
the O +
retinol O +
structure O +
in O +
a O +
favorable O +
position O +
for O +
hydride O +
transfer O +
as O +
shown O +
by O +
previous O +
ADH O +
crystallographic O +
studies O +
[ O -
62 O -
] O +
. O +

Logarithmic O +
regression O +
plots O +
of O +
the O +
zinc O +
distances O +
versus O +
the O +
contact O +
scores O +
for O +
each O +
retinol O -
- O -
ADH B-Gene +
combination O +
show O +
that O +
docked O +
orientations O +
which O +
are O +
closer O +
to O +
the O +
zinc O +
show O +
higher O -
, O +
more O +
favorable O +
contact O +
scores O +
for O +
both O +
enzyme B-Gene +
active O +
sites O +
( O -
Fig. O +
3 O +
) O -
, O +
thus O +
illustrating O +
the O +
lock O -
- O -
and O -
- O -
key O +
concept O +
between O +
substrate O +
and O +
enzyme B-Gene -
. O +

Logarithmic O +
regression O +
plots O +
of O +
the O +
zinc O +
distances O +
versus O +
the O +
force O +
field O +
scores O +
show O +
that O +
ADH1B B-Gene +
and O +
ADH4 B-Gene +
differ O +
markedly O +
in O +
the O +
energy O +
of O +
docked O +
orientations O +
( O -
Fig. O +
4 O +
) O -
. O +

In O +
the O +
case O +
of O +
all O -
- O -
trans O +
-retinol O +
docked O +
in O +
the O +
ADH1B B-Gene +
active O +
site O -
, O +
it O +
can O +
be O +
seen O +
that O +
docked O +
orientations O +
which O +
are O +
closer O +
to O +
the O +
catalytic O +
zinc O +
have O +
higher O +
( O -
less O +
favorable O -
) O +
energies O +
than O +
those O +
further O +
away O -
, O +
whereas O +
the O +
reverse O +
is O +
true O +
for O +
docking O +
in O +
the O +
ADH4 B-Gene +
active O +
site O +
( O -
Fig. O +
4A O +
) O -
. O +

For O +
9-cis O +
-retinol O +
there O +
is O +
no O +
significant O +
change O +
in O +
energy O +
as O +
it O +
approaches O +
the O +
catalytic O +
zinc O +
of O +
ADH1B B-Gene -
, O +
but O +
there O +
is O +
a O +
significant O +
decrease O +
in O +
energy O +
as O +
9-cis O +
-retinol O +
approaches O +
the O +
catalytic O +
zinc O +
of O +
ADH4 B-Gene +
as O +
well O +
as O +
a O +
closer O +
approach O +
( O -
Fig. O +
4B O +
) O -
. O +

For O +
3,4-didehydroretinol O +
it O +
is O +
observed O +
that O +
force O +
field O +
scores O +
rise O +
sharply O +
for O +
docked O +
orientations O +
as O +
they O +
approach O +
the O +
catalytic O +
zinc O +
of O +
ADH1B B-Gene -
, O +
but O +
a O +
significant O +
decrease O +
in O +
force O +
field O +
scores O +
is O +
observed O +
for O +
ADH4 B-Gene +
docking O +
( O -
Fig. O +
4C O +
) O -
. O +

In O +
contrast O -
, O +
4-oxo O -
- O -
retinol O +
and O +
4-hydroxy O -
- O -
retinol O +
docked O +
orientations O +
show O +
a O +
drop O +
in O +
their O +
force O +
field O +
scores O +
for O +
both O +
enzymes B-Gene +
as O +
these O +
substrates O +
approach O +
the O +
catalytic O +
zinc O +
( O -
Fig. O +
4D O -
, O -
E O +
) O -
. O +

3.3 O +
Most O +
favorable O +
orientations O +
of O +
docked O +
retinols O +
relative O +
to O +
the O +
catalytic O +
zinc O -
, O +
NAD O -
, O +
and O +
Thr48 O +
Docking O +
results O +
for O +
the O +
most O +
favorable O +
orientation O +
of O +
each O +
retinol O +
in O +
either O +
the O +
ADH1B B-Gene +
or O +
the O +
ADH4 B-Gene +
active O +
sites O +
are O +
shown O +
( O -
Table O +
2 O +
) O -
. O +

The O +
zinc O +
and O +
NAD O +
distances O +
are O +
indicated O +
as O +
well O +
as O +
the O +
distances O +
between O +
the O +
substrate O +
hydroxyl O +
group O +
and O +
Thr48 O +
which O +
form O +
a O +
hydrogen O +
bond O +
[ O -
62 O -
] O +
. O +

With O +
the O +
exception O +
of O +
9-cis O +
-retinol O +
and O +
3,4-didehydroretinol O +
in O +
the O +
ADH1B B-Gene +
active O +
site O -
, O +
all O +
these O +
docked O +
structures O +
exhibit O +
distances O +
from O +
the O +
catalytic O +
zinc O +
( O -
1.9–2.4 O +
Å O -
) O -
, O +
NAD O +
( O -
3.2–3.6 O +
Å O -
) O -
, O +
and O +
Thr48 O +
( O -
2.6–3.1 O +
Å O -
) O +
which O +
favorably O +
orient O +
the O +
substrate O +
hydroxyl O +
group O +
and O +
adjacent O +
C-15 O +
for O +
hydride O +
transfer O +
from O +
C-15 O +
of O +
the O +
substrate O +
to O +
C-4 O +
of O +
NAD O -
. O +

Docking O +
of O +
9-cis O +
-retinol O +
and O +
3,4-didehydroretinol O +
in O +
the O +
ADH1B B-Gene +
active O +
site O +
results O +
in O +
orientations O +
unfavorable O +
for O +
alcohol O +
oxidation O +
since O +
the O +
closest O +
distances O +
from O +
the O +
catalytic O +
zinc O +
( O -
5.3–5.9 O +
Å O -
) O -
, O +
NAD O +
( O -
4.5–4.7 O +
Å O -
) O -
, O +
and O +
Thr48 O +
( O -
4.6–4.9 O +
Å O -
) O +
were O +
too O +
far O +
to O +
promote O +
hydride O +
transfer O -
. O +

The O +
force O +
field O +
scores O +
and O +
contact O +
scores O +
for O +
these O +
most O +
favorable O +
orientations O +
provide O +
a O +
good O +
indication O +
of O +
the O +
relative O +
docking O +
abilities O +
of O +
ADH1B B-Gene +
and O +
ADH4 B-Gene -
. O +

The O +
force O +
field O +
scores O +
for O +
all O +
five O +
retinols O +
examined O +
were O +
much O +
more O +
favorable O +
when O +
docked O +
to O +
ADH4 B-Gene +
( O -
−22.3 O +
to O +
−27.5 O +
kcal O -
/ O -
mol O -
) O +
as O +
opposed O +
to O +
ADH1B B-Gene +
( O -
−1.2 O +
to O +
−14.0 O +
kcal O -
/ O -
mol O -
) O +
( O -
Table O +
2 O +
) O -
. O +

Also O -
, O +
for O +
all O +
retinols O +
except O +
4-oxo O -
- O -
retinol O +
the O +
contact O +
scores O +
were O +
higher O +
when O +
docked O +
to O +
ADH4 B-Gene +
rather O +
than O +
ADH1B B-Gene +
( O -
Table O +
2 O +
) O -
. O +

Computer O -
- O -
generated O +
images O +
of O +
the O +
most O +
favorable O +
docked O +
orientations O +
for O +
all O -
- O -
trans O +
-retinol O -
, O +
9-cis O +
-retinol O -
, O +
3,4-didehydroretinol O -
, O +
and O +
4-oxo O -
- O -
retinol O +
are O +
shown O +
( O -
Fig. O +
5 O +
) O -
. O +

The O +
docked O +
structures O +
for O +
4-oxo O -
- O -
retinol O +
and O +
4-hydroxy O -
- O -
retinol O +
were O +
essentially O +
identical O +
( O -
image O +
not O +
shown O +
for O +
the O +
latter O -
) O -
. O +

It O +
is O +
seen O +
that O +
the O +
ADH4 B-Gene +
active O +
site O +
is O +
wider O +
than O +
that O +
of O +
ADH1B B-Gene +
as O +
reported O +
previously O +
[ O -
51 O -
] O +
. O +

The O +
images O +
clearly O +
show O +
that O +
all O -
- O -
trans O +
-retinol O +
and O +
4-oxo O -
- O -
retinol O +
gain O +
close O +
access O +
to O +
the O +
ADH1B B-Gene +
catalytic O +
zinc O +
and O +
NAD O +
as O +
well O +
as O +
Thr48 O +
which O +
is O +
hydrogen O -
- O -
bonded O +
to O +
the O +
substrate O +
hydroxyl O +
( O -
Fig. O +
5A O -
, O -
D O +
) O -
. O +

In O +
contrast O -
, O +
9-cis O +
-retinol O +
and O +
3,4-didehydroretinol O +
can O -
not O +
fully O +
enter O +
the O +
ADH1B B-Gene +
active O +
site O -
, O +
having O +
zinc O -
, O +
NAD O -
, O +
and O +
Thr48 O +
distances O +
all O +
in O +
excess O +
of O +
4.5 O +
Å O +
( O -
Fig. O +
5B O -
, O -
C O +
) O -
. O +

In O +
the O +
case O +
of O +
the O +
ADH4 B-Gene +
active O +
site O +
it O +
is O +
seen O +
quite O +
clearly O +
that O +
all O +
four O +
retinol O +
structures O +
dock O +
closely O +
to O +
the O +
catalytic O +
zinc O -
, O +
NAD O -
, O +
and O +
Thr48 O +
( O -
Fig. O +
5E O -
– O -
H O +
) O -
. O +

3.4 O +
ADH4 B-Gene +
has O +
a O +
more O +
favorable O +
retinol O -
- O -
binding O +
site O +
than O +
ADH1B B-Gene +
The O +
much O +
lower O +
force O +
field O +
scores O +
attained O +
for O +
docking O +
of O +
all O +
five O +
retinols O +
in O +
the O +
ADH4 B-Gene +
active O +
site O +
relative O +
to O +
the O +
ADH1B B-Gene +
active O +
site O -
, O +
as O +
well O +
as O +
the O +
ability O +
of O +
9-cis O +
-retinol O +
and O +
3,4-didehydroretinol O +
to O +
closely O +
approach O +
the O +
catalytic O +
zinc O +
only O +
in O +
ADH4 B-Gene -
, O +
indicate O +
that O +
ADH4 B-Gene +
is O +
more O +
well O +
designed O +
for O +
binding O +
diverse O +
retinols O -
. O +

This O +
correlates O +
with O +
in O +
vitro O +
enzymatic O +
activity O +
assays O +
for O +
oxidation O +
of O +
all O -
- O -
trans O +
-retinol O +
indicating O +
catalytic O +
efficiencies O +
for O +
human O +
ADH4 B-Gene +
of O +
1.9–4.5 O +
μM−1 O +
min−1 O +
and O +
for O +
human O +
ADH1B B-Gene +
( O -
β1 O +
β1 O +
) O +
of O +
0.02–0.04 O +
μM−1 O +
min−1 O +
, O +
a O +
difference O +
of O +
approx O -
. O +

100-fold O +
[ O -
5,7 O -
] O +
. O +

Interestingly O -
, O +
the O +
β2 B-Gene +
β2 I-Gene +
variant I-Gene +
of I-Gene +
human I-Gene +
ADH1B I-Gene +
( O -
which O +
differs O +
from O +
β1 B-Gene +
β1 I-Gene +
only O +
by O +
having O +
histidine O +
at O +
residue O +
47 O +
rather O +
than O +
arginine O -
) O +
has O +
been O +
reported O +
to O +
have O +
a O +
catalytic O +
efficiency O +
for O +
retinol O +
oxidation O +
of O +
1.8 O +
μM−1 O +
min−1 O +
, O +
thus O +
only O +
about O +
2-fold O +
less O +
than O +
ADH4 B-Gene +
[ O -
9 O -
] O +
. O +

However O -
, O +
another O +
report O +
indicates O +
that O +
the O +
catalytic O +
efficiency O +
for O +
β2 B-Gene +
β2 I-Gene +
is O +
0.18 O +
μM−1 O +
min−1 O +
using O +
different O +
assay O +
conditions O -
, O +
thus O +
still O +
about O +
20-fold O +
less O +
active O +
than O +
ADH4 B-Gene +
[ O -
7 O -
] O +
. O +

In O +
either O +
case O +
the O +
β2 B-Gene +
β2 I-Gene +
variant I-Gene +
is O +
more O +
active O +
for O +
retinol O +
oxidation O +
than O +
the O +
β1 B-Gene +
β1 I-Gene +
variant I-Gene -
. O +

This O +
may O +
be O +
due O +
to O +
less O +
tight O +
binding O +
of O +
NAD O +
by O +
β2 B-Gene +
β2 I-Gene +
leading O +
to O +
a O +
faster O +
turnover O +
rate O +
since O +
residue O +
47 O +
is O +
involved O +
in O +
coenzyme O +
binding O +
[ O -
48 O -
] O +
. O +

These O +
observations O +
indicate O +
that O +
the O +
ability O +
of O +
ADHs B-Gene +
to O +
use O +
retinol O +
is O +
governed O +
not O +
only O +
by O +
the O +
overall O +
size O +
of O +
the O +
active O +
site O -
, O +
but O +
also O +
by O +
residue O +
47 O +
lying O +
immediately O +
adjacent O +
to O +
the O +
active O +
site O +
residue O +
Thr48 O -
. O +

Enzyme B-Gene +
activity O +
assays O +
with O +
9-cis O +
-retinol O +
and O +
9-cis O +
-retinal O +
have O +
shown O +
that O +
human O +
ADH4 B-Gene +
is O +
very O +
active O +
with O +
these O +
substrates O +
demonstrating O +
catalytic O +
efficiencies O +
of O +
9.0–13.3 O +
μM−1 O +
min−1 O +
[ O -
8 O -
] O +
, O +
whereas O +
human O +
ADH1B B-Gene +
has O +
nearly O +
undetectable O +
activity O +
for O +
9-cis O +
-retinal O +
demonstrating O +
a O +
catalytic O +
efficiency O +
of O +
only O +
0.0084 O +
μM−1 O +
min−1 O +
[ O -
5 O -
] O +
. O +

Our O +
docking O +
models O +
predict O +
that O +
both O +
9-cis O +
-retinol O +
and O +
3,4-didehydroretinol O +
can O +
function O +
as O +
very O +
good O +
substrates O +
for O +
ADH4 B-Gene -
, O +
but O +
not O +
for O +
ADH1B B-Gene -
. O +

Our O +
models O +
further O +
predict O +
that O +
4-oxo O -
- O -
retinol O +
and O +
4-hydroxy O -
- O -
retinol O +
can O +
function O +
as O +
substrates O +
for O +
both O +
enzymes B-Gene +
with O +
ADH4 B-Gene +
having O +
a O +
much O +
higher O +
catalytic O +
efficiency O +
as O +
is O +
the O +
case O +
for O +
all O -
- O -
trans O +
-retinol O -
. O +

Our O +
findings O +
indicate O +
that O +
9-cis O +
-retinol O +
and O +
3,4-didehydroretinol O +
can O -
not O +
assume O +
conformations O +
which O +
allow O +
full O +
access O +
into O +
the O +
relatively O +
narrow O +
ADH1B B-Gene +
active O +
site O -
. O +

In O +
the O +
case O +
of O +
9-cis O +
-retinoids O +
it O +
is O +
already O +
clear O +
that O +
the O +
presence O +
of O +
a O +
cis O +
as O +
opposed O +
to O +
a O +
trans O +
double O +
bond O +
configuration O +
at O +
C-9 O +
has O +
a O +
significant O +
effect O +
upon O +
the O +
ability O +
of O +
the O +
carboxylic O +
acid O +
forms O +
to O +
bind O +
to O +
retinoid B-Gene +
X I-Gene +
receptors I-Gene +
which O +
have O +
a O +
strong O +
selectivity O +
for O +
9-cis O +
-retinoic O +
acid O +
over O +
all O -
- O -
trans O +
-retinoic O +
acid O +
[ O -
37,38 O -
] O +
. O +

Our O +
docking O +
models O +
predict O +
that O +
ADH1B B-Gene +
has O +
a O +
selectivity O +
for O +
trans O +
as O +
opposed O +
to O +
cis O +
retinol O +
substrates O -
. O +

The O +
inability O +
of O +
9-cis O +
-retinol O +
to O +
enter O +
the O +
ADH1B B-Gene +
active O +
site O +
may O +
be O +
due O +
to O +
steric O +
hindrance O +
of O +
the O +
C-19 O +
methyl O +
group O +
( O -
Fig. O +
5B O +
) O -
. O +

This O +
situation O +
is O +
not O +
true O +
for O +
ADH4 B-Gene +
which O +
has O +
a O +
wider O +
active O +
site O +
than O +
ADH1B B-Gene +
due O +
to O +
deletion O +
of O +
Gly117 O +
and O +
substitution O +
of O +
Leu O +
for O +
Tyr110 O +
[ O -
52,54 O -
] O +
leading O +
to O +
an O +
accommodation O +
of O +
the O +
C-19 O +
methyl O +
group O +
of O +
9-cis O +
-retinol O +
( O -
Fig. O +
5F O +
) O -
. O +

However O -
, O +
the O +
inability O +
of O +
3,4-didehydroretinol O +
to O +
fully O +
enter O +
the O +
ADH1B B-Gene +
active O +
site O +
is O +
less O +
obvious O -
. O +

We O +
suggest O +
that O +
the O +
presence O +
of O +
the O +
extra O +
double O +
bond O +
in O +
the O +
ring O +
structure O +
of O +
3,4-didehydroretinol O +
produces O +
a O +
smaller O +
ring O +
configuration O +
which O +
is O +
more O +
conformationally O +
restrictive O -
, O +
thus O +
placing O +
the O +
C-19 O +
methyl O +
group O +
in O +
an O +
unfavorable O +
position O +
for O +
entry O +
into O +
the O +
narrow O +
ADH1B B-Gene +
active O +
site O +
( O -
Fig. O +
5C O +
) O +
but O +
without O +
restricting O +
access O +
to O +
the O +
wider O +
ADH4 B-Gene +
active O +
site O +
( O -
Fig. O +
5 O -
G O +
) O -
. O +

3.5 O +
Conclusions O +
The O +
retinol O +
docking O +
strategy O +
described O +
here O +
has O +
provided O +
results O +
which O +
are O +
consistent O +
with O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
holo B-Gene -
- I-Gene -
CRBPII I-Gene +
[ O -
57 O -
] O +
, O +
with O +
the O +
known O +
binding O +
properties O +
of O +
CRBPII B-Gene +
for O +
all O -
- O -
trans O +
-retinol O -
, O +
9-cis O +
-retinol O -
, O +
and O +
3,4-didehydroretinol O +
[ O -
61 O -
] O +
, O +
and O +
with O +
the O +
enzymatic O +
properties O +
of O +
ADH1B B-Gene +
and O +
ADH4 B-Gene +
for O +
all O -
- O -
trans O +
-retinol O +
and O +
9-cis O +
-retinol O +
[ O -
5,8,52 O -
] O +
. O +

The O +
studies O +
reported O +
here O +
use O +
the O +
known O +
crystal O +
structures O +
for O +
both O +
ADH1B B-Gene +
and O +
ADH4 B-Gene -
, O +
and O +
demonstrate O +
that O +
the O +
ADH4 B-Gene +
active O +
site O +
is O +
well O +
suited O +
to O +
bind O +
all O -
- O -
trans O +
-retinol O -
, O +
9-cis O +
-retinol O -
, O +
3,4-didehydroretinol O -
, O +
4-oxo O -
- O -
retinol O -
, O +
and O +
4-hydroxy O -
- O -
retinol O -
, O +
whereas O +
ADH1B B-Gene +
has O +
a O +
more O +
restrictive O +
active O +
site O +
which O +
will O +
accommodate O +
only O +
all O -
- O -
trans O +
-retinol O -
, O +
4-oxo O -
- O -
retinol O -
, O +
and O +
4-hydroxy O -
- O -
retinol O -
, O +
and O +
these O +
to O +
a O +
lesser O +
extent O +
than O +
ADH4 B-Gene -
. O +

This O +
suggests O +
that O +
ADH4 B-Gene +
plays O +
a O +
major O +
role O +
in O +
the O +
metabolism O +
of O +
a O +
diverse O +
array O +
of O +
natural O +
retinol O +
structures O +
implicated O +
as O +
precursors O +
for O +
the O +
active O +
retinoid B-Gene +
receptor I-Gene +
ligands O +
all O -
- O -
trans O +
-retinoic O +
acid O -
, O +
9-cis O +
-retinoic O +
acid O -
, O +
3,4-didehydroretinoic O +
acid O -
, O +
4-oxo O -
- O -
retinoic O +
acid O -
, O +
and O +
4-hydroxy O -
- O -
retinoic O +
acid O -
. O +

The O +
docking O +
models O +
suggest O +
that O +
ADH1B B-Gene +
plays O +
only O +
a O +
minor O +
role O +
if O +
any O +
in O +
the O +
metabolism O +
of O +
9-cis O +
-retinol O +
or O +
3,4-didehydroretinol O -
, O +
and O +
that O +
this O +
enzyme B-Gene +
is O +
more O +
likely O +
to O +
participate O +
in O +
the O +
metabolism O +
of O +
4-oxo O -
- O -
retinol O -
, O +
4-hydroxy O -
- O -
retinol O -
, O +
and O +
to O +
a O +
lesser O +
extent O +
all O -
- O -
trans O +
-retinol O -
. O +

The O +
ability O +
of O +
ADH1B B-Gene +
and O +
ADH4 B-Gene +
active O +
sites O +
to O +
accommodate O +
various O +
retinol O +
substrates O +
provides O +
impetus O +
to O +
further O +
examine O +
how O +
broad O +
a O +
role O +
ADH B-Gene +
plays O +
in O +
the O +
production O +
of O +
active O +
ligands O +
for O +
retinoid O +
signaling O -
. O +

Acknowledgements O +

We O +
thank O +
H.L. O +
Ang O -
, O +
L. O +
Deltour O -
, O +
R.J. O +
Haselbeck O -
, O +
and O +
I. O +
Hoffmann O +
for O +
critical O +
discussions O -
, O +
and O +
D. O +
Zimmerman O +
in O +
the O +
Burnham O +
Institute O +
Computer O +
Resources O +
Department O +
for O +
computational O +
expertise O -
. O +

This O +
work O +
was O +
supported O +
by O +
National O +
Institutes O +
of O +
Health O +
Grant O +
AA07261 O -
. O +

Pyrethroids O +
belong O +
to O +
the O +
most O +
frequently O +
used O +
pesticides O -
. O +

People O +
exposed O +
to O +
pyrethroids O +
do O +
not O +
only O +
include O +
workers O +
in O +
the O +
chemical O +
industry O +
( O -
production O -
, O +
filling O -
, O +
formulation O -
) O -
, O +
farmers O +
and O +
pest O +
control O +
operators O +
but O +
also O +
the O +
consumers O -
. O +

In O +
humans O -
, O +
pyrethroids O +
are O +
rapidly O +
metabolised O +
by O +
esterases B-Gene -
, O +
mainly O +
in O +
the O +
liver O -
. O +

The O +
detoxified O +
metabolites O +
are O +
renally O +
eliminated O -
, O +
the O +
elimination O +
half O -
- O -
life O +
time O +
( O -
t O +
1 O -
/ O -
2 O +
) O +
for O +
the O +
metabolites O +
being O +
about O +
6 O +
h O +
( O -
Leng O +
et O +
al. O -
, O +
1997a O +
) O -
. O +

After O +
cyfluthrin O +
exposure O +
93 O -
% O +
of O +
the O +
metabolites O +
are O +
eliminated O +
during O +
the O +
first O +
24 O +
h O +
( O -
Leng O +
et O +
al. O -
, O +
1997a O +
) O -
. O +

For O +
assessing O +
a O +
cyfluthrin O +
exposure O +
the O +
metabolites O +
are O +
routinely O +
determined O +
in O +
urine O +
( O -
Leng O +
et O +
al. O -
, O +
1996 O -
, O +
1997b O +
) O -
. O +

Although O -
, O +
several O +
studies O +
have O +
shown O +
that O +
there O +
is O +
no O +
correlation O +
between O +
the O +
metabolite O +
concentration O +
in O +
urine O +
and O +
the O +
symptoms O +
mentioned O +
( O -
Kolmodin O -
- O -
Hedman O +
et O +
al. O -
, O +
1995 O -
; O +
Leng O -
, O +
1998a O -
; O +
Wieseler O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

As O +
a O +
marker O +
of O +
biological O +
effects O +
the O +
unchanged O +
pyrethroid O +
has O +
to O +
be O +
determined O +
in O +
plasma O -
. O +

Here O -
, O +
the O +
problem O +
is O +
that O +
pyrethroids O +
are O +
only O +
present O +
for O +
a O +
few O +
hours O +
after O +
exposure O +
( O -
Leng O +
et O +
al. O -
, O +
1997b O -
; O +
Leng O +
and O +
Lewalter O -
, O +
1998b O +
) O -
. O +

As O +
local O +
symptoms O +
occurring O +
after O +
pyrethroid O +
exposure O +
mostly O +
skin O +
paresthesia O +
and O +
irritations O +
of O +
the O +
upper O +
respiratory O +
tract O +
are O +
reported O +
( O -
He O +
et O +
al. O -
, O +
1988 O +
) O -
. O +

In O +
general O -
, O +
the O +
occurrence O -
, O +
kind O +
and O +
extend O +
of O +
a O +
symptom O +
depends O +
on O +
the O +
route O +
of O +
exposure O +
( O -
oral O +
or O +
inhalative O +
and O +
dermal O -
) O -
, O +
the O +
pyrethroid O +
dose O -
, O +
the O +
particle O +
size O +
or O +
the O +
local O +
concentration O +
of O +
the O +
pyrethroid O +
on O +
the O +
nerve O +
ending O -
. O +

But O +
the O +
individual O +
occurrence O +
or O +
even O +
the O +
severity O +
of O +
a O +
symptom O +
like O +
skin O +
paresthesia O +
can O -
not O +
be O +
explained O +
by O +
this O +
alone O -
. O +

Here O -
, O +
the O +
individual O +
metabolic O +
capacity O +
of O +
e.g. O +
the O +
skin O +
seems O +
to O +
play O +
a O +
very O +
important O +
role O -
. O +

For O +
pyrethroids O +
no O +
marker O +
of O +
susceptibility O +
is O +
known O +
yet O -
. O +

This O +
is O +
in O +
contrast O +
to O +
organophosphates O +
and O +
carbamates O -
. O +

Here O -
, O +
cholinesterase B-Gene +
variants O +
are O +
known O +
to O +
be O +
responsible O +
for O +
the O +
individual O +
susceptibility O +
regarding O +
the O +
occurrence O +
and O +
severity O +
of O +
the O +
related O +
symptom O -
. O +

Paraoxonase B-Gene +
present O +
in O +
human O +
plasma O +
was O +
shown O +
to O +
be O +
under O +
genetic O +
control O +
with O +
high O +
and O +
low O +
activities O -
. O +

Variations O +
in O +
plasma O +
paraoxonase B-Gene +
activity O +
may O +
contribute O +
to O +
interindividual O +
variations O +
in O +
susceptibility O +
( O -
McCracken O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

Apart O +
from O +
the O +
cholinesterases B-Gene +
the O +
membrane O +
bound O +
non O -
- O -
specific O +
carboxylesterases B-Gene +
( O -
EC B-Gene +
3.1.1.1 I-Gene -
, O +
systematic O +
name O -
: O +
carboxylic B-Gene -
- I-Gene -
ester I-Gene +
hydrolase I-Gene -
) O +
are O +
known O +
to O +
detoxify O +
xenobiotics O +
containing O +
aliphatic O +
esters O -
. O +

This O +
enzyme B-Gene +
is O +
inhibited O +
by O +
organophosphates O +
like O +
paraoxon O +
( O -
Junge O +
et O +
al. O -
, O +
1974 O -
; O +
Tsujita O +
and O +
Okuda O -
, O +
1983 O +
) O -
. O +

Carboxylesterases B-Gene +
are O +
present O +
e.g. O +
in O +
skin O -
, O +
muscle O -
, O +
kidney O -
, O +
brain O +
and O +
serum O +
with O +
the O +
highest O +
esterase B-Gene +
activity O +
found O +
in O +
the O +
liver O +
( O -
Satoh O -
, O +
1987 O +
) O -
. O +

Aim O +
of O +
this O +
study O +
was O +
to O +
find O +
out O +
which O +
markers O +
correlate O +
with O +
pyrethroid O +
induced O +
adverse O +
effects O -
. O +

Therefore O -
, O +
the O +
use O +
of O +
determining O +
pyrethroids O +
in O +
plasma O -
, O +
pyrethroid O +
metabolites O +
in O +
urine O +
and O +
esterase B-Gene +
activities O +
was O +
evaluated O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Study O +
1—Pyrethroid O +
metabolites O +
in O +
urine O +
Twenty O -
- O -
two O +
pest O +
control O +
operators O +
regularly O +
exposed O +
to O +
the O +
pyrethroids O +
cyfluthrin O +
( O -
n O +
= O -
16 O -
) O -
, O +
permethrin O +
( O -
n O +
= O -
3 O -
) O -
, O +
deltamethrin O +
( O -
n O +
= O -
2 O -
) O +
and O +
cypermethrin O +
( O -
n O +
= O -
1 O -
) O +
as O +
well O +
as O +
a O +
non O -
- O -
exposed O +
control O +
group O +
of O +
20 O +
subjects O +
were O +
investigated O -
. O +

At O +
the O +
end O +
of O +
the O +
working O +
week O +
24 O +
h O +
urine O +
was O +
collected O +
and O +
the O +
concentration O +
of O +
the O +
metabolites O +
was O +
determined O +
by O +
GC O -
/ O -
MS O +
( O -
LOD O -
: O +
0.5 O +
μg O -
/ O -
l O -
) O +
( O -
Kühn O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Moreover O -
, O +
a O +
medical O +
interview O +
was O +
performed O +
in O +
which O +
reported O +
symptoms O +
were O +
documented O +
( O -
Wieseler O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

2.2 O +
Study O +
2—Half O -
- O -
life O +
time O +
of O +
cyfluthrin O +
metabolites O +
in O +
urine O +
Four O +
healthy O +
male O +
volunteers O +
were O +
exposed O +
for O +
60 O +
min O +
to O +
a O +
mean O +
cyfluthrin O +
concentration O +
of O +
160 O +
μg O -
/ O -
m3 O +
( O -
Leng O +
et O +
al. O -
, O +
1997a O +
) O -
. O +

The O +
study O +
design O +
and O +
the O +
medical O +
surveillance O +
of O +
the O +
volunteers O +
was O +
approved O +
by O +
an O +
independent O +
ethical O +
committee O +
after O +
a O +
review O +
of O +
data O +
on O +
animal O +
toxicity O +
and O +
consideration O +
of O +
the O +
dose O +
levels O +
in O +
relation O +
to O +
a O +
proposed O +
acceptable O +
daily O +
intake O +
( O -
ADI O -
) O +
of O +
0.02 O +
mg O -
/ O -
kg O +
per O +
day O +
cyfluthrin O -
. O +

Urine O +
was O +
collected O +
in O +
the O +
following O +
intervalls O -
: O +
before O +
and O +
immediately O +
after O +
the O +
exposure O -
, O +
1–2 O +
h O -
/ O -
2–3 O +
h O -
/ O -
3–4 O +
h O -
/ O -
4–5 O +
h O -
/ O -
5–6 O +
h O -
/ O -
6–12 O +
and O +
12–24 O +
h O +
after O +
exposure O -
. O +

Cyfluthrin O +
metabolites O +
cis O +
- O +
and O +
trans O +
- O +
3- O -
( O -
2,2-dichlorovinyl O -
) O -
-2,2-dimethylcyclopropanecarboxylic O +
acid O +
( O -
DCCA O -
) O +
and O +
fluorophenoxybenzoic O +
acid O +
( O -
FPBA O -
) O +
were O +
determined O +
in O +
urine O +
by O +
GC O -
/ O -
MS O +
( O -
Kühn O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

As O +
a O +
first O +
order O +
kinetic O +
for O +
the O +
urinary O +
excretion O +
of O +
cyfluthrin O +
metabolites O +
was O +
assumed O -
, O +
a O +
linear O +
regression O +
analysis O +
was O +
performed O +
on O +
urinary O +
rate O +
versus O +
mid O -
- O -
point O +
time O +
from O +
peak O +
excretion O +
to O +
24 O +
h O +
after O +
exposure O -
. O +

The O +
t O +
1 O -
/ O -
2 O +
was O +
estimated O +
from O +
the O +
expression O +
0.693 O -
/ O -
( O -
slope O -
× O -
2.303 O -
) O -
. O +

2.3 O +
Study O +
3—Half O -
- O -
life O +
time O +
of O +
cyfluthrin O +
in O +
plasma O +
Eight O +
workers O +
in O +
the O +
chemical O +
industry O +
were O +
investigated O +
after O +
intoxications O +
( O -
Leng O +
and O +
Lewalter O -
, O +
1998b O +
) O -
. O +

Four O +
workers O +
were O +
exposed O +
to O +
cyfluthrin O +
and O +
four O +
were O +
exposed O +
to O +
cyfluthrin O +
and O +
methyl O -
- O -
parathion O -
. O +

Blood O +
was O +
drawn O +
30 O +
min O +
after O +
exposure O +
and O +
3 O +
h O +
later O -
. O +

Both O +
pesticides O +
were O +
determined O +
in O +
plasma O +
and O +
the O +
t O +
1 O -
/ O -
2 O +
of O +
cyfluthrin O +
in O +
plasma O +
was O +
calculated O +
with O +
the O +
assumption O +
of O +
a O +
simple O +
first O +
order O +
decay O +
( O -
t O +
1 O -
/ O -
2 O +
= O -
0.693 O -
/ O -
slope O -
× O -
2.303 O -
) O -
. O +

2.4 O +
Determination O +
of O +
transfluthrin O +
in O +
human O +
plasma O +
Native O +
human O +
plasma O +
naturally O +
containing O +
cholinesterase B-Gene +
and O +
carboxylesterase B-Gene +
was O +
dotated O +
with O +
transfluthrin O +
( O -
1 O +
mg O -
/ O -
l O -
) O -
. O +

The O +
change O +
of O +
transfluthrin O +
concentration O +
during O +
time O +
was O +
measured O -
. O +

In O +
another O +
experiment O -
, O +
2 O +
U O -
/ O -
ml O +
commercially O +
available O +
carboxylesterase B-Gene +
( O -
EC B-Gene +
3.1.1.1 I-Gene +
from O +
porcine O +
liver O -
, O +
1000 O +
units O -
, O +
Sigma O -
) O +
was O +
added O -
. O +

Transfluthrin O +
concentration O +
change O +
was O +
again O +
documented O -
. O +

The O +
method O +
for O +
the O +
determination O +
of O +
transfluthrin O +
in O +
plasma O +
is O +
described O +
elsewhere O +
( O -
Kühn O -
, O +
1997 O +
) O -
. O +

2.5 O +
Determination O +
of O +
carboxylesterase B-Gene +
activity O +
in O +
human O +
isolated O +
lymphocytes O +
A O +
total O +
of O +
5 O +
ml O +
venous O +
blood O +
was O +
drawn O +
from O +
which O +
2–3 O +
mio O +
( O -
theoretically O +
6–10 O +
mio O -
) O +
lymphocytes O -
/ O -
ml O +
were O +
isolated O +
and O +
quantified O +
on O +
slides O +
under O +
the O +
microscope O -
. O +

Lymphocytes O +
were O +
solved O +
in O +
1 O +
ml O +
100 O +
mM O +
buffer O +
( O -
pH O +
8) O +
containing O +
13.6 O +
g O +
KH2 O +
PO4 O +
/l O +
and O +
17.4 O +
g O +
K2 O +
HPO4 O +
/l O -
. O +

As O +
a O +
substrate O -
, O +
10 O +
μl O +
of O +
a O +
cyfluthrin O +
solution O +
( O -
cyano O -
- O -
group O +
containing O +
pyrethroid O -
) O +
was O +
added O +
( O -
30 O +
mg O +
cyfluthrin O +
/10 O +
ml O +
DMF O -
) O -
. O +

As O +
a O +
positive O +
control O +
commercially O +
available O +
carboxylesterase B-Gene +
was O +
used O +
( O -
5 O +
U O -
/ O -
25 O +
μl O +
buffer O -
) O -
. O +

The O +
sample O +
was O +
incubated O +
for O +
30 O +
min O +
at O +
40 O -
° O -
C O -
. O +

A O +
total O +
of O +
1 O +
ml O +
of O +
the O +
lymphocyte O +
suspension O +
was O +
placed O +
in O +
a O +
glass O +
tube O +
with O +
screw O +
cap O -
. O +

The O +
applied O +
method O +
is O +
based O +
on O +
kryptate O +
formation O +
using O +
Kryptofix O +
222 O +
B O +
polymer O +
as O +
a O +
phase O -
- O -
transfer O -
- O -
catalyst O +
to O +
transfer O +
the O +
cyanide O +
anion O +
formed O +
by O +
the O +
degradation O +
of O +
cyfluthrin O +
from O +
the O +
aqueous O +
alkaline O +
solution O +
to O +
the O +
organic O +
dichloromethane O +
phase O +
( O -
Chen O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

As O +
a O +
derivatization O +
agent O +
pentafluorobenzyl O +
bromide O +
was O +
used O +
and O +
the O +
formated O +
pentafluorobenzyl O +
cyanide O +
was O +
determined O +
by O +
GC O -
/ O -
MS O -
. O +

2,3,5,6-tetrachloronitrobenzol O +
served O +
as O +
an O +
internal O +
standard O -
. O +

A O +
total O +
of O +
100 O +
μl O +
of O +
the O +
organic O +
phase O +
was O +
removed O +
into O +
a O +
micro O +
vial O -
. O +

The O +
injection O +
vol O -
. O +

was O +
1 O +
μl O -
. O +

Capillary O +
gas O +
chromatography O +
was O +
applied O +
using O +
a O +
Hewlett O -
- O -
Packard O +
MSD O +
with O +
a O +
GC O +
5890 O -
, O +
an O +
autoinjector O +
HP O +
7673 O +
and O +
a O +
HP O +
5973 O +
mass O +
selective O +
detector O +
equipped O +
with O +
an O +
apolar O +
DB-5 O +
MS O +
fused O +
silica O +
capillary O +
( O -
50 O +
m O +
length O -
, O +
0.2 O +
mm O +
i.d O -
. O -
, O +
0.33 O +
μm O +
film O -
) O +
attached O +
to O +
a O +
retention O +
gap O +
with O +
helium O +
as O +
a O +
carrier O +
gas O +
at O +
a O +
pressure O +
of O +
160 O +
kPa O -
. O +

The O +
split O +
was O +
open O +
during O +
injection O -
, O +
closed O +
after O +
0.2 O +
min O +
for O +
1 O +
min O +
and O +
remained O +
open O +
during O +
GC O +
run O -
. O +

The O +
following O +
GC O +
temperature O +
program O +
was O +
used O -
: O +
The O +
capillary O +
column O +
was O +
maintained O +
at O +
35 O -
° O -
C O +
for O +
2 O +
min O +
and O +
programmed O +
from O +
35 O -
° O -
C O +
at O +
10 O -
° O -
C O -
/ O -
min O +
to O +
230 O -
° O -
C O -
, O +
holding O +
for O +
2 O +
min O +
and O +
then O +
programmed O +
from O +
230 O -
° O -
C O +
at O +
20 O -
° O -
C O -
/ O -
min O +
to O +
280 O -
° O -
C O -
. O +

The O +
injector O +
temperature O +
was O +
held O +
at O +
280 O -
° O -
C O +
and O +
the O +
detector O +
temperature O +
was O +
set O +
at O +
300 O -
° O -
C O +
( O -
MSD O -
- O -
transfere O +
line O -
) O -
. O +

For O +
identification O +
and O +
quantitation O +
mass O +
spectra O +
were O +
obtained O +
by O +
electron O +
impact O +
( O -
EI O -
, O +
70 O +
eV O -
) O +
using O +
selected O +
ion O +
monitoring O +
( O -
SIM O -
) O +
( O -
Chen O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

The O +
signal O -
- O -
to O -
- O -
noise O +
value O +
of O +
pentafluorobenzyl O +
cyanide O +
at O +
a O +
concentration O +
level O +
of O +
25 O +
μg O -
/ O -
l O +
of O +
cyanide O +
was O +
3:1 O -
. O +

The O +
average O +
in O +
run O -
- O -
coefficient O +
of O +
variation O +
was O +
10 O -
% O +
( O -
50 O +
μg O -
/ O -
l O -
, O +
n O +
= O -
10 O -
) O -
. O +

3 O +
Results O +
3.1 O +
Study O +
1—Pyrethroid O +
metabolites O +
in O +
urine O +
In O +
Fig. O +
1 O +
the O +
symptoms O +
mentioned O +
by O +
22 O +
pest O +
control O +
operators O +
and O +
20 O +
control O +
subjects O +
are O +
presented O -
. O +

There O +
was O +
no O +
significant O +
difference O +
between O +
these O +
groups O -
. O +

Fig. O +
2 O +
shows O +
that O +
there O +
was O +
no O +
correlation O +
between O +
the O +
concentration O +
of O +
pyrethroid O +
metabolites O +
in O +
urine O +
and O +
the O +
occurrence O +
of O +
symptoms O -
. O +

3.2 O +
Study O +
2—Half O -
- O -
life O +
time O +
of O +
cyfluthrin O +
metabolites O +
in O +
urine O +
By O +
determining O +
the O +
interindividual O +
differences O +
in O +
cyfluthrin O +
metabolism O +
in O +
human O +
volunteers O +

it O +
was O +
obvious O +
that O +
there O +
were O +
subjects O +
with O +
a O +
slow O +
and O +
with O +
a O +
fast O +
rate O +
of O +
metabolism O +
( O -
Fig. O +
3 O +
) O -
. O +

Overall O -
, O +
the O +
longer O +
the O +
t O +
1 O -
/ O -
2 O +
, O +
the O +
more O +
the O +
symptom O -
. O +

3.3 O +
Study O +
3—Half O -
- O -
life O +
time O +
of O +
cyfluthrin O +
in O +
plasma O +
Table O +
1 O +
shows O +
the O +
interindividual O +
differences O +
in O +
cyfluthrin O +
metabolism O +
following O +
a O +
single O +
cyfluthrin O +
as O +
well O +
as O +
a O +
mixed O +
cyfluthrin O +
and O +
methyl O -
- O -
parathion O +
exposure O -
. O +

As O +
a O +
result O -
, O +
an O +
equal O +
amount O +
of O +
cyfluthrin O -
, O +
shown O +
by O +
nearly O +
identical O +
cyfluthrin O +
concentrations O +
in O +
plasma O -
, O +
leads O +
to O +
different O +
t O +
1 O -
/ O -
2 O +
of O +
cyfluthrin O +
in O +
plasma O -
. O +

In O +
case O +
skin O +
paresthesia O +
occurred O -
, O +
a O +
comparable O +
long O +
cyfluthrin O +
t O +
1 O -
/ O -
2 O +
was O +
found O -
. O +

Concerning O +
a O +
mixed O +
exposure O +
( O -
pyrethroid O +
plus O +
organophosphate O -
) O -
, O +
a O +
similar O +
amount O +
of O +
exposure O +
leads O +
to O +
t O +
1 O -
/ O -
2 O +
of O +
cyfluthrin O +
variing O +
between O +
1 O +
and O +
14 O +
h. O +
In O +
general O -
, O +
in O +
case O +
of O +
a O +
mixed O +
exposure O +
there O +
was O +
a O +
tendency O +
of O +
a O +
longer O +
t O +
1 O -
/ O -
2 O +
of O +
cyfluthrin O +
in O +
plasma O -
. O +

Skin O +
paresthesia O +
was O +
not O +
mentioned O +
in O +
case O +
of O +
a O +
short O +
t O +
1 O -
/ O -
2 O +
. O +

3.4 O +
Determination O +
of O +
transfluthrin O +
in O +
human O +
plasma O +
Transfluthrin O +
was O +
hydrolysed O +
very O +
slowly O +
( O -
> O -
60 O +
h O -
) O +
in O +
human O +
plasma O -
, O +
i.e. O +
cholinesterase B-Gene +
does O +
not O +
seem O +
to O +
be O +
responsible O +
for O +
transfluthrin O +
metabolism O -
. O +

In O +
case O +
carboxylesterase B-Gene +
was O +
added O -
, O +
hydrolysis O +
was O +
much O +
faster O +
( O -
< O -
30 O +
min O -
) O -
. O +

3.5 O +
Determination O +
of O +
carboxylesterase B-Gene +
activity O +
in O +
human O +
isolated O +
lymphocytes O +
Fig. O +
4 O +
shows O +
the O +
dependance O +
of O +
cyanic O +
acid O +
production O +
on O +
the O +
cyfluthrin O +
concentration O -
. O +

The O +
amount O +
of O +
carboxylesterase B-Gene +
was O +
constant O -
, O +
i.e. O +
1 O +
U O -
/ O -
ml O +
commercially O +
available O +
carboxylesterase B-Gene +
or O +
5 O +
mio O +
isolated O +
lymphocytes O -
/ O -
ml O -
. O +

Moreover O -
, O +
having O +
a O +
constant O +
substrate O +
concentration O -
, O +
the O +
amount O +
of O +
cyanic O +
acid O +
produced O +
was O +
dependant O +
on O +
the O +
amount O +
of O +
carboxylesterase B-Gene +
used O -
. O +

First O +
hints O +
for O +
interindividual O +
differences O +
in O +
cyanic O +
acid O +
production O +
are O +
demonstrated O +
in O +
Fig. O +
5 O +
. O +

4 O +
Discussion O +
This O +
study O +
demonstrates O +
that O +
the O +
individual O +
susceptibility O +
plays O +
a O +
major O +
role O +
in O +
pyrethroid O +
induced O +
adverse O +
effects O +
like O +
skin O +
paresthesia O -
. O +

In O +
humans O -
, O +
pyrethroids O +
are O +
assumed O +
to O +
be O +
rapidly O +
metabolized O +
by O +
a O +
hydrolytic O +
cleavage O +
( O -
esterases B-Gene -
) O +
into O +
their O +
corresponding O +
metabolites O +
cis O +
- O +
and O +
trans O +
-3- O -
( O -
2,2-dichlorovinyl O -
) O -
-2,2-dimethylcyclopropane O +
carboxylic O +
acid O +
or O +
cis O +
-3- O -
( O -
2,2-dibromovinyl O -
) O -
-2,2-dimethylcyclopropane O +
carboxylic O +
acid O -
. O +

The O +
alcohol O +
moiety O +
is O +
oxidised O +
( O -
mixed O -
- O -
functional O +
oxidases B-Gene -
) O +
to O +
4-fluoro-3-phenoxybenzoic O +
acid O +
or O +
3-phenoxybenzoic O +
acid O +
( O -
Kühn O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

The O +
acids O +
are O +
partly O +
conjugated O +
to O +
e.g. O +
glucuronic O +
acid O +
and O +
finally O +
renally O +
eliminated O +
( O -
Wollen O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

The O +
determination O +
of O +
the O +
t O +
1 O -
/ O -
2 O +
of O +
eighter O +
pyrethroids O +
in O +
plasma O +
or O +
metabolites O +
in O +
urine O +
is O +
a O +
good O +
tool O +
to O +
get O +
indirect O +
information O +
about O +
individual O +
pyrethroid O +
metabolism O -
. O +

It O +
turned O +
out O +
that O +
only O +
in O +
case O +
of O +
a O +
long O +
t O +
1 O -
/ O -
2 O +
of O +
cyfluthrin O +
in O +
plasma O +
skin O +
paresthesia O +
occurred O -
. O +

The O +
t O +
1 O -
/ O -
2 O +
of O +
cyfluthrin O +
in O +
plasma O +
was O +
longer O +
in O +
case O +
of O +
a O +
mixed O +
exposure O +
than O +
in O +
case O +
of O +
a O +
single O +
one O -
. O +

This O +
might O +
be O +
explained O +
by O +
the O +
inhibition O +
of O +
the O +
cyfluthrin B-Gene +
degrading I-Gene +
esterase I-Gene +
by O +
the O +
organophosphate O +
methyl O -
- O -
parathion O -
. O +

In O +
case O +
of O +
a O +
direct O +
measurement O +
of O +
pyrethroid O +
susceptibility O +
the O +
activity O +
of O +
the O +
esterase B-Gene +
responsible O +
for O +
pyrethroid O +
metabolism O +
has O +
to O +
be O +
determined O -
. O +

In O +
contrast O +
to O +
organophosphates O +
and O +
carbamates O -
, O +
the O +
cholinesterase B-Gene +
does O +
not O +
seem O +
to O +
play O +
a O +
role O +
in O +
pyrethroid O +
metabolism O -
. O +

Apart O +
from O +
the O +
cholinesterase B-Gene +
the O +
carboxylesterase B-Gene +
is O +
a O +
widespread O +
esterase B-Gene +
as O +
well O -
. O +

It O +
is O +
known O +
that O +
several O +
carboxylesterases B-Gene +
exist O +
with O +
wide O +
and O +
overlapping O +
substrate O +
specifities O -
. O +

As O +
a O +
model O +
substrate O +
for O +
carboxylesterase O +
1-naphthyl O +
acetate O +
( O -
which O +
produces O +
1-naphtol O -
) O +
is O +
often O +
used O +
( O -
Williams O -
, O +
1985 O +
) O -
. O +

After O +
pyrethroid O +
exposure O +
skin O +
paresthesia O +
is O +
frequently O +
reported O -
. O +

There O +
are O +
interindividual O +
differences O +
concerning O +
the O +
occurrence O +
and O +
the O +
severity O +
of O +
this O +
symptom O -
. O +

This O +
might O +
be O +
explained O +
by O +
individual O +
different O +
levels O +
of O +
carboxylesterase B-Gene +
activity O +
in O +
the O +
skin O +
as O +
it O +
is O +
known O +
that O +
the O +
human O +
skin O +
contains O +
at O +
least O +
four O +
different O +
carboxylesterases B-Gene +
( O -
Heymann O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

With O +
the O +
help O +
of O +
in O -
- O -
vitro O +
experiments O +
it O +
was O +
demonstrated O +
that O +
pyrethroids O +
are O +
hydrolyzed O +
by O +
carboxylesterases B-Gene -
. O +

As O +
in O +
comparison O +
to O +
rats O +
human O +
plasma O +
contains O +
only O +
very O +
little O +
carboxylesterase B-Gene +
( O -
McCracken O +
et O +
al. O -
, O +
1993 O +
) O +
and O +
the O +
liver O +
is O +
not O +
easily O +
accessible O +
for O +
routine O +
measurements O -
, O +
we O +
wanted O +
to O +
find O +
out O +
if O +
there O +
is O +
a O +
measurable O +
carboxylesterase B-Gene +
activity O +
in O +
human O +
isolated O +
lymphocytes O -
. O +

Cyfluthrin O -
, O +
a O +
pyrethroid O +
containing O +
a O +
cyano O -
- O -
group O -
, O +
was O +
used O +
as O +
a O +
substrate O -
. O +

As O +
a O +
parameter O +
of O +
carboxylesterase B-Gene +
activity O +
the O +
production O +
of O +
cyanic O +
acid O +
was O +
measured O -
. O +

First O +
hints O +
showed O +
that O +
the O +
determination O +
of O +
carboxylesterase B-Gene +
acitivity O +
in O +
lymphocytes O +
is O +
a O +
most O +
promising O +
start O +
to O +
measure O +
the O +
individual O +
pyrethroid O +
susceptibility O -
. O +

5 O +
Conclusion O +

The O +
determination O +
of O +
the O +
carboxylesterase B-Gene +
activity O +
in O +
human O +
isolated O +
lymphocytes O +
is O +
a O +
first O +
step O +
in O +
the O +
search O +
of O +
a O +
marker O +
of O +
pyrethroid O +
susceptibility O +
in O +
man O -
. O +

To O +
obtain O +
information O +
concerning O +
the O +
individual O +
rate O +
of O +
metabolism O -
, O +
the O +
t O +
1 O -
/ O -
2 O +
of O +
the O +
pyrethroids O +
in O +
plasma O +
and O +
of O +
the O +
pyrethroid O +
metabolites O +
in O +
urine O +
should O +
be O +
determined O -
. O +

As O +
a O +
marker O +
of O +
exposure O +
the O +
determination O +
of O +
pyrethroid O +
metabolites O +
in O +
urine O +
is O +
indicated O -
. O +

Acknowledgements O +
The O +
authors O +
thank O +
Dr O +
K O -
.- O -
H. O +
Kühn O +
( O -
Institute O +
of O +
Hygiene O -
, O +
University O +
Duesseldorf O -
) O +
and O +
D. O +
Ellrich O +
( O -
Bayer O +
AG O -
, O +
Leverkusen O -
) O +
for O +
the O +
GC O -
/ O -
MS O +
measurements O -
. O +

Cancer O +
in O +
various O +
forms O +
is O +
one O +
of O +
the O +
leading O +
causes O +
of O +
death O +
in O +
the O +
human O +
population O -
. O +

Chemoprevention O +
and O +
chemotherapy O +
are O +
employed O +
in O +
reducing O +
human O +
mortality O +
due O +
to O +
cancer O +
or O +
in O +
the O +
control O +
of O +
cancer O -
. O +

There O +
are O +
several O +
natural O +
products O +
of O +
plant O +
origin O +
( O -
phytochemicals O -
) O +
that O +
are O +
of O +
potential O +
value O +
as O +
chemopreventive O +
or O +
therapeutic O +
agents O -
. O +

As O +
therapeutic O +
agents O -
, O +
the O +
phytochemicals O +
kill O +
the O +
cancer O +
cells O +
or O +
stop O +
their O +
growth O -
, O +
leading O +
to O +
cancer O +
remission O -
. O +

Some O +
of O +
the O +
new O +
cancer O +
chemotherapeutic O +
agents O +
derived O +
from O +
plants O +
in O +
current O +
clinical O +
use O +
are O +
paclitaxel O +
( O -
Taxol O -
) O -
, O +
vincristine O +
( O -
Oncovin O -
) O -
, O +
podophyllotoxin O +
and O +
captothecin O +
( O -
Pezutto O -
, O +
1997 O +
) O -
. O +

A O +
screening O +
test O +
using O +
human O +
cancer O +
cell O +
lines O +
is O +
usually O +
performed O +
as O +
an O +
initial O +
step O +
in O +
the O +
evaluation O +
of O +
chemicals O +
for O +
cancer O +
prevention O +
and O +
treatment O +
( O -
Skehan O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

Those O +
compounds O +
that O +
are O +
found O +
to O +
be O +
potent O +
in O +
killing O +
cancer O +
cells O +
or O +
inhibiting O +
cell O +
growth O +
are O +
then O +
further O +
screened O +
for O +
their O +
ability O +
to O +
suppress O +
the O +
growth O +
of O +
tumours O +
in O +
animal O +
models O -
. O +

One O +
group O +
of O +
compounds O +
with O +
potential O +
antitumour O +
activities O +
are O +
flavonoids O -
, O +
which O +
are O +
either O +
synthetic O +
or O +
natural O +
constituents O +
of O +
foods O +
or O +
drink O +
( O -
tea O +
and O +
fruit O +
juices O -
) O +
consumed O +
by O +
humans O -
. O +

Flavonoids O +
are O +
composed O +
of O +
different O +
chemical O +
classes O +
such O +
as O +
flavones O +
( O -
7,8-benzoflavone O +
or O +
α O +
-naphthoflavone O -
) O -
, O +
isoflavones O +
( O -
genistein O -
) O -
, O +
flavonols O +
( O -
quercetin O -
) O -
, O +
flavanols O +
[ O -
( O -
+ O -
) O -
-catechin O -
] O -
, O +
flavanones O +
( O -
naringenin O -
) O +
and O +
chalcones O +
( O -
xanthohumol O -
) O -
. O +

These O +
compounds O +
differ O +
in O +
the O +
level O +
of O +
oxidation O +
of O +
the O +
flavane O +
nucleus O +
and O +
in O +
the O +
number O +
and O +
position O +
of O +
hydroxyl O +
and O +
methoxyl O +
substituents O +
( O -
Lee O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

Flavanones O +
lack O +
the O +
double O +
bond O +
in O +
the O +
2,3-position O +
of O +
the O +
C O +
ring O +
present O +
in O +
the O +
flavane O +
nucleus O -
. O +

Opening O +
of O +
the O +
C O -
- O -
ring O +
of O +
naringenin O +
yields O +
the O +
chalcone O -
, O +
chalconaringenin O -
. O +

Chalcones O +
are O +
open O +
C O -
- O -
ring O +
flavonoids O +
in O +
which O +
the O +
two O +
aromatic O +
rings O +
are O +
joined O +
by O +
a O +
three O -
- O -
carbon O +
α O +
, O -
β O +
-unsaturated O +
carbonyl O +
system O +
( O -
Bohm O -
, O +
1994 O +
) O -
. O +

Chalcones O +
are O +
converted O +
to O +
flavanones O +
chemically O +
by O +
treatment O +
of O +
the O +
former O +
with O +
sodium O +
acetate O +
in O +
methanolic O +
solution O +
or O +
enzymatically O +
by O +
chalcone B-Gene +
isomerase I-Gene +
( O -
Stevens O +
et O +
al. O +
1997 O -
, O +
1998 O +
) O -
. O +

Flavonoids O -
, O +
including O +
chalcones O +
and O +
flavanones O -
, O +
have O +
been O +
shown O +
to O +
inhibit O +
the O +
proliferation O +
of O +
cancer O +
cells O +
and O +
inhibit O +
tumour O +
growth O +
( O -
Anto O +
et O +
al. O -
, O +
1995 O +
; O +
De O +
Vincenzo O +
et O +
al. O -
, O +
1995 O +
; O +
Middleton O +
and O +
Kandaswami O -
, O +
1994 O +
; O +
Satomi O -
, O +
1993 O +
; O +
Seo O +
et O +
al. O -
, O +
1997 O +
; O +
Wattenberg O +
et O +
al. O -
, O +
1994 O +
; O +
Yit O +
and O +
Das O -
, O +
1994 O +
) O -
. O +

The O +
biological O +
effects O +
of O +
the O +
chalcones O +
depend O +
on O +
their O +
chemical O +
structure O -
. O +

For O +
example O -
, O +
methyl O +
and O +
hydroxy O +
substituted O +
chalcones O +
are O +
cytotoxic O +
in O +
Ehrlich O +
ascites O +
cells O +
and O +
Dalton O -
's O +
lymphoma O +
ascites O +
cells O -
, O +
whereas O +
only O +
hydroxy O +
substituted O +
chalcones O +
reduce O +
ascites O +
tumours O +
in O +
mice O +
( O -
Anto O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

Of O +
several O +
chalcones O +
studied O -
, O +
3′-methyl-3-hydroxy O -
- O -
chalcone O +
showed O +
the O +
strongest O +
antitumour O +
and O +
antitumour O -
- O -
promoting O +
activity O +
( O -
Nishino O +
et O +
al. O -
, O +
1993 O +
; O +
Satomi O -
, O +
1993 O +
; O +
Shibata O -
, O +
1994 O +
) O -
. O +

This O +
compound O +
was O +
found O +
to O +
inhibit O +
the O +
proliferation O +
of O +
various O +
kinds O +
of O +
human O +
malignant O +
tumour O +
cells O +
representing O +
gastric O +
cancer O -
, O +
cervical O +
cancer O -
, O +
pancreatic O +
cancer O +
and O +
neuroblastoma O +
( O -
Satomi O -
, O +
1993 O +
) O -
. O +

Thus O -
, O +
substitutions O +
on O +
the O +
chalcone O +
structure O +
have O +
a O +
profound O +
influence O +
on O +
the O +
anticarcinogenic O +
effects O +
of O +
chalcone O +
compounds O -
. O +

Recently O -
, O +
six O +
chalcones O +
( O -
xanthohumol O -
, O +
2′,4′,6′,4-tetrahydroxy-3′-prenylchalcone O -
, O +
2′,4′,6′,4-tetrahydroxy-3′-geranylchalcone O -
, O +
5′-prenylxanthohumol O -
, O +
dehydrocycloxanthohumol O +
and O +
dehydrocycloxanthohumol O +
hydrate O -
) O +
and O +
three O +
flavanones O +
( O -
isoxanthohumol O -
, O +
6-prenylnaringenin O +
and O +
8-prenylnaringenin O -
) O +
have O +
been O +
isolated O +
from O +
hops O +
by O +
Stevens O +
et O +
al. O +
( O -
1997 O -
) O +
. O +

Four O +
of O +
the O +
hop O +
flavonoids O +
with O +
prenyl O +
groups O +
( O -
xanthohumol O -
, O +
isoxanthohumol O -
, O +
6-prenylnaringenin O +
and O +
8-prenylnaringenin O -
) O +
are O +
found O +
in O +
hopped O +
beers O +
( O -
Stevens O +
et O +
al. O +
1998 O -
, O +
1999 O +
) O -
. O +

Xanthohumol O +
is O +
the O +
most O +
abundant O +
prenylated O +
flavonoid O +
in O +
hops O +
whereas O +
isoxanthohumol O +
is O +
the O +
most O +
abundant O +
flavonoid O +
in O +
all O +
types O +
of O +
beer O +
tested O +
( O -
Stevens O +
et O +
al. O -
, O +
1998 O +
, O +
1999 O -
) O -
. O +

Isoxanthohumol O +
in O +
beer O +
is O +
produced O +
by O +
the O +
isomerization O +
of O +
xanthohumol O +
during O +
the O +
brewing O +
process O +
( O -
Stevens O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

The O +
potential O +
of O +
the O +
major O +
prenylated O +
hop O +
compounds O -
, O +
xanthohumol O +
and O +
isoxanthohumol O -
, O +
as O +
antineoplastic O +
agents O +
is O +
not O +
known O -
. O +

Other O +
prenylated O +
flavonoids O +
display O +
cytotoxic O +
activity O +
against O +
several O +
human O +
cancer O +
cell O +
lines O +
( O -
Seo O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

It O +
is O +
possible O +
that O +
the O +
prenylated O +
flavonoids O +
from O +
hops O +
and O +
beer O +
may O +
have O +
the O +
ability O +
to O +
inhibit O +
the O +
proliferation O +
of O +
cancer O +
cells O -
, O +
making O +
them O +
potentially O +
useful O +
as O +
cancer O +
chemopreventive O +
agents O -
. O +

Thus O -
, O +
the O +
objective O +
of O +
this O +
research O +
project O +
was O +
to O +
examine O +
the O +
antiproliferative O +
and O +
cytotoxic O +
activities O +
of O +
prenylated O +
flavonoids O +
from O +
hops O +
( O -
Humulus O +
lupulus O +
) O +
in O +
human O +
breast O +
cancer O +
( O -
MCF-7 O -
) O -
, O +
colon O +
cancer O +
( O -
HT-29 O -
) O +
and O +
ovarian O +
cancer O +
( O -
A-2780 O -
) O +
cells O +
in O +
vitro O +
. O +

The O +
cytotoxicity O +
of O +
these O +
hop O +
compounds O +
in O +
primary O +
cultures O +
of O +
rat O +
hepatocytes O +
was O +
also O +
evaluated O +
in O +
an O +
effort O +
to O +
determine O +
their O +
potential O +
to O +
cause O +
liver O +
toxicity O +
in O +
the O +
intact O +
animal O -
. O +

Hepatic O +
toxicity O +
is O +
one O +
of O +
the O +
early O +
issues O +
that O +
need O +
to O +
be O +
addressed O +
in O +
drug O +
development O +
and O +
is O +
therefore O +
pertinent O +
in O +
our O +
investigation O +
on O +
the O +
overall O +
evaluation O +
of O +
hop O +
flavonoids O +
as O +
potential O +
preventive O +
agents O +
for O +
cancer O +
in O +
humans O -
. O +

2 O +
Materials O +
and O +
Methods O +
2.1 O +
Chemicals O +
The O +
chalcone O +
compounds O +
( O -
Fig. O +
1 O +
) O +
tested O +
for O +
their O +
growth O -
- O -
inhibitory O +
activities O +
were O +
xanthohumol O +
( O -
XN O -
) O -
, O +
2′,4′,6′,4-tetrahydroxy-3′-prenylchalcone O +
( O -
TP O -
) O -
, O +
2′,4′,6′,4-tetrahydroxy-3′-geranylchalcone O +
( O -
TG O -
) O -
, O +
dehydrocycloxanthohumol O +
( O -
DX O -
) O -
, O +
and O +
dehydrocycloxanthohumol O +
hydrate O +
( O -
DH O -
) O -
. O +

The O +
other O +
chalcone O -
, O +
5′-prenylxanthohumol O -
, O +
isolated O +
from O +
hops O +
was O +
not O +
available O +
in O +
sufficient O +
quantities O +
for O +
this O +
study O -
. O +

Isoxanthohumol O +
( O -
IX O -
) O -
, O +
a O +
flavanone O +
derivative O +
of O +
XN O +
which O +
is O +
present O +
in O +
hops O +
( O -
Stevens O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
was O +
also O +
examined O +
for O +
its O +
antiproliferative O +
activity O +
for O +
comparative O +
purposes O -
. O +

Sulforhodamine O +
B O +
( O -
SRB O -
) O +
was O +
obtained O +
from O +
Sigma O +
Chemical O +
Co. O +
( O -
St O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

Culture O +
media O +
and O +
supplements O +
were O +
purchased O +
from O +
Gibco O +
BRL O +
( O -
Grand O +
Island O -
, O +
NY O -
, O +
USA O -
) O -
. O +

Collagenase B-Gene +
( O -
Type O +
2 O -
) O +
was O +
obtained O +
from O +
Worthington O +
Biochemical O +
Corporation O +
( O -
Freehold O -
, O +
NJ O -
) O -
. O +

[ O -
Methyl O +
-3 O +
H O -
] O -
thymidine O +
( O -
25 O +
μ O +
Ci O -
/ O -
μ O +
mol O -
) O +
was O +
purchased O +
from O +
Amersham O +
( O -
Arlington O +
Heights O -
, O +
IL O -
, O +
USA O -
) O -
. O +

2.2 O +
Cell O +
cultures O +
Three O +
established O +
human O +
cancer O +
cell O +
lines O +
[ O -
oestrogen B-Gene +
receptor I-Gene -
- O -
positive O +
breast O +
cancer O +
cells O +
( O -
MCF-7 O -
) O -
, O +
human O +
colon O +
cancer O +
cells O +
( O -
HT-29 O -
) O +
and O +
human O +
ovarian O +
cancer O +
cells O +
( O -
A-2780 O -
) O -
] O +
were O +
used O +
for O +
the O +
cytotoxicity O +
studies O -
. O +

These O +
cell O +
lines O +
( O -
except O +
A-2780 O -
) O +
were O +
obtained O +
from O +
the O +
American O +
Type O +
Culture O +
Collection O +
( O -
ATCC O -
) O +
( O -
Rockville O -
, O +
MD O -
, O +
USA O -
) O -
. O +

The O +
ovarian O +
cancer O +
cell O +
line O -
, O +
A-2780 O -
, O +
was O +
generously O +
provided O +
by O +
Dr O +
Raymond O +
Taetle O -
, O +
MD O -
, O +
Arizona O +
Cancer O +
Center O -
, O +
Tucson O -
, O +
AZ O -
. O +

2.3 O +
Sulforhodamine O +
assay O +
The O +
sulforhodamine O +
B O +
( O -
SRB O -
) O +
assay O -
, O +
developed O +
by O +
the O +
National O +
Cancer O +
Institute O +
for O +
in O +
vitro O +
antitumour O +
screening O +
( O -
Rubinstein O +
et O +
al. O -
, O +
1990 O +
; O +
Skehan O +
et O +
al. O -
, O +
1990 O +
) O -
, O +
was O +
employed O +
to O +
determine O +
the O +
relative O +
potencies O +
of O +
the O +
individual O +
hop O +
compounds O +
in O +
inhibiting O +
the O +
growth O +
of O +
cancer O +
cells O +
and O +
in O +
determining O +
the O +
differential O +
sensitivities O +
of O +
three O +
human O +
cancer O +
cell O +
lines O +
to O +
the O +
antiproliferative O +
effects O +
of O +
the O +
individual O +
flavonoids O -
. O +

The O +
SRB O +
assay O +
measures O +
whole O -
- O -
culture O +
protein B-Gene +
content O +
as O +
an O +
index O +
of O +
tumour O +
cell O +
viability O -
. O +

Experimental O +
cell O +
cultures O +
were O +
plated O +
on O +
a O +
96-well O +
microtitre O +
plate O +
( O -
Costar O -
, O +
Cambridge O -
, O +
MA O -
, O +
USA O -
) O -
, O +
with O +
each O +
well O +
containing O +
0.2 O +
ml O +
growth O +
medium O +
per O +
well O +
at O +
a O +
density O +
of O +
5 O -
× O -
103 O +
cells O -
/ O -
well O -
. O +

After O +
1 O +
or O +
2 O +
days O +
of O +
incubation O +
at O +
37 O -
° O -
C O +
in O +
a O +
humidified O +
atmosphere O +
of O +
95 O -
% O +
air O -
/ O -
5 O -
% O +
CO2 O +
, O +
the O +
cells O +
( O -
30–40 O -
% O +
confluent O -
) O +
were O +
exposed O +
to O +
culture O +
medium O +
containing O +
the O +
hop O +
flavonoids O +
at O +
varying O +
concentrations O +
( O -
0.01 O -
, O +
0.1 O -
, O +
1.0 O -
, O +
10 O -
, O +
or O +
100 O +
μ O +
m O +
) O -
. O +

The O +
flavonoids O +
were O +
initially O +
dissolved O +
in O +
ethanol O +
before O +
being O +
added O +
to O +
the O +
culture O +
media O -
. O +

Vehicle O -
- O -
treated O +
controls O +
contained O +
ethanol O +
at O +
the O +
same O +
concentration O +
( O -
0.1 O -
% O -
) O +
as O +
in O +
the O +
treated O +
media O -
. O +

The O +
culture O +
medium O +
was O +
phenol O +
red O -
- O -
free O +
RPMI O +
( O -
for O +
HT-29 O +
and O +
A-2780 O -
) O +
or O +
Ham O -
's O +
F-12 O -
/ O -
DMEM O +
( O -
FD O -
) O +
( O -
for O +
MCF-7 O -
) O +
supplemented O +
with O +
5 O -
% O +
foetal O +
bovine O +
serum O +
( O -
FBS O -
) O +
plus O +
penicillin O +
( O -
100 O +
U O -
/ O -
ml O -
) O +
and O +
streptomycin O +
( O -
100 O +
μ O +
g O -
/ O -
ml O -
) O -
. O +

The O +
cell O +
doubling O +
times O +
in O +
these O +
media O +
were O +
38 O -
, O +
30 O +
and O +
48 O +
hr O +
for O +
MCF-7 O -
, O +
HT-29 O +
and O +
A-2780 O +
cells O -
, O +
respectively O -
. O +

2 O -
, O +
4 O +
or O +
6 O +
days O +
following O +
incubation O +
with O +
the O +
test O +
materials O +
or O +
ethanol O +
( O -
control O +
cultures O -
) O -
, O +
the O +
culture O +
medium O +
was O +
aspirated O +
and O +
the O +
cells O +
were O +
fixed O +
by O +
gentle O +
addition O +
of O +
200 O +
μ O +
l O +
cold O +
10 O -
% O +
trichloroacetic O +
acid O +
( O -
TCA O -
) O -
. O +

The O +
control O +
cells O +
were O +
in O +
the O +
proliferative O +
stage O +
during O +
the O +
6-day O +
period O +
and O +
were O +
semiconfluent O +
or O +
100 O -
% O +
confluent O +
after O +
6 O +
days O -
. O +

The O +
plates O +
were O +
incubated O +
for O +
1 O +
hr O +
at O +
4 O -
° O -
C O +
and O +
then O +
washed O +
five O +
times O +
with O +
tap O +
water O +
to O +
remove O +
TCA O -
. O +

Plates O +
were O +
air O -
- O -
dried O +
and O +
then O +
stained O +
for O +
30 O +
min O +
with O +
0.4 O -
% O +
( O -
w O -
/ O -
v O -
) O +
SRB O +
dissolved O +
in O +
1 O -
% O +
acetic O +
acid O -
. O +

SRB O +
was O +
removed O +
and O +
cultures O +
were O +
quickly O +
rinsed O +
four O +
times O +
with O +
1 O -
% O +
acetic O +
acid O +
to O +
remove O +
unbound O +
dye O -
. O +

Residual O +
wash O +
solution O +
was O +
removed O +
and O +
the O +
cultures O +
were O +
air O -
- O -
dried O -
. O +

The O +
bound O +
dye O +
was O +
then O +
solubilized O +
with O +
200 O +
μ O +
l O +
10 O +
mm O +
unbuffered O +
Tris O +
base O +
( O -
pH O +
10.5 O -
) O -
. O +

The O +
absorbance O +
of O +
each O +
well O +
at O +
564 O +
nm O +
was O +
read O +
in O +
a O +
SpectraMax O +
250 O +
microplate O +
reader O +
( O -
Molecular O +
Devices O -
, O +
Menlo O +
Park O -
, O +
CA O -
, O +
USA O -
) O -
. O +

At O +
day O +
zero O +
( O -
day O +
of O +
treatment O -
) O -
, O +
the O +
readings O +
of O +
the O +
control O +
wells O +
in O +
the O +
96-well O +
plates O +
ranged O +
from O +
0.4 O +
to O +
0.6 O +
OD O -
. O +

The O +
antiproliferative O +
activity O +
was O +
calculated O +
from O +
the O +
ratio O +
of O +
the O +
absorbance O +
readings O +
of O +
the O +
treated O +
wells O +
to O +
those O +
of O +
the O +
control O +
wells O -
. O +

Vehicle O -
- O -
treated O +
control O +
cells O +
were O +
grown O +
in O +
four O +
wells O +
in O +
every O +
96-well O +
plate O +
used O -
. O +

For O +
every O +
cell O +
line O -
, O +
all O +
the O +
flavonoids O +
were O +
tested O +
simultaneously O +
at O +
the O +
designated O +
times O +
to O +
avoid O +
day O -
- O -
to O -
- O -
day O +
variation O -
. O +

At O +
each O +
time O +
period O -
, O +
intra O -
- O -
assay O +
( O -
plate O +
to O +
plate O -
) O +
variation O +
in O +
vehicle O -
- O -
treated O +
cells O +
was O +
minimal O +
as O +
shown O +
by O +
standard O +
errors O +
of O +
4 O -
% O +
or O +
less O +
from O +
three O +
individual O +
plates O -
. O +

For O +
example O -
, O +
the O +
absorbance O +
reading O +
( O -
mean±SEM O -
) O +
of O +
vehicle O -
- O -
treated O +
control O +
cells O +
in O +
three O +
plates O +
( O -
four O +
wells O +
per O +
plate O -
) O +
after O +
2 O +
days O +
of O +
treatment O +
of O +
MCF-7 O +
cells O +
was O +
1.53±0.03 O -
. O +

The O +
average O +
of O +
four O +
wells O +
per O +
treatment O +
was O +
used O +
for O +
the O +
calculation O +
of O +
the O +
IC50 O +
( O -
the O +
concentration O +
of O +
flavonoid O +
resulting O +
in O +
a O +
50 O -
% O +
inhibition O +
of O +
cell O +
growth O -
) O +
using O +
the O +
Data O +
Analysis O +
and O +
Technical O +
Graphics O +
software O +
( O -
Origin O +
5.0 O -
) O +
from O +
Microcal O +
Software O -
, O +
Inc. O -
, O +
Northampton O -
, O +
MA O -
, O +
USA O -
. O +

2.4 O +
Effects O +
of O +
XN O +
and O +
IX O +
on O +
viability O +
of O +
MCF-7 O +
cells O +
determined O +
by O +
the O +
trypan O +
blue O +
exclusion O +
method O +
MCF-7 O +
cells O +
( O -
50,000 O +
cells O -
/ O -
well O -
) O +
were O +
seeded O +
into O +
12-well O +
plates O +
( O -
Corning O -
) O +
in O +
a O +
final O +
volume O +
of O +
1 O +
ml O +
phenol O +
red O -
- O -
free O +
Ham O -
's O +
F-12 O -
/ O -
DMEM O +
containing O +
10 O -
% O +
FBS O -
. O +

After O +
24 O +
hr O +
in O +
culture O -
, O +
the O +
cells O +
were O +
treated O +
with O +
XN O +
or O +
IX O +
at O +
concentrations O +
of O +
0.01 O -
, O +
0.1 O -
, O +
1.0 O -
, O +
10 O +
and O +
100 O +
μ O +
m O +
in O +
FD O +
medium O +
containing O +
5 O -
% O +
FBS O -
. O +

Control O +
cells O +
were O +
incubated O +
under O +
identical O +
conditions O +
in O +
1 O +
ml O +
culture O +
medium O +
containing O +
0.1 O -
% O +
ethanol O -
. O +

After O +
8 O -
, O +
24 O +
and O +
48 O +
hr O +
of O +
treatment O -
, O +
the O +
cells O +
were O +
trypsinized O +
and O +
cells O +
were O +
counted O +
in O +
a O +
haemacytometer O +
using O +
the O +
trypan O +
blue O +
exclusion O +
method O +
to O +
quantify O +
cell O +
viability O -
. O +

To O +
determine O +
population O +
doubling O +
time O -
, O +
untreated O +
cells O +
were O +
counted O +
in O +
a O +
haemacytometer O +
after O +
incubation O +
in O +
FD O +
medium O +
containing O +
5 O -
% O +
FBS O +
for O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
4 O -
, O +
5 O +
and O +
6 O +
days O -
. O +

The O +
cytotoxic O +
and O +
antiproliferative O +
activities O +
of O +
XN O +
and O +
IX O +
on O +
MCF-7 O +
cells O +
were O +
determined O +
by O +
using O +
the O +
method O +
described O +
by O +
Jain O +
et O +
al. O +
( O -
1997 O -
) O +
as O +
follows O -
: O +
Antiproliferative O +
activity O +
= O -
( O -
Viable O +
cells O +
control O +
−Viable O +
cells O +
treated O +
) O +
Viable O +
cells O +
control O +
×100 O +
Cytotoxicity O +
= O -
% O +
cell O +
viability O +
control O +
−% O +
cell O +
viability O +
treated O +
) O +
% O +
cell O +
viability O +
control O +
×100 O +
2.5 O +
Effects O +
of O +
XN O +
and O +
IX O +
on O +
DNA O +
synthesis O +
in O +
MCF-7 O +
cells O +
MCF-7 O +
cells O +
( O -
5000 O +
cells O -
/ O -
well O -
) O +
were O +
seeded O +
into O +
96-well O +
plates O +
( O -
Corning O -
) O +
in O +
a O +
final O +
volume O +
of O +
0.2 O +
ml O +
phenol O +
red O -
- O -
free O +
FD O +
medium O +
containing O +
10 O -
% O +
FBS O -
. O +

After O +
a O +
24-hr O +
incubation O -
, O +
the O +
cells O +
were O +
treated O +
with O +
increasing O +
concentrations O +
of O +
XN O +
or O +
IX O +
in O +
FD O +
medium O +
containing O +
5 O -
% O +
FBS O -
. O +

Control O +
cells O +
were O +
incubated O +
in O +
FD O +
medium O +
containing O +
0.1 O -
% O +
ethanol O -
. O +

After O +
1 O -
, O +
2 O +
and O +
4 O +
days O -
, O +
the O +
cells O +
were O +
washed O +
once O +
with O +
phenol O -
- O -
red O +
free O +
FD O +
medium O +
and O +
then O +
incubated O +
with O +
0.2 O +
ml O +
of O +
[ O -
methyl O +
-3 O +
H O -
] O -
thymidine O +
( O -
1 O +
μ O +
Ci O -
/ O -
well O -
) O +
for O +
3 O +
hr O -
. O +

The O +
medium O +
was O +
removed O +
and O +
the O +
cells O +
were O +
fixed O +
by O +
incubation O +
in O +
10 O -
% O +
TCA O +
for O +
1 O +
hr O +
at O +
4 O -
° O -
C O -
. O +

The O +
cells O +
were O +
then O +
washed O +
twice O +
with O +
10 O -
% O +
TCA O +
to O +
remove O +
unbound O +
radioactivity O -
. O +

The O +
plates O +
were O +
air O -
- O -
dried O +
and O +
the O +
cells O +
were O +
lysed O +
with O +
1 O +
n O +
NaOH O +
( O -
0.2 O +
ml O -
/ O -
well O -
) O -
. O +

A O +
0.1-ml O +
aliquot O +
of O +
the O +
lysate O +
was O +
neutralized O +
with O +
HCl O +
prior O +
to O +
the O +
addition O +
of O +
scintillation O +
fluid O +
( O -
Opti O -
- O -
Fluor O -
) O -
. O +

The O +
radioactivity O +
of O +
the O +
samples O +
was O +
counted O +
in O +
a O +
liquid O +
scintillation O +
counter O +
( O -
Packard O +
Instrument O +
Company O -
, O +
Meriden O -
, O +
CT O -
, O +
USA O -
) O -
. O +

The O +
counts O +
( O -
disintegrations O +
per O +
min O -
) O +
of O +
four O +
wells O +
in O +
each O +
treatment O +
were O +
averaged O +
and O +
expressed O +
as O +
percent O +
of O +
controls O +
( O -
ethanol O -
- O -
treated O +
cells O -
) O -
. O +

2.6 O +
Agarose O +
gel O +
analysis O +
of O +
DNA O +
fragmentation O +
This O +
experiment O +
was O +
performed O +
to O +
determine O +
whether O +
XN O +
and O +
IX O +
induce O +
apoptosis O +
in O +
MCF-7 O +
cells O +
using O +
the O +
DNA O +
fragmentation O +
assay O +
on O +
agarose O +
gels O -
. O +

Semiconfluent O +
MCF-7 O +
cells O +
growing O +
in O +
12-well O +
plates O +
were O +
incubated O +
in O +
FD O +
medium O +
containing O +
5 O -
% O +
FBS O +
and O +
different O +
concentrations O +
( O -
0.1 O -
, O +
0.5 O -
, O +
1 O -
, O +
5 O -
, O +
10 O -
, O +
40 O +
and O +
100 O +
μ O +
m O +
) O +
of O +
XN O +
or O +
IX O -
. O +

Control O +
wells O +
contained O +
0.1 O -
% O +
ethanol O +
instead O +
of O +
flavonoids O -
. O +

After O +
8 O +
or O +
24 O +
hr O +
of O +
incubation O +
at O +
37 O -
° O -
C O +
in O +
5 O -
% O +
CO2 O +
, O +
the O +
test O +
media O +
were O +
collected O +
in O +
microfuge O +
tubes O +
and O +
200 O +
μ O +
l O +
lysis O +
buffer O +
( O -
DNAzol O +
Reagent O -
, O +
Gibco O -
/ O -
BRL O -
) O +
was O +
added O +
to O +
each O +
well O -
. O +

The O +
tubes O +
containing O +
the O +
test O +
media O +
were O +
centrifuged O +
at O +
10,000 O +
g O +
for O +
10 O +
min O -
. O +

The O +
supernatant O +
was O +
removed O +
and O +
50 O +
μ O +
l O +
lysis O +
buffer O +
was O +
added O +
to O +
each O +
tube O -
. O +

For O +
each O +
sample O -
, O +
the O +
lysate O +
from O +
the O +
wells O +
was O +
combined O +
with O +
lysate O +
in O +
the O +
microfuge O +
tube O -
. O +

Absolute O +
ethanol O +
( O -
150 O +
μ O +
l O -
) O +
was O +
added O +
to O +
each O +
tube O +
containing O +
the O +
combined O +
lysate O +
to O +
precipitate O +
the O +
DNA O -
. O +

The O +
DNA O +
was O +
spooled O +
with O +
a O +
pipette O +
tip O +
and O +
attached O +
to O +
the O +
wall O +
near O +
the O +
top O +
of O +
the O +
tube O -
. O +

The O +
supernatant O +
was O +
carefully O +
aspirated O +
and O +
the O +
DNA O +
remaining O +
in O +
the O +
tube O +
was O +
washed O +
with O +
0.5 O +
ml O +
of O +
95 O -
% O +
ethanol O -
. O +

The O +
DNA O +
was O +
air O -
- O -
dried O -
, O +
dissolved O +
in O +
100 O +
μ O +
l O +
sterile O +
water O +
and O +
an O +
aliquot O +
was O +
used O +
for O +
DNA O +
estimation O +
from O +
the O +
absorbance O +
reading O +
at O +
260 O +
nm O -
. O +

The O +
isolated O +
DNA O +
( O -
6 O +
μ O +
g O -
) O +
was O +
electrophoresed O +
on O +
a O +
1.5 O -
% O +
agarose O +
gel O +
containing O +
ethidium O +
bromide O +
for O +
1.5 O +
hr O +
in O +
TAE O +
buffer O +
( O -
40 O +
mm O +
Tris O -
- O -
acetate O +
and O +
1 O +
mm O +
EDTA O -
, O +
pH O +
8) O -
. O +

Gels O +
were O +
stained O +
with O +
ethidium O +
bromide O -
, O +
then O +
destained O +
in O +
water O +
containing O +
RNAse B-Gene +
A I-Gene +
and O +
viewed O +
on O +
a O +
UV O +
transilluminator O -
. O +

Photos O +
were O +
taken O +
using O +
a O +
digital O +
camera O +
attached O +
to O +
a O +
computer O +
with O +
a O +
video O +
processor O +
( O -
UVP O +
Image O +
Store O +
7500 O -
, O +
Ultra O +
Violet O +
Products O -
, O +
Upland O -
, O +
CA O -
, O +
USA O -
) O -
. O +

2.7 O +
Preparation O +
and O +
treatment O +
of O +
primary O +
cultures O +
of O +
rat O +
hepatocytes O +
Primary O +
cultures O +
of O +
rat O +
hepatocytes O +
were O +
obtained O +
from O +
8–11-day O -
- O -
old O +
Sprague O -
– O -
Dawley O +
rats O +
using O +
a O +
procedure O +
originally O +
described O +
by O +
Acosta O +
et O +
al. O +
( O -
1980 O -
) O +
. O +

The O +
liver O +
was O +
perfused O +
by O +
retrograde O +
perfusion O +
of O +
the O +
portal O +
vein O +
with O +
a O +
modified O +
Hanks O -
' O +
calcium O -
- O -
free O +
balanced O +
salt O +
solution O +
containing O +
collagenase B-Gene +
Type I-Gene +
II I-Gene +
( O -
80 O +
U O -
/ O -
ml O -
) O -
. O +

The O +
pellet O +
( O -
hepatocytes O -
) O -
, O +
obtained O +
after O +
several O +
steps O +
of O +
mechanical O +
dissociation O +
and O +
low O -
- O -
speed O +
centrifugation O +
of O +
the O +
tissue O +
homogenates O -
, O +
was O +
resuspended O +
in O +
Williams O -
' O +
medium O +
E O +
containing O +
0.001 O -
% O +
( O -
w O -
/ O -
v O -
) O +
insulin O -
, O +
0.005 O -
% O +
( O -
w O -
/ O -
v O -
) O +
hydrocortisone O -
, O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
newborn O +
bovine O +
serum O -
, O +
potassium O +
penicillin O +
G O +
( O -
200 O +
U O -
/ O -
ml O -
) O +
streptomycin O +
sulfate O +
( O -
200 O +
μ O +
g O -
/ O -
ml O -
) O -
, O +
and O +
amphotericin O +
B O +
( O -
4 O +
μ O +
g O -
/ O -
ml O -
) O -
. O +

The O +
cell O +
suspension O +
was O +
strained O +
through O +
a O +
sterile O +
nylon O +
strainer O +
( O -
100 O +
μ O +
m O -
) O +
into O +
a O +
50-ml O +
centrifuge O +
tube O -
. O +

Cell O +
viability O +
was O +
greater O +
than O +
95 O -
% O +
as O +
determined O +
with O +
the O +
trypan O +
blue O +
dye O +
exclusion O +
test O -
. O +

The O +
cell O +
suspension O +
was O +
diluted O +
to O +
1.0 O -
× O -
106 O +
cells O -
/ O -
ml O +
and O +
transferred O +
to O +
24-well O +
plates O +
at O +
0.5 O +
ml O -
/ O -
well O -
. O +

Hepatocyte O +
cultures O +
were O +
grown O +
in O +
a O +
CO2 O +
incubator O +
with O +
95 O -
% O +
air O +
and O +
5 O -
% O +
CO2 O +
at O +
37 O -
° O -
C O +
and O +
maintained O +
at O +
a O +
pH O +
of O +
7.2–7.4 O -
. O +

At O +
24 O +
hr O +
from O +
the O +
initial O +
plating O -
, O +
the O +
culture O +
plate O +
was O +
shaken O +
in O +
a O +
circular O +
motion O -
, O +
cell O +
debris O +
was O +
removed O +
and O +
culture O +
medium O +
was O +
replaced O +
with O +
fresh O +
medium O -
. O +

The O +
incubation O +
medium O +
was O +
changed O +
every O +
24 O +
hr O -
. O +

Hepatocytes O +
were O +
grown O +
in O +
culture O +
to O +
near O +
confluence O +
for O +
2 O +
days O +
prior O +
to O +
treatment O +
with O +
the O +
hop O +
flavonoids O -
. O +

The O +
primary O +
hepatocyte O +
cultures O +
were O +
exposed O +
to O +
the O +
flavonoids O +
( O -
in O +
ethanol O -
) O +
at O +
concentrations O +
of O +
0 O -
, O +
0.1 O -
, O +
1.0 O -
, O +
10 O +
or O +
100 O +
μ O +
m O +
( O -
only O +
XN O +
and O +
IX O +
were O +
used O +
at O +
the O +
highest O +
concentration O -
) O -
. O +

The O +
final O +
concentration O +
of O +
ethanol O +
in O +
the O +
incubation O +
medium O +
was O +
0.1 O -
% O -
, O +
which O +
did O +
not O +
affect O +
the O +
viability O +
of O +
the O +
hepatocytes O -
. O +

Control O +
incubations O +
contained O +
ethanol O +
( O -
0.1 O -
% O -
) O -
. O +

Untreated O +
cells O +
( O -
no O +
ethanol O -
) O +
were O +
also O +
incubated O +
to O +
help O +
assess O +
the O +
effect O +
of O +
ethanol O +
itself O +
on O +
the O +
viability O +
of O +
the O +
hepatocytes O -
. O +

After O +
1 O -
, O +
6 O -
, O +
24 O +
and O +
48 O +
hr O +
of O +
incubation O -
, O +
aliquots O +
of O +
the O +
cell O +
supernatants O +
( O -
after O +
centrifugation O -
) O +
were O +
analysed O +
for O +
lactate B-Gene +
dehydrogenase I-Gene +
( O -
LDH B-Gene -
) O +
activity O +
using O +
a O +
Sigma O +
diagnostic O +
kit O +
( O -
Cat O -
. O +

No. O +
500 O -
) O +
in O +
a O +
96-well O +
microplate O +
reader O +
( O -
SpectraMax O +
250 O -
, O +
Molecular O +
Devices O -
, O +
Sunnyvale O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Enzyme O +
activity O +
was O +
expressed O +
as O +
units O -
/ O -
ml O +
of O +
culture O +
medium O -
. O +

2.8 O +
Statistical O +
analysis O +
Statistical O +
significance O +
was O +
determined O +
by O +
Student O -
's O +
t O +
-test O -
. O +

In O +
all O +
cases O -
, O +
P O +
values O +
< O -
0.05 O +
were O +
considered O +
statistically O +
significant O -
. O +

3 O +
Results O +
3.1 O +
Sulforhodamine O +
assay O +
The O +
SRB O +
assay O +
is O +
an O +
indirect O +
measure O +
of O +
cell O +
density O +
or O +
number O +
of O +
live O +
cells O +
attached O +
to O +
the O +
culture O +
plate O +
( O -
Skehan O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

As O +
shown O +
by O +
Skehan O +
et O +
al. O +
( O -
1990 O -
) O +
, O +
the O +
SRB O +
results O +
are O +
linear O +
with O +
the O +
number O +
of O +
viable O +
cells O +
and O +
protein B-Gene +
content O +
in O +
the O +
wells O +
at O +
densities O +
from O +
sparse O +
subconfluence O +
to O +
multilayered O +
supraconfluence O -
. O +

In O +
agreement O +
with O +
these O +
results O -
, O +
we O +
found O +
that O +
dead O +
cells O +
detached O +
from O +
the O +
plate O +
and O +
were O +
removed O +
with O +
the O +
culture O +
media O +
during O +
the O +
SRB O +
assay O -
. O +

Microscopic O +
examination O +
of O +
the O +
individual O +
wells O +
of O +
the O +
culture O +
plate O +
showed O +
this O +
detachment O +
of O +
dead O +
cells O -
. O +

The O +
antiproliferative O +
activity O +
was O +
then O +
measured O +
as O +
a O +
ratio O +
of O +
the O +
number O +
of O +
viable O +
cells O +
( O -
expressed O +
as O +
OD O +
units O -
) O +
in O +
flavonoid O -
- O -
treated O +
wells O +
and O +
in O +
ethanol O +
( O -
vehicle O -
) O -
-treated O +
wells O -
. O +

Cytotoxicity O +
was O +
inferred O +
from O +
the O +
SRB O +
assay O +
by O +
comparing O +
the O +
OD O +
units O +
of O +
the O +
wells O +
with O +
flavonoid O -
- O -
treated O +
cells O +
at O +
designated O +
times O +
after O +
treatment O +
with O +
those O +
wells O +
with O +
untreated O +
cells O +
at O +
day O +
zero O +
( O -
cells O +
in O +
plates O +
before O +
treatment O +
with O +
flavonoid O +
or O +
ethanol O -
) O -
. O +

Lower O +
OD O +
readings O +
after O +
2 O -
, O +
4 O +
or O +
6 O +
days O +
of O +
treatment O +
compared O +
with O +
OD O +
readings O +
at O +
day O +
zero O +
indicate O +
occurrence O +
of O +
cell O +
death O +
or O +
cytotoxicity O -
, O +
instead O +
of O +
growth O +
inhibition O +
or O +
antiproliferative O +
activity O -
. O +

With O +
this O +
method O -
, O +
our O +
results O +
showed O +
that O +
cell O +
death O +
occurred O +
in O +
the O +
MCF-7 O -
, O +
HT-29 O +
and O +
A-2780 O +
cells O +
treated O +
with O +
any O +
of O +
the O +
hop O +
flavonoids O +
when O +
used O +
at O +
100 O +
μ O +
m O +
concentration O +
( O -
data O +
not O +
shown O -
) O -
. O +

Cytotoxicity O +
of O +
the O +
flavonoids O +
at O +
this O +
concentration O +
was O +
verified O +
by O +
microscopic O +
examination O +
of O +
the O +
96-well O +
plates O -
. O +

Fig. O +
2 O +
shows O +
the O +
dose O -
– O -
response O +
relationship O +
of O +
the O +
five O +
chalcones O +
and O +
one O +
flavanone O +
( O -
IX O -
) O +
with O +
the O +
growth O +
( O -
as O +
percent O +
of O +
control O -
) O +
of O +
human O +
breast O +
cancer O +
cells O +
( O -
MCF-7 O -
) O +
after O +
a O +
2-day O +
( O -
A O -
) O +
or O +
4-day O +
( O -
B O -
) O +
period O +
of O +
treatment O -
. O +

At O +
0.1 O +
and O +
1.0 O +
μ O +
m O +
, O +
only O +
DX O +
caused O +
a O +
significant O +
inhibition O +
of O +
growth O +
of O +
breast O +
cancer O +
cells O +
after O +
2 O +
days O +
of O +
exposure O +
( O -
Fig. O +
2 O +
A O -
) O -
. O +

At O +
10 O +
μ O +
m O +
, O +
XN O +
was O +
most O +
growth O -
- O -
inhibitory O +
followed O +
by O +
DX O -
, O +
IX O +
and O +
TG O +
in O +
that O +
order O -
. O +

At O +
100 O +
μ O +
m O +
, O +
all O +
the O +
flavonoids O +
except O +
TP O +
almost O +
completely O +
inhibited O +
the O +
growth O +
of O +
breast O +
cancer O +
cells O -
. O +

A O +
greater O +
inhibition O +
of O +
growth O +
of O +
breast O +
cancer O +
cells O +
was O +
obtained O +
with O +
10 O +
μ O +
m O +
XN O -
, O +
DX O +
and O +
IX O +
at O +
4 O +
days O +
( O -
Fig. O +
2 O +
B O -
) O +
than O +
at O +
2 O +
days O +
of O +
exposure O +
and O +
XN O +
was O +
the O +
most O +
active O +
flavonoid O -
. O +

At O +
100 O +
μ O +
m O +
, O +
all O +
the O +
flavonoids O +
almost O +
completely O +
inhibited O +
the O +
growth O +
of O +
breast O +
cancer O +
cells O +
after O +
4 O +
days O +
of O +
treatment O +
( O -
Fig. O +
2 O +
B O -
) O -
. O +

The O +
effects O +
of O +
the O +
hop O +
flavonoids O +
on O +
growth O +
of O +
human O +
colon O +
cancer O +
cells O +
( O -
HT-29 O -
) O +
are O +
shown O +
in O +
Fig. O +
3 O +
. O +

Unlike O +
MCF-7 O +
cells O -
, O +
the O +
growth O +
of O +
human O +
colon O +
cancer O +
cells O +
( O -
HT-29 O -
) O +
was O +
only O +
slightly O +
inhibited O +
( O -
less O +
than O +
11 O -
% O +
inhibition O -
) O +
at O +
10 O +
μ O +
m O +
of O +
XN O +
and O +
DX O +
after O +
2 O +
days O +
of O +
treatment O +
( O -
Fig. O +
3 O +
A O -
) O -
. O +

Approximately O +
8–12 O -
% O +
of O +
the O +
HT-29 O +
cells O +
exposed O +
to O +
100 O +
μ O +
m O +
TP O -
, O +
DH O +
and O +
IX O +
survived O +
after O +
2 O +
days O +
of O +
treatment O -
. O +

After O +
4 O +
days O +
of O +
treatment O +
of O +
colon O +
cancer O +
cells O -
, O +
flavonoids O +
did O +
not O +
inhibit O +
cell O +
growth O +
at O +
10 O +
μ O +
m O +
or O +
lower O +
concentration O -
. O +

However O -
, O +
all O +
the O +
flavonoids O +
almost O +
completely O +
inhibited O +
cell O +
growth O +
at O +
100 O +
μ O +
m O +
( O -
Fig. O +
3 O +
B O -
) O -
. O +

The O +
response O +
of O +
ovarian O +
cancer O +
cells O +
( O -
A-2780 O -
) O +
to O +
the O +
antiproliferative O +
activity O +
of O +
hop O +
flavonoids O +
is O +
depicted O +
in O +
Fig. O +
4 O +
. O +

The O +
growth O +
of O +
these O +
cancer O +
cells O +
was O +
significantly O +
inhibited O +
by O +
all O +
the O +
flavonoids O +
at O +
10 O +
μ O +
m O +
and O +
by O +
XN O -
, O +
TP O +
and O +
TG O +
at O +
1 O +
μ O +
m O +
after O +
2 O +
days O +
of O +
treatment O +
( O -
Fig. O +
4 O +
A O -
) O -
. O +

Significant O +
inhibition O +
of O +
cell O +
growth O +
was O +
observed O +
even O +
at O +
0.1 O +
for O +
TP O +
and O +
TG O -
. O +

At O +
100 O +
μ O +
m O +
, O +
all O +
the O +
flavonoids O +
were O +
highly O +
toxic O +
to O +
the O +
cells O -
. O +

After O +
4 O +
days O -
, O +
none O +
of O +
the O +
flavonoids O +
( O -
at O +
0.1 O -
, O +
1 O +
or O +
10 O +
μ O +
m O +
) O -
, O +
except O +
XN O +
( O -
10 O +
μ O +
m O +
) O -
, O +
inhibited O +
the O +
growth O +
of O +
ovarian O +
cancer O +
cells O +
( O -
Fig. O +
4 O +
B O -
) O +
but O +
at O +
100 O +
μ O +
m O +
, O +
all O +
the O +
flavonoids O +
almost O +
completely O +
inhibited O +
their O +
growth O -
. O +

An O +
expanded O +
range O +
of O +
doses O +
( O -
0.01 O -
, O +
0.1 O -
, O +
1.0 O -
, O +
2.5 O -
, O +
5 O -
, O +
10 O -
, O +
20 O -
, O +
40 O -
, O +
60 O +
and O +
100 O +
μ O +
m O +
) O +
was O +
then O +
used O +
to O +
further O +
evaluate O +
the O +
relative O +
growth O -
- O -
inhibitory O +
activity O +
of O +
XN O -
, O +
DX O +
and O +
IX O +
in O +
A-2780 O +
and O +
MCF-7 O +
cells O +
by O +
calculating O +
and O +
comparing O +
their O +
IC50 O +
values O -
. O +

These O +
three O +
flavonoids O +
were O +
chosen O +
for O +
further O +
evaluation O +
because O +
they O +
differed O +
widely O +
in O +
their O +
ability O +
to O +
inhibit O +
growth O +
of O +
A-2780 O +
and O +
MCF-7 O +
cells O -
. O +

The O +
dose O -
– O -
response O +
curve O +
revealed O +
that O +
the O +
antiproliferative O +
activity O +
of O +
XN O +
at O +
10 O +
μ O +
m O +
or O +
greater O +
was O +
similar O +
at O +
2 O -
, O +
4 O +
and O +
6 O +
days O +
in O +
human O +
ovarian O +
cancer O +
cells O +
( O -
A-2780 O -
) O +
( O -
Fig. O +
5 O +
) O -
. O +

However O -
, O +
at O +
lower O +
concentrations O -
, O +
the O +
growth O -
- O -
inhibitory O +
activity O +
of O +
XN O +
to O +
A-2780 O +
cells O +
decreased O +
with O +
time O +
of O +
exposure O -
. O +

The O +
calculated O +
IC50 O +
of O +
XN O +
at O +
2 O -
, O +
4 O +
and O +
6 O +
days O +
of O +
exposure O +
were O +
0.52 O -
, O +
5.2 O +
and O +
6.7 O +
μ O +
m O +
, O +
respectively O -
. O +

Similarly O +
to O +
XN O -
, O +
DX O +
and O +
IX O +
also O +
displayed O +
lower O +
IC50 O +
values O +
in O +
A-2780 O +
cells O +
at O +
2 O +
days O +
than O +
at O +
4 O +
days O +
of O +
treatment O +
( O -
Table O +
1 O +
) O -
. O +

However O -
, O +
in O +
human O +
breast O +
cancer O +
cells O +
( O -
MCF-7 O -
) O -
, O +
the O +
flavonoids O +
( O -
XN O -
, O +
DX O +
and O +
IX O -
) O +
were O +
more O +
inhibitory O +
( O -
lower O +
IC50 O +
) O +
at O +
4 O +
days O +
than O +
at O +
2 O +
days O +
of O +
treatment O +
( O -
Table O +
1 O +
) O -
. O +

XN O +
was O +
more O +
effective O +
than O +
DX O +
or O +
IX O +
in O +
inhibiting O +
the O +
growth O +
of O +
MCF-7 O +
cells O +
at O +
both O +
times O +
of O +
exposure O -
. O +

3.2 O +
Antiproliferative O +
effects O +
of O +
XN O +
and O +
IX O +
on O +
MCF-7 O +
cells O +
as O +
determined O +
by O +
cell O +
counting O +
using O +
the O +
trypan O +
blue O +
exclusion O +
method O +
Another O +
method O +
to O +
determine O +
the O +
antiproliferative O +
activities O +
of O +
XN O +
and O +
IX O +
on O +
MCF-7 O +
cells O +
is O +
to O +
use O +
a O +
haemacytometer O +
to O +
count O +
the O +
number O +
of O +
viable O +
cells O +
remaining O +
after O +
the O +
designated O +
treatment O +
period O -
. O +

Using O +
this O +
cell O +
counting O +
method O -
, O +
it O +
was O +
determined O +
that O +
XN O +
and O +
IX O -
, O +
at O +
0.01 O +
to O +
10 O +
μ O +
m O +
, O +
did O +
not O +
affect O +
the O +
proliferation O +
of O +
MCF-7 O +
cells O +
after O +
8 O +
hr O +
of O +
treatment O +
( O -
Fig. O +
6 O +
A O -
) O -
. O +

However O -
, O +
at O +
100 O +
μ O +
m O +
, O +
both O +
flavonoids O +
significantly O +
inhibited O +
the O +
growth O +
of O +
MCF-7 O +
cells O +
during O +
the O +
same O +
period O -
. O +

After O +
1 O +
day O +
of O +
treatment O -
, O +
XN O +
significantly O +
inhibited O +
the O +
proliferation O +
of O +
MCF-7 O +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
, O +
from O +
0.01 O +
to O +
100 O +
μ O +
m O +
( O -
Fig. O +
6 O +
B O -
) O -
. O +

In O +
contrast O -
, O +
IX O +
was O +
only O +
inhibitory O +
at O +
100 O +
μ O +
m O +
. O +

After O +
2 O +
days O -
, O +
growth O +
inhibition O +
induced O +
by O +
XN O +
became O +
more O +
pronounced O +
( O -
Fig. O +
6 O +
C O -
) O -
. O +

IX O +
became O +
inhibitory O +
at O +
10 O +
μ O +
m O +
, O +
and O +
at O +
100 O +
μ O +
m O +
, O +
both O +
XN O +
and O +
IX O +
produced O +
a O +
complete O +
inhibition O +
of O +
cell O +
growth O -
. O +

The O +
population O +
doubling O +
of O +
untreated O +
MCF-7 O +
cells O +
in O +
FD O +
medium O +
containing O +
5 O -
% O +
FBS O +
was O +
estimated O +
to O +
be O +
1.3 O +
days O -
. O +

3.3 O +
Cytotoxic O +
effects O +
of O +
XN O +
and O +
IX O +
on O +
MCF-7 O +
cells O +
as O +
determined O +
by O +
cell O +
counting O +
using O +
the O +
trypan O +
blue O +
exclusion O +
method O +
Cytotoxicity O +
of O +
XN O +
and O +
IX O +
in O +
MCF-7 O +
cells O +
was O +
investigated O +
using O +
the O +
trypan O +
blue O +
exclusion O +
method O -
. O +

Neither O +
XN O +
nor O +
IX O -
, O +
at O +
0.01–10 O +
μ O +
m O +
, O +
produced O +
cytotoxicity O +
in O +
these O +
cells O +
after O +
8 O +
hr O +
of O +
treatment O +
( O -
Fig. O +
7 O +
A O -
) O -
. O +

At O +
100 O +
μ O +
m O +
, O +
these O +
two O +
flavonoids O +
were O +
toxic O +
to O +
MCF-7 O +
cells O -
. O +

After O +
24 O +
hr O -
, O +
XN O +
but O +
not O +
IX O +
was O +
slightly O +
toxic O +
at O +
10 O +
μ O +
m O +
( O -
Fig. O +
7 O +
B O -
) O -
. O +

When O +
the O +
treatment O +
period O +
was O +
increased O +
to O +
2 O +
days O -
, O +
XN O +
became O +
slightly O +
toxic O +
to O +
MCF-7 O +
cells O +
at O +
0.01 O +
μ O +
m O +
or O +
higher O +
( O -
Fig. O +
7 O +
C O -
) O -
. O +

At O +
this O +
time O -
, O +
10 O +
μ O +
m O +
IX O +
showed O +
significant O +
toxicity O +
to O +
MCF-7 O +
cells O -
. O +

At O +
100 O +
μ O +
m O +
XN O +
or O +
IX O -
, O +
virtually O +
all O +
the O +
cells O +
were O +
killed O +
after O +
2 O +
days O +
of O +
exposure O -
. O +

Microscopic O +
examination O +
showed O +
that O +
most O +
of O +
the O +
dead O +
cells O +
were O +
in O +
the O +
culture O +
media O -
, O +
not O +
attached O +
to O +
the O +
culture O +
plate O -
. O +

3.4 O +
Effects O +
of O +
XN O +
and O +
IX O +
on O +
DNA O +
synthesis O +
in O +
MCF-7 O +
cells O +
The O +
effects O +
of O +
XN O +
and O +
IX O +
on O +
DNA O +
synthesis O -
, O +
as O +
determined O +
by O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
into O +
MCF-7 O +
cells O -
, O +
are O +
shown O +
in O +
Fig. O +
8 O +
. O +

Both O +
XN O +
and O +
IX O +
caused O +
a O +
dose O -
- O -
dependent O +
inhibition O +
of O +
DNA O +
synthesis O +
after O +
one O +
day O +
of O +
treatment O +
( O -
Fig. O +
8 O +
A O -
) O -
. O +

XN O +
inhibited O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
at O +
much O +
lower O +
concentrations O +
than O +
IX O -
. O +

The O +
doses O +
at O +
which O +
a O +
significant O +
decrease O +
in O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
was O +
initially O +
observed O +
were O +
0.5 O +
μ O +
m O +
for O +
XN O +
and O +
5 O +
μ O +
m O +
for O +
IX O -
. O +

A O +
similar O +
pattern O +
of O +
inhibition O +
of O +
DNA O +
synthesis O +
was O +
obtained O +
after O +
2 O +
days O +
of O +
exposure O +
( O -
Fig. O +
8 O +
B O -
) O -
. O +

However O -
, O +
after O +
4 O +
days O -
, O +
IX O +
was O +
more O +
effective O +
than O +
XN O +
in O +
inhibiting O +
thymidine O +
incorporation O +
at O +
5 O +
μ O +
m O +
or O +
lower O +
( O -
Fig. O +
8 O +
C O -
) O -
. O +

At O +
10 O +
and O +
20 O +
μ O +
m O +
, O +
XN O +
was O +
more O +
inhibitory O +
than O +
IX O -
. O +

XN O +
caused O +
an O +
unusual O +
pattern O +
of O +
inhibition O +
of O +
thymidine O +
incorporation O +
into O +
MCF-7 O +
cells O +
in O +
that O +
a O +
significant O +
inhibition O +
was O +
observed O +
at O +
0.01 O -
, O +
0.1 O -
, O +
0.5 O -
, O +
10 O +
and O +
20 O +
μ O +
m O +
but O +
not O +
at O +
1 O +
or O +
2.5 O +
μ O +
m O +
. O +

The O +
degree O +
of O +
inhibitory O +
effect O +
of O +
XN O +
at O +
5 O +
and O +
10 O +
μ O +
m O +
was O +
relatively O +
greater O +
at O +
2 O +
days O +
than O +
at O +
4 O +
days O +
of O +
treatment O -
. O +

3.5 O +
Agarose O +
gel O +
analysis O +
of O +
DNA O +
fragmentation O +
One O +
of O +
the O +
hallmarks O +
of O +
apoptosis O +
is O +
the O +
production O +
of O +
characteristic O +
DNA O +
fragments O +
when O +
the O +
DNA O +
is O +
cleaved O +
by O +
Ca++ O +
-dependent O +
endonucleases B-Gene +
at O +
the O +
linker O +
sites O +
between O +
nucleosomes O +
( O -
Arends O +
and O +
Wyllie O -
, O +
1991 O +
) O -
. O +

The O +
ultimate O +
DNA O +
fragments O +
are O +
multimers O +
of O +
180-bp O +
fragments O +
that O +
resolve O +
into O +
a O +
" O -
DNA O +
ladder O -
" O +
during O +
electrophoresis O +
on O +
agarose O +
gels O -
. O +

Neither O +
XN O +
nor O +
IX O +
at O +
10 O -
, O +
40 O +
or O +
100 O +
μ O +
m O +
induced O +
internucleosomal O +
DNA O +
fragmentation O +
in O +
MCF-7 O +
cells O +
after O +
8 O +
( O -
Plate O +
I O +
A O -
) O +
or O +
24 O +
hr O +
( O -
Plate O +
I O +
B O -
) O +
of O +
treatment O -
. O +

3.6 O +
Toxicity O +
of O +
hop O +
flavonoids O +
in O +
rat O +
hepatocyte O +
cultures O +
The O +
toxicity O +
of O +
XN O -
, O +
TP O -
, O +
TG O -
, O +
DH O +
and O +
IX O +
in O +
primary O +
cultures O +
of O +
rat O +
hepatocytes O +
was O +
measured O +
by O +
the O +
release O +
of O +
lactate B-Gene +
dehydrogenase I-Gene +
into O +
the O +
culture O +
medium O -
. O +

Cell O +
viability O +
was O +
not O +
significantly O +
affected O +
by O +
the O +
flavonoids O +
at O +
10 O +
μ O +
m O +
or O +
lower O +
after O +
24 O +
hr O +
of O +
treatment O +
( O -
Fig. O +
9 O +
) O +
or O +
after O +
1 O -
, O +
6 O +
or O +
48 O +
hr O +
of O +
treatment O +
( O -
data O +
not O +
shown O -
) O -
. O +

At O +
100 O +
μ O +
m O +
, O +
XN O +
and O +
IX O +
were O +
highly O +
toxic O +
to O +
the O +
hepatocytes O -
. O +

The O +
toxicity O +
of O +
TP O -
, O +
TG O +
and O +
DH O +
at O +
100 O +
μ O +
m O +
was O +
not O +
evaluated O +
because O +
of O +
insufficient O +
supply O +
of O +
these O +
flavonoids O +
at O +
the O +
time O +
of O +
the O +
study O -
. O +

For O +
the O +
same O +
reason O -
, O +
no O +
toxicity O +
data O +
from O +
the O +
rat O +
hepatocyte O +
studies O +
for O +
DX O +
could O +
be O +
presented O +
in O +
this O +
report O -
. O +

Additional O +
preliminary O +
studies O +
showed O +
that O +
the O +
five O +
hop O +
flavonoids O +
do O +
not O +
inhibit O +
mitochondrial O +
respiration O +
and O +
do O +
not O +
uncouple O +
oxidative O +
phoshorylation O +
in O +
isolated O +
rat O +
liver O +
mitochondria O +
at O +
10 O +
μ O +
m O +
or O +
lower O +
( O -
R.J. O +
Rodriguez O -
, O +
C.L. O +
Miranda O -
, O +
J.F. O +
Stevens O -
, O +
M.L. O +
Deinzer O +
and O +
D.R. O +
Buhler O -
, O +
unpublished O +
observations O -
) O -
. O +

4 O +
Discussion O +
Previous O +
studies O +
have O +
shown O +
that O +
certain O +
synthesized O +
or O +
naturally O -
- O -
occurring O +
chalcone O +
compounds O +
( O -
not O +
found O +
in O +
hops O -
) O +
exhibit O +
antiproliferative O +
activities O +
in O +
human O +
cancer O +
cell O +
lines O +
( O -
De O +
Mello O +
et O +
al. O -
, O +
1974 O +
; O +
Ramanathan O +
et O +
al. O -
, O +
1993 O +
; O +
Satomi O -
, O +
1993 O +
; O +
Yit O +
and O +
Das O -
, O +
1994 O +
) O -
. O +

The O +
potency O +
of O +
the O +
chalcones O +
( O -
butein O -
, O +
2′-hydroxychalcone O -
, O +
2-hydroxychalcone O -
, O +
2′,6′-dihydroxy-4′-methoxychalcone O +
and O +
2′,4-dihydroxychalcone O -
) O +
as O +
inhibitors O +
of O +
growth O +
of O +
human O +
colon O +
adenocarcinoma O +
cell O +
line O -
, O +
CCL O +
220.1 O -
, O +
was O +
dependent O +
on O +
the O +
position O +
and O +
number O +
of O +
hydroxyl O +
groups O +
in O +
the O +
chalcone O +
nucleus O +
( O -
Yit O +
and O +
Das O -
, O +
1994 O +
) O -
. O +

In O +
both O +
primary O +
and O +
established O +
ovarian O +
cancer O +
cells O -
, O +
the O +
presence O +
of O +
an O +
α O +
-β O +
double O +
bond O -
, O +
the O +
hydroxylation O +
at O +
the O +
2 O +
or O +
3 O +
position O +
of O +
ring O +
B O +
and O +
the O +
absence O +
of O +
a O +
prenyl O +
group O +
were O +
important O +
to O +
the O +
antiproliferative O +
activity O +
of O +
chalcones O +
( O -
De O +
Vincenzo O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

Thus O -
, O +
it O +
was O +
of O +
interest O +
to O +
determine O +
whether O +
chalcone O +
compounds O +
found O +
in O +
hops O +
have O +
antiproliferative O +
effects O +
in O +
certain O +
human O +
cancer O +
cell O +
lines O -
. O +

The O +
results O +
of O +
the O +
present O +
study O +
using O +
the O +
sulforhodamine O +
assay O +
showed O +
that O +
of O +
the O +
five O +
hop O +
chalcones O +
tested O -
, O +
XN O +
was O +
the O +
most O +
effective O +
antiproliferative O +
agent O +
in O +
human O +
breast O +
cancer O +
cells O +
( O -
MCF-7 O -
) O -
, O +
colon O +
cancer O +
cells O +
( O -
HT-29 O -
) O +
and O +
ovarian O +
cancer O +
cells O +
( O -
A-2780 O -
) O -
. O +

IX O +
was O +
the O +
least O +
effective O +
inhibitor O +
of O +
growth O +
of O +
A-2780 O +
cells O +
whereas O +
TP O +
and O +
DH O +
were O +
least O +
active O +
in O +
MCF-7 O +
cells O -
. O +

Of O +
the O +
three O +
cell O +
lines O +
studied O -
, O +
A-2780 O +
was O +
more O +
sensitive O +
than O +
MCF-7 O +
cells O +
to O +
the O +
antiproliferative O +
activities O +
of O +
all O +
five O +
hop O +
flavonoids O +
tested O -
. O +

The O +
differential O +
activity O +
of O +
the O +
chalcones O +
tested O +
in O +
this O +
study O +
can O +
be O +
ascribed O +
to O +
the O +
nature O +
and O +
position O +
of O +
substituents O +
in O +
the O +
chalcone O +
molecule O -
. O +

The O +
presence O +
of O +
a O +
methoxy O +
group O +
( O -
in O +
XN O -
) O -
, O +
instead O +
of O +
a O +
hydroxyl O +
group O +
( O -
in O +
TP O -
) O +
at O +
the O +
6′ O +
position O +
in O +
the O +
A O +
ring O -
, O +
appeared O +
to O +
increase O +
the O +
growth O +
inhibitory O +
activity O +
of O +
the O +
chalcone O +
for O +
MCF-7 O +
( O -
Fig. O +
2 O +
) O +
and O +
HT-29 O +
( O -
Fig. O +
3 O +
) O +
cells O +
but O +
not O +
for O +
A-2780 O +
cells O +
( O -
Fig. O +
4 O +
) O -
. O +

Substitution O +
of O +
the O +
prenyl O +
group O +
with O +
a O +
geranyl O +
group O +
at O +
the O +
3′ O +
position O +
( O -
TP O +
to O +
TG O -
) O +
resulted O +
in O +
reduced O +
growth O +
of O +
A-2780 O +
but O +
not O +
of O +
MCF-7 O +
cells O -
. O +

The O +
addition O +
of O +
a O +
hydroxyl O +
group O +
to O +
DX O -
, O +
as O +
in O +
DH O -
, O +
decreased O +
the O +
antiproliferative O +
activity O +
in O +
MCF-7 O +
cells O -
, O +
but O +
not O +
in O +
A-2780 O +
cells O -
. O +

Conversion O +
of O +
a O +
chalcone O +
to O +
a O +
flavanone O +
( O -
XN O +
to O +
IX O -
) O +
also O +
resulted O +
in O +
reduced O +
antiproliferative O +
activity O +
in O +
MCF-7 O +
and O +
A-2780 O +
cells O -
. O +

IX O +
is O +
a O +
trace O +
component O +
of O +
hops O +
but O +
is O +
the O +
most O +
abundant O +
flavonoid O +
in O +
hopped O +
beer O +
as O +
a O +
result O +
of O +
the O +
isomerization O +
of O +
XN O +
during O +
the O +
brewing O +
process O +
( O -
Stevens O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

The O +
ovarian O +
cancer O +
cell O +
line O +
( O -
A-2780 O -
) O +
was O +
more O +
sensitive O +
than O +
the O +
colon O +
and O +
breast O +
cancer O +
cell O +
lines O +
to O +
the O +
toxic O +
effects O +
of O +
XN O -
, O +
TP O +
and O +
TG O +
after O +
2 O +
days O +
of O +
exposure O -
. O +

In O +
A-2780 O +
cells O -
, O +
these O +
chalcones O +
were O +
cytotoxic O +
at O +
concentrations O +
as O +
low O +
as O +
0.1 O +
μ O +
m O +
. O +

However O -
, O +
a O +
4-day O +
treatment O +
with O +
TP O +
or O +
TG O +
at O +
concentrations O +
up O +
to O +
10 O +
μ O +
m O +
did O +
not O +
inhibit O +
ovarian O +
cancer O +
cell O +
growth O -
. O +

Furthermore O -
, O +
the O +
IC50 O +
of O +
XN O +
increased O +
from O +
0.5 O +
μ O +
m O +
at O +
2 O +
days O +
to O +
5.2 O +
μ O +
m O +
at O +
4 O +
days O +
in O +
A-2780 O +
cells O -
. O +

The O +
increase O +
in O +
IC50 O +
values O +
in O +
these O +
cells O +
at O +
4 O +
days O +
was O +
also O +
observed O +
with O +
DX O +
and O +
IX O -
. O +

These O +
results O +
suggest O +
that O +
the O +
ovarian O +
cancer O +
cells O +
became O +
less O +
sensitive O +
to O +
the O +
hop O +
flavonoids O +
with O +
increased O +
length O +
of O +
exposure O -
. O +

There O +
are O +
several O +
possibilities O +
that O +
may O +
explain O +
the O +
decreased O +
sensitivity O +
of O +
the O +
ovarian O +
cancer O +
cells O +
with O +
increased O +
length O +
of O +
exposure O -
. O +

The O +
loss O +
of O +
antiproliferative O +
activity O +
of O +
the O +
hop O +
flavonoids O +
in O +
A-2780 O +
cells O +
could O +
be O +
attributed O +
to O +
detoxification O +
of O +
the O +
flavonoids O +
by O +
the O +
ovarian O +
cancer O +
cells O -
. O +

During O +
the O +
4-day O +
exposure O -
, O +
the O +
culture O +
medium O +
was O +
not O +
replaced O +
with O +
fresh O +
medium O +
containing O +
the O +
flavonoids O -
. O +

The O +
concentration O +
of O +
the O +
flavonoids O +
or O +
their O +
inhibitory O +
metabolites O +
may O +
have O +
decreased O +
over O +
time O +
in O +
the O +
incubation O +
medium O +
due O +
to O +
detoxification O +
or O +
non O -
- O -
enzymatic O +
degradation O -
. O +

Nielsen O +
et O +
al. O +
( O -
1998 O -
) O +
have O +
found O +
that O +
rat O +
P450 B-Gene +
enzymes I-Gene +
are O +
capable O +
of O +
hydroxylating O +
and O +
demethylating O +
flavanones O -
, O +
flavones O +
or O +
flavonols O -
. O +

Preliminary O +
studies O +
in O +
our O +
laboratory O +
showed O +
that O +
cytochrome B-Gene +
P450 I-Gene +
enzymes I-Gene +
are O +
involved O +
in O +
the O +
metabolism O +
of O +
XN O +
in O +
rat O +
liver O +
microsomes O +
( O -
unpublished O +
data O -
) O -
, O +
and O +
it O +
is O +
possible O +
that O +
the O +
human O +
cancer O +
cells O +
can O +
detoxify O +
the O +
hop O +
flavonoids O -
. O +

Studies O +
on O +
the O +
metabolic O +
transformation O +
of O +
hop O +
flavonoids O +
by O +
the O +
human O +
cancer O +
cell O +
lines O +
may O +
help O +
explain O +
the O +
differential O +
sensitivity O +
of O +
the O +
three O +
human O +
cancer O +
cells O +
to O +
these O +
compounds O -
. O +

In O +
particular O -
, O +
these O +
metabolism O +
studies O +
may O +
explain O +
why O +
the O +
hop O +
chalcones O +
were O +
not O +
potent O +
in O +
inhibiting O +
the O +
growth O +
of O +
colon O +
cancer O +
cells O +
( O -
HT-29 O -
) O +
despite O +
previous O +
studies O +
showing O +
that O +
other O +
chalcones O +
are O +
highly O +
effective O +
as O +
antiproliferative O +
agents O +
in O +
colon O +
cancer O +
cells O +
( O -
Yit O +
and O +
Das O -
, O +
1994 O +
) O -
. O +

It O +
has O +
been O +
demonstrated O +
that O +
multidrug O +
resistant O +
A2780 O +
cells O +
can O +
be O +
obtained O +
by O +
exposure O +
of O +
the O +
cells O +
to O +
drugs O +
that O +
are O +
substrates O +
for O +
the O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene -
- O -
mediated O +
drug O +
efflux O +
( O -
Chu O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

Thus O -
, O +
after O +
4 O +
days O -
, O +
the O +
A-2780 O +
cells O -
, O +
as O +
well O +
as O +
HT-29 O -
, O +
may O +
have O +
higher O +
levels O +
of O +
expression O +
of O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
that O +
would O +
act O +
as O +
an O +
efflux O +
pump O +
to O +
move O +
XN O +
out O +
of O +
the O +
cells O -
, O +
making O +
the O +
cells O +
resistant O +
to O +
the O +
flavonoids O -
. O +

However O -
, O +
certain O +
prenylated O +
flavonoids O +
have O +
been O +
shown O +
to O +
inactivate O +
the O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
by O +
bifunctional O +
interactions O +
at O +
vicinal O +
ATP O +
and O +
steroid O -
- O -
binding B-Gene +
sites I-Gene +
of O +
the O +
protein B-Gene +
( O -
Conseil O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

If O +
the O +
hop O +
flavonoids O +
block O +
the O +
action O +
of O +
this O +
protein B-Gene -
, O +
then O +
they O +
should O +
still O +
be O +
growth O -
- O -
inhibitory O +
after O +
4 O +
days O +
in O +
A-2780 O +
and O +
HT-29 O +
cells O -
. O +

Studies O +
on O +
the O +
interaction O +
of O +
the O +
hop O +
flavonoids O +
with O +
P B-Gene -
- I-Gene -
glycoprotein I-Gene +
are O +
needed O +
to O +
further O +
understand O +
the O +
mechanism O +
for O +
the O +
development O +
of O +
resistance O +
of O +
cancer O +
cells O +
to O +
hop O +
flavonoids O +
with O +
increased O +
length O +
of O +
exposure O -
. O +

To O +
further O +
differentiate O +
the O +
antiproliferative O +
activity O +
from O +
the O +
cytotoxicity O +
of O +
XN O +
and O +
IX O +
in O +
MCF-7 O +
cells O -
, O +
another O +
experiment O +
using O +
12-well O +
plates O +
was O +
performed O +
in O +
which O +
dead O +
and O +
viable O +
cells O +
in O +
each O +
well O +
were O +
counted O +
in O +
a O +
haemacytometer O +
after O +
trypan O +
blue O +
exclusion O +
staining O -
. O +

Cells O +
attached O +
to O +
the O +
plate O +
and O +
in O +
the O +
culture O +
medium O +
were O +
counted O +
at O +
time O +
zero O +
( O -
before O +
addition O +
of O +
flavonoids O -
) O +
and O +
at O +
various O +
times O +
( O -
8 O -
, O +
24 O +
and O +
48 O +
hr O -
) O +
after O +
treatment O -
. O +

The O +
results O +
indicate O +
that O +
XN O +
inhibited O +
cell O +
growth O +
after O +
24 O +
or O +
48 O +
hr O +
at O +
concentrations O +
from O +
0.01 O +
to O +
10 O +
μ O +
m O +
but O +
caused O +
little O +
or O +
no O +
toxicity O +
( O -
cell O +
death O -
) O +
to O +
the O +
cells O +
( O -
Figs. O +
6 O +
and O +
7 O +
) O -
. O +

IX O +
was O +
growth O -
- O -
inhibitory O +
at O +
10 O +
μ O +
m O +
after O +
48 O +
hr O +
of O +
treatment O -
. O +

However O -
, O +
both O +
XN O +
and O +
IX O +
inhibited O +
the O +
growth O +
of O +
MCF-7 O +
cells O +
by O +
more O +
than O +
50 O -
% O +
after O +
8 O +
hr O +
of O +
exposure O +
and O +
by O +
more O +
than O +
90 O -
% O +
or O +
greater O +
after O +
24 O +
and O +
48 O +
hr O -
. O +

The O +
antiproliferative O +
activity O +
of O +
XN O +
and O +
IX O +
at O +
100 O +
μ O +
m O +
after O +
8 O +
hr O +
was O +
not O +
completely O +
attributed O +
to O +
the O +
cytotoxic O +
effects O +
of O +
these O +
flavonoids O +
at O +
this O +
concentration O +
since O +
percent O +
viability O +
was O +
greater O +
than O +
60 O -
% O +
at O +
this O +
time O -
. O +

After O +
24 O +
and O +
48 O +
hr O -
, O +
the O +
antiproliferative O +
activity O +
of O +
XN O +
and O +
IX O +
at O +
100 O +
μ O +
m O +
was O +
almost O +
completely O +
due O +
to O +
cell O +
killing O -
, O +
not O +
inhibition O +
of O +
cell O +
division O -
. O +

The O +
same O +
explanation O +
could O +
be O +
offered O +
for O +
the O +
effects O +
of O +
other O +
flavonoids O +
used O +
at O +
100 O +
μ O +
m O +
in O +
the O +
three O +
human O +
cancer O +
cell O +
lines O +
since O +
the O +
number O +
of O +
viable O +
cells O +
( O -
based O +
on O +
sulforhodamine O +
assay O +
and O +
microscopic O +
examination O +
of O +
cell O +
cultures O -
) O +
remaining O +
after O +
treatment O +
was O +
less O +
than O +
that O +
obtained O +
before O +
treatment O +
at O +
time O +
zero O +
as O +
stated O +
above O -
. O +

Inhibition O +
of O +
DNA O +
synthesis O +
may O +
be O +
one O +
of O +
the O +
mechanisms O +
by O +
which O +
XN O +
and O +
IX O +
exert O +
their O +
antiproliferative O +
activity O +
in O +
MCF-7 O +
cells O -
. O +

As O +
shown O +
in O +
Fig. O +
8 O +
, O +
XN O +
and O +
IX O +
caused O +
a O +
dose O -
- O -
dependent O +
inhibition O +
of O +
DNA O +
synthesis O +
( O -
as O +
measured O +
by O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O -
) O +
in O +
MCF-7 O +
cells O +
after O +
1 O -
, O +
2 O +
and O +
4 O +
days O +
of O +
treatment O -
. O +

After O +
4 O +
days O -
, O +
XN O +
was O +
surprisingly O +
less O +
active O +
than O +
IX O +
at O +
5 O +
μ O +
m O +
or O +
lower O +
in O +
inhibiting O +
thymidine O +
incorporation O -
. O +

This O +
finding O +
was O +
not O +
consistent O +
with O +
the O +
greater O +
inhibition O +
of O +
cell O +
growth O +
by O +
XN O +
than O +
IX O +
( O -
Fig. O +
2 O +
and O +
Table O +
1 O +
) O -
. O +

Therefore O -
, O +
there O +
must O +
be O +
other O +
mechanisms O +
to O +
explain O +
the O +
differential O +
antiproliferative O +
activity O +
of O +
XN O +
and O +
IX O +
in O +
MCF-7 O +
cells O -
. O +

The O +
isoflavone O +
genistein O +
induces O +
cytotoxicity O +
and O +
growth O +
inhibition O +
in O +
several O +
cancer O +
cell O +
lines O +
by O +
inhibition O +
of O +
DNA O +
synthesis O -
, O +
protein B-Gene +
tyrosine I-Gene +
kinases I-Gene -
, O +
inhibition O +
of O +
DNA B-Gene +
topoisomerases I-Gene -
, O +
inhibition O +
of O +
cell O +
cycle O +
events O -
, O +
and O +
induction O +
of O +
apoptosis O +
( O -
Barnes O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

The O +
synthetic O +
flavone O +
flavopiridol O +
induces O +
also O +
growth O +
arrest O +
and O +
apoptosis O +
in O +
leukaemia O +
cells O +
( O -
Konig O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Consequently O -
, O +
it O +
is O +
possible O +
that O +
hop O +
flavonoids O +
may O +
cause O +
growth O +
arrest O +
at O +
more O +
than O +
one O +
stage O +
of O +
the O +
cell O +
cycle O -
. O +

Certain O +
prenylated O +
chalcones O +
have O +
been O +
shown O +
to O +
induce O +
apoptosis O +
in O +
MCF-7 O +
cells O +
( O -
Pharmar O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Therefore O -
, O +
apoptosis O +
may O +
be O +
one O +
of O +
the O +
mechanisms O +
by O +
which O +
hop O +
flavonoids O +
such O +
as O +
XN O +
and O +
IX O +
cause O +
cell O +
death O +
in O +
MCF-7 O +
cells O -
. O +

However O -
, O +
our O +
preliminary O +
work O +
showed O +
that O +
treatment O +
with O +
XN O +
and O +
IX O +
for O +
8 O +
or O +
24 O +
hr O +
did O +
not O +
induce O +
apoptosis O +
in O +
MCF-7 O +
cells O +
based O +
on O +
the O +
DNA O +
laddering O +
assay O +
on O +
agarose O +
gels O +
( O -
Plate O +
Plate O +
I O +
) O -
. O +

Additional O +
studies O +
using O +
other O +
methods O +
to O +
assay O +
apoptosis O +
( O -
in O +
situ O +
TdT O +
labelling O -
, O +
morphological O +
examination O +
and O +
flow O +
cytometric O +
analysis O -
) O +
are O +
needed O +
to O +
confirm O +
that O +
XN O +
and O +
IX O +
do O +
not O +
induce O +
apoptosis O +
in O +
MCF-7 O +
cells O -
. O +

The O +
potential O +
of O +
XN O +
as O +
anti O -
- O -
neoplastic O +
agent O +
for O +
breast O +
cancer O +
can O +
be O +
evaluated O +
further O +
by O +
comparing O +
its O +
ability O +
to O +
inhibit O +
growth O +
of O +
MCF-7 O +
cells O +
in O +
vitro O +
with O +
that O +
of O +
other O +
flavonoids O +
such O +
as O +
genistein O -
. O +

Genistein O +
inhibited O +
the O +
growth O +
of O +
MCF-7 O +
cells O +
( O -
based O +
on O +
SRB O +
assay O -
) O +
with O +
an O +
estimated O +
IC50 O +
greater O +
than O +
40 O +
μ O +
m O +
after O +
4 O +
days O +
of O +
exposure O +
( O -
Hoffman O -
, O +
1995 O +
) O -
. O +

Shao O +
et O +
al. O +
( O -
1998 O -
) O +
reported O +
an O +
IC50 O +
of O +
20 O +
μ O +
m O +
for O +
genistein O +
in O +
MCF-7 O +
cells O +
after O +
6 O +
days O +
of O +
treatment O -
. O +

In O +
the O +
present O +
study O -
, O +
XN O +
gave O +
an O +
IC50 O +
of O +
3.47 O +
μ O +
m O +
in O +
MCF-7 O +
cells O +
after O +
4 O +
days O +
of O +
treatment O -
. O +

As O +
an O +
inhibitor O +
of O +
DNA O +
synthesis O +
in O +
MCF-7 O +
cells O -
, O +
genistein O +
has O +
an O +
IC50 O +
of O +
12.6 O +
μ O +
m O +
at O +
2 O +
days O +
( O -
Hoffman O -
, O +
1995 O +
) O +
whereas O +
XN O +
has O +
an O +
IC50 O +
of O +
1.5 O +
μ O +
m O +
( O -
calculated O +
from O +
Fig. O +
8 O +
) O -
. O +

These O +
observations O +
suggest O +
that O +
XN O +
is O +
several O +
fold O +
more O +
potent O +
as O +
an O +
antiproliferative O +
agent O +
than O +
genistein O -
, O +
a O +
flavonoid O +
currently O +
used O +
in O +
clinical O +
trials O +
as O +
a O +
chemopreventive O +
agent O +
for O +
breast O +
cancer O +
in O +
humans O -
. O +

Two O +
citrus O +
flavanones O -
, O +
naringenin O +
and O +
hesperetin O -
, O +
have O +
been O +
shown O +
to O +
inhibit O +
the O +
proliferation O +
of O +
oestrogen B-Gene +
receptor I-Gene -
- O -
negative O +
MDA O -
- O -
MB-235 O +
and O +
oestrogen B-Gene +
receptor I-Gene -
- O -
positive O +
MCF-7 O +
human O +
breast O +
cancer O +
cells O +
as O +
determined O +
by O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
into O +
growing O +
cells O -
. O +

After O +
2 O +
days O +
of O +
treatment O +
of O +
MDA O -
- O -
MB-435 O -
, O +
both O +
flavanones O +
gave O +
an O +
IC50 O +
of O +
18 O +
μ O +
g O -
/ O -
ml O +
( O +

So O +
et O +
al. O -
, O +
1996 O +
) O +
whereas O +
in O +
MCF-7 O +
cells O -
, O +
the O +
IC50 O +
for O +
naringenin O +
and O +
hesperetin O +
were O +
18 O +
and O +
12 O +
μ O +
g O -
/ O -
ml O -
, O +
respectively O +
( O -
So O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

In O +
the O +
present O +
study O -
, O +
IX O +
inhibited O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
in O +
MCF-7 O +
cells O +
with O +
an O +
IC50 O +
of O +
10 O +
μ O +
m O +
( O -
or O +
3.54 O +
μ O +
g O -
/ O -
ml O -
) O +
suggesting O +
that O +
the O +
prenylated O +
flavanone O +
from O +
hops O +
and O +
beer O +
is O +
more O +
effective O +
than O +
the O +
citrus O +
flavanones O +
as O +
an O +
antiproliferative O +
agent O +
for O +
MCF-7 O +
cells O -
. O +

Further O +
studies O +
are O +
needed O +
to O +
demonstrate O +
whether O +
IX O +
will O +
inhibit O +
tumour O +
growth O +
of O +
MCF-7 O +
cells O +
in O +
nude O +
mice O -
. O +

In O +
conclusion O -
, O +
XN O +
appeared O +
to O +
be O +
the O +
most O +
potent O +
of O +
the O +
five O +
hop O +
flavonoid O +
tested O +
in O +
inhibiting O +
the O +
proliferation O +
of O +
three O +
human O +
cancer O +
cell O +
lines O +
( O -
MCF-7 O -
, O +
HT-29 O +
and O +
A-2780 O -
) O -
. O +

In O +
particular O -
, O +
XN O +
( O -
the O +
most O +
abundant O +
flavonoid O +
in O +
hops O -
) O +
was O +
highly O +
potent O +
in O +
suppressing O +
the O +
growth O +
of O +
human O +
breast O +
cancer O +
cells O +
( O -
MCF-7 O -
) O +
and O +
ovarian O +
cancer O +
cells O +
( O -
A-2780 O -
) O -
. O +

IX O -
, O +
the O +
flavanone O +
isomer O +
of O +
XN O +
and O +
the O +
most O +
abundant O +
prenylated O +
flavonoid O +
in O +
hopped O +
beers O -
, O +
was O +
also O +
a O +
potent O +
inhibitor O +
of O +
growth O +
of O +
MCF-7 O +
cells O +
after O +
a O +
4-day O +
exposure O -
. O +

Inhibition O +
of O +
growth O +
of O +
MCF-7 O +
cells O +
by O +
XN O +
and O +
IX O +
was O +
associated O +
with O +
inhibition O +
of O +
DNA O +
synthesis O -
. O +

These O +
findings O +
indicate O +
that O +
an O +
evaluation O +
of O +
the O +
potential O +
anticancer O +
properties O +
of O +
XN O +
and O +
IX O +
in O +
the O +
intact O +
animal O +
is O +
warranted O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
the O +
Hop O +
Research O +
Council O -
, O +
Medical O +
Research O +
Foundation O +
of O +
Oregon O -
, O +
and O +
NIEHS O +
grant O +
ES00210 O -
. O +

This O +
manuscript O +
was O +
issued O +
by O +
the O +
Oregon O +
State O +
University O +
Agricultural O +
Experiment O +
Station O +
as O +
Technical O +
Paper O +
No. O +
11318 O -
. O +

The O +
authors O +
thank O +
Sam O +
Bradford O +
and O +
Chelsea O +
Johnston O +
for O +
technical O +
assistance O -
. O +

The O +
tetrasaccharides O +
lacto O -
- O -
N O +
-tetraose O +
( O -
1 O +
) O +
and O +
lacto O -
- O -
N O +
-neotetraose O +
( O -
2 O +
) O +
are O +
amongst O +
the O +
oligosaccharides O +
isolated O +
from O +
human O +
milk O +
[ O -
1,2 O -
] O +

; O +
the O +
former O +
was O +
the O +
first O +
aminodeoxy O +
oligosaccharide O +
that O +
was O +
found O +
to O +
occur O +
free O +
in O +
nature O +
[ O -
3–5 O -
] O +
. O +

Oligosaccharides O +
1 O +
and O +
2 O +
represent O +
core O +
structural O +
elements O +
of O +
more O +
complex O +
oligosaccharides O +
in O +
human O +
milk O +
[ O -
1,2 O -
] O +
, O +
in O +
glycolipids O -
, O +
such O +
as O +
paragloboside O +
and O +
sialosylparagloboside O -
, O +
and O +
in O +
glycoproteins B-Gene -
. O +

These O +
oligosaccharides O +
are O +
useful O +
in O +
the O +
recognition O +
of O +
the O +
acceptor O +
specificity O +
of O +
glycosyltransferases B-Gene -
, O +
the O +
substrate O +
specificity O +
of O +
glycosidases B-Gene -
, O +
and O +
the O +
structure O +
of O +
antigenic O +
determinants O +
[ O -
1 O -
] O +
. O +

Thus O -
, O +
the O +
sequence O +
contained O +
in O +
lacto O -
- O -
N O +
-neotetraose O +
had O +
been O +
recognized O +
by O +
an O +
antibody B-Gene +
bound O +
to O +
granulocytes O +
that O +
was O +
obtained O +
by O +
immunization O +
with O +
normal O +
human O +
granulocytes O +
[ O -
6 O -
] O +
. O +

Paragloboside O -
, O +
a O +
lactoneotetraosyl O +
ceramide O -
, O +
was O +
first O +
isolated O +
from O +
human O +
erythrocytes O +
[ O -
7 O -
] O +
; O +
it O +
was O +
also O +
identified O +
as O +
a O +
specific O +
surface O +
component O +
of O +
virus O +
polyoma O -
- O -
transformed O +
hamster O +
embryo O +
fibroblast O +
cells O +
[ O -
8 O -
] O +
and O +
thus O +
it O +
may O +
act O +
as O +
surface O +
antigen O +
associated O +
with O +
this O +
tumor O +
[ O -
9 O -
] O +
. O +

The O +
Neu5Ac O +
α- O -
( O -
2→6 O -
) O -
-lacto O -
- O -
N O +
-neotetraose O +
was O +
found O +
to O +
cause O +
inhibition O +
of O +
the O +
bacterial O +
infection O +
of O +
a O +
human O +
patient O +
suffering O +
from O +
pneumonia O +
[ O -
10 O -
] O +
. O +

Both O +
1 O +
and O +
2 O +
act O +
as O +
bacterial O +
receptors O +
for O +
pneumococci O +
[ O -
11,12 O -
] O +
. O +

The O +
pentasaccharide O +
HSO3 O +
-3Gal O -
- O -
β- O -
( O -
1→3 O -
) O -
-GlcNAc O -
- O -
β- O -
( O -
1→3 O -
) O -
-Gal O -
- O -
β- O -
( O -
1→4 O -
) O -
Glc O +
is O +
one O +
of O +
the O +
most O +
potent O +
oligosaccharide O +
ligands O +
for O +
human O +
E B-Gene -
- I-Gene -
selectin I-Gene +
[ O -
13 O -
] O +
. O +

It O +
is O +
a O +
strong O +
supporter O +
of O +
the O +
adhesion O +
of O +
E B-Gene -
- I-Gene -
selectin I-Gene -
- O -
expressing O +
cells O +
and O +
an O +
inhibitor O +
of O +
E B-Gene -
- I-Gene -
selectin I-Gene +
adhesion O -
. O +

Such O +
inhibitors O +
may O +
be O +
used O +
for O +
the O +
treatment O +
of O +
disorders O +
of O +
inflammation O +
and O +
for O +
minimizing O +
risk O +
of O +
metastasis O +
after O +
surgery O +
reactions O +
of O +
tumors O +
[ O -
13–15 O -
] O +
. O +

Partially O +
protected O +
lacto O -
- O -
N O +
-neotetraoses O +
were O +
prepared O +
as O +
intermediates O +
for O +
the O +
synthesis O +
of O +
blood O +
group O +
I O -
- O -
active O +
biantennary O +
neolacto O -
- O -
type O +
decaosyl O +
ceramide O +
[ O -
16,17 O -
] O +
. O +

One O +
of O +
the O +
crucial O +
points O +
in O +
the O +
syntheses O +
of O +
oligosaccharides O +
incorporating O +
2-amino-2-deoxy O -
- O -
d O +
-glucose O +
necessitates O +
its O +
availability O +
as O +
a O +
donor O +
that O +
requires O +
a O +
suitable O +
protection O +
of O +
the O +
amino O +
group O -
. O +

Various O +
protecting O +
groups O +
for O +
such O +
purposes O +
are O +
now O +
available O -
. O +

Thus O -
, O +
the O +
2-deoxy-2-phthalimido O +
sugars O +
were O +
used O +
as O +
glycosyl O +
donors O +
for O +
the O +
synthesis O +
of O +
lacto O -
- O -
N O +
-neotetraose O +
derivatives O +
[ O -
16,17 O -
] O +
, O +
of O +
p O +
-nitrophenyl O +
lacto O -
- O -
N O +
-tetraoside O +
[ O -
18 O -
] O +
, O +
and O +
of O +
benzyl O +
lacto O -
- O -
N O +
-neotetraoside O +
[ O -
19 O -
] O +
. O +

Also O +
lacto O -
- O -
N O +
-biose O +
was O +
prepared O +
by O +
the O +
phthalimide O +
method O +
[ O -
20,21 O -
] O +
. O +

The O +
benzyl O +
glycoside O +
of O +
2 O +
[ O -
22 O -
] O +
as O +
well O +
as O +
the O +
ceramide O +
of O +
1 O +
[ O -
23 O -
] O +
were O +
prepared O +
by O +
using O +
2-azido-2-deoxy O +
glucose O +
as O +
a O +
precursor O +
for O +
the O +
N O +
-acetylglucosamine O +
moiety O -
. O +

The O +
methyl O +
lacto O -
- O -
N O +
-neotetraoside O +
and O +
derivatives O +
thereof O +
were O +
prepared O +
by O +
the O +
phthalimide O +
method O +
[ O -
24–26 O -
] O +
and O +
the O +
oxazoline O +
method O +
[ O -
27,28 O -
] O +
. O +

The O +
latter O +
method O +
was O +
also O +
used O +
for O +
the O +
synthesis O +
of O +
lacto O -
- O -
N O +
-tetraose O +
by O +
a O +
route O +
utilizing O +
the O +
oxazoline O +
derivative O +
of O +
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→3 O -
) O -
-d O +
-glucosamine O +
( O -
lacto O -
- O -
N O +
-biose O +
I O -
) O +
as O +
a O +
donor O +
for O +
a O +
suitably O +
protected O +
lactose O +
acceptor O +
[ O -
29–31 O -
] O +
. O +

Also O +
the O +
2-O O +
-methyl O +
derivative O +
of O +
the O +
galactose O +
moiety O +
at O +
the O +
non O -
- O -
reducing O +
end O +
has O +
been O +
prepared O +
via O +
the O +
oxazoline O +
method O +
[ O -
32 O -
] O +
. O +

Recently O -
, O +
we O +
introduced O +
the O +
dimethylmaleoyl O +
( O -
DMM O -
) O +
group O +
as O +
a O +
new O +
amino O +
protecting O +
group O +
for O +
glucosamine O +
[ O -
33 O -
] O +
. O +

Its O +
ease O +
of O +
attachment O +
and O +
subsequent O +
cleavage O +
as O +
well O +
as O +
its O +
electron O -
- O -
withdrawing O +
property O +
make O +
the O +
d O +
-glucosamine O +
derivative O +
a O +
good O +
glycosyl O +
donor O +
with O +
an O +
enforced O +
capability O +
of O +
forming O +
a O +
β O -
- O -
linkage O -
. O +

Moreover O -
, O +
versatile O +
glycosyl O +
acceptors O +
containing O +
the O +
dimethylmaleoylamido O +
group O +
could O +
also O +
be O +
generated O +
and O +
successfully O +
employed O +
in O +
glycosylation O +
reactions O +
[ O -
33 O -
] O +
. O +

Owing O +
to O +
these O +
perspectives O +
of O +
the O +
DMM O +
group O -
, O +
we O +
report O +
herein O +
synthetic O +
routes O -
, O +
using O +
this O +
group O -
, O +
to O +
the O +
biologically O +
important O +
lacto O -
- O -
N O +
-neotetraose O +
( O -
2 O +
) O +
and O +
lacto O -
- O -
N O +
-tetraose O +
( O -
1 O +
) O -
. O +

The O +
generated O +
building O +
blocks O +
also O +
allow O +
their O +
further O +
use O +
as O +
donors O +
or O +
acceptors O +
for O +
the O +
preparation O +
of O +
various O +
oligosaccharides O -
. O +

2 O +
2 O -
. O +

Results O +
and O +
discussion O +
For O +
the O +
synthesis O +
of O +
the O +
target O +
tetrasaccharides O -
, O +
final O +
linkage O +
of O +
two O +
disaccharides O +
has O +
been O +
designed O -
. O +

Thus O -
, O +
the O +
disaccharide O +
donor O +
will O +
have O +
the O +
glucosamine O +
residue O +
containing O +
the O +
DMM O +
group O +
at O +
the O +
reducing O +
end O -
. O +

The O +
required O +
disaccharide O +
donor O +
7 O +
was O +
synthesized O +
in O +
three O +
steps O +
from O +
known O +
acceptor O +
4 O +
[ O -
33 O -
] O +
by O +
its O +
galactosidation O +
with O +
known O +
trichloroacetimidate O +
3 O +
[ O -
34 O -
] O +
under O +
the O +
catalysis O +
of O +
trimethylsilyl O +
trifluoromethanesulfonate O +
( O -
Me3 O +
SiOTf O -
) O +
to O +
give O +
the O +
β O -
- O -
linked O +
disaccharide O +
5 O +
in O +
84 O -
% O +
yield O -
. O +

Its O +
1 O +
H O +
NMR O +
spectrum O +
supported O +
the O +
assignment O -
; O +
two O +
doublets O +
for O +
H-1 O +
and O +
H-1′ O +
at O +
δ O +
5.10 O +
and O +
4.61 O +
with O +
a O +
J O +
value O +
of O +
8.0 O +
Hz O +
for O +
each O +
indicated O +
the O +
axial O +
nature O +
of O +
H-1 O +
and O +
H-2 O +
in O +
both O +
rings O -
. O +

The O +
tert O +
-butyldimethylsilyl O +
( O -
TBDMS O -
) O +
group O +
was O +
cleaved O +
from O +
5 O +
with O +
tetrabutylammonium O +
fluoride O +
( O -
TBAF O -
) O +
to O +
give O +
6 O +
, O +
which O +
can O +
be O +
readily O +
transformed O +
into O +
the O +
trichloroacetimidate O +
donor O +
7 O +
. O +

Its O +
reaction O +
with O +
the O +
known O +
disaccharide O +
acceptor O +
benzyl O +
( O -
2,4,6-tri O -
- O -
O O +
-benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-2,3,6-tri O -
- O -
O O +
-benzyl O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
8 O +
) O +
[ O -
35 O -
] O +
gave O +
the O +
desired O +
tetrasaccharide O +
9 O +
; O +
the O +
13 O +
C O +
NMR O +
spectrum O +
showed O +
the O +
presence O +
of O +
four O +
signals O +
at O +
δ O +
100.20 O -
, O +
100.70 O -
, O +
102.70 O -
, O +
and O +
102.80 O +
corresponding O +
to O +
the O +
four O +
β O -
- O -
linked O +
anomeric O +
carbons O -
. O +

Deblocking O +
of O +
the O +
DMM O +
group O +
from O +
9 O +
with O +
NaOH O +
to O +
open O +
the O +
DMM O +
ring O +
followed O +
by O +
treatment O +
with O +
HCl O +
to O +
cleave O +
the O +
presumably O +
formed O +
butenolide O +
and O +
then O +
intermediate O +
acetylation O +
gave O +
10 O +
in O +
71 O -
% O +
yield O -
. O +

On O +
the O +
other O +
hand O -
, O +
using O +
hydrazine O +
hydrate O +
as O +
a O +
deblocking O +
agent O +
followed O +
by O +
acetylation O +
led O +
to O +
the O +
formation O +
of O +
10 O +
in O +
54 O -
% O +
yield O -
. O +

The O +
success O +
of O +
this O +
transformation O +
was O +
readily O +
confirmed O +
by O +
1 O +
H O +
NMR O +
spectroscopy O -
, O +
which O +
exhibited O +
the O +
disappearance O +
of O +
the O +
methyl O +
signals O +
of O +
the O +
dimethylmaleoyl O +
group O +
and O +
the O +
appearance O +
of O +
an O +
NH O +
signal O +
at O +
δ O +
5.8 O +
and O +
of O +
a O +
new O +
methyl O +
signal O -
. O +

Catalytic O +
hydrogenation O +
led O +
to O +
deblocking O +
of O +
the O +
benzyl O +
groups O +
which O -
, O +
upon O +
acetylation O -
, O +
gave O +
11 O +
in O +
95 O -
% O +
yield O +
as O +
the O +
peracetyl O +
derivative O +
of O +
2 O +
. O +

The O +
1 O +
H O +
NMR O +
spectrum O +
of O +
11 O +
indicated O +
its O +
presence O +
as O +
a O +
mixture O +
of O +
α O +
( O -
δ O +
6.23 O -
) O +
and O +
β O +
( O -
δ O +
5.64 O -
) O +
anomers O +
in O +
a O +
ratio O +
of O +
3:2 O -
. O +

Almost O +
the O +
same O +
ratio O +
was O +
also O +
reported O +
based O +
on O +
the O +
calculation O +
of O +
specific O +
rotations O +
[ O -
28 O -
] O +
and O +
1 O +
H O +
NMR O +
spectroscopy O +
[ O -
21 O -
] O +
. O +

Deacylation O +
of O +
11 O +
gave O +
2 O +
in O +
91 O -
% O +
yield O -
. O +

The O +
13 O +
C O +
NMR O +
data O +
of O +
2 O +
were O +
in O +
accordance O +
with O +
published O +
values O +
[ O -
35 O -
] O +
; O +
reacetylation O +
of O +
2 O +
led O +
again O +
to O +
compound O +
11 O +
, O +
thus O +
confirming O +
the O +
structure O +
of O +
2 O +
( O -
Scheme O +
1 O +
) O -
. O +

For O +
the O +
synthesis O +
of O +
the O +
lacto O -
- O -
N O +
-tetraose O +
1 O +
, O +
two O +
approaches O +
were O +
designed O -
. O +

Both O +
methods O +
were O +
based O +
on O +
the O +
coupling O +
of O +
a O +
disaccharide O +
donor O +
with O +
the O +
disaccharide O +
acceptor O +
8 O +
[ O -
36 O -
] O +
. O +

The O +
designation O +
of O +
these O +
two O +
routes O +
has O +
been O +
developed O +
in O +
order O +
to O +
allow O +
for O +
the O +
presence O +
of O +
temporary O +
blocking O +
groups O +
on O +
the O +
resulting O +
tetrasaccharide O +
thus O +
making O +
it O +
suitable O +
as O +
acceptor O +
for O +
other O +
mono- O +
and O +
oligosaccharide O +
donors O -
. O +

In O +
the O +
first O +
approach O +
known O +
donor O +
12 O +
[ O -
33 O -
] O +
was O +
coupled O +
with O +
8 O +
to O +
give O +
13 O +
in O +
76 O -
% O +
yield O -
. O +

Although O +
its O +
1 O +
H O +
NMR O +
spectrum O +
showed O +
a O +
doublet O +
at O +
δ O +
5.27 O +
for O +
the O +
newly O +
formed O +
glycosidic O +
bond O +
with O +
a O +
J O +
value O +
of O +
8.4 O +
Hz O +
confirming O +
its O +
β O -
- O -
configuration O -
, O +
the O +
signals O +
for O +
the O +
anomeric O +
protons O +
are O +
hidden O +
under O +
other O +
signals O -
. O +

However O -
, O +
their O +
coupling O +
with O +
H-2 O +
can O +
be O +
depicted O +
from O +
the O +
signals O +
for O +
H-2 O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
13 O +
C O +
NMR O +
spectrum O +
showed O +
signals O +
at O +
δ O +
c O +
100.30 O -
, O +
100.50 O -
, O +
and O +
102.80 O +
corresponding O +
to O +
the O +
four O +
β O -
- O -
linked O +
anomeric O +
carbons O -
. O +

Debenzylidenation O +
of O +
13 O +
with O +
p O +
-TsOH O +
gave O +
14 O +
whose O +
NMR O +
spectra O +
showed O +
the O +
absence O +
of O +
the O +
benzylidene O +
CH O -
. O +

The O +
transformation O +
of O +
the O +
DMM O +
group O +
to O +
an O +
acetyl O +
group O +
was O +
achieved O +
by O +
the O +
action O +
of O +
alkali O +
and O +
then O +
acidification O +
followed O +
by O +
acetylation O +
to O +
give O +
15 O +
in O +
76 O -
% O +
yield O -
. O +

Catalytic O +
hydrogenation O +
of O +
15 O +
, O +
followed O +
by O +
acetylation O -
, O +
gave O +
the O +
peracetyl O +
derivative O +
16 O +
as O +
a O +
mixture O +
of O +
α O +
and O +
β O +
anomers O +
in O +
a O +
ratio O +
of O +
1:2 O -
, O +
respectively O +
( O -
Scheme O +
2 O +
) O -
. O +

Alternatively O -
, O +
the O +
required O +
disaccharide O +
donor O +
21 O +
was O +
prepared O +
from O +
known O +
17 O +
[ O -
33 O -
] O +
by O +
debenzylidenation O +
with O +
p O +
-TsOH O +
to O +
give O +
18 O +
whose O +
O O -
- O -
acetylation O +
gave O +
19 O +
. O +

Subsequent O +
removal O +
of O +
the O +
TBDMS O +
group O +
with O +
TBAF O +
gave O +
1-O O -
- O -
unprotected O +
20 O +
, O +
thus O +
being O +
suitable O +
for O +
the O +
activation O +
with O +
trichloroacetonitrile O +
in O +
the O +
presence O +
of O +
DBU O +
to O +
give O +
trichloroacetimidate O +
21 O +
. O +

Coupling O +
of O +
21 O +
with O +
8 O +
under O +
standard O +
conditions O +
gave O +
tetrasaccharide O +
22 O +
in O +
75 O -
% O +
yield O -
. O +

Its O +
1 O +
H O +
NMR O +
spectrum O +
showed O +
for O +
the O +
H-1c O +
a O +
doublet O +
at O +
δ O +
5.16 O +
with O +
a O +
coupling O +
constant O +
of O +
8.4 O +
Hz O -
, O +
thus O +
confirming O +
the O +
β O -
- O -
configuration O -
. O +

Moreover O -
, O +
its O +
13 O +
C O +
NMR O +
spectrum O +
showed O +
signals O +
at O +
δ O +
c O +
99.90 O -
, O +
100.50 O -
, O +
102.8 O +
( O -
2C O -
) O -
, O +
confirming O +
the O +
presence O +
of O +
the O +
four O +
anomeric O +
centers O -
. O +

Removal O +
of O +
the O +
DMM O +
group O +
from O +
22 O +
and O +
subsequent O +
acetylation O +
afforded O +
15 O +
, O +
which O +
was O +
identical O +
to O +
the O +
material O +
obtained O +
via O +
the O +
first O +
approach O +
( O -
Scheme O +
3 O +
) O -
. O +

In O +
conclusion O -
, O +
lacto O -
- O -
N O +
-tetraose O +
( O -
1 O +
) O +
and O +
lacto O -
- O -
N O +
-neotetraose O +
( O -
2 O +
) O +
were O +
successfully O +
synthesized O +
by O +
the O +
elaboration O +
of O +
the O +
newly O +
developed O +
protection O +
of O +
amino O +
sugars O +
with O +
dimethylmaleic O +
anhydride O +
providing O +
the O +
dimethylmaleimido O +
group O -
. O +

Cleavage O +
by O +
addition O +
of O +
alkali O +
followed O +
by O +
acid O +
can O +
be O +
successfully O +
performed O +
as O +
exhibited O +
in O +
our O +
first O +
report O +
[ O -
33 O -
] O +
, O +
using O +
this O +
group O +
for O +
amino O +
sugars O -
, O +
and O +
in O +
other O +
reports O -
, O +
using O +
it O +
for O +
amino O +
acids O +
and O +
proteins B-Gene +
[ O -
37–41 O -
] O +
. O +

Its O +
combination O +
with O +
the O +
trichloroacetimidate O +
leaving O +
group O +
[ O -
42 O -
] O +
at O +
C-1 O +
of O +
a O +
glucosamine O +
residue O +
either O +
in O +
monomeric O +
form O +
or O +
as O +
part O +
of O +
an O +
oligosaccharide O +
provides O +
good O +
glycosyl O +
donors O +
in O +
order O +
to O +
form O +
β O -
- O -
linkages O -
. O +

Moreover O -
, O +
the O +
DMM O +
group O +
tolerates O +
manipulations O +
of O +
the O +
common O +
temporary O +
protective O +
groups O +
required O +
during O +
oligosaccharide O +
synthesis O +
and O -
, O +
in O +
addition O -
, O +
it O +
can O +
be O +
selectively O +
removed O +
under O +
quite O +
mild O +
conditions O -
. O +

The O +
partially O +
protected O +
target O +
tetrasaccharides O +
prepared O +
in O +
this O +
paper O -
, O +
as O +
well O +
as O +
their O +
precursors O -
, O +
can O +
be O +
used O +
for O +
the O +
elaboration O +
of O +
various O +
higher O +
oligosaccharides O -
. O +

3 O +
3 O -
. O +

Experimental O +
3.1 O +
General O +
methods O +
Solvents O +
were O +
purified O +
in O +
the O +
usual O +
way O -
. O +

TLC O +
was O +
performed O +
on O +
plastic O +
plates O +
Silica O +
Gel O +
60 O +
F254 O +
and O +
on O +
HPTLC O +
plates O +
NH2 O +
F254 O +
S O +
( O -
E. O +
Merck O -
, O +
layer O +
thickness O +
0.2 O +
mm O -
) O -
. O +

The O +
detection O +
was O +
achieved O +
by O +
treatment O +
with O +
a O +
solution O +
of O +
20 O +
g O +
ammonium O +
molybdate O +
and O +
0.4 O +
g O +
cerium O -
( O -
IV O -
) O +
sulfate O +
in O +
400 O +
mL O +
10 O -
% O +
H2 O +
SO4 O +
or O +
with O +
15 O -
% O +
H2 O +
SO4 O +
, O +
and O +
heating O +
at O +
150 O +
° O -
C O -
. O +

Flash O +
chromatography O +
was O +
carried O +
out O +
on O +
silica O +
gel O +
( O -
Baker O -
, O +
30–60 O +
( O -
μm O -
) O +
and O +
Lichroprep O +
NH2 O +
, O +
particle O +
size O +
40–63 O +
μm O +
( O -
E. O +
Merck O -
) O -
. O +

Medium O -
- O -
pressure O +
liquid O +
chromatography O +
( O -
MPLC O -
) O -
: O +
LiChroprep O +
Si O +
60 O +
( O -
E. O +
Merck O -
; O +
size O +
15–25 O +
μm O -
) O -
, O +
detection O +
by O +
differential O +
refractometer O -
. O +

Optical O +
rotations O +
were O +
determined O +
at O +
25 O +
° O -
C O +
with O +
a O +
Perkin O -
– O -
Elmer O +
241 O -
/ O -
MC O +
polarimeter O +
( O -
1 O +
dm O +
cell O -
) O -
. O +

NMR O +
spectra O +
were O +
recorded O +
with O +
Bruker O +
AC O +
250 O +
and O +
600 O +
DRX O +
instruments O -
, O +
using O +
tetramethylsilane O +
as O +
internal O +
standard O -
. O +

The O +
assignments O +
of O +
1 O +
H O +
NMR O +
spectra O +
were O +
based O +
on O +
chemical O +
shift O +
correlation O +
( O -
DQFCOSY O -
) O +
and O +
rotating O +
frame O +
nuclear O +
Overhauser O +
effect O +
spectroscopy O +
( O -
ROESY O -
) O -
. O +

The O +
assignments O +
of O +
13 O +
C O +
NMR O +
spectra O +
were O +
based O +
on O +
carbon O -
– O -
proton O +
shift O -
- O -
correlation O +
heteronuclear O +
multiple O +
quantum O +
coherence O +
( O -
HMQC O -
) O -
. O +

MS O +
spectra O +
were O +
recorded O +
with O +
MALDI O -
- O -
Kompakt O +
( O -
Kratos O -
) O -
, O +
EI O +
and O +
FAB O +
with O +
Finningen O +
MAT O +
312 O -
/ O -
AMD O -
. O +

Microanalyses O +
were O +
performed O +
in O +
the O +
Microanalysis O +
Unit O +
at O +
the O +
Fakultät O +
für O +
Chemie O -
, O +
Universität O +
Konstanz O -
. O +

3.2 O +
tert O -
- O -
Butyldimethylsilyl O +
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-3,6-di O -
- O -
O O -
- O -
benzyl-2-deoxy-2-dimethylmaleimido O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
5 O +
) O +
A O +
solution O +
of O +
3 O +
( O -
0.25 O +
g O -
, O +
0.52 O +
mmol O -
) O +
and O +
4 O +
( O -
0.24 O +
g O -
, O +
0.4 O +
mmol O -
) O +
in O +
dry O +
CH2 O +
Cl2 O +
( O -
2 O +
mL O -
) O +
was O +
stirred O +
under O +
nitrogen O +
at O +
rt O +
for O +
10 O +
min O +
while O +
Me3 O +
SiOTf O +
( O -
0.01 O +
M O +
in O +
CH2 O +
Cl2 O +
, O +
0.46 O +
mL O -
) O +
was O +
added O +
dropwise O -
. O +

After O +
45 O +
min O -
, O +
the O +
reaction O +
mixture O +
was O +
neutralized O +
with O +
Et3 O +
N O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
2:1 O +
petroleum O +
EtOAc O -
) O +
to O +
yield O +
5 O +
( O -
0.32 O +
g O -
, O +
84 O -
% O -
) O +
as O +
an O +
oil O -
. O +

TLC O +
( O -
2:1 O +
petroleum O +
EtOAc O -
) O -
: O +
R O +
f O +
0.34 O -
, O +
[ O -
α O +
] O -
D O +
+ O -
19.8 O -
° O +
( O -
c O +
0.6 O -
, O +
CHCl3 O +
) O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.36–7.10 O +
( O -
m O -
, O +
10 O +
H O -
, O +
2 O +
Ph O -
) O -
, O +
5.26 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
2.9 O +
Hz O -
, O +
H-4b O -
) O -
, O +
5.13 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.0 O -
, O +
J O +
2,3 O +
10.4 O +
Hz O -
, O +
H-2b O -
) O -
, O +
5.10 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.0 O +
Hz O -
, O +
H-1a O -
) O -
, O +
4.86 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-3b O -
) O -
, O +
4.61 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1b O -
) O -
, O +
4.73 O -
, O +
4.50 O +
( O -
2 O +
d O -
, O +
2 O +
H O -
, O +
J O +
gem O +
12.2 O +
Hz O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.85 O -
, O +
4.41 O +
( O -
2 O +
d O -
, O +
2 O +
H O -
, O +
J O +
gem O +
12.4 O +
Hz O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.12 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
10.8 O -
, O +
J O +
3,4 O +
8.8 O +
Hz O -
, O +
H-3a O -
) O -
, O +
3.98–3.93 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-4a O -
, O +
H-6b O -
, O +
H-6′b O -
) O -
, O +
3.84 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2a O -
) O -
, O +
3.73 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.0 O -
, O +
J O +
5,6′ O +
3.4 O +
Hz O -
, O +
H-6′a O -
) O -
, O +
3.68–3.65 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-5b O -
, O +
H-6a O -
) O -
, O +
3.44 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.05 O -
, O +
1.99 O -
, O +
1.98 O -
, O +
1.95 O +
( O -
4 O +
s O -
, O +
12 O +
H O -
, O +
4 O +
CH3 O +
CO O -
) O -
, O +
1.80 O +
( O -
br.s O -
, O +
6 O +
H O -
, O +
2 O +
CH3 O +
) O -
, O +
0.72 O +
[ O -
s O -
, O +
9 O +
H O -
, O +
SiC O -
( O -
CH3 O +
) O -
3 O +
] O -
, O +
0.02 O +
( O -
s O -
, O +
3 O +
H O -
, O +
SiCH3 O +
) O -
, O +
−0.09 O +
( O -
s O -
, O +
3 O +
H O -
, O +
SiCH3 O +
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
170.31 O -
, O +
170.20 O -
, O +
170.03 O -
, O +
169.17 O +
( O -
4 O +
CH3 O +
C O +
O O -
, O +
2 O +
CO O -
) O -
, O +
139.10–136.69 O -
, O +
128.51–127.03 O +
( O -
2 O +
Ph O -
) O -
, O +
100.38 O +
( O -
C-1b O -
) O -
, O +
93.43 O +
( O -
C-1a O -
) O -
, O +
78.03 O +
( O -
C-4a O -
) O -
, O +
74.76 O +
( O -
C-3a O -
) O -
, O +
74.08 O +
( O -
C-5a O -
) O -
, O +
73.58 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
71.03 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
70.48 O +
( O -
C-3b O -
) O -
, O +
69.53 O +
( O -
C-5b O -
) O -
, O +
67.72 O +
( O -
C-2b O -
) O -
, O +
67.06 O +
( O -
C-6a O -
) O -
, O +
66.95 O +
( O -
C-4b O -
) O -
, O +
60.85 O +
( O -
C-6b O -
) O -
, O +
57.54 O +
( O -
C-2a O -
) O -
, O +
25.32 O +
[ O -
SiC O -
( O -
C O +
H3 O +
) O -
3 O +
] O -
, O +
20.75 O -
, O +
20.64 O -
, O +
20.59 O -
, O +
20.54 O +
( O -
4 O +
C O +
H3 O +
CO O -
) O -
, O +
17.57 O +
[ O -
SiC O +
( O -
CH3 O +
) O -
] O -
, O +
8.00 O +
( O -
2 O +
CH3 O +
) O -
, O +
−4.24 O +
( O -
SiCH3 O +
) O -
, O +
−5.62 O +
( O -
SiCH3 O +
) O -
. O +

FABMS O +
( O -
positive O +
mode O -
, O +
NBOH O -
/ O -
NaI O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
934 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C46 O +
H61 O +
NO16 O +
Si O +
( O -
912.04 O -
) O -
: O +
C O -
, O +
60.57 O -
; O +
H O -
, O +
6.74 O -
; O +
N O -
, O +
1.53 O -
. O +

Found O -
: O +
C O -
, O +
60.17 O -
; O +
H O -
, O +
6.94 O -
; O +
N O -
, O +
1.50 O -
. O +

3.3 O +
O- O +
[ O -
( O -
2,3,4,6-Tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-3,6-di O -
- O -
O O -
- O -
benzyl-2-deoxy-2-dimethylmaleimido O -
- O -
α O -
, O -
β O -
- O -
d O +
-glucopyranosyl O +
trichloroacetimidate O +
( O -
7 O +
) O +
A O +
solution O +
of O +
5 O +
( O -
3.0 O +
g O -
, O +
3.28 O +
mmol O -
) O +
in O +
dry O +
THF O +
( O -
8 O +
mL O -
) O +
in O +
an O +
ice O -
- O -
salt O +
bath O +
was O +
treated O +
with O +
glacial O +
AcOH O +
( O -
0.21 O +
mL O -
, O +
3.54 O +
mmol O -
) O +
and O +
TBAF O +
( O -
0.1 O +
M O -
, O +
3.6 O +
mL O -
, O +
3.6 O +
mmol O -
) O +
with O +
stirring O -
. O +

After O +
1 O +
h O -
, O +
the O +
ice O +
bath O +
was O +
removed O +
and O +
the O +
solution O +
was O +
stirred O +
overnight O +
then O +
diluted O +
with O +
a O +
saturated O +
NaCl O +
solution O +
( O -
20 O +
mL O -
) O +
and O +
extracted O +
with O +
CH2 O +
Cl2 O +
( O -
3 O -
× O -
20 O +
mL O -
) O -
. O +

The O +
organic O +
layer O +
was O +
separated O -
, O +
dried O +
over O +
anhydrous O +
magnesium O +
sulfate O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1.5:1 O +
EtOAc O -
– O -
petroleum O +
ether O -
) O +
to O +
yield O +
6 O +
( O -
2.2 O +
g O -
, O +
83 O -
% O -
) O +
as O +
a O +
white O +
foam O -
. O +

A O +
mixture O +
of O +
6 O +
( O -
2.2 O +
g O -
, O +
2.75 O +
mmol O -
) O -
, O +
trichloroacetonitrile O +
( O -
0.6 O +
mL O -
, O +
5.8 O +
mmol O -
) O +
and O +
1,8-diazabicyclo O -
( O -
5,4,0 O -
) O -
undec-7-ene O +
( O -
0.02 O +
mL O -
, O +
0.12 O +
mmol O -
) O +
in O +
dry O +
CH2 O +
Cl2 O +
( O -
6 O +
mL O -
) O +
was O +
stirred O +
at O +
rt O +
for O +
8 O +
h O +
and O +
then O +
concentrated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc+1 O -
% O +
triethylamine O -
) O +
to O +
yield O +
7 O +
( O -
2.23 O +
g O -
, O +
85 O -
% O -
) O +
as O +
a O +
pale O +
yellow O +
foam O +
in O +
the O +
α O -
: O -
β O +
ratio O +
1:3 O -
. O +

TLC O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc+1 O -
% O +
triethylamine O -
) O -
: O +
R O +
f O +
0.5 O +
( O -
β O -
- O -
form O -
) O +
and O +
R O +
f O +
0.6 O +
( O -
α O -
- O -
form O -
) O -
; O +
1 O +
H O +
NMR O +
( O -
250 O +
MHz O -
, O +
d O +
6 O +
-Me2 O +
SO O -
) O -
: O +
δ O +
9.92 O +
( O -
br.s O -
, O +
0.75 O +
H O -
, O +
NHβ O +
) O -
, O +
8.92 O +
( O -
s O -
, O +
0.25 O +
H O -
, O +
NHα O +
) O -
, O +
7.40–7.06 O +
( O -
m O -
, O +
10 O +
H O -
, O +
2 O +
Ph O -
) O -
, O +
6.11 O +
( O -
d O -
, O +
0.75 O +
H O -
, O +
J O +
1,2 O +
8.5 O +
Hz O -
, O +
H-1ab O +
) O -
, O +
5.84 O +
( O -
d O -
, O +
0.25 O +
H O -
, O +
J O +
1,2 O +
4.5 O +
Hz O -
, O +
H-1aa O +
) O -
, O +
5.25 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
2.7 O +
Hz O -
, O +
H-4b O -
) O -
, O +
5.10–3.41 O +
( O -
m O -
, O +
16 O +
H O -
) O -
, O +
2.07 O -
, O +
2.00 O -
, O +
1.96 O -
, O +
1.92 O -
, O +
1.75 O +
( O -
5 O +
s O -
, O +
18 O +
H O -
, O +
2 O +
CH3 O +
, O +
4 O +
COCH3 O +
) O -
. O +

FABMS O +
( O -
positive O +
mode O -
, O +
NBOH O -
/ O -
NaI O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
965 O +
[ O -
MNa+ O +
] O -
, O +
1115 O +
[ O -
MNaI O -
] O -
Na+ O +
. O +

Anal O -
. O +

Calcd O +
for O +
C42 O +
H47 O +
N2 O +
O16 O +
Cl3 O +
( O -
942.18 O -
) O -
: O +
C O -
, O +
53.53 O -
; O +
H O -
, O +
5.02 O -
; O +
N O -
, O +
2.97 O -
. O +

Found O -
: O +
C O -
, O +
53.18 O -
; O +
H O -
, O +
5.02 O -
; O +
N O -
, O +
3.09 O -
. O +

3.4 O +
Benzyl O +
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
- O -
( O -
3,6-di O -
- O -
O O -
- O -
benzyl-2-deoxy-2-dimethylmaleimido O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2,4,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-2,3,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
9 O +
) O +
A O +
mixture O +
of O +
7 O +
( O -
0.414 O +
g O -
, O +
0.439 O +
mmol O -
) O +
and O +
8 O +
( O -
0.333 O +
g O -
, O +
0.342 O +
mmol O -
) O +
in O +
dry O +
MeCN O +
( O -
2 O +
mL O -
) O +
was O +
stirred O +
under O +
nitrogen O +
at O +
rt O +
for O +
10 O +
min O +
while O +
Me3 O +
SiOTf O +
( O -
0.01 O +
M O +
in O +
MeCN O -
, O +
0.4 O +
mL O -
) O +
was O +
added O +
dropwise O -
. O +

After O +
2 O +
h O -
, O +
the O +
solution O +
was O +
neutralized O +
with O +
triethylamine O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
2:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
to O +
yield O +
9 O +
( O -
0.501 O +
g O -
, O +
83 O -
% O -
) O +
as O +
a O +
white O +
foam O -
. O +

TLC O +
( O -
2:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O -
: O +
R O +
f O +
0.14 O -
; O +
[ O -
α O +
] O -
D O +
+ O -
11.2 O -
° O +
( O -
c O +
0.4 O -
, O +
CHCl3 O +
) O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.34–7.07 O +
( O -
m O -
, O +
45 O +
H O -
, O +
9 O +
Ph O -
) O -
, O +
5.26 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
3.0 O +
Hz O -
, O +
H-4d O -
) O -
, O +
5.21 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.4 O +
Hz O -
, O +
H-1c O -
) O -
, O +
5.14 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.4 O -
, O +
J O +
2,3 O +
10.2 O +
Hz O -
, O +
H-2d O -
) O -
, O +
5.04 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.4 O +
Hz O -
, O +
CHH O +
Ph O -
) O -
, O +
4.92 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.5 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.88–4.82 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-3d O -
, O +
1.5 O +
CH O +
2 O +
Ph O -
) O -
, O +
4.69 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.8 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.66 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.8 O +
Hz O -
, O +
CHH O +
Ph O -
) O -
, O +
4.60–4.56 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-1d O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.48 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.4 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.47 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
12.1 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.44 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.8 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.39–4.26 O +
( O -
m O -
, O +
7 O +
H O -
, O +
H-1b O -
, O +
H-1a O -
, O +
2.5 O +
CH O +
2 O +
Ph O -
) O -
, O +
4.21–4.17 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-3c O -
, O +
CH O +
HPh O -
) O -
, O +
4.03–4.01 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-2c O -
, O +
H-4b O -
, O +
H-4c O -
) O -
, O +
3.93 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-6d O -
, O +
H-6′d O -
) O -
, O +
3.88 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-4a O -
) O -
, O +
3.77–3.71 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-6c O -
, O +
H-6′c O -
) O -
, O +
3.63 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5d O -
) O -
, O +
3.55–3.51 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-5c O -
, O +
H-6′b O -
, O +
H-2b O -
, O +
H-3b O -
, O +
H-6′a O -
) O -
, O +
3.40–3.35 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-6b O -
, O +
H-6a O -
, O +
H-5b O -
, O +
H-2a O -
, O +
H-3a O -
) O -
, O +
3.01 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.07 O -
, O +
1.99 O -
, O +
1.98 O -
, O +
1.97 O +
( O -
4 O +
s O -
, O +
12 O +
H O -
, O +
4 O +
CH3 O +
CO O -
) O -
, O +
1.56 O +
( O -
br.s O -
, O +
6 O +
H O -
, O +
2 O +
CH3 O +
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
102.80 O +
( O -
C-1a O -
) O -
, O +
102.70 O +
( O -
C-1b O -
) O -
, O +
100.70 O +
( O -
C-1d O -
) O -
, O +
100.20 O +
( O -
C-1c O -
) O -
, O +
83.40 O +
( O -
C-3a O -
) O -
, O +
82.50 O +
( O -
C-3b O -
) O -
, O +
82.00 O +
( O -
C-2a O -
) O -
, O +
79.30 O +
( O -
C-2b O -
) O -
, O +
78.20 O +
( O -
C-4c O -
) O -
, O +
77.30 O +
( O -
C-3c O -
) O -
, O +
76.90 O +
( O -
C-4b O -
) O -
, O +
76.40 O +
( O -
C-4a O -
) O -
, O +
75.80 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
75.30 O +
( O -
2 O +
C O +
H2 O +
Ph O -
) O -
, O +
75.20 O +
( O -
C-5a O -
) O -
, O +
74.70 O +
( O -
C-5 O -
, O +
C O +
H2 O +
Ph O -
) O -
, O +
74.60 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
74.20 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.80 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.50 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.30 O +
( O -
C-5b O -
) O -
, O +
71.30 O +
( O -
C O +
H2 O +
Ph O -
, O +
C-3d O -
) O -
, O +
70.80 O +
( O -
C-5d O -
) O -
, O +
69.90 O +
( O -
C-2d O -
) O -
, O +
68.60 O +
( O -
C-6b O -
) O -
, O +
68.30 O +
( O -
C-6c O -
) O -
, O +
68.20 O +
( O -
C-6a O -
) O -
, O +
67.20 O +
( O -
C-4d O -
) O -
, O +
60.90 O +
( O -
C-6d O -
) O -
, O +
56.40 O +
( O -
C-2c O -
) O -
. O +

MALDI O -
- O -
MS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
THF O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
1776 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C101 O +
H109 O +
NO26 O +
( O -
1752.89 O -
) O -
: O +
C O -
, O +
69.20 O -
; O +
H O -
, O +
6.26 O -
; O +
N O -
, O +
0.79 O -
. O +

Found O -
: O +
C O -
, O +
69.26 O -
; O +
H O -
, O +
6.68 O -
; O +
N O -
, O +
0.78 O -
. O +

3.5 O +
Benzyl O +
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
- O -
( O -
2-acetamido-2-deoxy-3,6-di O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2,4,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-2,3,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
10 O +
) O +
3.5.1 O +
Method O +
A O +
A O +
mixture O +
of O +
9 O +
( O -
0.542 O +
g O -
, O +
0.309 O +
mmol O -
) O +
and O +
NaOH O +
( O -
1.5 O +
g O -
, O +
0.037 O +
mol O -
) O +
in O +
MeOH O -
– O -
dioxane O -
– O -
water O +
( O -
5:2:1 O -
, O +
16 O +
mL O -
) O +
was O +
stirred O +
overnight O -
. O +

Then O -
, O +
the O +
solution O +
was O +
neutralized O +
with O +
1:1 O +
concd O +
HCl O -
– O -
H2 O +
O O +
and O +
the O +
pH O +
was O +
adjusted O +
to O +
5 O +
by O +
N O +
HCl O -
. O +

After O +
24 O +
h O -
, O +
the O +
solution O +
was O +
neutralized O +
with O +
ethanolamine O +
and O +
dried O +
well O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
treated O +
with O +
pyridine O -
– O -
AcOH O +
( O -
2:1 O -
, O +
24 O +
mL O -
) O -
. O +

After O +
20 O +
h O -
, O +
the O +
reaction O +
mixture O +
was O +
co O -
- O -
evaporated O +
with O +
toluene O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
diluted O +
with O +
water O +
( O -
30 O +
mL O -
) O +
and O +
extracted O +
with O +
CH2 O +
Cl2 O +
( O -
3 O -
× O -
30 O +
mL O -
) O -
. O +

The O +
organic O +
layers O +
were O +
combined O -
, O +
dried O +
over O +
MgSO4 O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1.5:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
and O +
the O +
unreacted O +
material O +
was O +
treated O +
similarly O +
to O +
yield O +
10 O +
( O -
0.370 O +
g O -
, O +
71 O -
% O -
) O +
as O +
a O +
colorless O +
oil O -
. O +

TLC O +
( O -
1.5:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O -
: O +
R O +
f O +
0.09 O -
; O +
[ O -
α O +
] O -
D O +
−6.2 O -
° O +
( O -
c O +
0.93 O -
, O +
chloroform O -
) O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.34–7.17 O +
( O -
m O -
, O +
45 O +
H O -
, O +
9 O +
Ph O -
) O -
, O +
5.80 O +
( O -
br.s O -
, O +
1 O +
H O -
, O +
NH O -
) O -
, O +
5.28 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
3.0 O -
, O +
H-4d O -
) O -
, O +
5.12 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
= O -
J O +
2,3 O +
9.0 O +
Hz O -
, O +
H-2d O -
) O -
, O +
5.01 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.6 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.98 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.6 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.92–4.31 O +
( O -
m O -
, O +
20 O +
H O -
, O +
H-1b O -
, O +
H-1a O -
, O +
H-1d O -
, O +
H-3d O -
, O +
H-1c O -
, O +
7.5 O +
CH O +
2 O +
Ph O -
) O -
, O +
4.18 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.6 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.01–3.90 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-6d O -
, O +
H-4a O -
, O +
H-4b O -
, O +
H-6′d O -
, O +
H-4c O -
) O -
, O +
3.78–3.72 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-6′a O -
, O +
H-6c O -
, O +
H-6′c O -
, O +
H-3c O -
, O +
H-2c O -
) O -
, O +
3.67–3.58 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-3b O -
, O +
H-5d O -
, O +
H-6a O -
, O +
H-2b O -
) O -
, O +
3.52–3.49 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-3a O -
, O +
H-6′b O -
, O +
H-5c O -
) O -
, O +
3.45–3.41 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-5b O -
, O +
H-2a O -
) O -
, O +
3.35 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-6b O -
) O -
, O +
3.24 O +
( O -
2 O +
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.01 O -
, O +
1.99 O -
, O +
1.98 O -
, O +
1.53 O +
( O -
4 O +
s O -
, O +
15 O +
H O -
, O +
5 O +
CH3 O +
CO O -
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
102.40 O +
( O -
C-1b O -
) O -
, O +
102.30 O +
( O -
C-1a O -
) O -
, O +
101.70 O +
( O -
C-1c O -
) O -
, O +
99.80 O +
( O -
C-1d O -
) O -
, O +
82.70 O +
( O -
C-3a O -
) O -
, O +
81.70 O +
( O -
C-3b O -
) O -
, O +
81.60 O +
( O -
C-2a O -
) O -
, O +
79.70 O +
( O -
C-2b O -
) O -
, O +
78.40 O +
( O -
C-3c O -
) O -
, O +
76.30 O +
( O -
C-4c O -
) O -
, O +
76.10 O +
( O -
C-4b O -
) O -
, O +
75.80 O +
( O -
C-4a O -
) O -
, O +
75.30 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
74.90 O +
( O -
C-5a O -
) O -
, O +
74.80 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
74.70 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
74.60 O +
( O -
C-5c O -
) O -
, O +
74.50 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.60 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.30 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.20 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.10 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.00 O +
( O -
C-5b O -
) O -
, O +
70.80 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
70.60 O +
( O -
C-3d O -
) O -
, O +
70.40 O +
( O -
C-5d O -
) O -
, O +
69.30 O +
( O -
C-2d O -
) O -
, O +
68.30 O +
( O -
C-6c O -
) O -
, O +
68.10 O +
( O -
C-6b O -
) O -
, O +
68.00 O +
( O -
C-6a O -
) O -
, O +
66.70 O +
( O -
C-4d O -
) O -
, O +
60.50 O +
( O -
C-6d O -
) O -
, O +
55.10 O +
( O -
C-2c O -
) O -
. O +

MALDIMS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
THT O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
1711 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C97 O +
H107 O +
N O +
O25 O +
( O -
1686.83 O -
) O -
: O +
C O -
, O +
69.06 O -
; O +
H O -
, O +
6.39 O -
; O +
N O -
, O +
0.83 O -
. O +

Found O -
: O +
C O -
, O +
68.64 O -
; O +
H O -
, O +
6.55 O -
; O +
N O -
, O +
0.71 O -
. O +

3.5.2 O +
Method O +
B O +
A O +
mixture O +
of O +
9 O +
( O -
0.153 O +
g O -
, O +
0.087 O +
mmol O -
) O -
, O +
hydrazine O +
hydrate O +
( O -
3.096 O +
g O -
, O +
0.06 O +
mol O -
, O +
3.0 O +
mL O -
) O +
in O +
dry O +
MeOH O +
( O -
6 O +
mL O -
) O +
was O +
heated O +
under O +
reflux O -
. O +

After O +
9 O +
h O -
, O +
the O +
solution O +
was O +
evaporated O +
under O +
reduced O +
pressure O +
and O +
treated O +
with O +
Ac2 O +
O O +
and O +
pyridine O +
as O +
described O +
in O +
Method O +
A O +
to O +
yield O +
10 O +
( O -
0.08 O +
g O -
, O +
54 O -
% O -
) O -
. O +

3.6 O +
( O -
2,3,4,6-Tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
- O -
( O -
2-acetamido-2-deoxy-3,6-di O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2,4,6-tri O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-1,2,3,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
α O -
, O -
β O -
- O -
d O +
-glucopyranose O +
( O -
11 O +
) O +
A O +
solution O +
of O +
10 O +
( O -
0.1 O +
g O -
, O +
0.059 O +
mmol O -
) O +
in O +
1:1:1 O +
AcOH O -
– O -
MeOH O -
– O -
dioxane O +
( O -
6 O +
mL O -
) O +
was O +
stirred O +
under O +
hydrogen O +
in O +
the O +
presence O +
of O +
palladium O +
on O +
carbon O +
( O -
10 O -
% O +
Pd O -
, O +
0.1 O +
g O -
) O +
at O +
rt O -
. O +

After O +
48 O +
h O -
, O +
the O +
reaction O +
mixture O +
was O +
filtered O +
through O +
Celite O +
and O +
washed O +
with O +
MeOH O -
. O +

The O +
combined O +
filtrates O +
were O +
concentrated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
treated O +
with O +
pyridine O +
( O -
10 O +
mL O -
) O -
, O +
Ac2 O +
O O +
( O -
5 O +
mL O -
) O +
and O +
stirred O +
at O +
rt O -
. O +

After O +
20 O +
h O -
, O +
the O +
reaction O +
was O +
worked O +
up O +
as O +
described O +
for O +
10 O +
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
2:1.5 O +
toluene O -
– O -
acetone O -
) O +
to O +
yield O +
11 O +
( O -
0.071 O +
g O -
, O +
95 O -
% O -
) O +
as O +
an O +
amorphous O +
mass O +
in O +
the O +
ratio O +
of O +
α O -
/ O -
β O +
3:2 O -
. O +

TLC O +
( O -
2:1.5 O +
toluene O -
– O -
acetone O -
) O -
: O +
R O +
f O +
0.19 O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
6.23 O +
( O -
d O -
, O +
0.6 O +
H O -
, O +
J O +
1,2 O +
= O -
J O +
1,2 O +
= O -
3.5 O +
Hz O -
, O +
H-1aα O +
) O -
, O +
5.63 O +
( O -
d O -
, O +
0.4 O +
H O -
, O +
J O +
1,2 O +
8.3 O +
Hz O -
, O +
H-1aβ O +
) O -
, O +
5.4 O +
( O -
t O -
, O +
0.6 O +
Hz O -
, O +
J O +
2,3 O +
= O -
J O +
3,4 O +
9.7 O +
Hz O -
, O +
H-3aα O +
) O -
, O +
5.32 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-4d O -
, O +
NH O -
) O -
, O +
5.28 O +
( O -
m O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
3.3 O +
Hz O -
, O +
H-4b O -
) O -
, O +
5.18–5.15 O +
( O -
m O -
, O +
1.4 O +
H O -
, O +
H-3c O -
, O +
H-3aβ O +
) O -
, O +
5.8 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
= O -
J O +
2,3 O +
8.2 O +
Hz O -
, O +
H-2d O -
) O -
, O +
5.02 O +
( O -
dd O -
, O +
0.4 O +
H O -
, O +
J O +
1,2 O +
8.3 O -
, O +
J O +
2,3 O +
9.2 O +
Hz O -
, O +
H-2aβ O +
) O -
, O +
4.99–4.95 O +
( O -
m O -
, O +
2.63 O +
H O -
, O +
H-3d O -
, O +
H-2b O -
, O +
H-2aα O +
) O -
, O +
4.76 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-6′c O -
) O -
, O +
4.65 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-1c O -
) O -
, O +
4.52 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
7.9 O +
Hz O -
, O +
H-1d O -
) O -
, O +
4.39–4.37 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-6′aβ O +
, O +
H-6′aα O +
) O -
, O +
4.31 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
7.9 O +
Hz O -
, O +
H-1b O -
) O -
, O +
4.13–4.02 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-6b O -
, O +
H-6′b O -
, O +
H-6d O -
, O +
H-6′d O -
, O +
H-6aβ O +
, O +
H-6aα O +
) O -
, O +
3.96–3.94 O +
( O -
m O -
, O +
1.6 O +
H O -
, O +
H-6c O -
, O +
H-5aα O +
) O -
, O +
3.85 O +
( O -
br.t O -
, O +
1 O +
H O -
, O +
H-5d O -
) O -
, O +
3.78–3.71 O +
( O -
m O -
, O +
4.4 O +
H O -
, O +
H-3b O -
, O +
H-5aβ O +
, O +
H-4aα O +
, O +
H-5b O -
, O +
H-4aβ O +
, O +
H-4c O -
) O -
, O +
3.49–3.47 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-5c O -
, O +
H-2c O -
) O -
, O +
2.16–1.88 O +
( O -
several O +
s O -
, O +
42 O +
H O -
, O +
14 O +
CH3 O +
CO O -
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
101.40 O +
( O -
C-1d O -
) O -
, O +
101.10 O -
, O +
100.70 O +
( O -
C-1b O -
) O -
, O +
100.50 O +
( O -
C-1c O -
) O -
, O +
91.80 O +
( O -
C-1aβ O +
) O -
, O +
89.20 O +
( O -
C-1aα O +
) O -
, O +
76.00 O +
( O -
C-3b O -
) O -
, O +
75.90 O +
( O -
C-4c O -
) O -
, O +
75.40 O +
( O -
C-4aα O +
) O -
, O +
75.30 O +
( O -
C-4aβ O +
) O -
, O +
73.90 O +
( O -
C-5aβ O +
) O -
, O +
73.00 O +
( O -
C-5c O -
) O -
, O +
72.60 O +
( O -
C-3aβ O +
) O -
, O +
72.10 O +
( O -
C-3c O -
) O -
, O +
71.40 O +
( O -
C-5b O -
) O -
, O +
71.30 O +
( O -
C-2aα O +
) O -
, O +
71.10 O +
( O -
C-3d O -
) O -
, O +
71.00 O +
( O -
C-5d O -
) O -
, O +
70.70 O +
( O -
C-2aβ O +
) O -
, O +
69.60 O +
( O -
C-3aα O +
) O -
, O +
69.50 O +
( O -
C-2b O -
) O -
, O +
69.40 O +
( O -
C-2d O -
) O -
, O +
69.10 O +
( O -
C-4b O -
) O -
, O +
66.90 O +
( O -
C-4d O -
) O -
, O +
62.10 O +
( O -
C-6aα O +
) O -
, O +
61.80 O +
( O -
C-6aβ O +
, O +
C-6b O -
) O -
, O +
61.00 O +
( O -
C-6d O -
) O -
, O +
60.50 O +
( O -
C-6c O -
) O -
, O +
55.20 O +
( O -
C-2c O -
) O -
. O +

MALDIMS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
THT O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
1277 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C52 O +
H71 O +
NO34 O +
( O -
1254.09 O -
) O -
: O +
C O -
, O +
49.79 O -
; O +
H O -
, O +
5.70 O -
; O +
N O -
, O +
1.11 O -
. O +

Found O -
: O +
C O -
, O +
49.81 O -
; O +
H O -
, O +
6.22 O -
; O +
N O -
, O +
1.15 O -
. O +

3.7 O +
( O -
β O -
- O -
d O +
-Galactopysranosyl O -
) O -
( O -
1→4 O -
) O -
- O -
( O -
2-acetamido-2-deoxy O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
( O -
1→3 O -
) O -
- O -
( O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-d O +
-glucopyranose O +
( O -
2 O +
) O +
A O +
mixture O +
of O +
11 O +
( O -
0.041 O +
g O -
, O +
0.0326 O +
mmol O -
) O -
, O +
MeOH O +
( O -
6.85 O +
mL O -
) O +
and O +
MeONa O +
soln O +
( O -
0.195 O +
M O -
, O +
0.45 O +
mL O -
, O +
0.087 O +
mmol O -
) O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
3 O +
days O -
, O +
the O +
mixture O +
was O +
neutralized O +
with O +
Amberlite O +
IR O +
120 O +
resin O +
( O -
H+ O +
form O -
) O -
, O +
filtered O -
, O +
evaporated O +
under O +
reduced O +
pressure O -
, O +
and O +
then O +
lyophilized O +
from O +
water O +
to O +
yield O +
2 O +
( O -
0.021 O +
g O -
, O +
91 O -
% O -
) O -
. O +

TLC O +
( O -
1:1:0.5 O +
CH2 O +
Cl2 O +
–MeOH O -
– O -
AcOH O -
) O -
, O +
R O +
f O +
0.08 O -
; O +
HPTLC O +
( O -
4:1 O +
EtOH O -
– O -
water O -
) O -
, O +
R O +
f O +
0.31 O -
. O +

MALDIMS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
THF O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
732 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C26 O +
H45 O +
NO21 O +
· O -
2H2 O +
O O +
( O -
743.64 O -
) O -
: O +
C O -
, O +
41.99 O -
; O +
H O -
, O +
6.64 O -
; O +
N O -
, O +
1.88 O -
. O +

Found O -
: O +
C O -
, O +
41.94 O -
; O +
H O -
, O +
6.64 O -
; O +
N O -
, O +
1.68 O -
. O +

The O +
1 O +
H O +
NMR O +
spectroscopy O +
data O +
( O -
600 O +
MHz O -
, O +
D2 O +
O O -
) O +
are O +
in O +
accordance O +
with O +
literature O +
data O +
[ O -
35 O -
] O +
. O +

3.8 O +
Benzyl O +
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
4,6-benzylidene-2-deoxy-2-dimethylmaleimido O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2,4,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-2,3,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
13 O +
) O +
A O +
mixture O +
of O +
12 O +
( O -
0.13 O +
g O -
, O +
0.15 O +
mmol O -
) O +
and O +
8 O +
( O -
0.123 O +
g O -
, O +
0.126 O +
mmol O -
) O +
in O +
dry O +
CH2 O +
Cl2 O +
( O -
1 O +
mL O -
) O +
was O +
stirred O +
under O +
nitrogen O +
at−30 O +
° O -
C O +
for O +
10 O +
min O +
while O +
Me3 O +
SiOTf O +
( O -
0.01 O +
M O +
in O +
CH2 O +
Cl2 O +
, O +
0.17 O +
mL O -
) O +
was O +
added O +
dropwise O -
. O +

After O +
40 O +
min O -
, O +
the O +
solution O +
was O +
neutralized O +
with O +
triethylamine O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
2:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
to O +
yield O +
13 O +
( O -
0.16 O +
g O -
, O +
76 O -
% O -
) O +
as O +
a O +
colorless O +
oil O -
. O +

TLC O +
( O -
2:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O -
: O +
R O +
f O +
0.12 O -
; O +
[ O -
α O +
] O -
D O +
−8.6 O -
° O +
( O -
c O +
0.5 O -
, O +
CHCl3 O +
): O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.40–7.10 O +
( O -
m O -
, O +
40 O +
H O -
, O +
8 O +
Ph O -
) O -
, O +
5.57 O +
( O -
s O -
, O +
1 O +
H O -
, O +
CH O +
Ph O -
) O -
, O +
5.27 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.4 O +
Hz O -
, O +
H-1c O -
) O -
, O +
5.22 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
2.6 O +
Hz O -
, O +
H-4d O -
) O -
, O +
5.00 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.0 O -
, O +
J O +
2,3 O +
10.3 O +
Hz O -
, O +
H-2d O -
) O -
, O +
4.94 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.3 O +
Hz O -
, O +
CHH O +
Ph O -
) O -
, O +
4.92 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.5 O +
Hz O -
, O +
CHH O +
Ph O -
) O -
, O +
4.86 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
12.1 O +
Hz O -
, O +
CHH O +
Ph O -
) O -
, O +
4.85 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.8 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.81 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
3.4 O +
Hz O -
, O +
H-3d O -
) O -
, O +
4.70 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.8 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.65 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
= O -
J O +
3,4 O +
9.5 O +
Hz O -
, O +
H-3c O -
) O -
, O +
4.61 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.5 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.57 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.5 O +
Hz O -
, O +
CH O +
HPH O -
) O -
, O +
4.54–4.51 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-1d O -
, O +
CH O +
HPh O -
) O -
, O +
4.48 O +
( O -
m O -
, O +
2 O +
H O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.39 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.5 O -
, O +
J O +
5,6′ O +
4.8 O +
Hz O -
, O +
H-6′c O -
) O -
, O +
4.36–4.28 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-1a O -
, O +
H-1b O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.27 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
12.1 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.22 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.8 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.14 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
9.5 O +
Hz O -
, O +
H-2c O -
) O -
, O +
4.05 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.0 O -
, O +
J O +
5,6′ O +
8.1 O +
Hz O -
, O +
H-6′d O -
) O -
, O +
3.91–3.83 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-6c O -
, O +
H-6d O -
, O +
H-4b O -
, O +
H-4a O -
) O -
, O +
3.77 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
= O -
J O +
4,5 O +
9.5 O +
Hz O -
, O +
H-4c O -
) O -
, O +
3.60–3.48 O +
( O -
m O -
, O +
6 O +
H O -
, O +
H-5d O -
, O +
H-6′b O -
, O +
H-6′a O -
, O +
H-2b O -
, O +
H-3b O -
, O +
H-5c O -
) O -
, O +
3.41–3.35 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-6a O -
, O +
H-6b O -
, O +
H-5b O -
, O +
H-3a O -
, O +
H-2a O -
) O -
, O +
2.98 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.09 O -
, O +
1.93 O -
, O +
1.90 O -
, O +
1.81 O +
( O -
4 O +
s O -
, O +
12 O +
H O -
, O +
4 O +
CH3 O +
CO O -
) O -
, O +
1.55 O +
( O -
br.s O -
, O +
6 O +
H O -
, O +
2 O +
CH3 O +
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
102.80 O +
( O -
C-1a O -
, O +
C-1b O -
) O -
, O +
101.90 O +
( O -
C O -
- O -
C O +
HPh O -
) O -
, O +
100.50 O +
( O -
C-1d O -
) O -
, O +
100.30 O +
( O -
C-1c O -
) O -
, O +
83.40 O +
( O -
C-3a O -
) O -
, O +
82.10 O +
( O -
C-2a O -
) O -
, O +
81.80 O +
( O -
C-3b O -
) O -
, O +
81.20 O +
( O -
C-4c O -
) O -
, O +
79.40 O +
( O -
C-2b O -
) O -
, O +
76.80 O +
( O -
C-4b O -
) O -
, O +
76.30 O +
( O -
C-4a O -
) O -
, O +
75.70 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
75.40 O +
( O -
C-3c O -
, O +
C O +
H2 O +
Ph O -
) O -
, O +
75.30 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
75.20 O +
( O -
C-5a O -
) O -
, O +
74.50 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.80 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.50 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.40 O +
( O -
C-5b O -
) O -
, O +
71.40 O +
( O -
C-3d O -
) O -
, O +
71.20 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
70.70 O +
( O -
C-5d O -
) O -
, O +
69.50 O +
( O -
C-2d O -
) O -
, O +
69.10 O +
( O -
C-6c O -
) O -
, O +
68.50 O +
( O -
C-6b O -
) O -
, O +
68.10 O +
( O -
C-6a O -
) O -
, O +
67.00 O +
( O -
C-4d O -
) O -
, O +
66.30 O +
( O -
C-5c O -
) O -
, O +
61.20 O +
( O -
C-6d O -
) O -
, O +
56.00 O +
( O -
C-2c O -
) O -
. O +

MALDIMS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
THT O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
1684 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C94 O +
H101 O +
NO26 O +
( O -
1660.75 O -
) O -
: O +
C O -
, O +
67.97 O -
; O +
H O -
, O +
6.13 O -
; O +
N O -
, O +
0.84 O -
. O +

Found O -
: O +
C O -
, O +
68.06 O -
; O +
H O -
, O +
6.41 O -
; O +
N O -
, O +
0.64 O -
. O +

3.9 O +
Benzyl O +
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2-acetamido-4,6-di O -
- O -
O O -
- O -
acetyl-2-deoxy O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2,4,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-2,3,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
15 O +
) O +
( O -
a O -
) O +
From O +
13 O +
. O +

A O +
mixture O +
of O +
13 O +
( O -
0.165 O +
g O -
, O +
0.099 O +
mmol O -
) O -
, O +
p O +
-TsOH O +
( O -
0.005 O +
g O -
, O +
0.026 O +
mmol O -
) O +
and O +
ethanethiol O +
( O -
0.1 O +
g O -
, O +
1.62 O +
mmol O -
, O +
0.12 O +
mL O -
) O +
in O +
dry O +
CH2 O +
Cl2 O +
( O -
1 O +
mL O -
) O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
24 O +
h O -
, O +
the O +
solution O +
was O +
neutralized O +
with O +
Et3 O +
N O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
to O +
yield O +
14 O +
( O -
0.118 O +
g O -
, O +
75 O -
% O -
) O +
as O +
an O +
oil O -
; O +
TLC O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O -
: O +
R O +
f O +
0.11 O -
. O +

A O +
mixture O +
of O +
the O +
aforementioned O +
oil O +
( O -
0.118 O +
g O -
, O +
0.075 O +
mmol O -
) O +
and O +
NaOH O +
( O -
0.17 O +
g O -
, O +
4.25 O +
mmol O -
) O +
in O +
a O +
dioxane O -
– O -
water O +
mixture O +
( O -
5:0.5 O -
, O +
5.5 O +
mL O -
) O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
24 O +
h O -
, O +
the O +
pH O +
of O +
the O +
solution O +
was O +
adjusted O +
and O +
kept O +
at O +
5 O +
by O +
N O +
HCl O -
. O +

After O +
24 O +
h O -
, O +
the O +
solution O +
was O +
neutralized O +
with O +
K2 O +
CO3 O +
and O +
dried O +
under O +
reduced O +
pressure O +
in O +
the O +
presence O +
of O +
ethanolamine O +
( O -
0.2 O +
mL O -
) O -
. O +

The O +
residue O +
was O +
treated O +
with O +
Ac2 O +
O O +
( O -
4 O +
mL O -
) O +
and O +
pyridine O +
( O -
8 O +
mL O -
) O +
and O +
stirred O +
at O +
rt O -
. O +

After O +
15 O +
h O -
, O +
the O +
solution O +
was O +
worked O +
up O +
as O +
described O +
for O +
10 O +
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
and O +
the O +
un O -
- O -
reacted O +
material O +
was O +
separated O +
and O +
deprotected O +
again O +
to O +
yield O +
15 O +
( O -
0.091 O +
g O -
, O +
76 O -
% O -
) O +
as O +
a O +
colorless O +
oil O -
. O +

TLC O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O -
: O +
R O +
f O +
0.09 O -
; O +
[ O -
α O +
] O -
D O +
−12.0 O -
° O +
( O -
c O +
0.15 O -
, O +
CHCl3 O +
) O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.40–7.10 O +
( O -
m O -
, O +
35 O +
H O -
, O +
7 O +
Ph O -
) O -
, O +
5.33 O +
( O -
br.s O -
, O +
1 O +
H O -
, O +
H-4d O -
) O -
, O +
4.99–4.84 O +
( O -
m O -
, O +
9 O +
H O -
, O +
NH O -
, O +
H-4c O -
, O +
H-1c O -
, O +
H-3d O -
, O +
H-2d O -
, O +
2.5 O +
CH O +
2 O +
Ph O -
) O -
, O +
4.73 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.9 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.69 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
10.5 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.63–4.57 O +
( O -
m O -
, O +
3 O +
H O -
, O +
1.5 O +
CH O +
2 O +
Ph O -
) O -
, O +
4.50 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.7 O +
Hz O -
, O +
CH O +
HPh O -
) O -
, O +
4.44–4.40 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-1b O -
, O +
H-1a O -
, O +
CH O +
HPh O -
) O -
, O +
4.34–4.33 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-1d O -
, O +
CH O +
HPh O -
) O -
, O +
4.21–4.15 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-3c O -
, O +
H-6′d O -
, O +
H-6c O -
, O +
H-6′c O -
, O +
CH O +
HPh O -
) O -
, O +
4.07 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-6d O -
) O -
, O +
3.98 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-4a O -
) O -
, O +
3.92 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-4b O -
) O -
, O +
3.83 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5d O -
) O -
, O +
3.76–3.74 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-5c O -
, O +
H-6′a O -
) O -
, O +
3.67–3.66 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-6a O -
, O +
H-2b O -
) O -
, O +
3.54–3.45 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-2c O -
, O +
H-2a O -
, O +
H-6′b O -
, O +
H-3a O -
, O +
H-3b O -
) O -
, O +
3.40 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5b O -
) O -
, O +
3.36 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-6b O -
) O -
, O +
3.28 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.13 O -
, O +
2.10 O -
, O +
2.05 O -
, O +
1.99 O -
, O +
1.95 O -
, O +
1.52 O +
( O -
6 O +
s O -
, O +
21 O +
H O -
, O +
7 O +
CH3 O +
CO O -
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
102.80 O +
( O -
C-1a O -
, O +
C-1b O -
) O -
, O +
101.20 O +
( O -
C-1c O -
) O -
, O +
101.10 O +
( O -
C-1d O -
) O -
, O +
83.10 O +
( O -
C-3a O -
) O -
, O +
82.10 O +
( O -
C-2a O -
, O +
C-3b O -
) O -
, O +
80.70 O +
( O -
C-2b O -
) O -
, O +
77.10 O +
( O -
C-3c O -
) O -
, O +
76.70 O +
( O -
C-4a O -
) O -
, O +
76.40 O +
( O -
C-4b O -
) O -
, O +
75.50 O +
( O -
C-5a O -
, O +
C O +
H2 O +
Ph O -
) O -
, O +
75.40 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
75.20 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
75.10 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.70 O +
( O -
2 O +
C O +
H2 O +
Ph O -
) O -
, O +
73.60 O +
( O -
C-5b O -
) O -
, O +
72.10 O +
( O -
C-5c O -
) O -
, O +
71.30 O +
( O -
C-3d O -
, O +
C O +
H2 O +
Ph O -
) O -
, O +
70.80 O +
( O -
C-5d O -
) O -
, O +
69.80 O +
( O -
C-4c O -
) O -
, O +
69.40 O +
( O -
C-2d O -
) O -
, O +
68.60 O +
( O -
C-6a O -
) O -
, O +
68.40 O +
( O -
C-6b O -
) O -
, O +
67.20 O +
( O -
C-4d O -
) O -
, O +
63.00 O +
( O -
C-6c O -
) O -
, O +
61.40 O +
( O -
C-6d O -
) O -
, O +
57.40 O +
( O -
C-2c O -
) O -
. O +

FABMS O +
( O -
positive O +
mode O -
, O +
NBOH O -
/ O -
NaI O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
1613 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C87 O +
H99 O +
NO27 O +
( O -
1590.66 O -
) O -
: O +
C O -
, O +
65.68 O -
; O +
H O -
, O +
6.27 O -
; O +
N O -
, O +
0.88 O -
. O +

Found O -
: O +
C O -
, O +
65.77 O -
; O +
H O -
, O +
6.58 O -
; O +
N O -
, O +
0.71 O -
. O +

( O -
b O -
) O +
From O +
22 O -
. O +

Compound O +
22 O +
( O -
0.169 O +
g O -
, O +
0.102 O +
mmol O -
) O +
was O +
treated O +
as O +
described O +
for O +
14 O +
to O +
yield O +
15 O +
( O -
0.116 O +
g O -
, O +
71 O -
% O -
) O -
. O +

3.10 O +
( O -
2,3,4,6-Tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2-acetamido-2-deoxy-4,6-di O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2,4,6-tri O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-1,2,3,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
α O -
/ O -
β O -
- O -
d O +
-glucopyranose O +
( O -
16 O +
) O +
According O +
to O +
the O +
procedure O +
described O +
for O +
the O +
preparation O +
of O +
11 O +
, O +
compound O +
15 O +
( O -
0.111 O +
g O -
, O +
0.07 O +
mmol O -
) O +
was O +
dissolved O +
in O +
1:1:1 O +
AcOH O -
– O -
MeOH O -
– O -
dioxane O +
( O -
4.5 O +
mL O -
) O +
and O +
hydrogenolized O +
in O +
the O +
presence O +
of O +
Pd O -
/ O -
C O +
( O -
10 O -
% O +
Pd O -
, O +
0.1 O +
g O -
) O +
at O +
rt O +
for O +
48 O +
h O -
, O +
then O +
worked O +
up O +
and O +
the O +
residue O +
was O +
acetylated O -
. O +

The O +
residue O +
was O +
purified O +
by O +
MPLC O +
( O -
1.5:1 O +
toluene O -
– O -
acetone O -
) O +
to O +
yield O +
16 O +
( O -
0.075 O +
g O -
, O +
86 O -
% O -
) O +
as O +
an O +
amorphous O +
mass O +
in O +
the O +
ratio O +
of O +
α O -
: O -
β O +
1:2 O -
. O +

TLC O +
( O -
1.5:1 O +
toluene O -
– O -
acetone O -
) O -
: O +
R O +
f O +
0.18 O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
6.23 O +
( O -
d O -
, O +
0.33 O +
H O -
, O +
J O +
1,2 O +
3.5 O +
Hz O -
, O +
H-1aa O +
) O -
, O +
5.65–5.63 O +
( O -
m O -
, O +
1.7 O +
H O -
, O +
NH O -
, O +
H-1aβ O +
) O -
, O +
5.41 O +
( O -
t O -
, O +
0.3 O +
H O -
, O +
J O +
2,3 O +
= O -
J O +
3,4 O +
9.8 O +
Hz O -
, O +
H-3aα O +
) O -
, O +
5.32–5.31 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-4b O -
, O +
H-4d O -
) O -
, O +
5.20 O +
( O -
t O -
, O +
0.7 O +
H O -
, O +
H-3aβ O +
) O -
, O +
5.11 O +
( O -
t O -
, O +
1 O +
H O -
, O +
H-1c O -
) O -
, O +
5.02–4.91 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-4c O -
, O +
H-3d O -
, O +
H-2aα O +
, O +
H-2b O -
, O +
H-2d O -
, O +
H-2aβ O +
) O -
, O +
4.54 O +
( O -
t O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
= O -
J O +
3,4 O +
9.8 O +
Hz O -
, O +
H-3c O -
) O -
, O +
4.44–4.38 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-6′aα O +
, O +
H-6′aβ O +
, O +
H-6′c O -
, O +
H-1d O -
) O -
, O +
4.33 O -
, O +
4.32 O +
( O -
2 O +
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
7.8 O +
Hz O -
, O +
H-1b O -
) O -
, O +
4.14 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
gem O +
12.1 O -
, O +
J5,6 O +
2.9 O +
Hz O -
, O +
H-6aα O +
, O +
H-6aβ O +
) O -
, O +
4.07–4.01 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-6b O -
, O +
H-6′b O -
, O +
H-6d O -
, O +
H-6′d O -
) O -
, O +
3.98–3.96 O +
( O -
m O -
, O +
1.3 O +
H O -
, O +
H-5aα O +
, O +
H-6c O -
) O -
, O +
3.82 O +
( O -
t O -
, O +
1 O +
H O -
, O +
H-5d O -
) O -
, O +
3.77–3.73 O +
( O -
m O -
, O +
3.7 O +
H O -
, O +
H-3b O -
, O +
H-5aβ O +
, O +
H-5b O -
, O +
H-4aα O +
, O +
H-4aβ O +
) O -
, O +
3.59 O +
( O -
br.d O -
, O +
1 O +
H O -
, O +
H-5c O -
) O -
, O +
2.80 O +
( O -
br.t O -
, O +
1 O +
H O -
, O +
H-2c O -
) O -
, O +
2.16–1.94 O +
( O -
several O +
s O -
, O +
42 O +
H O -
, O +
14 O +
CH3 O +
CO O -
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
101.30 O -
, O +
100.90 O +
( O -
C-1b O -
) O -
, O +
101.00 O +
( O -
C-1d O -
) O -
, O +
99.00 O +
( O -
C-1c O -
) O -
, O +
91.90 O +
( O -
C-1aβ O -
) O -
, O +
89.30 O +
( O -
C-1aα O -
) O -
, O +
76.50 O +
( O -
C-3b O -
) O -
, O +
76.30 O +
( O -
C-3c O -
) O -
, O +
75.50 O +
( O -
C-4aα O -
) O -
, O +
75.30 O +
( O -
C-4aβ O -
) O -
, O +
74.00 O +
( O -
C-5aβ O -
) O -
, O +
72.70 O +
( O -
C-3aβ O -
) O -
, O +
72.20 O -
, O +
71.60 O +
( O -
C-5c O -
) O -
, O +
71.40 O +
( O -
C-3d O -
) O -
, O +
71.20 O +
( O -
C-2aα O -
) O +
71.10 O +
( O -
C-5aα O -
) O -
, O +
70.90 O +
( O -
C-5d O -
) O -
, O +
70.70 O +
( O -
C-2aβ O -
) O -
, O +
69.90 O +
( O -
C-2d O -
) O -
, O +
69.70 O +
( O -
C-3aα O -
, O +
C-2b O -
) O -
, O +
69.50 O +
( O -
C-4d O -
) O -
, O +
69.20 O +
( O -
C-4c O -
) O -
, O +
67.20 O +
( O -
C-4b O -
) O -
, O +
62.00 O +
( O -
C-6a O -
) O -
, O +
61.80 O +
( O -
C-6b O -
) O -
, O +
61.70 O +
( O -
C-6c O -
) O -
, O +
61.20 O +
( O -
C-6d O -
) O -
, O +
59.30 O +
( O -
C-2c O -
) O -
. O +

MALDIMS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
THT O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
1278 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C52 O +
H71 O +
NO34 O +
( O -
1254.09 O -
) O -
: O +
C O -
, O +
49.79 O -
; O +
H O -
, O +
5.70 O -
; O +
N O -
, O +
1.11 O -
. O +

Found O -
: O +
C O -
, O +
49.85 O -
; O +
H O -
, O +
6.23 O -
; O +
N O -
, O +
1.08 O -
. O +

3.11 O +
β O -
- O -
d O +
-Galactopyranosyl- O -
( O -
1→3 O -
) O -
-2-acetamido-2-deoxy O -
- O -
β O -
- O -
d O +
-glucopyranosyl- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→4 O -
) O -
-d O +
-glucopyranose O +
( O -
1 O +
) O +
A O +
mixture O +
of O +
16 O +
( O -
0.053 O +
g O -
, O +
0.033 O +
mmol O -
) O -
, O +
MeOH O +
( O -
3.4 O +
mL O -
) O +
and O +
NaOMe O +
( O -
0.195 O +
M O +
in O +
MeOH O -
, O +
0.45 O +
mL O -
) O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
3 O +
h O -
, O +
water O +
( O -
3.4 O +
mL O -
) O +
and O +
NaOMe O +
( O -
0.195 O +
M O -
, O +
0.90 O +
mL O -
) O +
were O +
added O -
. O +

After O +
3 O +
days O -
, O +
the O +
reaction O +
mixture O +
was O +
worked O +
up O +
as O +
described O +
for O +
2 O +
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
on O +
amino O -
- O -
phase O +
Lichroprep O +
( O -
3:1 O +
EtOH O -
– O -
water O -
) O +
to O +
yield O +
1 O +
( O -
0.018 O +
g O -
, O +
78 O -
% O -
) O +
as O +
a O +
foam O -
. O +

HPTLC O +
( O -
4:1 O +
EtOH O -
– O -
water O -
) O -
: O +
R O +
f O +
0.19 O -
; O +
[ O -
α O +
] O -
D O +
+ O -
23.9 O -
° O +
( O -
c O +
0.5 O -
, O +
H O +
2 O +
O O -
, O +
3 O +
h O -
) O -
; O +
lit O -
. O +

[ O -
α O +
] O -
D O +
24 O +
+ O -
25.2 O -
° O +
( O +
final O +
value O -
) O +
( O +
c O +
1.5 O -
, O +
H O +
2 O +
O O -
) O +
[ O -
5 O -
] O +
. O +

MALDIMS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
NaI O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
731.6 O +
[ O -
MNa+ O +
] O -
. O +

The O +
1 O +
H O +
NMR O +
spectroscopy O +
data O +
( O -
600 O +
MHz O -
, O +
D2 O +
O O -
) O +
were O +
in O +
accordance O +
with O +
literature O +
data O +
[ O -
35 O -
] O +
. O +

3.12 O +
tert O -
- O -
Butyldimethylsilyl O -
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
-2-deoxy-2-dimethylmaleimido O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
18 O +
) O +
A O +
mixture O +
of O +
17 O +
( O -
1.51 O +
g O -
, O +
1.84 O +
mmol O -
) O -
, O +
p O +
-TsOH O +
( O -
0.008 O +
g O -
, O +
0.42 O +
mmol O -
) O +
and O +
ethanethiol O +
( O -
0.84 O +
g O -
, O +
13.46 O +
mmol O -
, O +
1.0 O +
mL O -
) O +
in O +
dry O +
CH2 O +
Cl2 O +
( O -
15 O +
mL O -
) O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
20 O +
h O -
, O +
the O +
solution O +
was O +
neutralized O +
with O +
triethylamine O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
to O +
yield O +
18 O +
( O -
1.096 O +
g O -
, O +
81 O -
% O -
) O +
as O +
a O +
white O +
foam O -
. O +

TLC O +
( O -
1:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O -
: O +
R O +
f O +
0.14 O -
; O +
[ O -
α O +
] O -
D O +
−6.4 O -
° O +
( O -
c O +
0.7 O -
, O +
chloroform O -
) O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
5.31 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
2.6 O +
Hz O -
, O +
H-4b O -
) O -
, O +
5.13 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.0 O -
, O +
J O +
2,3 O +
10.5 O +
Hz O -
, O +
H-2b O -
) O -
, O +
5.07 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.1 O +
Hz O -
, O +
H-1a O -
) O -
, O +
4.91 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
2.6 O +
Hz O -
, O +
H-3b O -
) O -
, O +
4.35 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1b O -
) O -
, O +
4.32 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
10.8 O -
, O +
J O +
3,4 O +
8.4 O +
Hz O -
, O +
H-3a O -
) O -
, O +
4.09 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-6b O -
, O +
H-6′b O -
) O -
, O +
3.95 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5b O -
) O -
, O +
3.91–3.88 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-6′a O -
, O +
H-2a O -
) O -
, O +
3.75 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.5 O -
, O +
J O +
5,6 O +
5.6 O +
Hz O -
, O +
H-6a O -
) O -
, O +
3.54 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
8.4 O -
, O +
J O +
4,5 O +
9.2 O +
Hz O -
, O +
H-4a O -
) O -
, O +
3.46 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.12 O -
, O +
2.05 O -
, O +
1.95 O -
, O +
1.92 O -
, O +
1.81 O +
( O -
5 O +
s O -
, O +
18 O +
H O -
, O +
2 O +
CH3 O +
, O +
4 O +
CH3 O +
CO O -
) O -
, O +
0.73 O +
[ O -
s O -
, O +
9 O +
H O -
, O +
SiC O -
( O -
CH3 O +
) O -
3 O +
] O -
, O +
0.02 O +
( O -
s O -
, O +
3 O +
H O +
SiCH3 O +
) O -
, O +
−0.07 O +
( O -
s O -
, O +
3 O +
H O -
, O +
SiCH3 O +
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
170.38 O -
, O +
170.10 O -
, O +
170.05 O -
, O +
168.68 O +
( O -
4 O +
CH3 O +
C O +
O O -
, O +
2 O +
CO O -
) O -
, O +
137.41 O +
( O -
2 O +
C O -
- O -
DMM O -
) O -
, O +
101.03 O +
( O -
C-1b O -
) O -
, O +
93.41 O +
( O -
C-1a O -
) O -
, O +
81.78 O +
( O -
C-3a O -
) O -
, O +
75.36 O +
( O -
C-5a O -
) O -
, O +
71.20 O +
( O -
C-5b O -
) O -
, O +
70.76 O +
( O -
C-4a O -
) O -
, O +
70.64 O +
( O -
C-3b O -
) O -
, O +
68.60 O +
( O -
C-2b O -
) O -
, O +
66.87 O +
( O -
C-4b O -
) O -
, O +
63.17 O +
( O -
C-6a O -
) O -
, O +
61.48 O +
( O -
C-6b O -
) O -
, O +
56.87 O +
( O -
C-2a O -
) O -
, O +
25.24 O +
[ O -
SiC O -
( O -
C O +
H3 O +
) O -
3 O +
] O -
, O +
20.58 O -
, O +
20.53 O -
, O +
20.47 O -
, O +
20.27 O +
( O -
4 O +
C O +
H3 O +
CO O -
) O -
, O +
17.48 O +
[ O -
SiC O +
[ O -
CH3 O +
) O -
] O -
, O +
8.73 O +
( O -
2 O +
C O -
– O -
CH3 O +
) O -
, O +
−4.10 O +
( O -
SiCH3 O +
) O -
, O +
−5.61 O +
( O -
SiCH3 O +
) O -
. O +

FABMS O +
( O -
positive O +
mode O -
, O +
NBOH O -
/ O -
NaI O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
754 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C32 O +
H49 O +
NO16 O +
Si O +
( O -
731.80 O -
) O -
: O +
C O -
, O +
52.51 O -
; O +
H O -
, O +
6.74 O -
; O +
N O -
, O +
1.91 O -
. O +

Found O -
: O +
C O -
, O +
52.63 O -
; O +
H O -
, O +
6.91 O -
; O +
N O -
, O +
1.77 O -
. O +
3.13 O +
tert O -
- O -
Butyldimethylsilyl O -
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
-4,6-di O -
- O -
O O -
- O -
acetyl-2-deoxy-2-dimethylmaleimido O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
19 O +
) O +
A O +
mixture O +
of O +
18 O +
( O -
1.51 O +
g O -
, O +
1.43 O +
mmol O -
) O -
, O +
pyridine O +
( O -
15 O +
mL O -
) O +
and O +
acetic O +
anhydride O +
( O -
7.5 O +
mL O -
) O +
was O +
stirred O +
at O +
rt O -
. O +

After O +
18 O +
h O -
, O +
the O +
solution O +
was O +
worked O +
up O +
as O +
described O +
for O +
10 O +
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1.5:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
to O +
yield O +
19 O +
( O -
1.141 O +
g O -
, O +
97 O -
% O -
) O +
as O +
a O +
white O +
foam O -
. O +

TLC O +
( O -
1.5:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
: O +
R O +
f O +
0.11 O -
; O +
[ O -
α O +
] O -
D O +
−6.6 O -
° O +
( O -
c O +
0.5 O -
, O +
CHCl3 O +
) O -
, O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
5.26 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
Hz O -
, O +
H-4b O -
) O -
, O +
5.06 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.1 O +
Hz O -
, O +
H-1a O -
) O -
, O +
4.93 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-2b O -
) O -
, O +
4.92 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-4a O -
) O -
, O +
4.84 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
10.4 O -
, O +
J O +
3,4 O +
3.4 O +
Hz O -
, O +
H-3b O -
) O -
, O +
4.54 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
10.8 O -
, O +
J O +
3,4 O +
9.3 O +
Hz O -
, O +
H-3a O -
) O -
, O +
4.20 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
7.8 O +
Hz O -
, O +
H-1b O -
) O -
, O +
4.13 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-6a O -
, O +
H-6′a O -
) O -
, O +
4.07 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-6b O -
, O +
H-6′b O -
) O -
, O +
3.95 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
10.8 O +
Hz O -
, O +
H-2a O -
) O -
, O +
3.76 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5b O -
) O -
, O +
3.70 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.10 O -
, O +
2.05 O -
, O +
2.04 O -
, O +
2.03 O -
, O +
2.02 O -
, O +
1.97 O -
, O +
1.91 O -
, O +
1.89 O +
( O -
8 O +
s O -
, O +
24 O +
H O -
, O +
2 O +
CH3 O +
, O +
6 O +
CH3 O +
CO O -
) O -
, O +
0.73 O +
[ O -
s O -
, O +
9 O +
H O -
, O +
SiC O -
( O -
CH3 O +
) O -
3 O +
] O -
, O +
0.02 O +
( O -
s O -
, O +
3 O +
H O -
, O +
SiCH3 O +
) O -
, O +
−0.06 O +
( O -
s O -
, O +
3 O +
H O -
, O +
SiCH3 O +
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
170.32 O -
, O +
170.19 O -
, O +
169.29 O -
, O +
169.10 O +
( O -
6 O +
CH3 O +
C O +
O O -
, O +
2 O +
CO O -
) O -
, O +
100.37 O +
( O -
C-1b O -
) O -
, O +
93.26 O +
( O -
C-1a O -
) O -
, O +
75.08 O +
( O -
C-3a O -
) O -
, O +
71.86 O +
( O -
C-5a O -
) O -
, O +
70.84 O +
( O -
C-3b O -
) O -
, O +
70.47 O +
( O -
C-5b O -
) O -
, O +
69.70 O +
( O -
C-4a O -
) O -
, O +
68.97 O +
( O -
C-2b O -
) O -
, O +
66.76 O +
( O -
C-4b O -
) O -
, O +
62.70 O +
( O -
C-6a O -
) O -
, O +
60.76 O +
( O -
C-6b O -
) O -
, O +
57.69 O +
( O -
C-2a O -
) O -
, O +
25.27 O +
[ O -
SiC O -
( O -
C O +
H3 O +
) O -
3 O +
] O -
, O +
20.78 O -
, O +
20.65 O -
, O +
20.53 O +
( O -
6 O +
C O +
H3 O +
CO O -
) O -
, O +
8.83 O +
( O -
2 O +
CH3 O +
) O -
, O +
−4.24 O +
( O -
SiCH3 O +
) O -
, O +
−5.60 O +
( O -
SiCH3 O +
) O -
. O +

FAB O +
MS O +
( O -
positive O +
mode O -
, O +
NBOH O -
/ O -
NaI O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
838 O +
[ O -
MNa+ O +
] O -
, O +
988 O +
[ O -
MNaI O -
] O -
Na+ O +
. O +

Anal O -
. O +

Calcd O +
for O +
C36 O +
H53 O +
NO18 O +
Si O +
( O -
815.87 O -
) O -
: O +
C O -
, O +
52.99 O -
; O +
H O -
, O +
6.54 O -
; O +
N O -
, O +
1.71 O -
. O +

Found O -
: O +
C O -
, O +
52.87 O -
; O +
H O -
, O +
6.73 O -
; O +
N O -
, O +
1.32 O -
. O +

3.14 O +
O- O -
[ O -
( O -
2,3,4,6-Tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
-4,6-di O -
- O -
O O -
- O -
acetyl-2-deoxy-2-dimethylmaleimido O -
- O -
α O -
/ O -
β O -
- O -
d O +
-glucopyranosyl O -
] O -
trichloroacetimidate O +
( O -
21 O +
) O +
A O +
mixture O +
of O +
19 O +
( O -
1.047 O +
g O -
, O +
1.28 O +
mmol O -
) O -
, O +
glacial O +
AcOH O +
( O -
0.084 O +
g O -
, O +
1.408 O +
mmol O -
, O +
85.0 O +
μL O -
) O +
and O +
TBAF O +
( O -
0.368 O +
g O -
, O +
1.41 O +
mmol O -
) O +
in O +
dry O +
THF O +
( O -
10 O +
mL O -
) O +
was O +
reacted O +
and O +
worked O +
up O +
as O +
described O +
for O +
6 O +
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
2:1 O +
EtOAc O -
– O -
petroleum O +
ether O -
) O +
to O +
yield O +
20 O +
( O -
0.9 O +
g O -
, O +
quantitative O -
) O +
as O +
a O +
white O +
foam O -
. O +

TLC O +
( O -
2:1 O +
EtOAc O -
– O -
petroleum O +
ether O -
) O -
: O +
R O +
f O +
0.24 O -
. O +

A O +
solution O +
of O +
the O +
aforementioned O +
foam O +
( O -
0.9 O +
g O -
, O +
1.28 O +
mmol O -
) O +
in O +
dry O +
CH2 O +
Cl2 O +
( O -
5 O +
mL O -
) O +
was O +
treated O +
by O +
trichloroacetonitrile O +
( O -
0.83 O +
mL O -
, O +
8.1 O +
mmol O -
) O +
and O +
DBU O +
( O -
0.03 O +
mL O -
, O +
1.8 O +
mmol O -
) O +
with O +
stirring O -
. O +

After O +
9 O +
h O -
, O +
the O +
solution O +
was O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1.5:1 O +
EtOAc O -
– O -
petroleum O +
ether+1 O -
% O +
Et3 O +
N O -
) O +
to O +
yield O +
21 O +
( O -
0.932 O +
g O -
, O +
85 O -
% O -
) O +
as O +
a O +
fluorescent O +
foam O +
in O +
the O +
ratio O +
of O +
α O -
: O -
β O +
1:5 O -
. O +

TLC O +
( O -
1.5:1 O +
EtOAc O -
– O -
petroleum O +
ether+1 O -
% O +
Et3 O +
N O -
) O -
: O +
R O +
f O +
0.28 O -
; O +
1 O +
H O +
NMR O +
( O -
250 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
8.66 O +
( O -
s O -
, O +
0.15 O +
H O -
, O +
NHα O +
) O -
, O +
8.62 O +
( O -
s O -
, O +
0.85 O +
H O -
, O +
NHβ O +
) O -
, O +
6.19 O +
( O -
d O -
, O +
0.15 O +
H O -
, O +
J O +
1,2 O +
3.2 O +
Hz O -
, O +
H-1aa O +
) O -
, O +
6.15 O +
( O -
d O -
, O +
0.85 O +
H O -
, O +
J O +
1,2 O +
8.9 O +
Hz O -
, O +
H-1aβ O +
) O -
, O +
5.31–3.76 O +
( O -
m O -
, O +
13 O +
H O -
) O -
, O +
2.13 O -
, O +
2.11 O -
, O +
2.08 O -
, O +
2.07 O -
, O +
1.98 O -
, O +
1.94 O -
, O +
1.81 O +
( O -
7 O +
s O -
, O +
24 O +
H O -
, O +
2 O +
CH3 O +
, O +
6 O +
CH3 O +
CO O -
) O -
. O +

FABMS O +
( O -
positive O +
mode O -
, O +
NBOH O -
/ O -
NaI O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
869 O +
[ O -
MNa+ O +
] O -
, O +
1019 O +
[ O -
MNaI O -
] O -
Na+ O +
. O +

Anal O -
. O +

Calcd O +
for O +
C32 O +
H39 O +
N2 O +
Cl3 O +
O18 O +
( O -
846.02 O -
) O -
: O +
C O -
, O +
45.42 O -
; O +
H O -
, O +
4.64 O -
; O +
N O -
, O +
3.31 O -
. O +

Found O -
: O +
C O -
, O +
44.86 O -
; O +
H O -
, O +
4.49 O -
; O +
N O -
, O +
3.43 O -
. O +

3.15 O +
Benzyl O +
( O -
2,3,4,6-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
4,6-di O -
- O -
O O -
- O -
acetyl-2-deoxy-2-dimethylmaleimido O -
- O -
β O -
- O -
d O +
-glucopyranosyl O -
) O -
- O -
( O -
1→3 O -
) O -
- O -
( O -
2,4,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-2,3,6-tri O -
- O -
O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
22 O +
) O +
A O +
mixture O +
of O +
21 O +
( O -
0.16 O +
g O -
, O +
0.177 O +
mmol O -
) O +
and O +
8 O +
( O -
0.15 O +
g O -
, O +
0.154 O +
mmol O -
) O +
in O +
dry O +
MeCN O +
( O -
1 O +
mL O -
) O +
was O +
stirred O +
under O +
nitrogen O +
at O +
rt O +
for O +
10 O +
min O +
while O +
Me3 O +
SiOTf O +
( O -
0.01 O +
M O +
in O +
MeCN O -
, O +
0.2 O +
mL O -
) O +
was O +
added O +
dropwise O +
and O +
the O +
mixture O +
was O +
stirred O +
overnight O -
, O +
then O +
neutralized O +
with O +
Et3 O +
N O +
and O +
evaporated O +
under O +
reduced O +
pressure O -
. O +

The O +
residue O +
was O +
purified O +
by O +
flash O +
chromatography O +
( O -
1.5:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O +
to O +
yield O +
22 O +
( O -
0.192 O +
g O -
, O +
75 O -
% O -
) O +
as O +
a O +
white O +
foam O -
. O +

TLC O +
( O -
1.5:1 O +
petroleum O +
ether O -
– O -
EtOAc O -
) O -
: O +
R O +
f O +
0.13 O -
; O +
[ O -
α O +
] O -
D O +
−12.3 O -
° O +
( O -
c O +
0.33 O -
, O +
CHCl3 O +
) O -
; O +
1 O +
H O +
NMR O +
( O -
600 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.30–7.10 O +
( O -
m O -
, O +
35 O +
H O -
, O +
7 O +
Ph O -
) O -
, O +
5.27 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
3.5 O +
Hz O -
, O +
H-4d O -
) O -
, O +
5.16 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
1,2 O +
8.4 O +
Hz O -
, O +
H-1c O -
) O -
, O +
4.97 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
= O -
J O +
4,5 O +
9.5 O +
Hz O -
, O +
H-4c O -
) O -
, O +
4.94–4.91 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-2d O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.86 O -
, O +
4.27 O +
( O -
2 O +
d O -
, O +
2 O +
H O -
, O +
J O +
gem O +
12.1 O +
Hz O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.78 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
2,3 O +
10.4 O -
, O +
J O +
3,4 O +
3.5 O +
Hz O -
, O +
H-3d O -
) O -
, O +
4.85 O -
, O +
4.70 O +
( O -
2 O +
d O -
, O +
2 O +
H O -
, O +
J O +
gem O +
10.8 O +
Hz O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.62–4.51 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-3c O -
, O +
2 O +
CH O +
2 O +
Ph O -
) O -
, O +
4.47 O +
( O -
d O -
, O +
1 O +
H O -
, O +
J O +
gem O +
11.5 O +
Hz O -
, O +
1 O +
H O -
, O +
CH O +
HPh O -
) O -
, O +
4.36–4.31 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-1b O -
, O +
H-1a O -
, O +
CH O +
2 O +
Ph O -
) O -
, O +
4.21–4.18 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-6c O -
, O +
H-6′c O -
, O +
CH O +
HPh O -
) O -
, O +
4.11–4.08 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-1d O -
, O +
H-2c O -
, O +
H-6d O -
, O +
H-6′d O -
) O -
, O +
3.96 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
J O +
3,4 O +
2.6 O +
Hz O -
, O +
H-4b O -
) O -
, O +
3.91 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-4a O -
) O -
, O +
3.75 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5c O -
) O -
, O +
3.71 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5d O -
) O -
, O +
3.60–3.50 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-6′b O -
, O +
H-3b O -
, O +
H-2b O -
, O +
H-6′a O -
) O -
, O +
3.41–3.36 O +
( O -
m O -
, O +
5 O +
H O -
, O +
H-6b O -
, O +
H-5b O -
, O +
H-6a O -
, O +
H-2a O -
, O +
H-3a O -
) O -
, O +
2.99 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5a O -
) O -
, O +
2.10–1.90 O +
( O -
6 O +
s O -
, O +
18 O +
H O -
, O +
6 O +
CH3 O +
CO O -
) O -
, O +
1.70 O +
( O -
br.s O -
, O +
3 O +
H O -
, O +
CH3 O +
) O -
, O +
1.50 O +
( O -
br.s O -
, O +
3 O +
H O -
, O +
CH3 O +
) O -
. O +

13 O +
C O +
NMR O +
( O -
150.9 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
102.80 O +
( O -
C-1a O -
, O +
C-1b O -
) O -
, O +
100.50 O +
( O -
C-1d O -
) O -
, O +
99.90 O +
( O -
C-1c O -
) O -
, O +
83.30 O +
( O -
C-3a O -
) O -
, O +
82.60 O +
( O -
C-3b O -
) O -
, O +
82.00 O +
( O -
C-2a O -
) O -
, O +
79.00 O +
( O -
C-2b O -
) O -
, O +
76.70 O +
( O -
C-4b O -
) O -
, O +
76.30 O +
( O -
C-4a O -
) O -
, O +
75.70 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
74.50 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
75.20 O +
( O -
C-5a O -
, O +
C O +
H2 O +
Ph O -
) O -
, O +
74.60 O +
( O -
C-3c O -
) O -
, O +
74.30 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.70 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.60 O +
( O -
C O +
H2 O +
Ph O -
) O -
, O +
73.40 O +
( O -
C-5b O -
) O -
, O +
71.90 O +
( O -
C-5c O -
) O -
, O +
71.10 O +
( O -
C-3d O -
, O +
C O +
H2 O +
Ph O -
) O -
, O +
70.80 O +
( O -
C-5d O -
) O -
, O +
69.70 O +
( O -
C-4c O -
) O -
, O +
69.30 O +
( O -
C-2d O -
) O -
, O +
68.50 O +
( O -
C-6b O -
) O -
, O +
68.10 O +
( O -
C-6a O -
) O -
, O +
67.00 O +
( O -
C-4d O -
) O -
, O +
62.80 O +
( O -
C-6c O -
) O -
, O +
60.90 O +
( O -
C-6d O -
) O -
, O +
56.20 O +
( O -
C-2c O -
) O -
. O +

MALDIMS O +
( O -
positive O +
mode O -
, O +
DHB O -
/ O -
THT O -
- O -
matrix O -
) O -
: O +
m O +
/z O +
1679 O +
[ O -
MNa+ O +
] O -
. O +

Anal O -
. O +

Calcd O +
for O +
C91 O +
H101 O +
NO28 O +
( O -
1656.72 O -
) O -
: O +
C O -
, O +
65.96 O -
; O +
H O -
, O +
6.14 O -
; O +
N O -
, O +
0.84 O -
. O +

Found O -
: O +
C O -
, O +
65.55 O -
; O +
H O -
, O +
5.96 O -
; O +
N O -
, O +
0.78 O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
the O +
European O +
Community O +
( O -
grant O +
No. O +
ERB O +
4061 O +
PL O +
95 O -
- O -
0372 O -
) O -
, O +
the O +
Deutsche O +
Forschungsgemeinschaft O +
and O +
the O +
Fonds O +
der O +
Chemischen O +
Industrie O -
. O +

M.R.E.A. O +
is O +
grateful O +
for O +
a O +
stipend O +
within O +
the O +
channel O +
program O +
of O +
the O +
Egyptian O +
Government O -
. O +

The O +
help O +
of O +
Dr O +
Armin O +
Geyer O +
in O +
structural O +
assignments O +
is O +
gratefully O +
acknowledged O -
. O +

Cholinesterases B-Gene +
have O +
been O +
extensively O +
studied O +
for O +
several O +
years O -
. O +

They O +
have O +
two O +
known O +
actions O -
: O +
acetylcholinesterase B-Gene +
( O -
AChE B-Gene -
, O +
EC B-Gene +
3.1.1.7 I-Gene -
) O +
plays O +
a O +
key O +
role O +
in O +
the O +
nervous O +
system O +
where O +
it O +
terminates O +
the O +
neurotransmitter O +
action O +
of O +
acetylcholine O -
, O +
and O -
, O +
when O +
present O +
in O +
non O -
- O -
cholinergic O +
contexts O -
, O +
as O +
is O +
for O +
example O +
vertebrate O +
butyrylcholinesterase B-Gene -
, O +
( O -
EC B-Gene +
3.1.1.8 I-Gene -
) O +
they O +
are O +
believed O +
to O +
metabolise O +
xenobiotics O -
. O +

These O +
enzymes B-Gene +
have O +
two O +
distinct O +
substrate O +
binding O +
sites O -
: O +
the O +
catalytic O +
site O +
which O +
lies O +
at O +
the O +
bottom O +
of O +
a O +
20 O +
Å O -
- O -
deep O +
gorge O +
and O +
a O +
peripheral O +
site O +
composed O +
of O +
numerous O +
aromatic O +
residues O +
lining O +
the O +
active O +
site O +
gorge O +
[ O -
1,2 O -
] O +
. O +

The O +
catalytic O +
site O +
can O +
be O +
divided O +
into O +
two O +
subsites O -
, O +
the O +
esteratic O +
site O +
represented O +
by O +
Ser200 O +
which O +
is O +
activated O +
by O +
a O +
catalytic O +
triad O +
and O +
the O +
catalytic O +
anionic O +
site O +
represented O +
by O +
Trp84 O +
which O +
participates O +
in O +
the O +
recognising O +
the O +
positively O +
charged O +
choline O +
part O +
of O +
the O +
substrate O -
. O +

Very O +
efficient O +
metabolization O +
of O +
acyl O +
esters O +
by O +
cholinesterases B-Gene +
takes O +
place O +
at O +
the O +
bottom O +
of O +
the O +
gorge O -
. O +

The O +
hydrolysis O +
of O +
acetylcholine O +
which O +
is O +
nearly O +
as O +
fast O +
as O +
allowed O +
by O +
diffusion O +
[ O -
3,4 O -
] O +
proceeds O +
in O +
three O +
steps O -
: O +
the O +
reversible O +
formation O +
of O +
a O +
Michaelian O +
complex O -
, O +
followed O +
by O +
the O +
acylation O +
and O +
subsequently O +
by O +
the O +
deacetylation O +
of O +
Ser200 O +
[ O -
5 O -
] O +
. O +

As O +
substrate O +
also O +
binds O +
to O +
the O +
peripheral O +
site O -
, O +
different O +
forms O +
of O +
the O +
enzyme B-Gene +
will O +
exist O +
depending O +
on O +
which O +
sites O +
are O +
occupied O -
. O +

In O +
the O +
insect O +
enzyme B-Gene -
, O +
hydrolysis O +
of O +
the O +
substrate O +
deviates O +
from O +
Michaelian O +
behaviour O -
, O +
with O +
activation O +
at O +
low O +
substrate O +
concentration O +
and O +
inhibition O +
at O +
high O +
concentration O +
[ O -
6 O -
] O +
. O +

To O +
describe O +
this O +
activity O -
, O +
we O +
recently O +
tested O +
various O +
kinetic O +
models O +
by O +
fitting O +
and O +
finally O +
proposed O +
a O +
putative O +
scheme O +
able O +
to O +
explain O +
all O +
our O +
data O +
sets O +
( O -
Scheme O +
1 O +
simplified O +
in O +
Scheme O +
2 O +
) O -
. O +

It O +
supports O +
a O +
secondary O +
substrate O +
binding O +
site O +
on O +
the O +
protein B-Gene +
distinct O +
from O +
the O +
catalytic O +
site O -
. O +

Binding O +
to O +
the O +
catalytic O +
site O +
located O +
at O +
the O +
bottom O +
of O +
the O +
gorge O +
seems O +
to O +
be O +
irreversible O -
, O +
suggesting O +
that O +
each O +
molecule O +
of O +
substrate O +
which O +
enters O +
the O +
active O +
site O +
gorge O +
is O +
metabolised O -
. O +

Reversible O +
binding O +
at O +
the O +
peripheral O +
site O +
is O +
high O +
affinity O +
in O +
the O +
free O +
enzyme B-Gene +
( O -
4 O +
μM O -
) O -
, O +
suggesting O +
that O +
this O +
increases O +
the O +
probability O +
of O +
the O +
substrate O +
entering O +
the O +
active O +
site O +
gorge O -
. O +

Active O +
site O +
occupation O +
then O +
leads O +
to O +
a O +
decrease O +
in O +
peripheral O +
site O +
affinity O +
( O -
30 O +
mM O -
) O -
. O +

Peripheral O +
site O +
occupation O +
decreases O +
the O +
rate O +
constant O +
for O +
a O +
entrance O +
of O +
the O +
second O +
substrate O +
molecule O +
into O +
the O +
catalytic O +
site O +
and O +
strongly O +
affects O +
the O +
catalytic O +
activity O +
of O +
the O +
enzyme B-Gene -
. O +

This O +
results O +
in O +
both O +
an O +
apparent O +
activation O +
at O +
low O +
substrate O +
concentration O +
and O +
a O +
general O +
inhibition O +
at O +
high O +
substrate O +
concentration O -
. O +

Certain O +
reversible O +
inhibitors O +
bind O +
to O +
all O +
enzymatic B-Gene +
forms O +
while O +
others O +
bind O +
only O +
to O +
some O +
of O +
them O -
, O +
such O +
as O +
the O +
free B-Gene +
or O +
the O +
acylated B-Gene +
enzyme I-Gene -
. O +

When O +
binding O +
occurs O +
at O +
the O +
catalytic O +
site O -
, O +
the O +
acetyl B-Gene -
– I-Gene -
enzyme I-Gene -
– O -
inhibitor O +
complex O +
usually O +
deacetylates O +
at O +
a O +
slower O +
rate O +
than O +
the O +
free O +
acetyl B-Gene -
- I-Gene -
enzyme I-Gene +
[ O -
7,8 O -
] O +
while O +
ligand O +
binding O +
at O +
the O +
peripheral O +
site O +
modulates O +
activity O +
[ O -
9,10 O -
] O +
by O +
destabilising O +
of O +
substrate O +
binding O +
at O +
the O +
catalytic O +
site O +
[ O -
11 O -
] O +
through O +
conformational O +
changes O +
[ O -
12 O -
] O +
. O +

Each O +
inhibitor O +
may O +
occupy O +
a O +
distinct O +
position O +
and O +
be O +
oriented O +
somewhat O +
differently O +
at O +
the O +
two O +
anionic O +
sites O +
as O +
evidenced O +
by O +
kinetics O +
[ O -
13 O -
] O +
, O +
in O +
vitro O +
mutagenesis O +
[ O -
14 O -
] O +
and O +
structural O +
data O +
[ O -
15 O -
] O +
. O +

Here O -
, O +
we O +
test O +
the O +
proposed O +
kinetic O +
model O +
for O +
insect O +
AChE B-Gene +
using O +
three O +
reversible O +
inhibitors O -
: O +
tetramethylammonium O +
( O -
TMA O -
) O -
, O +
edrophonium O +
and O +
choline O -
. O +

The O +
model O +
suggests O +
that O +
TMA O +
binds O +
to O +
two O +
sites O +
on O +
the O +
protein B-Gene +
including O +
the O +
catalytic O +
site O -
, O +
while O +
edrophonium O +
and O +
choline O +
bind O +
only O +
to O +
one O +
site O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
AChE B-Gene +
synthesis O +
and O +
purification O +
Drosophila O +
AChE B-Gene +
was O +
produced O +
in O +
baculovirus O +
infected O +
cells O -
, O +
purified O +
and O +
stabilized O +
according O +
to O +
Estrada O +
and O +
Fournier O +
[ O -
16 O -
] O +
. O +

Briefly O -
, O +
a O +
hydrophilic O +
protein B-Gene +
was O +
produced O +
by O +
cloning O +
a O +
cDNA O +
truncated O +
at O +
the O +
3′ O +
end O +
encoding O +
an O +
hydrophobic O +
peptide O +
exchanged O +
to O +
a O +
glycolipid O +
anchor O -
. O +

The O +
AChE B-Gene +
was O +
secreted O +
in O +
the O +
culture O +
medium O +
and O +
purified O +
by O +
affinity O +
chromatography O +
followed O +
by O +
diafiltration O +
and O +
anion O +
exchange O +
chromatography O +
to O +
eliminate O +
copurified O +
proteases B-Gene -
. O +

As O +
drosophila O +
AChE B-Gene +
was O +
not O +
stable O +
when O +
diluted O -
, O +
bovine B-Gene +
serum I-Gene +
albumine I-Gene +
was O +
added O +
to O +
the O +
sample O +
to O +
1 O +
mg O -
/ O -
ml O -
. O +

2.2 O +
Kinetics O +
of O +
substrate O +
hydrolysis O +
Kinetic O +
analysis O +
was O +
performed O +
at O +
25 O -
° O -
C O +
in O +
25 O +
mM O +
phosphate O +
buffer O +
pH O +
7.25 O -
. O +

Hydrolysis O +
of O +
acetylthiocholine O +
iodide O +
was O +
followed O +
at O +
412 O +
nm O +
using O +
the O +
method O +
of O +
Ellman O +
et O +
al. O +
[ O -
17 O -
] O +
, O +
with O +
substrate O +
concentrations O +
of O +
1 O +
μM O +
to O +
200 O +
mM. O +
Reversible O +
inhibitions O +
were O +
tested O +
from O +
0.25 O +
to O +
80 O +
mM O +
for O +
TMA O -
, O +
from O +
1 O +
to O +
100 O +
μM O +
for O +
edrophonium O +
and O +
from O +
0.01 O +
to O +
10 O +
mM O +
for O +
choline O -
. O +

2.3 O +
Data O +
analysis O +
Initial O +
rate O +
constants O +
obtained O +
in O +
the O +
presence O +
of O +
inhibitor O +
at O +
various O +
concentrations O +
were O +
analysed O +
according O +
to O +
the O +
mechanistic O +
models O +
previously O +
described O +
[ O -
18 O -
] O +
considering O +
that O +
the O +
inhibitor O +
molecule O +
can O +
bind O +
to O +
a O +
peripheral O +
site O +
and/or O +
to O +
the O +
catalytic O +
site O -
. O +

The O +
corresponding O +
rate O +
equations O +
were O +
derived O +
and O +
fitted O +
simultaneously O +
to O +
the O +
complete O +
set O +
of O +
data O +
for O +
each O +
inhibitor O -
. O +

Among O +
the O +
models O +
tested O +
corresponding O +
to O +
the O +
different O +
binding O +
possibilities O -
, O +
we O +
chose O +
the O +
simplest O +
one O +
which O +
fitted O +
all O +
data O -
. O +

Indeed O -
, O +
it O +
was O +
found O -
, O +
in O +
each O +
inhibition O +
mechanism O -
, O +
that O +
not O +
all O +
the O +
reaction O +
steps O +
were O +
necessary O -
, O +
so O +
in O +
the O +
analysis O +
of O +
kinetic O +
data O -
, O +
were O +
left O +
out O -
. O +

For O +
each O +
inhibitor O +
all O +
the O +
kinetic O +
constants O +
valid O +
in O +
the O +
presence O +
of O +
the O +
substrate O +
were O +
determined O -
. O +

Their O +
evaluations O +
were O +
carried O +
out O +
by O +
means O +
of O +
a O +
non O -
- O -
linear O +
regression O +
program O +
[ O -
19 O -
] O +
and O +
according O +
to O +
general O +
criteria O +
for O +
the O +
goodness O +
of O +
fit O +
[ O -
20 O -
] O +
. O +

3 O +
Results O +
and O +
discussion O +
Scheme O +
1 O +
presents O +
a O +
putative O +
model O +
allowing O +
the O +
analysis O +
the O +
kinetic O +
data O +
of O +
insect O +
AChE. B-Gene +
However O -
, O +
some O +
of O +
the O +
eight O +
kinetic O +
parameters O +
proved O +
to O +
be O +
unstable O +
and O +
thus O +
were O +
not O +
evaluated O +
correctly O -
. O +

Therefore O -
, O +
the O +
three O -
- O -
step O +
model O +
was O +
reduced O +
to O +
a O +
two- O +
step O +
model O +
[ O -
21 O -
] O +
. O +

Several O +
simplifications O +
are O +
possible O -
. O +

One O +
possibility O +
is O +
to O +
combine O +
acylation O +
and O +
deacylation O +
into O +
a O +
single O +
rate O +
constant O +
[ O -
22 O -
] O +
. O +

Although O +
this O +
simplified O +
model O +
is O +
useful O +
and O +
currently O +
used O +
[ O -
23 O -
] O +
, O +
it O +
can O +
only O +
explain O +
biphasic O +
kinetics O +
with O +
either O +
activation O +
or O +
inhibition O +
and O +
so O +
can O -
not O +
be O +
used O +
to O +
explain O +
our O +
experimental O +
data O +
unless O +
it O +
is O +
extended O +
to O +
three O +
binding O +
sites O +
for O +
the O +
substrate O -
. O +

Two O +
other O +
simplifications O +
resulting O +
in O +
the O +
same O +
equation O +
were O +
operative O +
for O +
all O +
our O +
experimental O +
data O -
, O +
obtained O +
with O +
different O +
mutated O +
enzymes B-Gene +
and O +
in O +
different O +
experimental O +
conditions O -
. O +

In O +
the O +
first O +
simplification O -
, O +
we O +
assume O +
that O +
each O +
molecule O +
which O +
enters O +
the O +
active O +
site O +
gorge O +
is O +
metabolised O +
and O +
thus O +
that O +
ES O +
complex O +
formation O +
is O +
an O +
irreversible O +
step O +
[ O -
24,25 O -
] O +
( O -
Scheme O +
2 O +
) O -
. O +

In O +
the O +
second O +
simplification O -
, O +
reversible O +
Michaelian O +
complex O +
formation O +
and O +
acylation O +
are O +
included O +
in O +
the O +
same O +
step O -
, O +
the O +
scheme O +
remains O +
identical O +
to O +
Scheme O +
2 O +
with O +
EA O +
instead O +
of O +
ES O -
. O +

In O +
the O +
presence O +
of O +
a O +
reversible O +
inhibitor O -
, O +
hydrolysis O +
can O +
be O +
described O +
by O +
Scheme O +
3 O +
assuming O +
that O +
two O +
binding O +
sites O +
exist O +
for O +
the O +
substrate O +
and O +
the O +
inhibitor O +
on O +
the O +
protein B-Gene +
( O -
the O +
catalytic O +
site O +
and O +
a O +
peripheral O +
site O -
) O -
. O +

From O +
this O +
scheme O -
, O +
the O +
kinetic O +
steady O -
- O -
state O +
rate O +
equation O +
was O +
derived: O -
( O -
1 O -
) O +
v O +
E O +
t O +
= O -
k3 O +
S O +
1+a O +
S O +
K4 O +
+ O -
c O +
I O +
K7 O +
k3 O +
ki O +
1+a O +
S O +
K4 O +
+ O -
c O +
I O +
K7 O +
1 O -
+ O +
S O +
K3 O +
+ O +
I O +
K6 O +
+ O +
I O +
K1 O +
+ O +
S O +
I O +
K2 O +
K3 O +
+ O +

I O +
2 O +
K5 O +
K6 O +
1+b O +
S O +
K3 O +
+ O -
d O +
I O +
K6 O +
+ O +
S O +
1 O -
+ O +
S O +
K4 O +
+ O +
I O +
K7 O +

The O +
values O +
of O +
all O +
relevant O +
kinetic O +
constants O +
are O +
presented O +
in O +
Scheme O +
4 O +
and O +
in O +
graphical O +
form O +
along O +
with O +
the O +
corresponding O +
experimental O +
data O +
in O +
Fig. O +
1 O +
. O +

The O +
analysis O +
of O +
experimental O +
data O +
obtained O +
in O +
the O +
presence O +
of O +
TMA O -
, O +
edrophonium O +
or O +
choline O +
was O +
performed O +
by O +
fitting O +
to O +
all O +
data O +
simultaneously O +
for O +
each O +
inhibitor O -
. O +

In O +
each O +
case O -
, O +
Eq. O +
( O -
1 O -
) O +
fits O +
the O +
experimental O +
results O +
well O -
. O +

Meanwhile O -
, O +
for O +
choline O +
and O +
edrophonium O -
, O +
experimental O +
data O +
can O +
be O +
resolved O +
by O +
a O +
simplified O +
scheme O +
using O +
only O +
10 O +
parameters O -
. O +

In O +
each O +
case O +
all O +
parameters O +
were O +
estimated O +
without O +
constraint O -
. O +

It O +
turned O +
out O +
that O +
the O +
values O +
of O +
the O +
six O +
parameters O +
corresponding O +
to O +
the O +
reaction O +
without O +
inhibitor O +
did O +
not O +
significantly O +
change O +
if O +
the O +
analysis O +
included O +
the O +
data O +
from O +
acetylcholinesterase B-Gene +
inhibition O -
. O +

For O +
edrophonium O +
and O +
choline O -
, O +
the O +
complex O +
IEI O +
is O +
not O +
necessary O +
to O +
describe O +
data O -
, O +
suggesting O +
that O +
there O +
is O +
only O +
one O +
binding O +
site O +
on O +
the O +
enzyme B-Gene -
. O +

The O +
binding O +
is O +
non- O +
competitive O +
for O +
the O +
peripheral O +
site O -
. O +

In O +
addition O -
, O +
the O +
complex O +
EIS O -
, O +
resulting O +
from O +
the O +
binding O +
of O +
an O +
inhibitor O +
molecule O +
to O +
ES O -
, O +
is O +
necessary O +
to O +
correctly O +
fit O +
the O +
kinetic O +
data O -
. O +

This O +
suggests O +
that O +
the O +
inhibitor O +
molecule O +
binds O +
at O +
the O +
catalytic O +
site O +
even O +
if O +
it O +
is O +
occupied O -
. O +

In O +
that O +
case O -
, O +
the O +
second O +
simplification O +
is O +
operative O +
and O +
ES O +
is O +
replaced O +
by O +
EA O +
in O +
Schemes O +
2–4 O +
. O +

Kinetic O +
and O +
structural O +
data O +
obtained O +
for O +
vertebrate O +
AChE B-Gene +
are O +
in O +
accordance O +
with O +
this O +
binding O +
at O +
the O +
catalytic O +
site O +
[ O -
15,26 O -
] O +
. O +

In O +
a O +
second O +
hypothesis O -
, O +
the O +
inhibitor O +
can O +
bind O +
to O +
the O +
enzymatic O +
form O +
ES O -
, O +
suggesting O +
that O +
it O +
binds O +
on O +
a O +
peripheral O +
site O +
different O +
from O +
that O +
of O +
the O +
substrate O -
. O +

Following O +
the O +
two O +
hypothesis O -
, O +
the O +
inhibitor O +
binding O +
to O +
the O +
protein B-Gene +
prevents O +
the O +
substrate O +
becoming O +
positionned O +
at O +
the O +
catalytic O +
site O +
and O +
decreases O +
the O +
acylation O +
and/or O +
the O +
deacylation O +
step O +
( O -
c O +
= O -
0.14 O +
and O +
0.23 O +
for O +
choline O +
and O +
edrophonium O +
respectively O -
) O -
. O +

For O +
TMA O -
, O +
the O +
total O +
Scheme O +
3 O +
must O +
be O +
used O +
since O +
all O +
simplifications O +
tested O +
resulted O +
in O +
a O +
decrease O +
of O +
the O +
correlation O +
coefficient O -
. O +

As O +
the O +
IEI O +
species O +
was O +
useful O +
to O +
describe O +
data O -
, O +
it O +
seems O +
that O +
the O +
TMA O +
competes O +
with O +
the O +
substrate O +
at O +
the O +
peripheral O +
and O +
the O +
catalytic O +
sites O -
. O +

Such O +
a O +
result O +
is O +
not O +
in O +
agreement O +
with O +
previous O +
reports O +
suggesting O +
that O +
TMA O +
binds O +
to O +
a O +
single O +
site O +
on O +
the O +
vertebrate O +
enzyme B-Gene +
[ O -
27,28 O -
] O +
but O +
could O +
be O +
related O +
to O +
the O +
enzyme B-Gene +
origin O +
which O +
shows O +
more O +
complex O +
kinetics O +
with O +
substrate O +
activation O +
and O +
inhibition O -
. O +

In O +
contrast O +
to O +
the O +
substrate O -
, O +
TMA O +
binding O +
at O +
the O +
peripheral O +
site O +
does O +
not O +
hinder O +
the O +
entrance O +
of O +
the O +
substrate O +
molecule O +
into O +
the O +
gorge O +
( O -
d O +
= O -
1 O -
) O +
since O +
it O +
is O +
a O +
smaller O +
molecule O +
than O +
the O +
substrate O -
. O +

Analysis O +
of O +
constants O +
obtained O +
without O +
inhibitors O +
( O -
Scheme O +
2 O +
) O +
suggests O +
that O +
binding O +
of O +
the O +
substrate O +
at O +
the O +
peripheral O +
site O +
decreases O +
the O +
rate O +
constant O +
of O +
substrate O +
entrance O +
into O +
the O +
active O +
site O +
gorge O +
( O -
123 O -
/ O -
21 O +
μM−1 O +
s−1 O +
) O -
, O +
and O +
decreases O +
substrate O +
hydrolysis O +
( O -
995 O -
/ O -
6.7 O +
s−1 O +
) O -
. O +

For O +
inhibitors O -
, O +
the O +
same O +
relation O +
was O +
observed O -
: O +
peripheral O +
site O +
occupation O +
by O +
a O +
substrate O +
molecule O +
decreases O +
the O +
affinity O +
of O +
the O +
inhibitor O +
at O +
the O +
catalytic O +
site O +
( O -
K O +
2 O +
is O +
always O +
greater O +
than O +
K O +
1 O +
) O -
. O +

The O +
effect O -
, O +
however O -
, O +
depends O +
on O +
the O +
inhibitor O -
: O +
it O +
is O +
strong O +
with O +
choline O +
but O +
weaker O +
with O +
edrophonium O +
and O +
TMA O -
. O +

This O +
interplay O +
between O +
the O +
two O +
sites O +
is O +
in O +
accordance O +
with O +
other O +
studies O +
which O +
also O +
showed O +
that O +
peripheral O +
site O +
occupation O +
by O +
a O +
substrate O +
molecule O +
modulates O +
the O +
activity O +
of O +
the O +
enzyme B-Gene +
by O +
destabilization O +
of O +
substrate O +
at O +
the O +
catalytic O +
site O +
[ O -
9–11,2,12,29 O -
] O +
. O +

Destabilization O +
seems O +
to O +
originate O +
from O +
conformational O +
changes O -
- O -
a O +
movement O +
of O +
the O +
Ω O +
loop O -
- O -
hich O +
modifies O +
the O +
orientation O +
of O +
a O +
main O +
element O +
of O +
the O +
catalytic O +
site O -
, O +
Trp84 O +
[ O -
30,31 O -
] O +
. O +

In O +
conclusion O -
, O +
this O +
study O +
shows O +
that O +
the O +
simple O +
model O +
which O +
was O +
proposed O +
for O +
the O +
reaction O +
between O +
Drosophila O +
AChE B-Gene +
and O +
its O +
substrate O +
is O +
also O +
able O +
to O +
describe O +
kinetics O +
with O +
the O +
simultaneous O +
action O +
of O +
the O +
substrate O +
and O +
a O +
reversible O +
inhibitor O -
. O +

Acknowledgements O +

We O +
thank O +
Frédéric O +
Magné O +
for O +
technical O +
assistance O -
. O +

This O +
research O +
was O +
supported O +
by O +
grants O +
from O +
DGA O -
, O +
and O +
CNRS O +
( O -
GDR O +
1105 O +
and O +
ACS.SV3 O -
) O -
. O +

At O +
least O +
some O +
of O +
the O +
behavioral O +
stimulant O +
effects O +
of O +
caffeine O +
in O +
laboratory O +
animals O +
appear O +
to O +
be O +
due O +
to O +
competitive O +
blockade O +
of O +
adenosine B-Gene +
A1 I-Gene +
and/or O +
A2A B-Gene +
receptors I-Gene -
. O +

These O +
include O +
increasing O +
the O +
locomotor O +
activity O +
of O +
rodents O +
( O -
Snyder O +
et O +
al. O -
, O +
1981 O +
) O +
and O +
the O +
rate O +
of O +
lever O +
pressing O +
of O +
monkeys O +
( O -
Spealman O -
, O +
1988 O +
) O -
. O +

In O +
addition O +
to O +
blocking O +
adenosine B-Gene +
receptors I-Gene -
, O +
caffeine O +
has O +
actions O +
on O +
intracellular O +
systems O -
; O +
for O +
example O -
, O +
it O +
inhibits O +
the O +
activity O +
of O +
cyclic B-Gene +
nucleotide I-Gene +
phosphodiesterases I-Gene -
. O +

These O +
actions O +
appear O +
to O +
contribute O +
to O +
the O +
behavioral O +
depressant O +
effects O +
of O +
high O +
doses O +
of O +
caffeine O +
and O +
might O +
limit O +
the O +
behavioral O +
stimulant O +
effects O +
of O +
lower O +
doses O +
( O -
Daly O -
, O +
1993 O +
) O -
. O +

9-Chloro-2- O -
( O -
2-furyl O -
) O -
[ O -
1,2,4 O -
] O -
triazolol O -
[ O -
1,5-c O +
] O -
quinazolin-5-amine O +
( O -
CGS O +
15943 O -
) O -
, O +
a O +
triazoloquinazoline O +
derivative O -
, O +
is O +
a O +
potent O +
antagonist O +
at O +
adenosine B-Gene +
receptors I-Gene -
, O +
with O +
some O +
selectivity O +
( O -
i.e. O -
, O +
5- O +
to O +
10-fold O -
) O +
for O +
the O +
adenosine B-Gene +
A2A I-Gene +
receptor I-Gene +
over O +
the O +
adenosine B-Gene +
A1 I-Gene +
receptor I-Gene +
( O -
Williams O +
et O +
al. O -
, O +
1987 O +
; O +
Jarvis O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

Like O +
caffeine O -
, O +
CGS O +
15943 O +
is O +
a O +
behavioral O +
stimulant O +
in O +
animals O -
. O +

It O +
dose O -
- O -
dependently O +
increases O +
the O +
locomotor O +
activity O +
of O +
rats O +
( O -
Holtzman O -
, O +
1991 O +
) O +
and O +
the O +
rate O +
at O +
which O +
squirrel O +
monkeys O +
press O +
a O +
lever O +
to O +
avoid O +
an O +
aversive O +
stimulus O +
( O -
Howell O +
and O +
Byrd O -
, O +
1993 O +
) O -
, O +
and O +
is O +
10–30 O +
times O +
more O +
potent O +
than O +
caffeine O +
in O +
doing O +
so O -
. O +

Unlike O +
caffeine O -
, O +
CGS O +
15943 O +
does O +
not O +
inhibit O +
the O +
activity O +
of O +
cyclic B-Gene +
nucleotide I-Gene +
phosphodiesterases I-Gene +
( O -
Williams O +
et O +
al. O -
, O +
1987 O +
) O -
, O +
increasing O +
the O +
likelihood O +
that O +
effects O +
that O +
the O +
two O +
drugs O +
have O +
in O +
common O +
are O +
mediated O +
by O +
the O +
blockade O +
of O +
adenosine B-Gene +
receptors I-Gene -
. O +

Adenosine B-Gene +
A2A I-Gene +
receptors I-Gene +
in O +
the O +
brain O +
are O +
localized O +
to O +
postsynaptic O +
neurons O +
of O +
the O +
basal O +
ganglia O -
, O +
often O +
co O -
- O -
expressed O +
with O +
dopamine B-Gene +
D2 I-Gene +
receptors I-Gene +
( O -
Martiniz O -
- O -
Mir O +
et O +
al. O -
, O +
1991 O +
; O +
Ferré O +
et O +
al. O -
, O +
1992 O +
) O -
. O +

Data O +
from O +
neurochemical O +
as O +
well O +
as O +
from O +
behavioral O +
studies O +
suggest O +
that O +
activation O +
of O +
these O +
receptors B-Gene +
reduces O +
neurotransmission O +
mediated O +
by O +
dopamine B-Gene +
D2 I-Gene +
-like I-Gene +
receptors I-Gene +
( O -
Ferré O +
et O +
al. O +
1991a O -
, O +
b O +
) O -
. O +

Similar O +
types O +
of O +
experimental O +
evidence O +
indicates O +
that O +
activation O +
of O +
adenosine B-Gene +
A1 I-Gene +
receptors I-Gene +
reduces O +
neurotransmission O +
mediated O +
by O +
dopamine B-Gene +
D1 I-Gene +
-like I-Gene +
receptors I-Gene +
( O -
Ferré O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

These O +
observations O +
have O +
led O +
to O +
the O +
hypothesis O +
that O +
behavioral O +
stimulant O +
effects O +
of O +
caffeine O +
reflect O -
, O +
in O +
part O -
, O +
the O +
enhancement O +
of O +
dopamine O -
- O -
mediated O +
neurotransmission O +
that O +
occurs O +
when O +
the O +
negative O +
modulatory O +
influence O +
of O +
adenosine O +
is O +
blocked O +
( O -
Ferré O +
et O +
al. O -
, O +
1992 O +
; O +
Ferré O -
, O +
1997 O +
) O -
. O +

Consistent O +
with O +
this O +
hypothesis O -
, O +
caffeine O -
- O -
induced O +
stimulation O +
of O +
the O +
locomotor O +
activity O +
of O +
rats O +
is O +
blocked O +
by O +
R O +
( O -
+ O -
) O -
-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H O +
-3-benzazepine O +
( O -
SCH O +
23390 O -
) O +
and O +
eticlopride O +
( O -
Garrett O +
and O +
Holtzman O -
, O +
1994 O +
) O -
, O +
antagonists O +
selective O +
for O +
the O +
dopamine B-Gene +
D1 B-Gene +
and O +
D2 B-Gene +
families O +
of O +
receptors B-Gene -
, O +
respectively O -
. O +

In O +
addition O -
, O +
rats O +
discriminating O +
a O +
low O +
dose O +
of O +
caffeine O +
( O -
i.e. O -
, O +
10 O +
mg O -
/ O -
kg O -
) O +
generalize O +
completely O +
to O +
nonxanthine O +
psychomotor O +
stimulants O -
, O +
such O +
as O +
cocaine O +
and O +
amphetamine O +
( O -
Mumford O +
and O +
Holtzman O -
, O +
1991 O +
) O -
, O +
drugs O +
whose O +
discriminative O +
effects O +
have O +
a O +
prominent O +
and O +
well O -
- O -
documented O +
dopamine O +
component O +
( O -
Goudie O -
, O +
1991 O +
; O +
Woolverton O -
, O +
1991 O +
) O -
. O +

These O +
rats O +
also O +
generalize O +
completely O +
to O +
CGS O +
15943 O -
. O +

Conversely O -
, O +
monkeys O +
discriminating O +
CGS O +
15943 O +
generalize O +
completely O +
to O +
caffeine O +
( O -
Holtzman O -
, O +
1996 O +
) O -
. O +

The O +
present O +
study O +
was O +
conducted O +
in O +
order O +
to O +
evaluate O +
the O +
role O +
of O +
dopamine O +
in O +
the O +
discriminative O +
stimulus O +
effects O +
of O +
CGS O +
15943 O +
in O +
squirrel O +
monkeys O -
. O +

Monkeys O +
with O +
a O +
stable O +
history O +
of O +
CGS O +
15943 O +
discrimination O +
were O +
tested O +
for O +
stimulus O +
generalization O +
to O +
dopamine B-Gene +
receptor I-Gene +
agonists O +
that O +
encompass O +
a O +
variety O +
of O +
mechanisms O +
and O +
sites O +
of O +
action O -
. O +

Some O +
of O +
those O +
drugs O -
, O +
notably O +
cocaine O +
and O +
amphetamine O -
, O +
interact O +
with O +
brain O +
monoamine O +
systems O +
in O +
addition O +
to O +
dopamine O -
. O +

Therefore O -
, O +
the O +
monkeys O +
also O +
were O +
tested O +
for O +
stimulus O +
generalization O +
to O +
selective O +
inhibitors O +
of O +
the O +
neuronal O +
uptake O +
of O +
norepinephrine O +
and O +
serotonin O -
. O +

The O +
ability O +
of O +
monoamine B-Gene -
- I-Gene -
receptor I-Gene +
antagonists O +
to O +
block O +
the O +
discriminative O +
effects O +
of O +
the O +
training O +
dose O +
of O +
CGS O +
15943 O +
also O +
was O +
determined O -
. O +

Morphine O +
and O +
phencyclidine O -
, O +
discriminable O +
drugs O +
whose O +
primary O +
actions O +
are O +
on O +
nonmonoamine O +
neuronal O +
systems O -
, O +
served O +
as O +
controls O +
for O +
pharmacological O +
selectivity O -
. O +

2 O +
Methods O +
2.1 O +
Subjects O +
The O +
subjects O +
were O +
four O +
adult O +
male O +
squirrel O +
monkeys O +
( O -
Saimiri O +
sciureus O +
) O -
, O +
designated O +
S85 O -
, O +
S88 O -
, O +
S90 O +
and O +
S92 O -
. O +

They O +
had O +
been O +
trained O +
previously O +
to O +
discriminate O +
between O +
i.m O -
. O +

injections O +
of O +
CGS O +
15943 O +
and O +
its O +
vehicle O +
and O +
had O +
undergone O +
generalization O +
testing O +
with O +
a O +
series O +
of O +
methylxanthine O +
derivatives O +
( O -
Holtzman O -
, O +
1996 O +
) O -
. O +

Between O +
experimental O +
sessions O -
, O +
the O +
monkeys O +
were O +
housed O +
two O +
per O +
cage O +
in O +
a O +
vivarium O +
where O +
they O +
had O +
continuous O +
access O +
to O +
food O +
and O +
water O -
. O +

The O +
lights O +
in O +
the O +
vivarium O +
were O +
illuminated O +
from O +
0700 O +
to O +
1900 O +
h. O +

The O +
care O +
and O +
use O +
of O +
the O +
monkeys O +
conformed O +
to O +
the O +
National O +
Institutes O +
of O +
Health O +
Guide O +
for O +
the O +
Care O +
and O +
Use O +
of O +
Laboratory O +
Animals O -
, O +
and O +
experiments O +
were O +
performed O +
according O +
to O +
a O +
protocol O +
that O +
had O +
been O +
approved O +
by O +
the O +
Institutional O +
Animal O +
Care O +
and O +
Use O +
Committee O +
of O +
Emory O +
University O -
. O +

2.2 O +
Procedure O +
The O +
monkeys O +
were O +
trained O +
and O +
tested O +
in O +
a O +
discrete O -
- O -
trial O +
avoidance O -
/ O -
escape O +
procedure O -
, O +
as O +
described O +
previously O +
( O -
Holtzman O -
, O +
1996 O +
) O -
. O +

During O +
experiments O -
, O +
they O +
were O +
seated O +
in O +
a O +
testing O +
chamber O +
and O +
secured O +
by O +
a O +
Plexiglas O +
waist O +
plate O -
. O +

The O +
chamber O +
was O +
inside O +
of O +
ventilated O +
enclosure O +
that O +
was O +
sound O -
- O -
attenuating O -
. O +

The O +
monkey O +
sat O +
facing O +
two O +
levers O +
that O +
were O +
mounted O +
10 O +
cm O +
apart O -
. O +

A O +
Plexiglas O +
barrier O +
separated O +
the O +
monkey O +
from O +
the O +
levers O -
. O +

The O +
barrier O +
had O +
2.5 O -
× O -
4.0 O +
cm O +
openings O +
on O +
each O +
end O -
; O +
a O +
monkey O +
could O +
press O +
a O +
lever O +
by O +
extending O +
its O +
arm O +
through O +
the O +
opening O +
on O +
the O +
same O +
side O +
as O +
that O +
lever O -
, O +
but O +
could O +
not O +
reach O +
both O +
levers O +
at O +
the O +
same O +
time O -
. O +

The O +
start O +
of O +
a O +
trial O +
was O +
signaled O +
by O +
illumination O +
of O +
the O +
house O +
light O +
in O +
the O +
testing O +
chamber O -
. O +

Beginning O +
5.0 O +
s O +
later O -
, O +
an O +
electric O +
current O +
of O +
constant O +
intensity O +
( O -
3.0–5.0 O +
mA O -
) O +
was O +
passed O +
through O +
a O +
pair O +
of O +
brass O +
electrodes O +
that O +
rested O +
lightly O +
on O +
a O +
shaved O +
portion O +
of O +
the O +
monkey O -
's O +
tail O -
. O +

The O +
current O +
was O +
applied O +
for O +
1.0 O +
s O +
every O +
3.0 O +
s. O +

In O +
training O +
sessions O -
, O +
a O +
response O +
on O +
the O +
correct O +
choice O +
lever O +
at O +
any O +
time O +
during O +
a O +
trial O +
ended O +
the O +
trial O -
, O +
extinguished O +
the O +
houselight O -
, O +
and O +
initiated O +
a O +
50-s O +
intertrial O +
interval O -
. O +

In O +
test O +
sessions O -
, O +
a O +
response O +
on O +
either O +
choice O +
lever O +
ended O +
the O +
trial O -
. O +

During O +
intertrial O +
intervals O +
a O +
yellow O +
stimulus O +
light O +
located O +
at O +
eye O +
level O +
between O +
the O +
two O +
lever O +
was O +
illuminated O +
and O +
each O +
response O +
resulted O +
in O +
the O +
delivery O +
of O +
a O +
30-ms O +
electrical O +
stimulus O +
to O +
the O +
tail O +
of O +
the O +
monkey O -
. O +

This O +
latter O +
contingency O +
helped O +
to O +
restrict O +
responding O +
to O +
the O +
period O +
when O +
a O +
trial O +
was O +
in O +
progress O -
. O +

A O +
response O +
on O +
the O +
incorrect O +
choice O +
lever O +
in O +
a O +
training O +
session O +
did O +
not O +
end O +
the O +
trial O +
and O +
that O +
trial O +
was O +
recorded O +
as O +
incorrect O -
. O +

In O +
the O +
absence O +
of O +
a O +
response O -
, O +
a O +
trial O +
ended O +
after O +
the O +
delivery O +
of O +
three O +
electrical O +
stimuli O +
and O +
was O +
recorded O +
as O +
an O +
incomplete O +
trial O -
. O +

Two O +
monkeys O +
had O +
been O +
trained O +
to O +
press O +
the O +
right O +
choice O +
lever O +
in O +
sessions O +
that O +
had O +
been O +
preceded O +
with O +
an O +
injection O +
of O +
1.0 O +
mg O -
/ O -
kg O +
CGS O +
15943 O +
and O +
to O +
press O +
the O +
left O +
choice O +
lever O +
in O +
sessions O +
that O +
had O +
been O +
preceded O +
with O +
an O +
injection O +
of O +
drug O -
- O -
free O +
vehicle O -
. O +

The O +
other O +
two O +
monkeys O +
had O +
the O +
opposite O +
lever O +
assignments O -
. O +

Training O +
and O +
test O +
sessions O +
consisted O +
of O +
25 O +
trials O -
. O +

Test O +
sessions O +
with O +
both O +
choice O +
lever O +
activated O +
usually O +
were O +
conducted O +
twice O +
weekly O -
, O +
3 O +
to O +
4 O +
days O +
apart O -
, O +
in O +
order O +
to O +
assess O +
stimulus O +
generalization O +
to O +
novel O +
drug O +
conditions O -
. O +

Training O +
sessions O +
with O +
only O +
the O +
correct O +
choice O +
lever O +
activated O +
were O +
conducted O +
at O +
least O +
three O +
times O +
each O +
week O +
to O +
maintain O +
stable O +
discrimination O +
performance O -
. O +

CGS O +
15943 O -
, O +
1.0 O +
mg O -
/ O -
kg O -
, O +
suspended O +
in O +
1 O -
% O +
methylcellulose O +
or O +
the O +
1 O -
% O +
methylcellulose O +
vehicle O +
was O +
injected O +
i.m O -
. O +

30 O +
min O +
before O +
a O +
training O +
session O -
; O +
drug O +
and O +
vehicle O +
were O +
administered O +
on O +
an O +
alternating O +
basis O -
. O +

If O +
a O +
monkey O +
failed O +
to O +
complete O +
correctly O +
at O +
least O +
22 O +
of O +
the O +
25 O +
trials O +
of O +
a O +
training O +
session O -
, O +
the O +
next O +
scheduled O +
test O +
session O +
was O +
postponed O +
until O +
correct O +
responding O +
in O +
22 O +
of O +
25 O +
trials O +
occurred O +
in O +
four O +
consecutive O +
training O +
sessions O -
. O +

Drugs O +
were O +
tested O +
for O +
stimulus O +
generalization O +
in O +
an O +
unsystematic O +
order O +
that O +
was O +
different O +
for O +
each O +
monkey O -
; O +
the O +
pretreatment O +
interval O +
was O +
30 O +
min O -
. O +

Tests O +
of O +
potential O +
antagonists O +
of O +
the O +
discriminative O +
effects O +
of O +
CGS O +
15943 O +
were O +
conducted O +
at O +
the O +
end O +
of O +
the O +
study O -
. O +

The O +
potential O +
antagonists O +
were O +
administered O +
15 O +
min O +
before O +
the O +
training O +
dose O +
of O +
CGS O +
15943 O -
, O +
45 O +
min O +
before O +
the O +
test O +
session O -
. O +

Doses O +
of O +
each O +
drug O +
initially O +
were O +
assigned O +
for O +
testing O +
in O +
a O +
random O +
sequence O +
that O +
also O +
included O +
the O +
vehicle O +
of O +
the O +
drug O +
being O +
tested O -
. O +

However O -
, O +
because O +
of O +
prominent O +
interanimal O +
differences O +
in O +
sensitivity O +
to O +
many O +
of O +
the O +
drugs O -
, O +
dose O +
ranges O +
often O +
were O +
readjusted O +
during O +
the O +
course O +
of O +
testing O +
a O +
particular O +
drug O +
in O +
a O +
particular O +
monkey O -
. O +

2.3 O +
Drugs O +
The O +
following O +
drugs O +
were O +
purchased O +
from O +
RBI O +
( O -
Natick O -
, O +
MA O -
) O -
: O +
CGS O +
15943 O -
, O +
apomorphine O +
hydrochloride O -
, O +
( O -
± O -
) O -
-1-phenyl-2,3,4,5-tetrahydro- O -
( O -
1H O +
) O -
-3-benzazepine-7,8-diol O +
HCl O +
( O -
SKF O +
38393 O -
) O -
, O +
R O +
( O -
− O -
) O -
-propylnorapomorphine O +
hydrochloride O +
( O -
NPA O -
) O -
, O +
( O -
− O -
) O -
-quinpirole O +
hydrochloride O -
, O +
( O -
± O -
) O -
-N O +
-allyl-1-phenyl-2,3,4,5-tetrahydro- O -
( O -
1H O +
) O -
-3-benzazepine-7,8-diol O +
HBr O +
( O -
( O -
± O -
) O -
-SKF O +
77434 O -
) O -
, O +
1- O -
[ O -
2- O -
[ O -
bis O -
( O -
4-fluorophenyl O -
) O -
methoxy O -
] O -
ethyl O -
] O -
-4- O -
[ O -
3-phenylpropyl O -
] O -
piperazine O +
diHCl O +
( O -
GBR O +
12909 O -
) O -
, O +
R O +
( O -
+ O -
) O -
-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H O +
-3-benzazepine O +
HCl O +
( O -
R O +
( O -
+ O -
) O -
-SCH O +
23390 O -
) O -
, O +
S O +
( O -
− O -
) O -
-eticlopride O +
hydrochloride O +
and O +
ketanserin O +
tartrate O -
. O +

d O +
-Amphetamine O +
sulfate O +
and O +
phentolamine O +
methanesulfonate O +
were O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
) O -
, O +
morphine O +
sulfate O +
was O +
obtained O +
from O +
Penick O +
( O -
Newark O -
, O +
NJ O -
) O -
, O +
cocaine O +
hydrochloride O +
and O +
phencyclidine O +
hydrochloride O +
( O -
PCP O -
) O +
were O +
provided O +
by O +
the O +
National O +
Institute O +
on O +
Drug O +
Abuse O +
( O -
Rockville O -
, O +
MD O -
) O -
, O +
and O +
nisoxetine O +
hydrochloride O +
and O +
fluoxetine O +
hydrochloride O +
were O +
provided O +
by O +
Eli O +
Lilly O +
and O +
Company O +
( O -
Indianapolis O -
, O +
IN O -
) O -
. O +

CGS O +
15943 O +
was O +
suspended O +
in O +
1 O -
% O +
methylcellulose O +
and O +
was O +
sonicated O +
before O +
injection O -
. O +

Amphetamine O -
, O +
cocaine O -
, O +
NPA O -
, O +
quinpirole O -
, O +
eticlopride O -
, O +
SCH O +
23390 O -
, O +
morphine O +
and O +
phencyclidine O +
were O +
dissolved O +
in O +
0.9 O -
% O +
saline O +
solution O -
. O +

SKF O +
38393 O -
, O +
SKF O +
77434 O -
, O +
nisoxetine O -
, O +
fluoxetine O -
, O +
phentolamine O +
and O +
ketanserin O +
were O +
dissolved O +
in O +
distilled O +
water O -
. O +

Apomorphine O +
was O +
dissolved O +
in O +
distilled O +
water O +
containing O +
0.2 O -
% O +
ascorbic O +
acid O +
and O +
GBR O +
12909 O +
was O +
dissolved O +
in O +
one O +
part O +
dimethylsulfoxide O +
and O +
three O +
parts O +
distilled O +
water O -
. O +

Drugs O +
and O +
vehicles O +
were O +
injected O +
into O +
a O +
thigh O +
muscle O +
in O +
a O +
volume O +
of O +
0.5–1.0 O +
ml O +
per O +
kg O +
of O +
body O -
. O +

All O +
drug O +
doses O +
refer O +
to O +
the O +
free O +
base O -
. O +

2.4 O +
Data O +
analysis O +
Discrimination O +
data O +
are O +
presented O +
as O +
the O +
number O +
of O +
trials O +
completed O +
on O +
the O +
CGS O +
15943-appropriate O +
choice O +
lever O -
; O +
the O +
remaining O +
trials O +
of O +
a O +
session O +
were O +
completed O +
on O +
the O +
lever O +
appropriate O +
for O +
the O +
methylcellulose O +
vehicle O -
. O +

The O +
ED50 O +
was O +
defined O +
as O +
the O +
drug O +
dose O +
that O +
would O +
have O +
resulted O +
in O +
selection O +
of O +
the O +
CGS O +
15943-appropriate O +
lever O +
in O +
12.5 O +
trials O +
of O +
a O +
test O +
session O -
. O +

It O +
was O +
estimated O +
for O +
each O +
animal O +
by O +
linear O +
regression O +
of O +
the O +
ascending O +
part O +
of O +
the O +
stimulus O -
- O -
generalization O +
curve O +
when O +
at O +
least O +
three O +
points O +
were O +
available O +
and O +
by O +
simple O +
interpolation O +
when O +
there O +
were O +
only O +
two O +
points O +
to O +
use O -
; O +
doses O +
were O +
transformed O +
to O +
logarithm10 O +
. O +

The O +
AD50 O +
was O +
defined O +
as O +
the O +
dose O +
of O +
drug O +
that O +
when O +
administered O +
before O +
1.0 O +
mg O -
/ O -
kg O +
CGS O +
15943 O +
reduced O +
selection O +
of O +
the O +
CGS O +
15943-appropriate O +
choice O +
lever O +
to O +
12.5 O +
trials O +
per O +
session O -
. O +

It O +
was O +
calculated O +
in O +
the O +
same O +
manner O +
as O +
the O +
ED50 O +
was O -
. O +

ED50 O +
s O +
and O +
AD50 O +
s O +
were O +
converted O +
from O +
mg O -
/ O -
kg O +
to O +
μmol O -
/ O -
kg O +
for O +
potency O +
comparisons O +
among O +
drugs O -
. O +

They O +
were O +
evaluated O +
by O +
analysis O +
of O +
variance O +
for O +
repeated O +
measures O -
, O +
followed O +
by O +
the O +
Student O -
– O -
Newman O -
– O -
Keuls O +
test O +
for O +
multiple O +
comparisons O +
among O +
all O +
means O -
. O +

3 O +
Results O +
The O +
sensitivity O +
of O +
the O +
monkeys O +
to O +
the O +
training O +
drug O +
in O +
the O +
present O +
study O +
[ O -
ED50 O +
( O -
95 O -
% O +
confidence O +
limits O -
) O -
: O +
0.38 O +
( O -
0.22–0.64 O -
) O +
mg O -
/ O -
kg O -
] O +
was O +
similar O +
to O +
their O +
sensitivity O +
in O +
the O +
preceding O +
study O +
( O -
Holtzman O -
, O +
1996 O +
) O +
in O +
which O +
they O +
were O +
tested O +
with O +
a O +
series O +
of O +
methylxanthine O +
derivatives O +
[ O -
ED50 O +
( O -
95 O -
% O +
confidence O +
limits O -
) O -
: O +
0.43 O +
( O -
0.27–0.67 O -
) O +
mg O -
/ O -
kg O -
] O -
. O +

Fig. O +
1 O +
contains O +
the O +
stimulus O +
generalization O +
curves O +
for O +
CGS O +
15943 O +
for O +
each O +
of O +
the O +
four O +
monkeys O -
. O +

Neither O +
the O +
vehicle O +
for O +
CGS O +
15943 O +
nor O +
the O +
vehicles O +
for O +
the O +
other O +
drugs O +
examined O +
resulted O +
in O +
an O +
average O +
of O +
more O +
than O +
one O +
trial O +
per O +
session O +
being O +
completed O +
on O +
the O +
CGS O +
15943-appropriate O +
choice O +
lever O -
; O +
for O +
the O +
sake O +
of O +
simplicity O -
, O +
data O +
for O +
drug O +
vehicles O +
are O +
not O +
shown O +
in O +
the O +
figures O -
. O +

All O +
of O +
the O +
monkeys O +
generalized O +
completely O +
or O +
almost O +
completely O +
to O +
the O +
eight O +
dopamine B-Gene +
receptor I-Gene +
agonists O +
that O +
were O +
tested O -
: O +
apomorphine O -
, O +
amphetamine O +
and O +
cocaine O +
( O -
Fig. O +
1 O +
) O -
, O +
SKF O +
38303 O -
, O +
SKF O +
77434 O -
, O +
quinpirole O +
and O +
NPA O +
( O -
Fig. O +
2 O +
) O -
, O +
and O +
GBR O +
12909 O +
( O -
Fig. O +
3 O +
) O -
. O +

Of O +
these O -
, O +
the O +
dopamine B-Gene +
D1 I-Gene +
receptor I-Gene +
agonist O +
SKF O +
77434 O +
was O +
the O +
most O +
potent O +
( O -
Fig. O +
2 O +
) O +
and O +
the O +
dopamine O +
uptake O +
inhibitor O +
GBR O +
12909 O +
was O +
the O +
least O +
potent O +
( O -
Fig. O +
3 O +
) O -
. O +

On O +
a O +
molar O +
basis O -
, O +
SKF O +
77434 O +
was O +
19 O +
times O +
more O +
potent O +
than O +
CGS O +
15943 O +
whereas O +
GBR O +
12909 O +
was O +
one O -
- O -
fifth O +
as O +
potent O +
( O -
Table O +
1 O +
) O -
. O +

As O +
is O +
evident O +
in O +
the O +
figures O -
, O +
interanimal O +
variability O +
in O +
sensitivity O +
to O +
the O +
dopamine B-Gene +
receptor I-Gene +
agonists O +
was O +
considerable O -
. O +

S90 O +
was O +
the O +
most O +
sensitive O +
monkey O +
in O +
tests O +
of O +
stimulus O +
generalization O +
to O +
six O +
of O +
the O +
eight O +
dopamine B-Gene +
receptor I-Gene +
agonists O +
and O +
monkey O +
S92 O +
displayed O +
the O +
greatest O +
sensitivity O +
to O +
the O +
other O +
two O -
, O +
cocaine O +
( O -
Fig. O +
1 O +
) O +
and O +
SKF O +
38393 O +
( O -
Fig. O +
2 O +
) O -
. O +

As O +
a O +
consequence O +
of O +
this O +
interanimal O +
variability O -
, O +
differences O +
in O +
potencies O +
among O +
apomorphine O -
, O +
agonists O +
selective O +
for O +
dopamine B-Gene +
D1 B-Gene +
or O +
D2 B-Gene +
receptors I-Gene -
, O +
amphetamine O +
and O +
cocaine O +
were O +
not O +
statistically O +
reliable O +
( O -
Table O +
1 O +
) O -
. O +

However O -
, O +
all O +
of O +
these O +
drugs O +
were O +
significantly O +
more O +
potent O +
than O +
GBR O +
12909 O -
, O +
and O +
SKF O +
77434 O +
and O +
amphetamine O +
were O +
significantly O +
more O +
potent O +
than O +
CGS O +
15943 O +
( O -
Table O +
1 O +
) O -
. O +

The O +
monkeys O +
also O +
generalized O +
completely O +
or O +
almost O +
completely O +
to O +
two O +
drugs O +
that O +
act O +
on O +
monoamine O +
neurotransmitter O +
systems O +
other O +
than O +
dopamine O -
: O +
fluoxetine O -
, O +
a O +
selective O +
inhibitor O +
of O +
the O +
serotonin B-Gene +
neuronal I-Gene +
transporter I-Gene -
, O +
and O +
nisoxetine O -
, O +
a O +
selective O +
inhibitor O +
of O +
the O +
norepinephrine B-Gene +
neuronal I-Gene +
transporter I-Gene +
( O -
Fig. O +
3 O +
) O -
. O +

Nisoxetine O +
was O +
significantly O +
more O +
potent O +
than O +
GBR O +
12909 O +
in O +
occasioning O +
selection O +
of O +
the O +
CGS O +
15943-appropriate O +
choice O +
lever O -
, O +
whereas O +
the O +
potency O +
of O +
fluoxetine O +
was O +
not O +
different O +
from O +
that O +
of O +
either O +
nisoxetine O +
or O +
GBR O +
12909 O +
( O -
Table O +
1 O +
) O -
. O +

In O +
contrast O -
, O +
neither O +
morphine O +
( O -
1.0–5.6 O +
mg O -
/ O -
kg O -
) O +
nor O +
phencyclidine O +
( O -
0.03–0.3 O +
mg O -
/ O -
kg O -
) O +
occasioned O +
substantial O +
CGS O +
15943-appropriate O +
responding O +
( O -
Fig. O +
4 O +
) O -
, O +
even O +
though O +
each O +
drug O +
was O +
tested O +
up O +
to O +
a O +
dose O +
that O +
caused O +
slumping O +
body O +
postures O +
indicative O +
of O +
motor O +
impairment O +
in O +
all O +
of O +
the O +
monkeys O -
. O +

The O +
discriminative O +
effects O +
of O +
the O +
1.0 O +
mg O -
/ O -
kg O +
training O +
dose O +
of O +
CGS O +
15943 O +
were O +
blocked O +
completely O +
by O +
pretreating O +
the O +
monkeys O +
with O +
either O +
the O +
dopamine B-Gene +
D1 I-Gene +
receptor I-Gene +
antagonist O +
SCH O +
23390 O -
, O +
the O +
dopamine B-Gene +
D2 I-Gene +
receptor I-Gene +
antagonist O +
eticlopride O -
, O +
or O +
the O +
5-HT2 B-Gene +
/5-HT1C I-Gene +
receptor I-Gene +
antagonist O +
ketanserin O +
( O -
Fig. O +
5 O +
) O -
. O +

SCH O +
23390 O +
was O -
, O +
by O +
far O -
, O +
the O +
most O +
potent O +
antagonist O +
of O +
the O +
three O -
, O +
blocking O +
the O +
discriminative O +
effects O +
of O +
CGS O +
15943 O +
completely O +
at O +
doses O +
of O +
only O +
1.0–10 O +
μg O -
/ O -
kg O -
, O +
depending O +
upon O +
the O +
individual O +
monkey O -
. O +

The O +
AD50 O +
s O +
( O -
and O +
95 O -
% O +
confidence O +
limits O -
) O +
of O +
the O +
antagonists O +
were O +
4.97 O +
( O -
1.83–13.5 O -
) O +
nmol O -
/ O -
kg O +
for O +
SCH O +
23390 O -
, O +
57.9 O +
( O -
17.5–192 O -
) O +
nmol O -
/ O -
kg O +
for O +
eticlopride O +
and O +
1.09 O +
( O -
0.27–4.46 O -
) O +
μmol O -
/ O -
kg O +
for O +
ketanserin O -
. O +

Thus O -
, O +
on O +
a O +
molar O +
basis O -
, O +
SCH O +
23390 O +
was O +
11.6 O +
times O +
more O +
potent O +
than O +
eticlopride O +
and O +
219 O +
times O +
more O +
potent O +
than O +
ketanserin O +
in O +
antagonizing O +
the O +
discriminative O +
effects O +
of O +
the O +
training O +
dose O +
of O +
CGS O +
15943 O -
. O +

In O +
contrast O -
, O +
pretreatment O +
with O +
the O +
α B-Gene -
- I-Gene -
adrenoceptor I-Gene +
antagonist O +
phentolamine O +
blocked O +
the O +
discriminative O +
effects O +
of O +
CGS O +
15943 O +
only O +
partially O +
and O +
inconsistently O -
, O +
even O +
at O +
a O +
dose O +
as O +
high O +
as O +
10 O +
mg O +
( O -
36 O +
μmol O -
) O -
/ O -
kg O +
( O -
Fig. O +
5 O +
) O -
. O +

4 O +
Discussion O +
The O +
results O +
of O +
this O +
study O +
demonstrate O +
that O +
there O +
is O +
a O +
prominent O +
dopamine O +
component O +
to O +
the O +
discriminative O +
stimulus O +
effects O +
of O +
CGS O +
15943 O +
in O +
squirrel O +
monkeys O -
. O +

CGS O +
15943 O +
generalized O +
with O +
a O +
variety O +
of O +
directly O +
and O +
indirectly O +
acting O +
dopamine B-Gene +
receptor I-Gene +
agonists O +
and O +
its O +
discriminative O +
effects O +
were O +
blocked O +
dose O -
- O -
dependently O +
and O +
completely O +
by O +
low O +
doses O +
of O +
dopamine B-Gene +
receptor I-Gene +
antagonists O -
. O +

These O +
findings O +
are O +
consistent O +
with O +
reports O +
of O +
dopamine O +
involvement O +
in O +
the O +
discriminative O +
effects O +
of O +
a O +
low O +
training O +
dose O +
of O +
caffeine O +
and O +
in O +
the O +
stimulation O +
of O +
locomotor O +
activity O +
by O +
caffeine O +
in O +
rats O +
( O -
Mumford O +
and O +
Holtzman O -
, O +
1991 O +
; O +
Garrett O +
and O +
Holtzman O -
, O +
1994 O +
) O -
. O +

They O +
also O +
are O +
consistent O +
with O +
a O +
growing O +
body O +
of O +
literature O +
suggesting O +
there O +
is O +
an O +
inverse O +
relationship O +
between O +
adenosine B-Gene +
receptor I-Gene +
activation O +
in O +
basal O +
ganglia O +
and O +
dopamine O -
- O -
mediated O +
neurotransmission O +
( O -
see O +
Section O +
1 O +
) O -
. O +

It O +
appears O +
that O +
activation O +
of O +
either O +
the O +
dopamine B-Gene +
D1 B-Gene +
or O +
D2 B-Gene +
families O +
of O +
receptors B-Gene +
is O +
sufficient O +
to O +
produce O +
CGS O +
15943-like O +
stimulus O +
control O +
of O +
behavior O -
. O +

The O +
dopamine B-Gene +
D1 I-Gene +
receptor I-Gene +
agonists O +
SKF O +
77434 O +
and O +
SKF O +
38393 O +
and O +
the O +
dopamine B-Gene +
D2 I-Gene +
receptor I-Gene +
agonists O +
quinpirole O +
and O +
NPA O +
were O +
equipotent O +
in O +
this O +
regard O -
. O +

In O +
addition O -
, O +
the O +
discriminative O +
effects O +
of O +
CGS O +
15943 O +
were O +
blocked O +
by O +
nanomolar O +
doses O +
of O +
either O +
the O +
dopamine B-Gene +
D1 I-Gene +
receptor I-Gene +
antagonist O +
SCH O +
23390 O +
or O +
the O +
dopamine B-Gene +
D2 I-Gene +
receptor I-Gene +
antagonist O +
eticlopride O -
. O +

These O +
effects O +
of O +
the O +
dopamine B-Gene +
receptor I-Gene +
antagonists O +
were O +
not O +
a O +
consequence O +
of O +
nonspecific O +
suppression O +
or O +
disruption O +
of O +
the O +
ongoing O +
behavior O -
. O +

The O +
monkeys O +
completed O +
all O +
session O +
trials O +
but O +
shifted O +
their O +
responding O +
in O +
an O +
orderly O +
manner O +
from O +
the O +
CGS O +
15943-appropriate O +
choice O +
lever O +
to O +
the O +
vehicle O -
- O -
appropriate O +
choice O +
lever O -
. O +

Similar O +
patterns O +
of O +
stimulus O +
generalization O +
and O +
antagonism O +
occur O +
in O +
squirrel O +
monkeys O +
discriminating O +
indirectly O +
acting O +
dopamine B-Gene +
receptor I-Gene +
agonists O -
, O +
such O +
as O +
cocaine O +
( O -
Spealman O +
et O +
al. O -
, O +
1991 O +
) O -
, O +
GBR O +
12909 O +
( O -
Melia O +
and O +
Spealman O -
, O +
1991 O +
) O +
and O +
methamphetamine O +
( O -
Tidey O +
and O +
Bergman O -
, O +
1998 O +
) O -
. O +

Dopamine O +
is O +
not O +
the O +
only O +
monoamine O +
that O +
appears O +
to O +
be O +
involved O +
in O +
the O +
discriminative O +
effects O +
of O +
CGS O +
15943 O -
. O +

The O +
monkeys O +
in O +
this O +
study O +
generalized O +
completely O +
to O +
nisoxetine O -
, O +
a O +
selective O +
inhibitor O +
of O +
the O +
neuronal B-Gene +
norepinephrine I-Gene +
transporter I-Gene -
. O +

This O +
finding O -
, O +
too O -
, O +
is O +
consistent O +
with O +
the O +
results O +
of O +
a O +
study O +
on O +
the O +
discriminative O +
effects O +
of O +
a O +
low O +
training O +
dose O +
of O +
caffeine O +
in O +
rats O -
, O +
indicating O +
an O +
important O +
noradrenergic O +
component O +
( O -
Holtzman O -
, O +
1986 O +
) O -
. O +

Monkeys O +
discriminating O +
amphetamine O +
( O -
Kamien O +
and O +
Woolverton O -
, O +
1989 O +
) O +
and O +
monkeys O +
( O -
Spealman O -
, O +
1995 O +
) O +
and O +
rats O +
( O -
Terry O +
et O +
al. O -
, O +
1994 O +
) O +
discriminating O +
a O +
low O +
dose O +
of O +
cocaine O +
( O -
Spealman O -
, O +
1995 O +
) O +
also O +
generalize O +
completely O +
with O +
nisoxetine O -
. O +

Contrasting O +
with O +
the O +
substitution O +
of O +
nisoxetine O +
for O +
CGS O +
15943 O +
is O +
the O +
failure O +
of O +
phentolamine O -
, O +
an O +
α B-Gene -
- I-Gene -
adrenoceptor I-Gene +
antagonist O -
, O +
to O +
block O +
the O +
discriminative O +
effects O +
of O +
the O +
training O +
drug O -
. O +

This O +
outcome O +
distinguishes O +
the O +
discriminative O +
effects O +
of O +
CGS O +
15943 O +
in O +
this O +
study O +
from O +
those O +
of O +
caffeine O +
in O +
rats O -
; O +
phentolamine O +
blocked O +
the O +
discriminative O +
effects O +
of O +
a O +
low O +
caffeine O +
training O +
dose O +
( O -
Holtzman O -
, O +
1986 O +
) O -
. O +

However O -
, O +
consistent O +
with O +
the O +
results O +
of O +
the O +
current O +
study O -
, O +
phentolamine O +
did O +
not O +
block O +
the O +
discriminative O +
effects O +
of O +
either O +
amphetamine O +
or O +
cocaine O +
in O +
monkeys O -
, O +
despite O +
the O +
fact O +
that O +
nisoxetine O +
generalized O +
with O +
the O +
training O +
drugs O +
( O -
Kamien O +
and O +
Woolverton O -
, O +
1989 O +
; O +
Spealman O -
, O +
1995 O +
) O -
. O +

There O +
are O +
several O +
possible O +
explanations O +
for O +
these O +
apparent O +
discrepancies O -
, O +
species O +
difference O -
, O +
for O +
example O -
. O +

The O +
pharmacokinetics O +
of O +
phentolamine O +
in O +
rats O +
and O +
monkeys O +
might O +
differ O -
, O +
as O +
might O +
the O +
qualitative O +
nature O +
of O +
the O +
discriminative O +
effects O +
that O +
arise O +
from O +
blockade O +
of O +
adenosine B-Gene +
receptors I-Gene +
and/or O +
the O +
relative O +
contribution O +
to O +
those O +
effects O +
of O +
α- B-Gene +
vs. O +
β B-Gene -
- I-Gene -
adrenoceptor I-Gene +
activation O -
. O +

Differences O +
among O +
the O +
training O +
drugs O +
must O +
also O +
be O +
considered O -
. O +

The O +
unique O +
spectrum O +
of O +
activity O +
of O +
caffeine O -
, O +
which O +
includes O +
inhibition O +
of O +
phosphodiesterases B-Gene -
, O +
might O +
make O +
a O +
noradrenergic O +
component O +
essential O +
to O +
the O +
stimulus O +
control O +
of O +
behavior O +
by O +
that O +
drug O -
. O +

Enhancement O +
of O +
noradrenergically O +
mediated O +
neurotransmission O +
might O +
be O +
sufficient O +
to O +
mimic O +
the O +
stimulus O +
effects O +
of O +
CGS O +
15943 O +
( O -
as O +
well O +
as O +
those O +
of O +
amphetamine O +
and O +
cocaine O -
) O +
but O +
not O +
be O +
essential O +
for O +
stimulus O +
control O +
of O +
behavior O +
by O +
CGS O +
15943 O -
. O +

A O +
third O +
monoamine O +
that O +
appears O +
to O +
have O +
a O +
role O +
in O +
the O +
discriminative O +
effects O +
of O +
CGS O +
15943 O +
is O +
serotonin O -
. O +

The O +
discriminative O +
effects O +
of O +
CGS O +
15943 O +
were O +
mimicked O +
( O -
completely O -
, O +
in O +
three O +
of O +
four O +
monkeys O -
) O +
by O +
fluoxetine O -
, O +
a O +
selective O +
inhibitor O +
of O +
serotonin O +
uptake O +
by O +
neurons O -
, O +
and O +
were O +
blocked O +
by O +
ketanserin O -
, O +
a O +
5-HT2 B-Gene +
receptor I-Gene +
antagonist O -
. O +

The O +
literature O +
contains O +
abundant O +
evidence O +
of O +
serotonergic O +
modulation O +
of O +
brain O +
dopamine O +
systems O -
. O +

Activation O +
of O +
serotonin B-Gene +
receptors I-Gene +
can O +
stimulate O +
dopamine O +
release O +
( O -
Parsons O +
and O +
Justice O -
, O +
1993 O +
; O +
Benloucif O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

Furthermore O -
, O +
serotonergic O +
mechanisms O +
appear O +
to O +
contribute O +
to O +
the O +
discriminative O +
and O +
reinforcing O +
stimulus O +
effects O +
of O +
psychomotor O +
stimulant O +
drugs O -
, O +
such O +
as O +
cocaine O +
( O -
Walsh O +
and O +
Cunningham O -
, O +
1997 O +
) O -
. O +

However O -
, O +
in O +
contrast O +
to O +
the O +
effects O +
of O +
fluoxetine O +
in O +
monkeys O +
discriminating O +
CGS O +
15943 O -
, O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
do O +
not O +
substitute O +
for O +
the O +
cocaine O +
cue O -
, O +
even O +
when O +
the O +
training O +
dose O +
of O +
cocaine O +
is O +
relatively O +
low O +
( O -
Terry O +
et O +
al. O -
, O +
1994 O +
; O +
Spealman O -
, O +
1995 O +
) O -
. O +

A O +
pattern O +
of O +
broad O +
stimulus O +
generalization O +
to O +
pharmacologically O +
diverse O +
drugs O +
can O +
be O +
the O +
consequence O +
of O +
a O +
functionally O +
low O +
training O +
dose O +
( O -
Holtzman O -
, O +
1983 O +
; O +
Overton O -
, O +
1984 O +
) O -
. O +

Several O +
lines O +
of O +
evidence O +
suggest O +
that O +
the O +
training O +
dose O +
of O +
CGS O +
15943 O +
was O -
, O +
indeed O -
, O +
functionally O +
low O -
. O +

First O -
, O +
the O +
discrimination O +
was O +
acquired O +
slowly O -
, O +
in O +
a O +
median O +
of O +
174 O +
( O -
range O -
: O +
82–222 O -
) O +
training O +
sessions O +
( O -
Holtzman O -
, O +
1996 O +
) O -
. O +

Second O -
, O +
SKF O +
38393 O +
and O +
SKF O +
77494 O -
, O +
which O +
are O +
low O -
- O -
efficacy O +
agonists O +
at O +
dopamine B-Gene +
D1 I-Gene +
receptors I-Gene +
( O -
Izenwasser O +
and O +
Katz O -
, O +
1993 O +
; O +
Weed O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
generalized O +
completely O +
with O +
CGS O +
15943 O -
. O +

In O +
contrast O -
, O +
SKF O +
38393 O +
occasioned O +
little O +
drug O -
- O -
appropriate O +
responding O +
in O +
squirrel O +
monkeys O +
trained O +
to O +
discriminate O +
SKF O +
81297 O -
, O +
a O +
high O -
- O -
efficacy O +
dopamine B-Gene +
D1 I-Gene +
receptor I-Gene +
agonist O +
( O -
Rosenzweig O -
- O -
Libson O +
and O +
Bergman O -
, O +
1993 O +
) O -
. O +

Third O -
, O +
the O +
ED50 O +
s O +
of O +
cocaine O -
, O +
nisoxetine O -
, O +
and O +
GBR O +
12909 O +
in O +
this O +
study O +
( O -
Table O +
1 O +
) O +
were O +
up O +
to O +
several O -
- O -
fold O +
lower O +
than O +
they O +
were O +
in O +
squirrel O +
monkeys O +
discriminating O +
a O +
" O -
low O -
" O +
dose O +
( O -
0.18–0.3 O +
mg O -
/ O -
kg O -
) O +
of O +
cocaine O +
( O -
Spealman O -
, O +
1995 O +
) O -
. O +

The O +
ED50 O +
of O +
a O +
drug O +
varies O +
directly O +
with O +
the O +
magnitude O +
of O +
the O +
discriminative O +
effects O +
of O +
the O +
training O +
drug O +
( O -
Holtzman O -
, O +
1983 O +
) O -
. O +

Therefore O -
, O +
these O +
results O +
suggest O +
that O +
the O +
training O +
dose O +
of O +
CGS O +
15943 O +
engendered O +
a O +
less O +
intense O +
stimulus O +
than O +
did O +
the O +
low O +
training O +
dose O +
of O +
cocaine O +
in O +
the O +
study O +
by O +
Spealman O +
( O -
1995 O -
) O +
. O +

A O +
discriminative O +
stimulus O +
of O +
relatively O +
low O +
intensity O +
might O +
also O +
account O +
for O +
the O +
variability O +
among O +
animals O +
in O +
their O +
responses O +
to O +
the O +
various O +
test O +
drugs O -
. O +

Despite O +
the O +
breadth O +
of O +
drugs O +
sharing O +
discriminative O +
effects O +
with O +
CGS O +
15943 O -
, O +
stimulus O +
control O +
of O +
behavior O +
by O +
the O +
training O +
drug O +
did O +
have O +
pharmacological O +
specificity O -
. O +

Morphine O -
, O +
a O +
μ B-Gene -
- I-Gene -
opioid I-Gene +
receptor I-Gene +
agonist O -
, O +
and O +
phencyclidine O -
, O +
a O +
noncompetitive O +
antagonist O +
at O +
the O +
N B-Gene +
-methyl I-Gene -
- I-Gene -
d I-Gene +
-aspartate I-Gene +
( O -
NMDA B-Gene -
) O +
glutamate B-Gene -
– I-Gene -
receptor I-Gene +
complex O -
, O +
occasioned O +
little O +
CGS O +
15943-appropriate O +
responding O -
, O +
even O +
though O +
they O +
were O +
tested O +
at O +
doses O +
that O +
are O +
discriminable O +
to O +
squirrel O +
monkeys O +
( O -
Schaefer O +
and O +
Holtzman O -
, O +
1977 O +
; O +
Holtzman O -
, O +
1982 O +
) O -
. O +

Rats O +
trained O +
to O +
discriminate O +
magnesium O +
chloride O +
from O +
saline O +
also O +
generalize O +
completely O +
to O +
cocaine O +
and O +
to O +
specific O +
inhibitors O +
of O +
the O +
uptake O +
of O +
dopamine O -
, O +
norepinephrine O +
and O +
serotonin O -
, O +
but O +
generalize O +
only O +
partially O +
to O +
PCP O +
and O +
other O +
NMDA B-Gene +
receptor I-Gene +
antagonists O +
( O -
Kantak O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

The O +
relationship O -
, O +
if O +
any O -
, O +
between O +
the O +
discriminative O +
effects O +
of O +
magnesium O +
chloride O +
and O +
those O +
arising O +
from O +
blockade O +
of O +
adenosine B-Gene +
receptors I-Gene +
is O +
obscure O -
. O +

In O +
conclusion O -
, O +
squirrel O +
monkeys O +
discriminating O +
an O +
adenosine B-Gene +
receptor I-Gene +
antagonist O +
that O +
does O +
not O +
inhibit O +
phosphodiesterase B-Gene +
activity O +
generalize O +
not O +
only O +
to O +
other O +
drugs O +
that O +
block O +
adenosine B-Gene +
receptors I-Gene +
( O -
Holtzman O -
, O +
1996 O +
) O -
, O +
but O +
also O +
to O +
drugs O +
that O +
enhance O +
neurotransmission O +
mediated O +
by O +
dopamine O -
, O +
norepinephrine O -
, O +
and O +
serotonin O -
. O +

Therefore O -
, O +
this O +
type O +
of O +
drug O +
discrimination O +
procedure O +
might O +
be O +
useful O +
for O +
studying O +
the O +
relationships O +
among O +
brain O +
adenosine O +
and O +
monoamine O +
systems O -
. O +

Acknowledgements O +
Ms. O +
Lora O +
O'Keefe O +
provided O +
technical O +
assistance O +
and O +
was O +
responsible O +
for O +
daily O +
training O +
and O +
test O +
sessions O -
. O +

Eli O +
Lilly O +
and O +
Company O +
generously O +
provided O +
nisoxetine O +
and O +
fluoxetine O -
. O +

This O +
research O +
was O +
supported O +
by O +
Grants O +
DA00541 O -
, O +
DA03413 O +
and O +
KO5 O +
DA00008 O -
, O +
all O +
from O +
the O +
National O +
Institute O +
on O +
Drug O +
Abuse O -
, O +
National O +
Institutes O +
of O +
Health O -
. O +

Humans O +
are O +
continuously O +
exposed O +
to O +
a O +
wide O +
variety O +
of O +
xenobiotics O +
either O +
voluntarily O +
or O +
from O +
environmental O +
exposure O -
. O +

Pesticides O +
represent O +
a O +
high O +
volume O +
of O +
widely O +
used O -
, O +
environmental O +
chemicals O +
and O +
there O +
is O +
a O +
continuous O +
debate O +
concerning O +
their O +
possible O +
role O +
in O +
many O +
chronic O -
, O +
human O +
health O +
conditions O +
including O +
cancer O -
. O +

Hence O -
, O +
a O +
great O +
deal O +
of O +
studies O +
were O +
carried O +
out O +
to O +
evaluate O +
their O +
possible O +
effects O +
on O +
the O +
population O +
in O +
general O +
and O +
on O +
the O +
environment O -
. O +

Dithianon O +
( O -
DT O -
) O +
( O -
5,10-dihydro-5,10-dioxo O -
- O -
naphto- O -
[ O -
2,3b O +
] O -
-p O +
-dithio-2,3-dicarbonitrile O -
) O -
, O +
a O +
non O -
- O -
chlorinated O +
quinone O +
derivative O +
( O -
Fig. O +
1 O +
) O +
, O +
is O +
a O +
protective O +
fungicide O +
mainly O +
used O +
against O +
apple O +
and O +
pear O +
scab O +
and O +
leaf O +
spot O +
on O +
cherry O +
trees O +
[ O -
1 O -
] O +
. O +

Toxicological O +
data O +
on O +
this O +
fungicide O +
are O +
lacking O +
and O +
only O +
a O +
little O +
information O +
about O +
its O +
toxicity O -
, O +
mutagenicity O +
and O +
embryotoxicity O +
has O +
been O +
reported O +
in O +
literature O +
[ O -
2 O -
] O +
. O +

Even O +
though O +
a O +
short O -
- O -
term O +
test O +
of O +
DT O +
mutagenicity O +
showed O +
negative O +
results O +
on O +
microbial O +
systems O +
[ O -
3 O -
] O +
and O +
the O +
Joint O +
FAO O -
/ O -
WHO O +
Meeting O +
on O +
Pesticide O +
Residues O +
( O -
JMPR O -
) O +
( O -
1992 O -
) O +
concluded O +
that O +
the O +
chemical O +
was O +
not O +
carcinogenic O -
, O +
it O +
could O +
induce O +
in O +
vitro O +
cell O +
transformation O +
on O +
BALB O -
/ O -
c O +
3T3 O +
cells O +
[ O -
4 O -
] O +
, O +
indicating O +
a O +
possible O +
promoting O +
effect O +
of O +
this O +
pesticide O -
. O +

These O +
data O +
indicate O +
that O +
DT O +
could O +
exert O +
a O +
co O -
- O -
carcinogenic O +
action O +
through O +
epigenetic O +
mechanisms O -
. O +

A O +
number O +
of O +
investigators O +
have O +
suggested O +
that O +
tumorigenesis O +
can O +
be O +
mediated O +
by O +
non O -
- O -
genotoxic O +
mechanisms O -
, O +
of O +
which O +
the O +
most O +
representative O +
are O +
the O +
following O -
: O +
unspecific O +
toxic O +
effects O +
from O +
administration O +
of O +
high O +
doses O +
( O -
MTD O -
) O +
of O +
the O +
compound O -
, O +
leading O +
to O +
cell O +
death O -
, O +
and O +
therefore O -
, O +
to O +
subsequent O +
stimulation O +
of O +
mitosis O +
[ O -
5 O -
] O +
; O +
increase O +
of O +
tubular O +
concentration O +
of O +
the O +
protein B-Gene +
α2 B-Gene +
microglobulin I-Gene +
and O +
disruption O +
of O +
calcium O +
reabsorption O +
in O +
renal O +
tumours O +
[ O -
5 O -
] O +
; O +
facilitation O +
of O +
biliary O +
clearance O +
of O +
thyroid O +
hormone O +
T4 O -
, O +
with O +
increased O +
incidences O +
of O +
TSH O +
production O -
, O +
thyroid O +
hypertrophy O -
, O +
hyperplasia O +
and O +
probably O +
tumours O +
[ O -
6 O -
] O +
; O +
increase O +
of O +
peroxisome O +
proliferation O +
in O +
rodent O +
liver O +
[ O -
7 O -
] O +
; O +
promotion O +
and O +
induction O +
regulation O +
of O +
cell O +
proliferation O +
[ O -
8,9 O -
] O +
; O +
pleiotropic O +
response O -
, O +
oxidative O +
stress O -
, O +
co O -
- O -
carcinogenesis O +
and O +
promotion O +
all O +
correlated O +
with O +
CYP B-Gene +
induction O +
[ O -
10–16 O -
] O +
. O +

Thus O -
, O +
the O +
outstanding O +
problems O +
faced O +
in O +
the O +
prediction O +
of O +
potential O +
carcinogens O -
, O +
being O +
mainly O +
toxicologically O +
non O -
- O -
genetic O +
[ O -
17 O -
] O +
, O +
prompted O +
us O +
to O +
investigate O +
the O +
toxicological O +
effects O +
at O +
metabolic O +
level O -
. O +

Many O +
chemicals O +
are O +
unique O +
for O +
their O +
ability O +
to O +
affect O +
a O +
wide O +
range O +
of O +
CYP B-Gene +
isoforms O +
belonging O +
to O +
different O +
families O +
and O +
subfamilies O -
. O +

In O +
our O +
laboratories O +
we O +
are O +
interested O +
in O +
the O +
study O +
of O +
certain O +
toxicological O +
effects O +
derived O +
by O +
the O +
modulation O +
of O +
CYP B-Gene -
- O -
associated O +
activities O -
, O +
the O +
most O +
important O +
apparatus O +
involved O +
in O +
phase O -
- O -
I O +
biotransformation O +
of O +
xenobiotics O +
( O -
drugs O +
and O +
environmental O +
pollutants O -
) O -
. O +

CYP B-Gene +
changes O -
, O +
altering O +
the O +
overall O +
metabolic O +
status O +
( O -
activation O -
/ O -
detoxication O +
ratio O -
) O -
, O +
can O +
affect O +
the O +
disposition O +
of O +
other O +
compounds O +
in O +
specific O +
organs O +
[ O -
10,12,18 O -
] O +
, O +
as O +
well O +
as O +
exert O +
co O -
- O -
carcinogenic O +
and O +
promoting O +
effects O +
[ O -
13,15 O -
] O +
. O +

Here O -
, O +
the O +
ability O +
of O +
DT O +
to O +
affect O +
various O +
microsomal O +
monooxygenases B-Gene +
in O +
murine O +
liver O -
, O +
kidney O +
and O +
lung O +
was O +
studied O -
, O +
using O +
the O +
regio- O +
and O +
stereo O -
- O -
selective O +
hydroxylation O +
of O +
testosterone O +
as O +
a O +
multibiomarker O +
of O +
effect O +
[ O -
19 O -
] O +
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Chemicals O +
NADP+ O +
, O +
16α O -
- O -
hydroxytestosterone O +
( O -
16α O -
- O -
TH O -
) O -
, O +
corticosterone O -
, O +
testosterone O +
and O +
4-androsten-3,17-dione O +
( O -
17-TH O -
) O +
were O +
purchased O +
from O +
Sigma O +
Chemical O +
Co. O +
( O -
St. O +
Louis O -
, O +
MO O -
) O -
; O +
glucose O +
6-phosphate O +
and O +
glucose O +
6-phosphate B-Gene +
dehydrogenase I-Gene +
from O +
Boehringer O -
- O -
Mannheim O +
( O -
Germany O -
) O -
, O +
HPLC O +
grade O +
methanol O -
, O +
tetrahydrofuran O +
and O +
dichloromethane O +
from O +
BDH O +
( O -
Pooley O -
, O +
UK O -
) O -
; O +
7α- O -
, O +
6β- O +
and O +
16β O -
- O -
hydroxytestosterone O +
from O +
Steraloids O +
( O -
Wilton O -
, O +
NH O -
) O -
; O +
6α- O -
, O +
2α- O +
and O +
2β O -
- O -
hydroxytestosterone O +
were O +
generous O +
gifts O +
from O +
Dr. O +
P.G. O +
Gervasi O +
( O -
CNR O +
Pisa O -
, O +
Italy O -
) O -
; O +
DT O +
( O -
5,10-dihydro-5,10-dioxo O -
- O -
naphtho- O -
[ O -
2,3b O +
] O -
-p O +
-dithio-2,3-dicarbonitrile O -
) O +
chemical O +
purity O +
99.6 O -
% O -
, O +
was O +
purchased O +
from O +
Lab O +
Service O +
( O -
Bologna O -
, O +
Italy O -
) O -
; O +
rabbit O +
polyclonal O +
antibodies B-Gene +
anti B-Gene -
- I-Gene -
CYP3A1 I-Gene -
/ O -
2 B-Gene +
were O +
purchased O +
from O +
Chemicon O +
International O +
Inc. O +
( O -
Temecula O -
, O +
CA O -
) O -
; O +
all O +
other O +
chemicals O +
and O +
solvents O +
were O +
of O +
the O +
highest O +
commercially O +
available O +
purity O -
. O +

2.2 O +
Animal O +
treatment O +
and O +
preparation O +
of O +
subcellular O +
fractions O +
Male O +
and O +
female O +
Swiss O +
albino O +
CD1 O +
mice O +
( O -
Harlan O -
- O -
Nossan O -
, O +
Correzzana O -
, O +
Milan O -
) O -
, O +
weighing O +
28–30 O +
g O -
, O +
were O +
housed O +
under O +
controlled O +
conditions O +
( O -
12 O +
h O +
light O -
– O -
dark O +
cycle O -
, O +
22 O -
° O -
C O -
, O +
60 O -
% O +
humidity O -
) O -
. O +

They O +
were O +
fed O +
a O +
standard O +
rodent O +
chow O +
and O +
had O +
tap O +
water O +
ad O +
libitum O -
. O +

DT O +
was O +
dissolved O +
in O +
corn O +
oil O +
and O +
administered O +
( O -
i.p O -
. O -
) O +
in O +
a O +
single O +
( O -
3 O +
or O +
6 O +
mg O -
/ O -
kg O +
body O +
wt O -
. O -
) O +
or O +
repeated O +
( O -
3 O +
mg O -
/ O -
kg O +
body O +
wt O -
. O +
daily O +
for O +
3 O +
consecutive O +
days O -
) O +
dose O -
. O +

Controls O +
received O +
the O +
vehicle O +
only O -
, O +
under O +
the O +
same O +
conditions O -
. O +

Mice O +
were O +
fasted O +
16 O +
h O +
prior O +
to O +
death O +
and O +
killed O +
humanely O +
in O +
accordance O +
with O +
approved O +
Home O +
Office O +
procedures O +
appropriate O +
to O +
the O +
species O -
. O +

Liver O -
, O +
kidney O +
and O +
lung O +
were O +
homogenized O +
in O +
4 O +
volumes O +
( O -
w O -
/ O -
v O -
) O +
of O +
0.05 O +
M O +
Tris O -
– O -
HCl O +
buffer O +
( O -
pH O +
7.4 O -
) O +
with O +
a O +
Teflon O +
pestle O +
( O -
Potter O -
- O -
Elvehjem O -
) O +
and O +
centrifuged O +
at O +
9000 O -
× O -
g O +
for O +
20 O +
min O -
. O +

The O +
post O -
- O -
mitochondrial O +
supernatant O +
obtained O -
, O +
was O +
centrifuged O +
for O +
60 O +
min O +
at O +
105 O +
000 O -
× O -
g O +
. O +

The O +
pellet O +
was O +
resuspended O +
in O +
0.1 O +
M O +
K3 O +
P2 O +
O7 O +
( O -
pH O +
7.4 O -
) O -
, O +
1 O +
mM O +
EDTA O +
and O +
20 O +
nM O +
BHT O -
, O +
and O +
centrifuged O +
again O +
for O +
60 O +
min O +
at O +
105 O +
000 O -
× O -
g O +
to O +
obtain O +
the O +
final O +
microsomal O +
fraction O -
. O +

The O +
resultant O +
washed O +
microsomes O +
were O +
then O +
resuspended O +
with O +
a O +
hand O -
- O -
driven O +
homogenizer O +
in O +
10 O +
mM O +
Tris O -
– O -
HCl O +
buffer O +
( O -
pH O +
7.4 O -
) O +
containing O +
1 O +
mM O +
EDTA O +
and O +
20 O -
% O +
glycerol O +
( O -
v O -
/ O -
v O -
) O -
. O +

Subcellular O +
preparations O +
were O +
immediately O +
frozen O +
in O +
liquid O +
nitrogen O -
, O +
stored O +
at O +
−80 O -
° O -
C O +
and O +
used O +
within O +
1 O +
week O +
[ O -
20 O -
] O +
. O +

2.3 O +
Testosterone B-Gene +
hydroxylase I-Gene +
activity O +
2.3.1 O +
Incubation O +
and O +
isolation O +
Incubations O +
contained O +
microsomes O +
( O -
equivalent O +
to O +
1–2 O +
mg O +
protein B-Gene -
) O -
, O +
0.6 O +
mM O +
NADP+ O +
, O +
8 O +
mM O +
glucose O +
6-phosphate O -
, O +
1.4 O +
units O +
glucose B-Gene +
6-phosphate I-Gene +
dehydrogenase I-Gene +
and O +
1 O +
mM O +
MgCl2 O +
, O +
in O +
a O +
final O +
volume O +
of O +
2 O +
ml O +
0.1 O +
M O +
phosphate O +
Na+ O +
/K+ O +
buffer O +
( O -
pH O +
7.4 O -
) O -
. O +

The O +
mixture O +
was O +
preincubated O +
for O +
5 O +
min O +
at O +
37 O -
° O -
C O -
. O +

The O +
reaction O +
was O +
performed O +
at O +
37 O -
° O -
C O +
by O +
shaking O +
and O +
started O +
by O +
the O +
addition O +
of O +
80 O +
mM O +
testosterone O +
( O -
dissolved O +
in O +
methanol O -
) O -
. O +

After O +
10 O +
min O -
, O +
the O +
reaction O +
was O +
stopped O +
with O +
the O +
addition O +
of O +
5 O +
ml O +
ice O -
- O -
cold O +
dichloromethane O +
and O +
12 O +
nmol O +
corticosterone O +
( O -
internal O +
standard O -
) O +
in O +
methanol O -
. O +

After O +
1 O +
min O +
vortexing O -
, O +
phases O +
were O +
separated O +
by O +
centrifugation O +
at O +
2000 O -
× O -
g O +
for O +
10 O +
min O +
and O +
the O +
aqueous O +
phase O +
was O +
extracted O +
once O +
more O +
with O +
2 O +
ml O +
dichloromethane O -
. O +

The O +
organic O +
phase O +
was O +
extracted O +
with O +
2 O +
ml O +
0.02 O +
N O +
NaOH O +
to O +
remove O +
lipid O +
constituents O -
, O +
dried O +
over O +
anhydrous O +
sodium O +
sulphate O +
and O +
transferred O +
to O +
a O +
small O +
tube O -
. O +

Dichloromethane O +
was O +
evaporated O +
at O +
37 O -
° O -
C O +
under O +
nitrogen O +
and O +
the O +
dried O +
samples O +
stored O +
at O +
−20 O -
° O -
C O -
. O +

The O +
samples O +
were O +
dissolved O +
in O +
100 O +
μl O +
methanol O +
and O +
analyzed O +
by O +
high O +
performance O +
liquid O +
chromatography O +
[ O -
21 O -
] O +
. O +

2.3.2 O +
HPLC O +
separation O +
and O +
quantification O +
Chromatographic O +
separations O +
were O +
performed O +
using O +
a O +
system O +
consisting O +
of O +
a O +
high O -
- O -
pressure O +
pump O +
( O -
Waters O +
Model O +
600E O -
, O +
Multisolvent O +
Delivery O +
System O -
) O -
, O +
a O +
sample O +
injection O +
valve O +
( O -
Rheodyne O +
Model O +
7121 O -
, O +
Cotati O -
, O +
CA O -
) O +
with O +
a O +
20 O +
μl O +
sample O +
loop O +
and O +
an O +
ultraviolet O +
detector O +
( O -
254 O +
nm O -
, O +
Waters O +
Model O +
486 O -
, O +
Tunable O +
Absorbance O +
Detector O -
) O +
connected O +
to O +
an O +
integrator O +
( O -
Millennium O +
2010 O -
, O +
Chromatography O +
Manager O -
) O -
. O +

For O +
reverse O -
- O -
phase O +
separation O +
of O +
metabolites O -
, O +
NOVA O -
- O -
PACK O +
C18 O +
analytical O +
column O +
( O -
60 O +
Å O -
, O +
4 O +
mm O -
, O +
3.9 O -
× O -
150 O +
mm O -
, O +
Waters O -
) O +
was O +
used O +
as O +
the O +
stationary O +
phase O -
. O +

The O +
mobile O +
phase O +
consisted O +
of O +
a O +
mixture O +
of O +
solvent O +
A O +
( O -
7.5 O -
% O +
( O -
v O -
/ O -
v O -
) O +
tetrahydrofuran O +
in O +
water O -
) O +
and O +
solvent O +
B O +
( O -
7.5 O -
% O +
( O -
v O -
/ O -
v O -
) O +
tetrahydrofuran O +
and O +
60 O -
% O +
( O -
v O -
/ O -
v O -
) O +
methanol O +
in O +
water O -
) O +
at O +
a O +
1 O +
ml O -
/ O -
min O +
flow O +
rate O -
. O +

Metabolite O +
separation O +
was O +
performed O +
by O +
a O +
gradient O +
from O +
30 O -
% O +
to O +
100 O -
% O +
( O -
v O -
/ O -
v O -
) O +
of O +
solvent O +
B O +
over O +
30 O +
min O -
. O +

The O +
eluent O +
was O +
monitored O +
at O +
254 O +
nm O +
and O +
the O +
area O +
under O +
the O +
absorption O +
band O +
was O +
integrated O -
. O +

The O +
concentration O +
of O +
metabolites O +
was O +
determined O +
by O +
the O +
ratio O +
between O +
respective O +
metabolite O +
peak O +
areas O +
and O +
corticosterone O +
( O -
internal O +
standard O -
) O +
and O +
the O +
calibration O +
curves O +
obtained O +
with O +
synthetic O +
testosterone O +
derivatives O +
[ O -
22,23 O -
] O +
. O +

2.4 O +
Protein B-Gene +
concentrations O +
Protein B-Gene +
was O +
determined O +
according O +
to O +
the O +
method O +
described O +
by O +
Lowry O +
[ O -
24 O -
] O +
and O +
Bailey O +
[ O -
25 O -
] O +
, O +
using O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
as O +
standard O -
. O +

Samples O +
were O +
diluted O +
200 O +
times O +
to O +
provide O +
a O +
suitable O +
protein B-Gene +
concentration O -
. O +

2.5 O +
Statistics O +
and O +
computer O +
analysis O +
Statistical O +
analysis O +
on O +
biochemical O +
data O +
was O +
performed O +
using O +
Wilcoxon O -
's O +
rank O +
method O +
as O +
reported O +
by O +
Box O +
and O +
Hunter O +
[ O -
26 O -
] O +
. O +

The O +
software O +
packages O +
used O +
were O +
Millennium O +
1.1 O +
and O +
Windows O +
3.1 O +
run O +
on O +
a O +
PC O +
486 O +
IBM O -
- O -
compatible O +
computer O -
. O +

2.6 O +
Electrophoresis O +
and O +
Western O +
immunoblot O +
Microsomes O +
from O +
both O +
control O +
and O +
DT O -
- O -
treated O +
mice O +
were O +
solubilized O +
in O +
SDS O +
and O +
resolved O +
by O +
PAGE O +
[ O -
27,28 O -
] O +
. O +

Western O +
blot O +
analysis O +
with O +
rabbit O +
polyclonal O +
antibodies B-Gene +
( O -
anti B-Gene -
- I-Gene -
CYP3A1 I-Gene -
/ O -
2 B-Gene -
) O -
, O +
raised O +
against O +
purified O +
rat O +
hepatic O +
CYP3A B-Gene +
[ O -
29 O -
] O +
, O +
was O +
performed O +
using O +
hepatic O +
and O +
kidney O +
microsomes O +
( O -
0.025 O +
mg O +
of O +
microsomal O +
protein B-Gene +
were O +
electrophoresed O +
each O +
time O -
) O +
and O +
visualized O +
with O +
4-chloro-1-naphthol O +
in O +
a O +
0.006 O -
% O +
hydrogen O +
peroxide O +
solution O -
. O +

3 O +
Results O +
The O +
expression O +
of O +
testosterone B-Gene +
hydroxylase I-Gene +
( O -
TH B-Gene -
) O +
activities O +
in O +
liver O +
microsomes O +
derived O +
from O +
male O +
and O +
female O +
mice O +
receiving O +
a O +
single O +
3 O +
or O +
6 O +
mg O -
/ O -
kg O +
body O +
wt O -
. O +

dose O +
of O +
DT O +
is O +
shown O +
in O +
Table O +
1 O +
. O +

In O +
males O +
DT O +
was O +
able O +
to O +
increase O +
( O -
mainly O +
at O +
the O +
lower O +
dose O -
) O +
the O +
different O +
TH B-Gene -
- O -
associated O +
activities O -
, O +
whereas O +
in O +
females O +
an O +
inactivating O +
effect O +
( O -
mainly O +
at O +
the O +
higher O +
dose O -
) O +
was O +
detected O -
. O +

At O +
the O +
lower O +
dose O -
, O +
all O +
TH B-Gene +
activities O +
were O +
significantly O +
( O -
P O +
< O -
0.01 O -
) O +
increased O +
from O +
∼2.8-fold O +
( O -
6β- B-Gene -
, O +
16α- B-Gene +
and O +
16β B-Gene -
- I-Gene -
TH I-Gene +
activities O -
) O +
to O +
16-fold O +
( O -
2β B-Gene -
- I-Gene -
TH I-Gene +
activity O -
) O +
in O +
males O -
. O +

In O +
particular O -
, O +
increases O +
of O +
6α- B-Gene +
( O -
3.7-fold O -
) O -
, O +
7α- B-Gene +
and O +
2α- B-Gene +
( O -
∼4.4-fold O -
) O +
and O +
17-TH B-Gene +
( O -
7.1-fold O -
) O +
activities O +
were O +
achieved O -
. O +

At O +
the O +
higher O +
dose O -
, O +
either O +
a O +
4-fold O +
increase O +
of O +
2β B-Gene -
- I-Gene -
TH I-Gene +
activity O +
or O +
a O +
65.2 O -
% O +
reduction O +
of O +
16β B-Gene -
- I-Gene -
TH I-Gene +
activity O +
was O +
observed O -
. O +

In O +
females O +
an O +
inactivating O +
effect O +
was O +
observed O +
mainly O +
at O +
the O +
higher O +
dose O +
tested O -
. O +

A O +
reduction O +
ranging O +
from O +
about O +
35 O -
% O +
( O -
7α- B-Gene +
and O +
17-TH B-Gene +
activities O -
, O +
higher O +
dose O -
, O +
and O +
16β B-Gene -
- I-Gene -
TH I-Gene +
activity O -
, O +
lower O +
dose O -
) O +
to O +
66.4 O -
% O +
( O -
16β B-Gene -
- I-Gene -
TH I-Gene +
activity O -
, O +
higher O +
dose O -
) O +
was O +
recorded O +
in O +
females O -
. O +

A O +
52 O -
% O +
suppression O +
was O +
seen O +
for O +
6α- B-Gene +
and O +
6β B-Gene -
- I-Gene -
TH I-Gene +
activities O +
at O +
higher O +
dose O -
, O +
whereas O +
a O +
42 O -
% O +
loss O +
of O +
16α B-Gene -
- I-Gene -
TH I-Gene +
activity O +
( O -
averaged O +
between O +
two O +
doses O -
) O +
was O +
observed O -
. O +

In O +
kidney O -
, O +
DT O +
significantly O +
( O -
P O +
< O -
0.01 O -
) O +
induced O +
6β B-Gene -
- I-Gene -
TH I-Gene +
activity O +
( O -
CYP3A B-Gene -
- O -
like O -
) O +
from O +
2.9- O +
to O +
4.8-fold O -
, O +
at O +
the O +
higher O +
and O +
lower O +
doses O -
, O +
respectively O -
, O +
and O +
2α B-Gene -
- I-Gene -
TH I-Gene +
activity O +
( O -
5.0-fold O -
) O +
at O +
the O +
lower O +
dose O +
in O +
male O +
mice O +
( O -
Table O +
2 O +
) O -
. O +

However O -
, O +
in O +
females O +
16α- B-Gene -
, O +
2α B-Gene -
- I-Gene -
and O +
2β B-Gene -
- I-Gene -
TH I-Gene +
activities O +
were O +
significantly O +
( O -
P O +
< O -
0.01 O -
) O +
reduced O +
up O +
to O +
50.2 O -
% O +
( O -
2β B-Gene -
- I-Gene -
TH I-Gene +
activity O -
) O +
at O +
doses O +
of O +
either O +
3 O +
or O +
6 O +
mg O -
/ O -
kg O +
body O +
wt O -
. O +

Expression O +
of O +
TH B-Gene +
activities O +
in O +
lung O +
microsomes O +
is O +
reported O +
in O +
Table O +
3 O +
. O +

Both O +
16α- B-Gene +
and O +
2α B-Gene -
- I-Gene -
TH I-Gene +
activities O +
were O +
significantly O +
( O -
P O +
< O -
0.01 O -
) O +
increased O +
( O -
7.1- O +
and O +
29.3-fold O -
, O +
respectively O -
) O +
at O +
the O +
lower O +
dose O +
in O +
males O -
. O +

An O +
increase O +
of O +
2β B-Gene -
- I-Gene -
TH I-Gene +
activity O +
from O +
3.1- O +
to O +
7.0-fold O +
( O -
lower O +
and O +
higher O +
dose O -
, O +
respectively O -
) O +
was O +
achieved O +
in O +
females O -
. O +

Again O -
, O +
a O +
2-fold O +
increase O +
in O +
2α- O +
and O +
16α O -
- O -
hydroxylations O +
was O +
also O +
achieved O +
in O +
females O +
at O +
the O +
6 O +
mg O -
/ O -
kg O +
body O +
wt O -
. O +

dose O -
. O +

In O +
contrast O -
, O +
repeated O +
DT O +
administrations O +
( O -
3 O +
mg O -
/ O -
kg O +
body O +
wt O -
. O -
, O +
daily O +
for O +
3 O +
consecutive O +
days O -
) O +
were O +
able O +
to O +
significantly O +
reduce O +
TH B-Gene +
activities O +
from O +
∼39 O -
% O +
( O -
6β- B-Gene +
and O +
2α B-Gene -
- I-Gene -
TH I-Gene +
activities O -
) O +
to O +
∼60 O -
% O +
( O -
16β- B-Gene +
and O +
2β B-Gene -
- I-Gene -
TH I-Gene +
activities O -
) O +
in O +
liver O +
microsomes O +
derived O +
from O +
male O +
animals O -
, O +
whereas O +
they O +
had O +
no O +
effect O +
in O +
females O +
( O -
Table O +
4 O +
) O -
. O +

In O +
kidney O -
, O +
repeated O +
treatment O +
determined O +
a O +
generalized O +
increase O +
of O +
several O +
TH B-Gene -
- O -
dependent O +
monooxygenases B-Gene -
. O +

For O +
example O -
, O +
enhancements O +
of O +
7α- B-Gene +
( O -
4.8-fold O -
) O -
, O +
2α- B-Gene +
and O +
17-TH B-Gene +
( O -
3.1-fold O -
) O -
, O +
6β- B-Gene +
( O -
2.9-fold O -
) O +
as O +
well O +
as O +
2β B-Gene -
- I-Gene -
TH I-Gene +
( O -
2.8-fold O -
) O +
activities O +
were O +
recorded O +
in O +
males O +
( O -
Table O +
5 O +
) O -
. O +

In O +
females O -
, O +
TH B-Gene +
activities O +
were O +
increased O +
from O +
2.8- O +
( O -
17-TH B-Gene +
activity O -
) O +
to O +
5.2-fold O +
( O -
2α B-Gene -
- I-Gene -
TH I-Gene +
activity O -
) O -
. O +

In O +
lung O -
, O +
an O +
increase O +
of O +
7α B-Gene -
- I-Gene -
TH I-Gene +
activity O +
( O -
7.9- O +
and O +
9.6-fold O -
, O +
males O +
and O +
females O -
, O +
respectively O -
) O +
was O +
observed O +
( O -
Table O +
6 O +
) O -
. O +

DT O +
was O +
also O +
able O +
to O +
induce O +
6β- B-Gene +
and O +
2α B-Gene -
- I-Gene -
TH I-Gene +
activities O +
( O -
∼4.0-fold O -
) O -
, O +
2β B-Gene -
- I-Gene -
TH I-Gene +
( O -
4.6-fold O -
) O +
and O +
17-TH B-Gene +
activities O +
( O -
3.1-fold O -
) O +
in O +
males O -
, O +
whereas O +
2β- B-Gene -
, O +
16α- B-Gene +
and O +
16β B-Gene -
- I-Gene -
TH I-Gene +
activities O +
were O +
increased O +
up O +
to O +
2.3-fold O +
and O +
6β B-Gene -
- I-Gene -
TH I-Gene +
activity O +
up O +
to O +
1.8-fold O +
in O +
females O -
. O +

The O +
induction O +
of O +
the O +
CYP3A B-Gene -
- O -
dependent O +
monooxygenases B-Gene +
in O +
liver O +
and O +
kidney O +
microsomes O +
from O +
male O +
mice O +
treated O +
with O +
a O +
single O +
DT O +
dose O +
was O +
sustained O +
by O +
means O +
of O +
Western O +
immunoblotting O +
analysis O -
, O +
using O +
rabbit O +
polyclonal O +
antibodies B-Gene +
anti O +
CYP3A1 B-Gene -
/ O -
2 B-Gene +
( O -
Fig. O +
2 O +
) O +
. O +

The O +
signal O +
shows O +
that O +
the O +
amount O +
of O +
CYP3A B-Gene +
apoprotein B-Gene +
is O +
enhanced O +
after O +
exposure O +
to O +
the O +
lower O +
DT O +
dose O +
in O +
both O +
liver O +
( O -
lane O +
2 O -
) O +
and O +
kidney O +
( O -
lane O +
4 O -
) O +
with O +
respect O +
to O +
control O +
animals O +
( O -
lanes O +
3 O +
and O +
5 O -
) O -
, O +
due O +
to O +
increased O +
transcription O +
or O +
enzyme B-Gene +
stabilization O -
. O +

4 O +
Discussion O +
In O +
investigating O +
whether O +
dithianon O +
was O +
able O +
to O +
interfere O +
with O +
non O -
- O -
genotoxic O +
mechanisms O -
, O +
changes O +
in O +
murine O +
CYP B-Gene +
isoforms O +
in O +
different O +
organs O +
of O +
both O +
sexes O +
were O +
detected O +
using O +
testosterone B-Gene +
hydroxylase I-Gene +
as O +
a O +
multibiomarker O +
of O +
effects O +
[ O -
30 O -
] O +
. O +

Testosterone O -
, O +
indeed O -
, O +
is O +
an O +
excellent O +
indicator O +
substrate O +
for O +
analysis O +
of O +
CYP B-Gene +
expression O -
, O +
since O +
it O +
undergoes O +
stereo- O +
and O +
regio O -
- O -
selective O +
hydroxylations O +
catalyzed O +
by O +
a O +
wide O +
variety O +
of O +
different O +
CYP B-Gene +
isozymes B-Gene +
[ O -
19 O -
] O +
. O +

Literature O +
shows O +
that O +
pesticides O +
are O -
, O +
in O +
general O -
, O +
poor O +
initiating O +
agents O +
and O +
their O +
carcinogenic O +
activity O +
is O +
due O +
mainly O +
to O +
epigenetic O +
mechanisms O -
. O +

In O +
the O +
present O +
investigation O +
we O -
, O +
therefore O -
, O +
considered O +
the O +
potentiality O +
of O +
DT O +
to O +
behave O +
as O +
a O +
toxic O -
/ O -
co O -
- O -
toxic O +
co O -
- O -
carcinogen O +
and O +
promoter O +
by O +
means O +
of O +
the O +
ability O +
of O +
this O +
fungicide O +
to O +
affect O +
CYP B-Gene -
. O +

It O +
is O +
noteworthy O +
that O +
the O +
aforementioned O +
detrimental O +
phenomena O -
, O +
taken O +
together O -
, O +
can O +
increase O +
the O +
toxicological O +
risk O +
independently O +
of O +
the O +
possible O +
initiating O +
properties O +
of O +
the O +
chemical O -
. O +

DT O +
exhibited O +
a O +
complex O +
pattern O +
of O +
CYP B-Gene +
modulation O -
, O +
typical O +
of O +
pesticides O +
that O +
are O +
either O +
substrates O -
, O +
inducers O +
or O +
inhibitors O +
of O +
different O +
CYPs B-Gene -
. O +

Both O +
induction O +
and O +
suppression O +
may O +
be O +
isozyme- B-Gene -
, O +
organ- O +
and O +
sex O -
- O -
specific O -
, O +
and O +
different O +
CYPs B-Gene +
may O +
be O +
affected O +
in O +
different O +
ways O +
by O +
the O +
same O +
chemical O +
under O +
different O +
conditions O +
[ O -
31–34 O -
] O +
. O +

Results O +
show O +
that O +
DT O +
was O +
able O +
to O +
induce O +
or O +
suppress O +
various O +
CYPs B-Gene +
in O +
Swiss O +
albino O +
CD1 O +
mice O +
depending O +
on O +
sex O +
and O +
organ O -
; O +
after O +
a O +
single O +
treatment O +
males O +
were O +
more O +
responsive O +
to O +
induction O +
in O +
all O +
organs O +
( O -
liver O -
, O +
kidney O +
and O +
lung O -
) O +
whereas O +
females O +
were O +
responsive O +
to O +
either O +
suppression O +
( O -
liver O +
and O +
kidney O -
) O +
or O +
induction O +
( O -
lung O -
) O -
. O +

In O +
contrast O -
, O +
after O +
repeated O +
injections O +
DT O +
was O +
able O +
to O +
decrease O +
various O +
CYP B-Gene +
activities O +
in O +
male O +
liver O +
but O +
to O +
increase O +
them O +
in O +
kidney O +
and O +
lung O +
of O +
both O +
sexes O -
. O +

An O +
interesting O +
result O +
was O +
the O +
selective O +
induction O +
( O -
sustained O +
by O +
immunoblotting O +
analysis O -
) O +
and O +
suppression O +
of O +
the O +
CYP3A B-Gene +
isoform O -
, O +
confirming O +
previous O +
data O +
where O +
aminopyrine O +
was O +
used O +
as O +
the O +
preferential O +
CYP3A B-Gene +
probe O +
[ O -
2 O -
] O +
. O +

This O +
is O +
of O +
great O +
importance O +
because O +
CYP3A B-Gene +
isoform O +
is O +
the O +
most O +
abundant O +
cytochrome B-Gene +
present O +
in O +
human O +
liver O -
. O +

Modulation O +
of O +
the O +
different O +
CYP B-Gene +
isozymes B-Gene +
could O +
be O +
explained O +
by O +
considering O +
the O +
possible O +
competition O +
of O +
individual O +
CYPs B-Gene +
for O +
reductase B-Gene +
[ O -
35 O -
] O +
, O +
the O +
direct O +
inhibiting O +
effects O +
of O +
DT O +
or O +
the O +
direct O +
toxicity O +
derived O +
from O +
CYP B-Gene +
induction O +
per O +
se O +
[ O -
16,36 O -
] O +
. O +

It O +
is O +
possible O +
that O +
the O +
different O +
levels O +
of O +
testosterone O +
metabolites O +
in O +
the O +
various O +
organs O +
reflect O +
the O +
balance O +
between O +
induction O +
and O +
toxicity O +
[ O -
20 O -
] O +
. O +

The O +
observed O +
different O +
expressions O +
between O +
the O +
various O +
tissues O +
and O +
sexes O +
could O +
imply O -
: O +
( O -
a O -
) O +
different O +
induction O +
mechanisms O -
; O +
( O -
b O -
) O +
alteration O +
in O +
competing O +
pathways O +
involved O +
in O +
the O +
disposition O +
of O +
either O +
parent O +
compound O +
and O +
metabolite O -
; O +
( O -
c O -
) O +
differences O +
in O +
substrate O +
specificity O -
; O +
CYPs B-Gene +
coming O +
from O +
different O +
organs O +
can O +
elicit O +
different O +
metabolic O +
responses O +
[ O -
20 O -
] O +
due O +
to O +
different O +
substrate O +
specificity O -
. O +

The O +
observed O +
sex O +
differences O +
in O +
enzyme B-Gene +
modulation O +
( O -
induction O +
in O +
males O -
, O +
suppression O +
in O +
females O -
) O +
could O +
be O +
explained O +
in O +
terms O +
of O +
quantitative O +
or O +
qualitative O +
differences O +
in O +
the O +
CYPs B-Gene +
under O +
control O +
of O +
the O +
sex O +
hormones O -
. O +

DT O +
appears O +
to O +
affect O +
a O +
unique O +
spectrum O +
of O +
isozymes B-Gene +
in O +
mice O -
; O +
the O +
complex O +
pattern O +
of O +
induction O +
and O +
suppression O +
of O +
CYP B-Gene +
isoforms O +
has O +
potentially O +
significant O +
toxicological O +
consequences O -
, O +
increasing O +
or O +
in O +
some O +
instances O +
reducing O +
the O +
bioactivation O +
of O +
specific O +
xenobiotics O -
, O +
and O +
co O -
- O -
administered O +
drugs O -
, O +
as O +
well O +
as O +
a O +
profound O +
effect O +
on O +
endogenous O +
metabolism O +
and O +
cellular O +
functions O +
[ O -
37 O -
] O +
. O +

CYP B-Gene +
induction O +
can O +
also O +
determine O +
an O +
overproduction O +
of O +
oxygen O +
centred O +
radicals O -
, O +
due O +
to O +
the O +
autooxidation O +
of O +
the O +
CYP B-Gene -
- B-Gene -
Fe I-Gene +
2 I-Gene -
+ I-Gene +
-O2 I-Gene +
− I-Gene +
complex I-Gene +
[ O -
16,36 O -
] O +
, O +
and O +
a O +
pleitropic O +
response O -
, O +
with O +
the O +
increase O +
of O +
either O +
phase O +
I O -
, O +
phase O +
II O +
or O +
other O +
enzymes B-Gene +
[ O -
10 O -
] O +
, O +
correlated O +
to O +
both O +
co O -
- O -
carcinogenic O +
and O +
promoting O +
properties O +
[ O -
38,39 O -
] O +
. O +

It O +
is O +
significant O +
that O +
a O +
cell O +
transforming O +
activity O +
on O +
BALB O -
/ O -
c O +
3T3 O +
cells O +
induced O +
by O +
DT O +
was O +
found O +
by O +
Perocco O +
et O +
al. O +
[ O -
4 O -
] O +
. O +

Taken O +
as O +
a O +
whole O -
, O +
the O +
aforementioned O +
toxicological O +
properties O +
of O +
DT O +
indicate O +
that O +
a O +
potential O +
risk O +
could O +
be O +
associated O +
with O +
human O +
exposure O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
the O +
National O +
Research O +
Council O +
of O +
Italy O +
( O -
CNR O -
) O -
, O +
by O +
the O +
Ministry O +
of O +
the O +
University O +
and O +
of O +
Scientific O +
and O +
Technological O +
Research O +
( O -
MURST O +
ex O +
40 O -
% O +
and O +
60 O -
% O -
) O +
and O +
by O +
Interuniversitary O +
Biotechnology O +
Center O +
( O -
CIB O -
) O +
Bologna O -
, O +
grants O -
. O +

Enterobacteria O +
of O +
the O +
genus O +

Proteus O +
are O +
a O +
common O +
cause O +
of O +
urinary O +
tract O +
infections O +
in O +
human O -
, O +
which O +
often O +
result O +
in O +
severe O +
complications O -
, O +
such O +
as O +
pyelonephritis O +
and O +
formation O +
of O +
bladder O +
and O +
kidney O +
stones O +
[ O -
1 O -
] O +
. O +

Lipopolysaccharide O +
( O -
LPS O -
, O +
endotoxin O -
) O +
is O +
considered O +
as O +
one O +
of O +
the O +
virulence O +
factors O +
of O +
Proteus O +
which O -
, O +
after O +
being O +
released O +
from O +
bacterial O +
cells O -
, O +
mediates O +
the O +
infectious O +
processes O +
[ O -
1,2 O -
] O +
. O +

The O +
LPS O +
consists O +
of O +
three O +
moieties O -
: O +
a O +
lipid O +
part O +
( O -
lipid O +
A O -
) O +
which O +
anchors O +
LPS O +
into O +
the O +
outer O +
membrane O +
and O +
is O +
responsible O +
for O +
the O +
endotoxicity O +
of O +
the O +
LPS O -
, O +
an O +
oligosaccharide O +
core O +
region O -
, O +
and O +
an O +
O O -
- O -
specific O +
polysaccharide O +
chain O +
( O -
OPS O -
, O +
O O -
- O -
antigen O -
) O +
which O +
defines O +
the O +
immunospecificity O +
of O +
the O +
bacterium O -
. O +

On O +
the O +
basis O +
of O +
the O +
O O -
- O -
antigens O -
, O +
strains O +
of O +
Proteus O +
are O +
classified O +
serologically O +
into O +
more O +
than O +
60 O +
serogroups O +
[ O -
3–5 O -
] O +
. O +

A O +
serological O +
cross O -
- O -
reactivity O +
was O +
observed O +
for O +
strains O +
of O +
different O +
serogroups O +
[ O -
5 O -
] O +
, O +
thus O +
showing O +
that O +
the O +
existing O +
serogrouping O +
scheme O +
does O +
not O +
reflect O +
all O -
, O +
but O +
major O -
, O +
antigenic O +
relationships O +
between O +
Proteus O +
strains O -
. O +

Immunochemical O +
studies O +
of O +
LPSs O +
are O +
important O +
for O +
substantiation O +
of O +
the O +
serological O +
cross O -
- O -
reactivity O +
of O +
strains O +
on O +
the O +
molecular O +
level O +
and O +
for O +
improvement O +
of O +
the O +
classification O +
of O +
Proteus O +
on O +
the O +
chemical O +
basis O -
. O +

In O +
the O +
LPSs O +
of O +
most O +
Proteus O +
strains O +
studied O -
, O +
the O +
OPSs O +
are O +
acidic O +
due O +
to O +
the O +
presence O +
of O +
various O +
acidic O +
sugars O +
and O +
non O -
- O -
sugar O +
components O -
; O +
a O +
few O +
strains O +
of O +
Proteus O +
vulgaris O +
and O +
Proteus O +
penneri O +
have O +
neutral O +
OPSs O +
[ O -
5 O -
] O +
. O +

Now O -
, O +
we O +
report O +
the O +
structures O +
of O +
the O +
OPSs O +
of O +
two O +
serologically O +
cross O -
- O -
reactive O +
strains O +
of O +
Proteus O +
mirabilis O +
belonging O +
to O +
serogroups O +
O24 O +
and O +
O29 O -
. O +

Strains O +
of O +
these O +
serogroups O +
are O +
frequent O +
among O +
isolates O +
from O +
clinical O +
specimens O +
[ O -
3 O -
] O +
and O +
were O +
confirmed O +
in O +
this O +
work O +
to O +
play O +
a O +
role O +
in O +
human O +
pathology O -
. O +

Immunochemical O +
studies O +
of O +
the O +
OPSs O +
and O +
LPSs O +
were O +
performed O +
in O +
order O +
to O +
reveal O +
the O +
epitope O +
specificity O +
of O +
the O +
cross O -
- O -
reactive O +
anti B-Gene -
- I-Gene -
LPS I-Gene +
antibodies I-Gene -
. O +

Part O +
of O +
the O +
data O +
of O +
P. O +
mirabilis O +
O24 O +
has O +
been O +
reported O +
[ O -
6 O -
] O +
. O +

2 O +
Material O +
and O +
methods O +
2.1 O +
Bacterial O +
strains O -
, O +
isolation O +
and O +
degradation O +
of O +
the O +
LPSs O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
( O -
strains O +
PrK O +
47 O -
/ O -
57 O +
and O +
52 O -
/ O -
57 O -
, O +
respectively O -
) O +
came O +
from O +
the O +
Czech O +
National O +
Collection O +
of O +
Type O +
Cultures O +
( O -
Institute O +
of O +
Epidemiology O +
and O +
Microbiology O -
, O +
Prague O -
) O -
. O +

The O +
LPSs O +
were O +
isolated O +
using O +
the O +
phenol O -
- O -
water O +
procedure O +
[ O -
7 O -
] O +
and O +
purified O +
by O +
treatment O +
with O +
DNAse B-Gene +
and O +
RNAse B-Gene +
( O -
Sigma O -
, O +
USA O -
) O +
and O +
ultracentrifugation O +
as O +
described O +
[ O -
7,8 O -
] O +
. O +

The O +
isolated O +
LPSs O +
were O +
essentially O +
free O +
of O +
nucleic O +
acids O +
and O +
contained O +
< O -
2 O -
% O +
proteins B-Gene -
. O +

Delipidation O +
of O +
the O +
LPSs O +
was O +
performed O +
with O +
aqueous O +
2 O -
% O +
acetic O +
acid O +
at O +
100 O -
° O -
C O -
, O +
the O +
precipitate O +
was O +
removed O +
by O +
centrifugation O +
( O -
13 O +
000 O -
× O -
g O +
, O +
20 O +
min O -
) O -
, O +
and O +
the O +
supernatant O +
was O +
fractionated O +
on O +
a O +
column O +
( O -
2.5 O -
× O -
65 O +
cm O -
) O +
of O +
Sephadex O +
G-50 O +
( O -
Pharmacia O -
, O +
Sweden O -
) O +
in O +
0.05 O +
M O +
pyridinium O +
acetate O +
buffer O +
pH O +
4.5 O +
with O +
monitoring O +
by O +
a O +
Knauer O +
differential O +
refractometer O +
( O -
Germany O -
) O +
to O +
give O +
the O +
corresponding O +
high O +
molecular O +
mass O +
OPS O +
and O +
core O +
oligosaccharide O +
fractions O -
. O +

Alkali O -
- O -
treated O +
LPSs O +
were O +
prepared O +
by O +
saponification O +
of O +
the O +
LPSs O +
with O +
aqueous O +
0.25 O +
M O +
NaOH O +
( O -
56 O -
° O -
C O -
, O +
2 O +
h O -
) O -
. O +

Smith O +
degradation O +
of O +
the O +
alkali O -
- O -
treated O +
LPS O +
from O +
P. O +
mirabilis O +
O24 O +
was O +
performed O +
with O +
0.1 O +
M O +
NaIO4 O +
( O -
20 O -
° O -
C O -
, O +
48 O +
h O -
, O +
in O +
the O +
dark O -
) O -
, O +
the O +
resultant O +
product O +
was O +
reduced O +
with O +
NaBH4 O +
and O +
desalted O +
on O +
Sephadex O +
G-50 O -
. O +

2.2 O +
NMR O +
spectroscopy O +
NMR O +
spectra O +
were O +
recorded O +
with O +
a O +
Bruker O +
DRX-500 O +
spectrometer O +
for O +
a O +
solution O +
in O +
D2 O +
O O +
at O +
30 O +
or O +
60 O -
° O -
C O +
using O +
internal O +
acetone O +
( O -
δH O +
2.225 O -
, O +
δC O +
31.45 O -
) O +
as O +
reference O -
. O +

Standard O +
Bruker O +
software O +
( O -
XWINNMR O +
1.2 O -
) O +
was O +
used O +
to O +
acquire O +
and O +
maintain O +
the O +
NMR O +
data O -
. O +

A O +
mixing O +
time O +
of O +
200 O +
and O +
100 O +
ms O +
was O +
used O +
in O +
two O -
- O -
dimensional O +
TOCSY O +
and O +
NOESY O +
experiments O +
with O +
P. O +
mirabilis O +
O29 O +
OPS O -
, O +
respectively O -
, O +
or O +
300 O +
ms O +
in O +
a O +
NOESY O +
experiment O +
with O +
P. O +
mirabilis O +
O24 O +
OPS O -
. O +

The O +
1 O +
H- O +
and O +
13 O +
C O -
- O -
NMR O +
spectra O +
were O +
assigned O +
using O +
two O -
- O -
dimensional O +
COSY O -
, O +
TOCSY O -
, O +
and O +
H O -
- O -
detected O +
1 O +
H,13 O +
C O +
heteronuclear O +
multiple O -
- O -
quantum O +
coherence O +
( O -
HMQC O -
) O +
experiments O -
. O +

The O +
assignment O +
of O +
β O -
- O -
linked O +
sugars O +
was O +
confirmed O +
making O +
use O +
of O +
intraresidue O +
H1 O -
/ O -
H3 O -
, O +
H5 O +
correlations O +
revealed O +
by O +
a O +
NOESY O +
experiment O -
. O +

Spin O +
systems O +
of O +
monosaccharides O +
were O +
identified O +
based O +
on O +
the O +
typical O +
3 O +
J O +
H O -
, O -
H O +
coupling O +
constant O +
values O -
. O +

Amino O +
sugars O +
were O +
distinguished O +
by O +
correlations O +
of O +
protons O +
at O +
carbons O +
bearing O +
nitrogen O +
to O +
the O +
corresponding O +
carbons O +
at O +
δ O +
50–57 O -
, O +
which O +
were O +
revealed O +
by O +
a O +
1 O +
H,13 O +
C O +
HMQC O +
experiment O -
. O +

2.3 O +
Sugar O +
analysis O +
The O +
OPSs O +
were O +
hydrolyzed O +
with O +
2 O +
M O +
CF3 O +
COOH O +
( O -
120 O -
° O -
C O -
, O +
2 O +
h O -
) O +
or O +
methanolyzed O +
with O +
1 O +
M O +
HCl O -
/ O -
MeOH O +
( O -
80 O -
° O -
C O -
, O +
16 O +
h O -
) O -
. O +

Amino O +
sugars O +
were O +
identified O +
on O +
a O +
Biotronik O +
LC-2000 O +
amino O +
acid O +
analyser O +
( O -
Germany O -
) O +
equipped O +
with O +
a O +
column O +
( O -
0.4 O -
× O -
22 O +
cm O -
) O +
of O +
a O +
Ostion O +
LG O +
AN O +
B O +
cation O -
- O -
exchange O +
resin O +
using O +
0.35 O +
M O +
sodium O +
citrate O +
buffer O +
pH O +
5.28 O +
at O +
80 O -
° O -
C O -
. O +

Neutral O +
sugars O +
were O +
analysed O +
with O +
a O +
Biotronik O +
LC-2000 O +
sugar O +
analyser O -
, O +
using O +
a O +
column O +
( O -
0.4 O -
× O -
15 O +
cm O -
) O +
of O +
a O +
Dionex O +
A O -
× O -
8–11 O +
anion O -
- O -
exchange O +
resin O +
and O +
0.5 O +
M O +
sodium O +
borate O +
buffer O +
pH O +
8.0 O +
at O +
65 O -
° O -
C O -
. O +

Uronic O +
acids O +
were O +
analysed O +
by O +
GLC O +
as O +
acetylated O +
methyl O +
glycosides O +
using O +
a O +
Hewlett O -
- O -
Packard O +
Model O +
5890 O +
chromatograph O +
with O +
an O +
Ultra O +
2 O +
capillary O +
column O +
and O +
a O +
temperature O +
gradient O +
of O +
160 O -
° O -
C O +
( O -
1 O +
min O -
) O +
to O +
290 O -
° O -
C O +
at O +
10 O -
° O -
C O -
/ O -
min O -
. O +

The O +
absolute O +
configurations O +
of O +
monosaccharides O +
were O +
determined O +
by O +
GLC O +
of O +
acetylated O +
( O -
S O +
) O -
-2-butyl O +
glycosides O +
according O +
to O +
the O +
published O +
method O +
[ O -
9,10 O -
] O +
modified O +
as O +
described O +
[ O -
11 O -
] O +
. O +

2.4 O +
Preparation O +
of O +
sera O +
and O +
serological O +
assays O +
Rabbit O +
antisera O +
against O +
surface O +
heat O -
- O -
stabile O +
antigens O +
of O +
Proteus O +
were O +
obtained O +
as O +
described O +
[ O -
12 O -
] O +
. O +

Briefly O -
, O +
a O +
New O +
Zealand O +
rabbit O +
received O +
i.v O -
. O +

increasing O +
doses O +
of O +
heat O +
killed O +
bacteria O +
on O +
days O +
0 O -
, O +
4 O -
, O +
7 O +
and O +
11 O -
. O +

On O +
day O +
15 O -
, O +
20 O +
ml O +
blood O +
was O +
taken O +
by O +
cardiac O +
puncture O +
and O +
early O +
serum O +
was O +
prepared O -
. O +

After O +
a O +
single O +
booster O +
injection O +
on O +
day O +
50 O -
, O +
the O +
rabbit O +
was O +
extinguished O +
on O +
day O +
58 O +
to O +
give O +
late O +
serum O -
. O +

Unless O +
stated O +
otherwise O -
, O +
the O +
data O +
of O +
early O +
serum O +
are O +
given O -
. O +

Human O +
sera O +
were O +
collected O +
from O +
healthy O +
individuals O +
or O +
hospitalised O +
patients O +
who O +
gave O +
informed O +
consent O -
. O +

ELISA O +
and O +
passive O +
hemolysis O +
( O -
PH O -
) O +
were O +
performed O +
essentially O +
as O +
described O +
[ O -
12 O -
] O +
. O +

In O +
ELISA O -
, O +
human O +
or O +
rabbit O +
sera O +
were O +
dispensed O +
to O +
plates O +
containing O +
antigens O +
( O -
LPS O +
or O +
Proteus O +
whole O +
cells O -
) O -
, O +
and O +
fixed O +
antibodies B-Gene +
were O +
quantified O +
with O +
horseradish O +
peroxidase O -
- O -
conjugated O +
goat O +
anti O -
- O -
human O +
or O +
anti O -
- O -
rabbit O +
IgG B-Gene +
( O -
Sigma O -
) O -
. O +

Proteinase B-Gene +
K- I-Gene +
( O -
Sigma O -
) O +
treated O +
whole O +
bacterial O +
cells O +
or O +
LPSs O +
were O +
separated O +
by O +
SDS O -
- O -
PAGE O +
according O +
to O +
Laemmli O +
[ O -
13 O -
] O +
. O +

The O +
gels O +
were O +
silver O -
- O -
stained O +
according O +
to O +
Tsai O +
and O +
Frasch O +
[ O -
14 O -
] O +
or O +
electroblotted O +
onto O +
nitrocellulose O +
plates O +
( O -
Shleicher O +
and O +
Schull O -
, O +
Germany O -
) O -
, O +
which O +
were O +
incubated O +
with O +
diluted O +
( O -
1:100 O -
) O +
immune O +
rabbit O +
sera O +
as O +
primary O +
antibodies B-Gene +
and O +
then O +
with O +
horseradish B-Gene +
peroxidase I-Gene -
- O -
conjugated O +
goat O +
anti O -
- O -
rabbit O +
IgG B-Gene +
( O -
Sigma O -
) O +
as O +
secondary O +
antibodies B-Gene +
[ O -
15 O -
] O +
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Elucidation O +
of O +
the O +
structure O +
of O +
the O +
OPS O +
of O +
P. O +
mirabilis O +
O24 O +
Sugar O +
analysis O +
of O +
the O +
OPS O +
after O +
full O +
acid O +
hydrolysis O -
, O +
including O +
determination O +
of O +
the O +
absolute O +
configurations O +
of O +
monosaccharides O -
, O +
revealed O +
2-amino-2-deoxy O -
- O -
D O +
-glucose O +
and O +
2-amino-2-deoxy O -
- O -
D O +
-galactose O +
in O +
the O +
ratio O +
2:1 O -
, O +
as O +
well O +
as O +
D O +
-galactose O -
. O +

The O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
OPS O +
[ O -
6 O -
] O +
( O -
Table O +
1 O +
) O +
contained O +
signals O +
for O +
four O +
anomeric O +
carbons O +
in O +
the O +
region O +
δ O +
102.5–106.6 O -
, O +
three O +
carbons O +
linked O +
to O +
nitrogen O +
( O -
C2 O +
of O +
hexosamines O -
) O +
in O +
the O +
region O +
δ O +
53.0–56.2 O -
, O +
four O +
HOC O +
H2 O +
-C O +
groups O +
( O -
C6 O +
of O +
galactose O +
and O +
hexosamines O -
) O +
at O +
δ O +
61.4–62.4 O -
, O +
13 O +
other O +
sugar O +
ring O +
carbons O +
in O +
the O +
region O +
δ O +
69.9–82.8 O -
, O +
and O +
three O +
N O +
-acetyl O +
groups O +
at O +
δ O +
23.6–23.9 O +
( O -
CH3 O +
) O +
and O +
δ O +
175.4–175.7 O +
( O -
CO O -
) O -
. O +

Accordingly O -
, O +
the O +
1 O +
H O -
- O -
NMR O +
spectrum O +
of O +
the O +
OPS O +
( O -
Table O +
1 O +
) O +
contained O -
, O +
inter O +
alia O -
, O +
signals O +
for O +
four O +
anomeric O +
protons O +
in O +
the O +
region O +
δ O +
4.44–4.91 O +
and O +
three O +
N O +
-acetyl O +
groups O +
at O +
δ O +
2.04 O +
( O -
6H O -
) O +
and O +
2.09 O +
( O -
3H O -
) O -
. O +

Therefore O -
, O +
the O +
OPS O +
is O +
composed O +
of O +
tetrasaccharide O +
repeating O +
units O +
containing O +
one O +
residue O +
each O +
of O +
D O +
-galactose O +
and O +
2-acetamido-2-deoxy O -
- O -
D O +
-glucose O -
, O +
and O +
two O +
residues O +
of O +
2-acetamido-2-deoxy O -
- O -
D O +
-galactose O -
. O +

Relatively O +
large O +
coupling O +
constant O +
values O +
of O +
J O +
1,2 O +
7–8 O +
Hz O -
, O +
determined O +
from O +
the O +
1 O +
H O -
- O -
NMR O +
spectrum O +
of O +
the O +
OPS O -
, O +
showed O +
that O +
all O +
monosaccharide O +
residues O +
are O +
in O +
the O +
pyranose O +
form O +
and O +
β O -
- O -
linked O -
. O +

In O +
the O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
OPS O -
, O +
the O +
positions O +
of O +
the O +
signals O +
for O +
C2–C6 O +
of O +
Gal O +
at O +
δ O +
72.2 O -
, O +
74.2 O -
, O +
69.9 O -
, O +
76.1 O -
, O +
and O +
62.4 O +
( O -
or O +
62.0 O -
) O -
, O +
respectively O -
, O +
were O +
close O +
to O +
those O +
of O +
non O -
- O -
substituted O +
β O -
- O -
Galp O +
[ O -
16 O -
] O +
and O -
, O +
hence O -
, O +
Gal O +
occupies O +
the O +
terminal O +
position O +
in O +
the O +
side O +
chain O -
. O +

As O +
a O +
result O +
of O +
the O +
glycosylation O -
, O +
the O +
signals O +
for O +
C4 O +
of O +
one O +
of O +
the O +
GlcNAc O +
residues O +
( O -
GlcNAcI O +
) O -
, O +
C3 O +
of O +
the O +
other O +
residue O +
( O -
GlcNAcII O +
) O -
, O +
C3 O +
and O +
C4 O +
of O +
GalNAc O +
were O +
shifted O +
downfield O +
to O +
δ O +
81.0 O -
, O +
82.8 O -
, O +
81.8 O -
, O +
and O +
75.6 O -
, O +
respectively O -
, O +
compared O +
to O +
their O +
positions O +
in O +
the O +
spectra O +
of O +
the O +
corresponding O +
non O -
- O -
substituted O +
monosaccharides O +
[ O -
16 O -
] O +
. O +

These O +
data O +
showed O +
that O +
the O +
OPS O +
is O +
branched O +
and O +
allowed O +
determination O +
of O +
the O +
positions O +
of O +
substitution O +
of O +
the O +
monosaccharides O -
. O +

The O +
NOESY O +
spectrum O +
of O +
the O +
OPS O +
contained O +
interresidue O +
cross O -
- O -
peaks O +
between O +
the O +
following O +
protons O -
: O +
Gal O +
H1 O -
/ O -
GalNAc O +
H3 O +
( O -
strong O -
) O +
and O +
H4 O +
( O -
weak O -
) O -
, O +
GalNAc O +
H1 O -
/ O -
GlcNAcI O +
H4 O -
, O +
GlcNAcI O +
H1 O -
/ O -
GlcNAcII O +
H3 O -
, O +
and O +
GlcNAcII O +
H1 O -
/ O -
GalNAc O +
H4 O +
( O -
strong O -
) O -
, O +
H3 O +
and O +
H5 O +
( O -
both O +
weak O -
) O -
. O +

These O +
data O +
confirmed O +
the O +
positions O +
of O +
substitution O +
of O +
the O +
monosaccharide O +
residues O -
, O +
showed O +
that O +
GlcNAcII O +
and O +
Gal O +
are O +
attached O +
to O +
GalNAc O +
at O +
positions O +
4 O +
and O +
3 O -
, O +
respectively O -
, O +
and O +
allowed O +
determination O +
of O +
the O +
full O +
monosaccharide O +
sequence O +
in O +
the O +
repeating O +
unit O -
. O +

Therefore O -
, O +
the O +
OPS O +
of O +
P. O +
mirabilis O +
O24 O -
, O +
which O +
is O +
the O +
first O +
neutral O +
OPS O +
found O +
in O +
this O +
species O -
, O +
has O +
the O +
following O +
structure O -
: O +
3.2 O +
Elucidation O +
of O +
the O +
structure O +
of O +
the O +
OPS O +
of O +
P. O +
mirabilis O +
O29 O +
Sugar O +
analysis O +
showed O +
the O +
presence O +
of O +
2-amino-2-deoxy O -
- O -
D O +
-galactose O +
and O +
D O +
-glucuronic O +
acid O +
( O -
D O +
-GlcA O -
) O +
as O +
components O +
of O +
the O +
OPS O -
. O +

The O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
OPS O +
( O -
Fig. O +
1 O -
, O +
Table O +
1 O +
) O +
was O +
typical O +
of O +
a O +
regular O +
polymer O -
. O +

It O +
contained O +
signals O +
for O +
four O +
anomeric O +
carbons O +
at O +
δ O +
96.2–105.0 O -
, O +
three O +
HOC O +
H2 O +
-C O +
groups O +
( O -
C6 O +
of O +
GalN O -
) O +
at O +
δ O +
61.9 O -
, O +
three O +
carbons O +
bearing O +
nitrogen O +
( O -
C2 O +
of O +
GalN O -
) O +
at O +
δ O +
50.5 O -
, O +
51.5 O +
and O +
53.8 O -
, O +
13 O +
other O +
sugar O +
ring O +
carbons O +
at O +
δ O +
68.6–81.5 O -
, O +
and O +
N O +
-acetyl O +
groups O +
( O -
CH3 O +
at O +
δ O +
23.6 O -
, O +
CO O +
at O +
δ O +
175.2–176.2 O -
) O -
. O +

Accordingly O -
, O +
the O +
1 O +
H O -
- O -
NMR O +
spectrum O +
( O -
Table O +
1 O +
) O +
contained O +
signals O +
for O +
four O +
anomeric O +
protons O +
at O +
δ O +
4.52–5.08 O -
, O +
other O +
signals O +
of O +
sugar O +
ring O +
protons O +
at O +
δ O +
3.41–4.44 O -
, O +
and O +
three O +
N O +
-acetyl O +
groups O +
at O +
δ O +
2.06–2.10 O -
. O +

Therefore O -
, O +
the O +
OPS O +
has O +
a O +
tetrasaccharide O +
repeating O +
unit O +
containing O +
three O +
residues O +
of O +
2-acetamido-2-deoxy O -
- O -
D O +
-galactose O +
and O +
one O +
residue O +
of O +
D O +
-glucuronic O +
acid O -
. O +

The O +
coupling O +
constant O +
value O +
of O +
J O +
1,2 O +
3 O +
Hz O +
indicated O +
that O +
one O +
of O +
the O +
GalNAc O +
residues O +
( O -
GalNAcI O +
) O +
is O +
α O -
- O -
linked O -
, O +
whereas O +
the O +
values O +
of O +
J O +
1,2 O +
8 O +
Hz O +
showed O +
that O +
GlcA O +
and O +
two O +
other O +
GalNAc O +
residues O +
( O -
GalNAcII O +
and O +
GalNAcIII O +
) O +
are O +
β O -
- O -
linked O -
. O +

The O +
NOESY O +
spectrum O +
showed O +
GalNAcIII O +
H1 O -
/ O -
GalNAcII O +
H4 O +
and O +
GalNAcII O +
H1 O -
/ O -
GlcA O +
H4 O +
interresidue O +
cross O -
- O -
peaks O -
, O +
thus O +
demonstrating O +
a O +
GalNAcIII O +
( O -
1→4 O -
) O -
GalNAcII O +
( O -
1→4 O -
) O -
GlcA O +
sequence O -
. O +

H1 O +
of O +
GalNAcI O +
gave O +
two O +
interresidue O +
cross O -
- O -
peaks O -
, O +
with O +
H3 O +
and O +
H4 O +
of O +
GalNAcII O +
, O +
that O +
is O +
typical O +
of O +
α- O -
( O -
1→3 O -
) O -
-linked O +
disaccharides O +
with O +
the O +
same O +
absolute O +
configuration O +
of O +
the O +
constituent O +
monosaccharides O +
[ O -
17 O -
] O +
. O +

Likewise O -
, O +
H1 O +
of O +
GlcA O +
gave O +
two O +
cross O -
- O -
peaks O +
with O +
H3 O +
and O +
H4 O +
of O +
GalNAcIII O +
. O +

In O +
the O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
OPS O -
, O +
the O +
positions O +
of O +
the O +
signals O +
for O +
C2–C6 O +
of O +
GalNAcI O +
at O +
δ O +
50.5 O -
, O +
68.6 O -
, O +
69.4 O -
, O +
72.1 O -
, O +
and O +
61.9 O -
, O +
respectively O -
, O +
were O +
typical O +
of O +
the O +
non O -
- O -
substituted O +
α O -
- O -
Galp O +
NAc O +
[ O -
16 O -
] O +
. O +

Relatively O +
low O -
- O -
field O +
positions O +
of O +
the O +
signals O +
for O +
C3 O +
of O +
GalNAcIII O +
and O +
C4 O +
of O +
GlcA O +
at O +
δ O +
79.2 O +
and O +
81.5 O -
, O +
as O +
compared O +
with O +
those O +
in O +
non O -
- O -
substituted O +
β O -
- O -
Galp O +
NAc O +
and O +
β O -
- O -
Glcp O +
A O +
[ O -
16 O -
] O +
, O +
resulted O +
from O +
the O +
substitution O +
at O +
O3 O +
and O +
O4 O -
, O +
respectively O -
. O +

Taking O +
into O +
account O +
the O +
NOESY O +
data O -
, O +
one O +
could O +
conclude O +
that O +
GlcA O +
is O +
attached O +
to O +
GalNAcIII O +
at O +
position O +
3 O -
. O +

Of O +
the O +
signals O +
for O +
C3 O +
and O +
C4 O +
of O +
GalNAcII O +
, O +
only O +
that O +
for O +
C3 O +
was O +
shifted O -
, O +
as O +
expected O -
, O +
downfield O +
to O +
δ O +
77.3 O -
, O +
whereas O +
the O +
signal O +
for O +
C4 O +
remained O +
almost O +
at O +
the O +
same O +
position O +
at O +
δ O +
69.0 O +
as O +
in O +
non O -
- O -
substituted O +
β O -
- O -
Galp O +
NAc O +
[ O -
16 O -
] O +
. O +

This O +
could O +
be O +
accounted O +
for O +
by O +
strong O +
deviation O +
from O +
the O +
expected O +
regular O +
conformation O +
of O +
the O +
1→4-glycosidic O +
linkage O +
in O +
a O +
sterically O +
hindered O +
trisaccharide O +
fragment O +
of O +
three O +
GalNAc O +
residues O +
with O +
vicinal O +
substitution O +
at O +
positions O +
3 O +
and O +
4 O +
of O +
GalNAcII O +
( O -
compare O +
also O +
published O +
data O +
[ O -
18 O -
] O +
) O -
. O +

On O +
the O +
basis O +
of O +
the O +
data O +
obtained O -
, O +
it O +
was O +
concluded O +
that O +
the O +
OPS O +
of O +
P. O +
mirabilis O +
O29 O +
has O +
the O +
following O +
structure O -
: O +
As O +
the O +
OPS O +
of O +
P. O +
mirabilis O +
O24 O +
studied O +
in O +
this O +
work O +
and O +
most O +
other O +
Proteus O +
OPSs O +
with O +
known O +
structure O +
[ O -
5 O -
] O +
, O +
the O +
OPS O +
of O +
P. O +
mirabilis O +
O29 O +
is O +
enriched O +
in O +
N O +
-acetylamino O +
sugars O -
. O +

Also O +
typical O +
of O +
Proteus O +
OPSs O -
, O +
this O +
is O +
an O +
acidic O +
polysaccharide O +
containing O +
D O +
-glucuronic O +
acid O -
, O +
a O +
component O +
of O +
OPSs O +
of O +
many O +
other O +
Proteus O +
serogroups O +
[ O -
5 O -
] O +
. O +

Although O +
different O +
in O +
sugar O +
composition O -
, O +
the O +
main O +
chains O +
of O +
the O +
OPSs O +
of O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
exhibit O +
some O +
degree O +
of O +
structural O +
similarity O -
. O +

3.3 O +
Serological O +
studies O +
Sera O +
of O +
75 O +
healthy O +
volunteers O +
and O +
56 O +
hospitalised O +
patients O +
were O +
tested O +
in O +
ELISA O +
for O +
the O +
presence O +
of O +
IgG B-Gene +
class O +
antibodies B-Gene +
against O +
LPSs O +
of O +
P. O +
mirabilis O +
. O +

48.0 O -
% O +
and O +
49.3 O -
% O +
sera O +
of O +
volunteers O +
contain O +
anti O -
- O -
P. O +
mirabilis O +
O24 O +
and O +
anti O -
- O -
P. O +
mirabilis O +
O29 O +
antibodies B-Gene -
, O +
respectively O -
. O +

The O +
level O +
of O +
patients O -
' O +
sera O +
reacting O +
with O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
LPSs O +
was O +
significantly O +
higher O +
( O -
80.4 O -
% O +
and O +
67.9 O -
% O -
, O +
respectively O -
) O -
. O +

These O +
data O +
indicated O +
a O +
role O +
of O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
as O +
pathological O +
agents O +
in O +
humans O -
. O +

P. O +
mirabilis O +
O24 O +
LPS O +
reacted O +
with O +
rabbit O +
anti O -
- O -
P. O +
mirabilis O +
O24 O +
serum O +
at O +
high O +
titres O +
of O +
1:102 O +
400 O +
in O +
passive O +
hemolysis O +
( O -
PH O -
) O +
and O +
1:128 O +
000 O +
in O +
ELISA O -
. O +

Alkali O -
- O -
treated O +
LPS O +
demonstrated O +
the O +
same O +
reactivity O +
in O +
ELISA O +
as O +
LPS O -
, O +
whereas O +
P. O +
mirabilis O +
O24 O +
OPS O +
was O +
less O +
active O +
( O -
titre O +
1:16 O +
000 O -
) O -
. O +

A O +
weaker O +
reactivity O +
of O +
the O +
OPS O +
could O +
be O +
accounted O +
for O +
by O +
the O +
importance O +
of O +
the O +
core O -
- O -
lipid O +
A O +
moiety O +
of O +
LPS O +
in O +
the O +
exposure O +
of O +
the O +
OPS O +
chain O +
optimal O +
for O +
antibodies B-Gene +
binding O +
or O +
by O +
the O +
specificity O +
of O +
a O +
significant O +
fraction O +
of O +
antibodies B-Gene +
to O +
the O +
LPS O +
core O +
( O -
see O +
below O -
) O -
. O +

A O +
Smith O -
- O -
degraded O +
LPS O +
and O +
a O +
core O +
oligosaccharide O -
, O +
obtained O +
by O +
mild O +
acid O +
degradation O +
of O +
the O +
LPS O -
, O +
were O +
inactive O -
. O +

The O +
intact O +
LPS O +
and O +
alkali O -
- O -
treated O +
LPS O +
at O +
doses O +
of O +
4.9 O +
and O +
78 O +
ng O -
, O +
respectively O -
, O +
inhibited O +
the O +
reaction O +
in O +
ELISA O +
and O +
PH O +
in O +
the O +
homologous O +
system O +
of O +
anti O -
- O -
P. O +
mirabilis O +
O24 O +
serum O -
/ O -
P. O +
mirabilis O +
O24 O +
LPS O -
. O +

The O +
OPS O +
inhibited O +
the O +
reaction O +
only O +
in O +
ELISA O +
at O +
as O +
high O +
dose O +
as O +
625 O +
ng O -
, O +
whereas O +
the O +
Smith O -
- O -
degraded O +
LPS O +
and O +
the O +
core O +
oligosaccharide O +
were O +
inactive O -
. O +

Therefore O -
, O +
the O +
lateral O +
Gal O +
residue O -
, O +
which O +
is O +
destroyed O +
by O +
Smith O +
degradation O -
, O +
is O +
crucial O +
for O +
manifesting O +
of O +
the O +
O24 O +
specificity O -
. O +

LPSs O +
from O +
various O +
Proteus O +
strains O +
representing O +
more O +
than O +
30 O +
O O -
- O -
serogroups O +
were O +
tested O +
in O +
ELISA O +
with O +
rabbit O +
anti O -
- O -
P. O +
mirabilis O +
O24 O +
antiserum O -
. O +

A O +
strong O +
cross O -
- O -
reactivity O +
was O +
observed O +
between O +
anti O -
- O -
P. O +
mirabilis O +
O24 O +
serum O +
and O +
P. O +
mirabilis O +
O29 O +
LPS O +
( O -
titres O +
1:32 O +
000 O +
and O +
1:4000 O +
with O +
late O +
and O +
early O +
sera O -
, O +
respectively O -
) O -
. O +

Vice O +
versa O -
, O +
from O +
rabbit O +
anti O -
- O -
O O +
sera O +
against O +
over O +
30 O +
Proteus O +
strains O +
tested O -
, O +
only O +
that O +
to O +
P. O +
mirabilis O +
O29 O +
cross O -
- O -
reacted O +
in O +
ELISA O +
with O +
P. O +
mirabilis O +
O24 O +
LPS O +
to O +
a O +
high O +
dilution O +
of O +
1:16 O +
000 O -
. O +

The O +
close O +
serological O +
relatedness O +
of O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
LPSs O +
was O +
confirmed O +
by O +
PH O +
data O +
( O -
Table O +
2 O +
) O -
. O +

Preincubation O +
of O +
anti O -
- O -
P. O +
mirabilis O +
O24 O +
serum O +
with O +
the O +
homologous O +
LPS O +
abolished O +
the O +
reactivity O +
in O +
PH O +
with O +
both O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
LPSs O -
. O +

Preincubation O +
of O +
the O +
same O +
serum O +
with O +
the O +
heterologous O +
P. O +
mirabilis O +
O29 O +
LPS O +
reduced O +
slightly O +
the O +
reactivity O +
with O +
P. O +
mirabilis O +
O24 O +
LPS O +
and O +
abolished O +
the O +
reactivity O +
with O +
P. O +
mirabilis O +
O29 O +
LPS O -
. O +

Absorption O +
of O +
anti O -
- O -
P. O +
mirabilis O +
O29 O +
serum O +
by O +
the O +
LPS O +
of O +
P. O +
mirabilis O +
O29 O +
or O +
O24 O +
reduced O +
significantly O +
the O +
reactivity O +
with O +
both O +
antigens O -
. O +

Therefore O +
the O +
strong O +
two O -
- O -
way O +
cross O -
- O -
reactivity O +
of O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
is O +
due O +
to O +
the O +
presence O +
of O +
a O +
common O +
epitope O -
( O -
s O -
) O +
on O +
the O +
LPSs O -
. O +

A O +
cross O -
- O -
reactivity O +
of O +
Proteus O +
strains O +
belonging O +
to O +
different O +
O O -
- O -
serogroups O +
is O +
not O +
uncommon O +
[ O -
5 O -
] O +
. O +

Most O +
often O +
cross O -
- O -
reactive O +
antibodies B-Gene +
recognise O +
identical O +
or O +
similar O +
oligosaccharide O +
fragments O +
on O +
the O +
OPS O -
, O +
from O +
a O +
disaccharide O +
to O +
a O +
tetrasaccharide O -
. O +

The O +
main O +
chains O +
of O +
the O +
OPSs O +
of O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O +
are O +
structurally O +
similar O +
and O -
, O +
thus O -
, O +
might O +
share O +
a O +
cross O -
- O -
reactive O +
epitope O -
( O -
s O -
) O -
. O +

However O -
, O +
in O +
Western O +
immunoblotting O -
, O +
a O +
ladder O -
- O -
like O +
banding O +
typical O +
of O +
LPSs O +
with O +
variable O +
chain O +
length O +
OPSs O +
was O +
observed O +
only O +
with O +
homologous O +
anti O -
- O -
P. O +
mirabilis O +
O24 O +
and O +
anti O -
- O -
P. O +
mirabilis O +
O29 O +
sera O +
( O -
Fig. O +
2A O -
, O +
B O +
, O +
respectively O -
) O -
. O +

The O +
reaction O +
of O +
both O +
anti O -
- O -
O O +
sera O +
with O +
the O +
heterologous O +
LPSs O +
of O +
P. O +
mirabilis O +
O29 O +
and O +
O24 O +
was O +
limited O +
to O +
fast O -
- O -
migrating O +
bands O -
, O +
which O +
correspond O +
to O +
the O +
core O -
- O -
lipid O +
A O +
moiety O +
( O -
Fig. O +
2 O +
, O +
lanes O +
1 O +
and O +
3 O -
) O -
. O +

The O +
corresponding O +
heterologous O +
whole O +
cells O +
did O +
not O +
react O +
( O -
Fig. O +
2 O +
, O +
lanes O +
2 O +
and O +
4 O -
) O +
and O -
, O +
therefore O -
, O +
cross O -
- O -
reactive O +
epitopes O +
are O +
not O +
exposed O +
on O +
the O +
cell O +
surface O -
. O +

These O +
findings O +
suggested O +
that O +
antibodies B-Gene +
against O +
the O +
core O -
- O -
lipid O +
A O +
region O +
of O +
the O +
LPS O -
, O +
rather O +
than O +
those O +
against O +
the O +
OPS O -
, O +
are O +
responsible O +
for O +
the O +
cross O -
- O -
reactivity O +
observed O -
. O +

A O +
high O +
level O +
of O +
anti O -
- O -
core O -
- O -
lipid O +
A O +
antibodies B-Gene +
may O +
be O +
due O +
to O +
the O +
exposure O +
of O +
OPS O -
- O -
lacking O +
LPS O +
species O +
on O +
the O +
surface O +
of O +
P. O +
mirabilis O +
O24 O +
and O +
O29 O -
. O +

A O +
low O +
degree O +
of O +
substitution O +
of O +
the O +
core O +
by O +
the O +
OPS O +
has O +
been O +
demonstrated O +
for O +
P. O +
mirabilis O +
S1959 O +
LPS O +
( O -
serogroup O +
O3 O -
) O +
[ O -
19 O -
] O +
. O +

A O +
cross O -
- O -
reactivity O +
has O +
been O +
reported O +
for O +
some O +
other O +
Proteus O +
strains O +
with O +
structurally O +
different O +
OPSs O +
and O +
likewise O +
accounted O +
for O +
by O +
the O +
presence O +
of O +
antibodies B-Gene +
recognising O +
the O +
core O +
region O +
of O +
LPS O +
[ O -
20,21 O -
] O +
. O +

It O +
can O +
be O +
suggested O +
that O +
the O +
LPS O +
core O +
regions O +
in O +
the O +
cross O -
- O -
reactive O +
strains O +
are O +
similar O +
or O +
identical O -
, O +
but O +
their O +
exact O +
structures O +
remain O +
to O +
be O +
determined O -
. O +

Acknowledgments O +
This O +
work O +
was O +
supported O +
by O +
Grants O +
4-PO5A O +
from O +
the O +
Sciences O +
Research O +
Committee O +
( O -
KBN O -
, O +
Poland O -
) O +
for O +
W.K. O +
and O +
99 O -
- O -
04 O -
- O -
48279 O +
from O +
the O +
Russian O +
Foundation O +
for O +
Basic O +
Research O +
for O +
Y.A.K. O +

Abscisic O +
acid O +
( O -
ABA O -
) O +
is O +
a O +
sequiterpene O +
plant O +
hormone O +
that O +
modulates O +
seed O +
development O -
, O +
dormancy O -
, O +
cell O +
division O +
and O +
responses O +
to O +
environmental O +
stresses O +
such O +
as O +
drought O -
, O +
cold O -
, O +
salt O -
, O +
pathogen O +
attack O +
and O +
UV O +
light O +
[ O -
1–3 O -
] O +
. O +

It O +
is O +
ubiquitous O +
in O +
higher O +
plants O +
and O +
acts O +
via O +
multiple O +
pathways O -
, O +
inducing O +
rapid O +
closure O +
of O +
stomatal O +
pores O +
by O +
ion O +
efflux O +
from O +
guard O +
cells O +
and O +
slower O +
changes O +
in O +
gene O +
expression O +
[ O -
4 O -
] O +
. O +

Molecular O +
genetic O +
studies O +
in O +
the O +
model O +
organisms O +
maize O +
and O +
Arabidopsis O +
have O +
resulted O +
in O +
the O +
identification O +
of O +
downstream O +
components O +
of O +
ABA O +
and O +
stress O +
signalling O -
, O +
including O +
protein O +
phosphatases O +
and O +
kinases O -
, O +
transcription O +
factors O +
and O +
a O +
subunit O +
of O +
farnesyl O +
transferase O +
[ O -
4–10 O -
] O +
. O +

Reverse O +
genetic O +
and O +
biochemical O +
approaches O +
have O +
led O +
to O +
the O +
characterization O +
of O +
ABA- O +
and O +
stress O -
- O -
responsive O +
cis O +
-promoter O +
elements O +
and O +
transcription O +
factors O -
, O +
the O +
functional O +
cloning O +
of O +
a O +
syntaxin B-Gene +
and O +
demonstration O +
of O +
the O +
involvement O +
of O +
secondary O +
messengers O +
such O +
as O +
cyclic O +
ADP O +
ribose O +
and O +
calcium O +
[ O -
4,11–15 O -
] O +
. O +

Despite O +
this O +
rapid O +
progress O +
in O +
understanding O +
the O +
molecular O +
details O +
of O +
ABA O +
signalling O -
, O +
little O +
is O +
known O +
of O +
the O +
mechanisms O +
of O +
ABA O +
perception O -
. O +

Indirect O +
evidence O +
suggests O +
the O +
existence O +
of O +
multiple O +
ABA B-Gene +
receptors I-Gene +
[ O -
16,17 O -
] O +
, O +
but O +
with O +
the O +
exception O +
of O +
an O +
unconfirmed O +
report O +
in O +
1984 O +
[ O -
18 O -
] O +
no O +
such O +
receptors B-Gene +
have O +
yet O +
been O +
described O -
. O +

Although O +
ABA O +
binding O +
proteins B-Gene +
[ O -
19,20 O -
] O +
and O +
carrier- O +
mediated O +
uptake O +
of O +
ABA O +
have O +
been O +
reported O +
[ O -
21,22 O -
] O +
, O +
there O +
is O +
no O +
evidence O +
to O +
link O +
these O +
to O +
the O +
physiological O +
effects O +
of O +
ABA O -
. O +

In O +
this O +
report O -
, O +
we O +
describe O +
the O +
innovative O +
uses O +
of O +
surface O +
plasmon O +
resonance O +
( O -
SPR O -
) O +
and O +
flow O +
cytometry O +
to O +
demonstrate O +
biochemical O +
and O +
functional O +
interactions O +
of O +
the O +
monoclonal B-Gene +
antibody I-Gene +
JIM19 B-Gene +
with O +
plasma O +
membranes O +
( O -
PMs O -
) O +
and O +
protoplasts O +
derived O +
from O +
rice O +
embryonic O +
suspension O +
cultures O -
. O +

JIM19 B-Gene +
is O +
one O +
of O +
a O +
panel O +
of O +
monoclonal B-Gene +
antibodies I-Gene +
previously O +
generated O +
against O +
pea O +
guard O +
cell O +
protoplasts O +
[ O -
23 O -
] O +
that O +
was O +
shown O +
to O +
modulate O +
ABA O +
responses O +
in O +
barley O +
aleurone B-Gene +
protoplasts O -
, O +
another O +
target O +
cell O +
for O +
ABA O +
[ O -
24 O -
] O +
. O +

Our O +
data O +
show O +
that O +
JIM19 B-Gene +
binds O +
to O +
glycoproteins B-Gene +
( O -
GPs B-Gene -
) O +
in O +
rice O +
PMs O +
and O +
that O +
such O +
binding O +
is O +
antagonized O +
by O +
ABA O +
but O +
not O +
by O +
the O +
structurally O +
related O -
, O +
biologically O +
inactive O +
ABA O +
catabolite O -
, O +
phaseic O +
acid O +
( O -
PA O -
) O -
. O +

Transient O +
gene O +
expression O +
assays O +
using O +
β B-Gene -
- I-Gene -
glucuronidase I-Gene +
( O -
GUS B-Gene -
) O -
/ O -
luciferase B-Gene +
and O +
novel O +
flow O +
cytometric O +
quantitation O +
of O +
green B-Gene +
fluorescent I-Gene +
protein I-Gene +
( O -
GFP B-Gene -
) O +
demonstrate O +
that O +
ABA O +
but O +
not O +
PA O +
induces O +
Em O +
promoter O +
activity O -
; O +
such O +
ABA O -
- O -
induced O +
promoter O +
activity O +
is O +
antagonized O +
by O +
JIM19 B-Gene -
. O +

These O +
results O +
support O +
a O +
model O +
of O +
ABA O +
signalling O +
through O +
a O +
PM O +
complex O +
that O +
includes O +
an O +
ABA B-Gene +
receptor I-Gene +
and O +
JIM19 B-Gene +
epitope O -
- O -
presenting O +
GP B-Gene -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Embryonic O +
rice O +
( O -
Oryza O +
sativa O +
) O +
callus O +
cultures O +
( O -
Radon O +
6 O +
from O +
the O +
International O +
Rice O +
Research O +
Institute O -
, O +
Los O +
Baños O -
, O +
Phillipines O -
) O +
were O +
obtained O +
from O +
Dr. O +
Tom O +
Hodges O -
, O +
Purdue O +
University O -
, O +
West O +
Lafayette O -
, O +
IN O +
47909 O -
, O +
USA O -
. O +

Cultures O +
were O +
propagated O +
and O +
digested O +
for O +
making O +
protoplasts O +
as O +
previously O +
described O +
[ O -
25 O -
] O +
except O +
that O +
10 O +
mM O +
HEPES O +
( O -
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
, O +
pH O +
5.6 O -
, O +
was O +
substituted O +
for O +
phosphate O +
in O +
the O +
Krens O -
' O +
F O +
medium O +
and O +
2 O -
% O +
weight O -
/ O -
volume O +
( O -
w O -
/ O -
v O -
) O +
cellulase O +
YC O -
, O +
0.35 O -
% O +
( O -
w O -
/ O -
v O -
) O +
macerozyme B-Gene +
and O +
0.1 O -
% O +
( O -
w O -
/ O -
v O -
) O +
pectolyase O +
Y23 O +
were O +
used O +
for O +
overnight O +
digestion O +
( O -
Karlan O +
Research O +
Products O -
, O +
Santa O +
Rosa O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Phaseic O +
acid O +
was O +
obtained O +
from O +
Dr. O +
Sue O +
Abrams O -
, O +
Institute O +
of O +
Plant O +
Biotechnology O -
, O +
Saskatoon O -
, O +
Canada O -
. O +

( O -
± O -
) O -
Cis O +
, O +
trans O +
-ABA O +
( O -
Sigma O -
) O +
and O +
phaseic O +
acid O +
were O +
quantified O +
by O +
spectrometry O +
[ O -
26 O -
] O +
and O +
their O +
purity O +
and O +
relative O +
quantities O +
confirmed O +
by O +
mass O +
spectrometry O +
using O +
a O +
Finnegan O +
( O -
San O +
Jose O -
, O +
CA O -
, O +
USA O -
) O +
GCQ O +
ion O +
trap O +
[ O -
27 O -
] O +
. O +

2.2 O +
Immunological O +
studies O +
JIM19 B-Gene +
and O +
JIM20 B-Gene +
[ O -
23 O -
] O +
were O +
obtained O +
as O +
hybridoma O +
supernatants O +
from O +
Ms. O +
Jan O +
Peart O -
, O +
John O +
Innes O +
Centre O -
, O +
Norwich O -
, O +
UK O -
. O +

For O +
functional O +
assays O +
the O +
supernatants O +
were O +
desalted O +
by O +
passing O +
over O +
NAP-10 O +
columns O +
( O -
Amersham O -
- O -
Pharmacia O +
Biotech O -
. O -
, O +
Uppsala O -
, O +
Sweden O -
) O +
equilibrated O +
with O +
0.1 O +
M O +
phosphate O -
- O -
buffered O +
saline O +
( O -
PBS O -
) O -
, O +
pH O +
7.4 O -
, O +
or O +
dialyzed O +
against O +
PBS O +
to O +
remove O +
sodium O +
azide O +
and O +
low O +
molecular O +
weight O +
impurities O -
. O +

Immunoblotting O +
to O +
nitrocellulose O +
( O -
Schleicher O +
and O +
Schull O -
, O +
Dassel O -
, O +
Germany O -
) O +
of O +
PM O +
proteins B-Gene +
separated O +
by O +
SDS O -
- O -
PAGE O +
was O +
by O +
standard O +
methods O +
[ O -
28 O -
] O +
. O +

JIM19 B-Gene +
hybridoma O +
supernatant O +
was O +
used O +
to O +
probe O +
immunoblots O +
at O +
1 O -
/ O -
100 O +
dilution O -
; O +
JIM20 B-Gene +
was O +
used O +
at O +
1 O -
/ O -
10 O +
dilution O -
. O +

Rabbit O +
anti O -
- O -
rat O +
IgM B-Gene +
conjugated O +
to O +
alkaline B-Gene +
phosphatase I-Gene +
( O -
Zymed O -
, O +
South O +
San O +
Francisco O -
, O +
CA O -
, O +
USA O -
) O +
and O +
the O +
chromogenic O +
substrates O +
nitroblue O +
tetrazolium O +
chloride O +
and O +
5-bromo-4-chloro-3-indolyl O -
- O -
phosphate O +
( O -
Sigma O -
) O +
were O +
used O +
to O +
visualize O +
JIM B-Gene -
- O -
bound O +
antigens O -
. O +

The O +
titer O +
of O +
JIM19 B-Gene +
was O +
estimated O +
to O +
be O +
2-fold O +
higher O +
than O +
JIM20 B-Gene +
by O +
immunoblot O +
analysis O +
( O -
data O +
not O +
shown O -
) O -
. O +

Sodium O +
periodate O +
( O -
25 O +
mM O +
solution O +
in O +
50 O +
mM O +
NaOAc O -
, O +
pH O +
4.3 O -
) O +
was O +
applied O +
overnight O +
to O +
blotted O +
PM O +
proteins B-Gene +
to O +
oxidize O +
GP B-Gene +
carbohydrates O +
before O +
immunodetection O +
with O +
JIM B-Gene +
antibodies I-Gene -
. O +

Flow O +
cytometry O +
of O +
rice O +
protoplasts O +
was O +
performed O +
on O +
a O +
Becton O -
- O -
Dickinson O +
( O -
San O +
Jose O -
, O +
CA O -
, O +
USA O -
) O +
FACS O +
Vantage O +
dual O +
beam O +
instrument O +
equipped O +
with O +
a O +
200 O +
μm O +
nozzle O +
and O +
Lysis O +
II O +
acquisition O +
and O +
analysis O +
software O -
. O +

The O +
excitation O +
wavelength O +
for O +
flow O +
cytometry O +
was O +
488 O +
nm O -
. O +

Fluorescence O +
emission O +
detection O +
was O +
with O +
a O +
fluorescein O +
isothiocyanate O +
( O -
FITC O -
) O +
530 O -
/ O -
30 O +
nm O +
filter O +
set O -
. O +

For O +
Aequoria O +
victoria O +
GFP B-Gene +
studies O -
, O +
live O +
cells O +
were O +
analyzed O -
. O +

Cell O +
viability O +
was O +
determined O +
by O +
flow O +
cytometry O +
of O +
an O +
aliquot O +
of O +
live O +
protoplasts O +
treated O +
five O +
min O +
with O +
0.01 O -
% O +
( O -
w O -
/ O -
v O -
) O +
fluorescein O +
diacetate O +
( O -
Molecular O +
Probes O -
, O +
Eugene O -
, O +
OR O -
, O +
USA O -
) O -
. O +

For O +
immunofluorescence O +
studies O -
, O +
protoplasts O +
at O +
a O +
density O +
of O +
106 O +
/0.5 O +
ml O +
were O +
incubated O +
for O +
30 O +
min O +
in O +
Krens O -
- O -
HEPES O +
with O +
or O +
without O +
JIM19 B-Gene +
or O +
JIM20 B-Gene +
hybridoma O +
supernatant O +
( O -
1 O -
/ O -
10 O +
dilution O -
) O -
. O +

After O +
two O +
washes O +
with O +
Krens O -
- O -
HEPES O -
, O +
the O +
protoplasts O +
were O +
incubated O +
for O +
20 O +
min O +
with O +
goat O +
anti O -
- O -
rat O +
IgG B-Gene -
- O -
conjugated O +
FITC O +
( O -
1 O -
/ O -
20 O +
dilution O -
, O +
Sigma O -
) O -
, O +
washed O +
two O +
times O +
with O +
Krens O -
- O -
HEPES O +
and O +
fixed O +
in O +
1 O -
% O +
paraformaldehyde O +
in O +
0.1 O +
M O +
PBS O -
, O +
pH O +
7.4 O +
for O +
30 O +
min O -
. O +

2.3 O +
Plasma O +
membrane O +
preparation O +
by O +
aqueous O +
two O +
phase O +
partitioning O +
PMs O +
were O +
prepared O +
from O +
fresh O +
or O +
frozen O +
callus O +
cultures O +
according O +
to O +
Larsson O +
[ O -
29 O -
] O +
with O +
modifications O -
. O +

The O +
tissue O +
was O +
homogenized O +
by O +
sonication O +
in O +
50 O +
mM O +
Tris O -
, O +
0.25 O +
M O +
sucrose O -
, O +
3 O +
mM O +
EDTA O +
( O -
Sigma O -
) O -
, O +
1 O +
mM O +
MgSO4 O +
, O +
2 O +
mM O +
dithiothreitol O -
, O +
pH O +
7.8 O -
. O +

PEG-1540 O +
( O -
Polysciences O -
, O +
Warrington O -
, O +
PA O -
, O +
USA O -
) O +
was O +
used O +
instead O +
of O +
PEG-3350 O +
as O +
the O +
upper O +
phase O -
. O +

Membrane O +
marker O +
enzyme B-Gene +
assays O +
[ O -
30 O -
] O +
for O +
the O +
PM O +
( O -
vanadate O -
- O -
sensitive O +
ATPase B-Gene -
) O -
, O +
endoplasmic O +
reticulum O +
and O +
mitochondria O +
( O -
antimycin O +
A O -
- O -
resistant O +
and O +
-sensitive O +
cytochrome B-Gene +
c I-Gene +
reductases I-Gene -
, O +
respectively O -
) O +
indicated O +
a O +
PM O -
- O -
enrichment O +
over O +
total O +
membranes O +
of O +
7- O +
to O +
20-fold O +
( O -
data O +
not O +
shown O -
) O -
. O +

Protein B-Gene +
concentations O +
were O +
determined O +
by O +
the O +
dye O +
binding O +
method O +
[ O -
28 O -
] O +
( O -
Bio O -
- O -
Rad O -
, O +
Hercules O -
, O +
CA O -
, O +
USA O -
) O -
. O +

2.4 O +
Surface O +
plasmon O +
resonance O +
biosensor O +
analysis O +
The O +
immunoaffinity O +
purification O +
of O +
JIM19 B-Gene +
was O +
as O +
follows O -
. O +

Alkaline B-Gene +
phosphatase I-Gene -
- O -
conjugated O +
rabbit O +
anti O -
- O -
rat O +
IgM B-Gene +
( O -
15 O +
mg O -
; O +
Zymed O -
) O -
, O +
dialyzed O +
against O +
10 O +
mM O +
HEPES O -
, O +
pH O +
6.5 O -
, O +
was O +
covalently O +
bound O +
to O +
0.5 O +
ml O +
Affigel O -
- O -
Gel O +
10 O +
support O +
( O -
Bio O -
- O -
Rad O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

Active O +
esters O +
were O +
blocked O +
with O +
1 O +
M O +
ethanolamide O -
, O +
pH O +
8 O -
. O +

The O +
column O +
was O +
equilibrated O +
with O +
PBS O +
and O +
5 O +
ml O +
JIM19 B-Gene +
hybridoma O +
supernatant O +
passed O +
over O +
the O +
column O -
. O +

After O +
washing O +
with O +
10 O +
bed O +
volumes O +
of O +
PBS O -
, O +
the O +
JIM19 B-Gene +
antibody I-Gene +
was O +
eluted O +
with O +
2 O +
ml O +
100 O +
mM O +
Gly O -
, O +
pH O +
2.5 O +
and O +
collected O +
in O +
0.1 O +
volume O +
of O +
1 O +
M O +
KH2 O +
Pi O +
, O +
pH O +
8.0 O -
. O +

The O +
purified O +
JIM19 B-Gene +
was O +
dialyzed O +
against O +
PBS O +
and O +
frozen O +
at O +
−20 O -
° O -
C O +
until O +
further O +
use O -
. O +

Approximately O +
3 O +
ng O +
immunoaffinity O -
- O -
purified O +
JIM19 B-Gene +
was O +
immobilized O +
on O +
a O +
CM5 O +
carboxymethylated O +
dextran O +
chip O +
( O -
Pharmacia O +
Biotech O -
, O +
Uppsala O -
, O +
Sweden O -
) O +
by O +
amine O +
coupling O +
at O +
pH O +
4.6 O +
in O +
10 O +
mM O +
NaOAc O +
using O +
the O +
manufacturer O -
's O +
provided O +
kit O -
. O +

Detection O +
of O +
SPR O +
was O +
with O +
a O +
BIAcore O +
2000 O +
( O -
Pharmacia O -
) O -
. O +

The O +
JIM19 B-Gene +
chip O +
was O +
regenerated O +
after O +
PM O +
binding O +
by O +
passing O +
0.1 O +
N O +
NaOH O +
over O +
the O +
chip O +
for O +
60 O +
s. O +
The O +
concentration O +
of O +
immunoaffinity O -
- O -
purified O +
JIM19 B-Gene +
used O +
in O +
solution O +
competition O +
experiments O +
was O +
estimated O +
to O +
be O +
1 O +
ng O -
/ O -
μl O +
by O +
NanoOrange O +
( O -
Molecular O +
Probes O -
) O +
fluorescent O +
dye O +
binding O +
and O +
detection O +
with O +
a O +
Cytofluor O +
II O +
microplate O +
spectrofluorometer O +
( O -
Molecular O +
Dynamics O -
, O +
Sunnyvale O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Rabbit O +
anti O -
- O -
GUS B-Gene +
antibody B-Gene +
was O +
from O +
Molecular O +
Probes O -
. O +

2.5 O +
Functional O +
studies O +
Transformation O +
of O +
protoplasts O +
was O +
according O +
to O +
[ O -
31 O -
] O +
, O +
using O +
25 O +
μg O +
each O +
of O +
pBM207 O +
and O +
pAHC18 O +
and O +
3 O -
× O -
106 O +
protoplasts O -
/ O -
transformation O -
, O +
which O +
were O +
split O +
into O +
six O +
paired O +
samples O -
. O +

pBM207 O +
[ O -
32 O -
] O +
contains O +
the O +
650 O +
bp O +
wheat O +
Em O +
promoter O +
driving O +
uidA O +
expression O +
( O -
GUS O -
) O -
. O +

pAHC18 O +
contains O +
the O +
2.0 O +
kb O +
maize O +
ubiquitin B-Gene +
promoter O +
driving O +
firefly O +
luciferase B-Gene +
( O -
LUC B-Gene -
; O +
[ O -
33 O -
] O +
) O +
and O +
was O +
included O +
as O +
an O +
internal O +
reference O +
for O +
non O -
- O -
ABA O -
- O -
inducible O +
transient O +
transcription O -
. O +

pCR559 O +
contains O +
the O +
Em O +
promoter O +
driving O +
a O +
modified O +
GFP B-Gene +
( O -
sGFP B-Gene -
) O +
with O +
preferred O +
codons O +
and O +
the O +
S65 O -
T O +
mutation O +
that O +
gives O +
enhanced O +
fluorescence O -
, O +
faster O +
chromophore O +
formation O +
and O +
slower O +
photobleaching O +
[ O -
34 O -
] O +
. O +

It O +
was O +
made O +
by O +
ligation O +
of O +
the O +
3.3 O +
kb O -
. O +

Nco O +
I O -
– O -
Eco O +
RI O +
fragment O +
of O +
pBM207 O +
and O +
the O +
1.0 O +
kb O -
. O +

Nco O +
I O -
– O -
Eco O +
RI O +
fragment O +
of O +
p35SC4PPDK O -
- O -
sGFP O -
( O -
S65 O -
T O -
) O +
containing O +
the O +
nos O +
3′ O +
terminator O +
[ O -
34 O -
] O +
. O +

Transformed O -
, O +
washed O +
protoplasts O +
were O +
first O +
treated O +
with O +
1 O -
/ O -
10 O -
, O +
1 O -
/ O -
20 O -
, O +
1 O -
/ O -
40 O -
, O +
or O +
1 O -
/ O -
80 O +
volumes O +
of O +
JIM B-Gene +
antibody I-Gene +
and O +
after O +
15 O +
min O -
, O +
various O +
concentrations O +
of O +
ABA O +
added O +
to O +
give O +
a O +
final O +
volume O +
of O +
0.5 O +
ml O +
Krens O -
- O -
HEPES O +
and O +
0.05 O -
% O +
ethanol O -
. O +

For O +
enzyme B-Gene -
- O -
based O +
reporter O +
assays O -
, O +
after O +
18 O +
h O +
incubation O -
, O +
protoplasts O +
were O +
lysed O +
in O +
Reporter O +
Lysis O +
Buffer O +
plus O +
10 O +
mM O +
2-mercaptoethanol O +
and O +
LUC B-Gene +
activity O +
measured O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O +
( O -
Promega O -
, O +
Madison O -
, O +
WI O -
, O +
USA O -
) O +
on O +
a O +
Monolight O +
2010 O +
bioluminescence O +
luminometer O +
( O -
Analytical O +
Luminescence O -
, O +
San O +
Diego O -
, O +
CA O -
, O +
USA O -
) O -
. O +

The O +
LUC B-Gene +
limit O +
of O +
detection O +
for O +
a O +
linear O +
response O +
of O +
the O +
detector O +
was O +
approximately O +
7000 O +
relative O +
light O +
units O +
and O +
the O +
sample O +
activities O +
were O +
between O +
40 O +
000 O +
and O +
160 O +
000 O +
relative O +
light O +
units O -
/ O -
20 O +
μl O +
extract O -
. O +

GUS B-Gene +
activities O +
of O +
the O +
samples O +
were O +
determined O +
according O +
to O +
[ O -
35 O -
] O +
, O +
using O +
4-methylumbelliferone O +
glucuronide O +
( O -
Rose O +
Scientific O -
, O +
Edmonton O -
, O +
Alta O -
. O -
, O +
Canada O -
) O +
as O +
substrate O +
dissolved O +
in O +
50 O +
mM O +
NaPi O +
, O +
pH O +
7.0 O -
, O +
10 O +
mM O +
EDTA O -
, O +
0.1 O -
% O +
( O -
v O -
/ O -
v O -
) O +
Triton O +
X-100 O -
, O +
3.4 O +
mM O +
N O +
-lauryl O +
sarcosine O +
and O +
10 O +
mM O +
2-mercaptoethanol O -
. O +

Activities O +
ranged O +
between O +
4 O +
and O +
140 O +
pmol O +
4-methylumbelliferone O -
/ O -
h O -
/ O -
40 O +
μl O +
extract O -
. O +

Data O +
presented O +
are O +
of O +
experiments O +
that O +
were O +
repeated O +
once O +
with O +
similar O +
results O -
. O +

3 O +
Results O +
3.1 O +
JIM19 B-Gene +
and O +
JIM20 B-Gene +
recognize O +
cell O +
surface O +
glycoproteins B-Gene +
in O +
rice O +
Flow O +
cytometry O +
is O +
a O +
powerful O +
tool O +
that O +
is O +
relatively O +
unexploited O +
in O +
plant O +
biology O -
. O +

The O +
application O +
of O +
this O +
technique O +
to O +
embryonic O +
rice O +
protoplasts O +
immunodecorated O +
with O +
the O +
JIM19 B-Gene +
antibody I-Gene +
demonstrated O +
substantial O +
binding O +
to O +
the O +
cell O +
surface O -
, O +
i.e. O +
the O +
PM O +
( O -
Fig. O +
1 O +
) O -
. O +

Fig. O +
1B O +
shows O +
the O +
extent O +
of O +
JIM19 B-Gene +
binding O +
to O +
a O +
population O +
of O +
rice O +
protoplasts O +
measured O +
as O +
relative O +
fluorescence O +
intensity O +
of O +
FITC O -
- O -
labelled O +
anti O -
- O -
rat O +
IgG B-Gene +
secondary O +
antibody B-Gene -
. O +

Approximately O +
70 O -
% O +
of O +
the O +
protoplasts O +
are O +
labelled O +
by O +
JIM19 B-Gene -
, O +
based O +
on O +
a O +
threshold O +
of O +
background O +
fluorescence O +
of O +
control O +
protoplasts O +
labelled O +
with O +
secondary O +
antibody B-Gene +
alone O +
( O -
Fig. O +
1A O +
) O -
. O +

Similar O +
results O +
were O +
obtained O +
with O +
JIM20 B-Gene +
( O -
Fig. O +
1C O +
) O -
, O +
except O +
the O +
intensity O +
of O +
the O +
fluorescence O +
signal O +
was O +
less O +
than O +
half O +
that O +
of O +
JIM19 B-Gene -
. O +

JIM20 B-Gene +
is O +
related O +
to O +
JIM19 B-Gene +
[ O -
23 O -
] O +
but O +
had O +
no O +
biological O +
activity O +
[ O -
24 O -
] O +
. O +

Varying O +
the O +
concentration O +
of O +
JIM B-Gene +
antibodies I-Gene +
over O +
the O +
range O +
of O +
1 O -
/ O -
10 O +
to O +
1 O -
/ O -
80 O +
dilution O +
did O +
not O +
affect O +
significantly O +
the O +
percentage O +
of O +
cells O +
labelled O +
( O -
data O +
not O +
shown O -
) O -
. O +

These O +
data O +
suggest O +
that O +
the O +
affinity O +
of O +
JIM19 B-Gene +
for O +
rice O +
PM O +
epitopes O +
is O +
higher O +
than O +
that O +
of O +
JIM20 B-Gene -
. O +

In O +
order O +
to O +
characterize O +
further O +
the O +
surface O +
antigens O +
recognized O +
by O +
JIM19 B-Gene +
and O +
JIM20 B-Gene -
, O +
SDS O -
- O -
PAGE O +
and O +
immunoblot O +
analysis O +
were O +
performed O +
on O +
PMs O +
purified O +
by O +
aqueous O +
two O +
phase O +
partitioning O -
. O +

The O +
lability O +
of O +
the O +
rice O +
PM O +
JIM B-Gene +
epitopes O +
to O +
sodium O +
periodate O -
, O +
which O +
oxidizes O +
carbohydrates O +
was O +
tested O -
, O +
as O +
previous O +
work O +
suggested O +
that O +
JIM19 B-Gene +
and O +
JIM20 B-Gene +
recognize O +
the O +
carbohydrate O +
moieties O +
of O +
GPs B-Gene +
[ O -
23 O -
] O +
. O +

JIM19 B-Gene +
and O +
JIM20 B-Gene +
recognized O +
exclusively O +
the O +
carbohydrate O +
moieties O +
of O +
multiple O +
PM O +
GPs B-Gene -
, O +
evidenced O +
by O +
loss O +
of O +
all O +
immunoreactive O +
signals O +
after O +
treatment O +
of O +
immunoblots O +
with O +
sodium O +
periodate O +
( O -
Fig. O +
2 O +
) O -
. O +

Similar O +
treatment O +
of O +
an O +
electroblotted O +
non O -
- O -
GP B-Gene +
control O +
( O -
β B-Gene -
- I-Gene -
glucuronidase I-Gene -
) O +
had O +
no O +
effect O +
on O +
immunodetection O +
( O -
data O +
not O +
shown O -
) O -
. O +

At O +
least O +
five O +
GPs B-Gene +
ranging O +
in O +
relative O +
size O +
from O +
25 O +
kDa O +
to O +
more O +
than O +
175 O +
kDa O +
were O +
recognized O +
by O +
JIM19 B-Gene -
. O +

JIM20 B-Gene +
also O +
recognized O +
GPs B-Gene +
larger O +
than O +
approximately O +
100 O +
kDa O +
and O +
of O +
similar O +
size O +
to O +
the O +
proteins B-Gene +
recognized O +
by O +
JIM19 B-Gene -
. O +

However O -
, O +
there O +
are O +
also O +
unique O +
PM O +
proteins B-Gene +
in O +
the O +
range O +
of O +
25–60 O +
kDa O +
which O +
react O +
only O +
with O +
JIM19 B-Gene +
( O -
Fig. O +
2 O +
) O -
. O +

A O +
10-fold O +
higher O +
concentration O +
of O +
JIM20 B-Gene +
than O +
JIM19 B-Gene +
did O +
not O +
result O +
in O +
a O +
stronger O +
signal O +
or O +
detection O +
of O +
other O +
epitopes O +
( O -
Fig. O +
2 O +
) O -
, O +
consistent O +
with O +
the O +
flow O +
cytometry O +
data O +
( O -
Fig. O +
1 O +
) O +
indicating O +
that O +
the O +
affinity O +
of O +
JIM19 B-Gene +
for O +
PM O +
epitopes O +
is O +
higher O +
than O +
that O +
of O +
JIM20 B-Gene -
. O +

3.2 O +
Binding O +
of O +
plasma O +
membranes O +
to O +
JIM19 B-Gene +
is O +
specifically O +
antagonized O +
by O +
abscisic O +
acid O +
We O +
used O +
an O +
SPR O +
biosensor O +
[ O -
36 O -
] O +
to O +
characterize O +
the O +
binding O +
of O +
PM O +
epitopes O +
to O +
JIM19 B-Gene -
. O +

SPR O +
technology O +
allows O +
monitoring O +
of O +
specific O +
biomolecular O +
interactions O +
between O +
a O +
ligand O +
( O -
e.g. O +
antibody B-Gene -
) O +
and O +
an O +
analyte O +
( O -
e.g. O +
antigen O -
) O -
, O +
resulting O +
in O +
a O +
change O +
in O +
refractive O +
index O +
measured O +
as O +
arbitrary O +
resonance O +
output O +
units O -
. O +

A O +
major O +
strength O +
of O +
this O +
technology O +
is O +
the O +
sensitive O -
, O +
quantitative O -
, O +
direct O +
determination O +
of O +
real O +
time O +
binding O +
activity O +
in O +
crude O -
, O +
complex O +
mixtures O +
without O +
labelling O +
of O +
components O -
. O +

Three O +
ng O +
( O -
65 O +
fmol O +
of O +
IgM O +
binding O +
sites O -
, O +
assuming O +
10 O +
binding O +
sites O -
/ O -
IgM O -
) O +
of O +
immunoaffinity O -
- O -
purified O +
JIM19 B-Gene +
was O +
covalently O +
bound O +
to O +
a O +
carboxymethyl O +
dextran O -
- O -
coated O +
biosensor O +
chip O -
, O +
giving O +
a O +
baseline O +
SPR O +
signal O +
of O +
21 O +
600 O +
units O +
( O -
Fig. O +
3 O +
, O +
stage O +
1 O -
) O -
. O +

A O +
non O -
- O -
saturating O +
amount O +
of O +
PMs O +
( O -
5 O +
μg O +
of O +
protein B-Gene -
, O +
or O +
100 O +
pmol O +
of O +
' O -
average O -
' O +
[ O -
50 O +
kDa O -
] O +
sized O +
proteins B-Gene -
) O +
was O +
then O +
bound O +
to O +
the O +
JIM19 B-Gene +
chip O +
over O +
a O +
period O +
of O +
400 O +
s O -
, O +
after O +
which O +
time O +
the O +
binding O +
reaction O +
approached O +
steady O +
state O +
( O -
Fig. O +
3 O +
, O +
stage O +
2 O -
) O -
. O +

The O +
amount O +
of O +
PM O +
bound O +
to O +
the O +
chip O +
was O +
linearly O +
dependent O +
on O +
the O +
amount O +
injected O +
( O -
correlation O +
coefficient O +
r O +
= O -
0.98 O -
, O +
n O +
= O -
7 O -
; O +
data O +
not O +
shown O -
) O -
, O +
as O +
expected O +
for O +
concentrations O +
of O +
analyte O +
far O +
below O +
the O +
equilibrium O +
dissociation O +
constant O +
for O +
independent O +
ligand O +
sites O -
. O +

The O +
detection O +
limit O +
of O +
the O +
biosensor O +
for O +
PM O +
binding O +
was O +
calculated O +
as O +
three O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
baseline O +
SPR O +
signal O +
between O +
sample O +
injections O -
; O +
the O +
PM O +
binding O +
signal O +
was O +
on O +
average O +
more O +
than O +
six O +
times O +
higher O +
than O +
the O +
detection O +
limit O +
( O -
data O +
not O +
shown O -
) O -
. O +

About O +
400 O +
SPR O +
units O +
of O +
specific O +
PM O +
binding O +
were O +
observed O +
under O +
the O +
standard O +
binding O +
conditions O +
( O -
Table O +
1 O +
) O -
. O +

The O +
specificity O +
of O +
PM O +
binding O +
to O +
JIM19 B-Gene +
was O +
investigated O +
using O +
three O +
solution O +
competition O +
assays O +
for O +
JIM B-Gene +
antibody I-Gene +
specificity O -
. O +

Binding O +
of O +
PMs O +
to O +
the O +
JIM19 B-Gene +
chip O +
could O +
be O +
prevented O +
by O +
pre O -
- O -
incubation O +
of O +
PMs O +
with O +
increasing O +
amounts O +
of O +
JIM19 B-Gene +
( O -
Table O +
1 O +
) O -
. O +

JIM20 B-Gene +
also O +
antagonized O +
PM O +
binding O +
to O +
JIM19 B-Gene -
, O +
suggesting O +
that O +
JIM19 B-Gene +
and O +
JIM20 B-Gene +
do O +
indeed O +
share O +
specificity O +
for O +
the O +
high O +
molecular O +
weight O +
epitopes O +
observed O +
in O +
Fig. O +
2 O +
. O +

Non O -
- O -
specific O +
interference O +
with O +
PM O +
binding O +
was O +
low O -
, O +
as O +
measured O +
by O +
pre O -
- O -
incubation O +
of O +
PMs O +
with O +
an O +
unrelated O +
antibody B-Gene +
( O -
anti O -
- O -
GUS B-Gene -
, O +
Table O +
1 O +
) O -
. O +

Furthermore O -
, O +
JIM19 B-Gene +
did O +
not O +
bind O +
to O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
( O -
Table O +
1 O +
) O +
or O +
to O +
human O +
neutrophil O +
membrane O +
proteins B-Gene +
as O +
detected O +
by O +
immunoblotting O +
( O -
data O +
not O +
shown O -
) O -
. O +

Assuming O +
the O +
SPR O +
signal O +
due O +
to O +
binding O +
of O +
PM O +
vesicles O +
( O -
average O +
diameter O -
, O +
100 O +
nm O +
[ O -
29 O -
] O +
) O +
is O +
similar O +
to O +
that O +
of O +
other O +
cellular O +
ligands O +
( O -
Pharmacia O +
BIAtechnology O +
Note O +
# O -
105 O -
; O +
Uppsala O -
, O +
Sweden O -
) O -
, O +
the O +
observed O +
amount O +
of O +
specific O +
binding O +
corresponds O +
to O +
a O +
maximum O +
of O +
28 O +
fmol O +
of O +
average O -
- O -
sized O +
50 O +
kDa O +
proteins B-Gene +
[ O -
36 O -
] O +
, O +
or O +
less O +
than O +
0.03 O -
% O +
of O +
the O +
total O +
PM O +
proteins B-Gene +
applied O -
. O +

Because O +
previous O +
work O +
suggested O +
that O +
JIM19 B-Gene +
may O +
interact O +
with O +
ABA O +
signalling O +
mechanisms O +
[ O -
24 O -
] O +
, O +
we O +
tested O +
in O +
a O +
solution O +
competition O +
assay O +
the O +
effect O +
of O +
ABA O +
on O +
binding O +
of O +
PMs O +
to O +
the O +
JIM19 B-Gene +
chip O -
. O +

A O +
dose O -
- O -
dependent O +
partial O +
inhibition O +
by O +
ABA O +
of O +
PM O +
binding O +
to O +
JIM19 B-Gene +
was O +
observed O +
( O -
Fig. O +
4 O +
) O -
. O +

Statistical O +
analysis O +
of O +
the O +
ABA O +
treatments O +
showed O +
that O +
taken O +
together O -
, O +
the O +
three O +
highest O +
ABA O +
concentrations O +
( O -
> O -
10 O +
μM O -
) O +
resulted O +
in O +
significantly O +
higher O +
inhibition O +
of O +
JIM19 B-Gene +
binding O +
to O +
PMs O +
than O +
the O +
three O +
lowest O +
ABA O +
concentrations O +
( O -
< O -
0.1 O +
μM O -
; O +
P O +
< O -
0.04 O -
, O +
one O -
- O -
sided O +
t O +
-test O -
, O +
equal O +
variance O -
) O -
. O +

The O +
specificity O +
of O +
this O +
inhibition O +
by O +
ABA O +
was O +
demonstrated O +
by O +
control O +
experiments O +
with O +
phaseic O +
acid O +
( O -
PA O -
) O -
, O +
an O +
oxidized O +
catabolite O +
of O +
ABA O +
that O +
is O +
biologically O +
inactive O +
in O +
most O -
, O +
but O +
not O +
all O -
, O +
physiological O +
assays O +
[ O -
17 O -
] O +
. O +

Equivalent O +
concentrations O +
of O +
PA O +
did O +
not O +
affect O +
PM O +
binding O +
to O +
JIM19 B-Gene +
( O -
Fig. O +
4 O +
) O -
. O +

A O +
statistical O +
analysis O +
of O +
the O +
data O +
set O +
indicates O +
that O +
ABA O +
was O +
significantly O +
more O +
active O +
than O +
PA O +
in O +
antagonizing O +
the O +
binding O +
of O +
PMs O +
to O +
JIM19 B-Gene +
( O -
one O -
- O -
tailed O +
paired O +
Student O -
's O +
t O +
-test O -
, O +
P O +
< O -
0.0008 O -
, O +
n O +
= O -
16 O -
) O -
. O +

3.3 O +
Functional O +
analysis O +
of O +
JIM19 B-Gene +
effects O +
on O +
ABA O -
- O -
inducible O +
gene O +
expression O +
In O +
order O +
to O +
explore O +
the O +
biological O +
relevance O +
of O +
the O +
in O +
vitro O +
JIM19 B-Gene +
interaction O +
with O +
PMs O -
, O +
ABA O +
and O +
phaseic O +
acid O -
, O +
we O +
quantified O +
by O +
two O +
independent O +
methods O +
ABA O -
- O -
inducible O +
transient O +
expression O +
of O +
the O +
Em O +
promoter O +
[ O -
25,32 O -
] O +
in O +
rice O +
protoplasts O -
. O +

Fig. O +
5 O +
shows O +
the O +
results O +
of O +
an O +
enzyme B-Gene -
- O -
based O +
reporter O +
gene O +
assay O +
in O +
transiently O +
transformed O +
rice O +
protoplasts O -
. O +

Exogenous O +
ABA O +
activated O +
the O +
Em O +
promoter O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
, O +
whereas O +
phaseic O +
acid O +
was O +
not O +
active O +
in O +
triggering O +
Em O -
- O -
GUS B-Gene +
expression O +
( O -
Fig. O +
5 O +
) O -
. O +

Hill O +
et O +
al. O +
[ O -
17 O -
] O +
also O +
found O +
phaseic O +
acid O +
to O +
be O +
inactive O +
in O +
inducing O +
Em O +
gene O +
expression O +
in O +
cultured O +
barley O +
embryos O -
. O +

Thus O -
, O +
the O +
in O +
vivo O +
specificity O +
and O +
sensitivity O +
for O +
ABA O +
perception O +
leading O +
to O +
Em O +
gene O +
expression O +
( O -
Fig. O +
5 O +
) O +
correlate O +
well O +
with O +
the O +
in O +
vitro O +
specificity O +
for O +
ABA O +
antagonism O +
of O +
PM O +
binding O +
to O +
JIM19 B-Gene +
( O -
Fig. O +
4 O +
) O -
. O +

Because O +
protoplasts O +
are O +
a O +
heterogeneous O +
population O +
with O +
potentially O +
different O +
characteristics O +
that O +
might O +
complicate O +
analysis O +
of O +
signalling O +
pathways O -
, O +
we O +
developed O +
a O +
novel O -
, O +
quantitative O -
, O +
ABA O -
- O -
inducible O +
reporter O +
gene O +
expression O +
system O +
based O +
on O +
GFP B-Gene +
and O +
flow O +
cytometry O -
. O +

An O +
ABA O +
dose O -
- O -
GFP B-Gene +
intensity O +
response O +
curve O +
for O +
populations O +
of O +
protoplasts O +
transiently O +
expressing O +
GFP B-Gene +
driven O +
by O +
the O +
Em O +
promoter O +
is O +
shown O +
in O +
Fig. O +
6 O +
. O +

Transformation O +
efficiency O +
was O +
approximately O +
one O +
percent O +
( O -
data O +
not O +
shown O -
) O -
. O +

Cell O +
viability O +
of O +
the O +
population O +
was O +
affected O +
negatively O +
by O +
high O +
ABA O +
concentrations O +
( O -
Fig. O +
6 O +
) O -
. O +

Nonetheless O -
, O +
a O +
typical O +
log O -
- O -
linear O +
relationship O +
between O +
ABA O +
dose O +
and O +
GFP B-Gene +
abundance O +
in O +
individual O +
cells O +
was O +
observed O +
( O -
Fig. O +
6 O +
) O -
. O +

Therefore O -
, O +
flow O +
cytometry O +
allows O +
quantitative O +
analysis O +
of O +
Em O +
: O +
GFP B-Gene +
expression O +
on O +
a O +
per O +
cell O +
basis O -
. O +

The O +
concentrations O +
of O +
ABA O +
required O +
for O +
transactivation O +
of O +
the O +
Em O +
promoter O +
in O +
these O +
assays O +
( O -
Figs. O +
5 O +
and O +
6 O +
) O +
are O +
in O +
the O +
physiological O +
range O +
found O +
in O +
plant O +
tissues O +
[ O -
3 O -
] O +
and O +
correlate O +
well O +
with O +
concentrations O +
required O +
for O +
ABA O -
- O -
inhibition O +
of O +
PM O +
binding O +
to O +
JIM19 B-Gene +
( O -
Fig. O +
4 O +
) O -
. O +

In O +
an O +
attempt O +
to O +
correlate O +
further O +
the O +
in O +
vitro O +
and O +
in O +
vivo O +
effects O +
of O +
JIM19 B-Gene +
on O +
ABA O +
signalling O -
, O +
the O +
ability O +
of O +
JIM19 B-Gene +
to O +
antagonize O +
ABA O -
- O -
inducible O +
transient O +
Em O +
: O +
GUS B-Gene +
and O +
Em O +
: O +
GFP B-Gene +
expression O +
was O +
measured O -
. O +

Initial O +
experiments O +
demonstrated O +
that O +
JIM19 B-Gene +
inhibited O +
ABA O +
effects O -
, O +
but O +
that O +
JIM20 B-Gene +
had O +
no O +
activity O -
, O +
as O +
reported O +
previously O +
[ O -
24 O -
] O +
. O +

Consequently O -
, O +
we O +
used O +
JIM20 B-Gene +
as O +
a O +
control O +
to O +
account O +
for O +
any O +
non O -
- O -
specific O +
antibody B-Gene +
effects O -
. O +

The O +
inhibition O +
of O +
ABA O -
- O -
inducible O +
Em O +
promoter O +
activation O +
by O +
co O -
- O -
incubation O +
of O +
protoplasts O +
with O +
JIM19 B-Gene -
, O +
relative O +
to O +
JIM20 B-Gene +
treatment O -
, O +
was O +
low O +
but O +
highly O +
significant O +
( O -
Table O +
2 O +
; O +
one O -
- O -
tailed O +
paired O +
Student O -
's O +
t O +
-test O -
, O +
0.0003 O -
< O -
P O +
< O -
0.001 O -
) O -
. O +

About O +
45 O -
% O +
inhibition O +
of O +
the O +
ABA O -
- O -
inducible O +
expression O +
of O +
the O +
Em O -
- O -
GUS B-Gene +
reporter O +
gene O +
was O +
achieved O +
by O +
treatment O +
of O +
protoplasts O +
with O +
JIM19 B-Gene +
at O +
various O +
low O +
ABA O +
concentrations O +
( O -
Table O +
2 O +
) O -
. O +

The O +
inhibition O +
was O +
consistently O +
25 O -
% O +
when O +
measured O +
by O +
flow O +
cytometry O +
of O +
GFP B-Gene +
( O -
Table O +
2 O +
) O -
. O +

These O +
results O +
on O +
the O +
interaction O +
of O +
JIM19 B-Gene +
with O +
ABA O +
perception O +
leading O +
to O +
Em O +
promoter O +
activation O +
correlate O +
well O +
with O +
the O +
ABA O -
/ O -
PM O +
interaction O +
observed O +
in O +
vitro O +
( O -
Fig. O +
4 O +
) O -
. O +

4 O +
Discussion O +
The O +
techniques O +
of O +
SPR O +
and O +
flow O +
cytometry O +
have O +
allowed O +
us O +
to O +
probe O +
the O +
mechanisms O +
of O +
JIM19 B-Gene +
bioactivity O +
in O +
rice O +
protoplasts O -
. O +

Our O +
working O +
hypothesis O +
and O +
model O -
, O +
based O +
on O +
results O +
presented O +
here O -
, O +
is O +
that O +
the O +
JIM19 B-Gene +
antibody I-Gene +
recognizes O +
an O +
epitope O +
in O +
rice O +
PMs O +
that O +
interacts O +
with O +
an O +
ABA B-Gene +
receptor I-Gene -
. O +

It O +
may O +
be O +
that O +
interaction O +
of O +
JIM19 B-Gene +
with O +
a O +
surface O +
GP B-Gene +
adjacent O +
to O -
, O +
or O +
interactive O +
with O -
, O +
an O +
ABA B-Gene +
receptor I-Gene -
, O +
particularly O +
masks O +
an O +
ABA O +
binding O +
site O +
and O +
thereby O +
inhibits O +
ABA O +
responses O -
. O +

We O +
speculate O +
that O +
the O +
binding O +
of O +
ABA O +
to O +
a O +
receptor B-Gene +
complex O +
in O +
PMs O +
may O +
induce O +
a O +
conformational O +
change O +
that O +
alters O +
the O +
affinity O +
of O +
an O +
O O +
-linked O +
GP B-Gene +
epitope O +
for O +
JIM19 B-Gene -
. O +

In O +
this O +
context O +
it O +
is O +
interesting O +
to O +
note O +
that O +
a O +
putative O +
O B-Gene +
-glucosyl I-Gene +
transferase I-Gene +
( O -
SPY B-Gene -
) O -
, O +
when O +
overexpressed O +
in O +
barley O +
aleurone O +
cells O -
, O +
can O +
transactivate O +
the O +
ABA O -
- O -
inducible O +
DHN O +
promoter O +
[ O -
37 O -
] O +
. O +

There O +
are O +
at O +
least O +
five O +
different O +
GPs B-Gene +
that O +
are O +
bound O +
by O +
JIM19 B-Gene +
( O -
Fig. O +
2 O +
) O -
. O +

Solution O +
competition O +
assays O +
with O +
JIM20 B-Gene +
showed O +
a O +
high O +
degree O +
of O +
antagonism O +
of O +
PM O +
binding O +
to O +
JIM19 B-Gene +
( O -
Table O +
2 O +
) O -
, O +
suggesting O +
that O +
JIM19 B-Gene +
and O +
JIM20 B-Gene +
both O +
recognize O +
the O +
high O +
molecular O +
weight O +
epitopes O +
visualized O +
by O +
immunoblots O +
of O +
PM O +
proteins B-Gene +
( O -
Fig. O +
2 O +
) O -
. O +

Although O +
such O +
a O +
heterogeneous O +
system O +
complicates O +
biochemical O +
analyses O +
by O +
SPR O -
, O +
these O +
results O +
do O +
suggest O +
that O +
JIM19 B-Gene +
interacts O -
, O +
possibly O +
indirectly O -
, O +
with O +
ABA O +
signalling O +
mechanisms O -
. O +

The O +
semi O -
- O -
quantitative O +
capability O +
of O +
the O +
SPR O +
biosensor O +
allows O +
an O +
assessment O +
of O +
traditional O +
saturable O +
binding O +
assays O +
applied O +
to O +
the O +
postulated O +
ABA B-Gene +
receptor I-Gene -
, O +
assuming O +
that O +
the O +
calibration O +
of O +
the O +
SPR O +
signal O +
for O +
protein B-Gene +
also O +
holds O +
for O +
vesicles O -
. O +

Assuming O +
the O +
observed O +
ABA O -
- O -
antagonized O +
binding O +
of O +
PMs O +
to O +
JIM19 B-Gene +
is O +
due O +
to O +
stoichiometric O +
binding O +
of O +
ABA O +
to O +
an O +
ABA B-Gene +
receptor I-Gene +
which O +
interacts O +
with O +
one O +
of O +
the O +
GPs B-Gene -
, O +
then O +
the O +
observed O +
SPR O +
signal O +
corresponds O +
to O +
50 O +
pCi O +
3 O +
H O -
- O -
ABA O -
, O +
or O +
approximately O +
2 O +
Bq O +
( O -
120 O +
dpm O -
) O -
/ O -
μg O +
PM O +
protein B-Gene -
. O +

This O +
amount O +
of O +
label O +
is O +
near O +
the O +
limit O +
of O +
detection O +
of O +
binding O +
assays O -
. O +

The O +
SPR O +
PM O -
- O -
JIM19 B-Gene +
biosensor O +
assay O +
described O +
here O +
provides O +
a O +
novel O +
and O +
sensitive O +
method O +
for O +
characterization O +
of O +
an O +
activity O +
associated O +
with O +
ABA O +
perception O -
. O +

There O +
are O +
conserved O +
heterodimeric O +
GPs B-Gene +
in O +
plants O +
and O +
animals O -
, O +
viz O -
. O +
integrins B-Gene -
, O +
that O +
function O +
in O +
cell O +
surface O +
recognition O -
, O +
adhesion O +
and O +
signal O +
transduction O +
[ O -
38,39 O -
] O +
. O +

The O +
affinities O +
and O +
conformation O +
of O +
integrins B-Gene +
are O +
modulated O +
by O +
cations O +
and O +
receptor B-Gene +
activation O +
[ O -
40 O -
] O +
. O +

Consistent O +
with O +
an O +
integrin B-Gene +
model O +
of O +
ABA O +
signalling O +
is O +
the O +
agonistic O +
effect O +
of O +
multivalent O +
cations O +
on O +
ABA O -
- O -
regulated O +
gene O +
expression O +
[ O -
15,41 O -
] O +
. O +

In O +
addition O -
, O +
recent O +
reports O +
have O +
demonstrated O +
the O +
existence O +
in O +
plants O +
of O +
glycosylphosphatidylinositol O +
( O -
GPI O -
) O -
-anchored O +
arabinogalactan B-Gene +
proteins I-Gene +
[ O -
42 O -
] O +
, O +
with O +
exciting O +
implications O +
for O +
signal O +
transduction O +
pathways O -
. O +

Acknowledgements O +
The O +
authors O +
would O +
like O +
to O +
thank O +
Dr. O +
Jen O +
Sheen O +
for O +
p35SC4PPDK O -
- O -
sGFP O -
( O -
S65 O -
T O -
) O -
, O +
Patrick O +
Po O +
Fai O +
Ng O -
, O +
Leigh O +
Brian O +
and O +
Regina O +
Kit O +
Fong O +
Chak O +
for O +
assistance O +
with O +
rice O +
tissue O +
culture O +
and O +
protoplasts O -
, O +
Kim O +
Kam O -
- O -
Chi O +
Li O +
for O +
assistance O +
with O +
BIAcore O +
instrumentation O -
, O +
Frances O +
Shuk O -
- O -
Lan O +
Chan O +
for O +
assistance O +
with O +
flow O +
cytometry O -
, O +
Drs O -
. O +

Tom O +
Schultz O +
and O +
Ralph O +
Quatrano O +
for O +
sharing O +
unpublished O +
results O +
and O +
Drs O -
. O +

Yung O +
Hou O +
Wong O +
and O +
Kevin O +
Lee O +
for O +
critical O +
reading O +
of O +
the O +
manuscript O +
and O +
helpful O +
discussions O -
. O +

This O +
work O +
was O +
supported O +
by O +
Grant O +
# O -
JRS96 O -
/ O -
33 O +
from O +
the O +
United O +
Kingdom O -
/ O -
Hong O +
Kong O +
Joint O +
Research O +
Scheme O +
to O +
C.D.R. O +
and O +
S.J.N. O +
and O +
by O +
Competitive O +
Earmarked O +
Research O +
Grant O +
# O -
HKUST O +
6173 O -
/ O -
97 O -
M O +
from O +
the O +
Hong O +
Kong O +
Research O +
Grants O +
Council O +
to O +
C.D.R. O +

The O +
cytochrome B-Gene +
P450 I-Gene +
( O -
CYP B-Gene -
, O +
EC B-Gene +
1.14.14.1 I-Gene -
) O +
plays O +
an O +
important O +
role O +
in O +
the O +
metabolism O +
of O +
various O +
drugs O -
, O +
steroids O -
, O +
mutagens O +
and O +
carcinogens O +
[ O -
1 O -
] O +
. O +

It O +
can O +
metabolize O +
chemicals O +
into O +
reactive O +
intermediates O +
binding O +
spontaneously O +
to O +
proteins B-Gene -
, O +
nucleic O +
acids O -
, O +
lipids O +
and O +
to O +
CYP B-Gene +
itself O +
[ O -
2 O -
] O +
. O +

Organic O +
compounds O +
can O +
cause O +
CYP B-Gene +
destruction O +
by O +
irreversible O +
binding O +
of O +
their O +
metabolites O +
to O +
the O +
CYP B-Gene +
heme I-Gene -
, O +
apoprotein B-Gene -
, O +
or O +
both O +
[ O -
3–5 O -
] O +
. O +

It O +
was O +
postulated O +
that O +
CYP B-Gene +
can O +
be O +
destroyed O +
by O +
superoxide O +
anionradical O -
, O +
H2 O +
O2 O +
or O +
other O +
reactive O +
oxygen O +
species O +
formed O +
during O +
the O +
futile O +
cycle O +
without O +
substrate O +
[ O -
6 O -
] O +
or O +
via O +
reactive O +
oxygen O +
species O -
- O -
initiated O +
lipid O +
peroxidation O +
[ O -
7 O -
] O +
. O +

Some O +
CYP B-Gene +
isoforms I-Gene +
appear O +
to O +
be O +
more O +
sensitive O +
to O +
certain O +
substrates O +
[ O -
8–10 O -
] O +
. O +

An O +
inhibition O +
or O +
destruction O +
of O +
CYP B-Gene +
may O +
cause O +
prolongation O +
of O +
xenobiotic O +
action O -
, O +
increase O +
or O +
decrease O +
in O +
xenobiotic O +
toxicity O -
, O +
and O +
even O +
affect O +
physiological O +
functions O -
, O +
e.g. O +
steroid O +
biosynthesis O +
[ O -
11 O -
] O +
. O +

Selective O +
destruction O +
of O +
various O +
CYP B-Gene +
isoforms I-Gene +
alters O +
the O +
activation O -
/ O -
detoxification O +
ratio O +
of O +
procarcinogens O +
and O +
thus O +
may O +
increase O +
the O +
cancer O +
risk O +
in O +
conditions O +
of O +
combined O +
exposure O +
[ O -
10,12 O -
] O +
. O +

Benzene O +
is O +
an O +
established O +
human O +
and O +
animal O +
carcinogen O +
[ O -
13 O -
] O +
acting O +
through O +
an O +
epigenetic O +
mechanism O -
. O +

Benzene O -
- O -
induced O +
myelotoxic O +
and O +
carcinogenic O +
effects O +
are O +
supposed O +
to O +
be O +
caused O +
by O +
covalent O +
binding O +
of O +
its O +
metabolites O +
to O +
biomacromolecules O +
[ O -
14,15 O -
] O +
. O +

Exposure O +
to O +
benzene O +
was O +
reported O +
to O +
lower O +
the O +
cytochrome B-Gene +
P450 I-Gene +
content O +
and O +
activity O +
in O +
rats O +
pretreated O +
by O +
phenobarbital O +
in O +
vivo O +
[ O -
16 O -
] O +
. O +

The O +
role O +
of O +
benzene O +
in O +
CYP B-Gene +
destruction O +
was O +
also O +
studied O +
in O +
vitro O -
, O +
and O +
preliminary O +
results O +
revealed O +
that O +
the O +
main O +
destructive O +
agent O +
may O +
be O +
benzoquinone O +
[ O -
17 O -
] O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
explore O +
in O +
detail O +
the O +
mechanism O +
of O +
CYP B-Gene +
destruction O +
by O +
benzene O +
and O +
its O +
metabolites O -
. O +

Lipid O +
peroxidation O +
and O +
formation O +
of O +
reactive O +
oxygen O +
species O +
was O +
followed O +
up O +
as O +
well O +
as O +
the O +
concentration O +
of O +
superoxide O +
anionradical O -
. O +

Selectivity O +
in O +
destruction O +
of O +
inducible O +
and O +
constitutive O +
rat O +
CYP B-Gene +
isoforms I-Gene +
was O +
studied O +
and O +
a O +
comparison O +
of O +
the O +
sensitivity O +
of O +
human O +
and O +
rat O +
CYP B-Gene +
was O +
carried O +
out O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Chemicals O +

All O +
chemicals O +
used O +
were O +
of O +
analytical O +
grade O -
. O +

NADPH O -
, O +
NADP O -
, O +
glucose-6-phosphate O -
, O +
chlorzoxazone O -
, O +
7-pentoxyresorufin O -
, O +
7-ethoxyresorufin O -
, O +
resorufin O -
, O +
tolbutamide O -
, O +
nifedipine O -
, O +
β O -
- O -
naphtoflavone O -
, O +
pregnenolone O +
16α O -
- O -
carbonitrile O -
, O +
MgCl2 O +
, O +
Tris O -
, O +
KCl O -
, O +
and O +
chemicals O +
for O +
electrophoresis O +
and O +
immunoblotting O +
were O +
obtained O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

Glucose-6-phosphate B-Gene +
dehydrogenase I-Gene +
was O +
obtained O +
from O +
Boehringer O +
( O -
Mannheim O -
, O +
Germany O -
) O -
. O +

Solvents O +
used O +
in O +
HPLC O +
methods O +
were O +
products O +
of O +
Merck O +
( O -
Darmstadt O -
, O +
Germany O -
) O -
. O +

6-Hydroxychlorzoxazone O +
was O +
synthetized O +
at O +
Research O +
Institute O +
of O +
Pharmacy O +
and O +
Biochemistry O -
, O +
Czech O +
Republic O -
. O +

Polyclonal O +
anti O +
rat O +
CYP1A1 B-Gene -
/ O -
2 B-Gene -
, O +
2B1 B-Gene -
, O +
2E1 B-Gene -
, O +
and O +
3A1 B-Gene -
/ O -
2 B-Gene +
antibodies B-Gene +
were O +
generous O +
gifts O +
of O +
Magnus O +
Ingelman O -
- O -
Sundberg O +
( O -
Berzelius O +
Laboratory O -
, O +
Karolinska O +
Institutet O -
, O +
Stockholm O -
, O +
Sweden O -
) O -
. O +

Oxidized O +
nifedipine O +
and O +
hydroxytolbutamide O +
were O +
generous O +
gifts O +
of O +
F. O +
Peter O +
Guengerich O +
( O -
Center O +
in O +
Molecular O +
Toxicology O -
, O +
Vanderbilt O +
University O -
, O +
Nashville O -
, O +
TN O -
, O +
USA O -
) O -
. O +

Hydroquinone O +
and O +
catechol O +
was O +
purified O +
by O +
crystallization O +
and O +
benzoquinone O +
by O +
sublimation O +
before O +
use O -
. O +

2.2 O +
Animals O +
and O +
pretreatments O +
Adult O +
male O +
Wistar O +
rats O +
( O -
200–260 O +
g O -
, O +
VELAZ O -
, O +
Czech O +
Republic O -
) O +
were O +
fed O +
ad O +
libitum O +
on O +
pellet O +
chow O +
and O +
water O +
a O +
week O +
before O +
use O -
. O +

Four O +
groups O +
of O +
rats O +
( O -
n O +
= O -
3–8 O -
) O +
were O +
specifically O +
pretreated O +
to O +
induce O +
certain O +
CYP B-Gene +
isoforms I-Gene +
in O +
rat O +
liver O -
. O +

Control O +
microsomes O +
were O +
prepared O +
from O +
untreated O +
rats O -
. O +

One O +
pretreated O +
group O +
was O +
exposed O +
to O +
benzene O +
by O +
inhalation O -
, O +
4 O +
mg O -
/ O -
l O -
, O +
20 O +
h O -
/ O -
day O +
for O +
3 O +
days O +
as O +
described O +
before O +
[ O -
16 O -
] O +
to O +
induce O +
high O +
levels O +
of O +
CYP2E1 B-Gene -
. O +

Another O +
group O +
was O +
pretreated O +
with O +
pregnenolone O +
16α O -
- O -
carbonitrile O +
for O +
CYP3A B-Gene +
induction O +
in O +
five O +
i.g O -
. O +

intubations O -
, O +
25 O +
mg O -
/ O -
kg O +
in O +
olive O +
oil O +
in O +
12-h O +
intervals O +
during O +
3 O +
days O -
. O +

The O +
third O +
group O +
was O +
pretreated O +
with O +
sodium O +
phenobarbital O +
( O -
0.1 O -
% O +
in O +
drinking O +
water O +
for O +
5 O +
days O +
and O +
one O +
i.p O -
. O +

injection O -
, O +
80 O +
mg O -
/ O -
kg O -
, O +
24 O +
h O +
before O +
killing O -
) O +
to O +
induce O +
CYP2B1 B-Gene -
. O +

The O +
β O -
- O -
naphtoflavone O -
- O -
pretreated O +
rats O +
( O -
80 O +
mg O -
/ O -
kg O +
in O +
olive O +
oil O +
i.p O -
. O +

for O +
3 O +
days O -
) O +
were O +
the O +
source O +
of O +
CYP1A1 B-Gene -
/ O -
2-induced B-Gene +
microsomes O -
. O +

The O +
animals O +
were O +
killed O +
24 O +
h O +
after O +
the O +
last O +
inducer O +
dose O +
or O +
immediately O +
after O +
the O +
third O +
exposure O +
to O +
benzene O -
. O +

Livers O +
from O +
animals O +
in O +
particular O +
groups O +
were O +
pooled O +
for O +
preparation O +
of O +
microsomes O -
. O +

2.3 O +
Human O +
liver O +
samples O +
Human O +
liver O +
samples O +
were O +
obtained O +
from O +
the O +
Transplantation O +
Center O +
IKEM O -
, O +
Czech O +
Republic O -
, O +
from O +
donors O +
who O +
died O +
accidentally O +
as O +
a O +
result O +
of O +
brain O +
injury O -
. O +

Liver O +
samples O +
were O +
obtained O +
at O +
most O +
30 O +
min O +
after O +
death O +
and O +
were O +
stored O +
in O +
liquid O +
nitrogen O +
until O +
microsomes O +
were O +
isolated O -
. O +

Some O +
of O +
the O +
donors O +
were O +
subjected O +
to O +
therapy O +
including O +
antibiotics O +
( O -
chloramphenicol O -
, O +
penicillin O -
, O +
ampicillin O -
, O +
gentamycin O -
) O -
, O +
mannitol O -
, O +
or O +
hormones O +
( O -
hydrocortisone O -
, O +
dexamethasone O -
) O +
for O +
24–48 O +
h O +
before O +
death O -
. O +

2.4 O +
Isolation O +
of O +
microsomes O +
Microsomes O +
were O +
prepared O +
according O +
to O +
van O +
der O +
Hoeven O +
and O +
Coon O +
[ O -
18 O -
] O +
and O +
stored O +
in O +
aliquots O +
of O +
0.1 O +
ml O +
at O +
−80 O -
° O -
C O +
until O +
use O -
. O +

Protein B-Gene +
concentration O +
was O +
determined O +
immediately O +
after O +
preparation O +
of O +
microsomes O +
according O +
to O +
Lowry O +
et O +
al. O +
[ O -
19 O -
] O +
using O +
serum B-Gene +
albumin I-Gene +
as O +
a O +
standard O -
. O +

The O +
total O +
CYP B-Gene +
content O +
was O +
estimated O +
by O +
the O +
spectrophotometric O +
method O +
of O +
Omura O +
and O +
Sato O +
[ O -
20 O -
] O +
. O +

2.5 O +
Microsomal O +
incubations O +
Microsomes O +
( O -
1 O +
mg O +
protein B-Gene -
/ O -
ml O -
) O +
were O +
preincubated O +
with O +
1 O +
mM O +
catechol O -
, O +
hydroquinone O -
, O +
or O +
benzoquinone O +
without O +
NADPH O +
or O +
with O +
NADPH O +
generating O +
system O +
only O +
( O -
10 O +
mM O +
MgCl2 O +
, O +
10 O +
mM O +
glucose-6-phosphate O -
, O +
1 O +
mM O +
NADP O -
, O +
0.5 O +
U O -
/ O -
ml O +
glucose-6-phosphate B-Gene +
dehydrogenase I-Gene -
) O +
in O +
total O +
volume O +
of O +
2 O +
ml O +
of O +
150 O +
mM O +
KCl O -
/ O -
50 O +
mM O +
Tris O +
( O -
pH O +
7.4 O -
) O +
buffer O -
. O +

Preincubation O +
proceeded O +
for O +
60 O +
min O +
at O +
37 O -
° O -
C O +
in O +
a O +
shaking O +
water O +
bath O +
in O +
the O +
dark O -
. O +

After O +
preincubation O +
the O +
content O +
of O +
total O +
CYP B-Gene +
was O +
measured O +
by O +
the O +
spectrophotometric O +
method O +
of O +
Omura O +
and O +
Sato O +
[ O -
20 O -
] O +
. O +

In O +
order O +
to O +
avoid O +
interference O +
of O +
quinones O +
with O +
subsequent O +
analysis O +
after O +
preincubation O -
, O +
microsomes O +
were O +
pelleted O +
by O +
centrifugation O +
for O +
20 O +
min O +
at O +
180 O +
000 O -
× O -
g O +
at O +
4 O -
° O -
C O -
. O +

Pellets O +
were O +
resuspended O +
in O +
0.5 O +
ml O +
KCl O -
– O -
Tris O +
buffer O -
. O +

Determination O +
of O +
activity O +
and O +
apoprotein B-Gene +
level O +
of O +
CYP B-Gene +
isoforms I-Gene +
by O +
assay O +
of O +
metabolism O +
of O +
marker O +
substrates O +
and O +
immunoblotting O +
in O +
sample O +
aliquots O +
followed O +
as O +
well O +
as O +
estimation O +
of O +
concentration O +
of O +
OH O +
radicals O -
, O +
semiquinone O +
radicals O +
and O +
malondialdehyde O +
( O -
MDA O -
) O -
. O +

2.6 O +
Electrophoresis O +
and O +
immunoblotting O +
SDS O -
– O -
polyacrylamide O +
gel O +
electrophoresis O +
of O +
microsomal O +
proteins B-Gene +
was O +
performed O +
according O +
to O +
Laemmli O +
[ O -
21 O -
] O +
using O +
a O +
MiniProtean O +
II O +
apparatus O +
( O -
BioRad O -
, O +
Hercules O -
, O +
CA O -
) O -
. O +

For O +
immunoblotting O +
10 O -
% O +
polyacrylamide O +
gel O +
was O +
used O +
and O +
5 O +
μg O +
microsomal O +
protein B-Gene +
per O +
lane O +
were O +
applied O -
. O +

Immunoblotting O +
was O +
then O +
done O +
as O +
described O +
by O +
Towbin O +
et O +
al. O +
[ O -
22 O -
] O +
using O +
a O +
Miniblotter O +
device O +
( O -
BioRad O -
) O -
. O +

Blots O +
were O +
incubated O +
with O +
primary O +
antibody B-Gene +
for O +
1 O +
h O +
at O +
37 O -
° O -
C O +
in O +
PBST O +
buffer O +
( O -
20 O +
mM O +
potassium O +
phosphate O +
( O -
pH O +
7.4 O -
) O -
/ O -
150 O +
mM O +
NaCl O -
/ O -
0.05 O -
% O +
Tween O +
80 O -
) O +
Anti O -
- O -
rat O +
CYP1A1 B-Gene -
/ O -
2 B-Gene -
, O +
2B1 B-Gene -
, O +
2E1 B-Gene -
, O +
or O +
3A1 B-Gene -
/ O -
2 B-Gene +
polyclonal B-Gene +
antibodies I-Gene +
were O +
used O +
in O +
dilution O +
of O +
1 O -
/ O -
500 O +
for O +
2E1 O +
antiserum O +
and O +
1 O -
/ O -
2000 O +
for O +
the O +
rest O +
of O +
antisera O -
. O +

The O +
next O +
incubation O +
was O +
with O +
goat O +
anti O -
- O -
rabbit O +
IgG B-Gene +
coupled O +
to O +
horseradish B-Gene +
peroxidase I-Gene +
as O +
a O +
secondary O +
antibody B-Gene +
( O -
dilution O +
1 O -
/ O -
1000 O +
for O +
1 O +
h O +
at O +
room O +
temperature O -
) O -
. O +

For O +
visualization O +
of O +
the O +
bands O +
a O +
mixture O +
of O +
2.5 O +
mM O +
1-chloro-4-naphthol O +
and O +
15 O +
mM O +
H2 O +
O2 O +
in O +
PBS O +
buffer O +
was O +
used O -
. O +

2.7 O +
Enzyme B-Gene +
assays O +
7-Ethoxyresorufin O +
O O +
-deethylation O +
and O +
7-pentoxyresorufin O +
O O +
-depentylation O +
were O +
assayed O +
according O +
to O +
Lubet O +
et O +
al. O +
[ O -
23 O -
] O +
with O +
1.75 O +
or O +
5 O +
μM O +
substrate O -
, O +
respectively O -
, O +
0.25 O +
mM O +
NADPH O -
, O +
and O +
100 O +
pmol O +
CYP B-Gene +
for O +
20 O +
min O -
. O +

Coumarin O +
7-hydroxylation O +
was O +
assayed O +
as O +
described O +
by O +
Yun O +
et O +
al. O +
[ O -
24 O -
] O +
with O +
20 O +
μM O +
substrate O -
, O +
100 O +
pmol O +
of O +
total O +
CYP B-Gene +
for O +
20 O +
min O -
. O +

Tolbutamide O +
methylhydroxylation O +
was O +
performed O +
according O +
to O +
Knodell O +
et O +
al. O +
[ O -
25 O -
] O +
with O +
2.5 O +
mM O +
substrate O -
, O +
NADPH O -
- O -
generating O +
system O +
( O -
10 O +
mM O +
MgCl2 O +
, O +
10 O +
mM O +
glucose-6-phosphate O -
, O +
1 O +
mM O +
NADP O -
, O +
0.5 O +
U O -
/ O -
ml O +
glucose-6-phosphate B-Gene +
dehydrogenase I-Gene -
) O -
, O +
and O +
100 O +
pmol O +
CYP B-Gene +
for O +
30 O +
min O -
. O +

Chlorzoxazone O +
6-hydroxylation O +
was O +
followed O +
according O +
to O +
Peter O +
et O +
al. O +
[ O -
26 O -
] O +
with O +
0.1 O +
mM O +
substrate O -
, O +
NADPH O +
generating O +
system O +
( O -
see O +
above O -
) O -
, O +
and O +
100 O +
pmol O +
of O +
CYP B-Gene +
for O +
20 O +
min O -
. O +

Oxidation O +
of O +
nifedipine O +
was O +
determined O +
after O +
Guengerich O +
et O +
al. O +
[ O -
27 O -
] O +
with O +
80 O +
μM O +
substrate O -
, O +
NADPH O -
- O -
generating O +
system O +
( O -
see O +
above O -
) O -
, O +
and O +
100 O +
pmol O +
CYP B-Gene +
for O +
15 O +
min O -
. O +

All O +
incubations O +
were O +
carried O +
out O +
in O +
total O +
volume O +
of O +
0.5 O +
ml O +
of O +
KCl O -
– O -
Tris O +
buffer O +
at O +
37 O -
° O -
C O +
in O +
a O +
shaking O +
water O +
bath O -
. O +

2.8 O +
Other O +
assays O +
Concentration O +
of O +
OH O +
radicals O +
was O +
measured O +
as O +
described O +
[ O -
28 O -
] O +
and O +
lipid O +
peroxidation O +
was O +
estimated O +
according O +
to O +
Buege O +
and O +
Aust O +
[ O -
29 O -
] O +
. O +

Semiquinone O +
anion O +
radical O +
formation O +
was O +
evaluated O +
as O +
described O +
by O +
Gut O +
et O +
al. O +
[ O -
16 O -
] O +
. O +

2.9 O +
Statistics O +
All O +
results O +
are O +
expressed O +
as O +
the O +
average O +
of O +
two O +
measurements O -
, O +
means O +
( O -
±S.D. O +
or O +
subject O +
to O +
correlation O +
analysis O -
. O +

The O +
Student O -
's O +
t O +
-test O +
was O +
used O +
for O +
analysis O +
of O +
differences O +
between O +
groups O -
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
CYP B-Gene +
destruction O +
by O +
quinones O +
and O +
NADPH O -
: O +
spectrophotometric O +
evaluation O +
of O +
CYP B-Gene +
content O +
Microsomes O +
from O +
rats O +
pretreated O +
with O +
various O +
CYP B-Gene +
inducers O +
were O +
preincubated O +
with O +
either O +
NADPH O +
without O +
substrate O +
or O +
quinones O +
in O +
the O +
absence O +
of O +
NADPH O -
. O +

This O +
experiment O +
showed O +
that O +
various O +
rat O +
CYP B-Gene +
isoforms I-Gene +
differed O +
in O +
sensitivity O +
to O +
both O +
NADPH O +
and O +
benzoquinone O -
. O +

CYP B-Gene +
3A I-Gene +
isoforms I-Gene +
were O +
the O +
most O +
sensitive O +
to O +
destruction O +
by O +
the O +
futile O +
cycle O +
( O -
Fig. O +
1 O +
A O -
) O -
. O +

CYP B-Gene +
3A I-Gene +
as O +
well O +
as O +
CYP B-Gene +
1A I-Gene +
isoforms I-Gene +
were O +
also O +
found O +
to O +
be O +
the O +
most O +
sensitive O +
to O +
the O +
deleterious O +
action O +
of O +
benzoquinone O +
( O -
Fig. O +
1 O +
B O -
) O -
. O +

These O +
results O +
were O +
confirmed O +
by O +
electrophoresis O +
of O +
preincubated O +
microsomes O +
with O +
subsequent O +
immunochemical O +
detection O +
of O +
specific O +
CYP B-Gene +
isoforms I-Gene +
by O +
immunoblotting O +
( O -
Fig. O +
2 O +
) O -
. O +

Protein B-Gene +
bands O +
corresponding O +
to O +
rat O +
CYP B-Gene +
3A1 B-Gene -
/ O -
2 B-Gene +
and O +
1A1 B-Gene -
/ O -
2 B-Gene +
proteins B-Gene +
completely O +
disappeared O +
after O +
preincubation O +
of O +
microsomes O +
with O +
benzoquinone O +
while O +
that O +
of O +
CYP B-Gene +
2B1 I-Gene +
remained O +
visible O -
. O +

Assays O +
of O +
CYP B-Gene +
activity O +
showed O +
that O +
CYP B-Gene +
1A B-Gene +
and O +
3A B-Gene +
marker O +
activities O +
were O +
completely O +
destroyed O +
by O +
benzoquinone O +
( O -
100 O -
% O +
destruction O +
of O +
nifedipine O +
oxidation O +
and O +
99.5 O -
% O +
destruction O +
of O +
EROD B-Gene -
; O +
see O +
Table O +
1 O +
) O -
. O +

CYP B-Gene +
2B1 B-Gene +
and O +
2E1 B-Gene +
proteins B-Gene +
seemed O +
to O +
be O +
slightly O +
more O +
resistant O +
to O +
the O +
destructive O +
effect O +
of O +
benzoquinone O +
as O +
judged O +
by O +
comparison O +
of O +
measurement O +
of O +
total O +
CYP B-Gene +
content O -
, O +
immunochemical O +
detection O -
, O +
and O +
marker O +
activity O +
assays O +
( O -
96 O -
% O +
destruction O +
of O +
PROD B-Gene +
and O +
93 O -
% O +
destruction O +
of O +
chlorzoxazone O +
oxidation O -
) O -
. O +

Rat O +
constitutive O +
CYP B-Gene +
isoforms I-Gene +
present O +
in O +
untreated O +
microsomes O +
appeared O +
to O +
be O +
the O +
most O +
resistant O +
to O +
the O +
NADPH O -
- O -
mediated O +
futile O +
cycle O +
and O +
also O +
showed O +
higher O +
resistance O +
to O +
benzoquinone O +
than O +
highly O +
inducible O +
CYP B-Gene +
1A B-Gene +
and O +
3A B-Gene +
isoforms B-Gene +
( O -
Fig. O +
1 O +
) O -
. O +

No O +
significant O +
difference O +
between O +
various O +
types O +
of O +
microsomes O +
was O +
observed O +
in O +
sensitivity O +
to O +
hydroquinone O +
( O -
40–60 O -
% O +
destruction O +
of O +
total O +
CYP B-Gene -
) O -
. O +

It O +
seems O +
to O +
be O +
apparent O +
that O +
sensitivities O +
of O +
the O +
relevant O +
CYP B-Gene +
isoforms I-Gene +
( O -
particularly O +
CYP B-Gene +
1A B-Gene +
and O +
3A B-Gene +
isoforms I-Gene -
) O +
to O +
quinones O +
differ O +
( O -
Fig. O +
1 O +
, O +
Fig. O +
2 O +
, O +
and O +
Table O +
1 O +
) O -
. O +

On O +
the O +
contrary O +
Belisario O +
et O +
al. O +
observed O +
a O +
significantly O +
higher O +
inhibition O +
of O +
CYP B-Gene +
2B1 I-Gene +
than O +
CYP B-Gene +
1A I-Gene +
activity O +
by O +
avarol O -
- O -
sesquiterpenoid O +
hydroquinone O +
and O +
its O +
quinone O +
avarone O +
( O -
30 O +
μM O -
) O +
in O +
vitro O +
[ O -
30 O -
] O +
. O +

A O +
selective O +
inhibition O +
of O +
PROD B-Gene +
activity O +
( O -
in O +
comparison O +
with O +
EROD O -
) O +
in O +
rat O +
lung O +
microsomes O +
after O +
inhalation O +
of O +
a O +
benzene O +
derivative O +
m O +
-xylene O +
was O +
reported O +
as O +
well O +
[ O -
10 O -
] O +
. O +

Data O +
presented O +
here O +
do O +
not O +
suggest O +
higher O +
sensitivity O +
of O +
PROD B-Gene +
to O +
quinones O +
in O +
comparison O +
with O +
EROD B-Gene +
in O +
rat O +
liver O +
microsomes O +
in O +
vitro O -
. O +

One O +
possible O +
explanation O +
for O +
this O +
discrepancy O +
may O +
be O +
differences O +
in O +
the O +
amounts O +
of O +
quinones O +
presented O +
to O +
microsomal O +
proteins B-Gene -
. O +

Differences O +
in O +
the O +
distribution O +
of O +
CYP B-Gene +
proteins I-Gene +
in O +
the O +
lung O +
and O +
liver O +
may O +
play O +
a O +
role O +
as O +
well O -
. O +

3.2 O +
Mechanism O +
of O +
CYP B-Gene +
destruction O -
: O +
evaluation O +
of O +
the O +
role O +
of O +
OH O +
radicals O -
, O +
semiquinone O +
radical O -
, O +
and O +
lipid O +
peroxidation O +
OH O +
radical O +
formation O +
and O +
induction O +
of O +
lipid O +
peroxidation O +
was O +
measured O +
in O +
various O +
types O +
of O +
microsomes O +
after O +
preincubation O +
with O +
NADPH O +
without O +
substrate O -
, O +
hydroquinone O +
or O +
benzoquinone O +
in O +
the O +
absence O +
of O +
NADPH O +
( O +
Figs. O +
3 O +
and O +
4 O +
) O -
. O +

The O +
NADPH O -
- O -
mediated O +
futile O +
cycle O +
greatly O +
enhanced O +
production O +
of O +
both O +
OH O +
radicals O +
and O +
MDA O +
( O -
marker O +
of O +
lipid O +
peroxidation O -
) O +
in O +
all O +
kinds O +
of O +
microsomes O +
( O -
Fig. O +
3 O +
B O +
and O +
Fig. O +
4 O +
B O -
) O -
. O +

On O +
the O +
other O +
hand O +
both O +
quinones O +
significantly O +
decreased O +
production O +
of O +
OH O +
radicals O +
and O +
MDA O +
in O +
all O +
kinds O +
of O +
microsomes O +
( O -
Fig. O +
3 O +
C O +
and O +
Fig. O +
4 O +
C O -
) O -
. O +

Thus O +
it O +
seems O +
that O +
quinones O +
exerted O +
a O +
rather O +
protective O +
effect O +
against O +
OH O +
radical O +
production O +
and O +
lipid O +
peroxidation O -
. O +

Therefore O +
it O +
can O +
be O +
concluded O +
that O +
these O +
processes O +
do O +
not O +
play O +
a O +
significant O +
role O +
in O +
the O +
mechanism O +
of O +
CYP B-Gene +
destruction O +
by O +
quinones O -
. O +

Reactive O +
oxygen O +
species O -
- O -
scavenging O +
capacity O +
of O +
quinonic B-Gene +
substances I-Gene +
was O +
reported O +
[ O -
31,32 O -
] O +
. O +

The O +
protective O +
effect O +
of O +
quinones O +
against O +
reactive O +
oxygen O +
species O +
formation O +
and O +
induction O +
of O +
lipid O +
peroxidation O +
may O +
play O +
a O +
positive O +
role O +
in O +
the O +
antitumor O +
activity O +
of O +
various O +
cytostatics O +
of O +
a O +
quinone O +
nature O +
or O +
with O +
an O +
expected O +
formation O +
of O +
quinonic O +
metabolites O +
in O +
the O +
course O +
of O +
their O +
metabolic O +
pathways O +
( O -
e.g. O +
adriamycin O -
, O +
daunorubicin O -
, O +
etoposide O -
, O +
etc O -
) O -
. O +

The O +
level O +
of O +
OH O +
radicals O +
formation O +
did O +
not O +
correlate O +
with O +
total O +
CYP B-Gene +
destruction O +
mediated O +
by O +
NADPH O -
, O +
suggesting O +
that O +
OH O +
radicals O +
do O +
not O +
play O +
a O +
role O +
in O +
the O +
mechanism O +
of O +
CYP B-Gene +
destruction O +
by O +
NADPH O -
- O -
mediated O +
futile O +
cycle O -
. O +

Although O +
it O +
was O +
reported O +
that O +
CYP B-Gene +
2E1 I-Gene +
is O +
able O +
to O +
produce O +
higher O +
amounts O +
of O +
reactive O +
oxygen O +
species O +
and O +
initiate O +
lipid O +
peroxidation O +
[ O -
33 O -
] O +
, O +
increased O +
amounts O +
of O +
OH O +
radicals O +
or O +
MDA O +
in O +
microsomes O +
with O +
induced O +
CYP B-Gene +
2E1 I-Gene +
were O +
not O +
observed O +
( O -
Fig. O +
3 O +
) O -
. O +

Nevertheless O -
, O +
the O +
assay O +
conditions O +
used O +
by O +
Ekstroem O +
and O +
Ingelman O -
- O -
Sundberg O +
[ O -
33 O -
] O +
markedly O +
differed O +
from O +
those O +
used O +
in O +
this O +
study O +
( O -
different O +
CYP B-Gene +
inducers O -
, O +
incubation O +
buffer O -
, O +
temperature O +
and O +
time O +
of O +
incubation O -
, O +
measurement O +
of O +
O2 O +
− O +
and O +
H2 O +
O2 O +
) O -
. O +

On O +
the O +
other O +
hand O +
the O +
more O +
MDA O +
formed O +
in O +
the O +
presence O +
of O +
NADPH O +
without O +
substrate O -
, O +
the O +
higher O +
was O +
the O +
destruction O +
of O +
total O +
CYP B-Gene +
( O -
Fig. O +
1 O +
A O +
and O +
Fig. O +
4 O +
B O -
) O -
. O +

It O +
was O +
postulated O +
that O +
lipid O +
peroxidation O +
is O +
the O +
main O +
contributing O +
factor O +
in O +
CYP B-Gene +
destruction O +
by O +
the O +
NADPH O -
- O -
mediated O +
futile O +
cycle O +
[ O -
7 O -
] O +
and O +
data O +
obtained O +
in O +
this O +
study O +
further O +
support O +
this O +
conclusion O -
. O +

Semiquinone O +
radical O +
formation O +
( O -
Fig. O +
5 O +
) O +
did O +
not O +
correlate O +
with O +
the O +
rapid O +
course O +
of O +
CYP B-Gene +
destruction O +
produced O +
by O +
quinones O +
in O +
microsomes O +
from O +
phenobarbital O -
- O -
pretreated O +
rats O +
observed O +
previously O +
[ O -
17 O -
] O +
. O +

Taken O +
together O +
these O +
data O +
provide O +
new O +
evidence O +
to O +
support O +
the O +
previously O +
reported O +
conclusion O +
[ O -
17 O -
] O +
that O +
CYP B-Gene +
destruction O +
proceeds O +
by O +
direct O +
binding O +
of O +
the O +
oxidized O +
form O +
of O +
quinone O +
( O -
in O +
this O +
case O +
benzoquinone O -
) O +
to O +
protein B-Gene +
and O +
heme O +
moieties O +
of O +
CYP B-Gene -
. O +

These O +
results O +
also O +
comply O +
with O +
the O +
data O +
of O +
Lunte O +
and O +
Kissinger O +
[ O -
34 O -
] O +
who O +
found O +
that O +
in O +
microsomal O +
in O +
vitro O +
incubations O -
, O +
hydroquinone O +
was O +
oxidized O +
to O +
benzoquinone O -
, O +
which O +
resulted O +
in O +
an O +
increased O +
rate O +
of O +
covalent O +
binding O -
. O +

3.3 O +
CYP B-Gene +
destruction O +
in O +
human O +
liver O +
microsomes O +
Total O +
CYP B-Gene +
destruction O +
was O +
measured O +
in O +
microsomes O +
from O +
five O +
different O +
human O +
liver O +
samples O +
after O +
preincubation O +
with O +
NADPH O +
alone O +
or O +
quinone O +
without O +
NADPH O -
. O +

Microsomes O +
used O +
in O +
this O +
study O +
were O +
screened O +
for O +
activity O +
of O +
various O +
human O +
liver O +
CYP B-Gene +
isoforms B-Gene +
( O -
1A2 B-Gene -
, O +
2A6 B-Gene -
, O +
2C9 B-Gene -
, O +
2E1 B-Gene -
, O +
3A4-Table B-Gene +
2 O +
) O -
. O +

Surprisingly O -
, O +
human O +
liver O +
CYP B-Gene +
was O +
significantly O +
more O +
resistant O +
to O +
the O +
destructive O +
effect O +
of O +
the O +
NADPH O -
- O -
mediated O +
futile O +
cycle O +
in O +
comparison O +
with O +
rat O +
CYP B-Gene -
. O +

Some O +
of O +
the O +
microsomes O +
even O +
did O +
not O +
show O +
any O +
decrease O +
of O +
the O +
total O +
CYP B-Gene +
content O +
after O +
1-h O +
preincubation O +
with O +
NADPH O +
alone O -
. O +

On O +
the O +
other O +
hand O -
, O +
all O +
samples O +
of O +
human O +
liver O +
microsomes O +
showed O +
significantly O +
higher O +
sensitivity O +
to O +
the O +
deleterious O +
effect O +
of O +
benzoquinone O +
than O +
rat O +
microsomes O +
( O -
Fig. O +
6 O +
) O -
. O +

The O +
destructive O +
effect O +
of O +
reduced O +
quinones O +
( O -
hydroquinone O +
and O +
catechol O -
) O +
was O +
lower O +
than O +
that O +
of O +
the O +
oxidized O +
form O +
( O -
benzoquinone O -
) O -
. O +

A O +
striking O +
interindividual O +
variability O +
( O -
higher O +
than O +
in O +
rats O +
pretreated O +
with O +
various O +
inducers O -
) O +
was O +
observed O -
. O +

Correlation O +
analysis O +
of O +
activity O +
of O +
various O +
CYP B-Gene +
isoforms I-Gene +
and O +
extent O +
of O +
CYP B-Gene +
destruction O +
by O +
quinones O +
revealed O +
that O +
hydroquinone O -
- O -
dependent O +
destruction O +
correlated O +
with O +
EROD B-Gene +
activity O +
( O -
r O +
= O -
0.5 O -
) O +
and O +
benzoquinone O -
- O -
dependent O +
destruction O +
correlated O +
with O +
nifedipine O +
oxidation O +
( O -
r O +
= O -
0.74 O -
) O -
. O +

Due O +
to O +
the O +
low O +
number O +
of O +
individuals O +
used O +
in O +
this O +
study O +
the O +
level O +
of O +
significance O +
of O +
these O +
correlations O +
was O +
P O +
> O -
0.2 O +
and O +
thus O +
clearly O +
suggesting O +
a O +
non O -
- O -
significant O +
tendency O -
. O +

Similar O +
experiments O +
on O +
evaluation O +
of O +
CYP B-Gene +
destruction O +
in O +
human O +
liver O +
microsomes O +
have O +
not O +
been O +
published O +
and O +
thus O +
there O +
is O +
no O +
possibility O +
to O +
compare O +
these O +
results O +
with O +
data O +
in O +
the O +
literature O -
. O +

In O +
conclusion O -
, O +
the O +
results O +
presented O +
here O +
suggest O +
that O +
humans O +
may O +
be O +
more O +
susceptible O +
to O +
xenobiotics O +
and O +
especially O +
those O +
of O +
quinonic O +
nature O -
. O +

This O +
fact O +
should O +
be O +
taken O +
into O +
consideration O +
where O +
extrapolations O +
from O +
animal O +
studies O +
to O +
humans O +
are O +
done O +
and O +
environmental O +
hazards O +
of O +
human O +
exposure O +
to O +
xenobiotics O +
with O +
expected O +
quinonic O +
metabolites O +
are O +
assessed O -
. O +

Further O +
studies O +
with O +
higher O +
numbers O +
of O +
human O +
liver O +
samples O +
are O +
necessary O +
to O +
assess O +
the O +
sensitivity O +
of O +
specific O +
CYP B-Gene +
isoforms I-Gene +
to O +
quinone O +
action O +
and O +
thus O +
evaluate O +
the O +
reason O +
for O +
the O +
great O +
interindividual O +
variability O +
observed O -
. O +

Acknowledgements O +
Author O +
would O +
like O +
to O +
express O +
sincere O +
thanks O +
to O +
F. O +
Peter O +
Guengerich O +
and O +
Magnus O +
Ingelman O -
- O -
Sundberg O +
for O +
their O +
generous O +
gifts O -
. O +

Financial O +
support O +
was O +
provided O +
by O +
grant O +
of O +
Internal O +
Grant O +
Agency O +
of O +
the O +
Czech O +
Ministry O +
of O +
Health O -
, O +
grant O +
No. O +
IGA O +
3505 O -
- O -
3 O -
. O +

Hydrangeae O +
Dulcis O +
Folium O -
, O +
a O +
natural O +
medicine O +
indigenous O +
to O +
Japan O -
, O +
is O +
prepared O +
from O +
the O +
leaves O +
of O +
Hydrangea O +
macrophylla O +
seringe O +
var O -
. O +

thunbergii O +
makino O +
( O -
Saxifragaceae O -
) O +
via O +
several O +
processing O +
steps O +
such O +
as O +
crumpling O -
, O +
fermentation O +
and O +
drying O -
. O +

This O +
natural O +
medicine O +
is O +
listed O +
in O +
the O +
Japanese O +
Pharmacopoeia O +
XIII O +
and O +
is O +
extensively O +
used O +
in O +
confectionery O -
, O +
drinks O +
and O +
food O +
as O +
an O +
oral O +
refrigerant O +
and O +
a O +
sweetening O -
. O +

Two O +
dihydroisocoumarins O -
, O +
phyllodulcin O +
( O -
1 O +
) O +
and O +
hydrangenol O +
( O -
3 O +
) O -
, O +
have O +
been O +
isolated O +
as O +
the O +
principal O +
constituents O +
of O +
this O +
natural O +
medicine O +
( O -
the O +
processed O +
leaves O -
) O -
, O +
while O +
their O +
8-O O +
-glucosides O +
( O -
2 O +
, O +
4 O +
) O +
were O +
isolated O +
from O +
the O +
dried O +
leaves O +
of O +
Hydrangea O +
macrophylla O +
var O -
. O +

thunbergii O +
. O -
[ O -
1 O -
] O +
As O +
part O +
of O +
our O +
studies O +
of O +
the O +
bioactive O +
constituents O +
of O +
Hydrangeae O +
Dulcis O +
Folium, O -
[ O -
1 O -
, O +
2 O -
] O +
the O +
methanolic O +
extract O +
of O +
this O +
natural O +
medicine O +
was O +
found O +
to O +
show O +
potent O +
antiallergic O -
, O +
antibacterial O -
, O +
antioxidative O -
, O +
antiulcer O +
and O +
cholagoic O +
activities. O -
[ O -
3 O -
] O +

We O +
have O +
reported O +
the O +
isolation O +
and O +
structural O +
characterization O +
of O +
two O +
isocoumarins O +
[ O -
thunberginols O +
A O +
( O -
11 O +
) O +
and O +
B O +
( O -
12 O +
) O -
] O -
, O -
[ O -
4 O -
, O +
5 O -
] O +
three O +
dihydroisocoumarins O +
[ O -
thunberginols O +
C O +
( O -
6 O +
) O -
, O +
D O +
( O -
7 O +
) O -
, O +
and O +
E O +
( O -
8 O +
) O -
] O -
, O -
[ O -
6 O -
] O +
a O +
benzylideneph O -
- O -
thalide O +
[ O -
thunberginol O +
F O +
( O -
17 O +
) O -
] O -
, O -
[ O -
4 O -
] O +
three O +
dihydroisocoumarin O +
glucosides O +
[ O -
thunberginol O +
G O +
3′-O O +
-glucoside O -
, O +
( O -
+ O -
) O -
- O +
and O +
( O -
− O -
) O -
-hydrangenol O +
4′-O O +
-glucoside O +
( O -
5 O +
) O -
] O -
, O -
[ O -
6 O -
] O +
and O +
two O +
phthalides O +
[ O -
hydramacrophyllols O +
A O +
( O -
19 O +
) O +
and O +
B O +
( O -
20 O +
) O -
] O -
[ O -
7 O -
] O +
as O +
the O +
antiallergic O +
and O +
antibacterial O +
principles O +
of O +
this O +
natural O +
medicine O -
. O +

We O +
have O +
developed O +
an O +
efficient O +
method O +
for O +
transforming O +
dihydroisocoumarin O +
into O +
benzylidenephthalide O +
and O +
isocoumarin O +
using O +
regiospecific O +
lactonization O +
reaction O +
of O +
2-carboxystilbenes. O -
[ O -
7 O -
] O +
During O +
the O +
course O +
of O +
these O +
synthetic O +
studies O -
, O +
various O +
isocoumarins O -
, O +
phthalides O +
and O +
stilbenes O +
were O +
obtained O -
, O +
but O +
their O +
antiallergic O +
activities O +
have O +
not O +
been O +
clarified O -
. O +

In O +
this O +
paper O -
, O +
we O +
describe O +
the O +
inhibitory O +
activities O +
of O +
isocoumarins O -
, O +
phthalides O +
and O +
stilbenes O +
from O +
Hydrangeae O +
Dulcis O +
Folium O +
or O +
the O +
dried O +
leaves O +
of O +
Hydrangea O +
macrophylla O +
var O -
. O +

thunbergii O +
and O +
their O +
synthetic O +
derivatives O +
on O +
the O +
histamine O +
release O +
induced O +
by O +
antigen O -
- O -
antibody B-Gene +
reaction O +
other O +
than O +
compound O +
48 O -
/ O -
80 O +
and O +
calcium O +
ionophore O +
A23187 O -
, O +
which O +
were O +
partially O +
reported O +
previously. O -
[ O -
4–7 O -
] O +
Their O +
structural O +
requirements O +
for O +
the O +
inhibitory O +
activity O +
will O +
also O +
be O +
discussed O -
. O +

2 O +
Results O +
and O +
Discussion O +
We O +
investigated O +
the O +
structure O -
– O -
activity O +
relationships O +
of O +
the O +
constituents O +
isolated O +
from O +
Hydrangeae O +
Dulcis O +
Folium O +
and O +
related O +
compounds O -
. O +

Table O +
1 O +
Table O +
2 O +
Table O +
3 O +
Table O +
4 O +
show O +
the O +
IC50 O +
values O +
for O +
inhibition O +
of O +
histamine O +
release O +
by O +
15-min O +
pretreatment O -
. O +

Compound O +
48 O -
/ O -
80 O -
, O +
widely O +
used O +
to O +
analyze O +
the O +
mechanism O +
of O +
mast O +
cell O +
degranulation O -
, O +
mobilizes O +
Ca2 O -
+ O +
from O +
intracellular O +
Ca2 O -
+ O +
storage O +
sites O +
followed O +
by O +
extracellular O +
Ca2 O -
+ O +
influx O -
. O +

This O +
increase O +
in O +
Ca2 O -
+ O +
concentration O +
is O +
almost O +
entirely O +
dependent O +
on O +
intracellular O +
Ca2 O -
+ O +
. O +

Compound O +
48 O -
/ O -
80 O +
acts O +
to O +
a O +
pertussis O +
toxin O -
- O -
sensitive O +
GTP B-Gene +
binding I-Gene +
protein I-Gene +
and O +
activates O +
phospholipase B-Gene +
Cγ I-Gene +
( O -
PLCγ B-Gene -
) O -
. O +

As O +
a O +
result O -
, O +
the O +
level O +
of O +
inositol-1,3,5-triphosphate O +
( O -
IP3 O +
) O +
increases O +
followed O +
by O +
Ca2 O -
+ O +
mobilization O +
from O +
the O +
endplasmic O +
reticulum. O -
[ O -
8 O -
] O +

This O +
intracellular O +
Ca2 O -
+ O +
-dependent O +
event O +
progresses O +
in O +
less O +
than O +
10 O +
s O +
and O +
rapidly O +
induces O +
mast O +
cell O +
degranulation O -
. O +

The O +
percentage O +
of O +
compound O +
48 O -
/ O -
80-induced O +
histamine O +
release O +
was O +
in O +
the O +
range O +
of O +
14.6 O +
to O +
34.0 O -
% O -
. O +

Thunberginols O +
A O +
( O -
11 O +
) O -
, O +
B O +
( O -
12 O +
) O -
, O +
D O +
( O -
7 O +
) O -
, O +
E O +
( O -
8 O +
) O +
and O +
F O +
( O -
17 O +
) O +
and O +
piceatannol O +
( O -
25 O +
) O +
inhibited O +
the O +
histamine O +
release O +
with O +
IC O +
50 O +
values O +
of O +
less O +
than O +
100 O +
μM. O +
The O +
inhibitory O +
activities O +
of O +
isocoumarins O +
such O +
as O +
11 O +
and O +
12 O +
were O +
more O +
potent O +
than O +
those O +
of O +
dihydroisocoumarins O -
, O +
with O +
IC50 O +
values O +
of O +
22 O +
and O +
76 O +
μM O -
, O +
respectively O -
. O +

The O +
inhibitory O +
activity O +
of O +
a O +
benzilidenephthalide O -
, O +
17 O +
, O +
was O +
most O +
potent O +
among O +
the O +
examined O +
compounds O -
, O +
and O +
its O +
IC50 O +
value O +
was O +
9.8 O +
μM. O +
Other O +
than O +
hydrangenol O +
( O -
3 O +
) O -
, O +
7 O +
, O +
8 O +
, O +
25 O +
and O +
lunurarin O +
( O -
26 O +
) O -
, O +
many O +
dihydroisocoumarins O +
and O +
stilbenes O +
lacked O +
the O +
activity O -
. O +

A O +
reference O +
drug O -
, O +
DSCG O -
, O +
suppressed O +
the O +
histamine O +
release O +
at O +
high O +
concentration O +
( O -
37.7 O -
% O +
inhibition O +
at O +
1000 O +
μM O -
) O -
. O +

The O +
calcium O +
ionophore O +
A23187 O +
changes O +
cell O +
membrane O +
permeability O +
and O +
induces O +
transport O +
of O +
extracellular O +
Ca2 O -
+ O +
into O +
the O +
cells O -
. O +

This O +
dynamic O +
Ca2 O -
+ O +
influx O +
elevates O +
intracellular O +
Ca2 O -
+ O +
level O +
and O +
induces O +
mast O +
cell O +
degranulation. O -
[ O -
9 O -
] O +
The O +
percentage O +
of O +
A23187-induced O +
histamine O +
release O +
was O +
in O +
the O +
range O +
of O +
14.7 O +
to O +
25.9 O -
. O +

Thunberginols O +
A O +
( O -
11 O +
) O -
, O +
B O +
( O -
12 O +
) O -
, O +
C O +
( O -
6 O +
) O +
and O +
F O +
( O -
17 O +
) O +
and O +
lunurarin O +
( O -
26 O +
) O +
inhibited O +
the O +
histamine O +
release O +
and O +
their O +
IC50 O +
values O +
were O +
less O +
than O +
100 O +
μM. O +
Thunberginols O +
A O +
( O -
11 O +
) O +
and O +
F O +
( O -
17 O +
) O +
strongly O +
inhibited O +
this O +
histamine O +
release O +
as O +
well O +
as O +
that O +
induced O +
by O +
compound O +
48 O -
/ O -
80 O +
with O +
IC50 O +
values O +
of O +
9 O +
and O +
20 O +
μM O -
, O +
respectively O -
. O +

On O +
the O +
other O +
hand O -
, O +
an O +
isocoumarin O -
, O +
12 O +
, O +
showed O +
less O +
activity O +
than O +
11 O +
and O +
17 O +
. O +

Phyllodulcin O +
( O -
1 O +
) O -
, O +
dehydrophyllodulcin O +
( O -
14 O +
) O -
, O +
3′-hydoxyhydrangeaic O +
acid O +
( O -
22 O +
) O -
, O +
5-hydroxyhydrangeaic O +
acid O +
( O -
23 O +
) O +
and O +
piceatannol O +
( O -
25 O +
) O +
slightly O +
inhibited O +
the O +
histamine O +
release O -
. O +

DSCG O +
showed O +
only O +
a O +
low O +
level O +
of O +
activity O +
( O -
16.7 O -
% O +
inhibition O +
at O +
1000 O +
μM O -
) O -
. O +

The O +
signal O +
transmission O +
pathway O +
via O +
antigen O -
- O -
antibody B-Gene +
reaction O +
is O +
initiated O +
by O +
IgE B-Gene +
cross O -
- O -
linking O +
by O +
a O +
specific O +
antigen O -
. O +

The O +
aggregation O +
of O +
high O +
affinity O +
IgE B-Gene +
receptors I-Gene +
( O -
FcεRI B-Gene -
) O +
induces O +
phosphorylation O +
of O +
the O +
β B-Gene +
and O +
γ B-Gene +
subunits I-Gene +
of O +
FcεRI B-Gene -
[ O -
10 O -
] O +
followed O +
by O +
activation O +
of O +
tyrosine B-Gene +
kinases I-Gene +
such O +
as O +
Lyn B-Gene +
and O +
Syk. B-Gene -
[ O -
11 O -
, O +
12 O -
] O +
These O +
tyrosine B-Gene +
kinases I-Gene +
phosphorylate O +
phospholipase B-Gene +
Cγ I-Gene +
( O -
PLCγ B-Gene -
) O -
. O -
[ O -
13 O -
] O +
Subsequently O -
, O +
PLCγ B-Gene +
hydrolyzes O +
membrane O +
phospholipids O +
and O +
produces O +
diacyl O +
glycerol O +
( O -
DG O -
) O +
and O +
IP3 O +
. O +

The O +
elevation O +
of O +
IP3 O +
leads O +
to O +
Ca2 O -
+ O +
mobilization O +
from O +
intracellular O +
Ca2 O -
+ O +
storage O +
sites O -
[ O -
14 O -
] O +
followed O +
by O +
an O +
influx O +
of O +
extracellular O +
Ca2 O -
+ O +
. O -
[ O -
15 O -
] O +

The O +
rise O +
in O +
intracellular O +
Ca2 O -
+ O +
level O +
causes O +
mast O +
cell O +
degranulation O +
and O +
production O +
of O +
metabolic O +
arachidonate O +
mediators O -
. O +

The O +
percentage O +
of O +
IgE B-Gene -
- O -
mediated O +
histamine O +
release O +
was O +
in O +
the O +
range O +
of O +
15.0 O +
to O +
32.4 O -
% O -
. O +

Thunberginols O +
A O +
( O -
11 O +
) O -
, O +
B O +
( O -
12 O +
) O -
, O +
C O +
( O -
6 O +
) O -
, O +
E O +
( O -
8 O +
) O -
, O +
F O +
( O -
17 O +
) O -
, O +
and O +
G O +
( O -
9 O +
) O -
, O +
dehydrophyllodulcin O +
( O -
14 O +
) O -
, O +
resveratrol O +
( O -
24 O +
) O +
and O +
piceatannol O +
( O -
25 O +
) O +
showed O +
inhibitory O +
activities O +
at O +
less O +
than O +
100 O +
μM. O +
The O +
inhibitory O +
activity O +
of O +
11 O +
on O +
antigen O -
- O -
induced O +
histamine O +
release O +
was O +
less O +
than O +
those O +
of O +
compound O +
48 O -
/ O -
80 O +
or O +
calcium O +
ionophore O +
A23187 O +
( O -
IC50 O +
value O -
: O +
64 O +
μM O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
12 O +
showed O +
more O +
potent O +
activity O +
than O +
compound O +
48 O -
/ O -
80 O +
or O +
the O +
calcium O +
ionophore O +
A23187 O +
( O -
IC50 O +
value O -
: O +
10 O +
μM O -
) O -
. O +

Thunberginol O +
F O +
( O -
17 O +
) O +
also O +
showed O +
potent O +
activity O +
with O +
an O +
IC50 O +
value O +
of O +
10 O +
μM. O +
Thunberginol O +
D O +
( O -
7 O +
) O -
, O +
hydrangenol O +
( O -
3 O +
) O -
, O +
hydramacrophyllols O +
A O +
and O +
B O +
( O -
19 O +
and O +
20 O +
) O +
and O +
lunurarin O +
( O -
26 O +
) O +
slightly O +
inhibited O +
histamine O +
release O -
. O +

DSCG O +
showed O +
no O +
activity O +
under O +
these O +
conditions O -
. O +

In O +
comparison O +
of O +
the O +
inhibitory O +
effects O +
of O +
active O +
isocoumarins O +
( O -
11 O +
, O +
12 O +
) O +
or O +
their O +
3-dehydro O +
compounds O +
( O -
9 O +
, O +
7 O +
) O +
on O +
histamine O +
release O +
induced O +
by O +
various O +
stimuli O -
, O +
the O +
activities O +
of O +
isocoumarins O +
seemed O +
to O +
be O +
more O +
potent O +
than O +
those O +
of O +
dihydroisocoumarins O -
. O +

The O +
presence O +
of O +
a O +
double O +
bond O +
at O +
the O +
3-position O +
contributes O +
to O +
fixation O +
of O +
the O +
3-phenyl O +
group O +
to O +
the O +
lactone O +
moiety O -
, O +
so O +
that O +
isocoumarins O +
preserve O +
the O +
plane O +
structure O -
. O +

On O +
the O +
other O +
hand O -
, O +
as O +
the O +
3-phenyl O +
group O +
of O +
a O +
dihydroisocoumarin O +
is O +
not O +
fixed O +
to O +
the O +
lactone O +
moiety O -
, O +
its O +
position O +
was O +
suggested O +
to O +
be O +
crooked O +
or O +
rotated O +
relative O +
to O +
the O +
lactone O +
moiety O -
. O +

The O +
plane O +
structure O +
of O +
the O +
isocoumarin O +
was O +
presumed O +
to O +
contribute O +
to O +
the O +
expression O +
and O +
enhancement O +
of O +
the O +
activity O -
. O +

Thunberginol O +
A O +
( O -
11 O +
) O +
more O +
potently O +
inhibited O +
histamine O +
release O +
induced O +
by O +
non O -
- O -
physiological O +
stimulants O +
than O +
by O +
antigen O -
- O -
antibody B-Gene +
reaction O -
. O +

The O +
effect O +
of O +
11 O +
on O +
stimulation O +
by O +
the O +
calcium O +
ionophore O +
A23187 O +
was O +
more O +
potent O +
than O +
on O +
that O +
by O +
compound O +
48 O -
/ O -
80 O -
. O +

In O +
contrast O -
, O +
12 O +
showed O +
more O +
potent O +
activity O +
on O +
histamine O +
release O +
via O +
antigen O -
- O -
antibody B-Gene +
reaction O +
than O +
those O +
mediated O +
by O +
non O -
- O -
physiological O +
stimulants O -
. O +

The O +
effects O +
of O +
12 O +
on O +
stimulation O +
by O +
non O -
- O -
physiological O +
stimulants O +
were O +
similar O -
. O +

These O +
observations O +
suggested O +
that O +
11 O +
mainly O +
inhibits O +
the O +
Ca2 O -
+ O +
increase O +
induced O +
by O +
non O -
- O -
physiological O +
Ca2 O -
+ O +
mobilizers O -
, O +
especially O +
extracellular O +
Ca2 O -
+ O +
influx O -
, O +
and O +
lower O +
pathways O +
leading O +
to O +
histamine O +
release O -
. O +

On O +
the O +
other O +
hand O -
, O +
12 O +
seemed O +
to O +
suppress O +
the O +
intracellular O +
Ca2 O -
+ O +
increase O +
and O +
other O +
signal O +
transduction O +
pathways O +
initiated O +
by O +
antigen O -
- O -
antibody B-Gene +
reaction O +
such O +
as O +
tyrosine O +
phosphorylation O -
. O +

Kimura O +
et O +
al. O +
reported O +
the O +
inhibitory O +
effects O +
of O +
4-acyl O +
isocoumarins O +
such O +
as O +
oosponol O +
( O -
4-hydroxymethylketone-8-hydroxyisocoumarin O -
) O -
, O +
metabolic O +
products O +
isolated O +
from O +
Oospora O +
astringens O +
( O -
air O -
- O -
borne O +
fungi O +
originated O +
from O +
house O +
dust O -
) O -
, O +
on O +
compound O +
48 O -
/ O -
80-induced O +
histamine O +
release. O -
[ O -
16 O -
] O +

They O +
also O +
reported O +
the O +
structure O -
– O -
activity O +
relationships O +
which O +
an O +
acyl O +
group O +
at O +
the O +
4-position O +
was O +
important O +
for O +
inhibition O +
of O +
histamine O +
release O -
. O +

From O +
the O +
results O +
of O +
our O +
investigation O +
of O +
isocoumarins O +
and O +
dihydroisocoumarins O -
, O +
the O +
8-hydroxyl O +
group O +
appears O +
to O +
be O +
essential O +
for O +
the O +
activity O -
. O +

That O +
is O -
, O +
hydrangenol O +
( O -
3 O +
) O +
and O +
thunberginol O +
A O +
( O -
11 O +
) O +
suppressed O +
histamine O +
release O -
, O +
while O +
hydrangenol O +
8-O O +
-glucoside O +
( O -
4 O +
) O +
and O +
8-deoxythunberginol O +
A O +
( O -
13 O +
) O +
lacked O +
activity O -
. O +

The O +
reason O +
why O +
the O +
hydroxyl O +
group O +
at O +
the O +
8-position O +
is O +
essential O +
for O +
the O +
activity O +
is O +
unclear O -
. O +

However O -
, O +
it O +
may O +
be O +
important O +
for O +
the O +
proton O +
of O +
the O +
8-hydroxyl O +
group O +
to O +
form O +
a O +
hydrogen O +
bond O +
to O +
an O +
adjacent O +
carbonyl O +
group O +
at O +
the O +
1-position O -
. O +

The O +
4′-hydroxyl O +
group O +
seemed O +
to O +
be O +
essential O +
because O +
3 O +
showed O +
inhibitory O +
activity O -
, O +
while O +
( O -
− O -
) O -
-hydrangenol O +
4′-O O +
-glucoside O +
( O -
5 O +
) O +
and O +
hydrangenol O +
monomethyl O +
ether O +
( O -
10 O +
) O +
did O +
not O -
. O +

Comparison O +
of O +
phyllodulcin O +
( O -
1 O +
) O -
, O +
thunberginol O +
E O +
( O -
8 O +
) O +
and O +
10 O +
indicated O +
that O +
the O +
3′-hydroxyl O +
group O +
recovered O +
the O +
activity O +
of O +
the O +
inactive O +
compound O +
with O +
the O +
4′-methoxyl O +
group O -
. O +

Moreover O -
, O +
the O +
profile O +
of O +
the O +
activity O +
of O +
dehydrophyllodulcin O +
( O -
14 O +
) O +
was O +
subtly O +
different O +
from O +
that O +
of O +
thunberginol O +
A O +
( O -
11 O +
) O -
. O +

The O +
mechanisms O +
of O +
action O +
of O +
these O +
compounds O +
may O +
be O +
different O -
. O +

The O +
3′-hydroxyl O +
group O +
in O +
3-phenyl O +
isocoumarins O +
with O +
the O +
8-hydroxyl O +
group O +
seemed O +
to O +
be O +
essential O -
, O +
because O +
11 O +
suppressed O +
histamine O +
release O -
, O +
while O +
3′-deoxythunberginol O +
A O +
( O -
15 O +
) O +
did O +
not O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
6-hydroxyl O +
group O +
did O +
not O +
seem O +
to O +
be O +
important O +
for O +
the O +
activity O +
based O +
on O +
comparison O +
between O +
1 O +
and O +
8 O +
, O +
3 O +
and O +
6 O +
, O +
7 O +
and O +
9 O +
, O +
and O +
11 O +
and O +
12 O +
. O +

However O -
, O +
as O +
the O +
profile O +
of O +
the O +
activity O +
of O +
11 O +
on O +
various O +
types O +
of O +
histamine O +
release O +
reactions O +
was O +
different O +
from O +
that O +
of O +
12 O +
, O +
the O +
presence O +
of O +
the O +
6-hydroxyl O +
group O +
may O +
contribute O +
slightly O +
to O +
inhibition O +
of O +
signal O +
transmission O +
on O +
different O +
types O +
of O +
histamine O +
release O -
. O +

From O +
the O +
results O +
of O +
inhibitory O +
activities O +
of O +
phthalides O -
, O +
only O +
thunberginol O +
F O +
( O -
17 O +
) O -
, O +
which O +
conforms O +
to O +
the O +
plane O +
structure O +
due O +
to O +
the O +
presence O +
of O +
a O +
double O +
bond O +
at O +
the O +
3-position O -
, O +
potently O +
inhibited O +
histamine O +
release O -
. O +

The O +
activities O +
of O +
hydramacrophyllols O +
( O -
19 O +
, O +
20 O +
) O -
, O +
in O +
which O +
the O +
8-phenyl O +
groups O +
do O +
not O +
conform O +
to O +
the O +
plane O +
structure O +
against O +
phthalides O +
rings O -
, O +
showed O +
less O +
activity O -
. O +

3′-Deoxythunberginol O +
F O +
( O -
18 O +
) O +
lacking O +
the O +
3′-hydroxyl O +
group O +
showed O +
no O +
activity O -
. O +

These O +
results O +
suggested O +
that O +
the O +
plane O +
structure O +
and O +
the O +
3′-hydroxyl O +
group O +
are O +
essential O +
for O +
the O +
activity O +
similarly O +
to O +
the O +
case O +
of O +
isocoumarins O -
. O +

In O +
the O +
case O +
of O +
stilbenes O -
, O +
piceatannol O +
( O -
25 O +
) O +
potently O +
inhibited O +
the O +
histamine O +
release O +
induced O +
by O +
antigen O -
– O -
antibody B-Gene +
reaction O -
. O +

Tsuruga O +
et O +
al. O +
reported O +
that O +
25 O +
inhibited O +
histamine O +
release O +
from O +
rat O +
peritoneal O +
mast O +
cells O +
induced O +
by O +
compound O +
48 O -
/ O -
80 O +
and O +
concanavalin O +
A. O -
[ O -
17 O -
] O +
Our O +
observations O +
for O +
25 O +
using O +
antigen O -
– O -
antibody B-Gene +
reaction O +
agreed O +
with O +
this O +
report O -
, O +
although O +
the O +
structure O -
– O -
activity O +
relationships O +
were O +
not O +
clarified O -
. O +

The O +
time O +
courses O +
of O +
the O +
effects O +
of O +
the O +
active O +
compounds O -
, O +
thunberginols O +
A O +
( O -
11 O +
) O -
, O +
B O +
( O -
12 O +
) O +
and O +
F O +
( O -
17 O +
) O -
, O +
and O +
DSCG O +
were O +
examined O +
( O -
Table O +
5 O +
) O -
. O +

Thunberginols O +
A O +
( O -
11 O +
) O -
, O +
B O +
( O -
12 O +
) O +
and O +
F O +
( O -
17 O +
) O +
potently O +
inhibited O +
the O +
histamine O +
release O +
by O +
1- O +
to O +
15-min O +
pretreatment O +
at O +
the O +
concentration O +
of O +
100 O +
μM. O +
DSCG O +
showed O +
an O +
inhibitory O +
effect O +
after O +
only O +
1-min O +
pretreatment O +
at O +
the O +
concentration O +
of O +
1000 O +
μM O -
, O +
and O +
no O +
inhibitory O +
effects O +
were O +
observed O +
following O +
by O +
5- O +
or O +
15-min O +
pretreatment O -
. O +

These O +
results O +
suggested O +
that O +
the O +
inhibitory O +
mechanism O +
of O +
thunberginols O +
is O +
different O +
from O +
that O +
of O +
DSCG O -
. O +

3 O +
Conclusion O +

The O +
structural O +
requirements O +
of O +
constituents O +
of O +
Hydrangeae O +
Dulcis O +
Folium O +
and O +
related O +
compounds O +
for O +
inhibitory O +
activity O +
on O +
mast O +
cell O +
degranulation O +
were O +
clarified O +
as O +
follows O -
. O +

The O +
activities O +
of O +
isocoumarins O +
such O +
as O +
thunberginols O +
A O +
( O -
11 O +
) O +
and O +
B O +
( O -
12 O +
) O +
were O +
more O +
potent O +
than O +
those O +
of O +
dihydroisocoumarins O +
such O +
as O +
hydrangenol O +
( O -
3 O +
) O +
or O +
thunberginol O +
G O +
( O -
9 O +
) O -
. O +

The O +
double O +
bond O +
at O +
the O +
3-position O +
seemed O +
to O +
be O +
essential O +
for O +
the O +
activity O -
. O +

The O +
hydroxyl O +
groups O +
at O +
the O +
8- O -
, O +
3′- O +
and O +
4′- O +
positions O +
of O +
isocoumarin O +
were O +
essential O +
for O +
the O +
activity O -
, O +
while O +
the O +
hydroxyl O +
group O +
at O +
the O +
6-position O +
was O +
scarcely O +
needed O -
. O +

Since O +
the O +
activity O +
of O +
a O +
benzylidenephthalide O -
, O +
thunberginol O +
F O +
( O -
17 O +
) O -
, O +
was O +
more O +
potent O +
than O +
those O +
of O +
hydramacrophyllols O +
( O -
19 O +
, O +
20 O +
) O -
, O +
the O +
existence O +
of O +
a O +
double O +
bond O +
at O +
the O +
3-position O +
appeared O +
to O +
be O +
necessary O +
to O +
increase O +
the O +
activity O -
. O +

Moreover O -
, O +
the O +
hydroxyl O +
group O +
at O +
the O +
8-position O +
was O +
essential O +
for O +
the O +
activity O -
. O +

The O +
inhibitory O +
mechanism O +
of O +
thunberginols O +
A O +
( O -
11 O +
) O -
, O +
B O +
( O -
12 O +
) O +
and O +
F O +
( O -
17 O +
) O +
seemed O +
to O +
be O +
different O +
from O +
that O +
of O +
DSCG O -
. O +

4 O +
Experimental O +
4.1 O +
Animals O +
Rats O +
were O +
purchased O +
from O +
Kiwa O +
Laboratory O +
Animals O +
Co. O -
, O +
Ltd. O +
( O -
Wakayama O -
, O +
Japan O -
) O +
and O +
housed O +
in O +
an O +
air O -
- O -
conditioned O +
room O +
at O +
23±2 O -
° O -
C O +
for O +
more O +
than O +
3 O +
days O -
. O +

Standard O +
laboratory O +
chow O +
( O -
MF O -
, O +
Oriental O +
Yeast O +
Co. O -
, O +
Ltd. O -
) O +
and O +
tap O +
water O +
were O +
given O +
freely O -
. O +

4.2 O +
Materials O +
Anti O -
- O -
dinitrophenyl O +
( O -
Anti O -
- O -
DNP O -
) O +
IgE B-Gene +
was O +
purchased O +
from O +
Seikagaku O +
Co. O -
, O +
Ltd. O -
, O +
and O +
divided O +
into O +
small O +
volumes O +
and O +
stocked O +
at O +
−20 O -
° O -
C O -
. O +

Dinitrophenylated B-Gene +
bovine I-Gene +
serum I-Gene +
albumin I-Gene +
( O -
DNP B-Gene -
- I-Gene -
BSA I-Gene -
) O +
was O +
prepared O +
from O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
fraction O +
V O +
( O -
Sigma O -
) O +
and O +
sodium O +
dinitrobenzenesulfonate O +
( O -
Tokyo O +
Kasei O +
Organic O +
Chemicals O +
Co. O -
, O +
Ltd. O -
) O +
according O +
to O +
the O +
method O +
of O +
Tada O +
et O +
al. O -
[ O -
18 O -
] O +
Disodium O +
cromoglycate O +
( O -
DSCG O -
) O +
was O +
obtained O +
from O +
Biomol O +
Res O -
. O +

Lab O -
. O +

Inc. O +
The O +
mast O +
cell O +
medium O +
( O -
MCM O -
) O +
consisted O +
of O +
150 O +
mM O +
NaCl O -
, O +
2.7 O +
mM O +
KCl O -
, O +
0.9 O +
mM O +
CaCl2 O +
, O +
5.6 O +
mM O +
glucose O -
, O +
and O +
5 O +
mM O +
HEPES O +
in O +
distilled O +
water O -
, O +
and O +
pH O +
was O +
adjusted O +
to O +
7.4 O +
by O +
addition O +
of O +
3N O +
NaOH O -
. O +

The O +
test O +
samples O +
were O +
isolated O +
or O +
synthesized O +
according O +
to O +
previous O +
reports. O -
[ O -
1–7 O -
] O +
For O +
histamine O +
release O +
test O -
, O +
each O +
compound O +
was O +
diluted O +
in O +
DMSO O +
and O +
dispersed O +
with O +
MCM O -
. O +

The O +
final O +
concentration O +
of O +
DMSO O +
was O +
0.1 O -
% O -
. O +

4.3 O +
Histamine O +
release O +
from O +
rat O +
peritoneal O +
mast O +
cells O +
induced O +
by O +
compound O +
48 O -
/ O -
80 O -
, O +
calcium O +
ionophore O +
A23187 O -
, O +
and O +
antigen O -
– O -
antibody B-Gene +
reaction O +
Histamine O +
release O +
test O +
was O +
performed O +
according O +
to O +
a O +
slight O +
modification O +
of O +
the O +
method O +
reported O +
previously. O -
[ O -
4–7 O -
] O +
4.4 O +
Collection O +
of O +
rat O +
peritoneal O +
exudate O +
cells O +
Male O +
Wistar O +
rats O +
weighing O +
300 O +
to O +
400 O +
g O +
were O +
sacrificed O -
, O +
and O +
10 O +
mL O +
of O +
cooled O +
MCM O +
was O +
injected O +
into O +
the O +
abdominal O +
cavity O -
. O +

After O +
gentle O +
massage O +
of O +
their O +
belly O +
for O +
2 O +
min O -
, O +
the O +
cavity O +
was O +
opened O +
and O +
the O +
exudate O +
fluid O +
was O +
removed O +
to O +
a O +
plastic O +
tube O +
using O +
a O +
plastic O +
pipette O -
. O +

The O +
abdominal O +
cavity O +
was O +
repeatedly O +
washed O +
with O +
10 O +
mL O +
of O +
MCM O -
. O +

The O +
exudate O +
fluid O +
was O +
centrifuged O +
( O -
120 O -
× O -
g O +
, O +
4 O -
° O -
C O -
, O +
10 O +
min O -
) O +
and O +
washed O +
3 O +
times O +
with O +
MCM O -
. O +

The O +
peritoneal O +
exudate O +
cells O +
were O +
suspended O +
in O +
3 O +
mL O +
of O +
MCM O -
. O +

After O +
staining O +
cells O +
with O +
0.5 O -
% O +
toluidine O +
blue O +
in O +
0.1 O -
M O +
citrate O +
buffer O +
( O -
pH O +
4.8 O -
) O -
, O +
the O +
number O +
of O +
mast O +
cells O +
was O +
counted O +
under O +
a O +
microscope O -
. O +

The O +
viability O +
of O +
peritoneal O +
cells O +
was O +
determined O +
by O +
the O +
trypan O +
blue O +
exclusion O +
test O -
. O +

4.5 O +
Purification O +
of O +
rat O +
peritoneal O +
mast O +
cells O +
and O +
histamine O +
releaser O -
- O -
induced O +
histamine O +
release O +
Mast O +
cells O +
were O +
purified O +
from O +
peritoneal O +
exudate O +
cells O +
by O +
the O +
Percoll O +
density O +
gradient O +
separation O +
method. O -
[ O -
19 O -
] O +
Percoll O +
fluid O +
( O -
Pharmacia O -
) O +
and O +
decuple O +
concentrated O +
HAM O +
F-10 O +
medium O +
( O -
Gibco O -
) O +
were O +
mixed O +
at O +
a O +
ratio O +
of O +
9:1 O -
, O +
and O +
7 O +
mL O +
of O +
the O +
fluid O +
was O +
decanted O +
into O +
a O +
polycarbonate O +
centrifuge O +
tube O -
. O +

The O +
tube O +
was O +
centrifuged O +
( O -
17000 O -
× O -
g O +
, O +
4 O -
° O -
C O -
, O +
20 O +
min O -
) O +
using O +
an O +
angle O +
rotor O -
. O +

One O +
mL O +
of O +
peritoneal O +
exudate O +
cells O +
suspension O +
was O +
applied O +
gently O +
on O +
top O +
of O +
the O +
Percoll O +
density O +
gradient O -
, O +
followed O +
by O +
centrifugation O +
( O -
200 O -
× O -
g O +
, O +
4 O -
° O -
C O -
, O +
20 O +
min O -
) O +
in O +
a O +
swing O +
rotor O -
. O +

After O +
removal O +
of O +
the O +
erythrocyte O +
and O +
monocyte O +
layers O +
near O +
the O +
surface O +
of O +
the O +
gradient O +
fluid O -
, O +
the O +
mast O +
cell O +
fraction O +
was O +
collected O -
. O +

The O +
mast O +
cell O +
fraction O +
was O +
washed O +
3 O +
times O +
with O +
MCM O +
( O -
200 O -
× O -
g O +
, O +
4 O -
° O -
C O -
, O +
10 O +
min O -
) O -
, O +
and O +
suspended O +
in O +
3 O +
mL O +
of O +
MCM O -
. O +

The O +
number O +
of O +
mast O +
cells O +
was O +
counted O +
after O +
toluidine O +
blue O +
staining O -
, O +
and O +
the O +
viability O +
of O +
cells O +
was O +
checked O +
by O +
the O +
trypan O +
blue O +
exclusion O +
test O -
. O +

The O +
mast O +
cell O +
suspension O +
( O -
104 O +
cells O -
/ O -
1.8 O +
mL O -
) O +
in O +
a O +
plastic O +
tube O +
was O +
preincubated O +
at O +
37 O -
° O -
C O +
for O +
10 O +
min O -
, O +
and O +
200 O +
μL O +
of O +
the O +
test O +
sample O +
diluted O +
in O +
MCM O +
was O +
added O -
. O +

After O +
incubation O +
for O +
15 O +
min O -
, O +
222 O +
μL O +
of O +
compound O +
48 O -
/ O -
80 O +
( O -
5 O +
μg O -
/ O -
mL O -
) O +
or O +
calcium O +
ionophore O +
A23187 O +
( O -
10 O +
μg O -
/ O -
mL O -
) O +
was O +
added O -
, O +
and O +
incubation O +
was O +
continued O +
for O +
10 O +
min O -
. O +

The O +
plastic O +
tube O +
was O +
cooled O +
in O +
ice O +
water O +
for O +
more O +
than O +
10 O +
min O +
and O +
centrifuged O +
( O -
120 O -
× O -
g O +
) O +
for O +
10 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
released O +
histamine O +
in O +
supernatant O +
was O +
determined O +
by O +
the O +
o O +
-phthaldialdehyde O +
fluorescence O +
method O +
using O +
HPLC. O -
[ O -
20 O -
] O +
4.6 O +
Sensitization O +
of O +
mast O +
cells O +
with O +
anti B-Gene -
- I-Gene -
DNP I-Gene +
IgE B-Gene +
and O +
antigen O -
– O -
antibody B-Gene +
reaction O +
induced O -
- O -
histamine O +
release O +
from O +
mast O +
cells O +
One O +
mL O +
of O +
anti B-Gene -
- I-Gene -
DNP I-Gene +
IgE B-Gene +
( O -
PCA O +
titer O -
: O +
×1000 O -
, O +
diluted O +
in O +
MCM O -
) O +
was O +
added O +
to O +
3 O +
mL O +
of O +
peritoneal O +
exudate O +
cell O +
suspension O +
in O +
a O +
plastic O +
tube O -
, O +
and O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
1 O +
h. O +
After O +
sensitization O -
, O +
the O +
tube O +
was O +
cooled O +
in O +
ice O +
water O -
, O +
and O +
the O +
peritoneal O +
exudate O +
cells O +
were O +
washed O +
3 O +
times O +
with O +
5 O +
mL O +
of O +
MCM O -
. O +

The O +
mast O +
cells O +
in O +
peritoneal O +
exudate O +
cell O +
suspension O +
were O +
adjusted O +
to O +
104 O +
cells O -
/ O -
1.62 O +
mL O -
, O +
and O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
10 O +
min O -
. O +

The O +
test O +
sample O +
diluted O +
with O +
180 O +
μL O +
of O +
MCM O +
was O +
added O +
and O +
incubated O +
for O +
15 O +
min O -
. O +

One- O +
and O +
5-min O +
pretreatments O +
with O +
11 O +
, O +
12 O +
, O +
17 O +
and O +
DSCG O +
were O +
also O +
performed O +
for O +
time O +
course O +
study O -
. O +

Antigen O -
– O -
antibody B-Gene +
reaction O +
was O +
initiated O +
by O +
simultaneous O +
addition O +
of O +
200 O +
μL O +
of O +
phosphatidyl O +
l O +
-serine O +
( O -
1 O +
mg O -
/ O -
mL O -
) O +
and O +
222 O +
μL O +
of O +
DNP B-Gene -
- I-Gene -
BSA I-Gene +
( O -
1 O +
mg O -
/ O -
mL O -
) O -
. O +

After O +
20 O +
min O +
incubation O -
, O +
the O +
tube O +
was O +
cooled O +
in O +
ice O +
water O +
for O +
more O +
than O +
10 O +
min O +
and O +
centrifuged O +
( O -
120 O -
× O -
g O +
) O +
for O +
10 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
released O +
histamine O +
in O +
the O +
supernatant O +
was O +
determined O +
by O +
the O +
method O +
described O +
previously O -
. O +

The O +
inhibition O +
( O -
% O -
) O +
was O +
calculated O +
according O +
to O +
the O +
following O +
equation O -
. O +

Inhibition O +
( O -
% O -
) O -
= O +
1− O -
( O -
Histamine O +
released O +
by O +
reaction−Spontaneously O +
released O +
histamine O +
) O +
( O -
Total O +
histamine O +
in O +
mast O +
cells−Spontaneously O +
released O +
histamine O +
) O +
×100 O +

Ribonucleotide B-Gene +
reductase I-Gene +
( O -
EC B-Gene +
1.17.4.1 I-Gene -
; O +
RR B-Gene -
) O +
plays O +
a O +
central O +
role O +
in O +
the O +
de O +
novo O +
synthesis O +
of O +
deoxyribonucleotides O +
required O +
for O +
DNA O +
replication O +
and O +
repair O +
[ O -
1 O -
, O +
2 O -
] O +
and O +
there O +
is O +
a O +
strong O +
correlation O +
between O +
the O +
activity O +
of O +
the O +
enzyme B-Gene +
and O +
the O +
rate O +
of O +
cellular O +
replication O +
[ O -
3 O -
, O +
4 O -
] O +
. O +

As O +
such O -
, O +
RR B-Gene +
offers O +
a O +
particularly O +
attractive O +
target O +
for O +
neoplastic O +
agents O +
directed O +
against O +
rapidly O +
growing O +
tumors O -
. O +

The O +
mammalian O +
enzyme B-Gene +
is O +
composed O +
of O +
two O +
protein B-Gene +
dimer O +
subunits O -
, O +
referred O +
to O +
as O +
M1 B-Gene +
and O +
M2 B-Gene -
. O +

The O +
catalytic O +
core O +
of O +
the O +
M2 B-Gene +
subunit O +
contains O +
a O +
tyrosyl O +
free O +
radical O +
that O +
is O +
stabilized O +
by O +
a O +
non O -
- O -
heme O +
iron O +
center O +
[ O -
5 O -
] O +
. O +

Both O +
the O +
iron O +
and O +
the O +
tyrosyl O +
group O +
are O +
essential O +
for O +
catalytic O +
activity O -
. O +

A O +
number O +
of O +
compounds O +
have O +
been O +
identified O +
which O +
destabilize O +
the O +
iron O +
center O +
thereby O +
inactivating O +
the O +
enzyme B-Gene -
. O +

Hydroxyurea O +
( O -
HUr O -
) O +
is O +
the O +
only O +
one O +
of O +
these O +
agents O +
that O +
has O +
found O +
clinical O +
utility O -
; O +
however O -
, O +
HUr O +
has O +
a O +
low O +
affinity O +
for O +
the O +
enzyme B-Gene +
[ O -
6 O -
] O +
, O +
a O +
short O +
half O -
- O -
life O +
in O +
man O +
[ O -
7 O -
] O +
and O +
one O +
of O +
the O +
limitations O +
of O +
HUr O +
therapy O +
is O +
the O +
development O +
of O +
resistance O +
which O +
may O +
occur O +
via O +
several O +
different O +
mechanisms O +
involving O +
both O +
quantitative O +
and O +
qualitative O +
changes O +
in O +
RR B-Gene +
( O -
see O +
[ O -
8 O -
] O +
and O +
[ O -
9 O -
] O +
for O +
references O -
) O -
. O +

Inhibitors O +
of O +
RR B-Gene +
which O +
circumvent O +
some O +
of O +
these O +
limitations O +
of O +
HUr O +
could O +
likely O +
contribute O +
to O +
improvements O +
in O +
cancer O +
chemotherapy O +
regimens O -
. O +

The O +
α- O -
( O -
N O -
) O -
-heterocyclic O +
carboxaldehyde O +
thiosemicarbazones O +
( O -
HCTs O -
) O +
represent O +
a O +
class O +
of O +
compounds O +
that O +
are O +
among O +
the O +
most O +
potent O +
known O +
inhibitors O +
of O +
RR B-Gene +
activity O +
identified O +
to O +
date O +
[ O -
10 O -
] O +
. O +

The O +
first O +
observation O +
of O +
anticancer O +
activity O +
of O +
HCTs O +
was O +
made O +
over O +
40 O +
years O +
ago O +
with O +
the O +
demonstration O +
by O +
Brockman O +
and O +
colleagues O +
that O +
pyridine-2-carboxaldehyde O +
thiosemicarbazone O +
was O +
able O +
to O +
prolong O +
the O +
life O +
span O +
of O +
mice O +
bearing O +
the O +
L1210 O +
leukemia O +
[ O -
11 O -
] O +
. O +

Since O +
that O +
time O +
many O +
HCT O +
derivatives O +
have O +
been O +
synthesized O +
with O +
modifications O +
in O +
the O +
heterocyclic O +
ring O +
system O -
, O +
the O +
thiosemicarbazone O +
side O +
chain O -
, O +
as O +
well O +
as O +
with O +
variations O +
in O +
ring O +
substituents O +
( O -
see O +
[ O -
12–14 O -
] O +
for O +
examples O +
and O +
references O -
) O -
. O +

Detailed O +
structure O +
activity O +
relationships O +
were O +
established O +
in O +
several O +
murine O +
tumor O +
systems O +
for O +
these O +
early O +
HCTs O +
( O -
[ O -
15 O -
] O +
and O +
references O +
therein O -
) O +
which O +
ultimately O +
led O +
to O +
clinical O +
trials O +
in O +
humans O +
of O +
5-hydroxy-2-formyl O +
pyridine O +
thiosemicarbazone O +
( O -
5-HP O -
) O -
. O +

These O +
agents O +
strongly O +
complex O +
transition O +
metals O +
such O +
as O +
iron O -
, O +
copper O -
, O +
and O +
zinc O +
and O +
some O +
HCTs O +
have O +
the O +
capacity O +
to O +
remove O +
iron O +
from O +
ferritin B-Gene -
, O +
presumably O +
by O +
chelation O +
[ O -
16 O -
] O +
. O +

It O +
was O +
initially O +
assumed O +
that O +
their O +
ability O +
to O +
chelate O +
iron O -
, O +
which O +
is O +
required O +
for O +
stabilization O +
of O +
the O +
tyrosyl O +
radical O +
in O +
the O +
active O +
site O +
of O +
the O +
M2 B-Gene +
subunit O +
of O +
RR B-Gene -
, O +
was O +
responsible O +
for O +
the O +
inhibitory O +
activity O +
of O +
the O +
enzyme B-Gene -
. O +

Inhibition O +
could O +
occur O +
either O +
by O +
coordination O +
of O +
iron O +
in O +
the O +
metal O +
bound O +
enzyme B-Gene +
or O +
by O +
the O +
prior O +
formation O +
of O +
the O +
iron O -
- O -
HCT O +
chelate O +
which O +
then O +
interacts O +
with O +
the O +
enzyme B-Gene -
. O +

It O +
appears O +
likely O +
that O +
the O +
iron O -
- O -
thiosemicarbazone O +
complex O +
itself O +
is O +
the O +
inhibitory O +
species O +
[ O -
17 O -
] O +
. O +

Regardless O +
of O +
the O +
exact O +
mechanism O -
, O +
it O +
is O +
worth O +
noting O +
that O +
there O +
are O +
several O +
HCTs O +
which O +
are O +
greater O +
than O +
1000-fold O +
more O +
potent O +
than O +
HUr O +
as O +
inhibitors O +
of O +
RR B-Gene -
. O +

Of O +
the O +
many O +
members O +
of O +
this O +
class O +
that O +
have O +
been O +
synthesized O +
and O +
shown O +
to O +
be O +
effective O +
inhibitors O +
of O +
RR B-Gene +
activity O -
, O +
tumor O +
cell O +
growth O +
in O +
culture O -
, O +
and O +
animal O +
tumors O +
in O +
vivo O +
, O +
only O +
5-HP O +
has O +
been O +
evaluated O +
clinically O +
[ O -
18 O -
, O +
19 O -
] O +
. O +

The O +
results O +
of O +
Phase O +
I O +
trials O +
with O +
this O +
agent O +
were O +
not O +
encouraging O +
to O +
a O +
large O +
extent O +
because O +
5-HP O +
has O +
a O +
short O +
half O -
- O -
life O +
in O +
man O -
, O +
being O +
eliminated O +
primarily O +
as O +
the O +
inactive O +
O O +
-glucuronide O +
conjugate O +
[ O -
18 O -
] O +
. O +

Other O +
potentially O +
more O +
active O +
drugs O +
designed O +
to O +
be O +
resistant O +
to O +
O O +
-glucuronidation O +
have O +
recently O +
been O +
synthesized O +
and O +
evaluated O +
as O +
antitumor O +
agents O +
[ O -
20 O -
] O +
. O +

This O +
review O +
focuses O +
on O +
one O +
of O +
the O +
most O +
promising O +
agents O +
to O +
emerge O +
from O +
these O +
efforts O -
, O +
3-aminopyridine O +
carboxaldehyde O +
thiosemicarbazone O +
( O -
3-AP O -
) O -
, O +
which O +
is O +
currently O +
undergoing O +
Phase O +
1 O +
clinical O +
trials O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1.1 O +
Preparation O +
of O +
3-AP O +
3-AP O +
was O +
synthesized O +
by O +
the O +
methodology O +
shown O +
in O +
Fig. O +
1 O +
( O -
adapted O +
from O +
[ O -
20 O -
] O +
) O -
. O +

Oxidation O +
[ O -
21 O -
, O +
22 O -
] O +
of O +
3-nitro-2-picoline O +
( O -
1 O +
) O +
with O +
selenium O +
dioxide O +
in O +
refluxing O +
dioxane O +
gave O +
3-nitropyridine-2-carboxaldehyde O +
( O -
2 O +
) O -
. O +

The O +
nitro O +
group O +
was O +
reduced O +
to O +
the O +
amino O +
function O +
by O +
protecting O +
the O +
aldehyde O +
by O +
conversion O +
to O +
the O +
cyclic O +
ethylene O +
acetal O +
( O -
3 O +
) O -
, O +
which O +
was O +
then O +
reduced O +
by O +
catalytic O +
hydrogenation O +
using O +
Pd O -
/ O -
C O +
as O +
a O +
catalyst O +
to O +
yield O +
the O +
amino O +
acetal O +
( O -
4 O +
) O +
[ O -
23 O -
] O +
. O +

Compound O +
4 O +
was O +
then O +
reacted O +
with O +
thiosemicarbazide O +
in O +
ethanol O +
containing O +
10 O -
% O +
concentrated O +
hydrochloric O +
acid O +
to O +
form O +
3-aminopyridine-2-carboxaldehyde O +
thiosemicarbazone O +
hydrochloride O -
. O +

3-AP O +
( O -
5 O +
) O +
was O +
then O +
liberated O +
by O +
treatment O +
with O +
aqueous O +
sodium O +
bicarbonate O +
solution O -
. O +

2.1.2 O +
Animals O +
C3H O -
× O -
DBA2 O +
( O -
CD2 O +
F1 O +
) O +
mice O +
of O +
8–10 O +
weeks O +
of O +
age O +
were O +
obtained O +
from O +
the O +
National O +
Cancer O +
Institute O -
. O +

With O +
noted O +
exceptions O -
, O +
mice O +
were O +
treated O +
with O +
a O +
fine O +
suspension O +
of O +
3-AP O +
in O +
0.9 O -
% O +
NaCl O +
by O +
i.p O -
. O +

bolus O +
injection O +
( O -
0.01 O +
ml O -
/ O -
g O +
of O +
mouse O +
body O +
weight O -
) O -
. O +

2.1.3 O +
In O +
vivo O +
leukemia O +
studies O +
Female O +
CD2 O +
F1 O +
mice O +
were O +
inoculated O +
on O +
day O +
0 O +
with O +
1 O -
× O -
105 O +
cells O +
of O +
the O +
murine O +
L1210 O +
leukemia O -
. O +

Treatment O +
by O +
i.p O -
. O +

bolus O +
injection O +
was O +
initiated O +
24 O +
hr O +
later O +
and O +
continued O +
for O +
6 O +
consecutive O +
days O -
. O +

Post O +
inoculation O +
life O +
span O +
was O +
monitored O +
for O +
60 O +
days O -
. O +

2.1.4 O +
Growth O +
of O +
murine O +
L1210 O +
leukemia O +
cells O +
in O +
culture O +
L1210 O +
cells O +
were O +
maintained O +
at O +
37 O -
° O -
C O +
in O +
a O +
humidified O +
atmosphere O +
containing O +
5 O -
% O +
CO2 O +
in O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
10 O -
% O +
horse O +
serum O -
. O +

The O +
L1210 O +
cells O +
resistant O +
to O +
HUr O -
, O +
generated O +
and O +
characterized O +
by O +
Carter O +
and O +
Cory O +
[ O -
24 O -
] O +
, O +
were O +
maintained O +
under O +
the O +
same O +
conditions O +
as O +
the O +
parental O +
cells O +
with O +
the O +
addition O +
of O +
0.75 O +
mM O +
HUr O +
to O +
the O +
culture O +
medium O -
. O +

The O +
MTS O -
/ O -
PMS O +
microtiter O +
assay O +
of O +
Cory O +
et O +
al. O +
[ O -
25 O -
] O +
was O +
utilized O +
for O +
assessment O +
of O +
inhibition O +
of O +
L1210 O +
cell O +
growth O -
. O +

2.1.5 O +
Ribonucleotide B-Gene +
reductase I-Gene +
assay O +
The O +
non O -
- O -
heme O +
iron O +
and O +
effector O +
binding O +
subunits O +
of O +
RR B-Gene +
were O +
prepared O +
from O +
Ehrlich O +
ascites O +
tumor O +
cells O +
as O +
described O +
previously O +
[ O -
26 O -
, O +
27 O -
] O +
. O +

CDP B-Gene +
reductase I-Gene +
activity O +
was O +
assayed O +
by O +
the O +
method O +
of O +
Steeper O +
and O +
Steuart O +
[ O -
28 O -
] O +
. O +

The O +
assay O +
mixture O +
contained O +
3.75 O +
nmol O +
[ O -
14 O +
C O -
] O -
CDP O +
( O -
0.03 O +
μCi O -
) O -
, O +
900 O +
nmol O +
dithiothreitol O -
, O +
150 O +
nmol O +
ATP O -
, O +
and O +
aliquots O +
of O +
the O +
non O -
- O -
heme O +
iron O +
and O +
effector O +
binding O +
subunit O +
fractions O +
of O +
RR B-Gene +
in O +
a O +
final O +
vol O +
of O +
0.02 O +
ml O -
. O +

After O +
a O +
30 O +
min O +
incubation O +
at O +
37 O -
° O -
C O -
, O +
the O +
CDP B-Gene +
reductase I-Gene +
reactions O +
were O +
stopped O +
in O +
a O +
boiling O +
water O +
bath O -
. O +

The O +
nucleotides O +
were O +
converted O +
to O +
nucleosides O +
by O +
snake B-Gene +
venom I-Gene +
treatment O +
[ O -
28 O -
] O +
and O +
deoxycytidine O +
was O +
separated O +
from O +
cytidine O +
on O +
a O +
Dowex O +
1-borate O +
ion O -
- O -
exchange O +
column O -
. O +

2.1.6 O +
[ O -
3 O +
H O -
] O -
Thymidine O +
and O +
[ O -
3 O +
H O -
] O -
uridine O +
incorporation O +
The O +
effects O +
of O +
3-AP O +
on O +
RNA O +
and O +
DNA O +
syntheses O +
were O +
determined O +
by O +
measuring O +
the O +
incorporation O +
of O +
radiolabeled O +
uridine O +
and O +
thymidine O +
into O +
the O +
nucleic O +
acids O +
of O +
L1210 O +
cells O +
incubated O +
with O +
various O +
concentrations O +
of O +
the O +
drug O -
. O +

Cells O +
were O +
incubated O +
with O +
either O +
0.1 O +
μM O +
[ O -
3 O +
H O -
] O -
thymidine O +
( O -
0.5 O +
μCi O -
/ O -
ml O -
) O +
or O +
0.01 O +
μM O +
[ O -
3 O +
H O -
] O -
uridine O +
( O -
0.5 O +
μM O -
/ O -
ml O -
) O +
for O +
30 O +
min O +
at O +
37 O -
° O -
C O -
, O +
then O +
washed O +
with O +
ice O -
- O -
cold O +
PBS O -
. O +

The O +
nucleic O +
acids O +
were O +
precipitated O +
with O +
ice O -
- O -
cold O +
10 O -
% O +
trichloroacetic O +
acid O +
( O -
TCA O -
) O +
and O +
collected O +
on O +
Whatman O +
GF O -
/ O -
C O +
filters O -
. O +

The O +
filters O +
were O +
then O +
washed O +
3 O +
times O +
with O +
5 O +
ml O +
of O +
ice O -
- O -
cold O +
10 O -
% O +
TCA O +
followed O +
by O +
2 O +
washes O +
with O +
95 O -
% O +
ethanol O -
, O +
dried O +
and O +
incubated O +
with O +
0.25 O +
ml O +
of O +
4 O +
N O +
HCl O +
at O +
65 O -
° O -
C O +
for O +
1 O +
hr O -
. O +

The O +
samples O +
were O +
then O +
neutralized O +
by O +
addition O +
of O +
0.4 O +
ml O +
of O +
2.5 O +
N O +
NaOH O -
. O +

After O +
addition O +
of O +
5 O +
ml O +
of O +
scintillation O +
fluid O -
, O +
the O +
radioactivity O +
in O +
each O +
sample O +
was O +
quantified O +
by O +
scintillation O +
spectrometry O -
. O +

3 O +
Results O +
and O +
discussion O +
Growth O +
inhibitory O +
activity O +
of O +
3-AP O +
for O +
wildtype O +
and O +
HUr O -
- O -
resistant O +
L1210 O +
leukemia O +
cells O +
in O +
vitro O +
. O +

The O +
effectiveness O +
of O +
3-AP O +
as O +
an O +
inhibitor O +
of O +
the O +
growth O +
of O +
wildtype O +
and O +
HUr O -
- O -
resistant O +
L1210 O +
cells O +
has O +
been O +
determined O -
, O +
and O +
the O +
results O +
are O +
summarized O +
in O +
Table O +
1 O +
. O +

L1210 O +
cells O +
selected O +
for O +
resistance O +
to O +
HUr O +
did O +
not O +
exhibit O +
a O +
corresponding O +
decrease O +
in O +
sensitivity O +
to O +
3-AP O -
. O +

3-AP O +
also O +
exhibited O +
65-fold O +
greater O +
potency O +
than O +
HUr O +
against O +
the O +
parental O +
cells O -
. O +

These O +
properties O +
of O +
3-AP O +
may O +
impact O +
favorably O +
on O +
the O +
clinical O +
outcome O +
of O +
cancer O +
patients O +
requiring O +
inclusion O +
of O +
a O +
RR B-Gene +
inhibitor O +
in O +
their O +
treatment O +
regimen O +
if O +
3-AP O +
is O +
substituted O +
for O +
HUr O -
, O +
considering O +
the O +
likely O +
emergence O +
of O +
HUr O -
- O -
resistant O +
cancer O +
cells O +
and O +
the O +
suboptimal O +
pharmacologic O +
profile O +
of O +
HUr O +
that O +
limit O +
its O +
effectiveness O +
as O +
an O +
antineoplastic O +
agent O -
. O +

3.1.1 O +
In O +
vivo O +
antileukemic O +
activity O +
of O +
3-AP O +
When O +
3-AP O +
was O +
administered O +
twice O +
daily O +
for O +
six O +
consecutive O +
days O +
to O +
mice O +
inoculated O +
i.p O -
. O +

with O +
the O +
L1210 O +
leukemia O -
, O +
significant O +
increases O +
in O +
life O +
span O +
were O +
observed O +
with O +
each O +
dosage O +
employed O +
and O +
long O +
term O +
( O -
60 O +
day O -
) O +
survivors O +
were O +
produced O +
at O +
drug O +
dosage O +
levels O +
that O +
were O +
well O +
tolerated O +
by O +
the O +
hosts O +
( O -
Table O +
2 O +
) O -
. O +

Detailed O +
studies O +
to O +
optimize O +
the O +
treatment O +
regimen O -
/ O -
schedule O +
in O +
this O +
tumor O +
model O +
have O +
not O +
been O +
undertaken O -
. O +

The O +
fact O +
that O +
3-AP O +
as O +
a O +
single O +
agent O +
was O +
active O +
against O +
the O +
L1210 O +
leukemia O +
over O +
a O +
broad O +
range O +
of O +
dosages O +
and O +
was O +
curative O +
for O +
some O +
mice O +
suggests O +
that O +
this O +
agent O +
may O +
well O +
have O +
a O +
wide O +
range O +
of O +
therapeutic O +
utility O +
in O +
the O +
clinical O +
setting O -
. O +

3.1.2 O +
Inhibition O +
of O +
RR B-Gene +
activity O +
by O +
3-AP O +
The O +
reduction O +
of O +
CDP O +
to O +
dCDP O +
by O +
purified O +
RR B-Gene +
from O +
Ehrlich O +
ascites O +
cells O +
was O +
effectively O +
inhibited O +
by O +
3-AP O +
with O +
an O +
IC50 O +
of O +
0.3 O +
μM. O +
Thus O -
, O +
3-AP O +
is O +
1000-fold O +
more O +
potent O +
as O +
an O +
inhibitor O +
of O +
mammalian O +
RR B-Gene +
than O +
has O +
been O +
reported O +
for O +
HUr O +
[ O -
29 O -
] O +
and O +
ranks O +
among O +
the O +
most O +
potent O +
HCTs O -
, O +
with O +
an O +
IC50 O +
value O +
6-fold O +
lower O +
than O +
that O +
of O +
5-HP O -
. O +

3.1.3 O +
Effects O +
of O +
3-AP O +
on O +
nucleic O +
acid O +
synthesis O +
3-AP O +
selectively O +
inhibited O +
the O +
incorporation O +
of O +
radiolabeled O +
thymidine O +
into O +
the O +
acid O -
- O -
insoluble O +
fraction O +
of O +
L1210 O +
cells O +
compared O +
to O +
the O +
incorporation O +
of O +
radiolabeled O +
uridine O +
( O -
Fig. O +
2 O +
) O -
. O +

These O +
results O +
indicate O +
that O +
inhibition O +
of O +
DNA O +
synthesis O +
is O +
the O +
primary O +
action O +
of O +
3-AP O +
on O +
nucleic O +
acid O +
synthesis O -
. O +

3.1.4 O +
Role O +
of O +
iron O +
in O +
the O +
inhibitory O +
activity O +
of O +
3-AP O +
Although O +
interaction O +
with O +
the O +
iron O +
stabilized O +
tyrosyl O +
radical O +
is O +
involved O +
in O +
the O +
action O +
of O +
HUr O +
and O +
most O +
probably O +
in O +
the O +
action O +
of O +
3-AP O +
on O +
RR B-Gene -
, O +
the O +
exact O +
mechanisms O +
are O +
not O +
identical O -
. O +

This O +
is O +
evidenced O +
by O +
the O +
failure O +
of O +
the O +
iron O +
chelator O +
Desferal O +
to O +
augment O +
3-AP O +
induced O +
inhibition O +
of O +
RR B-Gene +
( O -
Table O +
3 O +
) O -
, O +
whereas O +
addition O +
of O +
Desferal O +
to O +
Adenocarcinoma O +
755 O +
cell O +
cultures O +
increased O +
the O +
inhibition O +
of O +
DNA O +
synthesis O +
and O +
growth O +
produced O +
by O +
HUr O +
[ O -
30 O -
] O +
. O +

In O +
fact O -
, O +
the O +
inhibition O +
of O +
RR B-Gene +
by O +
3-AP O +
was O +
almost O +
completely O +
abolished O +
by O +
Desferal O +
( O -
Table O +
3 O +
) O -
. O +

Moreover O -
, O +
the O +
preformed O +
metal O +
chelates O +
of O +
3-AP O +
produced O +
by O +
addition O +
of O +
exogenous O +
iron O -
, O +
copper O -
, O +
or O +
zinc O +
were O +
more O +
potent O +
as O +
inhibitors O +
of O +
CDP B-Gene +
reductase I-Gene +
than O +
3-AP O +
itself O +
and O -
, O +
with O +
the O +
exception O +
of O +
the O +
3-AP O -
- O -
Cu O +
( O -
II O -
) O +
chelate O -
, O +
were O +
more O +
effective O +
than O +
3-AP O +
as O +
inhibitors O +
of O +
the O +
growth O +
of O +
L1210 O +
cells O +
in O +
culture O +
( O -
Table O +
4 O +
) O -
. O +

The O +
Fe O +
( O -
II O -
) O +
and O +
Fe O +
( O -
III O -
) O +
complexes O +
of O +
3-AP O +
were O +
superior O +
to O +
the O +
Cu O +
( O -
II O -
) O +
and O +
Zn O +
( O -
II O -
) O +
chelates O +
in O +
both O +
systems O -
. O +

These O +
findings O +
provide O +
support O +
for O +
the O +
concept O +
that O +
the O +
relevant O +
inhibitory O +
species O +
is O +
the O +
iron O -
- O -
HCT O +
complex O +
rather O +
than O +
the O +
free O +
HCT O -
. O +

Like O +
HUr O -
, O +
the O +
effects O +
of O +
the O +
HCTs O +
on O +
cellular O +
proliferation O +
are O +
more O +
pronounced O +
on O +
cells O +
in O +
the O +
S O -
- O -
phase O +
of O +
the O +
cell O +
cycle O -
. O +

Thus O -
, O +
the O +
most O +
sensitive O +
cancers O +
to O +
the O +
cytotoxic O +
action O +
of O +
3-AP O +
when O +
used O +
alone O +
most O +
likely O +
are O +
those O +
with O +
high O +
growth O +
fractions O -
, O +
such O +
as O +
the O +
acute O +
leukemias O +
or O +
chronic O +
leukemias O +
in O +
blast O +
crisis O -
. O +

To O +
expand O +
the O +
applicability O +
of O +
3-AP O +
to O +
cancers O +
with O +
a O +
low O +
growth O +
fraction O -
, O +
such O +
as O +
occurs O +
with O +
most O +
solid O +
tumors O -
, O +
it O +
may O +
be O +
necessary O +
to O +
use O +
combinations O +
of O +
chemotherapeutic O +
agents O -
, O +
taking O +
advantage O +
of O +
the O +
ability O +
of O +
3-AP O +
to O +
synergize O +
with O +
drugs O +
that O +
damage O +
the O +
DNA O +
( O -
presumably O +
due O +
to O +
the O +
capacity O +
of O +
3-AP O +
to O +
inhibit O +
the O +
repair O +
of O +
lesions O +
in O +
DNA O -
) O -
. O +

Preliminary O +
data O +
from O +
our O +
laboratory O +
indicate O +
that O +
3-AP O +
has O +
the O +
capacity O +
to O +
synergize O +
with O +
1-acetyl-1,2-bis O -
( O -
methylsulfonyl O -
) O -
-2- O -
( O -
2-chloroethyl O -
) O -
hydrazine O +
[ O -
32 O -
] O +
, O +
cis O -
- O -
platin O -
, O +
and O +
etoposide O +
against O +
the O +
L1210 O +
leukemia O +
in O +
mice O -
. O +

These O +
findings O +
suggest O +
that O +
in O +
addition O +
to O +
the O +
activity O +
of O +
3-AP O +
as O +
a O +
single O +
agent O -
, O +
prevention O +
of O +
the O +
repair O +
of O +
DNA O +
lesions O +
by O +
3-AP O +
will O +
result O +
in O +
efficacious O +
drug O +
combinations O +
for O +
the O +
treatment O +
of O +
cancer O -
. O +

Additional O +
information O +
on O +
the O +
timing O +
of O +
the O +
repair O +
of O +
DNA O +
of O +
cancer O +
cells O +
following O +
damage O +
by O +
an O +
agent O +
acting O +
at O +
the O +
level O +
of O +
preformed O +
DNA O +
may O +
be O +
useful O +
in O +
optimizing O +
the O +
schedule O +
of O +
administration O +
of O +
the O +
RR B-Gene +
inhibitor O +
relative O +
to O +
the O +
treatment O +
with O +
a O +
DNA O +
damaging O +
agent O -
. O +

The O +
centrality O +
of O +
RR B-Gene +
in O +
cellular O +
proliferation O +
emphasizes O +
the O +
importance O +
of O +
developing O +
more O +
effective O +
inhibitors O +
in O +
order O +
to O +
exploit O +
any O -
/ O -
all O +
possible O +
needs O +
of O +
the O +
cancer O +
cell O -
. O +

HCTs O -
, O +
such O +
as O +
3-AP O -
, O +
with O +
insensitivity O +
to O +
O O +
-glucuronidation O -
, O +
a O +
major O +
factor O +
in O +
the O +
inactivity O +
as O +
an O +
anticancer O +
agent O +
in O +
humans O +
of O +
5-HP O -
, O +
may O +
prove O +
to O +
have O +
therapeutic O +
efficacy O -
. O +

In O +
preclinical O +
and O +
biochemical O +
studies O -
, O +
3-AP O +
appears O +
to O +
be O +
superior O +
to O +
any O +
of O +
the O +
other O +
HCTs O +
reported O +
to O +
date O +
and O -
, O +
therefore O -
, O +
its O +
consideration O +
as O +
a O +
candidate O +
for O +
clinical O +
trials O +
in O +
the O +
treatment O +
of O +
cancer O +
is O +
warranted O +
and O +
it O +
is O +
currently O +
undergoing O +
a O +
Phase O +
I O +
trial O -
. O +

4 O +
Summary O +
The O +
enzyme B-Gene +
RR B-Gene +
catalyzes O +
the O +
conversion O +
of O +
ribonucleoside O +
diphosphates O +
to O +
their O +
deoxyribonucleotide O +
counterparts O -
. O +

RR B-Gene +
is O +
critical O +
for O +
the O +
generation O +
of O +
the O +
cytosine O -
, O +
adenine O -
, O +
and O +
guanine O +
deoxyribonucleotide O +
5′-triphosphate O +
building O +
blocks O +
of O +
DNA O -
, O +
which O +
are O +
present O +
in O +
cells O +
as O +
exceedingly O +
small O +
intracellular O +
pools O -
. O +

Therefore O -
, O +
interference O +
with O +
the O +
function O +
of O +
RR B-Gene +
might O +
well O +
result O +
in O +
an O +
agent O +
with O +
significant O +
antineoplastic O +
activity O -
, O +
particularly O +
against O +
rapidly O +
proliferating O +
tumor O +
cells O -
. O +

HUr O +
is O +
the O +
only O +
inhibitor O +
of O +
RR O +
in O +
clinical O +
usage O -
; O +
this O +
agent O -
, O +
however O -
, O +
is O +
a O +
relatively O +
poor O +
inhibitor O +
of O +
the O +
enzyme B-Gene +
and O +
has O +
a O +
short O +
serum O +
half O -
- O -
life O -
. O +

Consequently O -
, O +
HUr O +
is O +
a O +
relatively O +
weak O +
anticancer O +
agent O -
. O +

In O +
an O +
effort O +
to O +
develop O +
a O +
more O +
potent O +
inhibitor O +
of O +
RR B-Gene +
with O +
utility O +
as O +
an O +
anticancer O +
agent O -
, O +
we O +
have O +
synthesized O +
3-AP O +
and O +
demonstrated O +
( O -
a O -
) O +
potent O +
inhibition O +
of O +
L1210 O +
leukemia O +
cells O +
in O +
vitro O +
, O +
( O -
b O -
) O +
curative O +
capacity O +
for O +
mice O +
bearing O +
the O +
L1210 O +
leukemia O -
, O +
( O -
c O -
) O +
marked O +
inhibition O +
of O +
RR B-Gene -
, O +
and O +
( O -
d O -
) O +
sensitivity O +
of O +
HUr O -
- O -
resistant O +
cells O +
to O +
3-AP O -
. O +

These O +
findings O +
collectively O +
demonstrate O +
the O +
clinical O +
potential O +
of O +
3-AP O +
as O +
an O +
antineoplastic O +
agent O -
. O +

Acknowledgements O +
This O +
research O +
was O +
supported O +
by O +
U.S. O +
Public O +
Health O +
Service O +
Grants O +
CA-53340 O +
( O -
ACS O -
) O +
and O +
CA-55540 O +
( O -
JGC O -
) O +
from O +
the O +
National O +
Cancer O +
Institute O -
. O +

RAF O +
is O +
a O +
Special O +
Fellow O +
of O +
the O +
Leukemia O +
Society O +
of O +
America O -
. O +

There O +
has O +
been O +
apparent O +
controversy O +
as O +
to O +
the O +
roles O +
nitric O +
oxide O +
( O -
NO O -
) O +
has O +
in O +
different O +
physiological O +
and O +
pathophysiological O +
mechanisms O +
at O +
the O +
molecular O +
level O -
. O +

Some O +
studies O +
show O +
that O +
NO O +
has O +
cytotoxic O +
properties O +
whereas O +
other O +
reports O +
demonstrate O +
that O +
NO O +
prevents O +
or O +
ameliorates O +
injurious O +
conditions O -
; O +
this O +
apparent O +
controversy O +
seems O +
to O +
be O +
due O +
to O +
the O +
fact O +
that O +
both O +
the O +
chemical O +
biology O +
of O +
NO O +
as O +
well O +
as O +
its O +
transducing O +
pathways O +
are O +
not O +
only O +
adopted O +
to O +
cytotoxicity O +
but O +
they O +
also O +
refer O +
to O +
cell O +
protection O +
( O -
for O +
review O -
, O +
see O +
Brune O +
et O +
al. O -
, O +
1998 O -
; O +
Wink O +
and O +
Mitchell O -
, O +
1998 O +
) O -
. O +

NO O +
is O +
a O +
widespread O +
signalling O +
molecule O +
involved O +
in O +
the O +
regulation O +
of O +
multiple O +
cellular O +
functions O +
( O -
for O +
a O +
review O -
, O +
see O +
Moncada O +
et O +
al. O -
, O +
1991 O +
) O -
, O +
most O +
of O +
which O +
are O +
exerted O +
by O +
increasing O +
cyclic O +
GMP O +
concentrations O +
via O +
activation O +
of O +
soluble O +
guanylate B-Gene +
cyclase I-Gene +
( O -
SGC B-Gene -
) O +
( O -
for O +
review O +
see O +
Ignarro O -
, O +
1990 O -
; O +
McDonald O +
and O +
Murad O -
, O +
1996 O +
) O -
, O +
although O +
direct O +
actions O +
of O +
the O +
NO O +
molecule O +
have O +
also O +
been O +
reported O -
. O +

In O +
the O +
case O +
of O +
oxidative O +
damage O -
, O +
NO O +
has O +
been O +
proposed O +
to O +
exert O +
direct O +
neuroprotective O +
actions O +
as O +
an O +
anti O -
- O -
oxidant O +
( O -
Wink O +
et O +
al. O -
, O +
1993 O -
; O +
Rauhala O +
et O +
al. O -
, O +
1996 O -
, O +
1998 O +
) O -
. O +

Interestingly O -
, O +
it O +
has O +
been O +
shown O +
that O +
cyclic O +
GMP O +
may O +
also O +
have O +
neuroprotective O +
actions O +
( O -
Weill O +
and O +
Greene O -
, O +
1984 O -
; O +
Garthwaite O +
and O +
Garthwaite O -
, O +
1988 O -
; O +
Barger O +
et O +
al. O -
, O +
1995 O -
; O +
Furukawa O +
et O +
al. O -
, O +
1996 O -
; O +
Barger O +
and O +
Mattson O -
, O +
1996 O -
; O +
Thippeswamy O +
and O +
Morris O -
, O +
1997 O -
; O +
Pantazis O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

In O +
this O +
context O -
, O +
we O +
have O +
recently O +
shown O +
that O +
superoxide B-Gene +
dismutase I-Gene +
( O -
SOD B-Gene -
) O +
potentiates O +
cell O +
death O +
caused O +
by O +
the O +
generator O +
of O +
NO O +
and O +
O2 O +
− O +
SIN-1 O -
, O +
an O +
effect O +
that O +
was O +
enhanced O +
by O +
the O +
NO O +
scavenger O +
HbO2 O +
, O +
abolished O +
by O +
catalase B-Gene +
and O +
accompanied O +
by O +
the O +
formation O +
of O +
H2 O +
O2 O +
, O +
suggesting O +
that O +
this O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
accounts O +
for O +
this O +
enhancing O +
effect O +
( O -
Moro O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Our O +
data O +
also O +
suggest O +
that O +
NO O +
released O +
in O +
these O +
conditions O -
, O +
via O +
cyclic O +
GMP O +
elevation O -
, O +
confers O +
selective O +
cytoprotection O +
against O +
this O +
oxidative O +
component O +
of O +
cell O +
death O -
. O +

In O +
the O +
current O +
report O +
we O +
decided O +
to O +
study O +
the O +
effects O +
of O +
an O +
NO O +
donor O -
, O +
DETA O -
- O -
NONOate O +
on O +
H2 O +
O2 O +
-induced O +
cell O +
death O +
in O +
1-week O -
- O -
old O +
rat O +
cortical O +
neurones O +
in O +
primary O +
culture O -
, O +
in O +
order O +
to O +
investigate O +
the O +
role O +
of O +
NO O +
as O +
a O +
neuroprotective O +
agent O +
in O +
oxidative O +
stress O -
. O +

We O +
have O +
used O +
also O +
used O +
1H O +
- O -
[ O -
1,2,4 O -
] O -
oxadiazolo O -
[ O -
4,3-a O +
] O -
quinoxalin-1-one O +
( O -
ODQ O -
) O -
, O +
as O +
a O +
specific O +
and O +
potent O +
inhibitor O +
of O +
SGC B-Gene +
( O -
Garthwaite O +
et O +
al. O -
, O +
1995 O -
; O +
Moro O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
and O +
8- O -
( O -
4-chlorophenylthio O -
) O -
guanosine-3′,5′-monophosphorothioate O -
, O +
Rp O -
- O -
isomer O +
( O -
Rp-8-pCPT O -
- O -
cGMPS O -
) O -
, O +
as O +
a O +
specific O +
inhibitor O +
of O +
cyclic B-Gene +
GMP I-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinases I-Gene +
( O -
Butt O +
et O +
al. O -
, O +
1994 O -
; O +
Smolenski O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
to O +
determine O +
whether O +
these O +
NO O +
effects O +
are O +
dependent O +
on O +
cyclic O +
GMP O +
and O +
cyclic B-Gene +
GMP I-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinases I-Gene -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Primary O +
culture O +
of O +
rat O +
cortical O +
neurones O +
Primary O +
cultures O +
of O +
cortical O +
cells O +
were O +
prepared O +
as O +
described O +
before O +
( O -
Fernández O -
- O -
Tomé O +
and O +
Segal O -
, O +
1987 O -
; O +
Moro O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

On O +
day O +
4 O -
, O +
the O +
medium O +
was O +
changed O +
to O +
a O +
defined O +
medium O +
( O -
serum O -
- O -
free O -
, O +
chemically O +
defined O +
medium O +
containing O +
30 O +
nM O +
selenite O -
, O +
5 O +
μg O -
/ O -
ml O +
insulin B-Gene +
from O +
bovine O +
pancreas O -
, O +
5 O +
μg O -
/ O -
ml O +
transferrin B-Gene -
, O +
20 O +
nM O +
progesterone O +
and O +
100 O +
μM O +
putrescine O +
in O +
MEM O -
) O -
, O +
which O +
was O +
replaced O +
twice O +
weekly O -
. O +

Studies O +
were O +
performed O +
at O +
in O +
vitro O +
day O +
8 O -
, O +
when O +
the O +
cultures O +
consisted O +
of O +
≥95 O -
% O +
neurones O +
( O -
Moro O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

To O +
expose O +
the O +
cells O +
to O +
the O +
various O +
agents O -
, O +
culture O +
medium O +
was O +
replaced O +
by O +
MEM O +
supplemented O +
with O +
0.6 O -
% O +
glucose O -
, O +
0.029 O -
% O +
glutamine O +
and O +
16 O +
mg O -
/ O -
l O +
gentamicin O -
. O +

2.2 O +
Cell O +
treatments O +
Cortical O +
cells O +
grown O +
in O +
96-multiwell O +
plates O +
( O -
50 O +
000 O +
cells O -
/ O -
well O -
) O +
were O +
treated O +
at O +
in O +
vitro O +
days O +
8–9 O -
. O +

Dilutions O +
of O +
H2 O +
O2 O +
were O +
made O +
fresh O +
from O +
a O +
30 O -
% O +
stock O +
solution O +
( O -
V O -
/ O -
V O -
) O +
into O +
culture O +
medium O +
immediately O +
before O +
each O +
experiment O +
and O +
exposures O +
were O +
performed O +
within O +
5 O +
min O +
after O +
dilution O -
. O +

In O +
the O +
first O +
experiments O -
, O +
cells O +
were O +
incubated O +
with O +
increasing O +
concentrations O +
of O +
hydrogen O +
peroxide O +
( O -
H2 O +
O2 O +
, O +
10–100 O +
μM O -
) O +
for O +
30 O +
min O -
. O +

In O +
a O +
different O +
set O +
of O +
experiments O -
, O +
cells O +
were O +
incubated O +
with O +
the O +
SGC B-Gene +
inhibitor O +
ODQ O +
( O -
1–10 O +
μM O -
) O -
, O +
DMSO O +
( O -
a O +
hydroxyl O +
radical O +
scavenger O -
; O +
0.5 O -
% O -
) O -
, O +
the O +
inhibitor O +
of O +
cyclic B-Gene +
GMP I-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinase I-Gene +
Rp-8-pCPT O -
- O -
cGMPS O +
( O -
100 O +
μM O -
) O +
or O +
vehicle O +
for O +
30 O +
min O -
. O +

After O +
this O +
time O -
, O +
cells O +
were O +
treated O +
with O +
H2 O +
O2 O +
( O -
20–40 O +
μM O -
) O +
plus O +
DETA O -
- O -
NONOate O +
( O -
0.1–30 O +
μM O -
) O +
for O +
30 O +
min O -
. O +

Except O +
for O +
H2 O +
O2 O +
, O +
the O +
other O +
molecules O +
were O +
included O +
both O +
during O +
and O +
after O +
H2 O +
O2 O +
treatment O -
. O +

Finally O -
, O +
in O +
other O +
experiments O -
, O +
cells O +
treated O +
with O +
H2 O +
O2 O +
( O -
20–40 O +
μM O -
, O +
30 O +
min O -
) O +
were O +
incubated O +
with O +
the O +
membrane O -
- O -
permeable O +
analogue O +
of O +
cyclic O +
GMP O +
8-bromoguanosine O +
3′:5′-cyclic O +
monophosphate O +
( O -
8-Br O -
- O -
cyclic O +
GMP O -
, O +
1 O +
mM O -
) O +
and O +
the O +
cyclic B-Gene +
GMP I-Gene +
phosphodiesterase I-Gene +
inhibitor O +
3-isobutyl-1-methylxanthine O +
( O -
IBMX O -
, O +
100 O +
μM O -
) O -
. O +

Cell O +
viability O +
was O +
evaluated O +
6–24 O +
h O +
after O +
the O +
treatment O +
without O +
changing O +
the O +
medium O +
unless O +
indicated O -
. O +

2.3 O +
Viability O +
studies O +
Cell O +
viability O +
was O +
monitored O +
by O +
the O +
colourimetric O +
MTT O +
( O -
3- O -
( O -
4,5-dimethylthiazol-2-yl O -
) O -
-2,5-diphenyl O +
tetrazolium O +
bromide O -
) O +
assay O +
as O +
previously O +
described O +
( O -
Mosmann O -
, O +
1983 O -
; O +
Hansen O +
et O +
al. O -
, O +
1989 O +
) O -
. O +

This O +
method O +
assesses O +
mitochondrial O +
activity O +
by O +
measuring O +
the O +
ability O +
of O +
cortical O +
cultures O +
to O +
reduce O +
MTT O +
to O +
a O +
coloured O +
formazan O -
, O +
using O +
a O +
microplate O +
reader O +
( O -
Molecular O +
Devices O -
) O -
. O +

In O +
all O +
these O +
assays O -
, O +
eight O +
wells O +
were O +
used O +
for O +
each O +
condition O -
, O +
and O +
each O +
experiment O +
was O +
repeated O +
at O +
least O +
three O +
times O -
. O +

In O +
a O +
previous O +
study O -
, O +
we O +
have O +
shown O +
that O +
results O +
from O +
MTT O +
assay O +
in O +
this O +
preparation O +
correlated O +
well O +
with O +
other O +
methods O +
of O +
quantifying O +
cell O +
viability O +
such O +
as O +
morphological O +
cell O +
counting O +
performed O +
by O +
Trypan O +
Blue O +
exclusion O +
( O -
Moro O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Viability O +
of O +
control O +
cultures O +
as O +
assessed O +
with O +
this O +
method O +
was O +
unaffected O +
during O +
the O +
duration O +
of O +
the O +
experiment O -
. O +

2.4 O +
Cyclic O +
GMP O +
concentrations O +
in O +
cortical O +
neurones O +
Cortical O +
neurones O +
grown O +
on O +
24-multiwell O +
plates O +
( O -
0.3 O -
× O -
106 O +
cells O -
/ O -
well O -
) O +
at O +
in O +
vitro O +
day O +
8 O +
were O +
incubated O +
for O +
an O +
additional O +
period O +
of O +
30 O +
min O +
at O +
37 O -
° O -
C O +
in O +
the O +
absence O +
or O +
presence O +
of O +
ODQ O +
( O -
1 O +
μM O -
) O +
in O +
fresh O +
MEM O +
containing O +
IBMX O +
( O -
1 O +
mM O -
) O -
. O +

They O +
were O +
then O +
incubated O -
, O +
either O +
alone O +
or O +
in O +
the O +
presence O +
of O +
H2 O +
O2 O +
( O -
40 O +
μM O -
) O -
±DETA O -
- O -
NONOate O +
( O -
1–3 O +
μM O -
) O +
for O +
30 O +
min O -
. O +

In O +
all O +
cases O -
, O +
the O +
final O +
volume O +
was O +
300 O +
μl O -
. O +

The O +
incubation O +
was O +
stopped O +
by O +
aspiration O +
of O +
the O +
medium O +
and O +
addition O +
of O +
0.5 O +
ml O +
of O +
ice O -
- O -
cold O +
ethanol O -
. O +

The O +
cyclic O +
GMP O +
concentrations O +
were O +
determined O +
by O +
enzyme B-Gene +
immunoassay O +
( O -
EIA O +
cyclic O +
GMP O +
assay O +
kit O -
, O +
Amersham O -
) O +
following O +
manufacturers O +
instructions O +
and O +
absorbance O +
was O +
measured O +
in O +
a O +
Molecular O +
Devices O +
microplate O +
reader O -
. O +

2.5 O +
Reagents O +
ODQ O +
was O +
from O +
Alexis O -
, O +
DETA O -
- O -
NONOate O +
was O +
from O +
Alexis O -
, O +
Rp-8-pCPT O -
- O -
cGMPS O +
was O +
from O +
Biolog O -
, O +
cyclic O +
GMP O +
enzyme B-Gene +
immunoassay O +
was O +
from O +
Amersham O +
and O +
other O +
reagents O +
were O +
from O +
Sigma O -
. O +

2.6 O +
Statistics O +
Results O +
are O +
mean±S.E.M. O +
of O +
at O +
least O +
3 O +
separate O +
experiments O -
. O +

One O -
- O -
way O +
ANOVAs O +
were O +
used O +
to O +
test O +
for O +
significant O +
differences O +
between O +
group O +
means O -
. O +

Post O +
hoc O +
analyses O +
employed O +
Newman O -
– O -
Keuls O +
tests O +
to O +
establish O +
significant O +
differences O -
, O +
corresponding O +
F O +
values O +
are O +
presented O +
in O +
each O +
figure O +
legend O +
and O +
P O +
< O -
0.05 O +
was O +
considered O +
as O +
statistically O +
significant O -
. O +

3 O +
Results O +
3.1 O +
Characterisation O +
of O +
H2 O +
O2 O +
-induced O +
neurotoxicity O +
in O +
primary O +
cortical O +
cultures O +
from O +
rat O +
brain O +
Incubation O +
of O +
cortical O +
neurones O +
with O +
H2 O +
O2 O +
( O -
10–100 O +
μM O -
) O +
resulted O +
in O +
a O +
concentration O -
- O -
dependent O +
neuronal O +
death O -
, O +
which O +
was O +
detectable O +
6 O +
h O +
after O +
the O +
treatment O -
. O +

This O +
toxic O +
effect O +
was O +
maximal O +
after O +
24 O +
h O +
( O -
LC50 O +
= O -
41.8±1.9 O +
μM O -
; O +
Fig. O +
1 O +
) O -
, O +
as O +
cell O +
death O +
caused O +
by O +
100 O +
μM O +
H2 O +
O2 O +
after O +
48 O +
h O +
was O +
not O +
significantly O +
different O +
from O +
that O +
obtained O +
at O +
24 O +
h O +
( O -
data O +
not O +
shown O -
) O -
. O +

Therefore O -
, O +
cell O +
viability O +
studies O +
were O +
performed O +
24 O +
h O +
after O +
the O +
treatment O -
. O +

The O +
neurotoxicity O +
induced O +
by O +
40 O +
μM O +
H2 O +
O2 O +
was O +
reversed O +
in O +
the O +
presence O +
of O +
DMSO O +
( O -
0.5 O -
% O -
; O +
91.1±2.1 O -
% O +
of O +
control O -
, O +
n O +
=3 O -
, O +
P O +
< O -
0.05 O -
) O -
. O +

3.2 O +
Effect O +
of O +
the O +
NO O +
donor O +
DETA O -
- O -
NONOate O +
on O +
H2 O +
O2 O +
-induced O +
neuronal O +
death O +
To O +
study O +
the O +
effects O +
of O +
the O +
NO O +
donor O +
DETA O -
- O -
NONOate O +
on O +
H2 O +
O2 O +
-induced O +
neurotoxicity O -
, O +
the O +
concentrations O +
of O +
H2 O +
O2 O +
used O +
were O +
20 O +
and O +
40 O +
μM. O +
The O +
addition O +
of O +
1–10 O +
μM O +
DETA O -
- O -
NONOate O +
( O -
P O +
< O -
0.01 O -
, O +
n O +
= O -
3–8 O -
; O +
Fig. O +
2 O +
) O -
, O +
but O +
not O +
of O +
lower O +
concentrations O +
( O -
0.3 O +
μM O -
; O +
P O +
> O -
0.05 O -
, O +
n O +
= O -
3–4 O -
; O +
Fig. O +
2 O +
) O +
inhibited O +
H2 O +
O2 O +
-induced O +
neuronal O +
death O -
. O +

These O +
concentrations O +
of O +
DETA O -
- O -
NONOate O +
did O +
not O +
have O +
any O +
effect O +
per O +
se O +
on O +
cell O +
viability O +
( O -
data O +
not O +
shown O -
) O -
. O +

3.3 O +
Reversal O +
by O +
ODQ O +
and O +
Rp-8-pCPT O -
- O -
cGMPS O +
of O +
the O +
neuroprotection O +
caused O +
by O +
DETA O -
- O -
NONOate O +
on O +
H2 O +
O2 O +
-induced O +
neurotoxicity O +
To O +
study O +
the O +
effects O +
of O +
ODQ O +
and O +
Rp-8-pCPT O -
- O -
cGMPS O +
on O +
DETA O -
- O -
NONOate O -
- O -
induced O +
neuroprotective O +
effects O -
, O +
the O +
concentration O +
of O +
H2 O +
O2 O +
used O +
was O +
40 O +
μM. O +
ODQ O +
( O -
1–10 O +
μM O -
) O +
reversed O +
the O +
neuroprotective O +
effect O +
caused O +
by O +
DETA O -
- O -
NONOate O +
( O -
1–10 O +
μM O -
) O +
on O +
H2 O +
O2 O +
-induced O +
neuronal O +
death O +
( O -
P O +
< O -
0.01 O -
, O +
n O +
= O -
3–5 O -
; O +
Fig. O +
3 O +
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
Rp-8-pCPT O -
- O -
cGMPS O +
( O -
100 O +
μM O -
) O +
also O +
reversed O +
the O +
neuroprotective O +
effect O +
induced O +
by O +
10 O +
μM O +
DETA O -
- O -
NONOate O +
on O +
H2 O +
O2 O +
-induced O +
neurotoxicity O +
( O -
n O +
=3 O -
, O +
P O +
< O -
0.05 O -
; O +
Fig. O +
4 O +
) O -
. O +

These O +
concentrations O +
of O +
ODQ O +
or O +
Rp-8-pCPT O -
- O -
cGMPS O +
by O +
themselves O +
did O +
not O +
affect O +
cell O +
viability O +
( O -
data O +
not O +
shown O -
) O -
. O +

3.4 O +
Effect O +
of O +
8-Br O -
- O -
cyclic O +
GMP O +
on O +
H2 O +
O2 O +
-induced O +
neuronal O +
death O +
The O +
decrease O +
in O +
cell O +
viability O +
caused O +
by O +
30 O +
and O +
40 O +
μM O +
H2 O +
O2 O +
was O +
significantly O +
reversed O +
when O +
cells O +
were O +
co O -
- O -
incubated O +
in O +
the O +
presence O +
of O +
8-Br O -
- O -
cyclic O +
GMP O +
( O -
1 O +
mM O -
; O +
Fig. O +
5 O +
; O +
n O +
=3 O -
, O +
P O +
< O -
0.05 O -
) O -
. O +

This O +
compound O +
did O +
not O +
affect O +
per O +
se O +
cell O +
viability O +
( O -
data O +
not O +
shown O -
) O -
. O +

3.5 O +
Effect O +
of O +
ODQ O +
and O +
H2 O +
O2 O +
on O +
DETA O -
- O -
NONOate O -
- O -
induced O +
increase O +
in O +
cyclic O +
GMP O +
The O +
basal O +
cyclic O +
GMP O +
concentration O +
of O +
cortical O +
neurones O +
( O -
0.3±0.1 O +
pmol O -
/ O -
0.3 O -
× O -
106 O +
cells O -
, O +
n O +
= O -
6 O -
) O +
was O +
significantly O +
inhibited O +
by O +
ODQ O +
( O -
1 O +
μM O -
, O +
not O +
detectable O -
, O +
n O +
=3 O -
, O +
P O +
< O -
0.05 O -
) O -
. O +

Incubation O +
of O +
cortical O +
cells O +
for O +
30 O +
min O +
with O +
1 O +
and O +
3 O +
μM O +
DETA O -
- O -
NONOate O +
increased O +
the O +
cyclic O +
GMP O +
concentration O +
to O +
2.3±0.4 O +
and O +
to O +
2.5±0.5 O +
pmol O -
/ O -
0.3 O -
× O -
106 O +
cells O -
, O +
respectively O +
( O -
n O +
=3 O -
, O +
Fig. O +
6 O +
) O -
. O +

This O +
increase O +
was O +
inhibited O +
by O +
ODQ O +
( O -
1 O +
μM O -
, O +
n O +
=3 O -
, O +
Fig. O +
6 O +
) O -
. O +

In O +
addition O -
, O +
H2 O +
O2 O +
( O -
40 O +
μM O -
) O +
did O +
not O +
significantly O +
affect O +
either O +
basal O +
or O +
stimulated O +
cyclic O +
GMP O +
levels O +
( O -
n O +
=3 O -
, O +
P O +
> O -
0.05 O -
, O +
Fig. O +
6 O +
) O -
. O +

4 O +
Discussion O +
Our O +
results O +
show O +
that O +
H2 O +
O2 O +
causes O +
neurotoxicity O +
in O +
1-week O -
- O -
old O +
rat O +
cortical O +
neurones O +
in O +
primary O +
culture O +
and O +
that O +
the O +
NO O +
donor O +
DETA O -
- O -
NONOate O +
at O +
concentrations O +
in O +
the O +
low O +
micromolar O +
range O +
inhibits O +
this O +
effect O -
. O +

This O +
effect O +
of O +
DETA O -
- O -
NONOate O +
is O +
mimicked O +
by O +
the O +
cyclic O +
GMP O +
analogue O +
8-Br O -
- O -
cyclic O +
GMP O +
and O +
reversed O +
by O +
the O +
selective O +
inhibitor O +
of O +
SGC B-Gene +
ODQ O +
and O +
the O +
specific O +
inhibitor O +
of O +
the O +
cyclic B-Gene +
GMP I-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinase I-Gene +
inhibitor O +
Rp-8-pCPT O -
- O -
cGMPS O -
. O +

This O +
action O +
of O +
ODQ O +
is O +
parallel O +
to O +
the O +
inhibition O +
of O +
the O +
DETA O -
- O -
NONOate O -
- O -
induced O +
increase O +
in O +
cyclic O +
GMP O +
concentrations O +
and O +
is O +
reversed O +
in O +
the O +
presence O +
of O +
8-Br O -
- O -
cyclic O +
GMP O -
, O +
which O +
mimics O +
the O +
actions O +
of O +
cyclic O +
GMP O -
. O +

H2 O +
O2 O +
caused O +
a O +
concentration O -
- O -
dependent O +
neurotoxicity O +
on O +
rat O +
cortical O +
neurones O -
, O +
which O +
was O +
maximal O +
1 O +
day O +
after O +
a O +
30-min O +
period O +
treatment O -
. O +

This O +
effect O +
was O +
reversed O +
in O +
the O +
presence O +
of O +
DMSO O -
, O +
suggesting O +
that O +
hydroxyl O +
radical O +
formation O +
is O +
involved O +
in O +
H2 O +
O2 O +
-induced O +
neurotoxicity O -
. O +

The O +
NO O +
donor O +
DETA O -
- O -
NONOate O +
causes O +
neuroprotection O +
from O +
H2 O +
O2 O +
( O -
20 O +
and O +
40 O +
μM O -
) O -
-induced O +
toxicity O +
which O +
is O +
maximal O +
at O +
1–3 O +
μM. O +
Direct O +
antioxidant O +
effects O +
of O +
the O +
NO O +
molecule O +
might O +
account O +
for O +
this O +
neuroprotective O +
effect O -
, O +
as O +
it O +
has O +
been O +
shown O +
previously O +
with O +
neurotoxicity O +
induced O +
by O +
different O +
agents O +
in O +
which O +
the O +
hydroxyl O +
radical O +
is O +
involved O +
( O -
Wink O +
et O +
al. O -
, O +
1993 O -
; O +
Rauhala O +
et O +
al. O -
, O +
1996 O -
, O +
1998 O -
; O +
Mohanakumar O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

However O -
, O +
we O +
have O +
shown O +
that O +
inhibition O +
of O +
SGC B-Gene +
with O +
ODQ O +
reverses O +
DETA O -
- O -
NONOate O +
protective O +
effects O +
on O +
H2 O +
O2 O +
-induced O +
cell O +
death O +
suggesting O +
that O +
NO O -
- O -
induced O +
cyclic O +
GMP O +
elevation O +
plays O +
a O +
protective O +
role O +
against O +
the O +
mechanism O +
causing O +
cell O +
death O +
in O +
these O +
conditions O -
. O +

This O +
was O +
corroborated O +
by O -
: O +
( O -
1 O -
) O +
the O +
data O +
showing O +
that O +
ODQ O +
inhibits O +
the O +
increases O +
in O +
cyclic O +
GMP O +
induced O +
by O +
DETA O -
- O -
NONOate O +
in O +
cortical O +
neurones O +
in O +
primary O +
culture O -
; O +
and O +
( O -
2 O -
) O +
the O +
experiments O +
in O +
which O +
8-Br O -
- O -
cyclic O +
GMP O -
, O +
a O +
membrane O -
- O -
permeant O +
cyclic O +
GMP O +
analogue O -
, O +
significantly O +
inhibits O +
H2 O +
O2 O +
-induced O +
neurotoxicity O -
. O +

It O +
has O +
been O +
suggested O +
that O +
part O +
of O +
the O +
neuronal O +
death O +
caused O +
by O +
H2 O +
O2 O +
may O +
be O +
associated O +
with O +
increases O +
in O +
intracellular O +
free O +
calcium O +
( O -
Whittemore O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

This O +
is O +
consistent O +
with O +
our O +
finding O +
showing O +
reversal O +
of O +
DETA O -
- O -
NONOate O -
- O -
induced O +
neuroprotective O +
effects O +
by O +
ODQ O -
, O +
since O +
a O +
general O +
functional O +
theme O +
for O +
cyclic O +
GMP O +
action O +
through O +
cyclic O +
GMP B-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinase I-Gene +
is O +
a O +
lowering O +
of O +
intracellular O +
calcium O +
concentration O +
( O -
for O +
a O +
review O -
, O +
see O +
Wang O +
and O +
Robinson O -
, O +
1997 O +
) O -
. O +

Supporting O +
this O +
theory O -
, O +
our O +
data O +
show O +
that O +
the O +
reversal O +
by O +
ODQ O +
of O +
DETA O -
- O -
NONOate O -
- O -
induced O +
inhibition O +
of O +
the O +
toxicity O +
caused O +
by O +
H2 O +
O2 O +
is O +
similar O +
to O +
that O +
achieved O +
after O +
incubation O +
of O +
the O +
cells O +
with O +
Rp-8-pCPT O -
- O -
cGMPS O -
, O +
an O +
inhibitor O +
of O +
cyclic B-Gene +
GMP I-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinase I-Gene -
, O +
suggesting O +
that O +
the O +
pathway O +
affording O +
protection O +
involves O +
activation O +
of O +
this O +
kinase B-Gene -
. O +

This O +
is O +
in O +
agreement O +
with O +
previous O +
studies O +
providing O +
evidence O +
that O +
activation O +
of O +
cyclic O +
GMP O +
or O +
cyclic O +
GMP O +
analogues O +
can O +
protect O +
neurones O +
against O +
metabolic O -
, O +
excitotoxic O +
and O +
oxidative O +
injury O +
via O +
a O +
decrease O +
in O +
intraneuronal O +
Ca2 O -
+ O +
concentration O +
caused O +
by O +
activation O +
of O +
K+ B-Gene +
channels I-Gene -
, O +
which O +
is O +
mediated O +
by O +
a O +
cyclic B-Gene +
GMP I-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinase I-Gene +
( O -
Barger O +
et O +
al. O -
, O +
1995 O -
; O +
Furukawa O +
et O +
al. O -
, O +
1996 O -
; O +
Barger O +
and O +
Mattson O -
, O +
1996 O +
) O -
. O +

In O +
this O +
context O -
, O +
it O +
has O +
also O +
been O +
shown O +
that O +
the O +
neuroprotective O +
effect O +
of O +
somatostatin O +
on O +
NMDA O -
- O -
induced O +
neuronal O +
death O +
is O +
also O +
mediated O +
by O +
cyclic B-Gene +
GMP I-Gene -
- I-Gene -
dependent I-Gene +
protein I-Gene +
kinase I-Gene -
, I-Gene +
presumably O +
by O +
regulation O +
of O +
the O +
intracellular O +
calcium O +
level O +
( O -
Forloni O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Higher O +
concentrations O +
of O +
DETA O -
- O -
NONOate O +
did O +
not O +
afford O +
any O +
further O +
protection O +
in O +
our O +
preparation O -
; O +
some O +
authors O +
have O +
suggested O +
that O +
the O +
hydroxyl O +
radical O +
results O +
from O +
the O +
interaction O +
between O +
NO O +
and O +
H2 O +
O2 O +
( O -
Nappi O +
and O +
Vass O -
, O +
1998 O +
) O -
, O +
and O +
this O +
might O +
counteract O +
the O +
neuroprotective O +
effects O +
that O +
we O +
have O +
observed O +
at O +
lower O +
concentrations O -
. O +

The O +
activation O +
of O +
SGC B-Gene +
is O +
accepted O +
to O +
be O +
the O +
main O +
target O +
for O +
NO O +
actions O +
( O -
Ignarro O -
, O +
1990 O -
; O +
McDonald O +
and O +
Murad O -
, O +
1996 O +
) O +
and O +
NO O +
released O +
from O +
DETA O -
- O -
NONOate O +
is O +
likely O +
to O +
be O +
responsible O +
for O +
cyclic O +
GMP O +
elevations O -
. O +

In O +
addition O -
, O +
H2 O +
O2 O +
could O +
be O +
another O +
candidate O +
as O +
it O +
has O +
been O +
shown O +
that O +
this O +
molecule O +
is O +
able O +
to O +
cause O +
activation O +
of O +
SGC B-Gene +
and O +
accumulation O +
of O +
cyclic O +
GMP O +
( O -
Burke O -
- O -
Wolin O +
et O +
al. O -
, O +
1991 O +
) O -
. O +

However O -
, O +
H2 O +
O2 O +
did O +
not O +
cause O +
any O +
change O +
in O +
cyclic O +
GMP O +
levels O +
in O +
our O +
system O -
. O +

In O +
summary O -
, O +
our O +
data O +
show O +
that O +
H2 O +
O2 O +
causes O +
neurotoxicity O +
and O +
that O +
NO O -
- O -
induced O +
cyclic O +
GMP O +
elevations O +
exert O +
a O +
neuroprotective O +
role O +
against O +
this O +
damage O +
in O +
primary O +
cultures O +
of O +
rat O +
cortical O +
neurones O -
. O +

In O +
addition O -
, O +
pharmacological O +
manipulation O +
of O +
the O +
NO O -
: O -
cyclic O +
GMP O +
pathway O +
may O +
provide O +
a O +
therapy O +
for O +
neurodegenerative O +
diseases O +
in O +
which O +
oxidative O +
stress O +
is O +
implicated O -
, O +
such O +
as O +
Alzheimer O -
's O +
and O +
Parkinson O +
diseases O -
, O +
amyothrophic O +
lateral O +
sclerosis O +
and O +
disorders O +
which O +
include O +
ischaemia O +
and O +
excitotoxicity O +
( O -
Coyle O +
and O +
Puttfarcken O -
, O +
1993 O -
; O +
Gutteridge O -
, O +
1994 O -
; O +
Bowling O +
and O +
Beal O -
, O +
1995 O +
) O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
DGICYT O +
PM O +
95 O -
- O -
0070 O -
, O +
DGES O +
PM97 O -
- O -
0054 O -
/ O -
97 O +
and O +
Fundación O +
Central O +
Hispano O -
. O +

Carbohydrate O +
structures O +
containing O +
a O +
Galα1→3 O +
Gal O +
terminus O -
, O +
namely O +
α O -
- O -
Gal O +
epitope O -
, O +
have O +
been O +
identified O +
as O +
xenoactive O +
antigens O +
and O +
are O +
considered O +
to O +
be O +
the O +
major O +
cause O +
for O +
hyperacute O +
rejection O +
in O +
xenotransplantation.1–6 O +
Similar O +
to O +
ABO O +
blood O -
- O -
mismatched O +
organ O +
allotransplants O -
, O +
transplants O +
from O +
species O +
other O +
than O +
Old O +
World O +
primates O +
are O +
rejected O +
within O +
minutes O +
by O +
human O +
natural O +
antibodies B-Gene -
, O +
so O -
- O -
called O +
anti B-Gene -
- I-Gene -
Gal I-Gene -
. O +

The O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibody I-Gene +
is O +
reported O +
at O +
levels O +
of O +
1–2 O -
% O +
of O +
total O +
IgG B-Gene +
and O +
3–8 O -
% O +
of O +
total O +
IgM B-Gene +
in O +
human O +
blood.2 O +
They O +
bind O +
specifically O +
to O +
an O +
α O -
- O -
Gal O +
epitope O +
on O +
the O +
surface O +
of O +
the O +
xenograft O +
cells O +
to O +
initiate O +
complement O -
- O -
mediated O +
lysis O +
of O +
the O +
cells.7 O +
Taking O +
advantage O +
of O +
this O +
humoral O +
response O +
from O +
the O +
human O +
body O -
, O +
we O +
report O +
the O +
design O -
, O +
synthesis O -
, O +
and O +
binding O +
of O +
α O -
- O -
Gal O +
epitope O +
containing O +
glycoconjugates O +
for O +
targeting O +
bacterial O +
cells O +
with O +
naturally O +
occurring O +
human O +
anti O +
α B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene -
. O +

The O +
feasibility O +
of O +
using O +
antibody B-Gene +
targeting O +
followed O +
by O +
mediated O +
immune O +
response O +
against O +
bacterial O +
cells O +
was O +
proved O +
by O +
Bertozzi O +
et O +
al.8,9 O +
However O -
, O +
antibody B-Gene +
based O +
immunotherapy O +
is O +
often O +
limited O +
by O +
immunogenicity O -
. O +

Development O +
of O +
humanized O +
antibodies B-Gene +
is O +
a O +
complex O +
and O +
difficult O +
task O -
. O +

Recently O +
the O +
direct O +
use O +
of O +
human O +
natural O +
antibodies B-Gene +
such O +
as O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
for O +
the O +
specific O +
deletion O +
of O +
target O +
cells O +
has O +
become O +
very O +
attractive.10,11 O +
In O +
this O +
paper O -
, O +
we O +
chose O +
bacterial O +
cells O +
as O +
a O +
model O +
system O -
. O +

Numerous O +
bacterial O +
strains O +
produce O +
surface O +
lectins B-Gene +
which O +
are O +
in O +
the O +
form O +
of O +
fimbriae O +
( O -
or O +
pili O -
) O +
that O +
are O +
filamentous O +
appendages O +
of O +
protein B-Gene +
subunits O -
. O +

They O +
are O +
found O +
to O +
be O +
responsible O +
for O +
cell O -
– O -
cell O +
recognition O +
and O +
infectious O +
disease O -
. O +

However O -
, O +
many O +
bacteria O +
undergo O +
genetic O +
changes O +
to O +
eschew O +
the O +
host O +
immune O +
system O -
. O +

In O +
spite O +
of O +
these O +
changes O -
, O +
the O +
binding O +
specificity O +
of O +
bacterial O +
cell O -
- O -
surface O +
lectins B-Gene +
is O +
conserved.12 O +
Many O +
of O +
the O +
bacterial O +
lectins B-Gene +
exhibit O +
distinct O +
sugar O +
specificities O -
. O +

Among O +
the O +
best O +
characterized O +
fimbrial O +
lectins B-Gene +
are O +
the O +
type B-Gene +
1 I-Gene +
fimbrial I-Gene +
lectins I-Gene +
which O +
are O +
specific O +
for O +
α O -
- O -
mannosides.13,14 O +
The O +
binding O +
affinity O +
of O +
the O +
mannose B-Gene +
receptor I-Gene +
to O +
a O +
mannose O +
ligand O +
falls O +
in O +
the O +
millimolar O +
range O -
. O +

Recently O +
it O +
has O +
been O +
found O +
that O +
the O +
avidity O +
of O +
carbohydrate O +
ligands O +
binding O +
to O +
proteins B-Gene +
can O +
be O +
increased O +
dramatically O +
when O +
carbohydrate O +
ligands O +
are O +
organized O +
as O +
multivalent O +
clusters.15–18 O +
The O +
mannose O -
- O -
containing O +
glycopolymers O +
and O +
glycodendrimers O +
have O +
been O +
reported O +
to O +
have O +
ideal O +
inhibitory O +
effect O +
of O +
binding O +
of O +
yeast O +
mannan O +
to O +
Concanavalin O +
A O +
and O +
Pea O +
lectins.19 B-Gene +

It O +
was O +
indicated O +
that O +
the O +
well O -
- O -
defined O +
glycodendrimers O +
were O +
not O +
as O +
effective O +
as O +
glycopolymer O -
. O +

We O +
synthesized O +
a O +
new O +
type O +
of O +
α O -
- O -
Gal O +
epitope O +
and O +
mannose O +
containing O +
glycopolymers O +
( O -
Fig. O +
1 O +
) O -
. O +

Binding O +
of O +
such O +
glycopolymers O +
to O +
mannose O +
specific O +
bacteria O -
, O +
followed O +
by O +
treatment O +
with O +
human O +
natural O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
should O +
result O +
in O +
complement O -
- O -
mediated O +
lysis O +
of O +
the O +
bacteria O -
. O +

The O +
binding O +
of O +
the O +
glycopolymers O +
to O +
bacteria O +
was O +
tested O +
for O +
inhibition O +
against O +
agglutination O +
of O +
yeast O +
mannan O +
( O -
S. O +
cerevisiae O +
) O +
to O +
E. O +
coli O +
. O +

Human O +
natural O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibody I-Gene +
binding O +
to O +
the O +
α O -
- O -
Gal O +
containing O +
glycopolymers O +
was O +
demonstrated O +
by O +
an O +
ELISA O +
inhibition O +
assay O -
. O +

Results O +
and O +
Discussion O +
Preparation O +
of O +
monomers O +
bearing O +
a O +
hydrophilic O +
spacer O +
from O +
lactose O +
and O +
mannose O +
Scheme O +
1 O +
shows O +
the O +
synthesis O +
of O +
β O -
- O -
lactosyl O +
acrylamide O +
( O -
5 O +
) O -
. O +

We O +
chose O +
commercially O +
available O +
2- O -
[ O -
2- O -
( O -
2-chloroethoxy O -
) O -
ethoxy O -
] O -
ethanol O +
( O -
1 O +
) O +
as O +
a O +
spacer O +
building O +
block O -
. O +

Complete O +
transformation O +
of O +
chloride O +
to O +
azide O +
2 O +
was O +
accomplished O +
in O +
DMF O +
at O +
80 O -
° O -
C O +
according O +
to O +
a O +
known O +
procedure.20 O +
Glycosylation O +
of O +
2 O +
with O +
α O -
- O -
lactosyl O +
bromide O +
heptaacetate O +
using O +
Köenigs O -
– O -
Knorr O +
glycosylation O +
method O +
gave O +
compound O +
3 O +
in O +
82 O -
% O +
yield O -
. O +

The O +
desired O +
β O -
- O -
configuration O +
was O +
confirmed O +
by O +
the O +
coupling O +
constant O +
of O +
anomeric O +
proton O +
( O -
J O +
12 O +
= O -
7.8 O +
Hz O -
) O -
. O +

The O +
glycoside O +
3 O +
was O +
deacetylated O +
by O +
the O +
Zemplén O +
method O +
to O +
give O +
water O +
soluble O +
4 O +
in O +
good O +
yield O -
. O +

Hydrogenation O +
of O +
compound O +
4 O +
, O +
followed O +
by O +
the O +
treatment O +
with O +
acryloyl O +
chloride O +
to O +
provide O +
monomer O +
precursor O +
5 O +
in O +
71 O -
% O +
yield O -
. O +

Scheme O +
2 O +
shows O +
a O +
similar O +
glycosylation O +
approach O +
toward O +
the O +
synthesis O +
of O +
α O -
- O -
mannosyl O +
acrylamide O +
( O -
8 O +
) O -
. O +

The O +
glycosylation O +
reaction O +
provided O +
compound O +
6 O +
in O +
moderate O +
yield O +
( O -
49 O -
% O -
) O -
. O +

The O +
α O -
- O -
configuration O +
was O +
determined O +
by O +
the O +
anomeric O +
proton O +
coupling O +
constant O +
( O -
J O +
12 O +
= O -
1.5 O +
Hz O -
) O +
along O +
with O +
a O +
characteristic O +
feature O +
that O +
no O +
carbon O +
chemical O +
shifts O +
around O +
76 O +
ppm O +
( O -
In O +
peracetylated O +
mannoside O -
, O +
C-5 O +
chemical O +
shift O +
is O +
76 O +
ppm O +
for O +
β O -
- O -
anomer O -
, O +
while O +
70 O +
ppm O +
for O +
α O -
- O -
anomer O -
) O -
. O +

Comparing O +
to O +
α O -
- O -
lactosyl O +
bromide O +
heptaacetate O -
, O +
α O -
- O -
mannosyl O +
bromide O +
tetraacetate O +
was O +
more O +
reactive O -
. O +

Consequently O -
, O +
more O +
by O -
- O -
products O +
were O +
observed O +
in O +
this O +
reaction O -
. O +

Enzymatic O +
synthesis O +
of O +
an O +
α O -
- O -
Gal O +
disaccharide O +
containing O +
monomer O +
precursor O +
Synthesis O +
of O +
Galα1→3Gal O +
acrylamide O +
monomer O +
precursor O +
11 O +
was O +
accomplished O +
by O +
a O +
one O -
- O -
pot O +
enzymatic O +
transglycosylation O +
reaction O +
catalyzed O +
by O +
α B-Gene -
- I-Gene -
galactosidase I-Gene +
from O +
green O +
coffee O +
beans O +
( O -
Scheme O +
3 O +
) O -
.21 O +

Although O +
the O +
yield O +
of O +
this O +
enzymatic O +
reaction O -
, O +
like O +
the O +
conventional O +
transglycosylation O -
, O +
is O +
relatively O +
low O -
, O +
the O +
concise O +
synthetic O +
approach O +
is O +
still O +
more O +
attractive O +
than O +
the O +
typical O +
protecting O -
- O -
deprotecting O +
chemical O +
synthesis O -
. O +

Transformation O +
of O +
the O +
nitro O +
group O +
of O +
compound O +
9 O +
to O +
the O +
N O +
-acryloyl O +
function O +
was O +
then O +
effected O +
by O +
hydrogenation O -
, O +
followed O +
by O +
the O +
treatment O +
with O +
acryloyl O +
chloride O +
in O +
methanol O +
to O +
give O +
compound O +
11 O +
. O +

Radical O +
terpolymerization O +
and O +
enzymatic O +
preparation O +
of O +
glycopolymers O +
containing O +
lactose O +
and O +
mannose O +
The O +
glycopolymers O +
bearing O +
α O -
- O -
Gal O +
epitope O +
were O +
constructed O +
through O +
two O +
different O +
routes O -
. O +

The O +
first O +
one O +
is O +
to O +
use O +
the O +
epitope O +
11 O +
to O +
copolymerize O +
with O +
mannose O +
monomer O +
precursor O +
8 O +
and O +
acrylamide O +
in O +
an O +
established O +
terpolymerization O +
method22 O +
( O -
Scheme O +
4 O +
) O -
. O +

The O +
polymerization O +
was O +
initiated O +
by O +
ammonium O +
persulfate O +
and O +
N O -
, O -
N O -
, O -
N′,N′ O +
-tetramethylethylenediamine O +
in O +
aqueous O +
solution O -
. O +

Thin O -
- O -
layer O +
chromatography O +
was O +
used O +
to O +
monitor O +
the O +
reaction O -
. O +

The O +
final O +
polymer O +
was O +
obtained O +
as O +
a O +
white O +
fluffy O +
material O +
after O +
separation O +
by O +
Bio O -
- O -
gel O +
P-2 O +
permeation O +
column O +
and O +
freeze O -
- O -
drying O +
( O -
76 O -
% O +
yield O -
) O -
. O +

The O +
1 O +
H O +
NMR O +
in O +
D2 O +
O O +
verified O +
the O +
incorporation O +
of O +
all O +
three O +
monomers O +
in O +
the O +
final O +
glycopolymer O +
12 O +
. O +

We O +
have O +
developed O +
an O +
efficient O +
chemoenzymatic O +
synthesis O +
of O +
α O -
- O -
Gal O +
epitope O +
using O +
a O +
recombinant O +
α1 B-Gene -
- I-Gene -
3 I-Gene +
galactosyltransferase.23 I-Gene +
The O +
second O +
route O +
is O +
to O +
use O +
the O +
recombinant B-Gene +
enzyme I-Gene +
to O +
transfer O +
a O +
galactose O +
from O +
uridine O +
5′ O +
diphosphate O +
galactose O +
( O -
UDP O -
- O -
Gal O -
) O +
to O +
a O +
lactosyl O +
acceptor O +
in O +
a O +
glycopolymer O +
containing O +
other O +
sugar O +
moieties O +
such O +
as O +
mannose O +
which O +
is O +
not O +
an O +
acceptor O +
of O +
the O +
enzyme B-Gene +
( O -
Scheme O +
5 O +
) O -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
example O +
showing O +
the O +
selective O +
modification O +
of O +
glycopolymers O +
bearing O +
different O +
sugar O +
moieties O -
. O +

Similar O +
enzymatic O +
transformations O +
to O +
the O +
polymers O +
bearing O +
single O +
type O +
of O +
sugar O +
ligand O +
have O +
been O +
reported.24–26 O +
In O +
order O +
to O +
enhance O +
the O +
transfer O +
efficiency O -
, O +
the O +
biocompatible O +
oligoethoxyl O +
group O +
was O +
employed O -
. O +

This O +
provided O +
the O +
lactosyl O +
acceptor O +
side O +
chains O +
with O +
adequate O +
space O +
away O +
from O +
the O +
bulky O +
polymer O +
main O +
chain O -
. O +

The O +
enzyme B-Gene +
then O +
can O +
bind O +
to O +
the O +
acceptor O +
completely O +
for O +
subsequent O +
transformation O -
. O +

As O +
anticipated O -
, O +
the O +
enzymatic O +
transformation O +
generated O +
the O +
modified O +
glycopolymers O +
15A O +
–B O +
in O +
nearly O +
quantitative O +
yield O +
( O -
confirmed O +
by O +
the O +
integration O +
ratio O +
of O +
anomeric O +
protons O -
) O -
. O +

It O +
is O +
noteworthy O +
that O +
all O +
the O +
glycopolymers O +
obtained O +
from O +
terpolymerization O +
have O +
a O +
high O +
molecular O +
weight O +
( O -
Mw O +
> O -
870 O +
kD O -
) O +
with O +
mean O +
hydrodynamic O +
diameter O +
of O +
polymer O +
chain O +
in O +
aqueous O +
solution O +
greater O +
than O +
69 O +
nm O +
at O +
ambient O +
temperature O -
. O +

The O +
choice O +
of O +
using O +
aromatic O +
13 O +
and O +
non O -
- O -
aromatic O +
8 O +
α O -
- O -
mannoside O +
ligands O +
for O +
the O +
glycopolymers O +
was O +
based O +
on O +
the O +
work O +
done O +
by O +
Firon O +
et O +
al.27,28 O +
They O +
found O +
that O +
E. O +
coli O +
. O +
showed O +
a O +
hydrophobic O +
region O +
close O +
to O +
mannose O -
- O -
binding O +
sites O +
which O +
favored O +
aromatic O +
α O +
-mannosides O +
such O +
as O +
p O +
-nitrophenyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O -
. O +

They O +
also O +
noticed O +
that O +
Salmonella O +
species O +
possessed O +
a O +
binding O +
site O +
which O +
was O +
smaller O +
than O +
that O +
of O +
E. O +
coli O +
. O -
, O +
and O +
devoid O +
of O +
a O +
hydrophobic O +
region O -
. O +

The O +
13 O +
C O +
NMR O +
spectrum O +
of O +
glycopolymer O +
15B O +
is O +
shown O +
in O +
Figure O +
2 O +
. O +

The O +
anomeric O +
region O +
is O +
expanded O +
and O +
clearly O +
shows O +
the O +
presence O +
of O +
lactose O +
with O +
103.5 O +
and O +
102.7 O +
ppm O -
, O +
mannose O +
with O +
99.1 O +
ppm O -
, O +
and O +
newly O +
formed O +
α O -
- O -
galactose O +
anomeric O +
carbon O +
resonance O +
of O +
96.0 O +
ppm O +
( O -
Fig. O +
3 O +
) O -
. O +

Chemoenzymatic O +
synthesis O +
of O +
monovalent O +
α O -
- O -
Gal O -
- O -
mannose O +
conjugate O +
As O +
shown O +
in O +
Scheme O +
6 O +
, O +
compound O +
19 O +
with O +
two O +
single O +
ligands O +
of O +
α O -
- O -
Gal O +
epitope O +
and O +
α O -
- O -
mannoside O +
was O +
constructed O +
for O +
a O +
control O +
experiment O +
comparing O +
with O +
the O +
multivalent O +
counterpart O +
15B O +
. O +

Glycosylation O +
of O +
methyl O +
6-hydroxyhexanoate O +
with O +
α O -
- O -
lactosyl O +
bromide O +
heptaacetate O +
using O +
the O +
same O +
Köenigs O -
– O -
Knorr O +
glycosylation O +
condition O +
as O +
in O +
Scheme O +
1 O +
afforded O +
compound O +
16 O +
. O +

The O +
glycoside O +
16 O +
was O +
deacetylated O +
by O +
the O +
Zemplén O +
method O -
, O +
followed O +
by O +
saponification O +
to O +
give O +
water O +
soluble O +
17 O +
with O +
a O +
free O +
carboxylic O +
group O -
. O +

The O +
lactosyl O +
derivative O +
was O +
then O +
coupled O +
with O +
p O +
-aminophenyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O +
using O +
diphenylphosphoryl O +
azide O +
( O -
DPPA O -
) O +
as O +
a O +
promoter O +
which O +
was O +
demonstrated O +
to O +
activate O +
glycopeptide O +
coupling O +
in O +
the O +
presence O +
of O +
free O +
hydroxyl O +
groups.29 O +
The O +
reaction O +
was O +
conducted O +
in O +
DMF O +
at O +
room O +
temperature O +
to O +
give O +
conjugate O +
18 O +
in O +
66 O -
% O +
yield O -
. O +

Enzymatic O +
galactosylation O +
of O +
compound O +
18 O +
using O +
α1 B-Gene -
- I-Gene -
3 I-Gene +
galactosyltransferase I-Gene +
provided O +
the O +
α O -
- O -
gal O +
epitope O +
containing O +
conjugate O +
19 O +
. O +

Binding O +
studies O +
of O +
α O -
- O -
Gal O -
- O -
mannose O +
glycoconjugates O +
to O +
bacteria O +
The O +
α O -
- O -
Gal O -
- O -
mannose O +
glycopolymers O +
were O +
tested O +
for O +
their O +
ability O +
to O +
function O +
as O +
multivalent O +
ligands O +
for O +
the O +
binding O +
of O +
E. O +
coli O +
K-12 O +
HB101 O +
bacterial O +
cells O -
. O +

This O +
E. O +
coli O +
strain O +
contains O +
mannose O -
- O -
binding O +
sites O +
located O +
on O +
the O +
surface O +
of O +
the O +
bacteria O -
, O +
which O +
can O +
bind O +
yeast O +
( O -
Saccharomyces O +
cerevisiae O +
) O -
, O +
resulting O +
in O +
visible O +
agglutination O -
. O +

To O +
evaluate O +
the O +
activity O +
of O +
our O +
glycopolymers O +
12 O +
and O +
15A O +
–B O +
, O +
we O +
compared O +
their O +
inhibitory O +
effects O +
on O +
agglutination O +
with O +
several O +
controls O +
including O +
the O +
monovalent O +
methyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O -
, O +
p O +
-nitrophenyl O +
α O -
- O -
d O +
-mannopyranoside O -
, O +
α O -
- O -
Gal O -
- O -
mannose O +
conjugate O +
19 O +
, O +
polyvalent O +
mannose O +
copolymers O +
15C O -
– O -
D O +
. O +

The O +
results O +
indicated O +
that O +
the O +
glycopolymers O +
12 O +
and O +
15A O +
–B O +
are O +
effective O +
in O +
preventing O +
agglutination O +
at O +
concentrations O +
as O +
low O +
as O +
100 O +
μM. O +
Comparing O +
to O +
methyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O -
, O +
dramatic O +
increase O +
in O +
the O +
inhibitory O +
efficacy O +
was O +
observed O +
with O +
polyvalent O +
mannose O -
. O +

However O -
, O +
p O +
-nitrophenyl O +
α O -
- O -
d O +
-mannopyranoside O +
was O +
found O +
to O +
be O +
the O +
most O +
potent O +
inhibitor O -
. O +

This O +
compound O +
showed O +
strong O +
inhibition O +
at O +
concentrations O +
as O +
low O +
as O +
90 O +
μM. O +
Monovalent O +
conjugate O +
19 O +
and O +
polymer O +
15B O +
bearing O +
a O +
hydrophobic O +
aromatic O +
ring O +
had O +
comparable O +
inhibitory O +
effects O -
. O +

The O +
polyvalency O +
here O +
is O +
unexpectedly O +
overshadowed O +
by O +
van O +
der O +
Waals O +
forces O +
resulting O +
from O +
the O +
packing O +
of O +
the O +
aromatic O +
ring O +
againt O +
a O +
hydrophobic O +
binding O +
pocket O +
on O +
the O +
surface O +
of O +
the O +
bacteria O -
. O +

It O +
is O +
noteworthy O +
that O +
no O +
inhibition O +
was O +
observed O +
with O +
p O +
-nitrophenyl O +
α O -
- O -
d O +
-galactopyranoside O -
. O +

This O +
indicates O +
the O +
mannose O -
- O -
binding O +
sites O +
are O +
highly O +
specific O -
. O +

α O -
- O -
Gal O +
residue O +
is O +
not O +
able O +
to O +
compete O +
with O +
mannose O +
in O +
binding O +
to O +
the O +
bacterial O +
mannose B-Gene +
receptors I-Gene +
( O -
Table O +
1 O +
) O -
. O +

Binding O +
studies O +
of O +
α O -
- O -
Gal O -
- O -
mannose O +
glycoconjugates O +
to O +
human O +
natural O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene +
using O +
an O +
ELISA O +
inhibition O +
assay O +
To O +
assess O +
the O +
activity O +
of O +
α O -
- O -
Gal O -
- O -
mannose O +
glycoconjugates O +
binding O +
to O +
the O +
anti B-Gene +
α I-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene -
, O +
we O +
applied O +
a O +
previously O +
reported O +
ELISA O +
inhibition O +
assay.30 O +
Mouse O +
laminin B-Gene +
having O +
α O -
- O -
Gal O +
epitopes O +
were O +
fixed O +
on O +
ELISA O +
plate O +
as O +
solid O -
- O -
phase O +
antigens O -
. O +

Test O +
glycoconjugates O +
were O +
then O +
incubated O +
with O +
human O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene +
on O +
the O +
ELISA O +
plate O -
. O +

The O +
plate O +
was O +
washed O +
and O +
incubated O +
with O +
horseradish B-Gene +
peroxidase I-Gene +
( O -
HRP B-Gene -
) O +
conjugated O +
anti O -
- O -
human O +
IgG B-Gene +
antibody I-Gene -
. O +

After O +
additional O +
washing O -
, O +
the O +
color O +
was O +
developed O +
by O +
HRP B-Gene +
reaction O +
using O +
a O +
chromogenic O +
compound O -
. O +

Monovalent O +
conjugate O +
19 O +
and O +
polymer O +
15B O +
were O +
tested O +
with O +
two O +
controls O +
α O -
- O -
Gal O +
epitope O +
( O -
Galα1→3Galβ1→4Glc O -
) O +
and O +
mannose O +
copolymer O +
15D O +
. O +

As O +
shown O +
in O +
Table O +
2 O +
, O +
conjugate O +
19 O +
and O +
polymer O +
15B O +
bind O +
effectively O +
to O +
human O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibody I-Gene -
. O +

The O +
polyvalency O +
of O +
α O -
- O -
Gal O +
epitope O +
on O +
polymer O +
15B O +
was O +
clearly O +
demonstrated O +
by O +
comparing O +
the O +
inhibition O +
of O +
compound O +
19 O +
with O +
polymer O +
15B O +
at O +
the O +
same O +
concentration O +
of O +
α O -
- O -
Gal O +
epitopes O -
. O +

Polymer O +
15D O +
without O +
having O +
α O -
- O -
Gal O +
epitope O +
had O +
no O +
binding O +
to O +
human O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibody I-Gene -
. O +

It O +
can O +
be O +
concluded O +
that O +
no O +
cross O +
reactivity O +
exists O +
between O +
mannose O +
and O +
human O +
natural O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene -
. O +

More O +
importantly O -
, O +
inhibition O +
stem O +
from O +
steric O +
stabilization31 O +
of O +
antibody B-Gene +
surface O +
was O +
not O +
observed O +
under O +
our O +
experimental O +
conditions O -
. O +

Conclusion O +
In O +
summary O -
, O +
we O +
have O +
used O +
chemoenzymatic O +
synthesis O +
to O +
effectively O +
construct O +
monovalent O +
and O +
multivalent O +
α O -
- O -
Gal O +
conjugates O +
containing O +
mannose O +
ligands O -
. O +

The O +
α O -
- O -
Gal O +
and O +
mannose O +
containing O +
compounds O +
were O +
subsequently O +
proved O +
to O +
be O +
potent O +
inhibitors O +
against O +
the O +
bindings O +
of O +
both O +
yeast O +
mannan O +
to O +
E. O +
coli O +
. O -
, O +
K-12 O +
and O +
human O +
natural O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene +
to O +
mouse O +
laminin B-Gene -
. O +

Cross O +
reactivities O +
of O +
mannose O +
binding O +
to O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene +
and O +
α O -
- O -
Gal O +
residue O +
binding O +
to O +
bacteria O +
were O +
not O +
observed O -
. O +

The O +
model O +
compounds O +
with O +
dual O +
binding O +
capacity O +
will O +
be O +
viable O +
ligands O +
to O +
redirect O +
human O +
natural O +
immunity O +
against O +
bacterial O +
pathogens O +
coated O +
with O +
xenoactive O +
epitopes O -
. O +

The O +
sandwiched O +
binding O +
motif O +
as O +
well O +
as O +
bacterial O +
killing O +
assay O +
will O +
be O +
further O +
reported O +
in O +
due O +
course O -
. O +

Experimental O +
General O +
1 O +
H O +
and O +
13 O +
C O +
spectra O +
were O +
recorded O +
on O +
a O +
300 O +
MHz O +
GE O +
Gemini O +
and O +
500 O +
MHz O +
Varian O +
Unity O +
spectrometers O -
. O +

Mass O +
spectra O +
( O -
FAB O +
or O +
ESI O -
) O +
were O +
run O +
on O +
the O +
mass O +
spectrometry O +
facility O +
at O +
the O +
University O +
of O +
California O -
, O +
Riverside O -
. O +

Molecular O +
weight O +
of O +
glycopolymers O +
were O +
measured O +
by O +
static O +
light O +
scattering O +
using O +
NICOMP O +
model O +
370 O +
submicron O +
particle O +
sizer O -
. O +

Thin O -
- O -
layer O +
chromatography O +
was O +
conducted O +
on O +
Baker O +
Si250F O +
silica O +
gel O +
TLC O +
plates O +
with O +
a O +
fluorescent O +
indicator O -
. O +

Column O +
chromatography O +
was O +
conducted O +
with O +
silica O +
gel O -
, O +
grade O +
62 O -
, O +
60–200 O +
mesh O -
, O +
150 O +
Å O +
and O +
Bio O -
- O -
Gel O +
P-2 O -
. O +

Dialysis O +
was O +
performed O +
against O +
deionized O +
water O +
using O +
dialysis O +
tubing O +
( O -
8000 O +
MW O +
cutoff O -
) O -
. O +

Mouse O +
laminin B-Gene +
( O -
L2020 B-Gene -
) O +
and O +
human O +
serum O +
derived O +
from O +
sterile O -
- O -
filtered O +
male O +
AB O +
plasma O +
were O +
obtained O +
from O +
Sigma O +
Co. O -
, O +
St. O +
Louis O -
, O +
MO O -
. O +

E. O +
coli O +
K-12 O +
HB101 O +
was O +
obtained O +
from O +
American O +
Type O +
Culture O +
Collection O +
( O -
ATCC O -
) O +
Rockville O -
, O +
MD O -
. O +

2- O -
[ O -
2- O -
( O -
2-Azidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O +
( O -
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
14 O -
) O -
-2,3,6-tri O -
- O -
O O +
-acetyl O -
- O -
β O -
- O -
d O +
-glucopyranoside O +
( O -
3 O +
) O +
2,3,4,6-Hepta O -
- O -
O O +
-acetyl O -
- O -
α O -
- O -
lactosyl O +
bromide O +
( O -
4.5 O +
g O -
, O +
6.4 O +
mmol O -
) O +
and O +
2- O -
[ O -
2- O -
( O -
2-azidoethoxy O -
) O -
ethoxy O -
] O -
-ethanol O +
( O -
1.6 O +
g O -
) O +
were O +
added O +
to O +
a O +
previously O +
flame O -
- O -
dried O +
flask O +
containing O +
6 O +
g O +
MS O +
4 O +
Å O +
and O +
50 O +
mL O +
anhydrous O +
CHCl3 O +
. O +

The O +
resulting O +
suspension O +
was O +
stirred O +
for O +
half O +
an O +
hour O -
. O +

HgO O +
( O -
1.4 O +
g O -
) O +
and O +
HgBr2 O +
( O -
cat O -
) O +
were O +
added O +
to O +
the O +
suspension O -
. O +

The O +
mixture O +
was O +
stirred O +
in O +
the O +
dark O +
at O +
ambient O +
temperature O +
for O +
48 O +
h. O +
The O +
resulting O +
mixture O +
was O +
passed O +
through O +
a O +
Celite O +
packed O +
glass O +
funnel O -
, O +
and O +
washed O +
with O +
saturated O +
NaHCO3 O +
and O +
water O -
. O +

The O +
organic O +
phase O +
was O +
dried O +
over O +
anhydrous O +
Na2 O +
SO4 O +
and O +
concentrated O +
in O +
vacuo O -
. O +

The O +
resulting O +
residue O +
was O +
chromatographed O +
( O -
hexane O -
: O -
EtOAc O -
, O +
1:1 O -
) O +
to O +
afford O +
product O +
3 O +
( O -
4.2 O +
g O -
, O +
82 O -
% O -
) O -
. O +

3 O +
: O +
1 O +
H O +
NMR O +
( O -
CDCl3 O +
) O +
Selected O +
δ O +
5.31 O +
( O -
d O -
, O +
J O +
= O -
2.4 O +
Hz O -
, O +
1H O -
) O -
, O +
5.16 O +
( O -
t O -
, O +
J O +
= O -
9.3 O +
Hz O -
, O +
1H O -
) O -
, O +
5.07 O +
( O -
dd O -
, O +
J O +
= O -
7.8 O +
Hz O -
, O +
10.2 O -
, O +
1H O -
) O -
, O +
4.85–4.94 O +
( O -
m O -
, O +
2H O -
) O -
, O +
4.54 O +
( O -
d O -
, O +
J O +
= O -
7.8 O +
Hz O -
, O +
1H O -
) O -
, O +
4.48–4.44 O +
( O -
m O -
, O +
2H O -
) O -
, O +
3.36–4.11 O +
( O -
m O -
, O +
18 O +
H O -
) O +
13 O +
C O +
δ O +
170.3 O -
, O +
170.1 O -
, O +
170.0 O -
, O +
169.7 O -
, O +
169.6 O -
, O +
169.0 O -
, O +
101.0 O -
, O +
100.5 O -
, O +
76.2 O -
, O +
72.7 O -
, O +
72.6 O -
, O +
71.6 O -
, O +
70.9 O -
, O +
70.6 O -
, O +
70.6 O -
, O +
70.3 O -
, O +
69.9 O -
, O +
69.1 O -
, O +
69.0 O -
, O +
66.6 O -
, O +
61.9 O -
, O +
60.8 O -
, O +
50.6 O -
, O +
20.5 O -
- O -
20.8 O -
. O +

MS O +
( O -
m O -
/ O -
z O +
) O +
816 O +
( O -
M+Na+ O +
) O -
; O +
HRMS O +
calcd O +
for O +
C32 O +
H47 O +
N3 O +
O20 O +
Na+ O +
816.2651 O -
, O +
found O +
816.2648 O -
. O +

2- O -
[ O -
2- O -
( O -
2-Azidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-glucopyranoside O +
( O -
4 O +
) O +
To O +
a O +
solution O +
of O +
3 O +
( O -
3 O +
g O -
) O +
in O +
anhydrous O +
methanol O +
( O -
200 O +
mL O -
) O +
at O +
0 O -
° O -
C O +
was O +
added O +
NaOMe O +
until O +
the O +
pH O +
was O +
10 O -
. O +

The O +
solution O +
was O +
stirred O +
for O +
3 O +
h. O +
Dowex O +
cation O +
exchange O +
resin O +
( O -
H O +
form O -
) O +
was O +
added O +
to O +
adjust O +
the O +
pH O +
to O +
6–7 O +
and O +
filtered O -
. O +

The O +
filtrate O +
was O +
evaporated O +
to O +
give O +
a O +
syrup O +
4 O +
in O +
quantitative O +
yield O -
. O +

4 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ4.35 O +
( O -
s O -
, O +
J O +
= O -
8.1 O +
Hz O -
, O +
1H O -
) O -
, O +
4.27 O +
( O -
d O -
, O +
J O +
= O -
7.8 O +
Hz O -
, O +
1H O -
) O -
, O +
3.32–3.91 O +
( O -
m O -
, O +
23 O +
H O -
) O -
, O +
3.17 O +
( O -
t O -
, O +
J O +
= O -
7.5 O +
Hz O -
, O +
1H O -
) O -
. O +

13 O +
C O +
δ O +
103.4 O -
, O +
102.5 O -
, O +
78.9 O -
, O +
75.8 O -
, O +
75.2 O -
, O +
74.8 O -
, O +
73.3 O -
, O +
73.0 O -
, O +
71.4 O -
, O +
70.0 O -
, O +
70.0 O -
, O +
69.9 O -
, O +
69.6 O -
, O +
69.2 O -
, O +
69.0 O -
, O +
61.5 O -
, O +
60.5 O -
, O +
50.6 O -
. O +

2- O -
[ O -
2- O -
( O -
2-N O +
-acryloyl O -
- O -
aminoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
- O -
( O -
1→4 O +
) O -
-β O -
- O -
d O +
-glucopyranoside O +
( O -
5 O +
) O +
In O +
the O +
presence O +
of O +
PtO2 O +
( O -
160 O +
mg O -
) O -
, O +
4 O +
( O -
1.6 O +
g O -
) O +
in O +
methanol O +
( O -
40 O +
mL O -
) O +
was O +
charged O +
with O +
hydrogen O +
( O -
50 O +
lb O -
/ O -
in2 O +
) O +
for O +
1 O +
h. O +
After O +
the O +
reaction O -
, O +
the O +
Pt O +
black O +
was O +
filtered O +
and O +
the O +
filtrate O +
was O +
evaporated O +
to O +
give O +
a O +
residue O -
. O +

To O +
a O +
solution O +
of O +
the O +
residue O +
in O +
cold O +
MeOH O +
( O -
120 O +
mL O -
) O +
was O +
added O +
TEA O +
( O -
2 O +
mL O -
) O +
and O +
acryloyl O +
chloride O +
( O -
0.6 O +
mL O +
in O +
20 O +
mL O +
chloroform O -
) O +
dropwise O +
at O +
0 O -
° O -
C O -
. O +

The O +
mixture O +
was O +
allowed O +
to O +
warm O +
to O +
room O +
temperature O +
and O +
stirred O +
for O +
2 O +
h. O +
The O +
solution O +
was O +
washed O +
with O +
anionic O +
resin O +
( O -
OH− O +
) O +
and O +
cationic O +
resin O +
( O -
H+ O +
) O +
successively O +
until O +
the O +
solution O +
reached O +
neutrality O -
. O +

The O +
solution O +
was O +
concentrated O +
and O +
purified O +
on O +
a O +
Bio O -
- O -
Gel O +
P2 O +
column O +
and O +
lyophilized O +
to O +
give O +
5 O +
( O -
1.2 O +
g O -
, O +
71 O -
% O -
) O -
. O +

5 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
6.04–6.12 O +
( O -
m O -
, O +
1H O -
) O -
, O +
5.58–5.61 O +
( O -
m O -
, O +
2H O -
) O -
, O +
4.27 O +
( O -
d O -
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
1H O -
) O -
, O +
4.34 O +
( O -
d O -
, O +
J O +
= O -
7.5 O +
Hz O -
, O +
1H O -
) O -
, O +
3.15–3.91 O +
( O -
m O -
, O +
23 O +
H O -
) O +
3 O +
C O +
δ O -
( O -
130.4 O -
, O +
128.0 O -
, O +
103.5 O -
, O +
102.7 O -
, O +
78.9 O -
, O +
76.0 O -
, O +
75.4 O -
, O +
74.9 O -
, O +
73.4 O -
, O +
73.1 O -
, O +
71.5 O -
, O +
70.3 O -
, O +
70.2 O -
, O +
70.1 O -
, O +
70.0 O -
, O +
69.3 O -
, O +
69.1 O -
, O +
61.6 O -
, O +
60.6 O -
, O +
39.6 O -
. O +

HRFABMS O +
calcd O +
for O +
C21 O +
H37 O +
NO14 O +
Na+ O +
550.2112 O -
, O +
found O +
550.2104 O -
. O +

2- O -
[ O -
2- O -
( O -
2-Azidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O +
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O +
( O -
6 O +
) O +
2,3,4,6-Tetra O -
- O -
O O +
-acetyl O -
- O -
α O -
- O -
mannosyl O +
bromide O +
( O -
7 O +
g O -
, O +
17 O +
mmol O -
) O +
and O +
2- O -
[ O -
2- O -
( O -
2-azidoethoxy O -
) O -
ethoxy O -
] O -
ethanol O +
1 O +
( O -
3 O +
g O -
) O +
were O +
added O +
to O +
a O +
previously O +
flame O -
- O -
dried O +
flask O +
containing O +
10 O +
g O +
MS O +
4 O +
Å O +
and O +
100 O +
mL O +
anhydrous O +
CHCl3 O +
. O +

The O +
resulting O +
suspension O +
was O +
stirred O +
for O +
half O +
an O +
hour O -
. O +

HgO O +
( O -
3.7 O +
g O -
) O +
and O +
HgBr2 O +
( O -
cat O -
) O +
were O +
added O +
to O +
the O +
suspension O -
. O +

The O +
mixture O +
was O +
stirred O +
in O +
the O +
dark O +
at O +
ambient O +
temperature O +
for O +
48 O +
h. O +
The O +
resulting O +
mixture O +
was O +
passed O +
through O +
a O +
Celite O +
packed O +
glass O +
funnel O -
, O +
and O +
washed O +
with O +
saturated O +
NaHCO3 O +
and O +
water O -
. O +

The O +
organic O +
phase O +
was O +
dried O +
over O +
anhydrous O +
Na2 O +
SO4 O +
and O +
concentrated O +
in O +
vacuo O -
. O +

The O +
resulting O +
residue O +
was O +
chromatographed O +
( O -
hexane O -
: O -
EtOAc O -
, O +
1:1 O -
) O +
to O +
afford O +
compound O +
6 O +
( O -
4.2 O +
g O -
, O +
49 O -
% O -
) O -
. O +

6 O +
: O +
1 O +
H O +
NMR O +
( O -
CDCl3 O +
) O +
δ O +
5.21–5.34 O +
( O -
m O -
, O +
3H O -
) O -
, O +
4.83 O +
( O -
d O -
, O +
J O +
= O -
1.5 O +
Hz O -
, O +
1H O -
) O -
, O +
4.25 O +
( O -
dd O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
12.3 O +
Hz O -
, O +
1H O -
) O -
, O +
4.00–4.07 O +
( O -
m O -
, O +
2H O -
) O -
, O +
3.74–3.80 O +
( O -
m O -
, O +
1H O -
) O -
, O +
3.67–3.61 O +
( O -
m O -
, O +
9H O -
) O -
, O +
3.36 O +
( O -
t O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
2H O -
) O -
, O +
2.11 O +
( O -
s O -
, O +
3H O -
) O -
, O +
2.06 O +
( O -
s O -
, O +
3H O -
) O -
, O +
2.00 O +
( O -
s O -
, O +
3H O -
) O -
, O +
1.95 O +
( O -
s O -
, O +
3H O -
) O +
13 O +
C O +
δ O -
( O -
170.6 O -
, O +
169.9 O -
, O +
169.8 O -
, O +
169.6 O -
, O +
97.7 O -
, O +
70.7 O -
, O +
70.6 O -
, O +
70.0 O -
, O +
69.5 O -
, O +
69.0 O -
, O +
68.4 O -
, O +
67.3 O -
, O +
66.1 O -
, O +
62.4 O -
, O +
50.6 O -
, O +
20.6 O -
- O -
20.8 O -
. O +

MS O +
( O -
m O -
/ O -
z O +
) O +
528 O +
( O -
M+Na+ O +
) O -
; O +
HRMS O +
calcd O +
for O +
C20 O +
H31 O +
N3 O +
O12 O +
Na+ O +
528.1805 O -
, O +
found O +
528.1853 O -
. O +

2- O -
[ O -
2- O -
( O -
2-Azidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl- O -
( O -
-d O +
-mannopyranoside O +
( O -
7 O +
) O +
To O +
a O +
solution O +
of O +
6 O +
( O -
3.6 O +
g O -
) O +
in O +
anhydrous O +
methanol O +
( O -
200 O +
mL O -
) O +
at O +
0 O -
° O -
C O +
was O +
added O +
NaOMe O +
until O +
pH O +
was O +
10 O -
. O +

The O +
solution O +
was O +
stirred O +
for O +
3 O +
h. O +
Dowex O +
cation O +
exchange O +
resin O +
( O -
H O +
form O -
) O +
was O +
added O +
to O +
adjust O +
the O +
pH O +
to O +
6–7 O +
and O +
filtered O -
. O +

The O +
filtrate O +
was O +
evaporated O +
to O +
give O +
a O +
syrup O +
7 O +
in O +
quantitative O +
yield O -
. O +

7 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O -
( O -
4.72 O +
( O -
s O -
, O +
1H O -
) O -
, O +
3.33–3.80 O +
( O -
m O -
, O +
18 O +
H O -
) O +
13 O +
C O +
δ O +
100.5 O -
, O +
73.3 O -
, O +
71.1 O -
, O +
70.5 O -
, O +
70.2 O -
, O +
70.1 O -
, O +
70.1 O -
, O +
69.9 O -
, O +
67.3 O -
, O +
67 O -
, O +
50.7 O -
. O +

2- O -
[ O -
2- O -
( O -
2-N O +
-acryloyl O -
- O -
aminoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl- O -
( O -
-d O +
-mannopyranoside O +
( O -
8 O +
) O +
In O +
the O +
presence O +
of O +
PtO2 O +
( O -
98 O +
mg O -
) O -
, O +
7 O +
( O -
1.5 O +
g O -
) O +
in O +
methanol O +
( O -
40 O +
mL O -
) O +
was O +
charged O +
with O +
hydrogen O +
( O -
50 O +
lb O -
/ O -
in2 O +
) O +
for O +
3 O +
h. O +
After O +
the O +
reaction O -
, O +
the O +
Pt O +
black O +
was O +
filtered O +
and O +
the O +
filtrate O +
was O +
evaporated O +
to O +
give O +
a O +
residue O -
. O +

To O +
a O +
solution O +
of O +
the O +
residue O +
in O +
cold O +
MeOH O +
( O -
120 O +
mL O -
) O +
was O +
added O +
TEA O +
( O -
2 O +
mL O -
) O +
and O +
acryloyl O +
chloride O +
( O -
0.5 O +
mL O +
in O +
20 O +
mL O +
chloroform O -
) O +
dropwise O +
at O +
0 O -
° O -
C O -
. O +

The O +
mixture O +
was O +
allowed O +
to O +
warm O +
to O +
room O +
temperature O +
and O +
stirred O +
for O +
2 O +
h. O +
The O +
solution O +
was O +
washed O +
with O +
anionic O +
resin O +
( O -
OH− O +
) O +
and O +
cationic O +
resin O +
( O -
H+ O +
) O +
successively O +
until O +
the O +
solution O +
reached O +
neutrality O -
. O +

The O +
solution O +
was O +
concentrated O +
and O +
purified O +
on O +
a O +
Bio O -
- O -
Gel O +
P2 O +
column O +
and O +
lyophilized O +
to O +
give O +
8 O +
( O -
1.4 O +
g O -
, O +
88 O -
% O -
) O -
. O +

8 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O -
( O -
6.13–6.00 O +
( O -
m O -
, O +
2H O -
) O -
, O +
5.59 O +
( O -
d O -
, O +
J O +
= O -
10.5 O +
Hz O -
, O +
1H O -
) O -
, O +
4.70 O +
( O -
s O -
, O +
1H O -
) O -
, O +
3.30–3.78 O +
( O -
m O -
, O +
18 O +
H O -
) O +
13 O +
C O +
δ O +
130.4 O -
, O +
128.0 O -
, O +
100.5 O -
, O +
73.3 O -
, O +
71.1 O -
, O +
70.1 O -
, O +
70.6 O -
, O +
70.2 O -
, O +
70.1 O -
, O +
70.1 O -
, O +
69.4 O -
, O +
67.3 O -
, O +
66.9 O -
, O +
61.5 O -
, O +
39.6 O -
. O +

HRFABMS O +
calcd O +
for O +
C15 O +
H27 O +
NO9 O +
Na+ O +
388.1584 O -
, O +
found O +
388.1589 O -
. O +

p O +
-Aminophenyl O +
3-O O +
-α O -
- O -
d O +
-galactopyranosyl O -
- O -
α O -
- O -
d O +
-galactopyranoside O +
( O -
10 O +
) O +
In O +
the O +
presence O +
of O +
10 O -
% O +
Pd O -
/ O -
C O +
( O -
20 O +
mg O -
) O -
, O +
9 O +
obtained O +
as O +
described O +
previously,21 O +
( O -
220 O +
mg O -
, O +
0.48 O +
mmol O -
) O +
was O +
charged O +
with O +
hydrogen O +
( O -
50 O +
lb O -
/ O -
in2 O +
) O +
in O +
methanol O +
( O -
25 O +
mL O -
) O +
for O +
overnight O -
. O +

After O +
the O +
reaction O -
, O +
the O +
Pd O +
black O +
was O +
filtered O +
and O +
the O +
filtrate O +
was O +
evaporated O +
to O +
give O +
a O +
residue O +
10 O +
( O -
200 O +
mg O -
, O +
97 O -
% O -
) O -
. O +

10 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
6.87 O -
, O +
6.67 O +
( O -
2d O -
, O +
each O +
2H O -
, O +
J O +
= O -
8.1 O +
Hz O -
) O -
, O +
5.37 O +
( O -
d O -
, O +
J O +
= O -
3.3 O +
Hz O -
, O +
1H O -
) O -
, O +
5.03 O +
( O -
d O -
, O +
J O +
= O -
3.3 O +
Hz O -
, O +
1H O -
) O -
, O +
4.14–3.55 O +
m O -
, O +
12 O +
H O -
) O -
, O +
13 O +
C O +
δ O +
150.2 O -
, O +
141.4 O -
, O +
119.5 O -
, O +
118.3 O -
, O +
98.9 O -
, O +
95.6 O -
, O +
74.6 O -
, O +
71.8 O -
, O +
71.5 O -
, O +
69.8 O -
, O +
69.7 O -
, O +
68.7 O -
, O +
67.0 O -
, O +
65.9 O -
, O +
61.6 O -
, O +
61.5 O -
. O +

N O +
-acryloyl O -
- O -
aminophenyl O +
3-O O +
-α O -
- O -
d O +
-galactopyranosyl O -
- O -
α O -
- O -
d O +
-galactopyranoside O +
( O -
11 O +
) O +
To O +
a O +
solution O +
of O +
compound O +
10 O +
( O -
100 O +
mg O -
, O +
0.23 O +
mmol O -
) O +
in O +
cold O +
MeOH O +
( O -
20 O +
mL O -
) O +
was O +
added O +
TEA O +
( O -
0.6 O +
mL O -
) O +
and O +
acryloyl O +
chloride O +
( O -
0.2 O +
mL O -
) O +
dropwise O +
at O +
0 O -
° O -
C O -
. O +

The O +
mixture O +
was O +
allowed O +
to O +
warm O +
to O +
room O +
temperature O +
and O +
stirred O +
for O +
2 O +
h. O +
The O +
solution O +
was O +
washed O +
with O +
anionic O +
resin O +
( O -
OH− O +
) O +
and O +
cationic O +
resin O +
( O -
H+ O +
) O +
successively O +
until O +
the O +
solution O +
reached O +
neutrality O -
. O +

The O +
solution O +
was O +
concentrated O +
and O +
purified O +
on O +
a O +
Bio O -
- O -
Gel O +
P-2 O +
column O +
and O +
lyophilized O +
to O +
give O +
11 O +
( O -
49 O +
mg O -
, O +
44 O -
% O -
) O -
. O +

11 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
7.29 O -
, O +
7.03 O +
( O -
2d O -
, O +
each O +
2H O -
, O +
J O +
= O -
8.5 O +
Hz O -
) O -
, O +
6.28–6.14 O +
( O -
m O -
, O +
2H O -
) O -
, O +
5.70 O +
( O -
d O -
, O +
J O +
= O -
10.0 O +
Hz O -
, O +
1H O -
) O -
, O +
5.53 O +
( O -
d O -
, O +
J O +
= O -
4.0 O +
Hz O -
, O +
1H O -
) O -
, O +
5.06 O +
( O -
d O -
, O +
J O +
= O -
4.0 O +
Hz O -
, O +
1H O -
) O -
, O +
4.15–3.57 O +
( O -
m O -
, O +
12H O -
) O +
13 O +
C O +
δ O +
130.2 O -
, O +
128.0 O -
, O +
123.5 O -
, O +
117.8 O -
, O +
97.4 O -
, O +
95.1 O -
, O +
74.1 O -
, O +
71.5 O -
, O +
71 O -
, O +
69.3 O -
, O +
69.2 O -
, O +
68.2 O -
, O +
66.5 O -
, O +
65.4 O -
, O +
61.2 O -
, O +
61.2 O -
. O +

HRFABMS O +
calcd O +
for O +
C21 O +
H29 O +
NO12 O +
Na+ O +
510.1587 O -
, O +
found O +
510.1601 O -
. O +

Poly O +
{ O -
acrylamide O -
- O -
co O +
-2- O -
[ O -
2- O -
( O -
2-N O +
-acrylamidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O -
- O -
co O +
-N O +
-acrylamidophenyl O +
3-O O +
-α O -
- O -
d O +
-galactopyranosyl O -
- O -
α O -
- O -
d O +
-galactopyranoside O -
} O +
( O -
12 O +
) O +
Compound O +
8 O +
( O -
70 O +
mg O -
) O -
, O +
compound O +
11 O +
( O -
48 O +
mg O -
) O +
and O +
acrylamide O +
( O -
80 O +
mg O -
) O +
were O +
dissolved O +
in O +
deoxygenated O +
dd O +
water O +
( O -
2 O +
mL O -
) O -
. O +

Ammonium O +
persulfate O +
( O -
40 O +
μL O +
of O +
a O +
stock O +
solution O -
, O +
50 O +
mg O -
/ O -
mL O -
) O +
and O +
TMEDA O +
( O -
5 O +
μL O -
) O +
were O +
then O +
added O -
. O +

The O +
reaction O +
mixture O +
was O +
stirred O +
under O +
argon O +
at O +
55 O -
° O -
C O +
overnight O -
. O +

The O +
cooled O +
reaction O +
mixture O +
was O +
dialyzed O +
( O -
8000 O +
MW O +
cutoff O -
) O +
exhaustively O +
against O +
deionized O +
water O -
. O +

The O +
aqueous O +
solution O +
of O +
the O +
polymer O +
was O +
lyophilized O +
to O +
afford O +
white O +
fluffy O +
powder O +
12 O +
( O -
150 O +
mg O -
, O +
76 O -
% O -
) O -
. O +

12 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
7.24 O +
( O -
s O -
, O +
2H O -
) O -
, O +
7.03 O +
( O -
d O -
, O +
J O +
= O -
7.0 O +
Hz O -
, O +
aromatic O +
proton O -
) O -
, O +
5.55 O +
( O -
s O -
, O +
anomeric O +
proton O -
) O -
, O +
5.06 O +
( O -
s O -
, O +
anomeric O +
proton O -
) O -
, O +
4.73 O +
( O -
s O -
, O +
anomeric O +
proton O -
) O -
, O +
3.26–4.15 O +
( O -
m O -
) O -
, O +
2.17 O +
and O +
2.02 O +
( O -
2bs O -
) O -
, O +
1.60 O +
and O +
1.48 O +
( O -
2bs O -
) O -
. O +

The O +
average O +
incorporation O +
molar O +
ratio O +
is O +
1 O -
/ O -
28 O -
/ O -
5 O +
( O -
Gal O +
α1→3 O +
Gal O -
/ O -
acrylamide O -
/ O -
mannose O -
) O -
. O +

Poly O +
{ O -
acrylamide O -
- O -
co O +
-2- O -
[ O -
2- O -
( O -
2-N O +
-acrylamidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O -
- O -
co O +
-2- O -
[ O -
2- O -
( O -
2-N O +
-acrylamidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
β O -
- O -
lactoside O -
} O +
( O -
14A O +
) O +
Compound O +
8 O +
( O -
330 O +
mg O -
) O -
, O +
compound O +
5 O +
( O -
176 O +
mg O -
) O +
and O +
acrylamide O +
( O -
214 O +
mg O -
) O +
were O +
dissolved O +
in O +
deoxygenated O +
dd O +
water O +
( O -
6 O +
mL O -
) O -
. O +

Ammonium O +
persulfate O +
( O -
100 O +
μL O +
of O +
a O +
stock O +
solution O -
, O +
50 O +
mg O -
/ O -
mL O -
) O +
and O +
TMEDA O +
( O -
10 O +
μL O -
) O +
were O +
then O +
added O -
. O +

The O +
reaction O +
mixture O +
was O +
stirred O +
under O +
argon O +
at O +
75 O -
° O -
C O +
for O +
4 O +
h. O +
The O +
cooled O +
reaction O +
mixture O +
was O +
dialyzed O +
( O -
8000 O +
MW O +
cutoff O -
) O +
exhaustively O +
against O +
deionized O +
water O -
. O +

The O +
aqueous O +
solution O +
of O +
the O +
polymer O +
was O +
lyophilized O +
to O +
afford O +
white O +
fluffy O +
powder O +
14A O +
( O -
600 O +
mg O -
) O -
. O +

14A O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
4.72 O +
( O -
s O -
, O +
mannose O +
anomeric O +
proton O -
) O -
, O +
4.35 O +
( O -
d O -
, O +
J O +
= O -
7.5 O +
Hz O -
, O +
anomeric O +
proton O -
) O -
, O +
4.28 O +
( O -
d O -
, O +
J O +
= O -
7.8 O +
Hz O -
, O +
anomeric O +
proton O -
) O -
, O +
3.26–4.79 O +
( O -
m O -
) O -
, O +
2.17 O +
and O +
2.01 O +
( O -
2bs O -
) O -
, O +
1.58 O +
and O +
1.47 O +
( O -
2bs O -
) O -
. O +

The O +
average O +
incorporation O +
molar O +
ratio O +
is O +
1:12:2 O +
( O -
lactose O -
: O -
acrylamide O -
: O -
mannose O -
) O -
. O +

Poly O +
{ O -
acrylamide O -
- O -
co O +
-N O +
-acryloyl O -
- O -
aminophenyl O +
α O -
- O -
d O +
-mannopyranoside O -
- O -
co O +
-2 O +
- O -
[ O -
2 O +
- O -
( O -
2 O +
-N O -
- O -
acrylamidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
β O -
- O -
lactoside O -
} O +
( O -
14B O +
) O +
Compound O +
13 O +
obtained O +
as O +
described O +
previously O +
19 O +
( O -
100 O +
mg O -
) O -
, O +
compound O +
5 O +
( O -
162 O +
mg O -
) O +
and O +
acrylamide O +
( O -
131 O +
mg O -
) O +
were O +
dissolved O +
in O +
deoxygenated O +
dd O +
water O +
( O -
4 O +
mL O -
) O -
. O +

Ammonium O +
persulfate O +
( O -
40 O +
μL O +
of O +
a O +
stock O +
solution O -
, O +
50 O +
mg O -
/ O -
mL O -
) O +
and O +
TMEDA O +
( O -
5 O +
μL O -
) O +
were O +
then O +
added O -
. O +

The O +
reaction O +
mixture O +
was O +
stirred O +
under O +
argon O +
at O +
90 O -
° O -
C O +
for O +
34 O +
min O -
. O +

The O +
cooled O +
reaction O +
mixture O +
was O +
dialyzed O +
( O -
8000 O +
MW O +
cutoff O -
) O +
exhaustively O +
against O +
deionized O +
water O -
. O +

The O +
aqueous O +
solution O +
of O +
the O +
polymer O +
was O +
lyophilized O +
to O +
afford O +
the O +
white O +
fluffy O +
powder O +
14B O +
( O -
320 O +
mg O -
) O -
. O +

14B O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
( O -
m O -
, O +
aromatic O +
protons O -
) O -
, O +
5.42 O +
( O -
bs O -
, O +
anomeric O +
proton O -
) O -
, O +
4.35 O +
( O -
d O -
, O +
J O +
= O -
7.5 O +
Hz O -
, O +
anomeric O +
proton O -
) O -
, O +
4.28 O +
( O -
d O -
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
anomeric O +
proton O -
) O -
, O +
4.00–3.20 O +
( O -
m O -
) O -
, O +
2.18 O +
and O +
2.03 O +
( O -
2bs O -
) O -
, O +
1.60 O +
and O +
1.48 O +
( O -
2bs O -
) O -
. O +

The O +
average O +
incorporation O +
molar O +
ratio O +
is O +
1:5.8:1 O +
( O -
lactose O -
: O -
acrylamide O -
: O -
mannose O -
) O -
. O +

Polymer O +
( O -
15A O +
) O +
Acceptor O +
glycopolymer O +
14A O +
( O -
100 O +
mg O -
, O +
47 O +
μmol O +
of O +
lactose O -
) O -
, O +
UDP O -
- O -
Gal O +
( O -
40 O +
mg O -
) O +
and O +
rα1 B-Gene -
- I-Gene -
3GalT I-Gene +
( O -
10 O +
unit O -
) O +
were O +
incubated O +
in O +
a O +
solution O +
of O +
Tris O -
– O -
HCl O +
buffer O +
( O -
50 O +
mM O -
, O +
pH O +
7 O -
) O +
containing O +
Mn2 O -
+ O +
( O -
10 O +
mM O -
) O +
for O +
48 O +
h O +
at O +
ambient O +
temperature O -
. O +

The O +
mixture O +
was O +
directly O +
applied O +
to O +
Bio O -
- O -
Gel O +
P-2 O +
with O +
water O +
as O +
the O +
eluent O -
. O +

The O +
fractions O +
containing O +
the O +
glycopolymer O +
were O +
collected O +
and O +
lyophilized O +
to O +
afford O +
the O +
white O +
powder O +
15A O +
in O +
quantitative O +
yield O -
. O +

15A O +
: O +
Selected O +
13 O +
C O +
NMR O +
( O -
D2 O +
O O -
) O +
103.5 O -
, O +
102.7 O -
, O +
99.1 O +
( O -
mannose O +
anomeric O +
carbon O -
) O +
96.0 O +
( O -
α O -
- O -
galactose O +
anomeric O +
carbon O -
) O -
, O +
79.2 O +
( O -
C-4 O +
of O +
glucose O -
) O -
, O +
77.8 O +
( O -
C-3 O +
of O +
β O -
- O -
galactose O -
) O -
. O +

Polymer O +
( O -
15B O +
) O +
Acceptor O +
glycopolymer O +
14B O +
( O -
120 O +
mg O -
, O +
93 O +
μmol O +
of O +
lactose O -
) O -
, O +
UDP O -
- O -
Gal O +
( O -
80 O +
mg O -
) O +
and O +
rα1 B-Gene -
- I-Gene -
3GalT I-Gene +
( O -
15 O +
unit O -
) O +
were O +
incubated O +
in O +
a O +
solution O +
of O +
Tris O -
– O -
HCl O +
buffer O +
( O -
50 O +
mM O -
, O +
pH O +
7 O -
) O +
containing O +
Mn2 O -
+ O +
( O -
10 O +
mM O -
) O +
for O +
48 O +
h O +
at O +
ambient O +
temperature O -
. O +

The O +
mixture O +
was O +
directly O +
applied O +
to O +
Bio O -
- O -
Gel O +
P-2 O +
with O +
water O +
as O +
the O +
eluent O -
. O +

The O +
fractions O +
containing O +
the O +
glycopolymer O +
were O +
collected O +
and O +
lyophilized O +
to O +
afford O +
the O +
white O +
powder O +
15B O +
in O +
quantitative O +
yield O -
. O +

15B O +
: O +
Selected O +
13 O +
C O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
103.4 O -
, O +
102.7 O -
, O +
100.4 O +
( O -
mannose O +
anomeric O +
carbon O -
) O +
95.9 O +
( O -
α O -
- O -
galactose O +
anomeric O +
carbon O -
) O -
, O +
79.1 O +
( O -
C-4 O +
of O +
glucose O -
) O -
, O +
77.7 O +
( O -
C-3 O +
of O +
β O -
- O -
galactose O -
) O -
. O +

Poly O +
{ O -
acrylamide O -
- O -
co O +
-2- O -
[ O -
2- O -
( O -
2-N O +
-acrylamidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O -
} O +
( O -
15C O +
) O +
Copolymer O +
15C O +
was O +
synthesized O +
using O +
compound O +
8 O +
following O +
the O +
procedure O +
described O +
for O +
terpolymer O +
14A O +
. O +

The O +
average O +
incorporation O +
molar O +
ratio O +
is O +
3:1 O +
( O -
acrylamide O -
: O -
mannose O -
) O -
. O +

Poly O +
{ O -
acrylamide O -
- O -
co O +
-N O +
-acryloyl O -
- O -
aminophenyl O +
α O -
- O -
d O +
-mannopyranoside O -
} O +
( O -
15D O +
) O +
Copolymer O +
15D O +
was O +
synthesized O +
using O +
compound O +
13 O +
following O +
the O +
procedure O +
described O +
before.8 O +
The O +
average O +
incorporation O +
molar O +
ratio O +
is O +
6:1 O +
( O -
acrylamide O -
: O -
mannose O -
) O -
. O +

Poly O +
{ O -
acrylamide O -
- O -
co O +
-2- O -
[ O -
2- O -
( O -
2-N O +
-acrylamidoethoxy O -
) O -
ethoxy O -
] O -
ethoxyl O -
- O -
β O -
- O -
lactoside O -
} O +
( O -
15E O +
) O +
Copolymer O +
15E O +
was O +
synthesized O +
using O +
compound O +
5 O +
following O +
the O +
procedure O +
described O +
for O +
terpolymer O +
14A O +
. O +

The O +
average O +
incorporation O +
molar O +
ratio O +
is O +
1:12 O +
( O -
lactose O -
: O -
acrylamide O -
) O -
. O +

Polymer O +
( O -
15F O +
) O +
Copolymer O +
15F O +
was O +
synthesized O +
following O +
the O +
procedure O +
described O +
for O +
polymer O +
15A O +
. O +

The O +
enzymatic O +
reaction O +
afforded O +
white O +
powder O +
15F O +
in O +
quantitative O +
yield O -
. O +

Compound O +
16 O +
2,3,4,6-Hepta O -
- O -
O O +
-acetyl O -
- O -
α O -
- O -
lactosyl O +
bromide O +
( O -
5 O +
g O -
, O +
7.1 O +
mmol O -
) O +
and O +
methyl O +
6-hydroxyhexanoate O +
( O -
1.3 O +
g O -
, O +
8.9 O +
mmol O -
) O +
were O +
added O +
to O +
a O +
previously O +
flame O -
- O -
dried O +
flask O +
containing O +
7 O +
g O +
MS O +
4 O +
Å O +
and O +
30 O +
mL O +
anhydrous O +
CHCl3 O +
. O +

The O +
resulting O +
suspension O +
was O +
stirred O +
for O +
half O +
an O +
hour O -
. O +

HgO O +
( O -
1.5 O +
g O -
) O +
and O +
HgBr2 O +
( O -
257 O +
mg O -
) O +
were O +
added O +
to O +
the O +
suspension O -
. O +

The O +
mixture O +
was O +
stirred O +
in O +
the O +
dark O +
at O +
ambient O +
temperature O +
for O +
48 O +
h. O +
The O +
resulting O +
mixture O +
was O +
passed O +
through O +
a O +
Celite O +
packed O +
glass O +
funnel O -
, O +
and O +
washed O +
with O +
saturated O +
NaHCO3 O +
and O +
water O -
. O +

The O +
organic O +
phase O +
was O +
dried O +
over O +
anhydrous O +
Na2 O +
SO4 O +
and O +
concentrated O +
in O +
vacuo O -
. O +

The O +
resulting O +
residue O +
was O +
chromatographed O +
( O -
hexane O -
: O -
EtOAc O -
, O +
1:1 O -
) O +
to O +
afford O +
product O +
16 O +
( O -
4.0 O +
g O -
, O +
74 O -
% O -
) O -
. O +

16 O -
: O +
1 O +
H O +
NMR O +
( O -
CDCl3 O +
) O +
δ O +
5.32 O +
( O -
d O -
, O +
J O +
= O -
2.5 O +
Hz O -
, O +
1H O -
) O -
, O +
5.17 O +
( O -
t O -
, O +
J O +
= O -
9.0 O +
Hz O -
, O +
1H O -
) O -
, O +
5.08 O +
( O -
dd O -
, O +
J O +
= O -
8.0 O -
, O +
10.5 O -
, O +
1H O -
) O -
, O +
4.93 O +
( O -
dd O -
, O +
J O +
= O -
3.5 O -
, O +
10.5 O -
, O +
1H O -
) O -
, O +
4.85 O +
( O -
dd O -
, O +
J O +
= O -
8.0 O -
, O +
10.5 O -
, O +
1H O -
) O -
, O +
4.47–4.44 O +
( O -
m O -
, O +
2H O -
) O -
, O +
4.42 O +
( O -
d O -
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
1H O -
) O -
, O +
4.11–4.04 O +
( O -
m O -
, O +
3H O -
) O -
, O +
3.87–3.80 O +
( O -
m O -
, O +
2H O -
) O -
, O +
3.77 O +
( O -
t O -
, O +
J O +
= O -
9.5 O +
Hz O -
, O +
1H O -
) O -
, O +
3.64 O +
( O -
s O -
, O +
3H O -
) O -
, O +
3.59–3.55 O +
( O -
m O -
, O +
1H O -
) O -
, O +
3.46–3.41 O +
( O -
m O -
, O +
1H O -
) O -
, O +
2.27 O +
( O -
t O -
, O +
J O +
= O -
7.5 O +
Hz O -
, O +
2H O -
) O -
, O +
2.13 O -
, O +
2.10 O -
, O +
2.04 O -
, O +
2.021 O -
, O +
2.020 O -
, O +
2.01 O -
, O +
1.94 O +
( O -
7s O -
, O +
7 O +
acetyl O +
groups O -
) O -
, O +
1.64–1.50 O +
( O -
m O -
, O +
4H O -
) O -
, O +
1.38–1.28 O +
( O -
m O -
, O +
2H O -
) O -
. O +

13 O +
C O +
δ174.7 O -
, O +
171.1 O -
, O +
171.0 O -
, O +
170.8 O -
, O +
170.7 O -
, O +
170.5 O -
, O +
170.3 O -
, O +
169.8 O -
, O +
101.7 O -
, O +
101.2 O -
, O +
77.0 O -
, O +
73.5 O -
, O +
73.3 O -
, O +
72.4 O -
, O +
71.7 O -
, O +
71.3 O -
, O +
70.5 O -
, O +
69.8 O -
, O +
67.3 O -
, O +
62.7 O -
, O +
61.5 O -
, O +
34.6 O -
, O +
29.7 O -
, O +
26.0 O -
, O +
25.2 O -
, O +
21.54 O -
, O +
21.49 O -
, O +
21.4 O -
( O -
b O -
) O -
, O +
21.3 O -
( O -
b O -
) O -
, O +
21.2 O -
( O -
b O -
) O -
. O +

HRFABMS O +
calcd O +
for O +
C33 O +
H48 O +
O20 O +
Na+ O +
787.2637 O -
, O +
found O +
787.2618 O -
. O +

Compound O +
17 O +
To O +
a O +
solution O +
of O +
16 O +
( O -
3 O +
g O -
) O +
in O +
anhydrous O +
methanol O +
( O -
200 O +
mL O -
) O +
at O +
0 O -
° O -
C O +
was O +
added O +
NaOMe O +
until O +
pH O +
10 O -
. O +

The O +
solution O +
was O +
stirred O +
for O +
3 O +
h. O +
Dowex O +
cation O +
exchange O +
resin O +
( O -
H O +
form O -
) O +
was O +
added O +
to O +
adjust O +
the O +
pH O +
to O +
6–7 O +
and O +
filtered O -
. O +

The O +
filtrate O +
was O +
evaporated O +
to O +
give O +
a O +
residue O +
which O +
was O +
dissolved O +
in O +
MeOH O -
: O -
H2 O +
O O +
( O -
1:1 O -
) O -
. O +

To O +
the O +
above O +
solution O +
was O +
added O +
LiOH O +
until O +
pH O +
11 O -
. O +

The O +
solution O +
was O +
stirred O +
for O +
1 O +
h. O +
Dowex O +
cation O +
exchange O +
resin O +
( O -
H O +
form O -
) O +
was O +
used O +
to O +
neutralize O +
the O +
above O +
solution O +
which O +
was O +
concentrated O +
to O +
afford O +
a O +
syrup O +
17 O +
in O +
quantitative O +
yield O -
. O +

17 O +
: O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
4.45 O +
( O -
d O -
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
1H O -
) O -
, O +
4.41 O +
( O -
d O -
, O +
J O +
= O -
7.6 O +
Hz O -
, O +
1H O -
) O -
, O +
3.96–3.49 O +
( O -
m O -
, O +
13 O +
H O -
) O -
, O +
3.26 O +
( O -
t O -
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
1H O -
) O -
, O +
2.22 O +
( O -
t O -
, O +
J O +
= O -
7.2 O +
Hz O -
, O +
2H O -
) O -
, O +
1.64–1.53 O +
( O -
m O -
, O +
4H O -
) O -
, O +
1.38–1.32 O +
( O -
m O -
, O +
2H O -
) O +
13 O +
C O +
δ183.3 O -
, O +
103.5 O -
, O +
102.6 O -
, O +
79.0 O -
, O +
76.0 O -
, O +
75.4 O -
, O +
75.1 O -
, O +
73.5 O -
, O +
73.1 O -
, O +
71.6 O -
, O +
71.1 O -
, O +
69.2 O -
, O +
61.6 O -
, O +
60.7 O -
, O +
37.1 O -
, O +
29.1 O -
, O +
25.8 O -
, O +
25.5 O -
. O +

HRFABMS O +
calcd O +
for O +
C18 O +
H32 O +
O13 O +
Na+ O +
479.1741 O -
, O +
found O +
479.1762 O -
. O +

Compound O +
18 O +
To O +
a O +
solution O +
of O +
17 O +
( O -
612 O +
mg O -
) O +
and O +
p O +
-aminophenyl O -
- O -
α O -
- O -
d O +
-mannopyranoside O +
( O -
400 O +
mg O -
) O +
in O +
DMF O +
( O -
10 O +
mL O -
) O +
at O +
0 O -
° O -
C O +
was O +
added O +
DPPA O +
( O -
328 O +
μL O -
) O +
and O +
TEA O +
( O -
400 O +
μL O -
) O -
. O +

The O +
solution O +
was O +
stirred O +
vigorously O +
overnight O -
. O +

The O +
solution O +
was O +
concentrated O +
in O +
vacuo O -
, O +
followed O +
by O +
gel O +
filtration O +
through O +
Bio O -
- O -
Gel O +
P-2 O +
column O +
eluted O +
by O +
water O -
. O +

The O +
fractions O +
containing O +
the O +
glycoconjugate O +
were O +
collected O +
and O +
lyophilized O +
to O +
afford O +
18 O +
628 O +
mg O +
( O -
66 O -
% O +
yield O -
) O -
. O +

Selected O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ5.39 O +
( O -
s O -
, O +
1H O -
, O +
anomeric O +
proton O +
of O +
mannose O -
) O -
, O +
4.26 O +
( O -
d O -
, O +
J O +
= O -
7.5 O +
Hz O -
, O +
2H O -
, O +
two O +
anomeric O +
protons O +
of O +
lactose O -
) O -
. O +

18 O +
: O +
Selected O +
13 O +
C O +
( O -
103.4 O +
( O -
C-1 O +
of O +
glucose O -
) O -
, O +
102.5 O +
( O -
C-1 O +
of O +
galactose O -
) O -
, O +
99.0 O +
( O -
C-1 O +
of O +
mannose O -
) O -
. O +

HRFABMS O +
calcd O +
for O +
C30 O +
H47 O +
NO18 O +
Na+ O +
732.2691 O -
, O +
found O +
732.2665 O -
. O +

Compound O +
19 O +
Acceptor O +
glycoconjugate O +
18 O +
( O -
250 O +
mg O -
) O -
, O +
UDP O -
- O -
Gal O +
( O -
256 O +
mg O -
) O -
, O +
0.1 O -
% O +
BSA B-Gene +
and O +
rα1 B-Gene -
- I-Gene -
3GalT I-Gene +
( O -
15 O +
unit O -
) O +
were O +
incubated O +
in O +
a O +
solution O +
of O +
Tris O -
– O -
HCl O +
buffer O +
( O -
50 O +
mM O -
, O +
pH O +
7 O -
) O +
containing O +
Mn2 O -
+ O +
( O -
10 O +
mM O -
) O +
for O +
48 O +
h O +
at O +
ambient O +
temperature O -
. O +

The O +
mixture O +
was O +
directly O +
applied O +
to O +
Bio O -
- O -
Gel O +
P-2 O +
with O +
water O +
as O +
the O +
eluent O -
. O +

The O +
fractions O +
containing O +
the O +
product O +
were O +
collected O +
and O +
lyophilized O +
to O +
afford O +
the O +
white O +
powder O +
19 O +
187 O +
mg O +
( O -
61 O -
% O +
yield O -
) O -
. O +

19 O +
: O +
Selected O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
) O +
δ O +
5.52 O +
( O -
s O -
, O +
1H O -
, O +
anomeric O +
proton O +
of O +
mannose O -
) O -
, O +
5.09 O -
, O +
( O -
d O -
, O +
J O +
= O -
3.2 O +
Hz O -
, O +
1H O -
, O +
anomeric O +
proton O +
of O +
α O -
- O -
galactose O -
) O -
, O +
4.45 O +
( O -
d O -
, O +
J O +
= O -
7.6 O +
Hz O -
, O +
1H O -
, O +
anomeric O +
proton O -
) O -
, O +
4.40 O +
( O -
d O -
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
1H O -
, O +
anomeric O +
proton O -
) O -
. O +

Selected O +
13 O +
C O +
δ O +
103.9 O +
( O -
C-1 O +
of O +
glucose O -
) O -
, O +
103.1 O +
( O -
C-1 O +
of O +
β O -
- O -
galactose O -
) O -
, O +
99.5 O +
( O -
C-1 O +
of O +
mannose O -
) O -
, O +
96.5 O +
( O -
C-1 O +
of O +
α O -
- O -
galactose O -
) O -
. O +

HRFABMS O +
calcd O +
for O +
C36 O +
H57 O +
NO23 O +
Na+ O +
894.3219 O -
, O +
found O +
894.3223 O -
. O +

Agglutination O +
assay O +
E. O +
coli O +
K12 O +
HB101 O +
was O +
grown O +
overnight O +
at O +
37 O -
° O -
C O +
in O +
static O +
LB O +
media O -
, O +
washed O -
, O +
and O +
suspended O +
with O +
PBS O +
to O +
a O +
final O +
concentration O +
of O +
1 O -
× O -
108 O +
cells O -
/ O -
mL. O +
Yeast O +
( O -
S. O +
cerevisiae O +
, O +
wild O +
type O -
) O +
was O +
incubated O +
on O +
YPD O +
media O +
at O +
25 O -
° O -
C O +
for O +
48 O +
h O -
, O +
washed O -
, O +
and O +
suspended O +
with O +
PBS O +
to O +
a O +
final O +
dilution O +
of O +
4 O -
× O -
107 O +
cells O -
/ O -
mL. O +
Agglutination O +
assays O +
were O +
carried O +
out O +
on O +
a O +
9-well O +
spot O +
plate O -
. O +

Aliquots O +
of O +
90 O +
μL O +
of O +
a O +
solution O +
of O +
the O +
test O +
compound O +
were O +
first O +
agitated O +
with O +
30 O +
μL O +
bacterial O +
suspension O +
for O +
30 O +
s. O +
After O +
that O -
, O +
30 O +
μL O +
yeast O +
suspension O +
was O +
added O -
, O +
and O +
allowed O +
to O +
develop O +
with O +
agitation O +
for O +
at O +
least O +
3 O +
min O -
. O +

Agglutination O +
was O +
observed O +
under O +
a O +
magnifying O +
glass O -
. O +

Purification O +
of O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
IgG I-Gene +
from O +
human O +
serum O +
Polyclonal O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene +
were O +
isolated O +
from O +
the O +
human O +
serum O +
according O +
to O +
a O +
modified O +
protocol O +
as O +
reported O +
previously.32 O +
Male O +
AB O +
type O +
serum O +
was O +
heat O -
- O -
inactivated O +
in O +
a O +
water O +
bath O +
at O +
56 O -
° O -
C O +
for O +
30 O +
min O -
. O +

The O +
α O -
- O -
Gal O +
Sepharose O +
affinity O +
column O +
was O +
washed O +
with O +
75 O +
mL O +
PBS O +
buffer O -
. O +

The O +
heat O -
- O -
inactivated O +
serum O +
( O -
25 O +
mL O -
) O +
was O +
run O +
over O +
the O +
column O +
three O +
times O -
, O +
and O +
the O +
flow O -
- O -
through O +
collected O -
. O +

The O +
column O +
was O +
washed O +
with O +
6 O +
mL O +
PBS O +
14 O +
times O +
until O +
an O +
OD280 O -
nm O +
reading O +
less O +
than O +
0.01 O +
of O +
the O +
flow O -
- O -
through O +
was O +
reached O -
. O +

The O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
antibodies I-Gene +
was O +
eluted O +
from O +
the O +
column O +
with O +
5 O +
mL O +
of O +
100 O +
mM O +
glycine·HCl O +
buffer O +
( O -
pH O +
2.8 O -
) O +
10 O +
times O +
until O +
sufficiently O +
low O +
OD280 O -
nm O +
readings O +
were O +
obtained O -
. O +

The O +
fractions O +
were O +
collected O -
, O +
neutralized O +
immediately O +
with O +
0.5 O +
M O +
sodium O +
bicarbonate O -
, O +
and O +
determined O +
by O +
ELISA O +
assays O -
. O +

ELISA O +
inhibition O +
assay O +
Mouse O +
laminin B-Gene +
( O -
10 O +
μg O -
/ O -
mL O +
in O +
carbonate O +
buffer O -
) O +
as O +
solid O -
- O -
phase O +
antigen O +
was O +
added O +
to O +
a O +
96-well O +
ELISA O +
( O -
Immulon O +
4 O -
) O +
microtiter O +
plate O -
, O +
and O +
incubated O +
overnight O +
at O +
4 O -
° O -
C O -
. O +

Test O +
compound O +
( O -
0.1 O +
or O +
1 O +
mM O -
) O +
was O +
incubated O +
with O +
55 O +
μL O +
of O +
a O +
PBS O +
solution O +
of O +
human O +
polyclonal O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
IgG I-Gene +
for O +
1 O +
h O +
at O +
37 O -
° O -
C O +
with O +
slow O +
agitation O -
. O +

The O +
human O +
anti B-Gene -
- I-Gene -
Gal I-Gene +
IgG I-Gene +
concentration O +
used O +
was O +
adjusted O +
to O +
cause O +
50 O -
% O +
of O +
maximal O +
binding O +
to O +
solid O -
- O -
phase O +
antigen O -
. O +

ELISA O +
plate O +
was O +
blocked O +
with O +
1 O -
% O +
BSA B-Gene +
in O +
PBS O -
, O +
and O +
incubated O +
45 O +
min O +
at O +
room O +
temperature O -
. O +

To O +
appropriate O +
wells O +
on O +
ELISA O +
plate O +
was O +
added O +
50 O +
μL O +
of O +
the O +
test O +
compound O -
/ O -
Ab O +
solution O -
. O +

The O +
solution O +
in O +
each O +
well O +
was O +
incubated O +
for O +
1.5 O +
h O +
at O +
room O +
temperature O -
. O +

The O +
wells O +
were O +
subsequently O +
washed O +
with O +
PBS O -
/ O -
0.05 O -
% O +
Tween O +
and O +
incubated O +
with O +
goat O +
anti O -
- O -
human O +
IgG B-Gene -
- I-Gene -
peroxidase I-Gene +
conjugate O +
for O +
1 O +
h O +
at O +
room O +
temperature O -
. O +

After O +
additional O +
washing O +
with O +
PBS O -
/ O -
0.05%Tween O -
, O +
the O +
peroxidase B-Gene +
reaction O +
was O +
performed O +
with O +
100 O +
μL O +
of O +
a O +
3,3′,5,5′-tetramethylbenzidine O +
( O -
TMB O -
) O -
/ O -
H2 O +
O2 O +
( O -
9 O +
1 O +
) O +
solution O -
, O +
and O +
the O +
UV O +
absorbance O +
was O +
measured O +
at O +
655 O +
nm O -
. O +

Acknowledgements O +

We O +
thank O +
Neose O +
Inc. O +
for O +
providing O +
uridine O +
5′ O +
diphosphate O +
galactose O +
( O -
UDP O -
- O -
Gal O -
) O -
. O +

This O +
work O +
was O +
generously O +
supported O +
by O +
Hercules O +
Inc O -
, O +
NSF O +
( O -
BES-9728366 O -
) O +
and O +
Herman O +
Frasch O +
Foundation O +
( O -
449-HF97 O -
) O -
. O +

We O +
also O +
thank O +
Prof. O +
Esin O +
Gulari O +
of O +
Chemical O +
Engineering O +
Department O +
for O +
providing O +
us O +
with O +
light O +
scattering O +
measurement O -
. O +

n- O +
Hexane O +
is O +
metabolized O +
by O +
microsomal O +
enzymes B-Gene +
giving O +
rise O +
to O +
several O +
oxidation O +
intermediates O +
( O -
Phase O +
I O +
metabolites O -
) O -
, O +
including O +
1-hexanol O -
, O +
2-hexanol O -
, O +
3-hexanol O -
, O +
2-hexanone O -
, O +
5-hydroxy-2-hexanone O -
, O +
2,5-hexanediol O -
, O +
4,5-dihydroxy-2-hexanone O +
and O +
2,5-hexanedione O +
( O -
' O -
free O -
' O +
2,5-HD O -
) O -
, O +
the O +
last O +
one O +
being O +
regarded O +
as O +
the O +
ultimate O +
neurotoxic O +
agent O +
( O -
Perbellini O +
et O +
al. O -
, O +
1981 O -
; O +
Mutti O +
et O +
al. O -
, O +
1984 O -
; O +
IPCS O -
, O +
1991 O +
) O -
. O +

Most O +
of O +
n- O +
hexane O +
metabolites O -
— O -
but O +
not O +
2,5-HD O +
and O +
2-hexanone O -
— O -
undergo O +
Phase O +
II O +
biotransformation O +
and O +
are O +
excreted O +
as O +
glucuronide O +
conjugates O +
( O -
-G O -
) O -
. O +

Their O +
determination O +
by O +
conventional O +
techniques O +
requires O +
preliminary O +
hydrolysis O +
( O -
Fedtke O +
and O +
Bolt O -
, O +
1987a O -
, O -
b O -
; O +
Kawai O +
et O +
al. O -
, O +
1990 O -
; O +
Perbellini O +
et O +
al. O -
, O +
1990 O -
; O +
Soriano O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
yielding O +
to O +
the O +
' O -
total O +
2,5-HD O -
' O +
but O +
also O +
a O +
number O +
of O +
analytical O +
artifacts O -
, O +
i.e. O +
γ O -
- O -
valerolactone O +
and O +
furan O +
derivatives O -
. O +

A O +
new O +
method O +
for O +
the O +
direct O +
determination O +
of O +
both O +
Phases O +
I O +
and O +
II O +
metabolites O +
of O +
n- O +
hexane O +
has O +
been O +
recently O +
developed O +
with O +
the O +
use O +
of O +
the O +
hyphenated O +
technique O +
liquid O +
chromatography O -
- O -
mass O +
spectrometry O +
( O -
LC O -
- O -
MS O -
; O +
Andreoli O +
et O +
al. O -
, O +
1998 O -
; O +
Manini O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

The O +
role O +
of O +
this O +
new O +
technique O +
in O +
the O +
field O +
of O +
metabolism O +
studies O +
is O +
becoming O +
more O +
important O -
, O +
documented O +
by O +
the O +
increasing O +
number O +
of O +
studies O +
published O +
every O +
year O +
all O +
over O +
the O +
world O +
( O -
Niessen O -
, O +
1998 O +
) O -
. O +

The O +
advantages O +
of O +
using O +
a O +
mass O +
spectrometer O -
, O +
a O +
system O +
sensitive O -
, O +
specific O +
and O +
selective O -
, O +
capable O +
of O +
analyte O +
identification O +
and O +
confirmation O -
, O +
as O +
a O +
detector O +
have O +
been O +
already O +
demonstrated O +
in O +
the O +
case O +
of O +
the O +
on O -
- O -
line O +
coupling O +
of O +
gas O +
chromatography O +
with O +
mass O +
spectrometry O -
. O +

The O +
application O +
field O +
of O +
gas O +
chromatography O -
- O -
mass O +
spectrometry O +
( O -
GC O -
- O -
MS O -
) O +
is O +
still O +
limited O +
to O +
volatile O +
and O +
non O -
- O -
thermally O +
labile O +
substances O -
, O +
with O +
relatively O +
low O +
molecular O +
weight O -
, O +
approximately O +
10 O -
% O +
of O +
all O +
the O +
organic O +
compounds O -
. O +

On O +
the O +
contrary O -
, O +
liquid O +
chromatography O +
is O +
suitable O +
for O +
the O +
analysis O +
of O +
polar O +
compounds O +
without O +
the O +
need O +
of O +
prior O +
derivatization O +
and O +
is O +
compatible O +
with O +
aqueous O +
matrices O -
, O +
such O +
as O +
urine O -
, O +
without O +
the O +
need O +
of O +
sample O +
pretreatment O -
. O +

These O +
peculiarities O +
make O +
chromatographic O +
techniques O +
coupled O +
with O +
mass O +
spectrometry O +
suitable O +
for O +
a O +
wide O +
range O +
of O +
applications O +
and O +
open O +
new O +
perspectives O +
in O +
the O +
study O +
of O +
the O +
metabolic O +
fate O +
of O +
drugs O -
, O +
pesticides O -
, O +
natural O +
substances O +
and O +
environmental O +
pollutants O -
. O +

LC O -
- O -
MS O +
allows O +
the O +
analysis O +
of O +
n- O +
hexane O +
metabolites O +
in O +
untreated O +
urine O +
samples O +
without O +
the O +
risk O +
of O +
artifact O +
generation O -
. O +

Objectives O +
of O +
this O +
study O +
were O -
: O +
( O -
i O -
) O +
to O +
assess O +
the O +
analytical O +
validity O +
of O +
conventional O +
techniques O +
and O +
related O +
assumptions O -
; O +
( O -
ii O -
) O +
to O +
evaluate O +
the O +
metabolic O +
pattern O +
of O +
conjugates O +
and O +
unconjugates O +
n- O +
hexane O +
metabolites O +
by O +
hyphenated O +
techniques O -
, O +
i.e. O +
LC O -
- O -
MS O +
and O +
GC O -
- O -
MS O -
; O +
and O +
( O -
iii O -
) O +
to O +
estimate O +
the O +
contribution O +
of O +
different O +
methods O +
of O +
sample O +
pretreatment O +
in O +
the O +
production O +
of O +
2,5-HD O +
and O +
analytical O +
artifacts O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Animals O +
and O +
chemicals O +
Sprague O +
Dawley O +
rats O +
( O -
200–250 O +
g O -
) O +
were O +
obtained O +
from O +
Charles O +
River O +
Laboratories O +
( O -
Calco O -
, O +
Como O -
, O +
Italy O -
) O -
. O +

The O +
animals O +
were O +
housed O +
under O +
conditions O +
of O +
constant O +
temperature O +
and O +
humidity O -
, O +
and O +
automatic O +
photocyle O -
. O +

They O +
had O +
free O +
access O +
to O +
food O +
and O +
water O -
, O +
and O +
only O +
to O +
water O +
during O +
urine O +
collection O -
. O +

All O +
experiments O +
were O +
carried O +
out O +
in O +
compliance O +
with O +
the O +
European O +
Community O +
Guide O +
for O +
the O +
Care O +
and O +
Use O +
of O +
Laboratory O +
Animals O -
. O +

2-Hexanol O -
, O +
2-hexanone O -
, O +
2,5-hexanedione O -
, O +
γ O -
- O -
valerolactone O -
, O +
2,5-hexanediol O +
were O +
purchased O +
from O +
Merck O +
( O -
Darmstadt O -
, O +
Germany O -
) O -
; O +
3-hexanol O -
, O +
2,5-dimethylfuran O +
from O +
Fluka O +
( O -
Buchs O -
, O +
Switzerland O -
) O -
; O +
cyclohexanone O +
( O -
I.S. O -
) O +
from O +
Sigma O -
. O +

High O +
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
water O -
, O +
methanol O -
, O +
acetonitrile O +
and O +
dichloromethane O +
were O +
obtained O +
from O +
Lab O -
- O -
Scan O +
( O -
Dublin O -
, O +
Ireland O -
) O -
; O +
n- O +
hexane O -
, O +
sodium O +
chloride O -
, O +
hydrochloric O +
acid O +
and O +
sodium O +
hydroxide O +
from O +
Carlo O +
Erba O +
( O -
Milan O -
, O +
Italy O -
) O -
. O +

β B-Gene -
- I-Gene -
Glucuronidase I-Gene -
/ O -
arylsulphatase B-Gene +
from O +
Helix O +
Pomatia O +
was O +
from O +
Boehringer O +
Mannheim O +
Italia O +
( O -
Monza O -
, O +
Italy O -
) O -
. O +

2.2 O +
Animal O +
exposure O +
and O +
urine O +
collection O +
Rats O +
were O +
treated O +
with O +
1.4 O +
mmol O +
of O +
pure O +
n- O +
hexane O +
by O +
subcutaneous O +
injection O +
of O +
the O +
solvent O +
once O +
a O +
day O +
on O +
3 O +
consecutive O +
days O -
. O +

After O +
the O +
treatment O -
, O +
the O +
rats O +
were O +
placed O +
in O +
individual O +
metabolic O +
cages O +
provided O +
with O +
urine O -
- O -
feces O +
separators O +
and O +
15 O +
h O +
urine O +
samples O +
( O -
17.8±3.8 O +
ml O -
) O +
were O +
collected O +
over O +
NaN3 O +
0.1 O -
% O -
. O +

Urine O +
samples O +
were O +
stored O +
at O +
−20 O -
° O -
C O +
until O +
analysis O -
. O +

2.3 O +
Sample O +
preparation O +
Rat O +
urine O +
was O +
divided O +
into O +
four O +
aliquots O -
, O +
undergoing O +
different O +
preparation O +
prior O +
to O +
chromatographic O +
analysis O -
: O +
( O -
a O -
) O +
no O +
hydrolysis O -
; O +
( O -
b O -
) O +
enzymatic O +
hydrolysis O -
: O +
2 O +
ml O +
of O +
urine O +
were O +
mixed O +
with O +
4 O +
ml O +
of O +
0.5 O +
M O +
acetate O +
buffer O -
, O +
pH O +
5.0 O -
, O +
and O +
20 O +
μl O +
of O +
β B-Gene -
- I-Gene -
glucuronidase I-Gene -
/ O -
arylsulphatase B-Gene -
, O +
then O +
incubated O +
for O +
24 O +
h O +
at O +
37 O -
° O -
C O -
; O +
( O -
c O -
) O +
acid O +
hydrolysis O -
: O +
2 O +
ml O +
of O +
urine O +
were O +
mixed O +
with O +
100 O +
μl O +
of O +
HCl O +
37 O -
% O -
, O +
pH<1.0 O -
, O +
then O +
put O +
in O +
a O +
boiling O +
water O +
bath O +
for O +
30 O +
min O -
; O +
and O +
( O -
d O -
) O +
enzymatic O +
hydrolysis O +
followed O +
by O +
acid O +
hydrolysis O -
. O +

Each O +
aliquot O +
was O +
ultrafiltered O +
before O +
LC O -
- O -
MS O +
analysis O -
. O +

Samples O +
for O +
GC O -
- O -
MS O +
analysis O +
were O +
extracted O +
with O +
a O +
solution O +
of O +
I.S. O +
in O +
dichloromethane O +
and O +
the O +
organic O +
phase O +
was O +
evaporated O +
to O +
small O +
volume O +
in O +
nitrogen O +
current O -
. O +

2.4 O +
Sample O +
analyses O +
The O +
chromatographic O +
analyses O +
of O +
n- O +
hexane O +
metabolites O +
in O +
rat O +
urine O +
samples O +
were O +
carried O +
out O +
as O +
described O +
earlier O +
( O -
Andreoli O +
et O +
al. O -
, O +
1998 O -
; O +
Manini O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

GC O -
- O -
MS O +
analysis O +
of O +
all O +
the O +
samples O -
, O +
prior O +
and O +
after O +
hydrolysis O +
was O +
performed O +
by O +
using O +
a O +
Hewlett O +
Packard O +
HP O +
6890 O +
gas O +
chromatograph O +
coupled O +
with O +
a O +
HP O +
5973 O +
Mass O +
Selective O +
Detector O +
( O -
MSD O -
) O -
. O +

Separations O +
were O +
obtained O +
on O +
a O +
HP-5MS O +
capillary O +
column O +
( O -
30 O +
m O -
× O -
0.25 O +
mm O -
, O +
0.25 O +
μm O +
film O +
thickness O -
) O +
using O +
hydrogen O +
as O +
a O +
carrier O +
gas O -
. O +

Instrument O +
control O -
, O +
data O +
acquisition O +
and O +
processing O +
were O +
performed O +
with O +
a O +
Hewlett O +
Packard O +
ChemStation O +
( O -
Hewlett O +
Packard O -
, O +
Palo O +
Alto O -
, O +
CA O -
, O +
USA O -
) O -
. O +

LC O -
- O -
MS O +
analyses O +
were O +
carried O +
out O +
using O +
a O +
Perkin O +
Elmer O +
series O +
200 O +
liquid O +
chromatograph O +
coupled O +
with O +
a O +
PE O -
- O -
Sciex O +
API O +
100 O +
single O -
- O -
quadrupole O +
mass O +
spectrometer O +
( O -
Sciex O -
, O +
Thornhill O -
, O +
Canada O -
) O +
equipped O +
with O +
a O +
heated O +
nebulizer O +
( O -
HN O -
) O +
interface O +
for O +
atmospheric O +
pressure O +
chemical O +
ionization O +
( O -
APCI O -
) O +
and O +
an O +
ionspray O +
interface O +
for O +
electrospray O +
ionization O +
( O -
ES O -
) O -
. O +

A O +
Power O +
Macintosh O +
7200 O -
/ O -
120 O +
computer O +
was O +
used O +
for O +
instrument O +
control O -
, O +
data O +
acquisition O +
and O +
processing O -
. O +

LC O -
- O -
MS O -
- O -
MS O +
experiments O +
were O +
performed O +
on O +
a O +
PE O -
- O -
Sciex O +
API O +
300 O +
triple O +
quadrupole O +
mass O +
spectrometer O -
. O +

Chromatography O +
of O +
conjugates O +
was O +
obtained O +
under O +
ion O -
- O -
suppressed O +
reversed O -
- O -
phase O +
conditions O -
, O +
by O +
using O +
high O -
- O -
speed O +
( O -
3 O +
cm O -
, O +
3 O +
μm O -
) O +
columns O +
and O +
formic O +
acid O +
( O -
2 O +
mM O -
) O +
as O +
modifier O +
in O +
the O +
mobile O +
phase O -
. O +

Glucuronides O +
were O +
identified O +
in O +
untreated O +
urine O +
samples O +
by O +
electrospray O +
( O -
ES O -
) O +
LC O -
- O -
MS O +
in O +
negative O -
- O -
ion O +
mode O +
and O +
peak O +
identity O +
was O +
confirmed O +
by O +
LC O -
- O -
MS O -
- O -
MS O +
experiments O -
. O +

For O +
the O +
analysis O +
of O +
free O +
metabolites O +
in O +
hydrolyzed O +
samples O -
, O +
the O +
APCI O +
interface O +
was O +
used O +
in O +
positive O -
- O -
ion O +
mode O +
after O +
separation O +
on O +
a O +
C-18 O +
column O -
. O +

3 O +
Results O +
In O +
untreated O +
urine O +
samples O -
, O +
four O +
glucuronides O +
were O +
identified O +
and O +
characterized O +
by O +
LC O -
- O -
MS O -
, O +
then O +
confirmed O +
by O +
LC O -
- O -
MS O -
- O -
MS O -
: O +
2-hexanol O -
- O -
G O +
and O +
5-hydroxy-2-hexanone O -
- O -
G O +
represented O +
the O +
main O +
conjugates O -
, O +
and O +
4,5-dihydroxy-2-hexanone O -
- O -
G O +
was O +
clearly O +
detectable O -
, O +
whereas O +
2,5-hexanediol O -
- O -
G O +
was O +
identified O +
only O +
in O +
trace O +
amount O -
. O +
' O +

Free O -
' O +
2,5-HD O +
was O +
detectable O +
in O +
non O -
- O -
hydrolyzed O +
samples O +
both O +
by O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O +
( O -
Fig. O +
1 O +
) O -
. O +

Identification O +
and O +
analytical O +
basis O +
for O +
the O +
quantitation O +
of O +
n O +
-hexane O +
glucuronides O -
, O +
whose O +
authentic O +
reference O +
materials O +
are O +
not O +
available O -
, O +
have O +
been O +
reported O +
in O +
a O +
previous O +
paper O +
( O -
Manini O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

The O +
proportion O +
of O +
main O +
metabolites O +
( O -
μmol O +
excreted O +
in O +
the O +
15 O +
h O +
following O +
administration O -
) O +
after O +
different O +
sample O +
treatments O +
is O +
shown O +
in O +
Table O +
1 O +
. O +

Values O +
are O +
arithmetic O +
means O +
and O +
SEM O +
of O +
six O +
urine O +
samples O -
. O +

Enzymatic O +
hydrolysis O +
did O +
not O +
increase O +
the O +
amount O +
of O +
2,5-HD O +
as O +
compared O +
to O +
untreated O +
samples O -
, O +
nor O +
did O +
it O +
produce O +
γ O -
- O -
valerolactone O -
. O +

Moreover O -
, O +
LC O -
- O -
MS O +
analysis O +
of O +
hydrolyzates O +
allowed O +
the O +
identification O +
of O +
the O +
following O +
deconjugated O +
metabolites O -
, O +
i.e. O +
5-hydroxy-2-hexanone O -
, O +
4,5-dihydroxy-2-hexanone O +
and O +
2,5-hexanediol O -
. O +

On O +
the O +
contrary O -
, O +
acid O +
hydrolysis O +
led O +
to O +
substantial O +
increases O +
in O +
2,5-HD O +
( O -
the O +
so O +
called O +
' O -
total O -
' O +
2,5-HD O -
) O +
and O +
produced O +
γ O -
- O -
valerolactone O -
. O +

Owing O +
to O +
its O +
complete O +
transformation O +
into O +
2,5-HD O +
and O +
γ O -
- O -
valerolactone O -
, O +
4,5-dihydroxy-2-hexanone O +
was O +
no O +
longer O +
detectable O +
in O +
LC O -
- O -
MS O +
chromatograms O +
from O +
samples O +
undergone O +
acid O +
hydrolysis O -
, O +
while O +
such O +
a O +
treatment O +
also O +
reduced O +
( O -
by O +
70 O -
% O -
) O +
the O +
concentration O +
of O +
5-hydroxy-2-hexanone O -
. O +

In O +
GC O -
- O -
MS O +
chromatograms O +
of O +
both O +
enzymatic O +
and O +
acid O +
hydrolyzates O -
, O +
measurable O +
amounts O +
of O +
2,5-dimethylfuran O +
were O +
found O -
. O +

No O +
differences O +
were O +
found O +
between O +
acid O +
and O +
enzymatic O +
followed O +
by O +
acid O +
hydrolysis O +
( O -
not O +
shown O -
) O -
. O +

The O +
effect O +
of O +
acid O +
hydrolysis O +
on O +
the O +
metabolite O +
proportions O +
in O +
the O +
second O +
aliquot O +
of O +
the O +
urine O +
of O +
rats O +
1 O +
and O +
2 O +
is O +
shown O +
in O +
Fig. O +
2 O +
. O +

In O +
urine O +
from O +
rat O +
1 O -
, O +
the O +
n O +
-hexanol O -
- O -
G O +
to O +
5-hydroxy-2-hexanone O -
- O -
G O +
ratio O +
was O +
2.85 O -
, O +
whereas O +
such O +
metabolites O +
were O +
excreted O +
in O +
comparable O +
amounts O +
by O +
rat O +
2 O -
. O +

Acid O +
hydrolysis O +
of O +
n O +
-hexanol O -
- O -
G O +
quantitatively O +
led O +
to O +
the O +
corresponding O +
n O +
-hexanols O -
. O +

The O +
hydrolysis O +
of O +
5-hydroxy-2-hexanone O +
was O +
not O +
complete O +
( O -
residual O +
conjugated O +
metabolite O +
35 O -
% O -
) O -
, O +
giving O +
rise O +
to O +
a O +
variable O +
increase O +
in O +
2,5-HD O +
( O -
by O +
440 O +
and O +
2330 O -
% O +
in O +
rats O +
1 O +
and O +
2 O -
, O +
respectively O -
) O +
and O +
to O +
the O +
generation O +
of O +
γ O -
- O -
valerolactone O +
( O -
undetectable O +
in O +
untreated O +
samples O -
) O -
, O +
in O +
addition O +
to O +
a O +
considerable O +
amount O +
of O +
free O +
5-hydroxy-2-hexanone O -
, O +
especially O +
in O +
the O +
case O +
of O +
rat O +
2 O -
. O +

As O +
a O +
result O -
, O +
whereas O +
' O -
free O -
' O +
2,5-HD O +
was O +
six O -
- O -
fold O +
higher O +
in O +
urine O +
from O +
rat O +
1 O +
than O +
in O +
samples O +
from O +
rat O +
2 O -
, O +
comparable O +
amounts O +
of O +
' O -
total O -
' O +
2,5-HD O +
were O +
found O +
after O +
extensive O +
acid O +
hydrolysis O -
. O +

4 O +
Discussion O +
The O +
origin O +
of O +
2,5-HD O +
and O +
sources O +
of O +
analytical O +
artifacts O +
in O +
urine O +
samples O +
from O +
rats O +
treated O +
with O +
n- O +
hexane O +
were O +
identified O +
and O +
characterized O +
by O +
using O +
both O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O -
. O +

Complementary O +
information O +
obtained O +
from O +
such O +
techniques O +
was O +
useful O +
to O +
clarify O +
controversial O +
issues O +
concerning O +
n- O +
hexane O +
metabolism O -
. O +

The O +
proposed O +
scheme O +
of O +
n O +
-hexane O +
metabolism O +
is O +
shown O +
in O +
Fig. O +
1 O +
. O +

In O +
a O +
previous O +
paper O -
, O +
we O +
demonstrated O +
that O +
the O +
total O +
2,5-HD O +
is O +
produced O +
during O +
acid O +
hydrolysis O +
starting O +
from O +
both O +
4,5-dihydroxy-2-hexanone O -
- O -
G O +
and O +
5-hydroxy-2-hexanone O -
- O -
G O +
and O +
that O +
the O +
artifact O +
γ O -
- O -
valerolactone O +
is O +
also O +
generated O +
from O +
the O +
same O +
conjugates O +
by O +
the O +
acid O +
treatment O +
( O -
Manini O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

By O +
contrast O -
, O +
during O +
enzymatic O +
hydrolysis O -
, O +
4,5-dihydroxy-2-hexanone O +
and O +
5-hydroxy-2-hexanone O +
are O +
deconjugated O -
, O +
but O +
neither O +
γ O -
- O -
valerolactone O +
nor O +
2,5-HD O +
increase O +
as O +
compared O +
to O +
untreated O +
samples O -
. O +

Already O +
in O +
1976 O -
, O +
it O +
was O +
demonstrated O +
that O +
5-hydroxy-2-hexanone O +
undergoes O +
dehydration O +
and O +
cyclization O +
in O +
the O +
GC O +
inlet O +
to O +
2,5-dimethyl-2,3-dihydrofuran O +
and O +
therefore O +
is O +
never O +
detectable O +
by O +
GC O +
( O -
Di O +
Vincenzo O +
et O +
al. O -
, O +
1976 O +
) O -
. O +

For O +
the O +
first O +
time O -
, O +
using O +
APCI O -
- O -
LC O -
- O -
MS O +
we O +
detected O +
considerable O +
amounts O +
of O +
free O +
5-hydroxy-2-hexanone O +
in O +
rat O +
urine O +
after O +
enzymatic O +
or O +
acid O +
hydrolysis O +
( O -
Andreoli O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
which O +
is O +
responsible O +
of O +
furans O +
in O +
GC O -
- O -
MS O +
chromatograms O +
of O +
hydrolyzates O +
( O -
both O +
acid O +
and O +
enzymatic O -
) O -
. O +

Because O +
5-hydroxy-2-hexanone O -
- O -
G O +
is O +
the O +
most O +
abundant O +
polioxygenated O +
metabolite O +
of O +
n- O +
hexane O +
in O +
rat O +
( O -
n O +
-hexanol O -
- O -
G O +
does O +
not O +
produce O +
artifacts O -
) O -
, O +
this O +
is O +
the O +
' O -
key O +
metabolite O -
' O +
generating O +
' O -
total O -
' O +
2,5-HD O -
, O +
γ O -
- O -
valerolactone O -
, O +
and O +
2,5-dimethylfuran O -
. O +

The O +
yield O +
of O +
hydrolysis O +
for O +
this O +
compound O +
is O +
variable O -
, O +
i.e. O +
33–38 O +
and O +
61–63 O -
% O +
after O +
enzymatic O +
and O +
acid O +
treatment O -
, O +
respectively O -
. O +

Thus O -
, O +
the O +
calculation O +
of O +
4,5-dihydroxy-2-hexanone O +
and O +
5-hydroxy-2-hexanone O +
by O +
the O +
difference O +
between O +
2,5-HD O +
and O +
γ O -
- O -
valerolactone O +
with O +
and O +
without O +
hydrolysis O +
( O -
Soriano O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
is O +
questionable O -
. O +

Although O +
based O +
on O +
animal O +
experiments O +
needing O +
further O +
validation O +
in O +
field O +
studies O -
, O +
the O +
present O +
investigation O +
gives O +
rise O +
to O +
some O +
conclusions O +
relevant O +
to O +
the O +
biomonitoring O +
of O +
n O +
-hexane O +
exposure O -
. O +

Since O +
the O +
variability O +
due O +
to O +
pre O -
- O -
analytical O +
( O -
hydrolysis O -
) O +
and O +
analytical O +
factor O +
should O +
be O +
kept O +
as O +
low O +
as O +
possible O -
, O +
we O +
suggest O +
not O +
to O +
use O +
acid O +
hydrolysis O -
, O +
but O +
rather O +
to O +
measure O +
' O -
free O -
' O +
2,5-HD O +
in O +
untreated O +
samples O -
. O +
' O +

Free O -
' O +
2,5-HD O +
is O +
meaningful O +
from O +
a O +
toxicological O +
point O +
of O +
view O -
, O +
since O +
it O +
is O +
thought O +
to O +
be O +
responsible O +
for O +
the O +
neurotoxic O +
effects O +
of O +
n- O +
hexane O +
and O +
methyl O -
- O -
n- O +
butyl O +
ketone O -
. O +

By O +
contrast O -
, O +
the O +
meaning O +
of O +
' O -
total O -
' O +
2,5-HD O +
is O +
also O +
questionable O +
for O +
toxicological O +
reasons O -
, O +
since O +
it O +
results O +
from O +
a O +
number O +
of O +
highly O +
soluble O +
glucuronated O +
compounds O +
rapidly O +
excreted O +
with O +
urine O +
and O +
meaningless O +
in O +
terms O +
of O +
toxic O +
risk O -
. O +

Although O +
' O -
total O -
' O +
2,5-HD O +
appears O +
correlated O +
with O +
airborne O +
n O +
-hexane O +
( O -
Kawai O +
et O +
al. O -
, O +
1991 O +
) O -
, O +
the O +
contribution O +
of O +
endogenous O +
compounds O +
seems O +
not O +
to O +
be O +
negligible O +
at O +
low O +
levels O +
( O -
Perbellini O +
et O +
al. O -
, O +
1993 O -
; O +
Mutti O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

Since O +
' O -
total O -
' O +
2,5-HD O +
is O +
not O +
the O +
unique O +
product O +
of O +
hydrolysis O +
of O +
several O +
glucuronated O +
metabolites O -
, O +
reference O +
values O +
for O +
' O -
total O -
' O +
2,5-HD O +
( O -
Bavazzano O +
et O +
al. O -
, O +
1998 O +
) O +
are O +
also O +
questionable O -
. O +

Despite O +
the O +
limited O +
number O +
of O +
rats O +
considered O +
in O +
these O +
experiments O -
, O +
two O +
rats O +
repeatedly O +
treated O +
with O +
the O +
same O +
dose O +
of O +
n O +
-hexane O +
produced O +
different O +
amounts O +
of O +
the O +
neurotoxic O +
metabolite O +
2,5-HD O -
. O +

From O +
the O +
visual O +
inspection O +
of O +
Fig. O +
2 O +
, O +
it O +
can O +
be O +
argued O +
that O +
interindividual O +
differences O +
exist O +
in O +
the O +
biotransformation O +
of O +
n O +
-hexane O -
, O +
resulting O +
in O +
different O +
proportions O +
among O +
Phases O +
I O +
and O +
II O +
metabolites O -
. O +

Interindividual O +
metabolic O +
differences O +
are O +
ignored O +
when O +
exposure O +
and O +
the O +
subsequent O +
neurotoxic O +
risk O +
are O +
assessed O +
on O +
the O +
basis O +
of O +
' O -
total O -
' O +
2,5-HD O -
. O +

Indeed O -
, O +
as O +
shown O +
in O +
the O +
same O +
Fig. O +
2 O +
, O +
the O +
urinary O +
concentrations O +
of O +
2,5-HD O +
from O +
both O +
rats O +
were O +
overlapping O -
. O +

Taking O +
into O +
account O +
that O +
the O +
risk O +
of O +
adverse O +
effects O +
is O +
attributable O +
not O +
only O +
to O +
the O +
intrinsic O +
properties O +
or O +
toxicity O +
of O +
a O +
chemical O +
agent O -
, O +
but O +
also O +
to O +
the O +
susceptibility O +
of O +
exposed O +
subjects O -
, O +
this O +
preliminary O +
and O +
partial O +
result O +
warrants O +
the O +
study O +
of O +
metabolic O +
profiles O +
from O +
n- O +
hexane O +
exposed O +
subjects O +
in O +
relation O +
to O +
relevant O +
polymorphic O +
drug B-Gene -
- I-Gene -
metabolizing I-Gene +
enzymes I-Gene -
. O +

Also O -
, O +
the O +
use O +
of O +
suitable O +
and O +
valid O +
techniques O +
is O +
a O +
pre O -
- O -
requisite O +
to O +
characterize O +
metabolic O +
interactions O +
among O +
components O +
of O +
complex O +
solvent O +
mixtures O -
. O +

Acknowledgements O +
This O +
work O +
was O +
financially O +
supported O +
by O +
the O +
European O +
Commission O +
( O -
ENV O -
- O -
CT-96 O -
- O -
173 O -
) O -
. O +

The O +
medical O +
use O +
of O +
the O +
extracts O +
of O +
Echinacea O +
purpurea O +
is O +
long O +
known O +
and O +
the O +
polysaccharide O +
components O +
of O +
these O +
extracts O +
have O +
been O +
systematically O +
investigated O +
by O +
Wagner O +
et O +
al. O +
[ O -
1–3 O -
] O +
. O +

As O +
a O +
result O +
of O +
these O +
studies O -
, O +
the O +
polysaccharides O +
of O +
Echinacea O +
purpurea O +
are O +
produced O +
in O +
industrial O +
scale O +
by O +
cell O +
cultures O +
[ O -
4,5 O -
] O +
. O +

These O +
polysaccharides O +
are O +
4-O- O +
methylglucuronoarabinoxylans O +
[ O -
3 O -
] O +
and O +
arabinorhamnogalactans O +
[ O -
3 O -
] O +
. O +

Most O +
recently O +
an O +
arabinogalactan O +
fraction O +
possessing O +
promising O +
biological O +
activity O +
was O +
isolated O +
[ O -
6 O -
] O +
( O -
Scheme O +
1 O +
) O -
. O +

Structure O +
elucidation O +
suggested O +
that O +
all O +
third O +
or O +
fourth O +
galactose O +
units O +
of O +
the O +
β- O -
( O -
1→6 O -
) O -
-linked O +
galactan O +
skeleton O +
contain O +
either O +
an O +
α O -
- O -
l O +
-arabinofuranosyl O +
or O +
an O +
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→5 O -
) O -
-α O -
- O -
l O +
-arabinofuranosyl O +
side O +
chain O -
. O +

The O +
presence O +
of O +
a O +
rather O +
similar O +
structural O +
unit O +
is O +
supposed O +
by O +
Albersheim O +
et O +
al. O +
[ O -
7 O -
] O +
in O +
the O +
polysaccharide O +
isolated O +
from O +
suspension O -
- O -
cultured O +
sycamore O +
maple O +
( O -
Acer O +
pseudoplatanus O +
) O -
. O +

Three O +
different O +
tetrasaccharide O +
derivatives O +
were O +
synthesized O +
most O +
recently O +
by O +
van O +
Boom O +
et O +
al. O +
[ O -
8 O -
] O +
for O +
the O +
characterisation O +
of O +
several O +
monoclonal B-Gene +
antibodies I-Gene +
elucidated O +
by O +
the O +
epitopes O +
of O +
polysaccharides O +
isolated O +
from O +
Acer O +
pseudoplatanus O +
. O +

2 O +
. O +

Results O +
and O +
discussion O +
The O +
aim O +
of O +
the O +
present O +
synthetic O +
work O +
was O +
to O +
establish O +
a O +
method O +
for O +
the O +
preparation O +
of O +
well O -
- O -
defined O +
parts O +
of O +
the O +
next O +
two O +
structural O +
units O +
and O +
employ O +
these O +
oligosaccharides O +
to O +
raise O +
monoclonal B-Gene +
antibodies I-Gene -
. O +

These O +
antibodies B-Gene +
might O +
be O +
suitable O +
tools O +
for O +
structure O +
elucidation O +
of O +
plant O +
polysaccharides O +
[ O -
9 O -
] O +
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O +
there O +
are O +
only O +
four O +
examples O +
in O +
the O +
literature O +
[ O -
8,10–12 O -
] O +
for O +
the O +
preparation O +
of O +
non O -
- O -
symmetrically O +
2,6-di O -
- O -
O- O +
glycosylated O +
β O -
- O -
d O +
-galactopyranosyl O +
derivatives O -
. O +

Now O +
we O +
report O +
our O +
first O +
results O +
obtained O +
with O +
some O +
oligosaccharides O +
having O +
the O +
desired O +
minimal O +
structural O +
unit O -
. O +

We O +
were O +
the O +
first O +
to O +
report O +
[ O -
13 O -
] O +
that O +
the O +
reaction O +
of O +
alkyl O +
β O -
- O -
d O +
-galactopyranosides O +
with O +
2,2-dimethoxypropane O +
in O +
the O +
presence O +
of O +
a O +
catalytic O +
amount O +
of O +
p O +
-toluenesulfonic O +
acid O +
resulted O +
in O +
alkyl O +
3,4-O- O +
isopropylidene-6-O O +
- O -
( O -
methoxydimethyl O -
) O -
methyl O -
- O -
β O -
- O -
d O +
-galactopyranosides O -
. O +

Other O +
authors O +
[ O -
14–16 O -
] O +
succesfully O +
used O +
this O +
procedure O +
for O +
the O +
preparation O +
of O +
different O +
galactopyranoside O +
derivatives O +
having O +
a O +
free O +
OH-2 O +
group O -
, O +
and O +
abbreviated O +
the O +
( O -
methoxydimethyl O -
) O -
methyl O +
group O +
as O +
MIP O +
( O -
2-methoxy O -
- O -
isopropyl O -
) O -
. O +

In O +
the O +
knowledge O +
of O +
this O +
reaction O -
, O +
our O +
strategy O +
was O +
to O +
galactosylate O +
a O +
galactopyranos O -
( O -
e O -
) O -
yl O +
unit O +
having O +
free O +
OH-6 O -
, O +
and O +
after O +
deprotection O +
of O +
the O +
second O +
galactosyl O +
unit O +
and O +
treatment O +
with O +
2,2-dimethoxypropane O -
, O +
a O +
partially O +
protected O +
digalactose O +
having O +
the O +
OH-2′ O +
free O +
was O +
expected O +
to O +
be O +
obtained O -
. O +

This O +
should O +
be O +
amenable O +
to O +
direct O +
arabinosylation O -
. O +

Based O +
on O +
the O +
above O +
considerations O -
, O +
1,2:3,4-di O -
- O -
O- O +
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
[ O -
17 O -
] O +
( O -
1 O +
) O +
was O +
glycosylated O +
with O +
α O -
- O -
acetobromo O -
- O -
d O +
-galactose O +
under O +
Helferich O +
conditions O +
( O +
Schemes O +
2 O +
and O +
3 O +
) O +
and O +
the O +
known O +
6-O O +
- O -
( O -
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
-1,2:3,4-di O -
- O -
O- O +
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
[ O -
18 O -
] O +
( O -
2 O +
) O +
was O +
obtained O -
. O +

Compound O +
2 O +
was O +
deacetylated O +
to O +
give O +
6-O O +
- O -
( O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
-1,2:3,4-di O -
- O -
O- O +
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
[ O -
19 O -
] O +
( O -
3 O +
) O -
, O +
and O +
this O +
disaccharide O +
was O +
treated O +
with O +
50 O +
equivalents O +
of O +
neat O +
2,2-dimethoxypropane O +
in O +
the O +
presence O +
of O +
p O +
-toluenesulfonic O +
acid O -
. O +

A O +
nearly O +
quantitative O +
reaction O +
yielded O +
6-O- O +
( O -
3,4-O- O +
isopropropylidene-6-O- O +
( O -
methoxydimethyl O -
) O -
methyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
-1,2:3,4-di O -
- O -
O- O +
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
4 O +
) O -
. O +

Compound O +
5 O +
with O +
6′-OH O +
free O +
was O +
formed O +
only O +
as O +
a O +
side O +
product O -
. O +

The O +
direct O +
treatment O +
of O +
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-d O +
-galactose O +
( O -
6 O +
) O +
with O +
2,2-dimethoxypropane O +
also O +
resulted O +
in O +
compound O +
4 O +
. O +

The O +
MIP O +
derivatives O +
show O +
very O +
easily O +
characterisable O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
signals O -
: O +
in O +
compound O +
4 O +
there O +
were O +
eight O +
C O -
- O -
methyl O +
signals O +
in O +
the O +
1 O +
H O +
NMR O +
spectrum O +
between O +
1.50 O +
and O +
1.30 O +
ppm O -
; O +
the O +
OCH3 O +
group O +
resonated O +
at O +
3.12 O +
ppm O -
. O +

In O +
the O +
13 O +
C O +
NMR O +
spectrum O +
the O +
quaternary O +
acetal O +
carbon O +
of O +
the O +
( O -
methoxydimethyl O -
) O -
methyl O +
group O +
resonated O +
at O +
100.1 O +
ppm O -
, O +
the O +
C-6 O +
showed O +
a O +
rather O +
strong O +
upfield O +
shift O +
at O +
60.26 O +
ppm O -
, O +
and O +
the O +
OCH3 O +
signal O +
appeared O +
at O +
48.53 O +
ppm O -
. O +

These O +
signals O +
also O +
helped O +
the O +
structure O +
elucidation O +
of O +
other O -
, O +
more O +
complex O +
oligosaccharide O +
derivatives O -
. O +

To O +
synthesize O +
the O +
trisaccharide O +
repeating O +
unit O +
of O +
structure O +
I O +
, O +
compound O +
4 O +
seemed O +
to O +
be O +
a O +
good O +
candidate O +
as O +
the O +
aglycone O -
. O +

Arabinosylation O +
of O +
4 O +
with O +
2,3,5-tri O -
- O -
O- O +
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl O +
bromide O +
[ O -
20 O -
] O +
( O -
7 O +
) O +
using O +
Hg O -
( O -
CN O -
) O -
2 O +
as O +
promoter O +
resulted O +
in O +
three O +
chromatographically O +
well O -
- O -
separable O +
substances O -
, O +
but O -
, O +
unfortunately O -
, O +
none O +
of O +
them O +
contained O +
the O +
MIP O +
group O -
. O +

The O +
fully O +
protected O +
compound O +
proved O +
to O +
be O +
6-O- O +
[ O -
2,6-di O -
- O -
O- O +
( O -
2,3,5-tri O -
- O -
O- O +
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl O -
) O -
-3,4-O- O +
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
] O -
-1,2:3,4-di O -
- O -
O- O +
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
8 O +
) O -
. O +

The O +
presence O +
of O +
three O +
quaternary O +
acetalic O +
signals O +
( O -
110.24 O -
, O +
108.99 O +
and O +
108.21 O +
ppm O -
) O -
, O +
the O +
four O +
anomeric O +
carbon O +
signals O +
( O -
105.67 O -
, O +
103.73 O -
, O +
101.19 O +
and O +
95.94 O +
ppm O -
) O -
, O +
the O +
absence O +
of O +
the O +
MIP O +
group O +
and O +
the O +
glycosylation O +
shift O +
at O +
the O +
carbon O +
C-6′ O +
verified O +
the O +
structure O +
of O +
compound O +
8 O +
. O +

The O +
second O +
product O +
in O +
the O +
reaction O +
mixture O +
proved O +
to O +
be O +
the O +
trisaccharide O +
9 O +
. O +

The O +
three O +
anomeric O +
carbon O +
signals O +
resonated O +
at O +
105.60 O -
, O +
103.36 O +
and O +
96.14 O +
ppm O -
, O +
the O +
C-6′ O +
was O +
glycosylated O +
( O -
C-6′ O -
: O +
65.72 O +
ppm O -
) O -
, O +
and O +
three O +
dioxolane O -
- O -
type O +
isopropylidene O +
groups O +
were O +
present O +
( O -
109.89 O -
, O +
109.35 O +
and O +
108.64 O +
ppm O -
) O -
. O +

Acetylation O +
of O +
9 O +
gave O +
the O +
monoacetyl O +
derivative O +
( O -
10 O +
) O +
and O +
one O +
proton O +
triplet O +
was O +
shifted O +
to O +
the O +
lower O +
field O -
. O +

The O +
acetylated O +
OH O +
group O +
was O +
assigned O +
as O +
OH-2′ O -
, O +
having O +
the O +
triplet O +
at O +
5.08 O +
ppm O -
, O +
and O +
8.5 O +
Hz O +
coupling O +
constants O +
assignable O +
to O +
J O +
1′,2′ O +
and O +
J O +
2′,3′ O +
. O +

The O +
third O +
( O -
minor O -
) O +
component O +
was O +
also O +
a O +
trisaccharide O +
( O -
11 O +
) O -
, O +
in O +
which O +
C-6′ O +
( O -
62.38 O +
ppm O -
) O +
was O +
free O -
, O +
three O +
acetal O +
rings O +
were O +
present O +
( O -
109.98 O -
, O +
109.46 O +
and O +
108.74 O +
ppm O -
) O -
, O +
and O +
an O +
arabinofuranosyl O +
unit O +
was O +
anchored O +
at O +
C-2′. O +
This O +
compound O +
was O +
the O +
planned O +
trisaccharide O -
, O +
although O +
without O +
the O +
terminal O +
MIP O +
substitutent O -
: O +
6-O- O +
[ O -
2-O- O +
( O -
2,3,5-tri O -
- O -
O- O +
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl O -
) O -
-3,4-O- O +
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
] O -
-1,2:3,4-di O -
- O -
O- O +
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
11 O +
) O -
. O +

In O +
the O +
knowledge O +
of O +
the O +
extreme O +
acid O -
- O -
sensitive O +
properties O +
of O +
the O +
MIP O +
derivatives O -
, O +
the O +
formation O +
of O +
the O +
above O +
oligosaccharides O +
( O -
8 O -
, O +
9 O +
and O +
11 O +
) O +
can O +
be O +
easily O +
explained O -
. O +

In O +
the O +
initial O +
stage O +
of O +
the O +
glycosylation O +
reaction O +
the O +
OH-2′ O +
is O +
the O +
only O +
nucleophilic O +
partner O +
and O +
the O +
MIP O -
- O -
containing O +
12 O +
( O -
vide O +
infra O -
) O +
was O +
produced O -
. O +

During O +
this O +
reaction O +
mercury O +
bromide O +
was O +
also O +
formed O +
and O +
this O +
rather O +
strong O +
Lewis O +
acid O +
hydrolysed O +
the O +
acid O -
- O -
sensitive O +
MIP O +
blocking O +
group O -
. O +

Then O -
, O +
reaction O +
of O +
the O +
more O +
nucleophilic O +
OH-6′ O +
resulted O +
in O +
the O +
trisaccharide O +
derivative O +
9 O +
, O +
and O +
the O +
excess O +
of O +
the O +
glycosyl O +
donor O +
glycosylated O +
it O +
to O +
the O +
tetrasaccharide O +
main O +
product O +
8 O +
. O +

The O +
small O +
amount O +
of O +
compound O +
11 O +
formed O +
from O +
its O +
6-OMIP O +
derivative O +
( O -
12 O +
) O -
, O +
which O +
did O +
not O +
lose O +
its O +
MIP O +
during O +
the O +
coupling O +
reaction O -
, O +
but O +
was O +
cleaved O +
during O +
the O +
work O -
- O -
up O +
procedure O -
. O +

Similar O +
reaction O +
mixtures O +
were O +
obtained O +
by O +
using O +
Ag2 O +
O O +
or O +
Ag2 O +
CO3 O +
promoters O -
. O +

To O +
avoid O +
the O +
cleavage O +
of O +
the O +
MIP O +
group O +
we O +
executed O +
the O +
glycosylation O +
reaction O +
promoted O +
by O +
AgOTf O +
in O +
the O +
presence O +
of O +
sym O +
-collidine O +
( O -
2,4,6-trimethylpyridine O -
) O -
, O +
hoping O +
that O +
this O +
strong O +
base O +
can O +
prevent O +
the O +
hydrolysis O +
of O +
the O +
acid O -
- O -
sensitive O +
mixed O +
acetalic O +
protecting O +
group O -
. O +

The O +
reaction O +
proceeded O +
with O +
an O +
acceptable O +
rate O +
and O +
two O +
products O +
( O -
12 O +
and O +
13 O +
) O +
were O +
formed O -
. O +

It O +
was O +
also O +
observed O +
that O +
the O +
chromatographically O +
faster O -
- O -
moving O +
component O +
( O -
12 O +
) O +
was O +
transformed O +
into O +
the O +
slower O -
- O -
moving O +
one O +
( O -
13 O +
) O -
. O +

Although O +
the O +
two O +
products O +
showed O +
very O +
similar O +
chromatographic O +
mobility O -
, O +
their O +
separation O +
could O +
be O +
achieved O +
rather O +
easily O -
. O +

The O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
of O +
the O +
faster O -
- O -
moving O +
component O +
showed O +
the O +
presence O +
of O +
the O +
MIP O +
group O +
( O -
δ O +
: O +
3.2 O +
ppm O -
, O +
OCH O +
3 O +
, O +
24 O +
H O +
was O +
integrated O +
between O +
δ O +
: O +
1.18–1.62 O +
ppm O -
) O -
, O +
and O +
three O +
benzoyl O +
moieties O +
were O +
also O +
present O -
. O +

The O +
13 O +
C O +
NMR O +
spectrum O +
was O +
more O +
informative O -
; O +
three O +
dioxolane O -
- O -
type O +
acetalic O +
carbon O +
signals O +
could O +
be O +
assigned O +
( O -
δ O +
: O +
110.15 O -
, O +
109.06 O +
and O +
108.31 O -
) O -
, O +
the O +
three O +
anomeric O +
carbon O +
atoms O +
resonated O +
at O +
103.82 O -
, O +
101.28 O +
and O +
96.04 O +
ppm O -
, O +
and O +
the O +
quaternary O +
acetalic O +
carbon O +
atom O +
of O +
the O +
MIP O +
appeared O +
at O +
100.10 O +
ppm O -
. O +

The O +
O-6′ O +
contained O +
the O +
-O- O +
C O -
( O -
CH3 O +
) O -
2 O +
-OCH3 O +
group O -
, O +
an O +
upfield O +
shift O +
of O +
∼2 O +
ppm O +
could O +
be O +
detected O +
( O -
δ O +
: O +
60.08 O +
ppm O -
) O +
and O +
the O +
OC O +
H3 O +
group O +
resonated O +
at O +
48.49 O +
ppm O -
. O +

Mild O +
acid O +
hydrolysis O +
of O +
the O +
MIP O +
group O +
in O +
compound O +
12 O +
resulted O +
in O +
11 O +
in O +
a O +
quantitative O +
yield O -
. O +

The O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
of O +
the O +
second O -
, O +
slower O -
- O -
moving O +
compound O +
( O -
13 O +
) O +
showed O +
a O +
trisaccharide O +
character O -
. O +

The O +
spectra O +
did O +
not O +
contain O +
OCH3 O +
signal O -
( O -
s O -
) O -
, O +
but O +
there O +
was O +
a O +
quaternary O +
carbon O +
signal O +
at O +
100.5 O +
ppm O +
which O +
could O +
be O +
an O +
acetalic O +
carbon O +
resonance O -
. O +

The O +
C-6′ O +
also O +
appeared O +
at O +
high O +
field O +
( O -
δ O +
: O +
60.18 O +
ppm O -
) O -
, O +
and O +
there O +
were O +
21 O +
hydrogens O +
in O +
the O +
methyl O -
- O -
proton O +
region O -
. O +

These O +
spectral O +
data O +
suggested O +
a O +
symmetrical O +
isopropylidene O +
acetal O +
structure O +
in O +
which O +
the O +
alcoholic O +
components O +
were O +
the O +
two O +
trisaccharide O +
molecules O -
; O +
its O +
composition O +
can O +
be O +
depicted O +
by O +
structure O +
13 O +
. O +

Formation O +
of O +
symmetrical O +
dimerization O +
products O +
of O +
monosaccharides O +
having O +
similar O +
structure O +
to O +
13 O +
was O +
reported O +
by O +
Barresi O +
and O +
Hindsgaul O +
[ O -
21 O -
] O +
in O +
a O +
publication O +
dealing O +
with O +
synthesis O +
of O +
β O -
- O -
mannopyranosides O +
by O +
intramolecular O +
aglycone O +
delivery O -
. O +

The O +
assumed O +
structure O +
of O +
13 O +
was O +
verified O +
by O +
MALDI O -
- O -
TOF O +
MS O +
measurement O +
giving O +
m O +
/z O +
: O +
1853.9 O -
. O +

In O +
the O +
spectrum O +
of O +
compound O +
13 O +
two O +
additional O +
fragments O +
appeared O +
with O +
m O +
/z O +
: O +
906.5 O +
and O +
946.5 O -
; O +
the O +
first O +
could O +
be O +
assigned O +
to O +
11 O +
and O +
the O +
second O +
to O +
the O +
6-O- O +
isopropenyl O +
ether O +
of O +
11 O +
. O +

The O +
symmetrical O +
acetalic O +
bond O +
in O +
compound O +
13 O +
is O +
more O +
stable O +
than O +
the O +
bonds O +
of O +
the O +
mixed O +
acetals O +
( O -
MIP O -
) O +
but O +
more O +
sensitive O +
than O +
the O +
cyclic O +
dioxolane O -
- O -
type O +
isopropylidene O +
acetals O -
. O +

Mild O +
acid O +
hydrolysis O +
of O +
13 O +
resulted O +
in O +
11 O +
with O +
a O +
quantitative O +
yield O -
. O +

Compound O +
11 O +
can O +
be O +
a O +
choice O +
as O +
the O +
aglycone O +
for O +
additional O +
glycosylation O -
, O +
or O +
even O +
an O +
aglycone O +
for O +
dimerisation O +
into O +
the O +
hexasaccharide O +
I O +
. O +

These O +
results O +
demonstrate O +
that O +
the O +
easily O +
available O +
MIP O +
derivatives O +
can O +
serve O +
as O +
aglycones O +
in O +
glycosylation O +
reactions O -
, O +
but O +
basic O +
or O +
neutral O +
conditions O +
are O +
required O +
for O +
the O +
coupling O +
reactions O +
and O +
also O +
for O +
the O +
work O -
- O -
up O +
procedure O -
. O +

It O +
is O +
known O +
that O +
the O +
MIP O +
derivatives O +
can O +
be O +
successfully O +
etherified O +
under O +
basic O +
conditions O +
[ O -
15 O -
] O +
( O -
Scheme O +
4 O +
) O -
. O +

Benzylation O +
of O +
compound O +
4 O +
gave O +
the O +
fully O +
protected O +
crystalline O +
disaccharide O +
14 O +
( O -
Scheme O +
2 O +
) O -
. O +

Selective O +
hydrolysis O +
of O +
the O +
MIP O +
fgroup O +
resulted O +
in O +
the O +
crystalline O +
6-O- O +
( O -
2-O- O +
benzyl-3,4-O- O +
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
-1,2:3,4-di O -
- O -
O- O +
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
15 O +
) O -
. O +

Complete O +
hydrolysis O +
of O +
the O +
isopropylidene O +
acetals O +
either O +
of O +
14 O +
or O +
15 O +
gave O +
6-O- O +
( O -
2-O- O +
benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
-d O +
-galactose O +
( O -
16 O +
) O -
. O +

Acetylation O +
of O +
16 O +
afforded O +
the O +
peracetylated O +
derivative O +
( O -
17 O +
) O +
from O +
which O -
, O +
after O +
hydrogenolysis O -
, O +
6-O- O +
( O -
3,4,6-tri O -
- O -
O- O +
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl O -
) O -
-1,2,3,4-tetra O -
- O -
O- O +
acetyl O -
- O -
α O -
, O -
β O -
- O -
d O +
-galactopyranose O +
( O -
18 O +
) O +
was O +
obtained O -
. O +

Compound O +
18 O +
could O +
be O +
arabinosylated O +
with O +
7 O +
and O +
the O +
persubstituted O +
trisaccharide O +
19 O +
was O +
isolated O -
. O +

For O +
the O +
removal O +
of O +
the O +
isopropylidene O +
groups O +
of O +
the O +
oligosaccharides O +
8 O +
, O +
9 O +
, O +
11 O +
and O +
13 O +
aqueous O +
90 O -
% O +
trifluoroacetic O +
acid O +
was O +
used O -
. O +

The O +
acyl O +
groups O +
were O +
removed O +
by O +
Zemplén O +
transesterification O +
to O +
furnish O +
the O +
tetrasaccharide O +
20 O +
from O +
compound O +
8 O +
and O +
the O +
trisaccharide O +
21 O +
from O +
the O +
protected O +
9 O +
. O +

The O +
target O +
trisaccharide O +
22 O +
was O +
obtained O +
from O +
three O +
different O +
protected O +
intermediates O -
: O +
11 O +
, O +
13 O +
and O +
19 O +
( O -
Scheme O +
5 O +
) O -
. O +

Detailed O +
two O -
- O -
dimensional O +
( O -
2D O -
) O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
studies O +
resulted O +
in O +
the O +
pertinent O +
spectral O +
assignments O -
. O +

The O +
13 O +
C O +
NMR O +
data O +
of O +
the O +
protected O +
derivatives O +
are O +
collected O +
in O +
Table O +
1 O +
. O +

Similar O +
measurements O +
were O +
done O +
in O +
the O +
case O +
of O +
the O +
free O +
oligosaccharides O -
, O +
too O -
. O +

These O +
trisaccharides O -
, O +
in O +
aqueous O +
solutions O -
, O +
occur O +
as O +
mixture O +
of O +
two O +
anomers O -
, O +
but O +
in O +
the O +
case O +
of O +
the O +
branched O +
tetrasaccharide O +
20 O +
, O +
the O +
reducing O +
d O +
-galactose O +
unit O +
existed O +
in O +
four O +
isomeric O +
forms O +
( O -
α- O -
, O +
β O -
- O -
pyranose O +
and O +
α- O -
, O +
and O +
β O -
- O -
furanose O +
forms O -
) O +
and O +
in O +
the O +
equilibrium O +
mixture O +
the O +
quadruplication O +
of O +
some O +
individual O +
carbon-13 O +
signals O +
could O +
be O +
detected O -
. O +

Similar O +
spectral O +
behaviours O +
have O +
been O +
reported O +
earlier O +
from O +
our O +
laboratory O +
[ O -
22,23 O -
] O +
( O -
Scheme O +
6 O +
) O -
. O +

3 O +
. O +

Experimental O +
3.1 O +
General O +
methods O +
Optical O +
rotations O +
were O +
measured O +
at O +
room O +
temperature O +
with O +
a O +
Perkin O -
– O -
Elmer O +
241 O +
automatic O +
polarimeter O -
. O +

Melting O +
points O +
were O +
determined O +
on O +
a O +
Kofler O +
apparatus O +
and O +
are O +
uncorrected O -
. O +

TLC O +
was O +
performed O +
on O +
Kieselgel O +
60 O +
F254 O +
( O -
E. O +
Merck O -
) O +
with O +
detection O +
by O +
charring O +
with O +
50 O -
% O +
of O +
aqueous O +
sulfuric O +
acid O -
. O +

Column O +
chromatography O +
was O +
performed O +
on O +
Silica O +
Gel O +
60 O +
( O -
E. O +
Merck O +
0.063–0.200 O +
mm O -
) O -
. O +

The O +
organic O +
solution O +
was O +
dried O +
over O +
MgSO4 O +
, O +
and O +
concentrated O +
in O +
a O +
vacuum O -
. O +

The O +
1 O +
H O +
( O -
200 O -
, O +
360 O +
and O +
500 O +
MHz O -
) O +
and O +
13 O +
C O +
NMR O +
( O -
50.3 O -
, O +
90.54 O -
, O +
125.76 O +
MHz O -
) O +
spectra O +
were O +
recorded O +
with O +
Bruker O +
WP-200 O +
SY O -
, O +
Bruker O +
AM-360 O +
and O +
Bruker O +
DRX-500 O +
spectrometers O +
in O +
CDCl3 O +
solutions O -
. O +

Internal O +
references O -
: O +
TMS O +
( O -
0.000 O +
ppm O +
for O +
1 O +
H O -
) O -
, O +
CDCl3 O +
( O -
77.00 O +
ppm O +
for O +
13 O +
C O -
) O -
. O +

3.2 O +
2,3,4,6-Tetra O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
2 O +
) O +
Powdered O +
Hg O -
( O -
CN O -
) O -
2 O +
( O -
16.4 O +
g O -
, O +
0.065 O +
mol O -
) O +
and O +
4 O +
Å O +
molecular O +
sieves O +
( O -
10 O +
g O -
) O +
were O +
added O +
to O +
a O +
solution O +
of O +
1 O +
( O -
13.0 O +
g O -
, O +
0.050 O +
mol O -
) O +
in O +
120 O +
mL O +
of O +
dry O +
CH3 O +
CN O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
overnight O -
. O +

To O +
the O +
mixture O +
was O +
added O +
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
α O -
- O -
d O +
-galactopyranosyl O +
bromide O +
( O -
24.6 O +
g O -
, O +
0.060 O +
mol O -
) O +
in O +
five O +
portions O -
. O +

After O +
2 O +
h O +
the O +
reaction O +
was O +
complete O +
( O -
TLC O -
, O +
23:2 O +
CH2 O +
Cl2 O +
–acetone O -
, O +
R O +
f O +
0.5 O -
) O -
. O +

The O +
mixture O +
was O +
diluted O +
with O +
500 O +
mL O +
of O +
CH2 O +
Cl2 O +
, O +
the O +
inorganic O +
salts O +
were O +
filtered O +
off O -
, O +
and O +
the O +
filtrate O +
was O +
concentrated O +
in O +
vacuo O -
. O +

The O +
residue O +
was O +
dissolved O +
in O +
1000 O +
mL O +
of O +
CH2 O +
Cl2 O +
, O +
the O +
inorganic O +
salts O +
were O +
filtered O +
off O +
again O -
, O +
the O +
filtrate O +
was O +
washed O +
with O +
aq O +
5 O -
% O +
KI O +
solution O +
( O -
4 O -
× O -
250 O +
mL O -
) O -
, O +
and O +
water O +
( O -
2 O -
× O -
250 O +
mL O -
) O -
. O +

The O +
organic O +
layer O +
was O +
dried O +
and O +
evaporated O -
. O +

The O +
syrupy O +
residue O +
was O +
purified O +
by O +
column O +
chromatography O +
( O -
CH2 O +
Cl2 O +
–acetone O -
, O +
96:4→92:8 O -
) O +
to O +
yield O +
2 O +
( O -
19.0 O +
g O -
, O +
64.4 O -
% O -
) O -
: O +
[ O -
α O +
] O -
D O +
22 O +
−44.2 O -
° O +
( O -
c O +
1.0 O -
, O +
CHCl3 O +
) O +
lit O -
. O +

−44 O -
° O +
[ O -
18 O -
] O +
; O +
1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
5.51 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1 O -
, O +
J O +
1,2 O +
4.9 O +
Hz O -
) O -
, O +
5.39 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-4′ O -
, O +
J O +
3′,4′ O +
3.4 O +
Hz O -
, O +
J O +
4′,5′ O +
1.0 O +
Hz O -
) O -
, O +
5.22 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2′ O -
, O +
J O +
1′,2′ O +
7.9 O +
Hz O -
, O +
J O +
2′,3′ O +
10.5 O +
Hz O -
) O -
, O +
5.03 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-3′ O -
) O -
, O +
4.59 O +
( O -
2 O +
d O -
, O +
2 O +
H O -
, O +
H-1′ O -
, O +
H-3 O -
, O +
J O +
3,4 O +
8.0 O +
Hz O -
) O -
, O +
4.30 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2 O -
, O +
J O +
2,3 O +
2.5 O +
Hz O -
) O -
, O +
4.16 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-5′ O -
, O +
H-6′a O -
, O -
b O -
, O +
J O +
gem O +
11.1 O +
Hz O -
) O -
, O +
4.04 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-6a O -
, O +
J O +
5,6a O +
3.2 O +
Hz O -
, O +
J O +
gem O +
11.5 O +
Hz O -
) O -
, O +
3.95–3.85 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-4 O -
, O +
H-5 O -
) O -
, O +
3.69 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-6b O -
, O +
J O +
5,6b O +
7.6 O +
Hz O -
) O -
, O +
2.15–1.95 O +
( O -
4 O +
s O -
, O +
each O +
3 O +
H O -
, O +
4 O +
CH3acetyl O +
) O -
, O +
1.55–1.30 O +
( O -
4s O -
, O +
each O +
3 O +
H O -
, O +
4 O +
CH3ip O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C26 O +
H38 O +
O15 O +
( O -
590.57 O -
) O -
: O +
C O -
, O +
52.87 O -
; O +
H O -
, O +
6.48 O -
. O +

Found O -
: O +
C O -
, O +
52.90 O -
; O +
H O -
, O +
6.51 O -
. O +
3.3 O +
β O -
- O -
d O +
-Galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
3 O +
) O +
To O +
a O +
stirred O +
solution O +
of O +
2 O +
( O -
16.5 O +
g O -
, O +
0.028 O +
mol O -
) O +
in O +
200 O +
mL O +
of O +
dry O +
MeOH O +
NaOMe O +
( O -
100 O +
mg O -
) O +
was O +
added O +
( O -
pH O +
∼8 O -
) O -
. O +

After O +
2.5 O +
h O +
the O +
TLC O +
( O -
85:15 O +
CH2 O +
Cl2 O +
–MeOH O -
, O +
R O +
f O +
0.5 O -
) O +
showed O +
complete O +
conversion O -
. O +

The O +
solution O +
was O +
neutralized O +
with O +
Amberlite O +
IR-120 O +
H+ O +
ion O -
- O -
exchange O +
resin O -
, O +
filtered O +
and O +
evaporated O +
to O +
yield O +
3 O +
as O +
a O +
white O +
foam O +
( O -
11.7 O +
g O -
, O +
98.8 O -
% O -
) O -
: O +
[ O -
α O +
] O -
D O +
22 O +
−63.1 O -
° O +
( O -
c O +
1.0 O -
, O +
CHCl3 O +
) O +
lit O -
. O +

−49.7 O -
° O +
( O -
c O +
2 O -
, O +
aq O +
0.5 O +
M O +
TRIS O -
) O +
[ O -
19 O -
] O +
; O +
1 O +
H O +
NMR O +
( O -
360 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
5.50 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1 O -
, O +
J O +
1,2 O +
5 O +
Hz O -
) O -
, O +
4.62 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1′ O -
, O +
J O +
1′,2′ O +
8 O +
Hz O -
) O -
, O +
4.40–3.45 O +
( O -
m O -
, O +
14 O +
skeleton O +
H O -
) O -
, O +
1.45 O +
( O -
m O -
, O +
12 O +
H O -
, O +
4 O +
CH3ip O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C18 O +
H30 O +
O11 O +
( O -
422.43 O -
) O -
: O +
C O -
, O +
51.17 O -
; O +
H O -
, O +
7.16 O -
. O +

Found O -
: O +
C O -
, O +
51.32 O -
; O +
H O -
, O +
7.13 O -
. O +

3.4 O +
3,4-O O -
- O -
Isopropylidene-6-O- O -
( O -
methoxydimethyl O -
) O -
methyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
4 O +
) O +
and O +
3,4-O O -
- O -
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
5 O +
) O +
To O +
a O +
solution O +
of O +
3 O +
( O -
11.5 O +
g O -
, O +
0.027 O +
mol O -
) O +
in O +
2,2-dimethoxypropane O +
( O -
170 O +
mL O -
, O +
1.36 O +
mol O -
) O +
was O +
added O +
400 O +
mg O +
of O +
p O +
-toluenesulfonic O +
acid O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
overnight O -
. O +

By O +
TLC O +
( O -
4:1 O +
CH2 O +
Cl2 O +
–acetone O -
; O +
+ O -
0.1 O -
% O +
Et3 O +
N O -
) O +
the O +
starting O +
material O +
disappeared O -
, O +
compounds O +
4 O +
( O -
R O +
f O +
0.54 O -
) O +
and O +
5 O +
( O -
R O +
f O +
0.25 O -
) O +
were O +
formed O +
in O +
a O +
ratio O +
of O +
4:1 O -
. O +

After O +
addition O +
of O +
Et3 O +
N O +
( O -
2 O +
mL O -
) O +
the O +
reaction O +
mixture O +
was O +
diluted O +
with O +
1 O +
L O +
of O +
CH2 O +
Cl2 O +
, O +
washed O +
with O +
water O +
( O -
3 O -
× O -
400 O +
mL O -
) O -
, O +
dried O +
and O +
evaporated O -
. O +

The O +
residue O +
was O +
chromatographed O +
with O +
CH2 O +
Cl2 O +
–acetone O -
, O +
9:1→8:2 O -
, O +
containing O +
1 O -
% O +
Et3 O +
N O +
to O +
give O +
4 O +
( O -
10.6 O +
g O -
, O +
72.5 O -
% O -
) O +
and O +
5 O +
( O -
2.5 O +
g O -
, O +
19.7 O -
% O -
) O -
. O +

The O +
same O +
products O +
in O +
similar O +
ratio O +
were O +
obtained O +
from O +
6 O +
by O +
treatment O +
of O +
50 O +
equivalents O +
of O +
2,2-dimethoxy O -
- O -
propane O +
and O +
catalytic O +
amount O +
of O +
p O +
-toluenesulfonic O +
acid O -
. O +

Compound O +
4 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−35.6 O -
° O +
( O -
c O +
1.3 O -
, O +
CHCl3 O +
) O -
; O +
1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
5.54 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1 O -
, O +
J O +
1,2 O +
5.0 O +
Hz O -
) O -
, O +
4.60 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-3 O -
, O +
J O +
2,3 O +
2.4 O +
Hz O -
, O +
J O +
3,4 O +
7.9 O +
Hz O -
) O -
, O +
4.31 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2 O -
) O -
, O +
4.28 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-1′ O -
, O +
J O +
1′,2′ O +
8.4 O +
Hz O -
) O -
, O +
4.24 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-4 O -
, O +
J O +
4,5 O +
1.7 O +
Hz O -
) O -
, O +
4.16 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-4′ O -
, O +
J O +
3′,4′ O +
5.4 O +
Hz O -
, O +
J O +
4′,5′ O +
2.1 O +
Hz O -
) O -
, O +
4.06 O +
( O -
m O -
, O +
2 O +
H O -
, O +
H-3′ O -
, O +
H-6a O +
, O +
J O +
2′,3′ O +
7.8 O +
Hz O -
) O -
, O +
4.00 O +
( O -
m O -
, O +
1 O +
H O -
, O +
H-5 O -
) O -
, O +
3.85 O +
( O -
dt O -
, O +
1 O +
H O -
, O +
H-5′ O -
, O +
J O +
5′,6a′ O +
= O -
J O +
5′,6b′ O +
6.2 O +
Hz O -
) O -
, O +
3.75–3.69 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-6a O +
, O +
H-6′a O -
, O -
b O -
) O -
, O +
3.59 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2′ O -
) O -
, O +
3.25 O +
( O -
s O -
, O +
3 O +
H O -
, O +
OCH3 O +
) O -
, O +
1.50–1.27 O +
( O -
8 O +
s O -
, O +
each O +
3 O +
H O -
, O +
8 O +
CH3ip O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C25 O +
H42 O +
O12 O +
( O -
534.58 O -
) O -
: O +
C O -
, O +
56.17 O -
; O +
H O -
, O +
7.91 O -
. O +

Found O -
: O +
C O -
, O +
56.31 O -
; O +
H O -
, O +
8.00 O -
. O +

Compound O +
5 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−29.6 O -
° O +
( O -
c O +
1.0 O -
, O +
CHCl3 O +
) O -
; O +
1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
5.48 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1 O -
, O +
J O +
1,2 O +
5.0 O +
Hz O -
) O -
, O +
4.55 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-3 O -
, O +
J O +
2,3 O +
2.4 O +
Hz O -
, O +
J O +
3,4 O +
7.9 O +
Hz O -
) O -
, O +
4.26 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2 O -
) O -
, O +
4.22 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-1′ O -
, O +
J O +
1′,2′ O +
8.0 O +
Hz O -
) O -
, O +
4.20 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-4 O -
, O +
J O +
4,5 O +
1.7 O +
Hz O -
) O -
, O +
4.09–3.66 O +
( O -
m O -
, O +
8 O +
H O -
) O -
, O +
3.49 O +
( O -
t O -
, O +
1 O +
H O -
, O +
H-2′ O +
J O +
2′,3′ O +
8.0 O +
Hz O -
) O -
, O +
1.50–1.27 O +
( O -
m O -
, O +
18 O +
H O -
, O +
6 O +
CH3ip O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C21 O +
H34 O +
O11 O +
( O -
462.49 O -
) O -
: O +
C O -
, O +
54.53 O -
; O +
H O -
, O +
7.40 O -
, O -
. O +

Found O -
: O +
C O -
, O +
54.31 O -
; O +
H O -
, O +
7.37 O -
. O +

3.5 O +
β O -
- O -
d O +
-Galactopyranosyl- O -
( O -
1→6 O -
) O -
-d O +
-galactose O +
( O -
6 O +
) O +
A O +
solution O +
of O +
4 O +
( O -
50 O +
mg O -
, O +
0.090 O +
mmol O -
) O +
in O +
1 O +
mL O +
of O +
90 O -
% O +
trifluoroacetic O +
acid O +
was O +
stirred O +
for O +
15 O +
min O -
, O +
and O +
concentrated O +
at O +
20 O +
° O -
C O +
in O +
vacuo O -
. O +

Ethyl O +
acetate O +
( O -
6 O +
mL O -
) O +
was O +
added O +
to O +
the O +
residue O -
, O +
and O +
the O +
precipitate O +
formed O +
was O +
washed O +
three O +
times O +
with O +
ethyl O +
acetate O +
to O +
yield O +
6 O +
( O -
20 O +
mg O -
, O +
64 O -
% O -
) O -
: O +

[ O -
α O +
] O -
D O +
22 O +
+ O -
17.3 O -
° O +
( O -
c O +
0.19 O -
, O +
H2 O +
O O -
) O -
; O +
R O +
f O +
0.4 O +
( O -
dichloromethane O -
: O +
methanol O -
: O +
H2 O +
O O -
, O +
80:50:13 O -
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C12 O +
H22 O +
O11 O +
( O -
342.29 O -
) O -
: O +
C O -
, O +
41.10 O -
; O +
H O -
, O +
6.47 O -
. O +

Found O -
: O +
C O -
, O +
41.44 O -
; O +
H O -
, O +
6.48 O -
. O +
3.6 O +
2,3,5-Tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→2 O -
) O -
- O -
[ O -
2,3,5-tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→6 O -
) O -
] O -
-3,4-O O -
- O -
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
8 O +
) O -
, O +
2,3,5-tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→6 O -
) O -
-3,4-O O -
- O -
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
9 O +
) O +
and O +
2,3,5-tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→2 O -
) O -
-3,4-O O -
- O -
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
11 O +
) O +
To O +
a O +
solution O +
of O +
4 O +
( O -
390 O +
mg O -
, O +
0.84 O +
mmol O -
) O +
in O +
5 O +
mL O +
of O +
dry O +
CH3 O +
CN O +
were O +
added O +
powdered O +
Hg O -
( O -
CN O -
) O -
2 O +
( O -
512 O +
mg O -
, O +
2.4 O +
equiv O -
) O +
and O +
4 O +
Å O +
molecular O +
sieves O +
( O -
0.5 O +
g O -
) O -
, O +
the O +
mixture O +
was O +
stirred O +
for O +
3 O +
h O +
and O +
1.0 O +
g O +
( O -
1.9 O +
mmol O -
) O +
of O +
7 O +
[ O -
20 O -
] O +
was O +
added O -
. O +

After O +
2 O +
h O +
the O +
TLC O +
( O -
49:1 O +
CH2 O +
CL2 O +
–acetone O -
) O +
showed O +
∼50 O -
% O +
conversion O +
of O +
4 O +
, O +
100 O +
mg O +
of O +
Hg O -
( O -
CN O -
) O -
2 O +
was O +
added O +
and O +
the O +
mixture O +
was O +
kept O +
at O +
50 O +
° O -
C O +
for O +
6 O +
h. O +
The O +
work O -
- O -
up O +
procedure O +
was O +
the O +
same O +
as O +
that O +
described O +
for O +
compound O +
2 O +
. O +

The O +
crude O +
product O +
was O +
purified O +
by O +
coloumn O +
chromatography O +
to O +
give O +
8 O +
( O -
280 O +
mg O -
, O +
24.7 O -
% O -
) O -
, O +
9 O +
( O -
190 O +
mg O -
, O +
24.8 O -
% O -
) O +
and O +
11 O +
( O -
40 O +
mg O -
, O +
5.3 O -
% O -
) O -
. O +

Compound O +
8 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
+ O -
2.7 O -
° O +
( O -
c O +
1.0 O -
, O +
CHCl3 O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C73 O +
H74 O +
O25 O +
( O -
1351.36 O -
) O -
: O +
C O -
, O +
64.88 O -
; O +
H O -
, O +
5.51 O -
. O +

Found O -
: O +
C O -
, O +
64.57 O -
; O +
H O -
, O +
5.53 O -
. O +

Compound O +
9 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−15.5 O -
° O +
( O -
c O +
1.0 O -
, O +
CHCl3 O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C47 O +
H54 O +
O18 O +
( O -
906.94 O -
) O -
: O +
C O -
, O +
62.24 O -
; O +
H O -
, O +
6.00 O -
. O +

Found O -
: O +
C O -
, O +
62.44 O -
; O +
H O -
, O +
6.04 O -
. O +

Compound O +
11 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−3.17 O -
° O +
( O -
c O +
0.82 O -
, O +
CHCl3 O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C47 O +
H54 O +
O18 O +
( O -
906.94 O -
) O -
: O +
C O -
, O +
62.24 O -
; O +
H O -
, O +
6.00 O -
. O +

Found O -
: O +
C O -
, O +
62.11 O -
; O +
H O -
, O +
5.97 O -
. O +

3.7 O +
2,3,5-Tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→6 O -
) O -
-2-O O -
- O -
acetyl-3,4-O O -
- O -
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
10 O +
) O +
To O +
a O +
solution O +
of O +
9 O +
( O -
50 O +
mg O -
) O +
in O +
pyridine O +
( O -
1 O +
mL O -
) O +
was O +
treated O +
with O +
acetic O +
anhydride O +
( O -
1 O +
mL O -
) O -
. O +

The O +
solution O +
was O +
evaporated O +
with O +
toluene O +
to O +
yield O +
10 O +
, O +
which O +
was O +
used O +
for O +
NMR O +
measurements O +
only O -
. O +

3.8 O +
2,3,5-Tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→2 O -
) O -
-3,4-O O -
- O -
isopropylidene-6-O- O -
( O -
methoxydimethyl O -
) O -
methyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
12 O +
) O +
and O +
2-propanone O +
bis- O -
[ O -
2,3,5-tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→2 O -
) O -
-3,4-O O -
- O -
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O -
] O -
-6,6 O +
acetale O +
( O -
13 O +
) O +
Powdered O +
4 O +
Å O +
molecular O +
sieves O +
( O -
1.2 O +
g O -
) O +
were O +
added O +
to O +
a O +
solution O +
of O +
4 O +
( O -
534 O +
mg O -
, O +
1.0 O +
mmol O -
) O +
and O +
7 O +
[ O -
20 O -
] O +
( O -
630 O +
mg O -
, O +
1.2 O +
mmol O -
) O +
in O +
dry O +
CH2 O +
Cl2 O +
( O -
20 O +
mL O -
) O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
in O +
dark O -
. O +

After O +
2 O +
h O -
, O +
the O +
reaction O +
mixture O +
was O +
cooled O +
to O +
−25 O +
° O -
C O -
, O +
sym O +
-collidine O +
( O -
0.29 O +
mL O -
, O +
2 O +
equiv O -
) O -
, O +
and O +
silver O +
triflate O +
( O -
514 O +
mg O -
, O +
2 O +
equiv O -
) O +
in O +
dry O +
toluene O +
( O -
4 O +
mL O -
) O +
were O +
added O -
. O +

After O +
2 O +
h O -
, O +
the O +
TLC O +
showed O +
complete O +
conversion O +
and O +
formation O +
of O +
two O +
products O -
, O +
Et3 O +
N O +
( O -
1 O +
mL O -
) O +
was O +
added O -
, O +
the O +
mixture O +
was O +
diluted O +
with O +
CH2 O +
Cl2 O +
and O +
filtered O +
through O +
a O +
pad O +
of O +
Celite O -
. O +

The O +
filtrate O +
was O +
washed O +
with O +
aq O +
10 O -
% O +
Na2 O +
S2 O +
O3 O +
and O +
water O -
, O +
dried O +
and O +
evaporated O -
. O +

The O +
products O +
were O +
separated O +
by O +
column O +
chromatography O +
( O -
23:2 O +
CH2 O +
Cl2 O +
–acetone O -
, O +
+ O -
1 O -
% O +
Et3 O +
N O -
) O +
to O +
give O +
12 O +
( O -
280 O +
mg O -
, O +
28.6 O -
% O -
) O +
and O +
13 O +
( O -
430 O +
mg O -
, O +
23.1 O -
% O -
) O -
. O +

Compound O +
12 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−13.4 O -
° O +
( O -
c O +
0.48 O -
, O +
CHCl3 O +
) O -
; O +
R O +
f O +
0.45 O +
( O -
in O +
the O +
chromatographic O +
eluent O -
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C51 O +
H62 O +
O19 O +
( O -
979.0 O -
) O -
: O +
C O -
, O +
62.56 O -
; O +
H O -
, O +
6.38 O -
. O +

Found O -
: O +
C O -
, O +
62.81 O -
; O +
H O +
6.33 O -
. O +

Compound O +
13 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−8.9 O -
° O +
( O -
c O +
0.76 O -
, O +
CHCl3 O +
) O -
; O +
R O +
f O +
0.40 O -
; O +
MALDI O -
- O -
TOF O +
MS O -
: O +
m O +
/z O +
[ O -
M+Na O -
] O -
+ O +
1876.9 O -
; O +
Anal O -
. O +

Calcd O +
for O +
C97 O +
H112 O +
O36 O +
( O -
1853.9 O -
) O -
: O +
C O -
, O +
62.84 O -
; O +
H O -
, O +
6.08 O -
. O +

Found O -
: O +
C O -
, O +
63.11 O -
; O +
H O -
, O +
6.07 O -
. O +

3.9 O +
2-O O -
- O -
Benzyl-3,4-O O -
- O -
isopropylidene-6-O- O -
( O -
methoxydimethyl O -
) O -
methyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
14 O +
) O +
To O +
a O +
stirred O +
solution O +
of O +
4 O +
( O -
10.0 O +
g O -
, O +
0.018 O +
mol O -
) O +
in O +
dry O +
N O +
, O -
N O +
-dimethyl O +
formamide O +
( O -
15 O +
mL O -
) O +
80 O -
% O +
NaH O +
( O -
672 O +
mg O -
, O +
0.022 O +
mol O -
) O +
was O +
added O +
at O +
0 O +
° O -
C O -
. O +

After O +
30 O +
min O +
benzyl O +
bromide O +
( O -
2.4 O +
mL O -
, O +
0.220 O +
mol O -
) O +
was O +
added O +
dropwise O -
, O +
and O +
the O +
mixture O +
was O +
stirred O +
for O +
3 O +
h. O +
The O +
mixture O +
was O +
diluted O +
with O +
400 O +
mL O +
of O +
CH2 O +
Cl2 O +
, O +
washed O +
with O +
water O +
until O +
neutral O -
, O +
dried O +
and O +
evaporated O -
. O +

The O +
crude O +
product O +
was O +
purified O +
by O +
column O +
chromatography O +
( O -
24:1 O +
CH2 O +
Cl2 O +
–acetone O -
) O +
to O +
yield O +
14 O +
( O -
8.2 O +
g O -
, O +
70.1 O -
% O -
) O -
; O +
mp O +
116–117 O +
° O -
C O +
( O -
MeOH O -
) O -
; O +
[ O -
α O +
] O -
D O +
22 O +
−7.09 O -
° O +
( O -
c O +
1.0 O -
, O +
CHCl3 O +
) O -
; O +
1 O +
H O +
NMR O +
( O -
360 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
7.53–7.28 O +
( O -
m O -
, O +
5 O +
H O -
, O +
Ph O -
) O -
, O +
5.63 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1 O -
, O +
J O +
1,2 O +
5 O +
Hz O -
) O -
, O +
4.93 O +
( O -
dd O -
, O +
2 O +
H O -
, O +
CH2 O +
-Ph O -
, O +
J O +
gem O +
12 O +
Hz O -
) O -
, O +
4.67 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-3 O -
, O +
J O +
2,3 O +
8 O +
Hz O -
, O +
J O +
3,4 O +
2.1 O +
Hz O -
) O -
, O +
4.44 O +
( O -
d O -
, O +
1 O +
H O -
, O +
H-1′ O -
, O +
J O +
1′,2′ O +
8 O +
Hz O -
) O -
, O +
4.38 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2 O -
) O -
, O +
4.32 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-4 O -
, O +
J O +
4,5 O +
1.7 O +
Hz O -
) O -
, O +
4.21–4.10 O +
( O -
m O -
, O +
4 O +
H O -
, O +
H-3′ O -
, O +
H-4′ O -
, O +
H-5 O -
, O +
H-6 O -
) O -
, O +
3.86 O +
( O -
dt O -
, O +
1 O +
H O -
, O +
H-5′ O -
, O +
J O +
4′,5′ O +
2 O +
Hz O -
, O +
J O +
5′,6a′ O +
= O -
J O +
5′,6b′ O +
6 O +
Hz O -
) O -
, O +
3.77 O +
( O -
m O -
, O +
3 O +
H O -
, O +
H-6 O -
, O +
H-6′ab O -
) O -
, O +
3.43 O +
( O -
dd O -
, O +
1 O +
H O -
, O +
H-2′ O -
, O +
J O +
2′,3′ O +
6 O +
Hz O -
) O -
, O +
3.28 O +
( O -
s O -
, O +
3 O +
H O -
, O +
OCH3 O +
) O -
, O +
1.61–1.32 O +
( O -
4 O +
s O -
, O +
each O +
3 O +
H O -
, O +
4 O +
CH3ip O +
. O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C32 O +
H48 O +
O12 O +
( O -
624,73 O -
) O -
: O +
C O -
, O +
61.52 O -
; O +
H O -
, O +
7.74 O -
. O +

Found O -
: O +
C O -
, O +
61.37 O -
; O +
H O -
, O +
7.72 O -
. O +

3.10 O +
2-O O -
- O -
Benzyl-3,4-O O -
- O -
isopropylidene O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2:3,4-di O -
- O -
O O -
- O -
isopropylidene O -
- O -
α O -
- O -
d O +
-galactopyranose O +
( O -
15 O +
) O +
To O +
a O +
solution O +
of O +
14 O +
( O -
3.0 O -
g O -
, O +
4.8 O +
mmol O -
) O +
in O +
50 O +
mL O +
of O +
CH2 O +
Cl2 O +
, O +
2 O +
mL O +
of O +
96 O -
% O +
acetic O +
acid O +
and O +
two O +
drops O +
of O +
water O +
were O +
added O -
, O +
and O +
the O +
solution O +
was O +
heated O +
at O +
reflux O +
temperature O +
for O +
3 O +
h. O +
The O +
mixture O +
was O +
diluted O +
with O +
CH2 O +
Cl2 O +
, O +
washed O +
with O +
aq O +
NaHCO3 O +
and O +
water O -
, O +
dried O +
and O +
evaporated O -
. O +

The O +
solid O +
residue O +
( O -
2.7 O +
g O -
) O +
was O +
crystallized O +
from O +
c O +
-hexane O +
to O +
yield O +
15 O +
( O -
2.4 O +
g O -
, O +
90.1 O -
% O -
) O -
; O +
mp O +
128–129 O +
° O -
C O -
; O +
R O +
f O +
0.45 O +
( O -
17:3 O +
CH2 O +
Cl2 O +
–acetone O -
) O -
; O +
[ O -
α O +
] O -
D O +
22 O +
−2.6 O -
° O +
( O -
c O +
1.3 O -
, O +
CHCl3 O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C28 O +
H40 O +
O11 O +
( O -
552.62 O -
) O -
: O +
C O -
, O +
60.85 O -
; O +
H O -
, O +
7.29 O -
. O +

Found O -
: O +
C O -
, O +
61.01 O -
; O +
H O -
, O +
7.27 O -
. O +

3.11 O +
3,4,6-Tri O -
- O -
O O -
- O -
acetyl-2-O O -
- O -
benzyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2,3,4-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
α O -
, O -
β O -
- O -
d O +
-galactopyranose O +
( O -
17 O +
) O +
To O +
a O +
stirred O +
solution O +
of O +
14 O +
( O -
300 O +
mg O -
, O +
0.48 O +
mmol O -
) O +
in O +
30 O +
mL O +
of O +
CH2 O +
Cl2 O +
, O +
3 O +
mL O +
of O +
trifluoroacetic O +
acid O +
and O +
one O +
drop O +
of O +
water O +
were O +
added O -
. O +

After O +
16 O +
h O +
triethylamine O +
was O +
added O -
, O +
and O +
the O +
mixture O +
was O +
evaporated O +
to O +
give O +
16 O +
( O -
R O +
f O +
0.53 O -
, O +
8:5:1 O +
CH2 O +
Cl2 O +
–acetone O -
– O -
water O -
) O +
which O +
was O +
acetylated O +
without O +
purification O +
in O +
a O +
mixture O +
of O +
5 O +
mL O +
of O +
pyridine O +
and O +
5 O +
mL O +
of O +
acetic O +
anhydride O +
to O +
give O +
17 O +
. O +

The O +
crude O +
product O +
was O +
purified O +
by O +
column O +
chromatography O +
( O -
93:7 O +
CH2 O +
Cl2 O +
–acetone O -
, O +
R O +
f O +
0.40 O -
) O +
to O +
yield O +
17 O +
( O -
230 O +
mg O -
, O +
74.5 O -
% O +
for O +
two O +
steps O -
) O -
; O +
[ O -
α O +
] O -
D O +
22 O +
+ O -
25.2 O -
° O +
( O -
c O +
1.0 O -
, O +
CHCl3 O +
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C26 O +
H42 O +
O18 O +
( O -
642.61 O -
) O -
: O +
C O -
, O +
48.59 O -
; O +
H O -
, O +
6.58 O -
. O +

Found O -
: O +
C O -
, O +
48.81 O -
; O +
H O -
, O +
6.61 O -
. O +

3.12 O +
3,4,6-Tri O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2,3,4-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
α O -
, O -
β O -
- O -
d O +
-galactopyranose O +
( O -
18 O +
) O +
Palladium O +
on O +
activated O +
carbon O +
( O -
30 O +
mg O -
) O +
was O +
added O +
to O +
a O +
solution O +
of O +
17 O +
( O -
300 O +
mg O -
) O +
in O +
ethyl O +
acetate O +
( O -
3 O +
mL O -
) O +
and O +
the O +
mixture O +
was O +
stirred O +
under O +
H2 O +
. O +

After O +
4 O +
h O +
the O +
mixture O +
was O +
diluted O +
with O +
ethyl O +
acetate O -
, O +
filtered O +
through O +
a O +
layer O +
of O +
Celite O -
, O +
and O +
evaporated O +
to O +
yield O +
18 O +
( O -
260 O +
mg O -
) O -
, O +
which O +
was O +
used O +
for O +
further O +
conversion O +
without O +
purification O -
. O +

3.13 O +
2,3,5-Tri O -
- O -
O O -
- O -
benzoyl O -
- O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→2 O -
) O -
-3,4,6-tri O -
- O -
O O -
- O -
acetyl O -
- O -
β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-1,2,3,4-tetra O -
- O -
O O -
- O -
acetyl O -
- O -
α O -
, O -
β O -
- O -
d O +
-galactopyranose O +
( O -
19 O +
) O +
A O +
mixture O +
of O +
18 O +
( O -
130 O +
mg O -
, O +
0.200 O +
mmol O -
) O -
, O +
powdered O +
Hg O -
( O -
CN O -
) O -
2 O +
( O -
110 O +
mg O -
, O +
2.2 O +
equivalents O -
) O -
, O +
and O +
4 O +
Å O +
molecular O +
sieves O +
( O -
500 O +
mg O -
) O +
in O +
dry O +
CH3 O +
CN O +
( O -
3 O +
mL O -
) O +
was O +
stirred O +
for O +
30 O +
min O -
. O -
, O +
compound O +
7 O +
( O -
200 O +
mg O -
, O +
0.380 O +
mmol O -
) O +
in O +
1 O +
mL O +
of O +
dry O +
CH3 O +
CN O +
was O +
added O +
and O +
the O +
mixture O +
was O +
stirred O +
overnight O -
. O +

The O +
work O -
- O -
up O +
procedure O +
was O +
the O +
same O +
as O +
that O +
described O +
for O +
compound O +
2 O +
. O +

The O +
residue O +
was O +
purified O +
by O +
column O +
chromatography O +
( O -
93:7 O +
CH2 O +
Cl2 O +
–acetone O -
, O +
R O +
f O +
0.55 O -
) O +
to O +
yield O +
19 O +
( O -
152 O +
mg O -
, O +
70.1 O -
% O -
) O -
, O +
which O +
was O +
characterized O +
after O +
deprotection O -
. O +

3.14 O +
α O -
- O -
l O +
-Arabinofuranosyl- O -
( O -
1→2 O -
) O -
- O -
[ O -
α O -
- O -
l O +
-arabinofuranosyl- O -
( O -
1→6 O -
) O -
] O -
-β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-d O +
-galactose O +
( O -
20 O +
) O +
To O +
a O +
solution O +
of O +
8 O +
( O -
370 O +
mg O -
, O +
0.270 O +
mmol O -
) O +
in O +
dry O +
MeOH O +
( O -
10 O +
mL O -
) O +
a O +
catalytic O +
amount O +
of O +
NaOMe O +
was O +
added O +
and O +
was O +
stirred O +
overnight O -
. O +

The O +
solution O +
was O +
neutralized O +
with O +
Amberlite O +
IR-120 O +
H+ O +
ion O -
- O -
exchange O +
resin O -
, O +
filtered O +
and O +
evaporated O -
. O +

The O +
residue O +
was O +
treated O +
with O +
aq O +
90 O -
% O +
trifluoroacetic O +
acid O +
for O +
15 O +
min O -
, O +
the O +
product O +
was O +
precipitated O +
by O +
addition O +
of O +
diethyl O +
ether O -
, O +
filtered O -
, O +
and O +
washed O +
twice O +
with O +
diethyl O +
ether O +
to O +
yield O +
20 O +
( O -
120 O +
mg O -
, O +
73.3 O -
% O +
for O +
two O +
steps O -
) O -
; O +
[ O -
α O +
] O -
D O +
22 O +
−26.38 O +
( O -
c O +
0.29 O -
, O +
H2 O +
O O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
90 O +
MHz O -
) O +
δ O +
108.79 O +
( O -
C-1″1″→2″ O +
) O -
, O +
108.49 O +
( O -
C-1″1″→6″ O +
) O -
, O +
103.75 O -
, O +
102.53 O +
( O -
C-1′ O -
) O -
, O +
97.32 O -
, O +
96.96 O +
( O -
C-1β O -
) O -
, O +
93.13 O -
, O +
92.93 O +
( O -
C-1α O -
) O -
, O +
70.06 O +
( O -
C-6α O -
) O -
, O +
69.95 O +
( O -
C-6β O -
) O -
, O +
67.87 O +
( O -
C-6′ O -
) O -
, O +
61.95 O -
, O +
61.75 O +
( O -
2 O -
× O -
C-5″ O -
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C22 O +
H38 O +
O19 O +
( O -
606.52 O -
) O -
: O +
C O -
, O +
43.56 O -
; O +
H O -
, O +
6.31 O -
. O +

Found O -
: O +
C O -
, O +
43.81 O -
; O +
H O -
, O +
6.33 O -
. O +

3.15 O +
α O -
- O -
l O +
-Arabinofuranosyl- O -
( O -
1→6 O -
) O -
-β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-d O +
-galactose O +
( O -
21 O +
) O +
Compound O +
21 O +
was O +
prepared O +
from O +
9 O +
by O +
the O +
same O +
method O +
as O +
described O +
for O +
20 O +
. O +

Compound O +
21 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−13.6 O +
( O -
c O +
0.35 O -
, O +
H2 O +
O O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
90 O +
MHz O -
) O +
δ O +
108.54 O +
( O -
C-1″ O -
) O -
, O +
103.80 O +
( O -
C-1′ O -
) O -
, O +
97.05 O +
( O -
C-1β O -
) O -
, O +
92.96 O +
( O -
C-1α O -
) O -
, O +
84.45 O +
( O -
C-4″ O -
) O -
, O +
81.63 O +
( O -
C-2 O -
) O -
, O +
77.03 O +
( O -
C-3″ O -
) O -
, O +
74.45 O +
( O -
C-5β O -
, O +
C-5′ O -
) O -
, O +
73.17 O +
( O -
C-3β O -
, O +
C-3′ O -
) O -
, O +
72.40 O +
( O -
C-2′ O -
) O -
, O +
71.31 O +
( O -
C-2β O -
) O -
, O +
70.13 O +
( O -
C-6α O -
) O -
, O +
70.11 O +
( O -
C-4α O -
) O -
, O +
69.86 O +
( O -
C-6β O -
, O +
C-3α O -
, O +
C-5α O -
) O -
, O +
69.38 O +
( O -
C-4β O -
, O +
C-4′ O -
) O -
, O +
68.89 O +
( O -
C-2α O -
) O -
, O +
67.99 O +
( O -
C-6′ O -
) O -
, O +
61.94 O +
( O -
C-5″ O -
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C17 O +
H30 O +
O15 O +
( O -
474.42 O -
) O -
: O +
C O -
, O +
43.03 O -
; O +
H O -
, O +
6.37 O -
. O +

Found O -
: O +
C O -
, O +
43.31 O -
; O +
H O -
, O +
6.36 O -
. O +

3.16 O +
α O -
- O -
l O +
-Arabinofuranosyl- O -
( O -
1→2 O -
) O -
-β O -
- O -
d O +
-galactopyranosyl- O -
( O -
1→6 O -
) O -
-d O +
-galactose O +
( O -
22 O +
) O +
To O +
a O +
solution O +
of O +
19 O +
( O -
90 O +
mg O -
, O +
0.083 O +
mmol O -
) O +
in O +
dry O +
MeOH O +
( O -
5 O +
mL O -
) O +
NaOMe O +
was O +
added O +
and O +
the O +
solution O +
was O +
stirred O +
overnight O -
. O +

The O +
solution O +
was O +
neutralized O +
with O +
Amberlite O +
IR-120 O +
H+ O +
ion O -
- O -
exchange O +
resin O -
, O +
filtered O +
and O +
evaporated O +
to O +
give O +
22 O +
( O -
36 O +
mg O -
, O +
91.4 O -
% O -
) O -
. O +

Compound O +
22 O +
was O +
also O +
prepared O +
starting O +
from O +
11 O +
and O +
from O +
13 O +
, O +
respectively O -
, O +
by O +
the O +
same O +
method O +
as O +
described O +
for O +
20 O +
. O +

Compound O +
22 O +
: O +
[ O -
α O +
] O -
D O +
22 O +
−17.5 O +
( O -
c O +
0.16 O -
, O +
H2 O +
O O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
90 O +
MHz O -
) O -
: O +
δ O +
108.81 O +
( O -
C-1″ O -
) O -
, O +
102.51 O +
( O -
C-1′ O -
) O -
, O +
97.00 O +
( O -
C-1β O -
) O -
, O +
92.96 O +
( O -
C-1α O -
) O -
, O +
84.80 O +
( O -
C-4″ O -
) O -
, O +
81.49 O +
( O -
C-2″ O -
) O -
, O +
77.44 O +
( O -
C-3″ O -
) O -
, O +
76.57 O +
( O -
C-2′ O -
) O -
, O +
75.66 O +
( O -
C-5′ O -
) O -
, O +
74.28 O +
( O -
C-5β O -
) O -
, O +
73.50 O +
( O -
C-3β O -
) O -
, O +
73.21 O +
( O -
C-2β O -
) O -
, O +
72.37 O +
( O -
C-3′ O -
) O -
, O +
69.94 O +
( O -
C-4α O -
) O -
, O +
69.87 O +
( O -
C-6α O -
) O -
, O +
69.86 O +
( O -
C-3α O -
) O -
, O +
69.74 O +
( O -
C-5α O -
) O -
, O +
69.59 O +
( O -
C-6β O -
) O -
, O +
69.39 O +
( O -
C-4β O -
, O +
C-4′ O -
) O -
, O +
68.86 O +
( O -
C-2α O -
) O -
, O +
61.94 O +
( O -
C-5″ O -
) O -
, O +
61.48 O +
( O -
C-6′ O -
) O -
. O +

Anal O -
. O +

Calcd O +
for O +
C17 O +
H30 O +
O15 O +
( O -
474.42 O -
) O -
: O +
C O -
, O +
43.03 O -
; O +
H O -
, O +
6.37 O -
. O +

Found O -
: O +
C O -
, O +
43.37 O -
; O +
H O -
, O +
6.40 O -
. O +

Acknowledgements O +
This O +
research O +
was O +
supported O +
by O +
the O +
Hungarian O +
Scientific O +
Research O +
Fund O +
( O -
OTKA O +
T025244 O -
) O -
. O +

It O +
has O +
become O +
increasingly O +
evident O +
from O +
epidemiologic O +
as O +
well O +
as O +
laboratory O +
studies O +
that O +
a O +
vast O +
variety O +
of O +
dietary O +
or O +
medicinal O +
phytochemicals O +
have O +
substantial O +
chemopreventive O +
properties O +
[ O -
1–3 O -
] O +
. O +

Curcumin O -
, O +
a O +
yellow O +
colouring O +
ingredient O +
present O +
in O +
turmeric O +
( O -
Curcuma O +
longa O +
Linn O -
, O +
Zingiberaceae O -
) O -
, O +
has O +
been O +
shown O +
to O +
exert O +
anti O -
- O -
carcinogenic O +
or O +
anti O -
- O -
mutagenic O +
effects O +
in O +
diverse O +
animal O +
models O +
and O +
also O +
in O +
cultured O +
cells O +
[ O -
4–10 O -
] O +
. O +

One O +
of O +
the O +
biochemical O +
mechanisms O +
of O +
cancer O +
chemopreventive O +
activities O +
of O +
curcumin O +
has O +
been O +
attributed O +
to O +
its O +
inhibition O +
of O +
tumor O +
promotion O +
( O -
reviewed O +
in O +
Ref O -
. O +

[ O -
6 O -
] O +
and O +
references O +
therein O -
) O -
. O +

Alpinia O +
oxyphylla O +
Miquel O +
that O +
also O +
belongs O +
to O +
the O +
ginger O +
family O +
( O -
Zingiberaceae O -
) O +
has O +
been O +
used O +
in O +
Oriental O +
herbal O +
medicine O -
. O +

Yakuchinone O +
A O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-7-phenyl-3-heptanone O -
) O +
and O +
yakuchinone O +
B O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-7-phenylhept-1-en-3-one O -
) O +
which O +
are O +
present O +
in O +
A. O +
oxyphylla O +
have O +
been O +
reported O +
to O +
be O +
strong O +
inhibitors O +
of O +
prostaglandin O +
biosynthesis O +
in O +
vitro O -
. O +

Like O +
curcumin O -
, O +
these O +
substances O +
have O +
a O +
diarylheptanoid O +
moiety O +
with O +
a O +
carbonyl O +
functional O +
group O +
( O -
see O +
structures O +
in O +
Fig. O +
1 O +
) O +
and O +
are O +
hence O +
anticipated O +
to O +
exhibit O +
the O +
cancer O +
chemopreventive O +
activity O -
. O +

Since O +
tumor O +
promotion O +
is O +
closely O +
linked O +
to O +
inflammation O +
and O +
oxidative O +
stress O +
[ O -
11 O -
, O +
12 O -
] O +
, O +
it O +
is O +
likely O +
that O +
compounds O +
with O +
strong O +
anti O -
- O -
oxidative O +
and O +
anti O -
- O -
inflammatory O +
activities O +
can O +
act O +
as O +
anti O -
- O -
tumor O +
promoters O -
. O +

In O +
the O +
present O +
work O -
, O +
we O +
have O +
evaluated O +
an O +
anti O -
- O -
tumor O +
promoting O +
potential O +
of O +
aforementioned O +
diarylheptanoids O +
derived O +
from O +
A. O +
oxyphylla O +
in O +
terms O +
of O +
their O +
capability O +
to O +
suppress O +
papilloma O +
formation O +
and O +
epidermal O +
ornithine B-Gene +
decarboxylase I-Gene +
( O -
ODC B-Gene -
) O +
activity O +
induced O +
by O +
the O +
tumor O +
promoter O -
, O +
12-O O +
-tetradecanoylphorbol-13-acetate O +
( O -
TPA O -
) O +
in O +
mouse O +
skin O -
. O +

Their O +
effects O +
on O +
TPA O -
- O -
stimulated O +
superoxide O +
generation O +
and O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene -
- I-Gene -
α I-Gene +
production O +
in O +
human O +
promyelocytic O +
leukemia O +
( O -
HL-60 O -
) O +
cells O +
and O +
on O +
DNA O +
binding O +
of O +
the O +
transcription B-Gene +
factor I-Gene -
, O +
activator B-Gene +
protein-1 I-Gene +
( O -
AP-1 B-Gene -
) O +
in O +
NIH3T3 O +
cells O +
were O +
also O +
examined O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
TPA O +
was O +
a O +
product O +
of O +
Alex O +
Biochemicals O +
( O -
San O +
Diego O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Thiobarbituric O +
acid O +
( O -
TBA O -
) O -
, O +
cytochrome B-Gene +
c I-Gene +
, O +
sodium O +
ascorbate O +
and O +
l O +
-ornithine O +
were O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

dl O +
- O -
[ O -
1−14 O +
C O +
] O -
Ornithine O +
was O +
a O +
product O +
of O +
Dupont O -
/ O -
NEN O +
Research O +
Products O +
( O -
Boston O -
, O +
MA O -
, O +
USA O -
) O -
. O +

RPMI O +
1640 O +
and O +
fetal O +
bovine O +
serum O +
were O +
obtained O +
from O +
Gibco O +
BRL O +
( O -
Grand O +
Island O -
, O +
NY O -
, O +
USA O -
) O -
. O +

Other O +
chemicals O +
and O +
solvents O +
used O +
were O +
of O +
highest O +
analytical O +
grade O -
. O +

Human O +
promyelocytic O +
leukemia O +
( O -
HL-60 O -
) O +
and O +
NIH3T3 O +
cells O +
were O +
purchased O +
from O +
American O +
Type O +
Culture O +
Collection O +
( O -
Rockville O -
, O +
MD O -
, O +
USA O -
) O -
. O +

2.2 O +
ODC O +
assay O +
The O +
ODC B-Gene +
activity O +
in O +
epidermal O +
soluble O +
fraction O +
was O +
assessed O +
by O +
measuring O +
the O +
release O +
of O +
14 O +
CO O +
2 O +
from O +
dl O +
- O -
[ O -
1−14 O +
C O +
] O -
ornithine O +
( O -
40–60 O +
mCi O -
/ O -
mmol O -
) O +
as O +
reported O +
previously O +
[ O -
13 O -
] O +
. O +

The O +
protein O +
concentration O +
was O +
determined O +
by O +
the O +
Bradford O +
method O +
[ O -
14 O -
] O +
using O +
bovine B-Gene +
serum I-Gene +
albumin I-Gene +
as O +
a O +
standard O -
. O +

2.3 O +
ELISA O +
assay O +
for O +
TNF B-Gene -
- I-Gene -
α I-Gene +
production O +
in O +
HL-60 O +
cells O +
The O +
exponentially O +
growing O +
HL-60 O +
cells O +
( O -
2.5 O -
× O -
105 O +
cells O -
/ O -
ml O -
) O +
maintained O +
in O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
fetal O +
bovine O +
serum O +
were O +
exposed O +
to O +
either O +
yakuchinone O +
A O +
or O +
yakuchinone O +
B O +
in O +
the O +
presence O +
of O +
3 O +
nM O +
TPA O +
at O +
37 O -
° O -
C O +
for O +
16 O +
h. O +
The O +
cells O +
were O +
collected O +
by O +
centrifugation O +
( O -
2000 O +
rpm O +
for O +
10 O +
min O -
) O +
and O +
the O +
amount O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
in O +
supernatant O +
was O +
measured O +
by O +
use O +
of O +
a O +
human O +
TNF B-Gene -
- I-Gene -
α I-Gene +
ELISA O +
kit O +
from O +
Amersham O +
Life O +
Science O +
( O -
Buckinghamshire O -
, O +
UK O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
instruction O -
. O +

2.4 O +
Measurement O +
of O +
superoxide O +
generation O +
in O +
differentiated O +
HL-60 O +
cells O +
HL-60 O +
cells O +
were O +
maintained O +
in O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
10 O -
% O +
heat O -
- O -
inactivated O +
fetal O +
bovine O +
serum O +
and O +
5 O +
μg O -
/ O -
ml O +
gentamicin O +
as O +
described O +
previously O +
[ O -
15 O -
] O +
. O +

The O +
cells O +
were O +
suspended O +
at O +
a O +
density O +
of O +
5 O -
× O -
105 O +
cells O -
/ O -
ml O +
in O +
RPMI O +
medium O +
containing O +
10 O -
% O +
fetal O +
bovine O +
serum O +
and O +
1.3 O -
% O +
DMSO O +
and O +
incubated O +
for O +
6 O +
days O +
at O +
37 O -
° O -
C O +
in O +
a O +
humidified O +
atmosphere O +
of O +
5 O -
% O +
CO2 O +
. O +

Cells O +
were O +
harvested O +
by O +
centrifugation O -
, O +
washed O +
with O +
and O +
resuspended O +
in O +
phosphate O -
- O -
buffered O +
saline O +
( O -
1 O -
× O -
106 O +
cells O -
/ O -
ml O -
) O -
. O +

Cells O +
were O +
preincubated O +
for O +
10 O +
min O +
with O +
and O +
without O +
a O +
test O +
compound O -
, O +
and O +
TPA O +
( O -
8 O +
μM O -
) O +
and O +
cytochrome B-Gene +
c I-Gene +
( O -
60 O +
μM O -
) O +
were O +
added O +
to O +
the O +
reaction O +
mixture O -
. O +

After O +
30 O +
min O +
incubation O +
at O +
37 O -
° O -
C O -
, O +
absorbance O +
at O +
550 O +
nm O +
was O +
read O -
. O +

2.5 O +
Lipid O +
peroxidation O +
in O +
rat O +
brain O +
homogenates O +
Brain O +
homogenates O +
from O +
young O +
adult O +
male O +
Sprague O -
– O -
Dawley O +
rats O +
were O +
prepared O +
in O +
0.15 O +
M O +
KCl O +
( O -
10 O -
% O -
, O +
w O -
/ O -
v O -
) O +
and O +
centrifuged O +
at O +
800 O -
× O -
g O +
for O +
10 O +
min O -
, O +
and O +
the O +
supernatant O +
was O +
used O +
for O +
in O +
vitro O +
lipid O +
peroxidation O +
assays O -
. O +

The O +
incubation O +
mixture O +
in O +
a O +
final O +
volume O +
of O +
1 O +
ml O +
contained O +
brain O +
homogenate O +
( O -
0.5 O +
ml O -
) O -
, O +
0.15 O +
M O +
KCl O -
, O +
and O +
varying O +
amounts O +
of O +
test O +
compounds O -
. O +

Lipid O +
peroxidation O +
was O +
initiated O +
by O +
addition O +
of O +
ferric O +
chloride O +
( O -
100 O +
μM O -
) O +
alone O +
or O +
in O +
combination O +
with O +
ascorbic O +
acid O +
( O -
100 O +
μM O -
) O -
. O +

After O +
incubation O +
for O +
20 O +
min O +
at O +
37 O -
° O -
C O -
, O +
the O +
reaction O +
was O +
terminated O +
by O +
addition O +
of O +
0.5 O +
ml O +
cold O +
trichloroacetic O +
acid O +
( O -
5.5 O -
% O -
) O +
and O +
the O +
equal O +
volume O +
of O +
TBA O +
( O -
2 O -
% O +
in O +
0.05 O +
M O +
NaOH O -
) O +
followed O +
by O +
heating O +
at O +
100 O -
° O -
C O +
for O +
10 O +
min O -
. O +

The O +
mixtures O +
were O +
then O +
centrifuged O +
at O +
1000 O -
× O -
g O +
for O +
10 O +
min O +
and O +
the O +
absorbance O +
of O +
the O +
supernatant O +
was O +
measured O +
at O +
532 O +
nm O -
. O +

2.6 O +
Electrophoretic O +
mobility O +
shift O +
assay O +
( O -
EMSA O -
) O +
for O +
determining O +
AP-1 B-Gene +
activation O +
NIH O +
3T3 O +
cells O +
were O +
maintained O +
in O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
10 O -
% O +
heat O -
- O -
inactivated O +
fetal O +
bovine O +
serum O +
and O +
penicillin O +
( O -
100 O +
unit O -
/ O -
l O -
) O +
and O +
streptomycin O +
( O -
100 O +
μg O -
/ O -
l O -
) O +
in O +
a O +
humidified O +
atmosphere O +
of O +
5 O -
% O +
CO2 O +
–95 O -
% O +
air O -
. O +

Nuclear O +
proteins B-Gene +
were O +
isolated O +
according O +
to O +
the O +
method O +
of O +
Dignam O +
et O +
al. O +
[ O -
16 O -
] O +
. O +

In O +
brief O -
, O +
cells O +
were O +
lysed O +
with O +
ice O -
- O -
cold O +
buffer O +
A O +
( O -
10 O +
mM O +
HEPES O -
, O +
pH O +
7.9 O -
; O +
10 O +
mM O +
KCl O -
; O +
0.1 O +
mM O +
EDTA O -
; O +
1 O +
mM O +
dithiothreitol O -
; O +
0.6 O -
% O +
NP-40 O -
) O +
containing O +
protease B-Gene +
inhibitor O +
cocktail O +
( O -
Boeringer O +
Mannheim O -
, O +
Mannheim O -
, O +
Germany O -
) O +
and O +
centrifuged O -
. O +

The O +
supernatant O +
was O +
removed O +
and O +
the O +
pellets O +
were O +
resuspended O +
in O +
buffer O +
C O +
( O -
20 O +
mM O +
HEPES O -
, O +
pH O +
7.9 O -
; O +
0.4 O +
M O +
NaCl O -
; O +
1 O +
mM O +
EDTA O -
; O +
1 O +
mM O +
dithiothreitol O -
) O +
containing O +
protease B-Gene +
inhibitor O +
cocktail O +
and O +
incubated O +
on O +
ice O +
for O +
1 O +
h. O +
After O +
centrifugation O -
, O +
the O +
supernatant O +
was O +
harvested O +
and O +
used O +
as O +
nuclear O +
extracts O -
. O +

The O +
protein B-Gene +
concentrations O +
of O +
nuclear O +
extracts O +
were O +
measured O +
by O +
the O +
Bradford O +
method O +
[ O -
14 O -
] O +
. O +

The O +
AP-1 B-Gene +
oligonucleotide O +
probe O +
was O +
prepared O +
by O +
labeling O +
a O +
double O -
- O -
strand O +
oligonucleotide O +
( O -
5′-CGC O +
TTG O +
ATG O +
ACT O +
CA O +
G O +
CCG O +
GAA-3′ O -
, O +
Santa O +
Cruz O +
Biotechnology O -
, O +
Santa O +
Cruz O -
, O +
CA O -
, O +
USA O -
) O +
containing O +
AP-1 B-Gene +
binding O +
sites O +
( O -
underlined O -
) O +
with O +
[ O -
α−32 O +
P O +
] O -
CTP O +
and O +
Klenow B-Gene +
enzyme I-Gene -
. O +

Five O +
micrograms O +
of O +
nuclear O +
proteins O +
were O +
incubated O +
with O +
equal O +
amounts O +
of O +
the O +
probe O +
in O +
the O +
presence O +
of O +
1 O +
μg O +
of O +
poly O -
( O -
dI O -
– O -
dC O -
) O +
( O -
Pharmacia O -
, O +
Piscataway O -
, O +
NJ O -
, O +
USA O -
) O +
at O +
room O +
temperature O +
for O +
15 O +
min O +
and O +
the O +
mixtures O +
were O +
loaded O +
onto O +
a O +
6 O -
% O +
polyacrylamide O +
gel O +
at O +
80 O +
V O +
in O +
0.5 O -
× O +
TBE O +
buffer O -
. O +

The O +
gel O +
was O +
dried O -
, O +
autoradiographed O +
and O +
exposed O +
to O +
an O +
X O -
- O -
ray O +
film O +
at O +
−75 O -
° O -
C O -
. O +

3 O +
Results O +
and O +
discussion O +
Results O +
of O +
our O +
previous O +
study O +
revealed O +
that O +
topical O +
application O +
of O +
the O +
methanol O +
extract O +
of O +
A. O +
oxyphylla O +
to O +
the O +
dorsal O +
epidermis O +
of O +
mice O +
during O +
the O +
process O +
of O +
tumor O +
promotion O +
markedly O +
suppressed O +
the O +
papilloma O +
formation O +
[ O -
15 O -
] O +
. O +

The O +
extract O +
also O +
attenuated O +
the O +
mouse O +
ear O +
edema O +
induced O +
by O +
the O +
tumor O +
promoter O -
, O +
TPA O +
[ O -
15 O -
] O +
. O +

In O +
the O +
present O +
study O -
, O +
we O +
have O +
found O +
that O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O -
, O +
major O +
pungent O +
ingredients O +
derived O +
from O +
A. O +
oxyphylla O +
, O +
have O +
the O +
anti O -
- O -
tumor O +
promoting O +
potential O +
as O +
determined O +
by O +
their O +
inhibition O +
of O +
phorbol O +
ester O -
- O -
induced O +
ODC B-Gene +
activity O -
. O +

ODC B-Gene +
is O +
a O +
rate O -
- O -
limiting O +
enzyme B-Gene +
in O +
the O +
synthesis O +
of O +
polyamines O +
that O +
play O +
pivotal O +
roles O +
in O +
cell O +
growth O +
and O +
proliferation O -
. O +

ODC B-Gene +
is O +
rapidly O +
induced O +
by O +
many O +
mitogenic O +
stimuli O +
including O +
TPA O +
and O +
has O +
been O +
regarded O +
as O +
a O +
biochemical O +
hallmark O +
of O +
tumor O +
promotion O +
[ O -
17–20 O -
] O +
. O +

Conversely O -
, O +
various O +
anti O -
- O -
tumor O +
promoting O +
agents O +
exhibit O +
inhibitory O +
effects O +
on O +
the O +
catalytic O +
activity O +
of O +
this O +
enzyme B-Gene +
and O +
its O +
mRNA O +
expression O +
[ O -
21–29 O -
] O +
. O +

When O +
applied O +
topically O +
onto O +
shaven O +
backs O +
of O +
mice O +
30 O +
min O +
prior O +
to O +
TPA O +
at O +
a O +
dose O +
of O +
50 O +
μmol O -
, O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
inhibited O +
the O +
epidermal O +
ODC B-Gene +
activity O +
by O +
52 O -
% O +
and O +
81 O -
% O -
, O +
respectively O +
( O -
Fig. O +
2 O +
) O +
5 O +
h O +
after O +
the O +
treatment O -
, O +
which O +
was O +
in O +
good O +
agreement O +
with O +
their O +
inhibition O +
of O +
skin O +
tumor O +
promotion O +
( O -
K O -
.- O -
S. O +
Chun O +
et O +
al. O -
, O +
manuscript O +
in O +
preparation O -
) O -
. O +

Inflammation O +
is O +
closely O +
associated O +
with O +
the O +
tumor O +
promotion O +
process O +
and O +
the O +
production O +
of O +
such O +
cytokines B-Gene +
as O +
IL-1α B-Gene +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
that O +
mediate O +
inflammatory O +
processes O +
has O +
been O +
shown O +
to O +
be O +
stimulated O +
by O +
phorbol O +
ester O +
[ O -
30–32 O -
] O +
. O +

Recent O +
studies O +
have O +
revealed O +
that O +
topical O +
application O +
of O +
TPA O +
to O +
mouse O +
skin O +
induces O +
elevated O +
expression O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
in O +
the O +
epidermis O +
[ O -
33–35 O -
] O +
, O +
suggesting O +
that O +
this O +
pleiotropic O +
cytokine B-Gene +
directly O +
or O +
indirectly O +
mediates O +
the O +
inflammatory O +
and O +
hyperplastic O +
responses O +
elicited O +
by O +
the O +
tumor O +
promoter O -
. O +

Furthermore O -
, O +
TNF B-Gene -
- I-Gene -
α I-Gene +
markedly O +
stimulated O +
transformation O +
of O +
BALB O -
/ O -
3T3 O +
cells O +
induced O +
by O +
3-methylcholanthrene O +
[ O -
36 O -
] O +
and O +
is O +
hence O +
considered O +
as O +
an O +
endogenous O +
tumor O +
promoter O -
. O +

Epigallocatechin O +
gallate O -
, O +
a O +
chemopreventive O +
polyphenol O +
present O +
in O +
green O +
tea O -
, O +
has O +
been O +
shown O +
to O +
suppress O +
TNF B-Gene -
- I-Gene -
α I-Gene +
mRNA O +
expression O +
in O +
BALB O -
/ O -
3T3 O +
cells O +
treated O +
with O +
the O +
tumor O +
promoter O +
okadaic O +
acid O +
[ O -
31 O -
] O +
. O +

When O +
HL-60 O +
cells O +
were O +
treated O +
with O +
TPA O +
( O -
3 O +
nM O -
) O -
, O +
the O +
production O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
increased O +
steadily O +
up O +
to O +
16 O +
h O +
after O +
the O +
treatment O +
( O -
Fig. O +
3 O +
) O -
. O +

Treatment O +
of O +
either O +
yakuchinone O +
A O +
or O +
yakuchinone O +
B O +
at O +
50 O +
or O +
100 O +
μM O +
significantly O +
suppressed O +
the O +
TPA O -
- O -
stimulated O +
production O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
in O +
HL-60 O +
cells O +
at O +
12 O +
h O +
( O -
Fig. O +
4 O +
) O -
. O +

Likewise O -
, O +
TPA O -
- O -
induced O +
expression O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
mRNA O +
in O +
HL-60 O +
cells O +
or O +
mouse O +
skin O +
was O +
also O +
attenuated O +
by O +
these O +
diarylheptanoids O +
( O -
K O -
.- O -
S. O +
Chun O +
and O +
Y O -
.- O -
J. O +
Surh O -
, O +
unpublished O +
data O -
) O -
. O +

There O +
has O +
been O +
increasing O +
evidence O +
that O +
oxidative O +
stress O +
caused O +
by O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
can O +
contribute O +
to O +
multi O -
- O -
stage O +
carcinogenesis O +
[ O -
37–41 O -
] O +
, O +
particularly O +
in O +
the O +
promotion O +
stage O +
and O +
a O +
variety O +
of O +
anti O -
- O -
oxidants O +
have O +
been O +
shown O +
to O +
be O +
effective O +
anti O -
- O -
tumor O +
promoters O +
[ O -
42–44 O -
] O +
. O +

Curcumin O -
, O +
for O +
instance O -
, O +
has O +
been O +
reported O +
to O +
alleviate O +
the O +
TPA O -
- O -
induced O +
oxidative O +
DNA O +
damage O +
in O +
mouse O +
epidermis O +
[ O -
45 O -
] O +
and O +
also O +
cultured O +
mouse O +
fibroblast O +
cells O +
[ O -
46 O -
] O +
. O +

The O +
compound O +
also O +
suppressed O +
superoxide O +
production O +
in O +
macrophages O +
activated O +
by O +
TPA O +
[ O -
47 O -
] O +
. O +

Likewise O -
, O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
attenuated O +
the O +
TPA O -
- O -
stimulated O +
generation O +
of O +
superoxide O +
anion O +
in O +
differentiated O +
HL-60 O +
cells O +
( O -
Fig. O +
5 O +
) O -
. O +

In O +
another O +
experiment O -
, O +
both O +
compounds O +
suppressed O +
lipid O +
peroxidation O +
in O +
rat O +
brain O +
homogenates O +
( O -
Table O +
1 O +
) O -
. O +

AP-1 B-Gene +
is O +
a O +
well O -
- O -
defined O +
transcription B-Gene +
factor I-Gene +
that O +
is O +
known O +
to O +
be O +
regulated O +
by O +
the O +
intracellular O +
redox O +
state O +
and O +
is O +
hence O +
implicated O +
in O +
the O +
inducible O +
expression O +
of O +
a O +
wide O +
variety O +
of O +
genes O +
involved O +
in O +
oxidative O +
stress O +
and O +
cellular O +
response O +
mechanisms O +
[ O -
48 O -
, O +
49 O -
] O +
. O +

Functional O +
activation O +
of O +
AP-1 B-Gene +
is O +
believed O +
to O +
play O +
a O +
pivotal O +
role O +
in O +
signal O +
transduction O +
mediating O +
TPA O -
- O -
induced O +
tumor O +
promotion O -
. O +

Enhanced O +
binding O +
of O +
AP-1 B-Gene +
to O +
the O +
TPA O +
response O +
element O +
( O -
TRE O -
) O +
in O +
TPA O -
- O -
stimulated O +
cells O +
has O +
been O +
associated O +
with O +
the O +
increased O +
transcription O +
of O +
different O +
responsive O +
genes O -
. O +

According O +
to O +
a O +
recent O +
study O +
by O +
Huang O +
et O +
al. O +
[ O -
50 O -
] O +
, O +
curcumin O +
suppresses O +
TPA O -
- O -
induced O +
TRE O -
- O -
binding O +
activity O +
of O +
c B-Gene -
- I-Gene -
Jun I-Gene -
/ O -
AP-1 B-Gene -
, O +
which O +
may O +
account O +
for O +
the O +
anti O -
- O -
tumor O +
promoting O +
effect O +
of O +
this O +
chemopreventive O +
agent O -
. O +

More O +
recently O -
, O +
curcumin O +
has O +
been O +
reported O +
to O +
inhibit O +
TNF B-Gene -
- I-Gene -
α I-Gene -
- O -
induced O +
binding O +
of O +
AP-1 B-Gene +
to O +
DNA O +
in O +
bovine O +
aortic O +
endothelial O +
cells O +
[ O -
51 O -
] O +
. O +

When O +
treated O +
to O +
mouse O +
fibroblast O +
cells O +
in O +
culture O +
at O +
a O +
concentration O +
of O +
100 O +
μM O +
for O +
1 O +
h O -
, O +
both O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
mitigated O +
the O +
TPA O -
- O -
induced O +
binding O +
of O +
AP-1 B-Gene +
to O +
TRE O +
( O -
Fig. O +
6 O +
) O -
. O +

Mitogen O -
- O -
induced O +
AP-1 B-Gene +
activation O +
has O +
been O +
shown O +
to O +
be O +
inhibited O +
by O +
anti O -
- O -
oxidants O -
, O +
suggesting O +
the O +
involvement O +
of O +
ROS O +
in O +
this O +
process O -
. O +

Based O +
on O +
these O +
findings O -
, O +
it O +
seems O +
likely O +
that O +
the O +
suppression O +
of O +
AP-1 B-Gene +
activation O +
by O +
yakuchinones O +
is O +
attributable O -
, O +
in O +
part O -
, O +
to O +
their O +
anti O -
- O -
oxidant O +
activity O -
. O +

In O +
early O +
studies O -
, O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
were O +
found O +
to O +
be O +
potent O +
anti O -
- O -
inflammatory O +
agents O +
as O +
determined O +
by O +
their O +
strong O +
inhibition O +
of O +
prostaglandin O +
biosynthesis O +
by O +
bovine O +
seminal O +
vesicle O +
cyclooxygenase B-Gene +
[ O -
52 O -
] O +
and O +
a O +
rabbit O +
renal O +
medulla O +
microsomal O +
fraction O +
[ O -
53 O -
, O +
54 O -
] O +
. O +

In O +
recent O +
years O -
, O +
there O +
is O +
an O +
expanding O +
body O +
of O +
data O +
supporting O +
that O +
suppression O +
of O +
prostaglandin O +
synthesis O +
through O +
selective O +
inhibition O +
of O +
cyclooxygenase B-Gene -
, O +
particularly O +
cyclooxygenase-2 B-Gene +
which O +
is O +
inducible O +
by O +
various O +
extracellular O +
stimuli O -
, O +
is O +
regarded O +
as O +
an O +
important O +
strategy O +
for O +
cancer O +
chemoprevention O +
[ O -
55 O -
] O +
. O +

Inhibitors O +
of O +
arachidonic O +
acid O +
metabolism O +
have O +
been O +
found O +
to O +
induce O +
programmed O +
death O +
or O +
apoptosis O +
in O +
certain O +
types O +
of O +
tumor O +
cells O +
[ O -
56–59 O -
] O +
. O +

Thus O -
, O +
some O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O -
, O +
including O +
sulindac O +
and O +
aspirin O -
, O +
exhibit O +
growth O -
- O -
inhibitory O +
and O +
anti O -
- O -
proliferative O +
properties O +
in O +
tumor O +
cells O +
via O +
induction O +
of O +
apoptosis O +
[ O -
60–62 O -
] O +
. O +

In O +
line O +
with O +
the O +
findings O +
on O +
the O +
capability O +
of O +
inhibitors O +
of O +
arachidonic O +
acid O +
metabolism O +
to O +
induce O +
apoptosis O +
or O +
suppress O +
proliferation O +
of O +
selected O +
malignant O +
or O +
transformed O +
cells O -
, O +
treatment O +
of O +
human O +
colon O +
cancer O +
( O -
HCA-7 O -
) O +
cells O +
with O +
prostaglandin O +
E2 O +
inhibited O +
apoptosis O +
via O +
induction O +
of O +
death B-Gene +
suppressing I-Gene +
protein I-Gene +
Bcl-2 B-Gene +
[ O -
63 O -
] O +
. O +

We O +
have O +
recently O +
reported O +
that O +
both O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
induce O +
apoptotic O +
death O +
in O +
HL-60 O +
cells O -
, O +
which O +
accounts O +
for O +
their O +
anti O -
- O -
proliferative O +
activity O +
[ O -
64 O -
] O +
. O +

Although O +
it O +
remains O +
unclear O +
whether O +
these O +
diarylheptanoids O +
induce O +
apoptosis O +
selectively O +
in O +
cancer O +
cells O -
, O +
they O +
appear O +
to O +
be O +
relatively O +
less O +
cytotoxic O +
in O +
normal O +
cells O -
. O +

In O +
this O +
context O -
, O +
it O +
is O +
of O +
interest O +
to O +
note O +
that O +
curcumin O +
induces O +
apoptosis O +
in O +
various O +
types O +
of O +
cell O +
lines O +
[ O -
9 O -
, O +
65 O -
, O +
66 O -
] O +
derived O +
from O +
human O +
tumors O -
, O +
but O +
the O +
compound O +
was O +
inactive O +
for O +
the O +
normal O +
cells O +
in O +
primary O +
culture O +
[ O -
66 O -
] O +
. O +

In O +
conclusion O -
, O +
this O +
study O +
demonstrates O +
that O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
derived O +
from O +
A. O +
oxyphylla O +
Miquel O -
, O +
inhibit O +
promotion O +
of O +
skin O +
tumorigenesis O +
and O +
tumor O +
promoter O -
- O -
induced O +
epidermal O +
ODC B-Gene +
activity O +
in O +
mice O -
. O +

These O +
diarylheptanoids O +
also O +
suppressed O +
TPA O -
- O -
stimulated O +
production O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
and O +
superoxide O +
in O +
cultured O +
HL-60 O +
cells O -
. O +

Furthermore O -
, O +
TPA O -
- O -
induced O +
c B-Gene -
- I-Gene -
Jun I-Gene -
/ O -
AP-1 B-Gene +
activation O +
was O +
also O +
attenuated O +
by O +
the O +
above O +
substances O -
. O +

Additional O +
studies O +
are O +
in O +
progress O +
to O +
elucidate O +
the O +
detailed O +
molecular O +
mechanisms O +
underlying O +
anti O -
- O -
tumor O +
promoting O +
effects O +
of O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B. O +
Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
the O +
G-7 O +
project O +
( O -
1541 O -
- O -
211 O -
) O +
sponsored O +
by O +
the O +
Ministry O +
of O +
Science O +
and O +
Technology O -
, O +
Republic O +
of O +
Korea O +
and O +
a O +
grant O +
from O +
Korea O +
Ministry O +
of O +
Health O +
and O +
Welfare O +
( O -
Grant O +
No. O -
, O +
HMP-96-D-2 O -
- O -
1034 O -
) O -
. O +

Heterocyclic O +
amines O +
are O +
potent O +
bacterial O +
mutagens O +
[ O -
1 O -
] O +
, O +
rodent O +
carcinogens O +
[ O -
2 O -
] O +
, O +
and O +
suspected O +
human O +
carcinogens O +
[ O -
3 O -
] O +
. O +

Formation O +
of O +
heterocyclic O +
amines O +
during O +
cooking O +
processes O +
( O -
reviewed O +
in O +
Refs O -
. O +

[ O -
4 O -
, O +
5 O -
] O +
) O +
suggests O +
that O +
exposure O +
to O +
these O +
compounds O +
is O +
largely O +
unavoidable O +
[ O -
6 O -
] O +
. O +

Therefore O -
, O +
other O +
means O +
of O +
controlling O +
heterocyclic O +
amine O -
- O -
induced O +
cancer O +
risk O +
need O +
to O +
be O +
considered O -
. O +

Numerous O +
dietary O +
components O +
have O +
been O +
shown O +
to O +
substantially O +
decrease O +
the O +
bacterial O +
mutagenicity O +
of O +
heterocyclic O +
amines O -
, O +
including O +
chlorophyllin O +
[ O -
7 O -
, O +
8 O -
] O +
, O +
extracts O +
and O +
isolated O +
polyphenolic O +
components O +
from O +
tea O -
, O +
coffee O +
and O +
other O +
plant O +
sources O +
[ O -
8–14 O -
] O +
, O +
isothiocyanates O +
[ O -
15 O -
] O +
and O +
1-O O +
-hexyl-2,3,5-trimethylhydroquinone O +
[ O -
16 O -
] O +
. O +

Extract O +
of O +
madder O +
root O +
( O -
Rubia O +
tinctorum O +
) O +
contains O +
a O +
number O +
of O +
hydroxyanthraquinones O +
and O +
has O +
been O +
used O +
as O +
a O +
treatment O +
for O +
kidney O +
and O +
bladder O +
stones O +
[ O -
17 O -
] O +
and O +
as O +
a O +
food O +
colouring O -
. O +

Purpurin O +
( O -
1,2,4-trihydroxy-9,10-anthraquinone O -
) O +
( O -
Fig. O +
1 O +
) O +
is O +
present O +
at O +
trace O +
amounts O +
in O +
R. O +
tinctorum O +
[ O -
18 O -
] O +
and O +
as O +
a O +
major O +
anthraquinone O +
component O +
of O +
R. O +
akane O +
, O +
Japanese O +
madder O +
( O -
communication O +
from O +
The O +
San O -
- O -
Ei O +
Gen O +
Foundation O +
for O +
Food O +
and O +
Chemical O +
Research O -
, O +
Osaka O -
) O -
. O +

Purpurin O +
is O +
non O -
- O -
mutagenic O +
in O +
the O +
majority O +
of O +
Ames O +
tester O +
strains O +
[ O -
18 O -
, O +
19 O -
] O +
and O +
is O +
only O +
weakly O +
mutagenic O +
in O +
TA1537 O +
[ O -
19 O -
] O +
. O +

We O +
have O +
investigated O +
the O +
possible O +
protective O +
role O +
of O +
this O +
polyphenolic O +
compound O +
against O +
bacterial O +
mutagenesis O +
induced O +
by O +
a O +
number O +
of O +
food O -
- O -
derived O +
heterocyclic O +
amines O -
, O +
particularly O +
3-amino-1-methyl-5H O +
-pyrido O -
[ O -
4,3-b O +
] O -
indole O +
( O -
Trp O -
- O -
P-2 O -
) O -
, O +
in O +
the O +
Ames O +
test O +
using O +
TA98 O -
. O +

The O +
metabolism O +
of O +
heterocyclic O +
amines O +
to O +
mutagenic O +
intermediates O +
is O +
catalyzed O +
mainly O +
by O +
the O +
cytochrome B-Gene +
P I-Gene +
4501A I-Gene +
( O -
CYP1A B-Gene -
) O +
isoforms B-Gene -
, O +
in O +
particular O +
CYP1A2 B-Gene +
( O -
Ref O -
. O +

[ O -
20 O -
] O +
and O +
references O +
therein O -
) O -
. O +

In O +
extrahepatic O +
tissues O +
there O +
is O +
also O +
some O +
contribution O +
to O +
bioactivation O +
by O +
prostaglandin B-Gene +
H I-Gene +
synthase I-Gene +
[ O -
21 O -
] O +
. O +

In O +
addition O -
, O +
there O +
is O +
some O +
evidence O +
for O +
a O +
free O +
radical O +
mechanism O +
involving O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene +
[ O -
22 O -
] O +
. O +

Previously O -
, O +
it O +
has O +
been O +
reported O +
that O +
chlorophyllin O +
[ O -
23 O -
] O +
and O +
several O +
anti O -
- O -
mutagenic O +
polyphenols O +
[ O -
10 O -
, O +
13 O -
, O +
16 O -
] O +
exert O +
their O +
effect O -
, O +
in O +
vitro O -
, O +
by O +
inhibition O +
of O +
CYP B-Gene -
- O -
dependent O +
metabolism O +
of O +
heterocyclic O +
amines O +
to O +
their O +
active O +
hydroxylamine O +
metabolites O -
. O +

Therefore O -
, O +
in O +
addition O +
to O +
the O +
regular O +
Ames O +
tester O +
strain O +
( O -
TA98 O -
) O -
, O +
we O +
investigated O +
the O +
anti O -
- O -
mutagenic O +
potential O +
of O +
purpurin O +
in O +
bacteria O +
expressing O +
human O +
drug B-Gene +
metabolizing I-Gene +
enzymes I-Gene +
( O -
human O +
CYP1A2 B-Gene -
, O +
human O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene -
, O +
and O +
Salmonella O +
O B-Gene +
-acetyltransferase I-Gene -
) O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Chemicals O +
Reagent O +
grade O +
purpurin O +
( O -
1,2,4-trihydroxy-9,10-anthraquinone O -
) O +
( O -
86 O -
% O +
pure O -
, O +
as O +
determined O +
by O +
reversed O -
- O -
phase O +
HPLC O -
) O +
and O +
all O +
heterocyclic O +
amines O +
were O +
obtained O +
from O +
Wako O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

Pure O +
grade O +
chlorophyllin O +
( O -
Cu O -
– O -
Na O +
salt O -
) O +
was O +
obtained O +
from O +
Nakalai O +
Tesque O +
( O -
Kyoto O -
, O +
Japan O -
) O +
and O +
epigallocatechin O +
gallate O +
( O -
EGCG O -
) O +
( O -
95 O -
% O +
pure O -
) O +
was O +
a O +
kind O +
gift O +
from O +
Dr. O +
I. O +
Sakata O +
( O -
Toyo O +
Hakka O +
Satasho O -
, O +
Okayama O -
) O -
. O +

Activated O +
heterocyclic O +
amines O +
were O +
prepared O +
by O +
incubation O +
of O +
the O +
parent O +
amine O +
with O +
rat O +
hepatic O +
S9 O +
mix O +
for O +
20 O +
min O +
at O +
37 O -
° O -
C O -
, O +
protein B-Gene +
precipitation O +
with O +
acetone O +
and O +
freeze O +
drying O +
of O +
the O +
supernatant O +
as O +
described O +
previously O +
[ O -
24 O -
] O +
. O +

Finally O -
, O +
purified O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
was O +
synthesized O +
from O +
Trp O -
- O -
P-2 O +
via O +
Trp O -
- O -
P-2 O -
( O -
NO2 O -
) O +
as O +
described O +
by O +
Saito O +
et O +
al. O +
[ O -
25 O -
] O +
. O +

2.2 O +
Animals O +
and O +
treatment O +
Induced O +
S9 O +
used O +
in O +
the O +
assay O +
systems O +
was O +
obtained O +
from O +
male O +
rats O +
pre O -
- O -
treated O +
with O +
PCB-54 O +
( O -
a O +
commercial O +
mixture O +
of O +
polychlorinated O +
biphenyls O -
, O +
Tokyo O +
Kasei O +
Chemical O -
) O +
as O +
described O +
previously O +
[ O -
26 O -
] O +
. O +

2.3 O +
Bacterial O +
strains O +
and O +
mutation O +
assays O +
Bacterial O +
strains O +
TA98 O -
, O +
and O +
TA98 O -
- O -
1,8-DNP6 O +
, O +
were O +
kind O +
gifts O +
from O +
Prof. O +
B.N. O +
Ames O +
( O -
University O +
of O +
California O -
, O +
Berkeley O -
) O -
, O +
and O +
Prof. O +
H. O +
Rosenkranz O +
( O -
Case O +
Western O +
Reserve O +
University O -
, O +
Cleveland O -
, O +
OH O -
) O -
, O +
respectively O -
. O +

Strains O +
TA1538R O -
, O +
TA1538AR O +
and O +
TA1538ARO O -
, O +
which O +
express O +
human O +
drug B-Gene +
metabolizing I-Gene +
enzymes I-Gene -
, O +
were O +
established O +
as O +
described O +
by O +
Suzuki O +
et O +
al. O +
[ O -
27 O -
] O +
. O +

Mutagenicity O +
assays O +
were O +
performed O +
using O +
the O +
methods O +
of O +
Maron O +
and O +
Ames O +
[ O -
28 O -
] O +
with O +
modifications O +
for O +
strains O +
expressing O +
recombinant B-Gene +
human O +
enzymes B-Gene +
as O +
described O +
previously O +
[ O -
27 O -
] O +
. O +

To O +
demonstrate O +
the O +
anti O -
- O -
mutagenic O +
activities O +
of O +
purpurin O -
, O +
the O +
mutagenic O +
heterocyclic O +
amines O +
were O +
assayed O +
with O +
the O +
use O +
of O +
the O +
pre O -
- O -
incubation O +
technique O +
of O +
Yahagi O +
et O +
al. O +
[ O -
29 O -
] O +
, O +
with O +
purpurin O +
added O +
before O +
the O +
pre O -
- O -
incubation O -
. O +

To O +
investigate O +
the O +
mechanism O +
of O +
anti O -
- O -
mutagenesis O -
, O +
a O +
two O -
- O -
stage O +
test O +
was O +
performed O -
, O +
in O +
which O +
an O +
initial O +
incubation O +
of O +
TA1538ARO O +
( O -
a O +
strain O +
expressing O +
human O +
CYP1A2 B-Gene -
, O +
human O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene -
, O +
and O +
bacterial O +
O B-Gene +
-acetyltransferase I-Gene -
) O +
bacterial O +
culture O +
( O -
100 O +
ml O -
) O +
with O +
or O +
without O +
the O +
addition O +
of O +
purpurin O +
with O +
shaking O +
at O +
20 O -
° O -
C O -
. O +

After O +
20 O +
min O -
, O +
aliquots O +
were O +
taken O +
and O +
centrifuged O +
to O +
harvest O +
the O +
bacteria O -
. O +

The O +
bacteria O +
were O +
washed O +
twice O +
by O +
resuspending O +
in O +
nutrient O +
broth O +
followed O +
by O +
centrifugation O -
. O +

The O +
final O +
bacterial O +
pellet O +
was O +
gently O +
resuspended O +
in O +
nutrient O +
broth O +
and O +
incorporated O +
into O +
the O +
Ames O +
test O -
. O +

2.4 O +
Measurement O +
of O +
CYP B-Gene +
and O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene +
Total O +
cytochrome B-Gene +
P I-Gene +
450 I-Gene +
content O +
was O +
measured O +
by O +
the O +
method O +
of O +
Omura O +
and O +
Sato O +
[ O -
30 O -
] O +
and O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene +
activity O +
was O +
determined O +
by O +
the O +
reduction O +
of O +
cytochrome B-Gene +
c I-Gene +
according O +
to O +
the O +
method O +
of O +
Phillips O +
and O +
Langdon O +
[ O -
31 O -
] O +
. O +

3 O +
Results O +
Fig. O +
2 O +
demonstrates O +
the O +
anti O -
- O -
mutagenic O +
potential O +
of O +
purpurin O +
against O +
heterocyclic O +
amine O -
- O -
induced O +
mutagenicity O +
using O +
Salmonella O +
typhimurium O +
TA98 O -
. O +

Purpurin O +
was O +
able O +
to O +
significantly O +
inhibit O +
the O +
mutagenicity O +
of O +
each O +
activated O +
heterocyclic O +
amine O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

This O +
inhibitory O +
effect O +
was O +
most O +
marked O +
for O +
Trp O -
- O -
P-1 O +
( O -
0.5 O +
nmol O -
) O +
and O +
Trp O -
- O -
P-2 O +
( O -
0.06 O +
nmol O -
) O +
with O +
greater O +
than O +
90 O -
% O +
inhibition O +
( O -
Fig. O +
2 O +
) O +
but O +
was O +
also O +
greater O +
than O +
60 O -
% O +
for O +
MeIQ O +
( O -
0.2 O +
nmol O -
) O -
, O +
IQ O +
( O -
0.1 O +
nmol O -
) O +
and O +
Glu O -
- O -
P-1 O +
( O -
5.0 O +
nmol O -
) O -
. O +

The O +
inhibition O +
of O +
Trp O -
- O -
P-2-dependent O +
mutagenicity O +
by O +
purpurin O +
and O +
two O +
other O +
established O +
anti O -
- O -
mutagens O -
, O +
EGCG O +
and O +
chlorophyllin O +
clearly O +
showed O +
that O +
purpurin O +
is O +
an O +
effective O +
inhibitor O +
of O +
mutagenicity O +
( O -
Fig. O +
3 O +
) O -
. O +

Even O +
when O +
the O +
molarities O +
of O +
the O +
added O +
compounds O +
are O +
taken O +
into O +
account O -
, O +
purpurin O +
( O -
17 O -
% O +
inhibition O +
per O +
nmol O +
added O -
) O +
is O +
comparable O +
to O +
the O +
other O +
two O +
anti O -
- O -
mutagens O +
( O -
EGCG O -
, O +
16 O -
% O +
per O +
nmol O +
and O +
chlorophyllin O -
, O +
13 O -
% O +
per O +
nmol O -
) O -
. O +

Inhibition O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
mutagenicity O +
was O +
investigated O +
at O +
pH O +
5 O +
and O +
pH O +
7.4 O -
. O +

At O +
neutral O +
pH O +
the O +
anti O -
- O -
mutagenic O +
effect O +
was O +
considerably O +
greater O +
( O -
94 O -
% O -
) O +
than O +
at O +
pH O +
5 O +
( O -
54 O -
% O -
) O -
. O +

However O -
, O +
the O +
mutagenic O +
response O +
at O +
pH O +
5 O +
was O +
only O +
25 O -
% O +
of O +
that O +
observed O +
at O +
pH O +
7.4 O +
( O -
Table O +
1 O +
) O -
. O +

TA98 O -
- O -
1,8-DNP6 O +
is O +
a O +
bacterial O +
strain O +
deficient O +
in O +
N B-Gene +
, I-Gene -
O I-Gene +
-acetyltransferase I-Gene +
[ O -
32 O -
] O +
. O +

In O +
aryl O +
amines O -
, O +
O O +
-acetylation O +
is O +
considered O +
a O +
bioactivation O +
pathway O +
and O +
consequently O -
, O +
it O +
is O +
possible O +
that O +
purpurin O +
exerts O +
its O +
anti O -
- O -
mutagenic O +
effect O +
by O +
having O +
an O +
influence O +
upon O +
acetylation O +
of O +
the O +
N O +
-hydroxylamine O -
. O +

However O -
, O +
the O +
mutagenic O +
response O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
in O +
TA98 O -
- O -
1,8-DNP6 O +
and O +
the O +
parent O +
TA98 O +
strains O +
were O +
very O +
similar O +
( O -
Table O +
2 O +
) O -
. O +

The O +
degree O +
of O +
inhibition O +
by O +
purpurin O +
was O +
the O +
same O +
in O +
both O +
strains O +
( O -
Table O +
2 O +
) O -
. O +

In O +
both O +
the O +
presence O +
and O +
absence O +
of O +
rat O +
hepatic O +
S9 O -
, O +
purpurin O +
did O +
not O +
affect O +
the O +
mutagenic O +
response O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
if O +
the O +
reaction O +
mixtures O +
were O +
not O +
pre O -
- O -
incubated O -
. O +

In O +
contrast O -
, O +
if O +
assay O +
mixtures O +
were O +
pre O -
- O -
incubated O +
for O +
40 O +
min O +
at O +
37 O -
° O -
C O -
, O +
purpurin O +
inhibited O +
the O +
mutagenic O +
response O +
in O +
both O +
the O +
presence O +
and O +
absence O +
of O +
S9 O -
. O +

Both O +
the O +
mutagenicity O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
and O +
the O +
inhibition O +
by O +
purpurin O +
were O +
more O +
marked O +
in O +
the O +
absence O +
of O +
S9 O +
mix O +
( O -
Fig. O +
4 O +
) O -
. O +

Purpurin O +
was O +
non O -
- O -
mutagenic O +
in O +
Salmonella O +
strains O +
TA1538R O -
, O +
TA1538AR O +
and O +
TA1538ARO O +
which O +
express O +
human O +
drug B-Gene +
metabolizing I-Gene +
enzymes I-Gene +
( O -
Table O +
3 O +
) O -
. O +

Some O +
cytotoxicity O +
was O +
observed O +
in O +
TA1538ARO O +
( O -
Table O +
3 O +
) O -
. O +

A O +
dose O -
- O -
dependent O +
inhibition O +
of O +
the O +
mutagenicity O +
of O +
Trp O -
- O -
P-2 O +
was O +
observed O +
for O +
purpurin O +
in O +
strain O +
TA1538ARO O +
with O +
a O +
10-fold O +
excess O +
of O +
purpurin O +
almost O +
entirely O +
removing O +
the O +
mutagenic O +
response O +
( O -
Fig. O +
5 O +
) O -
. O +

During O +
the O +
two O -
- O -
stage O +
mutagenicity O +
test O -
, O +
a O +
20-min O +
incubation O +
of O +
the O +
TA1538ARO O +
bacterial O +
culture O +
with O +
purpurin O +
resulted O +
in O +
a O +
dose O -
- O -
dependent O +
inhibition O +
of O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene +
and O +
a O +
dose O -
- O -
dependent O +
degradation O +
of O +
CYP B-Gene +
( O -
Fig. O +
6 O +
) O -
. O +

Consequently O -
, O +
when O +
these O +
bacteria O +
were O +
employed O +
in O +
the O +
Ames O +
test O -
, O +
the O +
mutagenic O +
response O +
obtained O +
with O +
a O +
range O +
of O +
Trp O -
- O -
P-2 O +
concentrations O +
also O +
decreased O +
dose O -
- O -
dependently O +
( O -
Fig. O +
7 O +
) O -
. O +

4 O +
Discussion O +
We O +
have O +
presented O +
here O +
the O +
possible O +
advantage O +
of O +
purpurin O +
as O +
an O +
inhibitor O +
of O +
heterocyclic O +
amine O -
- O -
induced O +
mutations O -
, O +
using O +
the O +
Ames O +
bacterial O +
test O +
system O -
. O +

Purpurin O +
markedly O +
inhibited O +
the O +
mutagenic O +
response O +
of O +
a O +
range O +
of O +
heterocyclic O +
amines O +
with O +
an O +
apparent O +
preference O +
for O +
inhibition O +
of O +
the O +
activated O +
pyrido O +
indoles O -
, O +
Trp O -
- O -
P-1 O +
and O +
Trp O -
- O -
P-2 O +
( O -
Fig. O +
2 O +
) O -
. O +

At O +
a O +
mutagen O -
: O -
purpurin O +
ratio O +
of O +
only O +
1:4 O +
a O +
90 O -
% O +
inhibition O +
of O +
Trp O -
- O -
P-1 O +
mutagenicity O +
was O +
observed O +
( O -
Fig. O +
2 O +
) O -
. O +

When O +
a O +
purified O +
sample O +
of O +
purpurin O +
was O +
used O +
( O -
purity O +
100 O -
% O -
, O +
a O +
kind O +
gift O +
from O +
The O +
San O -
- O -
Ei O +
Gen O +
Foundation O +
for O +
Food O +
Chemical O +
Research O -
, O +
Osaka O -
) O -
, O +
identical O +
results O +
were O +
obtained O +
( O -
data O +
not O +
shown O -
) O -
. O +

When O +
the O +
protective O +
effect O +
of O +
purpurin O +
against O +
activated O +
Trp O -
- O -
P-2 O +
was O +
compared O +
to O +
that O +
observed O +
with O +
the O +
established O +
anti O -
- O -
mutagens O -
, O +
EGCG O +
and O +
chlorophyllin O -
, O +
purpurin O +
was O +
found O +
to O +
be O +
equally O +
potent O +
( O -
Fig. O +
3 O +
) O -
. O +

Solutions O +
of O +
purpurin O +
at O +
different O +
pH O +
values O +
have O +
markedly O +
different O +
physical O +
appearances O -
. O +

At O +
pH O +
5 O -
, O +
a O +
purpurin O +
solution O +
is O +
orange O +
while O +
at O +
neutral O +
pH O +
and O +
alkaline O +
conditions O -
, O +
solutions O +
are O +
purple O -
. O +

The O +
inhibition O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
mutagenicity O +
was O +
investigated O +
at O +
neutral O +
( O -
7.4 O -
) O +
and O +
acidic O +
( O -
5 O -
) O +
pH O +
( O -
Table O +
1 O +
) O -
. O +

At O +
neutral O +
pH O -
, O +
addition O +
of O +
a O +
30-fold O +
excess O +
of O +
purpurin O +
almost O +
entirely O +
inhibited O +
the O +
mutagenic O +
response O -
, O +
but O +
at O +
pH O +
5 O +
the O +
decrease O +
in O +
revertant O +
colonies O +
was O +
only O +
60 O -
% O +
( O -
Table O +
1 O +
) O -
. O +

This O +
infers O +
that O +
whatever O +
change O +
there O +
may O +
be O +
in O +
the O +
structure O +
of O +
purpurin O +
occurring O +
in O +
acidic O +
solutions O +
blocks O +
the O +
anti O -
- O -
mutagenic O +
potential O -
. O +

However O -
, O +
at O +
pH O +
5 O +
the O +
mutagenicity O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
is O +
also O +
considerably O +
decreased O +
in O +
the O +
absence O +
of O +
purpurin O +
( O -
Table O +
1 O +
) O -
. O +

This O +
may O +
be O +
because O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
is O +
considerably O +
more O +
stable O +
under O +
acidic O +
conditions O +
and O +
consequently O -
, O +
does O +
not O +
degrade O +
so O +
readily O +
to O +
the O +
nitrenium O +
ion O -
. O +

Purpurin O +
could O +
act O +
at O +
neutral O +
pH O +
by O +
increasing O +
the O +
rate O +
of O +
degradation O +
of O +
the O +
hydroxylamine O +
to O +
a O +
non O -
- O -
mutagenic O +
intermediate O -
. O +

Degradation O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
to O +
less O +
mutagenic O +
intermediates O +
has O +
been O +
observed O +
previously O +
in O +
our O +
laboratory O +
for O +
other O +
natural O +
pigments O +
such O +
as O +
Monascus O +
red O +
and O +
Monascus O +
yellow O +
[ O -
33 O -
] O +
and O +
chlorophyllin O +
[ O -
34 O -
] O +
. O +

Many O +
aromatic O +
N O +
-hydroxylamines O +
undergo O +
further O +
metabolism O +
by O +
bacterial O +
N B-Gene +
, I-Gene -
O I-Gene +
-acetyltransferases I-Gene +
to O +
more O +
mutagenic O +
N O +
-acetoxyamines O -
. O +

To O +
determine O +
whether O +
purpurin O +
exerts O +
its O +
effect O +
upon O +
the O +
N O +
-hydroxylamine O +
or O +
the O +
N O +
-acetoxyamine O -
, O +
the O +
inhibition O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
mutagenicity O +
was O +
observed O +
in O +
TA98 O +
and O +
the O +
N B-Gene +
, I-Gene -
O I-Gene +
-acetyltransferase I-Gene -
- O -
deficient O +
TA98 O -
- O -
1,8-DNP6 O +
strains O -
. O +

Both O +
the O +
mutagenic O +
response O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
and O +
its O +
inhibition O +
by O +
purpurin O +
were O +
comparable O +
in O +
both O +
strains O +
( O -
Table O +
2 O +
) O -
. O +

The O +
absence O +
of O +
any O +
decrease O +
in O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O -
-induced O +
mutations O +
in O +
the O +
N B-Gene +
, I-Gene -
O I-Gene +
-acetyltransferase I-Gene -
- O -
deficient O +
strain O +
is O +
in O +
agreement O +
with O +
previous O +
investigations O +
[ O -
35–37 O -
] O +
. O +

It O +
has O +
been O +
suggested O +
that O +
this O +
is O +
because O +
the O +
N O +
-hydroxylamine O +
and O +
the O +
N O +
-acetoxyamine O +
of O +
Trp O -
- O -
P-2 O +
are O +
equally O +
capable O +
of O +
forming O +
the O +
nitrenium O +
ion O +
[ O -
37 O -
] O +
. O +

Consequently O -
, O +
these O +
results O +
demonstrate O +
that O +
purpurin O +
can O +
express O +
a O +
potent O +
anti O -
- O -
mutagenic O +
effect O +
by O +
interaction O +
with O +
the O +
N O +
-hydroxylamine O -
. O +

In O +
both O +
the O +
presence O +
and O +
the O +
absence O +
of O +
S9 O -
, O +
purpurin O +
had O +
no O +
effect O +
on O +
the O +
mutagenicity O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
if O +
the O +
direct O +
plate O -
- O -
incorporation O +
assay O +
was O +
employed O -
, O +
but O +
purpurin O +
acted O +
as O +
an O +
anti O -
- O -
mutagen O +
when O +
using O +
the O +
pre O -
- O -
incubation O +
method O +
( O -
Fig. O +
4 O +
) O -
. O +

This O +
observation O +
implies O +
that O +
pre O -
- O -
incubation O +
is O +
essential O +
for O +
an O +
inhibitory O +
response O +
but O +
a O +
simple O +
dilution O +
effect O +
can O -
not O +
be O +
ruled O +
out O -
. O +

In O +
the O +
presence O +
of O +
S9 O -
, O +
the O +
mutagenic O +
response O +
is O +
considerably O +
lower O -
, O +
probably O +
as O +
a O +
consequence O +
of O +
non O -
- O -
specific O +
binding O +
of O +
reactive O +
intermediates O +
to O +
protein B-Gene -
. O +

Even O +
in O +
the O +
absence O +
of O +
purpurin O -
, O +
pre O -
- O -
incubation O +
is O +
responsible O +
for O +
a O +
decrease O +
in O +
revertants O +
in O +
both O +
the O +
presence O +
and O +
absence O +
of O +
S9 O -
. O +

This O +
is O +
a O +
consequence O +
of O +
the O +
time O -
- O -
dependent O +
degradation O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O +
[ O -
38 O -
] O +
under O +
aerobic O +
conditions O -
. O +

However O -
, O +
the O +
presence O +
of O +
purpurin O +
is O +
responsible O +
for O +
a O +
significant O +
decrease O +
in O +
revertants O +
in O +
addition O +
to O +
the O +
aerobic O +
degradation O +
( O -
Fig. O +
4 O +
) O -
. O +

The O +
effect O +
of O +
purpurin O +
was O +
less O +
marked O +
in O +
the O +
presence O +
of O +
S9 O -
, O +
suggesting O +
that O +
enzymes B-Gene +
within O +
the O +
S9 O +
may O +
act O +
either O +
by O +
metabolizing O +
purpurin O +
to O +
a O +
less O +
effective O +
inhibitor O +
or O +
by O +
reversing O +
any O +
direct O +
effect O +
of O +
purpurin O +
on O +
the O +
mutagen O -
. O +

Several O +
hydroxyanthraquinones O -
, O +
including O +
purpurin O -
, O +
have O +
been O +
proposed O +
as O +
carcinogens O +
and O +
bacterial O +
mutagens O +
[ O -
18 O -
, O +
19 O -
, O +
39–44 O -
] O +
. O +

Chronic O +
feeding O +
of O +
a O +
high O +
dose O +
of O +
purpurin O +
( O -
1 O -
% O +
diet O -
, O +
520 O +
days O -
) O +
to O +
rats O +
was O +
responsible O +
for O +
increased O +
hyperplasia O +
of O +
the O +
renal O -
, O +
pelvic O +
epithelium O +
and O +
papilloma O +
and O +
carcinoma O +
development O +
in O +
the O +
urinary O +
bladder O +
[ O -
41 O -
] O +
. O +

These O +
effects O +
have O +
been O +
attributed O +
to O +
crystallization O +
of O +
purpurin O +
[ O -
41 O -
] O +
. O +

However O -
, O +
unlike O +
1-hydroxyanthraquinone O +
[ O -
40 O -
] O +
, O +
no O +
tumorigenic O +
or O +
toxicological O +
effects O +
were O +
observed O +
in O +
the O +
intestines O +
[ O -
41 O -
] O +
. O +

Therefore O -
, O +
lower O +
doses O -
, O +
which O +
may O +
avoid O +
crystallization O +
in O +
urinary O +
tract O -
, O +
may O +
not O +
be O +
tumorigenic O -
. O +

From O +
the O +
structure O +
of O +
purpurin O -
, O +
it O +
is O +
conceivable O +
that O +
it O +
forms O +
free O +
radicals O +
in O +
the O +
presence O +
of O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene -
. O +

Therefore O -
, O +
the O +
mutagenicity O +
of O +
purpurin O +
was O +
investigated O +
in O +
bacterial O +
strains O +
expressing O +
recombinant O +
enzymes B-Gene +
TA1538R O +
( O -
human O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene -
) O -
, O +
TA1538AR O +
( O -
human O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene +
and O +
human O +
CYP1A2 B-Gene -
) O -
, O +
and O +
TA1438ARO O +
( O -
human O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene -
, I-Gene +
human O +
CYP1A2 B-Gene -
, O +
and O +
bacterial O +
O B-Gene +
-acetyltransferase I-Gene -
) O +
[ O -
27 O -
] O +
. O +

At O +
the O +
concentrations O +
under O +
investigation O -
, O +
no O +
mutagenicity O +
was O +
detected O +
in O +
any O +
of O +
these O +
strains O +
( O -
Table O +
3 O +
) O -
. O +

Purpurin O +
did O +
display O +
some O +
cytotoxicity O +
in O +
TA1538R O +
and O -
, O +
to O +
a O +
greater O +
degree O -
, O +
in O +
the O +
TA1538ARO O +
strain O -
. O +

The O +
cytotoxicity O +
in O +
the O +
TA1538ARO O +
strain O +
implies O +
that O +
O O +
-acetylation O +
of O +
purpurin O +
is O +
responsible O +
for O +
the O +
formation O +
of O +
a O +
cytotoxic O +
metabolite O -
. O +

However O -
, O +
the O +
spontaneous O +
reversion O +
rate O +
did O +
not O +
decrease O +
when O +
the O +
concentration O +
of O +
purpurin O +
was O +
raised O +
above O +
2500 O +
pmol O +
( O -
Table O +
3 O +
) O +
and O +
did O +
not O +
decrease O +
below O +
that O +
observed O +
for O +
the O +
TA1538R O +
and O +
TA1538AR O +
strains O -
. O +

An O +
increase O +
in O +
the O +
spontaneous O +
reversion O +
rate O +
observed O +
with O +
bacterial O +
strains O +
expressing O +
O B-Gene +
-acetyltransferase I-Gene +
has O +
been O +
reported O +
previously O +
[ O -
45 O -
] O +
but O +
the O +
reason O +
for O +
it O +
is O +
unknown O -
. O +

When O +
purpurin O +
was O +
present O -
, O +
the O +
mutagenicity O +
of O +
Trp O -
- O -
P-2 O +
was O +
inhibited O +
dose O -
- O -
dependently O +
in O +
the O +
TA1538ARO O +
strain O -
, O +
with O +
the O +
addition O +
of O +
5 O +
nmol O +
purpurin O +
responsible O +
for O +
the O +
complete O +
removal O +
of O +
mutagenic O +
response O +
( O -
Fig. O +
5 O +
) O -
. O +

Similarly O -
, O +
use O +
of O +
a O +
two O -
- O -
stage O +
test O +
demonstrated O +
that O +
purpurin O +
successfully O +
enters O +
the O +
bacterial O +
cell O -
, O +
causes O +
a O +
concentration O -
- O -
dependent O +
degradation O +
of O +
CYP1A2 B-Gene +
and O +
inhibition O +
of O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene +
( O -
Fig. O +
6 O +
) O -
, O +
and O +
inhibited O +
the O +
bioactivation O +
of O +
Trp O -
- O -
P-2 O +
( O -
Fig. O +
7 O +
) O -
. O +

The O +
good O +
correlation O +
between O +
Trp O -
- O -
P-2 O +
( O -
125 O +
pmol O -
) O +
mutagenicity O +
and O +
CYP1A2 B-Gene +
degradation O +
( O -
R O +
2 O +
= O -
0.822 O -
) O +
and O +
the O +
excellent O +
correlation O +
between O +
Trp O -
- O -
P-2 O +
( O -
125 O +
pmol O -
) O +
mutagenicity O +
and O +
the O +
inhibition O +
of O +
NADPH B-Gene -
- I-Gene -
cytochrome I-Gene +
P I-Gene +
450 I-Gene +
reductase I-Gene +
( O -
R O +
2 O +
= O -
0.981 O -
) O +
demonstrates O +
that O +
purpurin O +
acts O +
by O +
inhibiting O +
the O +
bioactivation O +
of O +
Trp O -
- O -
P-2 O +
by O +
CYP1A2 B-Gene -
. O +

Whether O +
purpurin O +
truly O +
degrades O +
CYP1A2 B-Gene +
or O +
simply O +
binds O +
to O +
the O +
haemoprotein B-Gene +
preventing O +
quantification O +
using O +
the O +
carbon O +
monoxide O -
- O -
difference O +
spectra O +
was O +
not O +
determined O -
. O +

Certainly O -
, O +
the O +
structure O +
of O +
purpurin O +
is O +
suggestive O +
of O +
a O +
substrate O +
for O +
CYP1A B-Gene +
isoforms B-Gene -
. O +

Consequently O -
, O +
purpurin O +
may O +
compete O +
with O +
Trp O -
- O -
P-2 O +
for O +
access O +
to O +
the O +
active O +
site O +
of O +
CYP1A1 B-Gene +
and O +
CYP1A2 B-Gene -
. O +

To O +
conclude O -
, O +
purpurin O +
is O +
a O +
potent O +
inhibitor O +
of O +
heterocyclic O +
amine O -
- O -
induced O +
bacterial O +
mutagenesis O +
especially O +
that O +
of O +
activated O +
Trp O -
- O -
P-1 O +
and O +
Trp O -
- O -
P-2 O +
( O -
Fig. O +
2 O +
) O -
. O +

This O +
anti O -
- O -
mutagenic O +
potential O +
of O +
purpurin O +
is O +
comparable O +
to O +
that O +
of O +
recognized O +
anti O -
- O -
mutagens O -
, O +
EGCG O +
and O +
chlorophyllin O -
. O +

The O +
mechanism O +
of O +
inhibition O +
was O +
partially O +
characterized O +
using O +
activated O +
Trp O -
- O -
P-2 O +
and O +
was O +
found O +
to O +
be O +
dependent O +
upon O +
pH O -
, O +
being O +
more O +
effective O +
under O +
neutral O +
than O +
acidic O +
conditions O -
, O +
and O +
pre O -
- O -
incubation O -
. O +

The O +
mechanism O +
appears O +
to O +
constitute O -
, O +
at O +
least O +
in O +
part O -
, O +
an O +
inhibition O +
of O +
bioactivation O +
by O +
CYP1A2 B-Gene -
. O +

The O +
use O +
of O +
bacteria O +
expressing O +
human O +
drug B-Gene +
metabolizing I-Gene +
enzymes I-Gene +
demonstrated O +
that O +
these O +
observations O +
may O +
have O +
some O +
relevance O +
for O +
anticarcinogenesis O +
in O +
humans O -
. O +

Purpurin O +
also O +
inhibits O +
the O +
direct O +
mutagenicity O +
of O +
Trp O -
- O -
P-2 O -
( O -
NHOH O -
) O -
, O +
implying O +
that O +
it O +
has O +
a O +
second O -
, O +
so O +
far O +
unidentified O -
, O +
protective O +
mechanism O -
. O +

These O +
are O +
only O +
initial O +
observations O +
obtained O +
using O +
bacteria O -
. O +

Purpurin O +
has O +
been O +
proposed O +
as O +
a O +
possible O +
rodent O +
carcinogen O +
in O +
long O -
- O -
term O +
feeding O +
studies O +
[ O -
41 O -
] O +
. O +

Consequently O -
, O +
in O +
depth O +
in O +
vivo O +
investigations O +
in O +
suitable O +
animal O +
models O +
need O +
to O +
be O +
performed O +
before O +
purpurin O +
can O +
be O +
considered O +
a O +
true O +
chemopreventive O +
agent O -
. O +

Acknowledgements O +
The O +
authors O +
would O +
like O +
to O +
express O +
their O +
thanks O +
to O +
The O +
Japanese O +
Society O +
for O +
the O +
Promotion O +
of O +
Science O +
( O -
JSPS O -
) O +
for O +
their O +
generous O +
stipend O +
for O +
one O +
of O +
them O +
( O -
T.M O -
) O -
, O +
to O +
The O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O -
, O +
Japan O +
for O +
funding O +
the O +
research O +
through O +
the O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
JSPS O +
Fellows O +
( O -
No. O +
97439 O -
) O +
and O +
to O +
The O +
San O -
- O -
Ei O +
Gen O +
Foundation O +
for O +
Food O +
Chemical O +
Research O -
, O +
Osaka O -
, O +
for O +
their O +
funding O +
and O +
gift O +
of O +
pure O +
purpurin O -
. O +

Odorants O +
are O +
usually O +
small O +
hydrophobic O -
, O +
highly O +
volatile O +
molecules O +
which O +
have O +
great O +
importance O +
in O +
the O +
sensory O +
guidance O +
of O +
higher O +
animals O +
and O +
man O -
. O +

Their O +
receptors B-Gene +
belong O +
to O +
the O +
large O +
class O +
of O +
G B-Gene +
protein I-Gene -
- I-Gene -
coupled I-Gene +
receptors I-Gene +
with O +
seven O +
transmembrane O +
helices O -
. O +

These O +
proteins B-Gene +
are O +
selectively O +
expressed O +
on O +
the O +
cilia O +
of O +
olfactory O +
neurons O +
in O +
the O +
olfactory O +
epithelium O +
( O -
Schild O +
& O +
Restrepo O -
, O +
1998 O -
; O +
Buck O -
, O +
1996 O -
; O +
Mombaerts O -
, O +
1996 O -
; O +
Buck O +
& O +
Axel O -
, O +
1991 O -
) O +
. O +

The O +
odorant B-Gene +
receptors I-Gene +
have O +
been O +
identified O +
as O +
constituting O +
a O +
large O +
family O +
of O +
homologous B-Gene +
receptors I-Gene +
( O -
approximately O +
1000 O +
genes O -
) O -
, O +
allowing O +
exquisitely O +
specific O +
interactions O +
of O +
each O +
odorant O +
with O +
a O +
small O +
set O +
of O +
receptors B-Gene +
and O +
thus O +
odorant O +
identification O +
in O +
the O +
brain O -
. O +

Very O +
little O +
is O +
known O +
about O +
the O +
structure O +
of O +
the O +
binding O +
sites O +
and O -
, O +
consequently O -
, O +
of O +
the O +
molecular O +
basis O +
of O +
the O +
recognition O +
specificity O -
. O +

The O +
integral O +
transmembrane O +
nature O +
of O +
the O +
receptor B-Gene +
makes O +
experimentation O +
very O +
difficult O -
. O +

There O +
are O +
a O +
few O +
reported O +
examples O +
of O +
expression O +
of O +
small O +
amounts O +
of O +
odorant B-Gene +
receptors I-Gene +
in O +
insect O +
cells O +
( O -
Nekrasova O +
et O +
al O +
. O -
, O +
1996 O -
; O +
Raming O +
et O +
al O +
. O -
, O +
1993 O -
) O +
and O +
in O +
bacteria O +
( O -
Kiefer O +
et O +
al O +
. O -
, O +
1996 O -
) O +
, O +
but O +
only O +
recently O +
the O +
functionality O +
of O +
a O +
cloned O +
mammalian O +
receptor B-Gene +
has O +
been O +
clearly O +
proven O +
in O +
the O +
rat O +
( O -
Zhao O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

Small O +
carrier B-Gene +
proteins I-Gene +
have O +
been O +
shown O +
to O +
exist O +
in O +
insects O +
and O +
mammals O -
, O +
which O +
serve O +
to O +
shuttle O +
odor O +
or O +
pheromone O +
molecules O +
between O +
air O +
and O +
the O +
receptor B-Gene +
through O +
the O +
nasal O +
mucus O +
or O +
the O +
sensory O +
lymph O +
( O -
Pelosi O -
, O +
1994 O -
) O +
. O +

These O +
proteins B-Gene +
are O +
called O +
odorant B-Gene +
or O +
pheromone B-Gene -
- I-Gene -
binding I-Gene +
proteins I-Gene +
( O -
OBP B-Gene -
, O +
PBP B-Gene -
) O -
. O +

In O +
insects O -
, O +
the O +
PBP B-Gene -
/ O -
pheromone O +
specificity O +
is O +
very O +
strict O -
, O +
but O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
these O +
proteins B-Gene +
is O +
still O +
unknown O -
. O +

In O +
mammals O -
, O +
OBPs B-Gene +
display O +
apparently O +
very O +
little O +
specificity O -
, O +
since O +
they O +
were O +
found O +
to O +
be O +
able O +
to O +
bind O +
any O +
one O +
of O +
tens O +
of O +
different O +
odor O +
molecules O +
with O +
micromolar O +
affinities O +
( O -
Pelosi O -
, O +
1994 O -
) O +
. O +

The O +
structure O +
of O +
two O +
OBPs B-Gene -
, O +
alone O +
or O +
in O +
complex O -
, O +
have O +
been O +
solved O +
( O -
Tegoni O +
et O +
al O +
. O -
, O +
1996 O -
; O +
Bianchet O +
et O +
al O +
. O -
, O +
1996 O -
; O +
Spinelli O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

Antibodies B-Gene +
with O +
narrow O +
specificity O +
may O +
seem O +
an O +
ideal O +
surrogate O +
receptor B-Gene +
system O -
, O +
with O +
which O +
many O +
fundamental O +
features O +
of O +
highly O +
specific O +
interactions O +
of O +
such O +
small O +
hydrophobic O +
molecules O +
can O +
be O +
studied O -
, O +
even O +
though O +
the O +
topology O +
of O +
the O +
seven O -
- O -
helix O +
transmembrane O +
protein B-Gene +
will O +
almost O +
certainly O +
be O +
entirely O +
different O -
. O +

Furthermore O -
, O +
a O +
surrogate O +
receptor B-Gene +
system O +
such O +
as O +
antibodies B-Gene +
might O +
have O +
direct O +
biotechnological O +
applications O -
, O +
such O +
as O +
in O +
high O -
- O -
throughput O +
screening O +
for O +
odorants O -
, O +
or O +
as O +
a O +
controlled O +
release O +
system O -
, O +
in O +
which O +
the O +
odorant O +
is O +
given O +
off O +
once O +
the O +
protein B-Gene +
is O +
denatured O -
. O +

To O +
begin O +
to O +
study O +
such O +
questions O -
, O +
we O +
have O +
chosen O +
the O +
musk O +
odorant O +
traseolide O +
( O -
6-acetyl-1-isopropyl-2,3,3,5-tetramethyl O -
- O -
indane O -
) O +
as O +
a O +
model O +
system O -
. O +

Natural O +
musk O +
was O +
first O +
discovered O +
in O +
the O +
exocrine O +
scent O +
glands O +
of O +
the O +
deer O -
- O -
like O +
Moschus O +
animal O +
Moschus O +
moschiferus O -
, O +
which O +
lives O +
in O +
the O +
Himalayas O -
. O +

It O +
functions O +
as O +
territorial O +
marker O +
and O +
attracts O +
the O +
female O +
counterpart O +
( O -
Walbaum O -
, O +
1906 O -
; O +
Ohloff O -
, O +
1990 O -
) O +
. O +

Since O +
ca O +
1930 O -
, O +
compounds O +
with O +
moschus O +
( O -
musk O -
) O -
-like O +
odor O +
have O +
been O +
synthetically O +
manufactured O +
in O +
large O +
amounts O +
and O +
are O +
used O +
in O +
fragrances O +
for O +
cosmetic O +
and O +
household O +
products O +
( O -
Kevekordes O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

Here O +
we O +
report O +
the O +
characterization O +
of O +
antibodies B-Gene +
against O +
traseolide O -
, O +
their O +
fine O +
specificity O +
against O +
analogs O +
and O +
the O +
structural O +
basis O +
for O +
their O +
specificity O +
as O +
deduced O +
from O +
the O +
crystal O +
structure O +
of O +
a O +
Fab B-Gene +
fragment I-Gene -
, O +
complexed O +
with O +
traseolide O -
, O +
at O +
2.6 O +
Å O +
resolution O -
. O +

By O +
expressing O +
a O +
representative O +
member O +
of O +
each O +
family O +
of O +
the O +
anti O -
- O -
traseolide O +
immune O +
response O +
as O +
scFv O +
fragments O +
in O +
Escherichia O +
coli O +
, O +
the O +
foundations O +
for O +
further O +
controlled O +
release O +
applications O +
and O +
structure O +
activity O +
relationships O +
can O +
be O +
laid O -
. O +

Results O +
Production O +
and O +
screening O +
of O +
cell O +
lines O +
Mice O +
were O +
immunized O +
with O +
the O +
succinyl O +
derivative O +
of O +
the O +
traseolide O +
hapten O -
, O +
coupled O +
to O +
keyhole B-Gene +
limpet I-Gene +
haemocyanin I-Gene +
( O -
KLH B-Gene -
) O +
at O +
position O +
R1 O +
( O -
Figure O +
1 O -
) O +
. O +

Supernatants O +
of O +
stable O +
cell O +
lines O +
were O +
screened O +
in O +
ELISA O +
for O +
the O +
production O +
of O +
monoclonal B-Gene +
antibodies I-Gene +
recognizing O +
the O +
odor O +
molecule O +
traseolide O -
. O +

Most O +
of O +
the O +
heavy O +
chains O +
were O +
determined O +
to O +
be O +
of O +
subclass O +
IgG1 B-Gene -
, O +
while O +
light O +
chains O +
were O +
mostly O +
κ O -
- O -
chains O -
. O +

Antibody B-Gene +
variable O +
region O +
sequences O +
From O +
the O +
panel O +
of O +
antibody B-Gene -
- O -
producing O +
cells O -
, O +
eight O +
cell O +
lines O +
were O +
selected O +
for O +
sequence O +
determination O +
of O +
the O +
variable O +
regions O -
. O +

The O +
choice O +
depended O +
on O +
isotype O -
, O +
binding O +
and O +
production O +
levels O -
. O +

The O +
fragments O +
encoding O +
the O +
heavy O +
and O +
light O +
chain O +
variable O +
domains O +
were O +
cloned O +
and O +
sequenced O +
as O +
described O +
in O +
Materials O +
and O +
Methods O -
. O +

The O +
alignment O +
of O +
the O +
amino O +
acid O +
sequences O +
of O +
the O +
anti B-Gene -
- I-Gene -
traseolide I-Gene +
antibodies I-Gene +
reveals O +
that O +
six O +
sequences O +
are O +
highly O +
homologous O +
( O -
< O -
5 O -
% O +
differences O +
in O +
VH O +
and O +
in O +
VL O +
coding O +
sequences O -
) O -
. O +

They O +
are O +
using O +
the O +
same O +
Vκ O +
, O +
Jκ O +
, O +
VH O +
, O +
D O +
and O +
JH O +
elements O -
, O +
and O +
were O +
thus O +
most O +
likely O +
derived O +
from O +
the O +
same O +
B O -
- O -
cell O -
. O +

The O +
two O +
other O +
sequences O +
differ O +
considerably O +
in O +
both O +
framework O +
and O +
CDR O +
residues O +
( O -
Figure O +
2 O -
) O +
. O +

These O +
two O +
sequences O +
and O +
one O +
member O +
of O +
the O +
group O +
of O +
six O +
were O +
thus O +
chosen O +
for O +
further O +
characterization O +
as O +
scFv B-Gene +
fragments O +
( O -
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
M02 B-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M03 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
) O -
. O +

For O +
convenience O +
the O +
scFv B-Gene +
fragments O +
were O +
given O +
shorter O +
names O -
: O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene -
; O +
M03 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
S I-Gene +
( O -
for O +
its O +
serine O +
at O +
position O +
H92 O -
; O +
numbering O +
according O +
to O +
Kabat O +
et O +
al O +
. O -
, O +
1991 O +
) O -
; O +
M02 B-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
L I-Gene +
( O -
for O +
its O +
lambda O +
light O +
chain O -
) O -
. O +

The O +
cell O +
line O +
expressing O +
monoclonal B-Gene +
antibody I-Gene +
M02 I-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
yielded O +
more O +
protein B-Gene +
than O +
the O +
cell O +
line O +
expressing O +
the O +
homologous O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
sequence O -
. O +

Therefore O -
, O +
the O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
variant O +
was O +
chosen O +
for O +
crystallization O +
as O +
a O +
Fab B-Gene +
fragment I-Gene -
. O +

The O +
variable O +
regions O +
of O +
the O +
antibodies B-Gene +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
vary O +
in O +
eight O +
amino O +
acid O +
residue O +
positions O +
( O -
Figure O +
2 O -
) O +
. O +

M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
contains O +
one O +
somatic O +
mutation O +
located O +
in O +
the O +
binding O +
pocket O -
, O +
Ala O +
H93 O +
Val O -
, O +
as O +
became O +
apparent O +
from O +
the O +
X O -
- O -
ray O +
structure O +
of O +
the O +
complex O +
( O -
see O +
below O -
) O -
. O +

The O +
germline O +
sequence O +
( O -
Figure O +
2 O -
) O +
has O +
Ala O +
H93 O -
, O +
as O +
deduced O +
from O +
sequence O +
statistics O +
with O +
the O +
40 O +
most O +
closely O +
related O +
antibody B-Gene +
sequences O +
of O +
the O +
Kabat O +
database O +
( O -
for O +
details O -
, O +
see O +
Materials O +
and O +
Methods O -
) O -
. O +

The O +
other O +
somatic O +
point O +
mutations O +
do O +
not O +
appear O +
functionally O +
significant O -
, O +
as O +
they O +
are O +
not O +
in O +
the O +
binding O +
pocket O +
and O +
do O +
not O +
directly O +
contact O +
the O +
antigen O -
, O +
but O +
rather O +
simply O +
reflect O +
the O +
background O +
mutation O +
rate O -
. O +

Expression O -
, O +
isolation O +
and O +
detection O +
of O +
scFv B-Gene +
fragments O +
The O +
VH O +
and O +
VL O +
genes O +
were O +
cloned O +
in O +
scFv B-Gene +
format O +
( O -
VH O +
-linker O -
- O -
VL O +
) O +
with O +
a O +
N O -
- O -
terminal O +
FLAG O -
- O -
tag O +
and O +
a O +
C O -
- O -
terminal O +
Myc O +
and O +
His O -
- O -
tag O +
in O +
the O +
vector O +
pIG6 O +
( O -
Ge O +
et O +
al O +
. O -
, O +
1995 O -
) O +
. O +

The O +
scFv B-Gene +
fragments O +
were O +
expressed O +
in O +
the O +
periplasm O +
of O +
E. O +
coli O +
. O +

In O +
the O +
soluble O -
, O +
periplasmic O +
fraction O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
S I-Gene +
( O -
from O +
the O +
mAb B-Gene +
M03 I-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
) O +
and O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
L I-Gene +
( O -
from O +
the O +
mAb B-Gene +
M02 I-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene -
) O +
were O +
detected O +
in O +
reasonable O +
amounts O +
( O -
ca O +
1 O +
mg O -
/ O -
l O +
E. O +
coli O +
) O -
, O +
while O +
only O +
a O +
small O +
amount O +
of O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene +
( O -
from O +
the O +
mAb B-Gene +
M02 I-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
) O +
was O +
found O +
( O -
Figure O +
3 O -
( O -
a O -
) O -
) O +
. O +

In O +
the O +
insoluble O +
fraction O +
a O +
double O +
band O +
for O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene +
was O +
observed O +
( O -
data O +
not O +
shown O -
; O +
cf O -
. O +

Figure O +
3 O -
( O -
b O -
) O +
) O -
. O +

Examination O +
of O +
the O +
amino O +
acid O +
sequence O +
of O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene +
showed O +
a O +
rare O +
sequence O +
of O +
four O +
positively O +
charged O +
residues O +
in O +
CDR3 O +
of O +
the O +
heavy O +
chain O -
. O +

To O +
check O +
whether O +
these O +
residues O +
were O +
causing O +
the O +
problems O +
in O +
the O +
periplasmic O +
production O +
of O +
the O +
fragment O -
, O +
two O +
mutations O +
were O +
introduced O +
to O +
give O +
the O +
mutant O +
Tras B-Gene -
- I-Gene -
P I-Gene -
, O +
which O +
substituted O +
the O +
charged O +
residues O +
by O +
neutral O +
amino O +
acids O -
: O +
Arg O +
H100a O +
Leu O +
and O +
Lys O +
H100c O +
Gln O -
. O +

These O +
residues O +
were O +
selected O +
with O +
the O +
help O +
of O +
a O +
preliminary O +
model O +
structure O +
of O +
the O +
antibody B-Gene +
variable O +
fragment O -
, O +
applying O +
the O +
criterion O +
that O +
the O +
backbone O +
conformation O +
of O +
CDRH3 O +
would O +
stay O +
intact O +
( O -
A. O +
van O +
Beusekom O -
, O +
data O +
not O +
shown O -
) O -
. O +

The O +
subsequently O +
obtained O +
crystal O +
structure O +
( O -
see O +
below O -
) O +
showed O +
this O +
assumption O +
to O +
be O +
correct O -
. O +

The O +
CDRH3 O +
mutations O +
indeed O +
led O +
to O +
a O +
much O +
higher O +
yield O +
of O +
soluble O +
scFv B-Gene +
in O +
the O +
periplasm O +
( O -
Figure O +
3 O -
( O -
a O -
) O +
, O +
mutant O +
Tras B-Gene -
- I-Gene -
P I-Gene +
versus O +
Tras B-Gene -
- I-Gene -
X I-Gene -
) O -
. O +

On O +
a O +
Western O +
blot O +
developed O +
with O +
antibodies B-Gene +
recognizing O +
a O +
C O -
- O -
terminal O +
His O -
- O -
tag O -
, O +
the O +
insoluble O +
fraction O +
of O +
the O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene +
shows O +
a O +
double O +
band O +
( O -
Figure O +
3 O -
( O -
b O -
) O -
) O +
. O +

One O +
band O +
has O +
the O +
identical O +
molecular O +
mass O +
as O +
mutant O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
P I-Gene -
, O +
presumably O +
the O +
correctly O +
processed O +
scFv B-Gene +
protein I-Gene -
, O +
while O +
the O +
second O +
band O +
has O +
a O +
slightly O +
higher O +
molecular O +
mass O -
. O +

Only O +
the O +
lower O +
one O +
is O +
detected O +
in O +
the O +
Western O +
blot O +
developed O +
with O +
antibodies B-Gene +
recognizing O +
the O +
N O -
- O -
terminal O +
FLAG O +
sequence O +
( O -
Figure O +
3 O -
( O -
c O -
) O -
) O +
. O +

This O +
means O +
that O +
the O +
FLAG O +
sequence O +
is O +
not O +
at O +
the O +
N O +
terminus O +
in O +
the O +
upper O +
band O +
( O -
Knappik O +
& O +
Plückthun O -
, O +
1994 O -
) O +
, O +
and O +
is O +
therefore O +
not O +
recognized O +
by O +
this O +
anti B-Gene -
- I-Gene -
FLAG I-Gene +
antibody I-Gene -
, O +
but O +
Tras B-Gene -
- I-Gene -
X I-Gene +
must O +
carry O +
an O +
N O -
- O -
terminal O +
extension O -
, O +
most O +
likely O +
the O +
signal O +
sequence O -
. O +

Positive O +
charges O +
have O +
been O +
observed O +
before O +
to O +
interfere O +
with O +
transport O +
through O +
the O +
membrane O +
( O -
Ayala O +
et O +
al O +
. O -
, O +
1995 O -
; O +
Summers O +
et O +
al O +
. O -
, O +
1989 O -
; O +
von O +
Heijne O -
, O +
1986 O -
) O +
. O +

Thus O -
, O +
the O +
removal O +
of O +
two O +
positive O +
charges O +
in O +
CDRH3 O +
( O -
to O +
interrupt O +
the O +
positive O +
charge O +
cluster O -
) O +
improved O +
the O +
amount O +
of O +
periplasmic O +
protein B-Gene -
, O +
presumably O +
at O +
least O +
in O +
part O +
because O +
of O +
more O +
efficient O +
membrane O +
transport O -
. O +

Additionally O -
, O +
the O +
positively O +
charged O +
cluster O +
may O +
have O +
provided O +
a O +
protease B-Gene +
target O +
( O -
Volkin O +
& O +
Klibanov O -
, O +
1989 O -
; O +
Hammarberg O +
et O +
al O +
. O -
, O +
1990 O -
) O +
and O +
thus O +
the O +
mutations O +
may O +
have O +
stabilized O +
the O +
protein B-Gene -
, O +
once O +
it O +
is O +
in O +
the O +
periplasm O -
. O +

The O +
functionality O +
of O +
the O +
scFv B-Gene +
Tras B-Gene -
- I-Gene -
P I-Gene -
, O +
Tras B-Gene -
- I-Gene -
L I-Gene +
and O +
Tras B-Gene -
- I-Gene -
S I-Gene +
fragments O +
was O +
checked O +
qualitatively O +
by O +
an O +
inhibition O +
ELISA O +
assay O -
. O +

Equal O +
amounts O +
of O +
soluble O +
periplasmic O +
fractions O +
were O +
applied O +
to O +
microtiter O +
plates O +
coated O +
with O +
the O +
traseolide O +
antigen O -
, O +
and O +
the O +
inhibition O +
by O +
soluble O +
traseolide O +
was O +
determined O -
. O +

All O +
showed O +
specific O +
ELISA O +
signals O +
of O +
the O +
same O +
order O +
of O +
magnitude O +
( O -
data O +
not O +
shown O -
) O -
. O +

To O +
quantitatively O +
investigate O +
the O +
effect O +
of O +
the O +
CDRH3 O +
mutations O +
on O +
the O +
binding O +
properties O +
of O +
the O +
antibody B-Gene +
fragment O -
, O +
the O +
K O +
D O +
values O +
of O +
scFv B-Gene +
Tras B-Gene -
- I-Gene -
X I-Gene +
and O +
the O +
mutant O +
Tras B-Gene -
- I-Gene -
P I-Gene +
were O +
determined O +
by O +
fluorescence O +
titration O -
. O +

Both O +
fragments O +
were O +
produced O +
as O +
cytoplasmic O +
inclusion O +
bodies O +
in O +
E. O +
coli O +
, O +
refolded O +
and O +
purified O +
by O +
affinity O +
chromatography O +
with O +
the O +
hapten O +
traseolide O -
. O +

Using O +
this O +
method O -
, O +
the O +
positive O +
charges O +
could O +
not O +
affect O +
the O +
expression O +
of O +
the O +
scFv B-Gene +
fragment O -
. O +

The O +
binding O +
constant O +
was O +
determined O +
by O +
a O +
direct O +
fit O +
of O +
the O +
protein B-Gene +
fluorescence O +
signal O +
as O +
a O +
function O +
of O +
the O +
hapten O +
concentration O +
( O -
Jung O +
& O +
Plückthun O -
, O +
1997 O -
) O +
. O +

The O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene +
has O +
a O +
K O +
D O +
of O +
2.0 O +
× O +
10−7 O +
M O +
and O +
the O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
P I-Gene +
a O +
K O +
D O +
of O +
3.5 O +
× O +
10−7 O +
M O -
, O +
which O +
is O +
within O +
the O +
range O +
of O +
error O +
and O +
also O +
not O +
significantly O +
different O +
from O +
the O +
parent O +
antibody B-Gene +
( O -
see O +
below O -
) O -
. O +

Binding O +
assays O -
: O +
competition O +
BIAcore O +
and O +
fluorescence O +
titration O +
Fluorescence O +
titration O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
Fluorescence O +
titration O +
experiments O +
were O +
performed O +
with O +
the O +
mAb B-Gene +
and O +
the O +
scFv B-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene +
fragment O +
of O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
the O +
mAb B-Gene +
and O +
Fab B-Gene +
fragments I-Gene +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene -
. O +

M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
is O +
the O +
antibody B-Gene +
for O +
which O +
the O +
X O -
- O -
ray O +
structure O +
of O +
the O +
Fab B-Gene +
fragment I-Gene +
was O +
determined O +
( O -
see O +
below O -
) O -
, O +
and O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
is O +
closely O +
related O -
, O +
but O +
carries O +
the O +
germline O +
amino O +
acid O +
Ala O +
H93 O +
in O +
the O +
binding O +
pocket O -
. O +

The O +
binding O +
specificity O +
of O +
the O +
antibodies B-Gene +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene -
( I-Gene -
Val I-Gene +
H93 I-Gene -
) I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
( I-Gene -
Ala I-Gene +
H93 I-Gene -
) I-Gene +
was O +
investigated O +
quantitatively O +
by O +
determining O +
the O +
binding O +
constants O +
of O +
three O +
structurally O +
related O +
traseolide O +
variants O -
. O +

The O +
traseolide O +
variants O +
used O +
were O +
the O +
succinyl O +
derivatives O +
of O +
T+ O +
, O +
T− O +
and O +
Teth O +
( O -
Figure O +
1 O -
) O +
. O +

The O +
comparison O +
of O +
the O +
binding O +
characteristics O +
of O +
the O +
two O +
related O +
antibodies B-Gene +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
showed O +
that O +
the O +
binding O +
to O +
the O +
original O +
hapten O +
differs O +
significantly O -
: O +
the O +
K O +
D O +
of O +
the O +
antibody B-Gene +
M02 I-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Val I-Gene +
H93 I-Gene -
) I-Gene +
is O +
2.7 O +
× O +
10−9 O +
M O -
, O +
while O +
the O +
antibody B-Gene +
M02 I-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Ala I-Gene +
H93 I-Gene -
) I-Gene +
shows O +
a O +
K O +
D O +
of O +
1.6 O +
× O +
10−7 O +
M O +
for O +
the O +
same O +
hapten O -
, O +
which O +
corresponds O +
to O +
a O +
difference O +
in O +
dissociation O +
constant O +
of O +
a O +
factor O +
of O +
ca O +
75 O +
( O -
Table O +
1 O -
) O +
. O +

Another O +
remarkable O +
finding O +
is O +
that O +
for O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Ala I-Gene +
H93 I-Gene -
) I-Gene +
no O +
significant O +
differences O +
were O +
found O +
in O +
binding O +
constant O +
between O +
the O +
three O +
closely O +
related O +
traseolide O +
variants O -
. O +

For O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Val I-Gene +
H93 I-Gene -
) I-Gene -
, O +
however O -
, O +
the O +
odorless O +
variant O +
T− O +
, O +
lacking O +
one O +
methyl O +
group O +
( O -
Figure O +
1 O -
) O +
, O +
showed O +
a O +
tenfold O +
lower O +
affinity O +
than O +
the O +
original O +
T+ O +
hapten O -
. O +

The O +
Teth O +
variant O -
, O +
which O +
has O +
an O +
ethyl O +
group O +
instead O +
of O +
a O +
methyl O +
group O +
at O +
this O +
position O +
( O -
Figure O +
1 O -
) O +
, O +
bound O +
with O +
about O +
the O +
same O +
affinity O +
as O +
the O +
original O +
hapten O +
T+ O +
. O +

As O +
expected O -
, O +
the O +
Fab B-Gene +
fragment I-Gene +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
the O +
recombinant B-Gene +
scFv I-Gene +
Tras I-Gene -
- I-Gene -
X I-Gene +
( O -
from O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene -
) O +
fragment B-Gene +
have O +
very O +
similar O +
binding O +
behavior O +
as O +
their O +
parent O +
mAb B-Gene +
to O +
monomeric O +
soluble O +
hapten O -
, O +
and O +
the O +
small O +
differences O +
may O +
indicate O +
the O +
limits O +
of O +
the O +
accuracy O +
of O +
the O +
measurements O -
. O +

BIAcore O +
measurements O +
of O +
M02 B-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M03 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
Purified O +
monoclonal B-Gene +
antibodies I-Gene +
M02 B-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M03 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
( O -
the O +
parent O +
mAbs B-Gene +
of O +
scFv B-Gene +
Tras B-Gene -
- I-Gene -
L I-Gene +
and O +
Tras B-Gene -
- I-Gene -
S I-Gene -
) O +
were O +
used O +
for O +
K O +
D O +
determination O +
in O +
solution O +
by O +
competition O +
BIAcore O +
analysis O +
( O -
Karlsson O -
, O +
1994 O -
; O +
Nieba O +
et O +
al O +
. O -
, O +
1996 O -
; O +
Hanes O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

In O +
this O +
experiment O -
, O +
the O +
monoclonal B-Gene +
antibody I-Gene +
was O +
incubated O +
with O +
the O +
soluble O +
succinyl O +
derivative O +
of O +
traseolide O -
, O +
and O +
the O +
mixture O +
was O +
injected O +
on O +
a O +
BIAcore O +
chip O +
containing O +
immobilized O +
BSA B-Gene -
- O -
traseolide O +
conjugate O +
at O +
high O +
density O -
. O +

Only O +
free O +
antibody B-Gene -
, O +
but O +
not O +
hapten O -
- O -
bound O +
antibody B-Gene -
, O +
can O +
bind O +
to O +
hapten O +
on O +
the O +
surface O -
, O +
analogous O +
to O +
the O +
Friguet O -
- O -
Goldberg O +
ELISA O +
( O -
Friguet O +
et O +
al O +
. O -
, O +
1985 O -
) O +
. O +

The O +
observed O +
mass O -
- O -
transfer O +
limited O +
rates O +
therefore O +
indicated O +
the O +
amount O +
of O +
free O +
antibody B-Gene +
in O +
solution O +
as O +
a O +
function O +
of O +
hapten O +
concentration O -
. O +

In O +
this O +
way O -
, O +
the O +
correct O +
dissociation O +
constant O +
in O +
solution O +
could O +
be O +
obtained O -
, O +
independent O +
of O +
any O +
BIAcore O +
rebinding O +
errors O +
( O -
Schuck O -
, O +
1997 O -
) O +
. O +

The O +
slopes O +
of O +
the O +
BIAcore O +
signal O -
, O +
which O +
correspond O +
to O +
the O +
initial O +
binding O +
rates O +
( O -
k O +
obs O +
) O -
, O +
were O +
plotted O +
against O +
the O +
corresponding O +
total O +
hapten O +
concentration O -
, O +
and O +
fitted O +
to O +
determine O +
the O +
dissociation O +
constant O +
( O -
Hanes O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

The O +
K O +
D O +
of O +
M02 B-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene +
was O +
calculated O +
as O +
2.1 O +
× O +
10−9 O +
M O +
and O +
that O +
of O +
M03 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
as O +
1.8 O +
× O +
10−8 O +
M O +
( O -
Table O +
1 O -
) O +
. O +

X O -
- O -
ray O +
structure O +
of O +
bound O +
and O +
unbound O +
Fab B-Gene +
M02 I-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
The O +
three O -
- O -
dimensional O +
structures O +
of O +
Fab B-Gene +
M02 I-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
complexed O +
with O +
the O +
succinyl O +
derivative O +
of O +
the O +
traseolide O +
hapten O +
was O +
solved O +
at O +
2.6 O +
Å O +
resolution O -
. O +

The O +
quality O +
of O +
the O +
Fab B-Gene -
- I-Gene -
hapten I-Gene +
structure O +
can O +
be O +
estimated O +
from O +
the O +
diffraction O +
and O +
refinement O +
data O +
( O -
Table O +
2 O -
) O +
, O +
from O +
the O +
electron O +
density O +
map O +
( O -
Figure O +
4 O -
) O +
and O +
from O +
the O +
Ramachandran O +
plot O -
, O +
in O +
which O +
85 O +
% O +
of O +
the O +
residues O +
are O +
located O +
in O +
the O +
most O +
favorable O +
areas O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
" O -
elbow O -
" O +
angle O -
, O +
made O +
by O +
the O +
pseudo-2-fold O +
axes O +
relating O +
VH O +
to O +
VL O +
and O +
CH1 O +
to O +
CL O +
is O +
∼169 O -
° O -
, O +
giving O +
an O +
elongated O +
Fab B-Gene +
structure O +
with O +
few O +
intra O -
- O -
chain O -
, O +
interdomain O +
contacts O -
. O +

A O +
total O +
of O +
120 O +
water O +
molecules O +
were O +
fitted O +
to O +
the O +
Fab B-Gene -
- I-Gene -
hapten I-Gene +
model O -
. O +

The O +
electron O +
density O +
for O +
the O +
predominantly O +
bound O +
( O -
S O +
, O -
S O +
) O -
-traseolide O +
is O +
of O +
high O +
quality O -
, O +
making O +
it O +
possible O +
to O +
position O +
it O +
with O +
good O +
precision O +
( O -
Figure O +
4 O -
) O +
. O +

We O +
can O -
not O +
exclude O +
the O +
presence O +
of O +
some O +
minor O +
fraction O +
of O +
( O -
R O +
, O -
R O +
) O -
-traseolide O +
in O +
the O +
binding O +
site O -
. O +

At O +
a O +
contour O +
level O +
of O +
1.2σ O +
all O +
hapten O +
atoms O +
are O +
associated O +
with O +
electron O +
density O -
. O +

Accordingly O -
, O +
the O +
B O +
-factors O +
of O +
25.0 O +
Å2 O +
for O +
the O +
hapten O +
are O +
relatively O +
low O +
compared O +
to O +
the O +
average O +
( O -
40.5 O +
Å2 O +
; O +
Table O +
2 O +
) O -
. O +

The O +
variable O +
domains O +
have O +
very O +
long O +
complementarity O -
- O -
determing O +
regions O +
( O -
CDRs O -
) O -
, O +
especially O +
H3 O +
and O +
L1 O -
, O +
which O +
protrude O +
from O +
the O +
combining O +
site O +
and O +
form O +
a O +
very O +
deep O +
cleft O +
between O +
each O +
other O +
( O -
Figure O +
5 O -
) O +
. O +

The O +
long O +
CDRH3 O +
runs O +
in O +
the O +
middle O +
of O +
the O +
cleft O +
and O +
folds O +
back O -
, O +
forming O +
a O +
flat O +
floor O +
for O +
the O +
combining O +
site O -
. O +

The O +
traseolide O +
hapten O +
is O +
located O +
in O +
a O +
deep O +
hydrophobic O +
pocket O +
( O -
Figure O +
6 O -
) O +
involving O +
part O +
of O +
the O +
β O -
- O -
sheets O +
and O +
both O +
CDR3 O +
of O +
the O +
heavy O +
and O +
light O +
chain O +
( O -
H3 O +
and O +
L3 O -
) O +
( O -
Figure O +
5 O +
and O +
Table O +
3 O +
) O -
. O +

The O +
binding O +
pocket O +
is O +
approximately O +
12 O +
Å O +
deep O +
and O +
7 O +
Å O +
wide O -
, O +
which O +
is O +
sufficient O +
to O +
bury O +
in O +
the O +
complex O +
450 O +
Å2 O +
of O +
the O +
water O -
- O -
accessible O +
surface O +
area O +
of O +
traseolide O +
( O -
of O +
531 O +
Å2 O +
in O +
total O -
) O +
( O -
Figure O +
6 O -
) O +
. O +

As O +
expected O +
for O +
a O +
hydrophobic O +
hapten O -
, O +
the O +
nature O +
of O +
the O +
combining O +
site O +
is O +
hydrophobic O +
( O -
Figure O +
7 O +
and O +
Table O +
3 O +
) O -
. O +

The O +
hydrophobic O +
ring O +
system O +
is O +
contained O +
in O +
the O +
cavity O -
, O +
while O +
the O +
succinyl O +
moiety O +
is O +
directed O +
towards O +
the O +
solvent O +
and O +
is O +
hydrogen O -
- O -
bonded O +
to O +
two O +
water O +
molecules O -
, O +
W42 O +
and O +
W52 O -
, O +
located O +
at O +
2.5 O +
Å O +
and O +
3.9 O +
Å O -
, O +
respectively O +
( O -
Figure O +
7 O -
) O +
. O +

The O +
majority O +
of O +
aromatic O +
residues O +
are O +
found O +
within O +
6 O +
Å O +
of O +
the O +
hapten O -
: O +
Trp O +
H47 O -
, O +
Tyr O +
H50 O -
, O +
Trp O +
H103 O +
from O +
the O +
heavy O +
chain O -
, O +
and O +
Tyr O +
L49 O -
, O +
Tyr O +
L91 O -
, O +
Phe O +
L94 O -
, O +
Phe O +
L96 O -
, O +
Phe O +
L98 O +
from O +
the O +
light O +
chain O -
. O +

A O +
few O +
aliphatic O +
( O -
Ile O +
H37 O -
, O +
Val O +
H93 O -
, O +
Leu O +
H96 O -
, O +
Leu O +
L36 O +
and O +
Val O +
L89 O -
) O +
and O +
polar O +
non O -
- O -
charged O +
amino O +
acid O +
residues O +
( O -
Asn O +
H35a O -
, O +
Thr O +
H94 O -
, O +
Ser O +
H95 O -
, O +
Ser O +
H101 O +
and O +
Gly O +
L34 O -
) O +
complete O +
the O +
active O +
site O +
( O -
Figure O +
7 O -
) O +
. O +

Two O +
charged O +
residues O +
are O +
found O +
in O +
the O +
vicinity O +
of O +
the O +
hapten O -
. O +

Lys O +
H100c O +
is O +
located O +
at O +
4.5 O +
Å O +
from O +
the O +
carboxylate O +
of O +
the O +
succinyl O +
moiety O -
, O +
while O +
Glu O +
L55 O +
is O +
located O +
on O +
a O +
side O +
of O +
the O +
cavity O -
, O +
at O +
4.8 O +
Å O +
from O +
one O +
of O +
the O +
methyl O +
group O +
of O +
the O +
isopropyl O +
motif O +
of O +
the O +
hapten O -
. O +

This O +
is O +
not O +
a O +
close O +
distance O -
, O +
however O -
, O +
and O +
the O +
charge O +
of O +
Glu O +
L55 O +
is O +
compensated O +
by O +
Arg O +
H100d O +
and O +
Lys O +
L45 O -
. O +

The O +
shape O +
of O +
the O +
cavity O +
is O +
not O +
fully O +
complementary O +
to O +
that O +
of O +
the O +
ligand O -
. O +

There O +
is O +
enough O +
room O +
for O +
larger O +
substituents O +
of O +
the O +
cyclopentane O +
ring O -
. O +

Discussion O +
Variability O +
in O +
antibodies B-Gene +
directed O +
to O +
a O +
small O +
hapten O +
The O +
alignment O +
of O +
the O +
amino O +
acid O +
sequences O +
of O +
the O +
variable O +
domains O +
of O +
the O +
anti B-Gene -
- I-Gene -
traseolide I-Gene +
antibodies I-Gene +
( O -
Figure O +
2 O -
) O +
showed O +
that O +
antibodies B-Gene +
of O +
three O +
types O +
were O +
obtained O -
. O +

A O +
group O +
of O +
six O +
antibodies B-Gene -
, O +
derived O +
from O +
Kabat O +
subgroup O +
VH O +
IB O -
, O +
and O +
Vκ O +
II O -
, O +
M02 B-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene +
derived O +
from O +
VH O +
IB O -
, O +
and O +
Vλ O +
and O +
M03 O -
/ O -
01 O -
/ O -
01 O +
derived O +
from O +
VH O +
IIB O +
and O +
Vκ O +
II O -
. O +

The O +
heavy O +
chain O +
of O +
M03 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
contains O +
a O +
very O +
peculiar O +
mutation O -
, O +
the O +
highly O +
conserved O +
Cys O +
H92 O +
is O +
substituted O +
for O +
a O +
Ser O +
residue O -
, O +
and O +
thus O +
the O +
disulfide O +
bridge O +
in O +
the O +
heavy O +
chain O +
of O +
this O +
variable O +
domain O +
can O -
not O +
be O +
formed O -
. O +

The O +
consequences O +
for O +
stability O +
have O +
been O +
investigated O +
in O +
detail O +
elsewhere O +
( O -
Langedijk O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

The O +
sequence O +
diversification O +
by O +
somatic O +
mutations O +
has O +
been O +
studied O +
in O +
several O +
anti O -
- O -
hapten O +
systems O -
. O +

It O +
has O +
been O +
reported O +
that O +
mAbs B-Gene +
produced O +
against O +
small O +
ligands O +
such O +
as O +
arsonate O +
( O -
Wysocki O +
et O +
al O +
. O -
, O +
1987 O -
) O +
, O +
morphine O +
( O -
Kussie O +
et O +
al O +
. O -
, O +
1989 O -
) O +
, O +
cyclosporine O +
( O -
Schmitter O +
et O +
al O +
. O -
, O +
1990 O -
) O +
, O +
oxazolone O +
( O -
Solin O +
et O +
al O +
. O -
, O +
1992 O -
) O +
and O +
progesterone O +
( O -
Arevalo O +
et O +
al O +
. O -
, O +
1993 O -
) O +
tend O +
to O +
show O +
a O +
high O +
degree O +
of O +
restriction O +
in O +
the O +
germline O +
V O -
- O -
region O +
gene O +
usage O -
. O +

In O +
contrast O -
, O +
the O +
antibodies O +
raised O +
against O +
the O +
small O +
hapten O +
traseolide O +
show O +
some O +
diversity O +
in O +
the O +
heavy O +
and O +
light O +
chain O +
subclasses O +
used O -
. O +

Also O +
for O +
dioxin O +
( O -
Recinos O +
et O +
al O +
. O -
, O +
1994 O -
) O +
and O +
for O +
N O +
- O -
( O -
p O +
-cyanophenyl O -
) O -
-N O +
′- O -
( O -
diphenylmethyl O -
) O -
guanidineacetic O +
acid O -
, O +
a O +
high O +
potency O +
sweetener O +
( O -
Anchin O +
& O +
Linthicum O -
, O +
1993 O -
) O +
, O +
diverse O +
structural O +
solutions O +
for O +
the O +
recognition O +
problem O +
of O +
a O +
small O +
molecule O +
were O +
noted O -
. O +

Thus O -
, O +
for O +
small O +
compounds O +
both O +
restricted O +
and O +
diverse O +
immune O +
response O +
have O +
been O +
found O -
. O +

The O +
dissociation O +
constants O +
of O +
the O +
antibodies B-Gene +
from O +
the O +
different O +
sequence O +
groups O +
to O +
the O +
traseolide O +
hapten O +
were O +
determined O -
, O +
using O +
either O +
fluorescence O +
titration O +
or O +
competition O +
BIAcore O +
( O -
Table O +
1 O -
) O +
. O +

Although O +
small O +
differences O +
in O +
experimental O +
parameters O +
like O +
pH O +
and O +
temperature O +
will O +
always O +
be O +
present O -
, O +
the O +
data O +
may O +
be O +
compared O +
because O +
both O +
methods O +
are O +
based O +
on O +
measurements O +
in O +
solution O +
( O -
Nieba O +
et O +
al O +
. O -
, O +
1996 O -
) O +
. O +

M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
11 I-Gene -
/ I-Gene -
01 I-Gene +
bind O +
to O +
the O +
hapten O +
with O +
similar O +
free O +
energy O -
, O +
while O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M03 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
have O +
dissociation O +
constants O +
that O +
are O +
one O +
to O +
two O +
orders O +
of O +
magnitude O +
higher O -
. O +

Binding O +
sites O +
for O +
small O +
hydrophobic O +
ligands O +
There O +
are O +
two O +
driving O +
forces O +
to O +
antigen O +
binding O -
: O +
entropic O +
forces O +
by O +
the O +
hydrophobic O +
effect O +
( O -
liberation O +
of O +
water O +
molecules O +
from O +
apolar O +
protein B-Gene +
surfaces O +
upon O +
complex O +
formation O -
) O +
and O +
enthalpic O +
forces O +
( O -
Mariuzza O +
et O +
al O +
. O -
, O +
1994 O -
) O +
. O +

Antibodies B-Gene -
, O +
even O +
directed O +
to O +
the O +
same O +
target O -
, O +
differ O +
greatly O +
in O +
the O +
relative O +
contribution O +
of O +
each O +
component O -
, O +
and O +
no O +
general O +
rules O +
can O +
be O +
drawn O +
( O -
Malby O +
et O +
al O +
. O -
, O +
1994 O -
) O +
. O +

In O +
general O -
, O +
the O +
specificity O +
of O +
antibodies B-Gene +
is O +
dependent O +
on O +
the O +
precise O +
nature O +
of O +
the O +
binding O +
surface O +
and O +
the O +
presence O +
or O +
absence O +
of O +
hydrogen O +
bonds O +
and O +
charge O -
- O -
charge O +
interactions O -
. O +

Binding O +
of O +
small O +
hydrophobic O +
haptens O +
to O +
antibodies B-Gene +
usually O +
occurs O +
deep O +
in O +
the O +
hydrophobic O +
cleft O +
of O +
the O +
antibody B-Gene -
, O +
and O +
thus O +
involves O +
framework O +
residues O -
. O +

Specificity O +
is O +
generally O +
achieved O +
by O +
involving O +
charged O +
residues O +
and O +
hydrogen O -
- O -
bond O +
interactions O +
( O -
Webster O +
et O +
al O +
. O -
, O +
1994 O -
) O +
, O +
e.g. O +
steroid O +
hormones O +
( O -
Trinh O +
et O +
al O +
. O -
, O +
1997 O -
; O +
Arevalo O +
et O +
al O +
. O -
, O +
1994 O -
) O +
or O +
fluorescein O +
( O -
Omelyanenko O +
et O +
al O +
. O -
, O +
1993 O -
) O +
. O +

There O +
are O -
, O +
however O -
, O +
also O +
examples O +
of O +
specific O +
binding O +
devoid O +
of O +
these O +
polar O +
group O +
interactions O -
. O +

The O +
high O +
affinity O +
binding O +
of O +
antibody B-Gene +
26 I-Gene -
- I-Gene -
10 I-Gene +
for O +
digoxin O +
is O +
solely O +
derived O +
from O +
shape O +
complementarity O +
( O -
Jeffrey O +
et O +
al O +
. O -
, O +
1993 O -
) O +
. O +

The O +
traseolide O +
hapten O +
is O +
also O +
a O +
small O +
hydrophobic O +
molecule O -
, O +
and O +
binding O +
is O +
almost O +
entirely O +
due O +
to O +
van O +
der O +
Waals O +
forces O +
and O +
the O +
hydrophobic O +
effect O -
. O +

Both O +
the O +
keto O +
moiety O +
and O +
the O +
carboxylate O +
terminus O +
of O +
traseolide O +
do O +
not O +
seem O +
to O +
have O +
possibilities O +
for O +
hydrogen O +
bonding O +
in O +
close O +
vicinity O -
, O +
since O +
Lys O +
H100c O -
, O +
the O +
closest O +
charge O -
, O +
is O +
found O +
at O +
4.5 O +
Å O +
from O +
the O +
carboxylate O +
group O +
of O +
traseolide O +
( O -
Table O +
3 O -
) O +
. O +

This O +
was O +
expected O +
for O +
the O +
carboxylate O +
moiety O -
, O +
because O +
during O +
immunization O +
it O +
was O +
not O +
freely O +
accessible O -
, O +
but O +
coupled O +
to O +
KLH B-Gene -
. O +

Binding O +
specificity O -
: O +
affinity O +
for O +
related O +
hapten O +
variants O +
From O +
the O +
crystal O +
structure O +
of O +
Fab B-Gene +
M02 I-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
the O +
fit O +
of O +
the O +
hapten O -
- O -
antibody B-Gene +
contacting O +
surface O +
seems O +
remarkably O +
good O -
. O +

The O +
traseolide O +
hapten O +
has O +
been O +
found O +
in O +
a O +
deep O +
hydrophobic O +
pocket O +
lined O +
with O +
many O +
aromatic O +
residues O +
( O -
Figures O +
6 O +
and O +
7 O -
) O +
. O +

However O -
, O +
there O +
are O +
some O +
imperfections O +
in O +
that O +
cavities O +
remain O +
in O +
the O +
complex O -
. O +

The O +
side O +
of O +
the O +
binding O +
pocket O +
fits O +
well O +
with O +
the O +
hapten O -
, O +
while O +
the O +
bottom O +
of O +
it O +
is O +
not O +
that O +
close O +
to O +
the O +
molecular O +
surface O +
of O +
the O +
hapten O -
. O +

Visual O +
inspection O +
of O +
the O +
crystal O +
structure O +
showed O +
that O +
different O +
musk O +
molecules O +
could O +
be O +
fitted O +
as O +
well O -
. O +

Substituting O +
ethyl O +
for O +
methyl O +
in O +
the O +
R2 O +
position O +
( O -
Figure O +
1 O -
) O +
results O +
in O +
slightly O +
better O +
contacts O +
with O +
Leu O +
L36 O +
and O +
Trp O +
H103 O -
. O +

Substituting O +
a O +
methyl O +
group O +
by O +
an O +
hydrogen O +
atom O +
in O +
R2 O +
, O +
however O -
, O +
might O +
be O +
unfavorable O -
, O +
as O +
a O +
cavity O +
would O +
be O +
generated O +
unless O +
the O +
van O +
der O +
Waals O +
contact O +
is O +
maintained O +
by O +
rotation O +
of O +
the O +
whole O +
hapten O -
. O +

These O +
findings O +
fit O +
well O +
with O +
the O +
experimental O +
data O +
( O -
Table O +
1 O -
) O +
. O +

Filling O +
up O +
a O +
stable O +
empty O +
cavity O +
in O +
the O +
binding O +
pocket O +
by O +
the O +
ligand O +
might O +
be O +
a O +
general O +
strategy O +
to O +
improve O +
binding O +
energy O -
. O +

An O +
additional O +
4-methyl O +
group O +
attached O +
to O +
the O +
piperidine O +
ring O +
of O +
3-amidinophenylalanine O -
- O -
derived O +
inhibitors O +
to O +
thrombin B-Gene +
gave O +
rise O +
to O +
a O +
17-fold O +
better O +
binding O +
( O -
Bergner O +
et O +
al O +
. O -
, O +
1995 O -
) O +
. O +

The O +
more O +
complete O +
spatial O +
occupancy O +
of O +
the O +
hydrophobic O +
S2 O +
cavity O +
probably O +
accounts O +
for O +
an O +
increase O +
in O +
free O +
binding O +
energy O +
by O +
1.5 O +
kcal O -
/ O -
mol O -
. O +

Recently O -
, O +
Dougan O +
et O +
al O +
. O +

( O -
1998 O -
) O +
attempted O +
to O +
increase O +
the O +
binding O +
affinity O +
of O +
the O +
scFv B-Gene +
antibody I-Gene +
NC10 I-Gene +
for O +
its O +
anti O -
- O -
influenza O +
virus O +
antigen O -
. O +

A O +
cavity O +
in O +
the O +
binding O +
interface O +
was O +
filled O +
with O +
a O +
larger O +
antibody B-Gene +
side O -
- O -
chain O -
. O +

However O -
, O +
the O +
replacement O +
of O +
Leu O +
L94 O +
with O +
Tyr O +
or O +
Trp O +
abolished O +
binding O -
, O +
while O +
a O +
valine O +
residue O +
led O +
to O +
a O +
reduction O +
in O +
Gibbs O +
free O +
energy O +
( O -
ΔΔG O +
= O +
0.9 O +
kcal O -
/ O -
mol O -
) O -
. O +

The O +
cavity O +
creating O +
mutation O +
Leu O +
L94 O +
Ala O +
abolished O +
binding O +
completely O -
. O +

Effects O +
of O +
somatic O +
mutations O +
in O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
The O +
variable O +
regions O +
of O +
the O +
monoclonal B-Gene +
antibodies I-Gene +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
vary O +
in O +
eight O +
amino O +
acid O +
positions O -
. O +

M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
contains O +
one O +
somatic O +
mutation O +
that O +
makes O +
direct O +
van O +
der O +
Waals O +
contact O +
to O +
the O +
traseolide O +
hapten O -
: O +
Ala O +
H93 O +
Val O -
. O +

Apart O +
from O +
an O +
about O +
75-fold O +
improved O +
binding O +
energy O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
compared O +
to O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
for O +
traseolide O -
, O +
the O +
antibody B-Gene +
shows O +
also O +
an O +
increased O +
binding O +
specificity O +
as O +
it O +
discriminates O +
traseolide O +
better O +
from O +
its O +
non O -
- O -
smelling O +
derivative O +
( O -
Table O +
1 O -
) O +
. O +

Although O +
it O +
can O -
not O +
be O +
excluded O +
that O +
the O +
other O +
somatic O +
mutations O +
contribute O +
to O +
the O +
altered O +
binding O +
characteristics O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
the O +
Ala O +
H93 O +
Val O +
mutation O +
is O +
the O +
one O +
most O +
likely O +
to O +
be O +
responsible O -
. O +

The O +
presence O +
of O +
Ala O +
H93 O +
in O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
will O +
enlarge O +
the O +
cavity O +
compared O +
to O +
the O +
Val O +
H93 O +
in O +
the O +
structure O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
solved O +
here O -
. O +

This O +
may O +
explain O +
the O +
difference O +
in O +
fine O -
- O -
specificity O +
for O +
traseolide O +
variants O -
: O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
( O -
Val O +
H93 O -
) O +
has O +
a O +
slightly O +
higher O +
affinity O +
for O +
Teth O +
then O +
for O +
T+ O +
, O +
while O +
T− O +
binds O +
considerably O +
less O +
well O +
( O -
by O +
1.2 O -
( O -
±0.1 O -
) O +
kcal O -
/ O -
mol O -
; O +
Table O +
1 O +
) O -
. O +

For O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Ala I-Gene +
H93 I-Gene -
) I-Gene +
no O +
substantial O +
differences O +
in O +
binding O +
affinity O +
were O +
found O +
between O +
the O +
three O +
traseolide O +
variants O +
( O -
Table O +
1 O -
) O +
. O +

By O +
filling O +
an O +
existing O +
cavity O +
Val O +
H93 O +
provides O +
a O +
tighter O +
association O +
to O +
the O +
traseolide O +
hapten O -
, O +
leading O +
to O +
better O +
binding O +
affinities O +
and O +
fine O +
specificity O +
for O +
traseolide O +
variants O +
( O -
Figure O +
8) O +
. O +

This O +
binding O +
energy O +
is O +
lost O +
by O +
creating O +
a O +
cavity O -
, O +
either O +
by O +
removing O +
the O +
side O -
- O -
chain O +
of O +
Val O +
H93 O -
, O +
or O +
by O +
removing O +
the O +
methyl O +
group O +
on O +
C2 O +
of O +
traseolide O -
. O +

This O +
illustrates O +
how O +
increase O +
in O +
binding O +
energy O +
is O +
coupled O +
to O +
specificity O -
. O +

The O +
importance O +
of O +
FR3 O +
residue O +
H93 O +
was O +
described O +
before O +
for O +
VH B-Gene +
Ox1 I-Gene +
antibodies I-Gene -
, O +
where O +
Ala O +
H93 O +
plays O +
a O +
critical O +
role O +
in O +
the O +
formation O +
of O +
the O +
hydrophobic O +
phOx O +
binding O +
pocket O +
( O -
Alzari O +
et O +
al O +
. O -
, O +
1990 O -
) O +
. O +

In O +
the O +
Brookhaven O +
database O +
( O -
http://www.rcsb.org/pdb/ O +
) O +
very O +
few O +
structures O +
are O +
found O +
in O +
which O +
H93 O +
makes O +
contact O +
to O +
the O +
antigen O -
: O +
the O +
catalytic O +
antibodies B-Gene +
1eap O +
and O +
1kno O +
and O +
the O +
fluorescein O +
binding O +
Fab B-Gene +
fragment O +
4fab B-Gene -
. O +

As O +
residue O +
H93 O +
is O +
located O +
deep O +
in O +
the O +
binding O +
pocket O -
, O +
only O +
small O +
haptens O +
are O +
able O +
to O +
make O +
contact O +
to O +
it O -
. O +

The O +
increase O +
in O +
binding O +
due O +
to O +
the O +
somatic O +
Ala O -
- O -
Val O +
mutation O +
in O +
the O +
binding O +
pocket O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
corresponds O +
to O +
an O +
increase O +
in O +
free O +
energy O +
of O +
2.3 O +
kcal O -
/ O -
mol O +
( O -
Table O +
1 O -
) O +
. O +

This O +
value O +
is O +
in O +
the O +
range O +
that O +
is O +
generally O +
observed O +
for O +
such O +
a O +
change O -
. O +

Studies O +
on O +
enzyme B-Gene -
- O -
substrate O +
interactions O +
have O +
shown O +
that O +
the O +
contribution O +
of O +
hydrophobic O +
groups O +
to O +
binding O +
can O +
be O +
large O +
and O +
variable O -
, O +
up O +
to O +
3.5 O +
kcal O -
/ O -
mol O +
per O +
methylene O +
group O +
( O -
Fersht O -
, O +
1985 O -
) O +
. O +

For O +
comparison O -
, O +
the O +
contribution O +
of O +
a O +
buried O +
methylene O +
group O +
to O +
protein B-Gene +
stability O +
was O +
found O +
to O +
depend O +
on O +
its O +
local O +
environment O +
and O +
averages O +
ca O +
1.5 O -
( O -
±0.6 O -
) O +
kcal O -
/ O -
mol O +
( O -
Serrano O +
et O +
al O +
. O -
, O +
1992 O -
; O +
Jackson O +
et O +
al O +
. O -
, O +
1993 O -
) O +
, O +
and O +
this O +
can O +
be O +
a O +
decisive O +
contribution O +
to O +
the O +
free O +
energy O +
of O +
folding O -
, O +
which O +
is O +
generally O +
quite O +
small O -
, O +
typically O +
5 O -
- O -
15 O +
kcal O -
/ O -
mol O +
( O -
Privalov O -
, O +
1979 O -
) O +
. O +

Bode O +
( O -
1979 O -
) O +
measured O +
the O +
difference O +
in O +
free O -
- O -
energy O +
for O +
the O +
binding O +
of O +
dipeptides O +
to O +
p O +
-guanidinobenzoate O -
- O -
trypsinogen B-Gene -
. O +

Upon O +
substituting O +
a O +
Val O +
for O +
an O +
Ala O +
in O +
the O +
dipeptide O +
( O -
and O +
leaving O +
the O +
second O +
residue O +
identical O -
) O +
an O +
increase O +
of O +
2.9 O -
- O -
3.1 O +
kcal O -
/ O -
mol O +
in O +
binding O +
energy O +
was O +
found O -
. O +

Force O -
- O -
field O +
calculations O +
were O +
performed O +
to O +
rationalize O +
the O +
experimentally O +
observed O +
differences O +
in O +
ligand O +
binding O +
energies O +
of O +
the O +
closely O +
related O +
antibodies B-Gene +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Ala I-Gene +
H93 I-Gene -
) I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Val I-Gene +
H93 I-Gene -
) I-Gene -
, O +
and O +
to O +
provide O +
a O +
microscopic O +
description O +
of O +
the O +
processes O +
involved O -
. O +

The O +
binding O +
energies O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Val I-Gene +
H93 I-Gene -
) I-Gene +
and O +
M02 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
( I-Gene -
Ala I-Gene +
H93 I-Gene -
) I-Gene +
to O +
the O +
traseolide O +
variants O +
T+ O +
and O +
T− O +
were O +
calculated O +
using O +
the O +
TAFF O +
force O -
- O -
field O +
( O -
Clark O +
et O +
al O +
. O -
, O +
1989 O -
) O +
after O +
energy O +
minimization O +
of O +
the O +
complex O -
. O +

The O +
inter O -
- O -
molecular O +
van O +
der O +
Waals O +
energy O +
showed O +
the O +
same O +
trend O +
as O +
the O +
experimental O +
data O -
, O +
underlining O +
the O +
importance O +
of O +
the O +
surface O +
complementarity O -
. O +

However O -
, O +
the O +
absolute O +
binding O +
energies O +
were O +
not O +
predictive O -
, O +
probably O +
due O +
to O +
the O +
approximate O +
method O +
used O +
( O -
M. O +
Scarsi O -
, O +
unpublished O +
data O -
) O -
. O +

Receptor B-Gene +
mimicry O +
The O +
molecular O +
basis O +
for O +
the O +
mimicry O +
between O +
antibodies B-Gene +
and O +
receptors B-Gene +
has O +
been O +
questioned O -
; O +
the O +
observation O +
that O +
two O +
proteins B-Gene +
recognize O +
the O +
same O +
ligand O +
does O +
not O +
imply O +
that O +
they O +
share O +
common O +
structure O +
in O +
their O +
binding O +
sites O +
( O -
Amati O +
et O +
al O +
. O -
, O +
1995 O -
; O +
Ducancel O +
et O +
al O +
. O -
, O +
1996 O -
) O +
. O +

Nevertheless O -
, O +
the O +
working O +
concept O +
of O +
using O +
mAbs B-Gene +
as O +
" O -
surrogate O +
receptors B-Gene -
" O +
has O +
proved O +
useful O +
in O +
the O +
discovery O +
of O +
lead O +
compounds O +
for O +
pharmaceutical O +
and O +
related O +
purposes O -
, O +
because O +
antibodies B-Gene +
raised O +
against O +
receptor B-Gene -
- O -
specific O +
ligands O +
share O +
binding O +
properties O +
with O +
the O +
receptors B-Gene +
( O -
Cook O +
& O +
Drayer O -
, O +
1988 O -
; O +
Döring O +
et O +
al O +
. O -
, O +
1994 O -
) O +
. O +

The O +
binding O +
specificity O +
profile O +
of O +
monoclonal B-Gene +
antibody I-Gene +
NC6.8 I-Gene +
appears O +
to O +
correlate O +
with O +
the O +
sweetness O +
potencies O +
of O +
the O +
superpotent O +
sweetener O +
ligand O +
( O -
Anchin O +
et O +
al O +
. O -
, O +
1997 O -
) O +
, O +
and O +
the O +
antibody B-Gene +
1B7 I-Gene +
raised O +
against O +
the O +
β B-Gene -
- I-Gene -
adrenergic I-Gene +
receptor I-Gene +
ligand O +
alprenolol O +
demonstrated O +
high O +
affinity O +
and O +
stereoselectivity O +
for O +
both O +
β O -
- O -
adrenergic O +
agonists O +
and O +
antagonists O -
, O +
which O +
makes O +
it O +
an O +
ideal O +
model O +
of O +
the O +
receptor B-Gene -
's O +
binding O +
site O +
( O -
Sawutz O +
et O +
al O +
. O -
, O +
1985 O -
) O +
. O +

Also O -
, O +
the O +
Tras B-Gene +
antibodies I-Gene +
may O +
exhibit O +
some O +
chemical O +
and O +
structural O +
interaction O +
motifs O +
as O +
found O +
in O +
the O +
natural O +
biological O +
odorant B-Gene +
receptor I-Gene -
. O +

For O +
the O +
monoclonal B-Gene +
antibody I-Gene +
M02 I-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
used O +
in O +
this O +
study O +
it O +
was O +
found O +
that O +
musk O +
odorant O +
T+ O +
binds O +
better O +
than O +
the O +
odorless O +
T− O +
( O -
Table O +
1 O -
) O +
. O +

From O +
the O +
crystal O +
structure O +
of O +
Fab B-Gene +
M02 I-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
it O +
is O +
clear O +
that O +
a O +
methyl O +
group O +
connected O +
to O +
the O +
indane O +
ring O +
of O +
traseolide O +
will O +
give O +
a O +
better O +
shape O +
complementarity O -
. O +

The O +
affinity O +
for O +
Teth O +
( O -
very O +
weak O +
musk O -
) O +
seems O +
to O +
correlate O +
less O +
well O +
with O +
the O +
olfactive O +
description O +
and O +
is O +
antibody B-Gene +
dependent O -
: O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
bound O +
Teth O +
and O +
T+ O +
in O +
a O +
comparabe O +
manner O -
. O +

To O +
be O +
able O +
to O +
distinguish O +
such O +
an O +
enormous O +
variability O +
of O +
odorants O -
, O +
we O +
predict O +
that O +
the O +
ligand O +
would O +
have O +
to O +
fit O +
very O +
precisely O +
to O +
the O +
odorant B-Gene +
receptor I-Gene -
. O +

If O +
they O +
leave O +
a O +
cavity O -
, O +
the O +
specificity O +
would O +
be O +
lost O -
. O +

In O +
analogy O +
to O +
the O +
traseolide O +
binding O +
pocket O +
odorant O +
molecules O +
might O +
bind O +
deeply O +
in O +
a O +
binding O +
pocket O -
, O +
between O +
adjacent O +
trans O -
- O -
membrane O +
helices O -
, O +
but O +
probably O +
also O +
contacting O +
the O +
loops O +
connecting O +
the O +
helices O -
. O +

Very O +
recently O +
more O +
evidence O +
for O +
this O +
hypothesis O +
was O +
found O +
by O +
Krautwurst O +
et O +
al O +
. O +

( O -
1998 O -
) O +
. O +

They O +
expressed O +
full O -
- O -
length O +
odorant B-Gene +
receptors I-Gene +
in O +
HEK-293 O +
cells O +
and O +
found O +
that O +
the O +
mouse B-Gene +
17 I-Gene +
receptor I-Gene -
, O +
unlike O +
the O +
highly O +
homologous O +
rat B-Gene +
17 I-Gene +
receptor I-Gene -
, O +
prefers O +
heptanal O +
instead O +
of O +
octanal O -
. O +

Both O +
receptors B-Gene +
differ O +
by O +
a O +
single O +
valine O +
to O +
isoleucine O +
substitution O +
in O +
transmembrane O +
region O +
V O +
of O +
the O +
odorant B-Gene +
receptor I-Gene -
. O +

In O +
addition O -
, O +
the O +
preservation O +
of O +
complementarity O +
between O +
the O +
receptor B-Gene +
and O +
the O +
ligand O +
seems O +
to O +
play O +
a O +
key O +
role O +
in O +
odorant O +
recognition O -
. O +

Conclusions O +
A O +
small O +
hapten O +
like O +
the O +
musk O +
odorant O +
traseolide O +
is O +
able O +
to O +
create O +
an O +
antibody B-Gene +
response O +
of O +
significant O +
sequence O +
diversity O +
in O +
the O +
mouse O -
. O +

Obviously O -
, O +
binding O +
of O +
an O +
odorant O +
to O +
a O +
protein B-Gene +
can O +
occur O +
in O +
different O +
binding O +
modes O -
. O +

Fine O +
specificity O +
of O +
a O +
monoclonal B-Gene +
antibody I-Gene +
for O +
the O +
musk O +
odorant O +
traseolide O +
is O +
regulated O +
primarily O +
by O +
shape O +
complementarity O +
and O +
the O +
concomitant O +
desolvation O +
of O +
the O +
complementary O +
surfaces O -
; O +
there O +
are O +
no O +
apparent O +
energetic O +
contributions O +
from O +
ionic O +
or O +
hydrogen O -
- O -
bonding O +
interactions O -
. O +

The O +
increase O +
in O +
binding O +
energy O +
is O +
coupled O +
to O +
an O +
increase O +
in O +
specificity O -
: O +
a O +
single O +
somatic O +
mutation O +
in O +
the O +
binding O +
pocket O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
led O +
to O +
a O +
considerably O +
better O +
binding O +
of O +
the O +
traseolide O +
hapten O +
( O -
ΔΔG O +
= O +
− O +
2.3 O -
( O -
±0.1 O -
) O +
kcal O -
/ O -
mol O -
) O -
. O +

At O +
the O +
same O +
time O +
the O +
Ala O -
- O -
Val O +
mutation O +
caused O +
more O +
specificity O +
for O +
hapten O +
variants O -
: O +
the O +
non O -
- O -
smelling O +
traseolide O +
odorant O +
lacking O +
a O +
methyl O +
group O +
was O +
binding O +
about O +
a O +
factor O +
10 O +
less O +
tightly O +
than O +
the O +
original O +
traseolide O -
. O +

Materials O +
and O +
methods O +
Materials O +
and O +
strains O +
For O +
all O +
cloning O +
experiments O +
the O +
E. O +
coli O +
K12 O +
strain O +
JM83 O +
( O -
λ− O +
, O +
ara O +
, O +
Δ O -
( O -
lac O -
, O +
pro O +
AB O -
) O -
, O +
rpsL O +
, O +
thi O +
, O +
φ80 O -
, O +
dlac O +
ZΔM15 O -
) O +
( O -
Yanisch O -
- O -
Perron O +
et O +
al O +
. O -
, O +
1985 O -
) O +
was O +
used O -
. O +

The O +
scFv B-Gene +
proteins I-Gene +
were O +
expressed O +
as O +
soluble O +
proteins O +
in O +
the O +
periplasm O +
in O +
the O +
E. O +
coli O +
strain O +
JM83 O -
, O +
or O +
as O +
cytoplasmic O +
inclusion O +
bodies O +
in O +
the O +
E. O +
coli O +
strain O +
BL21 O -
( O -
DE3 O -
) O +
( O -
F− O +
, O +
ompT O +
− O +
, O +
rB O +
− O +
rB O +
− O +
, O +
( O -
λimm21 O -
, O +
lac O +
I O -
, O +
lac O +
UV5 O -
, O +
T7pol O -
, O +
int O +
) O -
) O +
with O +
the O +
T7 O +
polymerase O -
- O -
based O +
system O +
( O -
Studier O +
& O +
Moffatt O -
, O +
1986 O -
) O +
. O +

Immunization O -
, O +
fusion O +
and O +
subcloning O +
The O +
commercial O +
musk O +
odorant O +
traseolide O +
( O -
Quest O +
International O -
, O +
the O +
Netherlands O -
) O +
was O +
used O +
as O +
hapten O +
( O -
Figure O +
1 O -
) O +
. O +

Immunization O -
, O +
production O +
of O +
monoclonal B-Gene +
antibodies I-Gene -
, O +
screening O +
for O +
hapten O +
specificity O -
, O +
mRNA O +
isolation O +
and O +
subcloning O +
was O +
performed O +
as O +
described O +
( O -
Langedijk O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

Antibody B-Gene +
germline O +
determinations O +
The O +
40 O +
sequences O +
of O +
the O +
Kabat O +
database O +
( O -
http://immuno.bme.nwu.edu O +
) O +
most O +
closely O +
related O +
to O +
the O +
heavy O +
or O +
light O +
chain O +
sequence O +
of O +
interest O +
were O +
aligned O +
with O +
the O +
" O -
FASTA O -
" O +
option O +
of O +
the O +
GCG O +
package O +
( O -
Genetics O +
Computer O +
Group O -
, O +
1991 O -
; O +
Markiewcz O -
, O +
1991 O +
) O -
. O +

The O +
data O +
were O +
aligned O +
with O +
" O -
PILEUP O -
" O +
and O +
reformatted O +
with O +
the O +
" O -
PRETTY O -
" O +
command O -
, O +
using O +
the O +
same O +
package O -
. O +

Subsequently O +
the O +
data O +
were O +
imported O +
in O +
an O +
Excel O +
macro O -
, O +
to O +
highlight O +
deviations O +
from O +
the O +
consensus O +
sequence O +
( O -
developed O +
by O +
A. O +
Honegger O -
) O -
. O +

A O +
prerequisite O +
for O +
the O +
analysis O +
is O +
that O +
the O +
database O +
contains O +
enough O +
sequences O +
of O +
the O +
germline O +
corresponding O +
to O +
the O +
input O +
sequence O -
. O +

For O +
the O +
heavy O +
chain O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
the O +
germline O +
consensus O +
sequence O +
could O +
be O +
determined O -
, O +
because O +
24 O +
sequences O +
of O +
the O +
same O +
germline O +
were O +
present O +
in O +
the O +
database O -
. O +

The O +
light O +
chain O +
of O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
however O -
, O +
could O +
not O +
be O +
classified O -
, O +
because O +
no O +
sequences O +
of O +
antibodies B-Gene +
with O +
the O +
same O +
germline O +
were O +
found O +
( O -
data O +
not O +
shown O -
) O -
. O +

Construction O +
of O +
plasmids O +
The O +
VH O +
- O -
( O -
Gly4 O +
Ser O -
) O -
3 O +
-VL O +
construct O +
was O +
obtained O +
by O +
cloning O +
VH O +
and O +
VL O +
in O +
the O +
vector O +
pHJ300 O +
( O -
Knappik O +
& O +
Plückthun O -
, O +
1994 O -
) O +
. O +

Overlap O -
- O -
PCR O +
was O +
used O +
for O +
subcloning O +
the O +
scFv B-Gene +
gene O +
in O +
the O +
vector O +
containing O +
N O -
- O -
terminal O +
FLAG O +
and O +
C O -
- O -
terminal O +
Myc O +
and O +
His O -
- O -
tags O -
. O +

The O +
overlap O +
was O +
used O +
to O +
introduce O +
a O +
N O -
- O -
terminal O +
Eco O +
RV O +
site O +
and O +
a O +
C O -
- O -
terminal O +
Eco O +
RI O +
site O -
, O +
corresponding O +
to O +
the O +
vectors O +
used O -
. O +

For O +
periplasmic O +
expression O +
the O +
gene O +
was O +
subcloned O +
in O +
pIG6 O +
( O -
Ge O +
et O +
al O +
. O -
, O +
1995 O -
) O +
and O +
for O +
cytoplasmic O +
expression O -
, O +
the O +
gene O +
was O +
subcloned O +
in O +
pTFT74 O +
( O -
Freund O +
et O +
al O +
. O -
, O +
1993 O -
; O +
Ge O +
et O +
al O +
. O -
, O +
1995 O -
) O +
which O +
places O +
expression O +
under O +
control O +
of O +
the O +
T7 O +
promoter O -
. O +

The O +
mutant O +
antibody B-Gene +
fragment O +
Tras B-Gene -
- I-Gene -
P I-Gene +
was O +
constructed O +
by O +
site O -
- O -
directed O +
mutagenesis O +
using O +
PCR O +
with O +
primers O +
containing O +
the O +
desired O +
mutation O -
. O +

After O +
sequencing O +
the O +
mutated O +
part O -
, O +
the O +
gene O +
was O +
digested O +
and O +
ligated O +
in O +
the O +
original O +
plasmid O -
. O +

Periplasmic O +
scFv B-Gene +
expression O +
and O +
fractionation O +
LB O +
medium O +
( O -
25 O +
ml O -
) O +
containing O +
100 O +
μg O -
/ O -
ml O +
ampicillin O +
was O +
inoculated O +
with O +
an O +
E. O +
coli O +
overnight O +
culture O +
harboring O +
the O +
plasmid O +
encoding O +
the O +
respective O +
antibody B-Gene +
fragment O -
. O +

Cultures O +
were O +
incubated O +
at O +
room O +
temperature O +
( O -
RT O -
, O +
25 O +
° O -
C O -
) O +
until O +
an O +
A O +
600 O +
of O +
0.5 O +
was O +
reached O -
. O +

Then O +
IPTG O +
( O -
isopropyl O +
β O -
- O -
d O +
-thiogalactopyranoside O -
) O +
was O +
added O +
to O +
a O +
final O +
concentration O +
of O +
0.5 O +
mM O +
and O +
the O +
incubation O +
was O +
continued O +
for O +
three O +
hours O -
. O +

After O +
induction O -
, O +
aliquots O +
of O +
the O +
cell O +
cultures O +
( O -
with O +
an O +
equal O +
amount O +
of O +
E. O +
coli O +
cells O +
as O +
calculated O +
according O +
to O +
the O +
A O +
600 O +
-value O -
, O +
usually O +
20 O +
A O +
units O -
) O +
were O +
removed O -
, O +
and O +
the O +
cells O +
were O +
fractionated O +
with O +
an O +
osmotic O +
shock O +
according O +
to O +
a O +
modification O +
of O +
the O +
procedure O +
by O +
Witholt O +
et O +
al O +
. O +

( O -
1976 O -
) O +
. O +

After O +
centrifuging O +
the O +
cells O +
at O +
4500 O +
rpm O +
for O +
ten O +
minutes O -
, O +
the O +
cell O +
pellet O +
was O +
resuspended O +
in O +
0.5 O +
ml O +
spheroplast O +
buffer O +
( O -
200 O +
mM O +
Tris O -
- O -
HCl O -
, O +
0.5 O +
mM O +
EDTA O -
, O +
0.5 O +
M O +
sucrose O -
, O +
pH O +
8.0 O -
) O +
at O +
4 O +
° O -
C O -
. O +

The O +
suspension O +
was O +
gently O +
mixed O -
, O +
incubated O +
for O +
30 O +
minutes O +
on O +
ice O +
and O +
centrifuged O +
for O +
ten O +
minutes O +
at O +
4500 O +
rpm O +
at O +
4 O +
° O -
C O -
. O +

The O +
pellet O +
was O +
resuspended O +
in O +
the O +
same O +
volume O +
as O +
the O +
spheroplasts O -
, O +
0.5 O +
ml O +
of O +
mM O +
MgCl2 O +
, O +
and O +
incubated O +
on O +
ice O +
for O +
another O +
30 O +
minutes O +
and O +
centrifuged O +
as O +
above O -
. O +

Both O +
supernatant O +
fractions O +
were O +
pooled O +
as O +
the O +
soluble O +
periplasmic O +
fraction O -
, O +
whereas O +
the O +
pellet O +
was O +
dissolved O +
in O +
1 O +
ml O +
PBS O -
. O +

Cytoplasmic O +
scFv B-Gene +
expression O +
Inclusion O +
body O +
protein B-Gene +
was O +
produced O +
as O +
described O +
and O +
was O +
isolated O +
following O +
a O +
standard O +
protocol O +
( O -
Buchner O +
& O +
Rudolph O -
, O +
1991 O -
; O +
Langedijk O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

Purification O +
of O +
inclusion O +
body O +
protein B-Gene +
and O +
refolding O +
were O +
carried O +
out O +
as O +
described O +
by O +
Proba O +
et O +
al O +
. O +

( O -
1997 O -
) O +
, O +
except O +
that O +
the O +
formation O +
of O +
disulfide O +
bonds O +
was O +
allowed O +
by O +
the O +
presence O +
of O +
both O +
0.5 O +
mM O +
of O +
reduced O +
and O +
0.5 O +
mM O +
oxidized O +
glutathione O +
in O +
the O +
refolding O +
buffer O -
. O +

After O +
incubation O +
of O +
one O +
to O +
four O +
days O +
at O +
4 O -
° O -
C O +
the O +
refolding O +
mixture O +
was O +
applied O +
to O +
a O +
hapten O -
- O -
affinity O +
column O -
. O +

Hapten O -
- O -
affinity O +
chromatography O +
Refolded O -
, O +
functional O +
protein B-Gene +
was O +
purified O +
using O +
affinity O +
chromatography O +
with O +
non O -
- O -
specific O +
elution O +
with O +
acidic O +
buffer O +
( O -
100 O +
mM O +
glycine O -
, O +
pH O +
2.7 O -
) O +
and O +
immediate O +
neutralization O +
with O +
one O -
- O -
quarter O +
volume O +
of O +
1 O +
M O +
Tris O +
( O -
pH O +
8.0 O -
) O +
( O -
Langedijk O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O +

Purity O +
of O +
the O +
protein B-Gene +
was O +
controlled O +
by O +
Coomassie O -
- O -
stained O +
SDS O -
- O -
PAGE O -
. O +

If O +
necessary O +
the O +
purified O +
scFv B-Gene +
was O +
concentrated O +
by O +
centrifugal O +
filtration O +
with O +
an O +
Ultrafree O +
concentrator O +
( O -
Millipore O -
) O -
. O +

Yields O +
were O +
calculated O +
by O +
absorption O +
at O +
280 O +
nm O -
, O +
using O +
calculated O +
extinction O +
coefficients O +
( O -
Gill O +
& O +
von O +
Hippel O -
, O +
1989 O -
) O +
. O +

Protein B-Gene -
- O -
gel O +
electrophoresis O +
and O +
Western O +
blots O +
The O +
antibody B-Gene +
fragments O +
were O +
detected O +
by O +
reducing O +
SDS O -
- O -
PAGE O +
( O -
Laemmli O -
, O +
1970 O -
) O +
and O +
subsequent O +
Coomassie O +
staining O +
or O +
Western O +
blotting O -
. O +

For O +
periplasmically O +
expressed O +
proteins B-Gene -
, O +
the O +
samples O +
were O +
normalized O +
to O +
the O +
amount O +
of O +
cells O -
. O +

Polyacrylamide O +
gels O +
were O +
blotted O +
on O +
PVDF O +
membrane O +
( O -
Immobilon O -
- O -
P O +
, O +
Millipore O -
; O +
Tovay O +
& O +
Baldo O -
, O +
1987 O +
) O +
and O +
after O +
blotting O +
the O +
gel O +
was O +
immuno O -
- O -
stained O +
using O +
the O +
anti B-Gene -
- I-Gene -
FLAG I-Gene +
antibody I-Gene +
M1 I-Gene +
( O -
Kodak O -
) O +
( O -
Prickett O +
et O +
al O +
. O -
, O +
1989 O -
) O +
, O +
or O +
the O +
anti B-Gene -
- I-Gene -
His I-Gene +
tag I-Gene +
antibody I-Gene +
( O -
Lindner O +
et O +
al O +
. O -
, O +
1997 O -
) O +
as O +
the O +
first O +
antibody B-Gene -
, O +
and O +
then O +
an O +
Fc O -
- O -
specific O +
goat O +
anti O -
- O -
mouse O +
antiserum O +
conjugated O +
to O +
horseradish B-Gene +
peroxidase I-Gene +
( O -
HRP B-Gene -
) O +
as O +
second O +
antibody B-Gene +
( O -
Pierce O -
) O -
. O +

Luminescence O +
was O +
detected O +
with O +
the O +
ECL O -
™ O +
kit O +
( O -
Amersham O -
) O -
, O +
or O +
color O +
was O +
developed O +
with O +
BM O -
- O -
blue O +
peroxidase B-Gene +
precipitating O +
substrate O +
( O -
Boehringer O +
Mannheim O -
) O -
. O +

BIAcore O +
measurements O +
Competition O +
BIAcore O +
analysis O +
was O +
performed O +
under O +
mass O -
- O -
transport O +
limitation O +
as O +
described O +
( O -
Karlsson O -
, O +
1994 O -
; O +
Nieba O +
et O +
al O +
. O -
, O +
1996 O -
) O +
, O +
using O +
a O +
sensor O +
chip O +
CM5 O +
( O -
Pharmacia O -
) O +
coated O +
with O +
10,000 O +
RU O +
of O +
BSA B-Gene -
- O -
traseolide O +
conjugate O +
or O +
with O +
only O +
BSA B-Gene +
as O +
a O +
control O -
. O +

Immobilization O +
of O +
BSA B-Gene +
was O +
performed O +
as O +
follows O -
: O +
35 O +
μl O +
of O +
a O +
1:1 O +
mixture O +
of O +
0.1 O +
M O +
N O +
-hydroxysuccinimide O +
( O -
NHS O -
, O +
Fluka O -
) O +
and O +
0.2 O +
M O +
N O +
- O -
( O -
3-dimethylaminopropyl O -
) O -
-N O +
′-ethylcarbodiimide O +
hydrochloride O +
( O -
EDC O -
, O +
Fluka O -
) O +
was O +
pumped O +
across O +
the O +
chip O +
to O +
activate O +
the O +
carboxmethylated O +
dextran O +
surface O -
. O +

Subsequently O +
30 O +
μl O +
of O +
3 O +
μM O +
BSA B-Gene -
- O -
traseolide O +
( O -
or O +
BSA B-Gene -
) O +
solubilized O +
in O +
NH4 O +
Ac O +
( O -
pH O +
4.5 O -
) O +
was O +
pumped O +
across O +
the O +
activated O +
surface O -
. O +

After O +
coating O +
sufficient O +
protein B-Gene +
( O -
which O +
was O +
followed O +
by O +
the O +
increasing O +
resonance O +
units O -
) O +
the O +
residual O +
NHS O +
esters O +
were O +
inactivated O +
with O +
ethanolamine O -
. O +

Each O +
binding O -
- O -
regeneration O +
cycle O +
was O +
performed O +
with O +
a O +
constant O +
flow O +
rate O +
of O +
20 O +
μl O -
/ O -
minute O +
using O +
20 O +
mM O +
Hepes O +
( O -
pH O +
7.6 O -
) O -
, O +
150 O +
mM O +
NaCl O -
, O +
0.005 O +
% O +
( O -
v O -
/ O -
v O -
) O +
Tween-20 O +
( O -
HBST O -
) O -
. O +

Samples O +
of O +
200 O +
( O -
μl O +
of O +
antibody B-Gene +
in O +
HBST O -
, O +
containing O +
various O +
amounts O +
of O +
succinyl O +
derivatives O +
of O +
the O +
traseolide O +
hapten O +
and O +
preincubated O +
for O +
at O +
least O +
one O +
hour O +
at O +
4 O +
° O -
C O -
, O +
were O +
injected O +
via O +
the O +
sample O +
loop O +
of O +
the O +
system O -
, O +
followed O +
by O +
regeneration O +
of O +
the O +
surface O +
by O +
injection O +
of O +
15 O +
μl O +
of O +
100 O +
mM O +
glycine O +
( O -
pH O +
2.3 O -
) O -
. O +

Data O +
were O +
evaluated O +
using O +
BIAevaluation O +
software O +
( O -
Pharmacia O -
) O +
and O +
Kaleidagraph O +
( O -
Synergy O +
Software O -
, O +
USA O -
) O -
. O +

Slopes O +
of O +
the O +
association O +
phase O +
of O +
linear O +
sensograms O +
were O +
plotted O +
against O +
the O +
corresponding O +
total O +
hapten O +
concentrations O -
, O +
and O +
the O +
dissociation O +
constant O +
was O +
calculated O -
. O +

Fluorescence O +
titration O +
A O +
2 O +
ml O +
sample O +
of O +
20 O +
mM O +
Tris O -
, O +
100 O +
mM O +
NaCl O +
( O -
pH O +
7.6 O -
) O -
, O +
containing O +
0.1 O -
- O -
0.5 O +
μM O +
active O +
scFv B-Gene +
Tras I-Gene +
was O +
placed O +
in O +
a O +
cuvette O +
with O +
an O +
integrated O +
stirrer O -
, O +
equilibrated O +
at O +
17 O -
° O -
C O -
. O +

Aliquots O +
of O +
concentrated O +
traseolide O +
stock O +
( O -
0.6 O +
mM O -
) O +
were O +
added O +
and O +
after O +
ten O +
minutes O +
of O +
equilibration O +
a O +
spectrum O +
was O +
recorded O +
from O +
315 O +
to O +
360 O +
nm O +
( O -
excitation O +
wavelength O +
280 O +
nm O -
) O +
on O +
a O +
Timemaster O -
™ O +
fluorescence O +
spectrometer O +
( O -
Photon O +
Technology O +
Int O -
. O -
, O +
Brunswick O -
, O +
NJ O -
) O -
. O +

Fluorescence O +
emission O +
spectra O +
of O +
scFv B-Gene +
Tras I-Gene +
fragments O +
showed O +
quenching O +
of O +
fluorescence O +
upon O +
formation O +
of O +
a O +
complex O +
of O +
scFv B-Gene +
Tras I-Gene +
with O +
the O +
hapten O +
traseolide O -
. O +

The O +
emission O +
intensity O +
at O +
335 O +
nm O +
was O +
used O +
for O +
determining O +
the O +
degree O +
of O +
complexation O +
as O +
a O +
function O +
of O +
traseolide O +
concentration O -
. O +

The O +
K O +
D O +
value O +
was O +
determined O +
by O +
a O +
direct O +
fit O +
of O +
emission O +
intensity O +
versus O +
hapten O +
concentration O +
( O -
Jung O +
& O +
Plückthun O -
, O +
1997 O -
) O +
. O +

Papain B-Gene +
digestion O +
and O +
purification O +
of O +
Fab B-Gene +
fragments I-Gene +
Mouse O +
monoclonal B-Gene +
antibody I-Gene +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
( O -
IgG1 O -
) O +
was O +
obtained O +
from O +
tissue O +
culture O +
of O +
the O +
relevant O +
hybridoma O +
cell O +
culture O +
medium O +
and O +
purified O +
by O +
Protein B-Gene +
A O +
affinity O +
chromatography O +
( O -
MCA O -
, O +
Groningen O -
) O -
. O +

The O +
following O +
stock O +
solutions O +
in O +
PBS O +
were O +
added O +
to O +
10 O +
ml O +
of O +
a O +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
solution O +
( O -
4.4 O +
mg O -
/ O -
ml O +
in O +
PBS O -
) O -
: O +
250 O +
μl O +
of O +
0.4 O +
M O +
l O +
-cysteine O -
- O -
HCl O +
( O -
Sigma O -
, O +
C-1276 O -
) O +
adjusted O +
to O +
pH O +
7.4 O +
with O +
5 O +
N O +
NaOH O -
, O +
500 O +
μl O +
of O +
0.04 O +
M O +
EDTA O +
( O -
Merck O -
, O +
108418 O -
) O +
and O +
440 O +
μl O +
of O +
1 O +
mg O -
/ O -
ml O +
papain B-Gene +
( O -
Boehringer O +
Mannheim O -
, O +
108014 O -
) O -
. O +

Papain B-Gene +
digestion O +
was O +
allowed O +
for O +
three O +
hours O +
in O +
an O +
incubator O +
shaker O +
at O +
150 O +
rpm O +
at O +
37 O -
° O -
C O -
. O +

The O +
reaction O +
was O +
stopped O +
by O +
addition O +
of O +
500 O +
μl O +
of O +
0.15 O +
M O +
iodacetamide O +
( O -
Sigma O -
, O +
I-6125 O -
) O +
to O +
the O +
reaction O +
mixture O -
. O +

Fab B-Gene +
fragments I-Gene +
were O +
purified O +
by O +
ion O -
- O -
exchange O +
chromatography O -
. O +

The O +
digested O +
antibody O +
sample O +
was O +
dialyzed O +
against O +
running O +
buffer O +
( O -
20 O +
mM O +
Tris O -
- O -
HCl O +
( O -
pH O +
8.25 O -
) O -
) O +
and O +
subsequently O +
applied O +
onto O +
a O +
Q O -
- O -
Sepharose O +
Fast O +
Flow O +
column O +
( O -
Pharmacia O -
) O +
equilibrated O +
with O +
running O +
buffer O +
at O +
1 O +
ml O -
/ O -
minute O -
. O +

A O +
salt O +
gradient O +
was O +
run O +
in O +
order O +
to O +
separate O +
Fab B-Gene +
fragments I-Gene +
from O +
non O -
- O -
digested O +
antibodies B-Gene +
and O +
Fc B-Gene +
fragments I-Gene +
( O -
gradient O -
: O +
2 O +
mM O +
NaCl O -
/ O -
ml O +
in O +
20 O +
mM O +
Tris O -
- O -
HCl O +
( O -
pH O +
8.25 O -
) O +
at O +
1 O +
ml O -
/ O -
minute O -
) O -
. O +

Fab B-Gene +
fragments I-Gene +
were O +
eluted O +
into O +
two O +
major O +
protein B-Gene +
peaks O +
named O +
Fab-1 B-Gene +
and O +
Fab-2 B-Gene -
, O +
respectively O -
. O +

By O +
iso O -
- O -
electric O +
focusing O +
( O -
Fast O -
- O -
System O -
, O +
Pharmacia O -
) O +
the O +
pI O +
values O +
of O +
Fab-1 B-Gene +
and O +
Fab-2 B-Gene +
were O +
determined O +
and O +
found O +
to O +
be O +
7.4 O +
and O +
6.9 O -
, O +
respectively O -
. O +

In O +
order O +
to O +
obtain O +
highly O +
pure O +
Fab B-Gene +
fractions I-Gene -
, O +
both O +
samples O +
were O +
dialyzed O +
against O +
running O +
buffer O +
and O +
subsequently O +
applied O +
onto O +
a O +
Mono O -
- O -
Q O +
column O +
( O -
Pharmacia O -
, O +
1 O +
ml O -
) O +
as O +
described O +
above O -
. O +

A O +
salt O +
gradient O +
was O +
used O +
to O +
elute O +
the O +
Fab-1 B-Gene +
and O +
Fab-2 B-Gene +
samples O +
( O -
gradient O -
: O +
1 O +
mM O +
NaCl O -
/ O -
ml O +
at O +
1 O +
ml O -
/ O -
minute O -
) O -
. O +

One O +
major O +
Fab B-Gene +
fraction I-Gene +
was O +
identified O +
after O +
purification O +
of O +
the O +
Fab-1 B-Gene +
sample O -
. O +

The O +
Fab-2 B-Gene +
sample O -
, O +
however O -
, O +
was O +
separated O +
into O +
three O +
peaks O +
named O +
Fab-2 B-Gene -
, O +
Fab-2′ B-Gene +
and O +
Fab-2″ B-Gene -
, O +
respectively O -
. O +

The O +
four O +
Fab B-Gene +
fractions I-Gene +
were O +
collected O +
separately O +
and O +
dialyzed O +
against O +
50 O +
mM O +
Tris B-Gene -
- I-Gene -
HCl I-Gene -
, O +
100 O +
mM O +
NaCl O +
( O -
pH O +
7.5 O -
) O -
. O +

In O +
an O +
ELISA O +
assay O +
all O +
four O +
Fab B-Gene +
fractions I-Gene +
showed O +
similar O +
specific O +
activities O +
towards O +
the O +
traseolide O +
molecule O -
. O +

Crystallization O +
studies O +
showed O +
that O +
best O +
crystals O +
were O +
obtained O +
with O +
Fab B-Gene +
fragments I-Gene +
from O +
the O +
Fab-1 B-Gene +
subclass O -
. O +

All O +
further O +
studies O +
were O +
done O +
with O +
the O +
latter O +
fragment O -
. O +

Crystallization O +
and O +
data O +
collection O +
Prismatic O +
crystals O +
were O +
obtained O +
using O +
the O +
hanging O -
- O -
drop O +
vapor O +
diffusion O +
method O +
at O +
20 O -
° O -
C O -
. O +

Drops O +
consisting O +
of O +
2 O +
μl O +
of O +
a O +
protein B-Gene +
solution O +
with O +
or O +
without O +
hapten O +
( O -
5 O +
mM O +
hapten O +
and O +
12 O +
mg O +
Fab B-Gene +
per O +
ml O +
in O +
100 O +
mM O +
Tris O -
, O +
pH O +
7.0 O -
) O +
were O +
mixed O +
with O +
2 O +
μl O +
of O +
the O +
well O +
solution O +
( O -
18 O -
- O -
19 O +
% O +
( O -
w O -
/ O -
v O -
) O +
PEG8000 O -
, O +
75 O -
- O -
200 O +
mM O +
sodium O +
acetate O +
( O -
pH O +
4.0 O -
) O -
) O -
. O +

Crystals O +
belong O +
to O +
space O +
group O +
P O +
21 O +
21 O +
2 O +
with O +
cell O +
dimensions O +
a O +
= O +
134.42 O +
Å O -
, O +
b O +
= O +
84.5 O +
Å O +
and O +
c O +
= O +
40.5 O +
Å. O +
With O +
one O +
molecule O +
in O +
the O +
asymmetric O +
unit O +
( O -
assuming O +
a O +
molecular O +
mass O +
of O +
50 O +
kDa O -
) O +
the O +
specific O +
protein B-Gene +
volume O +
is O +
V O +
m O +
= O +
2.3 O +
Å3 O +
/Da O -
, O +
which O +
corresponds O +
to O +
a O +
solvent O +
content O +
of O +
47 O +
% O +
( O -
Matthews O -
, O +
1968 O -
) O +
. O +

The O +
diffraction O +
data O +
were O +
collected O +
on O +
a O +
MAR O -
- O -
Research O +
Imaging O +
Plate O +
( O -
MAR O -
, O +
Hamburg O -
, O +
Germany O -
) O +
placed O +
on O +
a O +
Rigaku O +
RU200 O +
rotating O +
anode O +
using O +
the O +
CuKα O +
radiation O -
. O +

Reflection O +
intensities O +
were O +
indexed O +
using O +
MARXDS O +
( O -
Kabsch O -
, O +
1988a O -
) O +
and O +
merged O -
/ O -
scaled O +
using O +
MARSCALE O +
( O -
Kabsch O -
, O +
1988b O -
) O +
. O +

Details O +
of O +
the O +
data O +
processing O +
are O +
given O +
in O +
Table O +
2 O +
. O +

Structure O +
determination O +
and O +
refinement O +
Both O +
rotational O +
and O +
translational O +
searches O +
for O +
the O +
Fab B-Gene +
fragment I-Gene +
were O +
performed O +
with O +
the O +
program O +
AMoRe O +
( O -
Navaza O -
, O +
1994 O -
) O +
. O +

Because O +
of O +
the O +
flexibility O +
of O +
the O +
elbow O +
region O -
, O +
two O +
rotation O +
functions O +
were O +
performed O -
, O +
one O +
for O +
the O +
VH O +
: O -
VL O +
and O +
one O +
for O +
the O +
CH O +
1 O -
: O -
CL O +
domains O -
. O +

The O +
search O +
model O +
consisted O +
of O +
the O +
variable O +
domains O +
of O +
an O +
anti B-Gene -
- I-Gene -
arsonate I-Gene +
antibody I-Gene +
( O -
PDB O +
file O +
2f19 O -
; O +
Lascombe O +
et O +
al O +
. O -
, O +
1989 O +
) O +
and O +
the O +
constant O +
domains O +
of O +
an O +
anti B-Gene -
- I-Gene -
oxazolone I-Gene +
antibody I-Gene +
( O -
P.M. O +
Alzari O +
& O +
S. O +
Spinelli O -
, O +
unpublished O +
results O -
; O +
Alzari O +
et O +
al O +
. O -
, O +
1990 O +
) O -
. O +

The O +
orientation O +
of O +
the O +
variable O +
and O +
the O +
constant O +
domains O +
were O +
given O +
by O +
the O +
two O +
highest O +
peaks O +
in O +
the O +
corresponding O +
rotation O +
functions O +
calculated O +
with O +
data O +
between O +
10.0 O +
and O +
3.5 O +
Å. O +
The O +
resulting O +
model O +
had O +
a O +
R O +
-factor O +
of O +
0.40 O +
and O +
a O +
correlation O +
coefficient O +
of O +
0.30 O -
. O +

All O +
maps O +
were O +
constructed O +
using O +
the O +
CCP4 O +
suite O +
of O +
programs O +
( O -
Collaborative O +
Computational O +
Project O +
Number O +
4 O +
1994 O -
) O +
, O +
side O -
- O -
chains O +
were O +
substituted O -
, O +
inserted O +
or O +
deleted O +
on O +
the O +
computer O +
graphics O +
according O +
to O +
the O +
sequence O +
of O +
the O +
authentic O +
anti B-Gene -
- I-Gene -
traseolide I-Gene +
Fab I-Gene +
with O +
the O +
program O +
Turbo O -
- O -
Frodo O +
( O -
Roussel O +
& O +
Cambillau O -
, O +
1989 O -
) O +
. O +

The O +
refined O +
structure O +
of O +
the O +
Fab B-Gene +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene -
, O +
complexed O +
with O +
traseolide O -
, O +
was O +
obtained O +
by O +
cycles O +
of O +
model O +
building O +
alternated O +
with O +
refinement O +
of O +
the O +
atomic O +
coordinates O +
by O +
standard O +
slow O -
- O -
cooling O +
protocol O +
using O +
data O +
between O +
12.0 O +
and O +
2.6 O +
Å O +
( O -
Brünger O +
et O +
al O +
. O -
, O +
1987 O -
) O +
. O +

As O +
the O +
low O -
- O -
resolution O +
data O +
were O +
employed O +
in O +
the O +
refinement O -
, O +
a O +
low O -
- O -
resolution O +
bulk O +
solvent O +
correction O -
, O +
as O +
implemented O +
in O +
the O +
XPLOR O +
program O +
version O +
3.843 O +
( O -
Brünger O -
, O +
1996 O -
) O +
was O +
applied O -
. O +

The O +
behavior O +
of O +
the O +
free O +
R O +
-factor O +
( O -
R O +
free O +
) O +
was O +
monitored O +
all O +
along O +
the O +
refinement O +
procedure O +
( O -
Brünger O -
, O +
1992 O -
) O +
. O +

Details O +
of O +
the O +
refinement O +
and O +
model O +
statistic O +
are O +
listed O +
in O +
Table O +
2 O +
. O +

Synthesis O +
of O +
musk O +
odorant O +
molecules O +
The O +
commercial O +
odorant O +
traseolide O +
( O -
6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane O -
) O +
is O +
a O +
musk O +
type O +
odorant O -
, O +
synthesized O +
by O +
Quest O +
International O +
( O -
Naarden O -
, O +
the O +
Netherlands O -
) O -
. O +

By O +
using O +
different O +
starting O +
materials O -
, O +
a O +
series O +
of O +
traseolide O +
analogs O +
was O +
synthesized O +
at O +
Quest O +
International O +
and O +
the O +
fragrance O +
of O +
these O +
analogs O +
was O +
evaluated O +
( O -
Figure O +
1 O +
; O +
Traas O +
et O +
al O +
. O -
, O +
1982 O +
) O -
. O +

In O +
order O +
to O +
be O +
able O +
to O +
raise O +
antibodies B-Gene +
against O +
traseolide O +
or O +
use O +
it O +
in O +
biological O +
assays O -
, O +
a O +
covalent O +
hydrophilic O +
linker O +
was O +
added O +
to O +
the O +
hydrophobic O +
odorant O -
. O +

This O +
allowed O +
attachment O +
to O +
a O +
carrier B-Gene +
protein I-Gene +
and O -
, O +
at O +
the O +
same O +
time O -
, O +
made O +
the O +
compound O +
better O +
soluble O +
in O +
aqueous O +
solutions O -
. O +

The O +
linker O +
should O +
preferably O +
not O +
interfere O +
with O +
the O +
structurally O +
important O +
parts O +
of O +
the O +
traseolide O -
, O +
so O +
that O +
antibodies O +
could O +
be O +
obtained O +
with O +
structures O +
resembling O +
the O +
olfactory O +
receptor O +
as O +
closely O +
as O +
possible O -
. O +

From O +
olfactive O +
studies O +
it O +
was O +
known O +
that O +
elongation O +
of O +
the O +
R1 O +
chain O +
did O +
not O +
have O +
a O +
significant O +
influence O +
on O +
the O +
fragrance O +
( O -
Quest O +
International O -
, O +
the O +
Netherlands O -
) O -
. O +

Therefore O +
it O +
was O +
decided O +
to O +
introduce O +
a O +
carboxylic O +
substituent O +
in O +
R1 O +
as O +
reactive O +
group O +
for O +
binding O +
to O +
the O +
carrier O +
proteins O +
( O -
the O +
succinyl O +
derivative O +
of O +
traseolide O -
; O +
Figure O +
1 O +
) O -
. O +

The O +
succinyl O +
derivative O +
of O +
the O +
original O +
traseolide O +
hapten O +
was O +
available O +
from O +
Unilever O +
Research O +
Vlaardingen O +
( O -
the O +
Netherlands O -
) O -
, O +
while O +
the O +
succinyl O +
derivatives O +
of O +
the O +
other O +
traseolide O +
variants O +
had O +
to O +
be O +
synthesized O +
from O +
traseolide O -
- O -
alcohol O +
1- O -
( O -
2-hydroxy-3-methylpropyl O -
) O -
-4-methylbenzene O +
( O -
Traas O +
et O +
al O +
. O -
, O +
1982 O -
) O +
. O +

First O +
isobutylene O -
, O +
or O +
2-methyl-2-pentene O +
respectively O -
, O +
was O +
allowed O +
to O +
react O +
with O +
traseolide O -
- O -
alcohol O +
in O +
a O +
[ O -
3 O +
+ O +
2 O -
] O -
cycloaddition O +
using O +
AlCl3 O +
as O +
Lewis O +
base O +
to O +
form O +
the O +
traseolide O -
- O -
indane O +
( O -
Angle O +
& O +
Arnaiz O -
, O +
1992 O -
) O +
. O +

Secondly O -
, O +
the O +
succinyl O +
derivative O +
was O +
formed O +
using O +
the O +
Friedel O +
Crafts O +
acylation O +
conditions O +
for O +
musk O +
odorants O +
( O -
Weber O +
et O +
al O +
. O -
, O +
1955 O -
) O +
. O +

The O +
purity O +
of O +
the O +
newly O +
synthesized O +
traseolide O +
succinyl O +
derivatives O +
was O +
checked O +
by O +
TLC O -
, O +
NMR O +
and O +
absorption O +
spectroscopy O +
( O -
estimated O +
purity O -
: O +
Teth O +
⩾ O +
95 O +
% O +
and O +
T− O +
⩾ O +
85 O +
% O +
pure O -
; O +
data O +
not O +
shown O -
) O -
. O +

NMR O +
spectra O +
of O +
traseolide O +
indicated O +
that O +
the O +
substituents O +
in O +
C1 O +
and O +
C2 O +
are O +
in O +
trans O +
( O -
Figure O +
1 O -
) O +
( O -
R. O +
Pepermans O -
, O +
unpublished O +
results O -
) O -
, O +
and O +
the O +
absolute O +
stereochemistry O +
is O +
deduced O +
from O +
the O +
electron O +
density O +
map O +
of O +
Fab B-Gene +
M02 B-Gene -
/ I-Gene -
05 I-Gene -
/ I-Gene -
01 I-Gene +
complexed O +
with O +
the O +
traseolide O +
hapten O -
. O +

The O +
( O -
S O +
, O -
S O +
) O +
enantiomer O +
is O +
predominantly O +
occupying O +
the O +
binding O +
pocket O -
, O +
but O +
it O +
can O -
not O +
be O +
excluded O +
that O +
some O +
( O -
R O +
, O -
R O +
) O +
enantiomer O +
is O +
also O +
present O -
. O +

Protein O +
Data O +
Bank O +
accession O +
number O +
Coordinates O +
of O +
the O +
complexed O +
Fab B-Gene +
M05 B-Gene -
/ I-Gene -
01 I-Gene -
/ I-Gene -
01 I-Gene +
have O +
been O +
deposited O +
in O +
the O +
Brookhaven O +
Protein O +
Data O +
bank O +
with O +
accession O +
number O +
1C12 O -
. O +

Acknowledgements O +
The O +
authors O +
thank O +
J.A.M. O +
Laan O +
for O +
synthesis O +
of O +
the O +
succinyl O +
derivative O +
of O +
traseolide O -
, O +
E.A. O +
de O +
Ron O +
for O +
production O +
of O +
monoclonal B-Gene +
antibodies I-Gene -
, O +
W.J. O +
Bos O +
for O +
sequencing O +
of O +
cDNA O -
, O +
L.F. O +
Frenken O +
for O +
suggesting O +
the O +
Tras B-Gene -
- I-Gene -
P I-Gene +
mutant O -
, O +
M. O +
Scarsi O +
for O +
performing O +
theoretical O +
calculations O +
of O +
binding O +
energies O +
and O +
preparing O +
Figure O +
8 O +
, O +
T. O +
Carell O +
of O +
the O +
ETH O +
for O +
the O +
opportunity O +
to O +
work O +
in O +
his O +
lab O -
, O +
and O +
J. O +
Maat O +
and O +
P. O +
de O +
Geus O +
for O +
initiating O +
the O +
project O -
. O +

This O +
work O +
was O +
supported O +
by O +
the O +
EC O -
- O -
grant O +
BIOCT-920367 O -
. O +

Piroxicam O +
( O -
PXM O -
) O +
( O -
Fig. O +
1 O +
) O -
, O +
a O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O -
, O +
is O +
widely O +
used O +
in O +
the O +
therapy O +
of O +
osteoarthritis O +
and O +
rheumatoid O +
arthritis O -
, O +
and O +
it O +
has O +
been O +
known O +
to O +
induce O +
photosensitivity O +
as O +
one O +
of O +
its O +
side O -
- O -
effects O +
[ O -
1 O -
] O +
. O +

The O +
photosensitive O +
eruption O +
occurs O +
within O +
a O +
few O +
days O +
after O +
starting O +
the O +
treatment O +
with O +
this O +
drug O -
, O +
suggesting O +
a O +
phototoxic O +
reaction O +
[ O -
2–4 O -
] O +
. O +

However O -
, O +
there O +
are O +
some O +
reports O +
that O +
PXM O -
- O -
induced O +
photosensitivity O +
is O +
mainly O +
due O +
to O +
photoallergy O +
[ O -
5–7 O -
] O +
. O +

Ampiroxicam O +
( O -
APX O -
) O +
is O +
a O +
prodrug O +
of O +
PXM O +
and O +
is O +
developed O +
to O +
minimize O +
gastric O +
side O -
- O -
effects O +
[ O -
8,9 O -
] O +
. O +

Inactive O +
APX O +
is O +
hydrolyzed O +
to O +
active O +
PXM O +
by O +
an O +
intestinal O +
esterase B-Gene +
during O +
absorption O +
through O +
the O +
intestinal O +
wall O +
[ O -
10 O -
] O +
. O +

Hence O -
, O +
the O +
mechanism O +
of O +
photosensitivity O +
induced O +
by O +
both O +
PXM O +
and O +
APX O +
has O +
been O +
considered O +
to O +
be O +
similar O +
[ O -
11–13 O -
] O +
. O +

However O -
, O +
we O +
have O +
recently O +
experienced O +
a O +
patient O +
with O +
photosensitivity O +
induced O +
by O +
APX O +
who O +
showed O +
positive O +
patch O +
testing O +
to O +
UVA O -
- O -
irradiated O +
APX O +
and O +
thiosalicylate O +
( O -
TOS O -
) O -
, O +
but O +
was O +
negative O +
to O +
UVA O -
- O -
irradiated O +
PXM O -
. O +

In O +
order O +
to O +
elucidate O +
the O +
mechanism O +
of O +
APX- O +
and O +
PXM O -
- O -
induced O +
photosensitivity O +
further O -
, O +
antigenicity O +
of O +
UVA O -
- O -
irradiated O +
APX O +
and O +
its O +
cross O -
- O -
reactivity O +
to O +
APX O +
and O +
TOS O -
, O +
which O +
is O +
thought O +
to O +
be O +
an O +
active O +
hapten O +
of O +
PXM O -
, O +
were O +
examined O +
using O +
an O +
in O +
vivo O +
model O +
of O +
contact O +
hypersensitivity O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Animals O +
Female O +
Hartley O +
strain O +
guinea O +
pigs O +
( O -
380–450 O +
g O +
weight O -
) O +
were O +
purchased O +
from O +
Saitama O +
Experimental O +
Animals O +
Supply O +
( O -
Saitama O -
, O +
Japan O -
) O -
. O +

2.2 O +
Reagents O +
and O +
chemicals O +
APX O +
and O +
PXM O +
were O +
kindly O +
provided O +
by O +
Toyama O +
Chemical O +
( O -
Tokyo O -
, O +
Japan O -
) O -
. O +

TOS O +
and O +
Freund O -
's O +
complete O +
adjuvant O +
were O +
obtained O +
from O +
Wako O +
Pure O +
Chemical O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

Other O +
chemicals O +
were O +
of O +
the O +
highest O +
grade O +
commercially O +
available O -
. O +

2.3 O +
Absorption O +
spectra O +
APX O +
( O -
0.01 O -
% O -
) O +
and O +
TOS O +
( O -
0.01 O -
% O -
) O +
were O +
dissolved O +
in O +
acetone O +
and O +
phosphate O +
buffer O +
( O -
pH O +
7.4 O -
) O -
, O +
respectively O -
. O +

Furthermore O -
, O +
the O +
solutions O +
of O +
APX O +
UVA O -
- O -
irradiated O +
or O +
non O -
- O -
irradiated O +
( O -
10 O +
J O -
/ O -
cm2 O +
) O +
were O +
taken O +
to O +
dryness O +
under O +
a O +
stream O +
of O +
nitrogen O -
, O +
and O +
the O +
residues O +
were O +
reconstituted O +
with O +
phosphate O +
buffer O +
( O -
pH O +
7.4 O -
) O -
. O +

Absorption O +
spectra O +
of O +
these O +
compounds O +
were O +
measured O +
using O +
an O +
automatic O +
spectrophotometer O +
( O -
U-2000 O -
; O +
Hitachi O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O +

2.4 O +
UVA O +
irradiation O +
procedure O +
Black O +
light O +
tubes O +
( O -
FL40S O +
BLB O -
; O +
Toshiba O -
, O +
Tokyo O -
, O +
Japan O -
) O +
were O +
set O +
15 O +
cm O +
distance O +
from O +
each O +
solution O -
. O +

The O +
light O +
passed O +
through O +
3-mm O +
thick O +
glass O -
. O +

In O +
vitro O +
irradiation O +
was O +
carried O +
out O +
at O +
12.5–25.5 O +
J O -
/ O -
cm2 O +
of O +
UVA O +
in O +
a O +
glass O +
tube O +
at O +
room O +
temperature O -
. O +

The O +
irradiation O +
dose O +
was O +
measured O +
with O +
a O +
UV O +
radiometer O +
( O -
UVR305 O -
/ O -
365DII O -
; O +
Toshiba O -
) O -
. O +

2.5 O +
Sensitization O +
Antigenecity O +
of O +
APX O +
and O +
PXM O +
were O +
evaluated O +
by O +
the O +
adjuvant O +
patch O +
test O +
method O -
, O +
i.e. O +
a O +
modified O +
maximization O +
test O +
for O +
detection O +
of O +
contact O +
hypersensitivity O +
allergens O +
in O +
guinea O +
pig O +
[ O -
14 O -
] O +
. O +

Each O +
animal O +
was O +
sensitized O +
with O +
UVA O +
( O -
12.5 O +
J O -
/ O -
cm2 O +
) O -
-irradiated O +
1 O -
% O +
APX O +
in O +
acetone O -
/ O -
olive O +
oil O +
( O -
A O -
/ O -
O O -
) O +
( O -
1 O -
: O +
4 O -
) O -
, O +
1 O -
% O +
PXM O +
in O +
A O -
/ O -
O O -
, O +
1 O -
% O +
TOS O +
in O +
ethanol O -
, O +
or O +
control O +
vehicle O -
. O +

At O +
the O +
first O +
induction O -
, O +
100 O +
μl O +
of O +
each O +
chemical O +
was O +
applied O +
with O +
a O +
patch O +
tested O +
occlusively O +
on O +
a O +
shaved O +
and O +
abraded O +
nuchal O +
skin O +
area O +
( O -
3 O -
× O -
4 O +
cm2 O +
) O -
, O +
which O +
was O +
defined O +
by O +
intradermal O +
injections O +
( O -
0.1ml O -
× O -
4 O -
) O +
of O +
emulsified O +
Freund O -
's O +
complete O +
adjuvant O +
at O +
the O +
corners O -
. O +

The O +
patch O +
tests O +
were O +
repeated O +
daily O +
for O +
3 O +
days O -
. O +

At O +
the O +
second O +
induction O -
, O +
10 O -
% O +
sodium O +
laulyl O +
sulfate O +
in O +
petrolatum O +
was O +
applied O +
topically O +
on O +
the O +
eighth O +
day O -
, O +
and O +
each O +
sample O +
was O +
patch O +
tested O +
occlusively O +
again O +
on O +
the O +
ninth O +
day O -
. O +

2.6 O +
Elicitation O +
and O +
evaluation O +
All O +
solutions O +
were O +
prepared O +
at O +
1 O -
% O +
concentration O +
by O +
mixing O +
with O +
A O -
/ O -
O. O +
Animals O +
were O +
tested O +
on O +
day O +
21 O +
by O +
applying O +
20 O +
μl O +
of O +
the O +
solution O -
, O +
which O +
was O +
open O +
application O +
on O +
the O +
shaved O +
skin O +
of O +
the O +
flank O -
. O +

Reading O +
was O +
scored O +
48 O +
h O +
later O +
according O +
to O +
the O +
following O +
scale O +
for O +
scoring O +
skin O +
reactions O -
. O +

( O -
A O -
) O +
Scale O +
for O +
erythema O -
: O +
0 O -
, O +
no O +
erythema O -
; O +
1 O -
, O +
very O +
slight O +
erythema O +
( O -
barely O +
perceptible O -
) O -
; O +
2 O -
, O +
well O -
- O -
defined O +
erythema O -
; O +
3 O -
, O +
moderate O +
to O +
severe O +
erythema O -
; O +
4 O -
, O +
severe O +
erythema O -
. O +

( O -
B O -
) O +
Scale O +
for O +
edema O -
: O +
0 O -
, O +
no O +
edema O -
; O +
1 O -
, O +
slight O +
edema O -
; O +
2 O -
, O +
moderate O +
edema O -
; O +
3 O -
, O +
severe O +
edema O +
( O -
raised O +
more O +
than O +
1 O +
mm O +
and O +
extending O +
beyond O +
the O +
area O +
of O +
exposure O -
) O -
. O +

The O +
( O -
A O -
) O +
and O +
( O -
B O -
) O +
score O +
were O +
totalled O -
. O +

A O +
total O +
score O +
greater O +
than O +
2 O +
was O +
expressed O +
as O +
positive O -
, O +
according O +
to O +
the O +
criteria O +
of O +
the O +
International O +
Contact O +
Dermatitis O +
Research O +
Group O +
( O -
ICDRG O -
) O +
[ O -
15 O -
] O +
. O +

2.7 O +
High O -
- O -
performance O +
liquid O +
chromatography O +
condition O +
and O +
apparatus O +
High O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
analysis O +
was O +
performed O +
on O +
a O +
capcell O +
pak O +
column O +
( O -
250 O +
mm O -
, O +
i.d O -
. O +

4.6 O +
cm O -
, O +
particle O +
size O +
5 O +
μm O -
) O +
type O +
SG120 O +
( O -
Shiseido O -
, O +
Tokyo O -
, O +
Japan O -
) O -
, O +
using O +
a O +
solvent O +
mixture O +
( O -
methanol O -
: O -
acetonitrile O -
: O -
distilled O +
water=2:3:5 O -
, O +
v O -
/ O -
v O -
) O +
as O +
the O +
mobile O +
phase O +
at O +
a O +
flow O -
- O -
rate O +
of O +
0.7 O +
ml O -
/ O -
min O -
. O +

The O +
apparatus O +
( O -
TOSOH O -
, O +
Tokyo O -
, O +
Japan O -
) O +
used O +
for O +
this O +
work O +
consisted O +
of O +
HPLC O +
pump O +
( O -
CCPD O -
) O +
and O +
a O +
UV O +
monitor O +
( O -
UV8020 O -
) O +
set O +
at O +
a O +
wavelength O +
of O +
250 O +
nm O -
. O +

The O +
sample O +
was O +
introduced O +
through O +
a O +
fixed O +
20 O +
μl O +
loop O +
injector O +
( O -
AS-8000 O -
) O +
and O +
the O +
peak O +
area O +
was O +
measured O +
on O +
an O +
integrator O +
( O -
chromatocorder O +
21 O -
) O -
. O +

The O +
UVA O -
- O -
irradiated O +
APX O +
and O +
PXM O +
were O +
prepared O +
in O +
acetone O -
. O +

The O +
solutions O +
were O +
evaporated O +
to O +
dryness O +
and O +
then O +
reconstituted O +
in O +
the O +
mobile O +
phase O -
. O +

3 O +
Results O +
3.1 O +
In O +
vivo O +
study O +
As O +
shown O +
in O +
Tables O +
1 O +
and O +
2 O +
, O +
contact O +
hypersensitivities O +
among O +
UVA O -
- O -
irradiated O +
APX O -
, O +
UVA O -
- O -
irradiated O +
PXM O +
and O +
TOS O +
were O +
examined O -
. O +

Animals O +
sensitized O +
with O +
UVA O -
- O -
irradiated O +
1 O -
% O +
APX O +
showed O +
positive O +
patch O +
testing O +
to O +
UVA O -
- O -
irradiated O +
APX O +
and O +
TOS O -
, O +
while O +
they O +
were O +
negative O +
in O +
challenge O +
by O +
UVA O -
- O -
irradiated O +
PXM O -
, O +
APX O +
and O +
PXM O -
. O +

None O +
of O +
the O +
UVA O -
- O -
irradiated O +
or O +
non O -
- O -
irradiated O +
APX O +
and O +
PXM O +
showed O +
positive O +
patch O +
testing O +
in O +
animals O +
sensitized O +
with O +
either O +
UVA O -
- O -
irradiated O +
PXM O +
or O +
control O +
vehicles O +
( O -
Table O +
1 O +
) O -
. O +

Animals O +
immunized O +
with O +
TOS O +
were O +
successfully O +
challenged O +
by O +
TOS O +
and O +
cross O -
- O -
reacted O +
to O +
UVA O -
- O -
irradiated O +
APX O -
; O +
however O -
, O +
they O +
failed O +
to O +
react O +
to O +
UVA O -
- O -
irradiated O +
PXM O -
, O +
APX O +
and O +
PXM O +
( O -
Table O +
2 O +
) O -
. O +

3.2 O +
In O +
vitro O +
study O +
The O +
absorption O +
spectra O +
of O +
APX O -
, O +
TOS O +
and O +
UVA O -
- O -
irradiated O +
APX O +
are O +
shown O +
in O +
Fig. O +
2 O +
. O +

The O +
maximal O +
absorption O +
of O +
APX O +
was O +
320 O +
nm O -
, O +
and O +
alternation O +
of O +
the O +
absorbance O +
spectrum O +
was O +
detected O +
after O +
irradiation O -
. O +

The O +
absorption O +
peak O +
shifted O +
to O +
shorter O +
wavelength O -
. O +

The O +
UVA O -
- O -
irradiated O +
APX O +
spectrum O +
resembles O +
that O +
of O +
TOS O -
. O +

The O +
maximal O +
absorbance O +
of O +
the O +
PXM O +
was O +
360 O +
nm O +
( O -
data O +
not O +
shown O -
) O -
. O +

Solutions O +
irradiated O +
with O +
UVA O +
were O +
submitted O +
to O +
HPLC O +
for O +
the O +
quantification O +
of O +
undegradated O +
compounds O -
. O +

Concentration O +
of O +
APX O +
was O +
easily O +
reduced O +
by O +
the O +
increase O +
in O +
UVA O +
irradiation O +
doses O -
, O +
as O +
compared O +
with O +
that O +
of O +
PXM O -
. O +

Finally O -
, O +
APX O +
almost O +
disappeared O +
at O +
the O +
UVA O +
irradiation O +
dose O +
of O +
12.5 O +
J O -
/ O -
cm2 O +
( O -
Fig. O +
3 O +
) O -
. O +

4 O +
Discussion O +
In O +
the O +
present O +
study O -
, O +
we O +
succeeded O +
in O +
the O +
development O +
of O +
a O +
novel O +
animal O +
model O +
reflecting O +
clinical O +
observations O +
that O +
a O +
patient O +
with O +
photosensitivity O +
induced O +
by O +
APX O +
showed O +
positive O +
patch O +
testing O +
to O +
UVA O -
- O -
irradiated O +
APX O +
and O +
TOS O -
, O +
but O +
negative O +
for O +
UVA O -
- O -
irradiated O +
PXM O -
. O +

The O +
animals O +
sensitized O +
with O +
UVA O -
- O -
irradiated O +
APX O +
might O +
be O +
a O +
useful O +
model O +
to O +
examine O +
the O +
common O +
antigenic O +
properties O +
of O +
drugs O +
that O +
develop O +
photosensitivity O -
. O +

Furthermore O -
, O +
our O +
results O +
suggest O +
that O +
contact O +
hypersensitivity O +
induced O +
by O +
UVA O -
- O -
irradiated O +
APX O +
could O +
be O +
developed O +
by O +
photoproducts O +
of O +
APX O +
itself O -
, O +
but O +
not O +
by O +
the O +
biotransformation O +
of O +
APX O +
to O +
PXM O -
. O +

Actually O -
, O +
it O +
is O +
better O +
that O +
sensitized O +
animals O +
are O +
challenged O +
with O +
systemic O +
administration O +
of O +
APX O +
and O +
following O +
UVA O +
irradiation O +
to O +
skin O +
for O +
evaluating O +
the O +
clinical O +
phenomena O -
. O +

However O -
, O +
we O +
have O +
a O +
final O +
plan O +
to O +
detect O +
the O +
antigenic O +
photoproducts O +
of O +
APX O +
in O +
a O +
future O +
study O -
. O +

Hence O -
, O +
UVA O +
irradiation O +
was O +
performed O +
in O +
vitro O +
in O +
the O +
present O +
experiments O -
. O +

It O +
has O +
been O +
reported O +
that O +
several O +
kinds O +
of O +
photoproducts O +
of O +
PXM O +
are O +
formed O +
by O +
UVA O +
irradiation O +
in O +
different O +
conditions O +
[ O -
4,16 O -
] O +
. O +

Ikezawa O +
et O +
al. O +
have O +
reported O +
that O -
, O +
in O +
the O +
animals O +
sensitized O +
with O +
TOS O -
, O +
patch O +
testing O +
is O +
positive O +
to O +
PXM O +
under O +
the O +
condition O +
that O +
UVA O +
is O +
irradiated O +
after O +
a O +
patch O +
of O +
PXM O +
to O +
the O +
skin O -
, O +
suggesting O +
that O +
the O +
presence O +
of O +
carrier O +
protein B-Gene +
would O +
be O +
necessary O +
to O +
become O +
an O +
active O +
hapten O +
possessing O +
antigenic O +
property O -
, O +
as O +
irradiated O +
UVA O +
in O +
the O +
case O +
of O +
PXM O +
differed O +
from O +
that O +
of O +
APX O +
[ O -
17 O -
] O +
. O +

Furthermore O -
, O +
they O +
have O +
also O +
shown O +
that O +
patch O +
testing O +
was O +
negative O +
to O +
UVA O -
- O -
irradiated O +
PXM O +
without O +
patch O +
to O +
the O +
skin O +
in O +
the O +
animals O +
sensitized O +
with O +
TOS O +
in O +
agreement O +
with O +
our O +
result O -
. O +

Indeed O -
, O +
we O +
directly O +
confirmed O +
that O +
PXM O +
was O +
not O +
affected O +
with O +
UVA O +
irradiation O +
under O +
conditions O +
used O +
in O +
this O +
study O -
. O +

As O +
one O +
of O +
reasons O +
for O +
this O +
result O -
, O +
it O +
is O +
thought O +
that O +
the O +
intensity O +
of O +
UVA O +
exposure O +
used O +
here O +
is O +
relatively O +
low O +
judging O +
from O +
other O +
reports O +
[ O -
16,17 O -
] O +
. O +

On O +
the O +
other O +
hand O -
, O +
APX O +
was O +
easily O +
decomposed O +
by O +
the O +
same O +
treatment O +
with O +
UVA O -
, O +
indicating O +
the O +
difference O +
of O +
character O +
between O +
APX O +
and O +
PXM O -
. O +

Interestingly O -
, O +
absorption O +
spectrum O +
of O +
UVA O -
- O -
irradiated O +
APX O +
was O +
similar O +
to O +
that O +
of O +
TOS O -
. O +

This O +
result O +
suggests O +
that O +
a O +
part O +
of O +
photoproducts O +
of O +
APX O +
might O +
have O +
common O +
chemical O +
structure O +
of O +
TOS O -
. O +

In O +
facts O -
, O +
TOS O +
showed O +
positive O +
reaction O +
in O +
the O +
animals O +
sensitized O +
with O +
UVA O -
- O -
irradiated O +
APX O -
, O +
and O +
vice O +
versa O -
, O +
i.e. O +
cross O -
- O -
reactivity O +
was O +
developed O +
between O +
UVA O -
- O -
irradiated O +
APX O +
and O +
TOS O -
. O +

Further O +
experiments O +
regarding O +
the O +
detection O +
of O +
photoproducts O +
of O +
APX O +
should O +
be O +
the O +
next O +
subject O -
. O +

Kurumaji O +
[ O -
11 O -
] O +
has O +
shown O +
that O +
the O +
positive O +
photo O -
- O -
patch O +
testing O +
is O +
due O +
to O +
biotransformation O +
of O +
APX O +
to O +
PXM O +
in O +
the O +
skin O -
. O +

However O -
, O +
taking O +
the O +
results O +
in O +
this O +
study O +
into O +
consideration O -
, O +
the O +
possibility O +
of O +
the O +
biotransformation O +
of O +
APX O +
to O +
PXM O +
in O +
contact O +
hypersensitivity O +
reactions O +
is O +
quite O +
low O -
. O +

Taken O +
together O -
, O +
it O +
appears O +
that O +
photoproducts O +
of O +
UVA O -
- O -
irradiated O +
APX O +
actually O +
contain O +
cross O -
- O -
reactive O +
substances O +
to O +
itself O +
or O +
TOS O -
, O +
and O +
that O +
contact O +
sensitivity O +
reaction O +
induced O +
by O +
APX O +
may O +
be O +
due O +
to O +
photoproducts O +
of O +
this O +
compound O -
, O +
but O +
not O +
that O +
of O +
PXM O -
. O +

In O +
conclusion O -
, O +
we O +
established O +
an O +
animal O +
model O +
reflecting O +
clinical O +
observation O +
in O +
a O +
patient O +
with O +
APX O -
- O -
induced O +
photosensitivity O -
. O +

The O +
data O +
shown O +
here O +
suggest O +
that O +
photoproducts O +
of O +
APX O +
possess O +
an O +
antigenic O +
property O -
. O +

In O +
addition O -
, O +
patch O +
of O +
APX O +
to O +
the O +
skin O +
before O +
UVA O +
irradiation O +
is O +
not O +
necessary O +
to O +
obtain O +
the O +
antigenic O +
photoproducts O +
of O +
APX O +
in O +
this O +
method O -
, O +
indicating O +
that O +
it O +
is O +
easy O +
to O +
recover O +
and O +
examine O +
the O +
antigenic O +
substances O +
of O +
APX O -
. O +

Therefore O -
, O +
the O +
detection O +
of O +
products O +
induced O +
by O +
irradiation O +
of O +
UVA O +
to O +
APX O +
might O +
assist O +
the O +
elucidation O +
of O +
the O +
mechanism O +
for O +
photoallergy O +
with O +
PXM O -
. O +

MDMA O -
, O +
or O +
' O -
Ecstasy O -
' O -
, O +
and O +
3,4-methylenedioxyethylamphetamine O +
( O -
MDEA O -
, O +
or O +
' O -
Eve O -
' O -
) O +
have O +
emerged O +
as O +
popular O +
recreational O +
drugs O +
of O +
abuse O +
over O +
the O +
last O +
decade O -
. O +

In O +
Western O +
Europe O -
, O +
due O +
to O +
the O +
erroneous O +
belief O +
that O +
these O +
are O +
relatively O +
safe O +
hallucinogens O -
, O +
the O +
use O +
of O +
such O +
substances O +
as O +
mood O +
enhancers O +
has O +
steadily O +
increased O -
, O +
especially O +
in O +
discotheques O -
, O +
during O +
the O +
1990s O +
[ O -
1 O -
] O +
. O +

Recreational O +
use O +
of O +
these O +
drugs O +
has O +
spread O +
in O +
Italy O +
in O +
the O +
last O +
few O +
years O +
[ O -
2 O -
] O +
. O +

Pharmacological O +
studies O +
indicate O +
that O +
these O +
substances O +
produce O +
a O +
mixture O +
of O +
central O +
stimulant O +
and O +
psychedelic O +
effects O -
, O +
many O +
of O +
which O +
appear O +
to O +
be O +
mediated O +
by O +
brain O +
monoamines O -
, O +
particularly O +
serotonin O +
and O +
dopamine O +
[ O -
3 O -
] O +
. O +

Recent O +
well O -
- O -
publicised O +
reports O +
of O +
deaths O +
resulting O +
from O +
MDMA O -
/ O -
MDEA O +
abuse O +
at O +
' O -
rave O -
' O +
parties O +
have O +
led O +
to O +
an O +
increased O +
understanding O +
of O +
the O +
pathology O +
of O +
their O +
misuse O -
. O +

Toxic O +
effects O +
and O +
the O +
occasional O +
death O +
following O +
ring O +
substituted O +
amphetamine O +
misuse O +
have O +
been O +
reported O +
but O +
postmortem O +
data O +
are O +
lacking O +
[ O -
4 O -
] O +
previous O +
to O +
a O +
recent O +
review O +
which O +
illustrates O +
seven O +
fatal O +
cases O +
with O +
a O +
detailed O +
examination O +
of O +
the O +
post O -
- O -
mortem O +
findings O +
[ O -
5 O -
] O +
. O +

Additionally O -
, O +
while O +
deaths O +
due O +
to O +
MDMA O -
/ O -
MDEA O +
have O +
been O +
reported O -
, O +
none O +
of O +
these O +
reports O +
have O +
on O +
focused O +
on O +
immunohistochemical O +
investigation O -
. O +

Three O +
cases O +
of O +
death O +
following O +
the O +
ingestion O +
of O +
these O +
substances O +
have O +
been O +
here O +
examined O +
to O +
better O +
define O +
the O +
histopathological O +
findings O +
related O +
to O +
MDMA O -
/ O -
MDEA O +
intoxication O -
. O +

One O +
case O +
has O +
been O +
reported O +
previously O +
[ O -
2 O -
] O +
. O +

In O +
all O +
cases O +
we O +
were O +
able O +
to O +
carry O +
out O +
a O +
complete O +
immunohistochemical O +
studies O +
on O +
autopsy O +
specimens O -
. O +

2 O +
Methods O +
2.1 O +
Case O +
1 O +
B.F. O -
, O +
19 O +
years O +
of O +
age O -
, O +
was O +
seen O +
ingesting O +
numerous O +
tablets O +
of O +
Ecstasy O +
in O +
a O +
discotheque O +
the O +
night O +
of O +
June O +
15th O -
, O +
1996 O -
, O +
for O +
the O +
entire O +
duration O +
of O +
the O +
party O +
until O +
early O +
morning O -
. O +

On O +
June O +
16th O -
, O +
in O +
the O +
late O +
morning O -
, O +
he O +
began O +
to O +
experience O +
respiratory O +
difficulty O -
, O +
uncoordinated O +
movements O -
, O +
generalised O +
hypertonia O +
and O +
hyperpyrexia O +
( O -
40.6 O -
° O -
C O -
) O -
. O +

He O +
was O +
transported O +
to O +
the O +
local O +
hospital O +
where O +
the O +
following O +
hematochemical O +
values O +
were O +
registered O +
at O +
18:00 O +
h O -
: O +
PT O +
50 O -
% O -
; O +
PTT O +
52.7″ O -
; O +
TT O +
24″ O -
; O +
AT O +
III O +
102 O -
% O -
; O +
fibrinogen O +
172 O +
mg% O -
; O +
WBC O +
15 O +
900 O -
/ O -
mm3 O +
; O +
RBC O +
5 O +
410 O +
000 O -
/ O -
mm3 O +
; O +
PLT O +
191 O +
000 O -
/ O -
mm3 O +
; O +
HB O +
15.2 O +
g O -
/ O -
dl O -
; O +
HCT O +
46 O -
% O -
; O +
BP O +
100 O -
/ O -
50 O +
mmHg O -
; O +
cardiac O +
rate O +
165 O -
/ O -
min O -
. O +

The O +
patient O +
was O +
given O +
artificial O +
ventilation O -
; O +
an O +
arterial O +
blood O +
gas O +
analysis O +
at O +
19:33 O +
h O +
revealed O -
: O +
pH O +
7.326 O -
; O +
p O +
CO2 O +
37 O +
mmHg O -
; O +
p O +
O2 O +
89,8 O +
mmHg O -
; O +
HCO3 O +
18.8 O +
mmol O -
/ O -
l O -
; O +
SBC O +
19.4 O +
mmol O -
/ O -
l O -
; O +
So2 O +
96.3 O -
% O -
. O +

He O +
was O +
diagnosed O +
disseminated O +
intravascular O +
coagulation O +
( O -
DIC O -
) O +
and O +
received O +
therapy O +
with O +
heparin O +
bolus O +
2000 O +
IU O +
( O -
25 O +
IU O -
/ O -
kg O -
) O +
and O +
heparin O +
infusion O +
at O +
7 O +
IU O -
/ O -
kg O -
/ O -
h O +
( O -
12 O +
500 O +
IU O +
for O +
24 O +
h O -
) O +
together O +
with O +
the O +
administration O +
of O +
three O +
bags O +
of O +
plasma O -
. O +

At O +
23:30 O +
h O +
he O +
suffered O +
a O +
severe O +
loss O +
of O +
blood O +
from O +
the O +
oral O +
cavity O +
and O +
injection O +
wounds O -
: O +
BP O +
60 O -
/ O -
30 O +
mmHg O -
, O +
PR O +
40 O -
/ O -
min O -
. O -
, O +
PT O +
21 O -
% O -
, O +
PTT O +
227.9″ O -
, O +
TT O +
199.4″ O -
, O +
AT O +
III O +
75 O -
% O -
, O +
fibrinogen B-Gene +
2 O +
mg% O -
, O +
WBC O +
17 O +
000 O -
/ O -
mm3 O +
, O +
RBC O +
3 O +
230 O +
000 O -
/ O -
mm3 O +
, O +
HB O +
9.1 O +
g O -
/ O -
dl O -
, O +
HCT O +
28 O -
% O -
, O +
PLT O +
74 O +
000 O -
/ O -
mm3 O +
, O +
uraemia O +
58.3 O +
mg O -
/ O -
dl O -
, O +
creatinine O +
level O +
3.83 O +
mg O -
/ O -
dl O -
, O +
K O +
5.37 O +
mEq O -
/ O -
l O -
, O +
Na O +
141 O +
mEq O -
/ O -
l O -
, O +
CPK B-Gene +
7395 O -
, O +
CPK B-Gene +
MB O +
50 O -
, O +
AST B-Gene +
222 O -
, O +
ALT B-Gene +
112 O -
. O +

At O +
01:50 O +
h O +
he O +
suffered O +
a O +
cardiac O +
arrest O +
unresponsive O +
to O +
cardiopulmonary O +
resuscitation O -
. O +

2.2 O +
Case O +
2 O +
C.C. O -
, O +
20 O +
years O +
of O +
age O -
, O +
went O +
with O +
some O +
friends O +
to O +
a O +
discotheque O -
, O +
where O +
he O +
remained O +
for O +
some O +
hours O +
and O +
where O +
he O +
was O +
seen O +
to O +
ingest O +
numerous O +
tablets O +
of O +
Ecstasy O -
. O +

When O +
he O +
returned O +
home O +
around O +
02:00 O +
h O +
on O +
December O +
26th O -
, O +
he O +
told O +
his O +
mother O +
that O +
he O +
felt O +
feverish O -
. O +

The O +
armpit O +
temperature O +
was O +
established O +
at O +
40 O -
° O -
C O +
and O +
he O +
immediately O +
went O +
to O +
bed O -
. O +

At O +
12:00 O +
h O +
he O +
was O +
found O +
dead O -
, O +
his O +
pillow O +
soaked O +
with O +
blood O -
. O +

2.3 O +
Case O +
3 O +

On O +
May O +
19th,1996 O +
at O +
15:00 O +
h O -
, O +
R.L. O -
, O +
19 O +
years O +
of O +
age O -
, O +
was O +
found O +
unconscious O +
near O +
a O +
discotheque O -
. O +

After O +
being O +
carried O +
to O +
the O +
Intensive O +
Care O +
Unit O +
of O +
the O +
local O +
hospital O -
, O +
the O +
following O +
clinical O +
and O +
laboratory O +
data O +
were O +
established O -
: O +
PT O +
52 O -
% O -
; O +
PTT O +
55,4″ O -
; O +
TT O +
29″ O -
; O +
fibrinogen B-Gene +
150 O +
mg% O -
; O +
WBC O +
11 O +
200 O -
/ O -
mm3 O +
; O +
RBC O +
5 O +
220 O +
000 O -
/ O -
mm3 O +
; O +
PLT O +
180 O +
000 O -
/ O -
mm3 O +
; O +
HB O +
14g O -
/ O -
dl O -
; O +
HCT O +
43 O -
% O -
; O +
BP O +
90 O -
/ O -
50 O +
mmHg O -
; O +
PR O +
170 O -
/ O -
min O -
; O +
T O +
40.5 O -
° O -
C O -
. O +

The O +
clinical O +
course O +
progressively O +
worsened O +
and O +
at O +
15:00 O +
h O +
on O +
May O +
20th O +
diffused O +
subcutaneous O +
petechiae O +
appeared O -
; O +
the O +
patient O +
sustained O +
convulsions O +
and O +
treatment O +
with O +
dopamine O +
was O +
started O +
because O +
of O +
progressive O +
hypotension O -
: O +
BP O +
60 O -
/ O -
40 O +
mmHg O -
; O +
PR O +
60 O -
/ O -
min O -
; O +
PT O +
20 O -
% O -
; O +
PTT O +
210″ O -
; O +
TT O +
195″ O -
; O +
fibrinogen O +
5 O +
mg% O -
; O +
WBC O +
15 O +
000 O -
/ O -
mm3 O +
; O +
RBC O +
3 O +
200 O +
000 O -
/ O -
mm3 O +
; O +
HB O +
9.8 O +
g O -
/ O -
dl O -
; O +
HCT O +
30 O -
% O -
; O +
PLT O +
90 O +
000 O -
/ O -
mm3 O +
; O +
uraemia O +
74 O +
mg O -
/ O -
dl O -
; O +
creatinine O +
level O +
5.05 O +
mg O -
/ O -
dl O -
; O +
K O +
5.6 O +
mEq O -
/ O -
l O -
; O +
Na O +
138 O +
mEq O -
/ O -
l O -
; O +
CPK B-Gene +
8200 O -
; O +
CPK B-Gene +
MB O +
40 O -
; O +
AST B-Gene +
110 O -
; O +
ALT B-Gene +
90 O -
; O +
T O +
40.9 O -
° O -
C O -
. O +

At O +
19:00 O +
h O +
on O +
May O +
20th O +
he O +
was O +
pronounced O +
dead O -
. O +

Amphetamines O +
were O +
detected O +
in O +
the O +
urine O +
of O +
the O +
subjects O +
by O +
immunoenzymatic O +
screening O -
. O +

Toxicological O +
analyses O +
by O +
solid O -
– O -
liquid O +
extraction O +
and O +
gas O +
chromatography O -
– O -
mass O +
spectrometry O +
analysis O +
were O +
therefore O +
carried O +
out O +
to O +
identify O +
and O +
quantify O +
the O +
individual O +
substances O +
present O +
in O +
the O +
biological O +
fluids O +
and O +
organs O -
. O +

Table O +
1 O +
shows O +
the O +
concentrations O +
of O +
MDMA O -
, O +
MDEA O +
and O +
MDA O +
( O -
metabolite O +
of O +
MDMA O -
) O +
in O +
current O +
cases O -
. O +

2.4 O +
Immunohistochemical O +
staining O +
Immunohistochemical O +
investigation O +
of O +
the O +
kidney O +
and O +
the O +
muscle O +
structures O +
was O +
performed O +
utilising O +
polyclonal B-Gene +
anti I-Gene -
- I-Gene -
myoglobin I-Gene +
antibodies I-Gene +
( O -
Dako O -
, O +
Germany O -
) O +
[ O -
6,7 O -
] O +
. O +

Lungs O +
were O +
examined O +
utilising O +
polyclonal B-Gene +
anti I-Gene -
- I-Gene -
fibrinogen I-Gene +
antibodies I-Gene +
( O -
Calbiochem O -
, O +
USA O -
) O -
. O +

Liver O +
structures O +
were O +
examined O +
utilising O +
polyclonal B-Gene +
anti I-Gene -
- I-Gene -
fibrinogen I-Gene +
antibodies I-Gene +
( O -
Calbiochem O -
, O +
USA O -
) O -
, O +
anti O -
- O -
FDP O -
- O -
D O +
( O -
AGC O -
, O +
USA O -
) O -
, O +
and O +
anti B-Gene -
- I-Gene -
FDP I-Gene -
- I-Gene -
E I-Gene +
antibodies I-Gene +
( O -
ICN O +
Biomedicals O -
, O +
USA O -
) O +
[ O -
8 O -
] O +
. O +

Sections O +
were O +
counterstained O -
, O +
dehydrated O -
, O +
coverslipped O +
and O +
observed O +
in O +
a O +
Leitz O +
Aristoplan O +
optical O +
microscope O -
. O +

2.5 O +
Other O +
tests O +
A O +
routine O +
microscopic O +
histopathological O +
study O +
was O +
performed O +
by O +
using O +
formalin O -
- O -
fixed O +
paraffin O +
embedded O +
tissue O +
sectioned O +
at O +
4 O +
μm O +
and O +
stained O +
with O +
haematoxylin O -
– O -
eosin O -
, O +
periodic O +
acid O -
- O -
Schiff O +
and O +
phosphotungstic O +
acid O -
– O -
haematoxylin O +
( O -
PTAH O -
) O -
. O +

3 O +
Results O +
3.1 O +
Pathological O +
findings O +
The O +
morphological O +
data O +
together O +
with O +
the O +
autopsy O +
findings O +
revealed O +
diffused O +
subserous O +
petechiae O -
, O +
polyvisceral O +
stasis O +
and O +
the O +
following O +
histo O -
- O -
pathological O +
alterations O -
: O +
3.1.1 O +
Brain O +
Massive O +
oedema O +
and O +
signs O +
of O +
neuronal O +
hypoxia O +
were O +
present O +
in O +
all O +
cases O -
; O +
in O +
one O +
case O +
perivascular O +
ring O +
haemorrhages O -
, O +
especially O +
in O +
the O +
cortical O +
zone O -
, O +
were O +
observed O -
. O +

3.1.2 O +
Heart O +
Coagulative O +
myocytolysis O +
was O +
present O +
in O +
two O +
cases O -
. O +

We O +
observed O +
plurifocal O +
foci O +
of O +
myocells O +
with O +
hypercontraction O +
of O +
the O +
whole O +
myocell O +
and O +
myofibrillar O +
rhexis O +
with O +
anomalous O +
deeply O +
eosinophilic O +
cross O -
- O -
bands O +
formed O +
by O +
hypercontracted O +
sarcomeres O -
. O +

More O +
advanced O +
stages O +
of O +
coagulative O +
myocytolysis O +
( O -
alveolar O +
or O +
healing O +
patterns O -
) O +
and O +
old O +
myocardial O +
fibrosis O +
were O +
absent O +
or O +
minimal O -
. O +

In O +
one O +
case O +
areas O +
of O +
subendocardial O +
haemorrhage O +
were O +
also O +
noticed O -
. O +

3.1.3 O +
Lung O +
All O +
cases O +
revealed O +
subpleural O +
and O +
intra O -
- O -
alveolar O +
haemorrhage O +
with O +
severe O +
oedema O +
and O -
, O +
in O +
two O +
cases O -
, O +
microthrombotic O +
formations O +
inside O +
lung O +
capillaries O -
. O +

3.1.4 O +
Liver O +
In O +
two O +
cases O +
there O +
was O +
evidence O +
of O +
microvescicular O +
steatosis O +
and O +
in O +
one O +
case O +
clear O +
centrilobular O +
necrosis O +
around O +
the O +
central O +
veins O -
. O +

Liver O +
cells O +
in O +
the O +
central O +
zones O +
revealed O +
coagulation O +
necrosis O +
with O +
precipitation O +
of O +
fibrin B-Gene +
in O +
the O +
whole O +
area O +
affected O +
by O +
necrosis O -
. O +

There O +
were O +
occasionally O +
fibrillar O +
or O +
fine O +
granular O +
fibrin O +
thrombi O +
and O +
Kupffer O +
cells O +
ingesting O +
fibrin O +
in O +
sinusoids O +
around O +
the O +
area O +
of O +
necrosis B-Gene -
. O +

The O +
PTAH O +
staining O +
method O +
was O +
revealed O +
to O +
be O +
suitable O +
for O +
organized O +
fibrin B-Gene +
molecules O -
, O +
but O +
not O +
for O +
fibrin B-Gene +
molecules O +
during O +
the O +
process O +
of O +
either O +
polymerization O +
or O +
degradation O -
. O +

In O +
contrast O +
an O +
indirect O +
peroxidase B-Gene +
antibody B-Gene +
method O +
using O +
anti B-Gene -
- I-Gene -
fibrinogen I-Gene -
, O +
anti B-Gene -
- I-Gene -
FDP I-Gene -
- I-Gene -
D I-Gene +
and O +
anti B-Gene -
- I-Gene -
FDP I-Gene -
- I-Gene -
E I-Gene +
antibodies I-Gene +
was O +
suitable O +
for O +
the O +
latter O -
, O +
but O +
not O +
for O +
the O +
former O +
[ O -
8 O -
] O +
. O +

Post O -
- O -
mortem O +
virology O +
was O +
not O +
performed O +
in O +
these O +
cases O -
. O +

3.1.5 O +
Kidney O +
Fibrin O +
thrombi O +
in O +
the O +
renal O +
glomeruli O +
were O +
observed O +
in O +
two O +
cases O -
. O +

All O +
glomeruli O +
thrombi O +
were O +
already O +
organised O +
and O +
were O +
stained O +
prominently O +
by O +
PTAH O -
. O +

In O +
one O +
case O +
acute O +
tubular O +
necrosis O +
was O +
observed O -
. O +

H&E O +
examination O +
revealed O +
numerous O +
reddish O -
- O -
brown O +
granular O +
and O +
amorphous O +
casts O +
within O +
the O +
renal O +
tubules O -
. O +

In O +
all O +
the O +
cases O +
the O +
presence O +
of O +
tubular O +
casts O +
was O +
studied O +
with O +
immunohistochemical O +
technique O -
, O +
thus O +
demonstrating O +
their O +
myoglobinic B-Gene +
nature O +
( O -
Figs. O +
1 O +
and O +
2 O +
) O -
. O +

3.1.6 O +
Muscle O +
In O +
two O +
cases O +
hypercontracted O +
fibers O +
with O +
an O +
absence O +
of O +
the O +
striations O +
and O +
cystic O +
cavities O +
adjacent O +
to O +
zones O +
of O +
fiber O +
ruptures O +
were O +
present O +
( O -
Fig. O +
3a O +
) O -
. O +

The O +
immunohistochemical O +
investigation O +
for O +
myoglobin B-Gene +
performed O +
according O +
to O +
Fechner O +
and O +
co O -
- O -
workers O +
[ O -
7,9 O -
] O +
showed O +
accumulation O +
of O +
the O +
protein B-Gene +
in O +
the O +
breakage O +
areas O +
of O +
the O +
fibres O +
especially O +
on O +
the O +
surface O +
of O +
the O +
contraction O +
caps O +
( O -
Fig. O +
3b O +
) O -
. O +

4 O +
Discussion O +
There O +
are O +
substantial O +
similarities O +
in O +
the O +
clinical O +
and O +
histopathological O +
findings O +
of O +
the O +
fatal O +
cases O +
herein O +
presented O -
. O +

Two O +
deaths O +
were O +
caused O +
by O +
single O +
intoxication O -
, O +
respectively O -
, O +
from O +
MDMA O +
and O +
MDEA O +
and O +
the O +
third O +
from O +
both O +
MDMA O +
and O +
MDEA O -
. O +

No O +
other O +
drugs O +
were O +
detected O -
. O +

In O +
the O +
present O +
study O +
the O +
pathological O +
data O +
are O +
in O +
accordance O +
with O +
a O +
well O +
studied O +
and O +
documented O +
clinical O +
entity O -
, O +
i.e. O +
hyperthermia O +
and O +
disseminated O +
intravascular O +
coagulation O +
[ O -
10–12 O -
] O +
; O +
however O +
the O +
macro O +
and O +
microscopic O +
findings O +
have O +
not O +
been O +
definitively O +
classified O +
or O +
defined O +
yet O -
. O +

After O +
the O +
onset O +
of O +
deaths O +
related O +
to O +
MDMA O +
ingestion O +
[ O -
13 O -
] O +
, O +
reports O +
have O +
been O +
compiled O +
about O +
fatal O +
arrhythmia O +
caused O +
by O +
the O +
ingestion O +
of O +
MDMA O +
[ O -
14 O -
] O +
or O +
cases O +
of O +
hyperthermia O +
followed O +
by O +
DIC O +
[ O -
15–19 O -
] O +
. O +

Clinical O +
proofs O +
of O +
hyperthermia O -
, O +
rhabdomyolysis O +
and O +
DIC O +
are O +
also O +
evident O +
in O +
deaths O +
caused O +
by O +
MDEA O +
intoxication O +
with O +
findings O +
of O +
subserous O +
haemorrhage O +
and O +
severe O +
polyvisceral O +
stasis O +
[ O -
20–24 O -
] O +
. O +

Similar O +
pathological O +
findings O +
are O +
described O +
in O +
the O +
cases O +
of O +
death O +
due O +
to O +
combined O +
intoxication O +
of O +
MDMA O +
and O +
MDEA O +
[ O -
2,25,26 O -
] O +
. O +

A O +
report O +
describes O +
acute O +
myocardial O +
infarction O +
associated O +
with O +
amphetamine O +
abuse O +
[ O -
27 O -
] O +
. O +

Potential O +
explanations O +
include O +
coronary O +
vasospasm O -
, O +
excessive O +
catecholamine O +
discharge O +
resulting O +
in O +
ischemic O +
myocardial O +
necrosis O -
, O +
and O +
catecholamine O +
mediated O +
platelet O +
aggregation O +
with O +
subsequent O +
thrombus O +
formation O -
. O +

The O +
syndrome O +
closely O +
resembles O +
acute O +
myocardial O +
infarction O +
due O +
to O +
cocaine O +
abuse O +
[ O -
3 O -
] O +
. O +

A O +
comparison O +
of O +
our O +
findings O +
with O +
presently O +
available O +
related O +
literature O +
reveals O +
slight O +
differences O +
in O +
histopathological O +
findings O -
, O +
particularly O +
of O +
the O +
heart O -
, O +
liver O +
and O +
kidneys O +
as O +
compared O +
to O +
those O +
described O +
in O +
previous O +
reports O -
. O +

The O +
types O +
of O +
myocardial O +
necrosis O +
found O +
in O +
our O +
cases O +
were O +
coagulative O +
myocytolysis O -
. O +

No O +
histological O +
signs O +
of O +
infarct O +
necrosis O +
were O +
detected O -
. O +

Coagulative O +
myocytolysis O -
, O +
even O +
if O +
confined O +
to O +
few O +
myocells O -
, O +
can O +
be O +
interpreted O +
as O +
a O +
histological O +
sign O +
of O +
adrenergic O +
overdrive O +
[ O -
28 O -
] O +
. O +

Coagulative O +
myocytolytic O +
changes O +
may O +
be O +
related O +
to O +
the O +
type O +
and O +
length O +
of O +
survival O -
, O +
particularly O +
in O +
subjects O +
predisposed O +
to O +
cardiac O +
adrenergic O +
response O -
. O +

It O +
remains O +
to O +
be O +
established O +
if O +
coagulative O +
myocytolysis O +
is O +
due O +
to O +
unspecific O +
agonal O +
stimuli O +
or O +
drug O +
action O -
. O +

In O +
other O +
words O -
, O +
any O +
attempt O +
to O +
evaluate O +
its O +
meaning O +
requires O +
the O +
recognition O +
of O +
older O +
stages O -
, O +
the O +
determination O +
of O +
survival O +
time O -
, O +
and O +
the O +
exclusion O +
of O +
reanimative O +
procedures O -
. O +

In O +
two O +
cases O -
, O +
the O +
study O +
of O +
muscle O +
samples O +
revealed O +
hypercontracted O +
fibers O +
with O +
disruption O +
of O +
the O +
cell O +
architecture O -
, O +
typical O +
pathological O +
changes O +
observed O +
in O +
deaths O +
due O +
to O +
malignant O +
hyperpyrexia O +
[ O -
29 O -
] O +
. O +

Malignant O +
hyperthermia O +
is O +
a O +
rare O -
, O +
inherited O +
abnormal O +
susceptibility O +
to O +
certain O +
drugs O -
, O +
mostly O +
inhalational O +
anaesthetics O +
[ O -
30 O -
] O +
. O +

It O +
is O +
possible O +
that O +
individual O +
susceptibility O +
to O +
the O +
adverse O +
effects O +
of O +
the O +
amphetamine O +
derivatives O +
exists O -
, O +
with O +
deficient O +
demethylation O +
of O +
MDMA O +
by O +
debrisoquine B-Gene +
hydroylase I-Gene +
( O -
CYP2D6 B-Gene -
) O -
, O +
being O +
shown O +
in O +
certain O +
individuals O -
. O +

The O +
absence O +
of O +
CYP2D6 B-Gene -
, O +
a O +
member O +
of O +
the O +
cytochrome B-Gene +
P450 I-Gene +
superfamily O +
of O +
enzymes B-Gene -
, O +
in O +
5–9 O -
% O +
of O +
whites O -
, O +
may O +
be O +
another O +
factor O +
explaining O +
apparently O +
idiosyncratic O +
or O +
severe O +
responses O +
to O +
the O +
drug O +
[ O -
31 O -
] O +
. O +

Rhabdomyolysis O +
and O +
myoglobinuria O +
are O +
often O +
described O +
[ O -
10,32 O -
] O +
. O +

The O +
presence O +
of O +
myoglobin B-Gene +
in O +
the O +
kidney O +
has O +
been O +
reported O +
in O +
a O +
histopathological O +
study O +
only O +
[ O -
2 O -
] O +
. O +

In O +
a O +
recent O +
review O -
, O +
myoglobin B-Gene +
was O +
not O +
detected O +
in O +
the O +
only O +
two O +
cases O +
in O +
which O +
the O +
kidneys O +
were O +
examined O +
[ O -
5 O -
] O +
. O +

We O +
were O +
able O +
to O +
demonstrate O +
the O +
presence O +
of O +
myoglobin B-Gene +
in O +
the O +
proximal O +
tubules O +
in O +
all O +
the O +
three O +
cases O +
here O +
examined O -
. O +

Two O +
cases O +
presented O +
microthrombosis O +
of O +
the O +
pulmonary O +
and O +
renal O +
microcirculation O +
related O +
to O +
DIC O -
. O +

Finally O -
, O +
in O +
two O +
cases O +
has O +
been O +
possible O +
to O +
demonstrate O +
a O +
hepatic O +
microvescicular O +
steatosis O +
and O +
aspects O +
of O +
centrilobular O +
necrosis O +
related O +
to O +
DIC O +
in O +
one O +
case O -
. O +

The O +
genesis O +
of O +
the O +
hepatic O +
damage O +
caused O +
by O +
MDMA O -
/ O -
MDEA O +
still O +
remains O +
unexplained O +
and O +
does O +
not O +
seem O +
to O +
be O +
related O +
to O +
the O +
dose O +
or O +
frequency O +
of O +
drug O +
ingestion O -
. O +

Idiosyncratic O +
reactions O +
or O +
individual O +
susceptibility O +
are O +
likely O +
pathogenic O +
causes O +
of O +
the O +
hepatic O +
pictures O +
described O +
[ O -
33,34 O -
] O +
. O +

The O +
quality O +
of O +
Ecstasy O +
tablets O +
should O +
also O +
be O +
considered O +
due O +
to O +
the O +
established O +
and O +
documented O +
presence O +
of O +
toxic O +
contaminants O +
[ O -
5 O -
] O +
. O +

The O +
increase O +
in O +
cases O +
of O +
toxicity O +
due O +
to O +
MDMA O +
and O +
drugs O +
sold O +
as O +
' O -
Ecstasy O -
' O +
deserves O +
to O +
be O +
publicised O +
for O +
various O +
reasons O -
. O +

First O -
, O +
it O +
is O +
not O +
possible O +
to O +
establish O +
the O +
cause O +
of O +
severe O +
or O +
fatal O +
complications O +
following O +
the O +
ingestion O +
of O +
Ecstasy O +
with O +
the O +
data O +
available O +
at O +
present O -
. O +

Individuals O +
who O +
experience O +
such O +
an O +
adverse O +
reaction O +
have O +
often O +
used O +
the O +
drug O +
previously O +
without O +
problems O +
[ O -
10 O -
] O +
. O +

Chemical O +
and O +
toxicological O +
analysis O +
of O +
post O -
- O -
mortem O +
biological O +
material O +
shows O +
variable O +
concentrations O +
of O +
amphetamines O -
, O +
suggesting O +
hypersensitivity O +
in O +
the O +
cases O +
of O +
low O +
doses O -
. O +

Individual O +
susceptibility O +
to O +
ring O +
substituted O +
amphetamines O +
may O +
be O +
related O +
to O +
its O +
metabolism O +
in O +
the O +
liver O +
[ O -
35 O -
] O +
and O +
can O +
explain O +
severe O +
or O +
fatal O +
responses O +
to O +
the O +
drug O +
[ O -
31 O -
] O +
. O +

Second O -
, O +
clinicians O +
should O +
be O +
aware O +
of O +
the O +
pattern O +
of O +
toxicity O +
so O +
as O +
to O +
be O +
able O +
to O +
perform O +
correct O +
diagnoses O +
and O +
treatments O -
. O +

Finally O -
, O +
from O +
a O +
diagnostic O +
standpoint O -
, O +
in O +
all O +
ring O -
- O -
substituted O +
amphetamines O -
- O -
related O +
deaths O -
, O +
a O +
complete O +
immunohistochemical O +
study O +
should O +
be O +
performed O +
especially O +
on O +
muscle O +
[ O -
36 O -
] O +
and O +
kidney O +
[ O -
37 O -
] O +
samples O -
. O +

Chlozolinate O +
[ O -
structure O +
and O +
chemical O +
names O +
in O +
Fig. O +
1 O +
, O +
log O +
octanol O -
– O -
water O +
partition O +
coefficient O +
( O -
log O +
P O +
o O -
/ O -
w O +
) O -
= O -
3.15 O -
, O +
solubility O +
in O +
water=32 O +
mg O -
/ O -
l O +
at O +
25 O -
° O -
C O -
] O +
is O +
a O +
fungicide O +
belonging O +
to O +
the O +
dicarboximide O +
group O +
which O +
is O +
used O +
on O +
a O +
variety O +
of O +
crops O -
: O +
fruiting O +
vegetables O -
, O +
stone O +
fruits O -
, O +
artichokes O -
, O +
carrots O -
, O +
grapes O -
, O +
potatoes O +
and O +
strawberries O -
. O +

It O +
was O +
included O +
in O +
the O +
first O +
list O +
of O +
compounds O +
re O -
- O -
evaluated O +
within O +
the O +
European O +
Union O +
in O +
the O +
framework O +
of O +
directive O +
91 O -
/ O -
414 O -
/ O -
EEC O +
[ O -
1,2 O -
] O +
. O +

Although O +
its O +
use O +
on O +
edible O +
crops O +
to O +
be O +
supported O +
in O +
the O +
future O +
will O +
be O +
restricted O +
to O +
stone O +
fruits O +
and O +
grapes O -
, O +
the O +
necessity O +
to O +
monitor O +
all O +
produce O +
for O +
residues O +
remains O -
. O +

Methods O +
published O +
in O +
the O +
literature O +
are O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
methods O +
based O +
on O +
that O +
of O +
Cabras O +
et O +
al. O +
[ O -
3 O -
] O +
, O +
which O +
enables O +
the O +
simultaneous O +
determination O +
of O +
dicarboximide O +
fungicides O +
and O +
their O +
degradation O +
product O +
3,5-dichloroaniline O -
, O +
and O +
are O -
, O +
therefore O -
, O +
group O +
specific O -
. O +

Although O +
chlozolinate O +
degrades O +
to O +
a O +
number O +
of O +
metabolites O -
, O +
the O +
residue O +
definition O +
proposed O +
includes O +
only O +
the O +
parent O +
compound O -
. O +

Two O +
gas O +
chromatography O +
( O -
GC O -
) O +
methods O +
specific O +
for O +
chlozolinate O +
which O +
use O +
thermionic O +
specific O +
detection O +
( O -
TSD O -
) O +
have O +
been O +
developed O +
by O +
the O +
manufacturing O +
company O +
ISAGRO O -
, O +
Milan O -
, O +
Italy O -
, O +
and O +
validated O +
satisfactorily O +
for O +
peaches O -
, O +
apricots O +
and O +
grapes O +
[ O -
4 O -
] O +
and O +
for O +
grapes O +
and O +
wine O +
[ O -
5 O -
] O +
. O +

However O -
, O +
for O +
routine O +
residue O +
control O +
it O +
is O +
desirable O +
to O +
be O +
able O +
to O +
analyse O +
residues O +
of O +
as O +
many O +
compounds O +
as O +
possible O +
simultaneously O +
and O +
it O +
is O -
, O +
therefore O -
, O +
important O +
to O +
examine O +
the O +
possibility O +
of O +
including O +
chlozolinate O +
in O +
multiresidue O +
methods O -
. O +

The O +
aim O +
of O +
this O +
work O +
was O +
to O +
investigate O +
the O +
possibility O +
of O +
determining O +
residues O +
of O +
chlozolinate O +
in O +
several O +
crops O +
using O +
a O +
routinely O +
applied O +
multiresidue O +
method O +
and O +
to O +
validate O +
this O +
method O +
for O +
the O +
fungicide O +
according O +
to O +
the O +
relevant O +
international O +
guidelines O +
[ O -
6–9 O -
] O +
. O +

2 O +
Experimental O +
2.1 O +
Analytical O +
method O +
Since O +
chlozolinate O +
contains O +
two O +
chlorine O +
atoms O +
compared O +
to O +
only O +
one O +
nitrogen O +
atom O -
, O +
greater O +
sensitivity O +
would O +
be O +
expected O +
with O +
electron O -
- O -
capture O +
detection O +
( O -
ECD O -
) O +
than O +
with O +
TSD O -
. O +

The O +
method O +
selected O +
for O +
this O +
study O +
was O +
a O +
simple O -
, O +
low O -
- O -
cost O -
, O +
multiresidue O +
method O +
for O +
electron O -
- O -
capturing O +
compounds O +
[ O -
10 O -
] O +
which O +
is O +
already O +
used O +
routinely O +
in O +
our O +
laboratory O +
for O +
monitoring O +
purposes O -
. O +

All O +
solvents O +
and O +
reagents O +
used O +
were O +
of O +
high O +
purity O +
and O +
suitable O +
for O +
pesticide O +
residue O +
analysis O -
. O +

A O +
25-g O +
homogenized O +
sample O +
( O -
reduced O +
from O +
50 O +
g O +
in O +
the O +
original O +
method O -
) O +
is O +
extracted O +
with O +
a O +
mixture O +
of O +
50 O +
ml O +
toluene O +
and O +
25 O +
ml O +
propan-2-ol O +
using O +
an O +
Ultra O -
- O -
Turrax O +
homogenizer O +
for O +
3 O +
min O -
. O +

The O +
upper O +
toluene O +
phase O +
is O +
decanted O +
through O +
a O +
funnel O +
with O +
a O +
plug O +
of O +
quartz O -
- O -
wool O +
into O +
a O +
separatory O +
funnel O +
and O +
clean O -
- O -
up O +
is O +
effected O +
in O +
two O +
stages O +
through O +
( O -
a O -
) O +
liquid O -
– O -
liquid O +
partitioning O +
with O +
two O +
125-ml O +
portions O +
of O +
an O +
aqueous O +
solution O +
of O +
2 O -
% O +
Na2 O +
SO4 O +
and O +
( O -
b O -
) O +
vigorous O +
shaking O +
for O +
1–2 O +
min O +
of O +
a O +
10-ml O +
aliquot O +
of O +
the O +
toluene O +
phase O +
with O +
1 O +
g O +
of O +
a O +
mixture O +
of O +
adsorbents O +
( O -
activated O +
charcoal O +
Altec O +
6 O -
/ O -
16 O +
granular O -
– O -
Celite O +
545 O -
; O +
3:1 O -
, O +
w O -
/ O -
w O -
) O +
followed O +
by O +
filtration O +
through O +
a O +
fluted O +
filter O +
paper O +
to O +
obtain O +
the O +
final O +
extract O -
. O +

2.2 O +
Matrices O +
and O +
fortification O +
levels O +
The O +
four O +
most O +
important O +
crops O -
, O +
grapes O -
, O +
peaches O -
, O +
apricots O +
and O +
plums O -
, O +
were O +
fortified O +
at O +
four O +
concentrations O +
( O -
1 O -
, O +
0.4 O -
, O +
0.1 O +
and O +
0.04 O +
mg O -
/ O -
kg O -
) O +
with O +
five O +
replicate O +
samples O +
at O +
each O +
level O -
. O +

Two O +
additional O +
levels O -
, O +
5 O +
and O +
0.004 O +
mg O -
/ O -
kg O -
, O +
were O +
included O +
for O +
grapes O +
in O +
order O +
to O +
test O +
the O +
method O +
at O +
residue O +
concentrations O +
around O +
the O +
proposed O +
maximum O +
residue O +
level O +
( O -
MRL O -
) O +
of O +
5 O +
mg O -
/ O -
kg O +
and O +
at O +
the O +
estimated O +
limit O +
of O +
quantitation O +
( O -
LOQ O -
) O -
. O +

Plums O -
, O +
as O +
representative O +
of O +
stone O +
fruits O -
, O +
were O +
also O +
fortified O +
at O +
0.004 O +
mg O -
/ O -
kg O -
. O +

A O +
second O +
set O +
of O +
measurements O +
was O +
carried O +
out O +
on O +
seven O +
crops O +
for O +
which O +
the O +
use O +
of O +
chlozolinate O +
is O +
still O +
authorised O +
but O +
is O +
likely O +
to O +
be O +
withdrawn O +
in O +
the O +
future O -
, O +
and O +
on O +
one O +
further O +
crop O -
, O +
apples O -
, O +
for O +
which O +
there O +
is O +
no O +
approved O +
use O -
. O +

Fortification O +
was O +
at O +
the O +
expected O +
residue O +
level O +
of O +
1 O +
mg O -
/ O -
kg O +
( O -
8 O +
to O +
12 O +
replicates O -
) O -
. O +

Extension O +
of O +
the O +
study O +
to O +
include O +
these O +
crops O +
covers O +
the O +
need O +
to O +
ensure O +
that O +
monitoring O +
programmes O +
will O +
detect O +
illegal O +
use O +
of O +
the O +
pesticide O -
. O +

In O +
addition O -
, O +
the O +
method O +
was O +
tested O +
for O +
grape O +
samples O +
with O +
incurred O +
residues O -
, O +
using O +
grapes O +
of O +
varieties O +
Cardinal O +
and O +
Victoria O +
from O +
plots O +
of O +
vineyards O +
of O +
table O +
grapes O +
which O +
had O +
been O +
treated O +
with O +
a O +
commercial O +
formulation O +
of O +
chlozolinate O -
, O +
as O +
described O +
elsewhere O +
[ O -
11 O -
] O +
. O +

2.3 O +
GC O +
determination O +
The O +
GC O +
determinations O +
were O +
carried O +
out O +
using O +
a O +
Hewlett O -
- O -
Packard O +
5890 O +
Series O +
II O +
gas O +
chromatograph O +
fitted O +
with O +
an O +
ECD O +
system O +
operated O +
at O +
300 O -
° O -
C O -
, O +
a O +
Hewlett O -
- O -
Packard O +
7673 O +
autosampler O +
and O +
a O +
split O -
– O -
splitless O +
injector O +
operated O +
in O +
the O +
splitless O +
mode O +
( O -
250 O -
° O -
C O -
, O +
60 O +
s O -
, O +
1 O +
μl O -
) O -
. O +

The O +
carrier O +
and O +
make O -
- O -
up O +
gases O +
were O +
helium O +
and O +
nitrogen O +
( O -
50 O +
ml O -
/ O -
min O -
) O -
, O +
respectively O -
, O +
and O +
two O +
fused O -
- O -
silica O +
chromatographic O +
columns O +
were O +
employed O -
: O +
an O +
Rtx-5 O +
column O +
( O -
5 O -
% O +
diphenyl–95 O -
% O +
dimethylpolysiloxane O +
stationary O +
phase O -
, O +
30 O +
m O -
× O -
0.250 O +
mm O +
I.D. O -
, O +
0.25 O +
μm O +
film O +
thickness O -
) O +
with O +
a O +
He O +
pressure O +
of O +
95 O +
kPa O +
and O +
an O +
HP608 O +
column O +
( O -
30 O +
m O -
× O -
0.530 O +
mm O +
I.D. O -
, O +
0.5 O +
μm O +
film O +
thickness O -
) O +
with O +
a O +
He O +
pressure O +
of O +
37 O +
kPa O -
. O +

The O +
following O +
oven O +
temperature O +
programme O +
was O +
used O -
: O +
80 O -
° O -
C O -
, O +
hold O +
1 O +
min O -
; O +
15 O -
° O -
C O -
/ O -
min O +
to O +
190 O -
° O -
C O -
; O +
3 O -
° O -
C O -
/ O -
min O +
to O +
280 O -
° O -
C O -
, O +
hold O +
5 O +
min O -
. O +

Quantification O +
was O +
carried O +
out O +
using O +
calibration O +
curves O +
with O +
three O +
to O +
five O +
levels O +
which O +
covered O +
relatively O +
small O +
concentration O +
ranges O +
( O -
typically O +
a O +
factor O +
of O +
10 O -
) O -
. O +

The O +
lowest O +
calibrated O +
level O +
and O +
highest O +
calibrated O +
level O +
were O +
chosen O +
in O +
each O +
case O +
so O +
as O +
to O +
ensure O +
that O +
the O +
range O +
of O +
pesticide O +
concentration O +
in O +
the O +
samples O +
of O +
the O +
batch O +
was O +
covered O -
, O +
and O +
bracketing O +
injections O +
of O +
standards O +
were O +
used O -
, O +
i.e. O -
, O +
standard O +
injections O +
were O +
made O +
both O +
preceding O +
and O +
following O +
each O +
batch O +
of O +
samples O -
. O +

Recoveries O +
for O +
grapes O -
, O +
plums O -
, O +
apricots O +
and O +
peaches O +
at O +
all O +
fortification O +
levels O +
and O +
for O +
apples O +
and O +
aubergines O +
at O +
1 O +
mg O -
/ O -
kg O +
were O +
determined O +
with O +
matrix O -
- O -
matched O +
standards O -
. O +

The O +
blank O +
commodity O +
used O +
for O +
matrix O -
- O -
matching O +
was O +
identical O +
to O +
that O +
used O +
for O +
preparation O +
of O +
the O +
spiked O +
samples O -
. O +

Recoveries O +
at O +
1 O +
mg O -
/ O -
kg O +
for O +
these O +
matrices O +
and O +
for O +
the O +
other O +
crops O +
included O +
in O +
the O +
study O +
were O +
determined O +
with O +
non O +
matrix O -
- O -
matched O +
standards O +
since O -
, O +
at O +
the O +
time O +
these O +
measurements O +
were O +
made O -
, O +
matrix O -
- O -
matching O +
of O +
GC O +
standards O +
was O +
not O +
routine O +
practice O +
in O +
our O +
laboratory O -
. O +

2.4 O +
Method O +
validation O +
The O +
validation O +
of O +
an O +
analytical O +
method O +
in O +
individual O +
laboratories O -
, O +
i.e. O -
, O +
in O -
- O -
laboratory O +
validation O -
, O +
generally O +
includes O +
testing O +
it O +
for O +
accuracy O -
, O +
precision O -
, O +
the O +
limits O +
of O +
detection O +
( O -
LOD O -
) O +
and O +
quantitation O +
( O -
LOQ O -
) O -
, O +
specificity O -
, O +
sensitivity O -
, O +
linearity O -
, O +
ruggedness O +
and O +
practicability O +
[ O -
6–9 O -
] O +
. O +

More O +
recent O +
requirements O +
involve O +
the O +
examination O +
of O +
matrix O +
effects O +
and O +
verification O +
of O +
the O +
stability O +
of O +
an O +
analyte O +
in O +
both O +
calibration O +
solutions O +
and O +
sample O +
extracts O +
[ O -
6,7 O -
] O +
. O +

The O +
basic O +
criteria O +
which O +
must O +
be O +
met O +
in O +
order O +
for O +
a O +
method O +
to O +
be O +
considered O +
quantitative O +
are O +
satisfactory O +
accuracy O +
and O +
precision O -
, O +
i.e. O -
, O +
a O +
recovery O +
in O +
the O +
range O +
70 O +
to O +
110 O -
% O +
( O -
mean O +
recovery O +
80–100 O -
% O -
) O +
and O +
a O +
relative O +
standard O +
deviation O +
( O -
RSD O -
) O +
within O +
±10 O -
% O -
. O +

Precision O +
is O +
characterised O +
through O +
data O +
on O +
( O -
a O -
) O +
repeatability O -
, O +
which O +
estimates O +
within O -
- O -
batch O +
variation O +
( O -
same O +
analyst O -
, O +
test O +
material O +
and O +
equipment O +
over O +
a O +
short O +
time O +
interval O -
) O -
, O +
and O +
( O -
b O -
) O +
internal O +
reproducibility O -
, O +
( O -
preferably O +
different O +
analysts O -
, O +
batches O +
of O +
reagents O -
, O +
and O +
possibly O +
the O +
use O +
of O +
different O +
equipment O +
over O +
a O +
longer O +
time O +
interval O -
) O -
. O +

Most O +
series O +
of O +
replicates O +
for O +
a O +
given O +
fortification O +
level O +
and O +
crop O +
were O +
carried O +
out O +
on O +
the O +
same O +
day O +
by O +
the O +
same O +
analyst O -
, O +
thus O +
providing O +
extensive O +
data O +
for O +
testing O +
the O +
repeatability O +
of O +
the O +
method O -
. O +

Internal O +
reproducibility O +
is O +
indicated O +
by O +
the O +
RSD O +
values O +
of O +
the O +
mean O +
recoveries O +
for O +
different O +
crops O +
fortified O +
at O +
1 O +
mg O -
/ O -
kg O -
. O +

These O +
were O +
carried O +
out O +
over O +
a O +
period O +
of O +
many O +
months O -
, O +
and O +
extracts O +
were O +
prepared O +
by O +
several O +
different O +
laboratory O +
assistants O -
, O +
some O +
of O +
whom O +
were O +
short O -
- O -
term O +
temporary O +
staff O +
with O +
no O +
previous O +
training O +
in O +
the O +
field O -
. O +

These O +
data O -
, O +
therefore O -
, O +
also O +
provide O +
a O +
test O +
of O +
the O +
ruggedness O +
and O +
practicability O +
of O +
the O +
method O -
. O +

The O +
calculation O +
of O +
the O +
LOD O +
was O +
made O +
based O +
on O +
three O -
- O -
times O +
the O +
standard O +
deviation O +
of O +
the O +
chlozolinate O +
concentration O +
found O +
for O +
ten O +
repeat O +
injections O +
of O +
the O +
extract O +
of O +
a O +
sample O +
fortified O +
at O +
the O +
estimated O +
LOQ O -
. O +

Measurements O +
were O +
made O +
for O +
both O +
grape O +
and O +
plum O +
extracts O -
. O +

The O +
LOQ O +
was O +
confirmed O +
by O +
calculation O +
of O +
the O +
RSD O +
of O +
the O +
recoveries O +
for O +
five O +
replicate O +
samples O +
each O +
of O +
grapes O +
and O +
plums O +
fortified O +
at O +
this O +
level O +
[ O -
7 O -
] O +
. O +

For O +
specificity O -
, O +
blanks O +
of O +
at O +
least O +
two O +
samples O +
of O +
each O +
crop O +
were O +
checked O +
for O +
interfering O +
peaks O +
on O +
the O +
two O +
chromatographic O +
columns O +
used O -
, O +
and O +
the O +
retention O +
times O +
of O +
a O +
wide O +
range O +
of O +
other O +
electron O -
- O -
capturing O +
compounds O +
were O +
checked O +
against O +
that O +
of O +
chlozolinate O -
. O +

Sensitivity O +
and O +
the O +
linearity O +
of O +
the O +
detector O +
response O +
to O +
the O +
analyte O +
were O +
examined O +
by O +
the O +
injection O +
of O +
matrix O -
- O -
matched O +
standard O +
solutions O +
of O +
chlozolinate O +
at O +
12 O +
concentrations O +
in O +
the O +
range O +
0.002 O +
to O +
10 O +
μg O -
/ O -
ml O -
. O +

The O +
effect O +
of O +
matrix O -
- O -
matching O +
on O +
recoveries O +
was O +
evaluated O +
by O +
repeating O +
some O +
of O +
the O +
earlier O +
analyses O +
for O +
which O +
matrix O -
- O -
matched O +
standards O +
had O +
not O +
been O +
used O -
. O +

Measurements O +
were O +
made O +
for O +
six O +
different O +
crops O +
at O +
the O +
1 O +
mg O -
/ O -
kg O +
fortification O +
level O -
. O +

In O +
order O +
to O +
test O +
the O +
stability O +
of O +
chlozolinate O -
, O +
the O +
extracts O +
from O +
samples O +
of O +
grapes O +
obtained O +
from O +
field O +
trials O +
with O +
the O +
pesticide O +
were O +
stored O +
at O +
−20 O -
° O -
C O +
and O +
reanalysed O +
after O +
six O +
months O -
. O +

The O +
stability O +
of O +
the O +
matrix O -
- O -
matched O +
calibration O +
standards O +
during O +
GC O +
analysis O +
was O +
assessed O +
by O +
comparison O +
of O +
the O +
detector O +
response O +
to O +
standards O +
left O +
on O +
the O +
instrument O +
for O +
three O +
days O +
with O +
that O +
of O +
freshly O -
- O -
prepared O +
standards O -
. O +

3 O +
Results O +
and O +
discussion O +
Table O +
1 O +
gives O +
the O +
percentage O +
recoveries O +
for O +
the O +
four O +
main O +
crops O +
( O -
grapes O -
, O +
plums O -
, O +
apricots O +
and O +
peaches O -
) O +
at O +
four O +
to O +
six O +
fortification O +
levels O +
and O +
for O +
apples O +
and O +
aubergines O +
fortified O +
at O +
1 O +
mg O -
/ O -
kg O -
. O +

All O +
the O +
mean O +
recoveries O +
lie O +
within O +
the O +
range O +
86 O +
to O +
99 O -
% O -
, O +
with O +
an O +
overall O +
recovery O +
of O +
94 O -
% O +
and O +
RSD O +
of O +
5 O -
% O -
. O +

The O +
repeatability O +
of O +
the O +
measurements O +
is O +
good O -
, O +
with O +
values O +
for O +
the O +
RSD O +
of O +
within O -
- O -
batch O +
measurements O +
lying O +
between O +
1 O +
and O +
8 O -
% O -
. O +

Table O +
2 O +
presents O +
recoveries O +
for O +
analyses O +
carried O +
out O +
without O +
matrix O -
- O -
matching O -
. O +

These O +
include O +
measurements O +
for O +
the O +
above O +
crops O +
fortified O +
only O +
at O +
1 O +
mg O -
/ O -
kg O +
in O +
addition O +
to O +
data O +
for O +
the O +
other O +
crops O +
included O +
in O +
the O +
study O -
. O +

The O +
range O +
of O +
RSD O +
values O +
for O +
within O -
- O -
batch O +
analyses O +
is O +
comparable O +
to O +
that O +
obtained O +
for O +
the O +
equivalent O +
matrix O -
- O -
matched O +
determinations O -
. O +

However O -
, O +
recoveries O +
for O +
individual O +
samples O +
are O +
sometimes O +
high O -
, O +
reaching O +
a O +
maximum O +
of O +
119 O -
% O +
compared O +
to O +
102 O -
% O +
when O +
matrix O -
- O -
matched O +
standards O +
are O +
used O -
. O +

Where O +
a O +
direct O +
comparison O +
can O +
be O +
made O +
( O -
for O +
six O +
crops O +
fortified O +
at O +
1 O +
mg O -
/ O -
kg O -
) O -
, O +
it O +
can O +
be O +
seen O +
that O +
an O +
increased O +
recovery O +
is O +
sometimes O -
, O +
but O +
not O +
always O -
, O +
observed O +
when O +
standards O +
are O +
not O +
matrix O -
- O -
matched O -
. O +

Internal O +
reproducibility O +
is O +
indicated O +
by O +
the O +
RSD O +
values O +
for O +
the O +
mean O +
recoveries O +
for O +
each O +
crop O +
in O +
Table O +
2 O +
. O +

These O +
range O +
from O +
4 O +
to O +
12 O -
% O -
, O +
with O +
all O +
except O +
one O +
value O +
below O +
10 O -
% O -
. O +

With O +
the O +
procedures O +
described O +
above O -
, O +
values O +
for O +
the O +
LOD O +
and O +
LOQ O +
of O +
the O +
method O +
were O +
0.001 O +
mg O -
/ O -
kg O +
and O +
0.004 O +
mg O -
/ O -
kg O -
, O +
respectively O -
. O +

The O +
lowest O +
calibrated O +
level O +
routinely O +
achieved O +
was O +
0.002 O +
μg O -
/ O -
ml O -
, O +
corresponding O +
to O +
a O +
concentration O +
in O +
the O +
crop O +
of O +
0.004 O +
mg O -
/ O -
kg O -
. O +

No O +
coextractives O +
from O +
the O +
crops O +
tested O +
were O +
found O +
to O +
interfere O +
with O +
the O +
quantification O +
of O +
chlozolinate O -
. O +

Fig. O +
2 O +
shows O +
chromatograms O +
of O +
( O -
A O -
) O +
a O +
typical O +
grape O +
control O +
sample O +
and O +
( O -
B O -
) O +
chlozolinate O +
standard O +
in O +
grape O +
extract O -
. O +

Of O +
the O +
50 O +
pesticides O +
routinely O +
sought O +
using O +
this O +
multiresidue O +
method O +
in O +
our O +
laboratory O -
, O +
those O +
giving O +
a O +
retention O +
time O +
within O +
0.2 O +
min O +
of O +
the O +
chlozolinate O +
peak O +
on O +
either O +
of O +
the O +
analytical O +
columns O +
used O +
are O +
given O +
in O +
Table O +
3 O +
. O +

Only O +
two O +
compounds O -
, O +
penconazole O +
and O +
heptachlor O +
epoxide O -
, O +
give O +
peaks O +
which O +
are O +
only O +
partially O +
resolved O +
from O +
that O +
of O +
chlozolinate O +
on O +
both O +
columns O -
. O +

Heptachlor O +
epoxide O +
is O +
a O +
superseded O +
compound O -
, O +
which O +
is O +
most O +
unlikely O +
to O +
occur O +
in O +
samples O +
monitored O +
for O +
chlozolinate O -
. O +

Although O +
the O +
partial O +
resolution O +
of O +
the O +
penconazole O +
and O +
chlozolinate O +
peaks O +
should O +
be O +
sufficient O +
to O +
prevent O +
confusion O +
of O +
the O +
two O +
compounds O -
, O +
the O +
identity O +
of O +
any O +
residue O +
would O +
be O +
better O +
confirmed O -
, O +
in O +
the O +
absence O +
of O +
GC O -
– O -
MS O +
capabilities O -
, O +
with O +
a O +
different O +
GC O +
column O -
. O +

For O +
example O -
, O +
with O +
an O +
Rtx-50 O +
column O +
( O -
50 O -
% O +
diphenyl–50 O -
% O +
dimethylpolysiloxane O +
stationary O +
phase O -
, O +
30 O +
m O -
× O -
0.250 O +
mm O +
I.D. O -
, O +
0.25 O +
μm O +
film O +
thickness O -
) O +
retention O +
times O +
are O +
22.68 O +
and O +
23.03 O +
min O +
for O +
chlozolinate O +
and O +
penconazole O -
, O +
respectively O -
. O +

Excellent O +
linearity O +
was O +
observed O +
over O +
a O +
wide O +
concentration O +
range O -
, O +
as O +
shown O +
in O +
Fig. O +
3A O +
. O +

The O +
detector O +
response O +
began O +
to O +
fall O +
off O +
only O +
above O +
5 O +
μg O -
/ O -
ml O -
. O +

Despite O +
the O +
regression O +
line O +
correlation O +
of O +
r O +
2 O +
= O -
1.000 O -
, O +
it O +
is O +
desirable O +
to O +
carry O +
out O +
quantification O +
with O +
a O +
calibration O +
curve O +
of O +
limited O +
range O +
because O +
of O +
very O +
slight O +
curvature O +
observed O +
when O +
concentrations O +
of O +
more O +
than O +
a O +
factor O +
of O +
ten O +
are O +
covered O -
. O +

This O +
is O +
particularly O +
important O +
for O +
low O +
concentrations O -
, O +
since O +
a O +
small O +
change O +
in O +
the O +
intercept O +
of O +
the O +
regression O +
line O +
may O +
have O +
a O +
relatively O +
large O +
effect O +
on O +
the O +
concentration O +
calculated O -
. O +

Fig. O +
3B O +
gives O +
the O +
regression O +
line O +
for O +
the O +
concentration O +
range O +
0.002 O +
to O +
0.02 O +
μg O -
/ O -
ml O +
for O +
comparison O +
with O +
that O +
for O +
the O +
full O +
concentration O +
range O -
. O +

The O +
results O +
obtained O +
for O +
the O +
study O +
of O +
the O +
stability O +
of O +
chlozolinate O +
in O +
the O +
extracts O +
of O +
grape O +
samples O +
with O +
incurred O +
residues O +
are O +
shown O +
in O +
Fig. O +
4 O +
. O +

There O +
is O +
no O +
indication O +
of O +
degradation O +
in O +
sample O +
extracts O +
stored O +
at O +
−20 O -
° O -
C O +
over O +
six O +
months O -
. O +

Similarly O -
, O +
no O +
instances O +
of O +
degradation O +
of O +
chlozolinate O +
in O +
calibration O +
solutions O +
were O +
observed O -
. O +

4 O +
Conclusions O +
The O +
multiresidue O +
method O +
tested O +
gives O +
good O +
accuracy O +
and O +
precision O +
for O +
the O +
analysis O +
of O +
chlozolinate O +
residues O +
in O +
all O +
the O +
crops O +
tested O -
. O +

In O +
addition O -
, O +
it O +
shows O +
good O +
sensitivity O +
and O +
specificity O +
and O +
the O +
sample O +
extracts O +
are O +
stable O +
under O +
the O +
conditions O +
required O +
for O +
GC O +
analysis O -
. O +

Although O +
the O +
effect O +
of O +
crop O +
enhancement O +
is O +
not O +
large O -
, O +
the O +
use O +
of O +
non O +
matrix O -
- O -
matched O +
calibration O +
standards O +
tends O +
to O +
lead O +
to O +
randomly O +
higher O +
recoveries O -
. O +

The O +
analytical O +
method O +
is O -
, O +
therefore O -
, O +
shown O +
to O +
be O +
suitable O +
for O +
the O +
monitoring O +
of O +
chlozolinate O +
residues O +
in O +
fruits O +
and O +
vegetables O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
the O +
National O +
Agricultural O +
Research O +
Foundation O +
( O -
N.AG.RE.F. O -
) O +
within O +
the O +
framework O +
of O +
the O +
" O -
DIMITRA O -
" O +
project O -
. O +

The O +
authors O +
are O +
grateful O +
to O +
Kalliopi O +
Kokkinaki O +
for O +
assistance O +
with O +
preparation O +
of O +
the O +
manuscript O -
. O +

Five O +
muscarinic B-Gene +
receptors I-Gene +
have O +
been O +
cloned O +
thus O +
far O +
( O -
for O +
a O +
recent O +
review O +
Wess O -
, O +
1996 O +
) O -
. O +

All O +
are O +
members O +
of O +
the O +
seven O -
- O -
transmembrane O +
G B-Gene -
- I-Gene -
protein I-Gene +
coupled I-Gene +
receptor I-Gene +
family O +
with O +
the O +
muscarinic B-Gene +
M1 B-Gene +
, O +
M3 B-Gene +
and O +
M5 B-Gene +
sub O -
- O -
types O +
linked O +
to O +
Gq B-Gene -
/ I-Gene -
11 I-Gene +
proteins I-Gene +
and O +
the O +
production O +
of O +
inositides O -
, O +
whereas O +
the O +
muscarinic B-Gene +
M2 B-Gene +
and O +
M4 B-Gene +
receptors I-Gene +
are O +
associated O +
with O +
the O +
Gi B-Gene +
proteins I-Gene +
and O +
adenylate B-Gene +
cyclase I-Gene +
activity O -
. O +

Most O +
of O +
these O +
receptors B-Gene +
are O +
widely O +
expressed O +
throughout O +
the O +
body O +
including O +
the O +
brain O -
. O +

However O -
, O +
their O +
respective O +
physiological O +
roles O +
remain O +
to O +
be O +
fully O +
established O -
, O +
primarily O +
because O +
of O +
the O +
limited O +
availability O +
of O +
truly O +
receptor B-Gene +
sub O -
- O -
type O +
selective O +
agonists O +
and O +
antagonists O -
. O +

Among O +
the O +
putative O +
roles O +
of O +
the O +
muscarinic B-Gene +
receptor I-Gene +
sub O -
- O -
groups O -
, O +
an O +
action O +
as O +
inhibitory O +
autoreceptors B-Gene +
regulating O +
the O +
release O +
of O +
acetylcholine O +
has O +
been O +
suggested O +
on O +
the O +
basis O +
of O +
anatomical O +
( O -
Levey O +
et O +
al. O -
, O +
1995 O -
) O +
, O +
pharmacological O +
( O -
Raiteri O +
et O +
al. O -
, O +
1984 O -
; O +
Quirion O +
et O +
al. O -
, O +
1995 O -
) O +
and O +
behavioral O +
( O -
Quirion O +
et O +
al. O -
, O +
1995 O -
) O +
data O -
. O +

However O -
, O +
it O +
is O +
not O +
clear O +
if O +
these O +
autoreceptors B-Gene +
are O +
of O +
the O +
muscarinic B-Gene +
M2 B-Gene +
( O -
Raiteri O +
et O +
al. O -
, O +
1984 O -
; O +
Quirion O +
et O +
al. O -
, O +
1995 O -
) O +
or O +
M4 B-Gene +
( O -
McKinney O +
et O +
al. O -
, O +
1993 O -
) O +
sub O -
- O -
type O +
because O +
of O +
the O +
lack O +
of O +
selective O +
antagonists O +
to O +
distinguish O +
between O +
these O +
two O +
related O +
receptor B-Gene +
sub O -
- O -
types O -
. O +

For O +
example O -
, O +
it O +
has O +
been O +
shown O +
that O +
BIBN-99 O -
, O +
a O +
muscarinic B-Gene +
M2 I-Gene +
receptor I-Gene +
antagonist O +
unable O +
to O +
fully O +
distinguish O +
between O +
muscarinic B-Gene +
M2 B-Gene +
and O +
M4 B-Gene +
receptors I-Gene -
, I-Gene +
is O +
capable O +
of O +
potently O +
reversing O +
cognitive O +
deficits O +
in O +
aged O +
memory O +
impaired O +
rats O +
( O -
Quirion O +
et O +
al. O -
, O +
1995 O -
) O +
. O +

This O +
information O +
suggests O +
the O +
possibility O +
of O +
targeting O +
muscarinic O +
M2 O +
receptors O +
as O +
a O +
means O +
of O +
alleviating O +
learning O +
deficits O -
. O +

It O +
is O +
thus O +
of O +
major O +
importance O +
to O +
clearly O +
establish O +
the O +
identity O +
of O +
the O +
muscarinic B-Gene +
receptor I-Gene +
sub O -
- O -
type O +
on O +
which O +
such O +
antagonists O +
are O +
likely O +
to O +
act O -
, O +
in O +
order O +
to O +
facilitate O +
acetylcholine O +
release O +
and O +
be O +
of O +
potential O +
clinical O +
relevance O +
in O +
diseases O +
associated O +
with O +
altered O +
cognition O -
. O +

Recently O -
, O +
PD102807 O +
has O +
been O +
developed O +
as O +
one O +
of O +
the O +
very O +
first O +
selective O +
muscarinic B-Gene +
M4 I-Gene +
receptor I-Gene +
antagonists O +
( O -
Nelson O +
et O +
al O -
, O +
1996 O -
) O +
. O +

In O +
the O +
present O +
study O -
, O +
we O +
used O +
this O +
molecule O +
in O +
addition O +
to O +
the O +
purported O +
muscarinic B-Gene +
M2 I-Gene +
receptor I-Gene +
antagonists O +
AF O -
- O -
DX O +
384 O +
and O +
BIBN-161 O +
( O -
Doods O +
et O +
al. O -
, O +
1993 O -
) O +
to O +
further O +
investigate O +
the O +
exact O +
nature O +
of O +
the O +
autoreceptor B-Gene +
sub O -
- O -
type O -
( O -
s O -
) O +
regulating O +
acetylcholine O +
release O +
in O +
the O +
rat O +
hippocampus O -
, O +
as O +
assessed O +
by O +
in O +
vivo O +
dialysis O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Animals O +
and O +
drugs O +
Male O +
Sprague O -
– O -
Dawley O +
rats O +
( O -
270–300 O +
g O -
) O +
were O +
purchased O +
from O +
Charles O +
River O +
Canada O +
( O -
St. O +
Constant O -
, O +
Quebec O -
) O -
. O +

Animals O +
were O +
kept O +
in O +
a O +
temperature- O +
( O -
22–24 O -
° O -
C O -
) O -
, O +
humidity O +
( O -
55±5 O -
% O -
) O +
and O +
light- O +
( O -
12 O +
h O +
light O -
– O -
dark O +
cycle O -
, O +
lights O +
on O +
at O +
07:00 O -
) O +
regulated O +
room O +
with O +
food O +
and O +
water O +
available O +
ad O +
libitum O +
for O +
at O +
least O +
3 O +
days O +
before O +
surgery O -
. O +

The O +
procedures O +
involving O +
animals O +
and O +
their O +
care O +
were O +
conducted O +
in O +
accordance O +
with O +
the O +
McGill O +
University O +
Animal O +
Care O +
Committee O +
and O +
the O +
Canadian O +
Council O +
on O +
Animal O +
Care O -
. O +

BIBN-161 O +
and O +
AF O -
- O -
DX O +
384 O +
were O +
obtained O +
from O +
Dr. O +
H. O +
Doods O -
, O +
Boehringer O +
Ingelheim O -
, O +
Germany O -
, O +
while O +
PD102807 O +
was O +
obtained O +
from O +
Dr. O +
R. O +
Schwarz O -
, O +
Parke O -
- O -
Davis O -
, O +
USA O -
. O +

AF O -
- O -
DX O +
384 O +
was O +
dissolved O +
in O +
water O -
, O +
whereas O +
BIBN-161 O +
and O +
PD102807 O +
were O +
dissolved O +
in O +
0.1 O +
N O +
HCl O +
and O +
brought O +
to O +
pH O +
5–6 O +
with O +
0.1 O +
N O +
NaOH O -
. O +

These O +
stock O +
solutions O +
were O +
then O +
diluted O +
appropriately O +
in O +
the O +
buffered O +
perfusate O +
( O -
see O +
below O -
) O -
. O +

2.2 O +
Surgery O +
and O +
in O +
vivo O +
dialysis O +
Animals O +
were O +
anesthetized O +
by O +
intramuscular O +
injection O +
of O +
acepromazine O +
( O -
0.5 O +
mg O -
/ O -
kg O -
, O +
Ayerst O +
Laboratories O -
, O +
Montreal O -
, O +
Quebec O -
) O -
, O +
xylazine O +
( O -
5 O +
mg O -
/ O -
kg O -
, O +
Miles O +
Canada O -
, O +
Etobicoke O -
, O +
Ontario O -
) O +
and O +
ketamine O +
( O -
50 O +
mg O -
/ O -
kg O -
, O +
MTC O +
Pharmaceuticals O -
, O +
Cambridge O -
, O +
Ontario O -
) O -
. O +

Transverse O +
probes O +
( O -
AN69 O +
hollow O +
fibers O -
, O +
molecular O +
weight O +
cut O +
off O +
< O -
60,000 O -
, O +
i.d.=220 O +
μm O -
, O +
o.d.=310 O +
μm O -
, O +
Hospal O -
- O -
Gambro O -
, O +
St O -
- O -
Leonard O -
, O +
Quebec O -
) O +
were O +
placed O +
in O +
the O +
dorsal O +
hippocampus O +
( O -
3.8 O +
mm O +
posterior O +
to O +
bregma O -
; O +
3.5 O +
mm O +
ventral O +
to O +
the O +
surface O +
of O +
the O +
skull O -
) O -
, O +
according O +
to O +
coordinates O +
obtained O +
from O +
the O +
atlas O +
of O +
Paxinos O +
and O +
Watson O +
( O -
1987 O -
) O +
. O +

Two O +
days O +
after O +
surgery O -
, O +
in O +
vivo O +
dialysis O +
was O +
performed O +
to O +
monitor O +
acetylcholine O +
release O -
, O +
as O +
described O +
in O +
detail O +
elsewhere O +
with O +
minor O +
modifications O +
( O -
Kitaichi O +
et O +
al. O -
, O +
1999 O -
) O +
. O +

Briefly O -
, O +
probes O +
were O +
perfused O +
at O +
a O +
flow O +
rate O +
of O +
2.34 O +
μl O -
/ O -
min O +
with O +
a O +
perfusate O +
containing O -
: O +
NaCl O +
( O -
125 O +
mM O -
) O -
, O +
KCl O +
( O -
3 O +
mM O -
) O -
, O +
CaCl2 O +
( O -
1.3 O +
mM O -
) O -
, O +
MgCl2 O +
( O -
1.0 O +
mM O -
) O -
, O +
NaHCO3 O +
( O -
23 O +
mM O -
) O +
in O +
aqueous O +
phosphate O +
buffer O +
( O -
1 O +
mM O -
, O +
pH O +
7.3 O -
) O -
, O +
100 O +
nM O +
neostigmine O +
( O -
RBI O -
, O +
Watick O -
, O +
MA O -
) O +
was O +
included O +
to O +
prevent O +
the O +
degradation O +
of O +
acetylcholine O -
. O +

After O +
a O +
1 O +
h O +
equilibration O +
period O -
, O +
dialysates O +
were O +
collected O +
every O +
10 O +
min O -
. O +

Immediately O +
after O +
basal O +
acetylcholine O +
release O +
stabilized O -
, O +
perfusate O +
containing O +
different O +
concentrations O +
of O +
AF O -
- O -
DX O +
384 O -
, O +
BIBN-161 O +
or O +
PD102807 O +
was O +
perfused O +
through O +
the O +
probes O +
until O +
the O +
end O +
of O +
the O +
experiment O -
. O +

The O +
precise O +
location O +
of O +
the O +
probes O +
was O +
verified O +
by O +
standard O +
histological O +
examination O -
. O +

2.3 O +
High O +
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
analysis O +
of O +
acetylcholine O +
The O +
concentration O +
of O +
acetylcholine O +
in O +
dialysates O +
was O +
measured O +
on O -
- O -
line O +
using O +
HPLC O +
coupled O +
with O +
post O -
- O -
column O +
enzymatic O +
reaction O +
and O +
electrochemical O +
detection O -
, O +
as O +
described O +
elsewhere O +
( O -
Day O +
et O +
al. O -
, O +
1998 O -
) O +
. O +

Acetylcholine O +
release O +
was O +
expressed O +
as O +
a O +
percentage O +
of O +
each O +
animal O +
individual O +
baseline O +
release O +
value O +
( O -
the O +
average O +
amount O +
of O +
acetylcholine O +
in O +
six O +
samples O +
collected O +
immediately O +
preceding O +
drug O +
treatment O -
) O -
. O +

All O +
data O +
are O +
expressed O +
as O +
mean±S.E.M. O +
3 O +
Results O +
As O +
shown O +
in O +
Fig. O +
1A O +
and O +
Table O +
1 O +
, O +
the O +
two O +
muscarinic B-Gene +
M2 I-Gene +
receptor I-Gene +
antagonists O +
AF O -
- O -
DX O +
384 O +
and O +
BIBN-161 O +
facilitated O +
acetylcholine O +
release O +
in O +
the O +
rat O +
hippocampus O +
in O +
a O +
concentration O +
dependent O +
manner O -
. O +

Both O +
drugs O +
yielded O +
a O +
significant O +
effect O +
at O +
100 O +
nM O +
( O -
Table O +
1 O -
) O +
but O +
AF O -
- O -
DX384 O +
was O +
slightly O +
more O +
potent O +
than O +
BIBN-161 O -
, O +
as O +
shown O +
in O +
Fig. O +
1C O +
. O +

Both O +
AF O -
- O -
DX O +
384 O +
( O -
10 O +
μM O -
) O +
and O +
BIBN-161 O +
( O -
50 O +
μM O -
) O +
were O +
able O +
to O +
potently O +
stimulate O +
acetylcholine O +
release O -
, O +
with O +
5–6 O +
fold O +
increments O +
in O +
release O +
seen O +
at O +
these O +
concentrations O -
. O +

In O +
contrast O -
, O +
the O +
purported O +
muscarinic B-Gene +
M4 I-Gene +
receptor I-Gene +
antagonist O +
PD102807 O +
was O +
unable O +
to O +
modulate O +
release O +
at O +
concentrations O +
lower O +
than O +
50 O +
μM O -
, O +
with O +
only O +
minimal O +
effects O +
( O -
1.6–1.7-fold O +
over O +
baseline O -
) O +
being O +
observed O +
at O +
very O +
high O +
concentrations O +
( O -
Fig. O +
1B O +
, O +
Table O +
1 O +
) O -
. O +

The O +
lack O +
of O +
significant O +
effects O +
of O +
PD102807 O +
on O +
hippocampal O +
acetylcholine O +
release O +
is O +
also O +
evident O +
in O +
the O +
graphed O +
representation O +
of O +
the O +
regression O +
analysis O +
performed O +
for O +
the O +
three O +
antagonists O +
tested O +
here O +
( O -
Fig. O +
1C O -
) O +
. O +

4 O +
Discussion O +
In O +
vivo O +
acetylcholine O +
release O +
in O +
the O +
adult O +
rat O +
hippocampus O +
was O +
clearly O +
stimulated O -
, O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O -
, O +
by O +
AF O -
- O -
DX384 O -
> O -
BIBN-161⋙PD102807 O -
. O +

The O +
first O +
two O +
molecules O +
have O +
higher O +
or O +
equal O +
affinities O +
for O +
the O +
cloned O +
muscarinic B-Gene +
M2 B-Gene +
than O +
the O +
M4 B-Gene +
receptor I-Gene +
sub O -
- O -
types O +
while O +
the O +
reverse O +
is O +
true O +
for O +
the O +
newly O +
developed O +
muscarinic B-Gene +
M4 I-Gene +
receptor I-Gene +
antagonist O +
PD102807 O +
( O -
Doods O +
et O +
al. O -
, O +
1993 O -
; O +
Nelson O +
et O +
al. O -
, O +
1996 O -
) O +
. O +

In O +
fact O -
, O +
the O +
apparent O +
IC50 O +
( O -
nM O -
) O +
values O +
of O +
AF O -
- O -
DX384 O +
are O +
325 O -
, O +
16 O -
, O +
150 O -
, O +
10 O -
, O +
and O +
1860 O +
for O +
the O +
M1 B-Gene +
, O +
M2 B-Gene +
, O +
M3 B-Gene +
, O +
M4 B-Gene +
and O +
M5 B-Gene +
sub O -
- O -
type O -
, O +
respectively O -
, O +
and O +
285 O -
, O +
15 O -
, O +
360 O -
, O +
52 O -
, O +
and O +
220 O +
for O +
BIBN-161 O -
. O +

In O +
contrast O -
, O +
PD102807 O +
has O +
its O +
highest O +
affinity O +
for O +
the O +
muscarinic B-Gene +
M4 I-Gene +
receptor I-Gene +
with O +
IC50 O +
( O -
nM O -
) O +
values O +
of O +
6600 O -
, O +
3400 O -
, O +
950 O -
, O +
90 O -
, O +
and O +
7400 O +
for O +
the O +
transfected O +
human O +
muscarinic B-Gene +
M1 B-Gene +
to O +
M5 B-Gene +
sub O -
- O -
types O +
( O -
Nelson O +
et O +
al. O -
, O +
1996 O -
) O +
. O +

Taken O +
together O -
, O +
those O +
data O +
support O +
the O +
hypothesis O +
that O +
the O +
muscarinic B-Gene +
receptor I-Gene +
regulating O +
acetylcholine O +
release O +
is O +
of O +
the O +
M2 B-Gene +
and O +
not O +
the O +
M4 B-Gene +
sub O -
- O -
type O -
, O +
at O +
least O +
in O +
the O +
rat O +
hippocampus O -
. O +

Earlier O +
anatomical O +
( O -
Levey O +
et O +
al. O -
, O +
1995 O -
) O +
and O +
functional O +
( O -
Raiteri O +
et O +
al. O -
, O +
1984 O -
; O +
Quirion O +
et O +
al. O -
, O +
1995 O -
) O +
data O +
also O +
suggested O +
the O +
preferential O +
role O +
of O +
the O +
muscarinic B-Gene +
M2 I-Gene +
receptor I-Gene +
as O +
a O +
negative O +
autoreceptor B-Gene +
regulating O +
acetylcholine O +
release O -
. O +

However O -
, O +
another O +
study O +
proposed O +
that O +
the O +
M4 B-Gene +
sub O -
- O -
type O +
was O +
in O +
fact O +
acting O +
as O +
the O +
autoreceptor B-Gene +
( O -
McKinney O +
et O +
al. O -
, O +
1993 O -
) O +
. O +

The O +
lack O +
of O +
adequately O +
selective O +
tools O +
to O +
distinguish O +
between O +
muscarinic B-Gene +
M2 B-Gene +
and O +
M4 B-Gene +
receptors I-Gene +
likely O +
explains O +
this O +
apparent O +
discrepancy O -
. O +

Recently O -
, O +
we O +
obtained O +
molecular O +
evidence O +
of O +
the O +
role O +
of O +
muscarinic B-Gene +
M2 I-Gene +
receptors I-Gene +
in O +
the O +
regulation O +
of O +
acetylcholine O +
release O +
( O -
Kitaichi O +
et O +
al. O -
, O +
1999 O -
) O +
. O +

Using O +
an O +
antisense O +
approach O +
combined O +
with O +
in O +
vivo O +
dialysis O -
, O +
we O +
have O +
shown O +
that O +
a O +
treatment O +
with O +
antisense O +
directed O +
against O +
the O +
muscarinic B-Gene +
M2 I-Gene +
receptor I-Gene +
blocked O +
the O +
ability O +
of O +
antagonists O +
such O +
as O +
AF O -
- O -
DX O +
384 O +
to O +
facilitate O +
acetylcholine O +
release O -
, O +
whereas O +
treatment O +
with O +
a O +
specific O +
muscarinic B-Gene +
M4 I-Gene +
receptor I-Gene +
antisense O +
( O -
or O +
missense O +
oligodeoxynucleotides O -
) O +
failed O +
to O +
alter O +
AF O -
- O -
DX O +
384 O -
's O +
ability O +
to O +
modulate O +
acetylcholine O +
release O +
in O +
the O +
rat O +
hippocampus O -
. O +

Hence O -
, O +
the O +
data O +
reported O +
in O +
the O +
present O +
study O +
are O +
in O +
agreement O +
with O +
those O +
obtained O +
using O +
a O +
molecular O +
approach O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
an O +
M.R.C. O +
of O +
Canada O +
grant O +
to O +
R. O +
Quirion O -
, O +
a O +
chercheur O -
- O -
boursier O +
of O +
the O +
F.R.S.Q. O +
J. O +
Day O +
holds O +
a O +
fellowship O +
award O +
from O +
the O +
M.R.C.C. O +
K. O +
Kitaichi O +
is O +
now O +
at O +
the O +
Department O +
of O +
Medical O +
Technology O -
, O +
Nagoya O +
University O +
School O +
of O +
Health O +
Sciences O -
, O +
Nagoya O -
, O +
Japan O -
. O +

Gangliosides O +
are O +
distributed O +
mainly O +
on O +
the O +
outer O +
surface O +
of O +
cell O +
membranes O +
and O +
play O +
important O +
roles O +
in O +
various O +
cellular O +
functions O +
including O +
adhesion O -
, O +
growth O -
, O +
differentiation O -
, O +
and O +
signal O +
transduction O +
[ O -
1–3 O -
] O +
. O +

C O -
- O -
series O +
gangliosides O +
are O +
characterized O +
by O +
the O +
presence O +
of O +
a O +
trisialosyl O +
residue O +
at O +
the O +
inner O +
galactose O +
of O +
the O +
hemato- O +
or O +
ganglio O -
- O -
oligosaccharide O +
structure O +
[ O -
4 O -
] O +
. O +

This O +
ganglioside O +
species O +
is O +
present O +
in O +
adult O +
fish O +
brain O +
of O +
certain O +
species O +
in O +
high O +
concentrations O +
[ O -
5 O -
] O +
. O +

In O +
avian O +
and O +
mammalian O +
brain O -
, O +
though O +
c O -
- O -
series O +
gangliosides O +
and O +
their O +
O O +
-acetyl O +
derivatives O +
are O +
temporarily O +
expressed O +
at O +
embryonic O +
stages O -
, O +
they O +
are O +
hardly O +
detected O +
at O +
adult O +
ages O +
[ O -
6–9 O -
] O +
. O +

Evidence O +
has O +
been O +
provided O +
suggesting O +
that O +
they O +
may O +
be O +
involved O +
in O +
growth O -
, O +
differentiation O +
and O +
migration O +
of O +
neuronal O +
cells O +
[ O -
10–12 O -
] O +
. O +

C O -
- O -
series O +
gangliosides O +
have O +
also O +
been O +
detected O +
in O +
tissues O +
and O +
cells O +
of O +
extra O -
- O -
neural O +
origin O -
, O +
including O +
swine O +
kidney O +
[ O -
13 O -
] O +
, O +
human O +
lung O +
[ O -
14 O -
] O +
, O +
bovine O +
buttermilk O +
[ O -
15 O -
] O +
, O +
cat O +
erythrocytes O +
[ O -
16 O -
] O +
, O +
pancreatic O +
islet O +
cells O +
[ O -
17 O -
] O +
, O +
and O +
different O +
types O +
of O +
cancer O +
cells O +
[ O -
18–20 O -
] O +
. O +

Expression O +
of O +
c O -
- O -
series O +
gangliosides O +
may O +
be O +
cell O -
- O -
specific O -
. O +

Our O +
recent O +
study O +
suggested O +
their O +
specific O +
localization O +
in O +
pancreatic O +
B O +
cells O +
among O +
islet O +
and O +
non O -
- O -
islet O +
cells O +
of O +
rat O +
pancreatic O +
tissue O +
[ O -
21 O -
] O +
. O +

Information O -
, O +
however O -
, O +
is O +
still O +
limited O +
about O +
the O +
distribution O +
and O +
function O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
extra O -
- O -
neural O +
tissues O +
and O +
cell O +
types O -
. O +

Iber O +
et O +
al. O +
[ O -
22 O -
] O +
investigated O +
sialyltransferase B-Gene +
activities O +
in O +
Golgi O +
preparations O +
from O +
rat O +
liver O +
and O +
reported O +
that O +
c O -
- O -
series O +
gangliosides O +
are O +
formed O +
by O +
the O +
same O +
set O +
of O +
glycosyltransferases B-Gene +
catalyzing O +
the O +
biosynthesis O +
of O +
asialo- O -
, O +
a- O +
and O +
b O -
- O -
series O +
gangliosides O -
. O +

This O +
finding O +
led O +
to O +
an O +
assumption O +
that O +
c O -
- O -
series O +
gangliosides O +
are O +
expressed O +
in O +
hepatocytes O +
and O +
carry O +
a O +
function O -
( O -
s O -
) O +
in O +
the O +
cells O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
examined O +
c O -
- O -
series O +
gangliosides O +
in O +
rat O +
hepatocytes O +
in O +
primary O +
culture O +
and O +
liver O +
tissues O +
from O +
rats O +
of O +
various O +
ages O +
using O +
a O +
specific O +
monoclonal B-Gene +
antibody I-Gene -
, O +
A2B5 B-Gene -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
purchased O +
from O +
a O +
commercial O +
breeder O -
. O +

An O +
A2B5-producing B-Gene +
hybridoma O +
CRL O +
1520 O +
was O +
obtained O +
from O +
American O +
Type O +
Culture O +
Collection O +
( O -
ATCC O -
, O +
USA O -
) O +
and O +
cultured O +
in O +
Dulbecco O -
's O +
modified O +
Eagle O -
's O +
medium O +
containing O +
10 O -
% O +
fetal O +
bovine O +
serum O +
( O -
FBS O -
, O +
Sigma O -
) O -
. O +

Culture O +
medium O +
containing O +
the O +
monoclonal B-Gene +
antibody I-Gene +
A2B5 B-Gene +
( O -
IgM B-Gene -
- O -
type O -
) O +
was O +
used O +
for O +
this O +
study O -
. O +

Another O +
monoclonal B-Gene +
antibody I-Gene -
, O +
D1.1 B-Gene +
( O -
IgG3-type B-Gene -
) O -
, O +
which O +
specifically O +
recognizes O +
9-O O +
-acetyl O +
GD3 O -
, O +
was O +
a O +
kind O +
gift O +
of O +
Dr. O +
Robert O +
K. O +
Yu O +
( O -
Virginia O +
Commonwealth O +
University O -
, O +
Richmond O -
, O +
VA O -
, O +
USA O -
) O -
. O +

An O +
antibody B-Gene +
against O +
GM1 O +
or O +
asialo O -
- O -
GM1 O +
( O -
IgG B-Gene -
- O -
type O +
for O +
both O -
) O +
was O +
prepared O +
by O +
immunizing O +
rabbits O +
with O +
purified O +
glycolipid O +
by O +
a O +
method O +
reported O +
previously O +
[ O -
23 O -
] O +
. O +

Other O +
chemicals O +
were O +
purchased O +
from O +
the O +
following O +
companies O -
: O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
( O -
EGF B-Gene -
) O -
, O +
fluorescein B-Gene +
isothiocyanate I-Gene +
( O -
FITC B-Gene -
) O -
- O +
or O +
peroxidase B-Gene -
- B-Gene -
conjugated I-Gene +
antibodies I-Gene +
against O +
mouse O +
IgM B-Gene +
or O +
rabbit O +
IgG B-Gene -
, O +
and O +
Arthrobacter O +
ureafaciens O +
sialidase B-Gene +
( O -
Sigma O -
) O -
, O +
Block O -
- O -
Ace O +
( O -
blocking O +
solution O -
, O +
Dainihon O -
- O -
Seiyaku O +
Co. O -
, O +
Japan O -
) O -
, O +
enhanced O +
chemiluminescence O +
( O -
ECL O -
) O +
Western O +
blotting O +
detection O +
kit O +
( O -
Amersham O -
) O -
, O +
cell O +
proliferation O +
MTT O +
and O +
ELISA O +
bromodeoxyuridine O +
( O -
BrdU O -
) O +
kits O +
( O -
Boehringer O -
- O -
Mannheim O -
) O -
, O +
thin O -
- O -
layer O +
chromatographic O +
( O -
TLC O -
) O +
plates O +
( O -
nanoplates O -
, O +
E. O +
Merck O -
) O -
, O +
and O +
purified O +
GD3 O +
and O +
bovine O +
brain O +
ganglioside O +
mixture O +
( O -
Matreya O -
, O +
USA O -
) O -
. O +

2.2 O +
Primary O +
culture O +
of O +
rat O +
hepatocytes O +
Hepatocytes O +
were O +
isolated O +
from O +
7-week O -
- O -
old O +
rat O +
liver O +
using O +
a O +
perfusion O +
method O +
reported O +
by O +
Seglen O +
[ O -
24 O -
] O +
. O +

The O +
purity O +
of O +
isolated O +
parenchymal O +
hepatocytes O +
was O +
judged O +
to O +
be O +
more O +
than O +
98 O -
% O +
under O +
microscopy O -
. O +

The O +
isolated O +
cells O +
were O +
suspended O +
in O +
L-15 O +
medium O -
, O +
seeded O +
in O +
collagen O -
- O -
coated O +
culture O +
dishes O -
, O +
and O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
24 O +
h O +
under O +
1 O -
% O +
CO2 O +
-99 O -
% O +
air O -
. O +

After O +
replacing O +
the O +
medium O +
with O +
media O +
containing O +
10 O -
% O +
FBS O -
, O +
10 O +
μg O -
/ O -
ml O +
of O +
insulin B-Gene -
, O +
10 O +
μM O +
dexamethasone O -
, O +
and O +
20 O +
ng O -
/ O -
ml O +
of O +
EGF B-Gene -
, O +
the O +
cells O +
were O +
cultured O +
for O +
5 O +
days O +
( O -
day O +
0 O +
to O +
day O +
5 O -
) O -
. O +

Practically O +
no O +
growth O +
of O +
non O -
- O -
parenchymal O +
cells O +
was O +
observed O +
throughout O +
culture O -
. O +

For O +
assessment O +
of O +
hepatocyte O +
proliferation O +
rates O -
, O +
either O +
the O +
MTT O +
or O +
the O +
BrdU O +
incorporation O +
assay O +
could O +
be O +
used O -
, O +
providing O +
comparable O +
proliferation O +
curves O +
( O -
data O +
not O +
shown O -
) O -
. O +

An O +
MTT O +
assay O +
was O +
used O +
in O +
the O +
present O +
study O -
. O +

2.3 O +
Immunofluorescence O +
of O +
cultured O +
hepatocytes O +
Primary O +
cultures O +
of O +
rat O +
hepatocytes O +
on O +
day O +
5 O +
were O +
fixed O +
with O +
4 O -
% O +
paraformaldehyde O -
, O +
followed O +
by O +
incubation O +
with O +
a O +
blocking O +
solution O +
( O -
Block O -
- O -
Ace O -
) O +
at O +
37 O -
° O -
C O +
for O +
1.5 O +
h. O +
The O +
fixed O +
cells O +
were O +
incubated O +
consecutively O +
with O +
an O +
anti B-Gene -
- I-Gene -
ganglioside I-Gene +
antibody I-Gene +
and O +
FITC B-Gene -
- I-Gene -
conjugated I-Gene +
second O +
antibody B-Gene +
at O +
37 O -
° O -
C O +
for O +
1.5 O +
h O -
, O +
followed O +
by O +
examination O +
under O +
fluorescence O +
microscopy O -
. O +

For O +
control O -
, O +
the O +
primary O +
antibody B-Gene +
was O +
replaced O +
by O +
diluted O +
culture O +
medium O +
( O -
for O +
A2B5 B-Gene +
or O +
D1.1 B-Gene -
) O +
or O +
preimmune O +
serum O +
( O -
for O +
anti B-Gene -
- I-Gene -
GM1 I-Gene +
antibody I-Gene -
) O -
. O +

2.4 O +
Isolation O +
of O +
gangliosides O +
Total O +
lipids O +
were O +
extracted O +
from O +
cultured O +
cells O +
or O +
liver O +
tissues O +
with O +
chloroform O -
/ O -
methanol O +
( O -
1:1 O -
) O +
and O +
separated O +
into O +
neutral O +
and O +
acidic O +
lipids O +
by O +
DEAE O -
- O -
Sephadex O +
column O +
chromatography O -
. O +

Acidic O +
lipids O +
were O +
treated O +
with O +
methanolic O +
0.2 O +
M O +
NaOH O +
at O +
37 O -
° O -
C O +
for O +
1 O +
h O -
, O +
followed O +
by O +
neutralization O +
with O +
acetic O +
acid O -
. O +

Purified O +
gangliosides O +
were O +
obtained O +
by O +
desalting O +
the O +
neutralized O +
sample O +
by O +
Sephadex O +
LH-20 O +
column O +
chromatography O -
. O +

Chicken O +
brain O +
gangliosides O +
were O +
purified O +
from O +
13-day O -
- O -
old O +
embryos O +
by O +
a O +
similar O +
method O -
. O +

2.5 O +
TLC O +
immunostaining O +
of O +
gangliosides O +
TLC O +
immunostaining O +
was O +
carried O +
out O +
based O +
upon O +
a O +
method O +
reported O +
previously O +
[ O -
25 O -
] O +
. O +

Gangliosides O +
were O +
developed O +
on O +
a O +
TLC O +
plate O +
with O +
a O +
solvent O +
system O +
of O +
chloroform O -
/ O -
methanol O -
/ O -
0.2 O -
% O +
CaCl2 O +
· O -
2H2 O +
O O +
( O -
45:40:10 O -
) O -
. O +

After O +
coating O +
with O +
a O +
0.4 O -
% O +
polyisobutylmethacrylate O +
solution O -
, O +
the O +
plate O +
was O +
overlaid O +
consecutively O +
with O +
an O +
anti B-Gene -
- I-Gene -
ganglioside I-Gene +
antibody I-Gene +
and O +
peroxidase B-Gene -
- B-Gene -
conjugated I-Gene +
second O +
antibody B-Gene +
at O +
room O +
temperature O +
for O +
1.5 O +
h. O +
The O +
responsive O +
band O -
( O -
s O -
) O +
were O +
detected O +
on O +
X O -
- O -
ray O +
film O +
by O +
an O +
ECL O +
Western O +
blotting O +
detection O +
kit O -
. O +

Gangliosides O +
on O +
the O +
plate O +
were O +
visualized O +
with O +
resorcinol O -
- O -
HCl O +
reagent O +
[ O -
26 O -
] O +
. O +

2.6 O +
Detection O +
of O +
gangliosides O +
having O +
a O +
gangliotetraose O +
oligosaccharide O +
structure O +
Core O +
structures O +
of O +
oligosaccharides O +
of O +
gangliosides O +
were O +
analyzed O +
using O +
TLC O +
immunostaining O +
with O +
in O +
situ O +
hydrolysis O +
of O +
gangliosides O +
by O +
sialidase B-Gene +
[ O -
27 O -
] O +
. O +

In O +
brief O -
, O +
gangliosides O +
were O +
developed O +
on O +
TLC O +
and O +
treated O +
in O +
situ O +
with O +
A. O +
ureafaciens O +
sialidase B-Gene +
( O -
100 O +
mU O -
/ O -
ml O -
, O +
pH O +
4.8 O -
) O +
at O +
room O +
temperature O +
for O +
1.5 O +
h. O +
Asialo O -
- O -
GM1 O -
, O +
which O +
was O +
generated O +
from O +
gangliotetraose O +
ganglioside O +
species O -
, O +
was O +
detected O +
by O +
TLC O +
immunostaining O +
with O +
an O +
anti B-Gene -
- I-Gene -
asialo I-Gene -
- I-Gene -
GM1 I-Gene +
antibody I-Gene -
. O +

The O +
antibody B-Gene +
used O +
was O +
shown O +
to O +
have O +
strict O +
specificity O +
for O +
asialo O -
- O -
GM1 O +
with O +
no O +
cross O -
- O -
reactivity O +
with O +
any O +
bovine O +
brain O +
gangliosides O +
[ O -
27 O -
] O +
. O +

3 O +
Results O +
3.1 O +
Detection O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
rat O +
hepatocytes O +
in O +
culture O +
The O +
specificity O +
of O +
the O +
antibody B-Gene +
preparation O +
used O +
in O +
this O +
study O +
was O +
examined O +
first O +
by O +
TLC O +
immunostaining O +
with O +
ganglioside O +
preparations O +
from O +
embryonic O +
chicken O +
brain O +
and O +
bovine O +
brain O -
; O +
the O +
former O +
is O +
known O +
to O +
express O +
c O -
- O -
series O +
gangliosides O +
at O +
higher O +
concentrations O +
[ O -
7,9 O -
] O +
. O +

As O +
shown O +
in O +
Fig. O +
1A O +
, O +
the O +
antibody B-Gene +
did O +
not O +
react O +
with O +
a- O +
and O +
b O -
- O -
series O +
gangliosides O +
in O +
bovine O +
brain O +
gangliosides O +
( O -
lane O +
2 O -
) O -
, O +
but O +
selectively O +
immunostained O +
three O +
ganglioside O +
species O +
among O +
chicken O +
brain O +
gangliosides O +
( O -
lane O +
1 O -
) O -
. O +

Based O +
upon O +
their O +
mobilities O +
on O +
TLC O -
, O +
these O +
gangliosides O +
were O +
assigned O +
to O +
GT3 O -
, O +
GQ1c O -
, O +
and O +
GP1c O +
[ O -
5 O -
] O +
. O +

Using O +
this O +
A2B5 B-Gene +
preparation O +
and O +
other O +
anti B-Gene -
- I-Gene -
ganglioside I-Gene +
antibodies I-Gene -
, O +
primary O +
cultures O +
of O +
adult O +
rat O +
hepatocytes O +
on O +
day O +
5 O +
were O +
examined O +
by O +
an O +
immunofluorescence O +
method O -
. O +

Rat O +
hepatocytes O +
were O +
stained O +
positively O +
with O +
A2B5 B-Gene +
( O -
Fig. O +
2 O +
) O -
. O +

The O +
cells O +
were O +
also O +
immunostained O +
with O +
an O +
anti B-Gene -
- I-Gene -
GM1 I-Gene +
antibody I-Gene -
, O +
but O +
hardly O +
stained O +
with O +
D1.1 B-Gene -
, O +
which O +
is O +
specific O +
for O +
9-O O +
-acetyl O +
GD3 O -
. O +

To O +
confirm O +
the O +
presence O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
rat O +
hepatocytes O -
, O +
gangliosides O +
were O +
isolated O +
from O +
cells O +
and O +
examined O +
for O +
their O +
reactivity O +
to O +
A2B5 B-Gene -
. O +

Five O +
positive O +
bands O +
( O -
i.e. O -
, O +
bands O +
a O -
, O +
b O -
, O +
c O -
, O +
d O -
, O +
and O +
X O -
) O +
were O +
observed O +
with O +
TLC O +
immunostaining O +
with O +
A2B5 B-Gene +
( O -
Fig. O +
1B O +
, O +
lane O +
1 O -
) O -
. O +

Of O +
these O +
acidic O +
lipid O +
bands O -
, O +
bands O +
a O -
, O +
b O -
, O +
c O -
, O +
and O +
d O +
had O +
chromatographic O +
mobilities O +
that O +
corresponded O +
respectively O +
to O +
GT3 O -
, O +
GT1c O -
, O +
GQ1c O -
, O +
and O +
GP1c O +
[ O -
5 O -
] O +
. O +

Gangliosides O +
of O +
rat O +
hepatocytes O +
were O +
further O +
characterized O +
using O +
TLC O +
immunostaining O +
with O +
in O +
situ O +
treatment O +
by O +
sialidase B-Gene -
. O +

Gangliosides O +
having O +
the O +
gangliotetraose O +
( O -
i.e. O -
, O +
GgOse4 O +
) O +
structure O +
can O +
be O +
detected O +
by O +
this O +
method O +
[ O -
27 O -
] O +
. O +

As O +
shown O +
in O +
Fig. O +
3 O +
, O +
GM1 O -
, O +
GD1a O -
, O +
GD1b O -
, O +
GT1b O -
, O +
and O +
GQ1b O -
, O +
but O +
not O +
GD3 O -
, O +
were O +
stained O +
positively O -
, O +
confirming O +
the O +
validity O +
of O +
this O +
method O -
. O +

In O +
addition O -
, O +
three O +
minor O +
gangliosides O +
with O +
a O +
gangliotetraose O +
backbone O +
were O +
detected O +
below O +
GT1b O -
, O +
below O +
GQ1b O -
, O +
and O +
far O +
below O +
GQ1b O +
on O +
TLC O -
; O +
their O +
mobilities O +
were O +
identical O +
to O +
A2B5-positive B-Gene +
bands O +
b O -
, O +
c O -
, O +
and O +
d O -
, O +
respectively O -
. O +

The O +
anti B-Gene -
- I-Gene -
asialo I-Gene -
- I-Gene -
GM1 I-Gene +
antibody I-Gene +
did O +
not O +
stain O +
any O +
hepatocyte O +
gangliosides O +
without O +
in O +
situ O +
sialidase B-Gene +
treatment O +
( O -
data O +
not O +
shown O -
) O -
. O +

Based O +
upon O +
these O +
findings O -
, O +
A2B5-reactive B-Gene +
bands O +
a O -
, O +
b O -
, O +
c O -
, O +
and O +
d O +
were O +
respectively O +
identified O +
as O +
GT3 O -
, O +
GT1c O -
, O +
GQ1c O -
, O +
and O +
GP1c O -
. O +

In O +
addition O +
to O +
these O +
c O -
- O -
series O +
gangliosides O -
, O +
an O +
acidic O +
lipid O +
( O -
band O +
X O -
) O -
, O +
which O +
migrated O +
between O +
GD3 O +
and O +
GD1a O +
on O +
TLC O -
, O +
was O +
observed O +
on O +
TLC O +
immunostaining O +
with O +
A2B5 B-Gene -
. O +

Since O +
the O +
ganglioside O +
preparation O +
had O +
already O +
been O +
subjected O +
to O +
base O +
treatment O +
during O +
isolation O -
, O +
it O +
is O +
unlikely O +
that O +
band O +
X O +
is O +
alkali O -
- O -
labile O +
O O +
-acetyl O +
GT3 O -
, O +
which O +
migrates O +
near O +
GD3 O +
[ O -
28 O -
] O +
. O +

The O +
possibility O +
that O +
band O +
X O +
is O +
GD3 O +
was O +
also O +
ruled O +
out O +
by O +
the O +
lack O +
of O +
reactivity O +
of O +
A2B5 B-Gene +
to O +
authentic O +
GD3 O +
( O -
data O +
not O +
shown O -
) O -
. O +

While O +
band O +
X O +
remained O +
positive O +
on O +
TLC O +
immunostaining O +
by O +
further O +
treatment O +
of O +
the O +
ganglioside O +
preparation O +
with O +
a O +
mild O +
base O +
( O -
0.2 O +
M O +
methanolic O +
NaOH O -
, O +
37 O -
° O -
C O +
for O +
1 O +
h O -
) O -
, O +
it O +
was O +
not O +
detected O +
when O +
the O +
lipid O +
was O +
purified O +
by O +
preparative O +
TLC O +
and O +
subjected O +
to O +
the O +
same O +
treatment O +
( O -
data O +
not O +
shown O -
) O -
. O +

It O +
thus O +
was O +
suggested O +
that O +
band O +
X O +
may O +
be O +
a O +
non O -
- O -
ganglioside O +
acidic O +
lipid O -
. O +

3.2 O +
Effects O +
of O +
EGF B-Gene +
on O +
the O +
expression O +
of O +
c O -
- O -
series O +
gangliosides O +
The O +
effects O +
of O +
EGF B-Gene +
on O +
the O +
expression O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
cultured O +
hepatocytes O +
were O +
examined O -
. O +

In O +
the O +
presence O +
of O +
EGF B-Gene -
, O +
hepatocytes O +
proliferated O +
actively O +
up O +
to O +
day O +
3 O +
and O +
ceased O +
proliferation O +
( O -
Fig. O +
4A O +
) O -
. O +

While O +
the O +
total O +
amount O +
of O +
c O -
- O -
series O +
gangliosides O +
increased O +
throughout O +
the O +
period O +
of O +
culture O -
, O +
individual O +
ganglioside O +
species O +
showed O +
different O +
time O -
- O -
course O +
profiles O +
( O -
Fig. O +
5A O +
) O -
. O +

The O +
content O +
of O +
GT3 O +
rapidly O +
increased O +
up O +
to O +
day O +
3 O +
and O +
reached O +
a O +
plateau O -
, O +
showing O +
a O +
profile O +
similar O +
to O +
the O +
growth O +
pattern O +
of O +
the O +
cells O -
. O +

The O +
concentrations O +
of O +
polysialo O +
species O +
such O +
as O +
GT1c O -
, O +
GQ1c O -
, O +
and O +
GP1c O +
exhibited O +
only O +
moderate O +
changes O +
during O +
the O +
period O +
of O +
active O +
proliferation O +
( O -
i.e. O -
, O +
up O +
to O +
day O +
1 O -
) O -
, O +
but O +
rapidly O +
increased O +
as O +
the O +
cells O +
became O +
confluent O -
. O +

When O +
EGF B-Gene +
was O +
removed O +
from O +
the O +
culture O +
medium O -
, O +
rat O +
hepatocytes O +
proliferated O +
only O +
on O +
the O +
first O +
day O +
of O +
culture O +
( O -
Fig. O +
4A O +
) O -
. O +

While O +
the O +
expression O +
of O +
GT3 O +
was O +
reduced O +
significantly O -
, O +
the O +
amounts O +
of O +
polysialo O +
species O +
at O +
day O +
5 O +
were O +
almost O +
the O +
same O +
as O +
observed O +
with O +
EGF B-Gene +
( O -
Fig. O +
5B O +
) O -
. O +

3.3 O +
Effects O +
of O +
cell O +
density O +
on O +
the O +
expression O +
of O +
c O -
- O -
series O +
gangliosides O +
Expression O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
rat O +
hepatocytes O +
was O +
also O +
modulated O +
by O +
cell O +
density O +
in O +
culture O -
. O +

Growth O +
rates O +
decreased O +
as O +
cells O +
were O +
cultured O +
at O +
higher O +
density O +
( O -
Fig. O +
4B O +
) O -
. O +

While O +
the O +
expression O +
of O +
GT3 O +
was O +
less O +
influenced O +
by O +
changes O +
in O +
cell O +
density O -
, O +
the O +
contents O +
of O +
polysialo O +
species O +
such O +
as O +
GT1c O -
, O +
GQ1c O -
, O +
and O +
GP1c O +
significantly O +
increased O +
at O +
higher O +
cell O +
density O +
( O -
Fig. O +
6 O +
) O -
. O +

3.4 O +
Developmental O +
changes O +
in O +
the O +
composition O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
liver O +
tissues O +
C O -
- O -
series O +
gangliosides O +
in O +
liver O +
tissues O +
were O +
examined O +
using O +
rats O +
of O +
ages O +
ranging O +
from O +
16 O +
embryonic O +
days O +
( O -
E16 O -
) O +
to O +
7 O +
postnatal O +
weeks O -
. O +

As O +
shown O +
in O +
Fig. O +
7 O +
, O +
the O +
composition O +
of O +
c O -
- O -
series O +
gangliosides O +
demonstrated O +
a O +
unique O +
developmental O +
pattern O -
. O +

While O +
GT3 O +
were O +
the O +
major O +
species O +
at O +
E16 O -
, O +
they O +
were O +
replaced O +
by O +
GQ1c O +
at O +
E19 O -
. O +

In O +
the O +
postnatal O +
period O -
, O +
polysialo O +
gangliosides O +
including O +
GP1c O +
became O +
dominant O +
with O +
advancing O +
age O -
. O +

In O +
addition O -
, O +
another O +
positive O +
band O +
( O -
band O +
Y O -
) O -
, O +
which O +
migrated O +
above O +
GM3 O +
on O +
TLC O -
, O +
was O +
observed O +
in O +
the O +
adult O +
stage O -
. O +

Band O +
Y O +
became O +
negative O +
on O +
TLC O +
immunostaining O +
after O +
further O +
treatment O +
of O +
the O +
ganglioside O +
preparation O +
with O +
a O +
mild O +
base O -
, O +
suggesting O +
that O +
this O +
band O +
is O +
not O +
a O +
c O -
- O -
series O +
ganglioside O +
or O +
derivative O +
( O -
data O +
not O +
shown O -
) O -
. O +

4 O +
Discussion O +
In O +
the O +
present O +
study O -
, O +
we O +
employed O +
monoclonal B-Gene +
antibody I-Gene +
A2B5 B-Gene +
for O +
analyzing O +
c O -
- O -
series O +
gangliosides O +
in O +
rat O +
hepatocytes O +
and O +
liver O +
tissues O -
. O +

Since O +
c O -
- O -
series O +
gangliosides O +
exist O +
as O +
minor O +
ganglioside O +
components O +
in O +
mammalian O +
tissues O -
, O +
they O +
are O +
difficult O +
to O +
analyze O +
by O +
conventional O +
visualization O +
methods O +
after O +
separation O +
on O +
TLC O -
. O +

Accordingly O -
, O +
specific O +
antibodies B-Gene +
for O +
c O -
- O -
series O +
gangliosides O +
have O +
been O +
developed O +
and O +
used O +
as O +
valuable O +
analytical O +
tools O +
[ O -
6,7,29,30 O -
] O +
. O +

Monoclonal B-Gene +
antibody I-Gene +
A2B5 B-Gene +
was O +
originally O +
prepared O +
by O +
immunizing O +
chicken O +
embryonic O +
retinal O +
cells O +
[ O -
29 O -
] O +
. O +

While O +
there O +
was O +
some O +
controversy O +
about O +
its O +
specificity O +
[ O -
31 O -
] O +
, O +
recent O +
studies O +
have O +
reported O +
strict O +
specificity O +
of O +
A2B5 B-Gene +
to O +
c O -
- O -
series O +
gangliosides O +
using O +
embryonic O +
chicken O +
brain O +
[ O -
9 O -
] O +
and O +
cod O +
fish O +
brain O +
[ O -
32 O -
] O +
. O +

The O +
present O +
study O +
has O +
provided O +
further O +
evidence O +
for O +
the O +
validity O +
of O +
this O +
monoclonal B-Gene +
antibody I-Gene -
's O +
specificity O -
. O +

Five O +
positive O +
bands O +
were O +
observed O +
on O +
TLC O +
immunostaining O +
of O +
hepatocyte O +
gangliosides O +
with O +
A2B5 B-Gene -
. O +

Among O +
these O +
bands O -
, O +
band O +
X O +
seemed O +
unaffected O +
by O +
mild O +
base O +
treatment O +
of O +
ganglioside O +
preparations O -
, O +
but O +
became O +
susceptible O +
to O +
the O +
same O +
treatment O +
after O +
purification O +
by O +
preparative O +
TLC O -
. O +

Band O +
Y O +
was O +
also O +
shown O +
to O +
be O +
alkali O -
- O -
labile O -
. O +

These O +
results O +
strongly O +
suggest O +
that O +
bands O +
X O +
and O +
Y O +
are O +
non O -
- O -
ganglioside O +
acidic O +
lipids O -
. O +

Gangliosides O +
of O +
hepatocytes O +
and O +
liver O +
tissues O +
are O +
considerably O +
low O +
in O +
their O +
contents O +
and O +
need O +
to O +
be O +
concentrated O +
extensively O +
before O +
analysis O -
. O +

These O +
non O -
- O -
ganglioside O +
lipids O +
may O +
also O +
be O +
concentrated O +
concomitantly O +
and O +
stained O +
non O -
- O -
specifically O +
on O +
TLC O +
immunostaining O -
. O +

Regarding O +
bands O +
a O -
, O +
b O -
, O +
c O -
, O +
and O +
d O -
, O +
evidence O +
has O +
been O +
provided O +
suggesting O +
that O +
they O +
belong O +
to O +
c O -
- O -
series O +
gangliosides O -
. O +

They O +
exhibited O +
chromatographic O +
mobilities O +
corresponding O +
to O +
GT3 O -
, O +
GT1c O -
, O +
GQ1c O -
, O +
or O +
GP1c O -
, O +
respectively O -
. O +

Structural O +
analysis O +
of O +
core O +
oligosaccharides O +
provided O +
evidence O +
suggesting O +
that O +
bands O +
b O -
, O +
c O -
, O +
and O +
d O +
share O +
the O +
gangliotetraose O +
oligosaccharide O +
backbone O -
. O +

From O +
these O +
data O -
, O +
it O +
was O +
concluded O +
that O +
bands O +
a O -
, O +
b O -
, O +
c O -
, O +
and O +
d O +
were O +
GT3 O -
, O +
GT1c O -
, O +
GQ1c O -
, O +
and O +
GP1c O -
, O +
respectively O -
. O +

The O +
presence O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
rat O +
hepatocytes O +
was O +
further O +
supported O +
by O +
positive O +
immunofluorescence O +
of O +
cultured O +
cells O +
with O +
this O +
A2B5 B-Gene +
preparation O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
that O +
rat O +
hepatocytes O +
express O +
c O -
- O -
series O +
gangliosides O -
. O +

TLC O +
immunostaining O +
of O +
rat O +
hepatocyte O +
gangliosides O +
with O +
A2B5 B-Gene +
demonstrated O +
that O +
the O +
content O +
and O +
composition O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
cells O +
were O +
influenced O +
by O +
EGF B-Gene +
or O +
cell O +
density O +
in O +
culture O -
. O +

Since O +
there O +
was O +
no O +
recognizable O +
growth O +
of O +
non O -
- O -
parenchymal O +
cells O -
, O +
it O +
was O +
concluded O +
that O +
hepatocytes O +
were O +
responsible O +
for O +
the O +
observed O +
ganglioside O +
changes O -
. O +

It O +
is O +
known O +
that O +
EGF B-Gene +
can O +
modulate O +
the O +
expression O +
of O +
major O +
gangliosides O +
in O +
different O +
cell O +
types O +
[ O -
33–36 O -
] O +
. O +

Treatment O +
of O +
rat O +
hepatocytes O +
with O +
EGF B-Gene +
produced O +
a O +
significant O +
increase O +
in O +
the O +
total O +
amount O +
of O +
c O -
- O -
series O +
gangliosides O -
. O +

Enhanced O +
expression O +
of O +
c O -
- O -
series O +
gangliosides O +
by O +
EGF B-Gene +
has O +
also O +
been O +
reported O +
with O +
cerebellar O +
neuronal O +
cells O +
[ O -
37 O -
] O +
and O +
neoplastic O +
glial O +
cells O +
[ O -
38 O -
] O +
. O +

Interestingly O -
, O +
the O +
effect O +
of O +
EGF B-Gene +
on O +
the O +
expression O +
of O +
c O -
- O -
series O +
gangliosides O +
was O +
differential O -
; O +
it O +
caused O +
significant O +
increases O +
in O +
the O +
amount O +
of O +
GT3 O -
, O +
but O +
affected O +
the O +
contents O +
of O +
polysialo O +
species O +
only O +
moderately O -
. O +

Since O +
the O +
amount O +
of O +
GT3 O +
and O +
growth O +
rate O +
of O +
cells O +
display O +
similar O +
time O +
courses O -
, O +
one O +
can O +
question O +
the O +
possibility O +
that O +
the O +
increased O +
expression O +
of O +
GT3 O +
may O +
reflect O +
the O +
growth O +
activity O +
of O +
rat O +
hepatocytes O +
in O +
culture O -
. O +

This O +
assumption O -
, O +
however O -
, O +
is O +
not O +
supported O -
; O +
no O +
correlation O +
was O +
observed O +
between O +
the O +
content O +
of O +
GT3 O +
and O +
growth O +
activity O +
of O +
cells O +
when O +
cells O +
were O +
cultured O +
at O +
different O +
cell O +
densities O -
. O +

We O +
have O +
recently O +
examined O +
the O +
effects O +
of O +
EGF B-Gene +
on O +
the O +
composition O +
of O +
major O +
gangliosides O +
in O +
rat O +
hepatocytes O +
in O +
primary O +
cultures O +
and O +
demonstrated O +
that O +
EGF B-Gene +
causes O +
augmented O +
expression O +
of O +
GM3 O +
and O +
GD3 O -
, O +
but O +
has O +
a O +
lesser O +
effect O +
on O +
other O +
ganglioside O +
species O +
including O +
GM1 O -
, O +
GD1a O -
, O +
GD1b O -
, O +
and O +
GT1b O +
[ O -
36 O -
] O +
. O +

As O +
described O +
in O +
Section O +
1 O +
, O +
the O +
sialylation O +
processes O +
of O +
a- O -
, O +
b- O -
, O +
and O +
c O -
- O -
series O +
gangliosides O +
are O +
catalyzed O +
by O +
the O +
same O +
set O +
of O +
sialyltransferases B-Gene +
[ O -
22 O -
] O +
. O +

Based O +
upon O +
these O +
results O +
about O +
major O +
gangliosides O +
in O +
cultured O +
hepatocytes O +
and O +
the O +
present O +
work O -
, O +
it O +
is O +
assumed O +
that O +
EGF B-Gene +
may O +
accelerate O +
the O +
steps O +
from O +
lactosylceramide O +
to O +
GM3 O -
, O +
from O +
GM3 O +
to O +
GD3 O -
, O +
and O +
from O +
GD3 O +
to O +
GT3 O -
, O +
but O +
have O +
less O +
influence O +
on O +
the O +
further O +
steps O +
for O +
the O +
biosynthesis O +
of O +
gangliosides O +
in O +
rat O +
hepatocytes O +
( O -
see O +
Fig. O +
8 O +
) O -
. O +

Thus O +
the O +
expression O +
of O +
GT3 O +
may O +
be O +
connected O +
to O +
a O +
specific O +
process O -
( O -
es O -
) O +
governed O +
by O +
EGF B-Gene -
. O +

In O +
this O +
context O -
, O +
it O +
is O +
noteworthy O +
that O +
GT3 O +
are O +
expressed O +
in O +
liver O +
tissues O +
only O +
in O +
the O +
early O +
embryonic O +
stage O -
, O +
in O +
which O +
EGF B-Gene +
may O +
function O +
as O +
a O +
dominant O +
growth O +
factor O +
for O +
hepatocytes O +
[ O -
39 O -
] O +
. O +

Expression O +
of O +
polysialo O +
species O +
was O +
less O +
affected O +
by O +
EGF B-Gene -
, O +
but O +
was O +
significantly O +
enhanced O +
by O +
higher O +
cell O +
density O -
. O +

This O +
finding O +
appears O +
to O +
be O +
in O +
harmony O +
with O +
previous O +
reports O +
that O +
the O +
proportion O +
of O +
polysialo O +
species O +
among O +
major O +
gangliosides O +
in O +
some O +
cell O +
types O +
increases O +
as O +
cells O +
become O +
confluent O +
[ O -
36,40–44 O -
] O +
. O +

Analysis O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
rat O +
liver O +
tissues O +
demonstrated O +
a O +
unique O +
developmental O +
profile O +
with O +
a O +
switch O +
from O +
a O +
GT3-dominant O +
composition O +
to O +
polysialo O +
species O -
- O -
dominant O +
patterns O +
at O +
late O +
embryonic O +
stages O -
. O +

Such O +
a O +
swift O +
and O +
complete O +
switch O +
in O +
the O +
composition O +
( O -
and O +
metabolism O -
) O +
of O +
c O -
- O -
series O +
gangliosides O +
has O +
not O +
been O +
observed O +
with O +
embryonic O +
neural O +
tissues O +
including O +
chicken O +
optic O +
lobes O +
[ O -
7 O -
] O +
or O +
rat O +
cerebral O +
cortex O +
[ O -
8 O -
] O +
. O +

While O +
these O +
neural O +
tissues O +
contain O +
many O +
different O +
cell O +
types O -
, O +
liver O +
tissues O +
are O +
more O +
homogeneous O -
, O +
largely O +
consisting O +
of O +
parenchymal O +
hepatocytes O -
. O +

The O +
changes O +
in O +
the O +
expression O +
of O +
c O -
- O -
series O +
gangliosides O +
in O +
this O +
period O +
may O +
closely O +
reflect O +
underlying O +
cellular O +
events O +
within O +
rat O +
hepatocytes O -
. O +

In O +
summary O -
, O +
we O +
have O +
demonstrated O +
that O +
rat O +
hepatocytes O +
express O +
c O -
- O -
series O +
gangliosides O +
in O +
a O +
growth- O +
and O +
development O -
- O -
dependent O +
manner O -
. O +

The O +
results O +
of O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
suggest O +
that O +
the O +
GT3 O +
and O +
polysialo O +
species O +
may O +
have O +
a O +
distinct O +
role O -
( O -
s O -
) O +
in O +
cellular O +
function O +
of O +
rat O +
hepatocytes O -
. O +

A O +
further O +
study O +
on O +
the O +
regulatory O +
mechanism O +
for O +
the O +
expression O +
of O +
c O -
- O -
series O +
gangliosides O +
is O +
being O +
undertaken O -
. O +

Acknowledgements O +

We O +
would O +
like O +
to O +
thank O +
Mr. O +
Harunari O +
Tanaka O +
and O +
Ms. O +
Hisayo O +
Kitamura O +
for O +
their O +
technical O +
assistance O +
throughout O +
this O +
work O -
. O +

α O -
- O -
l O +
-Fucose O +
is O +
an O +
important O +
constituent O +
of O +
the O +
carbohydrate O +
chains O +
of O +
glycoconjugates O +
involved O +
in O +
a O +
variety O +
of O +
biological O +
events O -
, O +
such O +
as O +
cell O -
– O -
cell O +
recognition O +
and O +
antigenicity O +
[ O -
1 O -
] O +
. O +

For O +
example O -
, O +
immunological O +
determinants O +
of O +
the O +
ABH O -
( O -
O O -
) O +
type O +
are O +
known O +
to O +
be O +
oligosaccharides O +
having O +
the O +
common O +
structure O +
of O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→2 O -
) O -
-β O -
- O -
d O +
-Gal O -
- O -
R. O +
Furthermore O -
, O +
( O -
1→2 O -
) O -
-linked O +
α O -
- O -
l O +
-fucosyllactose O +
is O +
a O +
major O +
component O +
of O +
human O +
milk O +
oligosaccharides O +
[ O -
2 O -
] O +
. O +

Great O +
attention O -
, O +
therefore O -
, O +
has O +
been O +
paid O +
to O +
chemical O +
and O +
enzymatic O +
syntheses O +
of O +
such O +
oligosaccharides O -
. O +

Chemical O +
procedures O +
have O +
been O +
extensively O +
developed O +
[ O -
3–6 O -
] O +
, O +
but O +
they O +
are O +
frequently O +
cumbersome O +
because O +
of O +
many O +
protection O +
and O +
deprotection O +
steps O -
. O +

The O +
enzymatic O +
approach O +
has O +
utilized O +
various O +
glycosyltransferases B-Gene +
and O +
glycosidases B-Gene -
. O +

Fucosylated O +
di- O +
and O +
trisaccharides O +
of O +
the O +
type O +
2 O +
ABO O +
blood O +
group O +
have O +
been O +
obtained O +
with O +
porcine O +
β B-Gene -
- I-Gene -
d I-Gene +
-galactoside I-Gene +
α- I-Gene -
( I-Gene -
1→2 I-Gene -
) I-Gene +
fucosyltransferase I-Gene +
[ O -
7 O -
] O +
. O +

From O +
a O +
practical O +
viewpoint O -
, O +
the O +
use O +
of O +
glycosidases B-Gene +
is O +
attractive O +
for O +
synthesizing O +
oligosaccharides O -
, O +
because O +
these O +
enzymes B-Gene +
are O +
generally O +
more O +
available O -
, O +
and O +
less O +
expensive O +
than O +
glycosyltransferases B-Gene -
, O +
and O +
do O +
not O +
require O +
expensive O +
sugar O +
nucleotide O +
donors O +
[ O -
8 O -
] O +
. O +

Svensson O +
and O +
Thiem O +
reported O +
an O +
enzymatic O +
synthesis O +
of O +
methyl O +
( O -
1→2 O -
) O -
- O +
and O +
( O -
1→6 O -
) O -
-linked O +
α O -
- O -
l O +
-fucopyranosyl O -
- O -
β O -
- O -
d O +
-galactosides O +
in O +
the O +
ratio O +
of O +
2:3 O +
with O +
an O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
porcine O +
liver O +
[ O -
9 O -
] O +
. O +

Ajisaka O +
and O +
Shirakabe O +
developed O +
the O +
regioselective O +
synthesis O +
of O +
disaccharides O +
containing O +
( O -
1→2 O -
) O -
- O -
, O +
( O -
1→3 O -
) O -
- O -
, O +
and O +
( O -
1→6 O -
) O -
-linked O +
α O -
- O -
l O +
-fucosyl O +
groups O +
by O +
use O +
of O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidases I-Gene +
from O +
various O +
microorganisms O +
[ O -
10 O -
] O +
. O +

The O +
object O +
of O +
the O +
present O +
investigation O +
was O +
to O +
develop O +
a O +
system O +
for O +
the O +
enzymatic O +
synthesis O +
of O +
fucosylated O +
trisaccharide O +
1 O +
of O +
the O +
determinant O +
of O +
type O +
2 O +
blood O +
group O +
H O +
substance O -
, O +
utilizing O +
β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-GlcNAc O +
( O -
LacNAc O -
) O -
, O +
which O +
has O +
been O +
readily O +
obtained O +
on O +
a O +
gram O -
- O -
scale O +
by O +
our O +
method O +
[ O -
11,12 O -
] O +
. O +

The O +
present O +
paper O +
reports O +
a O +
synthetic O +
procedure O +
for O +
α O -
- O -
l O +
-fucosyl O -
- O -
N O +
-acetyllactosamine O +
and O +
3′-O O +
-α O -
- O -
l O +
-fucosyllactose O +
through O +
α O -
- O -
l O +
-fucosidase O -
- O -
catalyzed O +
transglycosylation O -
. O +

2 O +
2 O -
. O +

Materials O +
and O +
methods O +
2.1 O +
Materials O +
α B-Gene -
- I-Gene -
l I-Gene +
-Fucosidase I-Gene +
from O +
Alcaligenes O +
sp. O +
was O +
kindly O +
supplied O +
by O +
Kumiai O +
Chemical O +
Industry O +
Co. O +
Ltd. O -
, O +
( O -
Shizuoka O -
, O +
Japan O -
) O -
. O +

Porcine O +
liver O +
extract O +
( O -
Catalase O +
L O +
' O -
Amano O -
' O -
) O +
was O +
kindly O +
supplied O +
by O +
Amano O +
Pharmaceutical O +
Co. O +
Ltd. O -
, O +
( O -
Nagoya O -
, O +
Japan O -
) O -
. O +

LacNAc O -
, O +
β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-Glc O -
- O -
OMe O -
, O +
β O -
- O -
d O +
-Gal- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Glc O -
- O -
OMe O -
, O +
and O +
β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-GlcNAc O -
- O -
OMe O +
were O +
prepared O +
by O +
our O +
methods O +
[ O -
11,12 O -
] O +
. O +

p O +
-Nitrophenyl O +
α O -
- O -
l O +
-fucopyranoside O +
( O -
Fucα O -
- O -
p O +
NP O -
) O +
and O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→2 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-Glc O +
( O -
2′-O O +
-α O -
- O -
l O +
-fucosyllactose O -
) O +
were O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

All O +
other O +
chemicals O +
were O +
obtained O +
from O +
commercial O +
sources O -
. O +

2.2 O +
Enzyme O +
assay O +
The O +
activity O +
of O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
the O +
porcine O +
liver O +
extract O +
was O +
assayed O +
as O +
follows O -
: O +
a O +
mixture O +
containing O +
0.4 O +
mM O +
Fucα O -
- O -
p O +
NP O +
in O +
0.9 O +
mL O +
of O +
50 O +
mM O +
NaOAc O +
buffer O +
( O -
pH O +
4.8 O -
) O +
and O +
an O +
appropriate O +
amount O +
of O +
enzyme B-Gene +
in O +
total O +
volume O +
of O +
1 O +
mL O +
was O +
incubated O +
for O +
10 O +
min O +
at O +
37 O +
° O -
C O -
. O +

The O +
reaction O +
was O +
stopped O +
by O +
adding O +
0.5 O +
mL O +
of O +
1 O +
M O +
Na2 O +
CO3 O +
solution O -
, O +
and O +
the O +
liberated O +
p O +
-nitrophenol O +
was O +
determined O +
spectrophotometrically O +
at O +
410 O +
nm O -
. O +

The O +
activity O +
of O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
Alcaligenes O +
sp. O +
was O +
assayed O +
in O +
a O +
similar O +
manner O +
with O +
50 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O +
and O +
incubation O +
at O +
50 O +
° O -
C O -
. O +

One O +
unit O +
of O +
activity O +
was O +
defined O +
as O +
the O +
amount O +
of O +
enzyme B-Gene +
that O +
hydrolyzes O +
1 O +
μmol O +
of O +
Fucα O -
- O -
p O +
NP O +
per O +
min O -
. O +

β B-Gene -
- I-Gene -
d I-Gene +
-Galactosidase I-Gene +
activity O +
was O +
assayed O +
as O +
follows O -
: O +
a O +
mixture O +
containing O +
2 O +
mM O +
o O +
-nitrophenyl O +
β O -
- O -
d O +
-galactopyranoside O +
( O -
Galβ O -
- O -
o O +
NP O -
) O +
in O +
0.9 O +
mL O +
of O +
50 O +
mM O +
NaOAc O +
buffer O +
( O -
pH O +
4.8 O -
) O +
and O +
an O +
appropriate O +
amount O +
of O +
enzyme B-Gene +
in O +
a O +
total O +
volume O +
of O +
1 O +
mL O +
was O +
incubated O +
for O +
10 O +
min O +
at O +
37 O +
° O -
C O -
. O +

The O +
reaction O +
was O +
stopped O +
by O +
adding O +
0.5 O +
mL O +
of O +
1 O +
M O +
Na2 O +
CO3 O +
solution O -
, O +
and O +
liberated O +
o O +
-nitrophenol O +
was O +
determined O +
spectrophotometrically O +
at O +
420 O +
nm O -
. O +

One O +
unit O +
of O +
enzyme B-Gene +
activity O +
was O +
defined O +
as O +
the O +
amount O +
of O +
the O +
enzyme B-Gene +
hydrolyzing O +
1 O +
μmol O +
of O +
Galβ O -
- O -
o O +
NP O +
per O +
min O -
. O +

2.3 O +
Analytical O +
methods O +
HPLC O +
was O +
performed O +
with O +
a O +
Hitachi O +
6000 O +
liquid O +
chromatograph O +
with O +
a O +
Shodex O +
Asahipak O +
NH2P-50 O +
column O +
( O -
4.6 O +
mm O +
diameter O -
× O -
250 O +
mm O -
, O +
Showadenko O +
Corp. O -
, O +
Tokyo O -
, O +
Japan O -
) O +
developed O +
with O +
1:3 O +
or O +
9:41 O +
water O -
– O -
MeCN O +
at O +
a O +
flow O +
rate O +
of O +
0.8 O +
mL O -
/ O -
min O +
with O +
an O +
L-4000 O +
UV O +
detector O +
and O +
an O +
L-3350 O +
RI O +
monitor O -
. O +

1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
were O +
recorded O +
with O +
a O +
Jeol O +
JNM O -
- O -
EX O +
270 O +
FT O -
- O -
NMR O +
spectrometer O -
. O +

Chemical O +
shifts O +
are O +
expressed O +
in O +
δ O +
values O +
relative O +
to O +
sodium O +
4,4-dimethyl-4-silapentanoate O +
as O +
the O +
external O +
standard O -
. O +

FABMS O +
analyses O +
were O +
carried O +
out O +
in O +
the O +
positive O +
ion O +
mode O +
using O +
a O +
Jeol O +
JMS O +
DS303HF O +
mass O +
spectrometer O -
, O +
coupled O +
to O +
a O +
Jeol O +
DA-800 O +
mass O -
- O -
data O +
system O -
. O +

An O +
accelerating O +
voltage O +
of O +
10 O +
kV O +
and O +
mass O +
resolution O +
of O +
1000 O +
were O +
employed O -
. O +

A O +
sample O +
of O +
1 O +
μL O +
in O +
distilled O +
water O +
was O +
loaded O +
onto O +
a O +
probe O +
tip O +
and O +
mixed O +
with O +
1 O +
μL O +
of O +
glycerol O +
as O +
a O +
matrix O -
. O +

Mass O +
calibration O +
was O +
done O +
with O +
Ultramark O -
. O +

2.4 O +
Preparation O +
of O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
porcine O +
liver O +
The O +
porcine O +
liver O +
extract O +
( O -
400 O +
mL O -
) O +
was O +
brought O +
to O +
20 O -
% O +
saturation O +
with O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
, O +
stirred O +
for O +
30 O +
min O -
, O +
and O +
kept O +
for O +
9 O +
h O +
at O +
4 O +
° O -
C O -
. O +

The O +
supernatant O +
obtained O +
by O +
centrifugation O +
was O +
brought O +
to O +
60 O -
% O +
saturation O +
with O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
and O +
stirred O +
for O +
1 O +
h. O +
The O +
precipitate O +
was O +
recovered O +
by O +
centrifugation O -
, O +
dissolved O +
in O +
200 O +
mL O +
of O +
50 O +
mM O +
NaOAc O +
buffer O +
( O -
pH O +
6 O -
) O -
, O +
and O +
dialyzed O +
overnight O +
against O +
the O +
same O +
buffer O -
. O +

The O +
dialyzed O +
enzyme B-Gene +
solution O +
was O +
then O +
charged O +
onto O +
a O +
CM O -
- O -
Sepharose O +
Fast O +
Flow O +
column O +
( O -
3.2 O +
cm O +
diameter O -
× O -
24 O +
cm O -
) O +
equilibrated O +
with O +
50 O +
mM O +
NaOAc O +
buffer O +
( O -
pH O +
6 O -
) O -
. O +

After O +
applying O +
the O +
sample O -
, O +
the O +
column O +
was O +
washed O +
with O +
400 O +
mL O +
of O +
the O +
same O +
buffer O -
. O +

The O +
column O +
was O +
then O +
eluted O +
with O +
a O +
linear O +
gradient O +
of O +
NaCl O +
concentration O +
from O +
0 O +
( O -
400 O +
mL O -
) O +
to O +
1 O +
M O +
( O -
400 O +
mL O -
) O +
and O +
the O +
eluate O +
was O +
collected O +
in O +
20-mL O +
fractions O -
. O +

Fractions O +
( O -
F. O +
nos. O +
21–27 O -
) O +
containing O +
α O -
- O -
l O +
-fucosidase O -
, O +
which O +
did O +
not O +
show O +
β B-Gene -
- I-Gene -
d I-Gene +
-galactosidase I-Gene +
activity O -
, O +
were O +
combined O +
and O +
concentrated O +
to O +
low O +
volume O +
with O +
an O +
Amicon O +
Diaflo O +
unit O +
equipped O +
with O +
a O +
PM-10 O +
membrane O +
operating O +
at O +
2 O +
kg O -
/ O -
cm2 O +
, O +
giving O +
a O +
specific O +
activity O +
of O +
0.04 O +
U O -
/ O -
mg O +
protein O -
. O +

2.5 O +
Preparation O +
of O +
α O -
- O -
l O +
-fucosidase O +
from O +
Alcaligenes O +
sp O +
Strain O +
KSF-9687 O -
, O +
which O +
has O +
been O +
deposited O +
in O +
the O +
National O +
Institute O +
of O +
Bioscience O +
and O +
Human O +
Technology O -
, O +
Ministry O +
of O +
International O +
Trade O +
and O +
Industry O -
, O +
Tsukuba O -
, O +
Japan O -
, O +
under O +
accession O +
no. O +
P-16944 O -
, O +
was O +
grown O +
in O +
a O +
medium O +
of O +
nutrient O +
broth O +
( O -
NB O -
) O -
. O +

The O +
culture O +
was O +
transferred O +
from O +
the O +
NB O +
to O +
a O +
500-mL O +
Erlenmeyer O +
flask O +
containing O +
100 O +
mL O +
of O +
0.25 O -
% O +
yeast O +
extract O -
, O +
0.5 O -
% O +
polypeptone O -
, O +
0.1 O -
% O +
KH2 O +
PO4 O +
, O +
and O +
0.05 O -
% O +
MgSO4 O +
· O -
7 O +
H2 O +
O O +
( O -
adjusted O +
to O +
pH O +
7 O +
with O +
0.2 O +
N O +
NaOH O +
before O +
the O +
sterilization O -
) O -
. O +

The O +
flask O +
was O +
shaken O +
on O +
a O +
rotary O +
shaker O +
for O +
48 O +
h O +
at O +
37 O +
° O -
C O +
at O +
200 O +
rpm O -
. O +

2.5.1 O +
Step O +
1 O -
: O +

Streamline O -
- O -
DEAE O +
A O +
4-L O +
broth O +
containing O +
the O +
cells O +
was O +
adjusted O +
to O +
pH O +
7 O +
with O +
0.5 O +
M O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O -
. O +

The O +
broth O +
was O +
applied O +
on O +
a O +
Streamline O -
- O -
DEAE O +
( O -
Amersham O +
Pharmacia O +
Biotech O -
) O +
column O +
( O -
5.0 O +
cm O +
diameter O -
× O -
20 O +
cm O -
) O +
equilibrated O +
with O +
10 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O +
at O +
room O +
temperature O -
. O +

After O +
the O +
column O +
had O +
been O +
washed O +
with O +
the O +
same O +
buffer O -
, O +
the O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
activity O +
was O +
eluted O +
with O +
the O +
same O +
buffer O +
containing O +
0.2 O +
M O +
NaCl O -
. O +

2.5.2 O +
Step O +
2 O -
: O +
Column O +
chromatography O +
on O +
Butyl O -
- O -
Toyopearl O +
650 O -
M O +
Solid O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
was O +
added O +
to O +
make O +
1.5 O +
L O +
of O +
the O +
active O +
fraction O +
from O +
Step O +
1 O +
up O +
to O +
1 O +
M O +
in O +
final O +
concentration O -
. O +

The O +
enzyme B-Gene +
solution O +
was O +
put O +
onto O +
a O +
Butyl O -
- O -
Toyopearl O +
650 O -
M O +
column O +
( O -
2.6 O +
cm O +
diameter O -
× O -
30 O +
cm O -
) O +
equilibrated O +
with O +
10 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O +
containing O +
1 O +
M O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
, O +
and O +
the O +
column O +
was O +
washed O +
with O +
the O +
same O +
buffer O +
at O +
4 O +
° O -
C O -
. O +

The O +
column O +
was O +
eluted O +
with O +
a O +
linear O +
gradient O +
of O +
( O -
NH4 O +
) O -
2 O +
SO4 O +
from O +
1 O +
M O +
( O -
300 O +
mL O -
) O +
to O +
0 O +
M O +
( O -
300 O +
mL O -
) O -
. O +

The O +
active O +
fractions O +
were O +
pooled O +
and O +
dialyzed O +
against O +
50 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O -
. O +

2.5.3 O +
Step O +
3 O -
: O +
Fucose O -
– O -
Cellulofine O +
column O +
chromatography O +
The O +
dialyzed O +
enzyme B-Gene +
solution O +
was O +
charged O +
onto O +
a O +
Fucose O -
– O -
Cellulofine O +
[ O -
13 O -
] O +
column O +
( O -
1.6 O +
cm O +
diameter O -
× O -
10 O +
cm O -
) O +
equilibrated O +
with O +
50 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O -
; O +
the O +
column O +
was O +
washed O +
with O +
the O +
same O +
buffer O -
, O +
and O +
the O +
enzyme B-Gene +
activity O +
was O +
then O +
eluted O +
with O +
50 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O +
containing O +
50 O +
mM O +
l O +
-fucose O +
at O +
4 O +
° O -
C O -
. O +

The O +
active O +
fractions O +
were O +
dialyzed O +
against O +
10 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
total O +
activity O -
, O +
56 O +
U O -
; O +
specific O +
activity O -
, O +
19.7 O +
U O -
/ O -
mg O -
) O -
. O +

2.6 O +
Preparation O +
of O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→2 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-GlcNAc O +
( O -
1 O +
) O +
and O +
its O +
isomers O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-GlcNAc O +
( O -
2 O +
) O +
and O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→6 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-GlcNAc O +
( O -
3 O +
) O -
, O +
utilizing O +
porcine O +
liver O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
( O -
Scheme O +
1 O +
) O +
To O +
a O +
solution O +
of O +
Fucα O -
- O -
p O +
NP O +
( O -
70 O +
mg O -
) O +
and O +
LacNAc O +
( O -
1.2 O +
g O -
) O +
in O +
9 O +
mL O +
of O +
50 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
4.8 O -
) O +
containing O +
0.5 O +
mL O +
of O +
MeOH O +
was O +
added O +
partially O +
purified O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
porcine O +
liver O +
( O -
0.45 O +
U O -
) O -
. O +

The O +
mixture O +
was O +
incubated O +
for O +
30 O +
h O +
at O +
40 O +
° O -
C O -
, O +
and O +
the O +
reaction O +
was O +
terminated O +
by O +
boiling O +
for O +
5 O +
min O -
. O +

The O +
resulting O +
insoluble O +
material O +
was O +
filtered O +
and O +
the O +
filtrate O +
was O +
placed O +
directly O +
onto O +
an O +
activated O +
charcoal O -
– O -
Celite O +
column O +
( O -
2.6 O +
cm O +
diameter O -
× O -
25 O +
cm O -
) O -
. O +

The O +
column O +
was O +
eluted O +
successively O +
with O +
500 O +
mL O +
of O +
water O +
and O +
500 O +
mL O +
of O +
12 O -
% O +
EtOH O -
, O +
and O +
then O +
eluted O +
with O +
a O +
linear O +
gradient O +
of O +
12 O -
% O +
( O -
500 O +
mL O -
) O +
to O +
40 O -
% O +
( O -
500 O +
mL O -
) O +
EtOH O -
. O +

The O +
elution O +
was O +
monitored O +
by O +
measuring O +
the O +
absorbance O +
at O +
210 O +
nm O +
for O +
the O +
characteristic O +
absorption O +
of O +
the O +
N O +
-acetyl O +
group O +
and O +
at O +
485 O +
nm O +
( O -
carbohydrate O +
content O -
, O +
determined O +
by O +
the O +
phenol O -
– O -
H2 O +
SO4 O +
method O -
) O -
. O +

The O +
chromatogram O +
( O -
Fig. O +
1 O +
) O +
showed O +
four O +
peaks O +
displaying O +
coincident O +
absorbance O +
at O +
210 O +
and O +
485 O +
nm O -
. O +

Fraction O +
F-1 O +
contained O +
LacNAc O +
used O +
as O +
the O +
acceptor O -
. O +

F-2 O -
, O +
F-3 O -
, O +
and O +
F-4 O +
were O +
collected O -
, O +
concentrated O -
, O +
and O +
lyophilized O +
to O +
afford O +
1 O +
( O -
6.8 O +
mg O -
) O -
, O +
2 O +
( O -
6.4 O +
mg O -
) O -
, O +
and O +
3 O +
( O -
3.9 O +
mg O -
) O -
, O +
respectively O -
. O +

Compound O +
1 O +
had O +
m O -
/ O -
z O +
530 O +
[ O -
M+H O -
] O -
+ O +
; O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
, O +
30 O +
° O -
C O -
) O -
: O +
δ O +
5.31 O +
( O -
H-1α O -
) O -
, O +
5.21 O +
( O -
d O -
, O +
J O +
1,2 O +
2.97 O +
Hz O -
, O +
H-1′′ O -
) O -
, O +
4.72 O +
( O -
d O -
, O +
J O +
1,2 O +
8.1 O +
Hz O -
, O +
H-1β O -
) O -
, O +
4.55 O +
( O -
d O -
, O +
J O +
1,2 O +
7.56 O +
Hz O -
, O +
H-1′α O -
) O -
, O +
4.48 O +
( O -
d O -
, O +
J O +
1,2 O +
8.1 O +
Hz O -
, O +
H-1′β O -
) O -
, O +
2.05 O +
( O -
s O -
, O +
3 O +
H O -
, O +
NAc O -
) O -
, O +
and O +
1.23 O +
( O -
d O -
, O +
J O +
5,6 O +
6.7 O +
Hz O -
, O +
H-6′′ O -
) O -
. O +

Compound O +
2 O +
had O +
m O -
/ O -
z O +
530 O +
[ O -
M+H O -
] O -
+ O +
; O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
, O +
30 O +
° O -
C O -
) O -
: O +
δ O +
5.23 O +
( O -
d O -
, O +
J O +
1,2 O +
2.43 O +
Hz O -
, O +
H-1α O -
) O -
, O +
5.20 O +
( O -
d O -
, O +
J O +
1,2 O +
4.05 O +
Hz O -
, O +
H-1′′ O -
) O -
, O +
4.56 O +
( O -
t O -
, O +
H-1′ O -
) O -
, O +
2.07 O +
( O -
s O -
, O +
3 O +
H O -
, O +
NAc O -
) O -
, O +
and O +
1.23 O +
( O -
d O -
, O +
J O +
5,6 O +
6.48 O +
Hz O -
, O +
H-6′′ O -
) O -
. O +

Compound O +
3 O +
had O +
m O -
/ O -
z O +
530 O +
[ O -
M+H O -
] O -
+ O +
; O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
, O +
30 O +
° O -
C O -
) O -
: O +
δ O +
5.16 O +
( O -
d O -
, O +
J O +
1,2 O +
2.45 O +
Hz O -
, O +
H-1α O -
) O -
, O +
4.89 O +
( O -
d O -
, O +
J O +
1,2 O +
3.65 O +
Hz O -
, O +
H-1α′′ O -
) O -
, O +
4.88 O +
( O -
d O -
, O +
J O +
1,2 O +
3.95 O +
Hz O -
, O +
H-1β′′ O -
) O -
, O +
4.44 O +
( O -
d O -
, O +
J O +
1,2 O +
7.6 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
2.03 O +
( O -
s O -
, O +
3 O +
H O -
, O +
NAc O -
) O -
, O +
and O +
1.27 O +
( O -
d O -
, O +
J O +
5,6 O +
6.7 O +
Hz O -
, O +
H-6′′ O -
) O -
. O +

2.7 O +
Preparation O +
of O +
compound O +
2 O +
and O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-Glc O +
( O -
4 O +
) O +
and O +
other O +
related O +
compounds O +
utilizing O +
Alcaligenes O +
sp. O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
( O -
Scheme O +
2 O +
) O +
2.7.1 O +
Compound O +
2 O +
Fucα O -
- O -
p O +
NP O +
( O -
60 O +
mg O -
) O +
and O +
LacNAc O +
( O -
2 O +
g O -
) O +
were O +
dissolved O +
in O +
20 O +
mL O +
of O +
20 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O -
, O +
and O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
Alcaligenes O +
sp. O +
( O -
0.6 O +
U O -
) O +
was O +
added O -
. O +

The O +
mixture O +
was O +
incubated O +
for O +
24 O +
h O +
at O +
50 O +
° O -
C O +
and O +
the O +
reaction O +
was O +
terminated O +
by O +
boiling O +
for O +
5 O +
min O -
. O +

The O +
resulting O +
insoluble O +
material O +
was O +
centrifuged O +
and O +
the O +
filtrate O +
was O +
put O +
directly O +
onto O +
an O +
activated O +
charcoal O -
– O -
Celite O +
column O +
( O -
2.2 O +
cm O +
diameter O -
× O -
95 O +
cm O -
) O -
. O +

The O +
column O +
was O +
eluted O +
successively O +
with O +
1 O +
L O +
of O +
water O +
and O +
1 O +
L O +
of O +
10 O -
% O +
EtOH O -
, O +
and O +
then O +
with O +
a O +
linear O +
gradient O +
of O +
10 O -
% O +
( O -
1 O +
L O -
) O +
to O +
40 O -
% O +
( O -
1 O +
L O -
) O +
EtOH O -
. O +

The O +
eluate O +
was O +
collected O +
in O +
20-mL O +
fractions O +
and O +
showed O +
one O +
main O +
peak O +
( O -
3100–3400 O +
mL O -
) O +
as O +
the O +
transfer O +
product O -
. O +

The O +
fraction O +
was O +
collected O -
, O +
concentrated O -
, O +
and O +
lyophilized O +
to O +
afford O +
2 O +
( O -
60.8 O +
mg O -
) O +
in O +
54 O -
% O +
yield O -
, O +
based O +
on O +
the O +
donor O +
added O -
. O +

2.7.2 O +
Compound O +
4 O +
Fucα O -
- O -
p O +
NP O +
( O -
60 O +
mg O -
) O +
and O +
lactose O +
( O -
1.4 O +
g O -
) O +
were O +
dissolved O +
in O +
20 O +
mL O +
of O +
20 O +
mM O +
potassium O +
phosphate O +
buffer O +
( O -
pH O +
7 O -
) O -
, O +
and O +
the O +
same O +
enzyme B-Gene +
( O -
0.6 O +
U O -
) O +
was O +
then O +
added O -
. O +

The O +
mixture O +
was O +
then O +
applied O +
to O +
an O +
activated O +
charcoal O -
– O -
Celite O +
column O +
as O +
already O +
described O -
, O +
with O +
the O +
same O +
elution O +
conditions O -
. O +

The O +
eluate O -
, O +
collected O +
in O +
20-mL O +
fractions O -
, O +
showed O +
one O +
main O +
peak O +
( O -
2020–2220 O +
mL O -
) O +
as O +
the O +
transfer O +
product O -
. O +

The O +
fraction O +
was O +
collected O -
, O +
concentrated O -
, O +
and O +
lyophilized O -
, O +
giving O +
4 O +
( O -
35.2 O +
mg O -
) O +
in O +
34 O -
% O +
yield O -
, O +
based O +
on O +
the O +
donor O -
. O +

Compound O +
4 O +
had O +
m O -
/ O -
z O +
489 O +
[ O -
M+H O -
] O -
+ O +
; O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
, O +
26 O +
° O -
C O -
) O -
: O +
δ O +
5.23 O +
( O -
d O -
, O +
J O +
1,2 O +
3.96 O +
Hz O -
, O +
H-1α O -
) O -
, O +
5.18 O +
( O -
d O -
, O +
J O +
1,2 O +
3 O +
96 O +
Hz O -
, O +
H-1′′ O -
) O -
, O +
4.68 O +
( O -
d O -
, O +
J O +
1,2 O +
8.25 O +
Hz O -
, O +
H-1β O -
) O -
, O +
4.52 O +
( O -
t O -
, O +
H-1′ O -
) O -
, O +
and O +
1.26 O +
( O -
H-6′′ O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
D2 O +
O O -
) O -
: O +
δ O +
105.33 O +
( O -
C-1′ O -
) O -
, O +
103.74 O +
( O -
C-1′′ O -
) O -
, O +
98.60 O +
( O -
C-1α O -
) O -
, O +
94.64 O +
( O -
C-1β O -
) O -
, O +
83.16 O +
( O -
C-3′ O -
) O -
, O +
81.31 O +
( O -
C-4α O -
) O -
, O +
8l.19 O +
( O -
C-4β O -
) O -
, O +
78.09 O +
( O -
C-5′ O -
) O -
, O +
77.61 O +
( O -
C-5β O -
) O -
, O +
77.23 O +
( O -
C-3β O -
) O -
, O +
76.64 O +
( O -
C-2β O -
) O -
, O +
74.59 O +
( O -
C-4′′ O -
) O -
, O +
74.29 O +
( O -
C-3α O -
) O -
, O +
73.98 O +
( O -
C-2α O -
) O -
, O +
73.24 O +
( O -
C-2′ O -
) O -
, O +
72.92 O +
( O -
C-5α O -
) O -
, O +
72.24 O +
( O -
C-3′′ O -
) O -
, O +
71.46 O +
( O -
C-4′ O -
) O -
, O +
71.27 O +
( O -
C-2′′ O -
) O -
, O +
69.99 O +
( O -
C-5′′ O -
) O -
, O +
63.77 O +
( O -
C-6′ O -
) O -
, O +
62.93 O +
( O -
C-6β O -
) O -
, O +
62.80 O +
( O -
C-6α O -
) O -
, O +
and O +
18.17 O +
( O -
C-6′′ O -
) O -
. O +

Other O +
related O +
compounds O -
, O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-Glc O -
- O -
OMe O -
, O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Glc O -
- O -
OMe O -
, O +
and O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-GlcNAc O -
- O -
OMe O -
, O +
were O +
prepared O +
according O +
to O +
the O +
same O +
method O +
as O +
already O +
described O -
. O +

The O +
yields O +
are O +
summarized O +
in O +
Table O +
2 O +
. O +

α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-Glc O -
- O -
OMe O +
had O +
m O -
/ O -
z O +
503 O +
[ O -
M+H O -
] O -
+ O +
; O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
, O +
26 O +
° O -
C O -
) O -
: O +
δ O +
5.18 O +
( O -
d O -
, O +
J O +
1,2 O +
3.96 O +
Hz O -
, O +
H-1′′ O -
) O -
, O +
4.51 O +
( O -
t O -
, O +
H-1′ O -
) O -
, O +
4.41 O +
( O -
d O -
, O +
J O +
1,2 O +
7.92 O +
Hz O -
, O +
H-1 O -
) O -
, O +
and O +
1.22 O +
( O -
H-6′′ O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
D2 O +
O O -
) O -
: O +
δ O +
105.91 O +
( O -
C-1′ O -
) O -
, O +
105.55 O +
( O -
C-1 O -
) O -
, O +
103.74 O +
( O -
C-1′′ O -
) O -
, O +
83.14 O +
( O -
C-3′ O -
) O -
, O +
81.22 O +
( O -
C-4 O -
) O -
, O +
78.09 O +
( O -
C-5′ O -
) O -
, O +
77.57 O +
( O -
C-5 O -
) O -
, O +
77.25 O +
( O -
C-3 O -
) O -
, O +
75.61 O +
( O -
C-2 O -
) O -
, O +
74.59 O +
( O -
C-4′′ O -
) O -
, O +
73.22 O +
( O -
C-2′ O -
) O -
, O +
72.22 O +
( O -
C-3′′ O -
) O -
, O +
71.45 O +
( O -
C-4′ O -
) O -
, O +
71.25 O +
( O -
C-2′′ O -
) O -
, O +
69.99 O +
( O -
C-5′′ O -
) O -
, O +
63.76 O +
( O -
C-6′ O -
) O -
, O +
62.89 O +
( O -
C-6 O -
) O -
, O +
60.04 O +
( O -
OC O +
H3 O +
) O -
, O +
and O +
18.15 O +
( O -
C-6′′ O -
) O -
. O +

α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Glc O -
- O -
OMe O +
had O +
m O -
/ O -
z O +
503 O +
[ O -
M+H O -
] O -
+ O +
; O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
, O +
26 O +
° O -
C O -
) O -
: O +
δ O +
5.19 O +
( O -
d O -
, O +
J O +
1,2 O +
3.96 O +
Hz O -
, O +
H-1′′ O -
) O -
, O +
4.74 O +
( O -
d O -
, O +
J O +
1,2 O +
7.26 O +
Hz O -
, O +
H-1 O -
) O -
, O +
4.43 O +
( O -
d O -
, O +
J O +
1,2 O +
8.25 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
and O +
1.22 O +
( O -
H-6′′ O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
D2 O +
O O -
) O -
: O +
δ O +
105.87 O +
( O -
C-1′ O -
) O -
, O +
105.77 O +
( O -
C-1 O -
) O -
, O +
103.74 O +
( O -
C-1′′ O -
) O -
, O +
87.31 O +
( O -
C-3 O -
) O -
, O +
83.38 O +
( O -
C-3′ O -
) O -
, O +
78.31 O +
( O -
C-5 O -
) O -
, O +
78.08 O +
( O -
C-5′ O -
) O -
, O +
75.58 O +
( O -
C-2 O -
) O -
, O +
74.57 O +
( O -
C-4′′ O -
) O -
, O +
73.44 O +
( O -
C-2′ O -
) O -
, O +
72.22 O +
( O -
C-3′′ O -
) O -
, O +
71.45 O +
( O -
C-2′′ O -
) O -
, O +
71.25 O +
( O -
C-4′ O -
) O -
, O +
71.09 O +
( O -
C-4 O -
) O -
, O +
70.01 O +
( O -
C-5′′ O -
) O -
, O +
63.76 O +
( O -
C-6′ O -
) O -
, O +
62.89 O +
( O -
C-6 O -
) O -
, O +
60.04 O +
( O -
OCH3 O +
) O -
, O +
and O +
18.15 O +
( O -
C-6′′ O -
) O -
. O +

α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-GlcNAc O -
- O -
OMe O +
had O +
m O -
/ O -
z O +
544 O +
[ O -
M+H O -
] O -
+ O +
; O +
1 O +
H O +
NMR O +
( O -
D2 O +
O O -
, O +
26 O +
° O -
C O -
) O -
: O +
δ O +
5.15 O +
( O -
d O -
, O +
J O +
1,2 O +
3 O +
96 O +
Hz O -
, O +
H-1′′ O -
) O -
, O +
4.51 O +
( O -
t O -
, O +
H-1′ O -
) O -
, O +
4.44 O +
( O -
d O -
, O +
J O +
1,2 O +
7.26 O +
Hz O -
, O +
H-1 O -
) O -
, O +
and O +
1.22 O +
( O -
H-6′′ O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
D2 O +
O O -
) O -
: O +
δ O +
177.55 O +
( O -
CO O -
) O -
, O +
105.55 O +
( O -
C-1′ O -
) O -
, O +
104.76 O +
( O -
C-1 O -
) O -
, O +
103.79 O +
( O -
C-1′′ O -
) O -
, O +
83.22 O +
( O -
C-3′ O -
) O -
, O +
81.38 O +
( O -
C-4 O -
) O -
, O +
78.15 O +
( O -
C-5′ O -
) O -
, O +
77.65 O +
( O -
C-5 O -
) O -
, O +
75.45 O +
( O -
C-3 O -
) O -
, O +
74.64 O +
( O -
C-4′′ O -
) O -
, O +
73.31 O +
( O -
C-2′ O -
) O -
, O +
72.29 O +
( O -
C-3′′ O -
) O -
, O +
71.50 O +
( O -
C-4′ O -
) O -
, O +
71.30 O +
( O -
C-2′′ O -
) O -
, O +
70.06 O +
( O -
C-5′′ O -
) O -
, O +
63.81 O +
( O -
C-6′ O -
) O -
, O +
62.95 O +
( O -
C-6 O -
) O -
, O +
59.98 O +
( O -
OCH3 O +
) O -
, O +
57.86 O +
( O -
C-2 O -
) O -
, O +
25.05 O +
( O -
COC O +
H3 O +
) O +
and O +
18.22 O +
( O -
C-6′′ O -
) O -
. O +

2.8 O +
Hydrolysis O +
reaction O +
of O +
Alcaligenes O +
sp. O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
on O +
O O -
- O -
α O -
- O -
l O +
-fucosyllactose O +
To O +
a O +
200 O +
μL O +
solution O +
containing O +
5 O +
mM O +
of O +
4 O +
or O +
2′-O O +
-α O -
- O -
l O +
-fucosyllactose O +
in O +
0.1 O +
M O +
sodium O +
phosphate O +
buffer O +
( O -
pH O +
8) O -
, O +
44 O +
mU O +
of O +
α O -
- O -
l O +
-fucosidase O +
from O +
Alcaligenes O +
sp. O +
was O +
added O -
. O +

The O +
solution O +
was O +
incubated O +
at O +
50 O +
° O -
C O +
and O +
samples O +
( O -
10 O +
μL O -
) O +
were O +
taken O +
out O +
at O +
appropriate O +
time O +
intervals O +
( O -
0 O -
, O +
3 O -
, O +
6 O -
, O +
9 O -
, O +
12 O -
, O +
and O +
15 O +
min O -
) O +
during O +
the O +
incubation O -
. O +

After O +
boiling O +
for O +
5 O +
min O -
, O +
the O +
mono- O +
and O +
oligosaccharides O +
were O +
derivatized O +
with O +
ethyl O +
p O +
-aminobenzoate O +
according O +
to O +
the O +
published O +
methods O +
[ O -
14,15 O -
] O +
. O +

The O +
derivatized O +
sugars O +
were O +
analyzed O +
on O +
a O +
Hitachi O +
F-1050 O +
fluorescence O +
spectrophotometer O +
by O +
HPLC O +
with O +
a O +
Wakosil O -
- O -
II O +
5C18 O +
HG O +
column O +
( O -
4.6 O +
cm O +
diameter O -
× O -
150 O +
mm O -
, O +
Wako O +
Pure O +
Chemical O +
Industries O -
, O +
Ltd. O -
, O +
Osaka O -
, O +
Japan O -
) O +
eluted O +
with O +
1:9 O +
MeCN–0.02 O -
% O +
trifluoroacetic O +
acid O +
at O +
a O +
flow O +
rate O +
of O +
1 O +
mL O -
/ O -
min O -
. O +

3 O +
3 O -
. O +

Results O +
and O +
discussion O +
3.1 O +
Transglycosylation O +
reaction O +
using O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
porcine O +
liver O +
A O +
crude O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
preparation O +
from O +
porcine O +
liver O -
, O +
prepared O +
by O +
precipitation O +
with O +
20–65 O -
% O +
saturated O +
ammonium O +
sulfate O -
, O +
was O +
applied O +
to O +
a O +
CM O -
- O -
Sepharose O +
Fast O +
Flow O +
column O -
. O +

Most O +
of O +
the O +
β B-Gene -
- I-Gene -
d I-Gene +
-galactosidase I-Gene -
, O +
which O +
hydrolyzes O +
the O +
LacNAc O +
used O +
as O +
acceptor O -
, O +
was O +
not O +
absorbed O +
by O +
the O +
gel O +
and O +
eluted O +
out O +
with O +
50 O +
mM O +
NaOAc O +
buffer O +
( O -
pH O +
6 O -
) O -
, O +
and O +
the O +
adsorbed O +
part O +
of O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
was O +
eluted O +
with O +
a O +
linear O +
gradient O +
of O +
NaCl O +
from O +
0 O +
to O +
1 O +
M. O +
The O +
partially O +
purified O +
enzyme B-Gene +
preparation O -
, O +
almost O +
devoid O +
of O +
β B-Gene -
- I-Gene -
d I-Gene +
-galactosidase I-Gene +
activity O -
, O +
was O +
used O +
for O +
the O +
fucosylation O +
reaction O +
without O +
further O +
purification O -
. O +

Transglycosylation O +
of O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
porcine O +
liver O +
was O +
performed O +
with O +
Fucα O -
- O -
p O +
NP O +
and O +
LacNAc O +
for O +
30 O +
h O +
at O +
40 O +
° O -
C O -
. O +

Compounds O +
1 O +
–3 O +
were O +
isolated O +
from O +
the O +
reaction O +
mixture O +
by O +
an O +
activated O +
charcoal O -
– O -
Celite O +
column O +
( O -
Fig. O +
1 O +
) O +
in O +
the O +
ratio O +
of O +
40:37:23 O -
. O +

These O +
products O +
were O +
obtained O +
in O +
13 O -
% O +
total O +
yield O -
, O +
based O +
on O +
the O +
donor O +
added O -
. O +

Compounds O +
1 O +
–3 O +
all O +
showed O +
molecular O +
ions O +
at O +
m O -
/ O -
z O +
530 O +
for O +
[ O -
M+H O -
] O -
+ O +
by O +
FABMS O -
, O +
together O +
with O +
fragment O +
ions O +
at O +
m O -
/ O -
z O +
204 O -
, O +
222 O -
, O +
366 O -
, O +
384 O -
, O +
and O +
512 O +
( O -
HexNAc O -
– O -
water O -
, O +
HexNAc O -
, O +
deoxyHex O -
- O -
HexNAc O -
, O +
Hex O -
- O -
HexNAc O -
, O +
and O +
deoxyHex O -
- O -
Hex O -
- O -
HexNAc O -
– O -
water O -
, O +
respectively O -
) O -
. O +

These O +
data O +
show O +
the O +
trisaccharides O +
to O +
consist O +
of O +
deoxyHex O -
- O -
Hex O -
- O -
HexNAc O -
. O +

Further O -
, O +
the O +
structures O +
of O +
1 O +
–3 O +
were O +
elucidated O +
by O +
1 O +
H O +
and O +
13 O +
C O +
NMR O -
. O +

Table O +
1 O +
summarizes O +
13 O +
C O +
NMR O +
spectral O +
data O +
of O +
these O +
compounds O -
. O +

Compounds O +
1 O +
–3 O +
were O +
thus O +
identified O +
as O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→2 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-GlcNAc O -
, O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-GlcNAc O -
, O +
and O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→6 O -
) O -
-β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-d O +
-GlcNAc O -
, O +
respectively O -
. O +

Fig. O +
2 O +
shows O +
the O +
transglycosylation O +
profile O +
induced O +
by O +
the O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
in O +
a O +
reaction O +
system O +
containing O +
LacNAc O +
acceptor O -
. O +

The O +
transfer O +
products O +
formed O +
were O +
analyzed O +
by O +
HPLC O -
. O +

The O +
time O +
at O +
which O +
maximal O +
production O +
of O +
the O +
total O +
amount O +
of O +
1 O +
–3 O +
was O +
24 O +
h O -
, O +
and O +
the O +
proportions O +
of O +
the O +
three O +
compounds O +
varied O +
little O +
during O +
reaction O -
. O +

The O +
fucosylation O +
shows O +
only O +
low O +
regioselectivity O -
, O +
because O +
it O +
occurs O +
without O +
discrimination O +
at O +
the O +
O-2 O -
, O +
O-3 O -
, O +
and O +
O-6 O +
positions O +
of O +
the O +
Gal O +
moiety O -
, O +
as O +
shown O +
in O +
Fig. O +
3 O +
. O +

As O +
a O +
result O -
, O +
the O +
desired O +
compound O +
1 O +
was O +
obtained O +
in O +
a O +
low O +
yield O +
of O +
5 O -
% O +
based O +
on O +
the O +
donor O -
. O +

No O +
transfer O +
product O +
was O +
observed O +
when O +
lactose O +
instead O +
of O +
LacNAc O +
was O +
used O +
as O +
an O +
acceptor O -
, O +
which O +
was O +
consistent O +
with O +
the O +
result O +
reported O +
by O +
Svensson O +
and O +
Thiem O +
[ O -
9 O -
] O +
. O +

The O +
porcine O +
liver O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene -
- O -
mediated O +
fucosylation O +
seems O +
to O +
recognize O +
subtle O +
differences O +
in O +
the O +
acceptor O +
structure O -
. O +

3.2 O +
Transglycosylation O +
reaction O +
utilizing O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
Alcaligenes O +
sp O +
An O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
the O +
culture O +
of O +
Alcaligenes O +
sp. O +
was O +
partially O +
purified O +
by O +
successive O +
chromatography O +
on O +
Streamline O -
- O -
DEAE O +
and O +
Butyl O -
- O -
Toyopearl O +
650 O -
M O +
columns O -
, O +
and O +
by O +
affinity O +
chromatography O +
on O +
a O +
Fucose O -
– O -
Cellulofine O +
column O -
. O +

The O +
partially O +
purified O +
enzyme B-Gene -
, O +
completely O +
devoid O +
of O +
β B-Gene -
- I-Gene -
d I-Gene +
-galactosidase I-Gene +
activity O -
, O +
was O +
used O +
for O +
the O +
enzyme B-Gene +
synthesis O -
. O +

Compound O +
2 O +
has O +
been O +
synthesized O +
by O +
a O +
chemical O +
method O +
[ O -
16 O -
] O +
. O +

However O -
, O +
it O +
involved O +
elaborate O +
procedures O +
for O +
protection O -
, O +
glycosylation O -
, O +
and O +
deprotection O +
[ O -
16 O -
] O +
. O +

In O +
the O +
present O +
study O -
, O +
compound O +
2 O +
was O +
efficiently O +
synthesized O +
from O +
LacNAc O +
and O +
Fucα O -
- O -
p O +
NP O +
on O +
a O +
100-mmol O +
scale O +
by O +
transglycosylation O +
utilizing O +
the O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene -
. O +

It O +
was O +
conveniently O +
isolated O +
by O +
activated O +
charcoal O -
– O -
Celite O +
chromatography O +
in O +
high O +
yield O +
( O -
54 O -
% O -
) O -
, O +
based O +
on O +
the O +
donor O +
added O -
. O +

In O +
this O +
case O -
, O +
the O +
molar O +
ratio O +
of O +
the O +
donor O +
to O +
acceptor O +
was O +
1:25 O +
and O +
the O +
total O +
substrate O +
concentration O +
was O +
∼10 O -
% O -
. O +

The O +
production O +
of O +
compound O +
2 O +
as O +
a O +
function O +
of O +
time O +
was O +
monitored O +
by O +
HPLC O +
with O +
an O +
Asahipak O +
NH2P-50 O +
column O -
. O +

The O +
chromatogram O +
showed O +
that O +
only O +
one O +
transfer O +
product O +
was O +
formed O +
during O +
the O +
entire O +
course O +
of O +
reaction O +
( O -
50 O +
h O -
) O -
. O +

This O +
is O +
also O +
the O +
case O +
for O +
the O +
formation O +
of O +
4 O +
in O +
the O +
reaction O +
with O +
lactose O +
as O +
the O +
acceptor O -
. O +

Compound O +
4 O +
was O +
obtained O +
as O +
a O +
single O +
transfer O -
- O -
product O +
in O +
high O +
yield O +
( O -
34 O -
% O -
) O -
, O +
based O +
on O +
the O +
donor O -
. O +

This O +
trisaccharide O +
has O +
been O +
synthesized O +
by O +
Baer O +
and O +
Abbas O +
[ O -
17 O -
] O +
. O +

Use O +
of O +
other O +
acceptors O -
, O +
β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-GlcNAcOMe O -
, O +
β O -
- O -
d O +
-Gal- O -
( O -
1→4 O -
) O -
-β O -
- O -
d O +
-GlcOMe O -
, O +
and O +
β O -
- O -
d O +
-Gal- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-GlcOMe O -
, O +
also O +
resulted O +
in O +
highly O +
regioselective O +
transglycosylation O +
from O +
Fucα O -
- O -
p O +
NP O +
to O +
the O +
3-position O +
of O +
the O +
Gal O +
moiety O +
by O +
use O +
of O +
the O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
( O -
Table O +
2 O +
) O -
. O +

This O +
result O +
indicates O +
that O +
introduction O +
of O +
the O +
methyl O +
group O +
at O +
the O +
β O +
anomeric O +
position O +
of O +
the O +
acceptors O +
enhanced O +
the O +
yield O +
of O +
transfer O +
products O -
. O +

These O +
reactions O +
were O +
efficient O +
enough O +
to O +
permit O +
one O -
- O -
pot O +
preparations O +
of O +
compound O +
2 O +
and O +
its O +
analogues O -
. O +

In O +
this O +
way O -
, O +
the O +
enzyme B-Gene +
fucosylated O +
the O +
O-3′ O +
position O +
of O +
the O +
galactose O -
- O -
containing O +
disaccharide O +
acceptors O +
regioselectively O -
, O +
in O +
contrast O +
with O +
the O +
porcine O +
liver O +
enzyme B-Gene -
, O +
and O +
generated O +
an O +
unusual O +
carbohydrate O +
linkage O -
. O +

The O +
α O -
- O -
l O +
-Fuc- O -
( O -
1→3 O -
) O -
-d O +
-Gal O +
linkage O +
is O +
not O +
found O +
in O +
glycoconjugates O +
isolated O +
from O +
diverse O +
sources O -
, O +
but O +
its O +
presence O +
has O +
been O +
reported O +
as O +
part O +
of O +
higher O +
homologues O +
of O +
oligosaccharides O +
from O +
human O +
milk O +
[ O -
18 O -
] O +
. O +

Miyauchi O +
et O +
al. O +
have O +
reported O +
that O +
antiserum O +
against O +
3′-O O +
-α O -
- O -
l O +
-fucosyllactose O -
– O -
p O +
-isothiocyanato O -
- O -
phenethylamine O -
– O -
BSA B-Gene +
preferentially O +
reacts O +
with O +
adenocarcinoma O +
and O +
embryonal O +
carcinoma O +
cells O +
[ O -
19 O -
] O +
. O +

It O +
was O +
shown O +
that O +
the O +
unusual O +
oligosaccharide O +
4 O +
is O +
useful O +
as O +
a O +
probe O +
for O +
investigating O +
biological O +
functions O -
. O +

In O +
a O +
separate O +
experiment O -
, O +
the O +
relative O +
rates O +
of O +
hydrolysis O +
of O +
2′-O O +
-α O -
- O -
l O +
-fucosyllactose O +
and O +
4 O +
were O +
examined O +
using O +
the O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
from O +
Alcaligenes O +
sp. O +

The O +
reactions O +
were O +
linear O +
from O +
3 O +
to O +
15 O +
min O -
, O +
and O +
the O +
rate O +
of O +
attack O +
on O +
4 O +
was O +
arbitrarily O +
set O +
at O +
100 O -
. O +

The O +
relative O +
hydrolysis O +
rate O +
of O +
2′-fucosyllactose O +
was O +
77.5 O +
as O +
compared O +
with O +
that O +
of O +
4 O +
, O +
a O +
difference O +
of O +
only O +
one O -
- O -
fourth O -
. O +

Thus O -
, O +
2′-O O +
-α O -
- O -
l O +
-fucosyllactose O +
seems O +
to O +
be O +
a O +
good O +
substrate O +
for O +
hydrolysis O -
. O +

In O +
general O -
, O +
glycosidases B-Gene +
are O +
known O +
to O +
be O +
responsible O +
for O +
both O +
hydrolytic O +
and O +
transfer O +
activities O -
. O +

Therefore O -
, O +
the O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene +
was O +
also O +
expected O +
to O +
produce O +
a O +
trisaccharide O +
substituted O +
by O +
an O +
α O -
- O -
l O +
-fucosyl O +
group O +
at O +
the O +
O-2′ O +
of O +
lactose O -
, O +
in O +
addition O +
to O +
the O +
O-3′ O +
substituted O +
product O -
. O +

However O -
, O +
the O +
enzyme B-Gene +
induced O +
highly O +
regioselective O +
transglycosylation O +
to O +
the O +
3-position O +
of O +
the O +
Gal O +
moiety O +
from O +
Fucα O -
- O -
p O +
NP O +
and O +
no O +
2′-O O +
-α O -
- O -
l O +
-fucosyllactose O +
was O +
detected O +
during O +
the O +
entire O +
reaction O -
, O +
as O +
already O +
mentioned O -
. O +

There O +
may O +
be O +
other O +
factors O +
affecting O +
the O +
regioselectivity O +
of O +
this O +
transglycosylation O +
reaction O -
. O +

In O +
conclusion O -
, O +
a O +
fucosylated O +
trisaccharide O +
1 O +
of O +
the O +
type O +
2 O +
blood O +
group O +
H O +
substance O +
was O +
prepared O +
by O +
using O +
porcine O +
liver O +
α B-Gene -
- I-Gene -
l I-Gene +
-fucosidase I-Gene -
- O -
mediated O +
transglycosylation O -
. O +

We O +
have O +
also O +
developed O +
a O +
practical O +
synthetic O +
method O +
for O +
obtaining O +
fucosylated O +
trisaccharides O +
2 O +
and O +
4 O +
, O +
which O +
contain O +
the O +
unusual O +
α- O -
( O -
1→3 O -
) O +
linkage O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
Grants O -
- O -
in O -
- O -
Aid O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O -
, O +
and O +
Culture O -
, O +
Japan O -
, O +
by O +
the O +
Research O +
Grant O +
for O +
Leading O +
Research O +
Utilizing O +
Potential O +
of O +
Regional O +
Science O +
and O +
Technology O +
from O +
Science O +
and O +
Technology O +
Agency O -
, O +
Japan O -
, O +
and O +

by O +
a O +
Research O +
Grant O +
from O +
the O +
Ministry O +
of O +
Agriculture O -
, O +
Forestry O +
and O +
Fisheries O -
, O +
Japan O -
. O +

Cytochrome B-Gene +
P450 I-Gene +
( O -
CYP B-Gene -
) O +
enzymes B-Gene +
are O +
heme B-Gene -
- I-Gene -
thiolate I-Gene +
proteins I-Gene +
that O +
are O +
responsible O +
for O +
the O +
oxidative O +
metabolism O +
of O +
a O +
wide O +
variety O +
of O +
xenobiotics O +
[ O -
1 O -
] O +
. O +

They O +
comprise O +
a O +
superfamily O +
of O +
related O +
enzymes B-Gene +
that O +
are O +
grouped O +
into O +
families O +
and O +
subfamilies O +
based O +
on O +
similarities O +
in O +
amino O +
acid O +
sequences O -
. O +

The O +
determination O +
of O +
the O +
CYP B-Gene +
enzymes I-Gene +
responsible O +
for O +
the O +
metabolism O +
of O +
new O +
chemical O +
entities O +
( O -
NCE O -
) O +
and O +
the O +
identification O +
of O +
interactions O +
with O +
a O +
specific O +
CYP B-Gene +
isozyme I-Gene +
( O -
e.g. O +
inhibition O +
of O +
that O +
isozyme B-Gene -
) O +
can O +
aid O +
in O +
predicting O +
clinical O +
drug O +
interactions O +
[ O -
2 O -
] O +
. O +

The O +
CYP B-Gene +
family I-Gene +
of I-Gene +
enzymes I-Gene +
has O +
been O +
shown O +
to O +
be O +
responsible O +
for O +
the O +
hydroxylation O +
of O +
steroids O +
and O +
related O +
compounds O -
. O +

Specifically O -
, O +
the O +
6β O -
- O -
hydroxylation O +
of O +
testosterone O +
is O +
known O +
to O +
be O +
mediated O +
by O +
the O +
CYP3A B-Gene +
family O +
of O +
CYP B-Gene +
enzymes I-Gene +
in O +
a O +
variety O +
of O +
species O +
[ O -
3 O -
] O +
. O +

By O +
measuring O +
the O +
rate O +
of O +
formation O +
of O +
the O +
testosterone O +
metabolite O -
, O +
6β O -
- O -
hydroxytestosterone O -
, O +
the O +
CYP3A B-Gene +
activity O +
of O +
a O +
preparation O +
of O +
hepatic O +
microsomes O +
can O +
be O +
determined O -
. O +

Several O +
HPLC O +
methods O +
have O +
been O +
reported O +
for O +
the O +
separation O +
of O +
testosterone O +
and O +
its O +
many O +
hydroxylated O +
metabolites O +
[ O -
3–9 O -
] O +
. O +

Most O +
use O +
gradient O +
elution O +
with O +
run O +
times O +
greater O +
than O +
30 O +
min O +
followed O +
by O +
an O +
additional O +
between O -
- O -
run O +
reequilibration O -
. O +

Some O +
of O +
these O +
methods O +
require O +
complex O +
gradient O +
systems O +
that O +
often O +
cause O +
significant O +
changes O +
in O +
the O +
baseline O +
that O +
affect O +
resolution O +
and O +
detection O +
of O +
later O -
- O -
eluting O +
peaks O -
. O +

In O +
an O +
attempt O +
to O +
alleviate O +
some O +
of O +
these O +
problems O -
, O +
an O +
isocratic O +
HPLC O +
method O +
has O +
been O +
developed O +
[ O -
8 O -
] O +
, O +
however O -
, O +
the O +
total O +
run O +
time O +
for O +
this O +
method O +
is O +
still O +
greater O +
than O +
30 O +
min O -
. O +

A O +
slightly O +
faster O +
capillary O +
electrophoretic O +
method O +
has O +
recently O +
been O +
reported O +
[ O -
10 O -
] O +
with O +
a O +
run O +
time O +
of O +
20 O +
min O +
and O +
two O +
between O -
- O -
run O +
rinses O +
totaling O +
5 O +
min O -
. O +

This O +
method O -
, O +
however O -
, O +
suffers O +
from O +
poor O +
sensitivity O +
and O +
poor O +
inter O -
- O -
day O +
migration O +
time O +
reproducibility O -
. O +

Watanabe O +
et O +
al. O +
have O +
reported O +
a O +
more O +
rapid O +
gas O +
chromatography O -
– O -
mass O +
spectrometry O +
( O -
GC O -
– O -
MS O -
) O +
method O +
[ O -
11 O -
] O +
, O +
but O +
it O +
requires O +
an O +
extraction O +
step O +
and O +
a O +
timely O +
multi O -
- O -
step O +
derivatization O +
of O +
the O +
hydroxylated O +
metabolites O -
. O +

In O +
addition O -
, O +
separable O +
syn O +
- O +
and O +
anti O +
-isomers O +
of O +
some O +
of O +
the O +
derivatized O +
metabolites O +
are O +
formed O -
. O +

A O +
rapid O +
non O -
- O -
chromatographic O +
procedure O +
employing O +
tritium O -
- O -
labeled O +
testosterone O +
was O +
also O +
recently O +
published O +
[ O -
12 O -
] O +
. O +

Safety O +
and O +
cost O +
considerations O +
make O +
this O +
method O +
far O +
from O +
ideal O -
. O +

Herein O +
is O +
described O +
a O +
method O +
for O +
the O +
determination O +
of O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
employing O +
gas O +
chromatography O +
with O +
selected O +
ion O +
monitoring O +
mass O +
spectrometric O +
detection O +
( O -
GC O -
– O -
SIM O -
– O -
MS O -
) O -
. O +

The O +
method O +
does O +
not O +
require O +
derivatization O +
and O +
testosterone O +
and O +
its O +
metabolites O +
are O +
separated O +
in O +
less O +
than O +
15 O +
min O -
. O +

In O +
addition O -
, O +
the O +
selectivity O +
and O +
specificity O +
of O +
the O +
mass O +
spectrometer O +
helps O +
eliminate O +
interferences O +
from O +
compounds O +
being O +
evaluated O +
using O +
this O +
methodology O +
which O +
is O +
occasionally O +
a O +
problem O +
when O +
using O +
the O +
HPLC O -
– O -
UV O +
or O +
CE O -
– O -
UV O +
methods O +
previously O +
reported O -
. O +

2 O +
Experimental O +
2.1 O +
Chemicals O +
Testosterone O -
, O +
17α O -
- O -
methyltestosterone O -
, O +
androstenedione O -
, O +
2β O -
- O -
hydroxytestosterone O +
phenylmethylsulfonyl O +
fluoride O +
( O -
PMSF O -
) O -
, O +
butylated O +
hydroxytoluene O +
( O -
BHT O -
) O -
, O +
and O +
Sigma O +
Ultra O +
grade O +
potassium O +
chloride O -
, O +
EDTA O -
, O +
HEPES O -
, O +
glycerol O -
, O +
and O +
magnesium O +
chloride O +
were O +
obtained O +
from O +
Sigma O +
Chemical O +
Co. O +
( O -
St. O +

Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

2α- O -
, O +
6β- O -
, O +
7α- O -
, O +
16α- O -
, O +
and O +
16β O -
- O -
hydroxytestosterone O +
were O +
obtained O +
from O +
Steraloids O -
, O +
Inc. O +
( O -
Wilton O -
, O +
NH O -
, O +
USA O -
) O -
. O +

HPLC O -
- O -
grade O +
methylene O +
chloride O +
( O -
J.T. O +
Baker O -
) O -
, O +
GC O -
– O -
MS O -
- O -
grade O +
methanol O +
( O -
Burdick O +
and O +
Jackson O -
) O -
, O +
and O +
UV O -
- O -
grade O +
acetonitrile O +
( O -
Burdick O +
and O +
Jackson O -
) O +
were O +
purchased O +
from O +
VWR O +
Scientific O +
Products O +
( O -
Suwanee O -
, O +
GA O -
, O +
USA O -
) O -
. O +

Bovine B-Gene +
serum I-Gene +
albumin I-Gene +
and O +
other O +
materials O +
for O +
determining O +
microsomal O +
protein B-Gene +
content O +
were O +
obtained O +
from O +
BioRad O +
( O -
Hercules O -
, O +
CA O -
, O +
USA O -
) O -
. O +

2.2 O +
Isolation O +
of O +
hepatic O +
microsomes O +
Human O +
liver O +
microsomes O +
were O +
prepared O +
using O +
a O +
differential O +
centrifugation O +
method O +
as O +
follows O -
: O +
Human O +
livers O +
rejected O +
for O +
transplant O +
were O +
received O +
fresh O +
from O +
the O +
International O +
Institute O +
for O +
the O +
Advancement O +
of O +
Medicine O +
( O -
Exton O -
, O +
PA O -
, O +
USA O -
) O +
in O +
less O +
than O +
36 O +
h O +
post O -
- O -
clamp O +
time O +
or O +
frozen O +
from O +
the O +
Association O +
of O +
Human O +
Tissue O +
Users O +
( O -
Tucson O -
, O +
AZ O -
, O +
USA O -
) O -
. O +

The O +
liver O +
tissue O +
was O +
minced O +
and O +
rinsed O +
in O +
a O +
1.15 O -
% O +
( O -
w O -
/ O -
v O -
) O +
KCl O +
solution O -
. O +

The O +
tissue O +
was O +
weighed O -
, O +
washed O +
in O +
three O +
volumes O +
of O +
a O +
homogenization O +
buffer O +
( O -
100 O +
mM O +
Tris O +
acetate O -
, O +
1 O +
mM O +
EDTA O -
, O +
100 O +
mM O +
KCl O -
, O +
20 O +
μM O +
BHT O -
, O +
pH O +
7.4 O -
) O +
and O +
then O +
homogenized O +
in O +
a O +
motorized O +
homogenizer O +
( O -
Omni O +
International O -
, O +
Atlanta O -
, O +
GA O -
, O +
USA O -
) O +
with O +
two O +
20 O +
s O +
bursts O -
. O +

The O +
homogenate O +
was O +
centrifuged O +
at O +
approximately O +
10 O +
000 O +
g O +
for O +
30 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
supernatant O +
( O -
s9 O -
) O +
was O +
transferred O +
to O +
fresh O +
centrifuge O +
tubes O +
and O +
then O +
centrifuged O +
at O +
approximately O +
100 O +
000 O +
g O +
for O +
70 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
pellet O +
was O +
washed O +
once O +
in O +
1.5 O +
volumes O +
of O +
a O +
buffer O +
containing O +
100 O +
mM O +
tetrapotassium O +
pyrophosphate O -
, O +
1 O +
mM O +
EDTA O -
, O +
and O +
20 O +
μM O +
BHT O +
( O -
adjusted O +
to O +
pH O +
7.4 O +
with O +
6 O +
M O +
HCl O -
) O +
by O +
resuspending O +
and O +
homogenizing O +
in O +
a O +
glass O +
dounce O +
homogenizer O -
. O +

The O +
resuspended O +
pellet O +
was O +
centrifuged O +
again O +
at O +
100 O +
000 O +
g O +
for O +
70 O +
min O +
at O +
4 O -
° O -
C O -
. O +

The O +
resulting O +
pellet O +
was O +
resuspended O +
in O +
a O +
storage O +
buffer O +
( O -
10 O +
mM O +
Tris O +
acetate O -
, O +
1 O +
mM O +
EDTA O -
, O +
100 O +
μM O +
PMSF O -
, O +
and O +
20 O -
% O +
glycerol O -
, O +
pH O +
7.4 O -
) O +
using O +
the O +
glass O +
dounce O +
homogenizer O -
, O +
aliquoted O +
( O -
1 O +
ml O -
) O +
into O +
screw O -
- O -
cap O +
cryovials O -
, O +
and O +
stored O +
at O +
−80 O -
° O -
C O +
until O +
use O -
. O +

Microsomal O +
protein B-Gene +
content O +
was O +
determined O +
using O +
the O +
Bradford O +
method O +
[ O -
13 O -
] O +
and O +
total O +
CYP B-Gene +
content O +
was O +
determined O +
spectrophotometrically O +
using O +
the O +
method O +
of O +
Omura O +
and O +
Sato O +
[ O -
14 O -
] O +
. O +

2.3 O +
Microsomal O +
incubations O +
A O +
total O +
incubation O +
volume O +
of O +
500 O +
μl O +
of O +
HEPES O +
buffer O +
( O -
50 O +
mM O +
HEPES O -
, O +
15 O +
mM O +
MgCl2 O -
, O +
0.1 O +
mM O +
EDTA O -
, O +
pH O +
7.6 O -
) O +
containing O +
an O +
NADPH O +
regeneration O +
system O +
( O -
1 O +
mM O +
NADP+ O +
, O +
10 O +
mM O +
glucose O +
6-phosphate O -
, O +
and O +
1 O +
IU O +
glucose O +
6-phosphate O +
dehydrogenase O -
) O +
and O +
hepatic O +
microsomes O +
( O -
0.5 O +
mg O +
protein B-Gene -
) O +
was O +
pre O -
- O -
incubated O +
at O +
37 O -
° O -
C O +
for O +
3 O +
min O -
. O +

The O +
enzymatic O +
reaction O +
was O +
initiated O +
upon O +
addition O +
of O +
testosterone O +
( O -
100 O +
μM O +
, O +
from O +
10 O +
mM O +
stock O +
in O +
MeOH O -
) O -
. O +

Blank O +
incubations O +
were O +
prepared O +
in O +
the O +
absence O +
of O +
the O +
NADPH O -
- O -
regeneration O +
system O -
. O +

Following O +
a O +
30 O +
min O +
incubation O +
at O +
37 O -
° O -
C O -
, O +
the O +
reaction O +
was O +
terminated O +
with O +
3 O +
ml O +
of O +
methylene O +
chloride O -
. O +

After O +
the O +
addition O +
of O +
50 O +
μl O +
of O +
methyltestosterone O +
internal O +
standard O +
solution O +
( O -
100 O +
μM O +
) O -
, O +
the O +
samples O +
were O +
vortexed O +
for O +
about O +
30 O +
s O +
and O +
then O +
centrifuged O +
at O +
1400 O +
g O +
for O +
2 O +
min O -
. O +

The O +
top O +
aqueous O +
layer O +
and O +
any O +
precipitate O +
at O +
the O +
phase O +
interface O +
was O +
aspirated O -
. O +

The O +
remaining O +
methylene O +
chloride O +
layer O +
was O +
evaporated O +
to O +
dryness O +
under O +
a O +
gentle O +
stream O +
of O +
nitrogen O -
. O +

Acetonitrile O +
( O -
0.5 O +
ml O -
) O +
was O +
added O -
, O +
and O +
each O +
tube O +
was O +
vortexed O +
briefly O -
. O +

Finally O -
, O +
the O +
content O +
of O +
each O +
tube O +
was O +
transferred O +
to O +
an O +
autosampler O +
vial O +
for O +
GC O -
– O -
SIM O -
– O -
MS O +
analysis O -
. O +

2.4 O +
Calibration O +
standard O +
preparation O +
A O +
stock O +
solution O +
containing O +
testosterone O +
( O -
1 O +
mM O +
) O +
and O +
6β O -
- O -
hydroxytestosterone O +
( O -
1 O +
mM O +
) O +
was O +
prepared O +
in O +
methanol O +
and O +
stored O +
at O +
4 O -
° O -
C O -
. O +

Working O +
solutions O +
of O +
varying O +
concentrations O +
down O +
to O +
2.5 O +
μM O +
were O +
prepared O +
from O +
dilutions O +
of O +
the O +
stock O +
solution O +
with O +
methanol O -
. O +

Calibration O +
standard O +
samples O +
( O -
0.25 O +
μM O +
, O +
0.50 O +
μM O +
, O +
1.0 O +
μM O +
, O +
5.0 O +
μM O +
, O +
10 O +
μM O +
, O +
50 O +
μM O +
, O +
and O +
100 O +
μM O +
) O +
covering O +
a O +
calibration O +
range O +
of O +
0.25 O +
to O +
100 O +
μM O +
were O +
prepared O +
by O +
adding O +
50 O +
μl O +
of O +
each O +
working O +
solution O +
to O +
400 O +
μl O +
water O +
and O +
50 O +
μl O +
of O +
HEPES O +
buffer O -
. O +

The O +
samples O +
were O +
spiked O +
with O +
50 O +
μl O +
of O +
methyltestosterone O +
internal O +
standard O +
solution O +
( O -
100 O +
μM O +
) O +
and O +
extracted O +
as O +
described O +
above O +
for O +
the O +
microsomal O +
incubates O -
. O +

2.5 O +
GC O -
– O -
MS O +
conditions O +
The O +
samples O +
were O +
analyzed O +
on O +
a O +
HP5890 O +
Series O +
II O +
Gas O +
Chromatograph O +
interfaced O +
to O +
a O +
HP5971A O +
Mass O +
Selective O +
Detector O +
( O -
Hewlett O -
- O -
Packard O -
, O +
Palo O +
Alto O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Testosterone O -
, O +
its O +
metabolites O -
, O +
and O +
the O +
internal O +
standard O +
were O +
separated O +
on O +
a O +
HP-5MS O +
capillary O +
column O +
( O -
30 O +
m O +
× O +
0.25 O +
mm O -
, O +
0.25 O +
μm O +
film O +
thickness O -
) O +
that O +
was O +
introduced O +
directly O +
into O +
the O +
source O +
of O +
the O +
mass O +
spectrometer O -
. O +

The O +
capillary O +
column O +
flow O -
- O -
rate O +
( O -
He O -
) O +
was O +
kept O +
constant O +
at O +
approximately O +
1 O +
ml O -
/ O -
min O -
. O +

using O +
electronic O +
pressure O +
control O -
. O +

A O +
1 O +
μl O +
splitless O +
injection O +
was O +
made O +
using O +
a O +
purge O +
activation O +
time O +
of O +
1 O +
min O -
. O +

The O +
injection O +
port O +
temperature O +
was O +
280 O -
° O -
C O -
. O +

The O +
oven O +
was O +
held O +
at O +
80 O -
° O -
C O +
for O +
1 O +
min O +
and O +
then O +
ramped O +
at O +
20 O -
° O -
C O +
per O +
min O +
to O +
a O +
final O +
temperature O +
of O +
300 O -
° O -
C O +
and O +
held O +
for O +
3 O +
min O -
. O +

Positive O -
- O -
ion O +
electron O +
ionization O +
mass O +
spectra O +
were O +
acquired O +
at O +
an O +
electron O +
energy O +
of O +
70 O +
eV O +
with O +
an O +
ion O +
source O +
temperature O +
of O +
170 O -
° O -
C O +
and O +
an O +
interface O +
temperature O +
of O +
280 O -
° O -
C O -
. O +

For O +
quantitation O -
, O +
the O +
mass O +
spectrometer O +
was O +
operated O +
in O +
the O +
selected O +
ion O +
monitoring O +
mode O +
and O +
set O +
to O +
monitor O +
ions O +
at O +
m O -
/ O -
z O +
288 O -
, O +
304 O -
, O +
and O +
302 O +
( O -
100 O +
ms O +
per O +
ion O -
) O +
for O +
testosterone O -
, O +
6β O -
- O -
hydroxytestosterone O -
, O +
and O +
methyltestosterone O -
, O +
respectively O -
. O +

3 O +
Results O +
and O +
discussion O +
3.1 O +
Method O +
development O +
Full O +
scan O +
positive O +
ion O +
electron O +
impact O +
mass O +
spectra O +
( O -
50–350 O +
amu O -
) O +
of O +
testosterone O -
, O +
methyltestosterone O -
, O +
and O +
6β O -
- O -
hydroxytestosterone O +
were O +
acquired O +
to O +
determine O +
the O +
ions O +
to O +
monitor O +
in O +
the O +
SIM O +
mode O -
. O +

Representative O +
spectra O +
are O +
shown O +
in O +
Fig. O +
1 O +
. O +

The O +
base O +
peak O +
in O +
the O +
mass O +
spectrum O +
of O +
testosterone O +
was O +
a O +
common O +
steroid O +
fragment O -
, O +
m O -
/ O -
z O +
124 O -
. O +

Therefore O -
, O +
the O +
molecular O +
ion O +
( O -
m O -
/ O -
z O +
288 O -
) O -
, O +
which O +
is O +
less O +
abundant O +
but O +
more O +
specific O -
, O +
was O +
chosen O +
for O +
testosterone O -
. O +

The O +
base O +
peaks O +
for O +
methyltestosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
were O +
the O +
molecular O +
ions O -
, O +
m O -
/ O -
z O +
302 O +
and O +
m O -
/ O -
z O +
304 O -
, O +
respectively O -
. O +

These O +
ions O +
were O +
selected O +
for O +
the O +
GC O -
– O -
SIM O -
– O -
MS O +
method O -
. O +

A O +
representative O +
chromatogram O +
from O +
a O +
sample O +
containing O +
testosterone O +
after O +
incubation O +
with O +
human O +
liver O +
microsomes O +
is O +
shown O +
in O +
Fig. O +
2 O +
. O +

The O +
retention O +
times O +
of O +
testosterone O -
, O +
methyltestosterone O -
, O +
and O +
6β O -
- O -
hydroxytestosterone O +
were O +
approximately O +
12.7 O -
, O +
12.8 O -
, O +
and O +
13.4 O +
min O -
, O +
respectively O -
. O +

Even O +
without O +
derivatization O -
, O +
no O +
significant O +
tailing O +
of O +
the O +
chromatographic O +
peaks O +
occurred O -
. O +

In O +
addition O -
, O +
no O +
thermal O +
degradation O +
of O +
the O +
steroids O +
was O +
observed O -
. O +

3.2 O +
Specificity O +
The O +
method O +
was O +
evaluated O +
for O +
possible O +
interferences O +
from O +
other O +
known O +
CYP450 B-Gene +
metabolites O +
of O +
testosterone O -
. O +

Androstenedione O +
( O -
12.6 O +
min O -
) O -
, O +
2α O -
- O -
hydroxy- O +
( O -
13.1 O +
min O -
) O -
, O +
2β O -
- O -
hydroxy- O +
( O -
13.0 O +
min O -
) O -
, O +
7α O -
- O -
hydroxy- O +
( O -
13.6 O +
min O -
) O -
, O +
16α O -
- O -
hydroxy- O +
( O -
13.8 O +
min O -
) O -
, O +
and O +
16β O -
- O -
hydroxytestosterone O +
( O -
13.9 O +
min O -
) O -
, O +
were O +
fully O +
resolved O +
from O +
testosterone O -
, O +
6β O -
- O -
hydroxytestosterone O -
, O +
and O +
methyltestosterone O -
. O +

In O +
addition O -
, O +
the O +
inherent O +
selectivity O +
and O +
specificity O +
of O +
the O +
mass O +
spectrometric O +
detector O +
has O +
eliminated O +
interferences O +
from O +
compounds O +
evaluated O +
using O +
this O +
methodology O -
. O +

3.3 O +
Linearity O +
Seven O +
calibration O +
standards O +
ranging O +
in O +
concentration O +
from O +
0.25 O +
to O +
100 O +
μM O +
for O +
both O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
were O +
interspersed O +
with O +
samples O +
for O +
each O +
analytical O +
run O -
. O +

Weighted O +
( O -
1 O -
/ O -
x O +
2 O +
) O +
linear O +
regressions O +
of O +
peak O +
area O +
ratios O +
of O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
to O +
the O +
internal O +
standard O -
, O +
methyltestosterone O -
, O +
as O +
a O +
function O +
of O +
concentration O +
were O +
performed O +
to O +
obtain O +
a O +
standard O +
curve O +
from O +
which O +
unknowns O +
were O +
quantified O -
. O +

Weighted O +
regressions O +
were O +
used O +
to O +
provide O +
homogeneity O +
of O +
variance O +
across O +
the O +
calibration O +
range O -
. O +

The O +
method O +
was O +
linear O +
from O +
0.25 O +
to O +
100 O +
μM O +
for O +
both O +
compounds O -
. O +

Regression O +
data O +
( O -
slope O -
, O +
intercept O -
, O +
and O +
correlation O +
coefficient O -
) O +
from O +
five O +
successive O +
analytical O +
runs O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

Excellent O +
correlation O +
and O +
slope O +
reproducibility O +
was O +
observed O +
for O +
each O +
compound O -
. O +

3.4 O +
Precision O +
and O +
accuracy O +
Inter O -
- O -
day O +
precision O +
and O +
accuracy O +
of O +
the O +
method O +
were O +
determined O +
from O +
the O +
back O -
- O -
calculated O +
results O +
for O +
the O +
seven O +
calibration O +
standards O +
for O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
from O +
the O +
five O +
runs O +
listed O +
in O +
Table O +
1 O +
. O +

Within O -
- O -
day O +
precision O +
was O +
determined O +
by O +
assaying O +
six O +
replicates O +
at O +
each O +
of O +
three O +
different O +
concentrations O +
of O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
in O +
one O +
analytical O +
run O -
. O +

The O +
results O +
are O +
shown O +
in O +
Table O +
2 O +
. O +

Within O -
- O -
day O +
and O +
inter O -
- O -
day O +
precision O +
( O -
expressed O +
as O +
relative O +
standard O +
deviation O -
) O +
was O +
less O +
than O +
5 O -
% O +
for O +
all O +
concentrations O +
of O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O -
. O +

Accuracies O +
ranged O +
from O +
95.8 O +
to O +
105.8 O -
% O +
for O +
testosterone O +
and O +
94.6 O +
to O +
104.2 O -
% O +
for O +
6β O -
- O -
hydroxytestosterone O -
. O +

3.5 O +
Extraction O +
recovery O +
The O +
extraction O +
recovery O +
of O +
the O +
analytes O +
and O +
internal O +
standard O +
was O +
determined O +
by O +
comparing O +
the O +
peak O +
areas O +
of O +
spiked O +
microsomal O +
samples O +
extracted O +
with O +
methylene O +
chloride O +
to O +
the O +
peak O +
areas O +
of O +
standard O +
solutions O +
at O +
the O +
same O +
concentration O +
not O +
carried O +
through O +
the O +
extraction O +
procedure O -
. O +

Recovery O +
was O +
determined O +
at O +
three O +
concentrations O +
( O -
0.5 O +
μM O +
, O +
5 O +
μM O +
, O +
and O +
50 O +
μM O +
) O +
across O +
the O +
concentration O +
range O +
for O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O -
, O +
and O +
at O +
10 O +
μM O +
for O +
methyltestosterone O -
. O +

Mean O +
percentage O +
recoveries O +
for O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
were O +
95%±2 O -
% O +
( O -
n O +
= O -
18 O -
) O +
and O +
98%±7 O -
% O +
( O -
n O +
= O -
18 O -
) O -
, O +
respectively O -
. O +

Mean O +
percentage O +
recovery O +
for O +
methyltestosterone O +
was O +
98%±3 O -
% O +
( O -
n O +
= O -
6 O -
) O -
. O +

3.6 O +
Applications O +
The O +
method O +
has O +
been O +
used O +
to O +
analyze O +
over O +
2500 O +
samples O +
for O +
6β O -
- O -
hydroxytestosterone O +
and O +
testosterone O -
. O +

It O +
has O +
been O +
used O +
to O +
characterize O +
the O +
CYP3A B-Gene +
metabolic O +
activity O +
of O +
multiple O +
preparations O +
of O +
human O -
, O +
rat O -
, O +
and O +
dog O +
hepatic O +
microsomes O -
, O +
precision O -
- O -
cut O +
slices O -
, O +
and O +
tissue O +
homogenates O -
. O +

The O +
method O +
has O +
also O +
been O +
used O +
to O +
screen O +
drugs O +
and O +
NCEs O +
for O +
inhibitory O +
effects O +
on O +
human O +
CYP3A4 B-Gene -
. O +

The O +
effect O +
of O +
troleandomycin O +
( O -
TAO O -
) O -
, O +
a O +
known O +
CYP3A4 B-Gene +
inhibitor O -
, O +
on O +
testosterone O +
6β O -
- O -
hydroxylation O +
has O +
been O +
determined O +
using O +
this O +
method O -
. O +

The O +
percent O +
inhibition O +
of O +
testosterone O +
6β O -
- O -
hydroxylation O +
( O -
as O +
compared O +
to O +
control O +
samples O +
with O +
no O +
TAO O +
present O -
) O +
was O +
plotted O +
as O +
a O +
function O +
of O +
TAO O +
concentration O +
( O -
Fig. O +
3 O +
) O -
. O +

The O +
inhibition O +
of O +
testosterone O +
6β O -
- O -
hydroxylation O +
by O +
TAO O +
determined O +
using O +
this O +
method O +
compares O +
favorably O +
to O +
results O +
reported O +
previously O +
[ O -
15 O -
] O +
. O +

Because O +
other O +
testosterone O +
metabolites O +
are O +
resolved O +
using O +
this O +
method O -
, O +
it O +
can O +
also O +
be O +
used O +
to O +
monitor O +
the O +
activity O +
of O +
other O +
CYP B-Gene +
enzymes I-Gene +
that O +
have O +
been O +
shown O +
to O +
produce O +
specific O +
hydroxylated O +
testosterone O +
metabolites O +
[ O -
3 O -
] O +
. O +

Chromatograms O +
from O +
incubations O +
of O +
testosterone O +
with O +
rat O +
liver O +
microsomes O +
with O +
and O +
without O +
NADPH O +
are O +
shown O +
in O +
Fig. O +
4 O +
. O +

The O +
reconstructed O +
ion O +
chromatogram O +
( O -
m O -
/ O -
z O +
304 O -
) O +
from O +
the O +
sample O +
of O +
testosterone O +
incubated O +
with O +
rat O +
liver O +
microsomes O +
and O +
NADPH O +
shows O +
evidence O +
for O +
2α- O -
, O +
2β- O -
, O +
6β- O -
, O +
7α- O -
, O +
and O +
16α O -
- O -
hydroxytestosterone O -
. O +

The O +
method O +
could O +
be O +
further O +
optimized O +
for O +
these O +
additional O +
metabolites O +
by O +
monitoring O +
the O +
most O +
abundant O +
ions O +
in O +
the O +
full O +
scan O +
mass O +
spectra O +
of O +
these O +
compounds O -
. O +

4 O +
Conclusions O +
A O +
method O +
has O +
been O +
developed O +
for O +
the O +
determination O +
of O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O +
using O +
GC O -
– O -
SIM O -
– O -
MS O -
. O +

The O +
run O +
time O +
of O +
the O +
method O +
( O -
15 O +
min O -
) O +
is O +
half O +
that O +
of O +
previously O +
reported O +
HPLC O +
and O +
CE O +
methods O -
. O +

The O +
method O +
displays O +
excellent O +
precision O +
and O +
accuracy O +
over O +
a O +
linear O +
range O +
of O +
0.25 O +
to O +
100 O +
μM O +
for O +
testosterone O +
and O +
6β O -
- O -
hydroxytestosterone O -
. O +

The O +
selectivity O +
of O +
the O +
mass O +
spectrometric O +
detector O +
helps O +
eliminate O +
possible O +
interferences O +
from O +
compounds O +
evaluated O +
using O +
this O +
methodology O -
. O +

The O +
assay O +
has O +
been O +
used O +
to O +
characterize O +
the O +
CYP3A B-Gene +
activity O +
of O +
preparations O +
of O +
hepatic O +
microsomes O -
, O +
precision O -
- O -
cut O +
slices O -
, O +
and O +
tissue O +
homogenates O +
from O +
a O +
variety O +
of O +
species O -
. O +

The O +
platinum O +
coordination O +
complexes O +
cisplatin O -
, O +
and O +
its O +
less O +
toxic O +
analog O -
, O +
carboplatin O +
represent O +
two O +
of O +
the O +
major O +
drugs O +
currently O +
used O +
in O +
the O +
treatment O +
of O +
cancer O -
. O +

However O -
, O +
for O +
some O +
time O +
it O +
has O +
been O +
recognised O +
that O +
these O +
two O +
drugs O +
are O +
active O +
against O +
broadly O +
the O +
same O +
types O +
of O +
tumour O +
[ O -
1 O -
] O +
. O +

Thus O +
one O +
major O +
theme O +
of O +
analog O +
development O +
has O +
involved O +
attempting O +
to O +
widen O +
the O +
spectrum O +
of O +
antitumour O +
activity O +
to O +
tumours O +
that O +
are O +
initially O -
, O +
or O +
have O +
become O -
, O +
unresponsive O +
to O +
cisplatin O -
/ O -
carboplatin O -
. O +

Despite O +
considerable O +
effort O +
illustrated O +
by O +
the O +
description O +
of O +
hundreds O +
of O +
analogs O -
, O +
and O +
the O +
phase O +
I O +
clinical O +
evaluation O +
of O +
around O +
25 O +
compounds O -
, O +
only O +
one O -
, O +
carboplatin O -
, O +
is O +
widely O +
registered O +
for O +
use O +
[ O -
2 O +
for O +
a O +
review O -
] O +
. O +

While O +
carboplatin O -
, O +
and O +
the O +
orally O +
active O +
platinum O +
drug O -
, O +
JM216 O +
[ O -
3,4 O -
] O +
have O +
addressed O +
issues O +
of O +
patient O +
quality O +
of O +
life O -
, O +
in O +
terms O +
of O +
circumvention O +
of O +
tumour O +
resistance O +
to O +
cisplatin O -
, O +
there O +
has O +
been O +
less O +
progress O -
. O +

Current O +
platinum O +
drugs O +
undergoing O +
clinical O +
trial O +
such O +
as O +
oxaliplatin O +
( O -
which O +
has O +
exhibited O +
some O +
activity O +
in O +
colorectal O +
cancer O -
, O +
especially O +
in O +
combination O +
with O +
5-fluorouracil O +
[ O -
5 O -
] O +
, O +
and O +
the O +
sterically O +
hindered O +
drug O -
, O +
AMD473 O +
( O -
ZD0473 O -
) O -
, O +
which O +
demonstrated O +
in O +
vivo O +
circumvention O +
of O +
acquired O +
cisplatin O +
resistance O +
in O +
human O +
tumour O +
xenografts O +
[ O -
6 O -
] O +
may O +
provide O +
some O +
widening O +
of O +
the O +
spectrum O +
of O +
antitumor O +
activity O +
obtained O +
with O +
the O +
parent O +
drugs O -
. O +

One O +
rational O +
approach O +
to O +
the O +
discovery O +
of O +
more O +
broad O -
- O -
spectrum O +
third O +
generation O +
platinum O +
drugs O +
is O +
to O +
design O +
novel O +
platinum O +
agents O +
which O +
bind O +
to O +
DNA O +
in O +
a O +
manner O +
distinct O +
from O +
that O +
of O +
cisplatin O +
and O +
carboplatin O -
, O +
which O +
both O +
ultimately O +
form O +
a O +
similar O +
spectrum O +
of O +
DNA O +
adducts O +
[ O -
7 O -
] O +
. O +

This O +
strategy O +
is O +
probably O +
best O +
exemplified O +
by O +
the O +
discovery O +
of O +
active O +
trans O +
platinum O +
complexes O -
, O +
initially O +
by O +
Farrell O +
and O +
co O -
- O -
workers O +
[ O -
8–10 O -
] O +
. O +

This O +
surprising O +
finding O +
broke O +
one O +
of O +
the O +
original O +
structure O -
- O -
activity O +
rules O +
for O +
platinum O +
complexes O -
, O +
namely O +
that O +
only O +
the O +
cis O +
isomers O +
were O +
endowed O +
with O +
antitumor O +
activity O +
[ O -
11 O -
] O +
. O +

Active O +
trans O +
platinum O +
complexes O +
have O +
also O +
been O +
described O +
based O +
on O +
platinum O -
( O -
II O -
) O +
iminoether O +
complexes O +
[ O -
12–14 O -
] O +
and O +
as O +
part O +
of O +
our O +
collaboration O +
with O +
the O +
Johnson O +
Matthey O +
Technology O +
Centre O -
, O +
namely O +
JM335 O +
[ O -
trans O +
ammine O +
( O -
cyclohexylaminedichlorodihydroxo O -
) O +
platinum O -
( O -
IV O -
) O -
] O +
[ O -
15 O -
] O +
. O +

Some O +
of O +
the O +
preclinical O +
antitumor O +
properties O +
of O +
JM335 O +
have O +
been O +
previously O +
described O +
[ O -
15–18 O -
] O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
undertake O +
a O +
detailed O +
comparative O +
analysis O +
of O +
the O +
cellular O +
pharmacological O +
properties O +
of O +
JM335 O -
, O +
its O +
cis O +
isomer O -
, O +
JM149 O +
and O +
their O +
respective O +
platinum O -
( O -
II O -
) O +
counterparts O -
, O +
trans O +
ammine O -
( O -
cyclohexylamine O -
) O +
dichloro O +
platinum O -
( O -
II O -
) O +
JM334 O -
, O +
and O +
its O +
cis O +
isomer O +
JM118 O +
( O -
which O -
, O +
notably O -
, O +
has O +
also O +
been O +
shown O +
to O +
be O +
the O +
major O +
in O +
vivo O +
metabolite O +
of O +
the O +
oral O +
platinum O +
drug O +
JM216 O +
[ O -
19,21 O -
] O +
) O -
. O +

The O +
study O +
has O +
used O +
three O +
human O +
ovarian O +
carcinoma O +
cell O +
lines O -
, O +
the O +
parent O +
relatively O +
cisplatin O -
- O -
sensitive O -
, O +
CH1 O -
, O +
an O +
acquired O +
cisplatin O -
- O -
resistant O +
subline O -
, O +
CH1cisR O -
, O +
and O +
the O +
relatively O +
intrinsically O +
resistant O -
, O +
SKOV-3 O -
. O +

Growth O +
inhibition O -
, O +
cellular O +
transport O -
, O +
DNA O +
platination O -
, O +
gene O -
- O -
specific O +
repair O +
of O +
platinum O +
drug O +
induced O +
DNA O +
adducts O +
and O +
induction O +
of O +
p53 O +
and O +
apoptosis O +
has O +
been O +
determined O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Cell O +
lines O +
Two O +
parent O +
human O +
ovarian O +
carcinoma O +
cell O +
lines O -
, O +
the O +
relatively O +
cisplatin O +
sensitive O +
CH1 O +
and O +
the O +
relatively O +
resistant O +
SKOV-3 O -
, O +
have O +
been O +
used O +
[ O -
22 O -
] O +
. O +

In O +
addition O -
, O +
a O +
subline O +
of O +
CH1 O +
possessing O +
acquired O +
resistance O +
to O +
cisplatin O -
, O +
CH1cisR O -
, O +
has O +
been O +
included O -
. O +

This O +
was O +
derived O +
through O +
in O +
vitro O +
exposure O +
as O +
described O +
previously O +
[ O -
23 O -
] O +
. O +

These O +
three O +
lines O +
have O +
been O +
used O +
by O +
us O +
previously O +
in O +
studies O +
of O +
cisplatin O -
- O -
induced O +
DNA O +
platination O +
[ O -
24 O -
] O +
and O +
apoptosis O +
[ O -
25 O -
] O +
. O +

Lines O +
were O +
grown O +
as O +
monolayers O +
in O +
Dulbecco O -
's O +
Modified O +
Eagle O -
's O +
Medium O +
containing O +
10 O -
% O +
heat O +
inactivated O +
foetal O +
bovine O +
serum O -
, O +
2 O +
mM O +
l O +
-glutamine O +
and O +
0.5 O +
μg O -
/ O -
ml O +
hydrocortisone O +
in O +
6 O -
% O +
CO2 O +
/94 O -
% O +
air O -
. O +

Cells O +
were O +
periodically O +
checked O +
and O +
confirmed O +
to O +
be O +
free O +
of O +
Mycoplasma O +
. O +

2.2 O +
Platinum O +
drugs O +
Cisplatin O -
, O +
JM118 O -
, O +
JM149 O -
, O +
JM334 O -
, O +
and O +
JM335 O +
were O +
synthesised O +
and O +
obtained O +
from O +
The O +
Johnson O +
Matthey O +
Technology O +
Centre O +
( O -
Reading O -
, O +
Berkshire O -
, O +
UK O -
) O -
. O +

Structures O +
are O +
shown O +
in O +
Fig. O +
1 O +
. O +

All O +
drugs O +
were O +
dissolved O +
in O +
sterile O +
0.9 O -
% O +
NaCl O +
solution O +
at O +
between O +
0.5 O +
and O +
1 O +
mM O +
and O +
sterile O +
filtered O +
prior O +
to O +
use O -
. O +

2.3 O +
Assessment O +
of O +
growth O +
inhibition O +
This O +
was O +
assessed O +
using O +
the O +
sulforhodamine O +
B O +
( O -
SRB O -
) O +
assay O +
as O +
used O +
previously O +
by O +
us O +
for O +
platinum O +
drugs O +
with O +
these O +
cell O +
lines O +
[ O -
3,16,23 O -
] O +
. O +

Briefly O -
, O +
aliquots O +
of O +
a O +
single O +
cell O +
suspension O +
were O +
seeded O +
into O +
96-well O +
microtitre O +
plates O +
( O -
4000 O +
per O +
well O -
) O +
and O +
allowed O +
to O +
attach O +
overnight O +
in O +
160 O +
μ1 O +
of O +
the O +
above O -
- O -
described O +
growth O +
medium O -
. O +

Platinum O +
drugs O +
( O -
made O +
up O +
fresh O +
immediately O +
before O -
) O +
were O +
then O +
added O +
to O +
the O +
wells O +
( O -
four O +
wells O +
per O +
concentration O -
) O +
at O +
up O +
to O +
ten O +
different O +
concentrations O -
. O +

Platinum O +
drug O +
exposure O +
was O +
for O +
2 O +
h. O +
Thereafter O -
, O +
drug O +
was O +
carefully O +
washed O +
out O +
using O +
phosphate O +
buffered O +
saline O +
( O -
PBS O -
) O +
and O +
growth O +
medium O +
replaced O -
. O +

After O +
4 O +
days O +
incubation O -
, O +
the O +
number O +
of O +
remaining O +
cells O +
was O +
compared O +
in O +
drug O -
- O -
exposed O +
versus O +
untreated O +
wells O +
using O +
0.4 O -
% O +
SRB O +
( O -
Sigma O +
Chemicals O -
, O +
Poole O -
, O +
UK O -
) O +
dissolved O +
in O +
1 O -
% O +
acetic O +
acid O -
. O +

Growth O +
inhibition O +
is O +
expressed O +
as O +
an O +
IC50 O +
— O +
the O +
concentration O +
required O +
to O +
reduce O +
the O +
absorbance O +
( O -
cell O +
number O -
) O +
in O +
control O +
wells O +
by O +
50 O -
% O -
. O +

2.4 O +
Platinum O +
uptake O +
and O +
DNA O +
binding O +
Intracellular O +
platinum O +
uptake O +
and O +
DNA O +
binding O +
( O -
total O +
platination O -
) O +
was O +
measured O +
in O +
each O +
cell O +
line O +
following O +
2 O +
h O +
drug O +
exposure O +
to O +
10 O -
, O +
25 O -
, O +
50 O +
and O +
100 O +
μM. O +
For O +
uptake O +
experiments O -
, O +
following O +
drug O +
exposure O -
, O +
cells O +
were O +
washed O +
twice O +
with O +
PBS O -
, O +
detached O +
by O +
scraping O +
into O +
2 O +
ml O +
ice O -
- O -
cold O +
PBS O +
and O +
sonicated O -
. O +

Results O +
from O +
the O +
uptake O +
experiments O +
are O +
expressed O +
as O +
nmoles O +
Pt O +
( O -
measured O +
using O +
flameless O +
atomic O +
absorption O +
spectroscopy O -
; O +
FAAS O -
, O +
Perkin O +
Elmer O +
1100b O -
/ O -
HGA O +
700 O -
, O +
Beaconsfield O -
, O +
UK O -
) O +
per O +
mg O +
protein B-Gene +
( O -
using O +
the O +
Lowry O +
assay O -
) O -
. O +

For O +
DNA O +
binding O +
experiments O -
, O +
cells O +
were O +
harvested O +
by O +
centrifugation O +
( O -
800 O -
× O -
g O +
for O +
5 O +
min O -
) O +
and O +
pellets O +
washed O +
twice O +
with O +
ice O +
cold O +
PBS O +
and O +
then O +
snap O -
- O -
frozen O +
in O +
liquid O +
nitrogen O -
. O +

DNA O +
was O +
then O +
extracted O +
using O +
phenol O +
and O +
ethanol O +
precipitation O +
as O +
described O +
previously O +
[ O -
24 O -
] O +
. O +

Dried O +
DNA O +
pellets O +
were O +
dissolved O +
overnight O +
at O +
37 O -
° O -
C O +
in O +
0.2 O -
% O +
nitric O +
acid O +
and O +
platinum O +
content O +
measured O +
by O +
FAAS O +
and O +
results O +
expressed O +
as O +
nmoles O +
of O +
platinum O +
per O +
gram O +
of O +
DNA O -
. O +

2.5 O +
Measurement O +
of O +
Pt O -
/ O -
DNA O +
lesions O +
using O +
quantitative O +
PCR O +
Formation O +
and O +
removal O +
of O +
platinum O +
induced O +
lesions O +
was O +
measured O +
in O +
the O +
N O -
- O -
ras O +
gene O +
by O +
QPCR O +
as O +
described O +
previously O +
[ O -
26,27 O -
] O +
. O +

Cells O +
in O +
midlog O +
phase O +
( O -
approximately O +
106 O +
) O +
were O +
incubated O +
for O +
5 O +
h O +
with O +
2 O -
× O -
IC50 O +
of O +
drug O +
and O +
harvested O +
by O +
trypsinisation O +
either O +
immediately O +
after O +
removal O +
of O +
drug O +
or O +
following O +
a O +
24 O +
h O +
incubation O +
in O +
drug O +
free O +
medium O -
. O +

Cells O +
were O +
lysed O +
in O +
340 O +
μl O +
of O +
solution O +
( O -
400 O +
mM O +
Tris O -
– O -
HCl O +
pH O +
8 O -
, O +
60 O +
mM O +
EDTA O -
, O +
150 O +
mM O +
NaCl O -
, O +
and O +
1 O -
% O +
w O -
/ O -
v O +
SDS O -
) O +
plus O +
100 O +
μl O +
5 O +
M O +
sodium O +
perchlorate O +
by O +
mixing O +
at O +
37 O -
° O -
C O +
for O +
20 O +
min O +
and O +
then O +
at O +
65 O -
° O -
C O +
for O +
a O +
further O +
20 O +
min O -
. O +

A O +
total O +
of O +
580 O +
μl O +
of O +
chloroform O +
was O +
added O +
to O +
the O +
lysate O -
, O +
the O +
solution O +
mixed O +
on O +
a O +
rotary O +
mixer O +
for O +
20 O +
min O +
at O +
room O +
temperature O +
followed O +
by O +
centrifugation O +
in O +
a O +
microfuge O +
at O +
top O +
speed O +
for O +
12 O +
min O -
. O +

Following O +
centrifugation O -
, O +
330 O +
μl O +
of O +
the O +
upper O +
layer O +
was O +
aliquoted O +
into O +
a O +
new O +
microtube O +
and O +
nuclear O +
material O +
precipitated O +
in O +
two O +
volumes O +
of O +
absolute O +
ethanol O -
. O +

The O +
precipitate O +
was O +
washed O +
twice O +
in O +
70 O -
% O +
ethanol O -
, O +
dried O +
in O +
an O +
incubator O +
over O +
night O +
at O +
37 O -
° O -
C O +
and O +
dissolved O +
in O +
400 O +
μl O +
H2 O +
O. O +
PCR O +
was O +
performed O +
using O +
25 O +
μl O +
of O +
DNA O +
sample O +
in O +
a O +
final O +
volume O +
of O +
100 O +
μl O +
containing O -
; O +
2 O +
units O +
( O -
0.2 O +
μl O -
) O +
of O +
Taq B-Gene +
polymerase I-Gene +
( O -
red O +
hot O -
) O -
, O +
4.8 O +
μl O +
of O +
a O +
dATP O -
, O +
dCTP O -
, O +
dGTP O -
, O +
dTTP O +
mix O +
( O -
120 O +
μM O +
each O -
) O -
, O +
3 O +
μl O +
( O -
0.75 O +
mM O -
) O +
MgCl2 O +
10 O +
μl O -
, O +
buffer O +
IV O +
( O -
Advanced O +
Biotechnologies O -
) O -
, O +
5 O +
μl O +
DMSO O -
, O +
1 O +
μl O +
each O +
of O +
3′ O +
and O +
5′ O +
primer O +
sequence O -
, O +
and O +
1 O +
μCi O +
( O -
α-32 O +
P O -
) O +
dCTP O -
. O +

The O +
amplification O +
of O +
the O +
N O -
- O -
ras O +
fragment O +
was O +
performed O +
using O +
the O +
forward O +
primer O +
5′–GCC O +
TGG O +
TTA O +
CTG O +
TGT O +
CCT O +
GT–3′ O +
and O +
the O +
reverse O +
primer O +
5′–GCC O +
AGC O +
CAC O +
ATC O +
TAC O +
AGT O +
AC–3′. O +
PCR O +
was O +
carried O +
out O +
using O +
a O +
Hybaid O +
Thermal O +
cycler O +
using O +
an O +
initial O +
2 O +
min O +
denaturation O +
step O +
at O +
94 O -
° O -
C O +
followed O +
by O +
25 O +
cycles O +
of O +
94 O -
° O -
C O +
for O +
1 O +
min O -
, O +
55 O -
° O -
C O +
for O +
1 O +
min O +
and O +
72 O -
° O -
C O +
for O +
1 O +
min O +
with O +
a O +
final O +
incubation O +
of O +
4 O +
min O +
at O +
72 O -
° O -
C O +
at O +
the O +
end O +
of O +
the O +
cycling O -
. O +

These O +
conditions O +
were O +
chosen O +
to O +
ensure O +
that O +
the O +
PCR O +
reaction O +
was O +
still O +
in O +
the O +
exponential O +
phase O +
when O +
the O +
reaction O +
had O +
stopped O -
. O +

PCR O +
products O +
were O +
quantified O +
by O +
precipitation O +
of O +
aliquots O +
of O +
40 O +
μl O +
of O +
reaction O +
mixture O +
with O +
1 O +
ml O +
ice O +
cold O +
5 O -
% O +
w O -
/ O -
v O +
trichloroacetic O +
acid O +
20 O +
mM O +
tetra O +
sodium O +
pyrophosphate O +
( O -
TCA O -
) O +
and O +
the O +
precipitate O +
captured O +
on O +
Whatman O +
GF O -
/ O -
C O +
filters O +
with O +
unincorporated O +
α-32 O +
P O -
- O -
dCTP O +
washed O +
through O +
with O +
10 O +
ml O +
of O +
the O +
TCA O +
and O +
10 O +
ml O +
of O +
absolute O +
ethanol O -
. O +

The O +
filters O +
were O +
placed O +
in O +
scintillation O +
fluid O +
and O +
the O +
PCR O +
product O +
quantitated O +
by O +
measuring O +
cpms O +
per O +
minute O -
. O +

Lesions O +
per O +
region O +
( O -
lesion O +
index O -
) O +
were O +
calculated O +
using O +
the O +
formula O -
: O +
−ln O +
Ad O +
/A O +
, O +
where O +
A O +
represents O +
PCR O +
product O +
( O -
cpm O -
) O +
from O +
control O +
sample O +
and O +
Ad O +
represents O +
cpm O +
from O +
treated O +
samples O -
. O +

Controls O +
containing O +
25 O +
and O +
50 O -
% O +
of O +
the O +
control O +
sample O +
were O +
included O +
to O +
ensure O +
that O +
the O +
PCR O +
was O +
quantitative O -
. O +

2.6 O +
Microscopy O +
Cells O +
were O +
collected O +
24 O +
h O +
following O +
a O +
2 O +
h O +
incubation O +
with O +
drug O -
. O +

Detached O +
cells O +
were O +
aspirated O +
from O +
the O +
tissue O +
culture O +
flasks O +
and O +
collected O +
from O +
the O +
culture O +
medium O +
by O +
centrifugation O -
. O +

Attached O +
cells O +
were O +
washed O +
twice O +
with O +
ice O +
cold O +
PBS O +
and O +
removed O +
by O +
incubation O +
with O +
0.25 O -
% O +
trypsin B-Gene +
for O +
5 O +
min O +
prior O +
to O +
collection O +
by O +
centrifugation O -
. O +

For O +
fluorescent O +
microscopy O -
, O +
cells O +
were O +
incubated O +
with O +
propridium O +
iodide O +
( O -
PI O -
) O +
1 O +
mg O -
/ O -
ml O +
for O +
10 O +
min O +
on O +
ice O +
and O +
nuclei O +
detected O +
by O +
red O +
fluorescence O -
. O +

2.7 O +
Field O +
inverted O +
gel O +
electrophoresis O +
( O -
FIGE O -
) O +
of O +
DNA O +
Cells O +
were O +
incubated O +
with O +
equitoxic O +
concentrations O +
of O +
agents O +
( O -
2 O -
× O -
, O +
5 O -
× O -
, O +
10 O -
× O -
IC50 O +
) O +
for O +
2 O +
h O +
and O +
then O +
at O +
24 O +
h O +
( O -
for O +
CH1 O +
and O +
CH1cisR O -
) O +
or O +
48 O +
h O +
( O -
for O +
SKOV-3 O -
) O +
attached O +
and O +
detached O +
cells O +
were O +
collected O +
by O +
centrifugation O -
. O +

Cell O +
pellets O +
of O +
approximately O +
5 O -
× O -
105 O +
were O +
then O +
incubated O +
in O +
lysis O +
buffer O +
[ O -
200 O +
mM O +
Tris O -
, O +
100 O +
mM O +
EDTA O -
, O +
2 O -
% O +
sodium O +
dodecyl O +
sulphate O -
] O +
containing O +
1 O +
mg O -
/ O -
ml O +
proteinase B-Gene +
K I-Gene +
for O +
1 O +
h O +
at O +
37 O -
° O -
C O -
. O +

RNA O +
was O +
removed O +
by O +
a O +
further O +
1 O +
h O +
incubation O +
following O +
the O +
addition O +
of O +
10 O +
μl O +
of O +
a O +
1 O +
mg O -
/ O -
ml O +
solution O +
of O +
RNAase B-Gene +
to O +
each O +
50 O +
μl O +
sample O -
. O +

Aliquots O +
of O +
cell O +
lysate O +
were O +
then O +
added O +
directly O +
to O +
the O +
gel O -
, O +
the O +
wells O +
being O +
sealed O +
with O +
1 O -
% O +
low O +
melting O +
point O +
agarose O -
. O +

FIGE O +
was O +
performed O +
with O +
1 O -
× O -
TAE O +
( O -
40 O +
mM O +
Tris O -
, O +
20 O +
mM O +
sodium O +
acetate O -
, O +
1 O +
mM O +
EDTA O -
) O +
using O +
a O +
Biorad O +
FIGE O +
mapper O -
. O +

Horizontal O +
gels O +
were O +
run O +
for O +
20 O +
h O +
in O +
1 O -
× O -
TAE O +
buffer O +
with O +
a O +
forward O +
voltage O +
of O +
10 O +
V O -
/ O -
cm O +
and O +
reverse O +
of O +
7 O +
V O -
/ O -
cm O +
with O +
linear O +
ramping O +
T O +
1 O +
= O -
1 O +
s O +
and O +
T O +
2 O +
= O -
12 O +
s. O +
The O +
temperature O +
of O +
the O +
TAE O +
buffer O +
was O +
controlled O +
at O +
14 O -
° O -
C O +
using O +
a O +
Biorad O +
1000 O +
mini O -
- O -
chiller O -
. O +

2.8 O +
Western O +
blot O +
analysis O +
Cells O +
( O -
8 O -
× O -
106 O +
) O +
were O +
incubated O +
with O +
equitoxic O +
concentrations O +
( O -
2 O -
× O -
IC50 O +
) O +
of O +
drug O +
for O +
2 O +
h O +
and O +
attached O +
cells O +
harvested O +
by O +
trypsinisation O +
at O +
various O +
time O +
points O +
following O +
drug O +
exposure O -
. O +

The O +
resulting O +
cell O +
pellets O +
were O +
resuspended O +
in O +
300 O +
μl O +
of O +
lysis O +
buffer O +
containing O +
150 O +
mM O +
NaCl O -
, O +
50 O +
mM O +
Tris O -
– O -
HCl O -
, O +
to O +
which O +
was O +
added O -
; O +
500 O +
μl O +
pf O +
20 O +
mM O +
phenylmethylsulphonylfluoride O +
( O -
PMSF O -
) O +
100 O +
μl O +
Na O +
orthovanadate O +
( O -
10 O +
mM O +
stock O -
) O -
, O +
100 O +
μl O +
NP40 O -
, O +
100 O +
μl O +
20 O -
% O +
SDS O -
, O +
2 O +
μl O +
aprotinin B-Gene +
( O -
10 O +
mg O -
/ O -
ml O +
stock O -
) O +
and O +
2 O +
μl O +
leupeptin O +
( O -
10 O +
mg O -
/ O -
ml O +
stock O -
) O +
and O +
incubated O +
on O +
ice O +
for O +
1 O +
h O -
) O -
. O +

The O +
lysed O +
samples O +
were O +
centrifuged O +
at O +
12 O +
000 O +
rpm O +
at O +
4 O -
° O -
C O +
for O +
15 O +
min O -
, O +
and O +
the O +
supernatant O +
collected O -
. O +

Samples O -
, O +
adjusted O +
to O +
contain O +
equal O +
protein B-Gene +
( O -
50 O +
μg O -
) O -
, O +
were O +
diluted O +
50 O -
/ O -
50 O +
with O +
Laemmli O +
buffer O +
and O +
incubated O +
at O +
95 O -
° O -
C O +
for O +
3 O +
min O -
. O +

Approximately O +
25 O +
μl O +
of O +
sample O +
and O +
3 O +
μl O +
of O +
standard O +
rainbow O +
marker O +
were O +
loaded O +
onto O +
8–16 O -
% O +
Novex O +
precast O +
PAGE O +
gels O +
and O +
run O +
at O +
30 O +
mA O +
per O +
gel O +
for O +
1 O +
h O +
and O +
then O +
transferred O +
to O +
nitrocellulose O +
membrane O +
at O +
300 O +
mA O +
for O +
2 O +
h. O +
Following O +
transfer O -
, O +
the O +
membranes O +
were O +
stained O +
with O +
Ponceau O +
S O +
to O +
check O +
the O +
efficiency O +
of O +
the O +
transfer O -
. O +

The O +
membranes O +
were O +
washed O +
twice O +
with O +
PBS O +
containing O +
0.1 O -
% O +
Tween O +
20 O +
( O -
PBST O -
) O -
, O +
excess O +
liquid O +
was O +
drained O +
off O +
and O +
then O +
placed O +
in O +
blocking O +
buffer O +
( O -
154 O +
mM O +
NaCl O -
, O +
10 O +
mM O +
Tris O -
, O +
0.5 O -
% O +
caesin B-Gene +
and O +
0.02 O -
% O +
thimerosal O -
, O +
at O +
pH O +
7.6 O -
) O +
and O +
agitated O +
for O +
1 O +
h. O +
The O +
membranes O +
were O +
subsequently O +
washed O +
in O +
PBST O +
for O +
5 O +
min O +
and O +
probed O +
for O +
the O +
protein B-Gene +
of O +
interest O +
with O +
primary O +
antibody B-Gene +
diluted O +
in O +
blocking O +
buffer O +
for O +
a O +
specified O +
time O -
. O +

For O +
example O -
, O +
1 O +
h O +
for O +
p53 O +
and O +
5 O +
h O +
for O +
bcl-2 O +
and O +
then O +
washed O +
thrice O +
for O +
10 O +
min O +
with O +
PBST O -
. O +

The O +
membranes O +
were O +
incubated O +
with O +
secondary O +
antibody B-Gene +
linked O +
with O +
horse B-Gene +
radish I-Gene +
peroxidase I-Gene +
for O +
at O +
least O +
1 O +
h O +
and O +
then O +
detected O +
with O +
ECL O +
reagents O +
( O -
Amersham O -
) O +
by O +
autoradiography O -
. O +

2.9 O +
Statistical O +
analysis O +
Where O +
appropriate O -
, O +
statistical O +
significance O +
was O +
evaluated O +
using O +
the O +
Student O -
's O +
t O +
-test O +
( O -
two O +
tailed O -
) O -
. O +

A O +
P O +
-value O +
of O +
< O -
0.05 O +
was O +
considered O +
significant O -
. O +

3 O +
Results O +
3.1 O +
Growth O +
inhibition O +
The O +
growth O +
inhibitory O +
properties O +
of O +
the O +
two O +
pairs O +
of O +
cis O +
and O +
trans O +
isomers O +
following O +
2 O +
h O +
exposure O +
to O +
the O +
three O +
ovarian O +
carcinoma O +
cell O +
lines O -
, O +
are O +
shown O +
in O +
Fig. O +
2 O +
. O +

Mean O +
IC50 O +
values O +
in O +
μM O +
against O +
CH1 O +
cells O +
were O +
1.3 O +
for O +
JM118 O -
, O +
3.4 O +
for O +
JM334 O -
, O +
35.3 O +
for O +
JM149 O +
and O +
18.6 O +
for O +
JM335 O -
. O +

A O +
degree O +
of O +
resistance O +
was O +
observed O +
in O +
CH1cisR O +
cells O +
to O +
all O +
four O +
agents O -
; O +
resistance O +
factors O +
( O -
Rf O -
; O +
IC50 O +
resistant O -
/ O -
IC50 O +
CH1 O +
cells O -
) O +
were O +
2.5 O +
for O +
JM118 O +
( O -
IC50 O +
3.3 O -
) O -
, O +
1.5 O +
for O +
JM334 O +
( O -
IC50 O +
5.1 O -
) O -
, O +
2.3 O +
for O +
JM149 O +
( O -
IC50 O +
83 O -
) O +
and O +
1.6 O +
for O +
JM335 O +
( O -
IC50 O +
31 O -
) O -
. O +

A O +
similar O +
effect O +
was O +
observed O +
with O +
the O +
SKOV-3 O +
cell O +
line O +
but O +
with O +
Rf O +
values O +
being O +
lower O +
for O +
the O +
two O +
trans O +
compounds O -
: O +

Rf O +
values O +
of O +
20.5 O +
for O +
JM118 O +
( O -
IC50 O +
27 O -
) O +
and O +
10 O +
for O -
, O +
JM149 O +
( O -
IC50 O +
350 O -
) O +
but O +
only O +
4.5 O +
for O +
JM334 O +
( O -
IC50 O +
15 O -
) O +
and O +
4.4 O +
for O +
JM335 O +
( O -
IC50 O +
83 O -
) O -
. O +

The O +
curves O +
are O +
generally O +
similar O +
in O +
shape O -
: O +
At O +
2 O -
× O -
IC50 O +
concentrations O -
, O +
the O +
range O +
in O +
cell O +
kill O +
observed O +
across O +
all O +
four O +
drugs O +
was O +
from O +
83 O +
to O +
90 O -
% O -
. O +

Typical O +
IC50 O +
values O +
for O +
cisplatin O +
[ O -
24 O -
] O +
are O +
CH1 O +
2.5 O +
μM O -
, O +
CH1cisR O +
7.5 O +
μM O +
( O -
Rf O +
of O +
3 O -
) O +
and O +
SKOV-3 O +
33 O +
μM O +
( O -
Rf O +
of O +
13 O -
) O -
. O +

Several O +
points O +
emerge O -
: O +
( O -
1 O -
) O +
the O +
Pt O -
( O -
II O -
) O +
compounds O +
JM118 O +
and O +
JM334 O +
are O +
more O +
potent O +
than O +
their O +
platinum O -
( O -
IV O -
) O +
counterparts O -
; O +
( O -
2 O -
) O +
the O +
trans O +
isomer O +
JM335 O +
was O +
more O +
potent O +
than O +
its O +
corresponding O +
cis O +
isomer O -
, O +
especially O +
in O +
the O +
relatively O +
cisplatin O -
- O -
resistant O +
SKOV-3 O +
cell O +
line O -
. O +

However O -
, O +
with O +
the O +
platinum O -
( O -
II O -
) O +
pair O -
, O +
the O +
cis O +
compound O +
JM118 O +
was O +
more O +
potent O +
that O +
the O +
trans O +
JM334 O +
in O +
the O +
CH1 O +
and O +
CH1cisR O +
lines O -
. O +

( O -
3 O -
) O +
In O +
terms O +
of O +
resistance O +
factors O -
, O +
the O +
trans O +
compounds O +
showed O +
better O +
circumvention O +
of O +
cisplatin O +
resistance O +
( O -
lower O +
Rf O +
values O -
) O +
than O +
the O +
cis O +
compounds O -
; O +
this O +
was O +
most O +
apparent O +
with O +
the O +
intrinsically O +
resistant O +
SKOV-3 O +
cell O +
line O +
( O -
e.g. O +
> O -
4-fold O +
lower O +
Rf O +
value O +
for O +
JM334 O +
versus O +
JM118 O -
) O -
. O +

3.2 O +
Platinum O +
accumulation O +
and O +
DNA O +
binding O +
Full O +
dose O -
– O -
response O +
curves O +
( O -
10–100 O +
μM O -
; O +
2 O +
h O +
exposure O -
) O +
were O +
obtained O +
for O +
each O +
drug O +
using O +
all O +
three O +
cell O +
lines O -
. O +

A O +
generally O +
linear O +
relationship O +
between O +
concentration O +
and O +
platinum O +
accumulation O +
( O -
expressed O +
as O +
nmoles O +
Pt O -
/ O -
mg O +
protein B-Gene -
) O +
was O +
obtained O +
( O -
data O +
not O +
shown O -
) O -
. O +

Comparative O +
accumulation O +
data O +
at O +
a O +
concentration O +
of O +
50 O +
μM O +
are O +
shown O +
in O +
Fig. O +
3 O +
A. O +
Platinum O +
accumulation O +
was O +
significantly O +
higher O +
following O +
exposure O +
to O +
the O +
trans O +
Pt O -
( O -
II O -
) O +
compound O +
JM334 O +
compared O +
to O +
both O +
its O +
cis O +
isomer O +
JM118 O +
( O -
e.g. O +
7-fold O +
higher O +
in O +
CH1 O +
and O +
CH1cisR O -
; O +
P O +
< O -
0.005 O -
) O +
and O +
compared O +
to O +
its O +
platinum O -
( O -
IV O -
) O +
homolog O -
, O +
JM335 O -
. O +

There O +
was O +
little O +
to O +
suggest O +
that O +
reduced O +
accumulation O +
contributed O +
to O +
either O +
the O +
acquired O +
resistance O +
of O +
CH1cisR O +
or O +
the O +
intrinsic O +
resistance O +
of O +
SKOV-3 O +
compared O +
to O +
the O +
parent O +
CH1 O +
line O -
; O +
uptake O +
values O +
were O +
similar O +
for O +
JM118 O +
across O +
all O +
three O +
cell O +
lines O -
, O +
uptake O +
was O +
higher O +
in O +
the O +
resistant O +
lines O +
following O +
exposure O +
to O +
JM149 O +
( O -
13-fold O -
; O +
P O +
< O -
0.005 O +
compared O +
to O +
CH1 O -
) O -
. O +

Platinum O +
uptake O +
for O +
the O +
two O +
trans O +
compounds O +
JM334 O +
and O +
JM335 O +
was O +
a O +
little O +
lower O +
in O +
SKOV-3 O +
compared O +
to O +
CH1 O -
. O +

Similarly O +
to O +
the O +
accumulation O +
data O -
, O +
representative O +
total O +
DNA O +
platination O +
for O +
the O +
four O +
compounds O +
in O +
the O +
three O +
cell O +
lines O +
are O +
shown O +
in O +
Fig. O +
3 O +
B O +
( O -
50 O +
μM O -
, O +
2 O +
h O +
drug O +
exposure O -
) O -
. O +

As O +
for O +
the O +
uptake O +
data O -
, O +
there O +
was O +
little O +
difference O +
in O +
DNA O +
platination O +
for O +
JM118 O +
across O +
the O +
three O +
cell O +
lines O -
. O +

In O +
contrast O -
, O +
the O +
very O +
high O +
uptake O +
values O +
observed O +
with O +
the O +
trans O +
Pt O -
( O -
II O -
) O +
compound O +
JM334 O +
compared O +
to O +
JM118 O +
and O +
its O +
platinum O -
( O -
IV O -
) O +
homolog O +
JM335 O +
( O -
especially O +
in O +
the O +
CH1 O +
and O +
CH1cisR O +
cell O +
lines O -
) O +
did O +
not O +
result O +
in O +
higher O +
DNA O +
platination O -
. O +

Indeed O -
, O +
platination O +
was O +
significantly O +
lower O +
for O +
JM334 O +
versus O +
JM118 O +
in O +
the O +
CH1 O +
and O +
CH1cisR O +
lines O +
( O -
P O +
< O -
0.05 O -
) O -
. O +

However O -
, O +
higher O +
platination O +
( O -
3-fold O -
, O +
P O +
< O -
0.05 O +
compared O +
to O +
CH1 O -
) O +
was O +
observed O +
in O +
the O +
intrinsically O +
cisplatin O +
resistant O +
SKOV-3 O +
cell O +
line O +
with O +
JM334 O -
. O +

For O +
the O +
two O +
Pt O -
( O -
IV O -
) O +
compounds O -
, O +
DNA O +
platination O +
was O +
higher O +
( O -
around O +
2–3-fold O -
) O +
for O +
the O +
trans O +
compound O +
compared O +
to O +
its O +
cis O +
isomer O -
. O +

3.3 O +
Gene O -
- O -
specific O +
repair O +
using O +
QPCR O +
As O +
a O +
further O +
means O +
of O +
studying O +
the O +
cellular O +
pharmacology O +
of O +
these O +
cis O +
and O +
trans O +
platinum O +
compounds O -
, O +
the O +
ability O +
of O +
the O +
CH1 O -
, O +
CH1cisR O +
and O +
SKOV-3 O +
cell O +
lines O +
to O +
remove O -
/ O -
repair O +
lesions O +
induced O +
by O +
the O +
compounds O +
( O -
and O +
cisplatin O -
) O +
has O +
been O +
studied O +
in O +
the O +
N O -
- O -
ras O +
gene O +
using O +
QPCR O -
. O +

In O +
keeping O +
with O +
published O +
studies O +
using O +
cisplatin O +
[ O -
27 O -
] O +
an O +
exposure O +
time O +
of O +
5 O +
h O +
was O +
used O +
and O +
removal O +
assessed O +
at O +
24 O +
h O +
post O +
drug O +
removal O -
. O +

Fig. O +
4 O +
A O +
shows O +
results O +
with O +
the O +
platinum O -
( O -
IV O -
) O +
cis O +
/trans O +
pair O +
using O +
a O +
concentration O +
of O +
2 O -
× O -
2 O +
h O -
- O -
IC50 O +
. O +

Notably O -
, O +
the O +
parent O -
, O +
cisplatin O -
- O -
sensitive O +
cell O +
line O +
CH1 O -
, O +
could O +
not O +
remove O +
lesions O +
by O +
either O +
of O +
the O +
two O +
platinum O +
drugs O +
( O -
illustrated O +
by O +
an O +
increase O +
in O +
lesion O +
index O +
at O +
24 O +
h O +
compared O +
to O +
5 O +
h O -
) O -
. O +

Similarly O -
, O +
the O +
CH1cisR O +
line O +
could O +
not O +
remove O +
lesions O +
induced O +
by O +
JM149 O -
. O +

In O +
contrast O -
, O +
the O +
intrinsically O +
cisplatin O +
resistant O +
SKOV-3 O +
cell O +
line O +
was O +
able O +
to O +
remove O +
adducts O +
formed O +
by O +
the O +
cis O +
compound O +
( O -
JM149 O -
) O +
but O +
not O +
by O +
the O +
trans O +
compound O -
, O +
JM335 O -
. O +

Results O +
for O +
the O +
Pt O -
( O -
II O -
) O +
pair O +
of O +
compounds O +
are O +
shown O +
in O +
Fig. O +
4 O +
B. O +
In O +
common O +
with O +
observations O +
made O +
with O +
the O +
Pt O -
( O -
IV O -
) O +
compounds O -
, O +
the O +
CH1 O +
cell O +
line O +
( O -
and O +
CH1cisR O +
line O -
) O +
was O +
unable O +
to O +
remove O +
adducts O +
formed O +
by O +
the O +
cis O +
Pt O -
( O -
II O -
) O +
compound O +
JM118 O -
. O +

As O +
for O +
the O +
Pt O -
( O -
IV O -
) O +
pair O -
, O +
notably O +
the O +
SKOV-3 O +
cell O +
line O +
removed O +
adducts O +
formed O +
by O +
the O +
cis O +
compound O +
JM118 O +
but O +
was O +
unable O +
to O +
remove O +
adducts O +
formed O +
by O +
the O +
trans O +
isomer O -
, O +
JM334 O -
. O +

Data O +
for O +
cisplatin O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

Results O +
showed O +
a O +
similar O +
pattern O +
of O +
response O +
to O +
that O +
observed O +
for O +
the O +
cis O +
compounds O +
JM118 O +
and O +
JM149 O +
with O +
removal O +
from O +
DNA O +
of O +
SKOV-3 O +
cells O +
but O +
not O +
the O +
CH1 O +
parental O +
line O -
. O +

In O +
contrast O -
, O +
however O -
, O +
removal O +
of O +
cisplatin O -
- O -
induced O +
lesions O +
was O +
apparent O +
in O +
CH1cisR O +
cells O -
. O +

3.4 O +
Cell O +
death O +
induced O +
by O +
cis O +
and O +
trans O +
platinum O +
compounds O +
As O +
described O +
previously O +
[ O -
20,25 O -
] O +
, O +
we O +
initially O +
determined O +
the O +
rates O +
of O +
cell O +
death O +
induced O +
by O +
the O +
compounds O +
by O +
measuring O +
cellular O +
detachment O +
from O +
the O +
monolayer O +
over O +
time O +
following O +
2 O +
h O +
drug O +
exposure O -
. O +

Results O +
for O +
the O +
CH1cisR O +
cell O +
line O +
for O +
all O +
four O +
compounds O +
used O +
at O +
an O +
equitoxic O +
( O -
2 O -
× O -
IC50 O +
) O +
concentration O +
are O +
shown O +
( O -
Fig. O +
5 O +
) O -
. O +

Similar O +
results O +
were O +
obtained O +
for O +
the O +
CH1 O +
and O +
SKOV-3 O +
cell O +
lines O +
( O -
data O +
not O +
shown O +
and O +
20 O +
for O +
JM149 O +
and O +
JM335 O +
in O +
the O +
CH1 O +
cell O +
line O -
) O -
. O +

Notably O -
, O +
a O +
slower O +
rate O +
of O +
detachment O +
was O +
induced O +
by O +
the O +
two O +
cis O +
isomers O +
JM118 O +
and O +
JM149 O +
compared O +
to O +
their O +
trans O +
counterparts O -
. O +

While O +
the O +
time O +
taken O +
for O +
50 O -
% O +
detachment O +
to O +
occur O +
with O +
the O +
trans O +
compounds O +
was O +
around O +
24 O +
h O -
, O +
for O +
the O +
two O +
cis O +
compounds O -
, O +
this O +
was O +
around O +
72 O +
h. O +
Detection O +
of O +
apoptosis O +
induced O +
by O +
cis O +
and O +
trans O +
platinum O +
compounds O -
. O +

To O +
determine O +
whether O +
the O +
cellular O +
detachment O +
and O +
cell O +
death O +
observed O +
in O +
the O +
cell O +
lines O -
. O +

occurred O +
through O +
apoptosis O -
, O +
two O +
complementary O +
means O +
of O +
detecting O +
apoptotic O +
cells O +
was O +
employed O -
; O +
fluorescence O +
microscopy O +
and O +
FIGE O +
of O +
DNA O -
. O +

Fig. O +
6 O +
shows O +
fluorescent O +
microscopy O +
of O +
detached O +
CH1 O +
cells O +
harvested O +
24 O +
h O +
after O +
exposure O +
for O +
2 O +
h O +
to O +
2 O -
× O +
or O +
10 O -
× O -
IC50 O +
of O +
either O +
the O +
cis O +
Pt O -
( O -
II O -
) O +
compound O +
JM118 O +
or O +
its O +
trans O +
counterpart O -
, O +
JM334 O -
. O +

Using O +
2 O -
× O -
IC50 O +
of O +
the O +
cis O +
isomer O +
JM118 O -
, O +
the O +
majority O +
of O +
detached O +
cells O +
exhibited O +
the O +
classical O +
morphology O +
of O +
apoptosis O +
( O -
condensation O +
and O +
fragmentation O +
pattern O +
of O +
chromatin O +
around O +
the O +
periphery O +
of O +
the O +
nucleus O +
— O +
6c O -
) O -
. O +

While O +
a O +
similar O +
appearance O +
was O +
seen O +
in O +
cells O +
exposed O +
to O +
either O +
10 O -
× O -
IC50 O +
of O +
JM118 O +
( O -
6d O -
) O +
or O +
2 O -
× O -
IC50 O +
of O +
JM334 O +
( O -
6e O -
) O -
, O +
cells O +
detaching O +
following O +
exposure O +
to O +
10 O -
× O -
IC50 O +
concentration O +
of O +
JM334 O +
exhibited O +
a O +
different O +
morphological O +
appearance O +
( O -
6f O -
) O -
. O +

In O +
contrast O -
, O +
the O +
chromatin O +
was O +
not O +
condensed O +
and O +
resembled O +
that O +
of O +
control O +
untreated O +
cells O +
( O -
6b O -
) O -
. O +

Moreover O -
, O +
there O +
was O +
evidence O +
of O +
extensive O +
vesiculation O +
in O +
these O +
cells O -
. O +

The O +
morphological O +
appearance O +
of O +
CH1cisR O +
or O +
SKOV-3 O +
cells O +
detaching O +
after O +
a O +
2 O +
h O +
exposure O +
to O +
2 O -
× O -
IC50 O +
concentrations O +
of O +
all O +
four O +
compounds O +
showed O +
that O -
, O +
in O +
each O +
case O -
, O +
the O +
detached O +
cells O +
exhibited O +
the O +
appearance O +
of O +
apoptotic O +
cells O -
. O +

Hence O -
, O +
at O +
2 O -
× O -
IC50 O +
concentrations O -
, O +
all O +
four O +
compounds O +
induced O +
apoptosis O +
in O +
all O +
three O +
cell O +
lines O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
results O +
of O +
FIGE O +
of O +
DNA O +
from O +
pooled O +
attached O +
and O +
detached O +
cells O +
of O +
all O +
three O +
cell O +
lines O +
exposed O +
to O +
2 O -
× O -
, O +
5 O -
× O -
, O +
or O +
10 O -
× O -
IC50 O +
of O +
all O +
four O +
compounds O +
is O +
shown O +
in O +
Fig. O +
7 O +
A O -
, O +
B O +
for O +
CH1 O +
and O +
for O +
CH1cisR O +
and O +
SKOV-3 O -
, O +
respectively O -
. O +

FIGE O +
was O +
used O +
in O +
preference O +
to O +
the O +
detection O +
of O +
DNA O +
laddering O +
by O +
gel O +
electrophoresis O +
since O +
previous O +
studies O +
using O +
these O +
lines O +
with O +
cisplatin O +
had O +
shown O +
that O +
internucleosomal O +
cleavage O +
could O +
not O +
be O +
detected O +
in O +
cells O +
undergoing O +
apoptosis O +
[ O -
25 O -
] O +
. O +

The O +
FIGE O +
results O +
indicate O +
that O +
none O +
of O +
the O +
attached O +
cell O +
populations O +
( O -
lanes O +
A3–5 O +
for O +
JM118 O -
, O +
A6–8 O +
for O +
JM334 O +
in O +
CH1 O +
cells O -
; O +
lanes O +
B1 O +
and O +
2 O +
for O +
CH1cisR O +
JM118 O +
and O +
JM334 O -
, O +
respectively O +
and O +
lanes O +
B3 O +
and O +
4 O +
for O +
SKOV3 O -
, O +
JM118 O +
and O +
JM334 O -
, O +
respectively O -
) O +
revealed O +
any O +
DNA O +
fragmentation O +
indicative O +
of O +
apoptosis O -
. O +

In O +
contrast O -
, O +
all O +
the O +
detached O +
cell O +
populations O +
of O +
cell O +
lines O +
following O +
exposure O +
to O +
the O +
cis O +
platinum O +
compounds O +
JM118 O +
( O -
lanes O +
A9–11 O +
for O +
CH1 O -
; O +
B5 O +
for O +
CH1cisR O +
and O +
B9 O +
for O +
SKOV-3 O -
) O +
and O +
JM149 O +
( O -
B7 O +
for O +
CH1cisR O +
and O +
B11 O +
for O +
SKOV-3 O -
) O +
revealed O +
the O +
presence O +
of O +
a O +
fragment O +
approximately O +
50 O +
kb O +
in O +
size O -
. O +

For O +
the O +
detached O +
cell O +
populations O +
exposed O +
to O +
the O +
trans O +
compounds O -
, O +
the O +
observed O +
fragmentation O +
was O +
concentration O +
dependent O -
. O +

At O +
low O +
( O -
2 O -
× O -
IC50 O +
) O +
concentrations O +
the O +
50 O +
kb O +
fragment O +
was O +
apparent O +
in O +
all O +
cases O +
( O -
lane O +
A12 O +
for O +
JM334 O +
in O +
CH1 O +
cells O -
, O +
lane O +
B6 O +
and O +
8 O +
for O +
JM334 O +
and O +
JM335 O -
, O +
respectively O +
in O +
CH1cisR O +
and O +
lane O +
B10 O +
and O +
12 O +
for O +
JM334 O +
and O +
JM335 O -
, O +
respectively O +
in O +
SKOV-3 O -
) O -
. O +

However O -
, O +
at O +
the O +
high O +
( O -
10 O -
× O -
IC50 O +
) O +
concentration O +
of O +
JM334 O +
in O +
the O +
CH1 O +
cells O +
( O -
lane O +
A14 O -
) O +
the O +
50 O +
kb O +
fragment O +
seen O +
at O +
lower O +
drug O +
concentrations O +
was O +
not O +
present O -
. O +

3.5 O +
Induction O +
of O +
P53 B-Gene +
protein I-Gene +
by O +
cis O +
and O +
trans O +
platinum O +
compounds O +
Our O +
studies O +
have O +
shown O +
that O +
the O +
CH1 O +
cell O +
lines O +
are O +
wild O +
type O +
in O +
terms O +
of O +
p53 O +
status O -
, O +
while O +
the O +
SKOV-3 O +
is O +
null O +
[ O -
28,29 O -
] O +
. O +

Therefore O -
, O +
in O +
order O +
to O +
the O +
study O +
the O +
induction O +
of O +
p53 O +
following O +
DNA O +
damage O +
induced O +
by O +
the O +
cis O +
and O +
trans O +
platinum O +
compounds O -
, O +
and O +
the O +
possible O +
correlation O +
to O +
the O +
apoptosis O +
observed O +
above O -
, O +
the O +
CH1 O +
and O +
CH1cisR O +
cell O +
lines O +
were O +
selected O +
for O +
study O -
. O +

Representative O +
results O +
for O +
the O +
CH1 O +
cell O +
line O +
using O +
the O +
JM149 O -
/ O -
JM335 O +
pair O +
of O +
isomers O +
( O -
similar O +
results O +
were O +
observed O +
with O +
CH1cisR O -
) O +
are O +
shown O +
in O +
Fig. O +
8 O +
A O +
and O +
B. O +
Results O +
indicate O +
that O -
, O +
following O +
2 O +
h O +
drug O +
exposure O +
at O +
2 O -
× O -
IC50 O +
concentrations O -
, O +
p53 O +
was O +
induced O +
by O +
5 O +
h O +
and O +
levels O +
remained O +
high O +
at O +
16 O +
and O +
24 O +
h O +
post O +
exposure O -
. O +

The O +
degree O +
of O +
induction O +
was O +
somewhat O +
higher O +
with O +
the O +
trans O +
compound O +
JM335 O +
compared O +
to O +
its O +
cis O +
counterpart O -
. O +

4 O +
Discussion O +
In O +
recent O +
years O +
within O +
the O +
platinum O +
drug O +
development O +
field O +
there O +
has O +
been O +
a O +
burgeoning O +
interest O +
in O +
trans O +
platinum O +
complexes O +
exemplified O +
by O +
the O +
discovery O +
of O +
active O +
trans O +
platinum O +
complexes O +
by O +
at O +
least O +
three O +
independent O +
Groups O -
. O +

Within O +
our O +
collaboration O +
with O +
the O +
Johnson O +
Matthey O +
technology O +
Company O -
, O +
we O +
previously O +
described O +
some O +
of O +
the O +
antitumor O +
and O +
pharmacological O +
properties O +
of O +
the O +
JM O +
mixed O +
amine O +
class O +
of O +
trans O +
platinum O +
compounds O +
exemplified O +
by O +
JM335 O +
[ O -
16–20 O -
] O +
. O +

These O +
studies O +
showed O +
that O +
JM335 O +
was O +
capable O +
of O +
circumventing O +
acquired O +
cisplatin O +
resistance O +
in O +
vitro O -
. O +

Furthermore O -
, O +
JM335 O +
produced O +
growth O +
delays O +
in O +
excess O +
of O +
15 O +
days O +
against O +
four O +
human O +
ovarian O +
xenografts O +
in O +
vivo O -
. O +

In O +
contrast O +
the O +
platinum O -
( O -
II O -
) O +
trans O +
counterpart O +
JM334 O +
was O +
not O +
active O +
in O +
vivo O +
probably O +
as O +
a O +
result O +
of O +
high O +
reactivity O -
/ O -
poor O +
pharmacokinetic O +
properties O +
[ O -
17 O -
] O +
. O +

The O +
underlying O +
reasons O +
for O +
the O +
promising O +
in O +
vitro O +
potency O +
of O +
JM335 O +
against O +
cisplatin O -
- O -
resistant O +
human O +
tumour O +
cell O +
lines O +
has O +
not O +
been O +
fully O +
elucidated O -
, O +
however O -
, O +
and O +
has O +
been O +
further O +
addressed O +
herein O -
. O +

This O +
study O +
describes O +
a O +
comparison O +
of O +
the O +
cellular O +
effects O +
of O +
two O +
pairs O +
of O +
cis O +
and O +
trans O +
platinum O +
isomers O +
in O +
an O +
intrinsically O +
cisplatin O +
resistant O +
human O +
ovarian O +
carcinoma O +
cell O +
line O +
( O -
SKOV-3 O -
) O +
versus O +
a O +
pair O +
of O +
ovarian O +
cell O +
lines O +
( O -
CH1 O +
and O +
a O +
subline O +
possessing O +
acquired O +
resistance O +
to O +
cisplatin O -
) O -
, O +
in O +
terms O +
of O +
growth O +
inhibition O -
, O +
drug O +
uptake O -
, O +
binding O +
to O +
DNA O -
, O +
gene O -
- O -
specific O +
DNA O +
repair O +
and O +
induction O +
of O +
cell O +
death O -
. O +

A O +
notable O +
feature O +
of O +
the O +
growth O +
inhibition O +
studies O +
was O +
the O +
improved O +
circumvention O +
of O +
both O +
acquired O +
and O +
intrinsic O +
cisplatin O +
resistance O +
by O +
the O +
two O +
trans O +
compounds O +
when O +
compared O +
to O +
their O +
cis O +
counterparts O -
. O +

This O +
interesting O +
effect O +
was O +
most O +
prominent O +
in O +
the O +
SKOV-3 O +
cell O +
line O +
where O +
the O +
level O +
of O +
cross O -
- O -
resistance O +
( O -
compared O +
to O +
the O +
CH1 O +
parent O +
line O -
) O +
to O +
the O +
cis O +
compounds O +
( O -
including O +
cisplatin O -
) O +
was O +
greater O +
than O +
10-fold O +
but O +
was O +
only O +
around O +
4-fold O +
for O +
the O +
two O +
trans O +
compounds O -
. O +

The O +
relative O +
potency O +
of O +
the O +
trans O +
Pt O +
compounds O +
against O +
the O +
SKOV-3 O +
cells O +
is O +
surprising O +
in O +
terms O +
of O +
the O +
relative O +
levels O +
of O +
glutathione O +
in O +
the O +
CH1 O +
versus O +
the O +
SKOV-3 O +
cell O +
line O +
( O -
GSH O +
levels O +
are O +
3-fold O +
higher O +
in O +
SKOV-3 O +
[ O -
30 O -
] O +
) O +
and O +
combined O +
with O +
the O +
previous O +
observation O +
that O +
the O +
trans O +
compound O +
JM335 O +
is O +
much O +
more O +
susceptible O +
to O +
inactivation O +
by O +
intracellular O +
GSH O +
than O +
its O +
cis O +
counterpart O +
[ O -
16 O -
] O +
. O +

The O +
explanation O +
for O +
the O +
promising O +
selective O +
activity O +
of O +
the O +
trans O +
compounds O +
against O +
the O +
intrinsically O +
cisplatin O +
resistant O +
SKOV-3 O +
appears O +
to O +
lie O +
at O +
the O +
level O +
of O +
DNA O +
binding O +
and O +
repair O -
. O +

The O +
most O +
striking O +
difference O +
between O +
the O +
cell O +
lines O +
and O +
the O +
trans O +
versus O +
cis O +
compounds O +
was O +
how O +
the O +
SKOV-3 O +
cell O +
line O +
handled O +
DNA O +
damage O +
induced O +
by O +
the O +
compounds O +
at O +
the O +
level O +
of O +
gene O -
- O -
specific O +
repair O -
. O +

Whereas O +
this O +
line O +
was O +
able O +
to O +
remove O +
adducts O +
from O +
a O +
fragment O +
of O +
the O +
N O -
- O -
ras O +
gene O +
within O +
24 O +
h O +
formed O +
by O +
both O +
cis O +
platinum O +
compounds O +
JM118 O +
and O +
JM149 O -
, O +
there O +
was O +
an O +
increase O +
in O +
measured O +
adducts O +
following O +
exposure O +
to O +
their O +
trans O +
counterparts O -
, O +
JM334 O +
and O +
JM335 O -
. O +

In O +
addition O -
, O +
there O +
was O +
a O +
small O +
increase O +
in O +
overall O +
DNA O +
platination O +
observed O +
immediately O +
following O +
a O +
2 O +
h O +
drug O +
exposure O +
for O +
the O +
two O +
trans O +
compounds O +
relative O +
to O +
their O +
cis O +
counterparts O +
in O +
the O +
SKOV-3 O +
cell O +
line O -
. O +

Interestingly O -
, O +
total O +
intracellular O +
platinum O +
accumulation O +
measurements O +
made O +
immediately O +
after O +
2 O +
h O +
drug O +
exposure O +
did O +
not O +
correlate O +
with O +
either O +
the O +
potencies O +
observed O +
in O +
the O +
growth O +
inhibition O +
studies O +
or O +
the O +
levels O +
of O +
binding O +
to O +
DNA O -
. O +

In O +
particular O -
, O +
the O +
trans O +
Pt O -
( O -
II O -
) O +
compound O +
JM334 O +
was O +
rapidly O +
taken O +
up O +
into O +
cells O +
resulting O +
in O +
significantly O +
higher O +
intracellular O +
platinum O +
levels O +
at O +
2 O +
h O +
drug O +
exposure O +
in O +
all O +
three O +
cell O +
lines O +
but O +
this O +
was O +
not O +
reflected O +
in O +
significantly O +
higher O +
DNA O +
platination O -
, O +
especially O +
in O +
the O +
CH1 O +
and O +
CH1cisR O +
cell O +
lines O -
. O +

This O +
is O +
probably O +
due O +
to O +
the O +
high O +
reactivity O +
of O +
JM334 O +
[ O -
17 O -
] O +
resulting O +
in O +
avid O +
binding O +
to O +
cytoplasmic O +
thiol O -
- O -
containing O +
species O -
. O +

While O +
the O +
SKOV-3 O +
cell O +
line O +
appeared O +
to O +
discriminate O +
at O +
the O +
level O +
of O +
gene O +
specific O +
repair O +
between O +
adducts O +
formed O +
by O +
cis O +
versus O +
trans O +
platinum O +
compounds O -
, O +
the O +
CH1 O +
appeared O +
repair O -
- O -
deficient O +
in O +
not O +
being O +
capable O +
of O +
removing O +
adducts O +
from O +
the O +
N O -
- O -
ras O +
gene O +
formed O +
by O +
any O +
of O +
the O +
compounds O -
. O +

This O +
repair O +
deficiency O +
probably O +
contributes O +
to O +
the O +
relative O +
sensitivity O +
of O +
the O +
CH1 O +
cell O +
line O +
compared O +
to O +
SKOV-3 O +
to O +
all O +
four O +
compounds O +
and O +
underlines O +
the O +
possible O +
importance O +
of O +
gene O -
- O -
specific O +
repair O +
in O +
determining O +
the O +
cytotoxicity O +
of O +
platinum O +
compounds O -
. O +

The O +
CH1 O +
line O +
has O +
also O +
been O +
shown O +
to O +
be O +
unable O +
to O +
remove O +
adducts O +
formed O +
by O +
JM216 O +
( O -
unpublished O +
observations O -
) O -
. O +

These O +
observations O +
support O +
those O +
of O +
others O +
using O +
cisplatin O +
who O +
have O +
correlated O +
increased O +
gene O +
specific O +
repair O -
, O +
especially O +
of O +
interstrand O +
cross O -
- O -
links O -
, O +
with O +
resistance O +
of O +
human O +
ovarian O +
cancer O +
cell O +
lines O +
[ O -
31–34 O -
] O +
. O +

Levels O +
of O +
platinum O +
bound O +
to O +
DNA O +
were O +
similar O +
in O +
the O +
CH1 O +
versus O +
CH1cisR O +
line O +
following O +
exposure O +
to O +
both O +
pairs O +
of O +
compounds O +
and O +
no O +
differences O +
could O +
be O +
measured O +
between O +
the O +
lines O +
in O +
terms O +
of O +
gene O +
specific O +
repair O -
, O +
induction O +
of O +
apoptosis O +
and O +
induction O +
of O +
p53 B-Gene +
protein I-Gene -
. O +

Hence O -
, O +
as O +
with O +
resistance O +
to O +
JM216 O +
in O +
the O +
acquired O +
JM216 O +
resistant O +
subline O +
of O +
CH1 O +
[ O -
35 O -
] O +
, O +
increased O +
tolerance O +
to O +
platinum O -
– O -
DNA O +
adducts O +
appears O +
to O +
represent O +
a O +
major O +
mechanism O +
of O +
resistance O +
to O +
these O +
cis O +
and O +
trans O +
compounds O +
in O +
CH1cisR. O +
All O +
four O +
platinum O +
compounds O +
induced O +
cell O +
death O +
by O +
apoptosis O +
in O +
the O +
three O +
lines O +
studied O -
. O +

The O +
presence O +
of O +
apoptotic O +
cells O +
following O +
drug O +
exposure O +
was O +
confirmed O +
by O +
both O +
fluorescence O +
microscopy O +
and O +
by O +
DNA O +
fragmentation O +
into O +
50 O +
kb O +
fragments O -
. O +

As O +
observed O +
previously O +
using O +
cisplatin O +
in O +
these O +
three O +
cell O +
lines O +
[ O -
25 O -
] O +
DNA O +
fragmentation O +
into O +
internucleosomal O +
DNA O +
ladders O +
was O +
not O +
observed O +
in O +
apoptotic O +
cells O -
. O +

One O +
notable O +
difference O +
between O +
the O +
cis O +
and O +
trans O +
platinum O +
compounds O +
was O +
in O +
the O +
kinetics O +
of O +
apoptosis O -
. O +

As O +
observed O +
previously O +
with O +
CH1 O +
cells O +
exposed O +
to O +
JM335 O +
and O +
JM149 O +
[ O -
20 O -
] O +
apoptosis O +
occurred O +
markedly O +
faster O +
in O +
CH1cisR O +
cells O +
exposed O +
to O +
JM334 O +
or O +
JM335 O +
when O +
compared O +
to O +
their O +
respective O +
cis O +
isomers O -
. O +

Interestingly O -
, O +
JM334 O +
induced O +
a O +
non O -
- O -
apoptotic O +
death O +
at O +
high O +
drug O +
concentrations O +
with O +
cells O +
neither O +
displaying O +
apoptotic O +
morphology O +
( O -
extensive O +
vesiculation O +
occurring O -
) O +
nor O +
a O +
50 O +
kb O +
fragment O +
by O +
FIGE O -
. O +

In O +
the O +
two O +
CH1 O +
cell O +
lines O +
possessing O +
wild O -
- O -
type O +
p53 B-Gene -
, O +
this O +
protein B-Gene +
was O +
induced O +
following O +
exposure O +
to O +
either O +
JM149 O +
or O +
JM335 O -
, O +
the O +
induction O +
being O +
somewhat O +
greater O +
with O +
the O +
trans O +
isomer O -
. O +

However O -
, O +
p53 B-Gene +
induction O +
was O +
not O +
essential O +
for O +
apoptosis O +
at O +
least O +
in O +
the O +
SKOV-3 O +
cells O +
which O +
is O +
null O +
for O +
p53 B-Gene +
but O +
where O +
apoptosis O +
clearly O +
occurred O -
. O +

In O +
terms O +
of O +
the O +
cell O +
cycle O +
response O +
to O +
the O +
compounds O -
, O +
all O +
induced O +
a O +
general O +
slowdown O +
in O +
S O -
- O -
phase O +
and O +
effects O +
similar O +
to O +
those O +
reported O +
previously O +
by O +
us O +
in O +
these O +
lines O +
using O +
cisplatin O +
[ O -
25 O -
] O +
( O -
data O +
not O +
shown O -
) O -
. O +

These O +
cellular O +
data O +
provide O +
further O +
evidence O +
previously O +
obtained O +
at O +
the O +
level O +
of O +
DNA O +
binding O +
with O +
these O +
compounds O +
[ O -
16,18 O -
] O +
and O +
other O +
trans O +
compounds O +
[ O -
13–15,36,37 O -
] O +
that O +
trans O +
compounds O +
all O +
behave O +
differently O +
to O +
cis O +
-oriented O +
platinum O +
compounds O -
. O +

For O +
example O -
, O +
we O +
showed O +
that O +
JM335 O +
formed O +
DNA O +
adducts O +
in O +
cells O +
which O +
were O +
not O +
recognised O +
by O +
a O +
monoclonal B-Gene +
antibody I-Gene +
raised O +
against O +
DNA O +
platinated O +
by O +
cisplatin O +
( O -
adducts O +
induced O +
by O +
JM149 O +
and O +
JM O +
118 O +
were O +
recognised O -
) O +
[ O -
18 O -
] O +
. O +

Also O -
, O +
while O +
JM335 O +
was O +
capable O +
of O +
forming O +
DNA O +
interstrand O +
cross O -
- O -
links O +
in O +
SKOV-3 O +
cells O -
, O +
in O +
CH1 O +
cells O -
, O +
unusually O +
for O +
platinum O +
complexes O -
, O +
DNA O +
single O +
strand O +
breaks O +
were O +
detected O +
[ O -
16,18 O -
] O +
. O +

The O +
trans O +
iminoethers O +
have O +
been O +
shown O +
to O +
preferentially O +
form O +
monofunctional O +
adducts O +
at O +
guanine O +
residues O +
when O +
incubated O +
in O +
cell O -
- O -
free O +
conditions O +
with O +
doublestranded O +
DNA O +
causing O +
unique O +
local O +
distortions O +
in O +
DNA O +
[ O -
13–15,36 O -
] O +
. O +

The O +
trans O +
-pyridine O +
complexes O +
resulted O +
in O +
greatly O +
increased O +
DNA O -
– O -
DNA O +
interstrand O +
cross O -
- O -
linking O +
and O +
conformational O +
changes O +
shown O +
by O +
increased O +
unwinding O +
of O +
supercoiled O +
DNA O +
[ O -
37 O -
] O +
. O +

Another O +
trans O +
compound O +
( O -
PtCl2 O +
( O -
NH3 O +
) O -
( O -
quinoline O -
) O -
) O +
has O +
also O +
recently O +
been O +
shown O +
to O +
form O +
more O +
interstrand O +
cross O -
- O -
links O +
than O +
transplatin O +
when O +
incubated O +
with O +
DNA O +
for O +
48 O +
h O +
[ O -
38 O -
] O +
. O +

In O +
summary O -
, O +
these O +
data O -
, O +
along O +
with O +
our O +
previous O +
studies O -
, O +
indicate O +
that O +
the O +
trans O +
platinum O +
complexes O +
JM334 O +
and O +
JM335 O +
possess O +
unique O +
cellular O +
pharmacological O +
properties O +
in O +
comparison O +
to O +
their O +
cis O +
counterparts O -
. O +

While O +
all O +
four O +
compounds O +
studied O +
induced O +
apoptosis O +
in O +
all O +
three O +
cell O +
lines O -
, O +
the O +
kinetics O +
of O +
cell O +
death O +
were O +
faster O +
for O +
the O +
trans O +
compounds O -
. O +

Their O +
selective O +
potency O +
against O +
the O +
intrinsically O +
cisplatin O +
resistant O +
SKOV-3 O +
cell O +
line O +
appears O +
to O +
be O +
due O +
mainly O +
to O +
a O +
slower O +
rate O +
of O +
removal O +
or O +
even O +
a O +
failure O +
to O +
remove O +
the O +
DNA O +
adducts O +
at O +
the O +
level O +
of O +
actively O +
transcribed O +
genes O -
. O +

T O +
cell O +
activation O -
, O +
which O +
plays O +
a O +
central O +
role O +
in O +
the O +
regulation O +
of O +
both O +
normal O +
and O +
pathogenic O +
immune O +
responses O -
, O +
involves O +
multiple O +
intracellular O +
signaling O +
events O +
emanating O +
from O +
the O +
cell O +
surface O +
TCR B-Gene -
/ O -
CD3 B-Gene +
complex O +
and O +
costimulatory O +
molecules O +
( O -
Cantrell O -
, O +
1996 O +
; O +
Alberola O -
- O -
Ila O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

These O +
signaling O +
events O +
can O +
be O +
largely O +
mimicked O +
by O +
artificial O +
stimulation O +
of O +
the O +
T O +
cells O -
, O +
such O +
as O +
combined O +
treatment O +
with O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
and O +
the O +
PKC B-Gene +
activator O -
, O +
PMA O +
( O -
Cantrell O -
, O +
1996 O +
; O +
Alberola O -
- O -
Ila O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

It O +
has O +
been O +
shown O +
that O +
under O +
both O +
physiological O +
and O +
artificial O +
conditions O +
of O +
stimulation O -
, O +
at O +
least O +
three O +
signal O +
transduction O +
pathways O -
, O +
dependent O +
respectively O +
on O +
the O +
activation O +
of O +
calcineurin B-Gene +
( O -
O'Keefe O +
et O +
al. O -
, O +
1992 O +
) O -
, O +
of O +
the O +
extracellular B-Gene +
signal I-Gene -
- I-Gene -
regulated I-Gene +
kinase I-Gene +
( O -
ERK B-Gene -
) O +
and O +
its O +
upstream O +
regulator O +
MEK1 B-Gene +
( O -
Seger O +
and O +
Krebs O -
, O +
1995 O +
) O -
, O +
and O +
of O +
the O +
c B-Gene -
- I-Gene -
Jun I-Gene -
- I-Gene -
N I-Gene +
terminal I-Gene +
kinase I-Gene +
( O -
JNK B-Gene -
) O +
( O -
Su O +
et O +
al. O -
, O +
1994 O +
) O +
ultimately O +
integrate O +
( O -
Cantrell O -
, O +
1996 O +
; O +
Alberola O -
- O -
Ila O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
leading O +
to O +
the O +
secretion O +
of O +
cytokines B-Gene +
and O +
the O +
acquisition O +
of O +
effector O +
functions O +
by O +
the O +
T O +
cells O -
. O +

In O +
particular O -
, O +
these O +
pathways O +
are O +
essential O +
for O +
the O +
production O +
of O +
IL-2 B-Gene +
( O -
O'Keefe O +
et O +
al. O -
, O +
1992 O +
; O +
Li O +
et O +
al. O -
, O +
1996 O +
; O +
Dumont O +
et O +
al. O -
, O +
1998 O +
; O +
Powell O +
et O +
al. O -
, O +
1998 O +
; O +
Werlen O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
the O +
major O +
T B-Gene +
cell I-Gene +
growth I-Gene +
factor I-Gene +
that O +
is O +
required O +
for O +
driving O +
T O +
cells O +
into O +
the O +
proliferation O +
cycle O -
. O +

Because O +
of O +
its O +
pivotal O +
immunoregulatory O +
function O -
, O +
T O +
cell O +
activation O +
provides O +
a O +
target O +
for O +
pharmacologic O +
modulation O +
aimed O +
at O +
achieving O +
clinically O +
useful O +
immunosuppression O -
. O +

This O +
is O +
well O +
demonstrated O +
by O +
the O +
therapeutic O +
efficacy O +
of O +
cyclosporin O +
A O +
( O -
CsA O -
) O +
and O +
FK506 O +
( O -
reviewed O +
in O +
Dumont O -
, O +
1996 O +
) O -
, O +
which O +
selectively O +
block O +
calcineurin B-Gene -
- O -
dependent O +
signaling O +
( O -
O'Keefe O +
et O +
al. O -
, O +
1992 O +
) O -
, O +
and O +
represent O +
the O +
mainstays O +
of O +
the O +
immunosuppressive O +
regimen O +
currently O +
available O +
for O +
the O +
management O +
of O +
graft O +
rejection O +
and O +
autoimmune O +
diseases O -
. O +

However O -
, O +
these O +
agents O +
are O +
less O +
than O +
perfect O +
as O +
their O +
use O +
is O +
often O +
associated O +
with O +
significant O +
and O +
limiting O +
side O -
- O -
effects O +
( O -
Dumont O -
, O +
1996 O +
) O -
, O +
and O +
there O +
is O +
a O +
pressing O +
need O +
for O +
novel O +
inhibitors O +
of O +
T O +
cell O +
activation O +
in O +
order O +
to O +
expand O +
the O +
immunosuppressive O +
therapeutic O +
armamentareum O -
. O +

Intense O +
screening O +
effort O +
of O +
natural O +
product O +
or O +
synthetic O +
compounds O +
are O +
therefore O +
ongoing O +
to O +
identify O +
such O +
inhibitors O -
. O +

This O +
search O +
led O +
us O +
to O +
discover O +
that O +
hypothemycin O -
, O +
a O +
resorcylic O +
acid O +
lactone O +
natural O +
product O -
, O +
previously O +
described O +
as O +
an O +
antibiotic O +
( O -
Nair O +
and O +
Carey O -
, O +
1980 O +
; O +
Nair O +
et O +
al. O -
, O +
1981 O +
; O +
Agatsuma O +
et O +
al. O -
, O +
1993 O +
) O -
, O +
exerts O +
potent O +
suppressive O +
activity O +
on O +
T O +
cell O +
activation O -
. O +

The O +
present O +
studies O +
characterized O +
the O +
effect O +
of O +
hypothemycin O +
on O +
several O +
parameters O +
of O +
mouse O +
and O +
human O +
T O +
cell O +
activation O +
in O +
vitro O -
. O +

We O +
showed O +
that O +
this O +
compound O +
inhibits O +
the O +
proliferation O +
of O +
T O +
cells O +
induced O +
by O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
treatment O +
and O +
PMA O +
in O +
a O +
manner O +
partially O +
reversed O +
by O +
exogenous O +
IL-2 B-Gene -
. O +

Moreover O -
, O +
hypothemycin O +
was O +
found O +
to O +
inhibit O +
the O +
production O +
of O +
IL-2 B-Gene -
, O +
IL-6 B-Gene -
, O +
IL-10 B-Gene -
, O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
while O +
enhancing O +
the O +
production O +
of O +
IL-4 B-Gene -
, O +
IL-5 B-Gene +
and O +
IL-13 B-Gene -
, O +
both O +
at O +
the O +
mRNA O +
and O +
protein B-Gene +
secretion O +
levels O -
. O +

Further O +
analyses O +
suggested O +
that O +
hypothemycin O +
disrupts O +
calcineurin B-Gene -
- O -
independent O +
signaling O -
, O +
through O +
an O +
inhibition O +
of O +
the O +
ERK B-Gene +
pathway O -
. O +

This O +
compound O +
therefore O +
represents O +
a O +
novel O +
type O +
of O +
T O +
cell O +
inhibitor O +
with O +
a O +
mode O +
of O +
action O +
distinct O +
from O +
that O +
of O +
CsA O +
or O +
FK506 O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Isolation O +
of O +
hypothemycin O +
Hypothemycin O +
was O +
isolated O +
from O +
fermentations O +
of O +
an O +
unidentified O +
fungal O +
culture O +
that O +
was O +
found O +
active O +
in O +
a O +
screen O +
for O +
inhibitors O +
of O +
T O +
cell O +
activation O -
. O +

The O +
dried O +
2-butanone O +
extract O +
of O +
the O +
fermentation O +
was O +
purified O +
by O +
silica O +
gel O +
column O +
chromatography O +
developed O +
with O +
a O +
step O +
gradient O +
of O +
methanol O +
in O +
dichloromethane O -
. O +

The O +
fractions O +
containing O +
hypothemycin O +
were O +
pooled O +
and O +
dried O -
. O +

Pure O +
( O -
> O -
98 O -
% O -
) O +
hypothemycin O +
was O +
obtained O +
by O +
crystallization O +
of O +
this O +
material O +
from O +
a O +
mixture O +
of O +
acetone O +
and O +
hexanes O -
. O +

The O +
compound O +
was O +
identified O +
based O +
on O +
comparison O +
of O +
spectroscopic O +
data O +
( O -
mass O +
spectrometry O -
, O +
UV O +
absorption O -
, O +
and O +
nuclear O +
magnetic O +
resonance O -
) O +
to O +
those O +
previously O +
published O +
for O +
hypothemycin O +
( O -
Nair O +
and O +
Carey O -
, O +
1980 O +
; O +
Nair O +
et O +
al. O -
, O +
1981 O +
; O +
Agatsuma O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

Hypothemycin O +
was O +
dissolved O +
at O +
10 O +
mg O -
/ O -
ml O +
in O +
DMSO O +
and O +
stored O +
in O +
aliquots O +
at O +
−70 O -
° O -
C O -
. O +

2.2 O +
Other O +
reagents O +
Zearalenone O +
( O -
Kuiper O -
- O -
Goodman O +
et O +
al. O -
, O +
1987 O +
) O +
was O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
) O +
and O +
stored O +
in O +
aliquots O +
( O -
10 O +
mg O -
/ O -
ml O -
, O +
DMSO O -
) O +
at O +
−70 O -
° O -
C O -
. O +

PD98059 O +
( O -
Dudley O +
et O +
al. O -
, O +
1995 O +
) O +
was O +
obtained O +
from O +
Biomol O +
( O -
Plymouth O +
Meeting O -
, O +
PA O -
) O -
. O +

PMA O -
, O +
ionomycin O +
and O +
anisomycin O +
were O +
obtained O +
from O +
Sigma O -
. O +

Anti B-Gene -
- I-Gene -
mouse I-Gene +
CD3 I-Gene +
mAb I-Gene +
( O -
2C11 B-Gene -
) O +
and O +
anti B-Gene -
- I-Gene -
human I-Gene +
CD3 I-Gene +
mAb I-Gene +
( O -
1XE B-Gene -
) O +
were O +
obtained O +
from O +
Pharmingen O +
( O -
San O +
Diego O -
, O +
CA O -
) O +
and O +
Research O +
Diagnostics O +
( O -
Flanders O -
, O +
NJ O -
) O -
, O +
respectively O -
. O +

Human O +
recombinant O +
IL-2 B-Gene +
was O +
purchased O +
from O +
Biosource O +
International O +
( O -
Camarillo O -
, O +
CA O -
) O -
. O +

Human O +
PHA O -
- O -
conditioned O +
media O +
( O -
T O -
- O -
stim O -
, O +
without O +
PHA O -
) O +
was O +
obtained O +
from O +
Fisher O +
Scientific O +
( O -
Springfield O -
, O +
NJ O -
) O -
. O +

Fluoresceinated O +
mAb B-Gene +
to O +
mouse O +
CD69 B-Gene +
was O +
obtained O +
from O +
Pharmingen O -
. O +

Unconjugated O +
and O +
biotin O -
- O -
conjugated O -
, O +
matched O +
anti B-Gene -
- I-Gene -
cytokine I-Gene +
antibody I-Gene +
pairs O +
for O +
quantitation O +
of O +
human O +
cytokines B-Gene +
by O +
ELISA O +
were O +
obtained O +
from O +
Genzyme O +
( O -
Cambridge O -
, O +
MA O -
) O +
( O -
IL-2 B-Gene -
) O -
, O +
Research O +
Diagnostics O +
( O -
IL-4 B-Gene -
, O +
IL-13 B-Gene -
) O -
, O +
or O +
Pharmingen O +
( O -
IL-5 B-Gene -
, O +
IL-10 B-Gene -
, O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
, O +
TNF B-Gene -
- I-Gene -
α I-Gene -
) O -
. O +

Poly B-Gene -
- I-Gene -
HRP I-Gene -
- I-Gene -
streptavidin I-Gene +
was O +
obtained O +
from O +
Research O +
Diagnostics O -
. O +

Polyclonal B-Gene +
antibodies I-Gene +
to O +
ERK1 B-Gene -
/ O -
2 B-Gene +
and O +
phosphospecific O +
antibodies B-Gene +
recognizing O +
the O +
catalytically O +
activated O +
forms O +
of O +
ERK1 B-Gene -
/ O -
2 B-Gene +
( O -
phosphorylation O +
at O +
Thr202 O -
/ O -
Tyr204 O -
) O +
were O +
obtained O +
from O +
New O +
England O +
Biolabs O +
( O -
Beverly O -
, O +
MA O -
) O -
. O +

2.3 O +
Cell O +
isolation O +
Mouse O +
splenic O +
T O +
cells O +
were O +
isolated O +
from O +
C57Bl O -
/ O -
6Tac O +
mice O +
by O +
nylon O +
wool O +
separation O -
. O +

Human O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O -
PBMC O -
) O +
were O +
separated O +
from O +
venous O +
whole O +
or O +
leukophoresed O +
blood O +
from O +
healthy O +
volunteers O +
( O -
New O +
York O +
Blood O +
Bank O +
or O +
University O +
of O +
Pennsylvania O +
Medical O +
Center O -
) O +
by O +
ficoll O -
/ O -
hypaque O +
centrifugation O +
( O -
LSM O -
, O +
Organon O +
Teknika O -
) O -
. O +

Highly O +
purified O +
T O +
cells O +
( O -
93–96 O -
% O +
CD3 O -
+ O +
) O +
were O +
isolated O +
by O +
E O -
- O -
rosetting O +
of O +
PBMC O +
with O +
neuraminidase B-Gene -
- O -
treated O +
sheep O +
red O +
blood O +
cells O +
followed O +
by O +
overnight O +
incubation O +
at O +
37 O -
° O -
C O +
in O +
plastic O +
flasks O +
to O +
remove O +
contaminating O +
adherent O +
cells O -
. O +

Mouse O +
or O +
human O +
cells O +
were O +
washed O +
and O +
resuspended O +
in O +
complete O +
culture O +
medium O +
made O +
of O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
10 O -
% O +
heat O -
- O -
inactivated O +
fetal O +
calf O +
serum O -
, O +
2 O +
mM O +
glutamine O -
, O +
1 O +
mM O +
sodium O +
pyruvate O -
, O +
2 O -
× O -
10−5 O +
M O +
2-mercaptoethanol O +
and O +
20 O +
ng O -
/ O -
ml O +
gentamycin O -
. O +

2.4 O +
Cell O +
cultures O +
Cell O +
cultures O +
were O +
set O +
up O +
in O +
flat O -
- O -
bottom O +
96-well O +
plates O -
; O +
each O +
well O +
receiving O +
200 O +
μl O +
of O +
cell O +
suspension O -
. O +

Purified O +
mouse O +
or O +
human O +
T O +
cells O +
were O +
seeded O +
at O +
a O +
concentration O +
of O +
5 O -
× O -
105 O +
cells O -
/ O -
ml O +
and O +
PBMC O +
at O +
a O +
concentration O +
of O +
106 O +
cells O -
/ O -
ml O -
. O +

For O +
stimulation O +
of O +
T O +
cells O -
, O +
the O +
appropriate O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
( O -
2C11 B-Gene -
: O +
100 O +
ng O -
/ O -
ml O -
; O +
1X2 O -
: O +
0.4 O +
μg O -
/ O -
ml O -
) O +
was O +
added O +
with O +
PMA O +
( O -
0.1 O -
, O +
1 O +
or O +
10 O +
ng O -
/ O -
ml O -
, O +
as O +
indicated O -
) O +
and O +
with O +
or O +
without O +
IL-2 B-Gene +
( O -
50 O +
U O -
/ O -
ml O -
) O -
. O +

For O +
stimulation O +
of O +
human O +
PBMC O -
, O +
the O +
1X2 O +
mAb B-Gene +
was O +
used O +
at O +
0.4 O +
μg O -
/ O -
ml O +
and O +
cultures O +
were O +
set O +
up O +
without O +
or O +
with O +
10 O -
% O +
T O -
- O -
stim O +
media O -
. O +

CTTL-2 O +
cells O +
( O -
American O +
Type O +
Culture O +
Collection O -
, O +
Rockville O -
, O +
MD O -
) O +
were O +
washed O +
extensively O +
and O +
incubated O +
for O +
3 O +
h O +
at O +
37 O -
° O -
C O +
in O +
the O +
absence O +
of O +
IL-2 B-Gene -
, O +
washed O +
again O +
and O +
resuspended O +
at O +
104 O +
cells O -
/ O -
ml O +
in O +
culture O +
medium O +
containing O +
100 O +
U O -
/ O -
ml O +
IL-2 B-Gene -
. O +

The O +
cell O +
suspension O +
was O +
then O +
distributed O +
at O +
200 O +
μl O -
/ O -
well O +
in O +
culture O +
plates O -
. O +

Working O +
solutions O +
of O +
compounds O +
were O +
prepared O +
extemporaneously O +
in O +
culture O +
medium O +
from O +
their O +
stock O +
solutions O +
and O +
added O +
1:10 O +
in O +
at O +
least O +
triplicate O +
wells O -
, O +
at O +
the O +
initiation O +
of O +
the O +
cultures O -
. O +

Plates O +
were O +
incubated O +
at O +
37 O -
° O -
C O +
in O +
a O +
humidified O +
atmosphere O +
with O +
5 O -
% O +
CO2 O +
. O +

2.5 O +
Measurement O +
of O +
proliferation O +
T O +
cell O +
cultures O +
were O +
pulsed O +
with O +
2 O +
μCi O -
/ O -
well O +
[ O -
3 O +
H O +
] O -
-TdR O +
( O -
specific O +
activity O -
: O +
5 O +
Ci O -
/ O -
mmole O -
, O +
Amersham O -
) O +
for O +
4 O +
h O +
on O +
day O +
2 O +
of O +
culture O +
( O -
mouse O -
) O +
or O +
for O +
8 O +
h O +
on O +
day O +
3 O +
of O +
culture O +
( O -
human O -
) O -
. O +

Cultures O +
were O +
harvested O +
in O +
a O +
Tomteck O +
harvester O +
( O -
Wallac O -
- O -
LKB O -
, O +
Gaithersburg O -
, O +
MD O -
) O -
. O +

Incorporated O +
radioactivity O +
was O +
measured O +
in O +
a O +
Betaplate O +
( O -
Wallac O -
- O -
LKB O -
) O +
liquid O +
scintillation O +
spectrometer O -
. O +

Results O +
were O +
calculated O +
as O +
means O +
of O +
replicate O +
wells O +
and O +
expressed O +
as O +
percent O +
of O +
the O +
control O +
response O +
of O +
cultures O +
stimulated O +
in O +
absence O +
of O +
compound O -
. O +

2.6 O +
Quantitation O +
of O +
cytokine B-Gene +
concentration O +
in O +
culture O +
supernatants O +
For O +
cytokine B-Gene +
measurements O -
, O +
supernatants O +
from O +
human O +
T O +
cells O +
were O +
collected O +
after O +
24 O +
or O +
48 O +
h O +
of O +
culture O +
and O +
stored O +
at O +
4 O -
° O -
C O +
or O +
at O +
−70 O -
° O -
C O +
until O +
analysis O -
. O +

Cytokine B-Gene +
levels O +
were O +
quantitated O +
by O +
sandwich O +
ELISA O +
using O +
matched O +
antibody B-Gene +
pairs O -
. O +

ELISA O +
plates O +
( O -
Maxisorb O -
, O +
Nunc O -
) O +
were O +
coated O +
overnight O +
with O +
anti B-Gene -
- I-Gene -
cytokine I-Gene +
mAb I-Gene +
in O +
0.1 O +
M O +
carbonate B-Gene -
/ O -
bicarbonate B-Gene +
buffer O -
, O +
pH O +
9.6 O -
. O +

After O +
washing O -
, O +
plates O +
were O +
blocked O +
with O +
casein B-Gene -
- O -
containing O +
blocking O +
buffer O +
( O -
Research O +
Diagnostics O -
) O -
, O +
and O +
washed O +
again O -
. O +

Appropriately O +
diluted O +
supernatant O +
samples O +
and O +
standards O +
were O +
distributed O +
in O +
duplicate O +
and O +
the O +
plates O +
were O +
incubated O +
for O +
2 O +
h O +
at O +
room O +
temperature O +
on O +
a O +
horizontal O +
shaker O -
. O +

Plates O +
were O +
washed O -
, O +
incubated O +
for O +
1 O +
h O +
with O +
biotinylated B-Gene +
anti I-Gene -
- I-Gene -
cytokine I-Gene +
Ab I-Gene +
and O +
washed O +
again O -
. O +

Plates O +
were O +
then O +
incubated O +
with O +
poly B-Gene -
- I-Gene -
HRP I-Gene +
streptavidin I-Gene +
for O +
30 O +
min O +
at O +
room O +
temperature O +
with O +
shaking O -
. O +

After O +
a O +
final O +
wash O -
, O +
substrate O +
was O +
added O +
( O -
DAKO O +
TMP O +
One O -
- O -
Step O +
Substrate O +
System O -
, O +
DAKO O -
, O +
Carpinteria O -
, O +
CA O -
) O -
. O +

The O +
reaction O +
was O +
stopped O +
by O +
addition O +
of O +
0.2 O +
M O +
sulfuric O +
acid O -
. O +

Plates O +
were O +
read O +
at O +
450 O +
nm O +
in O +
a O +
Molecular O +
Devices O +
UVmax O +
plate O +
reader O +
( O -
Menlo O +
Park O -
, O +
CA O -
) O -
, O +
and O +
the O +
data O +
were O +
calculated O +
using O +
the O +
SOFTtmax O +
program O +
from O +
Molecular O +
Devices O -
. O +

The O +
results O +
were O +
expressed O +
as O +
percent O +
of O +
the O +
control O +
level O +
of O +
cytokine B-Gene +
production O +
by O +
cells O +
stimulated O +
in O +
the O +
absence O +
of O +
compound O -
. O +

The O +
50 O -
% O +
inhibitory O +
concentration O +
of O +
compound O +
( O -
IC50 O +
) O +
was O +
calculated O +
by O +
linear O +
regression O +
analysis O -
. O +

2.7 O +
Analysis O +
of O +
cytokine B-Gene +
mRNA O +
expression O +
by O +
RNase B-Gene +
protection O +
assay O +
( O -
RPA O -
) O +
Purified O +
human O +
T O +
cells O +
were O +
cultured O +
in O +
T25 O +
flasks O +
( O -
106 O +
/ml O -
, O +
20 O +
ml O -
/ O -
flask O -
) O +
maintained O +
in O +
an O +
upright O +
position O -
. O +

The O +
cells O +
were O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
19 O +
h O +
in O +
the O +
presence O +
of O +
the O +
various O +
stimuli O -
, O +
with O +
or O +
without O +
compound O -
, O +
as O +
indicated O -
. O +

Cells O +
were O +
then O +
harvested O -
, O +
centrifuged O -
, O +
transferred O +
to O +
microtubes O -
, O +
and O +
washed O +
with O +
PBS O -
. O +

Cell O +
pellets O +
were O +
frozen O +
at O +
−70 O -
° O -
C O -
. O +

Total O +
RNA O +
was O +
extracted O +
using O +
RNAqueous O -
™ O +
RNA O +
isolation O +
kit O +
( O -
Ambion O -
, O +
Austin O -
, O +
TX O -
) O +
and O +
quantitated O +
by O +
absorbance O +
at O +
260 O +
nm O -
. O +

Cytokine B-Gene +
mRNAs O +
were O +
detected O +
with O +
the O +
RiboQuant O -
™ O +
Multi O -
- O -
Probe O +
RPA O +
system O +
from O +
PharMingen O +
( O -
San O +
Diego O -
, O +
CA O -
) O +
using O +
the O +
hCK-1 O +
multiprobe O -
- O -
template O -
. O +

Riboprobes O +
were O +
[ O -
32 O +
P O +
] O -
-labeled O +
and O +
hybridized O +
overnight O +
with O +
20 O +
μg O +
of O +
the O +
RNA O +
samples O -
. O +

The O +
hybridized O +
RNA O +
was O +
treated O +
with O +
RNase B-Gene +
and O +
purified O +
according O +
to O +
the O +
RiboQuant O -
™ O +
protocol O -
. O +

The O +
samples O +
were O +
then O +
electrophoresed O +
in O +
6 O -
% O +
polyacrylamide O +
Tris O -
– O -
borate O -
– O -
EDTA O -
– O -
urea O +
mini O -
- O -
gels O +
( O -
Novex O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
. O +

The O +
gels O +
were O +
dried O -
, O +
exposed O +
and O +
quantitated O +
in O +
a O +
PhosphorImager O +
( O -
Molecular O +
Dynamics O -
, O +
Sunnyvale O -
, O +
CA O -
) O -
. O +

2.8 O +
Flow O +
cytometry O +
( O -
FCM O -
) O +
analysis O +
of O +
CD69 O +
expression O +
Cultures O +
of O +
mouse O +
T O +
cells O +
( O -
106 O +
/ml O -
) O +
for O +
assessment O +
of O +
CD69 B-Gene +
induction O +
were O +
set O +
up O +
at O +
1 O +
ml O -
/ O -
well O +
in O +
24-well O +
plates O -
. O +

Cells O +
received O +
hypothemycin O +
or O +
FK506 O +
and O +
were O +
stimulated O +
with O +
PMA O +
( O -
10 O +
ng O -
/ O -
ml O -
) O +
or O +
ionomycin O +
( O -
2 O +
μg O -
/ O -
ml O -
) O -
. O +

The O +
culture O +
plates O +
were O +
incubated O +
for O +
14 O +
h O +
at O +
37 O -
° O -
C O -
. O +

At O +
the O +
time O +
of O +
harvesting O -
, O +
the O +
plates O +
were O +
placed O +
on O +
ice O +
for O +
30 O +
min O +
and O +
the O +
cells O +
were O +
collected O +
using O +
pasteur O +
pipettes O -
. O +

The O +
cells O +
were O +
stained O +
with O +
fluoresceinated O +
anti B-Gene -
- I-Gene -
CD69 I-Gene +
mAb I-Gene +
and O +
washed O -
. O +

FCM O +
analysis O +
( O -
10,000 O +
cells O -
/ O -
sample O -
) O +
was O +
performed O +
in O +
a O +
FACScan O +
( O -
Becton O +
Dickinson O -
) O +
using O +
propidium O +
iodide O +
and O +
light O +
scatter O +
signals O +
to O +
gate O +
out O +
dead O +
cells O +
and O +
debris O -
. O +

2.9 O +
Western O +
blot O +
analysis O +
of O +
ERK1 B-Gene -
/ O -
2 B-Gene +
phosphorylation O +
Mouse O +
or O +
human O +
T O +
cells O +
( O -
107 O +
in O +
1 O +
ml O +
culture O +
medium O -
) O +
were O +
preincubated O +
for O +
1 O +
h O +
at O +
37 O -
° O -
C O +
in O +
absence O +
or O +
presence O +
of O +
compound O -
. O +

The O +
cells O +
were O +
treated O +
with O +
PMA O +
for O +
ERK1 B-Gene -
/ O -
2 B-Gene +
stimulation O +
and O +
harvested O +
10 O +
min O +
thereafter O -
. O +

Samples O +
were O +
placed O +
on O +
ice O +
and O +
spun O -
. O +

Pellets O +
were O +
resuspended O +
in O +
lysing O +
buffer O +
and O +
frozen O +
until O +
analysis O -
. O +

Samples O +
were O +
electrophoresed O +
in O +
10 O -
% O +
tris O -
– O -
glycine O +
polyacrylamide O +
gels O -
. O +

Proteins B-Gene +
were O +
transferred O +
from O +
the O +
gels O +
to O +
PVDF O +
membranes O +
by O +
electroblotting O +
in O +
a O +
Milliblot O +
apparatus O +
( O -
Millipore O -
, O +
Bedford O -
, O +
MA O -
) O -
. O +

The O +
membranes O +
were O +
reacted O +
with O +
antibodies B-Gene +
to O +
ERK1 B-Gene -
/ O -
2 B-Gene +
( O -
New O +
England O +
Biolabs O -
) O -
. O +

The O +
reaction O +
was O +
detected O +
by O +
chemiluminescence O +
on O +
Hyperfilm O -
- O -
ECL O +
( O -
Amersham O -
, O +
Arlington O +
Heights O -
, O +
IL O -
) O -
. O +

3 O +
Results O +
3.1 O +
Hypothemycin O +
inhibits O +
T O +
cell O +
proliferation O +
in O +
a O +
manner O +
partially O +
reversible O +
by O +
exogenous O +
IL-2 B-Gene +
We O +
first O +
identified O +
hypothemycin O +
( O -
Fig. O +
1 O +
) O -
, O +
as O +
the O +
active O +
component O +
of O +
a O +
fungal O +
culture O +
broth O -
, O +
in O +
a O +
screen O +
for O +
inhibitors O +
of O +
T O +
cell O +
activation O +
using O +
murine O +
T O +
cells O +
activated O +
with O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb+PMA I-Gene -
. O +

As O +
shown O +
in O +
Fig. O +
2 O +
a O -
, O +
hypothemycin O +
was O +
found O +
to O +
inhibit O +
the O +
proliferative O +
response O +
in O +
such O +
cultures O +
with O +
an O +
IC50 O +
of O +
27.6±3.8 O +
nM O +
( O -
n O +
= O -
5 O -
) O -
. O +

A O +
control O +
compound O -
, O +
zearalenone O +
( O -
Kuiper O -
- O -
Goodman O +
et O +
al. O -
, O +
1987 O +
) O -
, O +
which O +
is O +
structurally O +
related O +
to O +
hypothemycin O +
( O -
Fig. O +
1 O +
) O -
, O +
failed O +
to O +
affect O +
proliferation O +
under O +
the O +
same O +
conditions O -
. O +

Hypothemycin O +
also O +
potently O +
inhibited O +
the O +
proliferation O +
of O +
purified O +
human O +
T O +
cells O +
stimulated O +
with O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
in O +
the O +
presence O +
of O +
a O +
low O +
concentration O +
of O +
PMA O +
( O -
0.1 O +
ng O -
/ O -
ml O -
) O -
, O +
with O +
an O +
IC50 O +
= O -
25.8±8.9 O +
nM O +
( O -
n O +
= O -
6 O -
) O +
( O -
Fig. O +
2 O +
b O -
) O -
. O +

The O +
proliferation O +
of O +
human O +
PBMC O +
( O -
T O +
cells+accessory O +
cells O -
: O +
monocytes O +
and O +
B O +
cells O -
) O +
induced O +
by O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
in O +
the O +
absence O +
of O +
PMA O +
was O +
also O +
potently O +
inhibited O +
by O +
the O +
compound O -
, O +
with O +
an O +
IC50 O +
= O -
57.1±5.5 O +
nM O +
( O -
n O +
=3 O -
) O +
( O -
Fig. O +
2 O +
c O -
) O -
. O +

However O -
, O +
stimulation O +
of O +
purified O +
T O +
cells O +
in O +
the O +
presence O +
of O +
PMA O +
at O +
1 O +
ng O -
/ O -
ml O -
, O +
rendered O +
the O +
proliferative O +
response O +
less O +
sensitive O +
to O +
the O +
effect O +
of O +
hypothemycin O +
( O -
IC50 O +
= O -
269.8±58.1 O +
nM O -
, O +
n O +
= O -
5 O -
) O +
( O -
Fig. O +
2 O +
d O -
) O -
. O +

The O +
addition O +
of O +
exogenous O +
IL-2 B-Gene +
( O -
50 O +
U O -
/ O -
ml O -
) O +
was O +
used O +
to O +
determine O +
whether O +
the O +
inhibitory O +
activity O +
of O +
hypothemycin O +
in O +
these O +
cultures O +
reflects O +
non O -
- O -
specific O +
toxicity O +
or O +
a O +
more O +
selective O +
effect O -
. O +

Fig. O +
2 O +
shows O +
that O +
such O +
an O +
addition O +
resulted O +
in O +
a O +
significant O +
reversal O +
of O +
the O +
inhibition O +
by O +
the O +
compound O -
. O +

In O +
the O +
case O +
of O +
mouse O +
T O +
cells O -
, O +
the O +
IC50 O +
increased O +
to O +
182.6±17.1 O +
nM O +
( O -
n O +
= O -
5 O -
) O +
( O -
Fig. O +
2 O +
a O -
) O -
. O +

For O +
human O +
T O +
cells O +
stimulated O +
with O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb+PMA I-Gene +
at O +
0.1 O +
ng O -
/ O -
ml O -
, O +
the O +
IC50 O +
in O +
presence O +
of O +
exogenous O +
IL-2 B-Gene +
was O +
236.0±66.1 O +
nM O +
( O -
n O +
= O -
6 O -
) O +
( O -
Fig. O +
2 O +
b O -
) O -
. O +

Moreover O -
, O +
in O +
the O +
case O +
of O +
human O +
PBMC O +
activated O +
by O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
alone O -
, O +
the O +
addition O +
of O +
10 O -
% O +
IL-2-containing B-Gene +
conditioned O +
medium O +
( O -
T O -
- O -
stim O -
) O +
completely O +
reversed O +
the O +
inhibitory O +
effect O +
of O +
hypothemycin O +
at O +
the O +
concentrations O +
tested O +
here O +
( O -
Fig. O +
2 O +
c O -
) O -
. O +

Addition O +
of O +
exogenous O +
IL-2 B-Gene +
to O +
purified O +
T O +
cell O +
cultures O +
stimulated O +
in O +
presence O +
of O +
PMA O +
at O +
1 O +
ng O -
/ O -
ml O +
did O +
not O +
appreciably O +
reduce O +
the O +
sensitivity O +
to O +
hypothemycin O -
, O +
suggesting O +
that O +
IL-2 B-Gene +
produced O +
endogenously O +
is O +
not O +
limiting O +
for O +
proliferation O +
under O +
these O +
conditions O +
( O -
data O +
not O +
shown O -
) O -
. O +

3.2 O +
Hypothemycin O +
potently O +
inhibits O +
the O +
secretion O +
of O +
IL-2 B-Gene +
but O +
affects O +
to O +
a O +
lesser O +
extent O +
the O +
response O +
to O +
IL-2 B-Gene +
The O +
finding O +
that O +
the O +
inhibitory O +
effects O +
of O +
hypothemycin O +
can O +
be O +
reversed O +
by O +
exogeneous O +
IL-2 B-Gene +
suggested O +
that O +
the O +
compound O +
may O +
act O +
by O +
interfering O +
with O +
the O +
production O +
of O +
IL-2 B-Gene -
. O +

We O +
therefore O +
measured O +
IL-2 B-Gene +
production O +
in O +
the O +
presence O +
of O +
hypothemycin O -
. O +

These O +
studies O +
were O +
conducted O +
in O +
human O +
T O +
cells O -
. O +

Pilot O +
experiments O +
using O +
cultures O +
stimulated O +
with O +
anti B-Gene -
- I-Gene -
CD3+PMA I-Gene +
at O +
0.1 O +
ng O -
/ O -
ml O +
showed O +
that O +
hypothemycin O +
suppressed O +
IL-2 B-Gene +
production O +
( O -
data O +
not O +
shown O -
) O -
. O +

However O -
, O +
the O +
level O +
of O +
IL-2 B-Gene +
released O +
under O +
these O +
conditions O +
was O +
very O +
low O +
and O +
could O +
not O +
be O +
measured O +
accurately O +
enough O +
by O +
ELISA O +
to O +
permit O +
an O +
estimation O +
of O +
the O +
potency O +
of O +
the O +
inhibition O +
by O +
the O +
compound O -
. O +

Further O +
studies O +
were O +
therefore O +
done O +
on O +
cultures O +
activated O +
with O +
anti B-Gene -
- I-Gene -
CD3+PMA I-Gene +
at O +
1 O +
ng O -
/ O -
ml O -
. O +

With O +
such O +
a O +
strong O +
stimulation O -
, O +
high O +
levels O +
of O +
IL-2 B-Gene +
( O -
10–30 O +
ng O -
/ O -
ml O -
) O +
were O +
detectable O +
in O +
the O +
supernatants O +
after O +
24 O +
h O +
of O +
culture O -
. O +

As O +
shown O +
in O +
Fig. O +
3 O +
a O -
, O +
hypothemycin O +
inhibited O +
this O +
production O +
of O +
the O +
cytokine B-Gene +
with O +
an O +
IC50 O +
of O +
9.2±1.1 O +
nM O +
( O -
n O +
= O -
5 O -
) O -
, O +
even O +
though O +
under O +
these O +
conditions O +
the O +
proliferation O +
was O +
not O +
potently O +
suppressed O +
( O -
Fig. O +
2 O +
d O -
) O +
possibly O +
because O +
the O +
residual O +
level O +
of O +
IL-2 B-Gene +
still O +
produced O +
in O +
presence O +
of O +
the O +
compound O +
was O +
sufficient O +
to O +
support O +
T O +
cell O +
growth O -
. O +

It O +
was O +
also O +
important O +
to O +
determine O +
the O +
effect O +
of O +
hypothemycin O +
on O +
the O +
responsiveness O +
of O +
T O +
cells O +
to O +
IL-2 B-Gene -
. O +

For O +
that O +
purpose O -
, O +
we O +
used O +
the O +
IL-2-dependent B-Gene +
murine O +
CTLL-2 O +
cell O +
line O -
. O +

As O +
shown O +
in O +
Fig. O +
3 O +
b O -
, O +
hypothemycin O +
did O +
inhibit O +
the O +
proliferation O +
induced O +
by O +
IL-2 B-Gene +
in O +
these O +
cells O +
but O +
with O +
a O +
potency O +
approximately O +
20-fold O +
lower O +
( O -
IC50 O +
= O -
194.2±13.2 O +
nM O -
, O +
n O +
= O -
8) O +
than O +
for O +
inhibition O +
of O +
IL-2 B-Gene +
production O +
by O +
normal O +
T O +
cells O -
. O +

This O +
degree O +
of O +
inhibition O +
of O +
cell O +
proliferation O +
by O +
the O +
compound O +
was O +
actually O +
similar O +
to O +
that O +
observed O +
with O +
normal O +
T O +
cells O +
stimulated O +
in O +
the O +
presence O +
of O +
exogeneous O +
IL-2 B-Gene +
( O -
Fig. O +
2 O +
) O -
. O +

3.3 O +
Hypothemycin O +
differentially O +
modulates O +
the O +
production O +
of O +
various O +
cytokines B-Gene +
Having O +
established O +
that O +
hypothemycin O +
inhibits O +
IL-2 B-Gene +
production O -
, O +
it O +
was O +
interesting O +
to O +
determine O +
the O +
effect O +
of O +
this O +
compound O +
on O +
other O +
cytokines B-Gene +
known O +
to O +
be O +
secreted O +
by O +
T O +
cells O +
upon O +
activation O -
. O +

This O +
was O +
done O +
using O +
human O +
T O +
cells O +
activated O +
for O +
2 O +
days O +
with O +
anti B-Gene -
- I-Gene -
CD3+PMA I-Gene +
at O +
1 O +
ng O -
/ O -
ml O -
, O +
such O +
that O +
the O +
levels O +
of O +
various O +
cytokines B-Gene +
released O +
in O +
the O +
supernatants O +
were O +
within O +
the O +
range O +
of O +
sensitivity O +
of O +
ELISA O +
measurements O -
. O +

At O +
this O +
time O -
- O -
point O -
, O +
hypothemycin O +
still O +
potently O +
inhibited O +
the O +
production O +
of O +
IL-2 B-Gene +
( O -
IC50 O +
= O -
12.9±1.8 O +
nM O -
, O +
n O +
= O -
10 O -
, O +
Fig. O +
4 O +
a O +
and O +
data O +
not O +
shown O -
) O -
. O +

The O +
data O +
in O +
Fig. O +
4 O +
demonstrate O +
that O +
hypothemycin O +
also O +
strongly O +
suppressed O +
the O +
production O +
of O +
IL-6 B-Gene +
( O -
IC50 O +
= O -
9.5±1.1 O +
nM O -
) O -
, O +
IL-10 B-Gene +
( O -
IC50 O +
= O -
18.5±2.6 O +
nM O -
) O -
, O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
( O -
IC50 O +
= O -
17.7±3.7 O +
nM O -
) O +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
( O -
IC50 O +
= O -
10.8±1.6 O +
nM O -
) O -
. O +

However O -
, O +
in O +
the O +
same O +
cultures O -
, O +
the O +
compound O +
was O +
found O +
to O +
exert O +
a O +
strikingly O +
different O +
dose O -
- O -
dependent O +
effect O +
on O +
the O +
levels O +
of O +
IL-4 B-Gene -
, O +
IL-5 B-Gene +
and O +
IL-13 B-Gene -
. I-Gene +

Although O +
completely O +
suppressed O +
at O +
264 O +
nM O -
, O +
the O +
production O +
of O +
all O +
three O +
of O +
these O +
cytokines B-Gene +
was O +
markedly O +
augmented O -
, O +
by O +
up O +
to O +
8-fold O -
, O +
in O +
the O +
presence O +
of O +
33–66 O +
nM O +
hypothemycin O +
( O -
EC50 O +
∼10 O +
nM O -
) O -
. O +

In O +
these O +
experiments O -
, O +
zearalenone O +
did O +
not O +
substantially O +
alter O +
the O +
production O +
of O +
any O +
of O +
the O +
cytokines B-Gene +
tested O -
. O +

3.4 O +
Hypothemycin O +
affects O +
cytokine B-Gene +
production O +
at O +
the O +
mRNA O +
level O +
To O +
define O +
at O +
which O +
stage O +
of O +
the O +
induction O +
process O +
hypothemycin O +
alters O +
the O +
production O +
of O +
cytokines B-Gene -
, O +
we O +
next O +
examined O +
its O +
effect O +
on O +
cytokine B-Gene +
mRNA O +
expression O -
. O +

Human O +
T O +
cells O +
( O -
106 O +
/ml O -
) O +
were O +
activated O +
with O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb+PMA I-Gene +
( O -
1 O +
ng O -
/ O -
ml O -
) O +
in O +
the O +
presence O +
or O +
absence O +
of O +
hypothemycin O -
, O +
or O +
zearalenone O -
. O +

After O +
19 O +
h O +
of O +
culture O -
, O +
total O +
RNA O +
was O +
extracted O +
and O +
the O +
expression O +
of O +
transcripts O +
for O +
multiple O +
cytokines B-Gene +
was O +
detected O +
by O +
multiprobe O +
RPA O +
analysis O -
. O +

As O +
shown O +
in O +
Fig. O +
5 O +
, O +
hypothemycin O +
strongly O +
suppressed O +
IL-2 B-Gene +
mRNA O +
induction O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
, O +
while O +
zearalenone O +
had O +
no O +
effect O -
. O +

Hypothemycin O +
also O +
clearly O +
inhibited O +
the O +
expression O +
of O +
transcripts O +
for O +
IL-10 B-Gene +
and O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
. O +

In O +
contrast O -
, O +
the O +
expression O +
of O +
transcripts O +
for O +
IL-4 B-Gene -
, O +
IL-5 B-Gene +
and O +
IL-13 B-Gene +
was O +
enhanced O -
, O +
with O +
a O +
maximal O +
effect O +
in O +
the O +
presence O +
of O +
66 O +
nM O +
hypothemycin O -
. O +

Again O -
, O +
zearalone O +
did O +
not O +
alter O +
this O +
expression O -
. O +

Therefore O -
, O +
for O +
these O +
particular O +
cytokines B-Gene -
, O +
the O +
modulation O +
of O +
mRNA O +
expression O +
parallels O +
that O +
of O +
protein B-Gene +
secretion O +
as O +
detected O +
in O +
culture O +
supernatants O +
( O -
Fig. O +
4 O +
) O -
, O +
suggesting O +
that O +
hypothemycin O +
affects O +
predominantly O +
gene O +
transcription O +
and/or O +
transcript O +
stability O -
. O +

Note O +
that O +
hypothemycin O +
was O +
also O +
found O +
to O +
inhibit O +
IL-9 B-Gene +
mRNA O +
expression O +
in O +
these O +
experiments O +
( O -
Fig. O +
5 O +
) O -
. O +

3.5 O +
Hypothemycin O +
inhibits O +
more O +
strongly O +
CD69 B-Gene +
expression O +
induced O +
by O +
PMA O +
than O +
by O +
ionomycin O +
As O +
mentioned O +
before O -
, O +
cytokine B-Gene +
induction O +
upon O +
T O +
cell O +
activation O +
depends O +
on O +
multiple O +
signaling O +
pathways O +
( O -
Cantrell O -
, O +
1996 O +
; O +
Alberola O -
- O -
Ila O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

As O +
an O +
approach O +
to O +
start O +
delineating O +
the O +
site O +
of O +
action O +
of O +
hypothemycin O +
within O +
T O +
cell O +
signaling O +
events O -
, O +
we O +
used O +
an O +
artificial O +
model O +
where O +
the O +
activation O +
of O +
the O +
T O +
cells O +
is O +
monitored O +
by O +
induction O +
of O +
expression O +
of O +
the O +
cell O +
surface O +
molecule O +
CD69 B-Gene -
. O +

This O +
induction O +
can O +
be O +
promoted O +
upon O +
treatment O +
either O +
by O +
PMA O -
, O +
which O +
recruits O +
PKC B-Gene -
- O -
dependent O -
, O +
calcineurin B-Gene -
- O -
independent O +
signaling O -
, O +
including O +
the O +
ERK1 B-Gene -
/ O -
2 B-Gene +
kinase B-Gene +
pathway O -
, O +
or O +
by O +
the O +
Ca2 O -
+ O +
ionophore O -
, O +
ionomycin O -
, O +
which O +
mimics O +
Ca2 O -
+ O +
signaling O +
and O +
activates O +
calcineurin B-Gene +
( O -
Taylor O -
- O -
Fishwick O +
and O +
Siegel O -
, O +
1995 O +
) O -
. O +

Previously O -
, O +
we O +
have O +
shown O +
that O +
PD98059 O -
, O +
a O +
selective O +
inhibitor O +
of O +
MEK1 B-Gene +
( O -
Dudley O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
markedly O +
suppresses O +
the O +
CD69 B-Gene +
response O +
induced O +
by O +
PMA O +
but O +
not O +
by O +
ionomycin O -
, O +
while O +
the O +
reverse O +
is O +
true O +
for O +
the O +
calcineurin B-Gene +
inhibitor O -
, O +
FK506 O +
( O -
Dumont O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

The O +
data O +
in O +
Fig. O +
6 O +
demonstrate O +
that O +
incubation O +
of O +
mouse O +
T O +
cells O +
for O +
14 O +
h O +
in O +
the O +
presence O +
of O +
PMA O +
( O -
10 O +
ng O -
/ O -
ml O -
) O +
induced O +
a O +
high O +
level O +
of O +
CD69 B-Gene +
cell O +
surface O +
expression O -
. O +

This O +
induction O +
was O +
suppressed O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
by O +
hypothemycin O -
, O +
whereas O +
FK506 O +
( O -
10 O +
nM O -
) O +
had O +
little O +
effect O -
. O +

In O +
contrast O -
, O +
CD69 B-Gene +
expression O +
elicited O +
by O +
treatment O +
with O +
ionomycin O +
( O -
2 O +
μg O -
/ O -
ml O -
) O +
was O +
less O +
inhibited O +
by O +
hypothemycin O +
than O +
by O +
FK506 O -
. O +

Therefore O -
, O +
hypothemycin O +
appears O +
to O +
preferentially O +
disrupt O +
CD69-induction B-Gene +
events O +
driven O +
by O +
PKC B-Gene +
activation O +
while O +
leaving O +
relatively O +
unaffected O +
those O +
driven O +
by O +
calcineurin B-Gene +
activation O -
. O +

3.6 O +
Effects O +
of O +
hypothemycin O +
on O +
ERK1 B-Gene -
/ O -
2 B-Gene +
activation O +
in O +
T O +
cells O +
Since O +
one O +
of O +
the O +
signaling O +
pathways O +
activated O +
by O +
PMA O +
in O +
T O +
cells O +
is O +
the O +
ERK1 B-Gene -
/ I-Gene -
2 I-Gene +
MAP I-Gene +
kinase I-Gene -
, O +
through O +
activation O +
of O +
its O +
upstream O +
kinase B-Gene -
, O +
MEK B-Gene +
( O -
Dumont O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
the O +
CD69 B-Gene +
data O +
mentioned O +
above O +
led O +
us O +
to O +
investigate O +
the O +
effect O +
of O +
hypothemycin O +
on O +
this O +
cascade O +
at O +
the O +
biochemical O +
level O +
in O +
T O +
cells O -
. O +

Activation O +
of O +
ERK1 B-Gene -
/ I-Gene -
2 I-Gene +
MAP I-Gene +
kinase I-Gene +
is O +
known O +
to O +
be O +
reflected O +
by O +
selective O +
phosphorylation O +
of O +
these O +
enzymes B-Gene +
which O +
can O +
be O +
detected O +
using O +
phosphospecific O +
antibodies B-Gene -
. O +

The O +
data O +
in O +
Fig. O +
7 O +
a O +
show O +
that O +
PMA O +
treatment O +
of O +
human O +
T O +
cells O +
( O -
107 O +
cells O -
/ O -
ml O -
) O +
resulted O +
within O +
10 O +
min O +
in O +
the O +
emergence O +
of O +
the O +
phosphorylated O +
forms O +
of O +
ERK1 B-Gene -
/ O -
2 B-Gene +
as O +
seen O +
by O +
immunoblot O +
analysis O +
of O +
the O +
cell O +
lysates O -
. O +

This O +
was O +
inhibited O +
by O +
hypothemycin O +
at O +
3 O +
and O +
0.3 O +
μM O +
but O +
not O +
by O +
zearalenone O +
at O +
3 O +
μM. O +
PD98059 O -
, O +
used O +
here O +
as O +
a O +
positive O +
control O -
, O +
also O +
inhibited O +
ERK1 B-Gene -
/ O -
2 B-Gene +
phosphorylation O -
. O +

These O +
compounds O +
did O +
not O +
affect O +
the O +
levels O +
of O +
ERK1 B-Gene -
/ O -
2 B-Gene +
protein B-Gene +
detectable O +
with O +
a O +
phosphorylation O -
- O -
independent O +
antibody B-Gene +
( O -
Fig. O +
7 O +
b O -
) O -
. O +

Similar O +
data O +
were O +
obtained O +
in O +
murine O +
T O +
cells O +
activated O +
with O +
PMA O +
at O +
10 O +
ng O -
/ O -
ml O +
( O -
data O +
not O +
shown O -
) O -
. O +

4 O +
Discussion O +
Through O +
screening O +
of O +
microbial O +
broths O -
, O +
we O +
have O +
identified O +
the O +
immunosuppressive O +
activity O +
of O +
hypothemycin O -
, O +
a O +
compound O +
previously O +
known O +
for O +
its O +
antibiotic O +
activity O +
( O -
Nair O +
and O +
Carey O -
, O +
1980 O +
; O +
Nair O +
et O +
al. O -
, O +
1981 O +
; O +
Agatsuma O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

The O +
present O +
study O +
provides O +
evidence O +
that O +
hypothemycin O +
affects O +
certain O +
events O +
of O +
T O +
cell O +
activation O +
that O +
lead O +
to O +
cytokine B-Gene +
production O +
and O +
proliferation O -
. O +

It O +
is O +
important O +
to O +
note O +
that O +
while O +
the O +
antibiotic O -
/ O -
cytotoxic O +
properties O +
of O +
hypothemycin O +
were O +
seen O +
only O +
in O +
the O +
high O +
micromolar O +
range O +
( O -
Nair O +
and O +
Carey O -
, O +
1980 O +
; O +
Nair O +
et O +
al. O -
, O +
1981 O +
; O +
Agatsuma O +
et O +
al. O -
, O +
1993 O +
) O -
, O +
the O +
effects O +
on O +
T O +
cells O +
reported O +
here O +
occurred O +
at O +
nanomolar O +
concentrations O +
of O +
the O +
compound O -
. O +

Furthermore O -
, O +
a O +
structurally O +
related O +
compound O -
, O +
zearalenone O -
, O +
which O +
has O +
estrogenic O +
activity O +
in O +
vivo O +
( O -
Kuiper O -
- O -
Goodman O +
et O +
al. O -
, O +
1987 O +
) O +
had O +
no O +
discernable O +
effect O +
at O +
micromolar O +
concentrations O +
in O +
our O +
experimental O +
system O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
mostly O +
utilized O +
artificial O +
modes O +
of O +
stimulation O +
of O +
the O +
T O +
cells O -
, O +
through O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
and O +
PMA O +
co O -
- O -
treatments O -
, O +
causing O +
a O +
vigorous O +
polyclonal O +
activation O +
of O +
the O +
T O +
cells O -
. O +

Under O +
these O +
conditions O -
, O +
hypothemycin O +
was O +
found O +
to O +
inhibit O +
the O +
proliferative O +
response O -
. O +

It O +
is O +
important O +
to O +
note O +
that O -
, O +
in O +
fact O -
, O +
this O +
inhibitory O +
activity O +
did O +
not O +
require O +
PMA O +
costimulation O +
since O +
it O +
was O +
also O +
observed O +
with O +
human O +
PBMC O +
stimulated O +
with O +
anti B-Gene -
- I-Gene -
CD3 I-Gene +
mAb I-Gene +
alone O -
. O +

Moreover O -
, O +
the O +
inhibition O +
of O +
T O +
cell O +
proliferation O +
by O +
hypothemycin O +
was O +
partially O +
reversed O +
by O +
exogeneous O +
IL-2 B-Gene -
, O +
a O +
feature O +
similar O +
to O +
the O +
inhibition O +
by O +
agents O +
known O +
to O +
suppress O +
IL-2 B-Gene +
production O +
rather O +
than O +
IL-2-responsiveness B-Gene -
, O +
such O +
as O +
CsA O +
and O +
FK506 O +
( O -
Dumont O -
, O +
1996 O +
) O -
. O +

Accordingly O -
, O +
hypothemycin O +
inhibited O +
potently O +
the O +
production O +
of O +
IL-2 B-Gene +
both O +
at O +
the O +
protein B-Gene +
and O +
mRNA O +
levels O -
. O +

This O +
production O +
was O +
found O +
to O +
be O +
affected O +
even O +
under O +
conditions O +
where O +
hypothemycin O +
had O +
reduced O +
activity O +
on O +
the O +
proliferation O -
, O +
namely O +
upon O +
activation O +
of O +
human O +
T O +
cells O +
in O +
the O +
presence O +
of O +
1 O +
ng O -
/ O -
ml O +
PMA O -
. O +

It O +
is O +
likely O +
that O -
, O +
in O +
this O +
situation O -
, O +
the O +
residual O +
amount O +
of O +
IL-2 B-Gene +
secreted O +
in O +
the O +
presence O +
of O +
hypothemycin O +
was O +
high O +
enough O +
to O +
support O +
the O +
proliferation O +
of O +
the O +
cells O -
. O +

Indeed O -
, O +
the O +
fact O +
that O +
the O +
antiproliferative O +
effect O +
of O +
hypothemycin O +
in O +
activated O +
T O +
cells O +
is O +
dependent O +
on O +
the O +
strength O +
of O +
the O +
stimulation O +
further O +
argues O +
in O +
favor O +
of O +
a O +
selective O +
mode O +
of O +
action O +
for O +
the O +
compound O -
. O +

The O +
T O +
cell O +
stimulation O +
modality O +
utilized O +
here O -
, O +
leading O +
to O +
an O +
array O +
of O +
cytokines B-Gene +
being O +
produced O +
in O +
sufficient O +
amounts O +
for O +
accurate O +
quantitation O +
enabled O +
us O +
to O +
examine O +
the O +
effect O +
of O +
hypothemycin O +
on O +
this O +
production O -
. O +

Besides O +
IL-2 B-Gene -
, O +
the O +
production O +
of O +
IL-6 B-Gene -
, O +
IL-9 B-Gene +
( O -
detected O +
at O +
the O +
mRNA O +
level O -
) O -
, O +
IL-10 B-Gene -
, O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene -
, O +
was O +
found O +
to O +
be O +
strongly O +
inhibited O +
by O +
hypothemycin O -
. O +

Therefore O -
, O +
this O +
compound O +
interrupts O +
signaling O +
events O +
of O +
T O +
cell O +
activation O +
that O +
are O +
required O +
for O +
the O +
positive O +
regulation O +
of O +
these O +
cytokines B-Gene -
. O +

In O +
marked O +
contrast O -
, O +
there O +
was O +
a O +
pronounced O +
augmentation O +
of O +
secretion O +
of O +
IL-4 B-Gene -
, O +
IL-5 B-Gene +
and O +
IL-13 B-Gene +
in O +
presence O +
of O +
certain O +
concentrations O +
of O +
the O +
compound O -
. O +

RPA O +
analysis O +
further O +
demonstrated O +
that O +
hypothemycin O +
affects O +
gene O +
regulation O +
rather O +
than O +
translational O +
events O +
governing O +
the O +
synthesis O +
of O +
these O +
cytokines B-Gene -
. O +

Since O +
IL-4 B-Gene -
, O +
IL-5 B-Gene +
and O +
IL-13 B-Gene +
are O +
mainly O +
produced O +
by O +
Th2 O +
cells O +
( O -
Muraille O +
and O +
Leo O -
, O +
1998 O +
) O -
, O +
their O +
up O -
- O -
regulation O +
under O +
conditions O +
where O +
the O +
other O +
cytokines B-Gene +
were O +
suppressed O +
is O +
particularly O +
intriguing O -
. O +

Such O +
a O +
differential O +
modulation O +
by O +
hypothemycin O +
may O +
point O +
to O +
distinct O +
signaling O +
mechanisms O +
for O +
induction O +
of O +
certain O +
Th2 B-Gene +
versus O +
Th1 B-Gene +
cytokines I-Gene -
, O +
as O +
indicated O +
by O +
a O +
number O +
of O +
recent O +
studies O +
( O -
Zheng O +
and O +
Flavell O -
, O +
1997 O +
; O +
Ranganath O +
et O +
al. O -
, O +
1998 O +
; O +
Dong O +
et O +
al. O -
, O +
1998 O +
; O +
Kuo O +
and O +
Leiden O -
, O +
1999 O +
; O +
Li O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

In O +
this O +
respect O -
, O +
hypothemycin O +
may O +
provide O +
a O +
useful O +
probe O +
to O +
explore O +
these O +
mechanisms O -
. O +

It O +
is O +
also O +
striking O +
that O +
the O +
differential O +
modulation O +
of O +
cytokine B-Gene +
production O +
by O +
hypothemycin O +
shown O +
here O +
differs O +
from O +
the O +
modulation O +
exerted O +
by O +
FK506 O +
under O +
similar O +
conditions O +
but O +
resembles O +
what O +
we O +
previously O +
disclosed O +
in O +
the O +
case O +
of O +
the O +
MEK1 B-Gene +
inhibitor O -
, O +
PD98059 O +
( O -
Dumont O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Further O +
evidence O +
that O +
hypothemycin O +
may O +
affect O +
T O +
cell O +
signaling O +
events O +
in O +
a O +
manner O +
distinct O +
from O +
FK5065 O +
and O +
similar O +
to O +
PD98059 O +
was O +
obtained O +
by O +
studying O +
the O +
effect O +
of O +
the O +
compounds O +
on O +
CD69 B-Gene +
induction O -
. O +

Although O +
CD69 B-Gene +
induction O +
may O +
occur O +
independently O +
from O +
cytokine B-Gene +
induction O +
( O -
Castellanos O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
it O +
provides O +
a O +
convenient O +
model O +
to O +
probe O +
for O +
the O +
site O +
of O +
action O +
of O +
T O +
cell O +
inhibitors O +
as O +
it O +
can O +
be O +
elicited O +
either O +
through O +
PKC B-Gene -
- O -
dependent O -
, O +
calcineurin B-Gene -
- O -
independent O +
mechanisms O +
by O +
PMA O +
or O +
through O +
Ca2 O -
+ O +
/calcineurin O -
- O -
dependent O +
mechanisms O +
by O +
ionomycin O +
( O -
Taylor O -
- O -
Fishwick O +
and O +
Siegel O -
, O +
1995 O +
) O -
. O +

Hypothemycin O +
inhibited O +
markedly O +
the O +
PMA O -
- O -
induced O +
response O +
but O +
to O +
a O +
lesser O +
extend O +
the O +
ionomycin O -
- O -
induced O +
response O -
, O +
whereas O +
FK506 O +
exerted O +
an O +
opposite O +
pattern O +
of O +
inhibition O -
. O +

In O +
a O +
previous O +
study O -
, O +
we O +
had O +
shown O +
that O +
PD98059 O +
also O +
is O +
able O +
to O +
inhibit O +
CD69 B-Gene +
induction O +
by O +
PMA O +
but O +
not O +
by O +
ionomycin O +
( O -
Dumont O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

The O +
similarities O +
between O +
the O +
cellular O +
effects O +
of O +
hypothemycin O +
and O +
of O +
PD98059 O +
led O +
us O +
to O +
examine O +
whether O +
hypothemycin O +
would O +
prevent O +
activation O +
of O +
the O +
MAP B-Gene +
kinases I-Gene +
ERK1 B-Gene -
/ O -
2 O +
in O +
T O +
cells O -
. O +

Our O +
data O +
demonstrated O +
that O +
hypothemycin O +
does O +
reduce O +
the O +
phosphorylation O +
of O +
these O +
enzymes B-Gene +
when O +
induced O +
by O +
PMA O +
treatment O +
in O +
T O +
cells O -
. O +

These O +
data O +
suggest O +
that O +
hypothemycin O +
is O +
capable O +
of O +
disrupting O +
the O +
ERK1 B-Gene -
/ O -
2 B-Gene +
cascade O +
in O +
T O +
cells O -
, O +
even O +
though O +
it O +
is O +
difficult O +
to O +
relate O +
directly O +
this O +
biochemical O +
alteration O +
to O +
the O +
effects O +
of O +
the O +
compound O +
on O +
proliferation O +
and O +
cytokine B-Gene +
production O -
, O +
because O +
of O +
the O +
artificial O +
stimulus O +
utilized O +
( O -
PMA O -
) O -
, O +
and O +
also O +
because O +
the O +
cell O +
concentrations O +
were O +
different O +
( O -
107 O +
/ml O +
vs. O +
5 O -
× O -
105 O +
/ml O -
) O +
in O +
the O +
two O +
systems O -
. O +

Nevertheless O -
, O +
our O +
observations O +
are O +
consistent O +
with O +
a O +
recent O +
studies O +
revealing O +
that O +
hypothemycin O +
potently O +
inhibits O +
the O +
enzymatic O +
activity O +
MEK1 B-Gene +
in O +
vitro O -
, O +
with O +
an O +
IC50 O +
of O +
15 O +
nM O +
( O -
Zhao O +
et O +
al. O -
, O +
1999 O +
) O -
. O +

Furthermore O -
, O +
analysis O +
of O +
several O +
hypothemycin O +
analogs O +
revealed O +
a O +
correlation O +
between O +
their O +
abilities O +
to O +
inhibit O +
MEK1 B-Gene +
in O +
vitro O +
and O +
to O +
inhibit O +
IL-2 B-Gene +
and O +
up O -
- O -
regulate O +
IL-4 B-Gene +
production O +
in O +
T O +
cells O +
( O -
Camacho O +
and O +
Dumont O -
, O +
unpublished O +
observations O -
) O -
. O +

A O +
close O +
structural O +
relative O +
of O +
hypothemycin O -
, O +
Ro O +
09 O -
- O -
2210 O -
, O +
was O +
also O +
reported O +
to O +
suppress O +
T O +
cell O +
proliferation O +
and O +
to O +
inhibit O +
MEK1 B-Gene +
with O +
an O +
IC50 O +
of O +
59 O +
nM O +
( O -
Williams O +
et O +
al. O -
, O +
1998 O +
) O -
. O +

Importantly O -
, O +
these O +
latter O +
studies O +
have O +
also O +
shown O +
that O +
neither O +
hypothemycin O +
( O -
Zhao O +
et O +
al. O -
, O +
1999 O +
) O +
nor O +
Ro O +
09 O -
- O -
2210 O +
( O -
Williams O +
et O +
al. O -
, O +
1998 O +
) O +
alter O +
the O +
enzymatic O +
activity O +
of O +
PKC B-Gene +
in O +
vitro O -
. O +

Therefore O -
, O +
the O +
inhibitory O +
effect O +
of O +
hypothemycin O +
on O +
T O +
cell O +
activation O +
may O +
be O +
attributed O -
, O +
at O +
least O +
partially O -
, O +
to O +
a O +
blockade O +
of O +
MEK1 B-Gene +
function O -
, O +
rather O +
than O +
a O +
direct O +
effect O +
on O +
PKC B-Gene -
. O +

However O -
, O +
in O +
experiments O +
not O +
shown O +
here O -
, O +
we O +
obtained O +
preliminary O +
evidence O +
that O +
MEK B-Gene +
may O +
not O +
be O +
the O +
only O +
biochemical O +
target O +
for O +
hypothemycin O +
in O +
T O +
cells O +
since O +
JNK B-Gene +
activation O +
by O +
anisomycin O +
was O +
also O +
affected O +
by O +
this O +
compound O -
. O +

In O +
this O +
respect O -
, O +
hypothemycin O +
appears O +
to O +
differ O +
from O +
PD98059 O -
, O +
which O +
does O +
not O +
inhibit O +
JNK B-Gene +
activation O +
( O -
Dudley O +
et O +
al. O -
, O +
1995 O +
) O -
. O +

At O +
the O +
moment O -
, O +
we O +
can O -
not O +
rule O +
out O +
that O +
hypothemycin O +
alters O +
other O +
targets O -
, O +
in O +
addition O +
to O +
the O +
ERK B-Gene +
and O +
JNK B-Gene +
pathways O -
. O +

This O +
might O +
well O +
be O +
the O +
case O +
at O +
micromolar O +
concentrations O +
of O +
the O +
compound O +
where O +
its O +
inhibitory O +
effect O +
on O +
proliferation O +
is O +
no O +
longer O +
reversed O +
by O +
exogeneous O +
IL-2 B-Gene -
. O +

Additional O +
biochemical O +
analyses O +
of O +
the O +
effect O +
of O +
hypothemycin O +
in O +
T O +
cells O -
, O +
especially O +
when O +
stimulated O +
through O +
the O +
CD3 B-Gene -
/ O -
TCR B-Gene +
complex O -
, O +
will O +
be O +
required O +
to O +
better O +
delineate O +
the O +
selectivity O +
of O +
this O +
compound O -
. O +

While O +
the O +
precise O +
mechanism O +
of O +
action O +
of O +
hypothemycin O +
remains O +
to O +
be O +
defined O -
, O +
the O +
present O +
studies O +
demonstrated O +
that O +
it O +
acts O +
as O +
a O +
potent O -
, O +
non O +
cytotoxic O +
inhibitor O +
of O +
T O +
cell O +
activation O -
, O +
in O +
a O +
manner O +
different O +
from O +
a O +
calcineurin B-Gene +
inhibitor O -
. O +

Further O +
evaluation O +
of O +
the O +
immunosuppressive O +
activity O +
of O +
hypothemycin O +
and O +
of O +
its O +
potential O +
ability O +
to O +
promote O +
T O +
cell O +
anergy O +
( O -
DeSilva O +
et O +
al. O -
, O +
1996 O +
; O +
Li O +
et O +
al. O -
, O +
1996 O +
; O +
Powell O +
et O +
al. O -
, O +
1998 O +
) O +
therefore O +
appears O +
justified O -
. O +

Acknowledgements O +

We O +
wish O +
to O +
thank O +
Jeanine O +
Regenthal O +
and O +
Paul O +
Fischer O +
for O +
assistance O +
with O +
the O +
FCM O +
analysis O +
experiments O -
. O +

Actin B-Gene +
is O +
present O +
at O +
high O +
concentrations O +
in O +
virtually O +
every O +
eukaryotic O +
cell O -
. O +

About O +
half O +
of O +
the O +
intracellular O +
actin B-Gene +
is O +
stabilized O +
in O +
its O +
monomeric O +
form O +
( O -
G B-Gene -
- I-Gene -
actin I-Gene -
) O +
by O +
interaction O +
with O +
sequestering O +
factors O +
[ O -
1 O -
] O +
. O +

This O +
monomeric B-Gene +
actin I-Gene +
can O +
be O +
used O +
for O +
fast O +
generation O +
of O +
new O +
actin B-Gene +
filaments O +
after O +
an O +
appropriate O +
intra- O +
or O +
extracellular O +
signal O +
[ O -
2 O -
] O +
. O +

The O +
β O -
- O -
thymosins O +
are O +
a O +
family O +
of O +
highly O +
conserved O +
polar O +
5 O +
kDa O +
peptides O +
that O +
are O +
present O +
in O +
many O +
tissues O +
and O +
cells O +
of O +
different O +
vertebrates O +
except O +
human O +
and O +
chicken O +
erythrocytes O +
( O -
[ O -
3 O -
] O +
, O +
unpublished O +
data O -
) O -
. O +

The O +
most O +
abundant O +
species O +
of O +
β O -
- O -
thymosins O +
in O +
mammalian O +
tissues O +
is O +
thymosin O +
β4 O +
, O +
which O +
was O +
originally O +
supposed O +
to O +
be O +
a O +
thymic O +
hormone O +
[ O -
4,5 O -
] O +
. O +

Safer O +
and O +
coworkers O +
demonstrated O +
in O +
1991 O +
that O +
thymosin O +
β4 O +
is O +
identical O +
to O +
the O +
actin B-Gene -
- B-Gene -
sequestering I-Gene +
factor I-Gene +
Fx B-Gene +
[ O -
6,7 O -
] O +
. O +

Thymosin O +
β4 O +
is O +
now O +
regarded O +
as O +
the O +
main O +
intracellular O +
G B-Gene -
- I-Gene -
actin I-Gene -
- O -
sequestering O +
peptide O +
in O +
most O +
mammalian O +
cells O +
[ O -
8–10 O -
] O +
and O +
it O +
forms O +
a O +
1:1 O +
complex O +
with O +
G B-Gene -
- I-Gene -
actin I-Gene -
, O +
thereby O +
inhibiting O +
salt O -
- O -
induced O +
polymerization O +
to O +
F B-Gene -
- I-Gene -
actin I-Gene +
[ O -
11–15 O -
] O +
. O +

We O +
had O +
found O +
that O +
thymosin O +
β4 O +
is O +
present O +
in O +
very O +
high O +
concentrations O +
in O +
blood O +
cells O -
, O +
with O +
the O +
exception O +
of O +
erythrocytes O +
[ O -
3 O -
] O +
. O +

The O +
concentration O +
of O +
thymosin O +
β4 O +
in O +
serum O +
is O +
normally O +
low O -
, O +
but O +
increases O +
if O +
the O +
serum O +
is O +
not O +
immediately O +
removed O +
from O +
clotted O +
blood O -
. O +

Cassimeris O +
et O +
al. O +
[ O -
16 O -
] O +
showed O +
first O +
that O +
thymosin O +
β4 O +
is O +
the O +
main O +
G B-Gene -
- I-Gene -
actin I-Gene +
sequestering O +
peptide O +
in O +
resting O +
human O +
platelets O +
and O +
later O +
the O +
same O +
group O +
showed O +
that O +
it O +
is O +
involved O +
in O +
cellular O +
events O +
after O +
activation O +
of O +
platelets O +
[ O -
17 O -
] O +
. O +

In O +
1995 O +
Grant O +
et O +
al. O +
reported O +
a O +
5-fold O +
increase O +
of O +
thymosin O +
β4 O +
mRNA O +
during O +
morphological O +
differentiation O +
of O +
endothelial O +
cells O +
into O +
capillary O -
- O -
like O +
tubes O +
[ O -
18 O -
] O +
. O +

The O +
peptide O +
itself O +
increases O +
the O +
migration O +
of O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
4–6-fold O +
in O +
vitro O +
and O +
in O +
vivo O +
[ O -
19 O -
] O +
. O +

Frohm O +
and O +
coworkers O +
reported O +
high O +
concentrations O +
of O +
thymosin O +
β4 O +
in O +
wound O +
and O +
blister O +
fluids O +
[ O -
20 O -
] O +
. O +

It O +
was O +
also O +
postulated O +
that O +
β O -
- O -
thymosins O +
may O +
play O +
a O +
role O +
in O +
apoptosis O +
[ O -
21 O -
] O +
. O +

Transglutaminases B-Gene +
are O +
Ca2 O -
+ O +
-dependent O +
enzymes O -
, O +
which O +
catalyze O +
the O +
posttranslational O +
modification O +
of O +
proteins B-Gene +
through O +
the O +
exchange O +
of O +
primary O +
amines O +
for O +
ammonia O +
at O +
the O +
carboxamide O +
group O +
of O +
glutamine O +
residues O -
. O +

Peptide B-Gene -
- O -
bound O +
lysine O +
residues O +
or O +
naturally O +
occurring O +
polyamines O +
serve O +
quite O +
unspecifically O +
as O +
primary O +
amine O +
substrates O +
[ O -
22,23 O -
] O +
. O +

In O +
the O +
case O +
of O +
peptide B-Gene -
- O -
bound O +
lysine O +
residues O +
covalent O +
isopeptide O +
bonds O +
were O +
formed O -
, O +
which O +
are O +
resistant O +
against O +
proteolysis O -
. O +

Transglutaminases B-Gene +
have O +
a O +
broad O +
specificity O +
for O +
primary O +
amine O +
substrates O -
, O +
whereas O +
the O +
number O +
of O +
proteins B-Gene +
which O +
serve O +
as O +
glutaminyl O +
substrates O +
is O +
highly O +
restricted O -
. O +

It O +
is O +
now O +
well O +
established O +
that O +
transglutaminases B-Gene +
are O +
implicated O +
in O +
a O +
wide O +
range O +
of O +
biological O +
phenomena O +
like O +
blood O +
coagulation O +
( O -
factor B-Gene +
XIIIa I-Gene -
) O -
, O +
wound O +
healing O -
, O +
terminal O +
differentiation O -
, O +
and O +
apoptosis O +
[ O -
22,23 O -
] O +
. O +

Safer O +
et O +
al. O +
described O +
cross O -
- O -
linking O +
of O +
Lys-38 O +
of O +
thymosin O +
β4 O +
to O +
Gln-41 O +
of O +
actin B-Gene +
by O +
reaction O +
with O +
transglutaminase B-Gene +
[ O -
24 O -
] O +
. O +

However O -
, O +
in O +
this O +
transglutamination O +
thymosin O +
β4 O +
served O +
as O +
an O +
aminyl O +
substrate O -
. O +

When O +
we O +
further O +
analyzed O +
the O +
possible O +
role O +
of O +
thymosin O +
β4 O +
as O +
a O +
substrate O +
of O +
transglutaminases B-Gene +
we O +
found O +
that O +
thymosin O +
β4 O +
was O +
labeled O +
with O +
dansylcadaverine O +
by O +
transglutaminase B-Gene -
, O +
hence O +
reacting O +
as O +
a O +
specific O +
glutaminyl O +
substrate O -
. O +

Here O -
, O +
we O +
describe O +
the O +
molecular O +
properties O +
of O +
the O +
products O +
formed O -
. O +

Additionally O -
, O +
we O +
show O +
that O +
labeling O +
of O +
thymosin O +
β4 O +
does O +
not O +
interfere O +
with O +
G B-Gene -
- I-Gene -
actin I-Gene -
- O -
sequestering O +
activity O +
and O -
, O +
therefore O -
, O +
may O +
serve O +
as O +
a O +
useful O +
tool O +
for O +
further O +
investigations O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Reagents O +
were O +
obtained O +
from O +
the O +
following O +
sources O -
: O +
LiChroprep O +
RP-18 O +
( O -
40–63 O +
μm O -
) O +
and O +
trifluoroacetic O +
acid O +
( O -
TFA O -
, O +
Uvasol O -
) O +
from O +
Merck O +
( O -
Darmstadt O -
, O +
Germany O -
) O -
; O +
1-ethyl-3- O -
[ O -
3- O -
( O -
dimethylamino O -
) O -
propyl O -
] O -
carbodiimide O +
( O -
EDC O -
) O -
, O +
monodansylcadaverine O +
[ O -
N O +
- O -
( O -
5-aminopentyl O -
) O -
-5- O -
( O -
dimethylamino O -
) O -
naphthalene-1-sulfonamide O -
] O +
( O -
DNC O -
) O -
, O +
and O +
guinea B-Gene +
pig I-Gene +
liver I-Gene +
transglutaminase I-Gene +
from O +
Sigma O -
; O +
AsnC B-Gene +
proteinase I-Gene +
from O +
PanVera O +
Corporation O +
( O -
Madison O -
, O +
WI O -
, O +
USA O -
) O +
and O +
trypsin B-Gene +
from O +
Boehringer O +
Mannheim O +
( O -
Mannheim O -
, O +
Germany O -
) O -
. O +

2.2 O +
Proteins O +
and O +
peptides O +
Actin B-Gene +
was O +
prepared O +
from O +
bovine O +
heart O +
or O +
rabbit O +
skeletal O +
muscle O +
by O +
the O +
method O +
of O +
Pardee O +
and O +
Spudich O +
[ O -
25 O -
] O +
and O +
further O +
purified O +
by O +
gel O +
filtration O +
[ O -
26 O -
] O +
on O +
a O +
Sephacryl O +
S300 O +
column O +
( O -
Pharmacia O -
) O +
equilibrated O +
with O +
G O +
buffer O +
( O -
2 O +
mM O +
Tris O -
– O -
HCl O -
, O +
0.2 O +
mM O +
ATP O -
, O +
0.2 O +
mM O +
CaCl2 O +
, O +
0.5 O +
mM O +
mercaptoethanol O -
, O +
0.05 O -
% O +
NaN3 O +
, O +
pH O +
8.0 O -
) O -
. O +

G B-Gene -
- I-Gene -
actin I-Gene +
was O +
stored O +
in O +
G O +
buffer O +
at O +
0 O -
° O -
C O -
. O +

Rabbit B-Gene +
skeletal I-Gene +
muscle I-Gene +
actin I-Gene +
was O +
pyrenylated O +
following O +
the O +
procedure O +
given O +
in O +
[ O -
27 O -
] O +
. O +

Thymosin O +
β4 O +
was O +
isolated O +
from O +
bovine O +
spleen O +
as O +
described O +
[ O -
28 O -
] O +
. O +

The O +
purity O +
of O +
the O +
preparations O +
was O +
demonstrated O +
by O +
reverse O +
phase O +
HPLC O -
. O +

The O +
concentrations O +
of O +
thymosin O +
β4 O +
and O +
actin B-Gene +
were O +
determined O +
by O +
amino O +
acid O +
analysis O +
after O +
acid O +
hydrolysis O +
( O -
6 O +
M O +
HCl O -
, O +
155 O -
° O -
C O -
, O +
1 O +
h O -
) O +
and O +
precolumn O +
derivatization O +
with O +
o O +
-phthaldialdehyde O -
/ O -
3-mercaptopropionic O +
acid O +
[ O -
29 O -
] O +
. O +

Proteolytic O +
fragments O +
of O +
peptides O +
( O -
thymosin O +
β4 O +
and O +
modified O +
thymosin O +
β4 O +
) O +
were O +
prepared O +
by O +
the O +
following O +
procedures O -
: O +
AsnC B-Gene +
endoproteinase I-Gene -
: O +
1 O +
μg O +
of O +
peptide O +
was O +
incubated O +
with O +
1 O +
μg O +
protease B-Gene +
in O +
10 O +
μl O +
reaction O +
buffer O +
( O -
50 O +
mM O +
sodium O +
acetate O -
, O +
pH O +
5.0 O -
, O +
0.2 O +
mM O +
DTT O -
, O +
0.2 O +
mM O +
EDTA O -
) O -
; O +
trypsin B-Gene -
: O +
50 O +
μg O +
peptide O +
TG51 O +
was O +
digested O +
with O +
2 O +
μg O +
trypsin B-Gene +
in O +
50 O +
μl O +
1 O -
% O +
NH4 O +
HCO3 O +
. O +

All O +
digestions O +
were O +
incubated O +
for O +
16 O +
h O +
at O +
room O +
temperature O -
. O +

Thereafter O -
, O +
reactions O +
were O +
stopped O +
by O +
adding O +
an O +
equal O +
volume O +
of O +
10 O -
% O +
TFA O -
. O +

Prior O +
to O +
analysis O +
by O +
MALDI O -
- O -
TOF O -
- O -
MS O +
the O +
samples O +
were O +
concentrated O +
in O +
vacuo O -
. O +

2.3 O +
HPLC O +
Chromatographic O +
conditions O +
were O +
controlled O +
by O +
a O +
Merck O -
- O -
Hitachi O +
L-6200 O +
system O +
supplemented O +
with O +
a O +
diode O +
array O +
UV O +
detector O +
( O -
L-7450A O -
, O +
Merck O -
- O -
Hitachi O -
) O +
and O +
with O +
a O +
fluorometer O +
( O -
F-1050 O -
, O +
Merck O -
- O -
Hitachi O -
) O -
. O +

The O +
diode O +
array O +
detector O +
signal O +
was O +
recorded O +
on O +
a O +
computer O +
using O +
D-7000 O +
HSM O +
software O +
( O -
Merck O -
) O +
and O +
the O +
fluorescence O +
signal O +
on O +
an O +
integrator O +
( O -
D-2500 O -
, O +
Merck O -
- O -
Hitachi O -
) O -
. O +

For O +
high O +
sensitivity O +
detection O +
of O +
peptides O -
, O +
a O +
postcolumn O +
derivatization O +
system O +
was O +
used O +
[ O -
30 O -
] O +
. O +

Analytical O +
separations O -
. O +

Flow O +
rate O -
: O +
0.75 O +
ml O -
/ O -
min O -
; O +
buffer O -
: O +
0.1 O -
% O +
TFA O -
; O +
gradient O -
: O +
linear O +
from O +
0 O +
to O +
40 O -
% O +
acetonitrile O +
in O +
60 O +
min O -
; O +
column O -
: O +
Beckman O +
ODS O +
Ultrasphere O +
( O -
5 O +
μm O -
, O +
4.6 O -
× O -
250 O +
mm O -
) O -
; O +
detection O -
: O +
UV O +
at O +
205 O +
nm O +
or O +
fluorescence O +
after O +
postcolumn O +
derivatization O +
with O +
fluorescamine O -
. O +

Preparative O +
separation O +
of O +
the O +
peptides O -
. O +

Flow O +
rate O -
: O +
0.75 O +
ml O -
/ O -
min O -
; O +
buffer O -
: O +
0.1 O -
% O +
trifluoroacetic O +
acid O -
; O +
gradient O -
: O +
linear O +
from O +
0 O +
to O +
40 O -
% O +
acetonitrile O +
in O +
120 O +
min O -
; O +
column O -
: O +
Pharmacia O +
SuperPac O +
Pep O -
- O -
S O +
( O -
5 O +
μm O -
, O +
4 O -
× O -
250 O +
mm O -
) O -
; O +
detection O -
: O +
UV O +
( O -
215 O +
nm O -
) O +
or O +
dansyl O +
fluorescence O +
( O -
λ O +
ex O +
= O -
290 O +
nm O -
, O +
λ O +
em O +
= O -
540 O +
nm O -
) O -
. O +

2.4 O +
Gel O +
electrophoretic O +
procedures O +
SDS O +
polyacrylamide O +
gel O +
electrophoresis O +
was O +
performed O +
either O +
by O +
the O +
method O +
of O +
Laemmli O +
[ O -
31 O -
] O +
or O +
using O +
Pharmacia O +
PhastGel O +
Gradient O +
10–15 O -
. O +

Native O +
gel O +
electrophoresis O +
was O +
performed O +
as O +
detailed O +
previously O +
[ O -
32 O -
] O +
. O +

2.5 O +
Transglutamination O +
of O +
thymosin O +
β4 O +
with O +
dansylcadaverine O +
To O +
determine O +
the O +
time O +
course O +
of O +
transglutamination O -
, O +
thymosin O +
β4 O +
( O -
120 O +
μM O -
) O +
was O +
incubated O +
with O +
dansylcadaverine O +
( O -
5 O +
mM O -
) O +
in O +
70 O +
μl O +
buffer O +
consisting O +
of O +
10 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
7.4 O -
, O +
15 O +
mM O +
CaCl2 O +
, O +
3 O +
mM O +
DTT O -
. O +

The O +
reaction O +
was O +
started O +
by O +
addition O +
of O +
0.1 O +
U O +
transglutaminase B-Gene -
. O +

Immediately O +
after O +
addition O +
of O +
the O +
enzyme B-Gene +
( O -
t O +
= O -
0 O -
) O +
and O +
at O +
indicated O +
times O -
, O +
10 O +
μl O +
were O +
taken O +
from O +
the O +
mixture O -
, O +
diluted O +
in O +
490 O +
μl O +
0.1 O -
% O +
TFA O +
to O +
stop O +
the O +
reaction O +
and O +
analyzed O +
by O +
HPLC O -
. O +

For O +
preparative O +
separation O +
of O +
labeled O +
peptides O -
, O +
500 O +
μg O +
thymosin O +
β4 O +
( O -
200 O +
μM O -
) O +
was O +
incubated O +
at O +
room O +
temperature O +
with O +
500 O +
μg O +
dansylcadaverine O +
( O -
3 O +
mM O -
) O +
and O +
0.5 O +
U O +
transglutaminase B-Gene +
in O +
500 O +
μl O +
of O +
the O +
buffer O +
described O +
above O -
. O +

After O +
1 O +
and O +
2 O +
h O -
, O +
10 O +
μl O +
was O +
subjected O +
to O +
analysis O +
by O +
HPLC O -
. O +

The O +
reaction O +
was O +
stopped O +
after O +
4 O +
h O +
by O +
addition O +
of O +
5 O +
μl O +
TFA O -
. O +

Thereafter O -
, O +
the O +
reaction O +
mixture O +
was O +
subjected O +
to O +
preparative O +
HPLC O -
. O +

Separated O +
peptides O +
were O +
concentrated O +
in O +
vacuo O +
and O +
then O +
characterized O +
by O +
amino O +
acid O +
analysis O +
and O +
MALDI O -
- O -
TOF O +
mass O +
spectrometry O -
. O +

2.6 O +
Matrix O -
- O -
assisted O +
laser O +
desorption O +
mass O +
spectrometry O +
Mass O +
determinations O +
were O +
performed O +
with O +
a O +
Biflex O -
™ O +
III O +
MALDI O -
- O -
TOF O +
mass O +
spectrometer O +
( O -
Bruker O +
Daltonics O -
, O +
Germany O -
) O -
. O +

The O +
instrument O +
is O +
equipped O +
with O +
a O +
nitrogen O +
laser O +
( O -
λ O +
= O -
337 O +
nm O -
) O +
and O +
a O +
reflectron O -
. O +

Laser O -
- O -
desorbed O +
positive O +
ions O +
were O +
analyzed O +
after O +
being O +
accelerated O +
by O +
19 O +
kV O +
in O +
the O +
reflection O +
mode O -
. O +

External O +
calibration O +
was O +
performed O +
by O +
use O +
of O +
a O +
standard O +
peptide O +
mixture O -
. O +

Usually O -
, O +
30 O +
individual O +
spectra O +
were O +
averaged O +
to O +
produce O +
a O +
mass O +
spectrum O -
. O +

Dried O +
peptide O +
samples O +
were O +
dissolved O +
in O +
0.1 O -
% O +
TFA O +
containing O +
33 O -
% O +
acetonitrile O +
to O +
a O +
final O +
concentration O +
of O +
about O +
20 O +
ng O -
/ O -
μl O -
. O +

Each O +
sample O +
( O -
1 O +
μl O -
) O +
was O +
mixed O +
with O +
2 O +
μl O +
of O +
a O +
saturated O +
solution O +
of O +
α O -
- O -
cyano-4-hydroxycinnamic O +
acid O +
( O -
Sigma O -
, O +
Germany O -
) O +
in O +
0.1 O -
% O +
TFA O -
, O +
33 O -
% O +
acetonitrile O +
and O +
1 O +
μl O +
of O +
this O +
mixture O +
was O +
spotted O +
onto O +
a O +
stainless O +
steel O +
target O -
. O +

2.7 O +
Viscosimetry O +
and O +
EDC O +
cross O -
- O -
linking O +
Viscosimetric O +
measurements O +
were O +
done O +
with O +
a O +
falling O -
- O -
ball O +
viscometer O +
according O +
to O +
Cooper O +
and O +
Pollard O +
[ O -
33 O -
] O +
, O +
at O +
an O +
angle O +
of O +
40 O -
° O +
relative O +
to O +
horizontal O -
, O +
distance O +
of O +
fall O -
: O +
45 O +
mm O -
; O +
ball O +
diameter O -
: O +
0.794 O +
mm O -
. O +

G B-Gene -
- I-Gene -
actin I-Gene +
solution O +
( O -
48 O +
μl O -
; O +
0.18 O +
mg O -
/ O -
ml O +
in O +
G O +
buffer O -
) O +
was O +
incubated O +
with O +
or O +
without O +
thymosin O +
β4 O +
or O +
dansylcadaverine O -
- O -
labeled O +
peptides O +
for O +
15 O +
min O +
at O +
room O +
temperature O +
and O +
thereafter O +
2 O +
μl O +
50 O +
mM O +
MgCl2 O +
was O +
added O -
. O +

The O +
mixture O +
was O +
filled O +
into O +
a O +
glass O +
capillary O +
( O -
diameter O +
0.92 O +
mm O -
, O +
50 O +
μl O +
micropipettes O -
, O +
Brand O +
No. O +
708733 O -
) O -
, O +
sealed O +
at O +
one O +
end O +
and O +
incubated O +
for O +
4 O +
h O +
before O +
measuring O +
time O +
of O +
fall O -
. O +

Thereafter O -
, O +
mixtures O +
were O +
removed O +
by O +
centrifugation O +
from O +
the O +
capillaries O +
and O +
incubated O +
with O +
5 O +
μl O +
of O +
an O +
EDC O +
solution O +
( O -
36 O +
mg O -
/ O -
ml O -
) O -
. O +

After O +
2 O +
h O -
, O +
an O +
additional O +
5 O +
μl O +
EDC O +
solution O +
was O +
added O +
for O +
another O +
2 O +
h O +
incubation O +
period O -
. O +

The O +
reaction O +
mixtures O +
were O +
dialyzed O +
overnight O +
in O +
microcollodion O +
bags O +
( O -
Sartorius O -
) O +
against O +
G O +
buffer O -
. O +

Prior O +
to O +
SDS O +
gel O +
electrophoresis O -
, O +
the O +
solutions O +
were O +
concentrated O +
in O +
vacuo O -
. O +

2.8 O +
Transglutamination O +
of O +
thymosin O +
β4 O +
in O +
the O +
presence O +
of O +
G B-Gene -
- I-Gene -
actin I-Gene +
G B-Gene -
- I-Gene -
actin I-Gene +
and O +
thymosin O +
β4 O +
were O +
incubated O +
with O +
transglutaminase B-Gene +
in O +
the O +
presence O +
or O +
absence O +
of O +
dansylcadaverine O +
in O +
a O +
buffer O +
consisting O +
of O +
10 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
8.0 O -
, O +
1 O +
mM O +
CaCl2 O +
, O +
5 O +
mM O +
DTE O -
, O +
0.5 O +
mM O +
ATP O -
, O +
0.2 O +
mM O +
NaN3 O +
overnight O +
at O +
room O +
temperature O -
. O +

3 O +
Results O +
3.1 O +
Derivatization O +
of O +
thymosin O +
β4 O +
with O +
dansylcadaverine O +
by O +
transglutaminase B-Gene +
To O +
elucidate O +
whether O +
thymosin O +
β4 O +
could O +
serve O +
as O +
a O +
glutaminyl O +
substrate O +
for O +
guinea B-Gene +
pig I-Gene +
transglutaminase I-Gene +
we O +
incubated O +
the O +
peptide O +
with O +
dansylcadaverine O -
, O +
a O +
well O -
- O -
known O +
fluorescent O +
aminyl O +
substrate O +
of O +
transglutaminase B-Gene -
. O +

HPLC O +
analyses O +
taken O +
directly O +
after O +
addition O +
of O +
the O +
enzyme O +
( O -
t O +
= O -
0 O -
) O +
and O +
after O +
2 O +
h O +
are O +
shown O +
in O +
Fig. O +
1 O +
. O +

At O +
the O +
beginning O +
of O +
the O +
reaction O +
( O -
A O -
) O -
, O +
the O +
chromatogram O +
showed O +
a O +
large O +
peak O +
for O +
thymosin O +
β4 O +
and O +
a O +
very O +
small O +
signal O +
for O +
its O +
sulfoxide O +
( O -
Tβ4 O +
( O -
o O -
) O +
) O -
. O +

After O +
2 O +
h O +
( O -
B O -
) O -
, O +
the O +
amounts O +
of O +
thymosin O +
β4 O +
sulfoxide O +
and O +
thymosin O +
β4 O +
were O +
diminished O +
while O +
five O +
new O +
peaks O +
arose O -
. O +

Because O +
of O +
the O +
presence O +
of O +
several O +
new O +
peaks O +
we O +
were O +
interested O +
to O +
elucidate O +
which O +
and O +
whether O +
more O +
than O +
one O +
of O +
the O +
three O +
possible O +
Gln O +
residues O +
were O +
derivatized O -
. O +

Therefore O +
we O +
measured O +
the O +
kinetics O +
of O +
the O +
derivatization O +
reaction O +
by O +
HPLC O +
analysis O +
as O +
described O +
in O +
Section O +
2 O +
. O +

Fig. O +
2 O +
shows O +
the O +
time O +
course O +
of O +
the O +
derivatization O +
reaction O -
, O +
where O +
the O +
amount O +
of O +
thymosin O +
β4 O +
( O -
• O -
) O +
decreased O +
in O +
a O +
logarithmic O +
manner O -
. O +

The O +
products O +
TG47 O +
( O -
○ O -
) O +
and O +
TG48 O +
( O -
■ O -
) O +
increased O +
during O +
the O +
first O +
30 O +
min O +
and O +
decreased O +
thereafter O -
. O +

The O +
third O +
product O +
TG49 O +
( O -
not O +
shown O +
in O +
Fig. O +
2 O +
) O +
increased O +
to O +
the O +
same O +
extent O +
as O +
thymosin O +
β4 O +
sulfoxide O +
decreased O +
( O -
Fig. O +
1 O +
) O -
. O +

Product O +
TG51 O +
( O -
▴ O -
) O +
first O +
developed O +
nearly O +
parallel O +
to O +
TG47 O +
and O +
TG48 O -
, O +
but O +
increased O +
further O +
and O +
constituted O +
the O +
main O +
product O -
. O +

After O +
about O +
2 O +
h O +
another O +
product O +
( O -
TG55 O -
, O +
▵ O -
) O +
was O +
detected O +
which O +
was O +
only O +
formed O +
to O +
a O +
small O +
extent O +
during O +
the O +
incubation O +
period O -
. O +

3.2 O +
Isolation O +
and O +
characterization O +
of O +
products O +
formed O +
For O +
isolation O +
and O +
characterization O +
of O +
the O +
products O -
, O +
we O +
carried O +
out O +
the O +
reaction O +
in O +
a O +
preparative O +
manner O +
as O +
described O +
in O +
Section O +
2 O +
. O +

After O +
preparative O +
HPLC O -
, O +
we O +
isolated O +
six O +
products O -
. O +

Amino O +
acid O +
analysis O +
of O +
the O +
isolated O +
peptides O +
showed O +
identical O +
amino O +
acid O +
compositions O +
for O +
all O +
isolated O +
products O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
peptides O +
were O +
then O +
characterized O +
by O +
mass O +
spectroscopy O -
. O +

Table O +
1 O +
summarizes O +
the O +
observed O +
molecular O +
masses O -
, O +
assigned O +
molecular O +
formulas O -
, O +
calculated O +
masses O +
and O +
their O +
deviations O -
. O +

These O +
data O +
showed O +
that O +
there O +
was O +
still O +
unreacted O +
thymosin O +
β4 O +
( O -
Tβ4 O +
) O -
, O +
two O +
mono O -
- O -
DNC O +
derivatives O +
( O -
[ O -
Tβ4 O +
∗ O -
( O -
DNC O -
) O -
1 O +
] O -
; O +
TG47 O +
and O +
TG48 O -
) O -
, O +
a O +
very O +
low O +
amount O +
of O +
bis O -
- O -
DNC O +
thymosin O +
β4 O +
sulfoxide O +
( O -
[ O -
Tβ4 O +
( O -
o O -
) O +
∗ O -
( O -
DNC O -
) O -
2 O +
] O -
; O +
TG49 O -
) O -
. O +

In O +
addition O +
to O +
a O +
small O +
amount O +
of O +
tris B-Gene -
- I-Gene -
DNC I-Gene +
thymosin I-Gene +
β4 I-Gene +
( O -
[ O -
Tβ4 B-Gene +
∗ I-Gene -
( I-Gene -
DNC I-Gene -
) I-Gene -
3 I-Gene +
] O -
; O +
TG55 B-Gene -
) O -
, O +
a O +
bis B-Gene -
- I-Gene -
DNC I-Gene +
thymosin I-Gene +
β4 I-Gene +
( O -
[ B-Gene -
Tβ4 I-Gene +
∗ I-Gene -
( I-Gene -
DNC I-Gene -
) I-Gene -
2 I-Gene +
] I-Gene -
; O +
TG51 B-Gene -
) O +
was O +
identified O +
as O +
the O +
main O +
product O -
. O +

3.3 O +
Localization O +
of O +
derivatized O +
Gln O +
residues O +
To O +
further O +
elaborate O +
which O +
of O +
the O +
three O +
possible O +
Gln O +
residues O +
were O +
modified O -
, O +
we O +
digested O +
thymosin O +
β4 O +
as O +
well O +
as O +
peptides O +
TG47 O -
, O +
TG48 O -
, O +
and O +
TG51 O +
with O +
AsnC B-Gene +
proteinase I-Gene +
and O +
analyzed O +
the O +
samples O +
by O +
MALDI O -
- O -
TOF O -
- O -
MS O -
. O +

Because O +
thymosin O +
β4 O +
possesses O +
only O +
one O +
Asn O +
residue O -
, O +
at O +
position O +
26 O -
, O +
this O +
digestion O +
produces O +
two O +
fragments O -
, O +
Tβ4 O +
1–26 O +
and O +
Tβ4 O +
27–43 O +
, O +
containing O +
one O +
and O +
two O +
of O +
the O +
Gln O +
residues O -
, O +
respectively O -
. O +

In O +
the O +
case O +
of O +
thymosin O +
β4 O +
, O +
the O +
two O +
expected O +
fragments O +
appeared O +
at O +
molecular O +
masses O +
of O +
3109.7 O +
( O -
m O +
/z O +
) O +
and O +
1871.7 O +
( O -
m O +
/z O +
) O +
( O -
Table O +
2 O +
) O -
. O +

In O +
the O +
MALDI O +
mass O +
spectra O +
of O +
digested O +
TG47 O +
the O +
C O -
- O -
terminal O +
fragment O +
was O +
shifted O +
to O +
2189.6 O +
( O -
m O +
/z O +
) O -
, O +
whereas O +
in O +
the O +
case O +
of O +
TG48 O +
the O +
signal O +
for O +
the O +
N O -
- O -
terminal O +
fragment O +
appeared O +
at O +
3430.8 O +
( O -
m O +
/z O +
) O +
corresponding O +
to O +
the O +
addition O +
of O +
one O +
DNC O +
( O -
335.5 O +
Da O -
) O -
. O +

This O +
indicated O +
that O +
Gln-23 O +
of O +
TG48 O +
and O +
either O +
Gln-36 O +
or O +
39 O +
of O +
TG47 O +
were O +
derivatized O -
. O +

In O +
the O +
case O +
of O +
digested O +
TG51 O -
, O +
both O +
peaks O +
were O +
shifted O -
. O +

Thus O -
, O +
we O +
concluded O +
that O +
Gln-23 O +
and O +
also O +
one O +
of O +
the O +
two O +
Gln O +
residues O +
close O +
to O +
the O +
C O -
- O -
terminus O +
had O +
been O +
derivatized O +
in O +
this O +
peptide O -
. O +

To O +
elucidate O +
which O +
of O +
these O +
two O +
residues O +
was O +
derivatized O -
, O +
we O +
digested O +
TG51 O +
with O +
trypsin B-Gene -
. O +

HPLC O +
analysis O +
of O +
TG51 O +
digested O +
with O +
trypsin B-Gene +
yielded O +
two O +
major O +
and O +
two O +
minor O +
fluorescent O +
peaks O +
( O -
Fig. O +
3 O +
) O -
. O +

The O +
two O +
major O +
peaks O +
were O +
identified O +
by O +
amino O +
acid O +
analysis O +
and O +
MALDI O -
- O -
TOF O -
- O -
MS O +
as O +
DNC O -
- O -
labeled O +
tryptic O +
fragments O +
TG5119–25 O +
( O -
m O +
/z O +
= O -
1181.4 O -
; O +
expected O +
1182.4 O -
) O +
and O +
TG5132–38 O +
( O -
m O +
/z O +
= O -
1194.6 O -
; O +
expected O +
1195.3 O -
) O -
. O +

The O +
two O +
minor O +
fluorescent O +
fragments O +
represented O +
amino O +
acid O +
residues O +
20–25 O +
( O -
m O +
/z O +
= O -
1053.3 O -
; O +
expected O +
1054.3 O -
) O +
and O +
20–31 O +
( O -
m O +
/z O +
= O -
1690.0 O -
; O +
expected O +
1691.0 O -
) O +
of O +
TG51 O -
. O +

No O +
DNC O -
- O -
labeled O +
fragment O +
corresponding O +
to O +
TG5139–43 O +
was O +
detected O -
. O +

Therefore O -
, O +
Gln-36 O +
is O +
the O +
second O +
residue O +
which O +
was O +
readily O +
modified O +
by O +
transglutaminase B-Gene -
. O +

3.4 O +
Interaction O +
of O +
modified O +
thymosin O +
β4 O +
with O +
G B-Gene -
- I-Gene -
actin I-Gene +
After O +
isolation O +
and O +
characterization O +
of O +
the O +
labeled O +
peptides O -
, O +
we O +
asked O +
how O +
these O +
modifications O +
of O +
thymosin O +
β4 O +
influenced O +
the O +
interaction O +
with O +
G B-Gene -
- I-Gene -
actin I-Gene -
. O +

We O +
first O +
studied O +
the O +
polymerization O -
- O -
inhibiting O +
capacity O +
of O +
the O +
peptides O +
using O +
viscosimetry O -
. O +

The O +
time O +
of O +
fall O +
for O +
polymerized O +
actin B-Gene +
was O +
55±5 O +
s O +
( O -
means±S.D. O -
, O +
n O +
= O -
6 O -
) O -
. O +

In O +
the O +
presence O +
of O +
an O +
equal O +
amount O +
of O +
thymosin O +
β4 O +
, O +
this O +
value O +
decreased O +
to O +
7±1.5 O +
s O +
( O -
n O +
= O -
6 O -
) O -
, O +
which O +
equaled O +
the O +
value O +
for O +
the O +
buffer O +
solution O +
and O +
represented O +
complete O +
inhibition O +
of O +
polymerization O -
. O +

Using O +
equimolar O +
amounts O +
of O +
thymosin O +
β4 O +
sulfoxide O +
( O -
Tβ4 O +
( O -
o O -
) O +
) O -
, O +
which O +
is O +
known O +
to O +
inhibit O +
the O +
polymerization O +
only O +
when O +
present O +
in O +
a O +
20-fold O +
excess O +
to O +
G B-Gene -
- I-Gene -
actin I-Gene -
, O +
but O +
not O +
at O +
equimolar O +
concentrations O +
to O +
actin O +
[ O -
13 O -
] O +
, O +
we O +
determined O +
a O +
value O +
of O +
40±3 O +
s O +
( O -
n O +
= O -
4 O -
) O -
. O +

For O +
all O +
labeled O +
peptides O -
, O +
values O +
in O +
the O +
range O +
of O +
7–10 O +
s O +
were O +
determined O +
at O +
equimolar O +
ratios O +
to O +
G B-Gene -
- I-Gene -
actin I-Gene -
. O +

This O +
indicates O +
that O +
the O +
modification O +
of O +
neither O +
a O +
single O +
nor O +
all O +
glutamyl O +
residues O +
of O +
thymosin O +
β4 O +
impaired O +
the O +
inhibition O +
of O +
the O +
salt O -
- O -
induced O +
polymerization O -
. O +

To O +
verify O +
these O +
results O -
, O +
we O +
further O +
analyzed O +
the O +
samples O +
by O +
cross O -
- O -
linking O +
with O +
the O +
zero O -
- O -
length O +
cross O -
- O -
linker O +
EDC O +
and O +
subsequent O +
SDS O -
- O -
PAGE O +
analysis O +
using O +
Pharmacia O +
PhastGel O +
Gradient O +
10–15 O -
. O +

Following O +
UV O +
analysis O +
( O -
365 O +
nm O -
) O +
of O +
fluorescent O +
bands O +
( O -
Fig. O +
4A O +
) O -
, O +
gel O +
was O +
stained O +
with O +
Coomassie O +
blue O +
( O -
Fig. O +
4B O +
) O -
. O +

Indeed O -
, O +
the O +
expected O +
fluorescent O +
bands O +
appeared O +
when O +
actin B-Gene +
was O +
cross O -
- O -
linked O +
with O +
labeled O +
peptides O -
. O +

Coomassie O +
blue O +
staining O +
indicated O +
that O +
all O +
peptides O +
were O +
cross O -
- O -
linked O +
to O +
G O -
- O -
actin O +
to O +
the O +
same O +
extent O -
. O +

Typically O -
, O +
about O +
50 O -
% O +
of O +
actin B-Gene +
was O +
cross O -
- O -
linked O +
by O +
EDC O +
to O +
β O -
- O -
thymosins O -
. O +

3.5 O +
Transglutamination O +
of O +
thymosin O +
β4 O +
in O +
the O +
presence O +
of O +
G B-Gene -
- I-Gene -
actin I-Gene +
G B-Gene -
- I-Gene -
actin I-Gene +
has O +
been O +
described O +
as O +
a O +
glutaminyl O +
substrate O +
of O +
transglutaminase B-Gene +
[ O -
34 O -
] O +
and O +
the O +
transglutaminase B-Gene +
reaction O +
has O +
been O +
used O +
to O +
cross O -
- O -
link O +
G B-Gene -
- I-Gene -
actin I-Gene +
and O +
thymosin O +
β4 O +
[ O -
24 O -
] O +
. O +

Therefore O +
we O +
studied O +
transglutamination O +
of O +
G B-Gene -
- I-Gene -
actin I-Gene +
in O +
the O +
presence O +
of O +
thymosin O +
β4 O +
and O +
dansylcadaverine O +
( O -
Fig. O +
5 O +
) O -
. O +

Detection O +
of O +
dansylcadaverine O +
fluorescence O +
after O +
SDS O -
- O -
PAGE O +
( O -
A O -
) O +
showed O +
that O +
the O +
amount O +
of O +
actin B-Gene -
– O -
thymosin O +
β4 O +
crosslink O +
was O +
very O +
low O +
in O +
the O +
presence O +
of O +
dansylcadaverine O +
and O +
transglutaminase B-Gene +
( O -
lane O +
5 O -
) O -
, O +
while O +
there O +
were O +
large O +
amounts O +
of O +
dansylcadaverine B-Gene -
- I-Gene -
labeled I-Gene +
thymosin O +
β4 O +
( O -
lane O +
5 O -
) O +
and O +
actin B-Gene +
( O -
lanes O +
3–5 O -
) O -
. O +

Subsequent O +
Coomassie O +
blue O +
staining O +
( O -
B O -
) O +
demonstrated O +
that O +
actin B-Gene +
and O +
thymosin O +
β4 O +
were O +
inefficiently O +
cross O -
- O -
linked O +
by O +
transglutaminase B-Gene +
( O -
lanes O +
1 O +
and O +
2 O -
) O -
. O +

The O +
amount O +
of O +
cross O -
- O -
link O +
further O +
decreased O +
in O +
the O +
presence O +
of O +
dansylcadaverine O +
competing O +
for O +
Lys O +
residues O +
of O +
either O +
G B-Gene -
- I-Gene -
actin I-Gene +
or O +
thymosin O +
β4 O +
( O -
100 O +
μM O -
, O +
lane O +
5 O -
) O -
. O +

In O +
the O +
absence O +
of O +
thymosin O +
β4 O +
, O +
dansylcadaverine B-Gene -
- I-Gene -
labeled I-Gene +
actin I-Gene +
polymerized O +
to O +
F B-Gene -
- I-Gene -
actin I-Gene +
as O +
revealed O +
by O +
fluorescence O +
detection O +
after O +
native O +
PAGE O +
( O -
Fig. O +
5A O +
, O +
lanes O +
3 O +
and O +
4 O -
) O -
. O +

This O +
was O +
caused O +
by O +
the O +
calcium O +
concentration O +
needed O +
for O +
activation O +
of O +
transglutaminase B-Gene +
( O -
1 O +
mM O -
) O -
. O +

In O +
contrast O -
, O +
actin B-Gene +
polymerization O +
was O +
drastically O +
inhibited O +
in O +
the O +
presence O +
of O +
100 O +
μM O +
thymosin O +
β4 O +
, O +
due O +
to O +
complex O +
formation O +
with O +
thymosin O +
β4 O +
( O -
lane O +
5 O -
) O -
. O +

Coomassie O +
blue O +
staining O +
of O +
native O +
gels O +
( O -
Fig. O +
5B O +
) O +
showed O +
that O +
both O +
G B-Gene -
- I-Gene -
actin I-Gene +
and O +
its O +
complex O +
with O +
thymosin O +
β4 O +
were O +
present O +
regardless O +
of O +
whether O +
dansylcadaverine O +
was O +
present O +
or O +
not O +
( O -
lanes O +
1 O -
, O +
2 O +
and O +
5 O -
) O -
. O +

4 O +
Discussion O +
In O +
this O +
work O -
, O +
we O +
demonstrated O +
that O +
thymosin O +
β4 O +
could O +
serve O +
as O +
a O +
glutaminyl O +
substrate O +
for O +
guinea B-Gene +
pig I-Gene +
liver I-Gene +
transglutaminase I-Gene +
at O +
concentrations O +
that O +
are O +
present O +
inside O +
cells O -
. O +

Using O +
proteolytic O +
fragmentation O +
and O +
MALDI O -
- O -
TOF O +
mass O +
spectroscopy O -
, O +
we O +
elucidated O +
that O +
Gln O +
residues O +
23 O +
and O +
36 O +
are O +
easily O +
available O +
for O +
transglutamination O -
, O +
whereas O +
Gln-39 O +
reacts O +
very O +
slowly O +
and O +
to O +
a O +
very O +
low O +
extent O -
. O +

Moreover O -
, O +
with O +
this O +
reaction O +
we O +
were O +
able O +
to O +
label O +
thymosin O +
β4 O +
with O +
dansylcadaverine O +
as O +
a O +
fluorescent O +
marker O +
without O +
abolishing O +
its O +
interaction O +
with O +
G B-Gene -
- I-Gene -
actin I-Gene -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
elucidate O +
whether O +
thymosin O +
β4 O +
could O +
serve O +
as O +
a O +
specific O +
glutaminyl O +
substrate O +
for O +
the O +
transglutaminase B-Gene +
reaction O -
. O +

In O +
recent O +
years O +
it O +
has O +
been O +
shown O +
that O +
thymosin O +
β4 O +
may O +
be O +
involved O +
in O +
cellular O +
events O +
like O +
angiogenesis O +
[ O -
18,19 O -
] O +
, O +
wound O +
healing O +
[ O -
20 O -
] O +
, O +
apoptosis O +
[ O -
21 O -
] O +
and O +
blood O +
coagulation O +
[ O -
3,16,17 O -
] O +
. O +

Because O +
transglutaminases B-Gene +
also O +
participate O +
in O +
all O +
these O +
cellular O +
reactions O +
we O +
investigated O +
whether O +
thymosin O +
β4 O +
and O +
transglutaminase B-Gene +
may O +
interact O -
. O +

Our O +
results O +
clearly O +
show O +
that O +
thymosin O +
β4 O +
could O +
serve O +
as O +
a O +
glutaminyl O +
substrate O +
for O +
guinea O +
pig O +
transglutaminase B-Gene +
at O +
concentrations O +
which O +
are O +
present O +
inside O +
cells O +
( O -
Fig. O +
1 O +
) O -
. O +

Consequently O +
it O +
is O +
likely O +
that O +
thymosin O +
β4 O +
, O +
which O +
is O +
present O +
in O +
human O +
platelets O +
in O +
a O +
concentration O +
of O +
about O +
500 O +
μM O +
[ O -
3,35 O -
] O +
, O +
serves O +
as O +
a O +
glutaminyl O +
substrate O +
for O +
factor B-Gene +
XIIIa I-Gene -
. O +

Our O +
data O +
also O +
verify O +
that O +
not O +
all O +
Gln O +
residues O +
of O +
thymosin O +
β4 O +
are O +
readily O +
accessible O +
for O +
the O +
transglutaminase B-Gene +
reaction O -
. O +

Gorman O +
and O +
Folk O +
have O +
studied O +
the O +
glutaminyl O +
substrate O +
specificity O +
of O +
factor B-Gene +
XIIIa I-Gene +
and O +
guinea B-Gene +
pig I-Gene +
liver I-Gene +
transglutaminase I-Gene +
[ O -
36 O -
] O +
. O +

They O +
performed O +
single O +
and O +
multiple O +
amino O +
acid O +
substitutions O +
of O +
a O +
synthetic O +
peptide O +
substrate O +
corresponding O +
to O +
amino O +
acid O +
residues O +
161–175 O +
of O +
β B-Gene -
- I-Gene -
casein I-Gene -
, O +
a O +
well O -
- O -
known O +
substrate O +
for O +
factor B-Gene +
XIIIa I-Gene +
( O -
Fig. O +
6 O +
) O -
. O +

It O +
was O +
found O +
that O +
substitution O +
of O +
Lys O +
by O +
a O +
Gly O +
residue O +
at O +
position O +
+ O -
2 O +
results O +
in O +
a O +
distinct O +
decrease O +
of O +
its O +
glutaminyl O +
donor O +
property O +
with O +
transglutaminase B-Gene -
, O +
which O +
is O +
even O +
more O +
pronounced O +
with O +
factor B-Gene +
XIIIa I-Gene -
. O +

In O +
the O +
case O +
of O +
Gln-23 O +
and O +
Gln-36 O +
of O +
thymosin O +
β4 O +
a O +
Lys O +
residue O +
follows O +
at O +
the O +
+ O -
2 O +
position O -
, O +
while O +
in O +
the O +
case O +
of O +
Gln-39 O +
a O +
Gly O +
residue O +
is O +
at O +
this O +
position O -
. O +

This O +
may O +
partly O +
explain O +
why O +
Gln-39 O +
of O +
thymosin O +
β4 O +
is O +
only O +
labeled O +
to O +
a O +
very O +
low O +
extent O -
. O +

Activity O +
of O +
both O +
enzymes B-Gene +
showed O +
a O +
distinct O +
or O +
drastic O +
decrease O +
by O +
truncation O +
of O +
four O +
C- O +
or O +
N O -
- O -
terminal O +
residues O -
. O +

This O +
may O +
be O +
an O +
additional O +
reason O +
for O +
the O +
low O +
derivatization O +
of O +
Gln-39 O -
. O +

The O +
environment O +
of O +
Gln-23 O +
is O +
highly O +
conserved O +
throughout O +
all O +
mammalian O +
β O -
- O -
thymosins O +
except O +
thymosin O +
β15 O +
( O -
Fig. O +
7 O +
) O -
, O +
which O +
has O +
been O +
described O +
to O +
be O +
highly O +
expressed O +
in O +
human O +
cancer O +
cells O +
with O +
high O +
metastatic O +
activity O +
[ O -
37 O -
] O +
. O +

Safer O +
et O +
al. O +
[ O -
6 O -
] O +
proposed O +
that O +
the O +
sequence O +
17 O +
LKKTETQEK25 O +
of O +
thymosin O +
β4 O +
may O +
be O +
involved O +
in O +
actin B-Gene +
sequestering O +
because O +
of O +
its O +
high O +
homology O +
with O +
the O +
well O -
- O -
known O +
actin B-Gene -
- O -
binding O +
sequence O +
of O +
actobindin B-Gene +
[ O -
38 O -
] O +
. O +

In O +
accordance O +
with O +
their O +
proposal O -
, O +
we O +
have O +
previously O +
demonstrated O +
that O +
truncation O +
of O +
up O +
to O +
13 O +
N O -
- O -
terminal O +
amino O +
acid O +
residues O +
does O +
not O +
abolish O +
chemical O +
cross O -
- O -
linking O +
to O +
G B-Gene -
- I-Gene -
actin I-Gene -
, O +
while O +
truncation O +
of O +
the O +
first O +
23 O +
amino O +
acid O +
residues O +
completely O +
destroys O +
interaction O +
[ O -
13 O -
] O +
. O +

Surprisingly O -
, O +
as O +
demonstrated O +
here O -
, O +
derivatization O +
of O +
Gln-23 O +
with O +
dansylcadaverine O +
did O +
not O +
abolish O +
G B-Gene -
- I-Gene -
actin I-Gene +
binding O -
, O +
suggesting O +
that O +
this O +
particular O +
position O +
may O +
not O +
be O +
essential O +
for O +
actin B-Gene +
binding O -
. O +

Indeed O -
, O +
Gln-23 O +
is O +
not O +
conserved O +
in O +
the O +
corresponding O +
sequences O +
of O +
actobindin B-Gene +
[ O -
38 O -
] O +
. O +

There O +
are O +
several O +
reports O +
dealing O +
with O +
G B-Gene -
- I-Gene -
actin I-Gene +
as O +
a O +
glutaminyl O +
substrate O +
for O +
the O +
transglutaminase B-Gene +
reaction O -
. O +

Takashi O +
has O +
shown O +
that O +
dansylcadaverine O +
can O +
be O +
cross O -
- O -
linked O +
to O +
Gln-41 O +
of O +
G B-Gene -
- I-Gene -
actin I-Gene +
and O +
that O +
this O +
leads O +
to O +
a O +
decrease O +
of O +
the O +
critical O +
concentration O +
and O +
faster O +
polymerization O +
of O +
labeled O +
G B-Gene -
- I-Gene -
actin I-Gene +
[ O -
34 O -
] O +
. O +

It O +
has O +
also O +
been O +
reported O +
that O +
actin B-Gene +
from O +
human O +
blood O +
platelets O +
and O +
rabbit O +
skeletal O +
muscle O +
actin B-Gene +
serves O +
as O +
a O +
substrate O +
for O +
factor B-Gene +
XIIIa I-Gene +
[ O -
39 O -
] O +
. O +

Moreover O -
, O +
the O +
cross O -
- O -
linked O +
matrix O +
from O +
platelets O +
formed O +
by O +
the O +
transglutaminase B-Gene +
reaction O +
contains O +
actin B-Gene +
[ O -
40 O -
] O +
. O +

Previously O -
, O +
Nemes O +
et O +
al. O +
[ O -
41 O -
] O +
have O +
shown O +
that O +
actin B-Gene +
seems O +
to O +
be O +
the O +
main O +
endogenous O +
substrate O +
for O +
tissue O +
transglutaminase B-Gene +
in O +
HL60 O +
and O +
U937 O +
cells O +
undergoing O +
apoptosis O -
. O +

For O +
detection O +
of O +
substrate O +
proteins B-Gene -
, O +
they O +
used O +
a O +
synthetic O +
hapten O -
- O -
labeled O +
lysine O +
derivative O -
, O +
which O +
is O +
able O +
to O +
cross O +
the O +
cell O +
membrane O -
. O +

After O +
inducing O +
apoptosis O -
, O +
they O +
detected O +
actin B-Gene +
as O +
the O +
major O +
protein O +
transglutaminated O +
with O +
hapten O -
- O -
labeled O +
lysine O +
by O +
Western O +
blot O +
analysis O -
. O +

Our O +
results O +
prove O +
that O -
, O +
at O +
least O +
under O +
the O +
conditions O +
used O +
in O +
our O +
assay O -
, O +
thymosin O +
β4 O +
serves O +
equally O +
well O +
as O +
a O +
substrate O +
for O +
guinea B-Gene +
pig I-Gene +
transglutaminase I-Gene +
compared O +
to O +
actin B-Gene +
( O -
Fig. O +
5 O +
) O -
. O +

Because O +
of O +
its O +
low O +
molecular O +
weight O +
and O +
high O +
solubility O +
thymosin O +
β4 O +
may O +
have O +
escaped O +
their O +
SDS O -
- O -
PAGE O +
analysis O -
. O +

Therefore O -
, O +
it O +
will O +
be O +
interesting O +
to O +
look O +
for O +
transglutamination O +
of O +
thymosin O +
β4 O +
during O +
apoptosis O +
using O +
HPLC O +
techniques O -
. O +

Taking O +
these O +
data O +
together O -
, O +
it O +
is O +
tempting O +
to O +
speculate O +
that O +
thymosin O +
β4 O +
may O +
serve O +
as O +
a O +
glutaminyl O +
substrate O +
for O +
transglutaminases B-Gene +
in O +
vivo O +
and O +
thus O +
may O +
possibly O +
play O +
an O +
important O +
role O +
in O +
transglutaminase B-Gene -
- O -
related O +
processes O -
. O +

Acknowledgments O +
We O +
express O +
our O +
appreciation O +
to O +
Doris O +
Jaegers O +
for O +
her O +
excellent O +
technical O +
assistance O -
. O +

The O +
most O +
common O +
octadecatrienoic O +
fatty O +
acid O +
in O +
plants O +
is O +
α O -
- O -
linoleic O +
acid O +
( O -
9Z O +
, O -
12Z O +
, O -
15Z O +
-18:3 O -
) O -
, O +
which O +
is O +
the O +
main O +
constituent O +
of O +
chloroplastic O +
membranes O +
[ O -
1 O -
] O +
. O +

Moreover O -
, O +
triacylglycerols O +
from O +
seeds O +
provide O +
an O +
easily O +
accessible O +
source O +
of O +
additional O +
conjugated O +
octadecatrienoic O +
acids O +
having O +
( O -
Z O +
, O -
E O +
, O -
E O +
) O +
or O +
( O -
Z O +
, O -
E O +
, O -
Z O +
) O +
geometries O +
[ O -
2 O -
] O +
. O +

At O +
least O +
five O +
different O +
regio O +
isomers O +
have O +
been O +
reported O +
within O +
plants O +
with O +
double O +
bond O +
systems O +
in O +
the O +
following O +
positions O -
: O +
( O -
Z O +
, O -
E O +
, O -
Z O +
) O -
- O +
and O +
( O -
E O +
, O -
E O +
, O -
Z O +
) O -
-8,10,12 O -
- O -
18:3 O +
and O +
( O -
Z O +
, O -
E O +
, O -
Z O +
) O -
- O -
, O +
( O -
Z O +
, O -
E O +
, O -
E O +
) O -
- O +
and O +
( O -
E O +
, O -
E O +
, O -
Z O +
) O -
-9,11,13 O -
- O -
18:3 O -
. O +

One O +
of O +
these O -
, O +
calendic O +
acid O +
( O -
8E O +
, O -
10E O +
, O -
12Z O +
-18:3 O -
) O -
, O +
is O +
the O +
major O +
constituent O +
of O +
the O +
seed O +
oil O +
of O +
Calendula O +
officinalis O +
, O +
Calendula O +
stellata O +
, O +
Osteospermum O +
spinescens O +
and O +
Osteospermum O +
hyoseroides O +
[ O -
1 O -
] O +
. O +

These O +
seed O +
oils O +
are O +
of O +
industrial O +
interest O -
, O +
because O +
the O +
oil O +
is O +
used O +
for O +
cosmetic O +
purposes O +
and O +
may O +
be O +
used O +
as O +
a O +
drying O +
oil O +
in O +
paintings O -
. O +

A O +
number O +
of O +
chemical O +
mechanisms O +
have O +
been O +
proposed O +
to O +
describe O +
the O +
biosynthesis O +
of O +
conjugated O +
octadecatrienoic O +
acids O -
. O +

These O +
include O +
the O +
formation O +
of O +
an O +
epoxy O +
derivative O +
of O +
linoleic O +
acid O +
as O +
an O +
intermediate O +
[ O -
3 O -
] O +
, O +
the O +
oxidation O +
of O +
linoleic O +
acid O +
[ O -
4 O -
] O +
, O +
the O +
isomerization O +
of O +
linolenic O +
acid O +
[ O -
5 O -
] O +
and O +
the O +
formation O +
of O +
a O +
radical O +
of O +
linoleic O +
acid O +
due O +
to O +
a O +
lipoxygenase B-Gene -
- O -
type O +
reaction O +
[ O -
6–8 O -
] O +
. O +

However O -
, O +
in O +
a O +
recent O +
publication O +
on O +
the O +
biosynthesis O +
of O +
α O -
- O -
eleostearic O +
acid O +
( O -
9Z O +
, O -
11E O +
, O -
13E O +
-18:3 O -
) O -
, O +
which O +
is O +
a O +
regio O +
isomer O +
of O +
calendic O +
acid O -
, O +
it O +
was O +
shown O +
that O +
the O +
conversion O +
of O +
linoleic O +
acid O +
to O +
this O +
conjugated O +
octadecatrienoic O +
acid O +
occurs O +
while O +
this O +
acyl O +
moiety O +
is O +
esterified O +
to O +
phosphatidylcholine O +
[ O -
9 O -
] O +
. O +

Based O +
on O +
these O +
data O +
one O +
may O +
assume O +
that O +
the O +
conversion O +
of O +
esterified O +
linoleic O +
acid O +
to O +
conjugated O +
octadecatrienoic O +
acids O +
is O +
catalyzed O +
by O +
a O +
new O +
type O +
of O +
( B-Gene -
1,4 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
acyl I-Gene +
lipid I-Gene +
desaturase I-Gene -
. O +

To O +
obtain O +
additional O +
information O +
on O +
the O +
biosynthesis O +
of O +
conjugated O +
octadecatrienoic O +
acids O +
we O +
decided O +
to O +
continue O +
the O +
analysis O +
of O +
the O +
biosynthesis O +
of O +
calendic O +
acid O +
( O -
8E O +
, O -
10E O +
, O -
12Z O +
-18:3 O -
) O +
in O +
the O +
developing O +
seeds O +
of O +
C. O +
officinalis O +
. O +

This O +
species O +
is O +
amenable O +
to O +
such O +
studies O -
, O +
because O +
it O +
is O +
easy O +
to O +
grow O -
, O +
its O +
seeds O +
contain O +
large O +
quantities O +
of O +
calendic O +
acid O -
, O +
and O +
most O +
of O +
the O +
studies O +
on O +
the O +
biosynthesis O +
of O +
conjugated O +
octadecatrienoic O +
acids O +
have O +
been O +
performed O +
with O +
seeds O +
from O +
this O +
plant O -
. O +

Here O -
, O +
we O +
describe O +
the O +
cloning O +
of O +
a O +
new O +
type O +
of O +
( B-Gene -
1,4 I-Gene -
) I-Gene -
-acyl I-Gene +
lipid I-Gene +
desaturase I-Gene -
, O +
a O +
( B-Gene -
8,11 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
desaturase I-Gene +
that O +
catalyzes O +
the O +
formation O +
of O +
a O +
conjugated O +
triene O -
, O +
calendic O +
acid O -
. O +

2 O +
Materials O +
and O +
methods O +
C. O +
officinalis O +
was O +
grown O +
from O +
seeds O +
in O +
a O +
greenhouse O +
under O +
16 O +
h O +
of O +
artificially O +
supplemented O +
illumination O +
at O +
a O +
temperature O +
ranging O +
between O +
22 O +
and O +
30 O -
° O -
C O -
. O +

For O +
all O +
experiments O +
developing O +
seeds O +
at O +
a O +
fully O +
expanded O +
green O +
stage O +
were O +
used O -
. O +

For O +
RNA O +
isolation O +
20 O +
g O +
of O +
plant O +
material O +
was O +
ground O +
in O +
liquid O +
nitrogen O -
, O +
100 O +
ml O +
of O +
extraction O +
buffer O +
I O +
( O -
100 O +
mM O +
Tris O -
- O -
HCl O -
, O +
pH O +
7.5 O -
, O +
25 O +
mM O +
EDTA O -
, O +
2 O -
% O +
( O -
w O -
/ O -
v O -
) O +
laurylsarcosyl O -
, O +
4 O +
M O +
guanidinium O +
thiocyanate O -
, O +
5 O -
% O +
( O -
w O -
/ O -
v O -
) O +
PVPP O -
, O +
1 O -
% O +
( O -
v O -
/ O -
v O -
) O +
β O -
- O -
mercaptoethanol O -
) O +
was O +
added O +
and O +
the O +
homogenate O +
was O +
shaken O +
for O +
15 O +
min O -
. O +

After O +
centrifugation O +
at O +
4000 O -
× O -
g O +
for O +
15 O +
min O +
the O +
floating O +
solid O +
lipid O +
phase O +
was O +
discarded O +
and O +
the O +
remaining O +
liquid O +
phase O +
was O +
extracted O +
twice O +
for O +
15 O +
min O +
with O +
PCI O +
( O -
phenol O -
: O -
chloroform O -
: O -
isoamyl O +
alcohol O -
, O +
25:24:1 O -
) O -
. O +

After O +
centrifugation O +
at O +
4000 O -
× O -
g O +
for O +
15 O +
min O +
the O +
upper O +
hydrophilic O +
phase O +
was O +
loaded O +
on O +
a O +
CsCl O +
cushion O +
( O -
5 O +
M O +
CsCl O -
) O +
of O +
8 O +
ml O +
and O +
centrifuged O +
at O +
18 O -
° O -
C O +
and O +
100 O +
000 O -
× O -
g O +
for O +
18 O +
h. O +
After O +
discarding O +
the O +
supernatant O +
the O +
RNA O +
precipitate O +
was O +
dried O -
, O +
washed O +
with O +
70 O -
% O +
ethanol O +
and O +
extracted O +
for O +
15 O +
min O +
with O +
a O +
mixture O +
consisting O +
of O +
7.5 O +
ml O +
of O +
extraction O +
buffer O +
II O +
( O -
100 O +
mM O +
Tris O -
- O -
HCl O -
, O +
pH O +
8.8 O -
, O +
100 O +
mM O +
NaCl O -
, O +
5 O +
mM O +
EDTA O -
, O +
2 O -
% O +
( O -
w O -
/ O -
v O -
) O +
SDS O -
) O +
and O +
10 O +
ml O +
PCI O -
. O +

After O +
centrifugation O +
at O +
4000 O -
× O -
g O +
for O +
15 O +
min O +
the O +
upper O +
hydrophilic O +
phase O +
was O +
washed O +
with O +
chloroform O +
and O +
the O +
remaining O +
RNA O +
was O +
precipitated O +
overnight O +
at O +
4 O -
° O -
C O +
by O +
adding O +
an O +
equal O +
volume O +
of O +
5 O +
M O +
LiCl O -
. O +

After O +
centrifugation O +
for O +
60 O +
min O +
at O +
12 O +
000 O -
× O -
g O +
at O +
4 O -
° O -
C O +
the O +
precipitate O +
was O +
washed O +
twice O +
with O +
70 O -
% O +
ethanol O -
, O +
dried O +
and O +
dissolved O +
in O +
500 O +
μl O +
water O -
. O +

From O +
this O +
total O +
RNA O +
fraction O +
mRNA O +
was O +
isolated O +
using O +
the O +
Poly O -
- O -
Attract O -
- O -
Kit O +
( O -
Promega O -
, O +
Mannheim O -
, O +
Germany O -
) O -
. O +

Single O +
stranded O +
cDNA O +
( O -
ss O -
- O -
cDNA O -
) O +
was O +
isolated O +
from O +
mRNA O +
of O +
developing O +
marigold O +
seeds O +
by O +
reversed O +
transcription O +
with O +
SuperscriptII O +
( O -
Gibco O +
BRL O -
, O +
Eggenstein O -
, O +
Germany O -
) O -
. O +

This O +
ss O -
- O -
cDNA O +
was O +
used O +
as O +
template O +
for O +
PCR O -
- O -
based O +
cloning O -
. O +

A O +
470 O +
bp O +
PCR O +
fragment O +
was O +
amplified O +
with O +
the O +
degenerate O +
sense O +
primer O +
A O +
5′-CCD O +
TAY O +
TTC O +
TCI O +
TGG O +
AAR O +
WWH O +
AGY O +
CAY O +
CG-3′ O +
and O +
antisense O +
primer O +
B O +
5′-CCA O +
RTY O +
CCA O +
YTC O +
IGW O +
BGA O +
RTC O +
RTA O +
RTG-3′ O +
derived O +
from O +
the O +
amino O +
acid O +
sequences O +
PYFSWK O -
( O -
Y O -
/ O -
I O -
) O -
SHR O +
and O +
HYDS O -
( O -
S O -
/ O -
T O -
) O -
EW O -
( O -
D O -
/ O -
N O -
) O -
W O -
, O +
respectively O -
. O +

The O +
PCR O +
reaction O +
was O +
carried O +
out O +
with O +
TfI O -
- O -
DNA O -
- O -
Polymerase B-Gene +
( O -
Biozym O -
, O +
Hess O -
. O +

Oldendorf O -
, O +
Germany O -
) O +
using O +
an O +
amplification O +
program O +
of O +
2 O +
min O +
denaturation O +
at O +
94 O -
° O -
C O -
, O +
followed O +
by O +
10 O +
cycles O +
of O +
30 O +
s O +
at O +
94 O -
° O -
C O -
, O +
45 O +
s O +
at O +
50 O -
° O -
C O -
, O +
1 O +
min O +
at O +
72 O -
° O -
C O -
, O +
followed O +
by O +
20 O +
cycles O +
of O +
30 O +
s O +
at O +
94 O -
° O -
C O -
, O +
45 O +
s O +
at O +
50 O -
° O -
C O -
, O +
1 O +
min O +
at O +
72 O -
° O -
C O +
( O -
time O +
increment O +
5 O +
s O -
) O +
and O +
terminated O +
by O +
2 O +
min O +
extension O +
at O +
72 O -
° O -
C O -
. O +

PCR O +
products O +
of O +
the O +
expected O +
length O +
were O +
cloned O +
in O +
pCR2.1-TOPO O +
( O -
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
, O +
USA O -
) O +
and O +
sequenced O -
. O +

The O +
fragment O +
CoDes2.2 O +
was O +
chosen O +
for O +
the O +
isolation O +
of O +
a O +
full O -
- O -
length O +
cDNA O +
clone O +
using O +
the O +
Marathon O +
cDNA O +
amplification O +
kit O +
( O -
Clontech O -
, O +
Heidelberg O -
, O +
Germany O -
) O -
. O +

To O +
amplify O +
the O +
5′- O +
and O +
3′-ends O +
of O +
CoDes2.2 O +
by O +
PCR O +
specific O +
primers O +
were O +
used O -
: O +
5′-race O -
: O +
primer O +
C O +
5′-GTG O +
AGG O +
GAG O +
TGA O +
GAG O +
ATG O +
GGT O +
GTG O +
GTG O +
C-3′ O -
, O +
primer O +
D O +
5′-AAC O +
ACA O +
CTT O +
ACA O +
CCT O +
AGT O +
ACT O +
GGA O +
ATT-3′ O -
; O +
3′-race O -
: O +
primer O +
E O +
5′-TAT O +
TCC O +
AAA O +
CTT O +
CTT O +
AAC O +
AAT O +
CCA O +
CCC O +
G-3′ O -
, O +
primer O +
F O +
5′-CAA O +
TTC O +
CAG O +
TAC O +
TAG O +
GTG O +
TAA O +
GTG O +
TGT O +
T-3′. O +
The O +
PCR O +
reaction O +
was O +
carried O +
out O +
according O +
to O +
the O +
supplier O -
's O +
instructions O -
. O +

The O +
fragments O +
were O +
cloned O +
in O +
pCR2.1-TOPO O +
and O +
sequenced O -
. O +

To O +
obtain O +
the O +
full O -
- O -
length O +
cDNA O +
clone O +
by O +
PCR O -
, O +
specific O +
primers O +
of O +
the O +
expected O +
open O +
reading O +
frame O +
of O +
the O +
entire O +
cDNA O +
of O +
1.2 O +
kb O +
were O +
used O +
for O +
amplification O -
: O +
sense O +
primer O +
G O +
5′-ATT O +
AGA O +
GCT O +
CAT O +
GGG O +
TGC O +
TGG O +
TGG O +
TCG O +
GAT O +
GTC O +
G-3′ O +
and O +
antisense O +
primer O +
H O +
5′-ATT O +
ACT O +
CGA O +
GTG O +
ACA O +
TAC O +
ACC O +
TTT O +
TTG O +
ATT O +
ACA O +
TCT O +
TG-3′. O +
The O +
PCR O +
reaction O +
was O +
carried O +
out O +
with O +
the O +
Expand O +
High O +
Fidelity O +
System O +
( O -
Boehringer O -
, O +
Mannheim O -
, O +
Germany O -
) O +
using O +
an O +
amplification O +
program O +
of O +
2 O +
min O +
denaturation O +
at O +
94 O -
° O -
C O -
, O +
followed O +
by O +
10 O +
cycles O +
of O +
30 O +
s O +
at O +
94 O -
° O -
C O -
, O +
35 O +
s O +
at O +
63 O -
° O -
C O -
, O +
2 O +
min O +
at O +
72 O -
° O -
C O -
, O +
followed O +
by O +
15 O +
cycles O +
of O +
30 O +
s O +
at O +
94 O -
° O -
C O -
, O +
35 O +
s O +
at O +
63 O -
° O -
C O -
, O +
1 O +
min O +
at O +
72 O -
° O -
C O +
( O -
time O +
increment O +
5 O +
s O -
) O +
and O +
terminated O +
by O +
2 O +
min O +
extension O +
at O +
72 O -
° O -
C O -
. O +

The O +
fragment O +
was O +
cloned O +
into O +
pGEM O -
- O -
T O +
and O +
the O +
resulting O +
plasmid O +
pCoDes8.11 O +
was O +
sequenced O -
. O +

For O +
expression O +
in O +
Sacharomyces O +
cerevisiae O +
the O +
open O +
reading O +
frame O +
of O +
pCoDes8.11 O +
was O +
cloned O +
as O +
a O +
Sac O +
I O -
/ O -
Xho O +
I O +
fragment O +
behind O +
the O +
galactose O -
- O -
inducible O +
promoter O +
GAL1 O +
into O +
the O +
shuttle O +
vector O +
pYES2 O +
( O -
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
, O +
USA O -
) O +
to O +
yield O +
plasmid O +
pYESDes8.11 O -
. O +

Plasmid O +
pYESDes8.11 O +
was O +
transformed O +
into O +
the O +
yeast O +
strain O +
INVSC1 O +
( O -
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
, O +
USA O -
) O +
by O +
the O +
polyethylene O +
glycol O +
method O +
[ O -
10 O -
] O +
. O +

The O +
expression O +
of O +
cells O +
harboring O +
plasmid O +
pYESDes8.11 O +
was O +
performed O +
essentially O +
as O +
described O +
before O +
including O +
the O +
exogenous O +
application O +
of O +
linoleic O +
acid O +
[ O -
11 O -
] O +
. O +

Cells O +
reaching O +
the O +
stationary O +
phase O +
were O +
washed O +
with O +
minimal O +
medium O -
, O +
harvested O +
by O +
centrifugation O +
and O +
stored O +
at O +
−20 O -
° O -
C O +
until O +
they O +
were O +
analyzed O -
. O +

For O +
analysis O +
of O +
the O +
calendic O +
acid O +
content O +
of O +
transformed O +
yeast O +
cells O -
, O +
the O +
cell O +
pellets O +
were O +
disrupted O +
using O +
a O +
sonifier O +
tip O +
and O +
lipids O +
were O +
extracted O +
with O +
hexane O -
/ O -
isopropanol O +
according O +
to O +
[ O -
12 O -
] O +
. O +

After O +
recovery O +
of O +
the O +
organic O +
phase O -
, O +
solvents O +
were O +
evaporated O +
by O +
vacuum O +
and O +
the O +
lipids O +
were O +
reconstituted O +
in O +
methanol O -
, O +
then O +
either O +
directly O +
analyzed O +
by O +
HPLC O +
or O +
subjected O +
to O +
alkaline O +
hydrolysis O +
as O +
described O +
[ O -
13 O -
] O +
. O +

HPLC O +
analysis O +
of O +
the O +
free O +
fatty O +
acid O +
derivatives O +
was O +
carried O +
out O +
by O +
RP O -
- O -
HPLC O +
as O +
described O +
before O +
[ O -
13 O -
] O +
. O +

Calendic O +
acid O +
eluted O +
with O +
an O +
retention O +
time O +
of O +
11.8 O +
min O +
exhibiting O +
the O +
characteristic O +
conjutriene O +
UV O +
spectrum O +
with O +
a O +
maximum O +
at O +
268 O +
nm O +
[ O -
14 O -
] O +
. O +

Linoleic O +
acid O +
eluted O +
with O +
a O +
retention O +
time O +
of O +
12.7 O +
min O +
exhibiting O +
maximal O +
absorbance O +
at O +
202 O +
nm O -
. O +

Co O -
- O -
injections O +
with O +
authentic O +
standards O +
were O +
performed O -
. O +

The O +
standard O +
of O +
calendic O +
acid O +
was O +
prepared O +
from O +
the O +
triacylglycerol O +
fraction O +
of O +
lipid O +
extracts O +
from O +
marigold O +
seeds O +
by O +
alkaline O +
hydrolysis O -
. O +

Alternatively O -
, O +
the O +
corresponding O +
fatty O +
acid O +
methyl O +
esters O +
were O +
analyzed O +
by O +
gas O +
chromatography O -
/ O -
mass O +
spectrometry O +
( O -
GC O -
/ O -
MS O -
) O -
. O +

For O +
derivation O +
the O +
free O +
fatty O +
acid O +
derivatives O +
were O +
incubated O +
with O +
diazomethane O -
. O +

GC O -
/ O -
MS O +
analysis O +
was O +
performed O +
with O +
a O +
Finigan O +
GCQ O +
GC O -
/ O -
MS O +
system O +
equipped O +
with O +
a O +
capillary O +
Rtx-5 O +
column O +
( O -
5 O -
% O +
diphenyl-95 O -
% O +
polydimethyl O +
siloxane O -
, O +
30 O +
m O -
× O -
0.25 O +
mm O -
; O +
0.25 O +
μm O +
coating O +
thickness O -
; O +
Restek O -
, O +
Germany O -
) O -
. O +

Helium O +
was O +
used O +
as O +
carrier O +
gas O +
( O -
40 O +
cm O -
/ O -
s O -
) O -
. O +

An O +
electron O +
energy O +
of O +
70 O +
eV O -
, O +
an O +
ion O +
source O +
temperature O +
of O +
150 O -
° O -
C O -
, O +
and O +
a O +
temperature O +
of O +
275 O -
° O -
C O +
for O +
the O +
transfer O +
line O +
were O +
used O -
. O +

The O +
samples O +
were O +
measured O +
in O +
the O +
EI O +
mode O -
, O +
and O +
the O +
splitless O +
injection O +
mode O +
( O -
opened O +
after O +
1 O +
min O -
) O +
with O +
an O +
injector O +
temperature O +
of O +
250 O -
° O -
C O -
. O +

The O +
temperature O +
gradient O +
was O +
60 O -
° O -
C–110 O -
° O -
C O +
at O +
25 O -
° O -
C O -
/ O -
min O -
, O +
110 O -
° O -
C O +
for O +
1 O +
min O -
, O +
110 O -
° O -
C–270 O -
° O -
C O +
at O +
10 O -
° O -
C O -
/ O -
min O -
, O +
and O +
270 O -
° O -
C O +
for O +
10 O +
min O -
. O +

Calendic O +
acid O +
eluted O +
with O +
a O +
retention O +
time O +
of O +
17.16 O +
min O -
, O +
linoleic O +
acid O +
eluted O +
with O +
a O +
retention O +
time O +
of O +
15.92 O +
min O -
, O +
and O +
α O -
- O -
linolenic O +
acid O +
eluted O +
with O +
a O +
retention O +
time O +
of O +
15.97 O +
min O -
. O +

3 O +
Results O +
3.1 O +
PCR O -
- O -
based O +
cloning O +
and O +
isolation O +
of O +
a O +
full O -
- O -
length O +
cDNA O +
For O +
PCR O -
- O -
based O +
cloning O +
degenerate O +
primers O -
, O +
deduced O +
from O +
conserved O +
regions O +
of O +
acyl B-Gene +
lipid I-Gene +
desaturases I-Gene -
, O +
were O +
synthesized O +
according O +
to O +
[ O -
11,15,16 O -
] O +
. O +

The O +
template O +
used O +
was O +
ss O -
- O -
cDNA O +
from O +
C. O +
officinalis O +
, O +
which O +
was O +
reverse O -
- O -
transcribed O +
from O +
mRNA O +
of O +
developing O +
seeds O +
at O +
a O +
fully O +
expanded O +
green O +
stage O -
. O +

PCR O +
products O +
of O +
the O +
expected O +
length O +
were O +
cloned O +
and O +
sequenced O -
. O +

Data O +
base O +
searches O +
and O +
alignments O +
with O +
these O +
fragments O +
indicated O +
similarities O +
to O +
plant O +
acyl B-Gene +
lipid I-Gene +
desaturases I-Gene +
with O +
different O +
regio O +
specificities O -
. O +

Except O +
for O +
one O +
( O -
CD2.2 O -
) O -
, O +
all O +
were O +
classified O +
either O +
as O +
putative O +
members O +
of O +
the O +
classical O +
Δ12 B-Gene +
desaturases I-Gene +
or O +
as O +
putative O +
sphingolipid B-Gene +
desaturases I-Gene +
based O +
on O +
identities O +
more O +
than O +
75 O -
% O +
[ O -
16 O -
] O +
. O +

However O -
, O +
the O +
470 O +
bp O +
fragment O +
CD2.2 O +
exhibited O +
highest O +
identities O +
to O +
the O +
Δ12 B-Gene +
fatty I-Gene +
acid I-Gene +
acetylenase I-Gene +
from O +
Crepis O +
alpina O +
and O +
the O +
Δ12 B-Gene +
fatty I-Gene +
acid I-Gene +
epoxygenase I-Gene +
from O +
Crepis O +
palaestina O +
[ O -
15 O -
] O +
. O +

To O +
isolate O +
the O +
full O -
- O -
length O +
cDNA O +
clone O -
, O +
PCR O +
with O +
specific O +
primers O +
was O +
used O +
to O +
amplify O +
the O +
5′- O +
and O +
3′-ends O +
of O +
CD2.2 O -
. O +

The O +
fragments O +
were O +
cloned O +
and O +
sequenced O -
. O +

With O +
specific O +
primers O +
for O +
the O +
expected O +
open O +
reading O +
frame O +
the O +
entire O +
cDNA O +
of O +
1.2 O +
kb O +
was O +
amplified O +
by O +
PCR O +
and O +
cloned O +
into O +
pGEM O -
- O -
T. O +
The O +
resulting O +
fragment O +
CoDes8.11 O +
was O +
sequenced O -
. O +

The O +
full O -
- O -
length O +
cDNA O +
had O +
a O +
length O +
of O +
1131 O +
bp O +
encoding O +
a O +
protein O +
of O +
377 O +
amino O +
acids O +
with O +
a O +
calculated O +
molecular O +
mass O +
of O +
43.6 O +
kDa O -
. O +

This O +
desaturase B-Gene +
sequence O +
showed O +
highest O +
identities O +
with O +
the O +
Δ12 B-Gene +
acetylenase I-Gene +
from O +
C. O +
alpina O +
( O -
74 O -
% O -
) O +
[ O -
15 O -
] O +
, O +
the O +
Δ12 B-Gene +
epoxygenase I-Gene +
from O +
C. O +
palaestina O +
( O -
73 O -
% O -
) O +
[ O -
15 O -
] O +
, O +
and O +
the O +
Δ12 B-Gene +
desaturase I-Gene +
from O +
borage O +
( O -
62 O -
% O -
) O +
[ O -
17 O -
] O +
( O -
Fig. O +
1 O +
) O -
. O +

The O +
three O +
characteristic O +
and O +
highly O +
conserved O +
histidine O +
regions O +
of O +
the O +
active O +
site O +
of O +
the O +
Δ12 B-Gene +
acyl I-Gene +
lipid I-Gene +
desaturases I-Gene +
are O +
indicated O +
by O +
boxes O -
. O +

These O +
findings O +
were O +
further O +
supported O +
by O +
phylogenetic O +
analysis O +
according O +
to O +
[ O -
17 O -
] O +
. O +

As O +
shown O +
in O +
Fig. O +
2 O +
, O +
the O +
newly O +
identified O +
( B-Gene -
8,11 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
desaturase I-Gene +
groups O +
with O +
the O +
Δ12 B-Gene +
acyl I-Gene +
lipid I-Gene +
desaturase I-Gene +
family O -
. O +

However O -
, O +
it O +
forms O +
one O +
subfamily O +
with O +
the O +
Δ12 B-Gene +
acetylenase I-Gene +
and O +
the O +
Δ12 B-Gene +
epoxygenase I-Gene -
. O +

All O +
members O +
of O +
this O +
subfamily O +
are O +
clearly O +
separated O +
from O +
the O +
classical O +
Δ12 B-Gene +
desaturases I-Gene +
and O +
12-hydroxylases B-Gene -
. O +

3.2 O +
Functional O +
expression O +
in O +
S. O +
cerevisiae O +
and O +
fatty O +
acid O +
analysis O +
In O +
order O +
to O +
elucidate O +
the O +
catalytic O +
properties O +
of O +
this O +
new O +
desaturase B-Gene -
, O +
CoDes8.11 O +
was O +
expressed O +
in O +
yeast O +
cells O +
under O +
the O +
control O +
of O +
the O +
galactose O -
- O -
inducible O +
promoter O +
GAL1 O +
. O +

Since O +
yeast O +
cells O +
do O +
not O +
contain O +
dienoic O +
fatty O +
acids O +
as O +
substrates O +
for O +
the O +
( B-Gene -
8,11 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
desaturase I-Gene +
[ O -
8 O -
] O +
, O +
the O +
expression O +
was O +
performed O +
with O +
supplementation O +
of O +
linoleic O +
acid O -
. O +

Galactose O -
- O -
induced O +
yeast O +
cells O +
were O +
used O +
for O +
the O +
analysis O +
either O +
of O +
fatty O +
acid O +
methyl O +
esters O +
by O +
GC O -
/ O -
MS O +
or O +
of O +
free O +
fatty O +
acids O +
by O +
HPLC O -
. O +

The O +
methyl O +
ester O +
of O +
calendic O +
acid O +
was O +
separated O +
from O +
the O +
classical O +
dienoic O +
and O +
trienoic O +
fatty O +
acids O +
by O +
GC O -
/ O -
MS O -
. O +

It O +
eluted O +
with O +
a O +
retention O +
time O +
of O +
17.16 O +
min O -
, O +
whereas O +
the O +
methyl O +
ester O +
of O +
linoleic O +
acid O +
eluted O +
with O +
a O +
retention O +
time O +
of O +
15.92 O +
min O -
, O +
and O +
that O +
of O +
α O -
- O -
linolenic O +
acid O +
eluted O +
with O +
a O +
retention O +
time O +
of O +
15.97 O +
min O +
( O -
data O +
not O +
shown O -
) O -
. O +

However O -
, O +
using O +
this O +
method O +
calendic O +
acid O +
was O +
only O +
identified O +
by O +
its O +
characteristic O +
retention O +
time O -
, O +
because O +
the O +
corresponding O +
mass O +
spectra O +
of O +
the O +
methyl O +
esters O +
of O +
calendic O +
acid O +
and O +
α O -
- O -
linolenic O +
acid O +
showed O +
no O +
characteristic O +
fragmentation O +
patterns O +
when O +
compared O +
against O +
each O +
other O -
. O +

The O +
spectra O +
differed O +
only O +
in O +
their O +
relative O +
intensities O +
of O +
the O +
obtained O +
fragments O +
( O -
data O +
not O +
shown O -
) O -
. O +

Therefore O -
, O +
we O +
decided O +
to O +
analyze O +
the O +
formation O +
of O +
calendic O +
acid O +
within O +
yeast O +
cells O +
overexpressing O +
CoDes8.11 O +
by O +
RP O -
- O -
HPLC O -
, O +
because O +
of O +
the O +
characteristic O +
UV O +
spectrum O +
of O +
calendic O +
acid O +
and O +
the O +
substantial O +
loss O +
of O +
calendic O +
acid O +
during O +
derivation O +
into O +
its O +
methyl O +
ester O +
for O +
GC O -
/ O -
MS O +
analysis O -
. O +

As O +
a O +
standard O +
calendic O +
acid O +
was O +
isolated O +
from O +
the O +
triacylglycerol O +
fraction O +
of O +
marigold O +
seeds O +
and O +
analyzed O +
by O +
RP O -
- O -
HPLC O +
( O -
Fig. O +
3 O +
, O +
upper O +
panel O -
) O -
. O +

The O +
retention O +
time O +
of O +
calendic O +
acid O +
was O +
11.8 O +
min O +
and O +
as O +
shown O +
in O +
the O +
inset O +
it O +
exhibited O +
a O +
characteristic O +
UV O +
spectrum O +
of O +
conjutrienes O +
with O +
the O +
three O +
relative O +
maxima O +
at O +
262 O +
nm O -
, O +
268 O +
nm O +
and O +
282 O +
nm O +
[ O -
14 O -
] O +
. O +

Yeast O +
cells O +
harboring O +
only O +
the O +
empty O +
vector O +
synthesized O +
no O +
calendic O +
acid O +
( O -
data O +
not O +
shown O -
) O -
. O +

However O -
, O +
S. O +
cerevisiae O +
cells O +
expressing O +
the O +
CoDes8.11 O +
cDNA O +
were O +
capable O +
of O +
forming O +
a O +
fatty O +
acid O +
which O +
co O -
- O -
elutes O +
with O +
calendic O +
acid O +
at O +
11.8 O +
min O +
and O +
exhibits O +
the O +
characteristic O +
UV O +
spectrum O +
of O +
conjutrienes O +
( O -
Fig. O +
3 O +
, O +
lower O +
panel O -
, O +
first O +
peak O +
at O +
11.8 O +
min O -
) O -
. O +

The O +
second O +
peak O -
, O +
eluting O +
close O +
behind O +
calendic O +
acid O +
at O +
12.7 O +
min O -
, O +
was O +
identified O +
as O +
linoleic O +
acid O -
. O +

This O +
indicates O +
that O +
the O +
newly O +
isolated O +
cDNA O +
encodes O +
a O +
desaturase B-Gene +
which O +
is O +
capable O +
of O +
converting O +
linoleic O +
acid O +
into O +
calendic O +
acid O +
upon O +
expression O +
in O +
yeast O +
cells O -
. O +

Moreover O -
, O +
no O +
calendic O +
acid O +
was O +
found O +
in O +
the O +
fraction O +
of O +
free O +
fatty O +
acids O +
( O -
data O +
not O +
shown O -
) O -
. O +

This O +
supports O +
the O +
idea O +
that O +
calendic O +
acid O +
formation O +
may O +
occur O +
while O +
the O +
acyl O +
moiety O +
is O +
esterified O +
to O +
phosphatidylcholine O -
, O +
as O +
has O +
been O +
suggested O +
before O +
[ O -
9 O -
] O +
. O +

4 O +
Discussion O +
Here O -
, O +
we O +
report O +
the O +
isolation O +
and O +
characterization O +
of O +
a O +
cDNA O +
encoding O +
a O +
new O +
type O +
of O +
desaturase B-Gene +
catalyzing O +
a O +
( O -
1,4 O -
) O -
-dehydrogenation O +
reaction O -
. O +

The O +
cDNA O +
encoding O +
an O +
( B-Gene -
8,11 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
desaturase I-Gene +
was O +
cloned O +
by O +
a O +
PCR O -
- O -
based O +
approach O +
as O +
has O +
been O +
described O +
before O +
[ O -
11,16 O -
] O +
. O +

So O +
far O -
, O +
this O +
cDNA O +
could O +
not O +
be O +
identified O +
by O +
EST O +
sequencing O +
of O +
cDNA O +
libraries O +
from O +
developing O +
marigold O +
seeds O -
, O +
indicating O +
that O +
the O +
expression O +
of O +
this O +
( B-Gene -
8,11 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
desaturase I-Gene +
gene O +
is O +
either O +
very O +
low O +
or O +
developmentally O +
regulated O -
. O +

The O +
deduced O +
protein B-Gene +
shared O +
highest O +
homologies O +
with O +
the O +
recently O +
identified O +
Δ12 B-Gene +
acetylenase I-Gene +
and O +
Δ12 B-Gene +
epoxygenase I-Gene +
from O +
Crepis O +
[ O -
15 O -
] O +
. O +

All O +
three O +
enzymes B-Gene +
convert O +
the O +
double O +
bond O +
in O +
the O +
Δ12 O +
position O +
of O +
linoleic O +
acid O +
esterified O +
to O +
phosphatidylcholine O +
into O +
groups O +
with O +
new O +
functionalities O -
. O +

In O +
addition O -
, O +
within O +
a O +
phylogenetic O +
analysis O +
these O +
three O +
enzymes B-Gene +
could O +
be O +
clearly O +
separated O +
from O +
the O +
other O +
members O +
of O +
the O +
Δ12 B-Gene +
acyl I-Gene +
lipid I-Gene +
desaturase I-Gene +
family O +
( O -
Fig. O +
2 O +
) O -
. O +

As O +
shown O +
by O +
heterologous O +
expression O +
in O +
yeast O +
cells O -
, O +
the O +
enzyme B-Gene +
converts O +
linoleic O +
acid O +
into O +
a O +
conjugated O +
octadecatrienoic O +
acid O +
( O -
Fig. O +
3 O +
) O -
. O +

Based O +
on O +
the O +
observation O +
that O +
linoleic O +
acid O +
is O +
the O +
precursor O +
of O +
calendic O +
acid O +
one O +
may O +
propose O +
a O +
new O +
reaction O +
mechanism O +
for O +
this O +
Δ12 B-Gene +
-type I-Gene +
desaturase I-Gene -
. O +

Whereas O +
within O +
the O +
classical O +
Δ12 B-Gene +
acyl I-Gene +
lipid I-Gene +
desaturases I-Gene +
a O +
( O -
1,2 O -
) O -
-syn O +
dehydrogenation O +
at O +
the O +
carbon O +
atoms O +
C-12 O +
and O +
C-13 O +
of O +
oleic O +
acid O +
may O +
occur O +
[ O -
18 O -
] O +
, O +
one O +
may O +
assume O +
in O +
the O +
case O +
of O +
this O +
new O +
desaturase B-Gene +
a O +
( O -
1,4 O -
) O -
-dehydrogenation O +
at O +
the O +
carbon O +
atoms O +
C-8 O +
and O +
C-11 O +
of O +
linoleic O +
acid O +
as O +
shown O +
in O +
a O +
speculative O +
reaction O +
scheme O +
in O +
Fig. O +
4 O +
. O +

Within O +
linoleic O +
acid O +
the O +
elimination O +
of O +
protons O +
at O +
these O +
two O +
positions O +
might O +
be O +
sterically O +
favored O -
, O +
because O +
the O +
carbon O +
atoms O +
at O +
the O +
positions O +
C-8 O +
and O +
C-11 O +
are O +
localized O +
near O +
each O +
other O +
in O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
the O +
fatty O +
acid O +
molecule O -
. O +

For O +
the O +
conversion O +
of O +
linoleic O +
acid O +
into O +
α O -
- O -
eleostearic O +
acid O +
one O +
may O +
assume O +
a O +
homologous O +
enzyme B-Gene +
catalyzing O +
a O +
( O -
1,4 O -
) O -
-dehydrogenation O +
at O +
the O +
carbon O +
atoms O +
C-14 O +
and O +
C-11 O +
of O +
linoleic O +
acid O -
. O +

Structural O +
determinants O +
which O +
point O +
to O +
this O +
new O +
regio O +
specificity O +
in O +
proton O +
abstraction O +
can O +
hardly O +
be O +
determined O +
by O +
sequence O +
comparison O -
. O +

However O -
, O +
conjugated O +
octadecatrienoic O +
acids O +
are O +
widespread O +
in O +
plant O +
seed O +
oils O +
[ O -
19 O -
] O +
. O +

Therefore O -
, O +
sequence O +
comparisons O +
between O +
this O +
enzyme B-Gene +
and O +
novel O +
yet O +
to O +
be O +
isolated O +
( B-Gene -
1,4 I-Gene -
) I-Gene -
-acyl I-Gene +
lipid I-Gene +
desaturases I-Gene +
might O +
help O +
to O +
identify O +
structural O +
characteristics O +
or O +
differences O +
in O +
these O +
enzymes B-Gene +
which O +
lead O +
to O +
the O +
observed O +
regio O +
and O +
stereochemical O +
specificities O +
within O +
this O +
subfamily O +
of O +
Δ12 B-Gene +
desaturases I-Gene -
. O +

Even O +
the O +
differences O +
between O +
this O +
( B-Gene -
8,11 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
desaturase I-Gene +
catalyzing O +
the O +
formation O +
of O +
calendic O +
acid O +
( O -
8E O +
, O -
10E O +
, O -
12Z O +
-18:3 O -
) O +
and O +
the O +
corresponding O +
( B-Gene -
8,11 I-Gene -
) I-Gene -
-linoleoyl I-Gene +
desaturase I-Gene +
catalyzing O +
the O +
formation O +
of O +
jacaric O +
acid O +
( O -
8Z O +
, O -
10E O +
, O -
12Z O +
-18:3 O -
) O +
from O +
Jacaranda O +
mimosifolia O +
[ O -
1 O -
] O +
is O +
an O +
interesting O +
but O +
open O +
question O -
. O +

With O +
the O +
isolation O +
of O +
this O +
enzyme B-Gene +
the O +
first O +
example O +
has O +
been O +
given O +
for O +
a O +
( O -
1,4 O -
) O -
-dehydrogenation O +
reaction O +
catalyzed O +
by O +
a O +
desaturase B-Gene +
on O +
a O +
dienoic O +
fatty O +
acid O -
. O +

However O -
, O +
this O +
reaction O +
has O +
been O +
suggested O +
recently O +
for O +
a O +
slightly O +
different O +
substrate O +
as O +
well O -
, O +
the O +
conversion O +
of O +
a O +
monoenoic O +
fatty O +
acid O +
into O +
a O +
conjudienoic O +
fatty O +
acid O +
within O +
the O +
biosynthesis O +
of O +
bombykol O -
, O +
a O +
sex O +
pheromone O +
of O +
the O +
female O +
moth O +
Bombyx O +
mori O +
[ O -
20 O -
] O +
. O +

Acknowledgements O +
The O +
authors O +
are O +
grateful O +
to O +
S. O +
Barth O +
and O +
A. O +
Zeuner O +
for O +
expert O +
technical O +
assistance O -
. O +

The O +
authors O +
thank O +
M.A. O +
Fuller O +
and O +
Prof. O +
Dr. O +
C. O +
Wasternack O +
for O +
critical O +
reading O +
of O +
the O +
manuscript O -
. O +

This O +
work O +
was O +
supported O +
by O +
the O +
BASF O +
AG O -
. O +

Cisplatin O +
is O +
one O +
of O +
the O +
most O +
active O +
chemotherapeutic O +
agents O +
available O +
for O +
the O +
treatment O +
of O +
a O +
variety O +
of O +
malignancies O -
, O +
especially O +
testicular O +
and O +
ovarian O +
carcinoma O -
. O +

However O -
, O +
the O +
drug O -
's O +
clinical O +
utility O +
is O +
restricted O +
by O +
both O +
toxicological O +
and O +
especially O +
tumour O +
resistance O +
considerations O -
. O +

For O +
example O -
, O +
while O +
high O +
response O +
rates O +
can O +
be O +
achieved O +
in O +
ovarian O +
cancer O -
, O +
the O +
long O -
- O -
term O +
results O +
are O +
disappointing O +
due O +
to O +
the O +
development O +
of O +
drug O +
resistance O +
leading O +
to O +
recurrence O +
and O +
subsequent O +
death O +
of O +
most O +
of O +
these O +
patients O +
[ O -
1 O -
] O +
. O +

Shortly O +
after O +
the O +
introduction O +
of O +
cisplatin O +
into O +
widespread O +
clinical O +
use O +
in O +
the O +
early O -
- O -
mid O +
1970s O -
, O +
a O +
collaborative O +
programme O +
of O +
analogue O +
development O +
was O +
begun O +
between O +
the O +
Institute O +
of O +
Cancer O +
Research O -
, O +
Sutton O -
, O +
and O +
Johnson O +
Matthey O +
to O +
address O +
these O +
limitations O -
. O +

Initially O -
, O +
the O +
focus O +
was O +
aimed O +
at O +
the O +
discovery O +
of O +
a O +
less O +
toxic O +
but O +
equally O +
efficacious O +
cisplatin O +
analogue O -
. O +

As O +
part O +
of O +
these O +
analogue O +
studies O -
, O +
important O +
structure O -
– O -
activity O +
rules O +
to O +
define O +
the O +
requirements O +
for O +
antitumour O +
activity O +
of O +
platinum O +
compounds O +
were O +
established O +
[ O -
2 O -
] O +
. O +

More O +
than O +
300 O +
complexes O +
were O +
examined O +
and O +
approximately O +
40 O +
identified O +
as O +
active O +
at O +
the O +
preclinical O +
level O -
. O +

From O +
a O +
shortlist O +
of O +
eight O +
candidates O -
, O +
two O -
, O +
i.e. O -
, O +
JM8 O +
( O -
diammine O +
( O -
1,1-cyclobutane O +
dicarboxylato O -
) O +
platinum O -
( O -
II O -
) O -
; O +
carboplatin O -
, O +
CBDCA O -
, O +
Paraplatin O -
® O +
) O +
and O +
JM9 O +
( O -
cis O +
-dichloro O -
- O -
trans O +
-dihydroxo O -
- O -
cis O +
-bis O -
( O -
isopropylamine O -
) O +
platinum O -
( O -
IV O -
) O -
, O +
CHIP O -
, O +
iproplatin O -
) O -
, O +
entered O +
clinical O +
trial O +
[ O -
3 O -
] O +
. O +

Structures O +
are O +
shown O +
in O +
Fig. O +
1 O +
. O +

Carboplatin O +
was O +
shown O +
to O +
be O +
less O +
toxic O +
( O -
myelosuppression O +
being O +
dose O -
- O -
limiting O -
) O +
than O +
cisplatin O +
( O -
or O +
iproplatin O -
) O -
, O +
equally O +
active O +
to O +
cisplatin O +
and O +
more O +
active O +
than O +
iproplatin O +
( O -
see O +
[ O -
4 O -
] O +
for O +
a O +
review O -
) O -
. O +

Carboplatin O +
is O +
now O +
registered O +
worldwide O -
, O +
and O +
has O +
emerged O +
as O +
the O +
first O -
- O -
line O +
treatment O +
of O +
choice O +
( O -
along O +
with O +
paclitaxel O -
) O +
for O +
patients O +
with O +
advanced O +
ovarian O +
cancer O -
. O +

The O +
next O +
phase O +
of O +
analogue O +
development O +
( O -
also O +
in O +
collaboration O +
with O +
Bristol O +
Myers O -
, O +
later O +
Bristol O +
Myers O +
Squibb O -
) O +
concerned O +
the O +
search O +
for O +
platinum O +
compounds O +
possessing O +
sufficient O +
oral O +
bioavailability O +
as O +
to O +
be O +
available O +
to O +
patients O +
as O +
tablets O -
/ O -
capsules O -
. O +

To O +
overcome O +
the O +
poor O +
bioavailability O +
of O +
cisplatin O +
and O +
carboplatin O -
, O +
a O +
new O +
series O +
of O +
platinum O -
( O -
IV O -
) O +
complexes O +
with O +
lipophilic O +
axial O +
ligands O -
, O +
the O +
platinum O -
( O -
IV O -
) O +
ammine O -
/ O -
amine O +
dicarboxylates O -
, O +
were O +
developed O -
. O +

From O +
around O +
50 O +
dicarboxylates O +
exhibiting O +
oral O +
antitumour O +
activity O +
against O +
the O +
murine O +
ADJ O -
/ O -
PC6 O +
subcutaneous O +
plasmacytoma O +
tumour O -
, O +
ten O -
, O +
including O +
JM221 O +
( O -
bis O -
- O -
butyrato O +
amminedichloro O -
( O -
cyclohexylamine O -
) O +
platinum O -
( O -
IV O -
) O -
) O +
and O +
JM216 O +
( O -
bis O -
- O -
acetato O +
amminedichloro O -
( O -
cyclohexylamine O -
) O +
platinum O -
( O -
IV O -
) O -
, O +
BMS O +
182751 O -
) O +
( O -
Fig. O +
1 O +
for O +
structures O -
) O +
were O +
selected O +
for O +
further O +
antitumour O +
evaluation O +
against O +
human O +
ovarian O +
carcinoma O +
xenografts O +
[ O -
5 O -
] O +
. O +

Parallel O +
in O +
vitro O +
studies O +
had O +
also O +
shown O +
that O +
the O +
platinum O -
( O -
IV O -
) O +
ammine O -
/ O -
amine O +
dicarboxylates O -
, O +
JM221 O +
[ O -
6 O -
] O +
and O +
JM216 O +
[ O -
7 O -
] O +
, O +
retained O +
activity O +
against O +
some O +
acquired O +
cisplatin O -
- O -
resistant O +
human O +
ovarian O +
carcinoma O +
cell O +
lines O +
and O +
that O +
longer O +
chain O +
dicarboxylates O +
such O +
as O +
JM221 O +
were O +
considerably O +
more O +
potent O +
than O +
cisplatin O -
. O +

A O +
consideration O +
of O +
oral O +
absorption O +
properties O -
, O +
antitumour O +
activity O +
and O +
toxicological O +
characteristics O +
( O -
especially O +
emetogenic O +
potential O +
in O +
the O +
ferret O -
) O +
led O +
to O +
JM216 O +
being O +
selected O +
for O +
clinical O +
trial O -
. O +

JM216 O +
entered O +
clinical O +
trial O +
at O +
the O +
Royal O +
Marsden O +
Hospital O -
, O +
Sutton O -
, O +
in O +
1992 O -
, O +
initially O +
given O +
as O +
a O +
single O +
oral O +
dose O +
every O +
3 O +
weeks O -
. O +

Subsequent O +
phase O +
I O +
trials O +
established O +
that O +
a O +
schedule O +
daily O +
for O +
5 O +
days O +
was O +
optimal O -
; O +
myelosuppression O +
( O -
thrombocytopenia O +
and O +
leucopenia O -
) O +
was O +
dose O -
- O -
limiting O +
[ O -
8 O -
] O +
. O +

The O +
drug O +
is O +
now O +
undergoing O +
various O +
phase O +
II O -
/ O -
III O +
trials O -
. O +

In O +
the O +
1990s O -
, O +
the O +
focus O +
of O +
the O +
collaboration O +
has O +
been O +
to O +
discover O +
platinum O +
analogues O +
capable O +
of O +
circumventing O +
cisplatin O +
resistance O -
. O +

The O +
mechanisms O +
underlying O +
tumour O +
resistance O +
to O +
cisplatin O +
are O +
known O +
to O +
be O +
multifactorial O +
and O +
include O +
decreased O +
drug O +
transport O -
, O +
increased O +
cellular O +
detoxification O +
due O +
to O +
increased O +
glutathione O +
and O +
metallothionein B-Gene -
, O +
changes O +
in O +
DNA O +
repair O +
involving O +
increased O +
nucleotide O +
excision O +
repair O +
( O -
NER O -
) O +
and/or O +
loss O +
of O +
mismatch O +
repair O +
( O -
MMR O -
) O -
, O +
increased O +
tolerance O +
of O +
DNA O +
adducts O +
and O +
alterations O +
in O +
the O +
apoptotic O +
cell O +
death O +
pathway O +
[ O -
9 O -
] O +
. O +

The O +
relative O +
importance O +
of O +
these O +
factors O +
clinically O +
is O +
not O +
known O +
but O +
strategies O +
to O +
overcome O +
cisplatin O +
resistance O +
could O +
improve O +
the O +
outcome O +
of O +
patients O +
with O +
ovarian O +
carcinoma O -
. O +

One O +
strategy O +
to O +
overcome O +
cisplatin O +
resistance O +
is O +
to O +
design O +
new O +
platinum O +
analogues O +
that O +
specifically O +
address O +
some O -
, O +
or O +
ideally O +
all O -
, O +
of O +
the O +
above O +
known O +
resistance O +
mechanisms O -
. O +

To O +
assist O +
in O +
the O +
identification O +
of O +
analogues O +
capable O +
of O +
circumventing O +
cisplatin O +
resistance O -
, O +
we O +
established O +
panels O +
of O +
human O +
ovarian O +
carcinoma O +
cell O +
lines O -
, O +
sensitive O +
and O +
resistant O +
to O +
cisplatin O +
and O +
analogues O +
[ O -
10,11 O -
] O +
. O +

A O +
key O +
feature O +
of O +
this O +
platinum O +
drug O +
discovery O +
cascade O +
was O +
the O +
inclusion O +
of O +
' O -
mechanism O -
- O -
directed O -
' O +
models O +
of O +
acquired O +
cisplatin O +
resistance O +
[ O -
11 O -
] O +
; O +
with O +
a O +
pair O +
of O +
lines O +
( O -
41M O -
/ O -
41Mcis O +
R O -
) O +
exhibiting O +
resistance O +
due O +
to O +
decreased O +
drug O +
transport O -
, O +
another O +
pair O +
( O -
CH1 O -
/ O -
CH1cis O +
R O -
) O +
with O +
resistance O +
mediated O +
at O +
the O +
level O +
of O +
DNA O +
repair O +
and O +
a O +
third O +
( O -
A2780 O -
/ O -
A2780cis O +
R O -
) O +
with O +
multifactorial O +
resistance O +
mechanisms O +
of O +
decreased O +
uptake O -
, O +
increased O +
glutathione O +
and O +
increased O +
DNA O +
repair O -
. O +

For O +
many O +
of O +
the O +
cell O +
lines O -
, O +
xenograft O +
counterparts O +
were O +
established O +
[ O -
12–14 O -
] O +
thereby O +
allowing O +
downstream O +
in O +
vivo O +
antitumour O +
evaluation O +
of O +
lead O +
molecules O +
( O -
i.e. O -
, O +
those O +
circumventing O +
cisplatin O +
resistance O +
in O +
vitro O -
) O -
. O +

Further O +
details O +
of O +
the O +
cascade O +
have O +
been O +
published O +
previously O +
[ O -
4 O -
] O +
. O +

From O +
an O +
in O +
vitro O +
evaluation O +
of O +
several O +
hundred O +
analogues O -
, O +
two O +
compounds O -
, O +
JM335 O +
( O -
trans O +
-ammine O +
( O -
cyclohexylaminedichlorodihydroxo O -
) O +
platinum O -
( O -
IV O -
) O -
) O +
and O +
ZD0473 O +
( O -
cis O +
-amminedichloro O -
( O -
2-methylpyridine O -
) O +
platinum O -
( O -
II O -
) O -
) O -
, O +
have O +
been O +
identified O +
as O +
lead O +
molecules O +
( O -
Fig. O +
1 O +
for O +
structures O -
) O -
. O +

The O +
latest O +
findings O +
with O +
these O +
drugs O +
form O +
the O +
basis O +
of O +
the O +
remainder O +
of O +
this O +
review O -
. O +

2 O +
JM335 O -
: O +
preclinical O +
studies O +
with O +
an O +
active O +
trans O +
platinum O +
complex O +
JM335 O +
represents O +
one O +
of O +
three O +
independent O +
classes O +
of O +
' O -
active O -
' O +
trans O +
platinum O +
complex O +
discovered O +
during O +
the O +
1990s O +
[ O -
15–17 O -
] O +
. O +

The O +
trans O +
-platinum O +
complexes O +
contravene O +
the O +
original O +
structure O -
– O -
activity O +
rules O +
assigned O +
to O +
platinum O +
complexes O +
[ O -
2 O -
] O +
and O +
represent O +
rationally O +
designed O +
molecules O +
aimed O +
at O +
inducing O +
a O +
different O +
spectrum O +
of O +
adducts O +
on O +
DNA O -
. O +

Early O +
studies O +
with O +
JM335 O +
showed O +
circumvention O +
of O +
acquired O +
cisplatin O +
resistance O +
in O +
vitro O +
against O +
at O +
least O +
some O +
cell O +
lines O +
( O -
e.g. O -
, O +
41Mcis O +
R O +
and O +
CH1cis O +
R O -
) O +
[ O -
15 O -
] O +
and O +
a O +
good O +
measure O +
of O +
in O +
vivo O +
antitumour O +
activity O +
against O +
both O +
human O +
ovarian O +
carcinoma O +
xenografts O +
[ O -
15,18 O -
] O +
( O -
but O +
less O +
than O +
that O +
observed O +
for O +
cisplatin O -
) O +
and O +
against O +
acquired O +
cisplatin O -
- O -
resistant O +
murine O +
ADJ O -
/ O -
PC6 O +
plasmacytoma O +
and O +
L1210 O +
leukaemia O +
models O +
[ O -
19 O -
] O +
. O +

Of O +
interest O +
was O +
that O +
the O +
platinum O -
( O -
II O -
) O +
counterpart O +
of O +
JM335 O +
( O -
JM334 O -
) O +
did O +
not O +
show O +
in O +
vivo O +
antitumour O +
activity O +
[ O -
18 O -
] O +
. O +

JM335 O +
has O +
been O +
shown O +
to O +
induce O +
lesions O +
on O +
DNA O +
distinct O +
from O +
those O +
induced O +
by O +
cisplatin O +
illustrated O +
by O +
the O +
lack O +
of O +
recognition O +
of O +
JM335-induced O +
adducts O +
on O +
DNA O +
extracted O +
from O +
treated O +
tumour O +
cells O +
by O +
a O +
monoclonal B-Gene +
antibody I-Gene +
raised O +
against O +
cisplatinated O -
- O -
DNA O +
[ O -
20 O -
] O +
. O +

Other O +
studies O +
revealed O +
that O +
JM335 O +
induced O +
apoptosis O +
in O +
the O +
CH1 O +
cell O +
line O +
[ O -
21 O -
] O +
. O +

Recent O +
studies O +
have O +
focused O +
on O +
gene O -
- O -
specific O +
repair O +
of O +
DNA O +
lesions O +
formed O +
by O +
JM335 O +
versus O +
its O +
cis O +
isomer O +
JM149 O +
and O +
cisplatin O +
in O +
two O +
human O +
ovarian O +
carcinoma O +
cell O +
lines O -
; O +
the O +
intrinsically O +
cisplatin O -
- O -
sensitive O +
CH1 O +
and O +
the O +
relatively O +
resistant O +
SKOV-3 O -
. O +

Fig. O +
2 O +
illustrates O +
the O +
ability O +
of O +
these O +
two O +
cell O +
lines O +
to O +
remove O +
DNA O +
lesions O +
induced O +
by O +
JM335 O -
, O +
JM149 O +
and O +
cisplatin O +
from O +
a O +
region O +
of O +
the O +
N O -
- O -
ras O +
gene O -
, O +
as O +
assayed O +
by O +
quantitative O -
- O -
PCR O -
. O +

Results O +
showed O +
that O +
the O +
CH1 O +
cell O +
line O +
was O +
unable O +
to O +
remove O +
adducts O +
at O +
24 O +
h O +
post O +
5 O +
h O +
drug O +
exposure O +
formed O +
by O +
any O +
of O +
the O +
three O +
agents O -
. O +

In O +
contrast O -
, O +
SKOV-3 O +
removed O +
adducts O +
formed O +
by O +
the O +
two O +
cis O +
-oriented O +
compounds O +
cisplatin O +
and O +
JM149 O +
but O +
not O +
adducts O +
formed O +
by O +
the O +
trans O +
compound O +
JM335 O -
. O +

Other O +
studies O +
investigating O +
the O +
ability O +
of O +
these O +
compounds O +
to O +
induce O +
cell O +
death O +
showed O +
that O +
all O +
three O +
compounds O +
induce O +
apoptosis O +
in O +
both O +
cell O +
lines O +
but O +
the O +
rate O +
of O +
death O +
was O +
markedly O +
faster O +
for O +
the O +
trans O +
isomer O +
( O -
e.g. O -
, O +
following O +
a O +
2 O +
h O +
exposure O +
to O +
2 O -
× O -
IC50 O +
concentrations O -
, O +
the O +
time O +
for O +
50 O -
% O +
of O +
cells O +
to O +
undergo O +
apoptotic O +
detachment O +
was O +
around O +
24 O +
h O +
for O +
JM335 O -
, O +
but O +
around O +
72 O +
h O +
for O +
JM149 O -
) O -
. O +

These O +
data O +
provide O +
further O +
evidence O +
that O +
the O +
cellular O +
pharmacological O +
properties O +
of O +
the O +
trans O +
compound O +
JM335 O +
differ O +
from O +
those O +
of O +
cisplatin O +
and O +
even O +
its O +
cis O +
isomer O -
. O +

The O +
future O +
challenge O +
is O +
to O +
achieve O +
adequate O +
delivery O +
of O +
these O +
intrinsically O +
relatively O +
reactive O +
platinum O +
drugs O +
to O +
tumours O +
in O +
vivo O -
. O +

To O +
date O -
, O +
including O +
JM335 O +
[ O -
18 O -
] O +
, O +
the O +
level O +
of O +
in O +
vivo O +
antitumour O +
activity O +
against O +
human O +
solid O +
tumours O +
has O +
not O +
matched O +
their O +
promising O +
in O +
vitro O +
and O +
cellular O +
pharmacological O +
properties O -
. O +

3 O +
ZD0473 O -
: O +
studies O +
with O +
a O +
sterically O +
hindered O +
platinum O +
drug O +
Many O +
previous O +
studies O +
of O +
platinum O +
drug O +
resistance O -
, O +
including O +
our O +
own O +
using O +
the O +
panel O +
of O +
human O +
ovarian O +
carcinoma O +
cell O +
lines O +
[ O -
22 O -
] O +
, O +
have O +
indicated O +
that O +
drug O +
inactivation O +
by O +
cytoplasmic O +
thiol O -
- O -
containing O +
species O -
, O +
principally O +
glutathione O +
( O -
GSH O -
) O +
and O +
metallothionein B-Gene +
( O -
MT B-Gene -
) O -
, O +
contributes O +
to O +
resistance O +
[ O -
9 O -
] O +
. O +

The O +
rational O +
design O +
of O +
a O +
platinum O +
drug O +
possessing O +
a O +
reduced O +
susceptibility O +
to O +
binding O +
to O +
thiols O +
would O +
offer O +
the O +
potential O +
to O +
lessen O +
the O +
impact O +
of O +
this O +
commonly O +
described O +
mechanism O +
of O +
resistance O -
. O +

This O +
was O +
achieved O +
in O +
ZD0473 O +
( O -
formerly O +
known O +
as O +
JM473 O +
and O +
AMD473 O -
) O +
by O +
increasing O +
the O +
steric O +
bulk O +
at O +
the O +
platinum O +
centre O +
using O +
the O +
2-methylpyridine O +
carrier O +
ligand O -
. O +

As O +
predicted O +
by O +
chemical O +
considerations O -
, O +
ZD0473 O +
was O +
shown O +
to O +
be O +
relatively O +
less O +
reactive O +
than O +
cisplatin O +
to O +
the O +
thiol O -
- O -
containing O +
molecules O -
, O +
methionine O +
and O +
GSH O +
[ O -
23,24 O -
] O +
. O +

The O +
drug O +
also O +
possesses O +
a O +
two O -
- O -
fold O +
slower O +
aquation O +
rate O +
in O +
water O +
than O +
that O +
of O +
cisplatin O +
[ O -
23 O -
] O +
. O +

ZD0473 O +
exhibited O +
a O +
promising O +
level O +
of O +
in O +
vitro O +
potency O +
against O +
the O +
41Mcis O +
R O -
, O +
CH1cis O +
R O +
and O +
A2780cis O +
R O +
acquired O +
cisplatin O -
- O -
resistant O +
cell O +
lines O +
[ O -
24 O -
] O +
. O +

At O +
the O +
level O +
of O +
DNA O +
binding O -
, O +
ZD0473 O +
was O +
shown O +
to O +
form O +
some O +
unique O +
adducts O +
when O +
compared O +
to O +
cisplatin O +
( O -
e.g. O -
, O +
novel O +
sites O +
on O +
naked O +
plasmid O +
DNA O -
) O +
and O +
displayed O +
a O +
much O +
slower O +
rate O +
of O +
formation O +
of O +
interstrand O +
crosslinks O +
[ O -
23,24 O -
] O +
. O +

ZD0473 O +
also O +
showed O +
in O +
vivo O +
antitumour O +
activity O +
by O +
both O +
the O +
intraperitoneal O +
and O +
oral O +
routes O -
, O +
including O +
against O +
some O +
models O +
of O +
acquired O +
cisplatin O +
resistance O +
[ O -
25,26 O -
] O +
. O +

In O +
rodents O -
, O +
ZD0473 O +
possesses O +
a O +
toxicity O +
profile O +
similar O +
to O +
carboplatin O +
with O +
myelosuppression O +
the O +
dose O -
- O -
limiting O +
toxicity O +
[ O -
25 O -
] O +
. O +

AMD473 O +
entered O +
clinical O +
trial O +
at O +
the O +
Royal O +
Marsden O +
NHS O +
Trust O +
Hospital O +
in O +
November O +
1997 O +
under O +
the O +
auspices O +
of O +
the O +
UK O +
Cancer O +
Research O +
Campaign O -
. O +

In O +
April O +
1998 O -
, O +
the O +
drug O +
was O +
licenced O +
from O +
AnorMED O +
to O +
Zeneca O +
as O +
ZD0473 O -
. O +

Using O +
an O +
intravenous O +
dosing O +
schedule O +
given O +
initially O +
every O +
3 O +
weeks O -
, O +
and O +
pharmacokinetically O +
guided O +
dose O +
escalation O +
from O +
12 O +
mg O -
/ O -
m2 O +
, O +
a O +
dose O -
- O -
limiting O +
toxicity O +
of O +
myelosuppression O +
( O -
thrombocytopenia O +
and O +
neutropenia O -
) O +
was O +
observed O +
at O +
the O +
130 O +
mg O -
/ O -
m2 O +
dose O -
- O -
level O -
. O +

In O +
addition O -
, O +
some O +
patients O +
at O +
this O +
dose O -
- O -
level O +
were O +
unable O +
to O +
receive O +
repeated O +
dosing O +
every O +
3 O +
weeks O -
. O +

Subsequent O +
investigations O +
of O +
lower O +
doses O -
, O +
110–120 O +
mg O -
/ O -
m2 O +
at O +
which O +
serious O +
toxicity O +
was O +
not O +
observed O -
, O +
suggested O +
that O +
non O -
- O -
heavily O +
pre O -
- O -
treated O +
patients O +
might O +
tolerate O +
higher O +
doses O +
and O +
patients O +
are O +
currently O +
being O +
treated O +
at O +
150 O +
mg O -
/ O -
m2 O +
. O +

There O +
has O +
been O +
no O +
nephro- O -
, O +
oto- O +
or O +
neuro O -
- O -
toxicity O +
noted O +
to O +
date O -
. O +

The O +
pharmacokinetics O +
of O +
total O +
and O +
free O +
platinum O +
were O +
linear O +
over O +
the O +
range O +
of O +
doses O +
used O +
with O +
free O +
platinum O +
decaying O +
in O +
a O +
tri O -
- O -
phasic O +
pattern O +
with O +
a O +
long O +
( O -
approx O -
. O +
72 O +
h O -
) O +
terminal O +
t O +
1 O -
/ O -
2γ O +
. O +

There O +
has O +
been O +
evidence O +
of O +
antitumour O +
activity O +
in O +
a O +
patient O +
with O +
ovarian O +
cancer O -
. O +

Additional O +
laboratory O -
- O -
based O +
studies O +
with O +
ZD0473 O +
have O +
focused O +
on O +
drug O +
metabolism O -
, O +
the O +
elucidation O +
of O +
mechanisms O +
of O +
resistance O +
to O +
ZD0473 O +
in O +
ovarian O +
cancer O +
cell O +
lines O +
and O +
effects O +
on O +
growth O +
inhibition O +
of O +
manipulating O +
intracellular O +
GSH O +
and O +
metallothionein B-Gene +
levels O +
in O +
tumour O +
cells O -
. O +

Compared O +
to O +
previous O +
metabolism O +
studies O +
performed O +
with O +
the O +
platinum O -
( O -
IV O -
) O +
dicarboxylate O +
oral O +
drug O -
, O +
JM216 O -
, O +
the O +
metabolism O +
of O +
ZD0473 O +
is O +
relatively O +
simple O +
with O +
the O +
major O +
products O +
being O +
the O +
aquated O +
cis O +
and O +
trans O +
species O -
. O +

The O +
drug O +
is O +
relatively O +
stable O +
and O +
even O +
with O +
incubation O +
of O +
ZD0473 O +
with O +
excess O +
glutathione O +
( O -
with O +
and O +
without O +
glutathione B-Gene -
- I-Gene -
S I-Gene +
-transferase I-Gene -
) O +
this O +
did O +
not O +
result O +
in O +
the O +
formation O +
of O +
any O +
glutathione O +
adducts O -
. O +

Similar O +
to O +
resistance O +
studies O +
performed O +
with O +
cisplatin O -
, O +
acquired O +
ZD0473-resistant O +
cell O +
lines O +
have O +
been O +
established O +
using O +
the O +
CH1 O +
and O +
A2780 O +
ovarian O +
lines O -
. O +

Both O +
the O +
CH1 O +
( O -
3.3-fold O -
- O -
resistant O -
) O +
and O +
A2780 O +
( O -
2.7-fold O -
- O -
resistant O -
) O +
ZD0473R O +
lines O +
showed O +
cross O -
- O -
resistance O +
to O +
cisplatin O +
and O +
carboplatin O -
. O +

Both O +
resistant O +
lines O +
showed O +
a O +
small O +
reduction O +
in O +
platinum O +
transport O +
following O +
exposure O +
to O +
ZD0473 O -
, O +
reflected O +
in O +
similar O +
decreases O +
in O +
DNA O +
platination O -
. O +

Interestingly O -
, O +
when O +
compared O +
to O +
their O +
parent O +
lines O -
, O +
both O +
resistant O +
lines O +
showed O +
an O +
elevation O +
in O +
GSH O +
levels O +
( O -
1.5-fold O +
in O +
A2780ZD0473R O +
and O +
2.7-fold O +
in O +
CH1ZD0473R O -
) O -
. O +

Hence O -
, O +
at O +
least O +
some O +
mechanisms O +
of O +
resistance O +
to O +
ZD0473 O +
are O +
shared O +
with O +
those O +
previously O +
described O +
in O +
many O +
lines O +
for O +
cisplatin O -
. O +

The O +
A2780ZD0473R O +
line O +
also O +
appears O +
to O +
possess O +
changes O +
in O +
proteins B-Gene +
associated O +
with O +
DNA O +
mismatch O +
repair O +
[ O -
27 O -
] O +
and O +
apoptosis O +
[ O -
28 O -
] O +
in O +
that O +
loss O +
of O +
hMLH1 O +
and O +
a O +
marked O +
increase O +
in O +
the O +
antiapoptotic O +
protein O +
BCL2 B-Gene +
in O +
comparison O +
to O +
A2780 O +
were O +
observed O -
. O +

In O +
contrast O -
, O +
in O +
a O +
series O +
of O +
acquired O +
cisplatin O -
- O -
resistant O +
ovarian O +
cell O -
- O -
line O +
pairs O -
, O +
there O +
was O +
no O +
consistent O +
pattern O +
of O +
BCL2 B-Gene +
expression O +
with O -
, O +
in O +
some O +
cases O -
, O +
levels O +
being O +
lower O +
in O +
resistant O +
versus O +
parent O +
lines O +
( O -
e.g. O -
, O +
41Mcis O +
R O -
/ O -
41 O -
M O -
) O -
, O +
whereas O +
levels O +
were O +
higher O +
in O +
CH1cis O +
R O +
versus O +
CH1 O -
. O +

Intriguing O +
effects O +
on O +
growth O +
inhibition O +
induced O +
by O +
ZD0473 O +
versus O +
cisplatin O +
have O +
been O +
obtained O +
by O +
manipulation O +
of O +
intracellular O +
thiol O +
levels O +
in O +
human O +
ovarian O +
cancer O +
cells O -
. O +

Fig. O +
3 O +
shows O +
the O +
effect O +
in O +
terms O +
of O +
fold O -
- O -
change O +
in O +
growth O +
inhibition O +
( O -
IC50 O +
) O +
of O +
( O -
a O -
) O +
increasing O +
GSH O +
levels O +
in O +
A2780 O +
cells O +
using O +
pre O -
- O -
exposure O +
to O +
GSH O -
- O -
ester O -
, O +
( O -
b O -
) O +
increasing O +
MT B-Gene +
levels O +
using O +
an O +
A2780 O +
subline O +
stably O +
transfected O +
with O +
MTIIA O +
cDNA O +
and O +
( O -
c O -
) O +
reducing O +
GSH O +
levels O +
by O +
approximately O +
80 O -
% O +
using O +
pre O -
- O -
exposure O +
of O +
SKOV-3 O +
cells O +
( O -
which O +
have O +
relatively O +
high O +
intrinsic O +
levels O -
) O +
to O +
buthionine O +
sulfoxamine O +
( O -
BSO O -
) O -
. O +

As O +
predicted O +
by O +
the O +
reduced O +
susceptibility O +
of O +
ZD0473 O +
to O +
bind O +
to O +
thiols O +
when O +
compared O +
to O +
cisplatin O -
, O +
increasing O +
either O +
GSH O +
or O +
MT B-Gene +
levels O +
reduced O +
the O +
growth O +
inhibitory O +
properties O +
of O +
cisplatin O +
to O +
a O +
greater O +
extent O +
than O +
for O +
ZD0473 O +
( O -
e.g. O -
, O +
with O +
increasing O +
MT B-Gene +
levels O -
; O +
7-fold O +
loss O +
in O +
potency O +
of O +
cisplatin O +
but O +
only O +
1.3-fold O +
loss O +
with O +
ZD0473 O -
) O -
. O +

In O +
contrast O -
, O +
and O +
surprisingly O -
, O +
the O +
reduction O +
of O +
GSH O +
levels O +
using O +
BSO O +
in O +
SKOV-3 O +
cells O +
resulted O +
in O +
a O +
greater O +
potentiation O +
with O +
ZD0473 O +
( O -
2.5-fold O -
) O +
than O +
with O +
cisplatin O +
( O -
1.5-fold O -
) O -
. O +

Although O +
BSO O +
may O +
exert O +
additional O +
effects O +
on O +
cells O +
such O +
as O +
affecting O +
drug O +
transport O -
, O +
metabolism O +
or O +
DNA O +
repair O +
[ O -
29 O -
] O +
these O +
data O +
indicate O +
that O +
further O +
studies O +
are O +
required O +
to O +
fully O +
elucidate O +
the O +
interactions O +
between O +
ZD0473 O +
and O +
sulphur O -
- O -
containing O +
molecules O +
in O +
tumour O +
cells O -
. O +

4 O +
Conclusions O +
Over O +
a O +
period O +
of O +
almost O +
20 O +
years O -
, O +
the O +
Institute O +
of O +
Cancer O +
Research O -
/ O -
Johnson O +
Matthey O -
/ O -
AnorMED O +
collaboration O +
has O +
resulted O +
in O +
three O +
platinum O +
complexes O +
entering O +
clinical O +
trial O -
: O +
carboplatin O +
is O +
registered O +
worldwide O -
, O +
the O +
oral O +
platinum O +
JM216 O +
is O +
undergoing O +
phase O +
II O -
/ O -
III O +
trials O +
and O +
ZD0473 O +
is O +
currently O +
in O +
phase O +
I O +
studies O -
. O +

The O +
trans O +
platinum O +
complex O +
JM335 O +
represents O +
one O +
of O +
a O +
small O +
series O +
of O +
trans O +
complexes O +
which O +
exhibits O +
promising O +
in O +
vitro O +
antitumour O +
properties O -
, O +
especially O +
against O +
acquired O +
cisplatin O -
- O -
resistant O +
cells O -
. O +

Acknowledgements O +
Laboratory O +
studies O +
at O +
the O +
CRC O +
Centre O +
for O +
Cancer O +
Therapeutics O -
, O +
formerly O +
the O +
Drug O +
Development O +
Section O -
, O +
of O +
the O +
Institute O +
of O +
Cancer O +
Research O +
were O +
supported O +
predominantly O +
by O +
grants O +
from O +
the O +
UK O +
Cancer O +
Research O +
Campaign O -
. O +

All O +
studies O +
were O +
conducted O +
in O +
collaboration O +
with O +
chemists O +
at O +
Johnson O +
Matthey O -
, O +
and O +
in O +
recent O +
years O -
, O +
AnorMED O -
. O +

Thanks O +
are O +
due O +
to O +
numerous O +
post O -
- O -
doctoral O +
scientists O -
, O +
scientific O +
officers O -
, O +
Ph.D. O +
students O -
, O +
clinical O +
fellows O +
and O +
research O +
nurses O +
who O +
have O +
contributed O +
over O +
the O +
20-plus O +
years O -
. O +

Special O +
recognition O +
is O +
reserved O +
for O +
Professor O +
Ken O +
Harrap O -
, O +
without O +
whose O +
leadership O +
little O +
of O +
this O +
research O +
would O +
have O +
occurred O -
. O +

Conformational O +
analysis O +
of O +
disaccharides O +
is O +
usually O +
accompanied O +
by O +
the O +
generation O +
of O +
a O +
Ramachandran O -
- O -
like O +
conformational O +
map O +
as O +
a O +
tool O +
in O +
understanding O +
oligosaccharide O +
conformational O +
structures O +
[ O -
1–3 O -
] O +
. O +

In O +
these O +
maps O +
the O +
energy O +
is O +
determined O +
for O +
all O +
mutual O +
orientations O +
of O +
the O +
two O +
monosaccharide O +
residues O -
, O +
expressed O +
by O +
the O +
glycosidic O +
angles O +
φ O +
and O +
ψ O +
. O +

First O +
studies O +
were O +
carried O +
out O +
by O +
rigid O +
residue O +
analysis O +
[ O -
3 O -
] O +
. O +

However O -
, O +
by O +
allowing O +
all O +
variables O +
to O +
relax O -
, O +
Melberg O +
and O +
Rasmussen O +
[ O -
4–6 O -
] O +
initiated O +
flexible O +
residue O +
analysis O +
by O +
1979 O -
. O +

These O +
studies O +
were O +
extended O +
in O +
the O +
late O +
1980s O +
[ O -
7–12 O -
] O +
, O +
giving O +
rise O +
to O +
the O +
first O +
fully O +
relaxed O +
energy O +
maps O +
of O +
many O +
disaccharides O -
. O +

When O +
generating O +
these O +
Ramachandran O +
maps O -
, O +
it O +
should O +
be O +
borne O +
in O +
mind O +
that O +
the O +
actual O +
conformational O +
hypersurface O +
of O +
a O +
disaccharide O +
carries O -
, O +
for O +
each O +
φ O +
, O +
ψ O +
combination O -
, O +
the O +
influence O +
of O +
the O +
orientations O +
of O +
secondary O +
hydroxyl O +
groups O -
, O +
hydroxymethyl O +
groups O +
and O +
the O +
primary O +
hydroxyl O +
groups O -
, O +
all O +
of O +
which O +
may O +
affect O +
the O +
calculated O +
final O +
energy O +
by O +
several O +
kilocalories O +
( O -
the O +
' O -
multiple O +
minimum O +
problem O -
' O +
[ O -
1–3 O -
] O +
) O -
. O +

For O +
a O +
disaccharide O +
formed O +
by O +
two O +
hexopyranose O +
residues O +
and O +
considering O +
the O +
three O +
staggered O +
positions O +
for O +
the O +
ten O +
exocyclic O +
groups O -
, O +
59,049 O +
( O -
310 O +
) O +
different O +
starting O +
points O +
are O +
possible O +
for O +
the O +
construction O +
of O +
the O +
map O +
[ O -
3,13,14 O -
] O +
. O +

Thus O -
, O +
different O +
starting O +
points O +
will O +
yield O +
different O +
minima O +
after O +
geometry O +
optimization O -
. O +

An O +
' O -
adiabatic O -
' O +
map O +
is O +
generated O +
by O +
plotting O +
the O +
lower O -
- O -
energy O +
values O +
found O +
at O +
each O +
grid O +
point O +
[ O -
15 O -
] O +
. O +

The O +
outcome O +
is O +
that O -
, O +
at O +
least O +
theoretically O -
, O +
the O +
true O +
adiabatic O +
map O +
for O +
a O +
disaccharide O +
can O +
only O +
be O +
obtained O +
after O +
calculating O +
59,049 O +
relaxed O +
maps O +
and O +
determining O -
, O +
for O +
each O +
φ O +
/ψ O +
combination O -
, O +
the O +
one O +
with O +
the O +
lowest O +
energy O -
. O +

Even O +
with O +
present O +
resources O -
, O +
and O +
using O +
a O +
fast O +
molecular O +
mechanics O +
method O -
, O +
this O +
task O +
is O +
very O +
difficult O +
( O -
one O +
adiabatic O +
map O +
in O +
a O +
20 O -
× O -
20 O -
° O +
grid O +
would O +
take O +
more O +
than O +
three O +
years O +
in O +
a O +
single O +
CPU O +
for O +
minimizations O +
taking O +
an O +
average O +
of O +
5 O +
s O +
each O -
) O -
. O +

This O +
problem O +
has O +
been O +
extensively O +
recognized O +
since O +
the O +
early O +
flexible O +
residue O +
analyses O +
[ O -
4–6,10–15 O -
] O +
. O +

However O -
, O +
it O +
was O +
found O +
that O +
the O +
hydroxymethyl O +
groups O +
in O +
monosaccharides O +
show O +
a O +
marked O +
trend O +
to O +
stay O +
at O +
preferential O +
positions O +
( O -
usually O +
gg O +
and O +
gt O +
) O +
[ O -
11,14 O -
] O +
. O +

Furthermore O -
, O +
it O +
was O +
determined O +
that O +
the O +
secondary O +
hydroxyl O +
groups O +
are O +
likely O +
to O +
form O +
a O +
' O -
crown O -
' O +
of O +
cooperative O +
hydrogen O +
bonds O -
, O +
oriented O +
either O +
clockwise O +
( O -
c O -
) O +
or O +
reverse O +
clockwise O +
( O -
r O -
) O +
around O +
the O +
pyranose O +
ring O +
[ O -
9 O -
] O +
. O +

In O +
this O +
way O -
, O +
each O +
monosaccharidic O +
unit O +
was O +
considered O +
[ O -
15,16 O -
] O +
only O +
in O +
the O +
gt O +
r O -
, O +
gt O +
c O -
, O +
gg O +
c O +
and O +
gg O +
r O +
conformations O -
, O +
thus O +
leading O +
to O +
only O +
16 O +
starting O +
points O +
for O +
the O +
disaccharide O -
. O +

This O +
approach O +
has O +
been O +
extensively O +
used O -
, O +
among O +
others O -
, O +
by O +
Dowd O +
et O +
al. O +
[ O -
16–19 O -
] O +
, O +
who O +
studied O +
different O +
disaccharides O +
using O +
MM3 O -
. O +

Sometimes O +
the O +
starting O +
conformers O +
were O +
not O +
just O +
16 O -
, O +
but O +
24 O +
when O +
a O +
different O +
arrangement O +
of O +
hydroxyl O +
groups O +
was O +
added O +
[ O -
17,18 O -
] O +
, O +
36 O +
when O +
the O +
hydroxymethyl O +
groups O +
were O +
considered O +
at O +
the O +
three O +
available O +
positions O +
[ O -
20,21 O -
] O +
or O +
some O +
other O +
figures O +
[ O -
22 O -
] O +
. O +

The O +
same O +
approach O +
was O +
even O +
adopted O +
to O +
emulate O +
aqueous O +
solutions O +
[ O -
23,24 O -
] O +
, O +
where O +
such O +
circuits O +
of O +
hydrogen O +
bonds O +
might O +
not O +
form O +
at O +
all O -
. O +

The O +
multiple O +
minimum O +
problem O +
was O +
also O +
tackled O +
with O +
less O +
systematic O +
procedures O -
, O +
such O +
as O +
iterative O +
manual O +
searches O +
[ O -
11,15,25–27 O -
] O +
. O +

Tvaroška O +
and O +
co O -
- O -
workers O +
tried O +
to O +
overcome O +
this O +
problem O +
with O +
the O +
program O +
ramm O +
, O +
which O +
finds O +
the O +
energetically O +
most O +
favorable O +
combinations O +
of O +
the O +
pendant O +
group O +
orientations O +
for O +
each O +
φ O +
, O -
ψ O +
pair O -
, O +
using O +
a O +
random O +
sampling O +
technique O +
[ O -
13,22,28 O -
] O +
. O +

Another O +
way O +
to O +
elude O +
the O +
multiple O +
minimum O +
problem O +
is O +
to O +
explore O +
the O +
conformational O +
space O +
of O +
disaccharides O +
by O +
molecular O +
dynamics O +
( O -
MD O -
) O +
simulations O +
[ O -
22,29,30 O -
] O +
, O +
an O +
expanding O +
methodology O -
. O +

These O +
simulations O +
were O +
also O +
combined O +
with O +
Monte O +
Carlo O +
techniques O +
in O +
order O +
to O +
increase O +
their O +
efficiency O +
to O +
cross O +
energy O +
barriers O +
[ O -
31,32 O -
] O +
. O +

French O +
and O +
co O -
- O -
workers O +
[ O -
14,16 O -
] O +
have O +
pointed O +
out O +
the O +
problems O +
arising O +
from O +
minimization O +
with O +
the O +
mm2 O +
' O -
standard O +
driver O -
' O -
, O +
for O +
which O +
the O +
inelastic O +
deformations O +
are O +
transmitted O +
to O +
the O +
next O +
structure O -
, O +
and O +
thus O +
suggested O +
the O +
use O +
of O +
a O +
driver O +
in O +
which O +
each O +
point O +
of O +
each O +
relaxed O +
surface O +
is O +
generated O +
directly O +
from O +
the O +
same O +
starting O +
point O -
, O +
in O +
order O +
to O +
avoid O +
these O +
propagations O +
of O +
deformations O -
. O +

Herein O +
is O +
presented O +
the O +
mapping O +
of O +
the O +
disaccharide O +
α O -
- O -
d O +
-Galp O +
- O -
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Galp O +
( O -
1 O +
) O +
[ O -
25–27 O -
] O +
using O +
MM3 O +
[ O -
33 O -
] O +
at O +
either O +
ε O +
=3 O +
or O +
ε O +
= O -
80 O -
. O +

The O +
influence O +
of O +
using O +
either O +
driver O +
systematically O -
, O +
and O +
of O +
an O +
iterative O +
manual O +
searching O +
procedure O -
, O +
on O +
the O +
adiabaticity O +
of O +
the O +
final O +
maps O +
is O +
discussed O -
. O +

2 O +
2 O -
. O +

Methods O +
Calculations O +
were O +
carried O +
out O +
on O +
a O +
Sun O +
SparcStation O +
10 O +
computer O -
, O +
using O +
the O +
molecular O +
mechanics O +
program O +
MM3 O +
( O -
92 O -
) O +
( O -
QCPE O -
, O +
Indiana O +
University O -
, O +
USA O -
) O -
, O +
developed O +
by O +
Allinger O +
and O +
co O -
- O -
workers O +
[ O -
33 O -
] O +
. O +

The O +
MM3 O +
routines O +
were O +
modified O +
as O +
suggested O +
[ O -
34 O -
] O +
by O +
changing O +
the O +
maximum O +
atomic O +
movement O +
from O +
0.25 O +
to O +
0.10 O +
Å. O +
Minimization O +
( O -
by O +
the O +
block O +
diagonal O +
Newton O -
– O -
Raphson O +
procedure O +
for O +
grid O +
points O -
, O +
using O +
the O +
full O -
- O -
matrix O +
procedure O +
for O +
the O +
minima O -
) O +
was O +
terminated O +
when O +
the O +
average O +
movement O +
converged O +
to O +
a O +
value O +
lower O +
than O +
10−4 O +
Å. O +

The O +
dihedrals O +
φ O +
and O +
ψ O +
( O -
also O +
called O +
φ O +
H O +
and O +
ψ O +
H O +
) O +
are O +
defined O +
by O +
atoms O +
H-1′C-1′O-3C-3 O +
and O +
H-3C-3O-3C-1′ O -
, O +
respectively O -
, O +
with O +
the O +
usual O +
sign O +
conventions O +
[ O -
27 O -
] O +
. O +

NOE O +
theoretical O +
calculations O +
and O +
average O +
linkage O +
rotations O +
were O +
calculated O +
as O +
reported O +
elsewhere O +
[ O -
25,27 O -
] O +
. O +

Sixteen O +
starting O +
conformers O +
of O +
the O +
disaccharide O +
were O +
generated O +
by O +
minimization O +
of O +
structures O +
with O +
the O +
adequate O +
geometry O -
: O +
their O +
glycosidic O +
torsional O +
angles O +
were O +
around O +
φ O +
, O +
ψ O +
−40 O -
° O -
,−40 O -
° O +
( O -
minimum O +
B O +
) O +
[ O -
27 O -
] O +
, O +
their O +
monosaccharide O +
constituents O +
were O +
4 O +
C O +
1 O +
ring O +
conformers O +
with O +
either O +
gt O +
( O -
θO-5C-5C-6O-6 O +
≈60 O -
° O -
) O +
or O +
gg O +
( O -
θO-5C-5C-6O-6 O +
≈−60 O -
° O -
) O +
orientation O +
of O +
the O +
hydroxymethyl O +
groups O -
. O +

As O +
suggested O +
[ O -
9 O -
] O +
, O +
clockwise O +
( O -
c O -
) O +
or O +
reverse O +
clockwise O +
( O -
r O -
) O +
orientations O +
were O +
chosen O +
for O +
the O +
secondary O +
hydroxyl O +
groups O -
. O +

The O +
primary O +
hydroxyl O +
groups O +
were O +
also O +
settled O +
in O +
a O +
position O +
that O +
may O +
give O +
hydrogen O -
- O -
bonding O +
possibilities O +
( O -
Table O +
1 O +
) O -
. O +

As O +
the O +
conformation O +
of O +
each O +
ring O +
is O -
, O +
a O +
priori O +
independent O +
from O +
that O +
of O +
the O +
other O -
, O +
four O +
orientations O +
of O +
hydroxyl O +
groups O +
and O +
four O +
of O +
hydroxymethyl O +
groups O +
are O +
possible O -
, O +
thus O +
leading O +
to O +
the O +
16 O +
starting O +
conformations O -
. O +

Each O +
starting O +
conformer O +
led O +
to O +
a O +
different O +
φ O +
/ψ O +
relaxed O +
map O -
. O +

Using O +
both O +
dihedral O +
drivers O +
( O -
see O +
below O -
) O -
, O +
φ O +
and O +
ψ O +
were O +
fully O +
varied O +
( O -
through O +
the O +
whole O +
−180 O +
to O +
180 O -
° O +
grid O -
) O +
using O +
a O +
20 O -
° O +
grid O +
step O -
. O +

At O +
each O +
point O -
, O +
energies O +
were O +
calculated O +
after O +
minimization O +
with O +
restraints O +
for O +
these O +
two O +
angles O +
but O +
allowing O +
the O +
other O +
variables O +
to O +
relax O -
. O +

Both O +
ε O +
=3 O +
and O +
ε O +
= O -
80 O +
were O +
applied O -
, O +
using O +
either O +
MM3 O +
Driver O +
2 O -
, O +
which O +
at O +
each O +
point O +
takes O +
the O +
previously O +
calculated O +
grid O +
point O +
as O +
the O +
starting O +
point O +
for O +
calculations O -
, O +
or O +
MM3 O +
Driver O +
4 O -
, O +
which O +
always O +
uses O +
the O +
same O +
starting O +
conformer O +
to O +
calculate O +
all O +
grid O +
points O +
directly O +
( O -
Fig. O +
1 O +
) O -
. O +
' O +

Adiabatic O -
' O +
maps O +
[ O -
15 O -
] O +
were O +
constructed O +
in O +
each O +
case O +
using O -
, O +
for O +
each O +
grid O +
point O -
, O +
the O +
lowest O -
- O -
energy O +
value O +
for O +
each O +
set O +
of O +
16 O +
relaxed O +
maps O -
. O +

The O +
contribution O +
of O +
each O +
relaxed O +
map O +
to O +
the O +
' O -
adiabatic O -
' O +
map O +
was O +
evaluated O +
from O +
their O +
probability O +
distributions O +
assuming O +
no O +
entropy O +
differences O -
: O -
Pi O +
= O -
∑φψ O +
exp O +
−Eφψ O +
/RT O +
∑i O +
∑φψ O +
exp O +
−Eφψ O +
/RT O +
In O +
a O +
different O +
procedure O -
, O +
another O +
' O -
adiabatic O -
' O +
map O +
was O +
generated O +
following O +
an O +
iterative O +
procedure O +
reported O +
elsewhere O +
[ O -
15,25–27 O -
] O +
. O +

Briefly O -
, O +
some O +
different O +
starting O +
geometries O +
were O +
chosen O -
, O +
using O +
the O +
lower O -
- O -
energy O +
conformations O +
for O +
α- O +
and O +
β O -
- O -
d O +
-galactose O +
[ O -
35 O -
] O +
and O +
checking O +
the O +
effects O +
of O +
rotations O +
of O +
alternate O +
pairs O +
of O +
hydroxymethyl O +
and O +
hydroxyl O +
groups O -
. O +

To O +
identify O +
the O +
lowest O +
energy O +
on O +
each O +
φ O +
, O +
ψ O +
grid O +
point O -
, O +
many O +
starting O +
conformations O +
were O +
minimized O -
. O +

The O +
generated O +
points O +
served O +
as O +
starting O +
points O +
for O +
the O +
next O +
ones O -
, O +
radially O +
from O +
each O +
starting O +
point O -
, O +
in O +
an O +
iterative O +
manner O -
. O +

As O +
it O +
was O +
pointed O +
out O +
[ O -
15 O -
] O +
, O +
the O +
amount O +
of O +
additional O +
searching O +
done O +
for O +
each O +
point O +
was O +
arbitrary O -
, O +
and O +
therefore O +
can O -
not O +
be O +
automated O -
. O +

3 O +
3 O -
. O +

Results O +
and O +
discussion O +
The O +
MM3-generated O +
conformational O +
maps O +
of O +
the O +
disaccharide O +
α O -
- O -
d O +
-Galp- O +
( O -
1→3 O -
) O -
-β O -
- O -
d O +
-Galp O +
( O -
1 O +
) O +
at O +
a O +
dielectric O +
constant O +
3.0 O +
were O +
obtained O +
both O +
using O +
the O +
MM3 O +
dihedral O +
drivers O +
2 O +
and O +
4 O +
( O -
Fig. O +
1 O +
) O -
, O +
starting O +
from O +
16 O +
different O +
initial O +
conformers O -
. O +

The O +
maps O +
with O +
the O +
lowest O -
- O -
energy O +
values O +
for O +
each O +
grid O +
point O +
are O +
shown O +
in O +
Fig. O +
2 O +
( O -
a O -
) O +
for O +
dihedral O +
driver O +
2 O +
and O +
Fig. O +
2 O +
( O -
b O -
) O +
for O +
dihedral O +
driver O +
4 O -
. O +

Fig. O +
2 O +
( O -
c O -
) O +
shows O +
the O +
map O +
obtained O +
with O +
an O +
iterative O +
method O +
( O -
see O +
Section O +
2 O +
) O -
. O +

With O +
those O +
three O +
' O -
adiabatic O -
' O +
maps O -
, O +
a O +
more O +
representative O +
' O -
true O -
' O +
adiabatic O +
map O +
was O +
constructed O +
( O -
Fig. O +
2 O +
( O -
d O -
) O -
) O -
, O +
in O +
which O +
each O +
grid O +
point O +
takes O +
the O +
lower O +
value O -
. O +

Fig. O +
3 O +
displays O +
the O +
energy O +
differences O +
between O +
the O +
' O -
adiabatic O -
' O +
map O +
obtained O +
by O +
each O +
method O +
and O +
the O +
' O -
true O -
' O +
adiabatic O +
map O -
. O +

As O +
shown O -
, O +
none O +
of O +
the O +
three O +
methods O +
produced O +
the O +
lower O -
- O -
energy O +
points O +
for O +
the O +
whole O +
grid O -
, O +
as O +
it O +
was O +
already O +
suggested O +
[ O -
3 O -
] O +
. O +

The O +
work O +
performed O +
with O +
Driver O +
4 O +
yielded O +
lower O -
- O -
energy O +
values O +
than O +
that O +
carried O +
out O +
with O +
Driver O +
2 O -
. O +

The O +
latter O +
gave O +
rise O +
to O +
many O +
high O -
- O -
energy O +
values O +
( O -
some O +
more O +
than O +
3 O +
kcal O +
mol−1 O +
above O +
those O +
obtained O +
by O +
other O +
methods O -
) O -
, O +
especially O +
for O +
the O +
strip O +
with O +
ψ O +
= O -
−60 O -
° O -
, O +
close O +
to O +
the O +
termination O +
of O +
the O +
cycle O -
, O +
where O +
inelastic O +
deformations O +
[ O -
14 O -
] O +
led O +
to O +
high O -
- O -
energy O +
values O +
for O +
the O +
16 O +
starting O +
conformers O -
. O +

Table O +
2 O +
indicates O +
the O +
contributions O +
of O +
each O +
of O +
the O +
three O +
methods O +
to O +
the O +
' O -
true O -
' O +
adiabatic O +
map O -
. O +

As O +
shown O -
, O +
using O +
Driver O +
2 O -
, O +
more O +
than O +
half O +
of O +
the O +
grid O +
points O +
have O +
energies O +
with O +
an O +
average O +
of O +
2.1 O +
kcal O +
mol−1 O +
above O +
their O +
minimum O +
values O -
. O +

Most O +
of O +
the O +
16 O +
starting O +
conformations O +
yielded O +
points O +
that O +
were O +
used O +
to O +
construct O +
the O +
maps O -
, O +
but O +
more O +
than O +
two O -
- O -
thirds O +
of O +
their O +
population O +
arises O +
from O +
conformers O +
with O +
the O +
β O -
- O -
d O +
-galactose O +
unit O +
in O +
gt O +
orientation O -
. O +

Also O -
, O +
starting O +
conformers O +
with O +
alternate O +
configurations O +
of O +
secondary O +
hydroxyl O +
groups O +
( O -
rc O +
and O +
cr O -
) O +
double O +
the O +
population O +
of O +
those O +
with O +
the O +
same O +
configuration O +
( O -
cc O +
and O +
rr O -
) O -
. O +

The O +
actual O +
minimum O -
- O -
energy O +
starting O +
point O +
corresponds O +
to O +
a O +
gggt O +
cr O +
orientation O -
. O +

Table O +
3 O +
shows O +
the O +
values O +
of O +
its O +
exocyclic O +
angles O -
. O +

The O +
same O +
procedures O +
were O +
repeated O +
with O +
ε O +
= O -
80 O -
. O +

Fig. O +
4 O +
shows O +
the O +
three O +
resulting O +
maps O -
, O +
Fig. O +
5 O +
shows O +
the O +
energy O +
differences O +
of O +
each O +
map O +
from O +
the O +
' O -
true O -
' O +
adiabatic O +
map O +
( O -
Fig. O +
4 O +
( O -
c O -
) O -
) O -
, O +
and O +
Table O +
4 O +
indicates O +
their O +
contributions O +
to O +
this O +
true O +
adiabatic O +
map O -
. O +

In O +
this O +
instance O -
, O +
the O +
iterative O +
search O +
procedure O +
by O +
itself O +
yielded O +
the O +
true O +
adiabatic O +
map O +
( O -
Figs. O +
4 O -
( O -
c O -
) O +
and O +
5 O +
, O +
Table O +
4 O +
) O -
. O +

Drivers O +
2 O +
and O +
4 O +
gave O +
rise O +
to O +
a O +
map O +
with O +
energies O +
averaging O +
0.6 O +
and O +
0.9 O +
kcal O +
mol−1 O +
above O +
the O +
adiabatic O +
map O -
, O +
respectively O -
. O +

Even O +
considering O +
points O +
with O +
0.5 O +
kcal O +
mol−1 O +
difference O -
, O +
Driver O +
4 O +
failed O +
to O +
find O +
true O +
minima O +
on O +
81 O -
% O +
of O +
the O +
grid O -
. O +

As O +
expected O -
, O +
the O +
deficiency O +
of O +
the O +
systematic O +
methods O +
at O +
this O +
dielectric O +
constant O +
arises O +
from O +
the O +
fact O +
that O +
none O +
of O +
the O +
initial O +
16 O +
starting O +
conformers O +
has O +
the O +
lower O -
- O -
energy O +
conformation O +
of O +
the O +
exocyclic O +
groups O -
. O +

This O +
is O +
obvious O +
when O +
using O +
a O +
method O +
where O +
the O +
electrostatic O +
contributions O +
were O +
intentionally O +
damped O +
[ O -
2,22,25 O -
] O +
by O +
using O +
a O +
dielectric O +
constant O +
of O +
80 O -
, O +
for O +
which O +
hydrogen O +
bonding O +
has O +
almost O +
no O +
effect O -
, O +
and O +
thus O +
the O +
r O +
and O +
c O +
circuits O +
are O +
meaningless O -
. O +

The O +
geometry O +
of O +
the O +
actual O +
global O +
minimum O +
( O -
found O +
by O +
the O +
iterative O +
search O +
procedure O -
) O +
is O +
shown O +
in O +
Table O +
3 O +
. O +

In O +
this O +
conformer O -
, O +
both O +
monosaccharide O +
units O +
had O +
hydroxymethyl O +
groups O +
in O +
gt O +
orientation O -
, O +
the O +
unit O +
of O +
β O -
- O -
galactose O +
had O +
their O +
secondary O +
hydroxyl O +
groups O +
in O +
an O +
r O +
arrangement O -
, O +
but O +
the O +
α O -
- O -
galactose O +
unit O +
has O +
no O +
recognizable O +
pattern O +
( O -
Table O +
3 O +
) O -
. O +

Contrasting O +
the O +
maps O +
generated O +
at O +
a O +
low O +
dielectric O +
constant O -
, O +
here O +
the O +
lower O -
- O -
energy O +
points O +
( O -
within O +
a O +
15 O +
kcal O +
mol−1 O +
low O -
- O -
energy O +
window O -
) O +
arise O +
from O +
a O +
few O +
starting O +
conformers O -
. O +

More O +
than O +
80 O -
% O +
of O +
the O +
population O +
of O +
the O +
Driver O +
4 O +
map O +
arises O +
from O +
starting O +
conformers O +
in O +
which O +
both O +
hydroxymethyl O +
groups O +
carry O +
gt O +
orientation O +
( O -
mainly O +
gtgt O +
rr O -
) O -
, O +
while O +
less O +
than O +
1 O -
% O +
arises O +
from O +
both O +
monosaccharidic O +
units O +
with O +
gg O +
orientation O -
. O +

No O +
major O +
effect O +
of O +
the O +
secondary O +
hydroxyl O +
group O +
arrangements O +
was O +
found O -
, O +
although O +
those O +
starting O +
with O +
r O +
orientation O +
yielded O +
a O +
higher O +
population O +
on O +
the O +
adiabatic O +
map O +
than O +
those O +
with O +
c O +
orientation O -
. O +

According O +
to O +
literature O +
[ O -
23,35 O -
] O +
, O +
the O +
hydroxymethyl O +
groups O +
of O +
galactose O +
are O +
oriented O +
gt O +
or O +
tg O +
rather O +
than O +
gg O +
. O +

However O -
, O +
in O +
this O +
calculation O +
gt O +
and O +
gg O +
orientations O +
were O +
used O -
, O +
because O +
it O +
was O +
found O +
that O +
tg O +
orientation O +
gives O +
abnormally O +
high O +
energy O +
values O +
in O +
molecular O +
mechanics O +
calculations O +
[ O -
35 O -
] O +
. O +

Table O +
5 O +
shows O +
the O +
average O +
NOE O +
and O +
linkage O +
rotations O +
predicted O +
from O +
the O +
adiabatic O +
maps O +
at O +
both O +
dielectric O +
constants O -
. O +

Their O +
comparison O +
with O +
experimental O +
values O +
indicates O +
a O +
better O +
agreement O +
with O +
the O +
calculations O +
carried O +
out O +
at O +
ε O +
= O -
80 O -
. O +

The O +
need O +
for O +
reliable O +
methods O +
for O +
generating O +
disaccharide O +
' O -
adiabatic O -
' O +
maps O +
was O +
recognized O +
at O +
an O +
earlier O +
time O +
[ O -
1 O -
] O +
and O +
discussed O +
extensively O +
[ O -
3,11,13–15 O -
] O +
. O +

French O +
and O +
co O -
- O -
workers O +
have O +
suggested O +
the O +
use O +
of O +
the O +
so O -
- O -
called O +
' O -
new O +
driver O -
' O +
[ O -
14,16 O -
] O +
( O -
later O +
brought O +
into O +
MM3 O +
as O +
Driver O +
4 O -
) O +
in O +
the O +
hope O +
of O +
arriving O +
at O +
better O +
results O -
, O +
together O +
with O +
a O +
combination O +
of O +
low O -
- O -
energy O +
starting O +
points O +
based O +
on O +
their O +
hydrogen O -
- O -
bonding O +
abilities O +
[ O -
9 O -
] O +
. O +

The O +
same O +
group O +
has O +
successfully O +
applied O +
the O +
method O +
to O +
the O +
MM3 O +
analysis O +
of O +
many O +
disaccharides O +
[ O -
16–19 O -
] O +
at O +
dielectric O +
constants O +
close O +
to O +
four O -
. O +

In O +
more O +
recent O +
papers O +
[ O -
23,24,37 O -
] O +
, O +
the O +
method O +
was O +
extended O +
to O +
simulations O +
of O +
water O +
behavior O +
by O +
using O +
a O +
dielectric O +
constant O +
close O +
to O +
80 O -
. O +

For O +
ionic O +
solutions O +
this O +
value O +
is O +
higher O +
than O +
that O +
of O +
the O +
water O +
in O +
the O +
first O +
solvation O +
shell O -
, O +
where O +
it O +
can O +
reach O +
values O +
as O +
low O +
[ O -
38 O -
] O +
as O +
six O -
. O +

The O +
effect O +
of O +
using O +
a O +
constant O +
close O +
to O +
80 O +
is O +
equivalent O +
to O +
neglecting O +
electrostatic O +
and O +
hydrogen O -
- O -
bonding O +
interactions O +
[ O -
22,25 O -
] O +
. O +

However O -
, O +
it O +
has O +
been O +
used O +
in O +
order O +
to O +
obtain O +
better O +
agreement O +
with O +
experimental O +
values O +
in O +
aqueous O +
solutions O +
[ O -
39 O -
] O +
, O +
as O +
in O +
this O +
work O +
( O -
Table O +
5 O +
) O -
. O +

This O +
paper O +
shows O +
that O -
, O +
at O +
least O +
with O +
the O +
disaccharide O +
under O +
study O -
, O +
high O -
- O -
dielectric O -
- O -
constant O +
MM3 O +
calculations O +
with O +
Driver O +
4 O +
exhibit O +
large O +
failures O +
to O +
produce O +
an O +
adiabatic O +
map O -
. O +

Furthermore O -
, O +
Driver O +
2 O +
gives O +
rise O +
to O +
a O +
far O +
better O +
map O -
, O +
which O +
can O +
even O +
be O +
improved O +
if O +
this O +
option O +
is O +
also O +
used O +
backwards O +
( O -
i.e. O +
from O +
ψ O +
= O -
−40 O -
° O +
to O +
lower O +
values O -
) O -
. O +

In O +
this O +
way O -
, O +
the O +
large O +
errors O +
appearing O +
in O +
the O +
regions O +
with O +
ψ O +
= O -
−60 O +
to O +
−140 O -
° O +
( O -
Fig. O +
5 O +
) O -
, O +
where O +
the O +
inelastic O +
deformations O +
appearing O +
in O +
the O +
long O +
way O +
that O +
leads O +
to O +
them O -
, O +
generating O +
high O +
energy O +
values O -
, O +
are O +
avoided O -
. O +

Actually O -
, O +
the O +
' O -
true O -
' O +
adiabatic O +
map O +
was O +
obtained O +
in O +
the O +
present O +
work O +
by O +
a O +
non O -
- O -
systematic O -
, O +
iterative O +
procedure O +
that O +
has O +
encountered O +
a O +
better O +
approach O +
to O +
the O +
true O +
surface O -
. O +

As O +
it O +
has O +
been O +
pointed O +
out O -
, O +
without O +
a O +
full O +
conformational O +
search O +
of O +
the O +
59,049 O +
starting O +
conformers O -
, O +
no O +
true O +
adiabatic O +
map O +
can O +
be O +
produced O +
[ O -
3,10,14,15 O -
] O +
. O +

However O -
, O +
it O +
is O +
possible O +
to O +
reach O +
near O +
adiabaticity O -
, O +
by O +
a O +
combination O +
of O +
the O +
three O +
methods O +
shown O +
previously O -
. O +

Certainly O -
, O +
it O +
is O +
impossible O +
to O +
automate O +
the O +
iterative O +
method O -
, O +
which O +
means O +
consuming O +
considerable O +
CPU O +
time O -
, O +
as O +
well O +
as O +
making O +
a O +
sizeable O +
demand O +
on O +
the O +
efforts O +
of O +
an O +
experienced O +
researcher O -
. O +

However O -
, O +
reports O +
of O +
adiabatic O +
maps O +
with O +
high O +
dielectric O +
constants O +
and O +
starting O +
conformers O +
with O +
the O +
classical O +
clockwise O -
– O -
anticlockwise O +
orientation O +
of O +
the O +
secondary O +
hydroxyl O +
groups O +
should O +
be O +
treated O +
with O +
due O +
care O -
. O +

There O +
are O +
alternative O +
approaches O +
for O +
the O +
creation O +
of O +
a O +
potential O -
- O -
energy O +
surface O -
, O +
like O +
the O +
use O +
of O +
random O +
sampling O +
techniques O +
[ O -
22 O -
] O +
such O +
as O +
ramm O +
[ O -
13,28 O -
] O +
, O +
the O +
use O +
of O +
heuristic O +
procedures O +
like O +
cicada O +
[ O -
40,41 O -
] O +
or O +
applications O +
of O +
simulations O +
based O +
on O +
molecular O +
dynamics O +
[ O -
22,29,30 O -
] O +
, O +
Monte O +
Carlo O +
[ O -
42 O -
] O +
, O +
or O +
combinations O +
of O +
both O +
[ O -
31,32 O -
] O +
. O +

Even O +
when O +
the O +
construction O +
of O +
an O +
adiabatic O +
map O +
is O +
not O +
attempted O +
[ O -
43 O -
] O +
, O +
the O +
generation O +
of O +
the O +
local O +
minima O +
is O +
usually O +
required O -
. O +

The O +
results O +
shown O +
in O +
this O +
paper O +
indicate O +
that O +
the O +
determination O +
of O +
the O +
local O +
minima O +
from O +
the O +
combination O +
of O +
a O +
small O +
number O +
of O +
relaxed O +
maps O +
may O +
fail O -
, O +
and O +
it O +
indeed O +
does O -
, O +
at O +
high O +
dielectric O +
constants O -
. O +

Although O +
the O +
conformational O +
maps O +
obtained O +
by O +
each O +
method O +
are O +
roughly O +
similar O +
( O -
Figs. O +
2 O +
and O +
4 O +
) O -
, O +
the O +
fact O +
that O +
many O +
properties O +
of O +
carbohydrates O +
depend O +
strongly O +
on O +
small O +
differences O +
in O +
energy O +
leads O +
to O +
a O +
struggle O +
for O +
the O +
greatest O +
possible O +
accuracy O +
[ O -
3 O -
] O +
on O +
the O +
actual O +
adiabatic O +
character O +
of O +
the O +
generated O +
maps O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
a O +
grant O +
from O +
UBA O +
( O -
TX-014 O -
) O -
. O +

Helpful O +
discussions O +
with O +
Drs O +
A.S. O +
Cerezo O -
, O +
R. O +
Erra O -
- O -
Balsells O +
and O +
M.S. O +
Maier O +
are O +
also O +
acknowledged O -
. O +

Activated O +
macrophages O +
can O +
generate O +
large O +
amounts O +
of O +
NO O +
from O +
L O +
-arginine O +
by O +
the O +
action O +
of O +
inducible B-Gene +
NO I-Gene +
synthase I-Gene +
( O -
iNOS B-Gene -
) O -
. O +

NO O +
is O +
an O +
important O +
intracellular O +
and O +
intercellular O +
regulatory O +
molecule O +
of O +
multiple O +
biological O +
functions O -
, O +
including O +
macrophage O -
- O -
mediated O +
cytotoxicity O -
, O +
neurotransmission O -
, O +
and O +
smooth O +
muscle O +
relaxation O +
[ O -
1,2 O -
] O +
. O +

Overproduction O +
of O +
NO O +
has O +
been O +
associated O +
with O +
oxidative O +
stress O +
[ O -
3,4 O -
] O +
and O +
with O +
the O +
pathophysiology O +
of O +
various O +
diseases O +
such O +
as O +
arthritis O -
, O +
diabetes O -
, O +
stroke O -
, O +
septic O +
shock O -
, O +
autoimmune O +
disease O -
, O +
and O +
chronic O +
inflammation O +
[ O -
5,6 O -
] O +
. O +

Cytokines B-Gene +
such O +
as O +
interferon B-Gene -
- I-Gene -
γ I-Gene +
( B-Gene -
IFN I-Gene -
- I-Gene -
γ I-Gene -
) O -
, O +
interleukin B-Gene +
( O -
IL B-Gene -
) O -
-2 B-Gene -
, O +
and O +
other O +
inflammatory O +
stimuli O +
such O +
as O +
bacterial O +
lipopolysaccharide O +
( O -
LPS O -
) O +
regulate O +
the O +
activity O +
of O +
iNOS B-Gene +
in O +
macrophages O +
[ O -
7,8 O -
] O +
. O +

It O +
has O +
also O +
been O +
shown O +
that O +
the O +
production O +
of O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene -
- I-Gene -
α I-Gene +
( O -
TNF B-Gene -
- I-Gene -
α I-Gene -
) O +
is O +
crucial O +
for O +
the O +
synergistic O +
induction O +
of O +
NO O +
synthesis O +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
and/or O +
LPS O -
- O -
stimulated O +
macrophages O +
[ O -
9,10 O -
] O +
. O +

In O +
macrophages O -
, O +
nuclear B-Gene +
factor I-Gene +
κB I-Gene +
( O -
NF B-Gene -
- I-Gene -
κB I-Gene -
) O +
in O +
cooperation O +
with O +
other O +
transcription O +
factors O +
coordinates O +
the O +
expression O +
of O +
genes O +
encoding O +
both O +
iNOS B-Gene +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene -
. O +

NF B-Gene -
- I-Gene -
κB I-Gene +
plays O +
a O +
critical O +
role O +
in O +
the O +
activation O +
of O +
immune O +
cells O +
by O +
upregulating O +
the O +
expression O +
of O +
many O +
cytokines B-Gene +
essential O +
to O +
the O +
immune O +
response O +
[ O -
11 O -
] O +
. O +

In O +
particular O -
, O +
NF B-Gene -
- I-Gene -
κB I-Gene +
stimulates O +
the O +
production O +
of O +
IL-1 B-Gene -
, O +
IL-6 B-Gene -
, O +
TNF B-Gene -
- I-Gene -
α I-Gene -
, O +
lymphotoxin B-Gene -
, O +
and O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
. O +

Furthermore O -
, O +
some O +
of O +
these O +
cytokines B-Gene -
, O +
e.g. O +
IL-1 B-Gene +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene -
, O +
activate O +
NF B-Gene -
- I-Gene -
κB I-Gene +
themselves O -
, O +
thus O +
initiating O +
an O +
autoregulatory O +
feedback O +
loop O -
. O +

NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
by O +
various O +
stimuli O +
occurs O +
upon O +
its O +
dissociation O +
from O +
the O +
inhibitory O +
protein B-Gene +
IκB B-Gene +
and O +
its O +
subsequent O +
nuclear O +
translocation O -
. O +

Several O +
lines O +
of O +
evidence O -
, O +
including O +
the O +
inhibition O +
by O +
various O +
antioxidants O -
, O +
suggest O +
that O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
is O +
subject O +
to O +
redox O +
regulation O +
[ O -
12,13 O -
] O +
. O +

Because O +
of O +
the O +
pivotal O +
role O +
of O +
NO O +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
in O +
the O +
antimicrobial O +
and O +
tumoricidal O +
activities O +
of O +
macrophages O -
, O +
a O +
significant O +
effort O +
has O +
focused O +
on O +
developing O +
therapeutic O +
agents O +
that O +
regulate O +
NO O +
production O +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
[ O -
14 O -
] O +
. O +

Epidemiological O +
reports O +
have O +
indicated O +
that O +
consumption O +
of O +
foods O +
rich O +
in O +
flavonoids O +
is O +
associated O +
with O +
a O +
lower O +
incidence O +
of O +
degenerative O +
diseases O -
. O +

Consistently O -
, O +
experimental O +
data O +
are O +
accumulating O +
regarding O +
phenolic O +
compounds O +
as O +
natural O +
phytochemical O +
antioxidants O +
that O +
possess O +
antiinflammatory O -
, O +
antiviral O -
, O +
antiproliferative O -
, O +
and O +
anticarcinogenic O +
properties O +
[ O -
15,16 O -
] O +
. O +

There O +
is O +
increasing O +
interest O +
in O +
the O +
biological O +
activities O +
of O +
plant O +
extracts O +
such O +
as O +
that O +
obtained O +
from O +
the O +
bark O +
of O +
the O +
French O +
maritime O +
pine O -
, O +
Pinus O +
maritima O +
. O +

Pine O +
bark O +
extract O +
( O -
Pycnogenol O -
, O +
PYC O -
) O +
is O +
a O +
unique O +
mixture O +
of O +
phenols O +
and O +
polyphenols O -
, O +
broadly O +
divided O +
into O +
monomers O +
( O -
e.g. O +
catechin O -
, O +
epicatechin O +
and O +
taxifolin O -
) O -
, O +
dimers O +
( O -
e.g. O +
procyanidin O +
B1 O -
, O +
B2 O -
, O +
B3 O -
, O +
and O +
B7 O -
) O -
, O +
trimers O +
( O -
e.g. O +
procyanidin O +
C1 O -
, O +
C2 O -
) O -
, O +
and O +
oligomers O +
up O +
to O +
5–7 O +
units O -
. O +

PYC O +
also O +
contains O +
phenolic O +
acids O +
such O +
as O +
caffeic O -
, O +
ferulic O +
and O +
p O +
-hydroxybenzoic O +
acid O +
as O +
minor O +
constituents O +
[ O -
17 O -
] O +
. O +

Bioflavonoids O +
participate O +
in O +
an O +
antioxidant O +
network O +
[ O -
18 O -
] O +
and O +
likely O +
spare O +
endogenous O +
cellular O +
vitamin O +
E O +
[ O -
19 O -
] O +
and O +
glutathione O +
[ O -
20 O -
] O +
. O +

PYC O +
also O +
modulates O +
NO O +
metabolism O +
in O +
stimulated O +
macrophages O +
by O +
affecting O +
both O +
iNOS B-Gene +
mRNA O +
expression O +
and O +
iNOS B-Gene +
activity O +
[ O -
21 O -
] O +
. O +

However O -
, O +
little O +
is O +
known O +
about O +
which O +
particular O +
constituents O +
of O +
PYC O +
mediate O +
its O +
immunomodulatory O +
properties O -
. O +

Therefore O -
, O +
the O +
objective O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
whether O +
purified O +
monomeric O -
, O +
dimeric O -
, O +
and O +
trimeric O +
flavonoids O +
in O +
comparison O +
to O +
PYC O +
can O +
modulate O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
as O +
well O +
as O +
NO O +
production O +
and O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
in O +
RAW O +
264.7 O +
macrophages O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Murine B-Gene +
recombinant I-Gene +
IFN I-Gene -
- I-Gene -
γ I-Gene +
( O -
1 O -
× O -
106 O +
U O -
/ O -
mg O -
) O -
, O +
murine B-Gene +
recombinant I-Gene +
TNF I-Gene -
- I-Gene -
α I-Gene +
( O -
1 O -
× O -
106 O +
U O -
/ O -
ml O -
) O -
, O +
rabbit B-Gene +
anti I-Gene -
- I-Gene -
murine I-Gene +
TNF I-Gene -
- I-Gene -
α I-Gene +
polyclonal I-Gene +
antibody I-Gene +
( O -
Ab B-Gene -
) O -
, O +
and O +
hamster B-Gene +
anti I-Gene -
- I-Gene -
murine I-Gene +
TNF I-Gene -
- I-Gene -
α I-Gene +
monoclonal I-Gene +
Ab I-Gene +
were O +
from O +
Genzyme O +
( O -
Munich O -
, O +
Germany O -
) O -
. O +

LPS O +
( O -
phenol O -
- O -
extracted O +
Salmonella O +
enteritidis O +
) O -
, O +
catechin O -
, O +
epicatechin O -
, O +
and O +
taxifolin O +
were O +
from O +
Sigma O +
Chemical O +
Co. O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

Fetal O +
calf O +
serum O +
and O +
antibiotics O +
were O +
from O +
the O +
University O +
of O +
California O -
, O +
San O +
Francisco O +
Cell O +
Culture O +
Facility O -
. O +

RPMI O +
containing O +
L O +
-arginine O +
( O -
200 O +
mg O -
/ O -
l O -
) O -
, O +
Hanks O -
' O +
balanced O +
salt O +
solution O -
, O +
and O +
other O +
tissue O +
culture O +
reagents O +
were O +
purchased O +
from O +
Life O +
Technologies O +
( O -
Gaithersburg O -
, O +
MD O -
, O +
USA O -
) O -
. O +

Pycnogenol O +
was O +
a O +
gift O +
from O +
Horphag O +
Research O +
Ltd. O +
( O -
Guernsey O -
, O +
UK O -
) O -
. O +

Procyanidins O +
B1 O -
, O +
B2 O +
( O -
both O +
from O +
apples O -
, O +
98 O -
% O +
purity O -
) O -
, O +
and O +
C2 O +
( O -
from O +
barley O -
, O +
93 O -
% O +
purity O -
) O +
were O +
a O +
gift O +
from O +
Tsukuba O +
Research O +
Laboratories O +
( O -
Kyowa O +
Hakko O +
Kogyo O -
, O +
Japan O -
) O -
. O +

2.2 O +
Macrophage O +
culture O +
The O +
murine O +
monocyte O -
/ O -
macrophage O +
cell O +
line O +
RAW O +
264.7 O +
was O +
obtained O +
from O +
the O +
American O +
Type O +
Culture O +
Collection O +
( O -
Rockville O -
, O +
MD O -
, O +
USA O -
) O -
. O +

Cells O +
were O +
cultured O +
in O +
75-cm2 O +
plastic O +
flasks O +
( O -
Falcon O -
- O -
Becton O +
Dickinson O +
Labwares O -
, O +
Franklin O +
Lakes O -
, O +
NJ O -
, O +
USA O -
) O +
and O +
maintained O +
in O +
RPMI O +
1640 O +
supplemented O +
with O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
fetal O +
calf O +
serum O +
and O +
antibiotics O +
( O -
100 O +
U O -
/ O -
ml O +
of O +
penicillin O -
, O +
100 O +
μg O -
/ O -
ml O +
of O +
streptomycin O -
) O -
. O +

For O +
experiments O -
, O +
macrophages O +
were O +
detached O +
by O +
vigorous O +
pipetting O +
and O -
, O +
after O +
centrifugation O -
, O +
incubated O +
with O +
fresh O +
medium O +
in O +
either O +
96-well O +
tissue O +
culture O +
plates O +
( O -
2 O -
× O -
105 O +
cells O -
/ O -
well O -
) O +
or O +
24-well O +
tissue O +
culture O +
plates O +
( O -
5 O -
× O -
105 O +
cells O -
/ O -
well O -
) O +
at O +
37 O -
° O -
C O +
in O +
an O +
atmosphere O +
of O +
5 O -
% O +
CO2 O +
plus O +
air O -
. O +

Cells O +
were O +
supplemented O +
with O +
the O +
test O +
compounds O +
for O +
1 O +
h O +
followed O +
by O +
their O +
stimulation O +
with O +
10 O +
U O -
/ O -
ml O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
and O +
further O +
incubated O +
for O +
various O +
periods O +
as O +
described O +
in O +
Section O +
3 O +
. O +

2.3 O +
Neutral O +
red O +
assay O +
Uptake O +
of O +
the O +
dye O +
neutral O +
red O +
was O +
used O +
as O +
a O +
measure O +
of O +
cell O +
viability O +
[ O -
22 O -
] O +
. O +

Cells O +
were O +
plated O +
in O +
24-well O +
plates O -
, O +
and O +
samples O +
were O +
treated O +
for O +
24 O +
h O +
in O +
500 O +
μl O +
of O +
medium O -
. O +

Thereafter O -
, O +
the O +
medium O +
was O +
removed O +
and O +
replaced O +
with O +
500 O +
μl O +
of O +
medium O +
containing O +
60 O +
μg O -
/ O -
ml O +
of O +
neutral O +
red O +
( O -
Fisher O +
Scientific O -
, O +
Pittsburgh O -
, O +
PA O -
, O +
USA O -
) O +
for O +
3 O +
h O +
at O +
37 O -
° O -
C O -
. O +

Following O +
incubation O +
with O +
the O +
neutral O +
red O +
dye O -
, O +
the O +
medium O +
was O +
removed O -
, O +
and O +
the O +
cells O +
were O +
extracted O +
with O +
500 O +
μl O +
of O +
50 O -
% O +
ethanol O -
, O +
49 O -
% O +
H2 O +
O O -
, O +
1 O -
% O +
glacial O +
acetic O +
acid O -
, O +
pH O +
4.2 O -
. O +

Quadruplicate O +
100-μl O +
samples O +
from O +
each O +
well O +
were O +
transferred O +
to O +
a O +
96-well O +
plate O -
, O +
and O +
the O +
absorbance O +
at O +
510 O +
nm O +
was O +
measured O +
with O +
a O +
microplate O +
reader O +
( O -
CS-931 O -
, O +
Shimadzu O +
Corporation O -
, O +
Columbia O -
, O +
MD O -
, O +
USA O -
) O -
. O +

2.4 O +
Assay O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
was O +
measured O +
by O +
modification O +
of O +
an O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O -
, O +
as O +
described O +
earlier O +
[ O -
23 O -
] O +
. O +

For O +
the O +
ELISA O -
, O +
96-well O +
plates O +
were O +
coated O +
with O +
6.25 O +
ng O -
/ O -
well O +
of O +
murine B-Gene +
monoclonal I-Gene +
Ab I-Gene +
with I-Gene +
specificity I-Gene +
for I-Gene +
murine I-Gene +
TNF I-Gene -
- I-Gene -
α I-Gene -
. O +

Before O +
use O +
and O +
between O +
subsequent O +
steps O +
in O +
the O +
assay O -
, O +
coated O +
plates O +
were O +
washed O +
twice O +
with O +
phosphate O -
- O -
buufered O +
saline O +
( O -
PBS O -
) O +
containing O +
0.05 O -
% O +
( O -
v O -
/ O -
v O -
) O +
Tween-20 O +
and O +
twice O +
with O +
PBS O +
alone O -
. O +

For O +
the O +
standard O +
curve O -
, O +
rTNF B-Gene -
- I-Gene -
α I-Gene +
was O +
added O +
to O +
serum O +
previously O +
determined O +
to O +
be O +
negative O +
for O +
endogenous O +
TNF B-Gene -
- I-Gene -
α I-Gene -
. O +

After O +
exposure O +
to O +
medium O -
, O +
assay O +
plates O +
were O +
sequentially O +
exposed O +
to O +
rabbit B-Gene +
anti I-Gene -
- I-Gene -
TNF I-Gene -
- I-Gene -
α I-Gene -
, O +
phosphatase B-Gene -
- B-Gene -
conjugated I-Gene +
goat I-Gene +
anti I-Gene -
- I-Gene -
rabbit I-Gene +
IgG I-Gene -
, O +
and O +
p O +
-nitrophenyl O +
phosphate O -
. O +

Optical O +
density O +
readings O +
at O +
410 O +
nm O +
were O +
taken O +
using O +
a O +
microplate O +
reader O -
. O +

2.5 O +
Measurement O +
of O +
nitrite O +
and O +
nitrate O +
concentration O +
NO O +
secretion O +
in O +
cultured O +
macrophages O +
was O +
measured O +
by O +
a O +
microplate O +
assay O +
method O -
, O +
as O +
described O +
earlier O +
[ O -
24,25 O -
] O +
. O +

To O +
measure O +
nitrite O +
( O -
NO2 O +
− O +
) O -
, O +
100 O +
μl O +
of O +
macrophage O +
culture O +
supernatant O +
was O +
collected O -
, O +
mixed O +
with O +
an O +
equal O +
volume O +
of O +
Griess O +
reagent O +
( O -
1 O -
% O +
sulfanilamide O -
/ O -
0.1 O -
% O +
N O +
- O -
( O -
1-naphthyl O -
) O -
-ethylenediamine O +
dihydrochloride O -
/ O -
2.5 O -
% O +
H3 O +
PO4 O +
) O +
and O +
incubated O +
for O +
10 O +
min O +
at O +
room O +
temperature O -
. O +

Nitrite O +
concentration O +
was O +
determined O +
by O +
measuring O +
the O +
absorbance O +
at O +
540 O +
nm O -
. O +

NaNO2 O +
was O +
used O +
for O +
external O +
calibration O -
. O +

Cell O -
- O -
free O +
medium O +
alone O +
contained O +
5–8 O +
μM O +
of O +
nitrite O -
; O +
this O +
value O +
was O +
determined O +
in O +
each O +
experiment O +
and O +
subtracted O +
from O +
the O +
value O +
obtained O +
for O +
each O +
cell O +
sample O -
. O +

Nitrate O +
( O -
NO3 O +
− O +
) O +
was O +
measured O +
by O +
reducing O +
nitrate O +
to O +
nitrite O +
with O +
bacterial O +
nitrate B-Gene +
reductase I-Gene -
, O +
then O +
measuring O +
nitrite O +
by O +
using O +
Griess O +
reagent O -
. O +

There O +
was O +
no O +
interference O +
of O +
the O +
test O +
compounds O +
either O +
with O +
the O +
ELISA O +
or O +
with O +
Griess O +
reagent O -
. O +

2.6 O +
Cell O +
transfection O +
and O +
reporter O +
gene O +
assay O +
RAW O +
264.7 O +
macrophages O +
were O +
plated O +
at O +
2 O -
× O -
105 O +
cells O +
per O +
cm2 O +
in O +
12-well O +
plates O -
, O +
and O +
24 O +
h O +
later O +
transiently O +
co O -
- O -
transfected O +
with O +
the O +
plasmids O +
pGL3 O -
- O -
4κB O -
- O -
Luc O +
and O +
pRL O -
- O -
TK O +
( O -
reference O +
plasmid O +
containing O +
a O +
Renilla O +
luciferase B-Gene +
gene O +
driven O +
by O +
a O +
minimal O +
thymidine B-Gene +
kinase I-Gene +
promoter O -
, O +
Promega O -
, O +
Madison O -
, O +
WI O -
, O +
USA O -
) O +
using O +
Fugene O +
6 O +
reagent O +
( O -
Roche O +
Molecular O +
Biochemicals O -
, O +
Indianapolis O -
, O +
IN O -
, O +
USA O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

Briefly O -
, O +
the O +
transfection O +
mixture O +
containing O +
0.35 O +
μg O +
of O +
pGL3 O -
- O -
4κB O -
- O -
Luc O +
and O +
0.15 O +
μg O +
of O +
pRL O -
- O -
TK O +
was O +
mixed O +
with O +
the O +
Fugene O +
6 O +
reagent O +
and O +
added O +
to O +
the O +
cells O -
. O +

Treatments O +
with O +
test O +
compounds O +
and O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
were O +
started O +
18 O +
h O +
after O +
transfection O -
. O +

Cell O +
lysis O +
was O +
performed O +
12 O +
h O +
after O +
treatments O +
and O +
luciferase B-Gene +
activities O +
were O +
measured O +
using O +
the O +
dual O -
- O -
luciferase B-Gene +
reporter O +
assay O +
system O +
( O -
Promega O -
) O +
with O +
an O +
LKB O -
/ O -
Wallac O +
luminometer O +
1250 O +
( O -
Wallac O -
, O +
Gaithersburg O -
, O +
MD O -
, O +
USA O -
) O -
. O +

The O +
dual O -
- O -
luciferase B-Gene +
system O +
is O +
based O +
on O +
the O +
subsequent O +
measurement O +
of O +
firefly O +
( O -
from O +
pGL3 O -
- O -
4κB O -
- O -
Luc O -
) O +
and O +
Renilla O +
( O -
from O +
pRL O -
- O -
TK O -
) O +
luciferase B-Gene +
activities O +
in O +
the O +
same O +
tube O +
with O +
the O +
same O +
extract O -
. O +

The O +
firefly O +
luciferase B-Gene +
activity O +
was O +
normalized O +
in O +
that O +
system O +
with O +
the O +
Renilla O +
luciferase B-Gene +
activity O +
to O +
correct O +
for O +
differences O +
in O +
the O +
transfection O +
efficiency O +
[ O -
26 O -
] O +
. O +

2.7 O +
Lipid O +
A O +
analysis O +
PYC O +
was O +
tested O +
for O +
the O +
presence O +
of O +
lipid O +
A. O +
Samples O +
and O +
reference O +
standard O +
( O -
deep O +
rough O +
chemotype O +
LPS O +
from O +
Escherichia O +
coli O +
D31m4 O -
) O +
were O +
treated O +
with O +
EDTA O -
, O +
and O +
purified O +
by O +
a O +
DEAE O -
- O -
cellulose O +
column O +
chromatography O +
as O +
previously O +
described O +
[ O -
27 O -
] O +
. O +

Samples O +
were O +
hydrolyzed O +
in O +
2 O +
ml O +
of O +
0.1 O +
M O +
HCl O +
at O +
100 O -
° O -
C O +
for O +
30 O +
min O +
to O +
yield O +
monophosphoryl O +
lipid O +
A. O +
Then O +
5 O +
ml O +
of O +
chloroform O -
/ O -
methanol O +
( O -
2:1 O -
, O +
v O -
/ O -
v O -
) O +
was O +
added O -
, O +
mixed O +
and O +
centrifuged O -
. O +

The O +
lower O +
organic O +
layer O +
was O +
recovered O -
, O +
filtered O +
and O +
dried O -
. O +

The O +
extracted O +
samples O +
were O +
applied O +
in O +
chloroform O -
/ O -
methanol O +
( O -
4:1 O -
, O +
v O -
/ O -
v O -
) O +
to O +
silica O +
gel O +
GHL O +
plate O +
( O -
250 O +
μm O -
) O +
and O +
irrigated O +
with O +
chloroform O -
/ O -
methanol O -
/ O -
water O -
/ O -
concentrated O +
ammonium O +
hydroxide O +
( O -
50:25:4:2 O -
, O +
v O -
/ O -
v O -
) O -
. O +

Spots O +
were O +
visualized O +
by O +
spraying O +
the O +
plate O +
with O +
dichromate O -
/ O -
sulfuric O +
acid O +
reagent O +
and O +
charring O -
. O +

2.8 O +
Statistics O +
or O +
reproducibility O +
Data O +
in O +
figures O +
are O +
the O +
mean±S.D. O +
of O +
at O +
least O +
three O +
different O +
experiments O +
performed O +
in O +
triplicate O -
. O +

3 O +
Results O +
3.1 O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
by O +
macrophages O +
is O +
modified O +
by O +
flavonoids O +
in O +
a O +
structure O -
- O -
dependent O +
manner O +
As O +
a O +
first O +
step O -
, O +
the O +
cytotoxic O +
activity O +
of O +
the O +
monomeric O -
, O +
dimeric O +
and O +
trimeric O +
flavonoids O +
as O +
well O +
as O +
PYC O +
in O +
the O +
absence O +
and O +
presence O +
of O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
was O +
assessed O +
using O +
the O +
neutral O +
red O +
assay O -
. O +

Pretreatment O +
of O +
both O +
unstimulated O +
and O +
stimulated O +
RAW O +
264.7 O +
macrophages O +
up O +
to O +
100 O +
μg O -
/ O -
ml O +
catechin O -
, O +
epicatechin O +
as O +
well O +
as O +
PCA O +
B1 O -
, O +
PCA O +
B2 O +
and O +
PCA O +
C2 O +
did O +
not O +
significantly O +
affect O +
the O +
cell O +
viability O +
( O -
data O +
not O +
shown O -
) O -
. O +

However O -
, O +
in O +
macrophages O +
treated O +
with O +
100 O +
μg O -
/ O -
ml O +
taxifolin O +
for O +
24 O +
h O +
a O +
slight O +
although O +
significant O +
cytotoxic O +
effect O +
could O +
be O +
observed O -
. O +

In O +
unstimulated O +
macrophages O +
only O +
small O +
amounts O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
were O +
secreted O +
into O +
the O +
medium O +
( O -
Fig. O +
1A O +
) O -
. O +

Pretreatment O +
of O +
unstimulated O +
cells O +
with O +
monomeric O +
or O +
dimeric O +
flavonoids O +
over O +
24 O +
h O +
did O +
not O +
result O +
in O +
any O +
change O +
in O +
the O +
secretion O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
into O +
the O +
medium O -
. O +

However O -
, O +
in O +
the O +
presence O +
of O +
PCA O +
C2 O +
or O +
PYC O +
the O +
secreted O +
levels O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
significantly O +
increased O -
. O +

The O +
stimulation O +
of O +
RAW O +
264.7 O +
cells O +
with O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
resulted O +
in O +
a O +
manifold O +
increase O +
in O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
monitored O +
24 O +
h O +
after O +
administration O +
( O -
Fig. O +
1B O +
) O -
. O +

All O +
monomeric O +
flavonoids O +
tested O +
( O -
catechin O -
, O +
epicatechin O -
, O +
and O +
taxifolin O -
) O +
decreased O +
the O +
secretion O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
almost O +
down O +
to O +
the O +
baseline O +
levels O +
as O +
measured O +
in O +
the O +
unstimulated O +
control O +
cells O -
. O +

While O +
the O +
dimeric O +
flavonoids O +
PCA O +
B1 O +
and O +
PCA O +
B2 O +
slightly O +
inhibited O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
induced O +
TNF O -
- O -
α O +
secretion O -
, O +
the O +
trimeric O +
flavonoid O +
PCA O +
C2 O +
induced O +
about O +
a O +
two O -
- O -
fold O +
increase O +
in O +
the O +
secretion O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
macrophages O -
. O +

Similar O +
to O +
PCA O +
C2 O -
, O +
PYC O +
potentiated O +
the O +
effect O +
of O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
on O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O -
. O +

The O +
secretion O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
due O +
to O +
PCA O +
C2 O +
and O +
PYC O +
increased O +
both O +
in O +
a O +
dose- O +
and O +
time O -
- O -
dependent O +
fashion O +
as O +
shown O +
in O +
Fig. O +
2A O -
, O -
B O +
, O +
respectively O -
. O +

3.2 O +
Effect O +
of O +
monomeric O -
, O +
dimeric O -
, O +
and O +
trimeric O +
flavonoids O +
on O +
NO O +
production O +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
macrophages O +
In O +
parallel O +
with O +
the O +
characterization O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
the O +
effect O +
of O +
the O +
different O +
flavonoids O +
on O +
NO O +
release O +
into O +
the O +
medium O +
measured O +
by O +
the O +
Griess O +
reaction O +
was O +
studied O -
. O +

Unstimulated O +
control O +
cells O +
produced O +
a O +
negligible O +
amount O +
of O +
NO O +
( O -
< O -
5 O +
μM O -
) O -
. O +

However O -
, O +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
cells O +
a O +
substantial O +
increase O +
in O +
the O +
production O +
of O +
NO O +
was O +
evident O +
( O -
Fig. O +
3 O +
) O -
. O +

Pretreatment O +
of O +
macrophages O +
with O +
catechin O -
, O +
epicatechin O -
, O +
and O +
taxifolin O +
significantly O +
decreased O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
induced O +
NO O +
production O +
by O +
40 O -
, O +
60 O -
, O +
and O +
75 O -
% O -
, O +
respectively O -
, O +
as O +
compared O +
to O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
treated O +
cells O -
. O +

The O +
dimeric O +
flavonoids O +
PCA O +
B1 O +
and O +
PCA O +
B2 O +
showed O +
a O +
moderate O +
inhibitory O +
effect O +
on O +
NO O +
production O -
. O +

In O +
contrast O +
to O +
the O +
monomeric O +
and O +
dimeric O +
procyanidins O +
pretreatment O +
of O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
macrophages O +
with O +
the O +
PCA O +
C2 O +
as O +
well O +
as O +
PYC O +
significantly O +
increased O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
induced O +
NO O +
production O -
. O +

3.3 O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
macrophages O +
is O +
modulated O +
by O +
flavonoids O +
Induction O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
and O +
iNOS B-Gene +
is O +
modulated O -
, O +
in O +
part O +
through O +
the O +
activation O +
of O +
NF B-Gene -
- I-Gene -
κB. I-Gene +
Consequently O +
the O +
effect O +
of O +
different O +
flavonoids O +
on O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
using O +
the O +
dual O -
- O -
luciferase B-Gene +
reporter O +
gene O +
assay O +
was O +
studied O -
. O +

Nearly O +
a O +
two O -
- O -
fold O +
increase O +
in O +
luciferase B-Gene +
activity O +
was O +
observed O +
when O +
RAW O +
264.7 O +
macrophages O +
were O +
stimulated O +
with O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
as O +
compared O +
to O +
unstimulated O +
control O +
cells O +
( O -
Fig. O +
4A O +
) O -
. O +

Similar O +
to O +
the O +
data O +
for O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
and O +
NO O +
production O +
the O +
monomeric O +
flavonoids O +
catechin O -
, O +
epicatechin O +
and O +
taxifolin O +
completely O +
counteracted O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
induced O +
NF B-Gene -
- I-Gene -
κB I-Gene +
transactivation O -
. O +

Pretreatment O +
of O +
macrophages O +
with O +
PCA O +
B1 O +
and O +
PCA O +
B2 O +
resulted O +
in O +
a O +
slight O +
decrease O +
in O +
the O +
luciferase B-Gene +
activity O -
. O +

However O -
, O +
different O +
to O +
the O +
monomers O +
and O +
dimers O -
, O +
PCA O +
C2 O +
and O +
PYC O +
significantly O +
increased O +
luciferase B-Gene +
activity O +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
cells O -
. O +

In O +
addition O +
both O +
PCA O +
C2- O +
and O +
PYC O -
- O -
induced O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
was O +
totally O +
inhibited O +
by O +
the O +
use O +
of O +
a O +
anti B-Gene -
- I-Gene -
murine I-Gene +
TNF I-Gene -
- I-Gene -
α I-Gene -
- I-Gene -
neutralizing I-Gene +
Ab I-Gene -
, O +
indicating O +
that O +
PCA O +
C2 O +
or O +
PYC O -
- O -
induced O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
is O +
crucial O +
for O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
in O +
macrophages O +
( O -
Fig. O +
4B O +
) O -
. O +

4 O +
Discussion O +
4.1 O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
TNF B-Gene -
- I-Gene -
α I-Gene +
was O +
produced O +
in O +
vanishingly O +
small O +
quantities O +
in O +
unstimulated O +
cells O +
as O +
reported O +
previously O +
[ O -
28 O -
] O +
. O +

However O -
, O +
when O +
macrophages O +
were O +
stimulated O +
with O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
, O +
a O +
manifold O +
increase O +
in O +
the O +
secretion O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
into O +
the O +
medium O +
was O +
observed O -
. O +

Interestingly O -
, O +
both O +
in O +
the O +
absence O +
and O +
in O +
the O +
presence O +
of O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
, O +
pretreatment O +
of O +
macrophages O +
with O +
the O +
trimer O +
PCA O +
C2 O +
as O +
well O +
as O +
PYC O +
substantially O +
elevated O +
TNF B-Gene -
- I-Gene -
α I-Gene +
release O +
from O +
undetectable O +
levels O +
up O +
to O +
2–4 O +
ng O -
/ O -
ml O -
. O +

Similar O +
to O +
PCA O +
C2 O +
and O +
PYC O +
the O +
flavonoid O +
drug O +
flavone-8-acetic O +
acid O +
( O -
FAA O -
) O -
, O +
which O +
augments O +
mouse O +
natural O +
killer O +
activity O -
, O +
has O +
been O +
shown O +
to O +
induce O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
in O +
J774 O +
cells O +
and O +
thereby O +
synergized O +
with O +
recombinant B-Gene +
IL-2 I-Gene +
for O +
the O +
treatment O +
of O +
murine O +
renal O +
cancer O +
[ O -
29 O -
] O +
. O +

Moreover O -
, O +
the O +
red O +
wine O +
polyphenol O +
resveratrol O +
has O +
been O +
reported O +
to O +
have O +
a O +
potent O +
effect O +
to O +
increase O +
basal O +
TNF B-Gene -
- I-Gene -
α I-Gene +
mRNA O +
expression O +
with O +
a O +
concomitant O +
increase O +
in O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
in O +
RAW O +
264.7 O +
macrophages O +
[ O -
30 O -
] O +
. O +

In O +
this O +
regard O +
it O +
is O +
hypothesized O +
that O +
TNF B-Gene -
- I-Gene -
α I-Gene +
induction O +
appears O +
to O +
be O +
one O +
critical O +
factor O +
in O +
the O +
antitumor O +
effects O +
of O +
this O +
class O +
of O +
compounds O -
. O +

However O -
, O +
in O +
contrast O +
to O +
PCA O +
C2 O +
and O +
PYC O +
the O +
monomeric O +
flavonoids O +
( O -
catechin O -
, O +
epicatechin O -
, O +
and O +
taxifolin O -
) O +
tested O +
in O +
the O +
present O +
study O +
had O +
a O +
strong O +
and O +
the O +
dimeric O +
flavonoids O +
PCA O +
B1 O +
and O +
PCA O +
B2 O +
a O +
slight O +
inhibitory O +
effect O +
on O +
the O +
secretion O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
into O +
the O +
medium O -
. O +

Consistent O +
with O +
these O +
findings O +
green O +
tea O +
polyphenols O +
also O +
significantly O +
decreased O +
TNF B-Gene -
- I-Gene -
α I-Gene +
and O +
NO O +
synthesis O +
in O +
elicited O +
murine O +
peritoneal O +
macrophages O +
as O +
well O +
as O +
in O +
the O +
BALB O -
/ O -
c O +
mouse O +
model O +
[ O -
31 O -
] O +
. O +

The O +
underlying O +
mechanisms O +
by O +
which O +
different O +
flavonoids O +
result O +
in O +
a O +
different O +
outcome O +
in O +
terms O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
and O +
NO O +
production O +
have O +
not O +
been O +
clarified O +
yet O -
. O +

4.2 O +
NO O +
production O +
The O +
monomeric O +
flavonoids O +
catechin O -
, O +
epicatechin O -
, O +
and O +
taxifolin O +
significantly O +
inhibited O +
NO O +
production O +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
cells O -
. O +

The O +
cellular O +
mechanisms O +
by O +
which O +
flavonoids O +
down O -
- O -
regulate O +
NO O +
production O +
are O +
not O +
completely O +
understood O -
. O +

It O +
is O +
suggested O +
that O +
this O +
effect O +
might O +
be O +
partially O +
mediated O +
due O +
to O +
the O +
combination O +
of O +
several O +
different O +
biological O +
activities O -
, O +
i.e. O +
NO O +
scavenging O +
activity O -
, O +
inhibition O +
of O +
iNOS B-Gene +
enzyme O +
activity O -
, O +
and O +
inhibition O +
of O +
iNOS B-Gene +
mRNA O +
expression O +
[ O -
32 O -
] O +
. O +

It O +
should O +
also O +
be O +
taken O +
into O +
consideration O +
that O +
macrophages O +
are O +
often O +
stimulated O +
with O +
LPS O +
in O +
order O +
to O +
ensure O +
a O +
high O +
production O +
of O +
NO O -
. O +

However O -
, O +
stimulation O +
of O +
macrophages O +
with O +
LPS O +
in O +
the O +
presence O +
of O +
flavonoids O +
seems O +
to O +
be O +
problematic O +
since O +
flavonoid O -
- O -
rich O +
extracts O +
have O +
been O +
recently O +
found O +
to O +
suppress O +
the O +
activity O +
of O +
LPS O +
and O +
lipid O +
A O +
preparations O +
regardless O +
of O +
the O +
origin O +
of O +
the O +
bacteria O +
in O +
the O +
Limulus O +
test O +
[ O -
33 O -
] O +
widely O +
used O +
for O +
diagnosis O +
of O +
Gram O -
- O -
negative O +
bacterial O +
endotoxins O -
. O +

It O +
is O +
suggested O +
that O +
an O +
inhibition O +
in O +
the O +
production O +
of O +
NO O +
is O +
not O +
exclusively O +
mediated O +
due O +
to O +
cellular O +
effects O +
of O +
the O +
flavonoids O +
per O +
se O +
but O +
might O +
also O +
be O +
partially O +
caused O +
by O +
a O +
direct O +
interaction O +
of O +
these O +
compound O +
with O +
the O +
LPS O +
molecule O -
. O +

Therefore O +
in O +
the O +
present O +
investigation O +
macrophages O +
were O +
stimulated O +
with O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
only O -
. O +

In O +
contrast O +
to O +
the O +
monomeric O +
and O +
dimeric O +
flavonoids O -
, O +
PCA O +
C2 O +
and O +
PYC O +
significantly O +
increased O +
the O +
production O +
of O +
NO O +
in O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
stimulated O +
macrophages O -
. O +

Under O +
the O +
conditions O +
investigated O -
, O +
treatment O +
of O +
unstimulated O +
macrophages O +
with O +
PCA O +
C2 O +
and O +
PYC O +
also O +
resulted O +
in O +
a O +
considerable O +
increase O +
in O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
into O +
the O +
medium O +
known O +
to O +
be O +
crucial O +
for O +
NO O +
synthesis O +
in O +
macrophages O -
. O +

Based O +
on O +
monophosphoryl O +
lipid O +
A O +
analysis O +
PYC O +
was O +
completely O +
devoid O +
of O +
lipid O +
A. O +
This O +
finding O +
suggests O +
that O +
PYC O +
contains O +
no O +
significant O +
amounts O +
of O +
Gram O -
- O -
negative O +
bacterial O -
- O -
type O +
LPS O +
to O +
contribute O +
to O +
its O +
biological O +
activities O +
in O +
terms O +
of O +
NO O +
production O -
, O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
and O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O -
. O +

In O +
the O +
absence O +
of O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
both O +
treatment O +
of O +
macrophages O +
with O +
PCA O +
C2 O +
and O +
PYC O +
alone O +
resulted O +
in O +
a O +
considerable O +
activation O +
of O +
NF B-Gene -
- I-Gene -
κB I-Gene +
( O -
Fig. O +
4B O +
) O +
that O +
was O +
significantly O +
inhibited O +
by O +
the O +
use O +
of O +
anti B-Gene -
- I-Gene -
murine I-Gene +
TNF I-Gene -
- I-Gene -
α I-Gene +
Ab I-Gene -
. O +

These O +
data O +
indicate O +
that O +
PCA B-Gene +
C2- I-Gene +
and O +
PYC O -
- O -
induced O +
changes O +
in O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
are O +
at O +
least O +
partially O +
responsible O +
for O +
the O +
observed O +
difference O +
in O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
which O +
again O +
can O +
affect O +
NO O +
synthesis O -
. O +

4.3 O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
The O +
biosynthesis O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
is O +
tightly O +
controlled O +
by O +
different O +
molecular O +
events O +
regulating O +
the O +
TNF B-Gene -
- I-Gene -
α I-Gene +
gene O -
, O +
mRNA O +
and O +
protein O -
. O +

At O +
the O +
transcriptional O +
level O -
, O +
besides O +
a O +
TATA O +
box O +
promoter O +
located O +
20 O +
bp O +
upstream O +
of O +
the O +
transcription O +
start O +
site O -
, O +
a O +
number O +
of O +
regulatory O +
sequences O +
are O +
also O +
found O +
upstream O +
of O +
the O +
TNF B-Gene -
- I-Gene -
α I-Gene +
gene O -
, O +
including O +
three O +
NF B-Gene -
- I-Gene -
κB I-Gene +
sites O +
κ1 O -
, O +
κ2 O -
, O +
κ3 O +
which O +
are O +
thought O +
to O +
be O +
implicated O +
in O +
the O +
mechanism O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
induction O -
. O +

Furthermore O -
, O +
two O +
upstream O +
DNA O +
regions O +
of O +
the O +
iNOS B-Gene +
promoter O -
, O +
the O +
RI O +
and O +
RII O +
domains O -
, O +
are O +
required O +
for O +
the O +
maximal O +
promoter O +
activation O +
by O +
LPS O -
, O +
and O +
the O +
RII O +
domain O +
mediates O +
promoter O +
trans O +
-activation O +
of O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
. O +

Both O +
of O +
these O +
domains O +
comprise O +
multiple O +
sequences O +
homologous O +
to O +
those O +
of O +
cis O +
elements O +
involved O +
in O +
transcription O +
activation O -
, O +
such O +
as O +
NF B-Gene -
- I-Gene -
κB I-Gene +
binding O +
sites O -
, O +
IFN B-Gene -
- I-Gene -
γ I-Gene +
response O +
elements O -
, O +
and O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
- O -
activated O +
factor O +
binding O +
[ O -
34 O -
] O +
. O +

Therefore O -
, O +
we O +
sought O +
to O +
study O +
the O +
effect O +
of O +
different O +
structure O -
- O -
related O +
flavonoids O +
in O +
terms O +
of O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
using O +
the O +
dual O -
- O -
luciferase B-Gene +
reporter O +
gene O +
assay O -
. O +

Consistent O +
with O +
data O +
for O +
both O +
TNF B-Gene -
- I-Gene -
α I-Gene +
and O +
NO O -
, O +
the O +
monomeric O +
flavonoids O +
decreased O +
whereas O +
PCA O +
C2 O +
and O +
PYC O +
increased O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
indicating O +
that O +
differences O +
in O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O +
and O +
NO O +
production O +
might O +
be O +
partially O +
mediated O +
due O +
to O +
difference O +
in O +
the O +
activation O +
or O +
inhibition O +
of O +
NF B-Gene -
- I-Gene -
κB. I-Gene +
Although O +
no O +
common O +
second O +
messenger O +
has O +
been O +
identified O -
, O +
many O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
activating O +
signals O +
have O +
been O +
shown O +
to O +
be O +
inhibited O +
by O +
antioxidants O -
. O +

Plumb O +
et O +
al. O +
[ O -
35 O -
] O +
recently O +
studied O +
the O +
antioxidant O +
properties O +
of O +
catechin O -
, O +
epicatechin O +
as O +
well O +
as O +
structure O -
- O -
related O +
dimeric O +
and O +
trimeric O +
flavonoids O +
similar O +
to O +
those O +
used O +
in O +
the O +
present O +
study O -
. O +

Interestingly O -
, O +
the O +
antioxidant O +
activity O +
in O +
the O +
aqueous O +
phase O +
increased O +
from O +
monomeric O +
to O +
trimeric O +
flavonoids O -
. O +

However O -
, O +
in O +
the O +
present O +
study O +
the O +
trimeric O +
flavonoid O +
PCA O +
C2 O +
as O +
well O +
as O +
PYC O +
induced O +
a O +
substantial O +
activation O +
of O +
NF B-Gene -
- I-Gene -
κB. I-Gene +
Hence O +
changes O +
in O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
due O +
to O +
flavonoids O +
do O +
not O +
necessarily O +
reflect O +
differences O +
in O +
the O +
antioxidant O +
properties O +
of O +
these O +
compounds O -
. O +

Virgili O +
et O +
al. O +
[ O -
21 O -
] O +
studied O +
the O +
effect O +
of O +
PYC O +
on O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O +
and O +
NO O +
production O +
in O +
IFN B-Gene -
- I-Gene -
γ+LPS I-Gene -
- O -
stimulated O +
murine O +
macrophages O +
using O +
the O +
same O +
cell O +
line O -
. O +

In O +
IFN B-Gene -
- I-Gene -
γ+LPS I-Gene -
- O -
stimulated O +
RAW O +
264.7 O +
cells O -
, O +
PYC O +
had O +
no O +
effect O +
on O +
NF B-Gene -
- I-Gene -
κB I-Gene +
activation O -
. O +

PYC O +
pretreatment O +
was O +
started O +
24 O +
h O +
before O +
the O +
IFN B-Gene -
- I-Gene -
γ+LPS I-Gene +
administration O -
. O +

However O -
, O +
in O +
the O +
present O +
experiment O +
cells O +
were O +
pretreated O +
with O +
PYC O +
only O +
1 O +
h O +
before O +
the O +
stimulation O +
with O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
. O +

Possibly O -
, O +
both O +
the O +
duration O +
of O +
PYC O +
pretreatment O +
and O +
the O +
characteristic O +
of O +
the O +
activating O +
signal O +
( O -
IFN B-Gene -
- I-Gene -
γ+LPS I-Gene +
vs. O +
IFN B-Gene -
- I-Gene -
γ I-Gene -
) O +
are O +
important O +
in O +
terms O +
of O +
PYC O -
- O -
induced O +
changes O +
in O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
in O +
activated O +
murine O +
macrophages O -
. O +

4.4 O +
Conclusion O +
Flavonoids O +
constitute O +
a O +
large O +
group O +
of O +
phenolic O +
phytochemicals O +
with O +
antioxidant O +
properties O +
in O +
vitro O -
. O +

Despite O +
an O +
increasing O +
number O +
of O +
publications O +
concerning O +
free O +
radical O -
- O -
scavenging O +
and O +
hydrogen O -
- O -
donating O +
activities O +
of O +
flavonoids O +
[ O -
15 O -
] O +
, O +
little O +
is O +
known O +
about O +
their O +
biological O +
activity O +
in O +
terms O +
of O +
cell O +
signaling O +
and O +
gene O +
expression O -
. O +

The O +
present O +
data O +
show O +
for O +
the O +
first O +
time O +
that O +
monomeric O -
, O +
dimeric O -
, O +
and O +
trimeric O +
flavonoids O +
as O +
well O +
as O +
PYC O +
display O +
a O +
selective O +
activity O +
in O +
terms O +
of O +
TNF B-Gene -
- I-Gene -
α I-Gene +
secretion O -
, O +
NO O +
production O +
and O +
NF B-Gene -
- I-Gene -
κB I-Gene -
- O -
dependent O +
gene O +
expression O +
in O +
RAW O +
264.7 O +
macrophages O -
. O +

In O +
addition O -
, O +
the O +
present O +
findings O +
suggest O +
that O +
the O +
degree O +
of O +
polymerization O +
of O +
flavonoids O +
seems O +
to O +
be O +
important O +
in O +
determining O +
the O +
mechanism O -
( O -
s O -
) O +
by O +
which O +
flavonoids O +
may O +
exert O +
their O +
immunomodulatory O +
and O +
antiinflammatory O +
activity O -
. O +

The O +
concentrations O +
of O +
flavonoids O +
used O +
in O +
the O +
present O +
study O +
are O +
higher O +
than O +
those O +
readily O +
available O +
in O +
food O +
sources O +
such O +
as O +
tea O +
[ O -
31 O -
] O +
or O +
chocolate O +
[ O -
36 O -
] O +
. O +

However O -
, O +
concentrated O +
forms O +
of O +
plant O +
extracts O +
are O +
now O +
being O +
made O +
available O +
thereby O +
opening O +
the O +
possibility O +
of O +
achieving O +
concentrations O +
equivalent O +
to O +
those O +
supplemented O +
in O +
the O +
present O +
investigation O -
. O +

Acknowledgements O +
G.R. O +
is O +
supported O +
by O +
a O +
grant O +
from O +
the O +
German O +
Research O +
Society O +
( O -
DFG O +
Forschungsstipendium O +
Ri O +
884 O -
/ O -
3 O -
- O -
1 O -
) O -
. O +

The O +
authors O +
are O +
grateful O +
to O +
Dr. O +
Kuni O +
Takayama O -
, O +
Mycobacteriology O +
Research O +
Laboratory O -
, O +
William O +
S. O +
Middleton O +
Memorial O +
Veterans O +
Hospital O -
, O +
Madison O -
, O +
WI O -
, O +
USA O +
for O +
providing O +
the O +
lipid O +
A O +
analysis O +
and O +
extend O +
their O +
gratitude O +
to O +
Dr. O +
Takashi O +
Okamoto O -
, O +
Department O +
of O +
Molecular O +
Genetics O -
, O +
Nagoya O +
City O +
University O -
, O +
Medical O +
School O -
, O +
Nagoya O -
, O +
Japan O +
for O +
providing O +
the O +
plasmid O +
pGL3 O -
- O -
4κB O -
- O -
Luc O -
. O +

Little O +
efforts O +
have O +
been O +
made O +
in O +
the O +
past O +
to O +
identify O +
compounds O +
from O +
the O +
brown O -
- O -
rot O +
fungus O +
Daedalea O +
quercina O +
( O -
L. O -
) O +
Pers O -
. O +

[ O -
syn O -
. O +

Trametes O +
quercina O +
( O -
L. O -
) O +
Pilát O -
] O -
, O +
which O +
grows O +
on O +
weak O +
or O +
dead O +
stumps O +
of O +
deciduous O +
trees O -
, O +
mainly O +
oak O +
trees O -
, O +
and O +
from O +
the O +
white O -
- O -
rot O +
species O +
Daedaleopsis O +
confragosa O +
var O -
. O +

tricolor O +
( O -
Bulliard O -
) O +
Bondarzew O +
[ O -
syn O -
. O +

Lenzites O +
tricolor O +
( O -
Bulliard O -
) O -
] O -
, O +
which O +
grows O +
on O +
various O +
deciduous O +
trees O -
. O +

Only O +
ergosterol O -
, O +
ergosta-7 O -
, O +
22-dien-3β O -
- O -
ol O -
, O +
ergosterol O +
peroxide O +
( O -
5α,8α O -
- O -
epidioxyergosta-6,22-dien-3β O -
- O -
ol O -
) O +
and O +
3α O -
- O -
carboxyacetoxyquercinic O +
acid O +
( O -
3α O -
- O -
carboxyacetoxy-24-methyl-23-oxolanost-8-en-26-oic O +
acid O -
) O +
have O +
been O +
isolated O +
from O +
fruiting O +
bodies O +
of O +
D. O +
quercina O +
( O -
Adam O +
et O +
al. O -
, O +
1967a O -
; O +
Turner O +
and O +
Aldridge O -
, O +
1983 O +
) O -
. O +

Ergosterol O +
peroxide O +
is O +
believed O +
to O +
be O +
an O +
artefact O +
( O -
Adam O +
et O +
al. O -
, O +
1967b O +
) O -
. O +

From O +
D. O +
confragosa O +
var O -
. O +

tricolor O +
only O +
some O +
unusual O +
fatty O +
acids O +
have O +
been O +
described O +
earlier O +
( O -
Dembitsky O +
et O +
al. O -
, O +
1993 O +
) O -
. O +

In O +
this O +
article O -
, O +
we O +
describe O +
the O +
isolation O +
and O +
characterization O +
of O +
12 O +
compounds O -
, O +
five O +
of O +
which O +
are O +
new O +
natural O +
products O -
. O +

2 O +
Results O +
and O +
discussion O +
Fresh O +
fruiting O +
bodies O +
of O +
both O +
species O +
were O +
cut O +
in O +
small O +
pieces O +
and O +
crushed O +
in O +
liquid O +
nitrogen O -
. O +

The O +
resulting O +
powders O +
were O +
extracted O +
with O +
n O +
-hexane O -
. O +

After O +
removing O +
the O +
solvent O -
, O +
D. O +
quercina O +
was O +
first O +
extracted O +
with O +
methanol O +
and O +
the O +
obtained O +
solid O +
extract O +
finally O +
extracted O +
with O +
dichloromethane O -
. O +

D. O +
confragosa O +
var O -
. O +

tricolor O +
was O +
directly O +
extracted O +
with O +
dichloromethane O -
. O +

Both O +
dichloromethane O +
extracts O +
and O +
the O +
n O +
-hexane O +
extract O +
of O +
D. O +
quercina O +
were O +
repeatedly O +
chromatographed O +
on O +
silica O +
gel O +
with O +
step O -
- O -
gradients O +
of O +
petroleum O +
ether O -
– O -
ethyl O +
acetate O +
and O +
chloroform O -
– O -
methanol O -
. O +

2.1 O +
Daedalea O +
quercina O +
Six O +
compounds O +
were O +
identified O +
by O +
one- O +
and O +
two O -
- O -
dimensional O +
NMR O +
spectroscopy O -
, O +
mass O +
spectrometry O +
and O +
comparison O +
with O +
literature O +
data O +
as O +
polyporenic O +
acid O +
C O +
( O -
1 O +
) O -
, O +
16α O -
- O -
hydroxy-24-methylene-3-oxolanost-8-en-21-oic O +
acid O +
( O -
2 O +
) O -
, O +
16-O O +
-acetylpolyporenic O +
acid O +
C O +
( O -
3 O +
) O -
, O +
16α O -
- O -
acetoxy-24-methylene-3-oxolanost-8-en-21-oic O +
acid O +
( O -
4 O +
) O -
, O +
3α O -
- O -
carboxyacetoxyquercinic O +
acid O +
( O -
5 O +
) O +
and O +
ergosterol O +
peroxide O +
( O -
6 O +
) O -
. O +

To O +
our O +
knowledge O -
, O +
compounds O +
3 O +
and O +
4 O +
are O +
new O +
natural O +
products O -
. O +

In O +
addition O -
, O +
compounds O +
1 O +
and O +
2 O +
are O +
reported O +
here O +
for O +
the O +
first O +
time O +
as O +
constituents O +
of O +
D. O +
quercina O +
, O +
and O +
the O +
NMR O +
data O +
of O +
compounds O +
2 O +
and O +
4 O +
were O +
not O +
reported O +
before O -
. O +

Compound O +
1 O +
was O +
previously O +
isolated O +
from O +
various O +
fungi O -
, O +
e.g. O +
Fomitopsis O +
pinicola O +
, O +
and O +
converted O +
to O +
its O +
16-O O +
-acetyl O +
derivative O +
( O -
Keller O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Compound O +
2 O +
was O +
isolated O +
previously O +
from O +
the O +
closely O +
related O +
fungus O +
Daedalea O +
dickinsii O +
( O -
Inouye O +
et O +
al. O -
, O +
1970 O +
) O -
. O +

The O +
NMR O +
data O +
of O +
compound O +
5 O +
was O +
described O +
earlier O +
( O -
Chairul O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

Some O +
of O +
the O +
earlier O +
assignments O +
appeared O +
to O +
be O +
incorrect O -
. O +

Compound O +
7 O +
showed O +
four O +
olefinic O +
carbons O +
( O -
δ O +
133.31 O -
, O +
135.16 O -
, O +
125.46 O -
, O +
148.05 O -
) O -
, O +
one O +
acid O +
( O -
δ O +
178.31 O -
) O +
and O +
two O +
ketone O +
carbon O +
signals O +
( O -
δ O +
201.83 O -
, O +
217.90 O -
) O -
. O +

The O +
chemical O +
shifts O +
of O +
the O +
keto O +
function O +
at O +
δ O +
201.83 O -
, O +
the O +
exocyclic O +
methylene O +
group O +
at O +
δ O +
125.46 O +
and O +
observed O +
long O -
- O -
range O +
correlations O +
indicated O +
a O +
lanost-8-ene O +
structure O +
with O +
a O +
23-oxo-24-methylene O +
functionalized O +
side O -
- O -
chain O +
and O +
an O +
acid O +
function O +
in O +
position O +
26 O +
which O +
is O +
common O +
to O +
previously O +
identified O +
triterpenic O +
acids O +
from O +
this O +
species O -
. O +

Analysis O +
of O +
the O +
NMR O +
spectra O +
( O -
DEPT O -
, O +
HMQC O -
, O +
HMBC O -
) O +
and O +
their O +
comparison O +
with O +
the O +
data O +
of O +
other O +
isolated O +
metabolites O +
indicated O +
the O +
structure O +
24-methylene-3,23-dioxolanost-8-en-26-oic O +
acid O +
for O +
which O +
we O +
propose O +
the O +
name O +
quercinic O +
acid O +
B. O +
Compound O +
8 O +
showed O +
two O +
olefinic O +
( O -
δ O +
133.33 O -
, O +
136.74 O -
) O +
and O +
two O +
hydroxylic O +
methine O +
carbons O +
( O -
δ O +
71.57 O -
, O +
74.64 O -
) O +
as O +
well O +
as O +
one O +
ketone O +
( O -
δ O +
213.31 O -
) O +
and O +
one O +
carboxylic O +
function O +
( O -
δ O +
178.04 O -
) O -
. O +

The O +
hydroxylic O +
methine O +
proton O +
at O +
δ O +
71.57 O +
showed O +
long O -
- O -
range O +
coupling O +
with O +
the O +
quaternary O +
carbons O +
13 O +
and O +
14 O +
( O -
δ O +
52.04 O -
, O +
49.36 O -
) O +
as O +
well O +
as O +
with O +
a O +
methylene O +
group O +
at O +
δ O +
34.62 O -
. O +

Further O +
analysis O +
left O +
carbon O +
12 O +
as O +
the O +
only O +
possible O +
position O +
for O +
this O +
hydroxy O +
function O -
. O +

The O +
other O +
hydroxyl O +
group O +
could O +
be O +
assigned O +
to O +
carbon O +
3 O +
as O +
the O +
proton O +
showed O +
long O -
- O -
range O +
couplings O +
with O +
carbons O +
2 O -
, O +
4 O -
, O +
5 O +
and O +
with O +
the O +
methyl O +
carbons O +
28 O +
and O +
29 O -
. O +

Futher O +
analysis O +
of O +
the O +
NMR O +
data O +
indicated O +
presence O +
of O +
a O +
24-methyl-23-oxo O +
side O +
chain O +
with O +
an O +
acid O +
function O +
in O +
position O +
26 O -
. O +

In O +
the O +
NOESY O +
spectrum O -
, O +
the O +
hydroxylic O +
methine O +
proton O +
( O -
δ O +
4.39 O -
) O +
only O +
showed O +
a O +
correlation O +
with O +
the O +
methyl O +
protons O +
at O +
carbon O +
30 O +
( O -
δ O +
0.94 O -
) O +
indicating O +
a O +
β O -
- O -
configuration O -
. O +

The O +
hydroxylic O +
methine O +
proton O +
at O +
carbon O +
3 O +
( O -
δ O +
3.63 O -
) O +
only O +
showed O +
a O +
correlation O +
with O +
the O +
protons O +
connected O +
to O +
carbon O +
28 O +
( O -
δ O +
0.92 O -
) O +
also O +
indicating O +
a O +
β O -
- O -
configuration O -
. O +

Therefore O -
, O +
this O +
compound O +
was O +
3β,12β O -
- O -
dihydroxy-24-methyl-23-oxolanost-8-en-26-oic O +
acid O +
for O +
which O +
we O +
propose O +
the O +
name O +
quercinic O +
acid O +
C. O +
Compound O +
9 O +
showed O +
two O +
olefinic O +
( O -
δ O +
133.84 O -
, O +
134.85 O -
) O +
and O +
two O +
methine O +
carbon O +
signals O +
( O -
δ O +
75.79 O -
, O +
79.73 O -
) O +
as O +
well O +
as O +
one O +
carboxylic O +
carbon O +
at O +
δ O +
177.36 O -
. O +

In O +
addition O -
, O +
a O +
quaternary O +
carbon O +
signal O +
at O +
δ O +
109.96 O +
was O +
found O +
which O +
corresponds O +
to O +
a O +
semi O -
- O -
acetalic O +
carbon O +
atom O -
. O +

The O +
latter O +
showed O +
long O -
- O -
range O +
couplings O +
with O +
the O +
hydrogen O +
atoms O +
at O +
carbons O +
25 O +
( O -
δ O +
2.22 O -
) O -
, O +
24 O +
( O -
δ O +
2.12 O -
) O -
, O +
20 O +
( O -
δ O +
2.24 O -
) O +
and O +
with O +
the O +
hydroxylic O +
methine O +
proton O +
at O +
carbon O +
12 O +
( O -
δ O +
4.34 O -
) O +
( O -
HMBC O -
) O -
. O +

This O +
led O +
to O +
the O +
conclusion O +
that O +
formation O +
of O +
a O +
cyclic O +
acetal O +
had O +
taken O +
place O +
involving O +
the O +
oxygen O +
at O +
position O +
12 O +
and O +
the O +
carbonyl O +
group O +
in O +
position O +
23 O +
of O +
quercinic O +
acid O +
C O +
( O -
8 O +
) O -
. O +

Comparison O +
of O +
the O +
chemical O +
shifts O +
of O +
the O +
carbons O +
in O +
ring O +
A O +
of O +
the O +
triterpene O +
skeleton O +
with O +
the O +
data O +
of O +
many O +
previously O +
identified O +
compounds O +
indicated O +
a O +
3α O -
- O -
configuration O -
, O +
so O +
that O +
this O +
compound O +
was O +
not O +
a O +
simple O +
artefact O +
of O +
compound O +
8 O +
. O +

Analysis O +
of O +
all O +
spectral O +
data O +
led O +
to O +
the O +
conclusion O +
that O +
compound O +
9 O +
was O +
12β,23-epoxy-3α,23-dihydroxy-24-methyllanost-8-en-26-oic O +
acid O +
for O +
which O +
we O +
propose O +
the O +
name O +
3α O -
- O -
oxepanoquercinic O +
acid O +
C. O +
From O +
the O +
n O +
-hexane O +
extract O -
, O +
a O +
15:1 O +
mixture O +
of O +
( O -
E O +
) O -
- O -
( O -
10 O +
) O +
and O +
( O -
Z O +
) O -
-methyl O +
4-methoxycinnamate O +
( O -
11 O +
) O +
was O +
isolated O -
. O +

The O +
identification O +
was O +
carried O +
out O +
by O +
comparison O +
of O +
the O +
GC O -
- O -
MS O +
and O +
NMR O +
spectra O +
with O +
literature O +
data O +
( O -
10 O +
: O +
van O +
Heerden O +
et O +
al. O -
, O +
1996 O +
, O +
11 O +
: O +
Jacobsen O +
et O +
al. O -
, O +
1994 O +
) O -
. O +

Compound O +
10 O +
was O +
previously O +
isolated O +
from O +
the O +
fungus O +
Lentinus O +
lepideus O +
( O -
Wat O +
and O +
Towers O -
, O +
1977 O +
) O -
. O +

A O +
reference O +
sample O +
of O +
methyl O +
( O -
E O +
) O -
-4-methoxycinnamate O +
was O +
prepared O +
by O +
treatment O +
of O +
authentic O +
( O -
E O +
) O -
-4-methoxycinnamic O +
acid O +
with O +
diazomethane O -
. O +

The O +
spectroscopic O +
data O +
corresponded O +
to O +
those O +
of O +
compound O +
10 O +
. O +

2.2 O +
Daedaleopsis O +
confragosa O +
var O -
. O +

tricolor O +
From O +
the O +
dichloromethane O +
extract O -
, O +
compounds O +
5 O +
and O +
6 O +
were O +
isolated O -
. O +

These O +
compounds O +
are O +
the O +
first O +
triterpene O +
derivatives O +
isolated O +
from O +
this O +
species O +
and O +
were O +
identified O +
by O +
comparison O +
of O +
their O +
spectral O +
data O +
with O +
literature O +
data O -
. O +

Furthermore O -
, O +
a O +
mixture O +
of O +
compound O +
5 O +
and O +
a O +
very O +
similar O +
compound O +
was O +
obtained O -
. O +

The O +
latter O +
one O +
showed O +
different O +
carbon O +
shifts O +
for O +
the O +
side O +
chain O +
compared O +
with O +
compound O +
5 O +
. O +

The O +
additional O +
presence O +
of O +
an O +
olefinic O +
methylene O +
carbon O +
at O +
δ O +
125.34 O +
and O +
a O +
quaternary O +
carbon O +
at O +
δ O +
148.05 O +
as O +
well O +
as O +
the O +
upfield O +
shift O +
of O +
the O +
carbonyl O +
carbon O +
to O +
δ O +
201.54 O +
indicated O +
that O +
this O +
compound O +
was O +
3α O -
- O -
carboxyacetoxy-24-methylene-23-oxolanost-8-en-26-oic O +
acid O +
( O -
12 O +
) O -
. O +

This O +
was O +
confirmed O +
by O +
analysis O +
of O +
the O +
two O -
- O -
dimensional O +
NMR O +
spectra O -
. O +

This O +
compound O +
has O +
been O +
isolated O +
previously O +
from O +
an O +
unidentified O +
Indonesian O +
Ganoderma O +
species O +
( O -
Chairul O +
et O +
al. O -
, O +
1990 O +
) O +
but O +
some O +
NMR O +
assignments O +
appeared O +
to O +
be O +
incorrect O -
. O +

3 O +
Experimental O +
3.1 O +
Plant O +
material O +
Fruiting O +
bodies O +
of O +
Daedalea O +
quercina O +
were O +
collected O +
in O +
October O +
1998 O +
near O +
Salzgitter O +
in O +
the O +
Harz O +
Mountains O +
and O +
fruiting O +
bodies O +
of O +
Daedaleopsis O +
confragosa O +
var O -
. O +

tricolor O +
in O +
September O +
1999 O +
in O +
the O +
Sachsenwald O +
near O +
Hamburg O +
( O -
both O +
in O +
northern O +
Germany O -
) O +
( O -
Gerhardt O -
, O +
1996 O +
) O -
. O +

3.2 O +
Extraction O +
3.2.1 O +
Daedalea O +
quercina O +
One O +
kilogram O +
of O +
fresh O +
fruiting O +
bodies O +
were O +
crushed O +
in O +
liquid O +
nitrogen O -
. O +

The O +
resulting O +
powder O +
was O +
extracted O +
twice O +
with O +
n O +
-hexane O +
( O -
2 O +
× O +
2 O +
l O -
, O +
6 O +
days O +
each O -
) O +
and O +
then O +
with O +
methanol O +
( O -
2 O +
l O -
, O +
6 O +
days O -
) O -
. O +

The O +
methanol O +
extract O +
( O -
5.3 O +
g O +
of O +
a O +
green O +
solid O -
) O +
was O +
extracted O +
with O +
250 O +
ml O +
of O +
dichloromethane O +
( O -
1 O +
day O +
under O +
stirring O -
) O +
yielding O +
4.8 O +
g O +
of O +
a O +
pale O +
green O +
solid O -
. O +

3.2.2 O +
Daedaleopsis O +
confragosa O +
var O -
. O +

tricolor O +
750 O +
g O +
of O +
fresh O +
fruiting O +
bodies O +
were O +
crushed O +
in O +
liquid O +
nitrogen O -
. O +

The O +
resulting O +
powder O +
was O +
extracted O +
twice O +
with O +
n O +
-hexane O +
( O -
2 O +
× O +
2 O +
l O -
, O +
6 O +
days O +
each O -
) O -
, O +
with O +
dichloromethane O +
( O -
2 O +
l O -
, O +
6 O +
days O -
) O -
, O +
yielding O +
6.7 O +
g O +
of O +
a O +
pale O +
green O +
solid O -
, O +
and O +
finally O +
with O +
methanol O +
( O -
2 O +
l O -
, O +
6 O +
days O -
) O -
. O +

3.3 O +
Isolation O +
3.3.1 O +
Daedalea O +
quercina O +
The O +
dichloromethane O +
extract O +
was O +
submitted O +
to O +
flash O +
column O +
chromatography O +
on O +
silica O +
gel O +
with O +
a O +
stepwise O +
gradient O +
of O +
petroleum O +
ether O -
– O -
ethyl O +
acetate O +
( O -
from O +
39:1 O +
to O +
0:1 O -
, O +
v O -
/ O -
v O -
) O +
and O +
was O +
rechromatographed O +
several O +
times O +
on O +
silica O +
gel O +
using O +
stepwise O +
gradients O +
of O +
petroleum O +
ether O -
– O -
ethyl O +
acetate O +
( O -
from O +
39:1 O +
to O +
0:1 O -
, O +
v O -
/ O -
v O -
) O +
and O +
chloroform O -
- O -
methanol O +
( O -
from O +
49:1 O +
to O +
9:1 O -
, O +
v O -
/ O -
v O -
) O -
. O +

The O +
following O +
yields O +
were O +
obtained O -
: O +
1 O +
( O -
see O +
below O -
) O -
, O +
2 O +
( O -
15 O +
mg O -
) O -
, O +
3 O +
, O +
4 O +
( O -
see O +
below O -
) O -
, O +
5 O +
( O -
30 O +
mg O -
) O -
, O +
6 O +
( O -
55 O +
mg O -
) O -
, O +
7 O +
( O -
14 O +
mg O -
) O -
, O +
8 O +
( O -
10 O +
mg O -
) O -
, O +
9 O +
( O -
50 O +
mg O -
) O -
. O +

compounds O +
3 O +
and O +
4 O +
were O +
obtained O +
only O +
as O +
a O +
mixture O +
and O +
1 O +
was O +
only O +
obtained O +
admixed O +
with O +
2 O +
, O +
but O +
because O +
of O +
the O +
existence O +
of O +
similar O +
reference O +
compounds O -
, O +
further O +
separation O +
was O +
not O +
necessary O -
. O +

The O +
n O +
-hexane O +
extract O +
was O +
chromatographed O +
in O +
the O +
same O +
manner O +
and O +
yielded O +
5 O +
mg O +
of O +
a O +
15:1 O +
mixture O +
of O +
10 O +
and O +
11 O +
. O +

3.3.2 O +
Daedaleopsis O +
confragosa O +
var O -
. O +

tricolor O +
The O +
dichloromethane O +
extract O +
was O +
chromatographed O +
in O +
the O +
same O +
manner O +
as O +
described O +
for O +
the O +
extracts O +
of O +
D. O +
quercina O -
. O +

Yields O -
: O +
5 O +
( O -
5 O +
mg O -
) O -
, O +
a O +
3:1 O +
mixture O +
of O +
5 O +
and O +
12 O +
( O -
100 O +
mg O -
) O +
and O +
6 O +
( O -
10 O +
mg O -
) O -
. O +

3.4 O +
TLC O +
Silica O +
gel O +
60F254 O +
( O -
Merck O -
) O -
; O +
eluent O +
chloroform-2-propanol O +
9:1 O -
, O +
v O -
/ O -
v O +
and O +
petroleum O +
ether O -
– O -
ethyl O +
acetate O -
, O +
1:1 O -
, O +
v O -
/ O -
v O -
; O +
detection O +
by O +
spraying O +
with O +
sulphuric O +
acid O +
( O -
10 O -
% O +
in O +
ethanol O -
) O -
. O +

3.5 O +
Column O +
chromatography O +
Various O +
column O +
sizes O +
with O +
silica O +
gel O +
0.063–0.040 O +
mm O +
( O -
Macherey O -
– O -
Nagel O -
) O -
. O +

3.6 O +
Gas O +
chromatography O +
Carlo O +
Erba O +
HRGC O +
5300 O +
Mega O +
Series O +
instrument O +
equipped O +
with O +
a O +
fused O +
silica O +
capillary O +
( O -
25 O +
m O -
) O +
coated O +
with O +
CPSil-5CB O +
( O -
Chrompack O -
) O -
, O +
split O +
injector O +
and O +
FID O -
. O +

Temperature O +
program O -
: O +
110–230 O -
° O -
C O -
, O +
3 O -
° O -
C O -
/ O -
min O -
. O +

Carrier O +
gas O -
: O +
hydrogen O -
. O +

3.7 O +
GC O -
- O -
MS O +
VG O +
Analytical O +
VG O +
70 O -
- O -
250S O +
mass O +
spectrometer O +
( O -
EI O -
, O +
70 O +
eV O -
) O +
coupled O +
to O +
a O +
Hewlett O -
- O -
Packard O +
HP O +
5890 O +
gas O +
chromatograph O -
. O +

Carrier O +
gas O -
: O +
helium O -
. O +

3.8 O +
NMR O +
spectroscopy O +
Bruker O +
WM O +
400 O +
at O +
400.16 O +
( O -
1 O +
H O -
) O +
and O +
100.61 O +
MHz O +
( O -
13 O +
C O -
) O +
and O +
Bruker O +
DRX O +
500 O +
at O +
500.13 O +
( O -
1 O +
H O -
) O +
and O +
125.76 O +
MHz O +
( O -
13 O +
C O -
) O -
. O +

All O +
NMR O +
shifts O +
are O +
relative O +
to O +
TMS O -
. O +

3.9 O +
Polarimetry O +
Perkin O -
– O -
Elmer O +
241 O -
, O +
l O +
= O -
1 O +
dm O -
, O +
λ O +
= O -
589 O +
nm O -
. O +

3.10 O +
EI O -
- O -
MS O +
70 O +
eV O -
, O +
VG O +
Analytical O +
70 O -
- O -
250S O -
, O +
exact O +
mass O +
measurement O +
at O +
resolution O +
10,000 O -
, O +
direct O +
probe O +
sample O +
introduction O -
. O +

3.11 O +
Compound O +
1 O +
, O +
polyporenic O +
acid O +
C O -
, O +
16α O -
- O -
hydroxy-24-methylene-3-oxolanosta-7,9 O -
( O -
11 O -
) O -
-dien-21-oic O +
acid O +
Obtained O +
only O +
as O +
a O +
mixture O +
with O +
2 O +
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
pyridine O -
- O -
d5 O +
): O +
see O +
Table O +
1 O +
. O +

3.12 O +
Compound O +
2 O +
, O +
16α O -
- O -
hydroxy-24-methylene-3-oxolanost-8-en-21-oic O +
acid O +
1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
pyridine O -
- O -
d5 O +
): O +
δ O +
0.98 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
3.1 O +
Hz O -
) O -
, O +
0.99 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
3.1 O +
Hz O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
s O +
, O +
H-29 O -
) O -
, O +
1.05 O +
( O -
3H O -
, O +
s O +
, O +
H-18 O -
) O -
, O +
1.13 O +
( O -
3H O -
, O +
s O +
, O +
H-19 O -
) O -
, O +
1.14 O +
( O -
3H O -
, O +
s O +
, O +
H-28 O -
) O -
, O +
1.46 O +
( O -
3H O -
, O +
s O +
, O +
H-30 O -
) O -
, O +
4.53 O +
( O -
1H O -
, O +
dd O +
, O +
J=7.6 O -
, O +
6.6 O +
Hz O -
, O +
H-16 O -
) O -
, O +
4.85 O +
( O -
1H O -
, O +
s O +
, O +
H-31a O +
) O -
, O +
4.98 O +
( O -
1H O -
, O +
s O +
, O +
H-31b O +
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
pyridine O -
- O -
d5 O +
): O +
see O +
Table O +
1 O +
. O +

3.13 O +
Compound O +
3 O +
, O +
16-O O +
-acetylpolyporenic O +
acid O +
C O -
, O +
16α O -
- O -
acetoxy-24-methylene-3-oxolanosta-7,9 O -
( O -
11 O -
) O -
-dien-21-oic O +
acid O +
Obtained O +
only O +
as O +
a O +
mixture O +
with O +
4 O +
. O +
13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
see O +
Table O +
1 O +
. O +

3.14 O +
Compound O +
4 O +
, O +
16α O -
- O -
acetoxy-24-methylene-3-oxolanost-8-en-21-oic O +
acid O +
Obtained O +
only O +
as O +
a O +
mixture O +
with O +
3 O +
. O +
13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
see O +
Table O +
1 O +
. O +

3.15 O +
Compound O +
5 O +
, O +
3α O -
- O -
carboxyacetoxyquercinic O +
acid O -
, O +
3α O -
- O -
carboxyacetoxy-24-methyl-23-oxolanost-8-en-26-oic O +
acid O +
1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
0.74 O +
( O -
3H O -
, O +
s O +
, O +
H-18 O -
) O -
, O +
0.87 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
7.6 O +
Hz O -
, O +
H-21 O -
) O -
, O +
0.89 O +
( O -
3H O -
, O +
s O +
, O +
H-29 O -
) O -
, O +
0.93 O +
( O -
3H O -
, O +
s O +
, O +
H-30 O -
) O -
, O +
0.94 O +
( O -
3H O -
, O +
s O +
, O +
H-28 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
s O +
, O +
H-19 O -
) O -
, O +
1.09 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
7.1 O +
Hz O -
, O +
H-31 O -
) O -
, O +
1.21 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6.9 O +
Hz O -
, O +
H-27 O -
) O -
, O +
3.45 O +
( O -
2H O -
, O +
s O +
, O +
H-2′ O -
) O -
, O +
4.76 O +
( O -
1H O -
, O +
br O -
. O +

s O +
, O +
H-3 O -
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
see O +
Table O +
1 O +
. O +

EI O -
- O -
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
528 O +
[ O -
M O +
− O +
CO2 O +
] O -
+ O +
( O -
9 O -
) O -
, O +
513 O +
[ O -
M O +
− O +
CO2 O +
− O +
Me O -
] O -
+ O +
( O -
13 O -
) O -
, O +
453 O +
( O -
80 O -
) O -
, O +
435 O +
( O -
21 O -
) O -
, O +
309 O +
( O -
52 O -
) O -
, O +
153 O +
( O -
71 O -
) O -
, O +
43 O +
( O -
100 O -
) O -
. O +

3.16 O +
Compound O +
6 O +
, O +
ergosterol O +
peroxide O -
, O +
5α,8α O -
- O -
epidioxyergosta-6,22-dien-3β O -
- O -
ol O +
Waxy O +
brown O +
solid O -
, O +
[ O -
α O +
20 O +
−20.0 O -
] O +
( O -
CHCl3 O +
, O +
c O +
0.2 O -
) O -
. O +

1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
0.82 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
12.6 O +
Hz O -
, O +
H-26 O -
) O -
, O +
0.82 O +
( O -
3H O -
, O +
s O +
, O +
H-18 O -
) O -
, O +
0.83 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
17.1 O +
Hz O -
, O +
H-27 O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
s O +
, O +
H-19 O -
) O -
, O +
0.91 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6.6 O +
Hz O -
, O +
H-21 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6.6 O +
Hz O -
, O +
H-28 O -
) O -
, O +
3.97 O +
( O -
1H O -
, O +
m O +
, O +
H-3 O -
) O -
, O +
5.14 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
15.3 O -
, O +
8.2 O +
Hz O -
, O +
H-23 O -
) O -
, O +
5.22 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
15.2 O -
, O +
7.6 O +
Hz O -
, O +
H-22 O -
) O -
, O +
6.24 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
8.7 O +
Hz O -
, O +
H-7 O -
) O -
, O +
6.51 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
8.7 O +
Hz O -
, O +
H-6 O -
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
see O +
Table O +
1 O +
. O +

EI O -
- O -
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
396 O +
[ O -
M O +
− O +
O2 O +
] O -
+ O +
( O -
30 O -
) O -
, O +
363 O +
( O -
15 O -
) O -
, O +
81 O +
( O -
41 O -
) O -
, O +
69 O +
( O -
100 O -
) O -
. O +

3.17 O +
Compound O +
7 O +
, O +
quercinic O +
acid O +
B O -
, O +
24-methylene-3,23-dioxolanost-8-en-26-oic O +
acid O +
Waxy O +
yellow O +
solid O -
, O +
[ O -
α O +
20 O +
+ O -
37.5 O -
] O +
( O -
CHCl3 O +
, O +
c O +
1.0 O -
) O -
. O +

1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
0.77 O +
( O -
3H O -
, O +
s O +
, O +
H-18 O -
) O -
, O +
0.90 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
8.1 O +
Hz O -
, O +
H-21 O -
) O -
, O +
0.91 O +
( O -
3H O -
, O +
s O +
, O +
H-30 O -
) O -
, O +
1.07 O +
( O -
3H O -
, O +
s O +
, O +
H-28 O -
) O -
, O +
1.10 O +
( O -
3H O -
, O +
s O +
, O +
H-29 O -
) O -
, O +
1.13 O +
( O -
3H O -
, O +
s O +
, O +
H-19 O -
) O -
, O +
1.36 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
7.2 O +
Hz O -
, O +
H-27 O -
) O -
, O +
5.95 O +
( O -
1H O -
, O +
s O +
, O +
H-31a O +
) O -
, O +
6.20 O +
( O -
1H O -
, O +
s O +
, O +
H-31b O +
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
see O +
Table O +
1 O +
. O +

EI O -
- O -
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
482 O +
[ O -
M O -
] O -
+ O +
( O -
8) O -
, O +
467 O +
[ O -
M O +
− O +
Me O -
] O -
+ O +
( O -
23 O -
) O -
, O +
449 O +
[ O -
M O +
− O +
Me O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
13 O -
) O -
, O +
325 O +
( O -
87 O -
) O -
, O +
151 O +
( O -
100 O -
) O -
, O +
69 O +
( O -
94 O -
) O -
. O +

3.18 O +
Compound O +
8 O +
, O +
quercinic O +
acid O +
C O -
, O +
3β,12β O -
- O -
dihydroxy-24-methyl-23-oxolanost-8-en-26-oic O +
acid O +
Amorphous O +
light O +
brown O +
solid O -
, O +
[ O -
α O +
20 O +
+ O -
86.0 O -
] O +
( O -
CH2 O +
Cl2 O +
, O +
c O +
0.05 O -
) O -
. O +

1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
pyridine O -
- O -
d5 O +
): O +
δ O +
0.92 O +
( O -
3H O -
, O +
s O +
, O +
H-28 O -
) O -
, O +
0.94 O +
( O -
3H O -
, O +
s O +
, O +
H-30 O -
) O -
, O +
1.05 O +
( O -
3H O -
, O +
s O +
, O +
H-18 O -
) O -
, O +
1.08 O +
( O -
3H O -
, O +
s O +
, O +
H-19 O -
) O -
, O +
1.15 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6.9 O +
Hz O -
, O +
H-31 O -
) O -
, O +
1.23 O +
( O -
3H O -
, O +
s O +
, O +
H-29 O -
) O -
, O +
1.34 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
7.2 O +
Hz O -
, O +
H-27 O -
) O -
, O +
1.35 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
7.3 O +
Hz O -
, O +
H-21 O -
) O -
, O +
2.57 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.3 O -
, O +
10.1 O +
Hz O -
, O +
H-20 O -
) O -
, O +
2.86 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.6 O -
, O +
6.9 O +
Hz O -
, O +
H-22a O +
) O -
, O +
3.17 O +
( O -
2H O -
, O +
m O +
, O +
H-24 O -
, O +
H-25 O -
) O -
, O +
3.63 O +
( O -
1H O -
, O +
br O -
. O +

s O +
, O +
H-3 O -
) O -
, O +
4.39 O +
( O -
1H O -
, O +
t O +
, O +
J O +
= O -
7.9 O +
Hz O -
, O +
H-12 O -
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
pyridine O -
- O -
d5 O +
): O +
see O +
Table O +
1 O +
. O +

EI O -
- O -
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
502 O +
[ O -
M O -
] O -
+ O +
( O -
7 O -
) O -
, O +
484 O +
[ O -
M O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
11 O -
) O -
, O +
469 O +
[ O -
M O +
− O +
H2 O +
O O +
− O +
Me O -
] O -
+ O +
( O -
100 O -
) O -
, O +
451 O +
[ O -
M O +
− O +
2 O +
H2 O +
O O +
− O +
Me O -
] O -
+ O +
( O -
47 O -
) O -
, O +
325 O +
( O -
38 O -
) O -
, O +
309 O +
( O -
31 O -
) O -
, O +
69 O +
( O -
74 O -
) O -
. O +

3.19 O +
Compound O +
9 O +
, O +
3α O -
- O -
oxepanoquercinic O +
acid O +
C O -
, O +
12β,23-epoxy-3α,23-dihydroxy-24-methyllanost-8-en-26-oic O +
acid O +
Amorphous O +
white O +
solid O -
. O +

1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
0.76 O +
( O -
3H O -
, O +
s O +
, O +
H-18 O -
) O -
, O +
0.84 O +
( O -
3H O -
, O +
s O +
, O +
H-29 O -
) O -
, O +
0.89 O +
( O -
3H O -
, O +
s O +
, O +
H-28 O -
) O -
, O +
0.98 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
8.2 O +
Hz O -
, O +
H-21 O -
) O -
, O +
0.99 O +
( O -
3H O -
, O +
s O +
, O +
H-19 O -
) O -
, O +
0.99 O +
( O -
3H O -
, O +
s O +
, O +
H-30 O -
) O -
, O +
1.10 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6.7 O +
Hz O -
, O +
H-31 O -
) O -
, O +
1.24 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O +
7.1 O +
Hz O -
, O +
H-27 O -
) O -
, O +
2.65 O +
( O -
1H O -
, O +
m O +
, O +
H-17 O -
) O -
, O +
4.34 O +
( O -
1H O -
, O +
t O +
, O +
J O +
= O -
8.1 O +
Hz O -
, O +
H-12 O -
) O -
, O +
4.74 O +
( O -
1H O -
, O +
br O -
. O +

s O +
, O +
H-3 O -
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
see O +
Table O +
1 O +
. O +

3.20 O +
Compound O +
10 O +
, O +
methyl O +
( O -
E O +
) O -
-4-methoxycinnamate O +
Obtained O +
only O +
as O +
a O +
mixture O +
with O +
11 O +
. O +

1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
3.80 O +
( O -
3H O -
, O +
s O +
, O +
OMe O -
) O -
, O +
3.85 O +
( O -
3H O -
, O +
s O +
, O +
COOMe O -
) O -
, O +
6.32 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
16.2 O +
Hz O -
, O +
H-8 O -
) O -
, O +
6.92 O +
( O -
2H O -
, O +
dt O +
, O +
J O +
= O -
9.1 O -
, O +
1.6 O +
Hz O -
, O +
H-3 O -
, O +
H-5 O -
) O -
, O +
7.49 O +
( O -
2H O -
, O +
dt O +
, O +
J O +
= O -
9.1 O -
, O +
1.6 O +
Hz O -
, O +
H-2 O -
, O +
H-6 O -
) O -
, O +
7.66 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
16.2 O +
Hz O -
, O +
H-7 O -
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
51.61 O +
( O -
q O +
, O +
COOMe O -
) O -
, O +
55.41 O +
( O -
q O +
, O +
OMe O -
) O -
, O +
114.36 O +
( O -
d O +
, O +
C-3 O -
, O +
C-5 O -
) O -
, O +
115.31 O +
( O -
d O +
, O +
C-8 O -
) O -
, O +
127.16 O +
( O -
s O +
, O +
C-1 O -
) O -
, O +
129.75 O +
( O -
d O +
, O +
C-2 O -
, O +
C-6 O -
) O -
, O +
144.56 O +
( O -
d O +
, O +
C-7 O -
) O -
, O +
153.74 O +
( O -
s O +
, O +
C-4 O -
) O -
, O +
161.43 O +
( O -
s O +
, O +
C-9 O -
) O -
. O +

EI O -
- O -
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
192 O +
[ O -
M O -
] O -
+ O +
( O -
72 O -
) O -
, O +
161 O +
[ O -
M O +
− O +
OMe O -
] O -
+ O +
( O -
100 O -
) O -
, O +
133 O +
[ O -
M O +
− O +
COOMe O -
] O -
+ O +
( O -
38 O -
) O -
, O +
118 O +
( O -
13 O -
) O -
, O +
89 O +
( O -
18 O -
) O -
. O +

3.21 O +
Preparation O +
of O +
methyl O +
( O -
E O +
) O -
-4-methoxycinnamate O +
Commercially O +
available O +
( O -
E O +
) O -
-4-methoxycinnamic O +
acid O +
was O +
recrystallized O +
from O +
chloroform O +
and O +
2 O +
mg O +
were O +
treated O +
with O +
diazomethane O +
solution O +
until O +
a O +
yellow O +
colour O +
remained O -
, O +
indicating O +
an O +
excess O +
of O +
diazomethane O -
. O +

Finally O -
, O +
the O +
solvent O +
and O +
the O +
diazomethane O +
were O +
removed O +
in O +
a O +
stream O +
of O +
nitrogen O +
yielding O +
pure O +
methyl O +
( O -
E O +
) O -
-4-methoxycinnamate O -
. O +

3.22 O +
Compound O +
11 O +
, O +
methyl O +
( O -
Z O +
) O -
-4-methoxycinnamate O +
Obtained O +
only O +
as O +
a O +
mixture O +
with O +
10 O +
. O +

1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
3.80 O +
( O -
3H O -
, O +
s O +
, O +
OMe O -
) O -
, O +
3.85 O +
( O -
3H O -
, O +
s O +
, O +
COOMe O -
) O -
, O +
5.85 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
12.7 O +
Hz O -
, O +
H-8 O -
) O -
, O +
6.86 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
12.7 O +
Hz O -
, O +
H-7 O -
) O -
, O +
6.90 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.7 O +
Hz O -
, O +
H-3 O -
, O +
H-5 O -
) O -
, O +
7.70 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.7 O +
Hz O -
, O +
H-2 O -
, O +
H-6 O -
) O -
. O +

EI O -
- O -
MS O +
m O -
/ O -
z O +
( O -
rel O -
. O +

int O -
. O -
) O -
: O +
192 O +
[ O -
M O -
] O -
+ O +
( O -
69 O -
) O -
, O +
161 O +
[ O -
M O +
− O +
OMe O -
] O -
+ O +
( O -
100 O -
) O -
, O +
133 O +
[ O -
M O +
− O +
COOMe O -
] O -
+ O +
( O -
44 O -
) O -
, O +
118 O +
( O -
21 O -
) O -
, O +
89 O +
( O -
32 O -
) O -
. O +

3.23 O +
Compound O +
12 O +
, O +
3α O -
- O -
carboxyacetoxy-24-methylene-23-oxolanost-8-en-26-oic O +
acid O +
Obtained O +
only O +
as O +
a O +
mixture O +
with O +
5 O +
. O +

1 O +
H O -
- O -
NMR O +
( O -
400.13 O +
MHz O -
, O +
CDCl3 O +
): O +
δ O +
0.74 O +
( O -
3H O -
, O +
s O +
, O +
H-18 O -
) O -
, O +
0.89 O +
( O -
3H O -
, O +
s O +
, O +
H-29 O -
) O -
, O +
0.90 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
7.6 O +
Hz O -
, O +
H-21 O -
) O -
, O +
0.93 O +
( O -
3H O -
, O +
s O +
, O +
H-30 O -
) O -
, O +
0.94 O +
( O -
3H O -
, O +
s O +
, O +
H-28 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
s O +
, O +
H-19 O -
) O -
, O +
1.36 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
7.2 O +
Hz O -
, O +
H-27 O -
) O -
, O +
3.46 O +
( O -
2H O -
, O +
s O +
, O +
H-2′ O -
) O -
, O +
4.76 O +
( O -
1H O -
, O +
br O -
. O +

s O +
, O +
H-3 O -
) O -
, O +
5.94 O +
( O -
1H O -
, O +
s O +
, O +
H-31a O +
) O -
, O +
6.20 O +
( O -
1H O -
, O +
s O +
, O +
H-31b O +
) O -
. O +

13 O +
C O -
- O -
NMR O +
( O -
100.61 O +
MHz O -
, O +
CDCl3 O +
): O +
see O +
Table O +
1 O +
. O +

Acknowledgements O +

The O +
financial O +
support O +
of O +
the O +
Fonds O +
der O +
Chemischen O +
Industrie O +
is O +
gratefully O +
acknowledged O -
. O +

We O +
also O +
thank O +
Helmut O +
and O +
Gisela O +
Rösecke O +
for O +
collecting O +
the O +
fruiting O +
bodies O +
of O +
Daedalea O +
quercina O +
. O +

Piper O +
methysticum O +
Forst O -
. O +

f. O +
( O -
Kava O +
Kava O -
) O +
belongs O +
to O +
the O +
family O +
Piperaceae O -
, O +
and O +
grows O +
as O +
a O +
perennial O +
shrub O +
in O +
Fiji O +
and O +
other O +
South O +
Pacific O +
islands O +
( O -
Singh O +
and O +
Blumenthal O -
, O +
1997 O +
) O -
. O +

The O +
South O +
Pacific O +
islanders O +
have O +
been O +
using O +
a O +
traditionally O +
prepared O +
beverage O +
from O +
kava O +
roots O +
for O +
thousands O +
of O +
years O +
in O +
social O -
, O +
recreational O +
and O +
ceremonial O +
events O -
, O +
and O +
also O +
as O +
a O +
remedy O +
for O +
stress O +
and O +
anxiety O +
( O -
Singh O +
and O +
Blumenthal O -
, O +
1997 O +
) O -
. O +

Due O +
to O +
its O +
beneficial O +
health O +
effects O -
, O +
P. O +
methysticum O +
has O +
gained O +
popularity O +
recently O +
in O +
western O +
countries O +
as O +
an O +
alternative O +
medicine O +
especially O +
for O +
the O +
treatment O +
of O +
anxiety O +
disorders O +
( O -
Singh O +
and O +
Blumenthal O -
, O +
1997 O +
) O -
. O +

Placebo O -
- O -
controlled O -
, O +
double O -
- O -
blind O +
studies O +
have O +
shown O +
Kava O +
extract O +
to O +
be O +
as O +
effective O +
as O +
the O +
standard O +
therapy O +
for O +
the O +
treatment O +
of O +
anxiety O +
disorders O +
with O +
a O +
more O +
favorable O +
toxicity O +
profile O +
and O +
minimal O +
physical O +
and O +
psychological O +
dependence O +
( O -
Singh O +
and O +
Blumenthal O -
, O +
1997 O -
; O +
Volz O +
and O +
Kieser O -
, O +
1997 O +
) O -
. O +

The O +
chemistry O +
of O +
P. O +
methysticum O +
has O +
been O +
extensively O +
studied O -
, O +
and O +
so O +
far O +
more O +
than O +
40 O +
compounds O +
belonging O +
to O +
the O +
classes O +
of O +
kavapyrones O -
, O +
alkaloids O -
, O +
steroids O -
, O +
chalcones O -
, O +
long O -
- O -
chained O +
fatty O +
acids O +
and O +
alcohols O +
have O +
been O +
isolated O +
and O +
identified O +
( O -
Parmar O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

Among O +
these O +
compounds O -
, O +
kavalactones O +
have O +
been O +
recognized O +
as O +
the O +
constituents O +
responsible O +
for O +
the O +
reported O +
biological O +
activities O +
in O +
Kava O +
( O -
Singh O +
and O +
Blumenthal O -
, O +
1997 O +
) O -
. O +

Eighteen O +
different O +
kavalactones O +
have O +
been O +
reported O +
from O +
the O +
root O +
extracts O +
of O +
Kava O +
and O +
desmethoxyyangonin O +
( O -
1 O +
) O -
, O +
yangonin O +
( O -
2 O +
) O -
, O +
dihydrokawain O +
( O -
3 O +
) O -
, O +
kawain O +
( O -
4 O +
) O -
, O +
dihydromethysticin O +
( O -
5 O +
) O +
and O +
methysticin O +
( O -
6 O +
) O +
are O +
the O +
most O +
abundant O +
( O -
Ganzera O +
and O +
Khan O -
, O +
1999 O +
) O -
. O +

Our O +
preliminary O +
investigation O +
on O +
anti O -
- O -
anxiolytic O +
properties O +
of O +
Kava O +
root O +
extract O +
and O +
of O +
the O +
six O +
major O +
kavalactones O +
in O +
an O +
animal O +
model O +
showed O +
that O +
the O +
activity O +
for O +
the O +
root O +
extract O +
was O +
higher O +
than O +
those O +
observed O +
for O +
each O +
major O +
individual O +
compound O +
( O -
Smith O +
et O +
al. O -
, O +
2001 O +
) O -
. O +

This O +
suggested O +
that O +
synergism O +
or O +
other O +
compounds O +
may O +
be O +
responsible O +
for O +
the O +
higher O +
activity O +
of O +
the O +
extract O -
. O +

Prompted O +
by O +
this O +
observation O -
, O +
an O +
isolation O +
and O +
identification O +
of O +
compounds O +
in O +
the O +
Kava O +
root O +
extract O +
were O +
carried O +
out O -
. O +

Chromatographic O +
separations O +
of O +
the O +
methylene O +
chloride O +
extract O +
of O +
Kava O +
root O -
, O +
followed O +
by O +
recrystallization O +
led O +
to O +
the O +
isolation O +
and O +
identification O +
of O +
nine O +
kavalactones O +
( O -
1–9 O +
) O -
, O +
together O +
with O +
three O +
chalcones O +
( O -
10–12 O +
) O -
, O +
3,4-methylenedioxycinnamylideneacetone O +
( O -
13 O +
) O +
and O +
stigmasterol O -
. O +

All O +
but O -
, O +
kavalactone O -
, O +
11-methoxy-5,6-dihydroyangonin O +
( O -
7 O +
) O +
were O +
previously O +
reported O +
from O +
P. O +
methysticum O +
( O -
Parmar O +
et O +
al. O -
, O +
1997 O +
) O -
. O +

This O +
is O +
the O +
first O +
report O +
of O +
11-methoxy-5,6-dihydroyangonin O +
( O -
7 O +
) O -
. O +

Structural O +
elucidation O +
of O +
above O +
compounds O +
was O +
carried O +
out O +
by O +
spectroscopic O +
means O +
and O +
by O +
comparison O +
of O +
the O +
physical O +
spectroscopic O +
data O +
with O +
those O +
in O +
the O +
literature O -
. O +

Though O +
18 O +
kavalactones O +
have O +
been O +
isolated O +
so O +
far O +
from O +
P. O +
methysticum O +
by O +
various O +
research O +
groups O +
( O -
Jössang O +
and O +
Molho O -
, O +
1967 O -
; O +
Achenbach O +
et O +
al. O -
, O +
1973 O -
; O +
Dutta O +
et O +
al. O -
, O +
1972 O -
; O +
Lopez O -
- O -
Avila O +
and O +
Benedicto O -
, O +
1997 O -
; O +
Parmar O +
et O +
al. O -
, O +
1997 O -
; O +
Singh O +
and O +
Blumenthal O -
, O +
1997 O -
; O +
Ganzera O +
and O +
Khan O -
. O -
, O +
1999 O +
) O -
, O +
complete O +
physical O +
data O +
and O +
13 O +
C O +
and O +
1 O +
H O +
NMR O +
assignments O +
are O +
available O +
( O -
Banerji O +
et O +
al. O -
, O +
1980 O +
) O +
only O +
for O +
kawain O +
( O -
4 O +
) O -
, O +
methysticin O +
( O -
6 O +
) O +
and O +
yangonin O +
( O -
2 O +
) O -
. O +

In O +
this O +
study O -
, O +
the O +
structure O +
elucidation O +
of O +
the O +
new O +
compound O -
, O +
11-methoxy-5,6-dihydroyangonin O +
and O +
complete O +
13 O +
C O +
and O +
1 O +
H O +
NMR O +
assignments O +
of O +
other O +
kavalactones O +
were O +
carried O +
out O +
using O +
COSY O -
, O +
HMQC O +
and O +
HMBC O +
experiments O -
. O +

2 O +
Results O +
and O +
discussion O +
Chromatographic O +
separation O +
of O +
the O +
methylene O +
chloride O +
extract O +
of O +
P. O +
methysticum O +
roots O +
yielded O +
fourteen O +
compounds O -
. O +

Preliminary O +
spectroscopic O +
analysis O +
indicated O +
that O +
these O +
fourteen O +
compounds O +
comprised O +
of O +
nine O +
kavalactones O -
, O +
three O +
chalcones O -
, O +
3,4-methylenedioxycinnamylideneacetone O +
and O +
stigmasterol O -
. O +

Detailed O +
NMR O +
spectroscopic O +
analysis O +
and O +
comparison O +
of O +
the O +
physical O +
and O +
spectroscopic O +
data O +
with O +
those O +
reported O +
confirmed O +
the O +
structures O +
of O +
3,4-methylenedioxycinnamylideneacetone O +
( O -
13 O +
) O +
( O -
Jössang O +
and O +
Molho O -
, O +
1967 O +
) O -
, O +
stigmasterol O +
and O +
the O +
chalcones O +
as O +
flavokawain O +
A O +
( O -
10 O +
) O +
( O -
Zhili O -
, O +
1998 O +
) O -
, O +
flavokawain O +
B O +
( O -
11 O +
) O +
( O -
Itokava O +
et O +
al. O -
, O +
1981 O +
) O +
and O +
flavokawain O +
C O +
( O -
12 O +
) O +
( O -
Seeram O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Analysis O +
of O +
the O +
NMR O +
spectra O +
of O +
the O +
kavalactones O +
using O +
HMQC O +
and O +
HMBC O +
experiments O +
permitted O +
the O +
determination O +
of O +
the O +
structures O +
of O +
these O +
compounds O +
and O +
the O +
assignments O +
of O +
13 O +
C O +
signals O -
. O +

These O +
compounds O +
were O +
identified O +
as O +
desmethoxyyangonin O +
( O -
1 O +
) O -
, O +
yangonin O +
( O -
2 O +
) O -
, O +
dihydrokawain O +
( O -
3 O +
) O -
, O +
kawain O +
( O -
4 O +
) O -
, O +
dihydromethysticin O +
( O -
5 O +
) O -
, O +
methysticin O +
( O -
6 O +
) O +
tetrahydroyangonin O +
( O -
8 O +
) O +
and O +
1-methoxytetrahydroyangonin O +
( O -
9 O +
) O +
( O -
Achenbach O +
et O +
al. O -
, O +
1973 O +
) O -
, O +
previously O +
isolated O +
and O +
identified O +
from O +
P. O +
methysticum O +
. O +

Analysis O +
of O +
compound O +
7 O +
by O +
HRMS O +
suggested O +
a O +
molecular O +
formula O +
C16 O +
H18 O +
O5 O +
( O -
[ O -
M+H O -
] O -
+ O +
= O -
291.1154 O -
) O -
. O +

The O +
1 O +
H O +
NMR O +
spectrum O +
of O +
this O +
compound O +
showed O +
three O +
methoxy O +
groups O +
and O +
a O +
typical O +
set O +
of O +
peaks O +
due O +
to O +
the O +
5,6 O +
-dihydrokavalactone O +
skeleton O +
( O -
see O +
Experimental O -
) O -
. O +

Further O +
analysis O +
of O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
7 O +
showed O +
an O +
AB O +
doublet O +
for O +
H-13 O -
. O +

The1 O +
H O +
NMR O +
signals O +
for O +
H-10 O +
and O +
H-14 O +
appeared O +
close O +
together O +
( O -
δ O +
6.91 O +
and O +
6.90 O -
, O +
respectively O -
) O +
and O +
a O +
part O +
of O +
H-14 O +
doublet O +
of O +
doublet O +
( O -
J O +
= O -
1.6 O +
and O +
7.8 O +
Hz O -
) O +
overlapped O +
with O +
the O +
H-10 O +
signal O +
to O +
give O +
a O +
broad O +
signal O -
. O +

These O +
data O +
suggested O +
the O +
11-methoxy-5,6-dihydroyangonin O +
structure O +
for O +
this O +
compound O -
, O +
which O +
was O +
confirmed O +
by O +
HMQC O +
and O +
HMBC O +
experiments O -
. O +

This O +
is O +
the O +
first O +
report O +
of O +
11-methoxy-5,6-dihydroyangonin O -
. O +

The O +
( O -
6R O +
) O -
-absolute O +
stereochemistry O +
was O +
determined O +
by O +
comparison O +
with O +
the O +
CD O +
data O +
reported O +
for O +
this O +
class O +
of O +
compounds O +
( O -
Snatzke O +
and O +
Hänsel O -
, O +
1968 O -
; O +
Achenbach O +
and O +
Theobald O -
, O +
1974 O +
) O -
. O +

The O +
13 O +
C O +
NMR O +
assignments O +
of O +
nine O +
kavalactones O +
were O +
made O +
using O +
HMQC O +
and O +
HMBC O +
experiments O -
. O +

The O +
assignments O +
for O +
compounds O +
2 O +
, O +
4 O +
and O +
6 O +
were O +
consistent O +
with O +
those O +
previously O +
reported O +
for O +
these O +
compounds O +
( O -
Banerji O +
et O +
al. O -
, O +
1980 O +
) O -
. O +

The O +
detailed O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectroscopic O +
data O +
for O +
these O +
compounds O +
are O +
presented O +
in O +
Table O +
1 O +
and O +
in O +
the O +
Experimental O -
. O +

3 O +
Experimental O +
Mps O +
( O -
uncorr O -
. O -
) O +
were O +
recorded O +
on O +
an O +
Electrothermal O +
9100 O +
instrument O -
. O +

UV O +
spectra O +
were O +
obtained O +
in O +
CD3 O +
OD O -
, O +
using O +
Hewlett O +
Packard O +
8452A O +
spectrometer O +
and O +
IR O +
spectra O +
were O +
taken O +
on O +
an O +
Ati O +
Mattson O +
( O -
Genesis O +
Series O -
) O +
FTIR O +
spectrophotometer O -
. O +

1 O +
H O +
NMR O +
and O +
13 O +
C O +
NMR O +
spectra O +
were O +
recorded O +
on O +
Bruker O +
Avance O +
DPX-300 O +
( O -
300 O +
MHz O +
for O +
1 O +
H O +
NMR O +
and O +
75.45 O +
MHz O +
for O +
13 O +
C O +
NMR O -
) O +
and O +
Bruker O +
Avance O +
DRX-500 O +
( O -
500 O +
MHz O +
for O +
1 O +
H O +
NMR O +
and O +
125 O +
MHz O +
for O +
13 O +
C O +
NMR O -
) O +
spectrometers O +
in O +
CDCl3 O +
and O +
MeOH O -
- O -
D4 O +
using O +
TMS O +
as O +
internal O +
standard O -
. O +

High O +
resolution O +
MS O +
( O -
HRMS O -
) O +
were O +
obtained O +
by O +
direct O +
probe O +
using O +
Bruker O +
Bioapex O -
- O -
FTMS O +
with O +
Electro O -
- O -
Spray O +
Ionization O -
. O +

Preparative O +
TLC O +
was O +
carried O +
out O +
using O +
silica O +
gel O +
F O +
254 O +
plates O +
( O -
thickness O +
1 O +
mm O -
) O -
. O +

3.1 O +
Extraction O +
and O +
isolation O +
Piper O +
methysticum O +
( O -
Kava O +
Kava O -
) O +
root O +
extract O +
( O -
1 O +
kg O -
) O +
( O -
Nutratech O -
, O +
Passaic O +
Avenue O -
, O +
Fairfield O -
, O +
NJ O +
07004 O -
, O +
USA O -
: O +
Lot O +
No. O +
40493240 O -
) O +
was O +
extracted O +
three O +
times O +
with O +
methylene O +
chloride O +
at O +
room O +
temperature O +
for O +
1 O +
h O +
under O +
sonication O -
. O +

The O +
combined O +
methylene O +
chloride O +
extract O +
was O +
evaporated O +
to O +
give O +
a O +
dark O +
green O +
viscous O +
semisolid O -
. O +

This O +
semisolid O +
was O +
dissolved O +
in O +
methanol O -
, O +
diluted O +
with O +
diethyl O +
ether O +
and O +
kept O +
at O +
−10 O +
° O -
C O +
for O +
12 O +
h O +
to O +
give O +
30 O +
g O +
of O +
a O +
crystalline O +
material O -
. O +

Recrystallization O +
of O +
this O +
material O +
from O +
methanol O +
yielded O +
yangonin O +
( O -
4.5 O +
g O -
) O +
and O +
the O +
mother O +
liquor O +
was O +
subjected O +
to O +
silica O +
gel O +
column O +
chromatography O -
. O +

Elution O +
of O +
the O +
column O +
with O +
increasing O +
amounts O +
of O +
acetone O +
in O +
hexane O +
as O +
the O +
solvent O +
gave O +
fractions O +
with O +
desmethoxyyangonin O +
( O -
1 O +
) O -
, O +
yangonin O +
( O -
2 O +
) O +
( O -
0.6 O +
g O -
) O -
, O +
dihydrokawain O +
( O -
3 O +
) O +
( O -
1.3 O +
g O -
) O -
, O +
kawain O +
( O -
4 O +
) O +
( O -
1.35 O +
g O -
) O -
, O +
dihydromethysticin O +
( O -
5 O +
) O +
( O -
2.15 O +
g O -
) O +
methysticin O +
( O -
6 O +
) O +
( O -
1.25 O +
g O -
) O -
, O +
stigmasterol O +
( O -
1.2 O +
g O -
) O +
and O +
flavokawain O +
A O +
( O -
10 O +
) O +
( O -
0.4 O +
g O -
) O +
as O +
major O +
compounds O +
and O +
were O +
further O +
purified O +
by O +
crystallization O -
. O +

The O +
mother O +
liquor O +
from O +
the O +
original O +
extract O +
was O +
also O +
subjected O +
to O +
column O +
chromatography O +
on O +
silica O +
gel O +
using O +
the O +
same O +
solvent O +
system O +
to O +
give O +
in O +
addition O +
to O +
the O +
above O +
compounds O +
several O +
fractions O +
with O +
minor O +
constituents O -
. O +

Preparative O +
TLC O +
of O +
these O +
fractions O +
using O +
methanol O -
/ O -
dichloromethane O +
or O +
hexane O -
/ O -
ethyl O +
acetate O +
mixtures O +
yielded O +
the O +
minor O +
compounds O +
7 O +
, O +
8 O +
, O +
9 O +
, O +
11 O +
, O +
12 O +
and O +
13 O +
in O +
pure O +
form O -
. O +

3.1.1 O +
Stigmasterol O +
Semisolid O -
, O +
identity O +
confirmed O +
by O +
1 O +
H O +
NMR O +
and O +
co O -
- O -
TLC O +
with O +
an O +
authentic O +
sample O -
. O +

3.1.2 O +
Desmethoxyyangonin O +
( O -
1 O +
) O +
White O +
amorphous O +
solid O +
( O -
0.21 O -
% O -
) O -
, O +
mp O +
138–140 O +
° O -
C O +
( O -
lit O +
138–140 O -
) O +
( O -
Rezende O +
et O +
al. O -
, O +
1971 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
7.48 O +
( O -
2H O -
, O +
m O +
, O +
H-10 O +
and O +
H-14 O -
) O -
, O +
7.44 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.9 O +
Hz O -
, O +
H-8 O -
) O -
, O +
7.35–7.31 O +
( O -
3H O -
, O +
m O +
, O +
H-11 O -
, O +
H-12 O +
and O +
H-13 O -
) O -
, O +
6.54 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
16.0 O +
Hz O -
, O +
H-7 O -
) O -
, O +
5.90 O +
( O -
1H O -
, O +
s O -
, O +
H-5 O -
) O -
, O +
5.44 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
1.4 O +
Hz O -
, O +
H-3 O -
) O -
, O +
3.76 O +
( O -
3H O -
, O +
s O +
, O +
H-15 O -
) O -
. O +

3.1.3 O +
Yangonin O +
( O -
2 O +
) O +
Yellow O +
needles O +
( O -
0.4 O -
% O -
) O -
, O +
mp O +
152–155 O +
° O -
C O +
( O -
lit O -
. O +

153–154 O -
) O +
( O -
Dutta O +
et O +
al. O -
, O +
1972 O +
) O -
. O +

1 O +
H O -
- O -
NMR O +
( O -
CDCl3 O +
): O +
δ O +
7.42 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.9 O +
Hz O -
, O +
H-8 O -
) O -
, O +
7.41 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.8 O +
Hz O -
, O +
H-10 O +
and O +
H-14 O -
) O -
, O +
6.87 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.8 O +
Hz O -
, O +
H-11 O +
and O +
H-13 O -
) O -
, O +
6.42 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
16.0 O +
Hz O -
, O +
H-7 O -
) O -
, O +
5.86 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
2.1 O +
Hz O -
, O +
H-5 O -
) O -
, O +
5.43 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
2.1 O +
Hz O -
, O +
H-3 O -
) O -
, O +
3.78 O +
( O -
3H O -
, O +
s O +
, O +
H-17 O -
) O -
, O +
3.76 O +
( O -
3H O -
, O +
s O +
, O +
15-H O -
) O -
. O +

3.1.4 O +
Dihydrokawain O +
( O -
3 O +
) O +
White O +
crystals O +
( O -
1.17 O -
% O -
) O -
, O +
mp O +
58–60 O +
° O -
C O -
, O +
( O -
lit O -
. O +

56–60 O -
) O +
( O -
Spino O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
7.27 O +
( O -
2H O -
, O +
m O +
, O +
H-11 O +
and O +
H-13 O -
) O -
, O +
7.18 O +
( O -
3H O -
, O +
m O +
, O +
H-10 O -
, O +
H-12 O +
and O +
H-14 O -
) O -
, O +
5.12 O +
( O -
1H O -
, O +
d O -
, O +
J= O +
1.3 O +
Hz O -
, O +
H3 O -
) O -
, O +
4.34 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
, O +
3.70 O +
( O -
3H O -
, O +
s O +
, O +
4-OCH3 O +
) O -
, O +
2.84 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.73 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.48 O +
( O -
1H O -
, O +
ddd O +
, O +
J O +
= O -
1.3 O -
, O +
11.9 O -
, O +
17.0 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.28 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
3.9 O -
, O +
17.0 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.11 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
1.91 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
. O +

3.1.5 O +
Kawain O +
( O -
4 O +
) O +
White O +
crystals O +
( O -
0.53 O -
% O -
) O -
, O +
mp O +
108–110 O +
° O -
C O -
, O +
( O -
lit O -
. O +

106–108 O -
) O +
( O -
Dutta O +
et O +
al. O -
, O +
1972 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
7.32 O +
( O -
2H O -
, O +
m O +
, O +
H-11 O +
and O +
H-13 O -
) O -
, O +
7.25 O +
( O -
2H O -
, O +
m O +
, O +
H-10 O +
and O +
H-14 O -
) O -
, O +
7.20 O +
( O -
1H O -
, O +
m O +
, O +
H-12 O -
) O -
, O +
6.70 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.9 O +
Hz O -
, O +
H-8 O -
) O -
, O +
6.23 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
6.14 O -
, O +
15.9 O +
Hz O -
, O +
H-7 O -
) O -
, O +
5.16 O +
( O -
1H O -
, O +
s O -
, O +
H-3 O -
) O -
, O +
5.02 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
, O +
3.72 O +
( O -
3H O -
, O +
s O +
, O +
H-15 O -
) O -
, O +
2.63 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.0 O -
, O +
10.7 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.51 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.0 O -
, O +
4.5 O -
, O +
Hz O -
, O +
H-5 O -
) O -
. O +

3.1.6 O +
Dihydromethysticin O +
( O -
5 O +
) O +
White O +
crystals O +
( O -
0.54 O -
% O -
) O -
, O +
mp O +
117–118 O +
° O -
C O +
( O -
lit O -
. O +

117–118 O -
) O +
( O -
Anon O -
. O +
1999 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
6.70 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
7.9 O +
Hz O -
, O +
H-13 O -
) O -
, O +
6.66 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
1.2 O +
Hz O -
, O +
H-10 O -
) O -
, O +
6.63 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
7.9 O -
, O +
1.2 O +
Hz O -
, O +
H-14 O -
) O -
, O +
5.89 O +
( O -
2H O -
, O +
s O +
, O +
O O -
– O -
CH2 O +
–O O -
) O -
, O +
5.11 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
1.2 O +
Hz O -
, O +
H-3 O -
) O -
, O +
4.33 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
, O +
3.70 O +
( O -
3H O -
, O +
s O +
, O +
H-12 O -
) O -
, O +
2.77 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.67 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.40 O +
( O -
1H O -
, O +
ddd O +
, O +
J O +
= O -
17.0 O -
, O +
12.0 O -
, O +
1.2 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.28 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
7.0 O -
, O +
3.8 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.04 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
1.85 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
. O +

3.1.7 O +
Methysticin O +
( O -
6 O +
) O +
White O +
crystals O +
( O -
0.44 O -
% O -
) O -
, O +
mp O +
134–136 O +
° O -
C O +
( O -
lit O -
. O +

134–136 O -
) O +
( O -
Dutta O +
et O +
al. O -
, O +
1972 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
6.88 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
1.4 O +
Hz O -
, O +
H-10 O -
) O -
, O +
6.79 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
8.0 O -
, O +
1.5 O +
Hz O -
, O +
H-14 O -
) O -
, O +
6.72 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
H-13 O -
) O -
, O +
6.59 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.8 O +
Hz O -
, O +
H-8 O -
) O -
, O +
6.06 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
6.4 O -
, O +
15.9 O +
Hz O -
, O +
H-7 O -
) O -
, O +
5.92 O +
( O -
2H O -
, O +
s O -
, O +
O O -
– O -
CH2 O +
–O O -
) O -
, O +
5.15 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
0.6 O +
Hz O -
, O +
H-3 O -
) O -
, O +
4.98 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
, O +
3.72 O +
( O -
3H O -
, O +
s O +
, O +
H-12 O -
) O -
, O +
2.61 O +
( O -
1H O -
, O +
ddd O +
, O +
J O +
= O -
17.2 O -
, O +
10.8 O -
, O +
0.7 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.48 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.1 O -
, O +
4.4 O +
Hz O -
, O +
H-5 O -
) O -
. O +

3.1.8 O +
11-Methoxy-5,6-dihydroyangonin O +
( O -
7 O +
) O +
Yellow O +
semi O -
- O -
solid O +
( O -
0.01 O -
% O -
) O -
, O +
[ O -
α O -
] O -
25 O +
D O +
+ O -
70.0 O -
° O +
( O -
CHCl3 O +
; O +
c O +
0.025 O -
) O -
. O +

CD O -
: O +
( O -
MeOH O -
: O -
c O +
0.01 O -
) O -
: O +
[ O -
Ø O -
] O +
232 O +
−2.98 O -
, O +
[ O -
Ø O -
] O -
240 O +
+ O -
6.6 O -
, O +
[ O -
Ø O -
] O +
246 O +
+ O -
6.9 O -
. O +

UV O -
: O +
λmax O +
MeOH O +
nm O +
( O -
log O +
ε O +
228 O +
( O -
4.04 O -
) O -
, O +
266 O +
( O -
3.87 O -
) O -
. O +

IR O +
cm−1 O +
νmax O +
( O -
neat O -
) O -
: O +
2924 O -
, O +
1707 O -
, O +
1623 O -
, O +
1514 O -
, O +
1462 O -
, O +
1222 O -
, O +
1025 O -
, O +
822 O -
. O +

HRMS O +
291.1154 O +
( O -
[ O -
M+H O -
] O -
+ O +
) O +
( O -
calculated O +
for O +
C16 O +
H18 O +
O5 O +
, O +
291.1154 O -
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
6.91 O +
( O -
1H O -
, O +
s O +
, O +
H-10 O -
) O -
, O +
6.90 O +
( O -
1H O -
, O +
d O +
, O +
J= O +
7.8 O -
, O +
1.6 O +
Hz O -
, O +
H-14 O -
) O -
, O +
6.79 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
H-13 O -
) O -
, O +
6.62 O +
( O -
1H O -
, O +
d O +
, O +
J= O +
15.9 O +
Hz O -
, O +
8-H O -
) O -
, O +
6.13 O +
( O -
1H O -
, O +
dd O +
, O +
J= O +
15.9 O -
, O +
6.6 O +
Hz O -
, O +
H-7 O -
) O -
, O +
5.15 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
0.7 O +
Hz O -
, O +
H-3 O -
) O -
, O +
5.00 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
, O +
3.89 O +
( O -
3H O -
, O +
s O +
, O +
H-17 O -
) O -
, O +
3.87 O +
( O -
3H O -
, O +
s O +
, O +
H-16 O -
) O -
, O +
3.76 O +
( O -
3H O -
, O +
s O +
, O +
H-15 O -
) O -
, O +
2.66 O +
( O -
1H O -
, O +
ddd O +
, O +
J O +
= O -
17.1 O -
, O +
11.0 O -
, O +
0.8 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.54 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.0 O -
, O +
4.2 O +
Hz O -
, O +
H-5 O -
) O -
. O +

3.1.9 O +
Tetrahydroyangonin O +
( O -
8 O +
) O +
( O -
Franca O +
et O +
al. O -
, O +
1973 O -
) O +
Yellow O +
semi O -
- O -
solid O +
( O -
0.015 O -
% O -
) O -
, O +
1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
7.12 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.5 O -
, O +
H-10 O +
and O +
H-14 O -
) O -
, O +
6.83 O +
( O -
2H O -
, O +
d O +
, O +
J= O +
8.4 O +
Hz O -
, O +
H-11 O +
and O +
H-13 O -
) O -
, O +
5.14 O +
( O -
1H O -
, O +
s O +
, O +
H-3 O -
) O -
, O +
4.35 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
, O +
3.78 O +
( O -
3H O -
, O +
s O +
, O +
H-17 O -
) O -
, O +
3.72 O +
( O -
3H O -
, O +
s O +
, O +
H-15 O -
) O -
, O +
2.81 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.72 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.50 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
16.9 O -
, O +
12.2 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.29 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.0 O -
, O +
3.7 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.09 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
1.89 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
. O +

3.1.10 O +
11-Methoxytetrahydroyangonin O +
( O -
9 O +
) O +
White O +
solid O +
( O -
0.011 O -
% O -
) O -
, O +
mp O +
121–123 O +
° O -
C O +
( O -
lit O -
. O +

121–123 O -
) O +
( O -
Franca O +
et O +
al. O -
, O +
1973 O +
) O -
. O +

[ O -
α O -
] O -
25 O +
D O +
: O +
+ O -
27.7 O -
° O +
( O -
CHCl3 O +
; O +
c O +
0.011 O -
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
6.76 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
8.6 O +
Hz O -
, O +
H-13 O -
) O -
, O +
6.71 O +
( O -
1H O -
, O +
s O +
, O +
H-10 O -
) O -
, O +
6.70 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
8.6 O +
Hz O -
, O +
H-14 O -
) O -
, O +
5.09 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
0.7 O +
Hz O -
, O +
H-3 O -
) O -
, O +
4.31 O -
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
, O +
3.82 O +
( O -
3H O -
, O +
s O +
, O +
H-16 O -
) O -
, O +
3.81 O +
( O -
3H O -
, O +
s O +
, O +
H-17 O -
) O -
, O +
3.68 O +
( O -
3H O -
, O +
s O +
, O +
H-15 O -
) O -
, O +
2.78 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.68 O +
( O -
1H O -
, O +
m O +
, O +
H-8 O -
) O -
, O +
2.46 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
17.1 O -
, O +
12.2 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.26 O +
( O -
1H O -
, O +
dd O +
, O +
J= O +
17.0 O -
, O +
3.7 O +
Hz O -
, O +
H-5 O -
) O -
, O +
2.06 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
1.87 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
. O +

3.1.11 O +
Flavokawain O +
A O +
( O -
10 O +
) O +
Yellow O +
crystalline O +
compound O +
( O -
0.46 O -
% O -
) O -
, O +
mp O +
111–115 O +
° O -
C O +
( O -
lit O -
. O +
116 O -
) O +
( O -
Jössang O +
and O +
Molho O -
, O +
1967 O +
) O -
. O +

1 O +
H O -
- O -
NMR O +
( O -
CDCl3 O +
): O +
δ O +
14.40 O +
( O -
1H O -
, O +
s O +
, O +
HO-2′ O -
) O -
, O +
7.79 O +
( O -
2H O -
, O +
s O +
, O +
H O -
- O -
α O +
and O +
H O -
- O -
β O -
) O -
, O +
7.56 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.8 O +
Hz O -
, O +
H-2 O +
and O +
H-6 O -
) O -
, O +
6.92 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.7 O +
Hz O -
, O +
H-3 O +
and O +
H-5 O -
) O -
, O +
6.09 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
2.3 O +
Hz O -
, O +
H-3′ O -
) O -
, O +
5.95 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
2.3 O +
Hz O -
, O +
H-5′ O -
) O -
, O +
3.91 O +
( O -
3H O -
, O +
s O -
, O +
6′-OCH3 O +
) O -
, O +
3.84 O +
( O -
3H O -
, O +
s O +
, O -
-OCH3 O +
) O -
, O +
3.82 O +
( O -
3H O -
, O +
s O +
, O +
4′-OCH3 O +
) O +
3.1.12 O +
Flavokawain O +
B O +
( O -
11 O +
) O +
Yellow O +
crystalline O +
compound O +
( O -
0.015 O -
% O -
) O -
, O +
mp O +
96–98 O +
° O -
C O +
( O -
lit O -
. O +

92 O -
) O +
( O -
Jössang O +
and O +
Molho O -
, O +
1967 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
14.29 O +
( O -
1H O -
, O +
s O -
, O +
HO-2′ O -
) O -
, O +
7.90 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.6 O +
Hz O -
, O +
H O -
- O -
β O -
) O -
, O +
7.78 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.6 O +
Hz O -
, O +
H O -
- O -
α O -
) O -
, O +
7.62–7.59 O +
( O -
2H O -
, O +
m O +
, O +
H-2 O +
and O +
H-6 O -
) O -
, O +
7.44–7.39 O +
( O -
3H O -
, O +
m O +
, O +
H-2 O -
, O +
H-3 O +
and O +
H-5 O -
) O -
, O +
6.11 O +
( O -
1H O -
, O +
J O +
= O -
2.3 O +
Hz O -
, O +
H-3′ O -
) O -
, O +
5.96 O +
( O -
1H O -
, O +
d O +
, O +
J= O +
2.3 O +
Hz O -
, O +
H-5′ O -
) O -
, O +
3.91 O +
( O -
3H O -
, O +
s O +
, O +
6′-OCH3 O +
) O -
, O +
3.80 O +
( O -
3H O -
, O +
s O +
, O +
4′-OCH3 O +
) O +
3.1.13 O +
Flavokawain O +
C O +
( O -
12 O +
) O +
Yellow O +
crystalline O +
compound O +
( O -
0.012 O -
% O -
) O -
, O +
mp O +
185–188 O +
° O -
C O +
( O -
lit O -
. O +

194–195 O -
) O +
( O -
Seeram O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

1 O +
H O +
NMR O +
( O -
CD3 O +
OD O -
) O -
:δ O +
7.72 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
16.2 O +
Hz O -
, O +
H O -
- O -
β O -
) O -
, O +
7.65 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.9 O +
Hz O -
, O +
H O -
- O -
α O -
) O -
, O +
7.44 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
8.6 O +
Hz O -
, O +
H-2 O +
and O +
H-6 O -
) O -
, O +
6.82 O +
( O -
2H O -
, O +
d O +
, O -
J O +
= O -
8.6 O +
Hz O -
, O +
H-3 O +
and O +
H-5 O -
) O -
, O +
6.02 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
2.3 O +
Hz O -
, O +
H-3′ O -
) O -
, O +
5.94 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
2.2 O +
Hz O -
, O +
H-5′ O -
) O -
, O +
3.86 O +
( O -
3H O -
, O +
s O +
, O +
6′-OCH3 O +
) O -
, O +
3.77 O +
( O -
3H O -
, O +
s O +
, O +
4′-OMe O -
) O +
3.1.14 O +
3,4-Methylenedioxycinnamylideneacetone O +
( O -
13 O +
) O +
( O -
Jössang O +
and O +
Molho O -
, O +
1967 O +
) O +

Semi O +
solid O +
( O -
0.018 O -
% O -
) O -
. O +

1 O +
H O +
NMR O +
( O -
CDCl3 O +
) O -
: O -
δ O +
7.18 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
15.4 O -
, O +
10.8 O +
Hz O -
, O +
H-3′ O -
) O -
, O +
6.92 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
1.7 O +
Hz O -
, O +
H-2 O -
) O -
, O +
6.85 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
8.0 O -
, O +
1.4 O +
Hz O -
, O +
H-6 O -
) O -
, O +
6.77 O +
( O -
1H O -
, O +
d O +
, O +
J= O +
15.5 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
6.72 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
8.0 O +
Hz O -
, O +
H-5 O -
) O -
, O +
6.62 O +
( O -
1H O -
, O +
dd O +
, O +
J O +
= O -
15.5 O -
, O +
10.8 O +
Hz O -
, O +
H-2′ O -
) O -
, O +
6.13 O +
( O -
1H O -
, O +
d O +
, O +
J O +
= O -
15.5 O +
Hz O -
, O +
H-4′ O -
) O -
, O +
5.91 O +
( O -
2H O -
, O +
s O +
, O +
O O -
– O -
CH2 O +
–O O -
) O -
, O +
2.23 O +
( O -
3H O -
, O +
s O +
, O +
H-6′ O -
) O -
. O +

13 O +
H O +
NMR O +
( O -
CDCl3 O +
): O +
δ O +
27.6 O +
( O -
C-6′ O -
) O -
, O +
101.8 O +
( O -
O O -
– O -
CH2 O +
–O O -
) O -
, O +
106.2 O +
( O -
C-2 O -
) O -
, O +
108.9 O +
( O -
C-5 O -
) O -
, O +
123.5 O +
( O -
C-6 O -
) O -
, O +
125.2 O +
( O -
C-2′ O -
) O -
, O +
130.1 O +
( O -
C-4′ O -
) O -
, O +
130.9 O +
( O -
C-1 O -
) O -
, O +
141.3 O -
( O -
C-1′ O -
) O -
, O +
143.9 O +
( O -
C-3′ O -
) O -
, O +
148.7 O +
( O -
C-3 O -
) O -
, O +
149.1 O +
( O -
C-4 O -
) O -
, O +
198.5 O +
( O -
C-5′ O -
) O -
. O +

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
the O +
United O +
States O +
Department O +
of O +
Agriculture O -
, O +
ARS O +
Specific O +
Cooperative O +
Agreement O +
No. O +
58 O -
- O -
6408 O -
- O -
7 O -
- O -
012 O -
. O +

The O +
authors O +
thank O +
Dr. O +
Chuck O +
Dunbar O +
for O +
performing O +
the O +
HRMS O +
analyses O +
and O +
Frank O +
Wiggers O +
for O +
obtaining O +
NMR O +
spectra O -
. O +

The O +
authors O +
also O +
thank O +
CromaDex O +
( O -
Irvine O -
, O +
CA O -
, O +
USA O -
) O +
for O +
financial O +
support O +
of O +
this O +
project O -
. O +

Solanum O +
torvum O +
Swartz O +
( O -
Solanaceae O -
) O +
is O +
a O +
small O +
shrub O +
distributed O +
widely O +
in O +
Thailand O -
. O +

Its O +
edible O +
fruits O -
, O +
commonly O +
available O +
in O +
the O +
markets O -
, O +
are O +
used O +
as O +
a O +
vegetable O +
and O +
are O +
regarded O +
as O +
an O +
essential O +
ingredient O +
in O +
Thai O +
cuisine O -
. O +

To O +
date O -
, O +
steroidal O +
glycosides O +
( O -
Mahmood O +
et O +
al. O -
, O +
1985 O -
; O +
Agrawal O +
et O +
al. O -
, O +
1989 O -
; O +
Cuervo O +
et O +
al. O -
, O +
1991 O -
; O +
Yahara O +
et O +
al. O -
, O +
1996 O -
; O +
Fayez O +
and O +
Saleh O -
, O +
1967 O +
) O -
, O +
and O +
long O +
chain O +
hydrocarbons O +
and O +
steroids O +
( O -
Mahmood O +
et O +
al. O -
, O +
1983 O +
) O +
have O +
been O +
previously O +
isolated O +
from O +
S. O +
torvum O +
. O +

However O -
, O +
little O +
is O +
known O +
on O +
the O +
biological O +
activities O +
of O +
these O +
isolated O +
compounds O -
. O +

We O +
report O +
herein O +
the O +
isolation O -
, O +
structure O +
elucidation O -
, O +
and O +
biological O +
activities O +
of O +
three O +
polar O +
constituents O +
( O -
1 O +
–3 O +
) O +
in O +
the O +
fruits O +
of O +
S. O +
torvum O +
. O +

A O +
new O +
isoflavonoid O +
sulfate O -
, O +
named O +
torvanol O +
A O +
( O -
1 O +
) O -
, O +
and O +
a O +
new O +
steroidal O +
glycoside O -
, O +
named O +
torvoside O +
H O +
( O -
3 O +
) O -
, O +
together O +
with O +
a O +
known O +
glycoside O -
, O +
torvoside O +
A O +
( O -
2 O +
) O -
, O +
have O +
been O +
isolated O +
from O +
a O +
MeOH O +
extract O +
of O +
S. O +
torvum O +
fruits1 O +
. O +

2 O +
Results O +
and O +
discussion O +
Torvanol O +
A O +
( O -
1 O +
) O +
was O +
obtained O +
from O +
a O +
MeOH O +
extract O +
of O +
S. O +
torvum O +
fruits O +
after O +
sequential O +
purification O +
with O +
gel O +
filtration O +
chromatography O +
on O +
Sephadex O +
LH-20 O +
and O +
preparative O +
( O -
reversed O +
phase O +
C18 O +
) O +
HPLC O -
. O +

Although O +
torvanol O +
A O +
( O -
1 O +
) O +
possesses O +
hydrophobic O +
components O +
( O -
e.g. O +
two O +
aromatic O +
rings O +
and O +
two O +
methyl O +
ethers O -
, O +
it O +
dissolves O +
remarkably O +
well O +
in O +
water O -
. O +

The O +
1 O +
H O +
NMR O +
spectrum O +
( O -
D2 O +
O O -
) O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
showed O +
two O +
prominent O +
methyl O +
ether O +
singlets O +
( O -
δ O +
H O +
3.75 O +
and O +
3.84 O -
) O -
, O +
non O -
- O -
equivalent O +
methylene O +
protons O +
attached O +
to O +
a O +
carbon O +
bearing O +
an O +
oxygen O +
atom O +
( O -
δ O +
H O +
4.17 O +
and O +
4.25 O -
) O -
, O +
methine O +
protons O +
( O -
δ O +
H O +
3.50 O +
and O +
5.53 O -
) O -
, O +
two O +
trans O +
olefinic O +
protons O +
( O -
δ O +
H O +
6.31 O +
and O +
7.24 O -
) O -
, O +
and O +
five O +
aromatic O +
protons O +
( O -
δ O +
H O +
6.72–7.10 O -
) O -
. O +

The O +
J O +
value O +
of O +
15.7 O +
Hz O +
of O +
olefinic O +
protons O +
( O -
H-7′ O +
and O +
H-8′ O -
) O +
revealed O +
a O +
trans O +
geometry O +
of O +
the O +
double O +
bond O +
between O +
C-7′ O +
and O +
C-8′. O +
The O +
13 O +
C O +
NMR O +
spectrum O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
revealed O +
20 O +
signals O +
which O +
were O +
classified O +
by O +
the O +
DEPT O +
technique O +
as O +
nine O +
methine O -
, O +
one O +
methylene O -
, O +
two O +
methyl O -
, O +
and O +
eight O +
quaternary O +
carbons O -
. O +

The O +
1 O +
H–1 O +
H O +
COSY O +
spectrum O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
revealed O +
a O +
partial O +
structure O +
from O +
H-2 O +
to O +
H-4 O -
, O +
and O +
the O +
existence O +
of O +
an O +
ABX O +
system O +
of O +
the O +
aromatic O +
ring O +
A O -
, O +
as O +
well O +
as O +
a O +
meta O +
coupling O +
between O +
aromatic O +
protons O +
H-2′ O +
and O +
H-4′. O +
The O +
HMBC O +
spectral O +
data O +
( O -
optimized O +
for O +
n O +
J O +
HC O +
= O -
8.0 O +
Hz O -
) O +
of O +
torvanol O +
( O -
1 O +
) O +
showed O +
correlations O +
of O +
H-2 O +
to O +
C-4 O +
and O +
C-1′ O -
; O +
H-3 O +
to O +
C-4a O +
and O +
C-1′ O -
; O +
H-4 O +
to O +
C-2 O +
and O +
C-5 O -
; O +
H-5 O +
to O +
C-4 O -
, O +
C-7 O +
and O +
C-8a O -
; O +
H-7 O +
to O +
C-5 O +
and O +
C-8a O -
; O +
H-8 O +
to O +
C-4a O +
and O +
C-6 O -
; O +
both O +
H-2′ O +
and O +
H-4′ O +
to O +
C-6′ O +
and O +
C-7′ O -
; O +
H-7′ O +
to O +
C-2′ O -
, O +
C-4′ O +
and O +
C-9′ O -
; O +
and O +
H-8′ O +
to O +
C-3′. O +
These O +
1 O +
H–1 O +
H O +
COSY O +
and O +
HMBC O +
spectral O +
data O +
readily O +
revealed O +
that O +
torvanol O +
A O +
( O -
1 O +
) O +
possesses O +
an O +
isoflavonoid O +
skeleton O -
. O +

Both O +
methoxy O +
groups O +
were O +
assigned O +
by O +
analyses O +
of O +
the O +
HMBC O +
and O +
NOESY O +
spectral O +
data O -
. O +

The O +
HMBC O +
spectrum O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
showed O +
correlation O +
of O +
6-OMe O +
protons O +
to O +
C-6 O -
, O +
and O +
5′-OMe O +
protons O +
to O +
C-5′ O -
, O +
while O +
the O +
NOESY O +
spectrum O +
of O +
( O -
1 O +
) O +
revealed O +
cross O +
peaks O +
between O +
6-OMe O +
protons O +
and O +
H-5 O -
, O +
as O +
well O +
as O +
between O +
5′-OMe O +
protons O +
and O +
H-4′. O +
The O +
chemical O +
shifts O +
at O +
C-4 O +
( O -
δ O +
H O +
5.53 O +
and O +
δ O +
C O +
88.3 O -
) O +
suggested O +
the O +
presence O +
of O +
an O +
ester O +
in O +
torvanol O +
A O +
( O -
1 O +
) O -
, O +
however O -
, O +
there O +
were O +
no O +
further O +
carbon O +
resonances O +
on O +
the O +
13 O +
C O +
NMR O +
of O +
torvanol O +
A O +
( O -
1 O +
) O -
, O +
implying O +
the O +
existence O +
of O +
an O +
inorganic O +
ester O +
in O +
1 O +
. O +

The O +
accurate O +
mass O +
of O +
m O +
/z O +
451.0677 O +
[ O -
( O -
M O -
– O -
H O -
) O -
− O +
, O +
Δ−2.2 O +
mmu O -
] O +
obtained O +
from O +
the O +
ESITOF O +
mass O +
spectrum O +
( O -
negative O +
ion O +
mode O -
) O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
revealed O +
a O +
molecular O +
formula O +
of O +
1 O +
as O +
C20 O +
H20 O +
O10 O +
S O -
, O +
suggesting O +
that O +
1 O +
possessed O +
a O +
sulfate O +
ester O -
. O +

The O +
IR O +
spectrum O +
of O +
1 O +
indicated O +
the O +
presence O +
of O +
hydroxyl O +
groups O +
( O -
ν O +
max O +
3448 O +
cm−1 O +
) O -
, O +
conjugated O +
carbonyl O +
( O -
ν O +
max O +
1638 O +
cm−1 O +
) O -
, O +
and O +
sulfate O +
ester O +
( O -
ν O +
max O +
1256 O +
cm−1 O +
) O -
. O +

The O +
presence O +
of O +
a O +
sulfate O +
ester O +
group O +
was O +
also O +
indicated O +
by O +
the O +
EIMS O +
spectrum O +
of O +
torvanol O +
A O +
( O -
1 O +
) O -
, O +
showing O +
the O +
prominent O +
peak O +
of O +
the O +
fragment O +
ion O +
at O +
m O +
/z O +
355 O +
[ O -
M-97 O -
] O -
, O +
due O +
to O +
the O +
loss O +
of O +
[ O -
HSO4 O +
] O -
− O +
. O +

The O +
solubility O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
in O +
water O +
suggested O +
that O +
1 O +
existed O +
in O +
the O +
form O +
of O +
a O +
sulfate O +
salt O -
. O +

Analysis O +
by O +
an O +
atomic O +
absorption O +
spectrophotometer O +
revealed O +
that O +
1 O +
was O +
a O +
potassium O +
salt O -
, O +
showing O +
the O +
stoichiometric O +
ratio O +
ca O -
. O +

1:1 O +
( O -
torvanol O +
A O +
( O -
1 O +
) O +
and O +
K O -
) O -
. O +

On O +
the O +
basis O +
of O +
these O +
spectral O +
data O -
, O +
the O +
chemical O +
structure O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
was O +
therefore O +
secured O -
. O +

The O +
assignments O +
of O +
protons O +
and O +
carbons O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
are O +
shown O +
in O +
Table O +
1 O +
. O +

The O +
3 O +
J O +
3,4 O +
value O +
of O +
6.4 O +
Hz O +
suggested O +
a O +
pseudo O +
axial O +
orientation O +
of O +
H-4 O -
, O +
and O +
the O +
respective O +
J O +
H-2ax O -
, O -
H-3 O +
and O +
J O +
H-2eq O -
, O -
H-3 O +
of O +
7.0 O +
and O +
4.7 O +
Hz O +
revealed O +
that O +
H-3 O +
was O +
also O +
pseudo O +
axial O -
. O +

The O +
NOESY O +
spectrum O +
of O +
torvanol O +
A O +
( O -
1 O +
) O +
showed O +
correlations O +
between O +
H-4 O +
and O +
H-2ax O -
, O +
and O +
H-3 O +
and O +
H-2eq O -
, O +
supporting O +
the O +
proposed O +
relative O +
stereochemistry O -
. O +

The O +
1 O +
H O +
NMR O +
spectrum O +
( O -
pyridine O -
- O -
d O +
5 O +
) O +
of O +
torvoside O +
H O +
( O -
3 O +
) O +
( O -
[ O -
α O +
] O -
29 O +
D O +
−58.15 O -
° O -
, O +
c O +
0.114 O +
in O +
MeOH O -
) O +
was O +
similar O +
to O +
that O +
of O +
the O +
known O +
glycoside O -
, O +
torvoside O +
A O +
( O -
2 O +
) O +
( O -
[ O -
α O +
] O -
29 O +
D O +
−50.16 O -
° O -
, O +
c O +
0.123 O +
in O +
MeOH O -
) O -
. O +

The O +
13 O +
C O +
NMR O +
spectrum O +
of O +
torvoside O +
H O +
( O -
3 O +
) O +
and O +
that O +
of O +
2 O +
were O +
also O +
similar O -
, O +
except O +
that O +
the O +
hydroxy O +
bearing O +
carbon O +
signal O +
at O +
δ O +
C O +
ca O -
. O +

71.0 O +
( O -
C-3 O -
) O +
in O +
2 O +
was O +
replaced O +
by O +
a O +
signal O +
at O +
δ O +
C O +
210.7 O +
in O +
3 O +
, O +
characteristic O +
of O +
a O +
ketone O +
functionality O -
. O +

The O +
ketone O +
moiety O +
was O +
also O +
confirmed O +
by O +
an O +
absorption O +
peak O +
at O +
1702 O +
cm−1 O +
in O +
the O +
IR O +
spectrum O +
of O +
3 O +
. O +

The O +
ESITOF O +
mass O +
spectral O +
data O +
( O -
negative O +
ion O +
mode O -
) O +
revealed O +
quasi O -
- O -
molecular O +
ions O +
at O +
m O +
/z O +
901 O +
[ O -
M O -
– O -
H O -
] O -
− O +
for O +
torvoside O +
H O +
( O -
3 O +
) O +
and O +
903 O +
[ O -
M O -
– O -
H O -
] O -
− O +
for O +
torvoside O +
A O +
( O -
2 O +
) O -
, O +
implying O +
the O +
hydroxyl O +
group O +
at O +
C-3 O +
in O +
2 O +
was O +
a O +
ketone O +
in O +
3 O +
. O +

On O +
enzymatic O +
hydrolysis O +
with O +
β B-Gene +
-glucosidase I-Gene -
, O +
torvoside O +
H O +
( O -
3 O +
) O +
gave O +
glucose O +
and O +
compound O +
5 O +
, O +
suggesting O +
that O +
3 O +
possessed O +
a O +
glucose O +
unit O +
at O +
C-26 O -
, O +
which O +
is O +
the O +
same O +
as O +
that O +
of O +
torvoside O +
A O +
( O -
2 O +
) O +
( O -
Yahara O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

The O +
ESITOF O +
mass O +
spectrum O +
( O -
negative O +
ion O +
mode O -
) O +
established O +
the O +
molecular O +
formula O +
of O +
compound O +
5 O +
as O +
C39 O +
H62 O +
O12 O +
, O +
showing O +
an O +
accurate O +
mass O +
at O +
m O +
/z O +
721.4155 O +
[ O -
( O -
M O -
– O -
H O -
) O -
− O +
, O +
Δ−0.8 O +
mmu O -
] O -
. O +

The O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectral O +
data O +
of O +
5 O +
were O +
less O +
complex O +
than O +
that O +
of O +
torvoside O +
H O +
( O -
3 O +
) O -
, O +
particularly O +
in O +
the O +
sugar O -
's O +
resonances O -
, O +
which O +
enabled O +
the O +
assignment O +
of O +
protons O +
and O +
carbons O +
in O +
5 O +
. O +

Analyses O +
of O +
DEPT O -
, O +
1 O +
H–1 O +
H O +
COSY O -
, O +
HMQC O +
and O +
HMBC O +
spectral O +
data O +
led O +
to O +
a O +
complete O +
assignment O +
of O +
both O +
protons O +
and O +
carbons O +
in O +
the O +
molecule O +
( O -
Table O +
2 O +
) O -
. O +

Important O +
1 O +
H–13 O +
C O +
long O -
- O -
ranged O +
correlations O +
on O +
the O +
HMBC O +
spectrum O +
of O +
compound O +
5 O +
were O +
as O +
follows O -
: O +
H-2 O +
and O +
H-4 O +
to O +
C-3 O -
; O +
H-4 O +
to O +
C-6 O -
; O +
H-18 O +
to O +
C-1 O +
and O +
C-5 O -
; O +
H-19 O +
to O +
C-12 O -
, O +
C-14 O +
and O +
C-17 O -
; O +
H-16 O +
to O +
C-20 O -
; O +
H-21 O +
to O +
C-17 O +
and O +
C-22 O -
; O +
H-24 O +
to O +
C-22 O -
; O +
and O +
H-26 O +
to O +
C-22 O -
, O +
C-24 O +
and O +
C-27 O -
. O +

The O +
HMBC O +
spectrum O +
of O +
5 O +
also O +
demonstrated O +
the O +
correlation O +
of O +
the O +
anomeric O +
proton O +
( O -
H O -
- O -
qui1 O -
) O +
of O +
quinovose O +
to O +
C-6 O +
and O +
that O +
of O +
the O +
anomeric O +
proton O +
( O -
H O -
- O -
rha1 O -
) O +
of O +
rhamnose O +
to O +
C O -
- O -
qui3 O -
. O +

These O +
HMBC O +
correlations O +
provided O +
useful O +
information O +
concerning O +
connectivities O +
between O +
quinovose O +
and O +
the O +
steroidal O +
aglycone O +
( O -
linkage O +
at O +
C-6 O -
) O -
, O +
as O +
well O +
as O +
that O +
between O +
quinovose O +
and O +
rhamnose O +
( O -
1→3 O +
linkage O -
) O -
. O +

The O +
downfield O +
shifts O +
of O +
H O -
- O -
qui3 O +
( O -
at O +
δ O +
H O +
4.21 O -
) O +
and O +
C O -
- O -
qui3 O +
( O -
at O +
δ O +
C O +
83.7 O -
) O +
in O +
the O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
of O +
5 O +
also O +
indicated O +
the O +
connectivity O +
( O -
1→3 O -
) O +
of O +
the O +
two O +
sugars O -
. O +

As O +
for O +
the O +
relative O +
configuration O +
of O +
the O +
sugars O +
in O +
5 O +
, O +
the O +
J O +
H O -
- O -
qui1,H O -
- O -
qui2 O +
( O -
7.8 O +
Hz O -
) O -
, O +
J O +
H O -
- O -
qui2,H O -
- O -
qui3 O +
( O -
9.0 O +
Hz O -
) O +
and O +
J O +
H O -
- O -
qui3,H O -
- O -
qui4 O +
( O -
9.0 O +
Hz O -
) O -
, O +
revealed O +
axial O +
orientations O +
of O +
H O -
- O -
qui1 O -
, O +
H O -
- O -
qui2 O -
, O +
H O -
- O -
qui3 O +
and O +
H O -
- O -
qui4 O -
, O +
respectively O -
, O +
while O +
those O +
of O +
J O +
H O -
- O -
rha2,H O -
- O -
rha3 O +
( O -
3.2 O +
Hz O -
) O -
, O +
J O +
H O -
- O -
rha3,H O -
- O -
rha4 O +
( O -
9.3 O +
Hz O -
) O +
and O +
J O +
H O -
- O -
rha4,H O -
- O -
rha5 O +
( O -
9.3 O +
Hz O -
) O +
readily O +
indicated O +
the O +
respective O +
configurations O +
of O +
H-2 O -
, O +
H-3 O -
, O +
H-4 O +
and O +
H-5 O +
as O +
equatorial O -
, O +
axial O -
, O +
axial O +
and O +
axial O -
. O +

Finally O -
, O +
the O +
presence O +
of O +
quinovose O +
and O +
rhamnose O +
( O -
1→3 O +
linkage O -
) O +
in O +
5 O +
was O +
confirmed O +
by O +
comparison O +
of O +
the O +
13 O +
C O +
signals O +
with O +
those O +
of O +
published O +
values O +
( O -
Yahara O +
et O +
al. O -
, O +
1996 O +
) O -
. O +

Torvoside O +
H O +
( O -
3 O +
) O +
exhibited O +
a O +
negative O +
optical O +
rotation O +
similar O +
to O +
that O +
of O +
torvoside O +
A O +
( O -
2 O +
) O -
, O +
it O +
is O +
therefore O +
not O +
unreasonable O +
to O +
assume O +
that O +
the O +
absolute O +
configurations O +
of O +
all O +
sugars O +
in O +
3 O +
are O +
the O +
same O +
as O +
those O +
in O +
2 O +
. O +

On O +
the O +
basis O +
of O +
these O +
spectral O +
data O -
, O +
compound O +
5 O +
is O +
( O -
25S O +
) O -
-6α O +
-hydroxy-5α O +
-spirostan-3-one O +
6-O O +
- O -
[ O -
α O +
-l O +
-rhamnopyranosyl- O -
( O -
1→3 O -
) O -
-β O +
-d O +
-quinovopyranoside O -
] O -
, O +
and O +
torvoside O +
H O +
( O -
3 O +
) O +
is O +
therefore O +
( O -
25S O +
) O -
-26-O O +
- O -
( O -
β O +
-d O +
-glucopyranosyl O -
) O -
-6α O +
, O -
26-dihydroxy-5α O +
-spirostan-3-one O +
6-O O +
- O -
[ O -
α O +
-l O +
-rhamnopyranosyl- O -
( O -
1→3 O -
) O -
-β O +
-D O -
- O -
quinovopyranoside O -
] O -
. O +

Torvanol O +
A O +
( O -
1 O +
) O -
, O +
torvoside O +
H O +
( O -
3 O +
) O +
and O +
compound O +
5 O +
exhibited O +
antiviral O +
activity O +
( O -
herpes O +
simplex O +
virus O +
type O +
1 O -
) O +
with O +
the O +
IC50 O +
values O +
of O +
9.6 O -
, O +
23.2 O +
and O +
17.4 O +
μg O -
/ O -
ml O -
, O +
respectively O -
. O +

Compounds O +
1 O +
–5 O +
were O +
inactive O +
( O -
at O +
50 O +
μg O -
/ O -
ml O -
) O +
against O +
BC O -
, O +
KB O +
and O +
Vero O +
cell O +
lines O -
. O +

Recently O -
, O +
antiviral O +
activity O +
( O -
herpes O +
virus O -
) O +
of O +
Solanum O +
steroidal O +
glycosides O +
has O +
been O +
demonstrated O +
( O -
Ikeda O +
et O +
al. O -
, O +
2000 O +
) O -
, O +
while O +
Chah O +
et O +
al. O +
( O -
2000 O -
) O +
reported O +
an O +
antimicrobial O +
activity O +
of O +
the O +
methanolic O +
extract O +
of O +
S. O +
torvum O +
fruits O -
. O +

3 O +
Experimental O +
3.1 O +
General O +
The O +
1 O +
H O -
, O +
13 O +
C O -
, O +
DEPTs O -
, O +
1 O +
H–1 O +
H O +
COSY O -
, O +
NOESY O -
, O +
HMQC O +
( O -
optimized O +
for O +
1 O +
J O +
HC O +
= O -
145 O +
Hz O -
) O +
and O +
HMBC O +
( O -
optimized O +
for O +
n O +
J O +
HC O +
= O -
8.0 O +
Hz O +
as O +
well O +
as O +
4.0 O +
Hz O -
) O +
spectra O +
were O +
recorded O +
on O +
a O +
Bruker O +
DRX O +
400 O -
, O +
operating O +
at O +
400.1 O +
MHz O +
for O +
proton O +
and O +
100.6 O +
MHz O +
for O +
carbon O -
. O +

The O +
ESITOF O +
mass O +
spectra O +
were O +
obtained O +
from O +
a O +
Micromass O +
LCT O +
mass O +
spectrometer O -
, O +
while O +
the O +
IR O +
spectra O +
were O +
measured O +
on O +
a O +
Perkin O -
- O -
Elmer O +
2000 O +
spectrometer O -
. O +

An O +
HPLC O +
pump O +
( O -
Waters O +
600 O -
) O +
was O +
equipped O +
with O +
a O +
UV O -
- O -
photodiode O +
array O +
detector O +
( O -
Waters O +
996 O -
) O -
. O +

The O +
metal O +
composition O +
in O +
torvanol O +
A O +
( O -
1 O +
) O +
was O +
analyzed O +
with O +
a O +
Perkin O +
Elmer O +
( O -
model O +
3100 O -
) O +
flame O +
atomic O +
absorption O +
spectrometer O -
. O +

3.2 O +
Plant O +
specimen O -
, O +
extraction O +
and O +
isolation O +
Fresh O +
fruits O +
( O -
2.5 O +
kg O -
) O +
of O +
S. O +
torvum O +
Swartz O +
were O +
bought O +
from O +
Pak O +
Klong O +
Talad O +
Market O -
, O +
Bangkok O -
, O +
Thailand O -
. O +

Crushed O +
fruits O +
were O +
macerated O +
in O +
MeOH O +
( O -
6 O +
l O -
) O +
for O +
2 O +
days O +
at O +
room O +
temperature O -
. O +

The O +
extract O +
was O +
evaporated O -
, O +
and O +
dissolved O +
in O +
70 O -
% O +
aqueous O +
MeOH O -
, O +
which O +
was O +
sequentially O +
extracted O +
with O +
hexane O +
and O +
EtOAc O +
( O -
equal O +
volume O -
, O +
three O +
times O -
) O -
. O +

Aqueous O +
MeOH O -
, O +
hexane O -
, O +
and O +
EtOAc O +
layers O +
were O +
evaporated O +
to O +
dryness O -
, O +
to O +
give O +
respective O +
yields O +
of O +
15.3 O -
, O +
10.0 O -
, O +
and O +
5.5 O +
g. O +
A O +
crude O +
extract O +
of O +
the O +
aqueous O +
MeOH O +
layer O +
was O +
applied O +
to O +
a O +
Sephadex O +
LH-20 O +
column O +
( O -
eluted O +
with O +
MeOH O -
) O -
. O +

Twenty O +
fractions O +
( O -
ca O -
. O +
100 O +
ml O -
) O +
were O +
collected O +
and O +
evaporated O +
to O +
dryness O +
in O +
vacuo O -
. O +

Fractions O +
15–20 O +
containing O +
torvanol O +
A O +
( O -
1 O +
) O +
were O +
combined O -
, O +
and O +
subsequently O +
purified O +
by O +
preparative O +
HPLC O +
( O -
C18 O +
reversed O +
phase O +
column O -
, O +
Prep O +
Nova O +
Pak O -
, O +
Waters O -
) O +
using O +
H2 O +
O O -
: O -
MeOH O +
( O -
90:10 O -
, O +
v O -
/ O -
v O -
) O +
as O +
eluent O -
, O +
yielding O +
torvanol O +
A O +
( O -
1 O +
) O +
( O -
25 O +
mg O -
) O -
. O +

Fractions O +
3–6 O +
obtaining O +
from O +
Sephadex O +
LH-20 O +
column O +
were O +
further O +
purified O +
by O +
MPLC O +
( O -
C18 O +
reversed O +
phase O +
column O -
) O +
using O +
H2 O +
O O -
: O -
MeOH O +
( O -
60:40 O -
, O +
v O -
/ O -
v O -
) O +
as O +
eluent O -
, O +
to O +
yield O +
torvoside O +
A O +
( O -
2 O +
) O +
( O -
2.1 O +
g O -
) O +
and O +
torvoside O +
H O +
( O -
3 O +
) O +
( O -
0.2 O +
g O -
) O -
. O +

3.3 O +
Bioassay O +
The O +
cytotoxic O +
assay O +
employed O +
the O +
colorimetric O +
method O +
( O -
Skehan O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

Ellipticine O -
, O +
the O +
reference O +
substance O -
, O +
exhibited O +
activity O +
toward O +
BC O +
and O +
KB O +
cell O +
lines O -
, O +
both O +
with O +
the O +
IC50 O +
of O +
0.3 O +
μg O -
/ O -
ml O -
. O +

Antiviral O +
activity O +
was O +
also O +
assessed O +
employing O +
the O +
colorimetric O +
method O +
( O -
Skehan O +
et O +
al. O -
, O +
1990 O +
) O -
. O +

Herpes O +
simplex O +
virus O +
type O +
1 O +
( O -
HSV-1 O -
) O +
was O +
maintained O +
in O +
the O +
Vero O +
cell O +
line O +
( O -
kidney O +
fibroblast O +
of O +
an O +
African O +
green O +
monkey O -
) O -
, O +
which O +
was O +
cultured O +
in O +
Eagle O -
's O +
minimum O +
essential O +
medium O +
( O -
MEM O -
) O +
with O +
addition O +
of O +
heat O -
- O -
inactivated O +
fetal O +
bovine O +
serum O +
( O -
FBS O -
) O +
( O -
10 O -
% O -
) O +
and O +
antibiotics O -
. O +

The O +
test O +
samples O +
were O +
put O +
into O +
wells O +
of O +
a O +
microtiter O +
plate O +
at O +
the O +
final O +
concentrations O +
ranging O +
from O +
20 O +
to O +
50 O +
μg O -
/ O -
ml O -
. O +

The O +
viral O +
HSV-1 O +
( O -
30 O +
PFU O -
) O +
was O +
added O +
into O +
the O +
96-well O +
plate O -
, O +
followed O +
by O +
plating O +
of O +
Vero O +
cells O +
( O -
1 O -
× O -
105 O +
cells O -
/ O -
ml O -
) O -
; O +
the O +
final O +
volume O +
was O +
200 O +
μl O -
. O +

After O +
incubation O +
at O +
37 O +
° O -
C O +
for O +
72 O +
h O -
, O +
under O +
5 O -
% O +
of O +
CO2 O +
atmosphere O -
, O +
cells O +
were O +
fixed O +
and O +
stained O -
, O +
and O +
optical O +
density O +
was O +
measured O +
at O +
510 O +
nm O -
. O +

Under O +
our O +
screening O +
conditions O -
, O +
the O +
reference O +
compound O -
, O +
Acyclovir O -
, O +
typically O +
exhibited O +
the O +
antiviral O +
HSV-1 O +
with O +
the O +
IC50 O +
of O +
2 O -
- O -
5 O +
μg O -
/ O -
ml O -
. O +

3.4 O +
Torvanol O +
A O +
( O -
1 O +
) O +
Amorphous O +
powder O -
: O +
mp O +
> O -
300 O +
° O -
C O +
[ O -
α O -
] O -
29 O +
D O +
−50 O -
° O +
( O -
c O +
0.280 O -
, O +
H2 O +
O O -
) O -
; O +
IR O +
ν O +
max O +
cm−1 O +
: O +
3448 O -
, O +
2362 O -
, O +
1638 O -
, O +
1610 O -
, O +
1545 O -
, O +
1499 O -
, O +
1389 O -
, O +
1330 O -
, O +
1256 O -
, O +
1145 O -
, O +
1065 O -
, O +
985 O -
, O +
851 O -
, O +
822 O -
, O +
761 O -
; O +
UV O +
( O -
MeOH O -
) O +
λ O +
max O +
nm O -
: O +
203 O -
, O +
234 O -
, O +
283 O -
; O +
ESITOF O +
MS O +
( O -
negative O +
ion O +
mode O -
) O -
: O +
m O +
/z O +
451.0677 O -
, O +
calc O -
. O +

for O +
C20 O +
H19 O +
O10 O +
S O +
( O -
M O -
– O -
H O -
) O -
− O +
, O +
free O +
acid O +
form O -
, O +
451.0699 O -
; O +
for O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
( O -
Table O +
1 O +
) O -
. O +

3.5 O +
Torvoside O +
H O +
( O -
3 O +
) O +
and O +
its O +
derivative O +
( O -
5 O +
) O +
Torvoside O +
H O +
( O -
3 O +
) O +
was O +
obtained O +
as O +
an O +
amorphous O +
powder O -
: O +
mp O +
170–172 O +
° O -
C O +
[ O -
α O +
] O -
29 O +
D O +
−58.15 O -
° O +
( O -
c O +
0.114 O -
, O +
MeOH O -
) O -
; O +
IR O +
ν O +
max O +
cm−1 O +
: O +
3422 O -
, O +
2932 O -
, O +
1702 O -
, O +
1655 O -
, O +
1648 O -
, O +
1458 O -
, O +
1420 O -
, O +
1381 O -
, O +
1074 O -
; O +
ESITOF O +
MS O +
( O -
negative O +
ion O +
mode O -
) O -
: O +
m O +
/z O +
901.465 O -
, O +
calc O -
. O +

for O +
C45 O +
H73 O +
O18 O +
( O -
M O -
– O -
H O -
) O -
− O +
, O +
901.479 O -
; O +
for O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
( O -
Table O +
2 O +
) O -
. O +

Torvoside O +
H O +
( O -
3 O +
) O +
( O -
70 O +
mg O -
) O +
was O +
incubated O +
with O +
commercial O +
almond B-Gene +
β I-Gene -
- I-Gene -
glucosidase I-Gene +
( O -
7 O +
mg O -
) O +
in O +
H2 O +
O O +
( O -
12.5 O +
ml O -
) O +
at O +
37 O +
° O -
C O +
for O +
24 O +
h. O +
After O +
evaporation O +
of O +
the O +
solvent O -
, O +
the O +
reaction O +
mixture O +
was O +
applied O +
to O +
a O +
silica O +
gel O +
column O -
, O +
eluted O +
with O +
CHCl3 O +
: O -
MeOH O +
( O -
3:1 O -
) O -
, O +
to O +
give O +
β O -
- O -
d O +
-glucose O +
and O +
a O +
derivative O +
5 O +
( O -
mp O +
180–183 O +
° O -
C O -
; O +
[ O -
α O +
] O -
29 O +
D O +
−63.72 O -
° O -
, O +
c O +
0.113 O +
in O +
MeOH O -
) O -
, O +
ESITOF O +
MS O +
( O -
negative O +
ion O +
mode O -
) O -
: O +
m O +
/z O +
721.4155 O -
, O +
calc O -
. O +

for O +
C39 O +
H61 O +
O12 O +
( O -
M O -
- O -
H O -
) O -
− O +
, O +
721.4163 O -
; O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
( O -
Table O +
2 O +
) O -
. O +

Acknowledgements O +
This O +
work O +
is O +
a O +
project O +
of O +
the O +
Center O +
for O +
Protein O +
Structure O +
and O +
Function O +
at O +
the O +
Faculty O +
of O +
Science O -
, O +
Mahidol O +
University O -
. O +

We O +
are O +
grateful O +
to O +
the O +
Biodiversity O +
Research O +
and O +
Training O +
Program O +
( O -
BRT O -
) O -
, O +
BIOTEC O -
/ O -
NSTDA O +
for O +
financial O +
support O -
. O +

D.A. O +
received O +
a O +
scholarship O +
from O +
the O +
Chulabhorn O +
Research O +
Institute O -
. O +

Y.T. O +
thanks O +
the O +
National O +
Science O +
and O +
Technology O +
Development O +
Agency O +
( O -
NSTDA O -
) O +
for O +
the O +
Senior O +
Research O +
Fellowship O +
Award O -
. O +

J.S. O +
is O +
a O +
Senior O +
Research O +
Fellow O +
of O +
the O +
Thailand O +
Research O +
Fund O -
. O +

Since O +
arachidonic O +
acid O +
( O -
20:4n-6 O -
, O +
AA O -
) O +
and O +
docosahexaenoic O +
acid O +
( O -
22:6n-3 O -
, O +
DHA O -
) O +
compose O +
the O +
major O +
portion O +
of O +
polyunsaturated O +
fatty O +
acids O +
( O -
PUFA O -
) O +
in O +
brain O +
lipids O -
, O +
these O +
PUFAs O +
are O +
suggested O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
regulation O +
of O +
functions O +
of O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
. O +

Most O +
importantly O -
, O +
DHA O +
has O +
been O +
demonstrated O +
to O +
be O +
essential O +
in O +
maintaining O +
normal O +
functions O +
of O +
CNS O -
, O +
which O +
has O +
been O +
demonstrated O +
by O +
the O +
impairment O +
of O +
memory O +
functions O +
occurring O +
in O +
experimental O +
rodents O +
with O +
n-3 O +
PUFA O +
deficiency O +
[ O -
1,2 O -
] O +
. O +

However O -
, O +
the O +
biochemical O +
basis O +
of O +
the O +
essentiality O +
of O +
DHA O +
in O +
the O +
functions O +
of O +
CNS O +
has O +
not O +
been O +
defined O -
. O +

On O +
the O +
other O +
hand O -
, O +
AA O +
itself O +
or O +
AA O -
- O -
derived O +
eicosanoids O +
modulates O +
neurotransmission O +
[ O -
3,4 O -
] O +
. O +

Therefore O -
, O +
the O +
functions O +
of O +
CNS O +
may O +
be O +
modified O +
by O +
dietary O +
supplementation O +
with O +
n-3 O +
PUFA O -
, O +
which O +
antagonizes O +
the O +
metabolism O +
and O +
actions O +
of O +
AA O +
[ O -
5 O -
] O +
. O +

Δ9 O +
-Tetrahydrocannabinol O -
, O +
a O +
psychoactive O +
compound O +
derived O +
from O +
marijuana O -
, O +
acts O +
through O +
either O +
the O +
CB1 B-Gene +
or O +
CB2 B-Gene +
receptor I-Gene -
; O +
the O +
former O +
is O +
highly O +
expressed O +
in O +
areas O +
of O +
CNS O +
[ O -
6 O -
] O +
and O +
the O +
latter O +
is O +
localized O +
mainly O +
in O +
peripheral O +
immune O +
cells O +
[ O -
7 O -
] O +
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
discovery O +
of O +
endogenous O +
ligands O +
of O +
cannabinoid B-Gene +
receptors I-Gene +
in O +
the O +
brain O +
has O +
facilitated O +
the O +
progress O +
of O +
research O +
on O +
the O +
regulation O +
of O +
cannabinoid B-Gene -
- I-Gene -
receptor I-Gene -
- O -
mediated O +
neuronal O +
functions O -
. O +

Recently O -
, O +
two O +
arachidonic O +
acid O +
( O -
20:4n-6 O -
, O +
AA O -
) O -
-containing O +
compounds O -
, O +
anandamide O -
, O +
( O -
N O +
-arachidonoylethanolamine O -
) O +
and O +
2-arachidonoylglycerol O +
( O -
2-AG O -
) O -
, O +
have O +
been O +
identified O +
as O +
the O +
endogenous O +
ligands O +
for O +
cannabinoid O +
receptors O +
and O +
these O +
molecules O +
have O +
been O +
detected O +
in O +
various O +
brain O +
regions O +
[ O -
8 O -
] O +
. O +

Furthermore O -
, O +
Sugiura O +
and O +
colleague O +
demonstrated O +
that O +
2-AG O +
is O +
the O +
major O +
monoacylglycerol O +
( O -
MG O -
) O +
molecular O +
species O +
in O +
the O +
rat O +
brain O +
and O +
its O +
potencies O +
for O +
CB1 B-Gene +
and O +
CB2 B-Gene +
receptors I-Gene +
are O +
much O +
greater O +
than O +
those O +
of O +
anandamide O +
[ O -
9–11 O -
] O +
. O +

Furthermore O -
, O +
it O +
has O +
been O +
reported O +
that O +
MG O +
molecular O +
species O +
containing O +
fatty O +
acids O +
other O +
than O +
AA O +
are O +
less O +
potent O +
for O +
both O +
CB1 B-Gene +
and O +
CB2 B-Gene +
receptors I-Gene +
[ O -
10,11 O -
] O +
. O +

Therefore O -
, O +
it O +
can O +
be O +
assumed O +
that O +
2-AG O +
plays O +
a O +
dominant O +
role O +
in O +
the O +
regulation O +
of O +
cannabinoid B-Gene +
receptor I-Gene +
functions O +
in O +
the O +
brain O -
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
sequential O +
hydrolysis O +
of O +
arachidonate O -
- O -
containing O +
phospholipids O +
is O +
one O +
of O +
the O +
major O +
biosynthetic O +
pathways O +
of O +
2-AG O +
in O +
the O +
brain O +
[ O -
12,13 O -
] O +
although O +
the O +
candidate O +
of O +
precursor O +
phospholipid O +
classes O +
as O +
well O +
as O +
the O +
enzymes B-Gene +
involved O +
in O +
2-AG O +
biosynthesis O +
have O +
not O +
been O +
identified O -
. O +

On O +
the O +
other O +
hand O -
, O +
MG O +
species O +
containing O +
EPA O +
and O +
DHA O +
were O +
demonstrated O +
to O +
be O +
less O +
potent O +
for O +
cannabinoid B-Gene +
receptors I-Gene +
than O +
2-AG O +
[ O -
10,11 O -
] O +
. O +

Therefore O -
, O +
the O +
manipulation O +
of O +
dietary O +
n-3 O +
PUFA O +
status O +
may O +
change O +
the O +
levels O +
of O +
2-AG O +
as O +
well O +
as O +
n-3 O +
PUFA O -
- O -
containing O +
MG O +
in O +
tissues O -
, O +
which O +
indicates O +
the O +
alteration O +
of O +
endogenous O +
ligand O +
activity O +
for O +
cannabinoid B-Gene +
receptors I-Gene -
. O +

To O +
test O +
this O +
hypothesis O -
, O +
we O +
determined O +
the O +
effects O +
of O +
chronic O +
n-3 O +
PUFA O +
deficiency O +
and O +
short O -
- O -
term O +
supplementation O +
with O +
a O +
DHA O -
- O -
rich O +
diet O +
on O +
brain O +
2-AG O +
levels O -
. O +

In O +
addition O -
, O +
we O +
analyzed O +
the O +
fatty O +
acid O +
composition O +
of O +
brain O +
phospholipids O +
in O +
mice O +
under O +
different O +
dietary O +
n-3 O +
PUFA O +
status O +
in O +
order O +
to O +
differentiate O +
the O +
levels O +
of O +
2-AG O +
in O +
their O +
brains O -
. O +

2 O +
Materials O +
and O +
methods O +
2.1 O +
Preparation O +
of O +
monoacylglycerol O +
standards O +
Triarachidonoylglycerol O -
, O +
trieicosapentaenoylglycerol O +
or O +
tridocosahexaenoylglycerol O +
( O -
Nu O -
- O -
Chek O -
- O -
Prep O +
Inc. O -
, O +
Elysian O -
, O +
MN O -
) O +
was O +
treated O +
with O +
lipase B-Gene +
from B-Gene +
Rhizopus I-Gene +
arrhizus I-Gene +
( O -
Type O +
XI O -
, O +
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O +
as O +
described O +
by O +
Schmid O +
et O +
al. O +
[ O -
14 O -
] O +
. O +

The O +
2-acyl O +
form O +
of O +
MG O +
was O +
the O +
primary O +
product O +
in O +
the O +
treatment O +
of O +
triacylglycerol O +
with O +
the O +
lipase B-Gene -
, O +
although O +
a O +
small O +
amount O +
of O +
the O +
1 O -
( O -
3 O -
) O -
-acyl O +
form O +
of O +
MG O +
was O +
generated O +
due O +
to O +
spontaneous O +
migration O +
of O +
the O +
acyl O +
moiety O +
from O +
the O +
Sn O +
-2 O +
position O +
to O +
the O +
Sn O +
-1 O -
( O -
3 O -
) O +
position O -
. O +

The O +
1 O -
( O -
3 O -
) O -
- O +
and O +
2-acyl O +
forms O +
of O +
MG O +
generated O +
during O +
the O +
lipase B-Gene +
treatment O +
of O +
triacylglycerols O +
were O +
extracted O +
from O +
the O +
reaction O +
mixture O +
with O +
diethylether O +
and O +
separated O +
from O +
each O +
other O +
by O +
silica O +
gel O +
thin O -
- O -
layer O +
chromatography O +
( O -
TLC O -
) O +
using O +
a O +
mixture O +
of O +
CHCl3 O +
/ethylacetate O -
/ O -
trimethoxyborane O +
( O -
100:20:7 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O +
[ O -
15 O -
] O +
as O +
a O +
developing O +
solvent O -
. O +

Each O +
MG O +
was O +
recovered O +
from O +
the O +
adsorbents O +
by O +
the O +
method O +
of O +
Bligh O +
and O +
Dyer O +
[ O -
16 O -
] O +
. O +

The O +
1 O -
( O -
3 O -
) O -
- O +
and O +
2-acyl O +
forms O +
of O +
monopalmitoylglycerol O +
and O +
monooleoylglycerol O +
were O +
purchased O +
from O +
Nu O -
- O -
Chek O -
- O -
Prep O +
and O +
Sigma O -
, O +
respectively O -
, O +
which O +
were O +
purified O +
by O +
the O +
above O -
- O -
mentioned O +
silica O +
gel O +
TLC O +
before O +
use O -
. O +

1-Heptadecanoylglycerol O +
( O -
Nu O -
- O -
Chek O -
- O -
Prep O +
Inc. O -
) O +
was O +
used O +
as O +
an O +
internal O +
standard O +
for O +
quantification O -
. O +

The O +
purity O +
and O +
quantity O +
of O +
all O +
the O +
MG O +
standards O +
used O +
were O +
determined O +
by O +
gas O -
– O -
liquid O +
chromatography O +
as O +
fatty O +
acid O +
methylesters O +
prepared O +
by O +
transmethylation O +
using O +
methanolic O +
HCl O +
( O -
5 O -
% O -
, O +
w O -
/ O -
v O -
) O +
in O +
the O +
presence O +
of O +
hepadecanoic O +
acid O +
( O -
17:0 O -
) O -
. O +

2.2 O +
Preparation O +
of O +
MG O +
dibenzoates O +
The O +
dried O +
MG O +
sample O +
was O +
treated O +
with O +
25 O +
μl O +
of O +
benzoylchloride O +
( O -
Nakalai O +
Tesque O -
, O +
Tokyo O -
) O +
in O +
the O +
presence O +
of O +
200 O +
μl O +
of O +
anhydrous O +
pyridine O +
( O -
Wako O +
Pure O +
Chem O -
. O +

Osaka O -
, O +
Japan O -
) O +
for O +
15 O +
min O +
at O +
60 O -
° O -
C O -
. O +

After O +
the O +
addition O +
of O +
1 O +
ml O +
of O +
distilled O +
water O -
, O +
the O +
mixture O +
was O +
heated O +
for O +
another O +
15 O +
min O +
and O +
then O +
1 O +
ml O +
of O +
30 O -
% O +
( O -
w O -
/ O -
v O -
) O +
aqueous O +
ammonium O +
hydroxide O +
was O +
added O -
. O +

MG O +
dibenzoates O +
were O +
extracted O +
three O +
times O +
with O +
2 O +
ml O +
of O +
n O +
-hexane O +
and O +
purified O +
by O +
silica O +
gel O +
TLC O +
using O +
a O +
solvent O +
system O +
of O +
benzene O -
/ O -
petroleum O +
ether O -
/ O -
diethyl O +
ether O +
( O -
50:45:5 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O +
[ O -
17 O -
] O +
. O +

A O +
spot O +
corresponding O +
to O +
MG O +
dibenzoates O +
( O -
R O +
f O +
= O -
0.26 O -
) O +
[ O -
17 O -
] O +
was O +
visualized O +
under O +
an O +
ultraviolet O +
light O +
after O +
spraying O +
with O +
purimurine O +
( O -
Nakalai O +
Tesque O -
) O +
dissolved O +
in O +
acetone O -
/ O -
water O +
( O -
4:1 O -
) O -
. O +

MG O +
dibenzoate O +
was O +
recovered O +
from O +
the O +
adsorbent O +
by O +
the O +
method O +
of O +
Bligh O +
and O +
Dyer O +
[ O -
16 O -
] O +
and O +
reconstituted O +
in O +
100 O +
μl O +
of O +
acetonitrile O +
for O +
subsequent O +
HPLC O +
analysis O -
. O +

2.3 O +
HPLC O +
separation O +
and O +
quantification O +
of O +
MG O +
dibenzoates O +
MG O +
dibenzoates O +
with O +
different O +
acyl O +
chains O +
were O +
separated O +
and O +
quantified O +
by O +
reverse O -
- O -
phase O +
HPLC O +
with O +
an O +
octadecylsilica O +
column O +
( O -
4.6 O -
× O -
150 O +
mm O -
, O +
Senshu O +
Pak O -
, O +
Senshu O +
Scientific O +
Co. O -
, O +
Ltd. O -
, O +
Tokyo O -
) O +
equilibrated O +
with O +
85 O -
% O +
aqueous O +
acetonitrile O +
at O +
a O +
flow O +
rate O +
of O +
1 O +
ml O -
/ O -
min O -
. O +

MG O +
dibenzoates O +
were O +
detected O +
by O +
ultraviolet O +
absorbance O +
at O +
230 O +
nm O +
( O -
SPD-6A O -
, O +
Shimadzu O -
, O +
Tokyo O -
) O -
. O +

The O +
standard O +
MG O +
dibenzoates O +
were O +
used O +
to O +
confirm O +
the O +
retention O +
time O +
of O +
those O +
prepared O +
from O +
mouse O +
brain O +
by O +
the O +
HPLC O -
. O +

Quantification O +
of O +
MG O +
dibenzoates O +
was O +
carried O +
out O +
by O +
comparing O +
their O +
peak O +
area O +
with O +
that O +
of O +
1-heptadecanoylglycerol O +
( O -
17:0MG O -
) O +
dibenzoate O +
added O +
as O +
an O +
internal O +
standard O -
. O +

The O +
peaks O +
observed O +
in O +
the O +
HPLC O +
analysis O +
of O +
mouse O +
brain O +
MG O +
were O +
further O +
identified O +
by O +
on O -
- O -
line O +
atmospheric O -
- O -
pressure O +
chemical O +
ionization O -
- O -
mass O +
spectrometry O +
( O -
APCI O -
- O -
MS O -
) O +
( O -
HP1100MSD O -
, O +
Yokagawa O +
Analytical O +
Systems O -
, O +
Tokyo O -
) O +
operating O +
in O +
the O +
positive O -
- O -
ionization O +
mode O +
at O +
90 O +
V. O +
2.4 O +
Animals O +
and O +
dietary O +
protocols O +
The O +
experimental O +
protocol O +
was O +
approved O +
by O +
the O +
Committee O +
of O +
Animal O +
Care O +
and O +
Use O +
of O +
Toyama O +
Medical O +
and O +
Pharmaceutical O +
University O +
( O -
Protocol O +
No. O +
2001 O -
- O -
31 O -
) O -
.Experiment O +
1 O +
Female O +
ddy O +
mice O +
at O +
4 O +
weeks O +
of O +
age O +
( O -
SLC O -
) O +
were O +
fed O +
a O +
diet O +
supplemented O +
with O +
either O +
5 O -
% O +
( O -
w O -
/ O -
w O -
) O +
safflower O +
oil O +
( O -
n-3-deficient O +
diet O -
) O +
or O +
safflower O +
oil O +
plus O +
DHA O +
ethylester O +
( O -
99:1 O -
) O +
( O -
n-3-sufficient O +
diet O -
) O +
for O +
23 O +
weeks O +
before O +
mating O +
with O +
male O +
ddy O +
mice O -
. O +

Male O +
pups O +
weaned O +
at O +
4 O +
weeks O +
old O +
were O +
fed O +
the O +
same O +
diet O +
as O +
their O +
dams O +
for O +
an O +
additional O +
6 O +
weeks O +
prior O +
to O +
analysis O -
. O +

The O +
fatty O +
acid O +
composition O +
of O +
the O +
dietary O +
fat O +
is O +
shown O +
in O +
Table O +
1 O +
. O +

Experiment O +
2 O +
Male O +
ddy O +
mice O +
at O +
4 O +
weeks O +
old O +
( O -
SLC O -
, O +
Shizuoka O -
, O +
Japan O -
) O +
were O +
divided O +
into O +
two O +
groups O -
. O +

Each O +
group O +
of O +
mice O +
was O +
assigned O +
to O +
an O +
AIN-76 O +
powdered O +
diet O +
( O -
Nihon O +
Nosan O +
Kogyo O -
, O +
Tsukuba O -
, O +
Japan O -
) O +
supplemented O +
with O +
either O +
10 O -
% O +
( O -
w O -
/ O -
w O -
) O +
linoleate O +
( O -
18:2n-6 O -
, O +
LA O -
) O -
-rich O +
safflower O +
oil O +
( O -
Nippon O +
Oil O +
Industry O -
, O +
Tokyo O -
) O +
( O -
low O -
- O -
DHA O +
diet O -
) O +
or O +
10 O -
% O +
DHA O -
- O -
rich O +
fish O +
oil O +
( O -
Nissui O -
, O +
Tsukuba O -
, O +
Japan O -
) O +
( O -
high O -
- O -
DHA O +
diet O -
) O +
for O +
4 O +
weeks O +
prior O +
to O +
analysis O -
. O +

The O +
fatty O +
acid O +
composition O +
of O +
the O +
dietary O +
fat O +
is O +
shown O +
in O +
Table O +
1 O +
. O +

2.5 O +
Lipid O +
extraction O +
from O +
mice O +
brain O +
Mice O +
lightly O +
anesthetized O +
with O +
diethylether O +
were O +
decapitated O +
and O +
their O +
heads O +
were O +
immediately O +
immersed O +
into O +
liquid O +
nitrogen O +
and O +
left O +
for O +
more O +
than O +
10 O +
min O -
. O +

Frozen O +
whole O +
brains O +
were O +
dissected O +
from O +
the O +
skull O +
and O +
homogenized O +
using O +
a O +
blender O +
in O +
chloroform O -
/ O -
methanol O +
( O -
1:2 O -
, O +
v O -
/ O -
v O -
) O +
in O +
the O +
presence O +
of O +
1-heptadecanoylglycerol O +
( O -
1.45 O +
nmol O -
) O +
as O +
an O +
internal O +
standard O -
, O +
and O +
total O +
lipids O +
were O +
obtained O +
according O +
to O +
the O +
method O +
of O +
Bligh O +
and O +
Dyer O +
[ O -
16 O -
] O +
. O +

Total O +
lipids O +
were O +
applied O +
to O +
a O +
silica O +
gel O +
cartridge O +
column O +
( O -
Sep O -
- O -
Pak O +
Plus O +
Si O -
, O +
Waters O -
, O +
Milford O -
, O +
MA O -
, O +
USA O -
) O +
that O +
had O +
been O +
pre O -
- O -
equilibrated O +
with O +
chloroform O -
. O +

Chloroform O +
( O -
10 O +
ml O -
) O +
was O +
loaded O +
onto O +
the O +
column O +
to O +
remove O +
almost O +
all O +
triacylglycerols O -
, O +
cholesterol O +
and O +
diacylglycerols O -
. O +

A O +
MG O -
- O -
rich O +
fraction O +
was O +
eluted O +
from O +
the O +
column O +
with O +
10 O +
ml O +
of O +
chloroform O -
/ O -
methanol O +
( O -
98:2 O -
, O +
v O -
/ O -
v O -
) O -
, O +
and O +
dried O +
using O +
nitrogen O +
gas O -
. O +

The O +
fraction O +
containing O +
total O +
phospholipids O +
was O +
then O +
eluted O +
from O +
the O +
column O +
with O +
20 O +
ml O +
of O +
chloroform O -
/ O -
methanol O -
/ O -
distilled O +
water O +
( O -
1:2:0.8 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O -
, O +
and O +
the O +
eluate O +
was O +
processed O +
to O +
obtain O +
total O +
phospholipids O +
according O +
to O +
the O +
method O +
of O +
Bligh O +
and O +
Dyer O +
[ O -
16 O -
] O +
. O +

2.6 O +
Analysis O +
of O +
fatty O +
acid O +
composition O +
of O +
phospholipids O +
in O +
mouse O +
brain O +
Phosphatidylcholine O +
( O -
PC O -
) O -
, O +
phosphatidylethanolamine O +
( O -
PE O -
) O -
, O +
phosphatidylserine O +
( O -
PS O -
) O +
and O +
phosphatidylinositol O +
( O -
PI O -
) O +
were O +
purified O +
from O +
the O +
total O +
phospholipids O +
by O +
two O -
- O -
dimensional O +
silica O +
gel O +
TLC O +
using O +
chloroform O -
/ O -
methanol O -
/ O -
formic O +
acid O -
/ O -
distilled O +
water O +
( O -
60:30:8:2 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
/ O -
v O -
) O +
and O +
chloroform O -
/ O -
methanol O -
/ O -
25 O -
% O +
ammonium O +
hydroxide O +
solution O +
( O -
60:40:6 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O +
for O +
the O +
first O +
and O +
second O +
developments O -
, O +
respectively O -
. O +

Fatty O +
acids O +
in O +
each O +
phospholipid O +
class O +
were O +
converted O +
into O +
their O +
corresponding O +
methylesters O +
by O +
boiling O +
in O +
methanol O +
containing O +
5 O -
% O +
( O -
w O -
/ O -
v O -
) O +
hydrogen O +
chloride O -
, O +
and O +
analyzed O +
by O +
gas O -
– O -
liquid O +
chromatography O +
with O +
a O +
capillary O +
column O +
( O -
DB-225 O -
, O +
J&B O +
Scientific O -
, O +
Folsom O -
, O +
CA O -
, O +
USA O -
) O -
. O +

2.7 O +
Statistical O +
analysis O +
Statistical O +
analysis O +
was O +
performed O +
using O +
Student O -
's O +
t O +
-test O +
to O +
confirm O +
significance O +
between O +
the O +
dietary O +
groups O -
. O +

3 O +
Results O +
3.1 O +
Separation O +
of O +
authentic O +
MG O +
dibenzoates O +
by O +
HPLC O +
Fig. O +
1 O +
presents O +
a O +
reverse O -
- O -
phase O +
HPLC O +
profile O +
of O +
the O +
dibenzoates O +
of O +
authentic O +
MG O -
. O +

Almost O +
all O +
1 O -
( O -
3 O -
) O -
- O +
and O +
2-acyl O +
isomers O +
of O +
MG O +
dibenzoates O +
with O +
different O +
acyl O +
groups O +
were O +
clearly O +
separated O -
, O +
except O +
that O +
the O +
derivatives O +
of O +
2-palmitoylglycerol O +
( O -
2 O -
- O -
16:0MG O -
) O +
and O +
1-octadecenylglycerol O +
( O -
1 O -
- O -
18:1MG O -
) O +
coeluted O -
. O +

When O +
1 O +
nmol O +
each O +
of O +
MG O +
standards O +
was O +
derivatized O +
and O +
separated O +
by O +
HPLC O +
( O -
Fig. O +
1 O +
) O -
, O +
the O +
peak O +
areas O +
obtained O +
were O +
almost O +
same O +
among O +
all O +
the O +
derivatives O +
( O -
data O +
not O +
shown O -
) O -
. O +

Therefore O -
, O +
we O +
calculated O +
the O +
amounts O +
of O +
MG O +
from O +
brain O +
extracts O +
using O +
the O +
following O +
equation O -
: O +
( O -
peak O +
area O +
of O +
dibenzoate O +
of O +
MG O +
interest O -
) O -
/ O -
( O -
peak O +
area O +
of O +
dibenzoate O +
of O +
1 O -
- O -
17:0MG O -
) O -
× O -
1.45 O +
nmol O -
. O +

3.2 O +
Identification O +
of O +
2-AG O +
and O +
other O +
MGs O +
in O +
mouse O +
brain O +
Dibenzoate O +
derivatives O +
of O +
mouse O +
brain O +
MG O +
were O +
separated O +
by O +
reverse O -
- O -
phase O +
HPLC O -
; O +
a O +
typical O +
HPLC O +
profile O +
is O +
shown O +
in O +
Fig. O +
2A O +
. O +

The O +
retention O +
time O +
of O +
peaks O +
I O +
and O +
II O +
were O +
identical O +
with O +
those O +
of O +
dibenzoates O +
of O +
1 O -
( O -
3 O -
) O -
-AG O +
and O +
2-AG O -
, O +
respectively O -
. O +

The O +
APCI O -
- O -
mass O +
spectrum O +
of O +
peak O +
II O +
included O +
several O +
signals O +
at O +
m O +
/z O +
604.4 O +
and O +
m O +
/z O +
609.4 O +
( O -
Fig. O +
2B O +
, O +
panel O +
a O -
) O -
; O +
these O +
signals O +
corresponded O +
to O +
mass O +
numbers O +
18 O +
or O +
23 O +
greater O +
than O +
the O +
predicted O +
molecular O +
weight O +
of O +
the O +
dibenzoate O +
of O +
monoarachidonoylglycerol O +
( O -
= O -
586.4 O -
) O -
, O +
respectively O -
. O +

Therefore O -
, O +
these O +
ion O +
signals O +
can O +
be O +
assumed O +
as O +
[ O -
M+NH4 O -
] O -
+ O +
and O +
[ O -
M+Na O -
] O -
+ O +
, O +
respectively O -
. O +

The O +
occurrence O +
of O +
[ O -
M+NH4 O -
] O -
+ O +
can O +
be O +
accounted O +
for O +
by O +
MG O +
dibenzoates O +
having O +
been O +
were O +
washed O +
with O +
ammonium O +
hydroxide O +
solution O +
before O +
their O +
TLC O +
purification O +
as O +
described O +
in O +
Materials O +
and O +
methods O -
. O +

In O +
this O +
APCI O +
mass O +
spectrum O -
, O +
another O +
ion O +
peak O +
at O +
m O +
/z O +
465.3 O +
was O +
also O +
obtained O +
in O +
both O +
mass O +
spectra O -
, O +
which O +
indicates O +
the O +
formation O +
of O +
[ O -
M O -
– O -
C6 O +
H5 O +
COO O -
] O -
+ O +
. O +

The O +
APCI O -
- O -
mass O +
spectrum O +
of O +
peak O +
I O +
whose O +
retention O +
time O +
corresponded O +
to O +
that O +
of O +
1 O -
( O -
3 O -
) O -
-AG O -
- O -
dibenzoate O +
was O +
quite O +
similar O +
to O +
that O +
of O +
peak O +
II O +
( O -
Fig. O +
2B O +
, O +
panel O +
a O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
earlier O +
peaks O +
III O +
and O +
IV O +
were O +
detected O +
and O +
identified O +
by O +
APCI O -
- O -
MS O +
as O +
dibenzoates O +
of O +
1 O -
( O -
3 O -
) O -
- O +
and O +
2-monodocosahexaenoylglycerol O +
( O -
DHG O -
- O -
MG O -
) O +
based O +
in O +
the O +
demonstration O +
of O +
[ O -
M+NH4 O +
] O -
+ O +
= O -
628.4 O -
, O +
[ O -
M+Na O -
] O -
+ O +
= O -
633.4 O +
and O +
[ O -
M O -
– O -
C6 O +
H5 O +
COO O -
] O -
+ O +
= O -
489.3 O +
( O -
Fig. O +
2B O +
, O +
panels O +
c O +
and O +
d O -
) O -
. O +

Similarly O -
, O +
several O +
other O +
peaks O +
were O +
identified O +
as O +
dibenzoates O +
of O +
monopalmitoylglycerol O -
, O +
monooleoylglycerol O +
and O +
monostearoylglycerol O -
, O +
although O +
2-palmitoylglycerol O +
and O +
1 O -
( O -
3 O -
) O -
-oleoylglycerol O +
derivatives O +
were O +
found O +
to O +
coelute O +
as O +
shown O +
in O +
Fig. O +
1 O +
( O -
data O +
not O +
shown O -
) O -
. O +

Thus O -
, O +
the O +
major O +
MG O +
molecular O +
species O +
in O +
mouse O +
brain O +
extracts O +
could O +
be O +
separated O +
by O +
HPLC O +
as O +
their O +
dibenzoate O +
derivatives O +
and O +
identified O +
by O +
subsequent O +
APCI O -
- O -
MS O -
. O +

3.3 O +
Effects O +
of O +
chronic O +
deficiency O +
of O +
n-3 O +
PUFA O +
on O +
the O +
levels O +
of O +
AA O +
and O +
DHA O +
in O +
phospholipids O +
and O +
MG O +
levels O +
in O +
brain O +
In O +
the O +
n-3-deficient O +
group O -
, O +
the O +
DHA O +
levels O +
in O +
brain O +
PC O -
, O +
PE O +
and O +
PS O +
were O +
markedly O +
lower O +
than O +
those O +
in O +
the O +
n-3-sufficient O +
group O +
( O -
Table O +
2 O +
) O -
. O +

As O +
reported O +
in O +
other O +
studies O +
[ O -
1,2 O -
] O +
, O +
the O +
decrease O +
in O +
the O +
DHA O +
level O +
in O +
brain O +
phospholipids O +
is O +
compensated O +
by O +
the O +
increase O +
in O +
22:5n-6 O +
and O +
22:4n-6 O +
levels O +
in O +
the O +
n-3 O +
deficient O +
group O +
( O -
data O +
not O +
shown O -
) O -
. O +

The O +
DHA O +
level O +
in O +
brain O +
PI O +
was O +
very O +
low O +
but O +
was O +
significantly O +
lower O +
in O +
the O +
n-3-deficient O +
group O +
than O +
in O +
the O +
n-3-sufficient O +
group O -
. O +

However O -
, O +
the O +
AA O +
levels O +
in O +
all O +
the O +
four O +
phospholipid O +
classes O +
were O +
similar O +
between O +
the O +
two O +
dietary O +
groups O -
. O +

As O +
shown O +
above O -
, O +
the O +
dietary O +
n-3 O +
PUFA O +
deficiency O +
induced O +
a O +
marked O +
reduction O +
of O +
the O +
DHA O +
level O +
without O +
changing O +
the O +
AA O +
level O +
in O +
brain O +
phospholipids O +
in O +
mice O -
. O +

However O -
, O +
the O +
brain O +
2-AG O +
level O +
in O +
the O +
n-3-deficient O +
group O +
was O +
significantly O +
higher O +
than O +
that O +
in O +
the O +
n-3-sufficient O +
group O +
( O -
Fig. O +
3 O +
) O -
. O +

In O +
the O +
n-3-deficient O +
group O -
, O +
the O +
brain O +
2-DHG O +
MG O +
level O +
was O +
significantly O +
lower O +
than O +
that O +
in O +
the O +
n-3-sufficient O +
group O -
. O +

In O +
addition O -
, O +
the O +
levels O +
of O +
2 O -
- O -
16:0MG O +
plus O +
1 O -
( O -
3 O -
) O -
-18:1MG O +
as O +
well O +
as O +
2 O -
- O -
18:1MG O +
were O +
higher O +
in O +
the O +
n-3-deficient O +
group O +
than O +
in O +
the O +
n-3-sufficient O +
group O -
. O +

1 O -
- O -
16:0MG O +
levels O +
were O +
similar O +
between O +
the O +
two O +
dietary O +
groups O -
. O +

3.4 O +
Effects O +
of O +
short O -
- O -
term O +
supplementation O +
with O +
DHA O +
rich O +
diet O +
on O +
AA O +
and O +
DHA O +
levels O +
in O +
phospholipids O +
and O +
on O +
MG O +
levels O +
in O +
brain O +
As O +
demonstrated O +
above O -
, O +
the O +
reduction O +
of O +
DHA O +
levels O +
in O +
brain O +
phospholipids O +
associated O +
with O +
dietary O +
n-3 O +
PUFA O +
deficiency O +
led O +
to O +
the O +
increase O +
in O +
the O +
brain O +
2-AG O +
level O -
. O +

We O -
, O +
therefore O -
, O +
confirm O +
whether O +
or O +
not O +
the O +
enrichment O +
with O +
DHA O +
in O +
brain O +
phospholipids O +
could O +
alter O +
brain O +
2-AG O +
levels O +
in O +
mice O -
. O +

A O +
relatively O +
short O -
- O -
term O +
of O +
dietary O +
enrichment O +
with O +
DHA O -
- O -
induced O +
significant O +
changes O +
in O +
the O +
levels O +
of O +
DHA O +
as O +
well O +
as O +
AA O +
in O +
brain O +
phospholipids O +
( O -
Table O +
3 O +
) O -
. O +

The O +
DHA O +
levels O +
in O +
brain O +
PC O +
and O +
PE O +
of O +
the O +
brain O +
were O +
significantly O +
higher O +
in O +
the O +
high O -
- O -
DHA O +
group O +
than O +
in O +
the O +
low O -
- O -
DHA O +
group O +
( O -
Table O +
3 O +
) O -
. O +

The O +
DHA O +
level O +
in O +
brain O +
PI O +
was O +
slightly O +
but O +
significantly O +
higher O +
in O +
the O +
high O -
- O -
DHA O +
diet O +
group O +
than O +
in O +
the O +
low O -
- O -
DHA O +
diet O +
group O -
. O +

By O +
contrast O -
, O +
the O +
AA O +
levels O +
in O +
brain O +
PC O +
and O +
PE O +
were O +
significantly O +
lower O +
in O +
the O +
high O -
- O -
DHA O +
diet O +
group O +
than O +
in O +
the O +
low O -
- O -
DHA O +
group O -
, O +
although O +
those O +
in O +
PI O +
and O +
PS O +
were O +
not O +
significantly O +
different O +
between O +
the O +
two O +
dietary O +
groups O -
. O +

The O +
brain O +
2-AG O +
level O +
was O +
significantly O +
lower O +
in O +
the O +
high O -
- O -
DHA O +
diet O +
group O +
than O +
in O +
the O +
low O -
- O -
DHA O +
diet O +
group O +
( O -
Fig. O +
4 O +
) O -
. O +

Although O +
1 O -
( O -
3 O -
) O -
-AG O +
was O +
a O +
minor O +
constituent O +
of O +
brain O +
MG O +
relative O +
to O +
2-AG O -
, O +
its O +
level O +
was O +
also O +
lower O +
in O +
the O +
high O -
- O -
DHA O +
diet O +
group O +
than O +
in O +
the O +
low O -
- O -
DHA O +
diet O +
group O -
. O +

There O +
was O +
no O +
significant O +
difference O +
in O +
the O +
levels O +
of O +
the O +
two O +
DHA O -
- O -
containing O +
MG O +
isomers O -
. O +

In O +
addition O -
, O +
the O +
levels O +
of O +
1 O -
- O -
16:0MG O +
and O +
2 O -
- O -
18:1MG O +
were O +
similar O +
between O +
the O +
two O +
dietary O +
groups O -
, O +
although O +
the O +
level O +
of O +
2 O -
- O -
16:0MG O +
plus O +
1 O -
( O -
3 O -
) O -
-18:1MG O +
was O +
lower O +
in O +
the O +
high O -
- O -
DHA O +
diet O +
group O +
than O +
in O +
the O +
low O -
- O -
DHA O +
diet O +
group O -
. O +

4 O +
Discussion O +
It O +
has O +
been O +
suggested O +
that O +
2-AG O +
is O +
generated O +
from O +
arachidonate O -
- O -
containing O +
phospholipids O +
through O +
their O +
sequential O +
hydrolysis O +
by O +
PLC B-Gene +
and O +
DG B-Gene +
lipase I-Gene +
[ O -
12 O -
] O +
. O +

Since O +
the O +
Sn O +
-2 O +
position O +
of O +
the O +
PI O +
of O +
mammalian O +
tissues O +
is O +
esterified O +
mainly O +
with O +
AA O +
and O +
the O +
existence O +
of O +
families O +
of O +
PLC B-Gene +
isozymes I-Gene +
specific O +
for O +
PI O +
have O +
been O +
demonstrated O +
in O +
the O +
brain O +
[ O -
18 O -
] O +
, O +
it O +
can O +
be O +
hypothesized O +
that O +
PI O +
is O +
the O +
most O +
likely O +
phospholipid O +
class O +
utilized O +
for O +
2-AG O +
biosynthesis O -
. O +

However O -
, O +
Bisogno O +
et O +
al. O +
[ O -
13 O -
] O +
demonstrated O +
in O +
mouse O +
neuroblastoma O +
that O +
AA O -
- O -
containing O +
phospholipids O +
are O +
hydrolyzed O +
by O +
phospholipase B-Gene +
D I-Gene +
to O +
phosphatidic O +
acid O -
, O +
followed O +
by O +
phosphatidate B-Gene -
- I-Gene -
hydrolyzing I-Gene +
phosphatase I-Gene +
and O +
then O +
DG B-Gene +
lipase I-Gene +
to O +
form O +
2-AG O -
. O +

More O +
recently O -
, O +
Lee O +
et O +
al. O +
[ O -
19 O -
] O +
demonstrated O +
that O +
the O +
enzymatic O +
activity O +
for O +
esterifying O +
glycerol O +
with O +
a O +
fatty O +
acid O +
in O +
the O +
brain O +
is O +
also O +
a O +
possible O +
pathway O +
of O +
2-AG O +
biosynthesis O -
. O +

We O +
demonstrated O +
that O +
the O +
dietary O +
supplementation O +
with O +
a O +
high O -
- O -
DHA O +
diet O +
reduced O +
the O +
2-AG O +
level O +
in O +
the O +
absence O +
of O +
the O +
reduction O +
of O +
the O +
AA O +
level O +
in O +
PI O +
as O +
compared O +
with O +
the O +
low O -
- O -
DHA O +
diet O +
group O +
( O -
Fig. O +
4 O +
and O +
Table O +
3 O +
) O -
. O +

The O +
reduction O +
of O +
the O +
AA O +
level O +
in O +
PC O +
and O +
PE O +
as O +
well O +
as O +
PS O +
by O +
a O +
high O -
- O -
DHA O +
diet O +
as O +
compared O +
with O +
the O +
low O -
- O -
DHA O +
diet O +
group O +
can O +
be O +
due O +
to O +
the O +
difference O +
in O +
brain O +
2-AG O +
levels O +
between O +
the O +
two O +
dietary O +
groups O -
. O +

Therefore O -
, O +
the O +
pathway O +
that O +
involves O +
the O +
utilization O +
of O +
phosphatidic O +
acid O +
[ O -
13 O -
] O +
, O +
presumably O +
derived O +
from O +
PC O +
or O +
PE O -
, O +
more O +
likely O +
accounts O +
for O +
our O +
observations O -
. O +

However O -
, O +
the O +
changes O +
in O +
AA O +
level O +
in O +
phospholipids O +
alone O +
could O +
not O +
account O +
for O +
the O +
alteration O +
of O +
the O +
brain O +
2-AG O +
levels O -
, O +
because O +
we O +
found O +
the O +
elevation O +
of O +
the O +
2-AG O +
level O +
in O +
the O +
mouse O +
brain O +
with O +
reduced O +
DHA O +
level O +
without O +
affecting O +
the O +
AA O +
level O +
in O +
all O +
the O +
four O +
phospholipid O +
classes O -
. O +

These O +
results O +
enable O +
us O +
to O +
consider O +
that O +
DHA O +
has O +
an O +
inhibitory O +
properties O +
for O +
2-AG O +
biosynthesis O +
in O +
the O +
brain O -
. O +

For O +
example O -
, O +
DHA O -
- O -
containing O +
phospholipids O +
may O +
inhibit O +
the O +
enzymatic O +
step O -
( O -
s O -
) O +
for O +
the O +
hydrolysis O +
of O +
AA O -
- O -
containing O +
phospholipids O -
, O +
presumably O +
PLC B-Gene +
or O +
PLD B-Gene -
. O +

This O +
mechanism O -
, O +
if O +
any O -
, O +
may O +
also O +
account O +
for O +
the O +
reduction O +
of O +
the O +
2-AG O +
level O +
in O +
brain O +
phospholipids O +
of O +
mice O +
fed O +
with O +
the O +
high O -
- O -
DHA O +
diet O -
. O +

However O -
, O +
the O +
biochemical O +
role O +
of O +
DHA O -
- O -
containing O +
phospholipids O +
in O +
regard O +
to O +
the O +
interaction O +
with O +
2-AG O +
biosynthesis O +
should O +
be O +
further O +
investigated O -
. O +

Unlike O +
2-AG O -
, O +
DHA O -
- O -
containing O +
MGs O +
have O +
very O +
low O +
levels O +
despite O +
the O +
abundance O +
of O +
DHA O -
- O -
containing O +
phospholipids O +
in O +
the O +
brain O +
( O -
Tables O +
2 O +
and O +
3 O +
) O -
. O +

In O +
addition O -
, O +
the O +
2 O -
- O -
22:6n-3MG O +
level O +
did O +
not O +
increase O +
even O +
when O +
the O +
DHA O +
level O +
in O +
brain O +
phospholipids O +
was O +
elevated O +
by O +
dietary O +
enrichment O +
with O +
DHA O +
( O -
Fig. O +
4 O +
and O +
Table O +
3 O +
) O -
. O +

These O +
results O +
indicate O +
that O +
the O +
enzymatic O +
system O -
( O -
s O -
) O +
preferentially O +
generate O +
2-AG O +
over O +
2 O -
- O -
22:6n-3MG O -
. O +

If O +
AA O -
- O -
containing O +
phospholipids O +
are O +
indeed O +
the O +
precursors O +
of O +
2-AG O -
, O +
DHA O -
- O -
containing O +
phospholipids O +
would O +
not O +
be O +
efficiently O +
utilized O +
for O +
2 O -
- O -
22:6n-3MG O +
synthesis O -
. O +

The O +
hydrolysis O +
of O +
DHA O -
- O -
containing O +
phospholipids O +
by O +
enzymes B-Gene +
such O +
as O +
PLC B-Gene +
or O +
PLD B-Gene +
should O +
be O +
examined O +
to O +
clarify O +
the O +
mechanism O +
of O +
preferential O +
generation O +
of O +
2-AG O +
over O +
2 O -
- O -
22:6n-3MG O -
. O +

There O +
are O +
reports O +
showing O +
that O +
the O +
administration O +
of O +
a O +
CB1 B-Gene +
antagonist O -
, O +
SR14716 O -
, O +
enhances O +
memory O +
functions O +
in O +
mice O +
and O +
rats O +
[ O -
20,21 O -
] O +
. O +

In O +
addition O -
, O +
CB1 B-Gene +
receptor I-Gene +
knockout O +
mice O +
retain O +
memory O +
longer O +
than O +
wild O -
- O -
type O +
controls O +
[ O -
22,23 O -
] O +
. O +

These O +
observations O +
suggest O +
that O +
endogenous O +
cannabinoid O +
ligands O +
exhibit O +
a O +
memory O -
- O -
disrupting O +
property O -
. O +

Furthermore O -
, O +
CB1 B-Gene +
knockout O +
mice O +
show O +
increased O +
aggressive O +
and O +
anxiogenic O -
- O -
like O +
responses O +
as O +
well O +
as O +
a O +
higher O +
sensitivity O +
to O +
a O +
chronic O +
unpredictable O +
mild O +
stress O +
as O +
shown O +
by O +
their O +
enhanced O +
depressive O -
- O -
like O +
responses O +
[ O -
24 O -
] O +
. O +

The O +
pharmacological O +
and O +
genetic O +
manipulations O +
of O +
endogenous O +
cannabinoid O +
action O +
obviously O +
clarified O +
its O +
role O +
in O +
the O +
functions O +
of O +
CNS O -
. O +

Accordingly O -
, O +
the O +
elevation O +
of O +
the O +
2-AG O +
level O +
in O +
the O +
brain O +
of O +
mice O +
under O +
chronic O +
n-3 O +
PUFA O +
deficiency O +
is O +
an O +
important O +
finding O +
which O +
could O +
elucidate O +
the O +
molecular O +
mechanism O +
of O +
their O +
abnormalities O +
in O +
memory O +
functions O +
[ O -
1,2 O -
] O +
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
reduction O +
of O +
2-AG O +
levels O +
in O +
the O +
brain O +
of O +
mice O +
fed O +
with O +
the O +
n-3 O +
PUFA O -
- O -
rich O +
diet O +
suggests O +
a O +
possibility O +
that O +
this O +
dietary O +
manipulation O +
may O +
improve O +
memory O +
and O +
emotional O +
functions O -
. O +

Lim O +
and O +
Suzuki O +
[ O -
25 O -
] O +
reported O +
that O +
dietary O +
supplementation O +
with O +
a O +
high O -
- O -
DHA O +
diet O +
enhances O +
the O +
learning O +
ability O +
of O +
mice O +
tested O +
using O +
a O +
maze O +
task O +
as O +
compared O +
with O +
low O -
- O -
DHA O +
diet O -
. O +

Recently O -
, O +
Berger O +
et O +
al. O +
have O +
demonstrated O +
that O +
a O +
short O -
- O -
term O +
supplementation O +
of O +
both O +
AA O +
and O +
DHA O +
in O +
liquid O +
formula O +
increases O +
the O +
levels O +
of O +
anandamide O +
( O -
N O +
-arachidonoylethanolamine O -
) O +
and O +
its O +
DHA O -
- O -
containing O +
analogue O +
( O -
N O +
-docosahexaenoylethanolamine O -
) O +
in O +
newborn O +
piglet O +
brain O +
[ O -
26 O -
] O +
. O +

However O -
, O +
under O +
the O +
same O +
conditions O -
, O +
the O +
levels O +
of O +
MG O +
containing O +
AA O +
or O +
DHA O +
did O +
not O +
increase O -
. O +

They O +
demonstrated O +
the O +
elevation O +
of O +
the O +
AA- O +
and O +
DHA O -
- O -
containing O +
N O +
-acylethanolamime O +
level O +
even O +
after O +
the O +
supplementation O +
with O +
only O +
a O +
small O +
amount O +
( O -
below O +
1 O -
% O +
of O +
total O +
fatty O +
acids O +
of O +
the O +
formula O -
) O +
of O +
these O +
PUFA O +
in O +
the O +
formula O +
for O +
newborn O +
piglets O +
for O +
a O +
relatively O +
short O +
period O +
( O -
18 O +
days O -
) O -
. O +

Therefore O -
, O +
AA O +
and O +
DHA O +
would O +
be O +
incorporated O +
into O +
these O +
pathways O +
of O +
N O +
-acylethanolamide O +
biosynthesis O +
more O +
rapidly O +
than O +
into O +
the O +
2-AG O +
synthetic O +
pathways O -
. O +

There O +
are O +
two O +
proposed O +
biosynthetic O +
pathways O +
for O +
anandamide O -
, O +
which O +
involves O +
the O +
formation O +
of O +
a O +
unique O +
precursor O -
, O +
N O +
-acylphosphatidylethanolamine O +
[ O -
27 O -
] O +
or O +
direct O +
N O +
-acylation O +
of O +
ethanolamine O +
[ O -
28 O -
] O +
. O +

Bisogno O +
et O +
al. O +
[ O -
29 O -
] O +
have O +
already O +
shown O +
the O +
formation O +
of O +
N O +
-docosahexaenoylphosphatidylethanolamine O +
as O +
a O +
possible O +
precursor O +
for O +
the O +
biosynthesis O +
of O +
N O +
-docosahexaenoylethanolamide O +
in O +
bovine O +
retinal O +
tissues O -
. O +

Although O +
the O +
precise O +
mechanism O +
by O +
which O +
dietary O +
supplementation O +
with O +
AA O +
and O +
DHA O +
preferentially O +
leads O +
to O +
the O +
incorporation O +
of O +
these O +
PUFAs O +
into O +
N O +
-acylethanolamines O +
is O +
still O +
unknown O -
, O +
these O +
results O +
also O +
suggest O +
that O +
the O +
manipulation O +
of O +
dietary O +
PUFA O +
can O +
modify O +
the O +
psychoemotional O +
status O +
through O +
the O +
change O +
in O +
the O +
levels O +
of O +
endogenous O +
cannabinoid O +
ligands O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
demonstrated O +
that O +
the O +
dietary O +
n-3 O +
PUFA O +
status O +
is O +
one O +
of O +
the O +
important O +
factors O +
that O +
influence O +
brain O +
2-AG O +
levels O -
. O +

On O +
the O +
other O +
hand O -
, O +
various O +
physiological O +
and O +
pathological O +
conditions O +
leading O +
to O +
the O +
alteration O +
of O +
endogenous O +
2-AG O +
levels O +
and O +
its O +
implication O +
to O +
these O +
events O +
have O +
been O +
reported O +
[ O -
30–33 O -
] O +
. O +

Therefore O -
, O +
our O +
findings O +
may O +
help O +
clarify O +
the O +
mechanism O +
by O +
which O +
the O +
manipulation O +
of O +
the O +
dietary O +
n-3 O +
PUFA O +
status O +
modulates O +
the O +
CNS O +
function O +
under O +
physiological O +
and O +
pathological O +
conditions O -
. O +

Acknowledgements O +

We O +
thank O +
Dr. O +
Kengo O +
Akimoto O +
( O -
Institute O +
for O +
Health O +
Care O +
Science O -
, O +
Research O -
, O +
Suntory O +
Ltd. O -
) O +
for O +
conducting O +
APCI O -
- O -
MS O +
analysis O +
and O +
helpful O +
discussion O +
on O +
the O +
molecular O +
identification O +
of O +
MG O -
. O +

